﻿   Table of Contents
Title Page
Introduction
About This Book
FDA
RFK Jr. declares MAHA war against the FDA | D Gorski
MAHA vs. the FDA: Dredging up old anti-regulation revisionist history | D Gorski
The FDA: Promoting Quack Nostrums Based on “Incredible Stories” While Rejecting Vaccines Despite Successful RCTs | J Howard
Regulating Health Care Products | S Novella
Patient Beware: Off-label drug promotion by pharmaceutical companies | J Bellamy
The Amarin case: off-label promotion and a double standard for prescription drugs vs. dietary supplements | J Bellamy
At Your Own Risk | J Bellamy
Stem cell therapy regulation plays catch up | J Bellamy
The FDA and Personalized Genetic Testing | S Novella
FDA & CDC find raw pet food unpalatable | J Bellamy
Personal Care Products Safety Act: Facelift for FDA Regulation or Lipstick on a Pig? | J Bellamy
Donald Trump and Peter Thiel vs. the FDA: Be afraid. Be very afraid. | Science-Based Medicine
The FDA Cracks Down on Fake Cancer Cures. Steven Novella 
FDA approval of drugs and transparency in clinical trial results. David Gorski
FDA versus Big Supp: Rep. Burton to the Rescue (Again) | J Bellamy
Too many lab tests still escape FDA review, threatening patient safety | J Bellamy
FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s | S Novella
FDA proposes ban on curcumin and other naturopathic favorites in compounded drugs | J Bellamy
US Department of Justice Goes After Supplements | S Novella
FDA promises industry-friendly “modernization” of dietary supplement regulation | J Bellamy
FDA blacklists cesium chloride, ineffective and dangerous naturopathic cancer treatment | J Bellamy
FDA warns companies selling illegal hangover remedies | J Bellamy
FDA Decision on Oleandra | S Novella
FDA warns public about exosome treatments | J Bellamy
FDA should pull the plug on thermography | J Bellamy
New FDA regulatory role threatens bogus diagnostic tests | J Bellamy
POM: Not So Wonderful | J Bellamy
FDA issues warning letter to “holistic” practitioner offering thermography for breast cancer detection | J Bellamy
FDA efforts to improve compounded drug safety upsets naturopaths | J Bellamy
New FDA rule cracks down on compounded drug ingredients | J Bellamy
FDA: No CBD in dietary supplements or foods for now, but let’s talk | J Bellamy
The FDA’s accelerated drug approval program is failing to protect cancer patients | D Gorski
Is the FDA embracing quackery? A draft proposal recommends that doctors learn about acupuncture and chiropractic for pain management. | D Gorski
The FDA under MAHA control: Weakening the quack Miranda warning on supplements | D Gorski
Why Does Dr. Vinay Prasad Refuse to Answer Questions About His Job Performance at the FDA? | J Howard
FDA v. Jack3d: Round 2 | J Bellamy
FDA poised to reshape the cold remedy aisle | S Gavura
Congress criticizes the FDA and the Aduhelm approval | S Gavura
Drug maker challenges FDA on animal testing | J Bellamy
Court overturns FDA ban on electric shock device used on special needs students | J Bellamy
Bogus Electrodermal Testing Devices and the Failure of Regulators to Act | H Hall
Protandim Update: New Studies and an FDA Warning Letter | H Hall
FDA Looks At Dubious Stem Cell Clinics | S Novella
Donald Trump versus the FDA: Is the standard of evidence for drug approval actually too low rather than too high? | D Gorski
Government watchdog warns about paid physician speeches touting drugs and medical devices | J Bellamy
The FDA vs. Compounding Pharmacies: GLP-1 Edition | S Gavura
Department of Justice prioritizes prosecution of clinical trial fraud, but systemic reform is needed | J Bellamy
Avastin and metastatic breast cancer: When science-based medicine collides with FDA regulation. David Gorski.
FDA Has Replaced its Leadership With Doctors Who Have Done Their “Research” | J Howard
No One Should Care About or Trust Anything Dr. Marty Makary Says Ever Again | J Howard
With Laura Loomer on One Side and Dr. Paul Offit on the Other, Our FDA Leaders are Caught in a Trap of Their Own Making | J Howard
A Letter to the American College of Surgeons: Don’t Censor Dr. Marty Makary, Amplify His Voice. | J Howard
Canada Bill C-51 – Regulating Natural Health Products. Steven Novella
Supplement Regulation: Be Careful What You Wish For. Scott Gavura.
Don’t supplement users deserve consumer protection, too? | S Gavura
Marketing Pharmaceuticals in today’s Regulatory Environment. Martin A. Lessem, J.D. 
Airborne Settles Case On False Advertising Steven Novella 
Threats to science-based medicine. When clinical trials for new drugs are designed by the marketing division. David Gorski
Cavalcade of Quackery: A Pantomine Horse. Wallace Sampson
“Integrative Medicine Experts”: Another Barrier to Effective Discipline. Kimball Atwood
The Pseudomedical Pseudoprofessional Organization (PPO*). Kimball Atwood
A New Twist for Autism: A Bogus “Biomedical” Board. Kimball Atwood
Bogus Diagnostic Tests. Kimball Atwood.
When you can’t win on science, invoke the law… David Gorski.
A victory for science-based medicine. Peter Lipson
Some Encouraging Backlash Against Nonsense. Steven Novella
The fall of Andrew Wakefield. David Gorski.
The General Medical Council to Andrew Wakefield: “The panel is satisfied that your conduct was irresponsible and dishonest” David Gorski.
The long, strange road to passing SB 276 appears to be near its end…finally | D Gorski
Electrodermal Testing Part II: Legal and Regulatory Aspects. Harriet Hall
HOMEOPATHY
The Baloney Protection Act | S Novella
A homeopathic win for consumers | S Gavura
The CAM Docket: Boiron I | J Bellamy
The CAM Docket: Boiron II | J Bellamy
The CAM Docket: Boiron III, et al. | J Bellamy
Should the FDA crack down on homeopathic “remedies”? | S Gavura
How should the FDA regulate homeopathic remedies? | J Bellamy
FDA and Homeopathy: Part Two. | M Crislip
FDA Proposes Changes to Homeopathy Regulation | S Novella
FDA strengthens homeopathic drug enforcement (but falls short of actually enforcing the law) | J Bellamy
The Federal Trade Commission takes on homeopathy—maybe | D Gorski
Homeopathic industry and its acolytes make poor showing before FDA | J Bellamy
Society for Science-Based Medicine: Comment to FDA on homeopathic drug regulation | J Bellamy
FDA Warns About Homeopathic Teething Products | S Novella
An Update on FDA Concerns Over Homeopathic Teething Products | C Jones
CVS sued for deceiving consumers in sale of homeopathic remedies | J Bellamy
Junk science helps homeopathic remedy company win class action | J Bellamy
Homeopathic Thuggery. Steven Novella
FTC Homeopathy Win | S Novella
Walmart sued for deceiving customers in selling homeopathic remedies | J Bellamy
Lawsuits against US pharmacy chains selling homeopathy to proceed | S Gavura
Taking On Homeopathy in Germany. Steven Novella.
The Truth vs. Alex Jones: How the DSHEA of 1994 gave conspiracy mongers the means to fund their empires | D Gorski
Bills eliminating school immunizations and other anti-vaccination measures confront state legislatures | J Bellamy
Federal appeals court strikes down conversion therapy bans | J Bellamy
Consumer and public health groups push for cancer warning on alcoholic beverages | J Bellmay
Anti-Smoking Laws – The Proof of the Pudding | S Novella
Supplements are the Wild West of health. One Attorney General is out to change that. | S Gavura
Dr. Marty Makary Was Paid $130,357 By Pharma. Is His “Undue Influence” Affecting the FDA? | J Howard
FTC
Supreme Court rules that FTC cannot seek restitution on behalf of consumers | J Bellamy
Battle of the feds: FTC tells FDA to do its job regulating homeopathy | J Bellamy
FTC Slaps Down “Brain Training” Claims | S Novella
FTC settles deceptive advertising claims against amniotic stem cell clinics | J Bellamy
FTC settles false advertising suit against low-level light therapy marketer with $22 million judgment | J Bellamy
The FTC cracks down on iV Bars for false advertising claims about its “intravenous micronutrient therapy” | D Gorski
FTC targets physicians’ COVID claims with cease-and-desist letters | J Bellamy
FTC warns naturopaths, acupuncturists, physicians, and chiropractors about false and misleading COVID-19 claims | J Bellamy
FTC Sues Predatory Journal | S Novella
Prevagen goes P-hacking | J Bellamy
Physician Misinformation | S Novella
COVID
The ABIM vs. medical misinformation: Better late than never? | D Gorski
The American Board of Internal Medicine finally acts against two misinformation-spreading doctors | D Gorski
The Federation of State Medical Boards vs. COVID-19 misinformation: A losing battle so far | D Gorski
The Ohio State Medical Board has finally suspended the medical license of antivax quack Sherri Tenpenny | D Gorski
State medical boards vs. COVID-19 misinformation, an update | D Gorski
State legislatures consider bills prohibiting COVID-19 vaccination mandates and other public health measures | J Bellamy
School mask mandate wars: Politics (Florida) v. Science (North Carolina) | J Bellamy
Tennessee hamstrings medical board fight against COVID misinformation and unproven treatments | JJ Bellamy
Florida Surgeon General declares single positive COVID test proves immunity forever | J Bellamy
Why are physicians threatened by efforts to report doctors to their state medical board for COVID-19 misinformation? | D Gorski
Government watchdog to investigate politicization of CDC and FDA during COVID-19 pandemic | J Bellamy
Is the FDA is Hiding “Evidence” the COVID Vaccine Killed Children? | J Howard
State legislators dispense with standard of care for COVID treatment and encourage medical misinformation | J Bellamy
Federal employment rights agency inundated with thousands of COVID-related discrimination claims | J Bellamy
Consumer groups urge feds to act against Mercola and his false COVID-19 claims | J Bellamy
Mercola and Kennedy sue Sen. Elizabeth Warren for combating their COVID misinformation | J Bellamy
Heritage Covid Commission Wants China Accountable… What About Trump? | A Neitzel
“Fauci Files” and Florida’s Grand Jury Investigations Fail to Deliver | M Harris
The Oregon Medical Board suspends the medical license of antivax pediatrician Dr. Paul Thomas | D Gorski
Florida strikes out against Brian Clement | J Bellamy
Florida tells Brian Clement to stop practicing medicine | J Bellamy
Personal Belief Exemptions for Vaccines | S Novella
Stanislaw Burzynski
Stanislaw Burzynski: Using 1990s techniques to battle the FDA today | D Gorski
The Texas Medical Board vs. Stanislaw Burzynski, 2014 edition | D Gorski
Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA really caves | D Gorski
The Center for Inquiry weighs in on the FDA’s mishandling of Stanislaw Burzynski’s clinical trials | D Gorski
Revealed by the FDA: The results of the most recent inspection of the Burzynski Clinic | D Gorski
Stanislaw Burzynski and Robert O. Young: How two quacks of a feather illustrate how poorly states regulate medical practice | D Gorski
The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine | D Gorski
Mandatory breast density reporting legislation: The law outpaces science, and not in a good way | D Gorski
Bait and switch in Oregon: Substituting quackery for opioids for Medicaid patients | D Gorski
Significant Ruling Against Conversion Therapy | S Novella
Lyme Testimony | M Crislip
Florida revokes medical license of “Lyme literate” doctor | J Bellamy
Another “Chronic Lyme” VIP disciplined by NY medical authorities: Bernard Raxlen | J Bellamy
State Medical Boards should not recognize board certification in “Integrative Medicine” | J Bellamy
Is there a distinct standard of care for “integrative” physicians? The Woliner case | J Bellam
Medical debt vs. universal health insurance: The interface between SBM and policy | D Gorski
Legislative alchemy and abortion: How the fall of Roe v. Wade will degrade science-based medicine | D Gorski
New Florida law forces physicians to endorse pseudoscience | J Bellamy
Is Australia’s Planned Vaping Ban A Good Idea? | S Novella
UKs Phased Smoking Ban | S Novella
State Attorneys General pursue consumer protection law claims against stem cell clinics | J Bellamy
Good faith doctoring or greedy drug dealing? SCOTUS hears opioid prescribing cases | J Bellamy
Plexus: MLM Strikes Again | H Hall
Decision Against Spelling to Communicate – A Small Victory for Science | S Novella
Washington bills: Christian Science no longer an excuse for denying medical care | J Bellamy
Ezekiel Stephan: Another Pediatric Death by World View | C Jones
Parents Convicted in Death of Toddler | S Novella
The Supreme Court of Canada orders a new trial for parents convicted in Ezekiel Stephan’s death | S Gavura
The Verdict is In: There is No Justice for Ezekiel Stephan | C Jones
Deconstructing Justice Terry Clackson’s outrageous acquittal of David and Collet Stephans for the death of their son Ezekiel | D Gorski
Washington State’s Unconscionable, Unconstitutional Child Protection Law | H Hall
A favorite tactic of the antivaccine movement: When science doesn’t support you, use the law | D Gorski
CAM Docket: Kardashian Diet Products Klass Action | J Bellamy
CAM Docket: Functional Endocrinology | J Bellamy
GSK Pays $3 Billion Fine | S Novella
GSK Investigated for Bribing Doctors | S Novella
Food fights in the courtroom | J Bellamy
Undermining the regulation of stem cell therapies in Italy: A warning for the future? | D Gorski
Nigeria Court Ruling on Benzene in Soft Drinks | S Novella
Medical Malpractice Lawsuits | H Hall
Lying for the State | P Lipson
Enbrel for Stroke and Alzheimer’s | S Novella
Another Lawsuit To Suppress Legitimate Criticism – This Time SBM | S Novella
Update on the Tobinick Lawsuit | S Novella
Lawsuit Update | S Novella
Tobinick Lawsuit Update – Justice Has Prevailed | S Novella
   
Science-Based Medicine Reviews: Regulations, FDA & FTC
A Critical Guide for the Health Practitioner and Consumer 
2025 Edition

Executive Editor Steven Novella MD
Managing Editor David Gorski MD PhD
Series Editor Mark Crislip MD

   Introduction 
Steven Novella
The world of health care is becoming an increasingly complex and challenging place. The internet is changing the way we generate and access information, and health information is one of the most popular uses of the internet. It represents an unprecedented democratization of information and opinion. 
While there are many advantages and benefits to such information access, there are also many challenges to health professionals, regulators, academics, and consumers. There is a proliferation of health related products and services, with many provocative health claims. Regulations are generally not keeping up, and often have been watered down, in the face of this onslaught of claims and products. 
The consumer is left with an overwhelming array of health claims, many of which challenge and even directly oppose the traditional experts and institutions. 
The mission of Science-Based Medicine (SBM) is to be a source of reliable information and analysis to help navigate the wild west of health information on the internet and elsewhere. The authors who contribute to this series of e-books are all physicians and other health care professionals who have a great deal of experience educating the public about complex medical issues. We especially take on controversial issues and try to expose pseudoscience and fraud wherever possible.
The Philosophy of Science-Based Medicine
The philosophy of SBM, at its core, is simple: Safe and effective health care is critical to everyone’s quality of life; so much so that it is generally considered a basic human right. Therefore, health care products and services that work and are safe are better than those that do not work or are unsafe. 
The best method for determining which interventions and health products are safe and effective is, without question, good science. Therefore it is in everyone’s best interest for health care to be systematically evaluated by the best science available.
Too often the nature of science itself is misunderstood or misrepresented to the public. Science is not an arcane and privileged discipline. By its very nature it is meant to be transparent and public. Science is nothing more than a systematic and careful use of evidence and logic to evaluate factual claims. And good science possesses certain virtues that are not unique to science but generic to all intellectual endeavors: fairly accounting for all available evidence, using valid and internally consistent logic, using unambiguous concepts and language, proper use of statistics, being quantitatively precise and accurate, and above all being honest.
And yet there are numerous and powerful influences in society that strongly appose the scientific basis of medicine. Driven by some combination of ideology or the desire for profit they wish to eliminate standards of science in health care, or (often under the guise of “health care freedom”) create a double standard in which unscientific methods and products can thrive unchecked. Others simply lack the training or knowledge to achieve minimal standards of quality for scientific medicine. And even the best traditions of scientific medicine can benefit from more critical analysis.
Recognition of the need for careful scientific analysis in medicine partly stems from a recognition that it is very difficult (almost impossible) to reliably assess treatments anecdotally. Human perception, memory, and cognition are prone to a host of flaws, weaknesses, and biases that will tend to mislead us, especially towards conclusions that we wish to be true. Placebo effects, confirmation bias, and simple statistics can make any intervention seem effective, even when they are worthless or harmful. 
Science-Based Medicine vs Evidence-Based Medicine
Within the practice of medicine there is already a recognition of the need to raise the standards of evidence and the availability of the best evidence to the practitioner and the consumer – formalized in the movement known as evidence-based medicine (EBM). 
EBM is a vital and positive influence on the practice of medicine, but it has its limitations. EBM tends to focus on clinical trial results to the exclusion of scientific plausibility. The focus on trial results (which, in the EBM lexicon, is what is meant by “evidence”) has its utility, but fails to properly deal with medical modalities that are highly implausible, or seem to defy well-established findings in science.
All of science describes the same reality, and therefore it must (if it is functioning properly) all be mutually compatible. Collectively, science builds one cumulative model of the natural world. This means we can make rational judgments about what is likely to be true based upon what is already well established. This does not necessarily equate to rejecting new ideas out-of-hand, but rather to adjusting the threshold of evidence required to establish a new claim based upon the prior scientific plausibility of the new claim. Failure to do so leads to conclusions and recommendations that are not reliable, and therefore medical practices that are probably not safe and effective.
The SBM Series
This is why the authors of this series strongly advocate for science based medicine – the use of the best scientific evidence available, in the light of our cumulative scientific knowledge from all relevant disciplines, in evaluating health claims, practices, and products. 
Some of the articles here will analyze individual studies, and explore the strengths and weaknesses of their methods, separating what the study really tells us from how it may be represented in the media. Other articles will summarize what many studies tell us about a specific medical question. 
We will also explore health information on the internet, separating out which information is reliable from that which is misleading, erroneous, or possibly even fraudulent. Likewise we will critique mainstream media coverage of health topics, giving the reader specific tools for to critically analyze health information for themselves.
Other articles will explore topics related to health regulation and academia. Regulations have struggled to keep up with the rapidly changing health care market place, with critical gaps that leave the health care consumer responsible for their own protection. Academic institutions themselves, long the defenders of high standards of scholarship in all fields, including medicine, have been infiltrated by promoters of pseudoscientific belief systems. The result is that there is no longer any single reliable guarantee of scientific integrity. 
The SBM series of e-books is organized by topic, such as acupuncture, chiropractic, homeopathy, and many others. The books are collections of essays, not intended to be a systematic reference, but rather to explore the various scientific issues related to each topic. The goal is to give the reader critical thinking skills and a deeper understanding of, not just the current findings of science, but the process of science, specifically how it relates to health care and the topic of each book. 
Science-based medicine can serve as your pocket guide through the wilderness of health information.

About This Book

As of 2025, there are over 5000 essays on the Science Based Medicine website. I do no know about you, but I find it difficult to find any post I wrote, much less one written by another contributor. 

So I have updated the books and include almost all the articles through 2025. The volumes are

CAM Concepts
Chiropractic
COVID 
Critical Thinking
Diet and Nutrition
Ethics and CAM
Herbs, Supplements, and Diet
Homeopathy
Infections and Immunity
Law and CAM
Media and Internet
Medicine, Public Health, Dentistry and Pediatrics
Miscellaneous CAM
Naturopathy
Neurology and Psychiatry
Placebo
Quackademic Medicine
Regulation. FDA and FTC
SBM or EBM
Stem Cells, Genetics, AI and Gender
Supplements, Vitamins and Herbs
Vaccine & Anivax
Vaccines and Autism
Vaccines and Preventable Infections

The articles are roughly organized by publication date and topic. Many articles will be in multiple volumes as an essay of, for example, chiropractic and law will be found in both the chiropractic volume and the law volume.
You may find the organization a bit odd. I do. But 4700 plus articles are difficult to organize and I have more to do in my retirement than work of these volumes.
Still, if you find I have missed a nentry or some glaring error, drop me a note and I will fix it for the next edition.

About the authors
Steven P. Novella, MD – Founder and Executive Editor Science Based Medicine.
Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD.
David H. Gorski, MD, PhD – Managing Editor. Science Based Medicine.
Mark A. Crislip, MD. Editor, Science Based Medicine Guides. 
He did he editing of all the volumes so is to blame for any mistakes.
As to all the other contributors, if you are interested click on the ‘Link’ at top of each essay to go the SBM site, where further information about each author can be found.
A Note On References
The chapters in this book were originally blog entries at ScienceBasedMedicine.org.
Blog and web pages lend themselves to hyperlinks to sources and references that are tedious to translate into footnotes for this ebook.
Under the title of each essay is a hyperlink, cleverly titled ‘Link’, to the original blog entry with all the hyperlinks and references, as well as the comments to the blogs, which often have interesting and thoughtful insights by our readers, as well as some curious comments by the not so thoughtful.
Graphs, tables and links to videos are not in included these essays due to issues of copyright and permission. However, thanks to the ‘Link’, the graphics are a click away.
Thanks for reading the site.
Mark Crislip 


FDA

RFK Jr. declares MAHA war against the FDA
In a post on X/Twitter, antivaxxer turned Trump supporter Robert F. Kennedy, Jr. declared MAHA war on the FDA, should Trump be elected. What would this actually mean in practice?
David Gorski on October 28, 2024
Link

As hard as it is to believe, I’ve been writing about Robert F. Kennedy, Jr. for nearly two decades. It all began in 2005 when RFK Jr. first “outed” himself as an antivaxxer by writing a conspiracy-laden “exposé” of the CDC falsely claiming that it was covering up evidence that the mercury-containing preservative thimerosal had been responsible for an “epidemic” of autism (it wasn’t). More recently, in August RFK Jr. bent the knee to Donald Trump, suspending his campaign to go all MAGA, in the hopes of landing a high-ranking health policy-related position in the Trump administration, should he win, to “make America healthy again,” which produced one of the more risibly silly acronyms I’ve ever seen, MAHA. Of course, in his MAHA agenda, RFK Jr. has thus far tried very hard to ignore or disguise his utterly bonkers antivax conspiracy mongering in favor of proposals ranging from the seemingly reasonable (decreasing regulatory capture at the FDA, although obviously I’m suspicious and the devil is in the details), to the dubious (getting rid of “chemicals” in food, in reality fear mongering about preservatives and GMOs), to the utterly pseudoscientific (promoting more research into alternative medicine quackery at the NIH). Although antivaxxers easily saw right through this misdirection, this sanewashing of RFK Jr.’s history by the Trump campaign is a strategy that unfortunately might work, as there are a lot of people susceptible to these sorts of fear mongering campaigns but just haven’t yet gone down the antivax rabbit hole yet.
I hadn’t really intended to write about RFK Jr.’s MAHA nonsense again unless Trump wins the election, but then over the weekend I saw this post by him on X, the hellsite formerly known as Twitter:
A few thoughts ran through my mind seeing this. First, it’s clear that RFK Jr. has now pivoted from being mainly antivaccine to a more general “health freedom” orientation frequently associated with the antivaccine movement that paints the Food and Drug Administration as the pharma-serving villain suppressing “natural” treatments, low cost medications, and “miracle cures.” Second, I can’t recall ever having seen the FDA being opposed to sunshine or exercise. I can see one twisting warnings about too much sun exposure being a risk factor for skin cancer that way, but when has the FDA ever opposed exercise as something that “advances human health”? (Answer: It hasn’t, except in the fevered delusions of people like RFK Jr.) Third, I realized that I should be surprised by this open attack on the FDA at all, given that it’s long been a goal of the “health freedom” movement to dismantle the FDA and return it at least to a pre-thalidomide state if not to eliminate it entirely. Recall that, before the thalidomide scandal, drug manufacturers were only required to submit evidence of safety, not efficacy, to win approval to market their products. Also recall that, contrary to the myths of quacks and “health freedom” advocates, the FDA actually worked; thalidomide was never approved for use in the US, thanks largely to the steadfastness of one of its scientists, Dr. Frances Oldham Kelsey , upon whom RFK Jr.’s uncle John F. Kennedy, bestowed the Presidential Medal of Freedom in 1962 for her refusal to buckle under pressure and support the approval of the drug.
Indeed, after Washington Post reporter Morton Mintz broke the story of Dr. Kelsey’s battle to keep thalidomide from being approved, public pressure mounted on Congress to do something. As a result, in 1962 Congress passed the Kefauver-Harris Drug Amendments to the Federal Food, Drug, and Cosmetic Act. These amendments required that drug companies not just show safety, as had been the case prior to the amendments, before their drugs could be FDA-approved, but also to provide substantial evidence of effectiveness for the product’s intended use. That evidence had to be in the form of adequate and well-controlled clinical trials, which at the time was considered a revolutionary requirement. (Believe it or not, no FDA requirement for high quality clinical trials showing evidence of efficacy and safety existed before 1962, and often the safety data used to obtain drug approval consisted largely of animal studies.) With tweaks over time in FDA regulations, amendments led to the current system of phase I, II, III, and IV clinical trials in force today. The amendments also included a requirement for informed consent of study subjects and codified good manufacturing processes, as well as the requirement that adverse events be reported, all very good things from the perspective of science-based medicine. Whatever shortcomings in the FDA approval process might exist now (and we’ve discussed many of them right here, indeed one time arguing that, if anything, the FDA drug approval process now might no longer be sufficiently rigorous), there is no doubt that since 1962 the FDA has been a far more effective guardian of drug safety than it was before the Kefauver-Harris Amendments were passed.
Of course, that’s what the “health freedom” warriors hate the most about the FDA and exactly why they wish to dismantle it.
“Health freedom” as epitomized by the antivaccine movement: A brief history
At this point, I’m half-tempted to quip that the main goal of the “health freedom” movement is freedom for quacks from pesky government laws and regulations that keep them from defrauding people by selling their ineffective and sometimes dangerous nostrums to them. While I certainly continue to argue that freedom from interference by government that prevents the sale of everything and anything to treat everything and everything (regardless of whether any of it is effective and/or at least safe) is certainly a major motivation behind “health freedom,” even I recognize that it’s far from the only motivation. It is, however, the one motivation that health freedom advocates tend to do their damnedest to downplay or disguise, although almost inevitably quacks rail against the FDA, even as they append “Quack Miranda” warnings about how their nostrums haven’t been approved by the FDA to their sales pitches, in order to try to ward off investigations.
Whenever I discuss the “health freedom” movement, I like to look back at some of the rhetoric of one of its major components, namely the antivaccine movement. Antivaccine rhetoric has long been steeped in the language of “freedom,” going back to the 19th century. Moreover, this sort of rhetoric, although mainly the province of the right these days, has broad appeal across the political spectrum. Back when I first started writing about the antivaccine movement in 2004, there existed an exaggerated if not outright false stereotype that antivaxxers tended to be hippy-dippy crunchy lefties, particularly suburban moms, in liberal enclaves like Marin County or Manhattan. To be sure, there was such a contingent of a “back to nature” crowd, but in reality that stereotype was very wrong in a number of ways. However, dating back to long before the pandemic, there has been a libertarian right-wing component to the antivaccine movement, for example, General Bert Stubblebine III’s Natural Solutions Foundation, far right libertarians, and others with extreme distrust of the government, including government-recommended vaccine schedules.
Antivaxxers using the rhetoric of “freedom” vs. “oppression” is nothing new, as this letter from 1907 demonstrates:
“Freedom!” cries the antivaxxer in 1907. It sounds a lot like what we hear in 2022, doesn’t it? The point is that this sort of messaging is nothing new. What is new is that the antivaccine movement has discovered how to use it to attract more mainstream right wing political groups.
And this cartoon from the 1880s also shows it:
Here’s one more from roughly the same time period:
None of this rhetoric would be out of place in 2024 among the antivaccine movement or the movement that promotes ivermectin to cure COVID-19 (and now cancer and almost everything else). The health freedom movement has always represented any attempt by the government—or even academia or companies—to protect the public from ineffective quackery and fraudulent claims about what a product can do or to urge the public to cooperate with interventions designed to improve public health and prevent disease as “tyranny.”
Many years ago, I routinely used to point out that the level of support for vaccination was pretty similar on both the right and the left. I also used to suggest that, back in Jenny McCarthy‘s heyday as the celebrity face of the antivaccine movement 14-15 years ago, it was the heavy representation of celebrities among famous antivaxxers that contributed to the public perception that the antivaccine movement was predominantly left wing, Hollywood celebrities like Rob Schneider (admittedly, I’m probably being generous in my definition of “celebrity”), Mayim Bialik, Alec Baldwin, and Robert De Niro (who, as an aside, teamed up with RFK Jr. in 2017 to promote a bogus antivaccine scientific “challenge”), among others. It’s also true that areas with a lot of affluent people on the coasts, whose politics tend to lean heavily liberal, have suffered outbreaks of vaccine-preventable illnesses in recent years leading up the pandemic due to low vaccine uptake. Then, of course, there was (and, alas, still is) Robert F. Kennedy, Jr.
Even then, though, with relatively few exceptions, the most motivated antivaxxers still tended to be conservative, with right wing media giving voice to antivaccine views. As early as 2011, Fox News was airing sympathetic segments on Andrew Wakefield, interviews with Dr. Bob Sears, SafeMinds’ anti-vaccine PSA campaign, and Louise Kuo Habakus (who was virulently anti-vaccine herself and politically active in New Jersey advocating for more easily obtained “philosophical exemption” laws). Politically, some of the most rabid anti-vaccine activists in government were conservative, for instance, Rep. Dan Burton (R-IN). Moreover, as was the case for anti-evolution beliefs, fundamentalist and evangelical Christianity was not uncommonly a motivation for antivaccine views, and, if anything, has become much more so.
I’ve been documenting the increasingly tight association between the right and the antivaccine movement, going back to when the political party formed by antivaxxers, The Canary Party, founded in 2011, started working with Tea Party-affiliated groups in California. Not long after, the Canary Party became known for sucking up to Rep. Darrell Issa (R-CA), with one of its major financial backers Jennifer Larson contributing a lot of money to Issa’s campaign (indirectly, of course) in order to buy influence and win a hearing by his committee examining autism and focused on vaccines as one potential cause. Around the same time, at the right-wing Libertarian FreedomFest in 2012 I was privileged to watch a debate between Julian Whitaker and Steve Novella about vaccines. At the debate, vaccine pseudoscience flowed freely from Whitaker in a most embarrassing fashion, and I couldn’t help but note that FreedomFest that year featured two screenings of Leslie Manookian’s antivaccine propaganda piece, The Greater Good and had featured antivaccine talks in previous years. I was there, too, and amazed at the merchandise and conspiracy theories being touted, although in retrospect, in the era before the rise of QAnon, conspiracy theories about the gold standard and New World Order now seem almost quaint.
This movement rightward by the antivaccine movement appears to have been turbocharged in 2015 during the debate about SB 277, the California law that banned nonmedical exemptions to school vaccine mandates. That was when antivaxxers pivoted from messaging that was primarily about “toxins” in vaccines and the false claim that vaccines caused autism, autoimmune disorders, sterility, and death to messaging that primarily emphasized “vaccine choice,” “freedom,” “parental rights,” and resistance to government mandates. It was a winning message that attracted those of a conservative/libertarian bent, and many of the groups formed in the wake of that political struggle were clearly conservative, such as Texans for Vaccine Choice, Empower Texans, Michigan for Vaccine Choice, and others. (Notice the common thread in the names of these groups?) It is there where the politicization of school vaccine mandates really took off, particularly after Donald Trump entered the mix. By 2015-2016, even Republican presidential candidates like Chris Christie, Ben Carson, and, of course, Donald Trump—Rand Paul, too, but I leave him out because he was always antivaccine—were invoking the same language to pander to the antivaccine movement under the guise of supporting personal and parental rights.
By 2018, I was personally observing this rightward shift and infiltration of conservatism, including the Republican Party, in my neck of the woods, when a candidate for the Republican nomination for my district’s Congressional seat held an antivaccine “vaccine choice roundtable” that I attended incognito and documented. In Michigan, openly antivax candidates were running for state governor and other offices. By 2019, Republicans in Oregon were openly opposing anything resembling tightening school vaccine mandates, and the Ohio Statehouse was rife with antivax legislators, to the point that antivaxxers were bragging about them. Also, to bring it around, antivaxxers in California were openly marching with the California State Militia, specifically the California State Militia, First Regiment, California Valley Patriots and the State of Jefferson.
Then came the pandemic, and the rest you know. Antivaxxers quickly allied themselves with antimaskers, pandemic minimizers, anti-“lockdown” protesters, ivermectin and hydroxychloroquine promoters, and QAnon, with antivaccine rhetoric becoming increasingly violent. One might, in fact, say that all these groups rapidly merged under the banner of “health freedom” opposed not just to public health but to government regulation of health and medicine in general. However, I will reiterate my contention that the fact that right here, right now, in 2024, the antivaccine movement is overwhelmingly right wing appears to be more a product of our times and its politics than of anything else. Again, back when Jenny McCarthy was leading her “Green Our Vaccines” rally in 2008, for instance, a lot of the appeal was to evironmentalism-based concerns appealing to people leaning more left in their politics.
Even before this, however, I used to like to point out that a key belief of the “health freedom” movement has long been that the FDA—or, in other countries, whatever government entity is responsible for regulating drugs and food safety—is not a benign force. Far from it, “health freedom warriors” tend to believe fervently in a conspiracy theory that there are all sort of fantastic “cures” out there that the FDA, through bureaucratic inertia and/or being in the thrall of big pharma, is keeping from you, thereby killing your loved ones, friends, and, ultimately, possibly even you. To illustrate this conspiracy theory, I often refer to a 2014 article by Nick Gillespie, who expressed this hostility towards The FDA quite clearly in a Daily Beast article entitled Kill The FDA (Before It Kills Again). In the article, referencing the movie Dallas Buyers Club, Gillespie proclaimed that the FDA “continues to choke down the supply of life-saving and life-enhancing drugs that will everyone agrees will play a massive role not just in reducing future health care costs but in improving the quality of all our lives.” And what was his rationale for arguing this? Get a load of this:
As my Reason colleague Ronald Bailey has written, this means the FDA’s caution “may be killing more people than it saves.” How’s that? “If it takes the FDA ten years to approve a drug that saves 20,000 lives per year that means that 200,000 people died in the meantime.”
Completely missing from Bailey’s and Gillespie’s equation was the number of drugs that the FDA doesn’t approve because they aren’t safe and don’t demonstrate sufficient efficacy in randomized clinical trial, which could result in even more than 20,000 people a year dying (or some of them even being actively killed). Even Baily had to conceded that the FDA had prevented approval of Thalidomide in the US and the rash of birth defects seen elsewhere in the world. Bailey’s argument is, at best, tenuous, at worse misleading. (I favor worst. It’s just plain misleading.)
You get the idea, though. Promoters of the “health freedom” movement often claim that the FDA is an impediment to innovation, often exaggerating legitimate complaints about the FDA to make this argument and basically arguing that the answer is to make the approval process less onerous. Moreover, there was indeed such an argument to be made during the AIDS epidemic in the 1980s and 1990s, when activists, facing a disease that would kill them in a time period much shorter than it would take for new drugs to be developed, pressured the FDA to accelerate its approval process for certain classes of drugs for deadly diseases, such as drugs designed to treat HIV. The government eventually listened, too, and the FDA developed its accelerated approval program that would tentatively approve drugs based on less evidence, with the proviso that the drug maker had to provide more rigorous evidence within a certain timeframe or risk having their drug’s approval reversed, and expanded access (sometimes called compassionate use) programs that would allow patients to gain access to an investigational drug to use in treatment outside of a clinical trial when no comparable or satisfactory alternative treatment options exist or are available. Unfortunately, as we and others have argued, it is quite possible that now the pendulum has already swung too far in the direction of too easy approval, as epitomized by the track record of the accelerated approval program for cancer drugs.
Let’s look at what RFK Jr. really means, though, when he argues that he’s going to declare war on the FDA.
War on the FDA?
Let’s start the discussion of what RFK Jr.’s plans would likely really mean, if realized, by revisiting his post:
Dr. Ley’s statement is even more true today than it was in 1968. pic.twitter.com/DPZfxnbTjr
— J Kerner (@JKernerOT) October 25, 2024
What’s often left out of this meme is that, after Dr. Ley left the FDA in 1969, he did private consulting work for drug companies until the early 1990s. That little tidbit aside, it is true that Dr. Ley said this in a New York Times interview in 1969, shortly after he left the FDA because the incoming Nixon administration had nominated its own candidate, Dr. Charles Edwards. One thing I like to point out is that this quote is juxtaposed in a significant way. It is true that he said:
The thing that bugs me is that people think the FDA is protecting them. It isn’t. What the FDA is doing and what the public thinks it is doing are as different as night and day.
However, nowhere in the 1969 NYT interview did Dr. Ley say, “The FDA protects the big drug companies and is subsequently rewarded,” or “Using the government’s police powers, they attack those who threaten the big drug companies.” I could not find any reliable source quoting Dr. Ley saying either of these things, and this “quote” appears to have been added somewhere over the last 55 years. (If anyone out there can find a reliable source for that part of the quote, please let me know, and I will amend my post.) What’s really interesting to me, though, is that Dr. Ley’s sentiments did not align with the health freedom movement. Indeed, after saying that he thought the FDA was failing to protect the public, Dr. Ley lamented that the agency lacked the funding and resources to fulfill its mission and that more money was needed for it to fulfill its functions. Later in the interview, he described at length incidents when he intense pressure was brought upon by pharmaceutical companies that his agency had to resist, including entreaties from Senators and Congressional Representative speaking for the drug companies. Indeed, he complained that there were days when he spent up to six hours fending off complaints by pharmaceutical companies.
Some things never change, do they? Then, as now, the FDA is grossly underfunded, outmanned, and outgunned compared to the forces arrayed against it. In the past, it was mainly big pharmaceutical companies, but now it also includes powerful politicians aligned with the health freedom movement, such as Senators Rand Paul and Ron Johnson—to whose ranks have been added Donald Trump and RFK Jr. There’s also another interesting article by Dr. Ley that I came across from 1970, The Doctor, the Patient, and the FDA. In it, Dr. Ley makes no bones about his belief that the FDA needed more funding and was totally correct to crack down on quackery, as it did when it issued public warnings about Hoxsey cancer treatments in the 1950s. Let’s just say that Dr. Ley was anything but an ally of the health freedom movement, his complaints about the FDA and what he had to deal with during his three year tenure as FDA Commissioner notwithstanding.
Onward, however. That additional little deception by RFK Jr. supporters aside, let’s look at RFK Jr.’s claims. Basically, it’s a misrepresentation of what the FDA has done and, of course, the promise of all the things listed. Again, I will start by saying that the FDA has never engaged in suppression, much less “aggressive suppression” of exercise or sunlight that I am aware of. Moreover, as we’ve complained about before, the FDA, if anything, has been far too lax in regulating, for example, quackery involving unproven stem cell treatments for conditions ranging from autism (for which quack clinics have even set up unethical and scientifically dubious pay-to-play clinical trials registered with ClinicalTrials.gov to sell their quackery), to stroke, to cancer. There are even profitable companies marketing stem cell quackery without evidence that it works. Ditto chelation therapy, which has never been shown to work for anything except acute toxicity from heavy metal poisoning and has even been studied for cardiovascular disease in two very expensive and unnecessary (and negative) randomized clinical trials. Let’s also not forget that neither hydroxychloroquine nor ivermectin have been demonstrated to work against COVID-19—quite the contrary, in fact—nor ivermectin shown to be efficacious against cancer. As for raw milk, it has no health benefits greater than pasteurized milk, but it does have produce a much higher risk of food borne infections. (It is, however, “natural,” I guess.)
Of course, nutraceuticals (and vitamins and supplements) are already legal and weakly regulated (if you can call it regulated at all), thanks to the Dietary Supplement Health and Education Act of 1994 (DSHEA), which we’ve written about here many, many times, most recently how it helped conspiracy theorist Alex Jones fund his media empire. Basically, as long as you are vague enough about the health claims for your supplement, nutraceutical, or vitamin concoction, you can sell it to treat almost anything, and the supplement industry has, through its powerful patrons, prevented any strengthening of the law to deal with all the quacks who claim without evidence that their supplements treat disease. On the rare occasions when the FDA does try to crack down on quacks selling unproven or even potentially harmful supplements, the health freedom movement inevitably portrays it as “fascist” or “jack-booted thugs” trying to “suppress” all those “natural” cures.
A field day for quacks if Donald Trump wins and RFK Jr. is put in charge of health policy?
So what would the FDA look like if Trump were to win next week and actually follow through with his appointment of RFK Jr. to a high-ranking health position? The answer illustrates a bit of the dilemma that the “health freedom” movement has, being, as it is, an uncomfortable alliance between crunchy “all natural” health freedom lovers and more hard core libertarians like Nick Gillespie, who believe that the “power of the free market” will “unleash innovation” if only the nasty old FDA were less strict about its standards for pharmaceutical companies. There is an inherent tension there between wanting to be more strict with the “bad” pharmaceutical companies, while approving modalities (or at least much more weakly regulating them) that alternative practitioners want.
On the one hand, MAHA would seem to want to muzzle the FDA with respect to all the quackery listed in RFK Jr.’s post, basically letting quacks do whatever they want with almost anything. Remember, a lot of what is in RFK Jr.’s list are not “natural.” Certainly extracting and isolating stem cells and injecting them into the bloodstream are not “natural,” nor are chelation therapy and hyperbaric oxygen—and especially ivermectin, hydroxychloroquine, peptides, and psychedelics, all of which are manufactured drugs. Again, what “health freedom” really wants is the freedom for quacks to ply their grift without interference from the government.
What will be fascinating to watch is how tensions between the libertarians who believe that big pharma should be unleashed in order to produce “innovation” and cures and the “natural” crunchy crowd and its overwhelming suspicion of anything produced by big pharma will be resolved. Don’t get me wrong, I really don’t want to see RFK Jr. in any sort of official capacity with power over federal health care policy, but, in the unfortunate event that Trump wins and he is appointed HHS Secretary (or, at least, keeps helping Trump pick leaders of the FDA, CDC, and NIH), in particular because his MAHA agenda conflicts with so much of Trump’s other agenda:
RFK’s health mission puts him at odds with Trump’s own track record. As president, Trump heavily subsidized the agricultural industry to alleviate pains he inflicted on farmers with his own tariff policies. His administration peeled back toxic chemical regulations and environmental rules. He undermined school lunch programs and flooded cafeterias with junk food, rejecting the healthy options pioneered by the Barack Obama administration.
The reason is, likely, this:
Being responsive to public opinion doesn’t necessarily make someone smart. It makes them pliable. And perhaps that’s why Kennedy and his followers are willing to take a chance on Trump. They see him as a person who—in his lust for adulation—can be changed or manipulated.
The challenging thing about being around RFK and his crowd is that while their ideas can be hard to take seriously, the underlying concerns they carry are basically unimpeachable: frighteningly high healthcare costs, the murky relationship between pharmaceutical companies and doctors who prescribe their pills, and a very real decline in overall health among the population.
But they are seeking solutions to real problems in the wrong places. Looking into the past won’t save us any more than forgoing your vaccine shots, drinking raw milk, or voting for Trump will.
That is precisely the issue. There are very real concerns about US health policy, but, as is the case with the nostrums RFK Jr. champions for disease and to demonize vaccines, he’s applying policy quackery to address these problems in a way that is inherently self-contradicting. After all, the “free market” contingent of the “health freedom” movement that wants to “unleash innovation” by neutering the FDA is good at manipulation too. I hope we never have to see which faction of the health freedom movement will triumph if there is a second Trump administration. I fear that federal health policy will end up being the worst of both worlds, with far less regulation on big pharma and much laxer standards for drug approval, plus a lot more freedom for quacks to peddle quackery like bogus stem cell therapies, chelation, and “repurposed” ivermectin for everything, while NIH is forced to waste even more money studying useless quackery.
As for a “corrupt system,” no one out-corrupts Donald Trump.

MAHA vs. the FDA: Dredging up old anti-regulation revisionist history
Recently, I’ve noticed articles from outlets aligned with MAHA calling for the elimination of the FDA. It’s all recycled “health freedom” revisionist history and ahistorical nonsense.
David Gorski on May 4, 2026
Link

Ever since the passage of the Kefauver-Harris Amendment, a.k.a. the “Drug Efficacy Amendment,” or Drug Amendments of 1962, to the Federal Food, Drug, and Cosmetic Act in the wake of the thalidomide debacle, the FDA has been mandated to hold to two standards when licensing drugs. It must require evidence that demonstrates convincingly that the drug is (1) safe for its intended use and (2) effective against the disease or symptoms that it is meant to treat. (Before this amendment, as hard as it is to believe, the FDA was only mandated by law to require evidence that a drug was safe before licensing it.) In brief, the amendment required drug manufacturers to submit evidence showing that the drugs they were applying to the FDA to license were safe and effective, expanded Food and Drug Administration (FDA) oversight over drug manufacturers through more rigorous postmarketing surveillance and oversight of manufacturing processes to prevent contamination and assure that what the label said was in a drug was actually in the drug, and set rules for drug advertisements and labels to minimize deceptive advertising. As part of this postmarketing surveillance, drug manufacturers were required to report adverse reactions to new medications to the FDA. Indeed, the Kefauver-Harris Amendment was a driving force in the the development of randomized controlled clinical trials (RCTs), both scientific and ethical, because increasingly after passage of the amendment, the FDA required high-quality RCTs to support applications to license new drugs, until the RCT became the gold standard science required. (Yes, I’m riffing.)
While the FDA has long been a bogey man for quacks and the “health freedom” movement, arguably in 1962 it be came the bogey man, as the Kefauver-Harris Amendment vastly expanded its purview and power. Since then, the conflict between commerce and the desire to bring drugs to market quickly versus FDA regulations and drug approval processes has increased. In addition, the desire on the parts of advocates or sufferers of serious diseases to access promising new therapies quickly versus the FDA’s more conservative mandate to make sure that such drugs are safe and effective before marketing them have frequently clashed, most notably when the AIDS pandemic hit in the 1980s, leading to narratives such as the one in Dallas Buyers’ Club, a movie featuring an inaccurate and highly deceptive plot in which a scrappy underdog with AIDS—played by the charismatic Matthew McConaughey, no less!—defies the FDA to bring unapproved drugs into the country to cure himself and others of the new and deadly disease. Ever since the 1980s, a common narrative coming from the “health freedom” movement—or, as I like to call it, the movement that wants freedom from any pesky laws and regulations governing medicine—has taken up the narrative that the FDA is “keeping cures from the people” through its hidebound insistence on sufficient pesky RCT evidence showing safety and efficacy as a requirement to approve new drugs. Indeed, narratives like this were behind the whole “right-to-try” movement that purported to let patients with terminal illnesses access experimental drugs, as long as they have passed only the lowest bar of evidence, a phase I clinical trial demonstrating safety. The claims of their supporters notwithstanding, these laws have done nothing for such patients.
While there are real and legitimate criticisms of how the FDA regulates drugs, I periodically feel the need to remind our readers that the real goal of the health-freedom movement has always been to weaken, neutralize, or even eliminate the FDA. Right-to-try has been just one tool to achieve this, under the banner of “freedom” and outrageously deceptive arguments by libertarians claiming that, because of how slow the process is to approve drugs, the FDA kills more people than it saves. Lately, I’ve been seeing publications aligned with President Donald Trump’s and Secretary of Health and Human Services Robert F. Kennedy Jr.‘s “make America healthy again” (MAHA) movement dredging up old libertarian tropes, attacks, and lies about the FDA, most recently in an article in Reason by Zach Weissmueller entitled The COVID Reckoning Doesn’t Go Nearly Far Enough. You might think that this isn’t about libertarian tropes about the FDA, but the splash page on social media gives the game away:
The public health establishment lost America's trust during the COVID-19 pandemic with its bureaucratic incompetence, "noble lies," and authoritarian mandates. https://t.co/7q2zZ0jz0x
— reason (@reason) April 24, 2026
Also note the tagline: “Real medical freedom will require something
greater than replacing the public health establishment: ending the
FDA’s monopoly.”
At least not-a-friend-of-the-blog Jeffrey Tucker over at the “free market” (and very antivax) Brownstone Institute was a lot more honest about what MAHA is thinking when he titled his post What if the FDA were eliminated?, a more accurate reflection of libertarian sentiment. Just to tweak your memory, Jeffery Tucker is a far right wing neo-Confederate prone to conspiracy theories about vaccines that rival those of Mike Adams.
Yes, MAHA is recycling old libertarian nonsense that I was writing about in 2014 when Nick Gillespie published an article at The Daily Beast entitled Kill the FDA (Before it Kills Again), not to mention in 2006, when Reason‘s Ronald Bailey just wanted to “suggest that the FDA’s increased obsession with safety may be killing more people than it saves.” More recently, RFK Jr., soon after coining the slogan “make America healthy again” (MAHA), in essence declared war on the FDA. Although he didn’t go nearly as far as Weissmueller, Gillespie, Bailey, and other libertarians have, in calling for its dismantling he did echo many of the same tropes long popular among the “health freedom” movement.
FDA’s war on public health is about to end. This includes its aggressive suppression of psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunshine, exercise, nutraceuticals and anything…
— Robert F. Kennedy Jr (@RobertKennedyJr) October 25, 2024
Notably missing from RFK Jr.’s manifesto is a single example when the
FDA ever “suppressed” vitamins, clean foods, sunshine, or exercise.
Let’s take a look at Weissmueller’s article first, as it wraps this old quack “health freedom” message in a post-COVID wrapper to justify it, and it even abuses Bayesian analysis, a favorite topic of this blog going back to its very inception in 2008.
Zach Weissmueller’s revisionist history of the FDA: “Bayesian analysis proves I’m right.” (It doesn’t.)
Zach Weissmueuller’s article is a marvel of recycling and repackaging “health freedom” tropes in a deceptive way. Basically, it’s revisionist history—not the rigorous, necessary historical revisionism that historians continually engage in as new evidence about the past comes to light, but rather very obviously ideologically motivated historical revisionism designed to demonize public health authorities in general and the FDA in particular.
Unsurprisingly, Weissmueller starts out with what is the now-standard narrative coming from MAHA and the health freedom movement, namely that federal public health authorities at the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH, and the FDA have “lost the public’s trust.” In these narratives, always conveniently missing is the tsunami of misinformation, disinformation, and ideologically-aligned attacks on public health coming from quacks, cranks, and contrarians, aided and abetted by social media algorithms. In any event, here we go (again):
The public health establishment lost America’s trust during the COVID-19 pandemic with its bureaucratic incompetence, “noble lies,” and authoritarian mandates.
It was about time. Agencies like the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have been failing the American public for decades. But the agency with the worst track record is the Food and Drug Administration (FDA), which, long before COVID, caused Americans to lose hundreds of thousands of life years by slowing down drug development. After COVID, the American public had finally started to catch on.
President Donald Trump put a new team in charge of the federal health apparatus, some of them truth-telling contrarians who risked their careers to expose the sins of the old guard. But it’s also a messy picture because the man in charge of Health and Human Services has controversial theories about the dangers of vaccination with little factual basis.
One notes that Weissmueller doesn’t actually specify the specific “noble lies” that the federal public health establishment supposedly told in the early months and years of the pandemic, probably because the vast majority of them were not “lies” unless you were a COVID contrarian, but he does pivot to focus the distrust of federal health agencies that developed during the pandemic to the FDA in particular. Of course, he can’t resist telling a not-so-noble lie of his own in the process, namely his nonsense claim that the FDA has long caused “Americans to lose hundreds of thousands of life years by slowing down drug development,” an evidence-free emotionally charge claim that has long been a staple of the libertarian fringe that wants to eliminate the FDA. The “logic,” such as it is, of this argument is that the power of the free market will lead to the unleashing of creativity and innovation that will bring cheap and highly effective treatments and cures to the people; that is, if you completely ignore history going back to the very founding of the FDA in 1906.
Also, while, I do give Weissmueller credit for at least acknowledging obliquely that RFK Jr. is a raging antivax loon in the gentlest way possible, his admission would be more convincing if he changed the word “controversial” to “dangerous and disproven” and “with little factual basis” to “based on bad science, pseudoscience, and raving conspiracy theories.” Amusingly, while crediting President Trump this time around with empowering cranks whose views he happens to like, euphemistically calling them “truth-telling contrarians who risked their careers to expose the sins of the old guard,” Weissmueller also conveniently forgets that the President during most of the first year of the pandemic was…Donald J. Trump!
Whoever’s in charge of the FDA, however, what Weissmueller wants is this:
Nobody, no matter their integrity or political persuasion, should have the power to decide what you or I put in our bodies. The only way to fix America’s regulatory health care apparatus is to dismantle it. A new guard has replaced the old. The COVID reckoning is here. But it hasn’t gone far enough.
There we go! I’m only surprised that it took him so long to get to the lede!
Over the years, I’ve expressed a little bit of sympathy towards the point of view that people should have the freedom to decide what is put into their bodies. However, I am also a realist, based on long experience and observation of what happens when regulations are too lax or even nonexistent. I also know from that long experience and observation that the “health freedom” movement has always been far less about the freedom of consumers to decide what is put into their bodies than it has been about the freedom of unscrupulous quacks to sell whatever snake oil that they can market those consumers and to use whatever distortions, deceptions, misinformation, and lies that they want in order to persuade them to purchase their nostrums and thereby yield hefty profits.
And here’s where the revisionist history gets super-duper revisionist, this time the history of the Kefauver-Harris Amendment:
The story of an overreaching public health state doesn’t begin with Robert F. Kennedy Jr. or Dr. Anthony Fauci. It begins with a law passed in 1962.
The FDA didn’t always throw up as much red tape as it does today. In its early days, its only job was to sign off on safety. Drug makers would submit safety evidence, and if the agency didn’t object within 60 days, the drug could go to market and be sold right over the counter. Back then, it was the drug company that decided whether to require a doctor’s prescription or not based on liability concerns.
This voluntary arrangement between drug manufacturers, patients, and doctors worked fairly well, says Jeffrey Singer, a practicing surgeon and senior fellow in the Department of Health Policy Studies at the Cato Institute.
“If [the drug manufacturer] thought that their drug was a little too risky and some people could have problems and they’ll get sued, they would say to the pharmacist, we only want our product to be sold to people who have a prescription,” he says.
It was a system based on informed consent and voluntary exchange.
How nice! This view makes me think of a Norman Rockwell painting of a kindly doctor with his patient. (It was always a male back then.) Who could possibly object to a system like this? Hardly anyone would object if what Weissmueller describes were an accurate reflection of the actual system in place before 1962. As I like to say, informed consent requires that accurate scientific information addressing the efficacy versus the risks and safety of a treatment be provided to patients in a dispassionate manner that allows their questions to be addressed. Remember, too, that when the Kefauver-Harris Amendment became law, medicine was still in its longstanding paternalistic era, where “doctor knows best,” and one didn’t question one’s doctor. (Think Dr. James Kildare or Dr. Marcus Welby rather than Dr. Nick Riviera.) Moreover, Weissmueller conveniently neglects the part of the Kefauver-Harris Amendment that empowered the FDA to regulate medical advertising for licensed drugs, specifically requiring accurate information about what is in the drug, adverse events found in clinical trials, and an accurate accounting of the expected efficacy compared to side effects and adverse events. Does he really think that such a provision wouldn’t have been part of the amendment if misleading claims about pharmaceutical products weren’t a problem? Seriously, misleading claims from manufacturers about pharmaceuticals are still a problem.
Also, I’ve discussed Dr. Singer before. Let’s just say that Dr. Singer is a general surgeon. Don’t get me wrong. My base training is as a general surgeon too; that is, before I subspecialized. However, Dr. Singer no detectable significant expertise in these matters beyond standard medical school learning who likes to liken medicine to religion, doctors to priests, and accuse doctors of “scientific gatekeeping.” He’s presented as an expert by Weissmueller, but he is anything but. He is, however, a senior fellow at the Cato Institute and on the Board of Scientific Advisors of the American Council on Science and Health (ACSH). Let’s just say that these groups, like Reason, have a fairly predictable ideology that supports anti-FDA rhetoric, for instance this article by Dr. Singer on the Cato Institute website entitled Abolish the FDA.
But let’s move on:
The economist Milton Friedman described this phenomenon in a 1999 interview with the Hoover Institution. “The pressure on the FDA is always to be late in approving,” Friedman said, “and there is enormous evidence that they have caused more deaths by their late approvals than they have saved by their early approvals.”
Funny, but I perused that interview with Friedman. He doesn’t actually present any evidence to support the claim that the FDA has caused more deaths than through its late approvals than it has saved through early approvals, other than to claim that there is “enormous evidence” for it. Basically, what Friedman is saying is utter bullshit. Really, there is no other word. Not that that stops Weissmueller from continuing:
Cancer researchers calculated that a five-year delay in approving a lung cancer drug with a modest one-percent cure rate would cost 282,000 life-years, while stricter trial regulations would save only 16. University of Chicago economists found that when the FDA did speed up approvals in the early ’90s, faster access saved between 180,000 and 310,000 life-years, compared to 56,000 life-years lost to drugs eventually withdrawn for safety reasons.
The first study from the U. of C. is a modeling study that doesn’t actually demonstrate that anything like what was modeled has actually happened, making it a hypothetical thought experiment rather than useful data. Indeed, the use of loaded language in the article, such as “regulatory fundamentalism,” are the tell that this article is more advocacy and ideology than strictly science:
When patients have poor outcomes or have been misled, regulators and others may be interrogated and censured by congressional committees and may be vilified by the press. “Regulatory fundamentalists,” who followed the exact letter of the regulations, are able to defend themselves by claiming to be faultless because they fully complied with and enforced all regulations. “Regulatory rationalists,” who instead exercised judgment in aiming to fulfill the intent of the regulations while attempting to facilitate progress, are much less able to defend themselves.51 This leads to enrichment of regulatory bodies with fundamentalists and fosters a fundamentalist reinterpretation of the regulations. Institutions, investigators, companies, and regulatory bodies then feel threatened and try to protect themselves from the uncertainty of both current and future fundamentalist reinterpretations of the regulations by taking steps that magnify the impact of the reinterpretations at the local level. This leads to greatly increased compliance rigidity, and this in turn leads to a massive regulatory traffic jam, with increased costs and delays and with decreased innovation and progress.
Or maybe people attracted to regulatory positions tend to be the sort to take their job seriously and actually enforce the regulations. Again, the loaded language tells you where the authors are coming from. What’s interesting to me are the sorts of “solutions” that they propose. Here are a few:
    • Preclinical toxicology: require only LD10 in rodents
    • Preclinical pharmacology: require only cytochrome p450 interactions
    • Permit PI to do protocol override/appropriate modifications without IRB/FDA approval
    • Stop the requirement for rapid reporting of all deviations/violations to IRB and sponsor
    • Accept higher level of risk for lethal diseases than for benign and nonlethal diseases
Of course, we already accept higher levels of risk in the clinical trials used to approve drugs than in benign and nonlethal diseases. That’s why drugs as toxic as chemotherapy can be tested in patients suffering from deadly cancers. As for the rest, these seem…unwise. Toxicity in rodents often maps unreliably to toxicity in humans and there’s more to pharmacology than cytochrome p450 interactions. Don’t get me wrong. There are a number of ways that clinical trial documentation and regulatory burden could be reduced without compromising the safety of patients enrolling in such trials. As one might expect in a study cited by libertarians, what is proposed in this paper goes way too far.
The second article cited is not a scientific study at all, but a 2007 article in Reason by Ronald Bailey. (Funny how Weissmueller seems unable to cite more recent evidence.) Bailey does, however, cite a 2005 study by economists, not medical researchers, published in the National Bureau of Economic Research. Interestingly, this paper doesn’t really directly address what Weissmueller claims. Rather, it looks at what happened after the FDA switched to the Prescription Drug User Fee Acts (PDUFA), which was passed in 1992 empowered the FDA to collect user fees from companies to fund the drug approval process and thereby sped up the drug approval process. (Ironically, it is also the PDUFA that has led to many MAHA types accusing the FDA of regulatory capture because it depends on user fees paid by drug companies for much of its revenue.) In any case, let’s just say that this study is old and has a number of limitations that to me lead me to view it more as very likely confusing correlation with causation. Moreover, Weissmueller failed to cite other data that have shown a correlation between faster drug approvals and increased adverse events, although the data are mixed and other studies show no statistically significant difference before and after PDUFA. Suffice to say that the picture is nowhere near the slam dunk in favor of speeding up drug approvals that Weissmueller argues.
Naturally, Weissmueller lists the litany of usual COVID contrarian complaints about missteps of the FDA during the pandemic, some legitimate, some exaggerated, even including the usual conspiracy theory that the FDA slow-walked the approval of COVID-19 vaccines until after the 2020 election in order to hurt Donald Trump’s chances of winning, even quoting not-a-friend-of-the-blog Dr. Vinay Prasad, who, before he was all about casting doubt on the safety and efficacy of COVID vaccines was all about promoting them because of their potential to stop the hated “lockdowns” and other public health interventions that drove proto-MAHA bonkers during the pandemic. Weissmueller also rather misleadingly quotes friend-of-the-blog and admired science advocate Dr. Paul Offit, who had expressed disagreement with what he considered to be the premature recommendation for a third COVID booster, which was a scientifically arguable point but in Weissmueller’s hands is presented as the most flagrant political interference in FDA decision-making that there could possibly have been.
Of course, medical regulatory agencies and public health officials all over the world were struggling with deciding what to do in the face of a pandemic due to a novel pathogen, and of course mistakes were made. Unfortunately, an honest and science-based acknowledgment of FDA mistakes is not what is happening under the current regime, as we (particularly Dr. Jonathan Howard) have been documenting ever since Trump took office for the second time. Instead, Weissmuller asks:
What if the FDA had run safety tests but had zero involvement in vaccine approval?
Some Americans might have chosen to accept the risk of getting the COVID vaccine early on in the pandemic, before it had been tested. Others might choose to wait years for better data on its effects to surface. We should be allowed to make our own medical decisions based on our risk tolerance, vulnerabilities, and individual health profiles.
Instead, the federal government prevented many of us from trying the vaccine, and then it attempted to coerce many of us into getting it.
This is one of the most brain-dead takes on FDA approval that I’ve ever seen, and I’ve seen a lot of them from libertarians. First of all, to make substantial progress at ending the pandemic, any vaccine would have to be effective, not just safe. Second, Weissmueller seems to forget that vaccine supply was highly constrained when it was first granted an emergency use approval by the FDA in December 2020. With such a constrained supply initially, decisions had to be made regarding who would be eligible for the vaccine first, and it made perfect sense that frontline healthcare workers, staff at long term care facilities such as nursing homes, and first responders should have bee at the front of the line, at least until supplies expanded. I admit that I was very quick to get on the waiting list at my cancer center to get the vaccine and got my first dose in mid-December 2020. Moreover, it was not the FDA that mandated vaccines. The FDA cannot do that. It can only approve or not approve vaccines for certain population groups. Weissmueller is deceptively conflating the FDA with the entire federal government as a means of pulling at truly silly “What if?” out of his nether regions.
The part of Weissmueller’s article that does the most mental gymnastics and contortions, though, is the part where he begins by listing RFK Jr.’s depredations against science as HHS Secretary, including firing the Advisory Committee on Immunization Practices (ACIP) and replacing its members with antivaxxers, but then pivots to approvingly citing Dr. Marty Makary, who is now FDA Commissioner:
He’s also signaled a shift toward Bayesian methods for evaluating drug effectiveness, in which the FDA acknowledges the limits of its own knowledge and acts more like a sports bettor, synthesizing information from many sources to wager on the likelihood that a treatment works for specific patients.
Hint: That is not quite what Bayesian methods do. Indeed, one of our founders, Dr. Kimball Atwood, wrote extensively about Bayesian methods as applied to trials of what was then known as “complementary and alternative medicine” (CAM). The earliest example that I can find is the most detailed as well. It was posted in 2008, a mere month and a half into this blog. First, though, let’s look at what Weissmueller thinks that Bayesian methods are:
Statistician Aaron Brown agrees with Prasad that many studies leading to FDA approval are poor or inconclusive. But Brown says even better clinical trials won’t tell us conclusively how a new drug will perform in the wild. The best approach is Bayesian—let doctors and patients try new drugs, and then we can gradually learn from their effects.
“Frequentists look for decisions,” Brown explains. “Approve the drug, don’t approve the drug. Make everybody get the vaccine. Let nobody take the vaccine. Bayesians want to hand you a list of odds and say, ‘OK, if you take this pill, there’s a 10 percent chance you’ll get cured, a two percent chance it’ll kill you.’ The recent FDA action is primarily directed at Bayesian practice. They wanna bring more Bayesian tools into what is basically a frequentist FDA.”
The Bayesian approach also takes into account the heterogeneity of human physiology. A drug that fails in a broad clinical trial, or that brings outsized risk for one class of patients, might be transformative—or at least worth trying—for another subset of the population.
Brown wonders whether a more Bayesian FDA might have avoided the pitfalls of the one-size-fits-all approach of COVID-era vaccine trials and recommendations.
As you might expect, Aaron Brown is a regular contributor at Reason. He holds an M.B.A. in Finance and Statistics from the University of Chicago and an S.B.in Applied Mathematics from Harvard. As far as I can tell, he has no advanced training or experience in clinical trial design, epidemiology, or other disciplines relevant to making such broad pronouncements about drug regulation. Moreover, as longtime—as in really longtime—readers know, we at SBM—including myself—tend to lean more Bayesian than frequentist, which is why we are able to describe why frequentist trials of homeopathy are not good evidence that homeopathy works. So what’s the problem with making FDA approval more “Bayesian”?
There wouldn’t be a huge problem if it were done correctly, and what Brown describes is anything but. First, he lays down a bunch of straw men, such as “”Approve the drug, don’t approve the drug. Make everybody get the vaccine. Let nobody take the vaccine.” That is an utterly nonsensical description of how the FDA approval process works. Moreover, then Brown states, “Bayesians want to hand you a list of odds and say, ‘OK, if you take this pill, there’s a 10 percent chance you’ll get cured, a two percent chance it’ll kill you.'” Seriously, these are the sorts of discussions that, for example, every oncologist has with cancer patients every day when they discuss whether a patient should undergo adjuvant chemotherapy after curative surgery: This is your chance of relapse and death with chemotherapy. This is your chance of relapse and death without chemotherapy. This is the chance that chemotherapy will make a difference. This is the chance that it will make no difference. This is the chance that you will suffer adverse reactions like X and Y. Based on this, I think it is/isn’t a good idea for you to take the chemotherapy. Seriously, I can tell from Brown’s characterization that he is utterly clueless about how science- and evidence-based medicine is actually practiced. By his own definition, we are Bayesians:
Brown wonders whether a more Bayesian FDA might have avoided the pitfalls of the one-size-fits-all approach of COVID-era vaccine trials and recommendations.
“If the FDA were entirely Bayesian,” he says, “They’d say, ‘OK who needs this [COVID vaccine] the most?’ Old people with risk factors who have high exposure to COVID—they need it the most…it can have a lot of bad effects and it’s still a good deal for them. So we give it to a bunch of them and we watch them very carefully…We’re seeing, how do they feel? When did they take the vaccine? When did they get COVID if they got it? What symptoms did they have? And we do trial and error…We’d never make it mandatory. We just slowly move to [encouraging vaccination], and we let people make their own decision based on their own circumstances.”
Again, this is utterly deceptive. Early on, when vaccine supply was constrained, groups were prioritized in just this manner, with the elderly and those with chronic diseases prioritized because they were most at risk of hospitalization and death from COVID. Brown is deceptively conflating postmarketing surveillance and adjustment of vaccine recommendations by ACIP based on the data thus obtained with the initial RCTs of the vaccine that demonstrated safety and efficacy while making an argument against mandates that his revisionist history doesn’t support. Those RCTs were a starting point, not an endpoint. They were enough to recommend emergency use approval. Then more research was done to fine-tune recommendations, identify adverse events not detected in the initial clinical trials, and calculate more accurate estimates of efficacy and safety, particularly as the virus mutated to evade vaccine-induced (and, always ignored by people like Weissmuller and Brown, post-infection) immunity.
Coming back to Bayesian reasoning, though, as Dr. Atwood described so well, all Bayesian reasoning involves, boiled down to its essence, is that, before a study is done, we estimate, based on the best available existing evidence, the prior probability that the study will show that the therapy has an effect, called P(B). I’ll now quote Dr. Atwood:
We might not know P(B), but it is a constant. Thus on the right side of the equation we can direct our attention to the terms in the numerator, which predict certain things: if the prior probability of a hypothesis is high, it will not require much in the way of confirming data to reassure us of that opinion. If the prior probability of a hypothesis is small, it will require a large amount of credible, confirming data to convince us to take it seriously. If the prior probability is exceedingly small, it will require a massive influx of confirming data to convince us to take it seriously (yes, extraordinary claims really do require extraordinary evidence). The simplest result, albeit one that many find discomfiting, is found if P(A) approaches zero: no amount of “confirming data”—especially of the error-prone sort generated by a clinical trial—should convince us to accept the hypothesis.
P(A) for homeopathy or reiki, for instance, is so small that it fits that last definition.
If you look at prior articles by Brown, you’ll see that he likens the estimation of prior probability that a treatment will work to betting lines on sports betting sites like FanDuel or by prediction markets like Kalshi. While it’s true that there will always be some subjectivity in determining prior probabilities, in Bayesian reasoning we try to come to the best estimate we can, not the seemingly highly subjective guess that Brown implies:
Bayesians accept that a patient’s response to a treatment is not random, just unknown. Bayesians are like bookies. They want to hand patients a list of bets they can make with different payouts—cure, death, unpleasant side effects, no change, etc.—and prices attached. Patients can consult with doctors and other experts to choose good bets based on their own additional information, if any, and their personal preferences. Importantly, the Bayesian statistician considers herself one of the people for whom she gives advice—she bets for herself and her loved ones using the same odds she quotes for the public.
This has little to do with regulation, and, again, where does Brown think that we get these lists of “different payouts” and “prices attached” if not from more frequentist clinical trials?
Of course, to Weissmueller, the real goal has little to do with Bayesian reasoning. Rather, it is this:
The problem isn’t who’s in charge; it’s that anybody is in charge at all. Health care decisions are best left to patients and their doctors.
But the health care system is so complex and interdependent that the entire system needs to be unravelled.
What does that involve? I’m sure you can guess:
Brown says the FDA would do a lot less harm if it filled a purely advisory role, stripped of its power to keep drugs off the market.
“I would love the FDA to decide it was only an informational agency,” he says. “You have to change the goal of the FDA. The goal of FDA is no longer telling people what to do. It’s no longer saying these things are forbidden, these things are required.”
In this scenario, if you want to take drugs that have FDA approval, go right ahead. If you want to try drugs that don’t have FDA approval, have at it. It’s more likely you’d have to pay for them out of pocket, but nobody should have the right to stop you.
Again, this assumes that the patient is a reasonably rational actor (usually true) and that there is no tsunami of misinformation to counter the information provided by the FDA under this scenario, misinformation that even trained scientists and physicians sometimes have difficulty recognizing and rebutting. You and I know how reasonable an assumption that is.
But what about our old friend Jeffrey Tucker?
Quoth Jeffrey Tucker: Abolish the FDA!
Unsurprisingly, Jeffrey Tucker begins his article What If the FDA Were Eliminated? with similar COVID contrarian tropes about the failures of the FDA and public health establishment during COVID, adding his own misinformation about how supposedly “deadly” COVID vaccines were. I won’t bother to quote it directly, as it’s all so tiresome and nothing that I (or any regular readers) haven’t heard a thousand times before. Instead, let’s jump right into what Tucker prescribes:
A worthy thought experiment: how would drug approvals and food safety be managed in the absence of such government agencies? The thesis: the free and competitive marketplace would likely be far more strict and exacting than these government agencies. Private solutions would emerge as the standard bearers of approvals, in a way similar to how the private Underwriters Laboratory (founded 1894) codifies the safety of appliances, the Better Business Bureau (founded 1912) polices fraud in business, and actuaries in many sectors assess and price risk.
Anyone in a free market can sell anything. Doing so profitably over the long term and earning consumer trust is an entirely different matter. Markets have their own way of regulating safety, efficacy, and quality, often in ways that are more strict than government agencies have traditionally permissioned.
I note that Weissmueller alluded to, but did not dwell, on a similar idea in his article:
If Makary makes the drug approval process less stringent, that would be progress, but who knows if the next administration will undo these reforms? He wouldn’t be the first FDA director to try and fail at slashing red tape.
That’s why the better outcome would be for the FDA close up shop and disappear.
As is often the case, Tucker presents a highly biased retelling of the history of the events leading up to Congress passing The Biologics Control Act of 1902, enacted in response to two separate incidents in 1901 involving the deaths of a total of 22 children from vaccines contaminated with tetanus, 13 from a diphtheria antitoxin and 9 due to contaminated smallpox vaccine. Tucker makes much of the history indicating that the manufacturers wanted this law in order to boost public confidence in their products and also because they were afraid that state governments would take over the manufacture of such products. According to Tucker:
Thus did the creation of the agency formed by the Congressional action (the Hygienic Laboratory, part of the Public Health and Marine Hospital Service, under the Treasury Department, and later to become the National Institutes of Health) served to create a private cartel of drug and vaccine manufacturers, crowding out private solutions and disabling the normal market-based rule of caveat emptor or buyer beware.
This is exactly what the biggest players in the industry intended. It was a brilliant strategy. Pretend to be deeply vexed by a government crackdown while pulling the strings behind the scenes of a new agency that the public trusts more than the industry. This was not only the birth of a new path toward public management of this one industry; it was the origin of the regulatory state itself insofar as it intervenes directly in the consumer marketplace.
One wonders if Tucker would have preferred state governments taking over the manufacture of such products. According to him, after the popularity of Upton Sinclair’s novel The Jungle (a book about the meatpacking industry of the time that everyone should read) the passage of the Pure Food and Drug Act of 1906 supposedly followed the same playbook, although Tucker can’t help but make the evidence-free claim that the law resulted in less safe meat, citing an article by himself that doesn’t actually demonstrate that the inspections mandated by law spread bacteria, even though it makes the claim. The regulatory well thus poisoned, Tucker tries to answer his own question regarding what would keep food and drugs safe if there were no FDA. It will surprise no one that he makes the tired old libertarian argument that the magic of the free market will do it:
Now to the original question: what would regulate these industries if the FDA were not around at all? In electronics and business quality, we find the answer. These two industries face strict control emerging organically from consumer demand alone.
Institutions like Underwriters Laboratory and the Better Business Bureau are titans in these sectors with no assistance from government. User ratings emerging in the digital era have a vast impact on sales success, as any Amazon seller can tell you. And in industries like sports, household construction, and driving skill, private insurers exercise a dominant influence through financial carrots and sticks, as directed by actuaries assessing risks.
The very existence of the FDA has crowded out such elaborate and complex systems in the case of food and drugs, which is precisely why their safety and efficacy is the subject of such huge public controversy.
Of course, the rebuttal to such ahistorical nonsense, a delusion so ridiculous that only die-hard libertarians can entertain it as potentially true, is to ask: Why hadn’t such a system arisen organically, thanks to the magic of the free market, before the government passed The Biologics Control Act of 1902 and the Pure Food and Drug Act of 1906? Why hadn’t, as Tucker suggests would happen in a free market, reputational damage due to selling of unsafe products led to vaccine manufacturers and meat packers going out of business, thus demonstrating the lack of a need for these laws? As for the idea that insurers would take up the burden by deciding which drugs they will and won’t reimburse for, this, too is ludicrous, because, after all, where do the data come from upon which insurers base their coverage decisions?
I also like his referring to “user ratings emerging in the digital era,” because it allows me to point you to my previous rebuttal of such nonsense that I wrote in 2017 in response to a potential FDA Commissioner candidate having advocated online reporting systems for drug efficacy and safety that he likened to a “Yelp for drugs.” The CliffsNotes version is that, for products and services like restaurants, rides, or home improvement, it’s very much apparent to the average end user whether the service “worked.” Think about it. Either the meal was good or it wasn’t. Either it was worth the price to the purchaser, or it wasn’t. Either the service was good or it wasn’t. Either the ride showed up on time and got you where you wanted to go at a reasonable price, or it didn’t. Either the home repair company fixed your home’s problem, or it didn’t. People can judge these things without specific special expertise. For drugs and devices, that’s just not so easily done. Whether a drug is working or not is not necessarily obvious to the user (although it can be sometimes). Also, thanks to something we discuss very frequently here at SBM, whether a drug “works” or not also can be affected by patient expectations and placebo effects, hence the need for randomized, double-blind clinical trials, often placebo-controlled. The idea of online user ratings for drugs as a means of verifying efficacy and safety is ludicrous on the surface.
Even Tucker himself can’t answer his own question, but he has a magical faith that the FDA is Evil:
Today there are many efforts on the part of nonprofits working to educate the public on many topics related to individual and public health. They work at cross purposes with these agencies that have worked to foist onto the markets what the market would have otherwise been inclined to either filter out, deprecate, or reject entirely.
Could we do without the FDA? We would likely be far better off.
How does Tucker know this? He doesn’t. He simply expects that his magical mystical all-powerful invisible hand of the free market will do it.
During the height of the pandemic and the rise of antivax disinformation targeting COVID-19 vaccines, I used to like to say that “everything old is new again.” What I meant at the time was very simple. None of the misinformation and conspiracy theories arising to spread fear, uncertainty, and doubt about COVID vaccines was anything new. All the fear mongering antivax narratives about COVID vaccines could be traced back to old antivax disinformation, even the claim that there was “DNA contamination” in the vaccines. Although the margins might change based on specific circumstances and diseases, the core of the false narratives about vaccines never change.
The same is true of the narratives behind the “health freedom” movement. To libertarian “health freedom” warriors like Weissmueller and Tucker, the FDA is always evil and aligned with big pharma. Things would always be better without the FDA, and without the FDA the invisible hand of the free market would come down from on high to magically guarantee that our food, medicines, and vaccines are safe and effective. In reality, it takes some serious revisionist history to make such a deluded argument, as Weissmueller and Tucker demonstrate. The FDA before Trump’s second administration was far from perfect, and there are perfectly reasonable arguments to be had based on science, medicine, economics, and ethics about the appropriate balance between regulatory speed versus drug safety, but that is not what either of these health freedom warriors are offering. Moreover, what history clearly tells us is that, absent reasonable government regulation, all that “health freedom” really means is the freedom of quacks, charlatans, and fraudsters to make money conning the public without pesky government interference, which is clearly what the result of Weissmueller and Tucker’s preferred policies with respect to food and drug regulation would unleash.

The FDA:  Promoting Quack Nostrums Based on “Incredible Stories” While Rejecting Vaccines Despite Successful RCTs
“Vaccines are radioactive now.”
Jonathan Howard on February 13, 2026
Link

“In drug development, lack of regulatory clarity and consistency can be more damaging than regulation itself.”
As wise SBM readers already know, Dr. Vinay Prasad unilaterally overruled apolitical FDA experts, personally deciding the agency would not even review Moderna’s mRNA flu vaccine even though Canada, Australia, and the EU, which includes Denmark, agreed to do so. The vaccine, which can be updated more rapidly than traditional flu vaccines, was studied in two phase 3 studies that enrolled over 43,800 participants at a cost of $750 million. It was 27% more effective at preventing symptomatic flu and 49% more effective against hospitalization than Fluarix, the comparator vaccine and ostensible source of controversy.
According to an article about Dr. Prasad’s edict by STAT:
In the “refusal-to-file” letter, Prasad wrote that the FDA does not consider the study in the application to be “adequate and well-controlled” — the standard for FDA approval under the law — because “your control arm does not reflect the best-available standard of care in the United States at the time of the study.” He added: “I note that this determination is consistent with FDA’s advice given to you prior to your study.”
In its press release, Moderna acknowledged that the FDA told the company the agency would prefer it use a different vaccine — one with a higher dose of influenza antigen targeted at older people, for whom the higher dose vaccines are recommended. But the company reproduced language from the FDA showing the agency had prefaced this request with: “while we agree it would be acceptable to use a licensed standard dose influenza vaccine as the comparator in your Phase 3 study.”
Notably, a recent RCT of 332,438 participants found that “a high-dose inactivated influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard dose among older adults.” Additionally, Moderna ran an immunogenicity trial of people older than 65 comparing their mRNA vaccine against a high-dose egg-based comparator. The mRNA vaccine was safe and resulted in superior inhibition titers.
The STAT article continued:
Stephen Hoge, Moderna’s president, told STAT in an interview that the company decided to compare its vaccine to Fluarix, a licensed vaccine made in chicken eggs by GSK, because that was the licensure path followed by other influenza vaccine-makers. He also pointed out that Moderna wanted to compare its vaccine to a single comparator across the 50-and-up age group, and said that using the high-dose vaccine might have complicated obtaining regulatory clearance in other countries.
The FDA “had previously indicated that it would be acceptable and it was exactly the same approach everyone has used,” Hoge said, adding that the company is “pretty surprised, pretty confused and want to seek an understanding of why has this changed so dramatically from a recommendation to we won’t even review the file.”
“Vaccines are radioactive now”
There is no question that Kennedy, who already decimated funding for mRNA vaccines, will be delighted with Dr. Prasad’s decree, as will top NIH officials Drs. Matthew Memoli and Jeffery Taubenberger, who were recently awarded a non-reviewed $500 million grant to develop a flu vaccine using an inactive virus. 
In contrast, who in their right mind would volunteer for a vaccine RCT today? What company would even bother trying? As Dr. Ruxandra Teslo wrote in her article The FDA Should not Change its Mind Last Minute:
I often say that in drug development, lack of regulatory clarity and consistency can be more damaging than regulation itself. Clear rules, even when stringent, can be understood and navigated. But unclear or constantly shifting expectations can be much harder to efficiently deal with.
That uncertainty doesn’t just slow individual programs, but also reshapes behavior across the biotech ecosystem in a negative way. Lack of regulatory clarity fosters a culture of defensive decision-making, where companies avoid innovative clinical development strategies and default to more conservative, expensive paths simply because they lack confidence in how the FDA might respond. Over time, this dynamic drives up trial costs, prolongs timelines, and ultimately reduces the number of truly innovative therapies that reach patients.
Indeed, even before this latest debacle, Moderna’s CEO said he was cutting back on vaccine trials thanks to MAHA, and responding to the latest news Seth Berkley, former CEO of Gavi, the Vaccine Alliance said:
This is going to change the dynamic, not just for Moderna, but for other vaccine companies. If you’re a manufacturer, now you’re saying, ‘do we know what the rules are?’ Because they changed the goalposts here after a very, very large clinical trial, to all of a sudden say they’re not going to even look at it.
“Vaccines are radioactive now,” said one biotech investor. Despite their professed love of data and evidence, this is the what the EBM gurus and “medical conservatives” delivered to us in the real-world.
“Incredible stories from doctors who have seen dramatic improvement”
While this is all bad enough, it’s worthwhile to remember how the FDA approached Kennedy’s pet autism “cures.” Listen as Dr. Makary says anecdotes alone are sufficient.
Shortly after that interview, the headlines read Largest Leucovorin-Autism Trial Retracted.
This is our FDA today. Quack nostrums get approved based on “incredible stories”, while vaccines get dismissed out of hand despite multiple successful RCTs. Our FDA leaders call this “gold-standard science, transparency and common sense”. At least they are not fooling anyone anymore. Everyone knows it’s anti-vaxx politics all the way down.


Regulating Health Care Products
How should we optimally regulate health care products to protect consumers? A conversation with the Acting Chairman of the FTC.
Steven Novella on February 15, 2017
Link
This week on the SGU we interviewed Maureen Ohlhausen, Acting Chairman of the Federal Trade Commission (FTC). We had an interesting discussion about how that agency should best regulate health care products in the marketplace. The areas of our agreement and disagreement were extremely interesting, and illuminate some of the challenges we face in promoting science-based medicine.
The FTC
The interview was partly inspired by a recent FTC decision regarding the regulation of homeopathic products. We were generally pleased with the decision, which essentially would tighten up the labeling on homeopathic products, requiring evidence to support efficacy claims. Here is a key component of the decision that we discussed during the interview:
However, the policy statement also notes that “the FTC has long recognized that marketing claims may include additional explanatory information to prevent the claims from being misleading. Accordingly, it recognizes that an OTC homeopathic drug claim that is not substantiated by competent and reliable scientific evidence might not be deceptive if the advertisement or label where it appears effectively communicates that: 1) there is no scientific evidence that the product works; and 2) the product’s claims are based only on theories of homeopathy from the 1700s that are not accepted by most modern medical experts.
During the interview Ohlhausen explained her basic philosophy, which is evident in the decision. First, one of the basic missions of the FTC is to protect the consumer from fraud and deception in the marketplace. She feels this goal should be accomplished first through market forces, and that regulation should avoid as much as possible reducing consumer choice. She does not want to take choices away from consumers, just give them all the information they need to make informed choices. If they still choose to purchase nonsense, then it’s on them.
She also pointed out that the FTC is not the only actor in this space, and that its mandate is limited. The FTC cannot remove products from the market, for example. Obviously the FDA has more authority in this area (which is why we anxiously await the FDA’s decision about its own regulation of homeopathy).
The SBM view
This is more my personal view, but it is the one that has been consistently articulated on SBM by me and others. I completely understand the FTC position, given their mandate and limitations. Some of my concerns also may be more appropriate for the FDA. Further, some changes to regulation would need to happen at the level of Congress passing new laws (such as removing or amending the Dietary Supplement Health and Education Act).
The major premise of Ohlhausen’s position is that more choice is always better for the consumer. Tied to this is the notion of free speech as far as it extends to commercial speech. Therefore, marketers have the right to put out information as long as that information is not misleading, and consumers should have the right to make their own decisions based on that information. That is a perfectly reasonable position, but it has limits. The real question is – what are or should be those limits?
Ohlhausen believes that of primary concern are the inherent safety of the products in question, and the seriousness of the illness they are intended to treat. These are reasonable factors to consider when prioritizing limited resources. What this means, however, is that if the product itself is inherently safe (not directly harmful) and it is marketed to symptoms or self-limited illness, then regulatory agencies should err on the side of “regulatory humility” and let the free market sort it out. Their role is limited to making sure no fraudulent or misleading claims are made.
Further, she says, in areas where the scientific evidence is limited or preliminary, marketers should be given some leeway to base claims on preliminary evidence. If we require too much evidence then we effectively make it impossible for the sellers of unpatentable products to fund the research.
I disagree on three major points: that the only important way to deceive the consumer is through packaging or direct marketing claims, that the only harm worth considering is direct toxic harm, and that we should give leeway to preliminary scientific findings.
Let me start with the point about giving leeway to products that are not inherently unsafe or intended for very serious illness. There is a tremendous amount of indirect harm from health products that are not directly toxic but are essentially worthless. There is financial harm (which the FTC recognizes as sufficient to trigger regulation), there is psychological harm (such as false hope), and there is downstream harm.
The downstream harm is difficult to quantify, but we see it all the time. One common scenario is this – a consumer purchases a homeopathic product for a self-limiting illness, like a cold. There is no possible benefit from the product, but the consumer is convinced it worked because of placebo effects and other psychological effects (such as wanting to believe they did not waste their money, or convincing their skeptical relatives who thought their purchase was silly). The consumer is now convinced that homeopathy works. That, in my opinion, is harm.
They are partly convinced because society allows homeopathic products to be packaged as if they are real medicine, with names and claims that imply that they are real medicine. They are sold in pharmacies alongside real medicine. The products are afforded the trappings of legitimacy. This also contributes to placebo effects.
Because of all this, when the hypothetical consumer eventually develops a serious illness, they will be more inclined to seek treatment from a practitioner of homeopathy. That is a choice that may cost them their life. That is harm that was contributed to by the lax regulation of homeopathic products. I don’t think that this connection is too tenuous to influence our regulatory policy.
If we look at the big picture, society is being harmed by increasing acceptance of loose scientific standards in health care specifically designed to allow for dubious products and practices. The consumer is being harmed by this, and each piece of lax regulation contributes to the overall phenomenon. This phenomenon includes convincing the public (and even many scientists and practitioners) that placebo effects alone justify a treatment, that anecdotes are useful, that unblinded studies can determine efficacy, and that certain special magical kinds of treatments cannot be tested by standard scientific methods. The alternative medicine phenomenon is playing off of and contributing to public scientific illiteracy. There is therefore also societal harm, which further includes wasting tremendous resources researching, regulating, and purchasing treatments that cannot possibly work.
This brings me to the next point, that the consumer is only deceived through direct claims made on packaging or advertising. Ohlhausen claims that if the consumer truly understands what homeopathy is, that it is based on 18th century science and its claims are not accepted by modern scientists, then they are not being deceived. I think very few consumers would fit into this category.
Every single patient and member of the public I have ever spoken to on the topic of homeopathy (excluding people I meet at skeptical events) does not have a functional understanding of what homeopathy is. Most think it is herbal medicine, or make a vague reference to “natural” medicine. Many are surprised and even disbelieving when I explain to them what the ingredients are and that it doesn’t matter because they are usually diluted out of existence. “That can’t be right,” is a common response, “because they sell it in the pharmacy.”
The point here is that homeopathic products do not exist in isolation. They have to be put into context. This may be a tall order for an agency like the FTC, but I think it should inform their regulatory decisions (again, maybe this needs to be fixed at the Congressional level). This context includes homeopaths who, as we speak, are promoting homeopathic potions to HIV patients in Africa, and recommending homeopathic nosodes instead of vaccines. Some homeopaths do treat serious illnesses, and products sold for cold symptoms are their foot in the door.
It is no coincidence that the public is massively misinformed about the true nature of homeopathy. Often they are described as using “small” doses, which is not true – they typically use nonexistent doses. There is a big difference between a small dose and zero dose.
Therefore, should the OTC homeopathic product industry be responsible for the overall homeopathy industry, including the misleading claims and deceptions that produce a public who generally does not know what homeopathy is? Is this cultural deception going to be fixed by a brief disclaimer on homeopathic product packaging?
Generally regulatory agencies recognize that if a company or industry creates a demand for their product through misleading claims, they are not entitled to benefit from the demand they fraudulently created, even if they are no longer making misleading claims on their packaging. I think this principle applies here. I don’t think we can tease apart all the various elements that contributed to common misconceptions about homeopathy. The entire industry is based on deception.
I would further argue that there is no possible benefit to the public from the availability of homeopathic products. There is no scenario in which the consumer is not harmed (even just by financial harm). Shouldn’t agencies like the FTC be able to consider these meta-questions – is the industry itself even legitimate? I don’t see the harm to consumers by taking this choice away from them. “Regulatory humility” is not relevant here, because there is no scientific doubt about this question. We are as certain as we can be that homeopathy cannot possibly work, and that it in fact does not work.
The final point is more nuance – how should we deal with preliminary evidence? Ohlhausen’s view is that, since there may be benefit to a product, the public has the right to know about that benefit, even before we have rock solid scientific evidence. Specifically, we should not use the same threshold we have for prescription drugs for things like food or supplements.
That latter point is valid, but more context is required here. For me an important question to ask is this – what are the odds that the preliminary evidence will turn out to be true? We can further look at it this way – what is the net harm vs benefit to the consumer by allowing marketing based on preliminary scientific evidence? There is also the smaller related point, should the marketers be the ones to make those claims to the public?
There is no easy answer to the question of how many preliminary health claims will turn out to be true, but we have spent years here at SBM examining that question. It is one of the core questions for SBM – where should the threshold for scientific evidence be placed so that we can be reasonably sure that claims are reliable? What is sufficient evidence to recommend a treatment?
The full answer is complex, but the simple summary is this – a lot higher than it currently is. There is no one article I can link you to that does a sufficient job of summarizing this topic, there are dozens of articles spread throughout SBM that address different aspects of this question. We know that most preliminary scientific studies will turn out to be wrong. There is a huge problem in science with p-hacking and with lack of reproducibility. There is a bias towards false positives, which is significantly higher in industry-funded studies.
If you combine all these factors together you come to the conclusion that any given health claim based on preliminary industry-funded research is almost certainly biased toward the industry and likely will not pan out. Those are precisely the claims that Ohlhausen thinks should be given leeway.
The net effect to the consumer, therefore, seems to be massively negative. I suspect that the net health effect of the entire OTC supplement industry (so I am not including supplements prescribed by doctors based upon valid evidence) on the public is negative. We are spending billions of dollars for no benefit, or a net negative health effect.
There is a proper balance somewhere, but I don’t think we are even close right now on supplements. We worry too much about delaying the marketing of a product that will eventually be vindicated, and not enough about the many, many more products that are worthless or even a little harmful that are being prematurely marketed to the public.
At the very least we need to come up with a much better way to communicate the current status of the science to the public. Maybe we need to have an easy-to-understand grading system for scientific evidence. Something like – based upon current scientific evidence there is a very low probability that this claim will turn out to be true.
Right now the regulation is binary – we either allow the claim or we don’t. We are therefore stuck forever in the false-positive vs false-negative debate. While I think it is clear right now we need to shift massively toward avoiding false positives, and perhaps we also need to get away from this binary system.
I think overall the FTC is moving in the right direction. I would simply go a lot further. We need a vigorous and evidence-based national discussion on this issue.

Patient Beware: Off-label drug promotion by pharmaceutical companies
Jann Bellamy on March 3, 2016
Link


Pharmaceutical companies and their sales reps can distribute information, such as medical journal articles, about unapproved (“off-label“) uses of their drugs as long as they adhere to FDA guidelines. However, the FDA takes the position that this information must be distributed separately from information that is “promotional in nature,” i.e., for marketing purposes, a position that is now open to question.
Off-label promotion of a drug for a use that has not been approved by the FDA is, in the FDA’s view, a violation of the federal Food, Drug & Cosmetic Act (FDC Act). It is subject to criminal prosecution, because promoting a drug for new, unapproved uses is evidence of an intent that the drug be used before it has gone through the extensive process of clinical trials and a review of the evidence of safety and efficacy by a panel of experts, as required by law before a drug can be marketed. Thus, off-label promotion is seen as an end-run around the approval process that perverts the purpose of the FDC Act, which is to protect the public from ineffective and unsafe drugs.
Studies show that personal sales visits to physicians by pharmaceutical reps (called “detailing”) drives prescriptions in favor of the drugs being promoted. This is true even though physicians’ view of detailing ranges from neutral to highly negative, a “necessary evil,” and physicians are aware of potential conflicts of interest these visits precipitate.
While there are restrictions on off-label promotion, off-label prescribing by a physician is not illegal. Physician practice is regulated by the states and not within the jurisdiction of the FDA. In fact, off-label prescribing is considered both ethical and within the standard of care in appropriate circumstances. (I am currently taking a drug for an off-label use, and was informed of this, plus the risks and benefits, by my physician prior to his prescribing it.) It is also common, according to an article by law professors Ryan Abbot and Ian Ayers in the Duke Law Journal, which is well worth reading:
for the 3 leading drugs in each of the 15 leading drug classes, off-label use accounts for approximately 21% of prescriptions. Moreover, off-label uses may be the norm in some areas of practice, such as oncology, pain management, and palliative care, and in some patient populations, such as children, the elderly, and the severely ill. For example, about 80 percent of all drug prescriptions for children are off-label, and between 80 and 90 percent of all drug prescriptions for rare diseases are off-label. [Footnotes omitted.]
As Abbott and Ayers explain, and as one might expect, evidence of safety and efficacy for off-label use is sometimes lacking. One estimate is that about 15% of all off-label drug uses lack scientific support for efficacy and over 70% lack significant scientific support. A 2008 study estimated that 67% of children treated with antipsychotic drugs were prescribed off-label treatments with an “uncertain” evidence base.
Patients do not seem to be aware of these facts. In a 2006 poll of the American public, about half of the respondents believed doctors were allowed to prescribe only for approved uses, and about half believed doctors should be prohibited from off-label prescribing.
In particular cases, an off-label drug may be the patient’s only option. Some drugs have a long history of safe and effective use and are supported by good evidence, including controlled clinical trials. And there are resources available to physicians that evaluate and disseminate evidence supporting off-label use, such as the American Hospital Formulary Service Drug Information. However, one review of compendia governing off-label oncological uses concluded that they were “lacking in consistency, quality, transparency and timeliness.”
In sum, FDA prohibitions on off-label promotion attempt to preserve the original purpose of the FDC Act, which is to protect the public health by requiring good evidence of safety and efficacy before a drug can be marketed for a particular use. Distribution of journal articles and like information to physicians by pharmaceutical companies is permitted, with the realization that off-label prescribing can be beneficial to patients, as long as the companies refrain from actively selling the physician on an off-label use.
The Caronia case
Into this somewhat delicate balance, the U.S. Court of Appeals for the Second Circuit dropped a bombshell of a decision that threatens to undermine the entire drug regulatory scheme, United States v. Caronia. Or maybe not so much, depending upon whom you ask. What is certain is that the effect of the decision is still being sorted out, with the FDA yet to issue new guidance on off-label promotion. The decision is also an exemplar of the expanding First Amendment protection of commercial speech by the federal courts.
Orphan Medical sales representative Alfred Caronia promoted the brand-name drug Xyrem to physicians. Xyrem is sodium oxybate. The active ingredient is gamma hydrooxybutyrate (GHB), also known as the “date rape” recreational drug. Xyrem was approved by the FDA in 2002 for use in narcolepsy with severe cataplexy, a rare clinical condition.
Another Orphan sales rep told the government that the company decided to start promoting Xyrem off-label to increase revenue and encouraged reps to market off-label uses to physicians, including those who were unlikely to see patients with narcolepsy. The U.S. Department of Justice began an investigation. A physician cooperating in the investigation wore a wire and recorded Caronia suggesting, without any prompting, that Xyrem was effective for a range of conditions, including insomnia, fibromyalgia, restless leg syndrome, chronic pain, Parkinson’s disease, and MS. Caronia also told the physician that the drug could safely be used in elderly and pediatric patients, although the FDA-approved labeling stated the drug had not been tested in these patients.
Caronia, Orphan Medical and a psychiatrist, who was assisting the company in this scheme, were prosecuted for conspiracy to introduce a misbranded drug into interstate commerce. The company pled guilty and paid civil and criminal fines of about $27 million. Caronia, however, did not enter a plea, went to trial, and was convicted.
Drug promotion is protected “commercial speech” under the First Amendment, as interpreted by the Supreme Court. (More on this later.) Thus, the implications of convicting Caronia for what was assumed to be truthful speech (more on that later also) were considered by the trial judge and rejected. The judge reasoned that
constraining the marketing options of manufacturers is one of the ‘few mechanisms available’ to the FDA to ensure that manufacturers will not seek approval for only certain limited uses of drugs, then promote that same drug for off-label uses, effectively circumventing the FDA’s new drug requirements. [citation omitted.]
The court looked at whether the FDA could employ non-speech restrictions that would serve the same purpose of ensuring the integrity of the new drug process and found that no such alternatives could be identified.
On appeal, Caronia argued that the government could not criminalize his speech, as long as his promotion of Xyrem was truthful and non-misleading. The U.S. Court of Appeals for the Second Circuit agreed, in a 2-1 decision. The government argued that it wasn’t prosecuting Caronia for his speech at all, rather it was merely using his speech as evidence of his intent to commit a crime, but that view was rejected by the appellate court.
At this point, some high-priced legal talent stepped in to assist Caronia’s criminal defense attorney on appeal. The Medical Information Working Group, a coalition of drug manufacturers represented by both Ropes & Gray and Sidley Austin, filed an amicus brief on behalf of Coronia. The Washington Legal Foundation, founded, in part, to “fight activist lawyers, regulators, and intrusive government agencies at the federal and state levels, in the courts and regulatory agencies across the country” also filed an amicus brief, represented by Jones Day. Obviously, it would be worth a great deal to the pharmaceutical industry to be rid of the prohibition on off-label promotion.
As mentioned, Albert Caronia’s speech (that is, his sales pitch) was protected by the First Amendment as “commercial speech,” an interesting concept. For about 200 years of First Amendment jurisprudence, commercial speech, such as advertising and sales promotion, was not considered protected at all. It was not until the 1970s that the Supreme Court decided commercial speech deserved some level of First Amendment protection, although not at the same level as political or social speech. In a 1980 case, Central Hudson, the Supreme Court developed a framework for evaluating commercial speech restrictions under the First Amendment. This framework is succinctly explained in an excellent article discussing Caronia authored by Aaron S. Kesselheim, M.D., J.D., M.P.H., and Michelle M. Mello, J.D., Ph.D., appearing in the North Carolina Law Review.
First, was the speech false or misleading, or did it concern unlawful activity? If so, the speech deserves no protection. Second, is the government’s interest in regulating the speech substantial? Third, does the regulation directly and materially advance the government’s interest? Finally, is the regulation narrowly tailored, meaning, no more extensive than necessary to serve that interest?
Unfortunately, because the government was using Caronia’s speech only as evidence of intent (even though the court said it wasn’t), it had no incentive to put on any evidence regarding the truthfulness of his speech at trial. (Although I have not researched the issue, I tend to doubt there is good evidence that Xyrem is safe and effective for all of the uses and all of the patient populations he claimed during his recorded conversation with the physician.)
Thus, on appeal, the court assumed the information was truthful. However, it noted, correctly, that the First Amendment protects only truthful and non-misleading speech, leaving open the possibility that, in future cases, the government could, in the court’s view, constitutionally prosecute a sales rep’s off-label promotion if it could show that the information given the physician was untruthful or misleading. A remaining question is whether off-label promotion is per se illegal anymore, even if the government makes it absolutely clear at trial that the rep’s speech is only being used as evidence of intent. We’ll return to that question at the end of this post.
The court recognized that the FDA certainly had a substantial interest in preventing off-label promotion: “preserving the efficacy and integrity of the FDA’s drug approval process and reducing patient exposure to unsafe and ineffective drugs.” The court then turned to the third and fourth prongs of the Central Hudson test and found that the FDA failed on both. It is here that the ruling is most disturbing.
The court decided that, far from advancing the FDA’s interest in public protection, the FDA was “paternalistically” interfering with information being given to physicians, a skilled and sophisticated audience, in the court’s view, who could more than adequately determine the usefulness of the sales rep’s information. With this information in hand, the court opined, physicians could actually serve the public interest by making sure “that decisions about the use of prescription drugs, including off-label usage, are intelligent and well-informed.”
As to the fourth Central Hudson prong, the court determined that restricting off-label promotion was overly broad because other means could achieve the same goal without interfering with protected speech. How? By educating physicians and patients to distinguish between “misleading and false promotion, exaggerations and embellishments, and truthful or non-misleading information,” require off-label use disclaimers, limit the number of off-label prescriptions, and warn physicians about tort liability from adverse outcomes due to off-label uses.
The government did not ask for a rehearing in front of the full Second Circuit Court of Appeals, nor did it petition the U.S. Supreme Court to hear the case, perhaps because it wanted to contain the damage and not risk, in the case of an adverse Supreme Court decision, nationwide impact.
One of the cases the court relied on in reaching its decision was Thompson v. Western States Medical Center, a case that should serve as a cautionary tale for courts looking to second guess the FDA’s regulatory scheme. In 2002, in Western States, the Supreme Court struck down a prohibition on advertising by compounding pharmacies. The FDA viewed the prohibition as recognition of the useful services compounding pharmacies could provide in local communities, regulated by the states and without federal oversight. At the same time, by prohibiting advertising, these pharmacies would be restrained from growing too big and essentially turning themselves into unregulated large-scale drug manufacturers.
With FDA regulation out of the way, that is exactly what happened. Many compounding pharmacies scaled up. One of these was a Massachusetts compounding pharmacy that manufactured, and extensively advertised, steroid injections. A decade after the Western States decision, these injections ended up sickening hundreds and killing dozens of people from fungal infections due to unsafe compounding practices.
Criticism of Caronia
The Caronia decision has garnered a good deal of criticism, according to an essay by law professor Christopher Robertson, J.D., Ph.D.:
Opinion leaders and scientific journal editors have expressed concern about the Caronia decision and the trend that it extends, as the latest in a wave of litigation and scholarship calling into question the constitutionality of FDA’s regulatory regime. The head of the Cleveland Clinic called the legitimation of off-label promotion ‘a potential catastrophe for patients.’ . . . Scholars are already predicting that, if it gets such a case, ‘the Supreme Court will find the FDA’s current regulatory scheme unconstitutional.’
This criticism starts in the case itself, in the dissent of one member of the three-judge panel, Judge Debra Ann Livingston. She viewed the majority’s opinion as “call[ing] into question the very foundations of our century-old system of drug regulation.” The majority, she said, would allow “any substance that may be legally sold for some purpose [to] be promoted by its manufacturer for any purpose – so long as the manufacturer’s statements are merely unsubstantiated, rather than demonstrably false or misleading.”
Kesselheim and Mello echo this criticism:
The decision appears to pave the way for medical product companies to conduct poor-quality studies for the purpose of showing products’ utility for unapproved indications. There is no need for companies to design these studies to meet the FDA’s standards for methodological rigor if the companies have no intention of submitting an application for approval of the new use but rather intend to use the study findings only in marketing communications. Companies can design studies in ways that maximize the chances of obtaining a desired result and select which studies to emphasize in promotional communications, ignoring others that do not support their promotional message.
Indeed, pharmaceutical companies would do well to borrow from the CAM playbook in constructing and interpreting studies. Here at SBM, we’ve documented the numerous ways one can play with the evidence to produce a desired result. For example, one can bury the damning results in a lot of noise. The study can be spun to suit one’s purposes. One can twist a negative study into a positive one by moving the goalposts on the study’s objectives and using fetching charts calibrated to make the results look good. Or, just do bad studies, as has been demonstrated time and again with acupuncture. And, as a last resort, there is always outright fraud, Andrew Wakefield-style.
With all due respect, I wouldn’t be so sanguine about physicians’ abilities to sort out all the evidence and come to the right conclusion. First, who has the time? Second, again turning to CAM as an example, the embrace of “integrative medicine” leaves one wondering if evaluating the evidence is within the skill set of a certain number of physicians. Although for entirely different reasons, Kesselheim and Mello are with me on this one: “courts have had greater confidence than is warranted in physicians’ ability to evaluate claims about off-label uses.”
Finally, in light of our experience with dietary supplements, it is wishful thinking to assume that educating physicians and patients to distinguish between “misleading and false promotion, exaggerations and embellishments, and truthful or non-misleading information,” is an achievable goal, or that disclaimers will protect the public.
Patient beware
The FDA has not officially changed its position that off-label promotion is a violation of the FDC Act, although the pharmaceutical industry is trying mightily to push it in that direction. The government is still prosecuting off-label promotion cases. Perhaps the FDA does not agree with critics of the Caronia decision that its ability to regulate drugs has been seriously undermined. At least one law firm representing drug companies warns against a hasty interpretation that Caronia is a get-out-of-jail-free card. It will likely take several years to sort all of this out.
In the meantime, patients should be aware that off-label prescribing is not unusual and that it is sometimes based on insufficient evidence, a problem that some experts think could be exacerbated by more liberal sales promotion practices. Patients have every right to ask their physicians the circumstances of his or her prescribing a drug and the evidence for doing so.

The Amarin case: off-label promotion and a double standard for prescription drugs vs. dietary supplements
Jann Bellamy on October 15, 2015
Link
A recent court decision enjoined the FDA from threatening prosecution against a drug manufacturer for off-label promotion of a prescription drug. Based on this and an earlier decision by an appellate court, it appears that the FDA can no longer prosecute a pharmaceutical manufacturer for a truthful and non-misleading off-label promotion to health care professionals, at least within the jurisdiction of the United States Court of Appeal for the Second Circuit, which covers Connecticut, New York and Vermont.
For this reason, the case, Amarin Pharma, Inc. v. FDA (Amarin), received a good deal of attention in the world of drug regulation. (Here is an excellent analysis by two attorneys who practice in the area of drug regulation.) First, we’ll take a look at the issue of off-label promotion. Then we’ll look at an issue that really didn’t engender much comment, but that I find fascinating: how the same substance can be subject to very different regulatory treatment, depending on whether it is sold as a dietary supplement or prescription drug.
Background: Initial approval of Vascepa and subsequent research
In 2012, the pharmaceutical manufacturer Amarin received FDA approval for a new drug, Vascepa, as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (triglycerides ≥ 500mg/dL). Approval was based on a single phase 3 clinical trial.
Following that approval, Amarin designed a second single phase 3 clinical trial to look at the effect of Vascepa on triglyceride levels among statin-treated patients with persistently high triglycerides (≥ 200 and ≤ 500 mg/dL). Pursuant to an agreement with the FDA that, if it met certain conditions, Vascepa would obtain approval for this use, Amarin proceeded with an FDA-approved protocol. As a further condition of the agreement, it also began enrolling patients in a third trial to see if Vascepa actually reduced major cardiac events.
The second trial showed that Vascepa did decrease triglyceride levels, and Amarin thought it had fulfilled the agreement’s requirements for approval. However, the FDA convened an advisory panel and called into question the clinical validity of the reduction in triglycerides achieved in the second trial. That is, the FDA questioned whether that result would translate into an actual reduction in cardiac events. This was based on other research indicating, according to the FDA, that indeed it did not. This research did not include the third trial’s results, designed to answer this very question, because that trial won’t be completed until 2017.
The FDA rescinded its agreement, did not approve Vascepa’s use for patients with persistently high triglycerides, and notified Amarin that any effort to market Vascepa for this unapproved use could constitute misbranding under the Food, Drug, and Cosmetic Act (FDCA).
I’ll see you in court
What happened next gives one the impression that the FDA’s actions really frosted Amarin. Instead of waiting for the FDA to come after it for promoting off-label use, it hauled the FDA into court and asked the judge for a preliminary injunction preventing the agency from taking any action against the company for truthful, non-misleading promotion of Vascepa to health care professionals for patients with persistently high triglycerides. And it won.
By now you might be wondering: what, exactly, is in this Vascepa? It’s fish oil. Or, if you’re a stickler for details, it is, according to the FDA:
icosapent ethyl or ethyl-eicosapentaenoic acid (EPA). . . The drug substance, icosapent ethyl, is a long-chain, polyunsaturated omega-3 fatty acid ester derived from fish oil.
The recommended daily dose for treatment of severe hypertriglyceridemia is 4 grams daily.
Off-label prescribing is not per se illegal, although a physician can get into trouble if he falls below the standard of care. And, because the FDA doesn’t regulate doctors (the states do that), it can’t prevent it. Actually, the FDA doesn’t disapprove of what it sees as responsible off-label use. The FDA’s concern is with off-label promotion by pharmaceutical companies, and it has taken the position that such promotion violates the Food, Drug and Cosmetic Act, even though there is no such proscription in the Act itself. It does so by reasoning that off-label promotion amounts to “misbranding” the drug.
The FDA has backed off this absolute position in the last decade, and issued draft guidance on the circumstances under which truthful information about an off-label use can be distributed. This includes, for example, distribution of journal articles and medical texts that include information on unapproved uses. As with all draft guidance, it is not binding on the FDA or anyone else.
The court’s opinion has some interesting statistics on the ubiquity of off-label prescribing:
    • The most comprehensive study on off-label prescriptions in the United States, conducted in 2001, found that approximately 21% of prescriptions were for off-label purposes.
    • According to a 2000-2006 study, more than 90% of antidepressants prescribed to children and adolescents in an outpatient care setting were for off-label purposes.
    • Based on review of Veterans Affairs databases, more than 60% of prescriptions of antipsychotic drugs in 2007 were for off-label use.
    • A study of medication orders for 414 patients in 37 intensive care units across nation showed that more than 35% were for an off-label purpose and that 97% of patients received at least one off-label medication.
Not included was the fact that the vast majority of prescriptions for fish-oil drugs are off-label, including an estimated 75% of a competitor’s prescriptions.
In ruling on Amarin’s request for a preliminary injunction, the district court had to decide whether it was likely Amarin could ultimately succeed on the merits of its case. This, in turn, required the court to address whether the FDA could prevent Amarin from promoting off-label use of Vascepa for patients with persistently high triglycerides, even when the information was truthful and not misleading. Relying heavily on a decision of Second Circuit Court of Appeals, United States v. Coronia, the court held that the FDA could not constitutionally prevent Amarin from:
engag[ing] in truthful and non-misleading speech promoting the off-label use of Vascepa, i.e., to treat patients with persistently high triglycerides, and under Coronia, such speech may not form the basis of a prosecution for misbranding.
In Coronia, the government criminally prosecuted a drug rep for off-label promotion but the appellate court overturned his conviction. The Second Circuit first decided that:
‘[s]peech in aid of pharmaceutical marketing . . . is a form of expression protected by the . . . First Amendment’ . . . It then applied to such speech truthfully promoting off-label drug use the four-prong test of [the U.S. Supreme Court’s decision in] Central Hudson, used to determine a restriction upon commercial speech violates the First Amendment.
We won’t go through the entire Central Hudson analysis here, but it’s worth noting that while the court recognized that the FDA has a legitimate interest in protecting the integrity of the FDCA drug approval process, it had chosen means (a criminal prosecution) that was broader than necessary to achieve that goal, that off-label promotion is not per se illegal, and the FDA’s ban:
‘paternalistically’ interferes with the ability of physicians and patients to receive potentially relevant treatment information.
Although the FDA tried to distinguish Coronia, the district court didn’t buy it. If anything, the FDA’s position in Amarin was even weaker than in Coronia. It was threatening to go after Amarin for telling physicians the results of a clinical trial that the FDA itself had approved and whose results the FDA didn’t dispute. And, as the court pointed out, if the FDA didn’t like the Coronia decision, it should have sought rehearing or review by the U.S. Supreme Court. Now, it is stuck with the decision, like it or not.
At some point in this imbroglio, the FDA backed off a bit, and the parties tried to reach an agreement on what representations about off-label use of Vascepa could, and could not, make. (Actually, at the end, they weren’t that far apart.) Having decided the FDA could not constitutionally prohibit truthful promotion, the court proceeded to settle this dispute for them.
Which brings us to dietary supplements
As you may recall, unlike drugs, there is no pre-market approval of dietary supplements by the FDA. Supplement manufacturers are supposed to have evidence backing up their “structure and function” claims, but they don’t have to show their evidence to the FDA or the public. However, under the Nutrition Labeling and Education Act of 1990, dietary supplements can also make “qualified health claims” if the FDA:
determines based on the totality of the publicly available evidence (including evidence from well-designed studies conducted in a manner which is consistent with generally recognized scientific procedures and principles), that there is significant scientific agreement among experts qualified by scientific training and experience to evaluate such claims, that the claim is supported by such evidence.
Fish oil is sold as a dietary supplement and, like Vascepa, is promoted for its ability to reduce triglycerides. But the connection between high triglycerides and cardiovascular risk is not yet fully understood. (The full document is behind a paywall, but Scott Gavura helpfully provided me with some of its information on fish oil.)
Although the contribution of triglycerides to cardiovascular risk has been debated in the past, it now seems clear that elevated triglyceride levels are independently associated with cardiovascular risk, particularly coronary risk. It remains uncertain, however, whether this association is causal, such that hypertriglyceridemia, independent of associated lipoprotein, inflammatory and hemostatic abnormalities, causes atherosclerosis. It is also uncertain whether lowering triglyceride levels reduces risk.
This is the very concern that, according to the FDA, led it to renege on its agreement with Amarin.
Yet, the FDA permits fish oil dietary supplements to make the following “qualified health claim”:
Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.
Which is, as noted above, true. But:
Active omega-3 fatty acids constitute only 30 to 50 percent of many fish oil supplements. In comparison, a commercial preparation (Lovaza in the United States and Omacor elsewhere) is 85 percent omega-3 fatty acids. In patients with severe hypertriglyceridemia, Lovaza (4 g/day) reduced triglyceride levels by 45 percent, but raised LDL-C levels by 31 percent. Another commercial preparation, Vascepa, is more than 95 percent icosapent-ethyl, the ethyl ester of EPA. Icosapent-ethyl (4 g/day) also reduced triglyceride levels by up to 45 percent, but did not significantly affect LDL-C levels. [References in original deleted.]
In fact, Amarin is using this difference between Vascepa and fish oil dietary supplements to promote its product. According to its website, you’d have to take 10 capsules of fish oil supplements a day to reduce triglycerides, and this could mean the supplement is actually more expensive than the prescription drugs. Plus, it says, low dose omega-3 fatty acids can raise “bad” cholesterol levels.
Amarin actually proposed to the FDA that it be allowed to make the same statement in its off-label promotion that the dietary supplement can make. Sounds reasonable.
The FDA said “no.” Why? Because, the statement:
would be potentially harmful to the public health, and [the FDA] would consider such conduct to be potentially misleading or potential evidence of intended use.
Further, according to the court, the FDA argued that the coronary heart disease claim could cause a physician to prescribe Vascepa in lieu of promoting health, dietary and lifestyle changes, or prescribing statin therapy.
However, the FDA stated that, if Amarin repackaged Vascepa as a dietary supplement, the FDA would not object to including the coronary heart disease claim, on certain conditions. That’s right. The company couldn’t promote it to doctors by making truthful coronary heart disease claims but selling it directly to consumers on that basis would be just fine.
In response, Amarin proposed adding the following information to the statement the dietary supplement manufacturers are allowed to use:
Vascepa should not be taken in place of a healthy diet and lifestyle or statin therapy.
The court agreed that, so qualified, Amarin could make this claim without exposing itself to liability for misbranding.
This result makes no sense whatsoever. True, it is an accurate reflection of the different statutory requirements for prescription drugs versus dietary supplements, and no one could find fault with the court for its decision permitting Amarin to make this qualified statement about Vascepa’s benefits. But, logically, it makes no sense. The law allows a claim to be made for a dietary supplement that cannot be made for a prescription drug, even though:
    • It’s essentially the same ingredient (derived from fish oil) although it is of pharmaceutical grade quality in Vascepa,
    • which can be taken at the same dose (it just takes more of the dietary supplement),
    • for the same purpose.
Yet, the prescription drug had to jump through all the hoops of a supplemental new drug approval, conduct a clinical trial, and, despite the favorable results, was denied approval. On the other hand, the dietary supplement companies, although they did have to meet the FDA’s standard for a qualified health claim, avoided all of this expense and didn’t have to go to court to protect their right to make this same statement to consumers without the further disclosure required of Amigen when promoting its product to doctors. And this is in spite of research showing that consumers don’t fully understand the level of evidence conveyed by a “qualified health claim.” (If you want to see how complicated the drug process actually was for Vascepa’s approved use, take a look at the FDA’s Approval Package for the drug.)
The side effects of Amarin
In addition to the salutary effect of providing an excellent example of why the regulation of dietary supplements should be reformed, what else does the Amarin decision portend? As one commentator noted, the Amarin case is different than the dozens of cases where pharmaceutical companies have paid billions of dollars in settling off-label promotion enforcement actions:
‘I don’t think it’s going to open the floodgates to irresponsible off-label promotion,’ said Dr. Daniel Carlat, a drug marketing expert and associate clinical professor of psychiatry at the Tufts University School of Medicine. ‘Companies are still going to have to be really cautious about what their sales reps say.’
Still, the case may raise questions about what constitutes truthful off-label marketing. Small clinical studies that are not well controlled that show a drug is effective for treating a particular condition or patient population may be held up as scientific data that is truthful and is not misleading. ‘That may be more likely to happen with a decision like this,’ Carlat said.
As a preventative against the FDA’s taking action, the court itself gave some sensible advice. It recommended that all manufacturers take advantage of the FDA’s guidance that a pharmaceutical manufacturer vet and script in advance statements about a drug’s off-label use. It warned that leaving drug reps “at liberty to converse unscripted with doctors about off-label use,” invites a misbranding action if false or misleading representations are made, adding that Caronia “leaves the FDA free to act against such lapses.”
After the decision, the parties jointly requested that the proceedings be stayed until October 30 to explore settlement of the matter. Even though a decision granting a preliminary injunction doesn’t preclude a finding in the FDA’s favor after a full adjudication on the merits, I think the FDA sees the handwriting on the wall.
Amarin has already inspired at least one other lawsuit. On September 8, pharmaceutical manufacturer Pacira filed a complaint in the U.S. District Court for the Southern District of New York seeking to prevent FDA from bringing an enforcement action against the company for what it claims is truthful and non-misleading speech concerning its product, Exparel.

At Your Own Risk
Jann Bellamy on March 21, 2013
Link
In 2011, Americans spent some $30 billion on dietary supplements. Yet, except for the industry itself and a few politicians and “health freedom” advocates, you’d be hard pressed to find anyone (who’s given it some thought) of the opinion that dietary supplement regulation is adequate. Three recent reports, two from the government and one from a newspaper, demonstrate why this near-universal conclusion is warranted.
Another government report on lax supplement regulation
Here’s how an October, 2012, Department of Health and Human Services Office of Inspector General’s (OIG) report described the FDA’s regulatory authority:
DSHEA [Dietary Supplement Health and Education Act] does not require manufacturers to submit dietary supplements to FDA for safety or approval prior to sale. As a result, FDA has no comprehensive list of dietary supplements on the market. Dietary supplement manufacturers must ensure that their products are safe, they have evidence to substantiate structure/function claims, and that product labels are truthful and not misleading.
In other words, the fox guards the henhouse.
Because there is much confusion about structure/function claims, here is a somewhat lengthy explanation from the report about what they are and how they are different from disease claims, which dietary supplement manufacturers aren’t supposed to make. (Citations omitted.)
In general, structure/function claims describe the role of a dietary supplement in the structure and function of human bodies, but the claims may not explicitly or implicitly claim to prevent, treat, mitigate, cure, or diagnose a disease. A structure/function claim may also:
• claim a benefit related to a classical nutrient deficiency disease (e.g., scurvy) and disclose the prevalence of such disease in the United States,
• characterize the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or
• describe general well-being from consumption of a nutrient or dietary ingredient.
For example, a supplement may claim that it “curbs appetite to help with weight loss,” but it may not claim to “aid weight loss to treat obesity” because obesity is a disease. Similarly, a supplement may claim to “support immunity,” but may not claim to “boost the immune system against colds and flu” because the latter references specific diseases. Although FDA has issued regulations and published guidance describing the difference between structure/function claims and disease claims, it acknowledges the challenge of distinguishing between the two.
If the FDA has trouble interpreting DSHEA and its own regulations, imagine the problems everyone else has with “the challenge of distinguishing between the two.” The report continues:
DSHEA requires manufacturers to meet three requirements for placing a structure/function claim on a supplement label: (1) substantiation that the claim is truthful and not misleading, (2) notification to FDA within 30 days of marketing the supplement with the claim, and (3) a disclaimer on the supplement label.
“Substantiation of structure/function claims” means:
Manufacturers must have substantiation for the structure/function claims on their products’ labels to ensure that they are truthful and not misleading. . . .
However, this substantiation requirement is, shall we say, substantially limited by the fact that:
In any legal proceeding concerning structure/function claims, FDA must prove that the claim is false or misleading.
A further limitation is:
DSHEA does not require manufacturers to submit the substantiation requirement to FDA to determine its adequacy and FDA may not compel manufacturers to produce substantial upon request.
So, let’s see. DSHEA requires substantiation of structure/ function claims but manufacturers are under no legal obligation share that information with the FDA even if the FDA asks for it. All the manufacturer has to do is notify the FDA of the structure/function claim and slap the Quack Miranda Warning on the label. Then it’s off to market. The burden is on the FDA to identify risky supplements, of which there are about 85,000, according to a recent New York Times story. And if the FDA takes a manufacturer to court it is up to the FDA to prove the lack of substantiation. In a classic case of bureaucratic understatement, this caused the OIG to conclude that the FDA “has limited authority to enforce the substantiation requirement.” Indeed.
And how is industry doing with that substantiation?
Even with these slack requirements, a sampling of 127 supplements marketed for weight loss and “immune system support” revealed manufacturers did not fully comply with FDA guidance on proper substantiation of claims. A wide variety of brands were selected from various locations across the country and the internet. A truly random sample was not possible because “no comprehensive list of dietary supplements or manufacturers exists.” The OIG would have looked at more supplements but only 61% of the manufacturers complied with its request for information. Here’s a sampling of structure/function claims from the report:
Based on its review, the OIG concluded:
    • Most substantiation was not derived from human studies. 56% would be considered background information (e.g., in vitro and animal studies), which are not primary sources of evidence and therefore may not be sufficient to support claims.
    • None of the human studies met all of the FDA’s recommendations for competent and reliable evidence.
    • Human studies rarely showed a direct relationship to the claim. For example, evidence submitted to support a supplement claim that it burns fat because it contains a green tea extract was actually a study of drinking green tea.
    • Most human studies did not appear to represent the totality of the evidence. In this conclusion, the OIG relied on NCCAM staff, who told them that a large body of evidence contradicts structure/function claims. But a whopping 96% of human studies the OIG received were favorable to the supplement’s claim.
    • Most studies were not consistent with FDA guidance on quality. Another whopping figure here – 85% were not randomized, double-blind, parallel group, placebo-controlled trials.
    • About a third were not consistent with FDA guidance on the meaning of the claim made.
    • 10% did not qualify as substantiation at all.
As an example of this last deficiency, the OIG noted:
One company submitted a 30-year-old handwritten college term paper . . . while others included articles from trade newsletters; press releases; advertisements; and links to Web pages, such as Wikipedia or an online dictionary.
Only drugs can legally make disease claims, yet 20% of the supplements made such claims. Another chart from the study:
The manufacturers couldn’t even get the bonehead requirements right. A majority of notification letters were missing required information. And 7% didn’t have the Quack Miranda Warning on the label.
In response to the report, the FDA said it would improve its notification system for structure/function claims, expand market surveillance to detect disease claims and enforce inclusion of the Quack Miranda Warning. However, as to the OIG’s recommendation that the FDA seek legislation requiring approval for all structure/function claims in labeling, the FDA would only commit to considering the possibility. Small wonder, given the fact that Congress has a conniption fit every time attempts are made to beef up regulation.
In addition to this report, the OIG issued another on dietary supplement regulation at the same time. Here, the title says it all:
Dietary Supplements: Companies May Be Difficult to Locate in an Emergency
True. When the government doesn’t know what products are out there or who makes them it would indeed be difficult to find the companies under the best of circumstances, much less in an emergency.
Putting a human face on the problem
Now to a feature story from Sunday’s New York Times, which recounts the heart-breaking tale of a body-building supplement and the death of a soldier.
In June of 2011, Michael Lee Sparling, a 22-year-old Army private stationed at Fort Bliss, Texas, collapsed after running in formation for about 10 minutes in 75 degree weather. He went into cardiac arrest and died later that day. Before the exercise, he had taken the recommended dose of Jack3d (pronounced “jacked”), a supplement sold by, among others, GNC, the retail dietary supplement chain, who advertised it as producing “ultra-intense muscle-gorging strength, energy, power and endurance.” Pvt. Sparling, who by all accounts was in excellent physical condition, purchased his Jack3d at an on-base GNC store.
Pvt. Sparling’s untimely death has once again ignited criticism of lax dietary supplement regulation in the United States, a subject we have addressed many times at SBM. Now joining the chorus of calls for reform are his parents, Leanne and Michael Sparling. Last month, the Sparlings filed a wrongful death lawsuit against GNC and Jack3d’s manufacturer, USPlabs. Ms. Sparling, who still wears her son’s dog tags, told the Times:
They just think they are too big and everybody’s afraid of them. They think I will just go away. Unfortunately for them, I won’t go away.
According to the Times, DMAA (dimethylamylamine), started out as an inhaled drug for nasal congestion. Because of potential side effects – tremors, headaches and nervousness – Eli Lilly withdrew it from the market voluntarily. In 2005, it reappeared as a dietary supplement based on the disputed claim that it can be found in a geranium grown in China. This doesn’t mean that any of the DMAA on the market actually comes from this plant, but such is the logic of the DSHEA.
Last April, the FDA sent warning letters to several supplement manufacturers saying it had no evidence DMAA is a legitimate dietary ingredient and citing its risks. (Health regulators in other countries, such as Sweden and Denmark, have actually banned DMAA-containing supplements.) Heart attacks, heart failure, kidney failure and liver failure were among the health problems reported to the FDA, as well as 5 deaths. GNC responded that it was “completely opposed to this unilateral, factually and legally unfounded action by the FDA.”
The Times story said that other organizations are also taking action. The World Anti-Doping Agency and Major League Baseball have banned methylhexaneamine, which is the same thing. The military removed supplements containing DMAA from base stores, including GNC. Col. Erin P. Edgar, a command surgeon with the U.S. Central Command, thinks the military, which sells “truckloads” of body-building supplements at its bases, should not be selling them at all.
And how did the industry respond?
Part of the problem is lack of any pre-market requirement of proof of safety and part of the problem is retailers like GNC, who aren’t regulated at all. As reported in the Times, both had predictable responses to the lawsuit and unfavorable publicity, as did the supplement industry.
The attorney for USPlabs said the company is “unaware” of any deaths from the proper use of Jack3d and that there is no evidence the reported deaths were caused by the product. Various spokespersons for GNC, which had about $4.2 billion in revenue last year, said the company had no reason to believe that DMAA is unsafe, that GNC sells legal products widely available from other retailers, and that it complies with all relevant regulatory guidelines. A spokesperson for the Council for Responsible Nutrition, an industry trade group, said that a majority of supplements are safe.
Unfortunately, all of these speakers are well within their rights. Manufacturers are under no obligation to test their supplements to see if they are fatal before they market them and they must report any deaths only if someone happens to complain. Even then, they are free to say there is no proven causal relationship. And if the FDA wants to challenge that, the FDA has the burden of proof. No doubt GNC does comply with all regulatory guidelines as there aren’t any regulations requiring retailers to inquire into safety or effectiveness. The Council spokesperson is probably right when he says that a majority of supplements are safe. We just don’t know which ones aren’t until we find out the hard way, when injury and death reaches a threshold that spurs further investigation. Or, as Dr. Amy Eichner, a special adviser to the anti-doping association for American Olympic athletes, told the Times:
No consumer can ever know what’s inside a bottle. We advise our athletes that all supplement use is at their own risk.
Great advice for all consumers, whether athletes or not. In fact, what we need instead of the Quack Miranda Warning on supplement labels is a more accurate disclaimer of FDA involvement in dietary supplement regulation:
FDA WARNING: Safety and effectiveness unknown. Use at your own risk.

Stem cell therapy regulation plays catch up
Jann Bellamy on August 9, 2012
Link
The burgeoning U.S. stem cell therapy industry was delivered a setback last month in the form of a U.S. District Court injunction against use of the “Regenexx™ Procedure,” which purports to treat joint, muscle, tendon or bone pain due to injury or other conditions. The court agreed with the FDA that the cell product used in the procedure is both a drug and a “biological product” subject to FDA regulation. Because a similar process is used in other stem cell therapies the decision increases the possibility that the FDA will take a like position in other cases.
The general term “stem cell therapy” comprises an array of treatments which range from the clinically proven to quackery. On one end of the spectrum is blood stem cell transplantation to treat diseases and conditions of the blood and immune system. On the other lies the kind of stem cell therapy tourism addressed by both Steve Novella (here and here) and Orac (here and here), which involves the injection of what may, or may not be, stem cells from what may, or may not be, humans. In between fall therapies which are plausible and have promise but have not been adequately tested in clinical trials. There is a concern that these therapies are being oversold by clinics which charge thousands of dollars (not reimbursed by insurance) to treat conditions including multiple sclerosis, musculoskeletal pain, and cardiac disease.

Here’s how the district court described the procedure it enjoined from further use, quoting from a document filed by its manufacturer, Regenerative Sciences, LLC, a Colorado company, and three of its officers (two of them physicians who developed the procedure), co-defendants in the case:
The Regenexx™ Procedure begins with a licensed physician taking a small bone marrow sample from the back of a patient’s hip though a needle. Blood samples are also taken from a vein in the patient’s arm. These samples are then sent to the Regenrative laboratory . . . where the mesenchymal stem cells (MSCs) are isolated from the bone marrow and then grown to greater numbers. This process uses the natural growth factors found in the patient’s blood to grow the MSCs. . . .
Once the cells pass quality assurance testing [about 2 weeks later], they are placed back in to the patient’s injured area (i.e. knee, hip, rotator cuff), typically 4-6 weeks after they were removed. The stem cells then begin to repair the patient’s degenerated or injured area.
The FDA notified Regenerative Sciences in 2008 that the FDA believed the cell product used in the Regenexx™ Procedure constituted a drug under the Federal Food Drug and Cosmetics Act (FFDCA) and a biological product under the Public Health Service Act (PHSA). In 2009 and 2010, the FDA investigated a Regenerative Sciences laboratory and determined that it did not operate in conformity with current good manufacturing practices. In 2010, the FDA filed suit to enjoin further use of the Regenexx™ Procedure claiming that it constitutes the manufacturing and holding for sale an unapproved biological drug product and that it violated the FFDCA’s prohibition on adulteration and misbranding a drug.
The main defense centered on the argument that this procedure is not a drug, but rather the practice of medicine as defined by Colorado law, over which the state, not the federal government, has exclusive regulatory jurisdiction. In this argument the defendants were joined by the Association of American Physicians and Surgeons and the American Association of Orthopaedic Medicine both of whom the district court allowed to file amicus curiae (“friend of the court”) briefs.
The Association of American Physicians and Surgeons (AAPS) has appeared on SBM before. The title of David Gorski’s post alone tells you a lot: The Journal of the American Physicians and Surgeons: Ideology trumps science-based medicine. For an even closer look, Kathleen Seidel posted an extensive review on the neurodiversity weblog. Among other eye-popping positions, the AAPS warns that “physicians must beware of accepting the concept of a standard of care that is itself evidence-based, threatening the autonomy of physicians and subjugating the patient’s interest to that of the collective.” (What must they think of science-based medicine?) It’s no fan of the FDA either and regards its existence as unconstitutional.
The American Association of Orthopaedic Medicine describes “orthopaedic medicine” on its website as
. . . a specialty devoted to the evaluation, diagnosis and non-operative treatment of painful musculoskeletal diseases. Diagnostic modalities include a comprehensive history, a detailed and specific physical examination, radiologic evaluations and local anesthetic blocks. Therapeutic modalities encompass manipulations, corticosteroid or proliferant injections [also known as prolotherapy] with and without fluoroscopic guidance, therapeutic exercise and use of pharmaceutical, nutriceutical, herbal and/or homeopathic based treatment.
That’s likely all you need to know to draw your own conclusions.
The FDA filed a motion for summary judgment in the case, arguing that based on the record before it the court could find that there were no material questions of fact and that the FDA was entitled to judgment in its favor as a matter of law. The FDA won its motion, and thereby won the lawsuit without having to go to trial.
“The question here,” the court said in its opinion granting the FDA’s motion, “is whether the Regenexx™ Procedure constitutes a drug (or biologic product) subject to FDA regulation or whether it is merely an intrastate method of medical practice subject only to the laws of the State of Colorado.” The court continued
The FFDCA defines ‘drug’ to mean ‘articles intended for use in the diagnosis, cure mitigation, treatment, or prevention of disease’ or ‘articles (other than food) intended to affect the structure or any function of the body of man or other animals.’ . . . Based on this definition, whether an ‘article’ is a ‘drug’ depends on its ‘intended use’ . . . [which turns on] the nature of the claims advanced on its behalf.
In addressing the “intended use,” the court found that
Defendants’ website and pleadings describe their ‘intended use’ for Regenexx™ Procedure. Defendants promote the Regenexx™ Procedure to treat a variety of orthopedic conditions and injuries. . . . Defendants describe the Regenexx™ Procedure as ‘an Alternative to Traditional Surgery’ that can treat ‘[f]ractures that have failed to heal, joint cartilage problems, partial tears of tendons, muscles, or ligaments, chronic bursitis, avascular necrosis of the bone, and lumbar disc bulges. . . .
Defendants’ pleadings confirm their intentions to use the Regenexx™ Procedure for ‘mitigation’ and ‘treatment,’ among others, of disease and injury. They explain how the ‘stem cells . . . begin to repair the patient’s degenerated or injured area.’ . . . how [it] is ‘for the treatment of orthopedic injuries and arthritis,’ [and] . . . ‘for the treatment of musculoskeletal and spinal injury.’ These statements of ‘intended use’ fully satisfy the statutory definition for a ‘drug.’ Similarly, Defendants’ admissions that the Regenexx ™ Procedure is based on mesenchymal stem cells derived from the patient’s bone marrow . . . and that it is intended to treat orthopedic conditions fully satisfy the definition of ‘biological product’ under the PHSA . . . .
The court also found that because the cells used in the procedure were more than “minimally manipulated” the defendants could not claim an exemption from regulation under FDA rules.
Among other issues, as noted above, the court also had to determine whether defendants’ actions were subject to federal regulation at all, or whether they were simply the practice of medicine subject solely to regulation by the state of Colorado, an issue hotly contested by the AAPS and AAOM. Here, the court determined that defendants’ combination of an antibiotic, doxycycline, with the cell product before it is administered to patients was sufficient, as doxycycline is shipped through interstate commerce prior to its administration.
One of the principals in Regenerative Sciences and a defendant in the case, Chris Centeno, M.D., told the journal Nature that the company plans to appeal. It has already moved the procedure enjoined in the U.S. to a clinic in the Cayman Islands, an action taken when the FDA ordered the company to stop using the product in 2010. The company will continue to offer three other stem cell products for joint pain in the U.S. based on its contention these products do not fall within FDA’s jurisdiction. Dr. Centeno told Nature that the FDA sees these other procedures as the practice of medicine and “has no issues” with them. Nature reported that until July 25th the Regenerative Sciences website claimed the three procedures were “FDA approved.” However, Nature determined that this was not the case and the claim was removed after its further inquiries to the company.
Interestingly, the safety and efficacy of the Regenexx™ Procedure was not at issue in the district court case, although those certainly will be issues now that it’s been deemed a drug should the defendants choose to pursue its use in the U.S. The Regenerative Sciences website lists some journal publications and other data which the company apparently feels support the safety and efficacy of its procedures. It also provides a number of testimonials. I do not have sufficient education and training to evaluate those claims. However, the International Society for Stem Cell Research (ISSCR), which describes itself as “an independent, nonprofit organization formed in 2002 to foster the exchange of information on stem cell research. . . . [w]ith more than 3,500 members worldwide” has this to say:
Other stem cell treatments, while promising, are still at very early experimental stages. For example, the mesenchymal stem cell, found throughout the body including in the bone marrow, can be directed to become bone, cartilage, fat and possibly even muscle. In certain experimental models, these cells also have some ability to modify immune functions. These abilities have created considerable interest in developing ways of using mesenchymal stem cells to treat a range of musculoskeletal abnormalities, cardiac disease and some immune abnormalities such as graft-versus-host disease following bone marrow transplant.
[Emphasis added.]
I’ll take this opportunity to plug the ISSCR website as a wonderful resource for anyone interested in stem cell research, including those contemplating any sort of stem cell therapy. In addition to information for scientists and physicians it has easily understandable information and advice directed to the layperson.
While the district court’s injunction puts stem cell clinics on notice that some of their procedures may fall within the FDA’s jurisdiction, what of other stem cell procedures which, like those still offered in the U.S. by Regenerative Science, might not be classified as drugs? Who is protecting the public’s health and safety in those cases? This task would appear to fall to the state medical boards, which, depending on factors such as budget, interest and politics, may not be up to the task.
Texas governor Rick Perry, himself a recipient of stem cell therapy for a back problem, has heavily promoted the stem cell therapy industry in Texas and millions of state funds are available for research. But criticism from bioethicists and others about promotion of unproven therapies and the lack of patient protection led the Texas Medical Board to adopt new rules in April governing their use, as reported in The Texas Tribune (here and here) and Science Insider, a publication of the American Association for the Advancement of Science. The rules require that stem cell treatments either be part of an NIH or FDA-approved protocol or study, or have approval from a local Institutional Review Board (IRB), which need not be affiliated with a hospital or academic institution. The response to the new rules seems to run the gamut from “it’s better than nothing” to concerns that the rules will fail to protect patients. Critics noted the opportunity for lax oversight by private, for-profit IRBs, which have financial incentives to approve procedures. William Smyth, a Medical Board member who voted against the rules, told the Tribune that, “if Texas wants to be a leader in this area, there are other ways to do this. You want to add a layer of protection? Put a moratorium on the use of these agents until they are proven.”
But that would require expensive, time-consuming clinical trials. And the companies who market stem cell therapies apparently don’t want to spend that kind of time or money.

The FDA and Personalized Genetic Testing
Steven Novella on November 27, 2013
Link
The company 23andMe provides personal genetic testing from a convenient home saliva sample kit. Their home page indicates that their $99 genetic screening will provide reports on 240+ health conditions in addition to giving you information on your genetic lineage. The benefits, they claim, are that you will learn about your carrier status and therefore the risk of passing on genetic diseases to your children. The information will also inform you about health risks so that you can change your behavior to manage them. Finally the genetic information will tell you about how you might respond to different drugs so that you can “arm your doctor with information.”
The home page also contains a link to testimonials about how their DNA testing has changed people’s lives.
This all sounds great – the promise of genomics that we have been hearing about now for about two decades. Isn’t this exactly what we were led to expect once we mapped the human genome?
Why, then, has the FDA recently sent a warning letter to 23andMe instructing them to discontinue marketing their Personal Genome Service (PGS)?
The primary reason appears to be a lack of documentation for the validity and reliability of the tests, but I have concerns that go even deeper. 
The FDA is concerned mostly with whether or not the genetic testing offered by 23andMe works as advertised. False positive and false negative testing could have significant medical consequences. The company is marketing its PGS specifically to aid in medical management, including drug management. Despite the fact that the website says “arm your doctor,” the FDA fears people will use the information to self-manage, for instance by adjusting their own dose of critical medication.
The FDA is also particularly concerned about genetic tests such as those for BRCA, which conveys risk for breast and ovarian cancer.
In other words, there are serious medical consequences to the genetic information being provided by 23andMe and they have not performed the due diligence required to make sure their tests are valid and reliable. The FDA letter documents their attempts over the last five years to work with the company to help them come into compliance, but to no avail.
I can only speculate that the company is not complying with the FDA because they cannot – they do not have the scientific information the FDA requires and they are dragging their heels on producing it. They may simply be trying to avoid the cost of such research, and hoping the FDA will eventually back off (perhaps they were hoping to hold out for an administration change). The FDA, however, is being tenacious.
I certainly like to see the FDA aggressively doing its job of protecting the public from unsubstantiated health claims and from products and services that are not adequately backed by scientific studies and proper quality control. The public expects that this is the case.
However, I also always marvel at the irony such cases highlight. Articles discussing this and similar cases often include quotes such as the following:
“Our society regulates medical products to protect public health. Without strong public oversight, we’re back to the era of snake oil,” said executive director Marcy Darnovsky. (of the Center for Genetics and Society)
I completely agree. Now let’s talk about the entire homeopathy industry, the lack of even basic quality control in the supplement industry, and the pathologically false health claims routinely made within the world of CAM (complementary and alternative medicine).
While I agree with the FDA going after 23andMe for noncompliance, I have to wonder why it has picked this company out of all the possible targets out there. I know that much of it has to do with their regulatory scope. They cannot take on homeopathy, for example, without Congress changing the law. But I can think of many other suitable targets that seem to be getting a free pass. Perhaps it simply comes down to the fact that they are not adequately funded to do their job given their regulatory limitations.
As I alluded to above, I have issues with personalized genetic testing that go beyond the stated concerns of the FDA. Even if the company provided data showing that its genetic tests were accurate, valid, and reliable, that does not mean that they are necessarily a good idea. The deeper question is – is the information itself useful, or will it perhaps have negative unintended consequences?
We have discussed the pitfalls of screening tests on SBM before. Superficially, screening tests seem like a good idea with no downside. More information is always better, right? That is certainly the approach that 23andMe is taking (of course, their business model involves providing that information).
However, there are potential issues with any screening test. Some do relate to sensitivity and specificity – how reliable are the tests. No test is 100% sensitive or specific, which means that even very good tests will have occasional false positives and false negatives. If the entity you are screening for is rare enough, then even a very accurate test may still provide more false positives, for example, than true positives.
This issue aside, meaning even if we had a 100% accurate test, we have to ask the further question – what is the net effect of providing this information? Potential negative consequences of accurate screening information include the unnecessary worry of learning that you have a predisposition or risk of developing a disease in the future. This may seem like a small thing, but it can have a significant impact on quality of life, even to the point of people being crippled by their fear of impending disease.
Further we have to consider what, exactly, will be done with the information. The implication is that drug treatment can be modified, and risk factors for disease can be addressed. But – is genetic testing (with our current knowledge base) the best way to approach such treatment? Will the genetic information cause people to change their behavior in a way that will have a net negative effect on their health?
Such behavioral changes may also include a false sense of security in those with negative screening for certain risk factors. If someone finds that they are in a low-risk group for heart disease, will they then feel free to engage in an unhealthy diet that will still be a risk factor for them?
Screening indicating a high risk may also motivate people to seek out unnecessary health care, which may lead to unnecessary tests that have their own false positive and negative rates.
There are downstream consequences to providing health information to large numbers of people. The 23andMe website is providing only handpicked testimonials with smiling faces about how their lives were improved. We have to wonder about cases of negative effects from the information provided. The only way to know net health effects is to properly study not just the accuracy of the test, but its effect on the people who receive the results. The FDA seems concerned only about the former, and not the latter (which may be appropriate given its scope).
What we have to consider as a society is how to regulate private companies directly marketing health services to the public, bypassing medical professionals. This is part of a larger issue with the public having increased access to information in general, including their own medical information. In general I am in favor of increased information access, but we can’t do this blindly. We need to consider consequences and how to put into place systems that can help put such information into proper context and use.
For example – electronic medical records systems mean that my patients can often now directly access their test results. This is convenient, and they certainly deserve to have access to their own information. But what often happens is that the test results contain misleading noise – numbers that are just outside of the normal range, or MRI findings that sound scary but are actually insignificant. I have seen this cause unnecessary anxiety on the part of patients, and take up more staff and physician time than if the results were filtered through the physician in the first place.
Conclusion
The FDA’s current problem with the PGS of 23andMe is concerning, as it indicates that the company has not provided proper documentation that the services they provide are valid and accurate. There are problems with the service, however, that go deeper than simply accuracy.
Our society has increasing information and public access to information. While it is difficult for me to think that this isn’t a good thing overall, we have to thoughtfully consider the possible unintended negative consequences. This case is part of a larger pattern of sacrificing quality-control filters for the sake of open access. This increasingly puts the burden on the public to make sense of sometimes complex and technical information.Everyone, now, can be their own geneticist.

FDA & CDC find raw pet food unpalatable
Jann Bellamy on June 25, 2015
Link


The FDA recently announced it would send field staff out to collect samples of commercially-manufactured raw dog and cat food. The samples will be analyzed for Salmonella, Listeria monocytogenes and E. coli, all of which have been found in raw pet food, in the animals who eat it, in their feces, on their bodies after eating it, in the areas they inhabit, and on their owner’s bodies. Not surprisingly, this has led to both pet and human infection and illness. If the FDA finds pathogens, it could result in a recall, a press release and Reportable Food Registry Submission. The next day, the CDC joined the effort to curb illness caused by pathogens in raw pet food by posting information on safe handling.
Because of the risk to public health, and the lack of any proven benefit of raw pet food diets, the FDA does not recommend them.
However, we understand that some people prefer to feed these types of diets to their pets.
And why is that? For some of the same reasons humans follow absurd diet fads: the “lone genius” discovery, it’s “natural,” anecdotal evidence, appeal to antiquity, anti-corporate sentiment, and “holistic” practitioner recommendations.
The “lone genius” discovery
Although he may not have been original inventor of the raw pet food diet, Australian vet Ian Billinghurst is its most ardent popularizer, in the form of his trademarked “Dr. Billinghurst’s BARF Diet.” BARF is an acronym for “Biologically Appropriate Raw Food,” although other gastrointestinal-related events are called to mind.
Billinghurst recounts how the health of his own dogs declined after he started feeding them high quality commercial pet food. (Oddly missing from this story is information about what he was feeding his pets before he started them on commercial pet food and why he didn’t just go back to this diet.) However, it took him two years to realize his error. That realization came only when he switched them to a diet of raw meat, including bones, and household scraps. The results, as you might imagine, were “immediate and dramatic.” He urged his clients to switch their pets’ diets as well, with the same amazing results.
He reasoned that raw meaty bones and vegetable scraps were “very close to the evolutionary diet of cats and dogs.” He was also influenced by his study of acupuncture, although it is unclear how that led to the BARF diet, other than a willingness to trade the scientific method for anecdotal evidence as a basis of one’s practice.
Billinghurst wrote a book in the 1980s, catchily titled Give Your Dog a Bone, setting forth his unique pet nutritional theories. It became something of a pet-owner cult hit and was followed by more books. He later partnered with Robert Mueller, a pharmacist (not the former FBI director) who wrote the similarly lone-genius discovery book, Living Enzymes: The World’s Best Kept Pet Food Secret. Together with another partner, they created “BARF World,” which sells, among other things, commercially prepared raw pet food. We’ll return to this enterprise in a moment.
Billinghurst makes big claims for BARF, or at least the “raw meaty bone-eating” element:
Raw meaty bone-eating dogs lived much longer than their commercially fed counterparts, . . . Bone-eating dogs have the wonderful benefits of clean teeth with no periodontal disease, wonderfully improved digestion, a reduction in obesity, fabulous eating exercise, healthy stools, no anal sac problems, and the wonderful psychological, emotional, and immune system benefits that eating raw meaty bones has conferred on dogs for millions of years.
The raw food diet for dogs is based on a combination of the naturalist and appeal to antiquity fallacies: the notion that your dog is really, at heart (and stomach, I guess), a wolf. And cats are tiny tigers, I suppose. While raw cat food is promoted as well, the whole “theory” appears to be largely dog-centric. Because wolves ate a raw diet, it must necessarily follow that raw meat, with a few herbs, is best for your dog. (Wolves got their plant matter by eating the stomach contents of their prey.)
In this, the diet also is a form of evolutionary medicine, which is based on the faulty assumption that chronic diseases and degenerative conditions arise from a mismatch between our (and our pet’s) Stone Age genes and recently adopted lifestyles, including diet. It is the same fallacy that lies at the heart of the paleo diet for us humans.
Brennen McKenzie, DVM, sliced and diced the “dog as wolf” theory nicely in a previous SBM post. (You can find more raw pet food posts on his blog, Skeptvet.) In summary,
    • Yes, dogs and wolves are both in the order Carnivora, but so are giant Pandas, who are almost exclusively herbivores.
    • Dogs have not been wolves for a very long time — like 100,000 years or so.
    • The claim that dogs and wolves are anatomically identical with respect to an appropriate diet is simply untrue:
If you try to picture a pack of Chihuahuas bringing down and savaging an elk, the impact of thousands of years of artificial selection is obvious. . . . Dogs have lived with humans, eaten our table scraps, and been intensively bred for features we desire, none of which is likely to make them ideally designed for the diet of a wolf.
    • Wolves don’t have such a great life in the wild anyway. Disease, parasites and malnutrition are major factors in wild wolf mortality and they don’t live as long as captive wolves. And captive wolf breeders have found that the best diet for their wolves is – guess what? – commercial dog food.
An analogous argument has sprung up that feral dogs and cats eat raw meat, as if this is some conscious healthy lifestyle choice on the animal’s part instead of the result of appalling neglect and irresponsibility on the part of pet owners. Of course, feral dogs and cats also lead terrible lives, subject to malnutrition and early death, and don’t live as long as pet dogs and cats.
Bad, bad commercial dog food
The other main argument in favor of raw pet food has the flavor of “death by medicine.” Like that argument, trotted out to demonize “conventional medicine,” the failings of the commercial pet food industry do nothing to make raw pet food more nutritious, less risky, or otherwise better for your pet.
It is also underpinned by some grossly exaggerated and downright false claims about the commercial pet food industry. (And here we use the term “commercial pet food” to mean “conventional” commercial pet food, even though raw pet food has become plenty “commercial” as well.) While the commercial dog food industry has its problems, it is not the bogeyman that raw pet enthusiasts make it out to be. Dr. McKenzie has shredded these arguments for us as well. Briefly:
    • No, commercial pet food doesn’t make your pet sick. Like humans, pets live longer because of better nutrition and medical care. This means that illnesses of the aging pet, like cancer and degenerative diseases, are more prevalent. Coupled with the lack of a full understanding of what causes these diseases, this leaves raw food enthusiasts an opening to claim it must be the food.
    • No, commercial pet food is not “toxic.” This is based on the fact that commercial pet food contains preservatives and artificial coloring, two favorite boogeymen of the “natural food” crowd.
    • Yes, dogs can digest the grains used in pet food, contrary to claims otherwise.
    • No, cooking does not destroy all the nutrients. Some, but not all, by a long shot. It also kills bacteria and parasites, two big plusses in any food.
    • No, dog food is not made from dead pets. This offensive urban myth was investigated by the FDA and found wanting.
There are other myths raw pet foodies like to promote, such as veterinary schools not teaching nutrition, and what little they learn is controlled by the pet food industry. But let’s get to the facts.
Once fully digested, the raw pet food movement doesn’t seem so palatable.
As noted, the FDA plans to send agents out into the field for testing. Why? Because:
the scientific literature indicates that feeding raw foods to household pets such as dogs or cats carries a risk to human and animal health. Even if the pets do not appear to be sick after consuming raw pet foods containing pathogens such as Salmonella and Listeria monocytogenes, they can become carriers of such pathogens and transfer the pathogens to the environment. Humans can be infected by contacting pathogens in the contaminated environment. Raw pet foods containing pathogens can also contaminate food contact surfaces and human hands that increase the risk of human exposure.
But that’s not the only risk. Julie Churchill, DVM, a specialist in companion animal nutrition at the University of Minnesota’s College of Veterinary Medicine, strongly disagrees with the BARF diet, because eating bones can be fatal.
Bones, even raw and ground ones, can perforate the [gastrointestinal] tract. This can lead to peritonitis, severe infections, require emergency surgery, and dogs die from this each year…
Risks aside, what about evidence that a raw food diet is better for your pet? There is none. In fact,
on the basis of published diet reviews, most home-prepared diets (both raw and cooked) are deficient in 1 or more essential fatty acids, vitamins, or minerals or a combination thereof. Although the perceived benefits of home-prepared diets may be reinforced daily to owners through a pet’s appetite or coat quality, nutrient deficiencies and excesses in adult animals are insidious and can lead to long-term complications if not detected and corrected.
In addition to the FDA and the CDC, the American Veterinary Medical Association, American College of Veterinary Nutritionists, American Animal Hospital Association, National Association of State Public Health Veterinarians and American Association of Feline Practitioners have all warned of the lack of benefit, as well as the dangers, of raw pet food diets. The American Holistic Veterinary Medical Association doesn’t take a position, in deference to the “holistic” vets who recommend raw diets and sell raw pet food products.
So, risks to pets and their owners from infections and, to pets, from bone fragments and nutritional deficiencies, and no evidence to support it supposed benefits.
Billinghurst rejects the lack of evidence with that ubiquitous CAM practitioner claim – “I’ve seen it work.” As far as the risks, he blows them off with the unfounded assertion that eating pathogens is no big deal, because dogs are “designed” to eat these things. It’s even ok for immune-compromised animals.
All of this is nonsense, but Billinghurst has his reputation and a raw pet food empire to think about. For example, you can get two 3 lb. bags of BARF World “Juicy Chicken Nuggets,” which contains not only chicken, but also vegetables, fruits, cayenne pepper and garlic, for a mere $37.97, plus $15.50 in shipping costs. If this is really what wolves eat, they are surely the unheralded gourmets of the animal world. Who knew animals used herbs and spices? But wait – there’s more: if you sign up for the BARF World automatic shipping plan (meaning, they’ll automatically send you the right amount of food, expertly calculated for your pet, in perpetuity) you get free shipping.
But what if your dog or cat doesn’t tolerate BARF World pet food? Not to worry. Some may exhibit brief symptoms of “detox,” like diarrhea and vomiting, but this is normal, especially when converting from a “processed diet.”
BARF World also sells a lot of other CAM stuff for your pet, such as Kefir and “Eastern Medicine” herbal supplement formulas. For example, “G.I Tract Herbal Formula for Dogs,” “harmonizes the stomach,” and, as an added bonus, “helps maintain contentment during travel” for dogs that have digestion issues, as well as those who “don’t want to travel in a vehicle.” You can even get a consultation with a “holistic” vet.
Although BARF World may have the imprimatur of Billinghurst himself, several other raw pet food companies have gotten on the gravy train, and at similar prices. No benefit, more risk, and higher prices. Yep, sounds like CAM to me.
If you want to subject yourself to unproven raw food fads, I suppose that’s your business. But leave your poor pet out of it.

Personal Care Products Safety Act: Facelift for FDA Regulation or Lipstick on a Pig?
Jann Bellamy on September 29, 2016
Link


The U.S. cosmetics industry, the largest in the world, is expected to reach $62 billion in revenues in 2016. Yet, despite the fact that its products are regularly applied to, and absorbed by, the body’s largest organ (the skin) and even ingested in small amounts, the cosmetics industry is largely self-regulating.
There are over 57,000 different chemicals used in cosmetics. According to one research report, on average, women use 12 personal care products every day, exposing themselves to 168 chemical ingredients. Men use about half that, but still expose themselves to 85 unique chemicals a day. Many of these may be perfectly safe, we just don’t know which ones because most have not been tested for safety.
Increasing concerns about everything from contact dermatitis to carcinogens led Senators Dianne Feinstein (D-California) and Susan Collins (R-Maine) to introduce the Personal Care Products Safety Act, giving the FDA greater regulatory oversight of the cosmetics industry. The Senate Committee on Health, Education, Labor & Pensions held a hearing, “Exploring Current Practices in Cosmetic Development & Safety” last Thursday. A similar bill has been introduced in the House of Representatives. At least one other House bill was introduced in 2013 attempting to strengthen FDA regulatory authority over cosmetics, but it went nowhere.
Cosmetics are regulated under the Food, Drug and Cosmetics Act in pretty much the same manner as when the Act was originally passed in 1938. A “cosmetic” is defined by its intended use:
articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body…for cleansing, beautifying, promoting attractiveness, or altering the appearance.
This covers a wide range of consumer products: skin moisturizers, perfumes, lipsticks, fingernail polishes, eye and facial makeup, shampoos, permanent waves, hair colors, and deodorants, but, interestingly, not soap. If a product makes therapeutic claims, it can also be classified as a drug. So, from a regulatory standpoint, your dandruff shampoo isn’t soap, but it is both a cosmetic and a drug. It is not, however, a “cosmeceutical,” a fictional category made up by the cosmetics industry.
The FDA’s light-handed regulation of cosmetics bears a striking resemblance to its minimal regulation of dietary supplements, although you can’t blame the FDA for either. The fault lies with Congress and only Congress can remedy the situation.
    • There is no required premarket testing for safety or efficacy. The FDA relies on the industry to assure that its products are safe and effective.
    • The FDA can act to remove a product from the market only if it is “adulterated” or “misbranded.” “Adulteration” generally refers to the product’s containing poisons are other deleterious substances and it’s being produced under unsanitary conditions. “Misbranded” covers violations involving improperly labeled or deceptively packaged products.
    • Ingredients must be listed and only a handful of ingredients are prohibited.
    • No warnings or directions for use are required unless failure to include them would render the product improperly labeled, except in a few circumstances where specific warnings are required on some products. In fact, the warning requirements for cosmetics are more stringent than those for dietary supplements.
    • The FDA does inspect cosmetic manufacturing facilities, but companies are not required to register with the FDA. (Dietary supplement companies are now required to register, although the response has been poor.)
    • Companies making therapeutic claims for cosmetics without going through the OTC or prescription drug approval process can be prosecuted by the FDA. (One cannot help but note that the majority of companies receiving FDA Warning Letters for making illegal drug claims are promoting “natural” products.)
Personal Care Products Safety Act improvements
According to Sen. Feinstein’s summary, the Personal Care Products Safety Act would strengthen regulation of the cosmetics industry in several ways:
    • Provide the FDA the authority to order recalls of certain personal care products that threaten consumer safety.
    • Provide the FDA the authority to require labeling of products that include ingredients not appropriate for children and those that should be professionally administered. Complete label information, including ingredients and product warnings, would also be required to be posted online since approximately 40 percent of personal care products are purchased over the Internet.
    • Require companies to provide contact information on their products for consumers and report serious adverse events to the FDA within 15 days, including death, hospitalization and disfigurement. Health effects that could have resulted in hospitalization without early intervention would also be required to be reported.
    • Require manufacturers to register annually with the FDA and provide the agency with information on the ingredients used in their personal care products.
    • Direct the FDA to issue regulations on Good Manufacturing Practices for personal care products.
The Act would also require the FDA to evaluate a minimum of five ingredients per year to determine their safety and appropriate use. According to Sen. Feinstein,
the review process set forth in the bill would provide companies with clear guidance about whether ingredients should continue to be used and if so, what the concentration levels should be and whether consumer warnings are needed. For example, a chemical may be deemed inappropriate for use in children’s products, or appropriate for professional application only.
The first set of chemicals for review includes:
     1.  Diazolidinyl urea, an antimicrobial preservative used in a wide range of products including deodorant, shampoo, conditioner, bubble bath and lotion.
     2.  Lead acetate, used as a color additive in hair dyes.
     3.  Methylene glycol/formaldehyde, used in hair treatments.
     4.  Propyl paraben, used as a preservative in a wide range of products including shampoo, conditioner and lotion.
     5.  Quaternium-15, used as a preservative in a wide range of products including shampoo, shaving cream, skin creams and cleansers.
To fund these new oversight activities, the bill would authorize the FDA to collect user-fees from personal care products manufacturers, like it does for medications and medical devices.
Methylene glycol/formaldehyde, which can irritate the eyes, skin and respiratory tract and is a potential carcinogen, is a good illustration of the how the FDA’s lack of sufficient regulatory authority over cosmetics ingredients can lead to harm. In 2013, Cosmetic Industry Review, which is funded by the cosmetic industry but claims scientific independence, published a paper finding that methylene glycol/formaldehyde “in the present practice of use and concentration” in hair smoothing/straightening products is unsafe. The FDA did issue a warning letter to the marketers of “Brazilian Blowout Acai Professional Smoothing Solution,” stating that, despite its claim of being “formaldehyde-free,”
based on FDA sample analysis, Brazilian Blowout contains methylene glycol, the liquid form of formaldehyde, which, under the conditions of use prescribed in the labeling, releases formaldehyde when hair treated with the product is heated with a blow dryer and then with a hot flat iron. Methylene glycol is a deleterious substance, which at the levels present in this product, may harm users under the conditions of use prescribed in the labeling thereof. FDA analysis of approximately 50 mg samples of Brazilian Blowout confirmed the presence of methylene glycol, the liquid form of formaldehyde, at levels ranging from 8.7 to 10.4%.
Yet, because the FD&C Act does not give the FDA mandatory recall authority, the FDA could not move to recall the product. The FDA could, but has not, banned the use of methylene glycol/formaldehyde in cosmetics. Fortunately, OSHA and state agencies have stepped in to fill the regulatory gap.
Industry and consumer support
The Act has support from both the cosmetics industry and consumer and medical groups like the Environmental Working Group, March of Dimes, the American Cancer Society, and the Endocrine Society. However, the Consumer Federation of America and a group of which I was previously unaware, the Campaign for Safe Cosmetics, are not fully on board.
The Campaign for Safe Cosmetics thinks the regulations are too weak and doesn’t like the fact that the Act will pre-empt state regulation. While the Campaign has the worthy goal of informing consumers about dangerous chemicals in cosmetics and increasing cosmetic consumer protection, and may well be correct that this bill is not all it could be, the Campaign turns a blind eye to pseudoscientific claims by its own industry supporters and appears to fall for the appeal to nature fallacy, all of which makes one suspicious about exactly where it is coming from in its opposition. For example, here’s a pitch from a company recommended by the Campaign, Golden Path Alchemy, “formulated by licensed acupuncturists and herbalists” for its “Sacred Space Alchymst:”
White Sage, a profound and sacred medicinal plant native to the American West, cleanses and purifies mind, body and spirit. Pink Salt helps remove toxins and boost circulation. Pink salt contains more than 84 minerals and trace elements. It ionizes the air to nourish, clear and calm any space. Cedar promotes emotional balance, heightened spiritual awareness and meditation.
Or this, from Healing Scents Natural Products:
Essential Oil and Herbal Blends for almost any problem you may have in your life . . . Our most popular is our Cold/Flu/Sinus Oil – don’t get sick; use essential oils to stay healthy when everyone else is ill.
And this, from Creating Harmony, LLC, describing its “flower remedy mists:”
Everything on this planet has its own energy field surrounding it. Flower Essences and Gem Elixirs are the result of the interplay of a mineral or flower and sun/moonlight and water. The energy of the sunlight transfers the energetic imprint of this pattern into the water which has the capacity to hold the integrity of the energetic pattern. . . When you use a mist, you breathe into your body and aura the plant and gem vibrations that match the healing you are seeking allowing you to practice a different vibration.
I also note, with dismay, that the Campaign lists the endorsement of the appalling anti-vaccination organization, Holistic Moms Network. It is all well and good to advocate for safer cosmetics, but credibility is undermined when an organization is simply substituting one form of bad science for another. Why the Breast Cancer Fund, which apparently started the Campaign, would tolerate these associations is beyond me.
According to STAT, the Senate is set to adjourn later this week, so it is unlikely the bill will move forward this year. It will probably be reintroduced in January. At a mandate of only five chemicals a year, it will take long past our lifetimes to get to all of them. On the other hand, at least the FDA will know what companies are out there (assuming industry compliance) and will have the power to recall dangerous cosmetics. It’s far from perfect, but it’s better than the current system and, with industry and bipartisan support, has a chance of passing. Sadly, in today’s political climate, perhaps that’s the best we can hope for.

Donald Trump and Peter Thiel vs. the FDA: Be afraid. Be very afraid.
Donald Trump’s three most likely picks for FDA Commissioner all favor loosening drug approval standards. Two are cronies of Peter Thiel, of which one believes that the FDA shouldn’t require evidence of efficacy, only safety, and the other believes that a “Yelp for drugs” would do a better job than the FDA. The third candidate is a bona fide, honest-to-goodness pharma shill. If any of them becomes FDA Commissioner, drug safety standards will take a nosedive.
David Gorski on January 16, 2017
Link

Here at the Science-Based Medicine blog, we argue that the best medicine is based on rigorous science. In today’s technological age, it’s easy to forget that, throughout most of its history, medicine was not very scientific at all. Ancient Egyptian physicians, for instance, were invariably also priests, and for the thousands of years after them medicine tended to be based in anecdote and mystical belief, largely because the tools to do otherwise had not yet been developed.
Indeed, it is almost certainly not a coincidence that the pace of discovery and innovation in medicine accelerated as more rigorous science was applied to it, and then after the Flexner Report science- and evidence-based practice was codified as part of medical education. As hard as it is to believe, this transformation is no more than 150 years old or so. Although there were important discoveries before that and others might choose other milestones (e.g., James Lind’s discovery that citrus fruit can prevent scurvy, which was the first-ever clinical trial), I tend to date the beginning of science-based medicine to the era of Louis Pasteur. However you date the beginning of the era of SBM, it is short compared to the overall history of medicine.
We also argue that the best medical policy is policy based on science. In my view, the purview of science-based medicine should not be so limited but should include any area where decisions, actions, or policy have a direct impact on health. Of course, this is more contentious an area, as SBM can produce a number of options in any given health policy area, each with their own advantages, disadvantages, and costs. Choices are also constrained by resources and what is politically possible at the time. Even so, I like to think that the best medical policy occurs when everyone agrees that the options must be strongly science-based. Nowhere is this more true than in the area laws and regulations governing drug and medical device approval, the purview of the Food and Drug Administration (FDA). There has always been a tension between protecting the public from dangerous products by making sure they have evidence of efficacy and safety before they are approved for market and not unduly delaying the approval of potentially life-saving products or making the regulatory hurdles to approval such that it is too expensive for companies to bring new drugs to the market. Indeed, the tension between the need to assure new drugs and devices are safe and effective and the desire for speedy approval is not a new one. Most recently, it has flared up in the “right-to-try” movement, which is being sold as a means of saving lives by letting terminally ill patients have unfettered access to experimental therapeutics but is in reality a cruel sham of false hope. This tension also produced the misguided 21st Century Cures Act, which promises to speed new drug approval by encouraging the FDA Commissioner to lower the bar of evidence for approval of new drugs.
Unfortunately, there is good reason to fear that SBM will take a hit at the FDA over the next four years. Two months ago, I wrote about my concerns about what will happen to medical science policy under Donald Trump. These concerns were several, but in particular I worried about what will happen to the FDA. There is good reason to be worried, as I now know of at least three different candidates who have been considered for FDA Commissioner, and they are all very scary if you support a strong, science-based FDA that protects the public by assuring that rigorous science is the basis for drug approval in the US. Let’s just put it this way. Two believe that the FDA is way too rigorous and too slow to approve drugs (even believing that the FDA shouldn’t need to require evidence of efficacy), and one is a bona fide, honest-to-goodness pharma shill. If any of these men are nominated and approved, we’ll have someone in charge of the FDA who very much wants to lower scientific standards for drug approval in the name “streamlining” the process. The only difference will be in degree.
Let’s take a look at the candidates. First, however, let’s look at who’s running the show.
Peter Thiel will likely pick the new FDA Commissioner
Peter Thiel is a Silicon Valley venture capitalist who is the co-founder of PayPal. He is also a fervent libertarian known for his belief in a technological singularity, which is, in brief, the hypothesis that the invention of artificial superintelligence will abruptly trigger runaway technological growth, resulting in unfathomable changes to human civilization. According to this hypothesis, an artificial intelligence that is self-upgradable would enter a “runaway reaction” of self-improvement cycles, with each new (and more intelligent) iteration appearing faster and faster, ultimately resulting in a superintelligence that would far surpass all human intelligence, resulting in a radical change in human civilization. Lots of science fiction is based on concepts very much like the singularity. For instance, basically The Terminator movies can be viewed in part as exploring what would happen if the singularity resulted in machine intelligence that decided humans are superfluous. Some believers in the singularity predict that the singularity will be the path to human immortality through evolving into something else, such as an immortal, ever-improving machine intelligence.
Thiel also strongly supports life extension research that often delves deep into woo. Indeed, Peter Thiel appears to want, more than anything else, to find a way to escape death and, to that end, has invested millions of dollars into startups working on anti-aging medicine. For instance, Thiel is into parabiosis, which Steve Novella refers to as “the next snakeoil.” Basically, it’s another “fountain of youth,” that postulates that the blood of the young (or, in this case, plasma) will reinvigorate and reverse aging in the old. There’s a bit of science there, but let’s just say the claims go far beyond what the science supports. Thiel is also very much into supporting seasteading, a movement whose mission is to “to establish permanent, autonomous ocean communities to enable experimentation and innovation with diverse social, political, and legal systems.” Basically, the idea is to escape existing governments to try to develop libertarian paradise.
Relevant to his influence on Donald Trump’s science policy is Thiel’s view that the government in general—the “progressive left” in particular (whatever that means)—always impedes scientific innovation:
Most of our political leaders are not engineers or scientists and do not listen to engineers or scientists. Today a letter from Einstein would get lost in the White House mail room, and the Manhattan Project would not even get started; it certainly could never be completed in three years. I am not aware of a single political leader in the U.S., either Democrat or Republican, who would cut health-care spending in order to free up money for biotechnology research — or, more generally, who would make serious cuts to the welfare state in order to free up serious money for major engineering projects. Robert Moses, the great builder of New York City in the 1950s and 1960s, or Oscar Niemeyer, the great architect of Brasilia, belong to a past when people still had concrete ideas about the future. Voters today prefer Victorian houses. Science fiction has collapsed as a literary genre. Men reached the moon in July 1969, and Woodstock began three weeks later. With the benefit of hindsight, we can see that this was when the hippies took over the country, and when the true cultural war over Progress was lost.
Today’s aged hippies no longer understand that there is a difference between the election of a black president and the creation of cheap solar energy; in their minds, the movement towards greater civil rights parallels general progress everywhere. Because of these ideological conflations and commitments, the 1960s Progressive Left cannot ask whether things actually might be getting worse. I wonder whether the endless fake cultural wars around identity politics are the main reason we have been able to ignore the tech slowdown for so long.
One can’t help but note that Robert Moses couldn’t have achieved anything like what he achieved without the full power of government behind him to condemn property, bulldoze opposition (literally and figuratively), and pour resources into projects that were often controversial. Ditto Oscar Niemeyer. In any case, to Thiel, it’s those nasty “aged hippies” and “Progressive Leftists” (why the capitalization, I wonder) who are to blame for the FDA’s problems through their damned “overcautious” insistence on scientific evidence that a drug is effective and that its risks do not outweigh its benefits (i.e., it is safe) before it is approved.
So who are the acolytes of Thiel under consideration for FDA Commissioner? Two names popped up the other day, one that was first floated over a month ago and a second that was new:
The two tech investors tied to Peter Thiel met with president-elect Donald Trump on Thursday, and discussed, among other things, the possible future of the FDA.
Balaji Srinivasan, CEO of bitcoin start-up 21.co, and Jim O’Neill, the managing director of investment firm Mithril Capital Management, were both scheduled to meet with Trump Thursday afternoon. Both “are being considered for positions in the FDA,” incoming White House press secretary Sean Spicer said on a daily briefing call.
Jim O’Neill’s name first appeared as a candidate for FDA Commissioner in December. The news story above is the first indication that Srinivasan was also under consideration. Let’s take a look at each of them in turn. It’s not clear which one of them is under consideration for Commissioner, as they might be under consideration for other positions in the FDA as well, but it seems likely that one of them is likely to be Trump’s nominee.
Jim O’Neill on the FDA approval of drugs: “Let’s prove efficacy after they’ve been legalized”
I first encountered Jim O’Neill’s name in the context of Trump’s vision for the FDA over a month ago in a Gizmodo article with an alarming title:
As far as jobs enshrined at the top of our impenetrable bureaucracy go, the head of the Food and Drug Administration is pretty important. The chief of the FDA is responsible for setting the course of an organization that oversees the safety and efficacy of a huge array of products that Americans use everyday [sic], from makeup and cell phones to food and drugs. In total, each year it oversees more than $1 trillion in consumer goods.
Which is why it is pretty freaking terrifying that President-elect Donald Trump is considering appointing staunch libertarian and Peter Thiel crony Jim O’Neill to head the FDA. In the past O’Neill has proposed FDA reforms that would dilute much of the agency’s regulatory authority. Among other things, he has advocated for the FDA to give up on vetting the efficacy of new drugs before they come to market. O’Neill, in other words, would like the FDA to stop performing one of its primary functions and let all of us act as lab mice. Such a move might allow drug makers to rake in tons of cash on untested medical treatments that might not ever work.
This is, of course, not a surprising view among libertarians and free market fundamentalists—or even a particularly unusual one. I’ve discussed it before on multiple occasions. The idea boils down to this: If only we’d slash those “onerous” FDA regulations and accelerate the approval process for drugs, thanks to the magic of the free market, cures would come flowing out of industry and academia. I can’t resist paraphrasing Donald Trump. Basically, from this view, if we “unleashed the power of the free market” and let it determine what is effective and safe, we’d win so much that we’d get tired of winning. Peter Thiel believes this, and, not surprisingly, so does Jim O’Neill. Granted, it’s true that any drug regulatory system has to balance caution and the requirement for evidence of safety and efficacy versus cost and time to market. Unfortunately, however, free market fundamentalists of O’Neill’s ilk exhibit a child-like faith that the free market alone (or with minimal government interference) can guarantee that drugs are safe and effective, and that tort law allowing victims of bad drugs to sue will keep drug companies honest.
I’ve also discussed many times how this view is very misleading at the least, given that the FDA actually approves drugs at least as quickly as its European counterparts, and often more quickly. Basically, slow drug approval was a problem that was largely addressed and mostly overcome with the various expedited approval pathways developed in response to the AIDS epidemic and the political activism of those affected by HIV in the 1980s and 1990s. An article by Nick Gillespie from 2014 entitled “Kill the FDA (Before It Kills Again)” gives you an idea where people like Gillespie and O’Neill are coming from, as does an article by Ronald Bailey, “What’s to Blame for Fewer New Pharmaceuticals?” The basic idea is that the FDA is so strict that people are dying in droves because it doesn’t approve new life-saving drugs fast enough. Of course, completely missing from Bailey’s and Gillespie’s equation is the number of drugs that the FDA doesn’t approve because they don’t show efficacy and safety that could allow even more people to die or even actively kill some of them.
But who is Jim O’Neill? First of all, let’s look at who he isn’t. He isn’t what the FDA Commissioner has traditionally been, a physician or a scientist with a medical research or policy background. He was, however, principal associate deputy secretary at the Department of Health and Human Services under George W. Bush, whatever that means. What he is is managing director at Mithril Capital Management, a venture firm founded by Peter Thiel to promote “risky” medical research. (No conflicts of interest there with the pharmaceutical and medical device companies that the FDA regulates, right?) Not surprisingly, O’Neill is also a free market fundamentalist, seemingly believing that all that pesky FDA regulation is unnecessary and that the magic of the free market will deliver life-saving drugs and devices at low prices while weeding out the bad stuff. As I like to say: This worked so well before the founding of the FDA in 1906. Anyone remember where the term “snake oil salesmen” came from?
He also appears to be into a fair amount of woo, in particular anti-aging woo. Now, if there’s one area where there’s a whole lot of quackery and dubious medicine, it’s anti-aging research. Remember, a lot of the stem cell clinics that use the hard sell to sell outright quackery to desperate patients claim that their stem cell treatments slow or reverse aging.
Articles about O’Neill focus on this particular quote by him:
“We should reform FDA so there is approving drugs after their sponsors have demonstrated safety — and let people start using them, at their own risk, but not much risk of safety,” O’Neill said in a speech at an August 2014 conference called Rejuvenation Biotechnology. “Let’s prove efficacy after they’ve been legalized.”
That quote comes from a speech which is still available on YouTube.
In it, O’Neill advocates approving drugs based on safety studies alone, and leaving those pesky efficacy studies for after approval. Of course, if a drug is approved based on safety studies alone, pharmaceutical companies would have much less incentive to actually do rigorous efficacy studies. This statement betrays an utter lack of understanding of how the drug approval process works. Matthew Herper explained.
I also note that the FDA approval process is a matter of law, specifically the 1962 Kefauver amendment that said drugs must be proved safe and effective before they can be sold. That law was passed in the wake of the thalidomide scandal. Fortunately, thanks to one stubborn woman, Frances Oldham Kelsey, an FDA scientist who insisted on more safety data and did not budge under pressure (and who, fortunately, was supported by her superiors even under intense pressure from the pharmaceutical company that wanted to market thalidomide in the US), thalidomide was never approved in the United States. For O’Neill to change the approval process would require a change in the law. There’s also a longstanding tradition of the FDA Commissioner not commenting on or meddling in the approval process of any given drug and instead leaving it to the career scientists at the FDA. This is a good tradition that should be maintained, but one wonders if O’Neill would maintain it. Unfortunately, the law also gives the FDA Commissioner fairly broad discretion about what evidence the FDA will consider sufficient evidence of efficacy, but fortunately much of that is codified into federal regulations, where there’s a process that has to be followed to change them. The recent 21st Century Cures Act might have made it easier for the FDA Commissioner lower the bar of scientific evidence to approve a drug, but it did not eliminate the fundamental requirement of the Kefauver amendment.
I also see in O’Neill’s talk is that he doesn’t understand why drug development is so hard compared to devices and platforms. He points out how software development is completely unregulated, while biotech is heavily regulated, which to him is why the pace of drug development has slowed down and biotech is very expensive compared to software. Seriously? O’Neill’s comparing apples and oranges. One reason why drug development is so hard these days is because the low-hanging fruit has all been picked, leaving only progressively more difficult targets. Yes, we have all this genomic information, but one wonders if O’Neill understands the concept of a “druggable target.” Basically, that’s an enzyme or molecule that a drug can be designed to target. What we find in all this genomic medicine and systems biology is that druggable targets are increasingly difficult to come by. Also, as a software engineer told me discussing this, most software is not life-or-death. No one will die if it doesn’t work properly. For software that is truly “mission critical,” where people can definitely die if it doesn’t work properly, standards are actually quite stringent. Basically, if O’Neill wants to compare software development to drug approval, he should look at the development of software for aircraft, where the certification process for every line of code ramps up into thousands of man-hours. That’s a better comparison.
So that’s Jim O’Neill. What about Balaji Srinivasan?
Balaji Srinivasan: Deleting his Twitter archive to hide his hostility to the FDA
Balaji Srinivasan is also a Silicon Valley entrepreneur. Like O’Neill, he is not a scientist, but rather CEO of bitcoin start-up 21.co. He is also a partner at venture firm Andreessen Horowitz and teaches at Stanford University. His primary expertise is in the area of digital payments and computational biology, and his expertise in health regulation stems from a start-up company he co-founded, Counsyl Inc., which offers DNA screening, especially for people considering having children. He also shares the same sort of views as Thiel and O’Neill:
Thiel, who’s advising Trump on science and technology in the new administration, is a libertarian who has advocated for disrupting society with technology in order to improve it. Srinivasan’s views about the U.S. government—and the FDA in particular—may create challenges in getting confirmed, if nominated. He’s called for letting Silicon Valley entrepreneurs secede from the U.S. and “build an opt-in society, ultimately outside the U.S., run by technology.”
It’s interesting to note that late last week after his meeting with Donald Trump, Srinivasan deleted his Twitter account, leaving only a single Tweet:
Don’t argue on Twitter.Build the future.
— Balaji S. Srinivasan (@balajis) January 14, 2017
So very “responsible,” right? So very oozing with self-righteousness! Of course, Srivivasan’s pious act is pretty disingenuous, given that, prior to meeting with Trump, he was well known for loving to mix it up on Twitter, much like Donald Trump, except that he actually responded to others. Not surprisingly, the deletion of his Twitter archive did not go unnoticed:
Possible FDA pick @balajis deleted all his tweets after mtg with Trump today. I archived some from the google cache: https://t.co/WgOHNijpNM
— Christa Peterson (@christapeterso) January 15, 2017
And:
Trump’s pick to lead the FDA, @balajis, just deleted his tweets, including this one: who needs the FDA when we have online reviews? pic.twitter.com/koexKqS4uk
— Christa Peterson (@christapeterso) January 14, 2017
Also, Peter Kafka at RECODE noted:
Why would Srinivasan delete his Twitter archive? It would be nice to hear from the man himself, but here’s a reasonable guess: He spent a lot of time criticizing the FDA, and he’d rather pretend those criticisms didn’t exist.
Then again, Srinivasan understands how technology works, so he certainly knows that deleting your tweets doesn’t make them disappear. You can get a sense of what Srinivasan used to tweet about by looking at this Google cache.
And you can get much more specific, courtesy of people who took screenshots of some of his tweets: In short, Srinivasan seems to think the FDA prevents drug companies and startups from innovating by imposing unnecessary regulations.
Kafka includes several examples of Srivinasan’s anti-FDA Twitter rants, many of which indicate that he shares O’Neill’s delusion that the free market is the best method for determining which drugs work the best. In fact, he goes even beyond O’Neill! For instance, in one Tweet from 2014, he said that we “can do vastly better than FDA w/ a Yelp for drugs, including MD star ratings (like all other products).” Last year, he made similar arguments, except that he used eBay, Uber, and Airbnb as the model, as noted here by Christa Peterson:
.@balajis is pretty into this whole replace-the-FDA-with-online-reviews thing pic.twitter.com/7YeGE4vzH1
— Christa Peterson (@christapeterso) January 14, 2017
Notice in one of these, Srivinasan is asked, “But how do you prevent quacks?” His answer: “Scaled Internet reputation systems. Works at massive scale in other areas.”
Yeah, right. Does this guy have any clue how ignorant of how drugs are developed he sounds?
Elsewhere:
idk if this needs to be said, but this is a really stupid idea.
— Christa Peterson (@christapeterso) January 15, 2017
Of course, there are many huge problems with a “Yelp for drugs” or using the Uber model. First of all, for restaurants or rides, it’s very much apparent to the end user whether the service “worked.” Either the food was good or it wasn’t. Either it was worth the price to the user or it wasn’t. Either the service was good or it wasn’t. Either the ride showed up on time and got you where you wanted to go at a reasonable price or it didn’t. People can judge these things without any specific expertise. For drugs and devices, that’s just not so easily done. Whether a drug is working or not is not necessarily obvious to the user (although it can be sometimes). Also, thanks to something we discuss very frequently here at SBM, whether a drug “works” or not also can be affected by patient expectations and placebo effects, hence the need for randomized, double-blind clinical trials. Peterson nails it again:
Even if we could get accurate descriptions of users’ experiences (we wouldn’t), we wouldn’t be getting the data we need to evaluate a drug.
— Christa Peterson (@christapeterso) January 15, 2017
She’s produced a pretty comprehensive archive of deleted Srivinasan Tweets regarding the FDA that’s worth perusing. His whole philosophy seems to boil down to this:
Don’t argue about regulation.Build Uber.Don’t argue about monetary policy.Build Bitcoin.Don’t argue about it.Build the alternative.
That’s nice. However, to build an alternative, you need to know how the existing system actually works and why. Srivinasan shows no sign of that with respect to the FDA, as this Tweet showed:
FDA bears responsibility for many deaths. Blocked many good drugs. http://www.theatlantic.com/health/archive/2011/12/before-occupy-how-aids-activists-seized-control-of-the-fda-in-1988
This is, of course, complete and utter nonsense, as I explained when I deconstructed Nick Gillespie and Ronald Bailey’s articles claiming the same thing.
So two of Trump’s FDA picks are libertarians, one who thinks that the FDA should only require evidence of safety and that the free market should figure out efficacy, the other who thinks that online reputation systems and ratings can replace FDA regulation. Who’s the third?
I’ll take Pharma Shills for $2,000, Alex.
Scott Gottlieb: An honest-to-goodness real pharma shill for FDA
So two of the candidates I’ve heard of for FDA Commissioner basically oppose the mission of the FDA. The third is different. No, he doesn’t support more stringent regulation. Perish the thought! Rather, he’s different in that he is a real, honest-to-goodness, bona fide pharma shill, as you will see. I’m referring to Scott Gottlieb, MD, who, unlike O’Neill and Srivinasan, is at least a physician. His name came up around the same time as O’Neill’s, as this Reuters report shows. Gottlieb is young and is currently a venture partner at New Enterprise Associates and a resident fellow at the American Enterprise Institute, a conservative think tank based in Washington. He’s also a pundit who frequently appears on TV and in print.
Scott Gottlieb is a bona fide, honest-to-goodness pharma shill. He works for pharma and has for a long time. In fact, because it amuses me, let me quote über-quack, Donald Trump supporter, and newly minted alt-right icon, Mike Adams about Gottlieb in 2008 (OK, not Adams himself, but one of his drones):
Scott Gottlieb, the former FDA Deputy Commissioner for medical and scientific affairs, is now actively involved in the marketing of Eli Lilly’s drug raloxifene, marketed as Evista.
Due to his Wall Street connections with the pharmaceutical industry, Gottlieb frequently had to recuse himself from discussions that were part of his FDA duties. He gained notoriety for calling the early termination of a multiple sclerosis drug study “an overreaction,” even though three participants had died, and was highly critical of the groundbreaking Women’s Health Initiative study, which found that hormone replacement therapy posed more risks than benefits to women’s health.
In 2005, Eli Lilly was convicted of illegally marketing osteoporosis drug Evista for off-label treatment and prevention of heart disease and cancer. According to Justice Department documents, Eli Lilly decided to market the drug off-label when early sales of the drug for osteoporosis alone proved disappointing.
Unlike the vast majority of what passes for “news” on NaturalNews.com, the above passage is actually accurate. After he left the FDA, Dr. Gottlieb went back to private practice but also worked for Eli Lilly on the side to market Evista, even after Eli Lilly had been shown to have marketed it for off-label indications. During his actual tenure at the FDA as Deputy Commissioner, he had so many financial conflicts of interest with pharma companies that he had to recuse himself from resource planning for a potential bird flu epidemic because of his financial ties to Sanofi-Aventis, as well as work related to Eli Lilly, Proctor & Gamble, and, yes, five—count ‘em, five!—other drug companies. And yes, he did show his pro-pharma bias in ways other than criticizing the halting of a trial in which three people died, for example:
And when FDA scientists rejected Pfizer’s osteoporosis drug candidate Oporia, forecast to earn $1 billion a year, underlings received accusatory emails from Gottlieb.
His on-to-Wall-Street approach succeeded in rushing Chantix, Pfizer’s stop smoking drug, varenicline, to market but a string of 2006 suicides and the violent death of Dallas musician Carter Albrecht leave many asking if that was such a good thing.
“The truth is, the FDA’s required trials reveal limited information,” Gottlieb wrote presciently in an oped in the Chicago Tribune in 2005. “In many cases, it is only after drugs are on the market for many years and given to thousands of patients that their true benefits (sic.) are revealed.”
Which is true but irrelevant and, above all, not an excuse to use less rigorous trials as the basis to approve drugs (or, if you’re Jim O’Neill or Balaji Srinivasan, to give up demonstrating efficacy altogether before approving drugs). If anything, it is a good reason for much stricter post-marketing regulations. One wonders if Dr. Gottlieb would support much stronger regulations of this type, one does. Somehow I doubt it. After all, as Reuters reports, Gottlieb’s ties to the pharmaceutical industry still run deep, with him sitting on the boards of multiple companies and advising others, including the British pharmaceutical giant GlaxoSmithKline Plc.
Here’s the thing. As bad as I find the potential pick of Dr. Gottlieb to run the FDA (albeit not as bad as Jim O’Neill would be), there is one good thing about it, and that’s the schadenfreude I’m feeling with respect to antivaccine activists and quacks. Why schadenfreude? Easy. Recall the open letter containing a wish list of what antivaccinationists would like to see from Trump after he becomes President. Although, the FDA wasn’t mentioned, I can’t help but wonder what antivaccine contingent would think of Scott Gottlieb as the FDA Commissioner, given that he is a real pharma shill (unlike the fake accusations of being a “pharma shill” favored by quackery lovers). Remember the H1N1 “swine flu” scare back during the 2009-2010 influenza season? Remember how it freaked out antivaccinationists, who envisioned “forced vaccination” and feared all manner of new and evil flu vaccines? Take a look at what Gottlieb was writing back then. Basically, he accused the FDA of being overly cautious and “shunning” new vaccines. Elsewhere, he wrote:
Too many of the policy choices we were confronted with in this crisis forced us to sacrifice speed and reliability of vaccine production to assuage concerns about vaccine safety. We also did not have adequate domestic vaccine capacities to serve our own population. Vaccine supplies are increasing, but we still do not have the quantities we expected, and we need them now.[5] Among other things, we chose to forgo the use of vaccine additives that could have boosted effectiveness and might have helped us stretch our limited supply of vaccine raw material over more shots.
Of course, Gottlieb’s views on vaccine policy, while a bit more aggressive than my own, are not entirely unreasonable. I agree that our vaccine development and manufacturing infrastructure could use some serious modernization and that it would be good to have new adjuvants. Of course, all of these positions are anathema to the antivaccine movement that loves Donald Trump.
Trump’s candidates for FDA Commissioner: A “Sophie’s choice”?
Obviously, I don’t like any of the candidates under consideration by the Trump transition team to become FDA Commissioner. Any of them would be very likely to significantly seriously weaken regulations that protect consumers from dangerous and/or ineffective drugs and contaminated food, some more than others. Basically, you have to pick your poison: Do you pick a libertarian who doesn’t think that the FDA should have to require the demonstration of efficacy before approving drugs, a libertarian who thinks that drug approval and regulation can be replaced by online reputation systems, or a bona-fide, honest-to-goodness pharma shill, someone who’s a pharma shill to a level that most pharma shills only dream of? It’s basically a Sophie’s choice here. No one, myself included, is saying that the FDA couldn’t use some reforms to make it function more efficiently, but one thing it doesn’t need is a bunch of reforms that would gut its ability to assure that new drugs are both safe and effective, which is basically what all three of the candidates Trump is considering for the job want to do in the name of “speeding up” and “modernizing” drug approval.
Unfortunately, we probably don’t have long to find out whom Trump will pick, and, as far as I can tell, it will almost certainly be one of these three. Given the news stories late last week about Trump meeting with Jim O’Neill and Balaji Srinivasan, coupled with his tight relationship with Peter Thiel, my guess is that Gottlieb’s star is on the wane and that it’s probably already a done deal that either O’Neill or Srinivasan will be the new FDA Commissioner, possibly with the other to be appointed Deputy Commissioner. Peter Thiel is basically calling the shots here, and these are his boys. Compared to them, Scott Gottlieb, who, being a physician with deep ties to pharma, would be a far more conventional conservative pick, probably doesn’t have a chance, although ironically, to me Gottlieb would be the “least bad” selection.
Ironically, for all their belief that the “free market” will solve the problem of drug safety and efficacy, neither O’Neill nor Srivinasan seems to understand that a lot of biotech entrepreneurs are actually a fan of a tough FDA, as Matt Herper points out:
Many biotech entrepreneurs are actually fans of a tough FDA. At the Forbes Healthcare Summit, pharmaceutical billionaire Leonard Schleifer, the founder and chief executive of Regeneron Pharmaceuticals, said that he was against “making it really easy to get your drug approved” at the Forbes Healthcare Summit last week, before news of that O’Neill was under consideration leaked.
Schleifer said that he couldn’t compete with companies like Pfizer or Eli Lilly, which have 10 to 100 times as many salespeople as Regeneron. But he can compete to get approved first, or to have a better drug that has more uses that the FDA allows it to advertise based on science.
“Having a high bar is a good thing, in my opinion, because it allows innovators to compete,” Schleifer said.
In reality, their claims to being a libertarian in favor of innovation and the little guy competing to come up with the “next big thing” in a little lab notwithstanding, both Srivinasan’s and O’Neill’s concept of a weak FDA would hugely favor big pharma over entrepreneurs.
Whoever is nominated, one thing is very certain. Drug approval standards and drug regulations will be loosened as far as the new FDA Commissioner can manage under existing law. Here’s to the next Vioxx.

   The FDA Cracks Down on Fake Cancer Cures
Steven Novella 
Link
The Food and Drug Administration (FDA), the agency that regulates the drug industry in the US, put out a press release yesterday warning “Individuals and Firms to Stop Selling Fake Cancer ‘Cures’.” The press release reports:
“Although promotions of bogus cancer ‘cures’ have always been a problem, the Internet has provided a mechanism for them to flourish,” said Margaret O’K. Glavin, the FDA’s associate commissioner for regulatory affairs. “These warning letters are an important step to ensure that consumers do not become the victim of false ‘cures’ that may cause greater harm to their health.”
The FDA therefore recognizes that this is a serious problem, and that is good. They also acknowledge that the problem of “bogus cancer cures” is a longstanding one, not a new or recent problem, but the reason they are taking action now is because the internet is significantly increasing the reach of these fake cures.
In the US the FDA regulates as drugs only those products that are already designated as a drug or for which disease claims are made. Everything else, in the context of regulation, is a supplement and is regulated under DSHEA – the Dietary Supplement Health and Education Act. For these substances sellers can make so-called “structure function” claims (that a product improves or supports a structure or function of the body) but cannot make claims that their product cures or alleviates a specific disease. In practice this is a fine line, but this is the line the FDA is now defending.
Essentially, the FDA is going after cancer supplement sellers who are stepping over the line and making claims that their product (which is not approved by the FDA) can cure cancer. They list the suspect claims as follows:
    • “Treats all forms of cancer”
    • “Causes cancer cells to commit suicide!”
    • “80% more effective than the world’s number one cancer drug”
    • “Skin cancers disappear”
    • “Target cancer cells while leaving healthy cells alone”
    • “Shrinks malignant tumors”
    • “Avoid painful surgery, radiotherapy, chemotherapy, or other conventional treatments”
What is more, the effort is part of a larger initiative to protect the public from such false treatments. The FDA sent 23 warning letters to US companies urging them to cease their fraudulent activity. In addition they state:
The Warning Letters are part of the FDA’s ongoing efforts, in collaboration with the Federal Trade Commission (FTC) and Canadian government agencies, to prevent deceptive products from reaching consumers. The initiative originated from consumer complaints and a web search for fraudulent cancer products conducted by the FDA, FTC and members of the Mexico–United States–Canada Health Fraud Working Group. Earlier this year, FTC sent Warning Letters to 112 Web sites falsely promoting cancer “treatments” and referred several others to foreign authorities.
In the US The FTC picks up where the FDA leaves off. Even if a company is not violating FDA regulations they still cannot lie to consumers or market a fraudulent or harmful product. Therefore it is necessary with such widespread abuse that the agencies work together. In addition, the internet means that increasingly fraudulent treatments are multi-national – a foreign-run website may be selling products to American or Canadian citizens. Therefore the FDA must increasingly cooperate with foreign regulatory agencies, like they are now with Mexico and Canada.
Even more encouraging is that the FDA is publishing warnings for consumers about health fraud in general. In this consumer update they warn about the signs of health fraud:
    • Statements that the product is a quick and effective cure-all or a diagnostic tool for a wide variety of ailments.
    • Suggestions that a product can treat or cure serious or incurable diseases.
    • Claims such as “scientific breakthrough,” “miraculous cure,” “secret ingredient,” and “ancient remedy.”
    • Impressive-sounding terms, such as “hunger stimulation point” and “thermogenesis” for a weight loss product.
    • Claims that the product is safe because it is “natural.”
    • Undocumented case histories or personal testimonials by consumers or doctors claiming amazing results.
    • Claims of limited availability and advance payment requirements.
    • Promises of no-risk, money-back guarantees.
    • Promises of an “easy” fix for problems like excess weight, hair loss, or impotency.
In the same document they further warn of the types of harm that fraudulent therapies can cause, including: direct harm from side effect, delaying appropriate and effective treatment, and interfering with effective treatment. I would add to these items: adding an unnecessary financial burden to a patient and family that is likely already burdened by illness, the emotional and psychological harm caused by giving false hope to the desperate, and the indirect harm done by fostering anti-scientific attitudes and beliefs.
While I applaud this new initiative, it also feels as if the FDA is coming a little late to this party – but better late than never. In the last 20-30 years fraudulent health care has been on the rise and has been increasing bypassing regulatory mechanisms designed to protect the public from fraud by hiding under more pleasing labels and rhetoric, such as “health care freedom,” alternative medicine,” and “natural cures.” These labels have been very success as marketing strategies, but they are all ultimately about selling treatments that do not meet reasonable standards of scientific plausibility and evidence.
The FDA now seems to recognize the problem, or (more likely) has gathered the political will to admit the problem exists and face it head on. This is only one of many fronts on which science-based medicine needs to be defended – but it is a critical one and it is heartening to see the FDA recognizing much of what we have been advocating on this blog.
Let’s hope their crack down on fake cancer cures metastasizes to all other fraudulent cures.

   FDA approval of drugs and transparency in clinical trial results
David Gorski
Link
One thing that science relies on almost absolutely is transparency. Because one of the most important aspects of science is the testing of new results by other investigators to see if they hold up, the diligent recording of scientific results is critical, but even more important is the publication of results. Indeed, the most important peer review is not the peer review that occurs before publication. After all, that peer review usually consists of an editor and anywhere from one to four peer reviewers on average. Most articles that I have published were reviewed by two or three reviewers. No, the most important peer review is what occurs after a scientist’s results are published. Then, all interested scientists in the field who read the article can look for any weakness in methodology, data analysis, or interpretations. They can also attempt to replicate it, usually as a prelude to trying to build on it.
Arguably nowhere is this transparency quite as critical as in the world of clinical trials. The reason is that medications are approved on the basis of these trials; physicians choose treatments; and different medications become accepted as the standard of care. Physicians rely on these trials, as do regulatory bodies. Moreover, there is also the issue of publication bias. It is known that “positive” trials, trials in which the study medication or treatment is found to be either efficacious compared to a placebo or more efficacious than the older drug or treatment it is to replace, are more likely to be published. That is why, more and more, steps are being taken to assure that all clinical trial results are made publicly available. For example, federal law requires that all federally-funded clinical trials be registered at ClinicalTrials.gov at their inception, and peer-reviewed journals will not publish the results of a clinical trial if it hasn’t been registered there. Also, beginning September 27, 2008, the US Food and Drug Administration Amendments Act of 2007 (FDAAA) will require that clinical trials results be made publicly available on the Internet through an expanded “registry and results data bank,” described thusly. Under FDAAA, enrollment and outcomes data from trials of drugs, biologics, and devices (excluding phase I trials) must appear in an open repository associated with the trial’s registration, generally within a year of the trial’s completion, whether or not these results have been published. Although there are some practical issues over this law, for example determining how much information can be disseminated this way without constituting prior publication, which is normally a reason to disqualify a manuscript from publication.
Today, a rather telling study was published in PLoS Medicine. Undertaken by Ida Sim and colleagues at the University of California at San Francisco, the study, entitled Publication of clinical trials supporting successful new drug applications: A literature analysis (press release here), suggests a need for greater transparency. Sim and colleagues took a rather obvious tack and went to the literature itself to look at the evidence used to support FDA approval of new drugs to see how much of it is actually published. The results, even if they overestimate the effect reported, are disturbing. It turns out that more than half of the clinical trials used to support FDA approval of drugs remain unpublished more than five years after that approval. There are several disturbing implications that derive from this observation. More on that later. But first let’s look at the study’s methodology.
Briefly, Sims et al conducted a cohort study of clinical trials supporting new drug applications (NDAs) that were approved between 1998 and 2000. Drugs were identified by a search of the FDA website. They further looked at trials deemed “pivotal.” Pivotal trials are trials that demonstrate the efficacy and safety of a drug for its proposed indication. They are the trials that, according to the manufacturer and the FDA, provide the most useful information for deciding whether to approve the drug and for clinical decision-making. Thus, trials were divided into “pivotal” and “nonpivotal.” In essence, trials described in the summary documents for each drug approval and/or in the “clinical studies” section of the correspponding drug label were categorized as “pivotal.” Sims et al then systematically searched common databases of medical journals in which the results of such trials would be likely to be published, including PubMed, the Cochrane Library, and the Cumulative Index for Nursing and Allied Health Literature (CINAHL). Searches were performed on the drug’s generic name and “Publication Type: Clinical Trial,” and all English-language medical literature was searched. Trials used in the FDA review of a drug were then matched to publications based on a number of characteristics. Finally, for trials not located this way, additional searches were performed using just the drug’s generic name and a number of keywords designed to locate clinical trials that might have been missed in the original search strategy. The results were smmarized as follows (you can read the entire article yourself for the full details):
We identified 909 trials supporting 90 approved drugs in the FDA reviews, of which 43% (394/909) were published. Among the subset of trials described in the FDA-approved drug label and classified as ‘‘pivotal trials’’ for our analysis, 76% (257/340) were published. In multivariable logistic regression for all trials 5 y postapproval, likelihood of publication correlated with statistically significant results (odds ratio [OR] 3.03, 95% confidence interval [CI] 1.78–5.17); larger sample sizes (OR 1.33 per 2-fold increase in sample size, 95% CI 1.17–1.52); and pivotal status (OR 5.31, 95% CI 3.30–8.55). In multivariable logistic regression for only the pivotal trials 5 y postapproval, likelihood of publication correlated with statistically significant results (OR 2.96, 95% CI 1.24– 7.06) and larger sample sizes (OR 1.47 per 2-fold increase in sample size, 95% CI 1.15–1.88). Statistically significant results and larger sample sizes were also predictive of publication at 2 y postapproval and in multivariable Cox proportional models for all trials and the subset of pivotal trials.
A depressing additional observation was that the percentage of trials published in the peer-reviewed literature ranged from 0-100%, with a mean of 55%. That’s right; there were drugs that had 0% of the trials supporting their FDA approval published over five years later. Overall, this is what the results looked like:
One thing that I found reassuring in the figure above is that there were in general approximately ten clinical trials for each new drug to be approved by the FDA. That is actually somewhat more than I would have expected, and it actually somewhat reassures me about our drug approval process. A lot of time, money, effort, and science go into approving a new drug. Of course, it is exatly alll that time, money, and effort that lead companies to expect a return on their investment, which is why they might be less likely to want to publish equivocal or negative studies. This survey isn’t perfect, but it does give a pretty good indications of the situation out there in terms of publication bias in favor of positive studies. If it is in error, it is most likely an error of underestimating how many clinical trials were published because of misclassification of some trials as being unpublished when they actually were published. However, the authors make a very good point about this potential problem:
However, we believe that for clinicians and policy makers, the most relevant publication rate is not the overall rate but the publication rate in journals that a typical clinician, consumer, or policy maker would have access to through a reasonable literature search. We believe our searches of PubMed, the Cochrane Library, and CINAHL reflect such a reasonable search. It would not be reasonable to expect a clinician, consumer, or policy maker to contact investigators or sponsors to determine a trial’s publication status.
Another potential weakness might be that five years wasn’t a long enough followup time. However, the authors found that nearly all publications occurred within three years after FDA approval. These limitations aside, this study is highly suggestive that in the early years after the approval of a drug there is a significant publication bias favoring clinical trials with positive results over those with negative results. Thus, initially the medical literature tends to contain publications that may exaggerate the advantages of new drugs over old or falsely suggest that new drugs are more efficacious and/or safer than old drugs, and this study estimates the approximate magnitude of that bias in the literature. This article in PLoS thus serves as a good estimate of the baseline for publication bias that can be used to determine the effect of the FDAAA.
Although on the surface, the dictates of the FDAAA might appear to be an unalloyed good, that may not entirely be the case. Indeed, Sims et al suggest paradoxical harm to transparency in reporting clinicial trials:
Paradoxically, however, this new law may increase rather than decrease publication bias. Might sponsors feel less compelled to publish equivocal trials because the basic results will already be in the public domain? Might the time pressure to submit manuscripts by 1 y postapproval focus sponsor efforts even more on submitting positive trials and trials of greatest interest to journals? Might the journals, if they accept manuscripts of trials with publicly posted results, change the criteria by which publication importance is judged, and how might this affect acceptance rates [28]? When more detailed protocol information must also be posted on ClinicalTrials.gov, to start no later than October 2010, the effect on publication practices is even harder to anticipate.
Indeed, three months ago, the PLoS editors, while generally strongly supporting the law, expressed similar concerns:
Under FDAAA, will the initial reporting instead become the sole province of those with the greatest financial or personal interest in a favorable result, without the benefit of dispassionate evaluation? Will the public find itself beset by press coverage of post-hoc subgroup analyses, overgeneralizations of results, or improper statistical treatments, slickly packaged as medical breakthroughs? Or will immediate and universal access via the Internet to an ever-increasing number of health-savvy readers provide a better level of scrutiny? (These savvy readers include experienced care providers, patient and professional organizations, consumer advocates, specialty bloggers, health reporters, and entire fields of researchers—not just the few selected to perform formal peer review of a given trial.) Given that trials results must now be released irrespective of “formal” publication in a journal, it surely makes sense to ensure that the public dataset for every trial contains sufficient information to permit objective evaluation of the trial’s findings for each prespecified study outcome.
In the best case, unfettered access by these parties would provide radical improvements over the current system, in which limited access to data hampers systematic review and abets disingenuous drug marketing. It’s not difficult to imagine a vigorous network of skilled evaluators serving as watchdogs over posted data that have been misrepresented or remain unpublished. Perhaps peer-reviewed journals will provide a forum for publishing independent analyses of such datasets. The appearance of such articles would mark a full circle affirming the contribution of formal peer review, but would also demonstrate the value of openly available results.
It would not be surprising if there were a “shake-out” period for this new law, in which there is some confusion and perhaps unintended effects. Indeed, I’d be surprised if there weren’t and would expect there to be consequences not forseen in either of the analysess quoted. How scientific data from clinical trials find their way to the peer-reviewed literature is complex and, yes, more than a little tradition-bound. It has only been relatively recently, with a series of controversies concerning the alleged suppression of safety risks of drugs such as rosiglitazone (Avandia), paroxetine (Paxil), and rofecoxib (Vioxx). Indeed, I wrote extensively about another form of corrupting the clinical trial evidence (i.e., seeding trials) about a month ago, a form of clinical trial corruption that I labeled at the time a “threat to science-based medicine.” In contrast, the publication bias revealed by Sims et al is a more insidious threat to science-based medicine in that it is a problem inherent in the system The FDAAA represents a necessary first step in correcting this this bias, but it will be impossible to estimate its effect without a baseline to compare to. By quantifying the publication bias inherent in the system and providing that baseline, Sims et al have done a service to science-based medicine.
REFERENCES:
1. Kirby Lee, Peter Bacchetti, Ida Sim, Mike Clarke (2008). Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis PLoS Medicine, 5 (9) DOI: 10.1371/journal.pmed.0050191
2. PLoS Editors (2008). Next Stop, Don’t Block the Doors: Opening Up Access to Clinical Trials Results PLoS Medicine, 5 (7) DOI: 10.1371/journal.pmed.0050160

FDA versus Big Supp: Rep. Burton to the Rescue (Again)
Jann Bellamy on March 8, 2012
Link
The Dietary Supplement Health and Education Act of 1994 (DSHEA) has been aptly described here at SBM as a travesty of a mockery of a sham. The supplement industry’s slick marketing, herb adulteration due to lack of pre-market controls, Quack Miranda Warning, and the many supplements for which claims of effectiveness failed to hold up under scientific scrutiny (e.g., antioxidants, collagen, glucosamine and hoodia) have been impaled on the sharp pens of SBM posters as well.
And we’re not the only ones. Investigations of the supplement industry (or, Big Supp) by reputable institutions such as the U.S. Government Accountability Office and the Institute of Medicine have resulted in numerous recommendations to improve dietary supplement safety by, in part, strengthening the FDA’s ability to effectively regulate the industry. Many of these have gone unheeded.
A recent federal law tried to ameliorate this situation by directing the FDA to take specific steps designed to increase supplement safety. Yet the ink of President’s Obama’s signature was barely dry when a bill was proposed in Congress to gut its provisions. In fact, there are now several bills pending in Congress which would actually weaken the government’s already puny regulatory authority over supplements. Yes, things could get even worse.
DSHEA refresher
First, a bit of a refresher on DSHEA. A 2005 article in the American Journal of Law and Medicine by Peter Cohen (1.), who holds both an M.D. and a J.D., provides what I think is an apt summary of the flawed thinking underlying DSHEA, identifying these “critical weaknesses:”
     1.  “DSHEA classifies compounds as dietary supplements based on their source, rather than their pharmacologic and physiologic properties.”
     2.  “DSHEA assumes that components of foods cannot cause harm, even when ingested in large amounts, and that therefore supplements should be subject only to regulations dealing with foods rather with the more stringent regulations applied to drugs.”
     3.  “DHSEA also assumes that since herbs and botanicals are ‘natural,’ they warrant regulation only to the same extent as food components, regardless of their pharmacologic, physiologic, or pathologic attributes, and irrespective of whether they are foods at all.”
     4.  “The marketing of dietary supplements must be accompanied by a statement indicating that these substances are not intended to treat disease but rather to maintain normal bodily function. . . a meaningless distinction to most consumers.”
The dubious principles at the heart of DSHEA are exacerbated by Congress’s essentially hog-tying the Food and Drug Administration (FDA) in its ability to police the safety and effectiveness of dietary supplements, which, pre-market, is left pretty much up to the manufacturers and distributors. It is only post-market, once the harm is done, that the FDA can come in and attempt to clean up the mess. Even then, it is hampered by lack of mandatory recall authority. To ban a supplement, the FDA bears the burden of proving that a supplement ingredient presents a significant or unreasonable risk of illness or injury. As the GAO report noted, this is made difficult by the fact that there is often little scientific evidence available for the supplement in question because no evidence of safety and efficacy is required by the FDA before the product can be marketed.
There is one requirement of DSHEA with the potential to improve safety but it has been largely ignored by the supplement industry and unenforced by the FDA. Manufacturers and distributors who want to market dietary supplements containing “new dietary ingredients” must notify the FDA. Notification must include support for their conclusion that the new dietary ingredient is reasonably expected to be safe under normal conditions of use. Ingredients existing on or before October 15, 1994, were grandfathered in and did not have to meet this requirement.
(And guess what one of those grandfathered supplement ingredients was? Ephedra!)
FDA asks, very nicely, for evidence of safety
As noted in a recent New England Journal of Medicine article (2.), more than 100 million Americans consume dietary supplements, spending more than $28 billion annually. Since DSHEA was passed in 1994, the number of dietary supplements has grown from an estimated 4,000 to over 55,000. We don’t know how many of these 51,000 or so new supplements include new dietary ingredients, which should have triggered the notification requirement, but we do know that the FDA has received adequate notification for fewer than 200.
This failure of compliance and enforcement, which was noted in the 2009 GAO report, led to a requirement in the FDA Food Safety Modernization Act, effective January 4, 2011, that the Secretary of Health and Human Services publish guidance clarifying, among other things, the level of evidence needed to document the safety of new dietary ingredients.
So it came to be that the FDA, in July of last year, presented its “Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues.” As might be expected, Big Supp was not pleased. The industry’s response has been duly noted by SBM’s own David Kroll, Ph.D. The usual giant strawman, Big Pharma, was trotted out, plus overblown claims to the effect that the FDA is attempting to “ban” dietary supplements.
Let us pause here to note that what the FDA issued is guidance, not actual rules, and draft guidance at that. These are not rules anyone has to follow, nor can the FDA enforce this guidance, as is made abundantly clear in the document itself:
This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the telephone number listed on the title page of this guidance.
In other words, if you don’t like what we want you to do, call us and we’ll work something out. I mean, how much more accommodating could the FDA get?
And what does the FDA say supplement makers and distributors need to do? I agree with Dr. Kroll that the guidance is “a bit complicated.” Dr. Pieter Cohen, author of the NEJM article mentioned above, summed it up this way:
The safety of supplements would be evaluated according to three key factors: documented history of use, . . . formulation and proposed daily dose, . . . and the recommended duration of use.
In some cases, a documented history of use will be enough to meet the “reasonable expectation of safety” standard. In others, in vitro or animal, but not human, studies would be required.
Dr. Cohen finds the guidelines a step in the right direction, but not far enough. He does not believe the FDA should accept historical use in lieu of experimental data, nor should it allow companies to avoid human studies. In addition, the companies can cherry-pick the evidence, as they do not need to turn over unfavorable data.
A friend to the rescue
The hyperbolic response of Big Supp was taken up by the National Health Freedom Coalition, which sent out an “Action Alert” e-mail last month:
FDA’s draft guidance for new dietary ingredients is looming and attempting to eliminate thousands of dietary supplements currently on the market . . . . FDA’s plan [is] to impose cost-prohibitive requirements on manufacturers of these life-saving products!
The FDA is doing nothing of the sort and there is no evidence I am aware of that this long-ignored requirement is “cost prohibitive.” And “life-saving?” Please! But the “Action Alert” did actually alert me to the fact that the supplement industry was calling on an old friend in Congress to bail it out, Rep. Dan Burton (R-IN). Rep. Burton has introduced H.R. 3380, the “Dietary Supplement Protection Act of 2011.”
The meat of the bill, in Section 3, is short and straightforward. It creates a “new dietary ingredient definition” by amending the provision of DSHEA that grandfathered in all new dietary ingredients existing prior to October 15, 1994. By changing that date to January 1, 2007, it grandfathers in another 12 plus years of new dietary ingredients, thereby wiping the slate clean on all those new dietary ingredients the industry didn’t provide safety information for, in violation of the law.
More interesting is Section 2, which contains Congressional findings purporting to support the bill. I don’t know where Rep. Burton found these findings, but I found them to be somewhere between misleading and patently false.
Let’s take it claim by claim:
(1)Improving the health status of United States citizens ranks at the top of the national priorities of the Federal Government. The importance of nutrition and the benefits of dietary supplements to health promotion and disease prevention are well known and have been documented in scientific studies.
I had no idea that my health was the federal government’s top priority. They had me fooled on that one. I have to agree that nutrition is important, but other than supplementation for a recognized vitamin or mineral deficiency, dietary supplements have little to do with nutrition. Further, I would argue that the role of dietary supplements is well known only in the sense that the ability of Cialis ™ to make bathtubs pop up out of nowhere is well known, that is, based on phenomenally successful advertising rather than actual fact. And we have seen this claim of documentation via scientific studies before in another industry-friendly bill, The Free Speech About Science Act (which is still pending), the subject of an SBM blog post by Dr. David Gorski. He noted, quite rightly, that “Of course I could argue that claims for the efficacy of homeopathy, reiki, and ‘energy healing’ quackery could similarly be ‘based entirely on the results of scientific studies,’ as well. That doesn’t make them any less quackery.”
(2) Since enactment of . . . DSHEA, dietary supplements have had an exemplary public health safety record. [Warning: non-sequiter approaching!] Based on national surveys, in 1994, 50 percent of the 260,000,000 Americans regularly consumed dietary supplements. In 2006, 232,000,000 adults over the age of 18 alone consumed dietary supplements, 53 percent of the United States adult population.
First, someone got his sums wrong. 232,000,000 is not 53% of the adult population in 2006, which only reached 300,000,000 total in October of that year. Second, it’s hard to argue that there is an exemplary safety record when manufacturers and distributors were not required to report serious adverse events until December of 2007. (They still don’t have to report mild to moderate adverse events.) As Dr. Pieter Cohen pointed out, quoting the IOM report, “even widespread historical use without documented ill effects is no guarantor of long-term safety.” Nevertheless, the bill makes the unfounded presumption that each new dietary ingredient introduced between 1994 and 2007 exhibits an “exemplary public health safety record” despite the fact that nobody had to report adverse events from these ingredients.
(3) There were 4,000 dietary supplements in the marketplace in 1994, and in 2006 an estimated 29,000 [different] dietary supplements were being consumed daily by Americans. Since the enactment of DSHEA, there has been 17 years of additional historical use-safety experience conducted by millions of Americans. Over 17 years, approximately 25,000 new supplements with new dietary ingredients have been approved by the Food and Drug Administration (FDA) under DSHEA and have and are being safely consumed by Americans.
This raises interesting questions: Did the health of Americans decline so over those 17 years that we required 25,000 new supplements to enhance our “structure and function?” Conversely, is there any evidence that the 29,000 we take daily have improved our health one bit? Shouldn’t we be a whole lot healthier than in 1994 if the supplements were working as advertised? Shouldn’t we be thoroughly cleansed of toxins, our immune systems boosted to the max, muscular and virile, slimmed down, impervious to cancer, with joints as supple as an acrobat’s, free of anxiety, depression, and cholesterol? I don’t know about you, but I just don’t see any evidence this has happened.
But we’re talking safety here, not effectiveness. On that point, isn’t the claim of historical use-safety experience “conducted by millions of Americans” pretty much an admission that the supplement industry has been engaged for years in a huge uncontrolled, non-IRB-approved clinical trial with all of us as unknowing subjects? And someone should go back and read the Federal Food, Drug and Cosmetic Act, where he will learn that the FDA doesn’t “approve” supplements at all, much less 25,000 of them.
(4) Since January 2007, FDA regulations governing dietary supplement manufacturer good manufacturing practices, dietary supplement adverse event reporting, and private sector voluntary testing and auditing for supplement quality and purity have improved postmarketing consumer safety. Before DSHEA, these mechanisms did not exist.
Whether true or not, what has may have happened since January, 2007, is totally irrelevant, as the bill addresses new dietary ingredients prior to January, 2007.
Sections (5) and (6) simply repeat, in different language, what has already been said about the presumed safety of supplements and has thus already been refuted.
So the rationale for deleting over 12 years of new dietary supplement ingredient safety reporting is wholly unconvincing. One wonders how much federal legislation is passed based on similarly shaky reasoning.
But wait, there’s more!
We’re not through with Rep. Burton yet. He is also a co-sponsor of two bills introduced by avowed libertarian and current Republican Presidential candidate Ron Paul (R-TX).
The first, HR 2044, is titled the “Health Freedom Act.” Currently, supplement manufacturers and distributors are limited to claims that a dietary supplement affects the body’s “structure” or “function.” They are not permitted to claim their supplements mitigate, treat or prevent any disease or condition. The bill would effectively repeal this prohibition by preventing the FDA from taking any action against such claims unless a federal court, following a trial on the merits, finds clear and convincing evidence based on qualified expert opinion and published peer-reviewed scientific research that the claim is materially false and misleading and there is no less restrictive alternative, such as a disclaimer, to render the claim not misleading.
In effect, this means that supplement makers and distributors could make such claims with impunity. First, because they don’t have to give the FDA any evidence of effectiveness prior to marketing, there is little incentive for the industry to conduct studies. So unless the FDA could convince the NIH or another entity to fund and conduct such studies, they won’t exist. Second, to mount a full-blown federal trial and to meet the “clear and convincing evidence” standard with this sort of evidentiary burden is hugely expensive and would require heavy outlays of staff time, including counsel, to prepare for trial.
The second bill, HR 2045, attacks the Federal Trade Commission, which is charged with regulating supplement advertising, and is entitled the “Freedom of Health Speech Act.” Among other limitations to be imposed on the FTC, solely with regard to supplement advertising, the bill
    • prohibits the FTC from even investigating supplement advertising without possession of clear and convincing evidence that the ad is false and misleading;
    • places the burden of proof on the FTC to show, again by clear and convincing evidence, that an ad is false, that the ad actually caused consumers to be misled into believing what is false to be true and that, but for the false content, the consumer would not have made the purchase at the price paid; and
    • proof of falsity must be based on expert scientific opinion and published in peer-reviewed scientific publications.
As if that weren’t enough, bills before the House and Senate would amend the Internal Revenue Code in favor of Big Supp. Federal tax law allows individual taxpayers to deduct from income certain medical expenses, the rationale being that, if your medical expenses exceed a certain amount, the government should help out a bit by allowing you to deduct those expenses from taxable income. Deductible items include prescription drugs, physician care, medical equipment, and other expenses, as long as they are “for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body.”
House Bill 2010 and Senate Bill 1098 would expand the definition of medical expenses to include, up to $1000 per year,
amounts paid to purchase herbs, vitamins, minerals, homeopathic remedies, meal replacement products, and other dietary and nutritional supplements.
Yes, just what we need. To add insult to injury, the purchase of dietary supplements and homeopathic “remedies” will have the opportunity to add to the federal deficit.
And guess who is a co-sponsor of the House bill? Rep. Dan Burton. And who introduced of the Senate bill? Sen. Orrin Hatch (R-UT). Naturally.
Notes 
(1.) Cohen PJ, Science, Politics, and the Regulation of Dietary Supplements: It’s Time to Repeal DSHEA, 31 Am J Law and Med 175, 176-77 (2005).
(2.) Cohen, PA, Assessing Supplement Safety – the FDA’s Controversial Proposal, 366 N Engl J Med 389 (2012).

Too many lab tests still escape FDA review, threatening patient safety
Even as the lab testing market grows, too many tests escape FDA review based on a meaningless categorization that has nothing to do with patient safety. Congress should pass the VALID Act of 2021, allowing the FDA to adequately regulate direct-to-consumer and other lab tests with the potential to harm the public.
Jann Bellamy on November 4, 2021
Link

A whopping 3.3 billion in-vitro diagnostic (IVD) tests are run each year in the U.S. according to a recent report from the Pew Charitable Trusts (Pew), the global public policy and research charitable organization. (Summary here, complete report here.) These tests analyze human samples, such as blood, saliva, tissue, and urine, and are used to diagnose disease and other health conditions and guide treatment decisions. Obviously, they are essential to modern medical practice. But the FDA actively regulates only some of these tests for safety and effectiveness, while an unknown number of other IVD tests go on the market without any FDA review.
For historical reasons we’ll get to in a moment, the level of review a test must undergo is based not on its potential for harm to the public from incorrect test results, but on where it comes from. As you’ll see, this distinction is nonsensical in today’s market. A bill currently before Congress attempts to rectify this by imposing a risk-based regulatory scheme that covers all IVDs.
(Caveat: Regulation of lab tests is extremely complex and I am simplifying my overview, hopefully without oversimplifying.)
First, a bit of background is necessary to understand how we got here. The FDA regulates IVDs as medical devices. However, in the past, the agency did not use its authority to regulate what are known as “laboratory-developed tests” (LDTs), tests developed and performed at a single laboratory, with all samples sent to that particular lab for testing. Instead, it focused on commercial test kits, which are broadly marketed to laboratories or the public. These tests must undergo the same pre-market approval process as other medical devices regulated by the FDA, including, in some cases, clinical studies demonstrating that the device is safe and effective for its intended use. The test must show both analytical validity, that is, whether it detects what it’s intended to detect, and clinical validity, whether it accurately diagnoses or predicts the risk of a particular clinical outcome.
Historically, LDTs were developed by hospitals, researchers and academic medical centers for their own use. That is no longer true. In the past couple of decades, there has been an explosion in the use of LDTs by commercial labs and biotechnology companies, with testing behemoths like Quest, Genova, and LabCorp now in the LDT business. One estimate is that there are about 11,000 LDTs offered by 2,000 laboratories but, as the recent Pew Report acknowledged, no one really knows the number of LDTs on the market or the extent of their use. (See the Congressional Research Service Report’s exhaustive analysis for more on the history and current use of IVDs, including LDTs.)
There is some regulatory oversight of labs that offer LDTs. A federal law, The Clinical Laboratories Improvement Act (CLIA), requires assessment of whether a lab is able to test according to instructions and the LDT’s analytical validity. However, a key element is missing in that evaluation: clinical validity.
And that is not the only way FDA-regulated IVDs and LDTs differ. This chart included in the Pew Report highlights the incongruities:
The end result is that, because the difference in regulation has nothing to do with the test itself, FDA-regulated IVDs and LDTs may do the same thing, but the former has undergone essentially the same premarket review as a medical device whereas the latter has not undergone any premarket review. Naturally, this has led manufacturers of FDA-reviewed tests to claim there is a double standard, and they are right.
In fits and starts, the FDA has tried to bring LDTs into the regulatory fold via its authority to regulate medical devices. However, in 2020, the Trump administration threw a monkey wrench into that plan by rescinding all previously-issued FDA guidance documents and informal statements of policy concerning LDTs, taking the position that any FDA regulation can be legally accomplished only through the process of notice and rule-making or new legislation passed by Congress, both of which can take years.
Needless to say, this greatly affected the FDA’s ability to oversee COVID-19 tests. Prior to the administration’s pulling the FDA’s jurisdiction, labs wanting to market COVID-19 LDTs were required to get emergency use authorizations (EUAs) from the FDA. Under this procedure, labs could begin using self-validated LDTs as long as they submitted an EUA to the FDA within 15 days, a requirement that had proven effective in weeding out some bad tests.
Before we get to Congress’s latest effort, the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (a somewhat tortured name apparently designed to yield a snappy acronym), let’s look at some of the practical effects of this nonsensically bifurcated regulatory scheme. We’ll also take a brief look at how fringe medical practitioners and quacks exploit lab testing.
According to research done by Pew,
LDTs are being used today for different reasons [than originally intended] and in new ways that increase the risk of faulty tests. For example, LDTs are increasingly used to identify and manage the treatment of more common and serious diseases where the risks posed by inaccurate results are dangerously high, such as for cancer, prenatal conditions, and genetic diseases.
Of the more than 40 noninvasive prenatal tests, all are LDTs and therefore none have been cleared by the FDA. These tests are used to determine the risk of genetic abnormalities like Down syndrome and “some companies advertise these tests for use in populations where their accuracy is less established, or to diagnose a broader range of conditions despite the limited evidence for those uses”, raising the possibility that expectant parents are misled about the risk of a chromosomal abnormality.
According to Pew, direct-to-consumer (DTC) genetic tests are almost exclusively LDTs. One study estimated that more than 26 million people had taken a DTC genetic health or ancestry test as of January 2019, expected to reach 100 million by the end of this year. Quality varies among manufacturers, with one small study finding that 40% of harmful genetic variants reported to consumers using a DTC test were false positives.
I would add that DTC genetic tests are also abused by fringe practitioners like self-appointed genetic “expert” and naturopath Ben Lynch. Lynch has misused DTC genetic tests to build a quack empire based on convincing people that MTHFR genetic “mutations” are the cause of all manner of health problems (both real conditions and those invented by naturopaths, like “adrenal fatigue“) and that his dietary supplements are the remedy, a business model he has exported to fellow naturopaths and other dispensers of dubious medical advice via his “educational” courses. So-called “functional medicine” practitioners have cooked up a similar scheme, which has been denounced by experts in genetic medicine.
Consumers can even skip the visit to a practitioner and get health advice directly from labs selling DTC genomic profiling tests claiming the ability to “predict traits such as sexual orientation, ‘loneliness’, and social communication problems” as well as giving “personalized” dietary advice to “optimize” your nutrition and assessing your “vaginal health“. Most disturbingly, a DTC genetic testing company has marketed a so-called “liquid biopsy” for early cancer detection which, as Dr. David Gorski explained, may be a “recipe for the ultimate in overdiagnosis” and its consequences, like overtreatment.
Of course, likely the most famous LDT of all times is the Theranos “Nanotainer” device, which falsely claimed the ability to run numerous tests based on blood drawn with a single finger stick. Theranos founder Elizabeth Holmes is now on trial in federal district court on a dozen felony fraud charges, facing up to 20 years in prison.
Call for reform
Pew recommends, sensibly, that LDTs be held to the same standards for reliability and accuracy that apply to other IVDs which, they say, “requires risk-based oversight from FDA and increased transparency from the entire diagnostics industry”.
In fact, the VALID Act of 2021 (Senate bill here) does create a tiered, risk-based system for what it calls In Vitro Clinical Tests (IVCT), which includes both the IVDs that are already subject to FDA regulation as medical devices as well as LDTs, thereby erasing the false distinction based on the test’s origin and folding all tests into one category for the purposes of regulation. As is true of medical devices, the FDA would subject high-risk IVCTs to a pre-approval review.
“High risk” means that, when used as intended, an “undetected inaccurate result . . . presents an unreasonable risk for serious or irreversible harm or death . . . or would otherwise cause serious harm to the public health” or ” is potentially likely to result in the absence, significant delay, or discontinuation of life-supporting or life-sustaining medical treatment”.
Middle tier IVCTs would also obtain approval but with less strict requirements. Low-risk IVCTs could come to market after listing with the FDA. The Act authorizes the FDA to establish performance standards that IVCTs can use to demonstrate clinical validity, analytical validity, and safety as applicable.
Per analyses of the VALID Act in The National Law Review, the FDA itself would “actively regulate” the highest risk IVCTs (about 10% of all tests), with “a robust third-party review program in place to handle the significant volume of low- and moderate-risk IVCTs”, a scheme that is “similar to existing third-party review programs for traditional medical devices”.
Through a novel “technology certification” program, an IVCT developer could submit a representative test to FDA for review and, if the agency approves, the developer could then use the technology certification to develop tests that are within the scope of that approval without submitting a test for FDA review each time. Certification would last for four years, with an option for renewal.
The FDA could establish performance standards for IVCTs “in much the same way standards are presently used for medical devices” and there would be registration and listing requirements for IVCTs that would, for the first time ever, provide an accurate record of tests on the market. Some IVCTs would require labels indicating, for example, their intended use, warnings and limitations of the test. Adverse event reporting would be required and the FDA would have the authority to recall tests.
A “grandfather clause” would exempt from the Act’s requirements any IVCT marketed prior to enactment if certain criteria are met. Notably, even grandfathered tests must meet the registration, listing and adverse event reporting requirements, and test results must carry a version of the Quack Miranda Warning, stating that the test has not been reviewed by the FDA. Also, any modification of an exempt test may trigger FDA review requirements.
(You can read a section-by-section summary of the bill here.)
Reaction to the VALID Act of 2021 has been mixed. While Pew and 17 patient advocacy organizations initially praised the bill and urged Congress to pass it, Pew has since called for changes to prioritize patient safety. AdvaMed, a trade group representing medical device and lab test manufacturers, called modernization “overdue” and has been generally positive. On the other hand, the American Clinical Laboratory Association (ACLA), in reviewing the 2020 version of the VALID Act, objected to requiring that all LDTs meet the same standards as other IVDs and to the registration requirements (which I find absolutely vital to reform). The ACLA says it is currently reviewing the 2021 bill, which retains the provisions the ACLA finds objectionable.
        ◦ The meaningless distinction between LDTs and other IVDs must be eradicated and all tests subject to regulation based on what they do (or don’t do), not where they were made. The VALID Act is certainly a big improvement, although I wish it more directly addressed the threat to consumers from quack and DTC diagnostic tests. Even though it has some bipartisan support, given the inability of Congress to do much of anything, I am not optimistic.

DA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s
Criticism of the FDA’s decision to approve aducanumab for Alzheimer’s disease.
Steven Novella on July 7, 2021
Link

Alzheimer’s disease (AD) is a complex neurodegenerative disease that causes progressive dementia. Patients have impaired memory and as the disease progresses they have increasing impairment of all cognitive function. Life expectancy is typically 3-11 years following diagnosis. Worldwide more than 25 million people suffer from AD, with a prevalence of 4.4% in those over 65. In the US for those over 70 the prevalence is 9.7%.
At present there are no treatments which are generally considered to be disease modifying, and nothing approaching a cure. Existing treatments are considered symptomatic in that they reduce the severity of impairment but do not prevent progression. It is clear there is a great need for an effective treatment for AD, and this has apparently driven the decision by the FDA (discussed by Scott Gavura last month) to give “fast track” approval to a new drug, aducanumab (brand name Aduhelm), based on preliminary evidence. But the decision has proven to be highly controversial.
In the FDA announcement they report:
Researchers evaluated Aduhelm’s efficacy in three separate studies representing a total of 3,482 patients. The studies consisted of double-blind, randomized, placebo-controlled dose-ranging studies in patients with Alzheimer’s disease. Patients receiving the treatment had significant dose-and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta plaque.
They also explain that, given the great need, they allowed for approval based upon a biomarker only, without clinical data. They argue this is because there is a plausible connection between the biomarker (reduction in amyloid beta plaque) and clinical disease. Further, they now require the company, Biogen, to conduct a clinical trial to prove benefit. If the trial does not show clinical benefit, then the FDA will withdraw approval.
That all sounds reasonable, or at least they give a justifiable reason for their decision. However, they leave out many details, such as the fact that out of their 11 member advisory panel of neurologists, 10 voted not to approve aducanumab and one abstained. There are several reasons offered for their advice to reject the application. One is the fact that of the two clinical trials, one did not show a significant reduction in amyloid plaque while the other did. The results were mixed at best.
The majority of FDA reviewers (outside the neurology advisory panel) did recommend approval of the drug (which is why it was approved). This included the pharmacological review and the clinical review. However, the statistical review recommended denial, because the statistical results were weak. One of the members of the advisory panel, Dr. Aaron Kesselheim, who resigned in protest after the approval, said:
If the FDA allows companies to get drugs approved on the basis of trials that are stopped early, trials that are reanalyzed, that sets a precedent.
An independent statistical analysis published in March in JAMA also took issue with the statistical analysis, concluding that the results were not statistically significant. Therefore, we have two clinical trials, one negative, the other mixed with questionable statistical significance at best. That seems like a low bar, especially if we are relying entirely on a marker for AD rather than net clinical outcomes.
Further, use of that biomarker, amyloid beta plaque, has also been criticized. This has been one of the challenging aspects of AD science – researchers find lots of biomarkers that correlate with disease progression. However, as is always the challenge with biomarkers, it is unclear if this is contributing to progression of the disease or is just a consequence of it. Specifically, we cannot assume that simply reducing the presence of the amyloid beta plaque will reduce progression of the disease.
As other critical experts have pointed out, there have been prior monoclonal antibody treatments which demonstrably reduce amyloid beta plaque in AD but which failed to produce any clinical improvement, specifically bapineuzumab and solanezumab (monoclonal antibody drug names all end in “mab”). While there is still debate on this issue, the evidence so far does not clearly support reduction in amyloid beta plaque as a predictive biomarker for clinical improvement.
Scientifically, therefore, aducanumab may not even work as advertised in terms of meaningful reduction in amyloid beta plaque in AD, and even if it does this may not result in clinical improvement. But there are some pragmatic considerations as well. One is that the company announced that the cost of the drug will be $56,000 per year. Monoclonal antibodies are not chemicals, as the name implies they are specifically created antibodies with a therapeutic target. They are expensive to make, hence the high price tag just for the drug (although critics claim the company is including a hefty profit in that price tag) but also are expensive to give. They are delivered through intravenous infusions. A reasonable estimate for total cost, therefore, is about double the drug cost, or over $100k per year.
Given the prevalence of AD this is a hefty price tag for a treatment based on such thin evidence. Further, there are likely to be inequities in availability and reimbursement.
Another concern (one we often point to with questionable medical treatments) is that treatment with aducanumab, because it is FDA approved, may displace other experimental treatments. Patients in clinical trials (and who may be getting a placebo) may want to pull in order to get aducanumab, or may never enter a clinical trial in the first place. If aducanumab truly worked, this would be OK, it would become the standard of care and the baseline with which further research would be compared. But given the dim view that many experts have for this treatment, the fear it the only net effect, in addition to wasting a lot of health care dollars, will be to slow further AD clinical research.
The one good thing about the aducanumab controversy is that the public debate on the topic has been nuanced and well-informed. The principles I have outlined above are all important concepts that are broadly applicable. We invoke them frequently in many contexts at SBM: biomarkers may not predict clinical outcome, statistical rigor is critical, preliminary results are poor predictors of ultimate efficacy, and diverting resources based on false hope can cause much harm. Let’s hope these lessons are learned well. They can be applied to just about the entire supplement industry and much of the alternative medicine industry, for example.

FDA proposes ban on curcumin and other naturopathic favorites in compounded drugs
Based on a thorough review of the evidence by experts, the FDA is proposing a ban on using curcumin, cesium chloride and other naturopathic favorites in compounded drugs.
Jann Bellamy on September 26, 2019
Link

On September 5th, the FDA issued a proposed rule rejecting eleven substances nominated by the American Association of Naturopathic Physicians (AANP) and like-minded organizations for use in drug compounding, including curcumin and cesium chloride. Curcumin was the active ingredient in an intravenous infusion that killed the patient of a California-licensed naturopathic doctor. Cesium chloride is a dangerous and ineffective naturopathic and “integrative” cancer treatment, previously the subject of an FDA safety alert. If finalized, which seems highly likely considering the solid science behind it, the rule will prohibit the use of these and other substances in compounded drugs.
(The entire list of the AANP’s nominated substances can be found in this document, under “Tab 2a, Cesium Chloride Nominations.” Links to substance nominations, the FDA’s evaluations, and the Pharmacy Compounding Advisory Committee’s analyses and recommendations are found in the proposed rule.)
The proposed ban comes on the heels of a recent FDA rule, several years in the making, establishing criteria for determining which substances can be used in compounded drugs. Based on the new criteria, several substances, like piracetam, also nominated by the AANP, have already been banned.
Compounded drugs are an exception to the Food, Drug and Cosmetics (FD&C) Act’s requirement that prescription drugs undergo extensive safety and efficacy testing before going on the market, as well as mandated good manufacturing practices and adverse event reporting. In the particular type of compounding that is the subject of the FDA’s new criteria, sometimes called traditional compounding, pharmacies and physicians (including naturopaths where they are state-licensed to do so) can create drugs in-house as long as the drug is made for an individual patient pursuant to a prescription (including prescribing by a naturopath where, again, permitted by state law.) When used appropriately, compounding can serve a useful purpose, such as allowing a pharmacist to make a drug in liquid form for a patient who cannot swallow capsules or without substances to which a patient is allergic.
The FDA has had the authority to regulate the substances used in making compounded drugs for years but, for various reasons, it chose to leave oversight of traditional compounding mostly to the states, which regulate the practices of medicine and pharmacy, as opposed to the drugs they prescribe and sell.
This regulatory void created a business opportunity for naturopaths and like-minded fringe medical practitioners, as well as the compounding pharmacies catering to them and their dubious prescriptions. Freed from the normal safety and efficacy evidence requirements for prescription drugs, these practitioners were able to create drugs based on scanty evidence or, in some cases, crackpot “theories” of disease processes at odds with science. This transformed compounding from a useful service to what is essentially experimentation on human subjects without the safeguards of a clinical trial or scientifically meaningful results.
In 2013, the FDA finally decided to exercise its oversight authority and invited nominations of bulk drug substances for inclusion on a list the agency would promulgate specifying which substances could legally be used in compounding, called the “503A Bulks List,” after Section 503A of the FD&C Act. It would evaluate these substances with the help of an expert panel, the Pharmacy Compounding Advisory Committee (PCAC), comprised of physicians, pharmacists, and industry and consumer representatives, including those with academic appointments at medical and pharmacy schools and hospital pharmacists from Duke and St. Jude’s Children’s Hospitals. The FDA would then decide, via the cumbersome and time-consuming administrative rulemaking process, which bulk drug substances could, and could not, be used in traditional compounding.
This process resulted in the new proposed rule, which is now open for public comment. (Instructions on submission of comments are in the proposed rule.) It lists 25 substances for exclusion from, and five for addition to, the 503A Bulks List. While some on the exclusion list, such as freeze-dried aloe vera and nettle, might be used by naturopaths and “integrative” doctors in their practices, they were nominated by other organizations, such as compounding pharmacies. We’ll focus here on the substances nominated by the AANP, along with their comrades in the “integrative” medicine biz, as it gives us insight into the vast divide between what they consider appropriate therapies and the actual evidence of safety and effectiveness for those therapies. And, as noted by the FDA,
Keep in mind that the FDA’s evaluation of the nominated substances is far less rigorous and less comprehensive than the Agency’s review of drugs as part of the new drug approval process.
It is ironic that naturopaths eschew FDA-approved prescription drugs in favor of their own “natural” treatments when, in fact, those treatments can consist of prescription drugs, in compounded form, that have not, and likely cannot, met the safety and efficacy standards of the drugs they reject.
The rejects
With that, let’s look at a brief summary of the reasons the FDA rejected the AANP’s nominations. (Other organizations, like compounding pharmacies, took the lead in making some of the nominations on the AANP’s list.)
7-keto DHEA: evaluated for treatment of Raynaud’s phenomenon and weight loss (also appears to be promoted by alternative practitioners for “adrenal fatigue”, for which the FDA did not evaluate it, presumably because it is a fake disease); could not adequately assess safety; insufficient data to establish effectiveness. Pharmacy Compounding Advisory Committee recommendation: don’t include on 503A Bulks List.
Acetyl-L-carnitine: evaluated for Alzheimer’s disease, chemotherapy-induced peripheral neuropathy, and hepatic encephalopathy; may affect blood clotting and pose risk for seizures; insufficient evidence of effectiveness. PCAC: don’t include.
Alanyl-L-glutamine: evaluated for nutrition support and reducing infectious complications in critically ill and surgical patients; toxicity concerns with potential impurities such as heavy metals; limited evidence of effectiveness. PCAC: don’t include.
Artemisinin: evaluated for malaria, helminthic infections, protozoal infections, stomach ulcers and cancer; short half-life and poor oral bioavailability; significant drug-drug interactions, serious adverse events, including drug-induced hepatitis with repeat dosing; likely effective for malaria but FDA-approved drugs available for treatment (a factor the FDA considers in evaluation). PCAC: don’t include.
BWSE [nominated as Boswellia]: evaluated for rheumatoid arthritis (RA) and osteoarthritis (OA); because it is a naturally derived botanical substance, physical and chemical characteristics can vary; may induce abortion; associated with gastrointestinal adverse events; has coagulant effect; may improve OA but not effective in inhibiting RA; are numerous FDA-approved drugs for these conditions. FDA notes that Boswellia has been used “for millennia particularly in Ayurvedic and traditional Chinese medicine” (proving, once again, that “thousands of years” of use does not guarantee safety). PCAC: don’t include.
Cesium chloride: evaluated for use in cancer; significant safety concerns, including hypokalemia, seizures, QT prolongation, cardiac arrhythmias; no evidence of effectiveness in preventing or treating cancer; numerous FDA-approved drugs for cancer. PCAC: don’t include.
Chrysin: evaluated for use as an aromatase inhibitor, FDA notes it is also compounded for bodybuilding, “men’s health”, and testosterone replacement; potential for mutagenicity and neurotoxicity; poor oral bioavailability and rapid metabolism and elimination; insufficient information to evaluate safety; no clinical data that chrysin effective in cancer treatment; FDA-approved aromatase inhibitors and testosterone replacement therapies available. PCAC: don’t include.
Curcumin: evaluated for familial adenomatous polyposis, gastric metaplasia, oral leukoplakia; FDA notes use for eczema and thrombocytopenia; poor bioavailability; lack of exposure-response for safety; lack of uniformity in product; lack of well-designed chemical trials; insufficient evidence effective for proposed conditions; risk of use in lieu of, or delay of, FDA-approved treatments. PCAC: don’t include.
Germanium sesquioxide: evaluated for treatment of cancer; can include impurities with significant toxicities, specifically inorganic germanium salts; limited safety information; prolonged use associated with renal failure and death; currently a restriction on importation of all germanium compounds except for semiconductors; very little clinical data on effectiveness in treating cancer; FDA-approved treatments available. PCAC: don’t include.
Glycyrrhizin: used to refer to a variety of licorice extracts; evaluated for treatment of hepatitis C by intravenous administration; association between glycyrrhizin and serious pseudo-hyperaldosterone effects well-established; no demonstrable antiviral effect; used for curative and flavoring “for 4,000 years”. PCAC: don’t include.
Rubindium chloride: evaluated for cancer treatment; insufficient information to determine whether use would be safe or effective; numerous FDA-approved drugs for cancer. PCAC: don’t include.
Vanadyl sulfate (on Bulks List of nominated substances as vanadium): evaluated for use in treatment of diabetes, hyperlipidemia and heart disease and for cancer prevention; data suggest potential for high toxicity profile; limited human safety data; insufficient evidence for effectiveness; no clinical effectiveness data for treatment of heart disease or cancer found; FDA-approved drugs available for these conditions. PCAC: don’t include.
The AANP’s nomination of vanadyl sulfate, joined by McGuff Compounding Pharmacy Services, the Integrative Medical Consortium (discussed below), and the Alliance for Natural Health USA, a faux “grassroots” organization promoting, among other things, “vaccine choice,” is an interesting case study in just how dangerous these people can be and how lacking in evidence their therapies are, as evidenced by the PCAC’s discussion of their nomination. One can only wish that state legislators, who credulously license naturopaths and give them a broad scope of practice, would be as astute in evaluating them.
The nomination listed “slow intravenous” as the “anticipated route of administration” for vanadyl sulfate, which raised serious concerns for Robert J. Smith, M.D., Professor of Medicine and Health Services at Brown University, who said he was “very familiar” with the substance, including human studies of its use in diabetes treatment. He was “very concerned about potential toxic effects” including the fact that it might “promote cell growth and might promote malignancy”. As well,
I have difficulty understanding what the IV use would be. . . . If we’re looking at an intravenous dose, then I think we have to ask what that might mean for vascular cells or . . . for the myocardium? And we have no data.
Michael A. Carome, MD, a representative from Public Citizen, added that
As a nephrologist, the fact that it accumulates in the kidneys and causes clearly in animals nephrotoxicity . . . I share your concerns that the toxicity signal here and the safety signal here is very, very strong and very worrisome.
Another physician, Jurgen Venitz, MD, PhD, a professor from Virginia Commonwealth University’s School of Pharmacy, noted that it also accumulates in the bones and has a half-life of 10 days.
Dr. Venitz did manage to add a note of levity to the discussion. Upon Dr. Smith’s inquiry about IV use, Dr. Venitz noted that, as the nominator (the AANP et al.) was not present,
The only thing I know is what’s on the nomination document. Let me just read it. “Vanadium is used for diabetes, hyperglycemia, hyperlipidemia, heart disease, edema, improving athletic performance in weight-training, preventing malignant cell development. It is also used for treating tuberculosis, diabetes, syphilis, and a form of microcytic anemia, chlorosis. It’s also used as a source trace mineral supplementation in vanadium-deficient cases.” And you can probably can clean your house with it too.
At which point the transcript notes:
Laughter.
A group calling itself the “Integrative Medicine Consortium”, has joined with the Academy of Integrative Health and Medicine, and two compounding pharmacies, Medisca, and McGuff Compounding Pharmacy Services, in an effort to block the evidence-based consideration of its compounding favorites by the FDA because, they say, apparently without irony, that “patients’ health is being compromised”. In addition to the AANP, the Consortium includes a couple of Pseudomedical Pseudoprofessional Organizations that have appeared on SBM before: the American Academy of Environmental Medicine and the American College for the Advancement in Medicine, as well as the International College of Integrative Medicine, a group that pushes chelation therapy for supposed “heavy metal toxicity”. All of the Consortium’s members are on Quackwatch’s list of Questionable Organizations. The Academy of Integrative Health and Medicine sponsors a “fellowship” program, not ACGME accredited, that allows one to sit for the American Board of Integrative Medicine exam and become board-certified in the dubious specialty known as “integrative medicine“. All of these obviously have a considerable financial interest in the 503A Bulks List.
In addition to filing a Citizens Petition protesting the FDA’s new compounding criteria, the group is trying to raise $100,000 for their fight and enlist their “grateful patients” in their campaign, with the possibility of another $150,000 needed to file a federal lawsuit. They also want Congress to “stop FDA’s overreach”, an effort that has been at least partially successful with the filing of H.R. 1959.
While commendable, the FDA’s actions will only go so far in curbing the use of unproven and sometimes dangerous therapies by naturopaths and “integrative” physicians. As long as states allow the licensure of naturopaths and protect physicians who use CAM in their practices, and the medical profession continues to embrace “integrative medicine”, patients will pay the price.

US Department of Justice Goes After Supplements
Steven Novella on November 18, 2015
Link

It is shaping up to be a good year for those of us advocating more effective regulation of supplements and unproven therapies in the US. The Food and Drug Administration (FDA) is reviewing its regulation of homeopathy, and recently also announced it is taking public comment on its regulation of the term “natural.” The Federal Trade Commission (FTC) is also reviewing the claims made by the homeopathy industry, and even gave a nudge to the FDA to fix its regulation.
Now the US Department of Justice (DOJ) is getting in on the fun:
USPlabs, which sold the best-selling workout supplement Jack3d, and six of its executives face criminal charges for the unlawful sale of nutritional supplements, the U.S. Justice Department said Tuesday in announcing a larger probe by federal agencies aimed at stemming the sale of unproven products.
This action by the DOJ raises the stakes to a new level – criminal charges. While the FDA and FTC do the best they can, they often lack teeth when it comes to supplements. The FDA might issue a polite request and then escalate to a stern warning when companies step out of line. The FTC can issue fines which amount to little more than a slap on the wrist – the cost of doing business. Both agencies are playing whack-a-mole and losing.
As an aside, homeopathy is different because legally it is regulated as a drug, meaning the FDA has much more regulatory power and could effectively shut down the industry if they wanted. All they have to do is require evidence of efficacy for any homeopathic product and the entire industry would evaporate.
Some background on supplements
Supplements are regulated under DSHEA – the Dietary Supplement Health and Education Act of 1996. This was essentially a gift to the supplement industry, effectively removing it from FDA regulation by creating massive loopholes. The legislation (thanks to senators Orin Hatch and Tom Harkin) is blatantly pro-industry and anti-consumer, even though it was sold to the public as being pro-consumer freedom.
The predictable result was that the supplement industry exploded. We now no longer need to speculate about what an ineffectively regulated health care product industry would look like – we have almost 20 years of the supplement industry as an example.
The idea of DSHEA is that market forces and consumer choice will lead to better products, with the FDA and FTC looking over industry’s shoulder and helping them self-regulate. That’s not what happened.
What did happen was that the supplements industry realized it could put almost anything in a bottle (as long as it didn’t contain an actual drug), and make whatever claims they wanted for it. They didn’t have to do any research or provide any evidence, just put a small disclaimer at the bottom saying the FDA has not reviewed the claims, a disclaimer the public was certain to ignore.
Even though the lax regulations created a formula for essentially making millions off of the placebo effect, the supplement industry pushed the limits even further. It has recently come to light that many supplements on the market don’t contain what’s on the label, and contain undisclosed fillers, substitutions, and contaminants.
Sometimes they even contain banned drugs – put a little Viagra in your male enhancement supplement, or a stimulant in your weight loss supplement, to get an edge on the competition. The FDA issues warning letters to companies who do this, but most fail to comply.
All of this is justified by those making millions off supplements, and those in the public who have been receptive to their advertising, by the assumption that supplements are “natural” and therefore magically safe and effective. This is not true. Herbs are drugs and can have drug side effects, toxicity, and interactions. This is why the FDA is now targeting regulation of the term “natural.”
Now the DOJ is involved
While the FDA and FTC struggle to contain this avalanche of what are essentially fake products defrauding the public, without really having the teeth or resources to do so effectively, now they are getting some help from the justice sector.
At the state level, earlier this year New York State attorney general’s office, after an investigation, filed a cease-and-desist order against GNC, Target, Walgreens, and Wal-Mart, ordering them to stop selling a number of herbal supplements that were found not to contain the ingredients on the label, and some of which contained unlisted fillers that were potential allergens.
Now at the federal level, the DOJ is getting involved, and with good reason. Here is perhaps the worst offense alleged in the indictment:
The indictment also said there were a rash of liver injuries associated with the product OxyElite Pro Advanced Formula in late 2013, and several users needed liver transplants.
USPlabs, when told of this, informed the U.S. Food and Drug Administration that it would stop marketing the supplement but instead tried to sell off inventories as quickly as possible even as executives ordered that two offending substances be removed from the formula, the indictment said.
Let that sink in – the executives were apparently told that their product was causing liver failure, so they sold off their inventory as fast as they could.
Conclusion: What will happen to the supplements industry?
We can think of the regulation and behavior of the supplement industry on three levels. The first level is where the supplement industry fully complies with current regulations. Even then, the industry is allowed to essentially sell unregulated drugs (herbs) with “structure function” health claims, testimonials, and endorsements without any burden of proof to back up their claims.
We now have a two-decade experiment on this regulation, and it is the utter failure that its critics said it would be. The net result was the public wasting billions of dollars a year on worthless supplements – and this is the best case scenario.
Level two is where the industry violates even these lax regulations, with poor quality control, inaccurate labeling, adulteration with regulated drugs, contamination, and making prohibited claims.
Now we are seeing level three – criminal corporate malfeasance. No one should be surprised that when lax regulations allow an industry to be dishonest, it attracts dishonest people.
What we need now is a complete overhaul of how the supplement industry is regulated. DSHEA should be repealed, or at least updated to fix its myriad problems (effectively repealed).
I have nothing against the free market, it can be a powerful tool to drive innovation and quality. In our current economic system companies can invest in research and product development, and then make a huge profit off of that development.
But the free market is a construct of regulations – there have to be rules or else you don’t have a free market, you have chaos. Especially with a vital industry like health care, thoughtful regulations are necessary to allow innovation while protecting the public health.
There is also a unique challenge for health care products in the free market – it is very difficult for consumers to evaluate long term effects of products and services. All product effects are obscured by placebo effects. Consumers cannot reasonably rely on their own anecdotal experience – they need to be informed by scientific evidence. That evidence will not be created and evaluated unless regulations demand it. Private consumer information companies also don’t have the resources to do this.
What we need is a system in which drugs are regulated as drugs, not food or vitamins. All health claims should be backed by adequate evidence. The industry needs to be carefully regulated for quality control, transparency, and accuracy in labeling.
Ironically, the public thinks this is what they already have. Most people have no idea that they are at the mercy of the supplement industry’s self-regulation.
Perhaps, however, we are reaching a tipping point where the political will exists to make some effective changes. Let’s hope so.

FDA promises industry-friendly “modernization” of dietary supplement regulation
The FDA promises the “most significant modernization of dietary supplement regulation” in 25 years while maintaining its industry-friendly regulatory scheme.
Jann Bellamy on February 14, 2019
Link

On Monday, FDA Commissioner Scott Gottlieb, MD, announced
a new plan for policy advancements with the goal of implementing one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years.
Depending on who you ask, this is either mostly unnecessary (the dietary supplement industry); a welcome development, albeit with insufficient resources (some consumer advocates); a meaningless PR move (another consumer advocate); or wholly insufficient (me).
Dr. Gottlieb begins with some interesting statistics: three out of four Americans regularly take a dietary supplement. For older Americans, that rate rises four in five; for children, it’s one in three. Since Congress passed the Dietary Supplement Health and Education Act (DSHEA) in 1994, the dietary supplement market has grown ten-fold, from a $4 billion to a $40 billion industry, and from 4,000 unique products to “more than 50,000 – and possibly as many as 80,000 or even more,” a tacit admission that the FDA doesn’t even know what dietary supplements are on the market because DSHEA has no requirement that the industry let the FDA know what products it’s selling to consumers.
According to Dr. Gottlieb, the FDA will focus on collaring the “bad actors”, those who market potentially dangerous products and make unproven or misleading claims about their products’ health benefits. While this is laudable, by narrowly defining the terms “potentially dangerous” and “unproven or misleading claims” in a manner suitable to the dietary supplement industry, the FDA fails to address the legally authorized health dangers and misleading claims baked into the dietary supplement regulatory scheme by DSHEA.
To Dr. Gottlieb, “potentially dangerous” means one of three things: (1) the supplement contains unlawful ingredients, including drugs like sildenafil or tadalafil; (2) the supplement is not manufactured in compliance with current good manufacturing practice regulations; or (3) the supplement has obviously inherently dangerous ingredients, like kratom or highly concentrated caffeine.
“Potentially dangerous” apparently does not include, however, products sold to consumers as beneficial to health but which are, in fact, not tested for safety or efficacy prior to their going on the market, a deficiency that necessarily eliminates any real risk/benefit calculation. That is because DSHEA does not require such testing. (The law does require submission of some safety, but not efficacy, information on new dietary ingredients, a topic we’ll return to in a moment.) Although manufacturers are supposed to have substantiation backing claims that their products benefit a structure (like the skeleton) or function (like digestion) of the body, the FDA is not permitted to see their evidence. (When a few dietary supplement manufacturers did agree to share their evidence with the government, a GAO report found it less than adequate.)
Dr. Gottlieb carefully elides the issue of efficacy in his statement. He says he has “personally benefitted from the use of dietary supplements” and recognizes the benefits of “certain” supplements in a comprehensive health plan. He says that it is “clear” to him that supplements “play an important role” as we “strive to stay healthy.” What he doesn’t do is quantify that role or identify which of the “certain” supplements actually have benefits. In fact, according to the best available evidence, with the possible exception of specific groups like pregnant women or those with verified nutritional deficiencies, the role of dietary supplements in health is miniscule to none and any health benefit remains unproven for the vast majority of supplements on the market
“Unproven or misleading claims”, are apparently limited, in Dr. Gottlieb’s view, to claims that a dietary supplement can prevent, treat, or cure disease. As he rightly points out, only drugs can legally claim they treat disease and must gain FDA approval before they are sold in order to help ensure they are safe and effective for their intended medical use. To bring home that message, the same day as Dr. Gottlieb’s statement appeared, the FDA sent warning and advisory letters to 17 companies whose products, including dietary supplements, are being illegally marketed to prevent, treat, or cure Alzheimer’s disease and other serious diseases, like diabetes and cancer.
What he does not mention, however, is that consumers cannot necessarily distinguish between the impermissible “prevent, treat, or cure” and the permissible, under DSHEA, structure/ function claims. Indeed, even the FDA itself has trouble telling the difference. To an older individual worried whether memory loss is the first sign of dementia, a dietary supplement’s claim that it “enhances memory” or “improves cognition” could well be read as “prevents dementia”. As a recent “Viewpoint” article in JAMA Network lamented, even though no known dietary supplement prevents cognitive decline or dementia, the promotion of supplements to improve cognition and brain health is itself a $3.2 billion industry that benefits from high-penetration consumer advertising.
Thus, in the schema of Dr. Gottlieb, the FDA’s job is to ratchet up its pursuit of the “bad actors” who “exploit the halo created by quality work of legitimate manufacturers” and other players in the industry “most of whom act responsibly”. In his view, all consumers need to “make healthy choices” is available, for the most part, within the current framework of DSHEA via access to “safe [meaning, basically, unadulterated], well-manufactured, and appropriately labeled products,” even if the information on those labels isn’t backed by solid scientific evidence and safety warnings (except for supplements containing iron) are not required. (Labels must, however, include the ineffective Quack Miranda Warning.)
Lest the supplement industry be alarmed by this newly energized FDA, Dr. Gottlieb’s statement contains assurances that the FDA will be “flexible enough” in evaluating product safety so as not to discourage “innovation,” a word he uses five times (plus one “innovate”) in a statement less than four pages long, mostly in the context of “promoting” this innovation and protecting innovation from “barriers.” He does not explain what innovation he is expecting. As it currently stands, “innovation” in the dietary supplement industry seems to me to consist of figuring out how to combine the same ingredients in different ways and sell the results as a new product.
Other than stepped-up enforcement actions against the bad actors, details about how the FDA is going to accomplish this modernizing and reforming are sketchy. Plans include the “Botanical Safety Consortium”, a “public-private partnership” to evaluate the safety of botanical ingredients and mixtures in dietary supplements to “promote the goals of safety and effectiveness”. That’s good news. According to the American Botanical Council, an industry group, herbal supplement sales increased 8.5% in 2017, topping $8 billion, the strongest sales growth in 15 years “and there appears to be no slowing in sight”.
Dr. Gottlieb also promises “communicating to the public as soon as possible when there is a concern about dietary supplement.” While admirable, this may not be effective. A small study, recently published, found that supplements still contained prohibited ingredients even after public notices targeting those ingredients had been issued, providing further evidence, according to the authors, that a post-market regulatory system is insufficient to ensure the safety of supplements.
In what The Washington Post described as “a nod to industry,” Dr. Gottlieb also says the FDA will review its regulations on new dietary ingredients “to make sure they are flexible enough to ensure product improvement”. If a supplement incorporates an ingredient not in use when DSHEA was passed in 1994, what the law calls a “new dietary ingredient” (NDI), its manufacturer must notify the FDA and include the NDI’s history of use or other evidence of safety. (I’m not equating “history of use” with “evidence of safety”, but the law does.) The industry has been miffed by the FDA’s interpretation of this requirement ever since the agency issued new draft guidance on NDIs in 2016. Apparently, Dr. Gottlieb took their complaints to heart.
Interestingly, Dr. Gottlieb hints that amendments to DSHEA might be part of the solution, although not one he or the FDA will commit to, at least for now. At this time, all he will admit to is that “there may be value in a broader public conversation about whether changes to the law might be helpful” while at the same time “preserving the law’s essential balance,” this balance apparently consisting of “preserving consumer access to lawful supplements,” (i.e., the current system of pro-industry regulation mandated by DSHEA) and fulfilling the FDA’s duty to protect the public from unsafe supplements. In fact, he maintains that none of this must impose “any significant new burdens on responsible firms”, which is, as you will recall, the majority of the supplement industry in his view.
One of the DSHEA amendments could be, he suggests, a list of products on the market and their ingredients. Right now, all manufacturers have to do is register their facilities with the FDA, although we don’t know how many are complying because we don’t know how many are out there or where they are. And we have no idea what they’re selling.
The industry is not universally warm to the idea of a mandatory registry. They are all for the “bad actor” initiative, which eliminates the most egregious offenders and the bad publicity for dietary supplements accompanying publication of their scandalous behavior. But, quarrels with NDI guidance aside, they very much like the current scheme, which guarantees, in their view, that “Americans have continued access to safe, natural, and affordable supplements.” Or at least they want some quid pro quo for cooperating with any tinkering with DSHEA. According to the American Herbal Products Association, this would include measures to
appropriately reduce burdens on the industry or create new opportunities for it and the consumers it serves, for example in the context of nutrient content claims.
Consumer advocates are generally positive, but at least one wonders where the authority, and resources, will come from to implement all of this. According to Peter Lurie, MD, MPH, former FDA official and president of The Center for Science in the Public Interest:
The FDA is hampered by a terrible law and drastically limited resources. Within that there’s only so much you can do.
He’s right on both counts. DSHEA is a terrible law, or, as we like to say here at SBM, it’s a travesty of a mockery of a sham. In 2017, an FDA official told a reporter that the agency patrolled the multi-billion dollar supplement industry and its tens of thousands of products with 26 people and a $5 million budget.
Pieter Cohen, MD, JD, who frequently exposes the dangers of dietary supplements in the medical literature, thinks Dr. Gottlieb is overselling the idea that the FDA is moving forward, characterizing this instead as “restating things they have been doing for years” and “a big PR push.”
In my view, while increased enforcement of DSHEA’s weak consumer protections is not a bad thing, this is lipstick on a pig. DSHEA needs to be tossed out and replaced with a new law, one that protects consumers and not the dietary supplement industry. That’s what Dr. Gottlieb should be saying, but won’t. Prior to his confirmation, he assured former Sen. Orrin Hatch, the industry’s protector-in-chief,
“As someone who uses dietary supplements every day, I believe they serve an important role in health promotion for millions of Americans, and I support consumer access to these products.” He also wrote that FDA’s current regulatory framework under DSHEA provides adequate enforcement tools to remove unsafe dietary supplements from the market and “if confirmed, I would commit to enforcing DSHEA, as intended by Congress.”

DA blacklists cesium chloride, ineffective and dangerous naturopathic cancer treatment
The FDA recently issued an alert warning of significant safety risks associated with cesium chloride. It is a mineral salt promoted by naturopathic “doctors” and “integrative” medicine practitioners as an alternative treatment for cancer, despite the lack of evidence of safety and efficacy in treating cancer or any other disease.
Jann Bellamy on August 2, 2018
Link


The FDA recently issued an alert warning of significant safety risks associated with cesium chloride (CsCl). CsCl is a mineral salt promoted by naturopathic “doctors” and “integrative” medicine practitioners as an alternative treatment for cancer, despite the lack of evidence of safety and efficacy in treating cancer or any other disease. In another chilling example of the harm so-called “complementary medicine” causes cancer patients, dangers cited by the FDA include death, QT prolongation (“a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm”), arrhythmias, cardiac arrest, low potassium, seizures, and fainting.
The FDA also announced that it would take regulatory action, such as issuing a warning letter, seizure of product, seeking a court injunction, or criminal prosecution, against any pharmacy or health care practitioner compounding a drug containing cesium chloride. Until the announcement, CsCl was on a list of substances, called “Category 1”, that could be used in compounding without fear of regulatory action, pending further review of the substance by the FDA. The FDA has now moved CsCl to what is known as the “Category 2” list, substances that are effectively banned from use in compounding because of significant safety risks.
The FDA took this action in response to a Citizen Petition filed by Public Citizen in December of 2017, and only then on the heels of a lawsuit filed by Public Citizen last month. The suit chastised the agency for sitting on its hands for two years after the FDA’s own reviewers determined that cesium chloride had not been shown to be effective for “the prevention or treatment of any form of cancer,” presented “serious safety concerns”, and is “not safe for human use”.
Given these grave concerns, how did cesium chloride ever get on the Category 1 list in the first place, enabling healthcare practitioners to use it as a bogus cancer treatment by either compounding it themselves, or having a pharmacy compound it, and injecting it into patients? Because the American Association of Naturopathic Physicians, the Alliance for Natural Health, the Integrative Medicine Consortium, and McGuff Compounding Pharmacy Services, citing a quack cancer treatment “theory” and cherry-picked evidence of safety, nominated it for Category 1. The FDA decided that this was “sufficient supporting information” for the FDA to refrain from taking any action against its use pending further review.
Before we return to this little rogues’ gallery and their successful efforts to fend off the FDA from banning their bogus cancer treatment, it’s helpful to understand a bit about compounding and how it is regulated.
Compounding 101
A licensed pharmacist or physician can legally combine ingredients to create a medication tailored to the needs of an individual patient. This is called “compounding.” Compounded drug products, when prescribed and produced appropriately, can, according to the FDA, serve an important role for patients whose clinical needs cannot be met by an FDA-approved drug product. However, precisely because they are not FDA-approved, compounded drugs have not undergone premarket review for safety, effectiveness, and quality, nor are pharmacists and healthcare practitioners who engage in traditional compounding required to comply with current good manufacturing practices.
In 2012, an outbreak of fungal meningitis due to contaminated injectable drug products shipped by a compounding pharmacy to patients and health care practitioners across the country resulted in 60 deaths and 750 cases of infection. In response, both Congress and the FDA took steps to clean up the compounding industry’s act.
As part of this effort, the FDA announced it would develop a list of approved substances (called the “503A list,” or “503A bulks list,” named after the section in the FD&C Act authorizing it) that could be legally used in compounding and that the agency would take nominations for inclusion on that list. (Substances that are already the subject of an USP or National Formulary monograph or are a component of an FDA-approved drug can be used in compounding without further review.) However, pending a more extensive review for inclusion on the FDA’s final approved 503A list, the agency divided nominated substances into three categories:
    • Category 1: substances nominated with sufficient supporting information to permit FDA to evaluate them.
    • Category 2: substances nominated with sufficient information for evaluation, but which pose “significant safety risks related to [their] use in compounding.”
    • Category 3: substances nominated without sufficient supporting information.
The FDA said it would forego any regulatory action against Category 1 substances, essentially allowing their use unless and until they fail to make the FDA’s final cut. Category 2 and 3 substances cannot currently be used in compounding, although they are still technically eligible for the 503A list.
Naturally, if you will, the FDA’s action was met with some consternation among naturopaths, who like to whip up concoctions of unproven remedies and inject their patients with them, sometimes with disastrous results. The turmeric injection that killed Jade Erick was a compounded remedy for eczema injected by her California-licensed naturopathic doctor.
In 2014, in response to the FDA’s new compounding regulatory scheme, the American Association of Naturopathic Physicians nominated favorites like Artemesia, Boswellia, calcium EDTA, Echinacea, DHEA, DMPS, DMSA, co-enzyme Q10, and germanium, along with cesium chloride, for FDA-approved use in compounding. It also wanted to dump the entire Homeopathic Pharmacopoeia of the United States and the USP Dietary Supplements Compendium on the approved list, even though the law specifically limits compendia to the USP or National Formulary.
The AANP complained bitterly that the FDA was requiring evidence – imagine that! – which busy naturopathic clinicians could not be bothered to supply, a tacit admission that naturopaths were using these substances without sufficient proof of safety and efficacy. The AANP also pontificated as to how the conventional medical system had failed the typical naturopathic patient (whose “immune systems are often depleted”), but, because naturopaths
are trained to find the underlying cause of a patient’s condition rather than focusing solely on symptomatic treatment, [they expertly prescribe and administer] safely compounded medications – including nutritional, herbal, and homeopathic remedies [which] prove efficacious to meet their needs every day in doctors’ offices across the country.
So, these substances are efficacious, according to the AANP, they just couldn’t tell the FDA how they came to that conclusion.
Germanium ended up on the FDA’s Category 2 list. Other naturopathic favorites are on the list of substances nominated without adequate support (Category 3) and therefore cannot legally be used in compounding. These include Coenzyme Q10, ginger root powder, ginkgo biloba standardized extract, nux vomica extract, and colloidal silver.
Cesium chloride
With that background, let’s turn to cesium chloride and its appearance on the FDA’s Category 1 list. As noted, CsCl was nominated by the AANP, joined in its efforts by representatives from the fringes of medicine: A group calling itself the “Integrative Medicine Consortium,” which includes a couple of Pseudomedical Pseudoprofessional Organizations that have appeared on SBM’s radar before – the American Academy of Environmental Medicine and the American College for the Advancement in Medicine – as well as the AANP and the International College of Integrative Medicine. The Integrative Medicine Consortium was also speaking on behalf of the Academy of Integrative Health and Medicine, whose mostly online “fellowship” program allows one to sit for the American Board of Integrative Medicine exam and become board-certified in the dubious specialty known as “integrative medicine“. The Alliance for Natural Health, a faux “grassroots” organization that advocates for the protection of quackery and against vaccination and fluoridation, and McGuff Compounding Pharmacy, whose self-interest in the subject should be obvious, rounded out the list of organizations nominating CsCl.
Supporters wanted to be able to compound up to 500 mg/mL in a multiple dose vial for injection for use in the treatment of cancer. (To access documents in support of their nomination, see Tab A, at p. 38, of this FDA Briefing Document.) In support of their nomination of CsCl as an effective treatment for cancer, they claimed:
Cesium chloride 500 mg/ml has been helpful and useful in combination with other natural substances in treating individuals with numerous types of cancers, by a presumed alkalinizing effect. Cancer has been found to thrive in a low-pH environment, and to be hindered in a high pH environment. It has been known for decades that a thriving cancer cell produces an acidic micro-environment, and a weak cancer cell does not. (Jahde and Rajewsky, “Tumorselective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues.” Cancer Research. 1982 Apr 42(4): 1505-12). This is known to be due to cancer’s product, lactic acid. However, it is also known that acidic fluid holds less oxygen than alkaline fluid. Thus the acidic, deoxygenated water in the cancer microenvironment is conducive to anaerobic metabolism, which is the default metabolism of cancer cells. Thus an alkaline agent that can be delivered to that intracellular and extracellular microenvironment indirectly has a selectively suppressive effect on cancer cells.
Wow! It’s pH woo déjà vu: “Dr.” Robert Young’s pH Miracle Living and the alkaline diet, all rolled into one and delivered via injection. Or, as the Memorial Sloan Kettering Cancer Center put it, more politely,
Supporters claim that cesium neutralizes the toxic material produced by tumor cells and prevents them from dividing. There is no scientific evidence to support these claims.
And this, from the nominators of CsCl:
Cesium chloride has a history of use among various professions in integrative medicine in the U.S., and many hundreds of patients have been helped by cesium chloride in their fight against cancer.
Of course, “a history of use among various professions in integrative medicine” is meaningless as far as evidence of safety and effectiveness is concerned. Homeopathy, which is demonstrably worthless as a treatment for anything, also has “a history of use among various professions in integrative medicine.” There is absolutely no reliable evidence that “many hundreds of patients have been helped” and none is cited.
Finally, these outrageous statements,
No existing drug matches the advantages of cesium chloride against cancer: the evident ability to enter the cancer cell together with the pH rise, as well as the high remission rate and lack of observed side effects at therapeutic dose. Generally safe and non-toxic substances such as cesium chloride are a viable alternative . . . No approved drug product exists that addresses the condition of cancer adequately. Conventional cytotoxic chemotherapy drugs are generally very poorly tolerated, having life threatening side effects, and a high mortality rate. With a realistic assessment of their odds, there are patients who choose to avoid chemotherapy, and have opted instead for alternatives, including cesium chloride.
As for safety, they ignored published animal studies and human safety data and minimized the few adverse events (e.g., “anecdotes on the internet”) they did recognize in their nomination.
For undisclosed reasons, the FDA found that CsCl was nominated “with sufficient information for evaluation” and placed in Category 1, pending further review.
Subsequently, in May, 2016, FDA’s expert reviewers recommended against adding cesium chloride to the 503A list substances approved for use in compounding, in part because of “serious safety concerns related to [its] use.” The reviewers cited animal studies showing CsCl caused ventricular tachycardia and other heart risks, decreased motor activity, autonomic disturbance, diarrhea, and developmental issues in offspring. Thus, “the toxicity profile of cesium chloride in animal studies weighs against its inclusion on the 503A list.” (Their report starts at p. 60 of the FDA Briefing Document.)
As for human risks, the reviewers concluded:
The limited information available about the safety of cesium chloride gives rise to significant concern about its use in compounding. The evidence of cesium chloride causing hypokalemia [low potassium levels], seizures, QT prolongation, and cardiac arrhythmias is particularly concerning.
Possibly as a rejoinder to the AANP’s swipe at chemotherapy drugs, the reviewers noted:
There are numerous FDA-approved agents that have demonstrated safety and efficacy for the treatment of patients with various cancers.
Speaking of efficacy,
Cesium chloride has not been shown to be efficacious for the prevention or treatment of any form of cancer. . . evidence of clinical benefit from cesium in human cancer is limited to one case series published in 1984 by Sartori [cited by the AANP et al.]. That case series has major flaws including its uncontrolled nature, retrospective design and probable case selection bias. Therefore, the results cannot be considered reliable.
The reviewers also noted:
In addition, use of cesium chloride may cause a patient to delay the use of treatments that have been found to be safe and effective for treating cancer.
Thus, the reviewers concluded that cesium chloride is not a suitable substance for the 503A list.
In June, 2016, the FDA’s Pharmacy Compounding Advisory Committee considered the nomination of CsCl to the 503A list and recommended, based on the reviewers’ concerns as well as their own, by a unanimous vote of 11-0, that the FDA should not place CsCL on the list. (Transcript here, see p. 75.) As one committee member, a pharmacology professor, said:
So even if you state the point that the efficacy is not demonstrated, it has a major safety issue, and safe doses have not been established, forget the fact that we know nothing about effective doses.
The Committee’s recommendation awaits final FDA action.
The only problem was, even in light of the FDA’s own damning review, CsCl remained on the Category 1 list, meaning nothing was stopping naturopathic doctors and integrative physicians from plugging their patients with CsCl. This prompted Public Citizen to file its Citizen Petition in December of last year, asking the FDA (1) to immediately add cesium chloride to the Category 2 list of substances that raise significant safety risks, thereby effectively prohibiting it use for the time being, and (2) to promulgate a rule excluding CsCl from the 503A list, thereby permanently prohibiting its use.
The FDA did nothing until suit was filed against it in federal district court by Public Citizen in July, seeking to compel the agency to act on its Petition. Within hours, the FDA granted the Petition in part, issued its alert warning “of significant safety risks associated with cesium chloride” and moved CsCl to Category 2. In addition to the data discussed in the Pharmacy Compounding Advisory Committee’s 2016 recommendation, the FDA conducted a comprehensive review and found three more published cases of adverse events related to cesium chloride describing “life-threatening neurologic and cardiac toxicity”. The agency declined, however, to promulgate a rule excluding CsCl from the 503A list, although it said it will make a final determination at some point.
On the same day suit was filed, Public Citizen filed another Citizen Petition asking the FDA to immediately remove dietary supplements containing CsCl from the market. The Petition is based on the same safety risks and lack of efficacy recognized by the FDA and the promotion of CsCl-containing dietary supplements in the treatment of cancer. The FDA has yet to respond.
It’s hard to imagine that cesium chloride will make it onto the final 503A list of substances approved for compounding in the treatment of cancer given the Pharmacy Compounding Advisory Committee’s recommendation. For now, its use in compounding risks regulatory action, including a criminal complaint, by the FDA. Of course, unless the FDA acts to ban it as a dietary supplement ingredient as well, it will remain available and its promotion as a quack cancer treatment will continue.
FDA inaction aside, what this whole episode should demonstrate to everyone (including state legislators and medical boards) is the absolute disregard for evidence of safety and effectiveness on the part of naturopathic “doctors” and integrative physicians and their “professional” organizations. Not only did they cherry-pick the published literature on safety, which alone should disqualify cesium chloride’s use, they credulously promoted a highly dubious mechanism of action and questionable case reports as evidence of efficacy, all the while complaining that they had to provide the FDA with evidence in the first place. I realize that the naturopaths may not have known better, given their substandard education and training. As for the integrative physicians, I’ll chalk it up to their “specialty’s” penchant for mendacity and colluding (if I may use that word) with naturopathic “oncologists“.

FDA warns companies selling illegal hangover remedies
The FDA recently warned seven companies not to claim that their dietary supplements can prevent, treat, or cure a hangover, because only FDA-approved drugs can make such claims. The agency also warned that NAC, a popular supplement ingredient, cannot legally be used in dietary supplements.
Jann Bellamy on September 10, 2020
Link

The FDA recently sent warning letters to seven companies selling dietary supplements that claim to prevent, treat, or cure hangovers. Under the federal Food, Drug, and Cosmetic Act (FD&C Act), only FDA-approved drugs can legally make such claims regarding a disease. As the FDA points out:
Unlike drugs approved by the FDA, there has been no FDA evaluation of whether these unapproved products are effective for their intended use, what the proper dosage might be, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns.
In addition to warning marketers to avoid illegal disease prevention and cure claims, the FDA raised an issue of potentially greater importance to the dietary supplement industry: the use of N-acetyl-L-cysteine (NAC), an ingredient in several of the hangover remedies. The FDA takes the position that NAC is never a proper ingredient in any dietary supplement, a point we’ll return to later.
The warning letters were issued to the colorfully-named Vita Heaven LLC (doing business as Hangover Heaven), Happy Hour Vitamins, Mind, Body & Coal LLC, and Purple Biosciences LLC, as well as Double Wood LLC, Ebnsol Inc., and LES Labs.
These companies are part of a burgeoning industry. A 2019 Washington Post article quoted sources estimating there some 2.6 billion hangovers in the U.S. annually, and that was before the pandemic hit. Analysts put the global hangover remedy industry at nearly $1 billion. (The global alcoholic beverages market was valued at $1.4 trillion in 2017.)
But before we go further: What, exactly, is a hangover, from a medical perspective? Here’s an explanation from a pharmacy professor:
Hangovers are generally the result of the unpleasant after-effects of consuming ethanol, the main psychoactive ingredient in alcoholic beverages. They’re often characterized by malaise, head and muscle aches, nausea, and lethargy, though the duration of these symptoms can vary.
The unpleasant feelings from a hangover are generally attributed to a combination of dehydration, toxic impurities found in some alcoholic beverages (congeners), and toxic byproducts of alcohol metabolism.
Ethanol is a diuretic that can suppress the release of antidiuretic hormone from the pituitary gland and result in excess diuresis. This can lead to the characteristic dry mouth, headache, and irritated eyes commonly associated with a hangover.
Congeners are impure fusel alcohols that are often present in “darker” spirits or red wine and can contribute to hangover symptoms following consumption. Ethanol is metabolized into the toxic metabolite acetaldehyde, which can cause nausea and malaise. Decreased blood sugar and secondary general inflammation from ethanol consumption may also play a role in hangover symptoms.
But is a hangover a “disease”, as the FDA’s warning letters seem to imply? Here’s how the agency explains its position:
A hangover can occur after alcohol intoxication. Alcohol intoxication, like all poisonings, causes dose-related dysfunction and damage, ranging from mild impairments to death. Alcohol intoxication causes temporary damage to brain function, causing impairments of judgment, attention, reflexes, and coordination.
In other words, a hangover is a sign or symptom of alcohol intoxication, which is a type of poisoning. Poisoning is a disease. Per federal law, a claim that a product has an effect on a sign or symptom of a specific disease is considered a claim that the product can mitigate, treat, cure, or prevent that disease, which the product cannot do unless it is an FDA-approved drug.
(There’s some real buzzkill for you from the federal government: in drinking alcohol, you are poisoning yourself.)
Hangover “cure” ingredients
One of most hyped ingredients in the illegal hangover remedies cited by the FDA is an extract from the Japanese (or Oriental) Raisin Tree (Hovenia dulcis) which one company said has been “used for centuries as an anti-alcohol herb and hangover cure in Asia.” Its active ingredient, dihydromyricetin (DHM), is “a liver detox and hangover prevention ingredient” which, when blended with electrolytes “may reduce hangover symptoms by up to 99%” and will “prevent hangovers after a night of drinking”, “reduce feelings of intoxication while drinking”, or “raise the alcohol intoxication threshold so you can have a few drinks without becoming intoxicated”. In other words, “NEVER SUFFER ANOTHER HANGOVER”.
(The hangover remedy industry appears to rely heavily on ALL CAPS as a sales tool, as you shall see.)
There is, in fact, some evidence that DHM is effective in reducing the ill effects of drinking alcohol. Recent research from the University of Southern California, funded in part by the NIH’s National Institute on Alcohol Abuse and Alcoholism,
support the utility of DHM as a dietary supplement to offset acute alcohol-related effects as well as long-term risks. In addition, the [study’s] authors say the substance likely has wider applications to help people cope with binge drinking, alcoholism and liver damage.
What got these supplement companies in trouble, though, is not the lack of evidence of effectiveness for their DHM-containing products. (Although they undoubtedly went beyond what evidence does exist.) It is, again, that federal law does not permit dietary supplements to make claims that they can prevent or cure disease. There is a legal procedure for allowing dietary supplements to make what are called health claims, that is, a claim that a substance has a particular effect on a disease or health-related condition (e.g., the association between dietary fiber and reduced risk of cancer [PDF]) if the claim meets certain requirements for supporting evidence (“significant scientific agreement among qualified experts”). Otherwise, supplement marketers are limited to claims like “supports liver health”. (Even this sort of “structure/function” claim is supposed to be backed by evidence, but supplement makers don’t have to disclose that evidence to consumers or the FDA.)
Other ingredients touted for hangover prevention and cure by the companies cited are milk thistle which “HELPS PREVENT HANGOVER SYMPTOMS” by protecting the liver from damage and, along with kudzu flower powder and artichoke leaf extract, will help “KILL YOUR HANGOVER BEFORE IT EVEN STARTS”. Actually, according to WebMD, at this point, there is not enough evidence to say whether milk thistle will help your liver.
Prickly pear cactus, per the supplement marketers, will “help prevent hangover symptoms” and you
can say goodbye to the day-after woes! By reducing inflammation associated with a hangover and increasing the ability for your cells to repair themselves after a night of drinking debauchery, you can feel better right away!
According to the Mayo Clinic, there is limited research suggesting prickly pear cactus can lessen the unpleasant effects of a hangover, possibly due to an anti-inflammatory effect, but side effects can include “mild diarrhea, nausea, increased stool volume, increased stool frequency and abdominal fullness.”
Supplement makers are not required to disclose these adverse effects, leaving consumers in the dark. In my view, these are not side effects one would want to risk while suffering from a hangover. In fact, they sound like a hangover.
One company, the cleverly-named Mind, Body & Coal, sells a dietary supplement capsule called Miracoal to “PUT YOUR HANGOVER TO BED”. Miracoal contains organic coconut charcoal with electrolytes “to flush away toxins and impurities in your digestive systems and provide fast detoxifying rejuvenation”.
While it is true, as Mind, Body & Coal claims, that activated charcoal is an effective treatment for poisoning, it should, according to the Mayo Clinic, only be administered for that purpose in a health care facility, where the product is mixed with a liquid and given orally as a drink or via a tube. The capsule form is not used for treating poisoning. Per our pharmacy professor, there is “no definitive evidence showing it does anything to prevent the severity and/or duration of hangovers”.
Four of the companies receiving warning letters are cited for using N-acetyl-L-cysteine (NAC) in their hangover remedies. The FDA takes the position that their products are not legally dietary supplements because supplements cannot contain substances approved as drugs unless the substances were marketed as foods or supplements prior to the drug’s approval. Because the FDA approved NAC for use as a mucolytic drug for the treatment of chronic respiratory disease in 1963, and there is no evidence NAC was marketed as a food or supplement prior to that date, it is not a legal supplement ingredient in the eyes of the FDA.
This (apparently new) position could cause difficulties for the supplement industry. An article in a supplement industry publication says that NAC
has been widely used in finished dietary supplements, frequently as a standalone product. A recent search on Amazon produced more than 400 products for sale mentioning the ingredient, which is usually positioned as a “cellular antioxidant”, or for liver support. Some major brand names were represented in that search. On the supply end, a search on Alibaba brings up more than 1,000 hits of bulk . . . NAC for sale . . . .
The president of an industry trade group told the publication that “people should be concerned” because the “FDA has suddenly decided to get serious about some of these ingredients that have these drug exemptions, like NAC and, of course, CBD”.
Given the huge liberties afforded the industry by Congress, in the form of the Dietary Supplement Health and Education Act, I doubt a few hangover remedies getting hit by the FDA, or even an FDA crackdown on the drug exemption issue, will cause much of a dent in the $40-billion-plus supplement industry.

FDA Decision on Oleandra
FDA rejects the application for oleandrin as a new dietary ingredient, but flaws in the regulations remain.
Steven Novella on September 9, 2020
Link

Last month I wrote about a proposed treatment for COVID-19 – an extract (oleandrin) from a plant known to be highly poisonous, Oleandra. This was news because the CEO of MyPillow (Mike Lindell) was pushing this new snake oil to President Trump through HUD secretary Ben Carson. Trump assured him that “We will look into it”. This is a perfect representation of what is wrong with supplement regulation in this country, I argued, because Lindell was simultaneously asking for approval as an investigational drug and, failing that, as a dietary supplement. It brazenly revealed how our lax supplement regulation is used to essentially market untested drugs, without any assurance of safety or efficacy.
Phoenix Biotechnology, the company that produces oleandrin (and in which Lindell now has a stake) recently received a letter from the FDA (clicking on this link will automatically download a PDF of the letter) on their decision regarding their disclosure of a potential new ingredient. For dietary supplements, manufacturers only need to inform the FDA at least 75 days before putting the new ingredient on the market. The FDA reviews the new ingredient on two criteria – does it meet the definition of a dietary supplement, and can it be generally regarded as safe (GRAS) based on prior use. Dietary supplements, in other words, are treated as if they were food.
However the regulations also allow companies to make pseudo-medical claims for their supplement ingredients, so-called structure-function claims. As long as they don’t mention a disease by name, they can make or imply claims that the supplement can be used to improve certain health conditions or symptoms. Of course, outside of direct company marketing, people (who may or may not be connected to the company) can make direct medical claims, creating a market for the supplement with health claims that have not been reviewed by the FDA.
The FDA letter to Phoenix Biotechnology has rejected their filing of oleandrin as a new dietary ingredient. The primary reason they cite is that oleandrin does not meet the definition of a dietary ingredient, because it contains:
…an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public
This is where the Phoenix Biotechnology strategy of hedging their bets has bit them in the backside. Because they are also asking to investigate oleandrin as an FDA approved drug, this excludes the substance from being considered a dietary supplement. That is the one thing you can’t put into your nutritional supplement – an actual drug. The FDA considers such products as “adulterated”. This is still a common occurrence. The FDA’s response when it discovers that a product is adulterated with a drug is to send them a strongly worded warning letter.
For example, a recent review found:
The authors found that between 2007 and 2016 the FDA identified 746 brands of supplements adulterated with pharmaceutical agents. The adulterants included prescription medications such as sildenafil and fluoxetine, withdrawn medications including sibutramine and phenolphthalein, and unapproved drugs including dapoxetine and designer steroids. Twenty percent of the adulterated supplements contained 2 or more undeclared drugs, for example, weight loss supplements containing both an anorectic and a laxative.
The FDA essentially asks the company for a voluntary recall. However:
Despite their limited effectiveness, voluntary recalls are the most common approach used by the FDA to remove adulterated supplements from commerce. In the current study, the agency discovered 746 distinct supplements to be adulterated but announced voluntary recalls for only 360. Only 360 of 746 (48%) were recalled, leaving the majority of adulterated supplements, more than 350 products, available for sale.
In the case of oleandrin, however, the FDA is preemptively rejecting approval as a new dietary ingredient on the grounds that it meets the definition of a drug.
FDA has concluded that the “Oleandrin” has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Further, FDA has carefully reviewed the information provided in your submission and other available information and has not identified any evidence to demonstrate that “Oleandrin” was marketed as a dietary supplement or as a food prior to such authorization.
This implies that if oleandrin were marketed as a supplement prior to being studied as a drug, it would be OK. Again this shows the blurry distinction between the two, and how the regulations are essentially just a way to market drugs without having to prove safety or efficacy.
Not only is oleandrin being tested as a potential drug, it is failing so far. The U.S. Army Institute of Infectious Diseases halted a neutralization test of oleandrin against COVID-19 because the results were “inconclusive”. So it did not even look promising on a preliminary study of potential effectiveness, and was abandoned to focus on other potential agents.
Finally, the FDA points out in the letter that, even if oleandrin could be considered a dietary ingredient:
…the agency has significant concerns about the evidence included in your submission as a basis for concluding that a dietary supplement containing “Oleandrin” will reasonably be expected to be safe under the conditions of use described in your notification.
They could not even meet the low bar of showing that the ingredient is probably safe, based on prior usage (as opposed to controlled clinical trials).
While this is a good decision from the FDA, it does also reflect the weakness of our current regulatory scheme. A company could, for example register as a new ingredient a substance that is not toxic and is not already being studied as a potential drug. If approved as a dietary ingredient (even though it is actually a pharmacological agent), the company could then market it as a way to help fight off COVID-19, by “boosting the immune system” or some other vague language. This is not the FDA’s fault, it’s Congress’s. They passed DSHEA, and have failed to revise it despite its blatant problems.

FDA warns public about exosome treatments
The FDA and Nebraska health authorities issued warnings after patients became seriously ill following treatment with exosomes, an unproven, potentially risky and, per the FDA, illegal product being promoted by dubious stem cell clinics.
Jann Bellamy on December 19, 2019
Link

The FDA and the Nebraska Department of Health and Human Services recently issued health warnings (also here) after several Nebraska patients became seriously ill following treatment with unapproved cell-based therapies containing exosomes derived from C-section placentas. Because an investigation is ongoing, state health officials could not share further details, including the name of the product used, the source of the placentas, the clinics where the treatments were administered, or the bacteria causing the infections, which included sepsis, although they did say “fewer than five” patients became ill.
According to the FDA, although there are currently no FDA-approved exosome products, clinics in the U.S., including some that market illegal stem cell products, are now also offering exosome treatments to patients. These clinics deceive patients with unproven claims about the potential for exosome products to prevent, treat, or cure various diseases and conditions. Some also claim that that exosome products do not fall under the law governing drugs and biological products, which the FDA says is “simply untrue”. Exosomes used to treat human diseases and conditions are subject to same premarket review and approval requirements as other drugs and biologics.
The clinics currently offering these products outside of FDA’s review process are taking advantage of patients and flouting federal statutes and FDA regulations. This ultimately puts at risk the very patients that these clinics claim to want to help, by either delaying treatment with legitimate and scientifically sound treatment options, or worse, posing harm to patients, as evidenced by these recent reports of adverse events.
What are exosomes?
By Kalamedits
Exosomes are best defined as extracellular vesicles that are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.
Or, as Paul Knoepfler, Ph.D., Professor at the UC Davis School of Medicine, Department of Cell Biology and Human Anatomy, who helms the excellent Knoepfler Stem Cell Blog, more colorfully puts it for the less scientifically literate (like me):
Imagine if you could bubble up a pea-sized sphere off your skin full of good stuff without harming yourself and toss it over to your relative or friend like a mini-water balloon toss, whose skin would fuse with it and absorb the goodies in side, then becoming healthier.
Sounds like sci-fi at that imagined human scale, but cells do this kind of thing quite often. The cellular ‘water balloons’ are exosomes, tiny subcellular packages containing unique mixtures of various molecules including anything from RNA to proteins.
While Dr. Knoepfler agrees that there is a “growing amount of work and excitement in this area” he says “it’s not entirely clear that this cellular water balloon toss is always beneficial to other cells.” He notes that while stem cell clinics looking for new ways to profit have latched onto the legitimate buzz around exosome research, he “personally doubt[s] the effectiveness of unproven stem cell exosomes as a therapy for many conditions” and warns
there will be risks. Sometimes exosomes from one cell that end up as part of another cell, may negatively influence the health of the other cell. Multiply that by billions or trillions and you can envision possible tissue damage in a hypothetical scenario of things gone wrong.
According to MedPage Today, until 2007, scientists thought exosomes were just a way for cells to get rid of “trash”. However, Swedish researchers showed that some cells use exosomes to transfer genetic material, but what is in them, and their true function, remains a subject of debate.
Like Dr. Knoepfler, Sean Morrison, Ph.D., a stem cell biologist and director of the Children’s Medical Research Institute at the University of Texas Southwestern, is critical of clinics pushing exosomes. He told MedPage Today that “a lot more evidence is required to understand what they are, and it may be that a lot of claims about what they do in the end go by the wayside.” According to Dr. Morrison, the disagreement over whether exosomes have a physiologic function or if they are simply “just some cellular waste product” continues. He added that even the methods for purifying exosomes grown from culture are controversial among scientists “raising questions about what’s in the vials being used in treatment”.
‘What these snake oil salesmen do is they pick a word out of the scientific literature that gets people excited, and they start to sell it,’ Morrison told MedPage Today.
‘The same companies that are willing to ignore FDA requirements for safety and efficacy testing are the same ones willing to ignore regulations for good manufacturing practices and cut corners to sell things that are contaminated with bacteria’, he added.
The Nebraska Department of Health and Human Services warned health care providers and patients that, according to the FDA and CDC, potential risks of unproven stem cell treatments, including placental and umbilical cord blood derived products containing exosomes, include:
Failure of the cells to work as expected
Injection site reaction
Growth of tumors
Infections
Potential for contamination of the product
The ability of cells to move from placement sites and multiply or change into inappropriate cell types
These potential risks are present even if a patient’s own stem cells are being used.
Other medical and ethical issues are raised by the sourcing of exosomes from C-section placentas. An investigative report revealed that mothers facing C-sections, some in emergency situations, are being solicited to donate their placentas based on the understanding that they will be used to create therapies to help other patients. They are not told that some of these placentas are ultimately sold to the stem-cell industry for use in their dubious treatments.
The growing exosome market
As noted by Dr. Knoepfler, “exosomes are gaining more traction in the unproven stem cell clinic sphere, perhaps in part because of the actions against adipose stem cell clinics.” Google easily turned up clinics all over the country shilling exosomes for unproven uses, often in concert with a variety of questionable treatments, like ozone therapy and vitamin infusions, in addition to other dubious stem cell therapies. Some imply benefits while avoiding making direct claims of effectiveness, although their intent is obviously to make a sale, or at least to make patients inquire. (Otherwise, why would they mention the putative benefits?) Some also use disclaimers, saying that they are not giving medical advice or advising patients that treatments are not FDA-approved.
A sampling:
California: NAD Treatment Center: Innovators in Recovery and Wellness
The regenerative effect of exosomes has been reported in many tissues in the body, such as nerve, heart, liver, kidney, skeleton, cartilage, muscle, pancreas, and dental pulp. Unlike stem cells, they are able to travel systemically without a clumping effect as seen with large doses of stem cell injections, and are small enough to cross the blood-brain barrier. By utilizing exosomes, the cells in our bodies are able to revitalize and produce profound benefits throughout the body.
California: Optimal Health and Wellness [Run by two naturopaths.]
Exosome treatment is a more specialized and heightened version of stem cell enhancing therapy. While stem cells can be used to promote healing as they adapt to surrounding cells, exosomes carry specific signals to instruct cells what to do. . . During exosome treatment, exosomes deliver specific instructions to cells. Signals are directly delivered to cells to for optimal intercellular communication.
[Vastly overstating current scientific knowledge of exosome functioning.]
Delaware: Delaware Integrative Medicine
Exosomes may help regulate processes within the body. Patients with chronic inflammation, autoimmune disease, Lyme disease and other chronic degenerative diseases may benefit from including exosome therapy in their treatment regimen. Exosomes may also be beneficial as part of our Anti-Aging Therapy. Patients with degenerative joint disease have also experienced relief from the use of exosomes.
Missouri: Schoenwalder Health and Wellness
These [exosomes] produce an anti-inflammatory response due to the communication from the many proteins that downregulate inflammatory proteins. Other proteins will then recruit stem cells to the area that will help upregulate these cells to proliferate and promote organized healing through the regulated process. Then, once the task is complete, there are additional proteins that tell the cells when the healing has been completed.
[Again, vastly overstating what is known about the functioning of exosomes.]
Colorado: Aspen Institute for Anti-Aging and Regenerative Medicine
Exosomes . . . have been recently reported to play a major role in cell-free therapy of many diseases, including myocardial infarction, drug addiction, and status epilepticus. Our . . . exosome treatments are also thought to help ameliorate inflammation-induced preterm brain injury, liver injury, and various types of cancer.
Georgia: Regenerative Cell Therapy of Georgia
Exosome therapy may be used for the following: Musculoskeletal disorders such as back pain, knee pain, hip pain, cartilage, ligament, tendon damage, nerve injury, degenerated joints, joint pain issues and dysfunction, knee injuries, rotator cuff injury, meniscus damage, muscle tears.
Kansas: The Epigenetics Healing Center [Run by a chiropractor and an MD.]
Anybody with a degenerative or autoimmune condition could potentially benefit from the infusion of certain types of exosome therapies. At this time, it is believed that exosomes could benefit patients with conditions such as: Parkinson’s, Inflammation, Autoimmune diseases, MS. Alzheimer’s, brain injuries, cancer, Lyme disease, diabetes, obesity, and more.
Florida: MD Beauty Labs Spa and Wellness Center [Run by a nurse practitioner. Although Florida law requires nurse practitioners to be supervised by a physician per a written protocol, I could find no reference on the website as to who the supervising physician is.]
Exosomes treatment can be used to treat a range of health concerns. However, it is especially beneficial for those who are living with rheumatoid arthritis or other chronic joint pain.
[Some quotes were reformatted for easier reading.]
Except as noted, all of these clinics are run by MDs or DOs. While aggressive promotion of dubious treatments is par for the course for chiropractors and naturopaths, there is something deeply disturbing about the violation of ethical and professional norms evident when physicians offer treatments that they know perfectly well are unproven, potentially dangerous and, according to the FDA, illegal. Physicians who become aware of such conduct should remember their duty to report it to appropriate authorities, such as peer review bodies and state licensing boards. That duty is set forth in the AMA’s Code of Medical Ethics Opinion 9.4.2, “Reporting Incompetent or Unethical Behavior by Colleagues”.
The obligation to report incompetent or unethical conduct that may put patients at risk is recognized in both the ethical standards of the profession and in law and physicians should be able to report such conduct without fear or loss of favor.
Of course, neither the reporting party nor the treatment provider need be a physician to report “sketchy” stem cell clinics and there are a number of options for anyone to take action by alerting the appropriate state and federal authorities.
Patients beware
Presumably aware of the dubious clinical trials being run by some stem cell clinics, the FDA and the CDC give this advice to patients contemplating any stem cell or exosome therapy:
Check to make sure the product being considered is on the FDA’s approved list of stem cell treatments .
If the stem cell product is not on the approved list, ask the provider to show you that they have FDA permission to research a new drug, which requires what’s called an Investigational New Drug (IND) Application number and acknowledgement communication issued by the FDA.
Request the facts and ask questions if you don’t understand. To participate in a clinical trial that requires an IND application, you must sign a consent form that explains the experimental procedure. The consent form also identifies the Institutional Review Board (IRB) that assures the protection of the rights and welfare of human subjects. Make sure you understand the entire process and known risks before you sign. You also can ask the study sponsor for the clinical investigator’s brochure, which includes a short description of the product and information about its safety and effectiveness.
Ask for this information before getting treatment – even if the stem cells are your own.
The FDA is also asking health care professionals and consumers to report any adverse events related to exosome products (or any other unapproved product) to the FDA’s MedWatch Adverse Event Reporting program.

FDA should pull the plug on thermography
The FDA says there’s no good evidence that thermography can reliably screen for breast cancer or any other disease. Instead of pursuing the unlawful promotion of thermography for breast cancer detection on a case-by-case basis, the FDA should pull the plug on thermographic devices.
Jann Bellamy on May 23, 2019
Link

Here we go again.
The FDA recently issued a warning letter to Total Thermal Imaging, Inc., of La Mesa, California, and Linda Hayes, its president and co-owner, for illegally marketing and distributing an unapproved thermography machine as a sole screening device for breast cancer and other diseases. The FDA also issued a Safety Communication to warn patients, health care providers, and cancer treatment advocacy organizations that thermography is not cleared by the FDA as an alternative to mammography and should not replace mammography for breast cancer screening or diagnosis. This is one of several actions the FDA has taken in the last few years against marketers who misrepresent thermography’s utility for breast cancer screening, a subject we’ve covered several times on SBM (also here and here).
In my view, these and prior actions chasing scofflaws who flout the FDA by making false claims regarding thermography for breast cancer detection are insufficient to confront this threat to women’s health. Instead, the FDA should use existing law to ensure that this scam cannot continue. How this might be accomplished is an issue we’ll return to in a moment.
Briefly, thermography measures differences in temperature using infrared imaging. As Dr. David Gorski explained, there are several reasons why the temperature of breast cancers might be higher than the surrounding normal breast tissue and therefore potentially imaginable using infrared thermography. Unfortunately, thermography has proven an unreliable means of detecting breast cancer and the American Cancer Society, the American College of Radiology, and the American College of Obstetricians and Gynecologists do not recommend thermography for breast cancer screening. According to the American Cancer Society, thermography, including the newer digital infrared thermal imaging, failed to detect three out of four breast cancers known to be present. In addition to the high false negative rate, it has a high false positive rate as well.
The FDA regulates medical devices based on their intended use (what the device’s label says it is to be used for) and their indications for use (the conditions or reasons for using the device). Since 1982, “telethermographic systems” have been regulated as Class I devices when used as an adjunctive diagnostic screen for detection of breast cancer or other diseases. Class I devices, per the FDA, “present minimal potential for harm to the user” and include items like bandages and enema bags. If used alone for diagnostic screening, they are Class III, devices that “sustain or support life, are implanted, or present potential high risk of illness or injury”. HIV diagnostic tests are Class III, for example. No telethermographic system has received Class III approval, an event that is highly unlikely given the lack of evidence of effectiveness as a stand-alone screening method.
Class I medical devices receive a pre-market clearance from the FDA through one of several methods, each of which requires some demonstration of safety and effectiveness, even if only through claiming similarity to a previously-cleared device. That requirement makes this language in the FDA’s Safety Communication especially interesting:
There is no valid scientific data to demonstrate that thermography devices, when used on their own or with another diagnostic test, are an effective screening tool for any medical condition including the early detection of breast cancer or other diseases and health conditions.
[Emphasis in original.]
And:
the Society for Breast Imaging notes a lack of evidence that thermography has any effective role in breast cancer screening.
So, if thermography is not effective as a screening tool “for any medical condition” even “when used . . . with another diagnostic test,” why should it retain its Class I clearance for use as adjunctive diagnostic screening for breast cancer detection or any other disease or condition? It shouldn’t, especially given the continued disregard of the FDA’s limitations on thermography’s use by companies and health care practitioners who have no business advising women on appropriate screening methods in the first place, a problem the FDA’s Safety Communication acknowledges:
The FDA is aware that health spas, homeopathic clinics, mobile health units, and other health care facilities are using thermography inappropriately as a standalone tool for breast cancer screening or diagnosis.
The FDA has received reports that these types of facilities provide false information that can mislead patients into believing that thermography can find breast cancer years before it would be detected through other methods or thermography improves detection of cancer in dense breasts.
None of these claims are true or have any valid scientific evidence to support them.
Total Thermal Imaging (TTI) was cited by the FDA for marketing its Thermography Business Package, a combination of infrared cameras and software, as a sole screening device for breast cancer and other diseases. According to the warning letter, TTI claims:
Thermal Imaging is intended for early detection of the diagnosis of many disorders including breast cancer, inflammatory breast cancer, pre-stroke, heart disease, deep vein thrombosis, reflex sympathetic dystrophy/complex regional pain syndrome, back, leg or headache, and even unexplained pain, TMJ, and other disease.
You can’t prevent or cure breast cancer until it is detected. DON’T WAIT! Schedule an appointment with a certified clinical thermographer today. Start by visiting www.totalthermalimaging.com and find a thermal imaging center near you.
Share with your friends & family that there is an alternative to mammography that doesn’t involve any patient contact (no pain), will not cause cancer (no radiation), and is far more efficient at detecting cancer.
Breast Screening . . . This scan looks for inflammation, lymphatic congestion, hormonal imbalances. Early detection saves lives and breasts!
In the case of TTI, the harm caused by making false claims such as these is not just theoretical. ABC’s Good Morning America busted TTI in an investigative report featuring a woman, Morganne Delain, who went to TTI for a thermogram after discovering a lump in her breast. Linda Hayes’s TTI partner, chiropractor Greg Melvin, who we’ve met on SBM before, read the report, which
indicated she had a ‘mild to moderate risk of developing aggressive tissue.’ Melvin recommended exercises, a cleanse, and that she came back in three months for a comparative scan — his protocol for new patients.
Delain returned to TTI four months later, after worsening symptoms, but refused further scans. She was uninsured and unemployed and waited three more months for a mammography appointment. Her diagnosis: Stage 3 breast cancer. (According to ABC, she is now cancer-free after treatment.) Asked by a reporter why he didn’t immediately refer Delain, Melvin said “that they must wait three months to do a comparative scan to understand the results.”
Hayes’s and Melvin’s other excuse was that
they make it clear to patients that thermography is not meant to detect disease via a line at the bottom of the intake form: ‘The report will not tell me whether I have an illness, disease, or other condition.’
Really? Then why recommended it to a woman with a breast lump? (Delain says she never saw this disclaimer.)
In fact, ABC caught Hayes at a business conference saying “no one needs a mammogram.” A TTI brochure encouraged customers to schedule a thermal scan, stating “You can’t cure cancer until it is detected. Don’t wait.”
Unfortunately, while exposing thermography’s deficiencies, the ABC report does not mention the obvious: the lack of chiropractors’ qualifications to advise women on appropriate diagnostic methods and treatment in the face of breast cancer symptoms.
The exact statements quoted by the FDA are no longer on TTI’s website. However, TTI still claims that thermography can “distinguish dysfunction even when conventional blood tests and radiographic tests were negative”, “offers reproducible and scientifically valid information,” and “clearly shows future disease tendencies of [sic] those in the process of development.” These claims do not square with the FDA’s conclusion that there is no valid scientific data to support the use of thermography as a screening tool for any medical condition, either alone or as an adjunct to another diagnostic test.
TTI’s website also says that thermography “is an FDA approved adjunctive diagnostic device so the results can be trusted.” Actually, thermography devices are FDA-cleared, not approved, a much more rigorous process. TTI does not tell patients what “adjunctive diagnostic device” means: that it should be used only alongside a primary diagnostic test.
Thermography is not the only dubious healthcare service offered by TTI. Melvin still practices there, offering chiropractic “adjustments”, as well as “cranial facial release,” an oxygen bar (to – you guessed it – “boost your immune system”), and an infrared sauna (for “detoxification”). It appears TTI also offered what looks like thermographic facial reflexology (a new one on me) although this image has been removed from the website (but not the Wayback Machine).
In any event, correction of its original misrepresentations is not TTI’s only problem – according to the warning letter, TTI never obtained the necessary pre-market clearance for the thermography device it is marketing for any use. TTI is also cited for failure to comply with good manufacturing practices and for failure to register with the FDA.
The warning letter demands that TTI immediately cease distribution of the Thermography Business Package and take prompt action to correct the identified violations, and states that failure to do so can result in seizure, injunction, and civil money penalties. Other than changing claims on its website, we do not know what remedial action TTI has undertaken, if any. It is still marketing thermography for $250 to $550 a pop and does not take insurance. (Actually, insurers are unlikely to pay for it anyway.) TTI also offers a mobile thermography unit to health care practitioners, which includes a 15-minute presentation on what thermography is, how it works, and how it will benefit both patients and the practitioner, the latter by “growing” the practice and sending a check each week “for assistance in spreading the word about thermography”.
The FDA’s solution for all this is for the public to “be aware” that thermography is not a substitute for regular mammograms and should not be used in their place. The agency is calling on health care providers to “educate patients about the limitations of thermography”, including its high false negative and false positive rates, and to discourage its use.
The FDA says it will take additional steps necessary to address the risks associated with the use of thermography. Given thermography’s lack of valid scientific support and its continued misuse at the hands of marketers, including practitioners offering dubious healthcare advice like chiropractors and homeopaths, the additional step that would best protect the public is to reclassify thermographic systems used as an adjunct to other diagnostic methods from Class I to Class III. Class III requires a far more stringent FDA review, a review thermographic devices are highly unlikely to survive given the FDA’s own view about their lack of reliability.
Medical device regulation is nothing if not complicated, and there may be other means by which the FDA can take thermography devices off the market. However it gets there, the FDA has an obligation to the public to do more that ask patients to “be aware” of thermography’s dangers and health care practitioners to discourage thermography’s use. The FDA has the legal tools at its disposal to rid the public of this health scam and the scientific evidence to support its action.

New FDA regulatory role threatens bogus diagnostic tests
Jann Bellamy on January 15, 2015
Tweet

The FDA regulates in vitro diagnostic devices (IVDs) as medical devices. IVDs analyze human samples, such as blood, saliva, tissue and urine. However, in the past, the agency did not use its authority to regulate what are known as “laboratory-developed tests” (LDTs), tests developed and performed at a single laboratory, with all samples sent to that particular lab for testing. Instead, it focused on commercial tests kits, which are broadly marketed to laboratories or the public. These tests had to undergo the same pre-market approval process as other medical devices regulated by the FDA, including, in some cases, clinical studies demonstrating that the device is safe and effective for its intended use.
Historically, LDTs were developed by hospitals, researchers and academic medical centers for their own use. That is no longer true. In the past 15 years or so, there has been an explosion in the use of LDTs by commercial labs and biotechnology companies. The FDA now estimates that there are about 11,000 LDTs offered by 2,000 laboratories. One estimate is that the results of clinical lab tests (although not exclusively LDTs) influence 70% of health care decisions. (See the Congressional Research Service Report’s exhaustive analysis of FDA regulation of IVDs and inclusion of LDTs for more on the history and current use of LDTs.)
Do you have any idea whether the IVDs that have poked around in your blood or tissues are FDA-approved or unapproved LDTs? (Does your physician?) Do you know what evidence (if any) there is standing behind these tests? No? Me either. That’s because there is no requirement that anyone give you this information.
There is some already some regulatory oversight of labs that offer LDTs. A federal law, The Clinical Laboratories Improvement Act (CLIA), requires assessment of whether a lab is able to test according to instructions and detect what is intended to be detected, that is, the test’s analytical validity. However, a key element is missing in that evaluation: clinical validity. Does the test accurately diagnose or predict the risk of a particular clinical outcome?
The FDA announced last year that it would henceforth use its medical device regulatory authority to regulate LDTs. This caused a big brouhaha among the labs and others affected by the decision. Genetic testing companies are big players in the LDT market.
One reason for the consternation is (surprise!) money. Companies who jump through the FDA’s hoops and get approval say that labs using unapproved tests don’t have to shoulder that expense and are given an unfair competitive advantage. Some of these tests, they say, do the same thing as their approved tests, so why the difference in regulation? Labs using LDTs are up in arms that they may now have to go to the trouble of getting approved, and no doubt some of them have legitimate concerns. Of course, they also run the risk that their LDTs will be rejected by the FDA. (Some of them certainly should be, a point to which we’ll return in a minute.)
Lining up on the pro-FDA side are the American Cancer Society Action Network, the American Society of Clinical Oncology, and the Association of Public Health Laboratories. Lining up against the new requirements are some genetic researchers, a trade group representing clinical labs, and labs like ARUP, a non-profit lab owned by the University of Utah. ARUP runs a lot of tests for large teaching hospitals and government agencies that are rarely used and so not provided elsewhere. The American Medical Association doesn’t like the idea either.
Bogus tests shielded by lack of LTD regulation
Opponents have some rather unsavory company in the form of a “chronic Lyme disease” (CLD) proponent organization, Lymedisease.org, whose representative spoke at a public hearing on the FDA’s proposed actions last week. Lymedisease.org is incensed that the Infectious Diseases Society of America and the CDC have overly-narrow (in their view) criteria for Lyme disease diagnosis, as well as the FDA’s attempt to regulate labs tests that CLD proponents prefer over the ISDA and CDC’s judgment regarding testing.
Also in the “no” camp is the Alliance for Natural Health, the “health freedom” folks, who also had a rep at the public hearing. The ANH reliably finds a big corporate boogeyman behind every government regulation it doesn’t like, and, true to form, this time it’s the “drug, device, and biologics industry—the heavy-hitters who are LDTs’ chief competition.” Even though companies who employ LDTs are, by definition, part of the device industry.
According to the CRS Report, FDA oversight of LDT IVDs would include:
     1.  Regulation of the safety and effectiveness of the test
     2.  Pre-market review of the test
     3.  Demonstration of clinical validity
     4.  Systematic adverse event reporting
     5.  A process for corrections or results
The FDA issued draft guidance for industry on both the framework for, and notification requirements of, LDT oversight. Like regulation of other medical devices, its approach will be based on the risk of harm the test presents. In its discussion of the regulatory framework, the FDA says it:
has serious concerns regarding the lack of independent review of the evidence of clinical validity of LDTs. Clinical validity is the ability of a diagnostic device to measure or detect the clinical condition for which the device is intended. Clinical validity is not evaluated under [CLIA] regulations. LDTs that have not been properly clinically validated for their intended use and are used to make critical clinical decisions potentially put patients at risk of missed or incorrect diagnosis, failure to administer appropriate treatment or administration of potentially harmful treatment with no benefit.
And what better way to demonstrate the validity of the FDA’s concerns than the bogus laboratory-developed diagnostic tests used by practitioners of pseudomedicine, such as naturopaths? Results of these tests are used as a pretext to treat diseases and conditions a patient either doesn’t have or doesn’t require treatment. Like Bernie Madoff’s bogus investment account statements, the test results purport to something that isn’t there.
We’ve already touched on “chronic Lyme disease.” The American Lyme Disease Foundation explains what happens when validated testing is ignored, an analysis that could easily apply to the use of other nonstandard tests (emphasis added):
Despite [FDA and CDC] warnings, some physicians continue to order nonstandard tests for the diagnosis of Lyme disease, mistakenly believing that these tests — simply because they give positive results when other tests do not– are more sensitive; however, the results in most cases are falsely positive and lead to misdiagnosis…A false diagnosis of Lyme disease can have dire consequences in that a patient may be subjected to a prolonged and unproven treatment regimen to cure an infection that does not exist; this is often done at considerable personal expense. Aside from prolonging suffering and pain, misdiagnosis denies a patient the opportunity to receive proper care and treatment for the condition actually causing their symptoms. Under such circumstances, the patient is treated very much like a “guinea pig” and becomes a victim of an irrational process in which some unscrupulous practitioners derive significant financial gains from the administration of unproven and in many cases unsafe remedies.
CLD tests aren’t the only ones. Various “toxicities” are a go-to quack diagnosis for otherwise-vague or unexplained symptoms. And metals are a reliable cause of faux toxicity. To diagnose “heavy metal toxicity,” we have the popular LDT “provoked urine test.” As Orac explains:
urine levels of various metals are measured after a patient has received a chelating agent that results in the metals being excreted into the urine. Naturally, elevated levels of various chelated metals are routinely recorded because that’s exactly what one would expect after the administration of a chelating agent.
You may be less familiar with the “Organix” diagnostic test, a Genova LDT. Genova offers the “Organix Comprehensive nutritional test profile,” which “provides vital patient information from a single urine specimen.” I’ll have to give Genova that — if its website is to be believed, you do get a heck of a lot of information:
    • Functional vitamin and mineral status
    • Amino acid insufficiencies like carnitine and NAC
    • Oxidative damage and antioxidant need
    • Phase I & Phase II detoxification capacity
    • Functional B-complex vitamin need
    • Neurotransmitter metabolites
    • Mitochondrial energy production
    • Methylation sufficiency
    • Lipoic acid and CoQ10 status
    • Markers for bacterial and yeast overgrowth
And why is this important? Genova helpfully explains everything in an impressive 15-page “Organix Profile Interpretive Guide,” complete with illustrated charts.
The study of human metabolism has revealed how vitamins and minerals are used to perform those hundreds of necessary chemical reactions. This is a test that shows your doctor weaknesses in your metabolism. Many of the weaknesses can be overcome by increasing your intake of a vitamin or other essential nutrient …
Ah, so that’s it. Your doctor can use it to sell you vitamins and minerals. And maybe other stuff you don’t need, such as treatment for “yeast overgrowth.” If you’d like a more scientific evaluation, here’s one from an insurance company explaining why they won’t pay for the Organix LDT.
Finally, I don’t know how many of these tests are LDTs, but if you want to see an outrageous abuse of patients, take a look at this Great Plains Laboratory list of recommended lab tests for various diseases and conditions, including “vaccine injury.” One of the most recommended tests is the “IgG Food Allergy test with Candida.”
“Valid scientific evidence” could end pseudo-testing
According to the CRS Report on FDA regulation of IVDs, as with all medical devices, the FDA uses a risk-based scheme, divided into Class I (least risk), II, and III devices. For IVDs, risks are classified according to the intended use and risk relative to that use.
The intended use is established according to the claims the manufacturer or sponsor intends to make for the device, and includes the target population and the clinical setting for the use of an IVD…For IVDs, [the risk relative to use] is the risk to the patient of an incorrect test result.
Class III medical devices, including IVDs, are those that pose “potentially unreasonable risk of illness or injury” and are subject to premarket approval (PMA). A PMA application must provide “valid scientific evidence,” usually including clinical studies.
Any test that is used to diagnose a disease or condition that is not supported by sufficient evidence that it actually exists and is not recognized as a valid medical diagnosis (like the examples I have given) should necessarily be a Class III device and require PMA. This would eliminate at least some of the bogus testing used by pseudoscientific practitioners who prey on unsuspecting patients.
This is especially critical in light of the current health care practitioner licensing scheme we have in the US (discussed many times on the blog). If the states are not going rein in practitioners — like naturopaths and chiropractors, who have no respect for the scientific method and evidence — then at least the FDA could eliminate some abuse and exploitation of patients by getting rid of the illegitimate tests on which they rely.
You can comment on the FDA’s draft guidance until February 2, 2015. While there may be legitimate concerns about the FDA’s new approach to LDT regulation, I hope all supporters of science-based medicine will voice their support for eliminating bogus tests.

POM: Not So Wonderful
Jann Bellamy on May 31, 2012
Link
“POM Wonderful” is a brand of pomegranate juice. It is manufactured by a company owned by Linda and Stewart Resnick, California billionaires who pretty much single-handedly created a multi-million dollar market for pomegranate juice where none existed before. Or, as LA Times columnist Michael Hilzik wrote,
It has long been clear that the most wonderful thing about Pom Wonderful pomegranate juice is the spectacular marketing skill that persuades consumers to fork over their hard-earned cash for a liquid that sells for five to six times the price of, oh, cranberry juice.
He’s right about the expense: a daily 8 oz. dose of POM Wonderful juice costs about $780 annually according to a recent Federal Trade Commission case, which we’ll get to soon.
The Resnicks parlayed their success selling pomegranate juice into two additional products, both dietary supplements, in the form of POMx pills and POMx liquid. The Resnicks and their companies have shelled out $35 million in sponsored research to determine what health benefits might arise from ingesting pomegranate juice or its components, research they have not been shy about using in touting their products. The couple apparently has a flair for taking the mundane and making it appear, well, wonderful to the consumer – they also own Fiji Water and the Franklin Mint, among other business interests.
In 2010, the Federal Trade Commission (FTC) filed a complaint against Resnicks, one of their business partners, and two of their companies (which I’ll refer to collectively as “POM”), alleging unfair and deceptive trade practices. POM, according to the FTC complaint, made false and misleading claims that its POM products treat, prevent, and reduce the risk of heart disease, prostate cancer and erectile dysfunction.
An Administrative Law Judge (ALJ) agreed with the FTC and on May 17, 2012, issued a 335-page decision and cease and desist order, ruling POM lacked competent and reliable scientific evidence that drinking 8 ounces of POM Wonderful Juice daily, or taking one POMx pill, or one teaspoon of POMx liquid, treats, prevents or reduces the risk of heart disease, prostate cancer, or erectile dysfunction. In the Matter of POM Wonderful, LLC, et al., F.T.C. No. 9344 (May 17, 2012).

Battle of the Experts No. 1: What Consumers Think
POM denies it ever made such claims, but the FTC argued otherwise and the ALJ agreed with the FTC. In fact, it is undisputed that none of the ads under scrutiny expressly makes the contested claims. But the only legally relevant question is whether “consumers, acting reasonably under the circumstances, would interpret the advertisement to contain that message.”
Because a finding of deceptive trade practices necessarily looks at whether the advertisements are likely to affect consumers’ conduct or decision to purchase, consumer surveys, with accompanying expert testimony, were presented by both sides. These surveys show just how impressed consumers were by POM Wonderful’s claims. In a survey of POM juice drinkers, 91% said it “contains naturally occurring antioxidants,” 57% said it “promotes heart health,” 47% of men said it “helps protect against prostate cancer,” 45% said it “provides immunity from colds and flu,” and 43% said it “helps protect against other cancers (besides prostate).” These supposed benefits are important to consumers. In another survey of pomegranate juice drinkers, consumers ranked cardiovascular health as the first or second most important health benefit. The number two choice for men was “prostate.”
As noted, POM’s ads did not come out and flatly state that POM could prevent, treat or reduce the risk of disease. Rather POM implied this by giving the consumer information which would lead at least some consumers to come to that conclusion on their own. For example, the ALJ found that POM made claims about the effectiveness of POM products in treating, preventing or reducing the risk of heart disease
indirectly and obliquely, typically by presenting, through words and images, a logical syllogism that: free radicals cause or contribute to heart disease; the POM Products contain antioxidants that neutralize free radicals; and, therefore, the POM Products are effective for heart disease.
The ALJ found POM used a similar approach in its prostate cancer claims:
These advertisements typically communicate the claim by juxtaposing statements and representations that prostate cancer is a leading cause of death in men; antioxidants, such as those provided by the POM Products, may help prevent cancer; that PSA is an indicator of prostate cancer; that PSA doubling time is an indicator of prostate cancer progression; and that the POM Products have been shown in clinical testing to slow PSA doubling time.
In the erectile dysfunction ads, the claims are more direct. For example, POM ads claimed
    • Powerful antioxidants in the POM products enhance the actions of nitric oxide in vascular endothelial cells, showing potential for management of erectile dysfunction.
    • A preliminary study of “erectile function” showed that men who consumed POM Juice reported “a 50% greater likelihood of improved erections,” as compared to a placebo.
    • A pilot study involving 61 male subjects showed that men drinking 8 ounces of POM Juice daily for 4 weeks were “50% more likely to experience improved erections.”
In the dry language which often accompanies legal reasoning, the ALJ notes that as “Dr. Butters [one of POM’s expert witnesses on ad interpretation] acknowledged, contemporary speakers of American English could interpret the phrase ‘erectile function’ to relate to the ability of men to achieve and maintain erections. Erectile function and the absence of erectile dysfunction are closely related.” I suppose that in the field of expert witnesses, as in so much of modern life, areas of expertise are becoming more and more specialized. But I digress.
Battle of the Experts No. 2: Level of Substantiation Required
In determining whether POM’s ads were misleading or deceptive, a key issue was the level of substantiation required for a particular health claim, a decision controlled by five factors: the product involved, the type of claim, the benefits of a truthful claim, the ease of developing substantiation for the claim and – a big issue in this case – the amount of substantiation experts in the field would agree is reasonable. Needless to say, the experts in this case did not agree except in the most general sense: that “competent and reliable scientific evidence” was the appropriate standard for substantiation. Exactly what constituted “competent and reliable scientific evidence” was hotly disputed.
The ALJ decided that double-blind, placebo controlled randomized clinical trials were not required in this particular instance to substantiate POM’s claims that its products treated, prevented, or reduced the risk of serious diseases like heart disease and prostate cancer. In this, the ALJ accepted the testimony of POM’s experts, including Dr. Dean Ornish, that RCTs were not required. However, for each of the three diseases in question in this case – heart disease, prostate cancer and erectile dysfunction – the ALJ determined that clinical trials, even if not RCTs, were required for each of POM’s claims.
Battle of the Experts No. 3: Evidence (vel non) of Effectiveness
The case then boiled down to another battle of the experts over whether POM’s disease claims indeed met the competent and reliable scientific evidence test. This included conflicting testimony over underpowered trials, endpoints chosen, valid surrogates for improvement in condition, and other matters which I am incompetent to evaluate and discuss. ( You should feel free, however.) In each case, POM fell short of the mark. Even Dr. Dean Ornish himself couldn’t overcome the lack of “competent and reliable scientific evidence” for ability of fruit juice to treat, prevent or reduce the risk of cardiovascular disease.
On the other hand, the ALJ ruled claims that POM Wonderful can “support prostate health” and “support erectile health” (whatever the heck those terms mean) were supported by competent, reliable scientific evidence.
“Cease and Desist” Order
Because of the seriousness and deliberateness of POM’s violations, the ALJ’s cease and desist order, based on his findings of fact and conclusions of law, covers not only the three pomegranate juice products, but “any food, drug, or dietary supplement” made by the manufacturer of POM products and several related companies for the next twenty years.
In the future, POM and the related companies must have competent and reliable scientific evidence to support both treatment, prevention or risk reduction claims, as well as general claims about the health benefits, performance, and efficacy of their products. This evidence must meet generally accepted standards in the relevant scientific field AND must be viewed in light of the entire body of relevant and reliable scientific evidence. (In other words, no cherry-picking allowed.) POM and related companies, as well as the Resnicks and a business partner [“Respondents”],
shall not make any representation in any manner, expressly or by implication, . . . that such product is effective in the diagnosis ,cure, mitigation, treatment, or prevention of any disease; . . . unless, at the time it is made, the representation is non-misleading and Respondents possessed and relied upon competent and reliable scientific evidence that is sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true.
“Competent and reliable scientific evidence” means
tests, analyses, research, or studies, conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.
The same prohibition applies to representations regarding the health benefits, performance or efficacy of any product covered by the order. The Respondents are further prohibited from misrepresenting, “in any manner, expressly or by implication, . . . the existence, contents , validity, results, conclusions, or interpretations of any test, study, or research.”
Response to the Order
The supplement industry put a positive spin on the decision. It found comfort in the fact that the ALJ did not require randomized double blind placebo controlled clinical trials in order to make claims for health benefits as well as refusing to require FDA approval of all future health claims, both of which the FTC sought to impose.
Several aspects of the ALJ’s ruling might cause the supplement industry to temper its enthusiasm for this decision. First, the ALJ did not say that double blind, placebo controlled RCTs would never be required for a supplement or food product making a health claim, and, in fact, case law cited in the decision makes it clear that this possibility remains open. What the ALJ did say is that where, as was true of the POM products, there was scientific evidence that these products were very safe and where there was no claim that they were a substitute for medical care, a lesser standard would suffice. In a future case, where safety is not as clear or a suggestion that the product is a substitute for medical care is made, the possibility of requiring a more stringent level of evidence remains.
Second, not requiring an RCT does not mean anything flies. The ALJ decided that claims for treatment, prevention and risk reduction of disease require “a heightened level of substantiation,” which the ALJ determined would be “competent and substantial evidence” based the standards generally accepted in the relevant scientific community. In other words, whether “competent and substantial evidence” supports a claim must be determined case by case and based on what experts in the particular field would regard as such. Again, this leaves open the possibility that in another case expert testimony could support a finding that one or more RTCs would be required to make a particular claim.
And POM’s response?
A random quote from the decision plucked out of context and run in ads like this:
And this:
According to the New York Times, a POM spokesman said “the company would run the new ads ‘as long as necessary to inform the public of the truth,’” but “declined to disclose the budget for them.” I know you are as relieved as I am that we consumers will be informed of “the truth.” Interestingly, in 2009 the UK Advertising Standards Authority ruled that a POM Wonderful ad displaying a cut hangman’s noose and the phrase “Cheat Death” was misleading and could not be used again.
Even a column in the usually business-friendly Forbes magazine found POM’s response “disturbing,” and went on to excoriate DSHEA as anti-consumer. That opinion was not universally shared.
Even if POM didn’t literally ‘win’ the case, consumer psychologist Kit Yarrlow calls its ad campaign ‘a sophisticated move.’ ‘Consumers are ready to battle, love to champion underdogs and consider the government to be a big ugly Goliath,’ says Yarrow, a Golden Gate University marketing professor.
We’ll wait and see.
Any of the parties can appeal the decision to the full Federal Trade Commission or the Commission can choose to review the decision on its own. According to the Canadian newspaper, The Star, a POM spokesperson said POM would appeal. No matter what the full Federal Trade Commission decides, that decision may not, and likely won’t, be the end of things. Any party can appeal the full Commission’s decision to a federal appellate court. Because of the stakes, I imagine this case will be around for a few more years.
Conclusion
The complaint in this case was filed in 2010. The administrative hearing began on May 24, 2011 and concluded on November 4, 2011. Twenty four witnesses, including 14 expert witnesses, testified. There were nearly 2000 exhibits and the transcript ran almost 3300 pages. All in all, I imagine this case cost hundreds of thousands of dollars to prosecute and defend. In fact, I wouldn’t be surprised if the total price tag is over $1 million. And it’s still not over.
This cat and mouse game between the food and supplement industry on the one hand, and government regulators on the other, is not in the best interest of anyone, least of all the consumer. Congress could fairly easily enact a law that would provide clear guidelines on the level of evidence which should be required to make a health claim for a product in a manner that is understood by consumers and backed by good science. While regulatory agencies such as the FDA and FTC can issue regulations and guidelines governing health claims, these are subject to challenges as well, ending in more litigation. Unfortunately, Congress is in the thrall of industry, as is evidenced by DSHEA. This means that litigation will continue to define the parameters of permissible claims, case by case. The cat and mouse will continue to play, and the lawyers and experts will continue to profit.

FDA issues warning letter to “holistic” practitioner offering thermography for breast cancer detection
Thermography for breast cancer detection is one of more than 65 products the FDA just announced it is going after for fraudulently claiming to prevent, diagnose, treat or cure cancer.
Jann Bellamy on April 27, 2017
Link


The FDA announced this week that it is taking action against 14 U.S.-based companies for illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. Products include pills, topical creams, ointments, oils, drops, syrups, teas and diagnostic devices, sold mostly on websites and social media platforms. In warning letters posted on the FDA’s website, the agency demanded responses within 15 days from the companies stating how the violations will be corrected. Failure to respond may result in legal action, including product seizure, injunction, and/or criminal prosecution. The FDA also posted “mug shots” of several of the products.
One of those letters went to Nature’s Treasures, Inc. In addition to selling quack cancer treatments for both humans and pets, Nature’s Treasures markets thermography for breast cancer detection. According to the FDA, the company’s claims for thermography “provides evidence that the device is intended for diagnostic screening for detection of breast cancer, including as a sole screening device,” which federal law prohibits.
The FDA’s warning letter says that “telethermographic systems,” as the agency calls them, are cleared as diagnostic medical devices only for adjunctive diagnostic screening for detection of breast cancer. The fact that Nature’s Treasure’s included the Quack Miranda Warning – that its “products are not intended to diagnose, treat, cure or prevent any disease” – was not the “get-out-of-jail-free” card the company apparently hoped for. As the FDA pointed out, that is exactly what the company claims for thermography: that it can diagnose disease.
We’ll get back to the company’s bogus claims in a minute, but first, some background on thermography.
Thermography’s deficiencies
SBM’s own breast cancer expert, Dr. David Gorski, covered thermography for breast cancer detection back in 2010:
What is thermography and how is it used to detect breast cancer? As its name implies, thermography measures differences in temperature. Most systems use infrared imaging to achieve these measurements. There’s nothing magical about it; the technology has been in use for various applications for decades. The rationale for applying thermography to the detection of breast cancer is that breast cancers tend to induce angiogenesis, which is nothing more than the ingrowth of new blood vessels into the tumor to supply its nutrient and oxygen needs. A tumor that can’t induce angiogenesis can’t grow beyond the diffusion limit in aqueous solution, which is less than 1 mm in diameter. These blood vessels result in additional blood flow, which results in additional heat. In addition, the metabolism of breast cancer cells tends to be faster than the surrounding tissue, and cancer is often associated with inflammation, two more reasons why the temperature of breast cancers might be higher than the surrounding normal breast tissue and therefore potentially imaginable using infrared thermography.
The problem is, as he pointed out, claims of “integrative” physicians, naturopaths, chiropractors and homeopaths notwithstanding,:
    • There aren’t any baseline measurements of sensitivity and specificity.
    • There are no widely agreed-upon standards for test performance and interpretation.
    • Even if there were accepted standards, we don’t know whether thermography is cost-effective.
    • There is the potential for over-diagnosis and over-treatment even if, as promoters claim, lesions are detected 5-10 years before mammography.
    • Even as an adjunct, thermography doesn’t provide any information that a breast MRI doesn’t provide, and provide better.
Just this month, UnitedHealthcare issued a new Medical Policy on Thermography, reviewing the evidence. It included a 2012 systematic review finding that
currently there is insufficient evidence to support the use of thermography in breast cancer screening. The authors stated that there is also insufficient evidence to show that thermography provides benefit to patients as an adjunctive tool to mammography or to suspicious clinical findings in diagnosing breast cancer.
The Medical Policy noted that the American Cancer Society (ACS), the American College of Radiology, and the American College of Obstetricians and Gynecologists (ACOG) do not recommend thermography for breast cancer detection. According to the ACS:
Thermography failed to detect 3 out of 4 cancers that were known to be present in the breast. Digital infrared thermal imaging (DITI) which some people believe is a newer and better type of thermography, has the same failure rate.
The American College of Clinical Thermography says that women with dense breasts can benefit from thermography, a claim rejected by the ACOG.
UnitedHealthcare notes that Medicare won’t cover thermography and neither will it, for anything:
There is insufficient evidence to conclude that thermography has a beneficial impact on health outcomes. The available evidence is limited and weak, and standards for image evaluation and cut-off values that would allow clinical recommendations based on this technology have not been established.
The FDA’s own consumer information recommends that
despite widely publicized claims to the contrary, thermography should not be used in place of mammography for breast cancer screening or diagnosis.
The FDA notes that it has previously issued warning letters to practitioners making misleading claims, including well-known anti-vaccinationist and quackery promoter Joe Mercola. (The link to the letter is no longer good, but you can find out more about the case on Quackwatch and in the Chicago Tribune.)
In sum, practitioners cannot legally advertise that thermography is a substitute for mammography or promote it as a stand-alone diagnostic tool for breast cancer. However, thermography devices have been cleared by the FDA for use as an adjunct, or additional, tool for detecting breast cancer, even though there is no reliable evidence it is useful for that either. With that in mind, let’s look at how the FDA saw through Nature’s Treasures claims.
Nature’s Treasures: Quackery galore, including thermography
Nature’s Treasures is run by Los Angeles-area “holistic health counselor and natural health educator,” who, oddly enough, doesn’t tell us her name in her bio. We can presume she is Raya Shanazarian, the person to whom the warning letter is addressed. She claims she “studied naturopathy” at “Trinity College,” (maybe Trinity School of Natural Health?) and received a diploma from Ashworth College in 2015, the same year this online school settled FTC charges it misled students about career prospects and transferability of credits. (An $11 million judgment was suspended based on the school’s inability to pay.)
Shanazarian is not a licensed California health care professional of any sort and seems to be skating mighty close to the unlicensed practice of medicine, although she may come under the aegis of California’s generous quack protection act, otherwise known as a “health freedom” law. That someone so grossly unqualified to offer medical advice and treatment practices openly is a testament to the sorry state of healthcare regulation in California. At least the FDA is taking action.
Shanazarian advertises all sorts of quackery on her Nature’s Treasures website. This, also from her bio, will give you the flavor of where she’s coming from:
I want people to know that the root cause of disease stems from the accumulation of toxins in the body, and daily exposure to a toxic living environment. These toxins come from air, water, genetically modified foods, pesticides, meat, dairy, soy, white flour, table salt, MSG (Monosodium Glutamate), microwaved foods, refined sugar, artificial sweeteners, caffeine, alcohol, electromagnetic radiation, heavy metals, parasites, industrial chemicals, prescription drugs and more.
In addition to her thermography claims, the FDA is warning her to take down statements regarding various nostrums she sells, such as:
    • “Oxicell is the best choice for Liver Disease or Cancer.”
    • “Dysbiocide . . . treat[s] patients suffering from stomach parasites.”
    • “Colostrum LD Capsules . . . eliminate[s] harmful pathogens and fight[s] infection.”
    • “NeurO2 . . . support[s] during neurodegenerative states, hypoxia states, stroke recovery, brain injury recovery.”
Clicking on “Thermography” takes you to the website of Thermography Today, also owned by Shanazarian, which offers both full body ($375) or breast ($275) thermography. With each, you get a report of the results, a consultation with Shanazarian, and “nutritional advice based on the report,” an obvious pretext for recommending dietary supplements and other dubious remedies of the sort Shanazarian sells on the Nature’s Treasures website.
The thermograms are presumably read by the two “doctors we work with,” “Dr. Ben Johnson, MD, NMD, DO,” who lives in Georgia and owns his own thermography firm in Chattanooga, Tennessee, and Gregory Melvin, a chiropractor.
So, what is Shanazarian saying about thermography that got caught the eye of the FDA? From the warning letter:
On the webpage titled “Breast-Cancer-Awareness”:
    • “[A]ll women 25 and older should get annual Thermography screenings…”
On the webpage titled “Mammography Vs Thermography”:
    • “[T]hermography looks for the body’s physiological response to cancer cells. These changes can often occur 8-10 years before the cells are large enough to be seen by a mammogram.”
    • “Thermography can detect the possibility of breast cancer much earlier…”
    • “Breast Thermography has: 99% Sensitivity, 90% Specificity, 90% Accuracy.”
    • “Thermography is far more sensitive than mammography.”
    • “Thermography benefits all women. They may be particularly useful for young women who want to monitor their breast health should start as early as possible.”
On the webpage titled “What is Breast Thermography”:
    • “As more and more women become knowledgeable in thermography they choose not to do mammography.”
    • “I myself have not done mammography since 2006, but have gone through the procedure of ultrasound twice.”
The FDA also found fault with Shanazarian’s description of the thermography process:
The webpage titled “What to Expect” discusses step-by-step how your firm uses the devices during an appointment. For example, Step 3 explains, “Your pictures will be sent out to our reading physician for analysis,” and Step 4 states, “We will set up an appointment to see you in ten days after your results have come back to us. You can share the report with your medical doctor and if he has further questions he can contact the doctor who read your report…” Step 5 concludes that “You will be recommended when to do your second thermography by the reading doctor.” This discussion promotes the use of the thermographic system with a report provided based solely on the thermographic image.
I had to chuckle when I read the part about sharing the report with your medical doctor. I’ve wondered what real physicians do when confronted with these worthless reports by patients who are understandably alarmed by the results. How do you tell a patient who has just shelled out $275 for breast thermography (and who may have shelled out even more for dietary supplements presumably indicated by the report) that she’s just wasted her money without alienating the patient?
It is interesting to note that while Shanazarian touts the putative advantages of thermography over mammography and says that she doesn’t use mammography, she never comes out and says that thermography is an actual substitute for a mammogram or that it is alone sufficient for diagnostic screening. Note also the FDA’s language about promoting the use of thermography “with a report based solely on the thermographic image.” This tells me that, if a practitioner is going to offer thermography for breast cancer screening, she’d better steer clear of the type of statements Shanazarian used, or make it absolutely clear that it is no substitute for mammography and is approved for adjunctive use only, although there’s no guarantee a qualifier would overcome statements like Shanazarian’s. I even question whether, based on the FDA’s warning, a practitioner could recommend thermography prior to mammography and without some rationale for why another diagnostic method is needed and a clear indication of what diagnostic uncertainty thermography is designed to clear up. Otherwise, she risks running afoul of the FDA.
Unfortunately, based on this testimonial on Thermography Today, discouraging mammography appears to be exactly what is happening:
I want to thank everyone who has been involved in the science of thermography. I am in my late 30s and I know I should not do mammogram.
Nor did the FDA approve of Shanazarian’s claims that “Digital Infrared Thermal Imaging is approved by the F.D.A.,” a statement the agency found “misleading . . . because such statements create an impression of official approval” when, in fact, the “FDA has never approved any telethermographic system for sole diagnostic screening . . .”
Shanazarian has 15 days to come up with a plan to comply with the law. If the violations are not corrected, they are punishable by up to one year in federal prison, five years’ probation and a fine of either $100,000 or twice the gain from the offense.
It is good to see the FDA going after cancer quackery, a “specialty” the agency has, unfortunately, aided and abetted in other cases. It is also good that the FDA included thermography among products it considers as making illegal cancer claims. Not that quacks care all that much about regulatory compliance, but at least the FDA’s action should make it clear to them that even implying thermography is in and of itself efficacious for breast cancer detection may cause the FDA to pull the plug on their claims.

FDA efforts to improve compounded drug safety upsets naturopaths
Jann Bellamy on July 7, 2016
Link

Favorite naturopathic treatments comprise pumping patients full of dubious mixtures by injection, including IV drips. Naturopaths also employ topicals (salves, ointments and creams), rectal, and vaginal suppositories, and oral medications, such as bio-identical hormone replacement therapy, all made from “natural” substances.
According to the American Association of Naturopathic Physicians (AANP)
these nutritional, herbal and homeopathic remedies are compounded to meet unique patient needs and are not typically available from the large drug manufacturers that don’t make small batches of such specialized products.
Not to mention the fact that it is highly doubtful these questionable remedies could make it through the FDA drug approval process, which requires proven safety and efficacy.
The FDA’s recent steps to improve drug compounding safety is a welcome curb on these practices. Draft Guidance issued in April addresses both compounding for office use and by prescription. (“Office use” refers to creating a supply of a compounded drug to be used by a health care practitioner as needed, as opposed to compounding a drug per a specific prescription for an individual patient.) In June, the FDA also issued an Interim Policy on substances that can be used in compounding a drug. We’ll discuss how these affect naturopathic practice in a moment.
Compounded drugs
But first, some background: A licensed pharmacist or physician can legally combine ingredients to create a medication tailored to the needs of an individual patient. This is called “compounding.”
Compounded drug products, when prescribed and produced appropriately, can, according to the FDA,
serve an important role for patients whose clinical needs cannot be met by an FDA-approved drug product, such a patient who has an allergy and needs medication to be made without a certain dye or an elderly patient or a child who cannot swallow a tablet and needs a medicine in a liquid dosage form that is not otherwise available.
Because they are not FDA-approved, compounded drugs have not undergone premarket review for safety, effectiveness, and quality, nor are pharmacists and physicians who engage in traditional compounding required to comply with current good manufacturing practices (CGMP).
While the FDA regulates drugs, state pharmacy boards have the authority to impose their own compounding regulations because the practice of pharmacy is governed by state law. States also control the practice of medicine, including “naturopathic medicine.” Unfortunately, in enacting “health freedom” laws and licensing naturopaths and other “CAM” practitioners, states have watered down, or eliminated, a standard of care. This allows health care practitioners to diagnose and treat patients with means that lack sufficient evidence of validity, safety and effectiveness, or, in some cases, lack even scientific plausibility. These means can include compounded drugs.
For example, as described in this article from the Natural Medicine Journal, naturopaths use high dose Vitamin C and other concoctions in treating cancer. Britt Hermes, the former naturopath who quit in disgust and started the Naturopathic Diaries blog, told me in an email that
the protocols described in this article are basically the bread and butter of naturopathic IV practice, as we use high dose Vitamin C and these Meyer’s [sic] cocktails for every single medical condition under the sun. It’s the norm to just copy these protocols and apply it to all patients. Also, this is how we learn these techniques. We read about it [in literature written] by other NDs, and then we go and practice it on patients. Since the article is cited, it provides the illusion of being “scientific” or “well-researched.”
But, in keeping with her previous descriptions of the terrible inadequacies of naturopathic education and training, IV administration was, at the time she was in school, an elective and not required to graduate. Her elective was a two-day weekend course where they practiced IV administration of these “medicinal” IVs on other students.
Although she did not learn compounding in naturopathic school, in practice naturopaths mix IV bags in the office.
We did a ton of this. One vial supplied many injections. We did not use only one vial per patient, or a sterile vial for each new injection.
In the clinic where she worked in Tucson, Arizona,
We were ordering bulk product [the substances used in creating compounded drugs] under one patient’s name and receiving large quantities of injectables. We were then administering this product to many, many other patients.
At least the naturopaths where Hermes practiced were licensed. In Colorado, prior to the law registering naturopaths going into effect, the state Medical Board had to issue warning letters to 28 naturopaths for practicing medicine without a license after the state Pharmacy Board reported them for dispensing prescribed medications from a compounding pharmacy.
I hasten to add that naturopaths are not the only ones who are free-wheeling in their use of compounded drugs. A recent government report found that spending by the Medicare Part D program for compounded medicines rose more than 600% from 2006 to 2015. Last year alone, spending for compounded drugs by the program increased by 56%. The report noted that there were several cases in which physicians received kickbacks for writing prescriptions for compounded drugs.
Fungal meningitis outbreak
In 2012, there was an outbreak of fungal meningitis due to contaminated injectable drug products shipped by a compounding pharmacy to patients and health care practitioners across the country. The outbreak resulted in 60 deaths and 750 cases of infection. According to the FDA, this was only the most serious outbreak in a long history of outbreaks associated with contaminated compounded drugs. Since 2012, the FDA has investigated numerous other outbreaks and other serious adverse events, including death, associated with compounded drugs that were contaminated or otherwise improperly compounded. The agency has also identified
many pharmacies that compounded drug products under insanitary conditions whereby the drug products may have been contaminated with filth or rendered injurious to health, and that shipped the compounded drug products . . . to patients and health care providers . . . sometimes in large amounts.
In response to the outbreak, Congress passed the ”Drug Quality and Security Act” (DQSA) in 2013, which added Section 503B to the Food, Drug and Cosmetic Act of 1938 (FD&C Act), creating more stringent controls over compounding pharmacies that produce sterile drugs. (503B defines “sterile drug” as a “drug that is intended for parenteral administration, an ophthalmic or oral inhalation drug in aqueous format, or a drug that is required to be sterile under Federal or State law.”) These include compliance with CGMP, restrictions on the substances that can be used in compounding, adverse event reporting, and registration with the FDA as an “outsourcing facility.”
Compounding drugs not produced by a registered outsourcing facility, referred to as “traditional compounding,” must meet the requirements of Section 503A of the FD&C Act. If a drug is not compounded in accordance with Section 503A or 503B, it is subject to all the requirements of the FD&C Act applicable to new drugs, including the extensive, and expensive, new drug approval process.
While 503A was not amended by the DQSA in a way relevant to our discussion here, the draft and interim guidance covering 503A compounding recently issued by the FDA is part of a series of agency actions taken after DSQA that seek to clean up the compounding industry’s act. These actions are of great concern to naturopaths, who wish to retain the ability to concoct remedies for patients in the manner they enjoyed back in the good old days, when Britt Hermes was practicing.
(This guidance applies only to traditional compounding in a retail pharmacy or practitioner’s office. Hospital and health care systems are governed by different FDA policy.)
According to the FDA’s new Draft Guidance, issued in April, in order to fall within the exemption provided by 503A from registering as an outsourcing facility or going through the new drug application process, a compounding pharmacy can compound a drug only after receipt of a prescription written for an individual patient, who must be identified. Likewise, a health care practitioner may compound a drug only after making a notation in the patient’s chart “who presents with a need for a compounded medication.” The FDA will permit compounding in anticipation of receiving a specific prescription only in very narrowly tailored circumstances based on a history of a patient’s having been prescribed a certain compounded drug in the past, as well as other criteria. The FDA warns that compounders should keep detailed records, which it can review if the need arises. This puts naturopaths and the compounding pharmacies who deal with them under threat of revelation of some funky naturopathic prescribing practices.
In other words, says the FDA, compounding for office use, i.e., stockpiling their favorite mixtures for ready use, either whipped up by a compounding pharmacy or in practitioner offices, is not permitted under 503A. If a practitioner wants to order non-patient-specific compounded drugs, he or she will need to order them from registered outsourcing facilities, which operate under limitations on what they are allowed to produce.
According to an article in Naturopathic Doctor News and Review (click on the print icon to read the article if it does not appear), to comply with 503A, naturopaths are also required to follow the United States Pharmacoepia (USP) standards in applicable circumstances (the author gives creating a Myer’s cocktail as an example), such as mixing ingredients in an enclosed, positive pressure environment, just like a compounding pharmacy would use. He advises naturopaths to familiarize themselves with USP 797, a formidable document. (You can find both the current version and proposed revision here.)
Not only does 503A limit the manner in which compounded drugs can be produced, it limits the substances that can be used in compounding. The FDA’s Interim Policy-Guidance for Industry, issued in June, says that, under 503A, these substances must fall into one of several categories or they cannot be used. Unfortunately for naturopaths, all categories require, in one way or another, some supporting evidence of safety and efficacy. If the substance is already the subject of an USP or National Formulary monograph, or is a component of an FDA-approved drug, it is permitted. If it fails those tests, the substance must be on an FDA list of substances approved for compounding.
The AANP lobbied for inclusion of naturopathic favorites like Artemesia, Boswellia, calcium EDTA, Echinacea, DHEA, DMPS, DMSA, co-enzyme Q10, and germanium on the list. It also wanted to dump the entire Homeopathic Pharmacopoeia of the United States and the USP Dietary Supplements Compendium on the approved list, even though 503A specifically limited compendia to the USP or National Formulary. It also complained bitterly that the FDA was actually requiring evidence – imagine that! – which busy naturopathic clinicians could not be bothered to supply, a tacit admission that naturopaths were using these substances without sufficient proof of safety and efficacy. The AANP explained how the conventional medical system had failed the typical naturopathic patient (whose “immune systems are often depleted”), but, because naturopaths
are trained to find the underlying cause of a patient’s condition rather than focusing solely on symptomatic treatment [they expertly prescribe and administer] safely compounded medications – including nutritional, herbal, and homeopathic remedies [which] prove efficacious to meet their needs every day in doctors’ offices across the country.
So, these substances are efficacious, according to the AANP, they just couldn’t tell the FDA how they came to that conclusion.
Until the FDA can establish a final policy, it will not take action against a pharmacy or health care practitioner using substances for which adequate information for evaluation was submitted to the FDA, pending the FDA’s completion of its evaluation. This list includes Boswellia, but the clock is ticking and its inclusion on the final list is not assured. Germanium is on the list of substances that raise significant health risks and cannot be used. Many other naturopathic favorites are on the list of substances nominated without adequate support and cannot legally be used in compounding. These include Coenzyme Q10, ginger root powder, ginkgo biloba standardized extract, nux vomica extract and colloidal silver.
Their problem is compounded, if you will, by the fact that outsourcing facilities (the only legitimate source for stockpiling compounded drugs per the FDA) are also limited to certain substances they can use in compounding. As with traditional compounding, the FDA will not take regulatory action against outsourcing facilities using substances for which adequate information has been submitted for the FDA, pending the agency’s final decision, but it will not permit the use of substances listed as having safety concerns or nominated without sufficient evidence.
Congress may intervene
Naturopaths are not the only ones upset with the FDA. There are legitimate medical groups concerned that the FDA’s position could adversely impact effective medical care. Organizations representing dermatologists, ophthalmologists, surgeons, and anesthesiologists have asked the FDA to revisit the issue of office compounding.
Representatives from the fringes of medicine have voiced their opposition as well. A group calling itself the “Integrative Medicine Consortium” wrote the FDA last year making complaints similar to that of the AANP. The Consortium includes a couple of Pseudomedical Pseudoprofessional Organizations that have appeared on SBM before: the American Academy of Environmental Medicine, the American College for the Advancement in Medicine, and the International College of Integrative Medicine. Joining them in this effort are the International Organization of Integrative Cancer Physicians, a group that promotes dubious cancer treatments.
Unfortunately, the American Academy of Dermatology Association, the lobbying outfit for the American Academy of Dermatology, and some state pharmacy associations, joined forces with the AANP and the Alliance for Natural Health, a faux “grassroots” organization that advocates for the protection of quackery and against vaccination and fluoridation, to object to the FDA’s new guidance.
Their objections are being heard. Some members of the House of Representatives are also upset that office compounding is all but eliminated by the FDA’s actions. This effort is headed by Rep. Chris Stewart, who, not surprisingly, hails from Utah, where the dietary supplement industry is king. On June 20th, he was joined by 60 of his fellow Representatives in a letter than begins with a none-too-subtle threat:
As the Congress considers appropriations for the Food and Drug Administration (FDA) for Fiscal Year 2017, we write to express our concern . . .
According to Rep. Stewart and the others, Congress had made it clear that office-use compounding was indeed
legitimate and permissible and explained how compounding pharmacists can engage in office-use compounding before the receipt of a patient-specific prescription consistent with the provisions of 503A of the FDCA.
Of course, whatever happens, there is no assurance that naturopaths will actually abide by the FDA’s guidance. Like the Colorado naturopaths, some portion of them may ignore the law altogether. And, as we know, a naturopathic regulatory board won’t necessarily see violation of federal drug laws as an offense worthy of anything more than a slap on the wrist for the naturopath’s illegal conduct.
If the states are going to act as handmaidens to the “alternative” and “integrative” medicine industry by freely allowing practitioners to ignore evidence of safety and effectiveness, federal regulation of at least one means used to fleece patients is a welcome curb on the pseudoscience that permeates health care. Regrettably, the FDA cannot distinguish between the type of provider or the legitimacy of his or her treatments in regulating office use compounding. The same policy must apply to all. However, even if the FDA’s guidance on office use compounding falls to Congressional objections, it will still be able to prevent the use of unproven and unsafe substances in compounded drugs.

New FDA rule cracks down on compounded drug ingredients
A new FDA rule will require evidence of safety and effectiveness for substances used in compounded drugs, alarming naturopaths and integrative physicians. Experts have recommended that a number of naturopathic compounding favorites be banned.
Jann Bellamy on April 11, 2019
Link

The FDA recently issued a final rule, several years in the making, establishing criteria for determining which substances can be used in compounded drugs. Naturopaths and fringe medical practitioners have exploited decades of FDA inattention to create what is, in effect, a shadow drug manufacturing industry which operates free of the Food, Drug & Cosmetics Act’s (FD&C Act) safety and efficacy requirements for prescription drugs. Based on the new criteria, several substances previously used in compounded drugs have been banned and unfavorable evaluation of other substances by experts portends the prohibition of even more, causing the American Association of Naturopathic Physicians (AANP) and others in the CAM industry great anxiety.
Compounded drugs are an exception to the FD&C Act’s requirement that prescription drugs undergo extensive safety and efficacy testing before going on the market, as well as mandated good manufacturing practices and adverse event reporting. In the particular type of compounding that is the subject of the FDA’s new rule, sometimes called traditional compounding, pharmacies and physicians (including naturopaths where they are state-licensed to do so) can create drugs in-house as long as the drug is made for an individual patient pursuant to a prescription. When used appropriately, compounding can serve a useful purpose, such as allowing a pharmacist to make a drug in liquid form for a patient who cannot swallow capsules or without substances to which a patient is allergic.
(Note that hospital compounding and compounding in larger quantities by outsourcing facilities are the subject of different FDA requirements and not part of our discussion here.)
The FDA has had the authority to regulate the substances that could be used to make compounded drugs for years but, for various reasons, it chose to leave oversight of traditional compounding mostly to the states, which regulate the practices of medicine and pharmacy, as opposed to the drugs they prescribe and sell.
This regulatory void created a business opportunity for naturopaths and like-minded fringe medical practitioners, as well as the compounding pharmacies catering to them and their dubious prescriptions. Freed from the normal safety and efficacy evidence requirements for prescription drugs, these practitioners were able to create drugs based on scanty evidence or, in some cases, crackpot “theories” of disease processes at odds with science. This transformed compounding from a useful service to what is essentially experimentation on human subjects without the safeguards of a clinical trial or scientifically meaningful results.
Not surprisingly, this led to some tragedies. A patient died after a naturopath injected her with compounded curcumin to remedy her eczema, one of many conditions he advertised as treatable with IV curcumin. Another patient was killed upon her 13th infusion of a compounded solution containing selenium, prescribed by her naturopathic doctor for wound healing post-cancer surgery. IV chelation therapy with compounded products, prescribed for dozens of unproven uses, has also caused fatalities. Injections of compounded cesium chloride, promoted as a quack cancer treatment by naturopaths and some “integrative” physicians, resulted in severe adverse events, including death. Of course, without adverse event reporting requirements, we cannot know the true incidence of harm.
A well-publicized 2012 outbreak of fungal meningitis traced to compounded drugs caused Congress to enact a new law governing large-scale compounding, giving the FDA increased regulatory authority. The FDA took this opportunity to take a fresh look at its authority over traditional compounding as well. In 2013, the FDA invited interested persons to nominate bulk drug substances for inclusion on a list the agency would promulgate specifying which substances could legally be used in compounding, called the “503A Bulks List,” after Section 503A of the FD&C Act.
Based on these nominations, for which supporting evidence was required, the FDA created three categories:
     1.  Substances nominated with sufficient evidence and under evaluation for the 503A Bulks List.
     2.  Substances that raised significant safety concerns.
     3.  Substances nominated without adequate supporting evidence.
Pending further review and a final ruling by the FDA, only Category 1 substances could be used in compounding without risk of regulatory action. This caused great consternation among naturopaths, who griped, among other things, that they were too busy to provide the evidence of safety and efficacy necessary to get numerous substances onto the Category 1 list. The FDA was unmoved.
In 2016, the FDA issued a proposed rule that enumerated the circumstances under which a substance could be used in compounding, prompting further griping from naturopaths. In March of this year, the FDA issued its final rule, making its criteria legally binding. Needless to say, the naturopaths, “integrative” physician groups, a few compounding pharmacies, and their sympathizers are unhappy. In fact, they appear to be in somewhat of a panic, a topic we will return to in a moment.
(Note that the new rule applies only to the 503A Bulks List. Substances that comply with a USP or NF monograph and substances that are components of FDA-approved drugs can also legally be used in compounding.)
The FDA’s new criteria are:
     1.  the physical and chemical characterization of the substance;
     2.  any safety issues raised by the use of the substance in compounded drug products;
     3.  the available evidence of effectiveness or lack of effectiveness of a drug product compounded with the substances, if any such evidence exists;
     4.  historical use of the substance in compounded drug products including information about the medical condition(s) the substances has been used to treat and any references in peer-reviewed medical literature.
To any reasonable person, these would seem to be perfectly sound criteria. However, among other objections, the CAM crowd wanted the FDA to consider historical use dispositive in some cases, to include substances that are generally recognized as safe for use in food, didn’t want the FDA to consider the seriousness of the condition the compounded product is proposed to treat or the fact that an FDA-approved drug was available to treat a condition, the “unreasonable” high standards for evidence set by the FDA, and the FDA’s refusal to automatically include substances that are dietary supplements and homeopathic remedies. The FDA was also accused of “unfairly screen[ing]” and cherry-picking the evidence, misrepresentation, and manipulation.
The dissenters also objected that no naturopaths were included on the Pharmacy Compounding Advisory Committee (PCAC), the group of experts established to advise the FDA on the 503A Bulks List, and that “neither the FDA nor the PCAC has the necessary expertise to make judgments on the nominated bulk drug substances.” Actually, the PCAC has expertise in spades. It is comprised of physicians, pharmacists and a veterinarian with academic appointments at medical, pharmacy, and veterinary medicine schools, hospital pharmacists from Duke and St. Jude’s Children’s Hospitals, representatives from the compounding industry and the FDA, and consumer representatives.
Fortunately, the FDA rejected each of these objections.
The FDA, after consideration of the evidence, also promulgated a rule placing six substances on the 503A Bulks List and rejecting four others. (For you chemistry and pharmacy fans out there, included were Brilliant Blue G, and, for topical use only, cantharidin, diphenylcyclopropenone (DCPC), acetyl-D-glucosamine, Squaric acid dibutyl ester, and thymol iodide. Excluded were oxitriptan, piracetam, silver protein mild, and tranilast.) Notably, the FDA will include and exclude substances from the list via rulemaking, meaning the agency will have to publish a proposed rule and accept public comment on each substance included or excluded.
While only ten substances have made it through the entire FDA approval process, a number of substances nominated by the AANP or otherwise supported by the naturopathic community have been voted down by the PCAC, some with unanimous “no” votes.
    • Quercetin dihydrate
    • 7-Keto-dehydroepiandrosterone
    • Resveratrol
    • Artemisinin
    • Cesium chloride (banned by the FDA subsequent to the vote)
    • Sodium dichloroacetate
    • Chrysin
    • DMPS (approved but limited to IV in-hospital use)
    • Boswellia
    • Acetyl-L-carnitine
    • Methylsulfonylmethane (MSM)
    • Curcumin
    • Germanium sesquioxide (already on the FDA’s Category 2 list of substances that can’t be compounded due to safety concerns)
    • Rubidium chloride
    • Alanyl-L-glutamine
    • Glycyrrhizin
Of note, Paul Anderson, ND, testified before the PCAC in support of sodium dichloroacetate, stating that his group had administered over 10,000 doses orally and IV as an adjunct treatment for cancer. Anderson testified at the same committee meeting in favor of cesium chloride. Both substances were voted down unanimously by the PCAC and cesium chloride was ultimately banned by the FDA.
Although the PCAC’s vote is not dispositive, this does not bode well for the naturopaths and like-minded practitioners, or their wallets. Thus, the AANP has initiated a campaign to “save” compounded medications, including a GoFundMe campaign.
The AANP misleadingly cites medically accepted uses of compounded medications (e.g., allergies to ingredients, different dosing requirements) as reasons to object to the FDA’s action, conveniently eliding the fact that experts are rejecting their nominations because they lack evidence of efficacy and safety or are known to be inefficacious or unsafe. In fact, the reasons the AANP cites normally apply only to substances that have been through the FDA drug approval process, not random ingredients naturopaths use to concoct their compounded remedies. These inconvenient truths would reveal to their patients the fact that naturopaths want prescribe and administer drugs that couldn’t even make it through a review far less rigorous than FDA-approved prescription drugs.
As part of its campaign, the AANP filed a Citizens Petition on behalf of itself and the American Academy of Environmental Medicine, American College or Advancement in Medicine, American College of Integrative Medicine, and Academy of Integrative Health and Medicine (whose mostly online “fellowship” program allows participants to become board certified in “Integrative Medicine”), along with two compounding pharmacies. (Note that you can comment on the Petition.)
They also plan to “ask Congress to pass a bill to stop FDA’s overreach”, apparently with some success. A bill has been introduced that will, according to the Alliance for Natural Health, (an organization that promotes your “right” to pseudoscientific treatments) allow some dietary supplements to be automatically included among approved substances for compounding. (The actual text is not yet available on congress.gov.)
Although the FDA’s process is painfully slow, the agency’s renewed interest in traditional compounding is an important step in curbing the abuse of patients by naturopaths and other fringe practitioners. A fortunate side effect is the creation of a record, through nominations of substances for the 503A Bulks List and testimony and other evidence presented to the PCAC, exposing just how steeply entrenched in pseudoscience naturopaths are and how little regard they have for the health and safety of their patients. It’s like “What naturopaths say to each other when they think no one’s listening” (also here): a transcript of their pseudoscientific thinking plus expert evaluation of their claims, but all on the public record. It’s a target-rich environment, and one whose revelations I hope to pursue further in a future post.

FDA: No CBD in dietary supplements or foods for now, but let’s talk
The FDA reminds everyone that (no matter what your state says) CBD is not a legal ingredient in dietary supplements and foods. The agency is willing to explore changes to the law but unproven claims for CBD health benefits, such cancer cures, will not be tolerated.
Jann BellamyonMay 9, 2019
Link

The FDA is slowly clearing the fog of confusion surrounding consumer products under its jurisdiction containing cannabis or cannabis derivatives, including drugs, dietary supplements, foods, and cosmetics. As one of his final acts before leaving the FDA on April 5, Commissioner Scott Gottlieb, M.D., announced new steps
to advance [the] agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
with a particular focus on cannabidiol (CBD).
CBD is one of more than 100 biologically active chemical compounds in the cannabis plant and one of the most commonly known. Unlike THC, another well-known compound found in cannabis, CBD is not intoxicating. It is marketed in a variety of forms, such as oil, drops, capsules, syrups, teas, and topical lotions, often sold online, not necessarily legally.
Some confusion surrounding CBD’s legal status was generated by the Agricultural Improvement Act of 2018, which legalized hemp, basically defined as cannabis plants and derivatives containing no more than 0.3 percent THC (dry weight). Although legal hemp may contain CBD, that does not mean that CBD in any form, from any source, is also legal, contrary to popular misconception. Hemp-derived CBD is legal, according to this Brookings Institution publication,
if and only if that hemp is produced in a manner consistent with the [Agricultural Improvement Act], associated federal regulations, associated state regulations, and by a licensed grower. All other cannabinoids [including CBD] produced in any other setting, remain a Schedule I substance under federal law and are thus illegal.
“Associated federal regulations” include the Food, Drug & Cosmetics (FD&C) Act and the rules enacted by the FDA under the authority conferred on the agency by the FD&C Act, a subject we explore in more detail below.
(In this post, we’ll look at federal law only. State laws on CBD are all over the map. Over the past few decades, many states have legalized cannabis for medical purposes and some for adult recreational use. All of those uses remain illegal under federal law.)
Like other cannabis products, CBD is being promoted for near-miracle health benefits, which remain unproven. (SBM’s own Dr. David Gorski has done a good job of evaluating such claims in a series of posts, finding them wanting.) Right now, in Florida, where I live, yet another sad case of parents vying with the state to choose “natural” remedies over chemotherapy for their child is proceeding through the courts. A three-year-old boy who was diagnosed last month with acute lymphoblastic leukemia has been temporarily removed from the custody of his parents by the state, which is seeking permission from the court to re-start his chemotherapy, offering a cure rate of over 90% after a full 2 ½ year-regimen. His parents’ attorney told reporters that they want to start the child on medical marijuana (legalized by the Florida legislature) which “is a far superior treatment to chemotherapy” and that he will present studies to the court that “show cannabis causes ‘cell death of cancer’ without harmful side effects.” These are exactly the type of claims that are getting companies who make them in trouble with the FDA.
When (if ever) are CBD products legal?
While hinting that there may be an avenue forward for CBD-containing dietary supplements and foods, the FDA is making clear it will not tolerate companies illegally selling CBD products that claim to prevent, diagnose, treat, or cure disease, claims that can legally be made only by FDA-approved drugs (sometimes referred to as “drug claims”). To bring home the point, the FDA, in conjunction with the FTC, recently issued warning letters to three companies – Advanced Spine and Pain (headed by an M.D.), Nutra Pure, and PotNetwork Holdings – making what Dr. Gottlieb said were “unfounded, egregious claims” that their products containing CBD could treat cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, putting consumers at risk. As he pointed out, when products make unproven claims to treat serious or life-threatening diseases
patients may be misled to forgo otherwise effective, available therapy and opt instead for a product that has no proven value or may cause them serious harm.
Examples include:
CBD successfully stopped cancer cells in multiple different cervical cancer varieties.
CBD also decreased human glioma cell growth and invasion, thus suggesting a possible role of CBD as an antitumor agent.
For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.
CBD has demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms responsible for the pain associated with migraines, fibromyalgia, IBS and other related disorders.
Cannabidiol May Be Effective for Treating Substance Use Disorders.
Obviously, making claims that are legally limited to FDA-approved drugs will put you in the crosshairs of the agency as well as the FTC, and rightly so. How, then, might a company legally sell CBD-containing products, in the FDA’s view? For the answer to that question, we turn to a new agency webpage: “FDA Regulation of Cannabis and Cannabis-Derived Products,” and other recent FDA statements on the subject.*
Can I sell CBD at all?
According to the FDA,
It depends, among other things, on the intended use of the product and how it is labeled and marketed.
As noted, the Agriculture Improvement Act legalized hemp, which may contain CBD. However, as the FDA has taken pains to point out, Congress explicitly preserved the agency’s authority to regulate products containing cannabis or cannabis-derived compounds, including CBD. Thus, the fact that hemp is legal doesn’t automatically mean you can use it in an FDA-regulated product (e.g., dietary supplements), as we shall see below. And, whether it’s legal hemp-derived CBD or not, it’s important to remember that a seller can never legally (under federal law) market a CBD product for the prevention, cure or mitigation of a disease.
Can CBD be used in dietary supplements?
No, regardless of whether the CBD is hemp-derived or not. Under the Dietary Supplement Health and Education Act (DSHEA), dietary supplements can’t contain substances that are active ingredients in an FDA-approved drug or authorized for investigation as a new drug. In June, 2018, the FDA approved a new drug, Epidiolex, which contains cannabis-derived CBD, for the treatment of seizures associated with two rare and severe forms of epilepsy. (Prior to approval, the FDA had taken the position that supplements couldn’t contain CBD because Epidiolex was the subject of a new drug investigation [NDI]).
There would be an exception to this rule if CBD had been marketed as a dietary supplement prior to the NDI or FDA approval of Epidiolex, but the FDA says there’s no evidence this is the case. It is, however, willing to revisit this conclusion based on new evidence, a possible path forward for CBD-containing supplements. (There are two other possible exceptions to the ban on CBD in supplements and foods, although much harder to come by, which we’ll get to in a minute.)
Can CBD be added to foods, including animal foods?
No again, if the food is introduced, or delivered for introduction, into interstate commerce, for the same reason that CBD cannot be an ingredient in dietary supplements – because it’s an active ingredient in an FDA-approved drug. However, since the FDA’s authority over foods in this case is based on Congress’s constitutional authority to regulate interstate commerce, the FDA apparently does not claim jurisdiction over your locally-made, locally-sold CBD-laced brownies, cookies, gummies, and the like, as long as the sellers aren’t shipping them out-of-state. They may still be illegal under federal law, however, depending on the CBD’s source
Can CBD be an ingredient in cosmetics?
Currently, there is no FDA regulation prohibiting the use of CBD in cosmetics, which do not require pre-market approval (except for color additives), as long as the cosmetic otherwise complies with the law, including refraining from making drug claims or false advertising. The FDA can take action if any ingredient, including CBD, proves unsafe to consumers. Again, no matter the FDA’s position, the CBD in cosmetics may still be illegal under federal law.
Can CBD be used in drug compounding?
This is one question the FDA does not address: Whether and under what circumstances pharmaceutical-grade CBD can be used in traditionally compounded drugs. While components of FDA-approved drugs can legally be used in compounding, other restrictions may prevent CBD’s use in compounded drugs. (It’s complicated.) If that is not the case, we should worry about doctors, including naturopaths with prescription privileges, prescribing compounded CBD for unproven uses.
Prohibitions aside, Dr. Gottlieb’s recent FDA Statement also announced
a number of important new steps and actions to advance our consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under our existing authorities.
Toward this end, the FDA will
    • hold a public hearing on May 31, giving “stakeholders” the opportunity to provide the FDA with information relevant to the its current regulation of cannabis products and possible “lawful pathways” for marketing these products. Presumably this will include an opportunity to argue with the FDA about whether CBD was already being marketed as a dietary supplement ingredient prior to Epidiolex’s approval.
    • take written public comments “to share . . . experiences and challenges with these products, including information and views related to product safety.”
    • form a “high-level agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”
There are apparently two potential “lawful pathways” in the FDA’s thinking. One, obviously, would be for Congress to change the law (as it did with hemp), allowing dietary supplements and foods to contain CBD within a framework, in Dr. Gottlieb’s view, that defines permitted concentration levels.
The other is the FDA’s enacting a regulation, through notice-and-comment rulemaking, which can take years, permitting CBD in supplements and food. However, the FDA thinks it is critical to answer “open questions . . . regarding the safety conditions raised by their widespread use.” For example, during its review of Epidiolex, the FDA identified safety risks, including potential liver injury. As Dr. Gottlieb points out, these risks can be managed with medical supervision, but it is not clear how to address them when CBD is used with no medical oversight and without the labeling requirements for prescription drugs. He says there are also questions regarding cumulative exposure if consumers access CBD across a broad range of consumer products as well as questions of CBD’s “intended functionality” in these products.
Either way, it is clear to Dr. Gottlieb that Congress wants action on CBD:
Every meeting I go into on Capitol Hill, almost every meeting, I get asked about this.
Given the current disarray in Congress and the FDA’s lack of resources, it’s likely that we’ll continue to muddle along with conflicting federal and state laws, outlandish claims of health benefits, and confused sellers and consumers for the time being.

*While I am a lawyer, I am not your lawyer. This post is my interpretation of the FDA’s position on CBD, not legal advice to you, and you should not rely on it as such. If you want legal advice on CBD, including, but not limited to, whether and in what form you might sell it or any other cannabis product, consult a licensed attorney who specializes in this area of the law.

The FDA’s accelerated drug approval program is failing to protect cancer patients
Drug approval is a process that should be and, for the most part, is rooted in rigorous science. However, there is always a countervailing pressure to approve new drugs rapidly, particularly in cancer. That’s why the FDA created the accelerated approval program in the early 1990s. Unfortunately, increasingly this approval process appears to be failing us in oncology. Reform is needed.
David Gorski on June 3, 2019
Link

There is a tension inherent in the drug approval process between the desire to approve new drugs rapidly in order to treat suffering people and the need to be cautious, to make sure that new drugs are safe and effective before they are approved for sale. This weighing of the risks of too-rapid approval of drugs that doesn’t work (or doesn’t work well) and might cause harm versus the harm that can be caused by delaying approval of an effective drug that might help millions longer than necessary is complex, as is balancing the benefits of rapidly approving effective drugs versus the benefits of a more rigorous approval process that catches potentially dangerous drugs before they are approved.
Even under ideal circumstances, value judgments must be made, but add politics and profit to the mix, and it’s a very contentious process, with multiple players, most of whom don’t like delay. Drug companies want their drugs approved rapidly because of the potential profit. Patient advocates with serious diseases want promising new drugs sooner. Conservatives opposed to regulation like to push for faster drug approval as a means of making the Food and Drug Administration (FDA) less powerful, which was, of course, the origin of unethical “right-to-try” laws. Those harboring distrust of big pharma (which is often justified) want a more rigorous approval because they believe that the existing process is rigged in favor of the drug companies and don’t trust its results. It’s an uneasy tension that’s existed for many decades, ever since the formation of the FDA in 1906, through the 1962 Kefauver-Harris Drug Amendments to the Federal Food, Drug, and Cosmetic Act, which mandated evidence of efficacy in addition to evidence of safety before a drug could be approved. This was a law passed in the wake of the thalidomide disaster.
Since then, depending on who was in office and who the FDA Commissioner was, the pendulum has shifted back and forth over how rigorously safety and efficacy have to be show before a drug can be approved. In response to the HIV/AIDS crisis, for instance, the accelerated approval process was initiated to allow approval for drugs that fill an urgent unmet need for the treatment of serious conditions to be approved based on surrogate endpoints:
The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.
Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.
It was a reasonable response to a tough problem; or at least it seemed so at the time. Drugs in this pathway could, after 1992, be approved by the FDA if their makers could demonstrate an effect on a surrogate measure or intermediate clinical end point that is, according to the program, “reasonably likely” to predict a real clinical end point, such as changes in symptoms or mortality rates. Certainly, surrogate endpoints can be measured in a much shorter time frame than the several years it usually takes to identify improvements in overall survival. The accelerated approval program, however, rests on a big assumption, namely that the surrogate endpoint chosen is a good predictor of clinical outcome. So it’s reasonable to ask: How often do drugs approved through this process ultimately pan out and provide significant benefit to patients? A study asking this question was published in JAMA Internal Medicine last week, which made it into the news:
Many cancer patients and oncologists may turn to the US Food and Drug Administration’s accelerated approval program, which provides access to new cancer drugs faster — especially when a life-threatening cancer needs swift treatment or relief.
Yet a new study questions the clinical benefit of some drugs in the program and suggests ways in which the program could be improved.
It turns out that the study, carried out by researchers at Brigham and Women’s Hospital and Queen’s University in Canada, found that only one-fifth of oncology drugs that received accelerated approval were ultimately validated in confirmatory trials to have an effect on overall survival. Basically, the study calls into question the entire rationale of the FDA’s accelerated approval system, at least in oncology. Let’s dig in.
Surrogate endpoints in oncology versus real endpoints
Cancer therapies are generally evaluated using a number of endpoints. The most commonly used include overall survival (OS), progression-free survival (PFS), or recurrence-free survival (RFS). There are, of course, other endpoints related to survival that are measured, but these three are the most relevant for this discussion. Overall survival is what it sounds like: How long do patients survive their cancer after diagnosis? Period. It’s hard for an endpoint to be more objective than that: At a certain timepoint after diagnosis, either the patient is alive or she is dead. This number is usually expressed in terms of median survival, which is the period of time after which half of the patients under study are still alive and half have died. It should be noted that OS includes all causes of death, not just cancer. If a patient with cancer under study dies of a heart attack that is not related to his cancer or his cancer treatment, that counts.
Traditionally, OS has been the “gold standard” endpoint in measuring the efficacy of a cancer therapy, because the primary goal has been to prolong survival, the ideal case being prolonging survival to the point where it is indistinguishable from life expectancy if the patient never had cancer in the first place. PFS, on the other hand, is survival without progression; i.e., how long the patient with cancer survives without evidence that his or her tumor has measurably grown or metastasized, with dying of other causes with disease counting in the calculation. While PFS is often measured as well as OS, it’s generally considered less useful because it is entirely possible for a treatment to prolong PFS without prolonging OS. This sort of result can happen when the treatment is effective at shrinking a tumor and/or slowing its progression but its toxicities contribute to death from other causes. In such a case, PFS improves with no improvement in OS. Finally, RFS (also called disease-free survival, or DFS) is how long the patient survives without a recurrence of her cancer after successful initial treatment. PFS and RFS are often used as surrogate endpoints in cancer therapy clinical trials, although increasingly there is one other. In neoadjuvant chemotherapy (chemotherapy given before surgery), a pathologic complete response (pCR) has traditionally been considered a good surrogate endpoint. A pCR occurs when, at surgery, there are viable cancer cells detectable in the specimen removed at surgery. There is some controversy about this, in breast cancer at least, but in aggressive forms of breast cancer the correlation between pCR and improved overall survival is good, with a relatively recent meta-analysis having found that there is an 84% decreased chance of death in women with an aggressive subtype of cancer known as “triple negative” whose neoadjuvant treatment achieves a pCR.
Other surrogate endpoints include response rate (RR), defined as the percentage of patients whose tumor shrinks significantly in response to the therapy (usually 30% or more is the cutoff); and time to tumor progression (TTP, which is the same as PFS but doesn’t include deaths; it just measures time until the tumor detectably progresses). To these is being added a dizzying array of molecular surrogate endpoints that are less accepted, and it’s hard not to be tempted to pick your favorites if you’re an oncology researcher.
The debate about the use of surrogate endpoints in oncology has been going on as long as I can remember, dating back to before I entered the field of surgical oncology as a fellow back in the mid-1990s, and, as this study shows, is still going on. Unfortunately, the relationship between these surrogate endpoints and overall survival is not always clear or as tight as we would like to think. Nine years ago, I discussed in depth one such case, Avastin (bevacizumab), an angiogenesis inhibitor, and its use for advanced breast cancer. The drug had achieved accelerated approval for this indication in 2008 on the basis of trials showing improvements in PFS. However, by 2010, followup trials had failed to show an improvement in OS, and the FDA rescinded its provisional approval. When Avastin was approved, a prominent breast cancer oncologist justified Avastin’s approval based on PFS thusly:
Dr. Kathy Albain, a breast cancer specialist at Loyola University Medical Center in Maywood, Ill., polled colleagues and patients and found overwhelming support for approving drugs based on delaying tumor progression. It would be ideal to show that a drug also prolongs life, but that may not be realistic, she said. The reason is that when a woman’s cancer progresses, doctors change the drugs they use, hoping to slow the cancer. That dilutes any impact of the first drug — in this case Avastin.
At the time, I noted that, although I could see where Dr. Albain was coming from, I had always been uneasy with this view. I could see the utility of a drug that slows tumor progression but does not prolong survival, but I could only see its usefulness in one situation: There must also be good evidence that that drug also improves quality of life, evidence that was definitely lacking for Avastin, which, if anything, increased complication rates and was very expensive, to boot.
In any event, the FDA’s removal of its approval for Avastin for advanced breast cancer shows another problem with accelerated approval. When a drug is provisionally approved and then its approval rescinded based on later clinical trials, no one is happy. Certainly breast cancer advocates were very unhappy. I even experienced some of their wrath when I foolishly agreed to be on a radio show to discuss the issue. What I wasn’t told was that there would also be a breast cancer advocate on the show as well, an advocate who was receiving Avastin and believed that it was responsible for her continued survival. Politics also intruded. The Affordable Care Act had just been passed into law at the time, and conservative opponents of the ACA attacked the FDA’s decision on Avastin as “evidence” of the impending arrival of socialized medicine-style rationing, thanks, of course, to “Obamacare”, characterizing the decision as the FDA being made complicit in “rationing” health care.
It is a very thorny issue, which is why the study under discussion, by Bishal Gyawali at Brigham and Women’s Hospital, asks a very pertinent question: How often do oncology drugs approved by the accelerated approval mechanism show improvements in OS in the subsequent confirmatory clinical trials required by the FDA?
Disappointing results
To answer this question, Gyawali et al looked at drugs approved by the FDA based on surrogate endpoints. In the introduction, it is noted:
The FDA recently published an article on the 25-year experience with the accelerated approval pathway that examined the fate of 93 oncology indications granted accelerated approval from December 11, 1992, through May 31, 2017.9 The review found that 81 (87%) of the original 93 accelerated approvals were based on response rates—a surrogate marker in which the effect of an intervention is determined based on a change in tumor size. In addition, 8 (9%) of 93 accelerated approvals were based on PFS or time to tumor progression (TTP) and 4 (4%) were based on DFS or recurrence-free survival (RFS). Progression-free survival and TTP are surrogate markers that measure the time between the start of treatment and tumor growth beyond a certain size in the case of metastatic disease, whereas DFS and RFS measure the time from the start of treatment to disease recurrence when the drug is used as adjuvant therapy.
The FDA reported that in 51 (55%) of the 93 indications, confirmatory trials verified clinical benefit. In 5 cases (5%), approval for an indication was withdrawn in light of postapproval trial results, and postapproval evaluations were ongoing for the remaining 37 (40%) indications.9 The FDA concluded that the low failure rate in confirmatory trials was evidence that the accelerated approval pathway was operating effectively. We assessed the nature of the end points used for the verification of benefit in confirmatory trials and provide an update on the current status of the remaining indications for which confirmatory trials were ongoing at the time of the FDA’s analysis.
Gyawali et al wanted to update the outcomes reported by the FDA. So in May 2018, which was one year after closure of data collection for the FDA’s study, they searched PubMed, as well as the FDA database of postmarketing requirements and commitments, to determine the current status for postmarket trials for the indications that were labeled as “ongoing” in the FDA report. Confirmatory trials were categorized into three groups: (1) a trial that used OS or a quality-of-life end point, (2) a trial that used a surrogate measure different from the one used in the preapproval trial, and (3) a trial that used the same surrogate measure used in the preapproval trial. Here is the “money table,” which summarizes the study’s findings:
So, looking at the updated figures, I see that on the surface, it looks as though, for 62% of oncology drug approvals, clinical benefit was confirmed. But if you look more closely, you’ll see that only 20% of all 93 cancer drug accelerated approvals, or one-third of the ones claiming confirmation, had improvement in OS noted in confirmatory trials. What about the other 40%? 20% had improvement in the same surrogate in their confirmatory trial, which led me to a major facepalm when I read this result. What on earth is the purpose of just doing another study using the same surrogate endpoint? How does that “confirm” anything? The other 21% had improvement in a different surrogate in a confirmatory trial, which led me to a less vigorous, but still painful facepalm. Apparently it did the same to the authors, who wrote in the discussion:
Studying the same surrogate efficacy measure that had been used to earn accelerated approval was considered sufficient by the FDA to confirm approval in certain cases, although it is not clear that such follow-up studies should be used as verification of benefit. Rather, a postapproval trial that uses the same surrogate measure as its primary end point should be described as corroborating the effect on the surrogate measure, perhaps in a larger or different patient population, unless the surrogate measure has been well validated. In other cancer drug approvals that we reviewed, the confirmatory trials used a different surrogate end point than the one used in the preapproval trial. In this situation, patients and physicians continue to lack information about whether the cancer drug improves survival or quality of life, which is essential in the benefit-risk evaluation for clinical decision making, unless the new surrogate is a validated surrogate.
Indeed. What was the point of using surrogate endpoints in a second trial, meant to be confirmatory? That doesn’t “confirm” anything either. As for the rest, five drug accelerated approvals (5%) have been withdrawn and an additional three (3%) did not demonstrate improvement in the primary end point in confirmatory trials. Five (5%) trials were delayed, 9 (10%) remain ongoing, 10 (11%) remain pending, and one each were terminated and released. Thus, a significant percentage of confirmatory studies are delayed or pending, which means that considerable time can elapse between the approval of a drug and the completion of its confirmatory trials.
The authors also note:
In describing the accelerated approval pathway, current FDA rules state that confirmatory trials of a drug should “verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate end point to clinical benefit, or of the observed clinical benefit to ultimate outcome…such studies must also be adequate and well-controlled.” Although this language does not explicitly require that a confirmatory trial evaluate a clinical end point like OS, these rules do highlight that postapproval studies should be designed to resolve the uncertainty of the association between the surrogate measure and clinical benefit. This standard will be difficult to achieve via postapproval studies that use the same surrogate measures as those used in preapproval studies.
That last sentence is about as sarcastic a remark as you will ever find in a peer-reviewed medical study. Nice shade there, Dr. Gyawali!
In fairness, the authors do recognize the debate in oncology whether OS should remain the “gold standard” for oncology drug approval, or “whether achieving durable responses in single-arm trials should be sufficient to judge the clinical efficacy of a cancer drug”. The problem with this approach, from my perspective, is that many of these drugs are toxic, which means that a durable response could be at the cost of toxicity that negates (or worse, more than negates) any potential survival benefit attributable to the durable response.
There’s also a second study in the same issue of JAMA Internal Medicine by Chen et al, that looked at cancer drugs approved using only RR as the surrogate endpoint. (Shockingly, one-third of cancer drugs in the US are approved based only on RR.) Basically, they performed a comprehensive review of available package inserts for all oncology drugs that were FDA-approved on the basis of RR end points for any adult malignant disease from January 1, 2006, to September 30, 2018, including both accelerated and regular approvals. Of the 85 approvals that they examined, they reported that 14 (16%) had an RR less than 20%, 28 (33%) had an RR less than 30%, and 40 (47%) had an RR less than 40%, noting that “many cancer drugs are approved on the basis of low or modest RRs, typically in single-arm studies.” They noted in their conclusion:
Finally, many of these drugs have remained on the market for years without subsequent confirmatory data. When accelerated approvals based on RR were converted to full approval, 23 of 29 were made on the basis of surrogate end points (PFS or RR), 7 of 29 were made on the basis of RR, and only 6 of 29 were made on the basis of OS, an end point of clinical benefit. In summary, our analysis of drugs approved on the basis of RR end points suggests marked flexibility on behalf of the FDA to use this surrogate end point in the absence of randomized clinical trials.
These are shockingly low numbers.
What can be done?
An accompanying commentary by Richard Lehmann and Cary Gross notes that this is time of “unprecedented hope in the development of treatments for cancer.” noting that in comparison to many other regulatory agencies, the FDA “works to high standards of rigor and transparency” but that it “also works amid constant political clamor for faster access to innovative treatments.” They also note that these two studies “serve as a reminder that the accelerated approval pathway is a permissive process that tolerates nonrandomized trial methods and a variety of outcome measures that bear an uncertain relationship to patient benefit.” This is all true, unfortunately, and, as Chen et al show, there are a lot of drugs out there that undergo regular FDA approval based on surrogate endpoints and whose benefits in terms of OS are unproven. As Lehmann and Gross observe:
Such findings build on a growing body of work, which in aggregate, demonstrate a postmarketing evaluation process that is serving neither patients nor society well. First, the surrogates used for accelerated approval are poor predictors of clinically meaningful outcome. Second, study designs of postmarketing studies may not provide adequate information about comparative efficacy because some studies may not use appropriate control groups or rigorously account for treatment assignment bias. Third, there are concerns about whether postmarketing studies are being completed; it has been consistently reported that nearly half of postmarketing studies are delayed, and the proportion of completed studies remains low.1 Finally, nearly a quarter of these studies are not being publicly disseminated, even when completed.2
In other words, the postmarketing evaluation process is broken. As is noted in another accompanying editorial by Sarah DiMagno, Aaron Glickman, and Ezekiel Emanuel:
Second, using surrogate end points such as response rate to get drugs to patients quickly is only defensible if the studies’ findings are quickly evaluated in confirmatory postapproval trials that validly quantify overall risks and benefits, which inform physician and patient decision making. Manufacturers are required to conduct postapproval trials to ensure the signal from surrogate end points is real rather than noise.
Clearly, this is not being done nearly as fast or well as it should be. It’s a problem that needs to be fixed.
A complementary way to approach the problem is to find better surrogate endpoints and to work on assessing the correlation between the ones we use and clinical benefit in OS. As Gyawali et al note, their results, that only 20% of drugs approved based on surrogate endpoints improve OS, are consistent with other findings, and the use of these endpoints is not particularly rigorous. For example, a recent study by Kim and Prasad that found that in 56% of accelerated approvals and 37% of traditional approvals there was no formal analysis of the strength of the surrogate-survival correlation and that for accelerated approvals just four approvals (16%) were “made where a level 1 analysis (the most robust way to validate a surrogate) had been performed, with all 4 studies reporting low correlation (r≤0.7).” The conclusion? The use of surrogate end points for drug approval often lacks formal empirical verification of the strength of the surrogate-survival association. In another paper, Robert Kemp and Vinay Prasad noted:
We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm.
In other words, as I have argued before, if anything the FDA’s approval standards are arguably not rigorous enough, contrary to the arguments of anti-regulation ideologues who like to make ridiculous claims that the FDA is “killing” thousands of people by being too slow to approve life-saving new drugs or that you can replace the FDA approval process with, in essence, a “Yelp for drugs.”
I think DeMangno et al come closest to getting it right in their editorial when it comes to proposed solutions. Three problems are noted: that response rates are not meaningful clinical outcomes; that using surrogate endpoints to approve drugs is defensible only if the followup studies are done quickly and acted upon, which is not the case; and that the FDA still approves drugs even when the confirmatory data show no substantive benefit on clinically meaningful end points. They also note that there is no reason why the FDA has to rely on so many single trials using surrogate endpoints given that randomized trials in patients with metastatic disease could be done almost as quickly, given the shorter expected survival times. They then conclude:
Together, these 2 articles suggest that the ship of regulation has veered too far to one side, requiring at least 3 policy changes. First, the end point for confirmatory trials should never be the same surrogate end point used in the original study, and a new surrogate end point should be used only if there is a proven correlation between that end point and overall survival or improved quality of life. Most confirmatory trials should use overall survival and/or quality-of-life end points. Second, approval of drugs should be rapidly withdrawn when confirmatory trials report serious toxic effects or do not report meaningful clinical improvements. Finally, the confirmatory trials must be conducted promptly, with credible threats of reversed approval. Having more than a quarter of trials incomplete years after accelerated approval is unacceptable.
Lehmann and Gross note that postmarketing clinical trials are “expensive, requiring substantive infrastructure and oversight.” Of course, one argument for accelerated approval is that regular drug approval is too expensive and takes too long, implying that accelerated approval “gets cures to the patients” faster and for less money. Unfortunately, that observation can be countered by simply pointing out that many of these new drugs are nonetheless very expensive, and, as we have seen, too many of them are of marginal benefit at best, meaning that in far too many cases we pay a lot for not very much benefit. Clearly the FDA needs to do, at minimum, what DeMango et al suggest. Unfortunately, in the present political environment, all the political headwinds are pushing in a direction opposite of more rigorous standards for drug approval.

Is the FDA embracing quackery? A draft proposal recommends that doctors learn about acupuncture and chiropractic for pain management.
Chiropractors and acupuncturists have lobbied for a greater role in treating pain. They might well have won it. Last week, the FDA released proposed changes Wednesday to its blueprint on educating health care providers about treating pain, which now recommend that doctors learn about chiropractic care and acupuncture as therapies that might help patients avoid opioids. There’s still time to stop this.
David Gorski on May 15, 2017
Link

Last week, I wrote about acupuncture, specifically how acupuncturists are unhappy that the UK National Institute for Health and Care Excellence (NICE), which provides guidelines for recommended treatments for diseases and conditions, does not recommend acupuncture for the treatment of knee osteoarthritis but does recommend arthroscopic washouts and debridement, for which the evidence is weak. My retort was simple: If this is true, the answer is not for NICE to start recommending quackery like acupuncture, but rather for it to stop recommending conventional medical and surgical treatments with very little evidence for efficacy. Unfortunately, across the pond, our FDA appears poised to go in the opposite direction, as discussed in an article in STAT News, “FDA proposes that doctors learn about acupuncture for pain management“:
Chiropractors and acupuncturists who have lobbied for a bigger role in treating pain have won a preliminary endorsement from federal health officials.
The Food and Drug Administration released proposed changes Wednesday to its blueprint on educating health care providers about treating pain. The guidelines now recommend that doctors get information about chiropractic care and acupuncture as therapies that might help patients avoid prescription opioids.
“[Health care providers] should be knowledgeable about the range of available therapies, when they may be helpful, and when they should be used as part of a multidisciplinary approach to pain management,” the agency wrote in the proposal.
The suggested changes come as chiropractors and other alternative medicine providers have stepped up lobbying Congress and state legislatures to elevate their role in treating chronic pain. They’ve scored several big victories in recent years.
The draft document is entitled “FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain (May 2017)“, and it is the culmination of an effort on the part of alternative medicine practitioners to use the opioid epidemic as a rationale to promote their pseudoscience as “nonpharmacologic treatments” for pain. I’ll give Megan Thielking credit for a sharp eye, as the relevant passage in the FDA document doesn’t dwell on acupuncture or chiropractic, but only mentions each once. Once is enough, however. First, the stage is set early on, as the FDA discusses pain management and the various strategies that might be used to control chronic pain:
Possible constituents of the treatment plan – The HCP [health care provider] should be knowledgeable about which therapies can be used to manage pain and how these should be implemented.
    • Nonpharmacologic therapies – includes psychological, physical rehabilitative, surgical approaches; and complementary therapies
    • Pharmacologic therapies – non-opioid, opioid, and adjuvant medications
Which leads to this:
A number of nonpharmacologic therapies are available that can play an important role in managing pain, particularly musculoskeletal pain and chronic pain.
    • Psychological approaches – e.g., cognitive behavioral therapy
    • Physical rehabilitative approaches – e.g., physical therapy, occupational therapy
    • Surgical approaches
    • Complementary therapies – e.g., acupuncture, chiropracty
HCPs should be knowledgeable about the range of available therapies, when they may be helpful, and when they should be used as part of a multidisciplinary approach to pain management.
Notice how the FDA lists “complementary therapies,” like acupuncture and chiropractic, as, in essence, co-equals with conventional medical nonpharmacologic therapies for treating pain. This is profoundly misleading, given that acupuncture is nothing more than a theatrical placebo. As I like to put it, it doesn’t matter where you place the needles or even if you place the needles. The effect is the same, and consistent with placebo effects.
How did we get to this point?
“Integrative” medicine and rebranding
It’s no secret that the US is in the midst of an opioid addiction epidemic. Opioid overuse and abuse are major problems, and government at all levels has started to take notice. A recent article in The Economist provides some perspective on the scope of the problem:
THEY have America in a deadly grip. In 2015, the most recent year for which full statistics are available, 33,091 Americans died from opioid overdoses, according to the Centres for Disease Control—almost three times the number who perished in 2002. Nearly as many Americans were killed by opioids in 2015 as were killed by guns (36,132) or in car crashes (35,092). In the state of Maryland, which releases more timely figures, drug-overdose deaths were 62% higher in the first nine months of 2016 than a year earlier.
The opioid epidemic is quite unlike past drug plagues. Deaths are highest in the Midwest and north-east, among middle-aged men, and among whites. Some of the worst-affected counties are rural. In 2013 a 40-year-old woman walked into a chemist’s shop in the tiny settlement of Pineville, West Virginia, pulled out a gun, and demanded pills. Don Cook, a captain in the local sheriff’s department, says he continues to nab many people for illegally trading prescription painkillers.
I first noted proponents of “integrative medicine” (or, as I like to refer to it, the “integration” of quackery into real medicine) using the opioid epidemic as a rationale to promote their preferred brand unscientific medicine about a year ago, when the National Center for Complementary and Integrative Health (NCCIH) released its strategic plan for 2016-2021. In that plan, the “nonpharmacologic management of pain” and difficult-to-control symptoms leapt front and center to become a major scientific priority, explicitly invoking the opioid crisis as the external problem that its leaders believed that “integrative medicine” could make some headway with.
More recently, the NCCIH made its intent even more explicit when it held a Twitter chat on Pain and Complementary Health Approaches under the hashtag #TalkPain, after having released a review article on complementary approaches for five painful conditions. The review was widely touted as demonstrating the following “positive” results for pain:
    • Acupuncture and yoga for back pain
    • Acupuncture and tai chi for osteoarthritis of the knee
    • Massage therapy for neck pain—with adequate doses and for short-term benefit
    • Relaxation techniques for severe headaches and migraine.
As I pointed out at the time, the methodology used to construct the review was quite weak, and even the positive conclusions listed above were quite suspect. Yet in the press coverage, never (or almost never) was heard a discouraging word regarding these treatments. The NCCIH spin on its own questionable review was pretty much parroted without skepticism, other than in a few skeptic blogs.
It just goes to show that the new preferred framing of “integrative medicine” (or “complementary and alternative medicine,” i.e., CAM) is working. That framing flows from a common device that has been used by CAM advocates since the 1990s at least. It’s a devilishly simple and plausible-sounding frame, too. In this frame, potentially science-based interventions based on lifestyle changes, such as dietary interventions and exercise, have been co-opted as being somehow “complementary” or “integrative,” even though there is nothing “alternative” about them. I realize I use this example fairly frequently, but that’s because it’s a good one, especially if there are any newbies to SBM reading. Think about it this way: What is the first science- and evidence-based intervention for type II diabetes? It’s to alter diet, lose weight, and to start to exercise, with the hope of losing enough weight to reverse the disease, or at least to prevent the need to begin pharmacological management with metformin. There’s another example I like to use from my own personal life, too: Hypertension. I remember when I was first diagnosed with hypertension several years ago, partially likely thanks to the curse of genetics but also influenced by my sedentary lifestyle. My doctor insisted on at least three visits to see if I could bring my blood pressure down without drugs through dietary changes and exercise, even though I myself thought my blood pressure was probably too high for that. I couldn’t; so I ended up on an antihypertensive. I realize this is just one anecdote, but it does suggest that a lot of primary care doctors don’t go straight to the prescription pad, contrary to the stereotype promoted by CAM advocates.
What’s happening with the opioid crisis as a pretext for promoting the embrace of quackery is different from the “rebranding” I described above, but it’s also related. In CAM, the “rebranding” of science-based treatments based on lifestyle, diet, and exercise is not enough. Rather, it serves to give cover to the quackery that is also labeled CAM or “integrative medicine,” such as acupuncture, naturopathy, and so many other pseudoscientific or prescientific modalities. If CAM and “integrative medicine” only “integrated” these forms of quackery into medicine, it would be much harder to gain traction. However, if CAM practitioners can somehow convince patients and their fellow physicians that there’s something somehow “complementary” about diet, exercise, and healthy lifestyle modification and claim them as CAM, then they add plausibility to at least some of their treatments.
So we come to the rebranding of various CAM modalities as “nonpharmacological.” Basically, after co-opting sensible and potentially science-based lifestyle interventions as being “complementary” or “integrative,” CAM advocates divide interventions into two categories, “pharmacological” and “non-pharmacological.” Naturally, CAM claims all the non-pharmacological interventions for its own, furthering the stereotype that science- and evidence-based medicine is about nothing more than drug therapy, while they are about the “whole” patient.
Quacks see an opening in the opioid crisis to seek legitimization
In her article on the FDA, Thielking doesn’t go into much depth about how aggressively CAM practitioners have used the opioid crisis as a convenient pretext to persuade desperate legislators that they offer a solution (or at least a major part of the solution). However, back in April she did a story on just that basically confirming what I’ve been saying all along about integrative medicine advocates using the opioid epidemic to brand their specialty as legitimate “nonpharmacologic treatments” for pain. Chief among them are naturopaths (nearly all of whom offer some forms of traditional Chinese medicine, like acupuncture) and, of course, chiropractors:
Seizing on the opioid epidemic as a chance to expand their reach, naturopaths and chiropractors are aggressively lobbying Congress and state governments to elevate the role of alternative therapies in treating chronic pain. They’ve scored several victories in recent months, and hope the Trump administration will give them a further boost.
Their most powerful argument: We don’t prescribe addictive pain pills.
Shunning pharmaceuticals, they treat pain with everything from acupuncture to massage to castor oil ointments. They offer herbal supplements and homeopathic pills.
Yes, it’s true that naturopaths, acupuncturists, and chiropractors don’t prescribe addictive pain pills. They do, however, frequently prescribe boatloads of supplements and use treatments with little basis in evidence. With the new administration, coupled with a bipartisan consensus that something needs to be done to combat opioid addiction, CAM practitioners see an opening that they hope to drive a Mack truck full of acupuncture needles and chiropractic tables through:
Hoping to make even more inroads, both naturopaths and chiropractors are lobbying Congress to push the Veterans Affairs health system to hire alternative providers. Chiropractors are also pushing for a role in the National Health Service Corps, which puts providers to work in community health centers, often in rural areas.
And this month, naturopaths will descend on Washington, D.C., for a meeting all about chronic pain. “Naturopathic doctors are poised to be the leaders in combating the opioid epidemic,” the promotional materials claim.
The pain workshops will be followed by a three-day conference to set a lobbying agenda and teach naturopaths organizing techniques.
The American Association of Naturopathic Physicians clearly sees an opening to make gains: The arrival of the Trump administration and a new, Republican-controlled Congress “opens up new opportunities for AANP to push for insurance non-discrimination, to have [naturopaths] included in the VA, and to emphasize that naturopathic care is a much-needed alternative to opioids for the treatment of chronic pain,” the AANP website declares.
Unfortunately, the Veterans Administration (VA) medical system has been heavily infiltrated by advocates of subjecting our veterans, to whom we owe so much, to quackery. Naturopaths have been lobbying to be hired as practitioners at the VA for at least two years. Indeed, in 2015, the American Veterans (AMVETS) teamed up with the American Association of Naturopathic Physicians (AANP, which unfortunately shares an abbreviation with the American Association of Nurse Practitioners and must be distinguished from such a respectable organization) to lobby Congress to pass a bill that would pay for “natural, non-pharmacological approaches to treating veterans suffering from chronic pain.” The argument was basically a classic quack talking point: Opiate pain relievers, as effective as they are, have a downside, including dependence, addiction, and overdosing. Because of these problems, a common problem with opioids is that physicians are often overly cautious prescribing opioids, resulting in undertreatment of chronic pain. What “non-pharmacologic” treatments of chronic pain would help? The AMVETS press release didn’t say.
I’ve written before about “battlefield acupuncture,” a form of ear acupuncture that has actually been foisted upon our injured soldiers. As I like to say, as goes the military, so goes the VA. Indeed, the VA, led by Dr. Tracy Gaudet, director of the VHA’s Office of Patient Centered Care and Cultural Transformation, is a big fan of CAM, including naturopathy, acupuncture, and chiropractic. Indeed, Dr. Gaudet spoke at the AANP legislative initiative mentioned in Thielking’s story, characterizing naturopathy as “a huge answer for the country, for practice, for patients” that is available “at a pivotal transformational moment” in health care and referring to them as “pioneers” who have been practicing integrative medicine “all along.” One notes that, before being hired by the VHA, Dr. Gaudet was a very high profile promoter of “integrative medicine,” having served as the director of Duke Integrative Medicine, a “pioneer” institution in quackademic medicine, as well as, before that, the founding director of the University of Arizona Program in Integrative Medicine with Dr. Andrew Weil.
Basically, the bottom line is that, as in the NCCIH and medical academia, advocates of unscientific and vitalistic treatments like acupuncture, chiropractic, and naturopathy are in ascendance. The might not always win, but they always come back again and again and again until they do.
But what about the FDA?
Will the FDA give its blessing to chiropractic and acupuncture for pain?
The law mandates that new drugs and devices must be shown through rigorous clinical evidence to be safe and effective for the indication for which they are intended. Over the last few years, there has been a push by free market fundamentalists, who have co-opted the narrative by falsely claiming that the caution and slow bureaucratic pace of FDA approval is keeping the free market from unleashing a flood of cures to the people. Indeed, this narrative is supported by a couple of truly scary men, one of whom believes that the FDA should require evidence only of safety, not efficacy, before approval (because, you know, the free market will sort efficacy out), the other of whom thinks that online rating systems (as in a Yelp or Über for drugs) can replace rigorous science for drug approval. So bad were these two Peter Thiel associates that it was actually a relief that we got the pharma shill, Scott Gottlieb, as FDA director. Gottlieb will likely champion “streamlining” and deregulation, but not beyond the pale of what we would see in any Republican administration.
The FDA doesn’t move that rapidly when it comes to draft policies; so most likely this recently released draft has been under development since before the election. Be that as it may, the FDA has a bit of a strange relationship with CAM modalities, such as acupuncture. For instance, the FDA does regulate acupuncture needles as Class II medical devices, which means that the needles are regarded as safe and effective when used appropriately by a licensed practitioner. Manufacturers must include on the label the statement “for single use only” and provide information about device material sterility and compatibility with the body, and the needles must also bear a prescription label restricting use to qualified practitioners as determined by individual states.
If you want to get an idea of how…complicated…the FDA’s relationship with CAM products is, it’s worth perusing Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Guidance for Industry. The document quite reasonably points out that botanical products and probiotics might, depending upon what they are and what they are used for, be subject to FDA regulation. However, when the FDA starts discussing “energy medicine,” things get weird. First, the FDA distinguishes between veritable energy fields (which can be measured and use either mechanical vibrations or electromagnetic forces, including visible light, magnetism, monochromatic radiation, and other light rays) from putative energy fields (have defied measurement to date by reproducible methods and include things like the “human energy field” in therapeutic touch). Then it says:
In a sense, “conventional” medicine already uses various forms of “energy” medicine. For example, a magnetic resonance imaging (MRI) device uses electromagnetic waves to create images of internal body organs and tissues. As another example, an ultrasound machine uses sound waves to create images of body organs, tissues, and fetuses. Given their intended uses, we regulate these products as medical devices under the Act.
CAM products that use veritable energy fields in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease in man or animals or to affect the structure or any function of the body of man or animals may be medical devices under the Act.10 Additionally, if the product is electronic and emits radiation, it may be subject to additional requirements to ensure that there is no unnecessary exposure of people to radiation.
CAM products that use putative energy fields in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man or animals may be medical devices under the Act. For example, we regulate acupuncture needles as “class II” medical devices.
Talk about asking how many angels can dance on the head of a pin!
Manipulative therapies, such as chiropractic, are more straightforward:
To the extent that manipulative and body-based practices involve practitioners physically manipulating a patient’s body, without using tools or machines, we do not believe that such practices are subject to regulation under the Act or the PHS Act. If, however, the manipulative and body-based practices involve the use of equipment (such as massage devices) or the application of a product (such as a lotion, cream, or oil) to the skin or other parts of the body, those products may be subject to regulation under the Act, depending on the nature of the product and its intended use.
So basically, the FDA has tried to thread the needle, stating that the equipment used to do acupuncture and chiropractic can be regulated but saying nothing about the efficacy of acupuncture or chiropractic themselves. That’s part of the reason why this new FDA draft policy is disturbing. It goes from an approach that is (mostly) nonjudgmental about the treatments themselves and concentrates only on regulating the equipment, which is definitely suboptimal, to one that is even worse, recommending that physicians know about acupuncture and chiropractic for pain and consider them as valid treatments on par with the real medical treatments.
One can’t help but wonder how the FDA interpreted existing evidence to come to this conclusion. As Steve Novella notes, whenever acupuncture is compared with sham acupuncture, there is no detectable difference and usually both sham and “real” acupuncture produce modest improvement in pain completely consistent with placebo effects. Yes, there is a large meta-analysis that found otherwise for knee osteoarthritis, but we’ve discussed it before. Its flaws render its results highly questionable, particularly given that the actual magnitude of the clinical benefit reported was less than the “minimally clinically important difference” (MCID). In any case, the vast preponderance of evidence is consistent with acupuncture having no specific effect for any condition and for all its claimed “effects” being due to placebo.
The evidence for chiropractic is a little more complex, but, boiled down to its essence, not that much. I like to refer to chiropractors as undertrained physical therapists with delusions of grandeur. What I mean by that is that chiropractors claim to be able to treat a lot of diseases and conditions not related to the spine or musculoskeletal system through spinal manipulation, such as allergies, hence the delusions of grandeur. Whatever benefit might derive from chiropractic is likely limited to the effect of spinal manipulation on back pain, which could well be nonexistent.
So, basically, in this draft FDA education blueprint for healthcare providers on managing chronic pain, the FDA is about to put its imprimatur on chiropractic, which makes no sense given that physical therapy does everything that chiropractic does, minus the woo and plus modalities other than spinal manipulation. It goes beyond no sense to do the same for acupuncture, an ancient, prescientific treatment that originated as bloodletting and was retconned by Chairman Mao Zedong into having always been practiced in its present form, a treatment that is nothing more than a theatrical placebo. To add the proverbial insult to injury, the FDA lists these forms of quackery alongside evidence-based treatments, as though they were on close to equal footing.
It’s not too late to stop this
Fortunately, the FDA being a federal government regulatory agency and all, this revised draft guideline is not final, and there is a period for public comment:
The FDA’s draft blueprint isn’t final — and drug makers, doctors, and alternative medicine providers will all have a chance to weigh in. The FDA will take public comments through July 10.
The blueprint released this week is part of a strategy the FDA rolled out in 2011 to address a crisis of prescription drug abuse. The FDA required opioid manufacturers to provide education for health providers who prescribe their pain medications — but didn’t mention chiropractic care or acupuncture in its initial blueprint for what that education ought to look like.
Interesting. I wonder how that one line recommending acupuncture and chiropractic found its way into the revised draft guidelines.
However it happened, you know what to do. The FDA needs to hear from supporters of science-based medicine. The opioid epidemic is a serious problem, and it needs science-based medical solutions, not the liberal application of fairy dust, if we are to dramatically reduce the toll taken by opioid addiction.

The FDA under MAHA control: Weakening the quack Miranda warning on supplements
The FDA sent a letter to the supplement industry assuring that it would make it easier for them to hide disclaimers (which we like to call “quack Miranda warnings”) about unproven health claims for supplements. What does this tell us about MAHA?
David Gorski on December 15, 2025
Link

Ever since life events made it impossible for me to maintain two blogs (this one and my not-so-super-secret other blog, which other than a handful of original posts has been mostly fallow for several months), one frustration that I’ve found with once-a-week blogging in the age of President Donald Trump and his Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr.‘s “make America healthy again” (MAHA) is that there’s just too damned much material. Every week, since January I have a truly difficult time choosing between multiple horrors to write about. Sometimes the choice is obvious, such as when the CDC Advisory Committee on Immunization Practices (ACIP) meeting led to last week’s post about how RFK Jr. and the Trump administration will invoke a distorted version of “best practices” of other countries that don’t recommend vaccination against as many diseases as the US does to justify rolling back as many vaccine requirements as possible or my post from the week before writing about the director of the FDA Center for Biologics Evaluation and Research (CBER), Dr. Vinay Prasad, sending an email memo blaming ten pediatric deaths on COVID-19 vaccines without actually showing the work that led to that conclusion or citing the evidence, all while telling anyone who disagrees with his approach that they should resign. This time around, the choice was less obvious, with multiple horrors continuing to best science-based medicine and health policy, but one post on X, the hellsite formerly known as Twitter, led me to revisit a longtime topic that we at SBM haven’t written much about in a while. Does anyone remember the Dietary Supplement Health Education Act (DSHEA) of 1994?
MAHA does:
Deeply predictable. So on-brand. Still maddening.

RFK Jr & his anti-science crew plan to:

1) Lessen labelling requirement for grifters pushing bunk & unproven supplements

2) Put warning labels on highly studied, safe & monitored COVID vaccines

Holy mental gymnastics, Batman! pic.twitter.com/Jibmd9k9kO
— Timothy Caulfield (@CaulfieldTim) December 13, 2025
The DSHEA disclaimer, by the way, is something that, back in the day, we used to refer to as the “quack Miranda warning,” as I couldn’t resist taking to the same hellsite to mention:
So @SecKennedy is weakening the Quack Miranda warning. Quelle surprise! https://t.co/XbeibODlxd
— David Gorski, MD, PhD (@gorskon) December 12, 2025
I could have discussed more about the MAHA war on vaccines, but then I would neglect another RFK Jr. action that, in addition to being consistent with MAHA, is also consistent with the Trump administration’s deregulatory agenda and therefore much more likely to slide in under the radar, unlike RFK Jr.’s war on vaccines. I realize that some of this might come across as too much “inside baseball” to some of our readers, but it’s totally been in our wheelhouse here at SBM since the very beginning 18 years ago. Moreover, there are plenty of others writing about RFK Jr.’s latest attacks on vaccines, but I haven’t seen much written (yet) about this. (Indeed, a search of X only finds two posts about it.)
To return to the topic at hand, the quack Miranda warning is our term for the DSHEA disclaimer, which generally reads, “This/these statement/statements has/have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Often there will be other optional flourishes, such as saying that these statements are for “informational purposes only” and/or “not intended as medical advice,” all with a “see your doctor” finale. If there’s one thing we’ve discussed here again and again over the years, it’s how the DSHEA weakened supplement regulation and how a quack Miranda warning on a website is a major red flag that it is likely selling quackery.
I always knew that, sooner or later, RFK Jr. and his MAHA minions whom he’s placed in key positions in the regulatory agencies of HHS would get around to dietary supplements, because of course they would. After all, just look at key MAHA allies. One great example is Dr. Peter McCullough, cardiologist turned COVID grifter during the pandemic and now the “chief scientific officer” for The Wellness Company, which, in addition to selling ivermectin to treat and prevent COVID-19, also sells various supplements to treat COVID-19 “vaccine injury.” Indeed, the wellness influencers who got their start during the pandemic have now become indistinguishable from the quacks of old who used to sell all manner of unproven (and disproven) supplements.
So what is the FDA doing about the quack Miranda warning? Before I discuss how the above proposal will weaken the already weak DSHEA labeling requirement, most likely as a first step towards weakening dietary supplement regulation further, let’s discuss what the DSHEA is (and is not) and how it set the stage for the proliferation of unproven supplements sold as medicine with a not-so-subtle, “wink-wink, nudge-nudge.” (It also provide a mechanism for huge revenue streams for quacks like Joe Mercola and right wing conspiracy theorist influencers, like Alex Jones.)
The DSHEA and the Quack Miranda warning
I’ve known that the quack Miranda warning would be on RFK Jr.’s target list ever since late summer of 2024, when, after having abandoned his independent campaign for President and bent the knee to Donald Trump in return for the position of HHS Secretary if Trump won, he published what I called a “MAHA manifesto” in the Wall Street Journal and then, a week before the election, declared MAHA war on the FDA thusly:
Of course, peptides and “nutraceuticals” are often sold as dietary supplements, complete with marketing claiming health benefits and the treatment of some diseases, as are some chelating compounds. It was at this point that it became clear to me that RFK Jr. had pivoted from being primarily antivaccine to embracing a more general “health freedom” orientation frequently associated with the antivaccine movement that paints the Food and Drug Administration as the pharma-serving villain suppressing “natural” treatments, low cost medications, and “miracle cures.” I also realized that I shouldn’t have been surprised by this open attack on the FDA, given that it’s long been a goal of the “health freedom” movement to dismantle the FDA and return it at least to a pre-thalidomide state if not to eliminate the FDA entirely. Recall that, before the thalidomide scandal, drug manufacturers were only required to submit evidence of safety, not efficacy, to win approval to market their products. After the thalidomide scandal, Congress passed the Kefauver-Harris Amendments in 1962. These Amendments to the federal Food, Drug, and Cosmetic Act tasked the FDA with additional requirements and responsibilities:
    • Efficacy requirement: Manufacturers must provide substantial evidence that a drug is effective for its intended use before it can be sold.
    • Retroactive review: The FDA was required to review the effectiveness of drugs approved between 1938 and 1962, a review that by the early 1970s had categorized approximately 600 medicines as “ineffective” and forced their removal from the market.
    • Informed consent: The amendment mandated that subjects provide informed consent before participating in clinical trials.
    • Good manufacturing practices: The amendments established rules for drug manufacturing and required routine inspections of production facilities.
    • Adverse event reporting: Manufacturers were for the first time required to report serious side effects to the FDA.
    • Advertising regulation: The amendments transferred the regulation of prescription drug advertising from the Federal Trade Commission (FTC) to the FDA and required more truthful and informative advertisements. Drug manufacturers were required to inform consumers of side effects and contraindications in their advertising.
You can see why the “health freedom” movement that ultimately spawned MAHA over six decades later did not like these amendments. But where does the DSHEA fit in? Basically, it’s a law that, by intent, made it difficult for the FDA, even when it wanted to, to act on dubious health claims for unproven, disproven, and sometimes even outright harmful supplements. As one of our former bloggers here at SBM, Dr. Peter Lipson, once described it long ago, the DSHEA is a “travesty of a mockery of a sham.”
According to the FDA‘s discussion of the DSHEA of 1994:
A dietary supplement is a product intended for ingestion that, among other requirements, contains a “dietary ingredient” intended to supplement the diet. The term “dietary ingredient” includes vitamins and minerals; herbs and other botanicals; amino acids; “dietary substances” that are part of the food supply, such as enzymes and live microbials (commonly referred to as “probiotics”); and concentrates, metabolites, constituents, extracts, or combinations of any dietary ingredient from the preceding categories.
There are two types of ingredients that may be used in dietary supplements: “dietary ingredients,” discussed above, and “other ingredients.” These “other ingredients” include substances such as fillers, binders, excipients, preservatives, sweeteners, and flavorings.
As you can see, one thing that the DSHEA does is to make a distinction between food and medicine. It also requires that dietary supplements be ingested and not injected or breathed in, which also makes sense. While on its surface distinguishing between food and medicine would seem to be quite reasonable (after all, it wouldn’t make a lot of sense to hold food to the same standards to which drugs are held), as implemented by the DSHEA this distinction has a pernicious effect in that in practice it allows manufacturers to label all sorts of botanicals, many of which with pharmacological activity, as “supplements,” and supplements, being defined as food and not medicine, do not require prior approval by the FDA before marketing:
FDA regulates both finished dietary supplement products and dietary ingredients. FDA regulates dietary supplements under a different set of regulations than those covering “conventional” foods and drug products. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA):
    • Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded. That means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that they meet all the requirements of the Federal Food, Drug, and Cosmetic Act as amended by DSHEA and FDA regulations.
    • FDA has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market.
In other words, when a supplement is marketed it’s more or less the honor system. No registration with the FDA is required. After all, supplements are food, not medicine! (Just like “fish are friends, not food”?) Even though there are exceptions that require manufacturers to notify the FDA if they add a new ingredient to a supplement, in effect, the government can’t really do much of anything unless problems are reported after the supplement is marketed. Even worse, the definition of “supplement” has become very broad, as Quackwatch pointed out:
The Food, Drug, and Cosmetic Act defines “drug” as any article (except devices) “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure or function of the body.” These words permit the FDA to stop the marketing of products with unsubstantiated “drug” claims on their labels.
To evade the law’s intent, the supplement industry is organized to ensure that the public learns of “medicinal” uses that are not stated on product labels. This is done mainly by promoting the ingredients of the products through books, magazines, newsletters, booklets, lectures, radio and television broadcasts, oral claims made by retailers, and the Internet.
DSHEA worsened this situation by increasing the amount of misinformation that can be directly transmitted to prospective customers. It also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
In other words, under the DSHEA, substances that are clearly not foods can be marketed as supplements, including herbs and other botanicals (the vast majority of which are marketed as having a beneficial medicinal effect and some of which contain chemicals that do act as drugs).As long as the manufacturer is careful not to make specific health claims, it’s all good. In other words, a “nutritional support” statement claimed for a supplement must not be a “drug” claim; i.e., it must not claim that the supplement can be used for the treatment or prevention of a disease. Supplement manufacturers easily evade this requirement by making vaguer claims related to organs or systems, such as claiming that a product “boosts the immune system,” “supports heart health,” or something similar, often accompanied by what Dr. Lipson has sarcastically referred to as the “quack Miranda warning.“
Arguably, the DSHEA was the greatest boon to supplement manufacturers ever. In its wake, the supplement industry exploded, racking up huge increases in sales. Indeed, by 2007 a GAO report estimated that the supplement industry had grown to a $23.7 billion industry, and, in 2025, Grand View Research estimated that the size of the dietary supplement industry has reached $112.6 billion and also forecast it to grow at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2030. Moreover, so lax was the regulation of supplements even before RFK Jr, and MAHA took over HHS, that it took a very extreme and egregious act, namely the marketing of an industrial chelator as an “antioxidant” supplement for the treatment of autism, before the FDA finally acted, and the FDA has seldom acted forcefully even over the one aspect of supplement regulation that the DSHEA does give it, to recall products due to “adulteration.”
Over the years, supporters of science-based medicine and sound public policy have made efforts in Congress to alter or repeal the DSHEA, such as the Dietary Supplement Safety Act of 2010, which would, among other things, have mandated reporting of all adverse events due to supplements to the FDA and given the FDA mandatory recall power over supplements that cause harm. All have failed to pass, as the DSHEA has had powerful patrons, such as its co-sponsors Sen. Tom Harkin (D-Iowa) and Sen. Orrin Hatch (R-Utah), and Utah is home to many supplement manufacturers. Sens. Harkin and Hatch might have retired from the Senate years ago, but they have many successors in Congress. With MAHA ascendant, supplement manufacturers in their stans are more powerful than ever, as is the Congressional Dietary Supplement Caucus. Yes, that’s a real thing, and, although Republicans do outnumber Democrats in the caucus, the caucus is currently pretty bipartisan, with a ratio of Republicans to Democrats of roughly 3:2.
Next, let’s look at what the FDA plans to do.
Too many quack Miranda warnings?
Let’s take a look at the text of the FDA letter to supplement manufacturers from Kyle Diamantas, Deputy Commissioner for Human Foods. The letter is dated December 11, and entitled Letter to the Dietary Supplement Industry on the DSHEA Disclaimer. The first thing I noted is that the letter starts out by stating that the FDA has “received several requests to amend our labeling regulation at 21 CFR 101.93(d),1 which governs the placement of the disclaimer required under section 403(r)(6)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).” Specifically, the FDA has required that the DSHEA disclaimer (a.k.a. the quack Miranda warning) be placed on every panel in supplement documentation in which a health claim is made.
According to the letter, currently the requirement mandates:
This regulation states the DSHEA disclaimer shall be placed adjacent to the statement with no intervening material or linked to the statement with a symbol (e.g., an asterisk) at the end of each statement described in section 403(r)(6) of the FD&C Act, such as a structure/function claim, (i.e., a “403(r)(6) claim”). The regulation goes on to state “the disclaimer shall appear on each panel” of a product label where there is a 403(r)(6) claim.
A “structure-function” claim is another way that the DSHEA allows supplement manufacturers to bypass the requirement that they cannot claim to treat or prevent any diseases. You’ve seen these sorts of structure-function claims before. Examples include:
    • “Supports [specific organ] health.” Examples include: “supports prostate health”; “supports brain health”; “supports immune health”; “helps maintain a healthy heart.”
    • The ever-popular “boosts the immune system” or “supports immunity”
    • “Builds strong bones”
A study from several years ago found that 87% of advertisements for supplements contain structure-function claims, with an average of 2.5 claims per ad. There is a great PowerPoint presentation from Venable, LLP outlining the differences between permissible and impermissible structure-function claims based on eleven (!) FDA criteria. If you peruse the list, you’ll find that some of these are truly splitting hairs, like, for example, these two (click to embiggen):
Examples of permissible and impermissible structure-function claims
In any event, regardless of the structure-function claim, there has to be at least an asterisk leading to a quack Miranda warning for every instance, at least under current FDA regulations.
So what does the FDA now want to do? Back to the letter:
Based on FDA’s initial review, we expect that revising this regulation to remove the requirement for the DSHEA disclaimer to appear on each panel of a product label where there is a 403(r)(6) claim would be consistent with section 403(r)(6)(C) of the FD&C Act while reducing label clutter and unnecessary costs. Further, FDA recognizes that we have rarely, if ever, enforced this requirement. If FDA does not identify significant concerns as we continue our review of the available data and information regarding this request, we are likely to propose a rule to amend this requirement.
I like how Diamantas basically admits that the FDA wasn’t really enforcing this requirement very much anyway and the goes on to say that the FDA will exercise “enforcement discretion regarding the requirement for the DSHEA disclaimer to appear on each panel of a product label where a 403(r)(6) claim appears,” while still requiring that the DSHEA disclaimer appear at least once.
Why, you might ask, would the supplement manufacturers want this regulation changed so badly? One obvious answer, of course, is that if the quack Miranda appears only once in the product’s labeling it will be very easy for consumers to overlook it, as opposed to when it is required to appear on every panel in which a structure-function claim is made. There’s another reason, though, that was revealed in the congratulatory messages posted by supplement manufacturing groups, such as the Council for Responsible Nutrition (CRN), which “applauded FDA clarification on DSHEA disclaimer after years of industry advocacy“:
For nearly 30 years, FDA practice has allowed the use of an asterisk to direct consumers to the full DSHEA disclaimer elsewhere on the label, consistent with section 403(r)(6)(C) of the Food, Drug & Cosmetic Act and 21 C.F.R. § 101.93(d). However, a recent uptick in class-action lawsuits has relied on an alternative interpretation, arguing that the full disclaimer must be placed on every panel where a structure/function claim is used on a product label. These legal challenges have created confusion, prompted unnecessary litigation, and imposed costly and disproportionate burdens on responsible manufacturers—without improving consumer understanding.
Earlier this year, CRN called on FDA [starting on page 23] to revise section 101.93(d) to clarify that the law does not require duplicative use of the DSHEA disclaimer on multiple panels of the same product. CRN offered then that making the change “would maintain adequate levels of consumer protection while reducing unnecessary, redundant regulatory burdens on companies,” and argued that a single disclaimer on a dietary supplement product’s label linked by an asterisk or other symbol to structure/function claims adequately informs consumers of the existence of additional information and satisfies the legislative intent to have a structure/function statement “contain” the disclaimer. Separately, CRN made clear to the agency that it was prepared to file a citizen petition to formally escalate the matter if needed.
Those pesky citizen activists and their class-action suits, getting in the way of supplement industry obfuscation about its products! Make no mistake, the supplement industry sees this as a big win and a harbinger of things to come. Here’s the American Herbal Products Association’s take:
This significant action comes directly in response to sustained advocacy from AHPA dating back to and continuing since 2021. AHPA and others have argued that the existing “every panel” requirement (found in 21 C.F.R. § 101.93(d)) is overly prescriptive and exceeds the demands of DSHEA. AHPA has long advocated for FDA to update the regulation to reflect historical industry practice: prominently displaying the disclaimer once on the product label or labeling, not necessarily on every panel, and connecting each claim to the disclaimer via symbols (e.g., asterisks). The contemplated revision would also accord the technical requirements of the regulation with FDA’s historical enforcement approach; as conceded in the letter, and consistent with AHPA’s analysis of agency documents, FDA has “rarely, if ever, enforced this requirement.”
“This news is a major win for the dietary supplement industry,” said AHPA President & CEO Graham Rigby. “AHPA has long led the charge for this sensible regulatory reform, and we thank FDA for taking action on an unenforced provision that has fueled opportunistic litigation. This is a strong, positive signal of the agency’s commitment to modernizing regulations, and AHPA looks forward to continued engagement in shaping a rational and modern regulatory environment for this vital category of products.”
Again, I realize that this might strike some readers as too much “inside baseball,” but there are real consequences. Some readers might reasonably wonder why it matters if the quack Miranda warning appears on every panel where disease treatment claims barely disguised as “structure-function” claims or not. I found the most succinct explanation here:
Moreover:
yeah the DSHEA disclaimer was expressly provided by Congress in the statute, they can’t (lawfully) get rid of it, they’re just trying to let companies hide it more than the current version of the implanting reg allowswww.ecfr.gov/current/titl…
— ❀°。Der Siebenschläfer *.ﾟ✿ ⋆ (@sababausa.bsky.social) 2025-12-13T07:15:28.218Z
The current relevant regulations state:
The disclaimer shall be placed adjacent to the statement with no intervening material or linked to the statement with a symbol (e.g., an asterisk) at the end of each such statement that refers to the same symbol placed adjacent to the disclaimer specified in paragraphs (c)(1) or (c)(2) of this section. On product labels and in labeling (e.g., pamphlets, catalogs), the disclaimer shall appear on each panel or page where there such is a statement. The disclaimer shall be set off in a box where it is not adjacent to the statement in question.
Getting rid of the requirement for the DSHEA on each panel will make it a lot easier for supplement manufacturers to hide the “prominent” disclaimer, to bury it somewhere else and then refer to it by an asterisk.
What does this mean, and does it matter?
As I mentioned before, I realize that to many people this change seems minor. Indeed, one can argue if DSHEA disclaimers (or, as we prefer to call them, quack Miranda warnings) even matter that much to consumers, if they dissuade them from purchasing a product. After all, Cheerios claims to help maintain a healthy cholesterol in its ads, along with a quack Miranda warning. This is about more than just supplement manufacturers. Many food manufacturers use the DSHEA as well to justify structure-function health claims for their products.
Nonetheless, given RFK Jr.’s declaration of MAHA war on the FDA, I nonetheless believe that this proposed change is important for a number of reasons. First, it signals to the supplement industry that RFK Jr. is on its side now and that the FDA will be far more compliant in terms of doing the industry’s bidding than ever before. Second, this step is clearly meant as a first step in deregulating supplements using the most industry-friendly interpretation of the DSHEA that RFK Jr. and his cronies can come up with. The next steps, I predict, will be to loosen the restrictions on what is considered a “structure-function” claim, so that supplement manufacturers can make more explicit disease treatment and prevention claims without the evidence that would be required for a manufacturer of a drug to make a similar claim.
Finally, as Tim Caulfield, whose X post was quoted above notes, one only has to look at the regulatory double standard in terms of evidence required between supplements, for which RFK Jr. clearly plans to lower the bar as much as possible, and vaccines to see what MAHA is really about. News reports now indicate that, based on a non-transparent “analysis” of pediatric deaths linked with COVID vaccines that has only been referred to thus far in a leaked memo and blames the vaccines for killing at least ten children without explaining how the FDA came to the conclusion of causation, the FDA plans on adding a black box warning to COVID vaccines. A “black box” warning is the FDA’s strongest warning included in the package insert for a drug, medical device, vaccine or biological. Usually such warnings are about a significant risk of death or serious injury due to a product that must be weighed against the product’s benefit. Sometimes such warnings are targeted to certain groups most at risk, for example the warning for Accutane of potential birth defects when used during pregnancy. It’s also interesting to note how the FDA is going through the standard regulatory process to change the requirements for how a quack Miranda warning must be displayed but is, according to news reports, not doing so with its changes to the package insert for COVID vaccines:
“I guess my concern is that in this case, there’s not a process,” said Kesselheim, who has studied the impact of black box warnings on drug labels. “There isn’t that same opportunity for discussion and good-faith review of the data on which this decision is being made.
“My concern is that this will be seen as yet another in the long line of decisions that this FDA is making based on its own political goals, rather than after a dutiful and thoughtful and public review of the science.”
When I first noted that RFK Jr. is coming for your vaccines, I outlined six strategies that he would use. Strategy #6 read: Co-opt the FDA to make approval of new vaccines more difficult and issue black-box warnings based on antivax fear mongering for existing vaccines. (I hate to say I told you so, but…) I further noted that RFK Jr. would, through his minions, cherry pick and misrepresent evidence to portray vaccines as dangerous in order to accomplish this.
This double-standard is inherent in MAHA: Massively lower standards for unproven treatments that “health freedom” and wellness influencers like and profit from, such as supplements, quack treatments, unproven stem cell treatments, and the like, while increasing the regulatory bar for vaccines and certain pharmaceuticals to impossible levels, with the goal being to ultimately remove them from the market. Adding a black box warning to COVID vaccines is just one step.
I hate to end without a bit of hope. As we all know, the Trump administration is all about deconstructing the administrative state and deregulating favored industries, using Project 2025 as a playbook, the better to turn staffing the government back to the spoils system, one manifestation of which is how MAHA wants to turn the criteria for NIH funding of research away from pure scientific merit and towards patronage and political loyalty, the better to make it a tool to enforce ideological conformity. There is one area in which this deregulatory drive is running afoul of MAHA activists, specifically the dismantling of the Environmental Protection Agency, which is angering “MAHA moms,” as reported in the New York Times over the weekend, to the point that EPA Administrator Lee Zeldin recently met with a group of very unhappy MAHA moms who are accusing the agency of prioritizing chemical industry interests over public health through its efforts to loosen restrictions on harmful chemicals, and approve new pesticides, loosen pollution regulations, not to mention Trump’s having appointed several former chemical industry executives and lobbyists to senior roles overseeing pesticides and toxic chemicals.
Of course, as I pointed out last week, this was always part of the Faustian bargain RFK Jr. made when he bent the knee to Donald Trump: Abandon the environmentalist activism for which he was primarily known before turning antivax activist in return for a chance at getting rid of as many vaccines as he can. When it comes to loosening restrictions on supplements while ratcheting up restrictions on vaccines to untenable levels, there is no conflict. The same might not be true when it comes to being complicit in the extreme deregulatory agenda being promoted at the EPA. I suspect that not even RFK Jr. can square that circle indefinitely. At least I hope not.
Unfortunately, in the meantime, massive damage has already been done to the vaccine program and the regulatory apparatus that assures safe and effective drugs, with over three years for this administration to do worse.
    • 
    • 

Why Does Dr. Vinay Prasad Refuse to Answer Questions About His Job Performance at the FDA?
Although he took softball questions from MAHA sycophant Bari Weiss, Dr. Vinay Prasad, a public servant, refuses to leave his safe space to answer tough, but fair questions from credible reporters like Lizzy Lawrence.
Jonathan Howard on February 27, 2026
Link

“Had Collins, a man who has contributed greatly to science, chosen dialogue instead of contributing to animosity and combativeness, we might have been in a better place today.”
The Great Barrington Declaration was written in October 2020 by 3 laptop class doctors who had already drastically underestimated COVID multiple times by that early point in the pandemic. It claimed the mass infection of unvaccinated “not vulnerable” people would lead to herd immunity in 3-6 months, and it “called for” public health officials to make that miracle happen. It wasn’t an actionable plan for them. Rather, it was merely a list of demands for them, and that wasn’t an impressive achievement.
Others, however, saw immense value in this 1-page online petition. Dr. Vinay Prasad, for example, felt that public health leaders had an obligation to publicly debate the authors of the GBD as COVID raged. He wrote a scathing article titled At a Time When the U.S. Needed Covid-19 Dialogue Between Scientists, Francis Collins Moved to Shut It Down. What had Dr. Collins done to deserve this rebuke? In a private e-mail, he called for a “devastating takedown” of the premises of the GBD. That’s it. In contrast, Dr. Prasad felt the GBD’s premises were sacrosanct, and Dr. Collins had a duty to honor them with a public display of fealty and respect. He wrote:
What concerns me about the NIH director’s email and his interview on television is that he appeared unwilling to have this dialogue. Collins’s day job does not make him arbiter of scientific truth, the Pope for all scientists. On questions of unprecedented pandemic policy, he is surely entitled to his opinion — as we all are — but his is just one opinion of many.
When it comes to lockdowns or school closures, the answer to the question of whether the benefits exceed the harms and, if so, under what conditions, is far from certain, and scientists will continue to study this for decades. As a good scientist, Collins should have recognized the massive uncertainty around these policies.
Collins’s response to a memo signed by thousands of scientists should not have been to call for an immediate and devastating take down, but to use his pulpit as NIH director to hold a series of public discussions and dialogues. In a world where scientists were trapped in their own homes for months, a series of dialogues — even virtual ones — made available for the broader scientific community, policy makers, and the public would have benefited us all.
Dr. Prasad concluded:
Had Collins, a man who has contributed greatly to science, chosen dialogue instead of contributing to animosity and combativeness, we might have been in a better place today.
“Press representatives from the Health and Human Services Department and the FDA did not respond to requests for comment in time for publication. Neither did Prasad.”
So where is Vinay Prasad today?
Now that he is the medical establishment, I am calling for him to host a series of public discussions and dialogues with his critics. We know he “loves President Trump“, but not much else. Yet, from allegations of sexual harassment, retaliation, and waste of taxpayer money to political and pharma influence at the FDA, there are a lot of very legitimate questions about his leadership. He rarely shows up to work and is under investigation for his abusive behavior. Moreover, like his predecessors, Dr. Prasad is not the arbiter of scientific truth, the Pope for all scientists. Dr. Prasad is entitled to his opinion — as we all are — but his is just one opinion of many.
However, instead of openly communicating with the public and holding public debates as he called for previously, Dr. Prasad is in hiding. As measles devastates children, he refuses to use his platform as chief vaccine regulator to advocate for the MMR. He keeps Americans in the dark about his intentions and guessing at his next steps. He is wildly unpredictable, guilty of regulatory whiplash, and unwilling to have this dialogue, even with patient advocates. An article titled Rare Disease Advocates Fume Over FDA’s Mixed Signals quoted Jeff Carroll, a Huntington’s researcher and gene carrier, as saying:
I just wish one of them, somebody from the FDA, would be like, ‘Hi, my name is Dr. Smith, and this is why I made this decision, and here’s the policy that explains why and how you will have to jump in the future to get these kinds of therapies done.
On the rare occasions he does speak, people wisely don’t trust him. The article also quoted Wilson Bryan, who previously directed the gene therapy division at the FDA.
Bryan said he just ignores what Makary and Prasad say on stage.
“Their public statements are, to me, just like pharmaceutical company press releases,” he said. “So I don’t put any stock in what they say publicly. I just don’t think it matters.”
Although Dr. Prasad took softball questions from MAHA sycophant Bari Weiss, he refuses to leave his safe space to answer tough, but fair questions from credible reporters. For example, an article by award winning journalist Lizzy Lawrence titled Under Vinay Prasad, Employees at a Key FDA Center Fear Speaking Out, Look for the Exits said:
Press representatives from the Health and Human Services Department and the FDA did not respond to requests for comment in time for publication. Neither did Prasad.
Nearly every report about Dr. Prasad’s incompetence and malevolence- and there are many- contains some version of this phrase- Prasad didn’t respond to a text with questions about the complaints and Prasad didn’t respond to requests for comment.
This is both unacceptable and bizarre. Dr. Prasad is not a camera-shy shrinking violet after all. As a private citizen, he never exercised his right to remain silent. He shared his overly confident opinions about everything, everywhere, all the time. He even wrote articles such as Why Was My Talk at a Medical Conference Canceled?, bemoaning his supposed “cancellation.” “If you care about free speech and the free flow of ideas, this should alarm you,” he said.  Today, his Sensible Medicine business partners absurdly claim that if only Dr. Prasad was allowed to explain himself over a glass of wine, we’d all come to appreciate his brilliance. 
Of course, Dr. Prasad is allowed to explain himself. He just refuses to. Now that he works for the American taxpayer, Dr. Prasad has silenced, censored, and cancelled himself rather than publicly defend his track record at the FDA.
Why might that be?

FDA v. Jack3d: Round 2
Jann Bellamy on May 16, 2013
Link
Jack3d is a dietary supplement manufactured by USPlabs and promoted by the giant supplement retailer GNC as producing “ultra-intense muscle-gorging strength, energy, power and endurance.” A key ingredient is DMAA, which the FDA doesn’t think is a proper dietary supplement ingredient at all and wants Jack3d and other products containing it removed from the shelves and the web. The FDA also questions its safety.
As discussed in a previous post on the subject, both USPlabs and GNC maintain Jack3d (pronounced “jacked”) is safe when properly used. Apparently few agree with them on this point: not the FDA, not the U.S. military, not the countries and athletic associations which have banned DMAA. And certainly not the parents of Michael Lee Sparling, a 22-year-old Army private. The Sparlings filed a lawsuit alleging Jack3d caused the death of their son, who went into cardiac arrest and died after using it.
Here is where we left off the last time we looked at DMAA:
Last April [2012], the FDA sent warning letters to several supplement manufacturers saying it had no evidence DMAA is a legitimate dietary ingredient and citing its risks. (Health regulators in other countries, such as Sweden and Denmark, have actually banned DMAA-containing supplements.) Heart attacks, heart failure, kidney failure and liver failure were among the health problems reported to the FDA, as well as 5 deaths. GNC responded that it was “completely opposed to this unilateral, factually and legally unfounded action by the FDA.”
Now to Round 2.
Ding!
The FDA has a separate web page devoted exclusively to DMAA, its dangers, and efforts to get it off the market. A sense of the agency’s frustration at the limitations imposed by the Dietary Supplement Health and Education Act (DSHEA) on its power to police the dietary supplement market comes through in a description of these efforts:
Unlike drugs, dietary supplements do not have pre-market approval for safety or effectiveness. If a safety issue arises post-market, FDA can investigate and take steps to remove products that may be unsafe from the market. However, in order for FDA to ban a compound in a dietary supplement, FDA is required under the statute to undertake a series of lengthy scientific and legal steps. In the interim, FDA can take direct action by issuing warning letters to industry to obtain removal of ingredients in dietary supplements and protect the public from potentially harmful products. FDA can also bring a seizure action to remove products from the market or obtain an injunction against a company to prevent it from manufacturing and distributing illegal products.
Note that the FDA must initiate a federal court proceeding and meet the applicable burden of proof before getting a court order permitting seizure or granting an injunction.
The FDA sent warning letters to 11 supplement manufacturers, accounting for “most of” the manufacturers using DMAA. As you may recall, the FDA does not have a complete list of all manufacturers or distributors of dietary supplements or know what supplements are out there because there is no requirement in the DSHEA that companies register themselves or their products with the agency. The letters raised the following issues:
    • Because DMAA had not been marketed as a dietary supplement ingredient prior to 1994 it was considered a “new dietary ingredient” (“NDI”). Manufacturers are required to notify the FDA of evidence supporting their conclusion that their use of NDIs is safe. The companies failed to do this.
    • The FDA was not aware of any evidence or history of use that indicated DMAA is safe. In fact, DMAA is known to narrow blood vessels and arteries which can elevate blood pressure and lead to cardiovascular events. Serious adverse events had been reported, including cardiac disorders, nervous system disorders, psychiatric disorders, and death.
    • Synthetically-produced DMAA is not a “dietary ingredient” and therefore cannot be used as an active ingredient in a supplement.
Eventually 10 of the 11 complied and agreed to stop making supplements containing DMAA; the remaining supplier is still in the market. The lone holdout was USPlabs. In fact, USPlabs seems to think the safety issue is cause for a bit of fun. The company puts a faux “Black Box Warning” on the Jack3d label:
This product produces an intense sensation of drive, focus, energy, motivation & awareness. In addition, it allows for rapid increases in strength, speed, power & endurance. Therefore, extreme caution must be exercised & should not be used by novice athletes. Use with caution under strict dosing products.
Such marketing cleverness!
USPlabs plays defense
USPlabs wrote the FDA back, defending its claim that DMAA is a dietary ingredient by arguing it is a constituent of a type of Chinese geranium. The FDA was having none of it. It notified the company on April 10 of this year that it found the information insufficient, with an official warning letter to follow. USPlabs was still defending its product in an April 12 New York Times story. However, on April 16, USPlabs announced it would phase out products containing DMAA.
The formal warning letter was issued nevertheless, on April 18. In a Gorski-style takedown of studies relied upon by USPlabs in its attempt to convince the FDA that DMAA is a dietary ingredient, the agency shredded the studies cited. Because the details of these studies would interest only those familiar with such things as “gas chromatography (GC)–mass spectrometry (MS) analysis” and methods of authenticating the source of plant materials (which is way more complicated than you might imagine), I will spare you the details. (You’re welcome.)
Actually, I couldn’t begin to understand what they are talking about, but I will share this amusing (to me) bit of comeback to USPlabs’ claim that DMAA is a dietary ingredient because it is “a dietary substance for use by man to supplement the diet by increasing total dietary intake.” The FDA retorted:
. . . the possibility that geraniums may have been consumed as a food or drink by humans does not demonstrate that DMAA is a dietary substance because, as explained above, the totality of the scientific evidence does not demonstrate the presence of DMAA as a constituent of geraniums.
Somehow the thought of people eating and drinking geraniums struck me as funny, although that possibility shouldn’t be at all surprising considering what I’ve learned about “complementary and alternative” medicine.
Because the FDA determined DMAA is not a legitimate dietary ingredient the agency found it unnecessary to address USPlabs’ contention that DMAA is safe.
During this controversy, USPlabs sued a retailer in Nevada for defamation. The complaint alleges that a Max Muscle retail outlet franchisee said Jack3d is “the equivalent of rat poison” in a radio interview.
NEW! IMPROVED!
Although the remaining stock of Jack3d is still available from some retailers, including GNC, USPlabs has reformulated the product, now sold as “Jack3d Micro” and promises to deliver another new Jack3d product in the future, although it does not say whether this product will contain the same ingredients as the Micro version. (It is, in addition, reformulating OxyElite Pro, which also contains DMAA.) The only common ingredient between the new and old versions is caffeine. Interestingly, a sales pitch for Jack3d Micro on the company’s website is presented as a comparison with the original DMAA-containing formula:There is no mention of the controversy about DMAA, although it does not appear that the original Jack3d is still sold on its website, unlike other internet outlets. The website still touts the safety and effectiveness of DMAA-containing products.
The faux Black Box warning is gone but the label does advise the purchaser to consult with a physician before using, especially if he is taking prescription medications or has certain pre-existing medical conditions, and to discontinue prior to surgery. It also advises the purchaser not to use the product if taking certain named medications as well as warning against using it in combination with other stimulants, such as caffeine-containing products, or alcohol. The label tells the purchaser to “consult your health care professional if you experience any adverse reaction to this product.” What it does not do is warn the purchaser of what those adverse reactions might be.
The FDA requires dietary supplement labels to list ingredients. Here is the ingredient list for Jack3d Micro.Assuming the role of a diligent consumer, but one with no background in medicine or science (in other words, me) I tried to locate reliable information about the safety and effectiveness of these ingredients. None of this information is available to the consumer on the USPlabs website as far as I could determine, although I only searched the website using specific ingredient names listed on the label. WebMD does have an easy-to-use way to search for information about dietary supplement ingredients, but not all of those found in Jack3d Micro were on their website. Of course, WebMD’s analysis must compete with the tremendous amount of hype about supplement ingredients from supplement sellers and other sources available on the internet.
Here’s the information not mentioned on the warning label that I thought a consumer should be concerned about, all from WebMD unless otherwise indicated. (Some ingredients have more than one name.)
3,4-Dihydroxycinnamic acid, caffeic acid (stimulant, ingredient in many foods, such as coffee)
    • Effects when taken by people unknown.
    • No information available on interactions with other supplements or drugs.
    • Insufficient evidence for use to enhance athletic performance and for exercise-related fatigue.
    • Not enough evidence to know if safe when taken as a supplement or to determine appropriate range of doses.
Higenamine, Norcoclaurine (stimulant)
    • Insufficient evidence for use to enhance athletic performance.
    • Possibly unsafe when taken orally. Not studied in people therefore safety unclear.
    • Aconite (a plant) shown to cause serious heart-related side effects including arrhythmias and death; effects may be caused in part by higenamine in aconite. Warning about irregular heartbeat repeated in information, although it’s not clear whether this is based on additional evidence.
    • Not enough evidence to determine appropriate range of doses.
L-citrulline (amino acid)
    • Possibly safe.
    • Insufficient evidence for exercise performance. May not be effective for improving exercise performance. In one test, did not improve performance on treadmill and people taking it actually became exhausted more quickly than those who did not take it.
    • No information available on interactions with other supplements or drugs.
    • Not enough evidence to determine appropriate range of doses.
Grape seed extract 
    • Headache, abdominal pain, sore throat, nausea, and diarrhea may occur.
    • Very serious allergic reaction to this product rare, but warning to seek immediate medical attention if any of the following symptoms of a serious allergic reaction appear: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Arginine nitrate and Agmatine sulfate
These ingredients are not listed on WebMD. Best I can tell, arginine nitrate is L-arginine bonded to nitrate. It is all the rage now in bodybuilding products and a supposed improvement over L-arginine, an amino acid. Agmatine sulfate is the decarboxylation product of arginine. (And good for you if you know what that means.) I could not find any information on the safety and effectiveness of either of these ingredients, when used in a dietary supplement for Jack3d Micro’s intended purpose, from any source I considered reliable and unbiased. I do not know if these new forms of L-arginine would retain the safety issues of that substance. According to WebMD, L-arginine is possibly safe for most people when taken appropriately by mouth in the short term, but it can have unpleasant gastrointestinal side effects and can cause swelling of the airways. There is concern that it may increase the risk of death after a heart attack and has known moderate interactions with high blood pressure drugs and sildenafil (Viagra). It has not been studied for athletic performance.
The Score
I suppose if I were scoring Round 2, I would count it even. The FDA will eventually see most, if not all, of the dietary supplements containing DMAA off the market. Of course, since DMAA is not a dietary ingredient, it should never have been on the market in the first place. And, because DSHEA allows it, supplements containing DMAA were sold without manufacturers having to demonstrate their safety and effectiveness to the FDA. As it turns out, the FDA concluded DMAA was not safe.
USPlabs has reformulated Jack3d, but, again, DSHEA allows it to go on sale without the company having to provide all the information a consumer should consider before taking it or proving its safety and effectiveness to the FDA. The consumer can do this research on his own but information about all of the ingredients is not readily available. Some of the ingredients have a potential for causing harm and there is no adequate research showing they are effective for their intended use. And apparently there is no research on the safety and effectiveness of using these ingredients in this combination and at this dose. In other words:
Safety and effectiveness unknown. Use at your own risk.

FDA poised to reshape the cold remedy aisle
The FDA is proposing to order the removal of phenylephrine from oral cough and cold remedies.
Scott Gavura on November 21, 2024
Link
Is phenylephrine destined for the history books?
On November 7, 2024, the FDA announced that it is proposing to remove oral phenylephrine as a drug that is permitted for use in over-the-counter (OTC) drug products. This is a good decision for consumers, because phenylephrine is ineffective as an ingredient, and should never have been authorized as a cold remedy.
In today’s post I want to review the long path to reconsider the FDA’s approval phenylephrine, and I will quote extensively from some of my past posts.
Colds are ubiquitous. Surprisingly, while there are literally dozens of cough and cold remedies on pharmacy shelves, they all use combinations of the same core handful of ingredients. And the evidence supporting some of these products is very, very weak.
In 1976, the FDA concluded that three medicines were safe and effective for the treatment of nasal congestion caused by colds, allergies, and sinusitis: phenylpropanolamine, pseudoephedrine, and phenylephrine. Almost 25 years later, phenylpropanolamine was withdrawn from the market after use was associated with strokes. Pseudoephedrine is an effective decongestant that is chemically very similar to methamphetamine, a addictive and controlled drug that is subject to abuse. Pseudoephedrine does not share the same stimulant properties as methamphetamine, though it can cause jitteriness, mild tremors, and insomnia. However, because pseudoephedrine can be used to manufacture methamphetamine, the over-the-counter sale of cough and cold products that contain this ingredient are not permitted. Sales were moved “behind the counter” in the US (it is more widely available in other countries), with the requirement for the customer to produce photo identification and the requirement for the pharmacy to maintain a log of all sales, tracked by customer name and address. Not surprisingly, this put a damper on sales.
When pseudoephedrine was moved behind the counter, manufacturers of cough and cold products either had to accept a much smaller market for their pseudoephedrine-containing product, or reformulate.
Some companies reformulated their products to contain phenylephrine instead, which was the last remaining non-prescription ingredient that the FDA permitted for use to treat congestion. Phenylephrine is from a category of drugs called alpha-1 agonists: they stimulate alpha-1 receptors that are present throughout the body, including the nasal passages. It is used as a nasal spray, but more commonly in the United States as a oral product taken to treat nasal congestion. There was a problem with FDA’s historical approval, however. There was little convincing evidence phenylephrine, when taken orally, was actually effective at reducing congestion.
The case against phenylephrine
Phenylephrine is a poorly-absorbed drug (i.e., it has low bioavailability). Most of the drug is broken down during the absorption process, after passing through the liver. So there have been persistent questions if the drug was actually effective.
In clinical trials, oral phenylephrine was compared to other decongestants in a randomized controlled trial of 20 patients (way back in 1971) and found to be no more effective than placebo in reducing lung airway resistance. Another trial compared single doses of four different decongestants against placebo in 88 patients with congestion. It also found that phenylephrine was no more effective than placebo. In a review of the data that the FDA had considered, that review noted that for the 10mg dose, 4 studies showed efficacy and seven showed no difference from placebo. The authors concluded that a systematic review did not support the FDA’s decision. Other trials conducted since that time (like this one in 2009) are supportive of the conclusion that the 10mg dose is ineffective.
The fact that we are relying on trials conducted in the 1970’s pretty much tells us what we need to know about phenylephrine. Given how poorly it is absorbed, there is the question of whether simply giving bigger doses will work – and it turns out it may. However, the 10mg dose is what’s available in US cough and cold products – and the best evidence shows that this drug is effectively a placebo at that dose. I will point out that the manufacturers of the consumer products that contain this ingredient continue to write their own papers suggesting that there is evidence of efficacy. However, despite the large sales of these products, they have not produced any new randomized controlled trials to show that they are effective.
The FDA’s re-review of the evidence
In March 2023 I blogged about how the FDA had committed to re-review the evidence for phenylephrine. The Non-Prescription Drug Advisory Committee met in September 2023. The committee concluded that the evidence does not support that phenylephrine is effective as a nasal decongestant. Here are a few of the key slides and conclusions from that review:
Phenylephrine has action against alpha receptors – not its metabolites.  Less than 1% of the drug is actually absorbed as the “active” drug. The maximum effective blood concentration (Cmax) is lower than the EC50, which is half maximal effective concentration. Finally, the drug is quickly eliminated from the body. All of this suggests that the drug will not be clinically effective. And here is their bottom line on the clinical data, which won’t be surprising based on the pharmacology of the drug in the body:
The agency commented that the data available today refutes some of the assumptions made back in the 1970’s (pg. 55):
Finally, the science has changed in the interim, and a full understanding of the clinical pharmacology of PE [phenylephrine] when administered orally was not appreciated at the time that the Panel issued its recommendations. We now know that in addition to PE having less than 1% systemic bioavailability, the half-life is also significantly shorter than the original 4-hour dosing interval. These data were not available to the Panel, nor was the technology to fully assess oral bioavailability available until around the turn of this century. Therefore, is it not surprising that the Panel considered the equivocal findings in the original studies as sufficient to support a finding of efficacy (and safety) of PE 10 mg administered orally every 4 hours.
and, interestingly (pg. 60),
After careful review, we note that there were many methodological and statistical issues with these studies. We believe that these issues significantly limit any judgement of a statistical “win”, and more importantly a clinical “win”, for any of these studies. In fact, if these studies were submitted to the Agency today all would at most be considered Phase 1 studies at best. As a result, we believe that these studies do not stand up to the new data that are now available with regard to the efficacy of orally administered PE as a nasal decongestant.
Ultimately, the committee unanimously concluded that the evidence does not support that the recommended dosage of orally administered phenylephrine is effective as a nasal decongestant. Importantly, no safety issues with use of oral phenylephrine at the recommended dose were identified.
Your chance to comment
The FDA is currently inviting comments on this proposed order. Options available to the FDA include a final order removing oral phenylephrine from the “OTC monograph” which means that cough and cold products would no longer be permitted to contain oral phenylephrine. The FDA says it would provide manufacturers with time to come up with new formulations, or remove these products from.
Does this restricts consumer choice? Yes, but only from being marketed products that do not work as labelled. Having oral phenylephrine available with the FDA’s apparent approval, when it’s ineffective, offers a false choice that preys on consumer ignorance. And a regulatory standard that ensures approved product are both safe and effective is ultimately a win for consumers. While overdue, it’s to the FDA’s credit that it is willing to scrutinize, reflect, and act on the evidence, even for a decision with a large, but positive, consumer impact.


Congress criticizes the FDA and the Aduhelm approval
A Congressional report on the approval of the Alzheimer’s drug Aduhelm identified serious concerns about the FDA’s processes
Scott Gavura on February 16, 2023
Link


Over decades, the US Food and Drug Agency (FDA) earned a worldwide reputation as a competent and trusted regulator, establishing standards for drug development and approval that have been mirrored worldwide. Through its efforts, drug safety catastrophes have been averted. It has been criticized, however, for not doing enough to prevent other catastrophes.
Regulatory capture is a term used to describe the behaviour of a regulator, created to work for the public interest, when begins to take positions or make decisions that favour that industry it is regulating – over those of the public. In 2021, the FDA approved a new Alzheimer’s disease drug, Aduhelm, despite negative clinical trial evidence and over the advice of its own advisory committee. This approval prompted questions about the FDA’s decision-making process, and Steven Novella and I both blogged about the approval (and its consequences) at the time. There were also questions about how the manufacturer, Biogen, could justify charging such a high cost for the drug (initial list price was USD$56,000 per year) given its benefits had yet to be proven. That same year, the House Committee on Oversight and Reform launched an investigation. The report was published in December 2022 and is worth a closer look to get some insight into the workings of the FDA and Biogen, and the process that led to this drug’s surprising approval.
The Approval of Aduhelm
I’ll refer the curious reader to past posts about Alzheimer’s disease and this drug, but the background is worth summarizing in brief.
Alzheimer’s disease (AD) is a neurological disease that is the most common cause of dementia. AD is common, and affects an estimated 6 million Americans, with that prevalence expected to increase based on population trends. How AD develops is not known, but it produces changes in the brain that are destructive, progressive, and irreversible. A common feature of AD is the accumulation of protein called “beta amyloid” in the form of plaques that are thought to interfere with signalling and eventually cause cell death. Decades of research and billions of dollars have been invested in developing and testing treatments against beta amyloid after trials in mice showed promising results. No treatments had shown benefit (slowing of disease progression) in phase 3 clinical trials until the lecanemab results were published in late 2022.
Biogen, a pharmaceutical company, has been studying aducanumab, an antibody which targets beta amyloid, for years. Two large Phase 3 clinical trials were established to evaluate the efficacy of the drug in patients with mild AD. These were 18 month trials that measured the effect of aducanumab in early AD. In March 2019 both trials were discontinued after an independent data safety monitoring board concluded that the trials were unlikely to meet their primary endpoint. That is, in the language of clinical trials, they were discontinued “for futility”. Given no drug with a similar mechanism of action had so far been shown to be successful, this was not surprising. Moreover, the drug was not free of harms. It can cause swelling of the brain called amyloid-related imaging abnormalities (ARIA), common to this category of drugs, which can cause symptoms like headache.
In analyses done after the trials were stopped (i.e., a “post-hoc” analysis), the manufacturer claimed the drug was in fact effective, and it filed for approval with the FDA. Aducanumab was reviewed in November 2020 at an FDA advisory committee meeting. (The briefing documents are here.) Among those documents included endorsements from FDA staff members supporting the manufacturer’s contention that the drug is effective. The report also contained comments from other FDA staff members criticizing the efficacy statements and the manufacturer’s reliance on post-hoc analyses, which were (understandably) described as biased. Ultimately the panel votes on the evidence were strongly negative. While the FDA is not required to follow its advisory committee recommendations, these recommendations are typically important. On June 8, 2021 the FDA granted accelerated approval for aducanumab, now branded Aduhelm, while requiring Biogen to do a confirmatory clinical trial over the next nine years. Surprisingly, it did not even limit approval to patients similar to those in the clinical trial, who had mild disease and confirmed amyloid plaques. Instead, it put no restrictions on its use.
Congressional Scrutiny
In June 2021 the House Committee on Oversight and Reform announced it would investigate Aduhelm’s FDA approval and its pricing. They pointed to the broad approval labeling and the decision to approve based on a surrogate endpoint. Following an 18 month investigation, in December 2022, the final report was released. Some of the findings it highlighted included:
FDA interactions with Biogen were “atypical” and failed to follows its own documentation protocol: Beginning in July 2019 there were over 115 meetings/calls/email exchanges between the FDA and Biogen including 40 “working group” meetings, with not all properly documented based on the FDA’s procedures. While this sounds atypical, there is no real way of knowing how different this is from the FDA’s interactions with other companies. Regardless, it failed to follow its own processes, leading to documentation gaps.
The FDA and Biogen collaborated on a joint briefing document for the FDA’s advisory committee that didn’t adequately represent differing views within the FDA: A joint briefing document was used and the FDA and Biogen even shared wording between the two organizations. The FDA’s own internal review (see page 16+ here), previously unpublished, had concluded that a joint briefing document was inappropriate, given the disagreements between the different FDA offices in terms of what the data meant. It should be noted that there were dissenting opinions presented in the briefing documents (e.g., start reading here at page 247), but how this is atypical is less clear. The internal review documents noted that joint briefing documents are not new, and have been positively received by the FDA’s advisory committees.
The FDA pivoted to the Accelerated Approval timeline: The drug was being considered under the “traditional” pathway for approval but the FDA changed it to the “accelerated” pathway which would allow for the use of surrogate data (i.e., the lack of actual patient-relevant endpoints). Why this approval was granted is not fully explained or justified.
The FDA approved a “broad label” despite the lack of clinical data – and Biogen’s own reservations. The FDA approved the drug in a population that was broader than the population studied in its clinical trials. Biogen accepted this label despite their own internal reservations (pg 57+) about the lack of evidence. Biogen subsequently sought a label update, narrowing the recommended patient population, but only after patient/provider confusion and public criticism.
Biogen’s price was intended to “Make History” for the company: Not surprisingly, Biogen viewed this as a significant financial opportunity, and they planned to “Establish Aduhelm as one of the top pharmaceutical launches of all time”. This is not surprising, although it is rare that internal documents are made public – like these one have been.
Biogen anticipated the high cumulative public cost of Aduhelm: With government programs covering an expected 90% of the patient population, Biogen forecast that Aduhelm could cost $12 billion in one year, representing 36% of the Medicare 2018 Part B budget.
Biogen planned a multi-billion marketing campaign, spending more on marketing than the total development cost of the drug: Biogen anticipated spending $3.3 billion on sales and marketing between 2020 and 2024, “more than two and a half times what Biogen spent in total development costs for aducanumab from 2007 until approval in June 2021”. An ongoing criticism of the pharmaceutical industry is that more is spent on marketing than research and development.
Lessons Learned?
The Aduhelm approval was perhaps inadvertently beneficial to drug regulation, in that it was at such odds with the evidence that it led to widespread criticism and public scrutiny of the FDA and its work.
Uptake of Aduhelm, given the controversy and persistent questions about efficacy, has been slow. Many private insurers have refused to cover the drug. The Centers for Medicare & Medicaid Services announced it would only fund the drug when patients take part in a clinical trial.The European Medicines Agency rejected the drug outright. In December 2021, the manufacturer lowered the annual cost of the drug to $28,200. In February 2022, Biogen’s financial statements revealed only $3 million in revenue for all of 2021, a trend that appears to have persisted through 2022. On a positive note, Biogen is doing the clinical trial that the FDA mandated as part of its approval.
Alzheimer’s is a devastating disease and we desperately need good therapies. As I noted back in 2021, a drug that meaningfully affects the course of Alzheimer’s disease justifiably should be a multi-billion dollar drug. Without good evidence that is rigorously assessed in an unbiased manner, we will not be able to determine if aducanumab, or any other potential therapy provides benefit in Alzheimer’s disease. While FDA drug approval has traditionally been seen as a worldwide gold-standard, they did serious damage to their own reputation with the Aduhelm approval. I hope that this investigation and its findings will drive the FDA to ensure its work is consistent with its mission to advance and protect public health.

Drug maker challenges FDA on animal testing
A drug maker claims an FDA-required toxicity study in animals is unnecessary to determine safety and urges others to question the routine use of animal testing.
Jann Bellamy on February 28, 2019
Link

Vanda Pharmaceuticals wants to start a year-long Phase II clinical trial of tradipitant, its drug in development for the treatment of gastroparesis. The FDA won’t allow the trial in human subjects to go forward until Vanda conducts a nine-month toxicity study in dogs. Vanda is challenging that decision in both federal court and the court of public opinion, claiming the toxicity study is unnecessary and would result in the needless deaths of dozens of animals.
Vanda filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia earlier this month asking the judge to order the FDA to lift its clinical hold (the formal name for the FDA’s action). It also wrote an “Open Letter to the Food and Drug Administration,” calling on drug companies, the scientific community, and the general public to join it in asking the FDA to revisit its “one-size-fits-all” animal testing policy, which Vanda claims is outdated and not scientifically justified.
In the Open Letter, Vanda does not dispute the necessity of animal testing in drug development and approval, which can include multiple animal studies of different lengths and in different species to identify potential toxicities that might pose a risk to humans. What Vanda does dispute is the FDA’s routine requirement of a nine-month non-rodent toxicity study which, it claims, is unnecessary in most cases.
Vanda summarizes the testing already done on tradipitant to emphasize its point. The drug has been the subject of several animal studies, including rat and dog toxicity studies at up to 300 times the intended human equivalent dose without “clinically significant safety signals” (although for a shorter time than the FDA is now demanding). This lack of safety issues, the company says, is consistent with animal studies of other drug ingredients that share tradipitant’s mechanism of action. Finally, tradipitant has been the subject of 15 clinical studies for indications other than gastroparesis without incident. (It does not appear any of these got final FDA approval.)
In imposing this testing, usually conducted in young beagles, but also other animals like monkeys and minipigs, the FDA, Vanda claims, “is ignoring a large body of published scientific evidence” concluding that nine-month dog studies “rarely, if ever, identify toxicities that were not already identified in previous animal studies of a drug in development.” Nor do they “yield new information that is important for the purpose of understanding how the drug will impact humans.”
Vanda asks the FDA to review the vast record of animal research it has accumulated in the drug development and approval process over the years and identify which animal studies are genuinely scientifically useful. This review, along with existing scientific evidence on the lack of necessity for animal studies, Vanda claims, should result in a policy where animal studies are the exception rather than the rule and are required only on a case-by-case basis when scientifically justified. Vanda is confident that the FDA would conclude nine-month toxicity studies in dogs and other animals should not be routine. The review would also “shed light on the need for other types of animal testing as well.”
Vanda points to the EPA as an example of how this could work. Based on the scientific literature and the agency’s own review of toxicity study results, the EPA abolished a blanket requirement that 12-month toxicity studies of dogs be conducted in the pesticide registration process and now requires them only on a case-by-case basis.
The Open Letter is graphic in its description of what happens to the animals studied and blunt in its judgment:
For the [nine-month toxicity] study, all of the animals must be euthanized (or “sacrificed,” in the scientific jargon) at the conclusion of their study participation so that their tissues can be analyzed. In many, if not most, cases, these longer term, non-rodent toxicity studies are unnecessary. Killing animals without a scientifically justified purpose is unethical and inhumane.
Vanda chides other drug companies for conducting animal studies for decades “reflexively, without challenging the FDA.” The FDA has relied on this industry complacency, it says, but Vanda will refuse “to sacrifice young beagles or other animals in a study that serves no scientific purpose”.
Lawsuit against FDA
Oversimplifying the 56-page complaint somewhat, Vanda alleges that, to impose the clinical hold, the FDA was legally required to find that tradipitant poses an unreasonable risk to human clinical trial subjects, something the FDA failed to do. Alternatively, Vanda complains that the FDA specifically relied on one of the agency’s non-binding guidances as the source of the study requirement instead of a properly enacted regulation. (This is a common criticism of the agency: Relying on guidance documents instead of enacting regulations, which require notice to the public and an opportunity to comment.) Thus, the FDA’s clinical hold was “arbitrary and capricious”, the legal standard Vanda must meet for a court to overturn an agency’s decision.
In what Vanda sees as a “white flag,” the FDA recently asked the court to send the matter back to the agency for further consideration of Vanda’s complaints, but it wants to continue the clinical hold while it does so. Vanda replied that it is perfectly willing for the FDA to reconsider the matter, but the court should lift the clinical hold when it sends the case back to the agency. And Vanda wants a full and fair consideration of its criticisms, not just “lipstick on a pig”, with the FDA retrofitting its decision so it can reach the same result.
This is good news for Vanda because, as the FDA Law Blog points out, the suit will be difficult to win, given the courts’ typical deference to agencies in questions of statutory interpretation and scientific judgment. And, as it also points out, even if Vanda wins, the court is likely to send the matter right back to the FDA for further consideration and justification for its decision, leaving Vanda in the same position it is now, only with several years of litigation having passed and the possibility of a competitor stepping in to fill the void.
To the authors of the FDA Law Blog, the lawsuit and the Open Letter do seem to evidence a real concern about animal welfare and animal testing. As might be expected, PETA has voiced its support for Vanda’s actions. Investors, not so much. Vanda’s stock dropped nearly 20% on news of the lawsuit and one stock analyst lowered its expectations for the stock, although the gloomy outlook is not shared by everyone.
Is animal testing in drug development necessary?
A 2016 article on the Pharmaceutical Technology website featured a debate between Dr. Jarrod Bailey of Cruelty Free International, which seeks a ban on all animal testing, and Chris Magee of Understanding Animal Research, which is supported by universities, research labs, and drug companies, among others. Both organizations are based in the U.K., which is part of the European ban on animal testing when there are available alternatives is in place. (There is no such law in the U.S., although some states do have similar laws banning animal testing for cosmetic products.)
Bailey argues that inter-species genetic variability means that “meaningful inferences between animal and human reactions is not feasible”. He points to HIV/AIDS vaccine and stroke treatment research in animals that have shown efficacy but failed to yield an actual vaccine and only a “precious few” stroke treatments. On the other hand, he says, drugs that proved safe in animal testing have turned out to cause harm in humans. According to the FDA, 92% of drugs that are successful in animal testing fail in human trials, a statistic Bailey sees as indicative that the animal testing paradigm is failing.
Magee points out that all but a few Nobel Prize winners for physiology and medicine have been animal researchers. Animal testing has elucidated the role of insulin in diabetes and other biological mechanisms and successful treatments have been based on animal physiology. He rejects the 92% failure rate as indicative of the failure of animal testing, as it includes other reasons a drug does not make it to approval, such as economic viability. He says the paucity of adverse events in human clinical trials demonstrates the contribution of animal testing, which successfully screens out harmful compounds.
Magee counters Bailey’s genetic differences argument by noting the potential of genetic manipulation to “humanize” test animals. In addition to drug trials, which make up only around 15% of animal testing, the contribution of animal research to basic knowledge underlying the development of new treatments is of vital importance, although the time between discovery and medical innovation can take years. As an example, he cites frog-cloning experiments in the 1960s that facilitated modern stem cell research.
Bailey and Magee agree that animal research is replaceable with other technologies, although they disagree on the degree to which that is currently possible. These technologies include stem cell platforms, 3D tissue and organ cultures, and computer simulation.
The author of the article featuring the debate believes
there may well come a time when technological advances turn animal research into a relic of the past, but the current best practice employed in Europe seems a sensible compromise until that time comes, and other regions would do well to follow suit.
I can see how having to determine whether alternatives are available and implementing them might be a burden and added expense in a climate where research dollars are a zero-sum game. But it is also difficult to defend the routine use of animals without giving some thought to whether the particular research is really necessary, the point Vanda makes. Then again, I am not a researcher and have no first-hand experience in dealing with these issues. I know I would like to see a cure for cancer(s) (and many other diseases) and that this is likely impossible without animal testing. On the other hand, it is hard not to think about the beagles.

Court overturns FDA ban on electric shock device used on special needs students
An FDA ban on using electric shock devices to control behavior in special needs students, a method deemed “torture” in a U.N. report, was overturned in a flawed court decision. The FDA should appeal.
Jann Bellamy on July 15, 2021
Link
In 2020, the FDA banned “electric stimulation devices” (ESDs), that is, devices delivering an electric shock to the skin and used to control self-harming and aggressive behavior in humans. The Judge Rotenberg Educational Center (JRC), a Massachusetts school for children and adults with emotional and psychiatric problems, intellectual disabilities, and autism spectrum disorder, many of whom are non-verbal, is the only place in the world currently using such a device and is thus the only entity affected by the ban.
JRC and some supportive parents petitioned the U.S. Court of Appeals for the D.C. Circuit to vacate (that is, overturn) the ban and, in a decision criticized by disability advocates, the Court recently held that the FDA lacked the authority to ban the device.
The overturned FDA ban applied only to electric shock devices used for aggressive and self-harming behavior. It did not ban such devices when used for smoking cessation, for example. The ban is only the third ever issued for a medical device by the FDA (the others were for prosthetic hair fibers and powdered gloves) and the first to be challenged in court.
The Court’s decision is just the latest chapter in a years-long battle between, on the one hand, the Judge Rotenberg Educational Center and parents who support using an electric shock device as a behavioral modification tool for special needs students and, on the other hand, government authorities, advocacy groups, and medical experts who consider this method ineffective, unsafe, and even torture.
Today, we’ll take a look at the JRC’s “graduated electronic decelerator” (GED), an electric shock device invented at the school, and its disturbing history, along with previous attempts to stop its use. Then we’ll see how the FDA used its power to regulate medical devices to issue the ban. Finally, we’ll find out why a two-judge majority of the Court ruled that the FDA did not have the authority to enact this ban, a conclusion criticized in a cogent dissent by one judge who highlights the ridiculous practical result of the ruling, a dissent with which I wholly agree.
But first, by way of background, a shallow dive into the extremely complex subject of medical device regulation. The FDA clears medical devices depending on the intended use of the device and its indications for use which, in turn, governs the type of regulation the device is subject to, based in part on its potential for harm to the patient. For example, tongue depressors aren’t cleared for just anything, they are cleared as a “device intended to displace the tongue to facilitate examination of the surrounding organs and tissues”. Further complicating this scenario is the fact that, once cleared, a medical device (just like an FDA-approved drug) can legally be used “off-label” for other purposes. Off-label use is considered “the practice of medicine” and therefore subject only to state, not federal, regulation. So, your doctor could legally use the tongue depressor off-label in other orifices (although that might raise different issues).
A shocking history
According to a 2018 news report in The Guardian, Matthew Israel, a psychologist and JRC’s founding director, came up with the idea of using “aversives” to control behavior after reading a book about a fictitious utopian community “where positive behavior is encouraged and negative behavior thwarted”. Israel began applying these “aversives” to JRC’s students in 1971, including spanking and pinching. In the 1990s, he switched to electric shocks, inventing his own electricity generator, naming it the “graduated electronic decelarator”, or GED for short. (Israel was forced to resign in 2011 as part of a plea deal to avoid prosecution for destroying evidence of abuse.) Based on its similarity to devices first approved by the FDA in 1979, the original GED was cleared by the FDA in 1994, although subsequent iterations were apparently not appropriately cleared and JRC received FDA warning letters.
In its current iteration, GEDs are carried in students’ backpacks, delivering up to 41 milliamps, 10 times the amperage used in most stun guns, according to a recent NBC News report. Shocks lasting up to two seconds are administered by staff using remote controls with the intention of causing pain and thereby discouraging unwanted behavior. The remotes hang on the staffs’ belts, labeled with photos to identify the applicable remote for the offending student.
In 2011, certain procedural safeguards were instituted by the State of Massachusetts before the GED could be used, but these apply only to students enrolled prospectively, not those currently under care plans, although those plans can be in effect for years.
JRC, which charges up to $275,000 per student per year (much of it paid by government funds), defends its methods by pointing to the fact that it accepts students with profound disabilities and those who are seriously troubled, refusing no one, even those who have been repeatedly thrown out of other facilities. It says the shocks are used only to intervene when students engage in the most dangerously aggressive and self-injurious conduct, such as head-banging, eye gouging, and tearing at their own flesh, and for whom other forms of therapy have proved ineffective.
Some parents and guardians of the students support the school in its use of the GED. One mother whose son has resided at the Center for two decades said he was a drugged “zombie” before coming to JRC and being subjected to the GED, which, she claims, stopped his aggression. Other family members of students who have struggled to find care, some of whom have a history of severe self-harm, defend the school and its methods and credit it with saving their children’s lives.
Outside of the school and its parent defenders, shocking special needs students as a means of behavior modification is pretty much universally condemned and has resulted in this years-long efforts to stop it through litigation and other methods, including appeals to the U.N. and the Organization of American States.
News reports and a Wikipedia history of the school belie the school’s claim that the GED is a method of last resort, used judiciously and only for the most harmful behavior. A former student reported that, beginning at age 8, electrodes were strapped to his legs and a 12-volt battery draped over his shoulders in a backpack. The electrodes, he says, remained there 24/7 for a decade, during which time he was shocked for relatively minor infractions like swearing, screaming, or refusing to follow directions, and even during his sleep. In 2002, another student was tied to a restraint board for seven hours and shocked 33 times, causing burns on his skin. In 2007, a student was shocked 77 times in one night when a prank caller pretended to be a staff member and instructed other staff to do so. (An extremely disturbing video of an incident came out in a 2012 civil trial. You can see a clip of the video, as well as students wearing the electrodes and backpack here.)
The FDA’s own investigation, reported in a 2016 proposed rule banning these devices, turned up additional evidence of the potential for, as well as actual, psychological and physical injuries in the medical literature, and from scientific experts, state authorities who had investigated complaints of injuries at JRC, health care professionals, and disability rights advocates, as well as from former JRC students and family members. This led the FDA to conclude there was either actual or potential risk of depression, fear, panic, aggression, catatonia, self-injury, burns, tissue damage, PTSD, learned helplessness, suicidal ideation, and heart palpitations, among others. There is also, of course, pain, which the FDA considers a negative but JRC sees as a feature, not a bug.
In a 2013, the U.N. special rapporteur on torture, Juan Mendez, presented a report to the U.N.’s Human Rights Council on so-called “treatments” for drug addiction and autism that he labeled “tantamount to torture or cruel, inhuman or degrading treatment.” The report singled out JRC, saying that
the rights of the students of the JRC subjected to . . . electric shock and physical means of restraints have been violated under the U.N. Convention against Torture and other international standards.
According to a Time article on the Mendez report, the U.S. Department of Justice (DOJ) was also investigating JRC. This was spurred by a 2009 letter to DOJ signed by 31 disability organizations asserting that JRC’s use of shock and other methods violated the Americans with Disabilities Act. Per the FDA’s review, the DOJ ultimately found the devices harmful and of uncertain effectiveness but decided not to proceed further.
Because the state funded students attending the school, officials in New York investigated as well. A 2006 report by the New York State Education Department found that the device was regularly used when there was no threat of serious physical harm or injury, including for such minor acts of noncompliance as failing to be neat, wrapping one’s foot around the leg of a chair, stopping work for more than ten seconds, and closing one’s eyes for more than five seconds.
In a matter not directly related to the electric shock device, but nevertheless indicating a lack of adherence to standards, Massachusetts fined the school almost $30,000 in 2009 for allowing 14 unlicensed clinicians to call themselves “psychologists”. Bills have been proposed in the Massachusetts legislature banning using electric shocks on students but they’ve not passed. To at least control, if not eliminate, the damage, Massachusetts authorities tried to restrict the use of the GED to fewer situations but, in another court victory, a state judge ruled in 2018 that JRC’s activities were legal and could continue.
In 2018, a coalition of advocacy groups tried yet another tack, this time writing to the Organization of American States, calling on it to demand that the U.S., one of 35 member states, impose a federal ban on shocking students.
The FDA’s ban
In 2016, the FDA issued a proposed rule banning these electric stimulation devices, which are, as noted, devices that deliver a shock to a person’s skin, when used to reduce or cease self-injurious behavior (SIB) or aggressive behavior (AB). The FDA finally issued a rule banning ESDs in March, 2020, after having reviewed hundreds of comments, both pro and con, received in response to its 2016 proposed rule. The “con” comments came almost exclusively from JRC staff, parents and guardians of students, and some former students. The “pros” came from everyone else.
Per the federal Food, Drug, and Cosmetic Act (FD&C Act) the FDA has the authority to ban a medical device presenting an “unreasonable and substantial risk of illness or injury”. Its analysis asks
whether the risks the device poses to individuals are important, material, or significant in relation to its benefits to the public health . . . and compares those risks and benefits to the risks and benefits posed by alternative treatments being used in current medical practice.
We’ve previously reviewed the risks. As for benefits, the FDA concluded both that the available evidence did not establish a durable conditioning effect for ESDs for this type of behavior and that
state-of-the-art treatments for SIB and AB are positive-based behavioral approaches along with pharmacotherapy, as appropriate. The medical community now broadly recognizes that conducting careful functional assessments and addressing the underlying causes of SIB and AB rather than suppressing behaviors with shocks not only avoids the risks posed by ESDs, but can achieve durable, long-term benefits.
In this regard, the FDA noted that
the overwhelming majority of patients exhibiting SIB or AB throughout the country are being treated without the use of EBD.
The FDA found, disturbingly, that the record belied JRC’s claim that the GED was used only when other methods failed. One expert testified that JRC’s methods of diagnosing individuals were outdated, did not include important information on how diagnoses were made, and were “kind of cut-and-paste”. The FDA found that formal functional behavioral assessments of students subjected to electric shocks were in many cases either not done or were inadequate. These assessments, the FDA said, were critical to implementing “empirically derived, individualized behavioral interventions”. Nor do the records adequately detail what interventions were attempted, how long they were tried, or what the effects were. The FDA particularly singled out JRC’s opposition to pharmacological therapies and its lack of effort in using them before employing electric shocks. In sum, without a proper diagnosis and functional assessment, an appropriate treatment plan could not be implemented and, in any event, evidence-based therapies were given insufficient consideration before JRC resorted to shocking its students.
JRC and parents and guardians of some students petitioned the U.S. Court of Appeals for the D.C. Circuit to vacate the ban. The petitioners argued that the evidence did not support the FDA’s decision, that the FDA lack the legal authority to issue the ban, and that the FDA had violated their constitutional rights in its decision-making process.
An impressive group filed a brief supporting the FDA, arguing the ban is well-supported by the evidence: the American Academy of Pediatrics, American Association on Intellectual and Developmental Disabilities, American Academy of Developmental Medicine and Dentistry, International Association for the Scientific Study of Intellectual and Developmental Disabilities, National Association of State Directors of Developmental Disabilities Services, National Association of State Directors of Special Education, and National Association for the Dually Diagnosed.
The Court begins its opinion with a curiously benign recitation of the facts, citing the procedural safeguards that must be met prior to using the GED. However, the Court fails to note that many of these safeguards do not apply to all students, nor does it raise any questions about whether these procedures are actually followed. The opinion does reveal that JRC “treats approximately 20% of its patients with this treatment at any one time”.
The Court, however, avoided reaching the question of supporting evidence by deciding the case based on an interpretation of the FDA’s authority to ban medical devices under the FD&C Act. Even though the statute clearly allows the FDA to approve medical devices for a particular use, and even though the statute clearly allows the FDA to ban a medical device, the Court ruled that the FD&C Act does not permit the FDA to ban a medical device if that ban applies only to a particular use, instead of for all uses. (Recall that the FDA’s ban applied only to using ESDs for SIB and AB, but not for other behaviors, like smoking.)
Why? Because of a provision in the FD&C Act which says
Nothing in this chapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship.
This section allows the previously noted off-label use medical devices. But as the FDA and the dissenting opinion point out (and I believe they are correct) this section applies only to the FDA’s authority over devices legally on the market, not to the section which specifically permits the FDA to ban a device. To read the FD&C Act otherwise leads to absurd results.
In essence, under the Court’s ruling, once a medical device is approved by the FDA for multiple uses, it cannot be banned for one use, no matter the evidence of harm or ineffectiveness, unless the FDA bans it for all purposes. Thus, a device that is proven dangerous and ineffective when used in a particular manner stays on the market. On the other hand, if a device cleared for only one use is later shown to present unreasonable risks, even if physicians are employing it off-label for other, effective and safe uses, banning it is no problem.
This dichotomy makes no sense, as the dissent points out, given the fact that the overarching goal of the FD&C Act is to protect consumers from unsafe medical devices. How does leaving a device on the market that the FDA specifically finds meets the standard Congress set for banning a device serve this purpose? And how does totally banning a device that physicians may well be using off-label for safe and beneficial purposes serve to safeguard the practice of medicine from FDA’s interference in cases where a partial ban is all that is needed to protect the public?
The FDA has 45 days to petition the U.S. Court of Appeals for the D.C. Circuit for a rehearing of the case en banc, that is, by all of the judges of the Court. The agency has 90 days to file a petition with the U.S. Supreme Court to review the Court of Appeals ruling. Given the rarity with which the FDA bans medical devices, it may choose to let the ruling stand and this barbaric practice will continue. The near-universal condemnation of this shocking device, on the other hand, should weigh in favor of seeing that it is banned for good.

Bogus Electrodermal Testing Devices and the Failure of Regulators to Act
Harriet Hall on March 5, 2013
Link
Electrodermal testing is a bogus procedure where measurements of skin conductance with a biofeedback device are entered into a computer to diagnose nonexistent health problems and “energy imbalances” and to recommend treatments for them, often involving the sale of homeopathic remedies and other useless products. It falls under the general category of EAV (Electro Acupuncture of Voll). The history and variants of EAV are explained in an article on Quackwatch.
I’ve written about electrodermal testing before. I’ve explained how it amounts to fooling patients with a computerized Magic 8 Ball and I’ve discussed the legal and regulatory issues.
Now Stephen Barrett (founder of Quackwatch and Vice-President of the Institute for Science in Medicine) has written an article in FACT (Focus on Alternative and Complementary Therapies) entitled “Bogus electrodermal testing devices: where are the regulators?” He points out that existing regulations are sufficient to ban these devices, but that regulators have failed to take appropriate action.
Claims of FDA approval are false. The people who promote these devices claim that they are FDA approved. They are not. Dr. Barrett explains:
[The FDA] classifies ‘devices that use resistance measurements to diagnose and treat various diseases’ as Class III devices that require FDA approval prior to marketing. No EAV device has ever been FDA-approved. A few companies have obtained 510(k) clearance (not approval) by telling the FDA that their devices are substantially similar to devices previously cleared for biofeedback or skin-resistance measurement. Their FDA applications fail to reveal that the device would be bundled with software intended to diagnose and/or prescribe, which would make them ineligible for 510(k) clearance.
Electroacupuncture devices are not biofeedback devices. Biofeedback is a relaxation technique that uses an electronic device that continuously signals pulse rate, muscle tension or other body function by tone or visual signal. In biofeedback, the signal originates and is influenced by the patient. In EAV, the signal is influenced by how hard the operator presses the probe against the patient’s skin. (Pressure makes the electric current flow more easily between the device and the patient’s skin.) The 510(k) clearance enables manufacturers to market these devices for biofeedback of skin-resistance measurement but not for diagnosis or treatment.
Inadequate action by regulators. There have been a few actions against users for practicing medicine without a license, and medical boards have looked at their use by licensed practitioners but have rarely acted against them. Sporadic enforcement efforts have banned importation of these devices into the US and have prosecuted or warned individual marketers. But there has been no systematic effort to eliminate them. As a result:
these bogus devices are being used throughout the world by many chiropractors, acupuncturists, dentists, holistic physicians, veterinarians, self-styled nutritionists and various unlicensed individuals. The most common use is for prescribing homeopathic products, dietary supplements and herbal products. The devices are also used to determine allergies, detect nutrient deficiencies and locate alleged problems in teeth that contain amalgam fillings. Some operators claim to tell whether a disease, such as cancer or acquired immunodeficiency syndrome, is absent. Some devices are claimed to treat the patient with electromagnetic impulses transmitted into the body or are used to energise products.
These devices are widely promoted through the Internet, and it would be easy to identify offenders for prosecution, but regulatory agencies don’t seem to care.
What’s the Harm? False health information and false beliefs can lead to unwise health decisions. Over the last 10 years, Dr. Barrett has personally heard from over 200 victims who were unnecessarily frightened about bogus findings and who were bilked of hundreds or thousands of dollars.
Conclusion
Electrodermal testing is clearly bogus and illegal. Inaction on the part of regulators has allowed it to persist and to defraud patients. Dr. Barrett’s article is a call to action. Will regulators answer that call?

Protandim Update: New Studies and an FDA Warning Letter
Multilevel distributors of the dietary supplement Protandim think that evidence from scientific studies supports their claims for their product. The FDA disagrees.
Harriet Hall on May 9, 2017
Link


On April 17, 2017, the FDA sent a warning letter to the LifeVantage Corporation advising them that their product Protandim NRF2 Synergizer was misbranded and violated regulations.
The claims on the websites www.nrf2science.com, www.lifevantage.com, and www.protandim.com establish that they are selling Protandim as a drug intended to prevent or treat diseases. The claims include prevention and/or treatment of cardiovascular disease, Alzheimer’s disease, high blood pressure, stomach ulcers, osteoarthritis, bacterial and viral infections, and several types of cancer (“shows ability to slow progression of and ‘kill’ cancer cells”). And much more.
The FDA gave them 15 working days to correct these violations. As of this writing, they have not yet done so.
Protandim is a mixture of 5 herbal supplements (milk thistle, bacopa extract, ashwagandha, green tea extract, and turmeric extract) intended to upregulate the body’s own production of antioxidants. It is sold through multilevel marketing. Its patent application said it was useful to treat or prevent an astounding 126 diseases and medical conditions, from tinnitus to aging, from hemorrhoids to cancer. Those claims are not supported by any credible scientific evidence.
Previous articles on Protandim
I first wrote about Protandim in 2005, followed by three articles on the Science-Based Medicine blog. The first, in 2009, was “Protandim: Another Kind of Antioxidant.”
The second, in 2011, was “Pursued by Protandim Proselytizers.” I described how I was getting a steady flow of emails from distributors and customers asking me to reconsider and look at new evidence. I looked at the new evidence, but it was not anything that would lead me to reconsider. I wrote:
We need good human studies showing that people who take Protandim have better clinical outcomes than people who don’t. For instance, fewer heart attacks or fewer cancers…not just higher levels on a TBARS test….I am only asking for the same kind of evidence that the scientific community requires before it accepts any new treatment. Please try to understand what I mean by clinical studies with meaningful outcomes and contact me again when such studies are available… and not before.
They didn’t listen. They kept sending me e-mails every time any new study was announced. In 2012 I wrote a brief update to cover a study that was so bad it made me laugh. Instead of studying any of the conditions Protandim was alleged to benefit, they chose to study alveolar epithelial permeability in alcoholics. The results? It performed significantly worse than placebo!
The new studies are not convincing
They still didn’t listen. I’m still getting emails, most recently this one:
Hi, I’m not even sure how I came across your article against Protandim, last 1 is from 2011. Would you please have a look at the studies now. [sic] I’d love to know if your opinion has changed. Your info is incorrect by stating all the studies are done by the company. Check out the NIA study on life extension or the osteo study by Montreals [sic] Osteoarthritis Research Centre. Surely you must have something to say about these? thank [sic] you for your time.
She didn’t provide details, so I had to do some sleuthing to figure out which studies she was referring to. I found the NIA life extension study. It was in mice, not humans. It found that Protandim significantly increased the median lifespan of male mice at one of the three testing centers but not at the other two; when data from all three sites was pooled, Protandim appeared to increase the median lifespan of male mice by 7%. It did not significantly increase the median survival of female mice. And it did not increase maximum lifespan. Anyway, what happens in mice may not apply to humans.
I located the osteo study. It’s behind a paywall, and the abstract is confusing. Apparently it was a combination of a mouse study and in vitro studies. They used a mouse model where osteoarthritis was surgically induced by destabilizing the medial meniscus. Then they injected Protandim directly into the joint, and the mice’s osteoarthritis scores decreased. Nice for the mice, but it doesn’t tell us anything about humans taking Protandim in pill form! Then they studied human and mouse cells in vitro and measured improvements in Nrf2 and GSTA4-4 expression. Interesting, but not the same as significant clinical improvements in humans with osteoarthritis or any other condition.
I also found this study in human athletes showing that:
Protandim® did not (1) alter 5-km running time, (2) lower TBARS at rest (3) raise antioxidant enzyme concentrations compared to placebo (with exception of SOD in those ≥ 35 years old) or, (4) affect quality of life compared to placebo.
This study is not mentioned on the Protandim website, presumably because of its negative results.
Other critics and concerns
I’m not the only one to critique Protandim. Supplement Geek covered the research thoroughly pointing out that the studies are mostly in rodents and in test tubes; there have only been three studies in humans, two of which were negative. And Consumer Lab was less than enthusiastic. And another review cites “very little evidence.”
And there’s also a Wikipedia page that points out that the in vitro and animal studies have not been replicated in human trials. It also reveals how Protandim was invented: Joe McCord was given a list of 41 potential ingredients and he rapidly penciled out 36 of them. Not very scientific!
For what it’s worth, there was a safety recall in 2012.
And the LifeVantage company is not BBB accredited. The BBB website mentions failure to respond to three complaints and includes a number of customer comments.
There is a Protandim Watch website that lists investigative resources, but it is not up to date.
Conclusion: not backed by scientific evidence
It seems nobody is very impressed with Protandim except for the people who are selling it!
So no, my opinion has not changed. My articles are not “against” Protandim. My opinion is not that it doesn’t work, but that no one knows whether it works; and the only way to find out if it works is through proper scientific testing of the company’s claims.
The good news is that if you don’t want to wait for scientific testing, it is probably safe to try. Over the 88 days of the negative trial on human athletes there were 233 reports of signs and symptoms in the Protandim group compared to 220 in the placebo group. Subjects taking Protandim reported more episodes of stomachache and headache, and less gas, but with only 19 subjects in each group, numbers were too small to draw any conclusions.

FDA Looks At Dubious Stem Cell Clinics
Steven Novella on September 7, 2016
Link
Using stem cells to treat disease or improve recovery is an exciting area of research. The potential is undeniably great – these are cells that have the potential to differentiate into mature cells of a specific type. They can be used to replace damaged cells or improve the environment for cell function and recovery. Ideally stem cells can be developed from cells harvested from the patient themselves, so there is no issue of rejection.
Stem cell technology, however, is tricky and currently in its infancy. One challenging hurdle is to prevent transplanted stem cells from turning into tumors. We also need the cells to do what we want and to survive long enough to be useful. Research is progressing, but the potential for stem cells has not yet been realized.
Quackery in the gap
Into this gap between the hype and potential of stem cells and the current reality of the research there is a space where dubious stem cell clinics can thrive. I first wrote about dubious stem cell clinics debuting in China nine years ago. Despite various regulatory efforts these clinics continue to thrive.
At first such clinics popped up in countries with relatively poor regulation of medical treatments, leading to an industry referred to as stem cell tourism. However, dubious stem cell clinics have started popping up in the US as well.
Just type “Stem Cells” and “US” into Google and the first hit is the US Stem Cell Clinic which claims to treat a long list of diseases. Just under the Neurological tab they include Parkinson’s disease, ALS, stroke, traumatic brain injury, and spinal cord injuries.
Published evidence to support such claims ranges from non-existent to preliminary. For stroke, for example, a recent systematic review found:
…reporting quality was high, but adherence to guidelines low. Serious adverse events were observed following five treatments; six improved outcomes. There was a trend toward larger treatment effects in non-blinded studies, younger participants, and higher dosages.
This is a typical preliminary finding. They are encouraging, but the quality of the data is largely poor (unblinded) and there are still safety issues. Results are similar for the other conditions. For ALS, for example, studies are only Phase I and Phase II, establishing safety but not efficacy.
David Gorski covered this issue here two months ago, pointing to the growing number of such clinics in the US. The major update is that the FDA is reviewing their regulation of stem cells and is accepting public comments.
FDA regulation
As is often the case with the latest technology, existing regulations may not be written to cover them. This allows for unregulated use until the relevant regulatory agency catches up by updating their rules.
For stem cells it is not even clear how treatments should be regulated. The FDA can regulate the cells themselves as a biological product. States have the right to regulate the practice of medicine, although it seems that they generally lack the resources, the political will, and sometimes even the regulatory power to do so effectively.
Stem cells are just one example of the lack of state effectiveness in protecting the public from outright quackery. A recent article in Nature gives an example of the problem:
Thomas Albini met his first patient blinded by a stem-cell ‘treatment’ last year. The elderly woman, who had macular degeneration, thought she was paying to participate in a clinical trial that would save her sight by injecting stem cells into both eyes. Instead, it left her legally blind.
By the time Albini, an ophthalmologist at the University of Miami in Florida, had treated two more women who had been blinded by the same procedure, he knew that there was a systemic problem. Two of the women had been lured by a posting in a clinical-trial registry — even though there was no real trial to speak of — and none of the injections had been administered by a physician. The clinic offering the injections claimed that its procedure did not require approval from the US Food and Drug Administration (FDA), in part because it used the patient’s own cells. Altogether, Albini found the cases shocking. “Any sort of review would have been helpful.”
This seems like a clear case of fraud to me, but for some reason such clinics are allowed to continue exploiting patients with bogus claims.
If states are not going to do their job, then perhaps federal regulation can provide at least somewhat of a safety net. The current problem is that the FDA rules are ambiguous. They state that transplanting a patient’s own cells back into their body is allowed as long as the cells have undergone “minimal manipulation” and are used for “homologous use.” Both of these terms are vague.
“Minimal manipulation” means that the cells could not have been significantly changed through genetic alteration or other treatments. No operational definition or specific examples are given, however.
“Homologous use” means that the cells will serve the same basic function in the body that they originally serve. Again, this is vague and ambiguous.
This is precisely the language that the FDA is currently reviewing. They could alter their rules so that autologous stem cell transplants would require FDA approval. This would mean that clinics providing such transplants would be subject to FDA investigation and might receive a sternly worded letter from the FDA (I know, but at least it’s a start).
Why is this even controversial?
To many it might seem like a no-brainer – these are serious medical interventions that are high risk. There are already many cases of actual harm occurring, as the above example indicates. Patients with the targeted diseases are a vulnerable population.
There is no question that these treatments represent practicing medicine. They should be appropriately regulated according to the standard of care. While they remain experimental, they should be regulated as experimental treatments with all that that implies.
So what’s the issue?
The problem is that there has been a many-decades-long campaign to confuse the public and regulators about the nature and effects of properly regulating the standard of care in medicine. The argument has been largely framed as one of freedom, the freedom of patients to receive any treatment they wish and the freedom of the market to sort it all out.
This is a compelling framing, especially in the US. It ignores, however, the need for quality control.
More importantly, in practice such “health care freedom” initiatives have been really about giving quacks the freedom to exploit the public, not about the freedom of the public. Health care deregulation is a con-artist’s dream.
Health care freedom is essentially the deeper con, the one that makes all the individual cons possible (or at least a lot easier).
This deeper con plays on common psychology. People generally are more averse to missing out on a possible benefit than they are at risking losing a resource. This is why people play the lottery. Trying unregulated health care treatments is playing the medical lottery, which people seem willing to do. And of course the more desperate they are the higher the risk they are willing to take.
At the same time patients feel like they will simultaneously be protected by the government, even while they are working to deprive the government the ability to do just that. They feel they can take the risk because there is still a safety net, not realizing that the con artists have just convinced them to remove the safety net.
Further, is seems that many people grossly overestimate the probability that a new or experimental treatment will work. There is a baseline medical techno-optimism that is completely disconnected from reality. The reality is that most new treatments don’t work. Many are even harmful.
We do research for a reason – because we really don’t know if a treatment works or not. We are not just dotting the “i’s” – we are experimenting with treatments that may or may not work, that may or may not be safe, knowing that most will not pan out.
The public generally feels, however, that the purpose of an experiment is simply to confirm that an effective treatment works. It is also common to feel that anecdotal evidence is compelling. So once there are anecdotes of a treatment working, why bother with actual research? They want the treatment now, and are happy to remove any regulatory barriers in their way.
The fix
The current rise of dubious stem cell clinics is a serious problem, but it is also a symptom of a far deeper and more serious problem – a destructive yet alluring narrative that there are many miraculous cures out there waiting for you, once the pesky government regulations are out of the way.
To solve the many problems that flow from this deceptive narrative we need to change the narrative. This will take a dedicated campaign of public education, which of course is what SBM tries to do but cannot do alone.
The reality is that medical science is complex. Most new ideas and new treatments will turn out to be wrong. It takes years of careful and high quality research to sort out which interventions are safe and effective.
Some maverick doctor shooting from the hip in their under-regulated clinic does not have a miracle cure for you. They only want to take your money and leave you blind or worse.

Donald Trump versus the FDA: Is the standard of evidence for drug approval actually too low rather than too high?
All of the candidates being considered by President Trump for FDA Commissioner believe that the FDA is too strict in its standards for approving new drugs. In a commentary in Nature last week, two bioethicists argued that, at least in terms of preclinical data, the standard of evidence is actually too low. Which is correct?
David Gorski on February 6, 2017
Link

There are good things and bad things about holding the Monday slot on this blog. One of the good things is that I tend to have more time to come up with material. However, one of the drawbacks of holding the Monday slot is that a lot of studies and news stories are published on Monday that I’d normally like to write about but can’t because by the time I see them my post is done. Then I have to wait until the following Monday, by which time something new has usually intervened, a shiny bright object to attract my attention from last Monday’s story, which, by the time I’m ready to write about it is old news. True, I can write about such stories on my not-so-super-secret other blog (and frequently do), but sometimes I like to take advantage of the greater exposure this blog provides.
So it was last Monday that Jonathan Kimmelman & Carole Federico published a commentary in Nature entitled “Consider drug efficacy before first-in-human trials.” I thought it an important topic considering the speculation over who will be pointed FDA Commissioner by President Trump. As I discussed three weeks ago and a New York Times article published yesterday discusses, Donald Trump’s three most likely picks for FDA Commissioner (that I knew of at the time) all favor loosening drug approval standards and could very well undo decades of safeguards. Two are cronies of technolibertarian Peter Thiel. Of these two, one (Jim O’Neill) believes that the FDA shouldn’t have to require evidence of efficacy, only safety, before approving drugs and devices for the market. (Apparently the free market will sort it all out.) The other (Balaji Srinivasan) believes that a “Yelp for drugs” would do a better job than the FDA in assuring drug safety. (Apparently he’s never actually spent much time reading online ratings systems.) The third candidate (Scott Gottlieb) is the closest thing I’ve ever seen to a bona fide, honest-to-goodness pharma shill, who called the early termination of a multiple sclerosis drug study “an overreaction,” even though three participants had died, defended the off-label marketing of Evista, and, when he was Deputy Commissioner of the FDA, harassed underlings when FDA scientists rejected Pfizer’s osteoporosis drug candidate Oporia, forecast to earn $1 billion a year.
Srinivani appears to be no longer in the running, thanks to his rookie mistake of not taking down his Twitter account before meeting with President Trump, allowing some of the dumber things he said about using the Uber model or the Yelp model for online reviews of drugs to be brought to light. However, there’s now a new candidate, Joseph Gulfo, executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University, the author of Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances and the former President and CEO of the medical device firm MELA Sciences. More on him later, but you can see from the title of his book that his philosophy is from the same mold as O’Neill’s and Srivinasan’s, but, unlike them, appears a bit more grounded in reality, although he appears to share O’Neill’s and Srivinasan’s unshakeable belief that the FDA is far too strict.

Basically, no matter who is finally chosen by the Trump administration to run the FDA, it is clear that the mandate will be to decrease regulation. Indeed, just last week President Trump told a gathering of pharmaceutical executives, “We’re going to get the approval process much faster.” The only question, thus, will be by how much. If it’s O’Neill or Srivinasan, I’d expect a push towards a radical overhaul of the FDA. If it’s Gulfo or Gottlieb, I’d expect a less radical, but still highly deregulatory, approach. Add to that President Trump’s recent executive order mandating that federal agencies eliminate two regulations for every new regulation they issue, as well as a legislative agenda designed to “decrease regulatory burden,” and under this administration we will almost certainly see a loosening of drug approval standards, all in the name of “fostering innovation.” It’s a process that actually began before Donald Trump with the passage in the waning days of the Obama administration of the misbegotten 21st Century Cures Act, which promised to get the cures flowing from industry by authorizing the FDA Commissioner to develop a framework decreasing the level of evidence needed for drug and device approval. That’s why this Nature commentary is so important now. It argues for a higher standard before even allowing a drug to be tested for the first time in humans, thus going very much against the prevailing sentiment in Washington right now.
A disaster in a “first in human” drug trial
Kimmelman and Federico begin by describing an incident to illustrate the problem. It’s not an example from the US, but it is a good starting point to discuss the dangers of “fast-tracking” new drugs:
On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France. Four of five other subjects receiving the same dose have serious, ongoing neurological complications. Investigations into the trial described many troubling safety practices, such as steep increases in dose levels delivered to sequential subjects without sufficient delays to check for safety.
The year since has brought intense scrutiny about how the debacle could have been anticipated and prevented. However, another issue is still largely overlooked: the duty to evaluate whether an experimental treatment is promising enough to warrant testing on people.
When thinking about drug approval, most people focus on phase III clinical trials, which are large randomized, double-blinded (when possible) trials designed to test the efficacy of an experimental drug versus placebo and/or existing drugs. However, phase III trials are only the culmination of the process of pre-approval drug development. Long before that there is preclinical research in chemistry, cell culture, and laboratory animals. Only when there is deemed to be sufficient evidence of promise does an experimental drug advance to phase I trials, also known as “first in human” trials. Incidents like the one above are one reason why I view “right-to-try” laws with such alarm, as such laws require nothing more than that a drug has passed phase I tests to be eligible for a patient to use them outside of a clinical trial.
Be that as it may, the French medicines safety agency (ANSM) ordered an investigation and re-examination of the data provided to the French ethics panel by the drug company Bial, based in Trofa, Portugal—in essence, the French version of what we in the US call the Institutional Review Board (IRB). This re-examination resulted in a report, with the following findings:
The report notes that the 63-page Investigator Brochure describing the trial included fewer than two pages of evidence that the drug had the desired pharmacological activity. It identified only two studies presented as evidence for efficacy, both problematic. In one, Bial had data for a different marketed drug showing it was more effective than Bial’s drug at relieving pain in animals, but did not include that information in a summary figure. Both preclinical studies showed only “moderate” positive effects. Moreover, Bial’s drug had been tested at a range of doses in mice that made it impossible to estimate the most likely effective dose in humans.
Press coverage following the tragedy quoted independent experts concluding that there was little evidence to support a trial, and that at least five other drugs designed to act in a similar way had been tested in people without success.(Bial maintains that toxicities were not predictable and that it has followed all human-testing norms. We approached the company for more information about the event for the purposes of this Comment but received no response.)
This incident is a good way to start a discussion about just how much preclinical evidence for a compound is enough to justify a first-in-human (FIH) clinical trial.
Efficacy versus safety in clinical trials
Kimmelman and Federico are bioethicists who have studied the ethics of first-in-human (FIH) and early-phase drug research for more than a decade. They wrote this editorial because they are concerned that there is a lack of emphasis on the efficacy of drug candidates observed in pre-clinical research during decisions about whether to advance a drug candidate to FIH clinical trials. They call for “infrastructure, resources and better methods to rigorously evaluate the clinical promise of new interventions before testing them on humans for the first time,” noting that more than half of all drugs that reach later stage trials (Stage II and III) fail because they do not demonstrate efficacy, going on to write:
Today, the evaluation of preclinical evidence is especially important. Favoured picks for the next commissioner of the US Food and Drug Administration (FDA) are likely to lower the current requirements that a drug must demonstrate efficacy in humans before entering the market. If so, low standards for launching clinical trials in the United States could result in ineffective drugs being approved, while also decreasing incentives.
Regulators in Europe and North America evaluate safety before human trials can proceed, but they do not currently demand evidence for potential efficacy. At a workshop of the US National Academy of Sciences in September, Robert Temple, a veteran at the FDA’s Center for Drug Evaluation and Research, said that the agency largely left it to drug sponsors to evaluate their rationale that an experimental drug was likely to work. “I can’t think of any cases where [FDA has] said you can’t do this [phase I] study because we’re just too sceptical.” The European Medicines Agency (EMA) — Europe’s drug regulator — is similarly silent about the evaluation of clinical promise, even in proposed revisions to guidelines prompted by the Bial affair.
I’d say that Kimmelman and Federico are, if anything, understating the case. Lowering drug approval standards with respect to efficacy would not only be likely to result in more ineffective drugs being approved, but, if coupled with a generalized anti-regulatory push and an attitude to approve more drugs, likely to lead also to a decrease in safety standards as well, as the two are coupled. Think of it this way. We accept high levels of toxicity in chemotherapy drugs because they treat a deadly disease, but would never tolerate toxic side effects as serious to treat, for instance, a headache. Perfect safety is never possible in any drug, but must always be weighed against efficacy and the seriousness of the condition for which the drug is to be marketed. If efficacy is overestimated or de-emphasized, then considerations of the benefit-risk ratio will be skewed.
Kimmelman and Federico go on to argue that commercial interests “cannot be trusted to ensure that human trials are launched only when the case for clinical potential is robust.” While I accept that this is true, I also can’t help but note that commercial interests also do not want to spend boatloads of money carrying out clinical trials on experimental drugs unlikely to be shown to be efficacious and safe. When a new drug fails phase III clinical trials, it’s a huge loss to a company, both in terms of development costs and in terms of the loss of projected revenue from sales of the drug, which explains why Scott Gottlieb was so upset when the FDA rejected Oporia. No, I’m not being sucked in to Jim O’Neill’s fantasy that the free market will guarantee drugs that are safe and effective. I’m just noting that the situation is…complicated. There are competing incentives, both regulatory and financial. Nor do I disagree that commercial interests should be trusted to ensure that the preclinical evidence is robust and bulletproof before launching a clinical trial. Rather, I’m emphasizing again that lowering the standards would shift the incentives to make it more worthwhile to pharmaceutical companies to see what they can get away with.
What is to be done?
It’s certainly true that very few FIH trials have resulted in disastrous outcomes like the one in France. Indeed, it’s noted that in Europe only 2 out of 3,100 FIH trials overseen by the European Medicines Agency since 2005 have had disasters like the one in France and that serious harm and that the record in the US is similarly good. However, Kimmelman and Federico are correct to point out:
But, even if individual participants are not harmed, trials of ineffective therapies place burdens on society. Drug development is costly, in terms of money and people. Patients, healthy volunteers and experts involved in testing a dud treatment are not available for more promising ones. Expenses wasted on ineffective therapies and uninformative trials result in higher drug prices. Investigators, host institutions and sponsors have a responsibility to consider all this before embarking on new research programmes.
Moreover, researchers have ethical obligations to “assure that the risks to subjects are reasonable in relation to the anticipated benefits”, according to FDA guidance. Such regulators explicitly delegate these appraisals to ethics review committees.
Basically, the problem is that drug developers can, in essence, cherry pick favorable preclinical evidence in order to make their case that a clinical trial should be allowed. The other problem is that regulatory agencies will accept weak evidence of efficacy in animal models. Basically, the three questions that have to be answered in assessing whether preclinical evidence justifies a FIH trial:
     1.  What is the likelihood that the drug will prove clinically useful? (In other words, have other similar drugs worked? What drugs already exist for the disease and how well do they work?)
     2.  Assume the drug works in humans. What is the likelihood of observing the preclinical results? (How robust and reproducible are the preclinical data? How large are the effects observed? Do the animal models used reflect human disease well enough?)
     3.  Assume the drug does not work in humans. What is the likelihood of observing the preclinical results? (How do we know that the preclinical observations aren’t due to random variation and bias?)
To address these questions and existing problems, the authors propose the following:
    • Require drugs sponsors to include negative results from animal studies in documents submitted to investigators and ethics committees. This is similar to the approach of All Trials in that greater transparency is recommended. Just as drug companies should have to report the results of negative preclinical trials, it only makes sense to apply the same standard to preclinical evidence submitted to support a FIH clinical trial. It’s even suggested that an additional way to discourage data cherry-picking would be to require that drug sponsors sign a statement testifying that the clinical and preclinical evidence presented on clinical promise is complete and unbiased.
    • Encourage reviewers to consider a broad base of evidence in assessing the probability that a drug will prove clinically useful: for example, how have other drugs in the same class performed in trials? One important part of any application, be it for a grant or for approval of a clinical trial is the “Background and Significance” section. That is the part of the application where the applicant summarizes the existing evidence base supporting the application, discusses shortcomings in current knowledge and potential controversies, and makes the case for the significance of what is proposed before presenting the applicant’s own preliminary data supporting the proposal. It’s very easy to cherry pick studies that are positive and leave out studies that are negative. If the reviewer examining the application is not very familiar with the field, he could easily be unaware of the information left out. Similarly, it makes sense not to consider a drug in isolation. If another member of the class of drugs as an experimental drug being considered for a clinical trial failed its clinical trials, it’s important to make a case for why this experimental drug is different, why this drug is expected to succeed where the others in its class failed.
    • Allow trials to proceed only after careful vetting of the preclinical evidence by independent experts. See above. Basically, in order to detect cherry picking and evaluate the evidence with a hard, cold eye, you need reviewers who are truly experts in the field and who have no vested interest in whether the FIH clinical trial proceeds or not.
Of course, all of this would require more investment. For example a new centralized FIH system is proposed:
Instead, we suggest the creation of a centralized FIH advisory system that combines ethical and scientific review. Several precedents exist. The Recombinant DNA Advisory Committee (which reviews new gene-transfer protocols) has assessed evidence of both risk and efficacy since it began reviewing human gene-transfer studies in 1989. Further examples of centralized, expert review of clinical trials in the United States include the SMART IRB Reliance Platform at the National Center for Advancing Translational Sciences; the National Cancer Institute’s Central IRB; and the Office for Human Research Protections’ ‘407 review process’ for certain paediatric trials.
The FIH advisory mechanism we envision would consist of subcommittees that specialize in clinical areas (for example, neurodegenerative disease, cancer and cardiovascular disease). Advisory-committee assessments would, like most of the above examples, be included in materials presented to physician–investigators and local ethics committees.
The authors anticipate some criticisms. For example, setting up a system like this would cost money. Their response is that such a review system might actually decrease cost and burden to the pharmaceutical companies, through the prevention of clinical trials unlikely to show a positive result by insuring a more sound basis for late-stage clinical trials, thus offsetting the cost at least partially.
Another anticipated criticism is exactly the sort of argument several of Trump’s candidates for FDA Commissioner make, namely that such a system could prevent truly promising candidates from being tested. Of course, I can’t help but point out that I’d be hard pressed to consider a candidate to be “truly promising” if the preclinical evidence supporting it is weak and or the effect size of the compound is small in animal models. The authors note:
However, we are not arguing that the preclinical evidence must be strong, rather that it be examined critically to inform ethical judgement. For diseases in which robust preclinical evidence is impossible — for instance, where animal models are clearly inadequate as in many neurodegenerative disorders — a limited suggestion of clinical promise might be enough to justify trials for a relatively benign drug candidate aimed at a great unmet medical need.
In other words, as I mentioned above, we need to look critically at all the evidence for new drugs and put it in the context of the seriousness of the disease, whether effective therapies already exist, and existing science and evidence.
Joseph Gulfo: Use biomarkers, not overall survival, to show drug efficacy
As I’ve discussed before, much of philosophy behind the Trump administration’s approach to the FDA seems to be based on a technolibertarian fantasy that, if only the “heavy hand” of government regulation were removed from entrepreneurs and industry, the cures would flow and the free market would sort out which drugs do and don’t work. That is not surprising, given that Peter Thiel, who’s never met a regulation he didn’t hate, appears to be having an outsized influence on whom Trump will nominate for FDA Commissioner, so much so that, ironically, I’m actually hoping for the pharma shill to be chosen rather than the Thiel cronies who want, in essence, to dismantle the FDA. The FDA could survive Scott Gottlieb (indeed, it already has). I don’t know if it could survive Jim O’Neill or Balaji Srinivasan. But what about Joseph Gulfo, whom I haven’t discussed before?

Joseph Gulfo doesn’t (quite) fit the mold of the Thiel cronies and was dismissive of Scott Gottlieb, even saying, “If you want safe snake oil, Jim O’Neill’s your man.” He also believes that the FDA should require evidence of efficacy before approving a drug. The problem is, though, that he defines “efficacy” differently from how the FDA does. Basically, he redefines efficacy by using a lower standard of evidence. In a WSJ editorial written in November, “A Trumpian Cure for the FDA’s Chronic Lethargy“, he explains:
The first change involves returning the FDA to its original role under the law. That is to prevent snake oil from getting on the market by ensuring that the only drugs approved for sale have demonstrated biological activity in fighting a disease and can be labeled for safe use. The FDA would no longer require approvals based on long-term health outcomes—a practice that dissuades development and increases the complexity, cost and duration of clinical trials.
This argument sounds at least semi-reasonable on the surface, but has huge holes in it, as you will see. You will also see that there is at least one area where Gulfo does fit in with the Thiel crony contingent:
This revision would pave the way for products proven safe and effective to be made available to determine which are most beneficial for individual patients. Patients and their physicians, not the FDA, need to make private health decisions; the Internet of Things would ensure that they have the best information to make these choices.
What is it with this touching faith in technology to fix all the problems in drug development that so many share?
But let’s get back to what, specifically, Gulfo means by returning the FDA to its original role:
The way to return the FDA to its proper role is to pass legislation that defines effectiveness categories for the agency, such as:
How the drug affects biomarkers, such as the lowering or raising of blood-test parameters associated with disease, e.g., glucose levels, blood coagulation parameters, and cancer proteins. How it affects clinical signs and symptoms, e.g., blood pressure, tumor-shrinkage, pain, fever and infection. How it affects disease modification, e.g., prevents joint damage, relapses of multiple sclerosis or migraines. And how it affects long-term outcomes, e.g., survival, stroke and heart attack.
These categories would form the basis of approval, and the labels would be color-coded so that physicians and patients know precisely the nature of the clinical evidence used to prove that the drugs are effective and what to expect when using them.
Yes, he wants to color code FDA-approved drugs based on the level of evidence—because there’s no way that can go wrong, right? In a more recent interview, Gulfo makes similar arguments.
None of this is a new debate, actually. In oncology, for instance, we’ve been debating over whether drugs should have to show a benefit in overall survival (OS) in order to be approved for at least two decades. Cancer therapies are generally evaluated using a number of endpoints. The most commonly used include OS and progression-free survival (PFS). OS is what it sounds like: How long do patients survive their cancer after diagnosis? Period. It’s hard for an endpoint to be more objective than that: Either the patient is alive or he is dead. This number is usually expressed in terms of median survival, which is the period of time after which half of the patients under study are still alive and half have died. This includes all causes, not just cancer. If a patient with cancer under study dies of a heart attack that is not related to his cancer or his cancer treatment, that counts. Traditionally, OS has been the “gold standard” endpoint in measuring the efficacy of a cancer therapy, because the primary goal has been to prolong survival, the ideal case being prolonging survival to the point where it is indistinguishable from life expectancy if the patient never had cancer in the first place. PFS is survival without progression; i.e., how long the patient with cancer survives before his or her tumor starts measurably growing again or metastasizes. While PFS is often measured as well as OS, it’s generally considered less useful because it is entirely possible for a treatment to prolong PFS without prolonging OS. This sort of result can happen when the treatment is effective at shrinking a tumor or slowing its growth but its toxicities can result in death. Thus, PFS can improve with no improvement in OS.
I mention this distinction because several years ago, the FDA approval for Avastin to treat metastatic breast cancer was revoked because it had been based on studies showing improvements in PFS but later studies failed to show an improvement in OS in a later study. I discussed the case in detail in 2010, if anyone’s interested. The point is that short term surrogate markers often don’t correlate with long term health outcomes. Sometimes they do. For instance, pathologic complete response (pCR) of breast cancer to chemotherapy (in which a tumor melts away completely, so that not even a single cell is detected when the area where the tumor was is resected) does correlate with long term survival, so much so that the FDA proposed allowing the use of pCR as a surrogate endpoint in clinical trials for the accelerated approval of drugs targeting breast cancer, although more recent work has suggested caution and pointed out that only in certain subtypes of breast cancer does the surrogate endpoint of pCR appear to predict OS.
Yes, again, it’s complicated. John LaMattina over at Forbes.com points out the major holes in Gulfo’s plan:
Let’s take Alzheimer’s Disease (AD). Just last week, Lilly reported very disappointing results for its AD drug, solanezumab, which failed in a long-term clinical trial. The drug was essentially safe, but it just didn’t work. Under Dr. Gulfo’s plan, solanezumab would have been approved years ago based on its effects on biomarkers and millions of desperate people would have taken it in the hopes that it would have halted or delayed the consequences of this ravaging disease. Furthermore, the healthcare system would have paid at least hundreds of millions, if not billions, of dollars for what essentially is a placebo. Under the Gulfo Plan, patients would have felt betrayed and cheated had they been taking an ineffective drug for five years or more, regardless of whatever color was on the label.
Didn’t Gulfo criticize Gottlieb as someone who’d approve a bunch of “safe snake oil”? Well, that’s basically what Gulfo’s plan would do—and likely to an even greater extent! That’s not all:
Furthermore, the importance of demonstrating real-world effectiveness is not just limited to AD drugs. There are drugs that were believed to be the ultimate answer for treating heart disease–the CETP inhibitors, developed by Pfizer, Roche and Lilly–that simultaneously raised “good cholesterol” (HDL) and lowered “bad cholesterol” (LDL). By totally remodeling one’s lipid profile, these drugs were hoped to be the answer in preventing heart attacks and strokes. Again, the Gulfo proposal would have had these drugs on the market for years before long-term cardiovascular outcome studies showed that not only were these drugs ineffective in reducing cardiovascular disease, but that they could actually be harmful despite the fact that these drugs more than doubled HDL levels and, in combination with statins, lowered LDL levels by 50-60%. Such activity was unprecedented and had heart patients and cardiologists very excited. Had these drugs been approved based solely on lipid modulation, their sales also would have been in the billion-dollar range. Yet, they ultimately offered no benefit to patients.
Yes, as LaMattina notes, not all drugs that shrink tumors prolong survival (Avastin for breast cancer) and not all drugs that lower blood glucose prevent the end complications of diabetes. Just because a drug changes your biomarkers doesn’t necessarily mean it’s improving your health. Yes, shortcuts are tempting. What researcher wouldn’t want to be able to do a two year trial based on surrogate endpoints and biomarkers instead of a ten year trial looking at long term health outcomes if the surrogate endpoints and biomarkers predict the long term health benefits? The problem is that, far more often than people like Gulfo seem to think, they don’t.

The FDA is almost certainly going to go in the wrong direction
Kimmelman and Federico lay out a persuasive case that there is insufficient attention paid to the robustness of preclinical evidence by the FDA and European regulatory agencies and that something should be done to correct this problem. Unfortunately, here in the US under President Trump, we are poised to go in exactly the wrong direction, thanks to a faith-based belief in the almighty power of the free market and an unrelenting hostility to even justified government regulation. No matter whom Trump appoints as FDA Commissioner, we can expect the level of clinical evidence necessary to approve drugs to become less rigorous, at least as much as current law allows, and we might even see legislation passed to make the approval of drugs even easier, in essence building on what the 21st Century Cures Act did. A new FDA Commissioner could undo regulation in several ways without Congressional approval though; e.g., by interpreting existing regulations as loosely as possible, so that requirements for certain clinical trials—especially large-scale ones that can take years and involve thousands of patients—can be weakened or eliminated. Ironically, the most effective way to speed up drug approval would be to add staff, not cut it; yet there’s no sign that the Trump administration has plans to do that.
I concede that a reasonable argument can be made for a drug that impacts surrogate endpoints but not long term health outcomes if it significantly improves patient quality of life. In oncology, for instance, it is sometimes argued that if a drug improves PFS, but not OS, it should be approved if it improves patient quality of life. (Unfortunately, in the case of Avastin, the evidence for improved quality of life was very weak.) However, that is not the primary argument being made by Gulfo, and it’s not the argument being made by any of Trump’s other candidates known to be under consideration for FDA Commissioner. All of them, particularly the Silicon Valley contingent under the thrall of Peter Thiel seem to think that an overly strict FDA is the key impediment to innovation, when in fact it is primarily the limits of our knowledge. Computer developers control the hardware and software. Medical researchers do not have that advantage, but technolibertarians keep making simplistic analogies to computer development when discussing drug development.
If the preclinical evidence requirements for efficacy are already too low, then lowering the clinical requirements for efficacy (e.g., by approving drugs based only on biomarker changes) will be an even bigger disaster than I thought before, because more ineffective drugs would be approved. Given that no drug is completely safe, the approval of such drugs could then result in harm and expense with no benefit. No one, least of all I, is saying that the FDA is perfect or that there aren’t ways of streamlining the FDA approval process, even though it is already fast compared to European agencies. Moreover, the FDA has already started to adapt to new science by incorporating biomarkers and new trial designs for precision medicine into its approval process. Dramatically decreasing the bar that new drugs have to clear to be approved is not the answer to developing treatments and cures for deadly diseases. It’s as though the Trump administration assumes that more and faster drug approvals will translate into better health when they would be unlikely to benefit patients and more likely to result in more expense and harm.

Government watchdog warns about paid physician speeches touting drugs and medical devices
Paid speeches at lavish events touting drugs and medical devices risk charges of anti-kickback law violations, warns a recent government Special Fraud Alert. Will companies and doctors take heed this time?
Jann Bellamy on December 3, 2020
Link

Last month, the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS) issued a rare Special Fraud Alert highlighting the fraud and abuse risks associated with paid speaker programs offered by drug and medical device companies. In the last 3 years, according to the OIG, these companies have paid nearly $2 billion to physicians and other health care professionals (HCPs) for speaking about a drug or device at company-sponsored events. In certain circumstances, such arrangements can violate the federal anti-kickback statute.
The anti-kickback law is designed to protect patients from health care providers whose decision-making, such prescribing a particular drug or medical device, may be influenced by inappropriate financial incentives. It is a criminal offense to knowingly offer or receive anything of value in exchange for referrals for, or orders of, products or services paid for by a federal health care program. These programs include big spenders like Medicare, Medicaid, and Tricare, the military’s health insurance program. Convictions can result in jail time, fines, and exclusion from federal health care programs. The government can also pursue civil actions for anti-kickback law violations.
The anti-kickback law targets not only companies offering, and speakers receiving, remuneration, but attendees at these events as well. Not only is there no free lunch, accepting that wine-and-dine at a high-end restaurant compliments of a drug company could end up costing the diner a lot more than its worth.
The pharmaceutical industry trade group PhRMA describes these events as health care professionals participating “in company-sponsored speaker programs in order to help educate and inform other health care professionals about the benefits, risks, and appropriate uses of company medicines”. The OIG says it is “skeptical” about their educational value:
Our investigations have revealed that, often, HCPs received generous compensation to speak at programs offered under circumstances that are not conducive to learning or to speak to audience members who have no legitimate reason to attend. Such cases strongly suggest that one purpose of the remuneration to the HCP speaker and attendees is to induce or reward referrals. Furthermore, studies have shown that HCPs who receive remuneration from a company are more likely to prescribe or order that company’s products. This remuneration . . . may skew their clinical decision making in favor of their own and the company’s financial interests, rather than the patient’s best interest.
The Special Fraud Alert listed characteristics of a speaker program that might indicate a violation of the anti-kickback statute. (In a moment, we’ll find out how one pharmaceutical giant would appear to have used this list as a playbook to get itself nabbed by the feds.) The list includes:
    • Little or no substantive information is presented at the program.
    • Alcohol or a meal exceeding modest value is provided to attendees (“the concern is heightened when alcohol is free”).
    • The program is held at a location not conducive to the exchange of educational information, such as restaurants or entertainment or sports venues.
    • The company sponsors a large number of programs on the same or substantially the same topic or product, especially in the absence of substantive changes in relevant information, such as when a significant period of time passes with no new scientific information or a new FDA-approved indication for the product.
    • Health care professionals attend programs on the same topics more than once, either as a repeat attendee or as an attendee after being a speaker on the same topic (an almost comical example of which we’ll get to in our discussion of the scofflaw pharmaceutical company).
    • Attendees include those who don’t have a legitimate business reason to be there, such as friends, family members, and staff of facilities for which the speaker is medical director.
    • Sales and marketing departments influence speaker selection, or speakers or attendees are selected based on expected revenue they will generate by prescribing or ordering the company’s products.
    • Speakers are paid more than fair market value or based on the value of past or future business generation.
A law firm specializing in drug and device law, noting that Special Fraud Alerts are rare (only 5 issued in the last 20 years), warns that OIG has “historically used Special Fraud Alerts to put providers on notice of what it considers to be potentially violative” of the anti-kickback statute and that the Alerts often suggest where the government will focus its enforcement and litigation strategies.
Whose turn is it to be paid speaker?
I can see why the OIG might find a stern warning necessary, seeing as how pharmaceutical companies don’t seem to be getting the message from being pursued in court by the government with allegations of anti-kickback law violations arising from speaker programs and similar promotional events. In December, 2019, Teva settled with the government for $54 million to resolve claims that it induced doctors to write prescriptions for the company’s multiple sclerosis and Parkinson’s disease drugs by paying them in connection with sham speaker programs and like events. In 2013, Amgen paid almost $25 million in a settlement with the government addressing, among other skullduggery, an illegal kickback scheme that included dubious speaker events. The government has also pursued cases alleging improper remuneration to doctors via promotional events against Bristol-Meyers Squibb, GlaxoSmithKline, Biogen Idec, Forest Labs, Cephalon, and Pfizer.
In 2010, the Department of Justice announced that pharmaceutical giant Novartis had agreed to pay over $400 million to resolve criminal and civil liability arising from the illegal marketing of its drugs, including claims that the company tried to “cloud physicians’ medical judgment through kickback practices and illegal promotional activities”. As part of that settlement, Novartis also signed a Corporate Integrity Agreement committing to more stringent internal oversight and transparency. At the time, the HHS Inspector General said that
OIG will carefully monitor the Corporate Integrity Agreement to ensure that Novartis is more transparent in its business transactions, that its Board of Directors is held more accountable, and that the names of physicians receiving payments are publicly disclosed . . . The result will be stronger protections for patients and the nation’s taxpayers.
Maybe so. But, as the OIG was about to discover, there was even more nefarious activity going on at Novartis.
The very next year, in 2011, a whistleblower filed a civil case in the U.S. District Court for the Southern District of New York, joined by the government in 2013, alleging that, between 2002 and 2011, Novartis paid kickbacks to doctors to induce them to prescribe several more Novartis drugs, these for hypertension and diabetes. That case was just settled in June of this year. The settlement requires Novartis to pay close to $600 million to the federal government to resolve the kickback charges, as well as almost $40 million in civil forfeitures and $48 million to several states. (A separate settlement resolved allegations that Novartis illegally used three foundations as conduits to pay the copayments of Medicare patients taking the company’s drugs.)
According to a Justice Department press release announcing the settlement agreement, the complaint alleged
that Novartis hosted tens of thousands of speaker programs and related events under the guise of providing educational content, when in fact the events served as nothing more than a means to provide bribes to doctors. Novartis paid physicians honoraria, purportedly as compensation for delivering a lecture regarding a Novartis medication, but, as Novartis knew, many of these programs were nothing more than social events held at expensive restaurants, with little or no discussion about the Novartis drugs. Indeed, some of the so-called speaker events never even took place; the speaker was simply paid a fee in order to induce the speaker to prescribe Novartis drugs.
Several of the drugs promoted by Novartis at “educational” events had been on the market for years, indicating that new information about prescribing them was unlikely. Lotrel, for example, was approved by the FDA in 1995, Diovan in 1996, and Diovan HCT in 1998.
According to the settlement agreement, Novartis sales reps were evaluated in their performance reviews on how much of their promotional program budget they had used and failing to spend the entire budgeted amount could be a seen as a negative. Using prescribing data, some sales reps selected high-prescribing physicians as speakers at promotional events, intending the honoraria paid, which could amount to tens or even hundreds of thousands of dollars, to induce these doctors to continue to prescribe Novartis products.
For example, over the nine-year period covered by the agreement, Novartis paid over $320,000 to a physician who wrote over 8,000 prescriptions of Novartis drugs, and over $220,000 to a physician writing over 9,000 prescriptions.
More juicy details of the company’s profligate spending on “educational” programs appear under the heading “Excessive Meal and Alcohol Spend” in the agreement. Novartis sales reps conducted these programs “at venues where the focus was on entertainment, including fishing trips, sporting events, wine tastings, and hibachi tables” as well as “hundreds of events at wineries and golf clubs.” The list of restaurants reads like the Michelin Guide: among them, Masa, Daniel, Gramercy Tavern, Le Bernardin and Eleven Madison Park, all in New York City. On the other end of the spectrum, Hooter’s was an occasional venue as well.
Over 12,000 of these events exceeded Novartis’s own guidelines on expenditures of $125 per person. For example, a program at a Ruth Chris Steakhouse in Maryland, for which the speaker received a $1,000 honorarium, was attended by only one doctor, whose tab was almost $450. At some events, “doctors demanded expensive bottles of wine” and “sometimes consumed alcohol in large quantities . . . to the point of intoxication”.
At many of these events, according to the settlement agreement, there was little to no medical discussion. The sales rep host did not require the speaker, who was being paid an honorarium, to deliver a presentation or allowed the speaker to click through a power point in a few minutes. Sometimes the events didn’t take place at all. In New York, one sales rep organized fraudulent speaker programs by arranging for a restaurant to create fake receipts, then used the funds budgeted for the phantom events to buy gift cards for high-prescribing doctors. Doctors were paid honoraria for “speaking” at these sham events.
Novartis’s “marketing science group” would calculate the return on investment (ROI) from speaker programs and roundtables based on the number of new prescriptions for its drugs written by doctors in attendance. One analysis, for example, showed that “educational” events for the drug Lortel yielded an ROI of 1,200% for doctors attending more than one event.
To achieve sales goals, “many Novartis representatives would repeatedly invite the same doctors to attend promotional programs with the same title and for the same drugs.”
In thousands of instances, Novartis paid for the same group of doctors, often colleagues or friends, to have dinners together repeatedly . . . Doctors in these groups would sometimes rotate being the speaker and receiving the honorarium payment. For example, five doctors in Harrisburg, Pennsylvania went to more than 100 speaker program events at which some or all of the five doctors were in attendance over the course of five years, sometimes as often as five times a month. At these events, [they] would take turns being the designated speaker and receiving the honorarium payment.
Interestingly, the complaint in the case against Novartis lists numerous incidents that, like the one described, are of dubious educational value but identifies the doctors involved only by their initials. Thus, I was unable to find out whether these doctors were also pursued for civil or criminal liability by the government or excluded from any government health care programs. (It does happen: this year a Manhattan physician was sentenced to 5 years in prison for his participation in a “speakers bureau” designed to promote Subsys, a powerful painkiller which can cost thousands of dollars a month.)
Novartis also entered into another Corporate Integrity Agreement with the HHS OIG. The company is prohibited from holding any speaker events at restaurants and serving, or allowing the sale of, alcohol at any event. The speaker program budget is limited to $100,000 for any one product or indication for using that product, and a total of $10,000 per speaker for any one drug or indication. (This takes into account the fact that some drugs are used for more than one condition.) Speaker events must be held within 18 months of government approval for a product or indication for the product’s use.
In light of this repeated egregious conduct, it is understandable that the HHS OIG would find it necessary to issue the rarely used Special Fraud Alert to send a message to drug and device manufacturers. Whether it will do any good remains to be seen.
I find these payments to doctors and other providers for bogus educational activities troubling for the same reason the government does: they can cloud the physician’s medical judgment and cost taxpayers, who pay for federal health care programs. I’d add that they undermine public trust in the medical profession and provide fodder for alternative medicine proponents, who use distrust of physicians as a marketing tool for their nostrums.

The FDA vs. Compounding Pharmacies: GLP-1 Edition
The FDA is determined to stop the sale of compounded GLP-1 drugs
Scott Gavura on July 30, 2026
Link

This past June, the FDA sent out 25 warning letters to telehealth companies selling compounded semaglutide and tirzepatide.This is the third enforcement wave in less than a year, following a batch of 30 letters in March, and more than 55 letters in September 2025.
Three waves of warnings in less than twelve months tells us a few things: this is a pervasive issue; the first two rounds of warnings didn’t fix the problem, and the FDA is determined to address this issue.
The targets aren’t backwater dispensaries. They are polished, direct-to-consumer (DTC) telehealth marketing companies with slick websites.
This story is often framed simply as “FDA crackdowns on counterfeit weight-loss drugs.” But from a pharmacy and regulatory perspective, the real issue is more subtle and is clearly having an effect: the deliberate creation of a “misleading net impression” that compounded peptides are equivalent from a safety and effectiveness perspective to FDA-evaluated and approved generic drugs. They are not.

What is a “compounded” drug?
I’ve discussed compounding before. Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved medicines.These products underwent clinical testing to evaluate their safety and effectiveness, and the FDA reviewed the clinical, safety, quality, and manufacturing data. FDA approval also means that the manufacturing facilities and processes meet strict regulatory standards, designed to ensure that products are consistently manufactured, and meet established specifications for quality, purity, strength, and potency. The FDA also reviews evidence demonstrating that the commercially manufactured product is comparable to the product used in clinical trials (which may have been made under very different circumstances). Together, these requirements provide confidence that the evidence from those clinical trials is directly relevant to the marketed product. Clinicians and patients can therefore expect similar benefits and risks to those that were observed in the research, while recognizing that real-world effects may differ.
A compounded version of semaglutide or tirzepatide may contain the same active ingredient as the approved drug, but it is not the drug that was reviewed and approved by the FDA. The FDA does not independently evaluate specific compounded products for safety, effectiveness, manufacturing quality, or consistency. This does not mean that a compounded product is unsafe, but it does mean that patients must rely on the standards and practices of the compounder rather than the extensive review and oversight that support an FDA-approved medicine.
The widespread compounding of semaglutide and tirzepatide in the past was permissible under FDA drug shortage provisions. Under U.S. law, “503A” pharmacies may compound patient-specific prescriptions, while “503B” refers to outsourcing facilities permitted to compound medications in larger quantities for healthcare providers and institutions. Under certain circumstances, both may compound products that contain the same active ingredient as FDA-approved drugs when those drugs appear on the FDA drug shortage list. Semaglutide and tirzepatide were compounded on a large scale because Wegovy, Ozempic, Zepbound, and Mounjaro faced supply shortages due to overwhelming demand. These provisions were intended as a temporary response to supply disruptions, not as a means for patent circumvention and production of approved medicines.
It’s notable that the FDA announced on May 1, 2026, that it proposes not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List, concluding that the evidence did not demonstrate a clinical need for outsourcing facilities to compound these drugs from bulk active ingredients. (The public comment period has been extended to July 30, 2026.) This remains a proposal rather than a final determination, but if finalized, it will eliminate the principal 503B bulk-compounding pathway that has supported much of the large-scale telehealth GLP-1 compounding market.
The FDA has taken an even stricter position with retatrutide and cagrilintide. Neither drug has been approved by the FDA, and neither appears on the agency’s drug shortage list. A product that isn’t approved cannot be in short commercial supply, so there is no regulatory pathway for routine compounding of these products. Unlike semaglutide or tirzepatide, there is no FDA-approved reference product whose safety, effectiveness, manufacturing quality, and labeling have been reviewed by regulators. Products marketed as compounded retatrutide or cagrilintide are consequently fully outside this framework for approved prescription drugs and shortages.
The “misleading net impression” problem
The legal hook FDA is using across all three enforcement waves is a longstanding advertising framework called misleading net impression. In short, you can’t build a misleading claim out of technically true pieces. If your website says “FDA-approved active ingredient,” shows a product photo with your own company’s name on the label, and describes your product’s outcomes as “the same” as the branded drug, none of those statements individually needs to be false for the overall impression to be false. Consumers will be left with the impression they’re getting a product that’s FDA approved, when that’s not the case.
One letter in June 2026 flagged marketing language describing a “body safe vitamin such as B12” added to a compounded semaglutide product, language that implies a formulation decision backed by some sort of clinical rationale. Others flagged product labels bearing the marketing company’s own name or clinic branding, which under FDA’s labeling rules is itself a representation that the named party is the manufacturer, when in fact they’re simply a marketer, sourcing product from a compounding pharmacy the consumer doesn’t see named.
The Surveillance Gap
As of May 2026, the FDA had logged more than 1,700 adverse events tied to compounded semaglutide and tirzepatide. As we don’t have a reliable denominator, there’s no way to compare it against an adverse event incidence rate for the FDA-approved products. With compounded products there is no manufacturer-mandated monitoring and reporting obligations, so any reporting is patients and prescribers doing it voluntarily. What this signals is that drug products with effectively no formal post-marketing monitoring have still generated over 1,700 reports. It’s certainly a fraction of the actual adverse events – there is no way to know what the actual number is.
The Exception that Became the Business Model
There is a legitimate, narrow purpose for compounding these drugs: a genuine, FDA-recognized shortage, filled temporarily by a licensed 503A or 503B facility compounding a chemically identical product under quality standards, with clarity that the product is not the same as an approved drug. That is not what these companies appear to be marketing. It’s access, convenience, and a lower price point, wrapped in the apparent veneer of FDA oversight, sold to consumers who may not appreciate the difference between “compounded because of a legally recognized shortage” and “compounded because it’s profitable and enforcement has been limited.” Three enforcement waves in under a year suggests FDA has noticed the gap between those two things, and they are determined to close it.


Department of Justice prioritizes prosecution of clinical trial fraud, but systemic reform is needed
The U.S. Department of Justice recently announced it is aggressively pursuing clinical trial fraud, where unethical players create fictional trial participants, steal the drugs under study, and fabricate results. But systemic reform of the clinical drug trial system is needed to halt those who endanger public safety with bogus trials.
Jann Bellamy on January 13, 2022
Link

A top health fraud prosecutor recently announced that clinical trial fraud will be a major priority of the U.S. Department of Justice (DOJ). Speaking at a Food and Drug Law Institute conference last month, Deputy Assistant Attorney General Arun Rao characterized the DOJ’s enforcement of clinical trial fraud cases as “aggressive”, citing two recent actions we’ll return to in a moment.
In his remarks, Rao noted that
[f]raud in clinical trials poses significant risks to the American public. The FDA relies on the veracity of clinical trial data when making drug approval determinations, with the ultimate goal of ensuring that all FDA-approved drugs are safe and effective for their approved indications. Fabricated clinical trial data can have dangerous consequences if relied upon by the FDA, drug researchers and medical doctors when making material decisions about the safety, efficacy and clinical use of drug products.
Rao supervises the DOJ’s Consumer Protection Branch, which brings criminal and civil actions to enforce health and safety-related laws, including the Food, Drug and Cosmetic Act.
SBM has covered dodgy clinical trials from the beginning, many involving “alternative” treatments that had no business being studied in the first place, such as the “Gonzalez Regimen” for cancer, Burzynski’s “antineoplastons”, what seems like umpteen thousand acupuncture trials, and most recently David Weinberg’s critique of US Stem Cell’s dubious efforts. Here, though, as much as we might wish the Department of Justice would show some interest in such matters, we’re talking about the more traditional type of fraud where, in a riff on the illegal drug trade, proceeds from fake studies of legit drugs are used to purchase luxury vehicles in South Florida.
The “Unlimited Medical Research” that wasn’t
According to the DOJ, Unlimited Medical Research, a Miami, Florida, company, was one of several firms hired by a pharmaceutical firm (identified elsewhere as GlaxoSmithKline [GSK]) to conduct a clinical trial designed to investigate the safety and efficacy of an asthma medication in children. From about 2013 to 2016, employees of the company falsified records to make it appear as though pediatric subjects made scheduled visits to Unlimited Medical Research, received physical exams from a clinical investigator, took study drugs as required, and received payments for their participation. Actually, none of this happened: children were not given exams, they did not take the study drugs, and they were not paid. In fact, there were no children at all. Employees, including a medical doctor who served as the primary investigator for the trial, fabricated the entire thing in a scheme to defraud the pharmaceutical company. The doctor used patients’ personal information from her private medical practice to create false information to be entered into case histories for the trial.
The purpose of the study was to measure the long-term safety of the inhaled asthma medication Advair Diskus in patients 4-11 years old. Results were published in the New England Journal of Medicine. According to GSK, once it became aware of possible misfeasance by Unlimited Medical Research, it excluded the fraudulent data from studies and reports and reported its suspicions to the FDA and Institutional Review Boards, hence the prosecutions.
There’s more than meets in eye in that published study and GSK’s response to the fraud, as you shall see.
Five individuals were charged in the scheme. The medical doctor plead guilty to one count of conspiracy to commit wire fraud and was sentenced to 60 months in prison and ordered to pay a $174,000 forfeiture. The study coordinator also plead guilty to conspiracy to commit wire fraud and was sentenced to 30 months in prison. At least one other person is scheduled for trial this year.
In another case mentioned in Deputy Assistant AG Rao’s remarks, a Coral Gables, Florida, medical doctor, a nurse practitioner, and two others were charged last March in a six-count indictment with crimes including wire fraud and money laundering. According to the indictment, from 2014 to 2016, the defendants fabricated clinical trial data while working at a Miami medical clinic, Tellus Clinical Research. The fraudulent trials were for drugs treating opioid dependency, irritable bowel syndrome, and diabetic nephropathy.
The indictment charges that the defendants knowingly enrolled subjects that failed to meet eligibility requirements, falsified lab results and medical records, and falsely represented that the trial participants were taking the drugs under study when, in fact, they weren’t. Personal information from friends and family were used to create fake profiles of trial participants and the drugs under study were tossed. Payments from pharmaceutical companies were used, among other things, to purchase a Land Rover.
Three defendants have plead guilty. In August, the nurse practitioner was sentenced to 46 months in prison and his co-defendant to 30 months. Both were ordered to pay just over $2 million in restitution. The third defendant, who faces up to 20 years in prison, will be sentenced next week.
Two additional recent incidents of alleged criminal clinical trial fraud not mentioned in Rao’s speech came to light in researching this post, courtesy of an international group of experts who run Rxisk.org, which they describe as an
independent website where you can research prescription drugs and report a drug side effect — identifying problems and possible solutions when it might still be possible to intervene and find a solution.
In July, 2020, an Ohio federal grand jury returned a 19-count indictment against eight defendants who worked for a company called Clinical Research Solutions [CRS], charging them with a scheme to defraud eight pharmaceutical companies and the FDA. A trial is scheduled for July of this year.
According to the DOJ, the defendants, one of whom is an MD specializing in allergies and immunology, agreed with pharmaceutical companies (who are unnamed) to conduct clinical trials of various drugs. Per the indictment, the defendants broke the law by
enrolling subjects in clinical trials under fictitious names, enrolling past subjects without their knowledge, and enrolling other subjects who did not meet pre-established criteria. In addition, the defendants allegedly fabricated and falsified medical records, informed consent forms, and other documentation for fictitious study subjects. . . [The] defendants were able to enrich themselves in this scheme by billing the [clinical trials’] sponsoring agencies for the time and participation of these fictitious subjects.
These schemes, as despicable as they are, pale in comparison to clinical trial fraud carried out by Sami Anwar, who, between 2013 and 2018, according to the DOJ,
directed and carried out a conspiracy to have his companies fraudulently pose as legitimate human clinical research trial sites and provide of false clinical research trial data regarding drug safety and drug efficacy to dozens of drug companies and, through them, the Food and Drug Administration (FDA). The false clinical research data . . . included safety data on dozens of different drugs and medicines designed to treat a wide variety of diseases and conditions including, but not limited to, heart disease, diabetes, asthma, pediatric illnesses, adolescent smoking, cirrhosis, scabies, depression, and opioid addiction to name just a few, according the evidence presented at [his] trial, [which] . . . indicated that Sami Anwar and his companies received over $5.6 million dollars from the fraud.
Anwar, who trained as a doctor in Pakistan but was not licensed in the U.S., forged the signatures of actual doctors he employed, whom he instructed to falsify records to admit dozens of ineligible research subjects. They falsified electrocardiograms and vital signs, obtained blood specimens from Anwar’s employees or stole them from patients of his medical center, and fabricated trial participant diary entries. Anwar and his employees disposed of study medications, falsely recording them as having been administered per the trial protocol, and stole opioids intended for study subjects.
According to a local newspaper, a three-year-old girl, who actually had eczema, was enrolled in a study for a new topical medication for scabies. The medication left her permanently scarred. A teenager, enrolled in study of a smoking cessation drug that Pfizer researchers worried might increase suicidal feelings, was hospitalized for attempted suicide. Another man died while participating in two different clinical trials at the same time.
Employees testified at Anwar’s trial that he not only directed the fraud but engaged in threats, retaliation, and intimidation in order to hide his crimes. They testified that Anwar filed false police reports, made false allegations to the Washington State Department of Health and the FDA, threatened them at their homes and at work, slashed their tires, and stalked them in order to prevent them from cooperating with the authorities.
In 2019, a federal jury found Anwar guilty of 47 counts of wire fraud, mail fraud, conspiracy, fraudulently obtaining controlled substances, and furnishing false material information to the Drug Enforcement Administration. He was sentenced to over 28 years in prison and he and his companies ordered to pay more than $7.5 million in restitution and forfeitures, the judge remarking that that “the extent of the fraud is astounding” and that Anwar had “endangered countless lives”. Anwar has appealed his conviction.
How did they get away with it?
Blog posts on Rxisk.org, the website I mentioned earlier, offer an interesting insight into how such egregious fraud can happen in the first place:
[A]ll these people [charged with clinical trial fraud] were working for multinational drug companies, doing the kind of research that gets published in top peer-reviewed journals. The kind of research that your doctor and mine rely on when deciding what treatments we ought to have.
The frauds went undetected for years: CRS [the Ohio firm] worked for seven companies before the eighth one noticed something wasn’t quite right. Tellus Research [in Miami] hummed along unnoticed until the CEO, Ms. Font, used the company account to buy herself a Range Rover.
When FDA inspections finally closed down Zain Research, Sami Anwar simply opened a new research center, in the same small town, at the same address, and was hired anew.
How the hell did that happen?
The answer, according to the blog posts’ author, Johanna Ryan, is “Contract Research Organizations: the Ubers of clinical research”. Most pharmaceutical giants, she says, rely on Contract Research Organizations (CROs), large commercial brokers that recruit and manage the hundreds of local sites and doctors in a “gig economy” of medical research. CROs “offer help with everything from designing the studies to writing up the research papers and pitching the newly-approved drug to doctors”.
She compares the doctors in this system, who work as independent contractors, to drivers who transport passengers one day for Uber and pizza the next day for Door Dash. If the drive is dangerous or the pizza arrives cold, Uber and the pizza parlor can deny responsibility, claiming it’s the driver’s fault. Likewise, she says, contract doctors provide similar plausible deniability for pharmaceutical companies. Thus,
when Dr. Bencosme [of Unlimited Medical Research] was arrested, the system allowed GSK to position themselves as victims not suspects. “As soon as we became aware of possible clinical trial fraud we conducted an internal investigation; excluded the data from the studies and reports, and reported the potential fraud to the FDA,” they told reporters. Parexel [the CRO managing the trials for GSK] for its part, sniffed that it had “no affiliation” with Unlimited Medical Research.
But it was Parexel who signed up Dr. Bencosme, as well as the Ohio doctor charged with fraud, to conduct the drug trials in the first place.
As for that NEJM article publishing the study results, Ryan points out it is unlikely that any of the authors in academic medicine
actually gave an inhaler to a patient and watched what happened. They simply signed off on the results of research done by 530 or so local doctors [in 32 countries]: some skilled, some unskilled; some extremely ethical, some not exactly.
It’s good to know that the DOJ is prioritizing clinical trial fraud, but if Ryan is correct in her analysis, the drug trial system is ripe for abuse by unethical players. Until that system is reformed, the DOJ can only come in and mop up the crime scene, and that’s only for the ones who get caught.

   Avastin and metastatic breast cancer: When science-based medicine collides with FDA regulation
David Gorski
Link
One of the most frustrating aspects of taking care of cancer patients is that in general, with only a few specific exceptions, we do not have good curative therapies for patients with stage IV cancer, particularly solid tumors. Consequently, patients with stage IV disease are viewed as “incurable” because, the vast majority of the time, they are incurable. Over the years, we have thrown everything but the kitchen sink at patients with stage IV disease, largely with dissapointing results. That’s not to say that the few specific exceptions to which I alluded are not a reason for hope. After all, patients with colorectal cancer and liver metastases used to have a median survival of around 6 months, but these days, with newer chemotherapeutic regimens like FOLFOX plus Avastin, median survival has more than tripled. While expecting to live less than two years is cold comfort to cancer patients with this particular clinical situation, the prognosis is far better than it was.
Of course, I specifically mentioned Avastin because it’s been in the news a lot recently with respect to my area of clinical specialty, breast cancer. Specifically, beginning in July there started appearing a spate of stories about the FDA considering revoking the approval of Avastin for advanced breast cancer based on recent studies that demonstrate that it does not prolong survival in these patients. Many lay people and patients find this reconsideration of Avastin to be quite puzzling, given that the drug was granted accelerated approval in 2008 and has since gone on to be used fairly widely. Given that the case of Avastin in breast cancer is rapidly becoming a classic case study of how messy science-based medicine can be when practiced in the public eye and debated among pharmaceutical companies, the government, and patient advocacy groups.
The promise of angiogenesis inhibitors
Avastin (generic name: bevacizumab) is a class of drug that attacks cancer by attacking its blood supply. Basically, Avastin targets a protein called vascular endothelial growth factor (VEGF), which is growth factor that stimulates the cells lining the blood vessels to undergo a process of angiogenesis, sprouting out new blood vessels in the direction of the cells secreting VEGF. Angiogenesis is a normal physiological function used during embryogenesis and pregnancy, wound healing, during the proliferative phase of the female menstrual cycle, and a variety of other processes. Diffusion of oxygen and nutrients through an aqueous medium is limited to around 1 mm, and malignant tumors get around this limitation by hijacking the normal process of angiogenesis by secreting large amounts of pro-angiogenic factors like VEGF in order to provide themselves with the oxygen and nutrients that they need to grow. During the 1990s, largely inspired by the work of one of my scientific heroes, Judah Folkman, scientists discovered strategies to target the process of angiogenesis to treat cancer. After spectacular results in mouse models of various cancers, however, as is all too often the case the use of angiogenesis inhibitors in humans produced far less dramatic results and, in some cases, didn’t work at all. However, for some cancers, such as colorectal cancer, combining Avastin with conventional chemotherapy has been effective. To those of us “in the biz” since the mid-1990s, this is not a revelation or surprise. In fact, I was involved with some of the first research demonstrating that combining anti-angiogenic therapy with radiation resulted in synergistic anti-tumor effects.
Over the last decade, Avastin has tended to be a magnet for controversy. The major reason that Avastin has attracted a lot of attention is that it’s so expensive (up to $100,000 a year per patient), and part of the reason it’s so expensive is that it is a protein rather than a small molecule. Basically, Avastin is an antibody directed against human VEGF. More specifically, it’s a humanized monoclonal antibody against VEGF. What that means is that the antibody has been modified to get rid of most of the mouse sequences that can provoke an immune reaction against the protein in humans. In any case, developing and producing such a molecule, which is a large protein, are not cheap. Even so, there has been considerable criticism of Genentech, the manufacturer of Avastin, for allegedly overpricing it. In addition, Genentech has pulled some very questionable stunts to protect its profits with regard to some off-label uses of Avastin, for example, for macular degeneration.
Be that as it may, the number of uses of Avastin have expanded to a number of cancers, now including colorectal, lung, breast, and renal cell cancers. Perhaps the most controversial expansion occurred in 2008, when the FDA approved Avastin on what is known as the “fast track” for use in metastatic breast cancer. This allows certain promising drugs for life-threatening conditions to be granted in essence provisional approval quickly, so that patients can have access to them before the usual large phase III randomized, double-blind trials are completed. To understand why this decision was controversial and why it is now being reconsidered, a brief review of terminology is required.
How to evaluate an anticancer therapy
Cancer therapies are generally evaluated using a number of endpoints. The most commonly used include overall survival (OS) and progression-free survival (PFS). There are, of course, other endpoints related to survival that are measured, but these two are the most relevant for this discussion. Overall survival is what it sounds like: How long do patients survive their cancer after diagnosis? Period. It’s hard for an endpoint to be more objective than that: Either the patient is alive or he is dead. This number is usually expressed in terms of median survival, which is the period of time after which half of the patients under study are still alive and half have died. This includes all causes, not just cancer. If a patient with cancer under study dies of a heart attack that is not related to his cancer or his cancer treatment, that counts. Traditionally, OS has been the “gold standard” endpoint in measuring the efficacy of a cancer therapy, because the primary goal has been to prolong survival, the ideal case being prolonging survival to the point where it is indistinguishable from life expectancy if the patient never had cancer in the first place. PFS is survival without progression; i.e., how long the patient with cancer survives before his or her tumor starts measurably growing again or metastasizes. While PFS is often measured as well as OS, it’s generally considered less useful because it is entirely possible for a treatment to prolong PFS without prolonging OS. This sort of result can happen when the treatment is effective at shrinking a tumor or slowing its growth but its toxicities can result in death. Thus, PFS improves with no improvement in OS.
Which brings us to Avastin.
In 2008, that’s exactly the sort of data upon which the FDA’s fast track approval of Avastin was based. Back in 2005, the National Cancer Institute (NCI) announced that in a randomized trial Avastin combined with paclitaxel had increased PFS approximately 4 months over the use of paclitaxel alone. Eventually, by the time an FDA panel voted to approve Avastin in 2007, the E2100 study published in the New England Journal of Medicine had reported encouraging results that Avastin improved PFS in women with metastastic breast cancer. Unfortunately, E2100 also failed to find any benefit in terms of OS. Specifically, Paclitaxel plus Avastin significantly prolonged progression-free survival compared to paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001). Adding Avastin to paclitaxel also increased the objective response rate (36.9% vs. 21.2%, P<0.001). Unfortunately, however, the overall survival rate (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P=0.16). Complications were also more frequent in the group receiving Avastin. Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P=0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P=0.02), all complications common from antiangiogenic therapies, were more frequent in patients receiving paclitaxel plus Avastin. Infection was more common in patients receiving paclitaxel plus Avastin (9.3% vs. 2.9%, P<0.001).
These data were thin gruel indeed to approve Avastin for the indication of metastatic breast cancer, which the FDA did in February 2008. Although the increase in PFS was impressive, the lack of effect on OS was very disturbing, strongly suggesting that drug toxicity was "taking back" all the benefit the addition of the drug was providing against the cancer. However, based on a program to "fast track" promising drugs that was developed in 1990s, the FDA gave provisional approval to Genentech to market Avastin for metastatic breast cancer with the condition that Genentech had to perform additional studies to verify the results upon which the original approval had been based. At the time, there was a great deal of argument over whether this was a wise decision, particularly given how expensive Avastin is and the lack of evidence that it improved quality of life or overall survival. Indeed, I recall attending a talk at ASCO in June 2008 in which the approval of Avastin was strongly defended and the speaker (who it was now escapes me) attacked the use of OS as the basis upon which to approve drugs and argued that PFS should be enough, given the potential improvements in quality of life that can result from a longer period of time without tumor progression.
In the press at the time, Dr. Kathy Albain at Loyola University defended the approval of Avastin thusly:
Dr. Kathy Albain, a breast cancer specialist at Loyola University Medical Center in Maywood, Ill., polled colleagues and patients and found overwhelming support for approving drugs based on delaying tumor progression. It would be ideal to show that a drug also prolongs life, but that may not be realistic, she said. The reason is that when a woman’s cancer progresses, doctors change the drugs they use, hoping to slow the cancer. That dilutes any impact of the first drug — in this case Avastin.
Personally, although I can see where Dr. Albain is coming from, I’ve always been uneasy with this view. Yes, I can see the utility of a drug that slows tumor progression but does not prolong survival. However, I can see its usefulness in only one situation: There must also be good evidence that that drug also improves quality of life, evidence that was lacking for Avastin. In fact, the evidence that existed was suggestive of increased complications due to Avastin. Now, it may be a bit of a judgment call whether it is worth it to slow down tumor progression if there is no improvement in survival and there are drug-related complications, but I remained unenthusiastic about a drug that didn’t prolong OS but did appear to produce markedly more complications. How is that improving the quality of life of a cancer patient? I can also understand the argument, which was made in 2008, that perhaps Avastin benefits certain subsets of patients; we just don’t know who they are yet. My response to that would be that we should be doing the studies to identify those patients rather than exposing large numbers of women to the risk of the drug outside the auspices of clinical trials that could identify them.
The promise is not confirmed
In any case, the followup studies, known as the AVADO and RIBBON-1 trials were indeed performed, and the results published. The AVADO trial was a phase III randomized double-blind clinical trial (N=736 subjects) comparing docetaxel with docetaxel plus Avastin in women with stage IV HER2-negative breast cancer. Its results were less than impressive. While it did demonstrate a decrease in PFS due to the addition of Avastin, PFS did not improve anywhere near the five months it did in the E2100 trial; rather it improved from 8.2 months to 9.0 months, a mere 0.8 month or 24 days. As in E2100, there was no detectable effect on OS. There was, however, a troubling trend towards a shorter OS in women who received Avastin. Even though the difference was not statistically significant, women who did not receive Avastin survived a median of 31.9 months; those who received the lower dose survived a median of 30.8 months; and those who received the higher dose level of Avastin survived a median of 30.2 months. In contrast to E2100, in the AVADO study Avastin did not increase the toxicity of treatment measurably. In the discussion, the authors of the AVADO study concluded:
Taken together with the results of the E2100 study, these data suggest that the combination of bevacizumab with taxane chemotherapy should be considered as an option for the first-line treatment of HER2-negative MBC.
The initial results of the RIBBON-1 trial were reported at the American Society of Clinical Oncology (ASCO) meeting last year and were similarly disappointing. In the trial, Avastin was tested in a randomized, double-blind study enrolling 1,237 patients. Oncologists could choose from capecitabine, taxane, or anthracycline-based chemotherapy, and patients would be randomized to that plus or minus Avastin. The results were that Avastin improved PFS by 2.9 months when added to capecitabine, and 1.2 months when added to anthracycline-based chemotherapy. Again, there was no improvement in OS in women receiving Avastin. In fact, it was these studies that led the FDA advisory panel to vote 12-1 to revoke FDA approval for Avastin for use in breast cancer:
An FDA advisory committee voted 12 to 1 on July 20 to withdraw Avastin’s authorization for advanced breast cancer based on two new studies that the advisers concluded had not shown that the drug extends life. Not only that, the committee concluded that the studies indicated the drug slowed tumor growth for even less time — perhaps as little as about a month. “The vast majority opinion of the committee was that the drug was not doing very much, and what it was doing was more than offset by the negative,” said Wyndham Wilson of the National Cancer Institute, who chaired the committee. Avastin can cause a variety of potentially serious side effects, including blood clots, bleeding and heart failure. “In our best judgment, we did not feel this drug was safe to give relative to its benefits,” Wilson said.
The recommendation has been praised by many cancer experts and by advocates for breast cancer patients.
“The FDA should never have approved Avastin for breast cancer to begin with,” said Fran Visco of the National Breast Cancer Coalition. “We don’t see evidence of benefit, but we do see evidence of harm.”
I tend to agree, although I must admit that back in 2008 I was ambivalent about the FDA approval of Avastin rather than necessarily opposed to it. Now, I’m more of the opinion that the FDA would be justified, based on science alone, in revoking Avastin’s approval, although I can also understand, if not agree, with a lot of the multitude of opinions in the breast cancer oncology world regarding the FDA’s decision. However, there is more than science at work, which is why where the rubber hits the road practicing science-based medicine in intersection with public policy can be so messy and contentious. Just practicing SBM alone is contentious enough, but add a biotech company trying to protect its profits and expand its market, regulatory agencies trying to fulfil their mandate in the case of ambiguous data, and advocacy organizations trying, well, to advocate for their members, and the whole debate can turn into a huge kerfuffle in a hurry. In this case, the FDA is scheduled to make a final determination in September. In the meantime, patients receiving Avastin are afraid, because if the FDA revokes its approval using Avastin for breast cancer will become and off-label use, and insurance companies will no longer pay for it.
Politics intrudes
The whole controversy, where science, economics, politics, and dying cancer patients intersect in what are sometimes very ugly ways, is taking an even uglier turn, thanks to the entire healt insurance reform debate and the intrusion of partisan politics and the unrelenting opposition of Republicans to what they often derisively term “Obamacare.” The reason is that right wing bloggers have jumped on the bandwagon of criticizing the FDA’s decision on Avastin as “evidence” of the impending arrival of socialized medicine-style rationing, thanks, of course, to “Obamacare.” For example, Senator Dave Vitter (R-LA) characterized the decision thusly:
Reviving allegations of government death panels, Sen. David Vitter of Louisiana said Wednesday that an FDA advisory panel’s negative recommendation on a contested breast cancer drug amounts to rationing health care. “I shudder at the thought of a government panel assigning a value to a day of a person’s life,” Vitter said in a press release about the drug Avastin. “It is sickening to think that care would be withheld from a patient simply because their life is not deemed valuable enough.”
Several right wing and rightward-leaning blogs, such as Red State, Hot Air, and Big Government characterized the decision as the FDA being made complicit in “rationing” health care. Perhaps the most despicable post I’ve seen about the matter is this one by Moe Lane at Red State, entitled Obamacare worth 17.5K dead women a year? This is, of course, utter demagoguery of the most vile and despicable sort, as my previous discussion of the evidence demonstrates and the simple observation that Avastin, even under the most optimistic scenario imaginable, only prolongs disease-free survival; it does not save lives of breast cancer patients, at least not as far as we can tell. Also at Red State, Ed Morrissey resorted to exaggerating the benefits and downplaying the results of clinical trials that failed to find much, if any, benefit and did find potential evidence of harm, even going so far as to accuse the FDA thusly:
With the new ObamaCare regime in place, the issue of cost has now become openly part of the FDA process. This is a perversion of their mission, which is supposed to only involve product safety and effectiveness, not bean-counting. If Medicare doesn’t want to cover Avastin, that should be a separate issue handled by CMS and HHS. This strongly suggests that the FDA has become politicized to a degree where their recommendations lose credibility — a dangerous situation for consumers and providers alike.
The Wall Street Journal chimed in with a fallacy- and demagoguery-filled editorial whose deconstruction would be worthy of a separate post of its own (perhaps an exercise for my more “insolent” friend elsewhere?), entitled The Avastin Mugging, in which the anonymous editorialist harped on the earlier E2100 trial and cherry picked the very best numbers out of the AVADO and RIBBON-1 trial, completely ignoring the fact that OS was no different with Avastin and that it might even be worse. He or she made liberal use of straw men arguments and even misquoted findings, at one point even claiming, “At any rate, even the 31% reduction in the risk of disease progression or death is better than the status quo.” The problem is that none of the studies showed a 31% decrease in the risk of death–or any decrease in the risk of death for that matter. The editorialist also referred to to chemotherapy as “savagery” and asserted:
The Avastin mugging is really an attempt to undermine regulatory modernization like accelerated approval that offends the FDA’s institutional culture of control and delay. It is also meant to discourage innovations like Avastin that the political and medical left has decided are too costly, with damaging implications for the next generation of cancer drugs.
No, the reconsideration of decisions like the decision to approve Avastin is an absolutely necessary part of the fast track approval of drugs. If we are going to approve drugs on the basis of relatively scarce preliminary evidence with the quite reasonable requirement that more studies be done and the issue of FDA approval be revisited after those studies are completed, we have to expect that we will find in at least some cases where follow up studies will suggest that FDA approval wasn’t justified, that the drug isn’t particularly useful, and that FDA approval should be revoked. If that doesn’t happen from time to time, then why bother requiring additional studies? Just use fast track approval and forget it, which is, of course, what the pharmaceutical companies would very much like to see.
Although it may not be unreasonable to be concerned that the law may evolve to consider cost more strongly, as the law exists now and as has been reported in the Wall Street Journal and the AP, FDA advisory panels do not consider the costs of the drugs they are evaluating, only the evidence. Whether they should or not is certainly something we as a nation will have to decide. I don’t consider it at all unreasonable to ask whether it’s worth over $8,000 a month to produce a 1.2 month increase in DFS, no increase in OS, and an increased risk of complications such as bleeding, stroke, hypertension, and bowel perforation.
FDA approval, science-based medicine, and politics
So how will this all play out on September 17, which is when the FDA is expected to make its final determination. The FDA could decide to side with the panel recommendation to revoke approval for Avastin, ignore the recommendation, or chart a middle course, continuing approval and asking for still more studies. It wouldn’t surprise me if the FDA chose that last option. It is also important to remember that Avastin may well have uses in breast cancer other than in stage IV disease. One area where it shows some promise is in the neoadjuvant therapy (therapy before surgery) of inflammatory breast cancer. However, the way to find out whether this promise will be realized is to wait for the clinical trials.
Whatever the FDA decides in this particular case, determining which drugs to approve for metastatic breast cancer (or nearly all metastatic solid malignancies) is a particular challenge to SBM because SBM cannot cure the disease. Consequently, the goals in treatment must be palliative; i.e., to relieve symptoms and prolong survival as much as possible. Sometimes these goals are in conflict. In the case of Avastin, this may well be the case. The drug improves PFS very modestly, but there must be a cost in terms of complications that decrease quality of life. The Avastin saga is a saga the likes of which we are probably going to see with increasing regularity.
Another lesson of the ongoing Avastin saga is about the very nature of science-based medicine itself. We have stated that we believe that medical care should be science-based. However, although medicine should be based on science, medicine itself can never be a pure science because so many non-science-based considerations impact on it. On the patient level, there is patient choice and how the doctor and patient weigh the patient’s personal situation and personal considerations in choosing from among science-based therapies. At the national level, considerations of cost, politics, and values cannot be separated from medical policy considerations. Science can tell us that Avastin does not prolong overall survival in breast cancer patients and that it only very modestly prolongs progression-free survival. It can tell us that even that modest increase in PFS comes at a cost of complications that prevent improved PFS from translating to improved OS. What science can’t tell us is whether that modest benefit is worth the cost. That’s a value judgment that must be made both at the level of society as a whole and at the level of each patient and physician.
With more research, I can only hope that science will soon be able to tell us which women with breast cancer are most likely to benefit the most from Avastin.

FDA Has Replaced its Leadership With Doctors Who Have Done Their “Research”
“Families that say” qualifies as hard data at the FDA.
Jonathan Howard on July 24, 2025
Link
It’s data from families that say their kids have been acting with bad behavior
Recent events reminded me of a satirical article titled Hospital to Replace Doctors With Parents Who Have Done Their Research. It said:
A large tertiary care center in Sydney, Australia is pulling out all the stops to try and cut their expenses. As of next month, all doctors and nurses currently on staff will be replaced by parents who have done research on the Internet.
Comments by Dr. Marty Makary, the head of the FDA, sparked my memory. He has been sounding very much like someone who has done his own “research”, using anecdotes to make decisions not just for himself, but for the entire country.
During one recent interview he said:
We have a lot of data and it may not necessarily be the traditional 50 year randomized control trial follow up. It’s data from families that say their kids have been acting with bad behavior … and they eliminate the petroleum-based food dyes and the behavior improves. That is data.
Actually, “families say” is not data. However, it is enough for him to make removing food dyes being from ice cream a top priority, a moment for public celebration. In the fictional MAHA universe, this is a major achievement that will have substantial health benefits for American children.
I personally know of people who have been injured by the vaccine.
While criticizing our medical establishment for these performative trivialities would be worthwhile in its own right, their embrace of personal testimonials as “data” reveals something more concerning- they confuse their wishes with reality, and it won’t be just Fruit Loops that are affected. This “research” method is now affecting vaccines. Dr. Makary also recently said:
I personally know of people who have been injured by the vaccine. I personally know of friends who have lost a loved one from the mRNA COVID vaccine … People have a right to be angry. They have been deceived … I would ask people to be patient with us as we do this the proper scientific way.
Apparently, Dr. Makary will do what no one has done previously and study the safety of COVID vaccines “the proper scientific way”. Until then, he personally knows people who have been injured by the vaccine and therefore, anyone who suggests it is safe has deceived the public.
This is a common tactic of our medical establishment. In this video, along with EBM guru Dr. Vinay Prasad, Dr. Makary spoke of people who told him about vaccine side-effects. Why else would someone develop an illness weeks after getting vaccinated, he asked? What other explanation could there be? He said that “hundreds of thousands” of Americans say they have been vaccine-injured, but those claims have not been investigated- until now. Dr. Prasad, who has used to own “research” to overrule vaccine-experts promised that under his leadership, vaccine-injured people would be taken seriously, and that his team was searching hard for more vaccine side effects.
Though these statements would rightly someone get one laughed out of a high school science class, none of this is new. Dr. Makary got his job precisely because he was willing to treat obvious, though malicious and painful hoaxes as irrefutable evidence when it comes to vaccines supposedly killing children. He was willing to praise and elevate America’s #1 anti-vaxxer, and this launched him to his current position.
There’s almost certainly an underlying, co-morbid condition.
While Dr. Makary spreads rumors regarding vaccine-harms, when it comes to viruses, he does the opposite. Instead of telling tall tales, he rejects reality. Nearly identical examples about measles and COVID are below. Compare the casual way he dismisses dead children with the seriousness and concern he showed for supposed vaccine injuries. Hoping to numb parents to potentially grave threats, he claims that viruses don’t kill healthy children. This obviously false, healthy children have died from COVID and measles. Moreover “soft eugenics” is appalling, and viruses can hurt kids without killing them.
Though Dr. Makary is eager to repeat the drone-like MAHA buzzwords gold-standard science, transparency and common sense, what he really means is that he’s just someone who has done his “research”. Unfortunately, he has significant power and can use his “discoveries” to impose his will on the American people. The FDA Has Replaced its Leadership With Doctors Who Have Done Their “Research”. Satire has become reality.
    • 

No One Should Care About or Trust Anything Dr. Marty Makary Says Ever Again
That, and 4 other thoughts on the resignation of Dr. Marty Makary.
Jonathan Howard on May 15, 2026
Link

With articles such as Why Marty Makary Was the Worst FDA Commissioner In 25 Years and Paranoia, Turmoil and Backlash: Inside the FDA Under Marty Makary, there’s no shortage of excellent reporting on Dr. Marty Makary’s dismal failure at the FDA and his dramatic downfall. There are several lessons to be salvaged from his train wreck. 
No One Should Care About or Trust Anything Dr. Marty Makary Says Ever Again
From his absurd claim that medical errors are the third leading cause of death to his infamous We’ll Have Herd Immunity by April, Dr. Makary has been a fountain of disinformation and vile accusations against other doctors and dedicated public servants for years. Here are some random examples, from before and during his failed tenure at the FDA.  
    • Nazi scientists released Lyme as a bioweapon
    • The COVID vaccine killed 10 children
    • The Omicron variant was “nature’s vaccine”
    • Leucovorin will treat most children with autism based on “incredible stories” 
    • “Measles has a very low mortality rate, extremely low”
    • Most of the county is at herd immunity, May 2021 
    • Natural immunity is “probably lifelong”, July 2021 
    •  Disinformation about Tylenol causing autism
    • Natural immunity is better than vaccine immunity
    • COVID is the flu, May 2021
    • Trump has “impeccable instincts”
    • Anti-Hep. B vaccine blather
    • “The FDA can be vindictive”
    • “The biggest spreader of misinformation during the pandemic has been the US government.”
    • A deluge of anti-vaccine disinformation to justify decimating the vaccine schedule
    • The COVID vaccine shouldn’t be available to healthy kids and pregnant women
    • Praising Kennedy’s anti-vaxx disinformation
These are Dr. Makary’s words, and this is his track record, though these videos just scratch the surface of his fabrications and allegations. Everything he says in the future should be interpreted with his past words in mind.
Doing this leads to an obvious conclusion- there’s no reason to trust anything he says ever again. When Dr. Makary inevitably resurfaces, bragging about his “accomplishments” at the FDA and whining about the forces that took him down, there’s absolutely no reason to believe him about anything. As the proverb goes “fool me once, shame on you; fool me twice, shame on me”.  
There’s also no reason for anyone to care about anything Dr. Makary says moving forward. Unless he’s willing to spill the dirt on Kennedy and Trump, he’s totally irrelevant, with no special insights or pearls of wisdom to offer any of us. His opinions, which once flowed freely on Fox News and the WSJ, don’t matter any more. He had his chance to reform the FDA, and he failed. As Dr. Benjamin Mazer put it:
Reforming an institution requires the ability to enact lasting change. Ultimately it doesn’t matter whether Makary or Prasad held the “right” views about medical evidence. Did they create positive changes that will outlast them? Seemingly not many.
He’s right, and while Dr. Makary should be remembered for the videos above, but his only utility is as a cautionary tale for medical students about the importance of humility in medicine.
Journalists Should Not Give Dr. Makary a Safe Space
I’d be very surprised if Dr. Makary did not return to public commentary. As an ex-public official, he should be held accountable for things that happened at the FDA under his watch, all of the politics and all of the drama. Any journalist who interviews him should relentlessly press him about his COVID disinformation and his false claims while leading the FDA- that Tylenol causes autism, that leucovorin was a miracle autism treatment, and that the COVID vaccine killed children, to pick a few. If he can’t answer questions about these topics, they should end the interview. There’s no reason to give Dr. Makary a safe space to disassemble about other issues.
Doctors Who Fluffed Dr. Makary Have No Credibility
While we here at SBM desperately tried to sound the alarm bells about Dr. Makary, other doctors sought to numb people to his in risk in articles such as Trump’s Choice to Lead the FDA Offers a Ray of Hope and Can We Give the New FDA Leadership a Chance. According to that second article by Dr. John Mandrola, Dr. Makary’s Sensible Medicine business partner and fellow disinformation superspreader:
The public town hall conversations are both a huge step in the right direction and a welcome change from the previous FDA leadership
As with all of Dr. Mandrola’s preposterous predictions, things didn’t work out that way. It turns out that the podcasting skills that helped our former FDA leaders obtain power weren’t that useful once they got there. Dr. Mandrola continued:
When Marty Makary and Vinay Prasad became leaders at FDA, many pundits worried they would damage public health. Both had “anti-vax” tendencies, went the narrative. Adam (Cifu) and I knew that was not true…
Again, things didn’t work out that way. Dr. Makary and his sidekick Dr. Vinay Prasad absolutely had “anti-vax” tendencies, and it’s no surprise that today the headlines read FDA Withdrew Studies Finding Covid and Shingles Vaccines Were Safe and FDA Refuses to Review Moderna’s New Flu Shot. Dr. Mandrola continued:
They also “convinced” the company to perform a proper placebo-controlled RCT for the vaccine in patients age 50-65 this year. We have not had a proper COVID therapy RCT in many years. I guess it took new leadership to induce companies to properly study their new vaccine…
Again, things didn’t work out that way. It’s a lot easier to “call for” RCTs than to get them done, and it’s no surprise that today the headlines read Pfizer, BioNTech Halt US COVID Vaccine Study After Recruitment Struggles. Dr. Mandrola concluded his article by saying:
I am excited and optimistic about the new leadership at FDA. They speak with clarity, humility and in a language the general public can understand. The transparency will begin to restore some of the lost trust. Good on them.
Again, things didn’t work out that way. It’s a lot easier to break trust than to rebuild it, and it’s no surprise that today the headlines read Trust in CDC, FDA, NIH Shrinks.
If the doctors who elevated Dr. Makary had any integrity, they would revisit their farcical forecasts and apologize for them. Regardless, like Dr. Makary himself, these doctors have forfeited the right to be taken seriously ever again. Either they didn’t know about Dr. Makary’s atrocious track record, or even worse they didn’t care about it. That’s permanently disqualifying in my book.
With COVID Out of the News, MAGA/MAHA is Cracking UP
MAHA/MAGA coalesced around a shared affinity for COVID disinformation, and Drs. Makary and Prasad foolishly thought the techniques that catapulted them to power would protect them once in office. This shows how badly they misread the moment. They told everyone else to stop talking about COVID, and unfortunately for them, everyone else stopped talking about COVID. It turns out that only they still cared about rare, temporary COVID vaccine side effects.
Without COVID disinformation to unite them, the cracks in the MAHA/MAGA coalition became irreparable fractures. This also shows how poorly Drs. Makary and Prasad understood the forces they legitimized and partnered with. We at SBM could have warned them that teaming up with Trump, Kennedy, and their ilk wasn’t going to end well for them. 
To the extent that Drs. Makary and Prasad were victims of Big Pharma, Big Tobacco, and anti-abortion activists, as their few remaining sycophants now claim, they were willing to work for and relentlessly fluff a President beholden to those interests. They chose to work for a President who was eager to do the bidding of a “group of tobacco executives and lobbyists“. They have no one but themselves to blame for this, and they are not off the hook for what Trump and Kennedy do moving forward. The MAHA/MAGA crack-up is just beginning, and things have the potential to get much worse. The FDA under Drs. Makary and Prasad was just one of many story lines in the soap opera they helped unleash on us all.
At least none of it was boring, like every other FDA commissioner in my lifetime.
The Medicial Community Failed
Perhaps the biggest lesson here is that the broader medical community failed to reign in its own bad actors. To say that there were warning signs about Dr. Makary and other MAHA doctors is like calling the Grand Canyon a pothole. Their risks were glaring and obvious. Just watch some of those videos.
Despite this, most doctors, especially medicine’s so-called “leaders”, shrugged and looked away as MAHA doctors spread both anti-vaxx disinformation as well as rage and doubt about the entire medical profession. Today, the FDA and other federal health agencies are shells of their former selves according to respected former employees. Medicine had a duty to warn and protect the public from the men who did this. It failed, and we’ll all be paying the price for years to come.

With Laura Loomer on One Side and Dr. Paul Offit on the Other, Our FDA Leaders are Caught in a Trap of Their Own Making
After years of bashing the medical establishment, Drs. Vinay Prasad and Marty Makary are stuck in a trap. Any attempt to escape only tightens its grip.
Jonathan Howard on July 25, 2025
Link
Stop Trusting Public Health
Drs. Vinay Prasad and Marty Makary rose to power by telling Americans to not to trust the medical establishment. In their telling, those who tried to limit COVID weren’t just mistaken, they were manipulative liars. Watch some of the videos below to see for yourself.
Drs. Prasad and Makary hammered this message of doubt relentlessly for years, and they succeeded. Many people no longer trust the medical establishment. However now that they are the medical establishment, it’s all coming full circle. Drs. Prasad and Makary are stuck in a finger trap of their own making. Any move they make only tightens its grip.
Now, with RFK Jr. as head of HHS—and two sycophants from the FDA at his side—the anti-vaccine movement is influencing policy. It’s a dangerous time to be a child in America.
On one side, there are vaccine-experts and doctors with real-world responsibility, pediatricians and obstetricians. They are justifiably furious that Drs. Prasad and Makary have limited COVID vaccines. “We will not stand by while a single federal official unilaterally and effectively strips Americans of their choice to vaccinate with actions that thoroughly disregard overwhelming scientific evidence and decades of established federal processes,” said Dr. Tina Tan, the president of the Infectious Disease Society of America. While these organizations ignored their misinformation previously, no one is holding back anymore. Dr. Makary is even being sued by multiple medical organizations. The gloves are off.
Science communicators such Jeremy Faust, Michael Osterholm, and the hosts of This Week in Virology, routinely expose their misinformation. In one recent article about Drs. Prasad and Makary, Don’t Trust the Old FDA, Trust Us, Dr. Paul Offit wrote:
For decades, anti-vaccine activists have been shouting their false claims about vaccine safety, cover-up, conspiracy, and corruption from the sidelines. Now, with RFK Jr. as head of HHS—and two sycophants from the FDA at his side—the anti-vaccine movement is influencing policy. It’s a dangerous time to be a child in America.
Their attempts to persuade other doctors in medical journals have failed as well. Their NEJM journal article, An Evidence-Based Approach to Covid-19 Vaccination, was widely panned. It didn’t change anyone’s mind, and their fellow doctors would be only further enraged if Drs. Prasad and Makary placed further restrictions on vaccines any more. So would millions of vulnerable Americans.
The appointment of Vinay Prasad represents a catastrophic vetting failure that demands immediate action to protect Trump’s transformative healthcare agenda.
However, scolding from legitimate doctors isn’t the biggest threat to our FDA leadership. We are a mere pebble in their shoe. Drs. Prasad and Makary have real jobs with vital, but unglamorous responsibilities. They have to make sure the FDA functions, and under their leadership the headlines read Inside the Collapse of the F.D.A.
They also have more dangerous opponents on the other side of the finger trap.
Fortunately, Drs. Prasad and Makary don’t really question whether COVID vaccines benefits vulnerable populations, and they don’t want dead and suffering grandmas on their hands. They know that COVID isn’t gone, it’s spreading now, and so they wisely used broad criteria to allow people to get a COVID vaccine.
However, their MAGA base, the forces they legitimized, amplified, normalized, and promoted, is in open revolt because they haven’t completely banned COVID vaccines. The rage and conspiracies Drs. Prasad and Makary nurtured for the past 4 years are now being directed back at them. It turns out when you tell people to stop trusting the medical establishment, they stop trusting the medical establishment.
This MAGA loathing of our FDA leaders isn’t limited to vaccines. A recent editorial in the Washington Times titled Trump Agenda For Biotech Being Sabotaged From Within was all about Dr. Prasad. It said:
Dr. Prasad’s rise is an example of what Mr. Trump means when he refers to “the deep state.” He is a careerist insider, left-wing ideologue working from within to hollow out the president’s biotech revolution by ceding administrative and regulatory power back to the bureaucrats and the woke elite. Mr. Trump should remove him from his posts before he pushes his personal, anti-MAGA agenda any further, causing irreparable harm to the American biotech industry.
Similarly, MAGA influencer Laura Loomer wrote an article titled Meet Vinay Prasad: The Progressive Leftist Saboteur Undermining President Trump’s FDA that used Dr. Prasad’s previous words against him. It said:
In a stunning betrayal of President Donald Trump’s “Make America Healthy Again” vision, Dr. Vinay Prasad, a self-proclaimed progressive, has infiltrated the FDA’s leadership, securing a pivotal role as Director of the Center for Biologics Evaluation and Research (CBER) after being nominated for the role by HHS Secretary Robert F Kennedy, Jr. in May of 2025. Far from being the reformist ally the Trump administration expected he may be, Prasad’s liberal ideology, outspoken anti-Trump rhetoric, and deliberate actions to obstruct the President’s deregulatory agenda make him a dangerous misfit in this critical position. His continued presence at the FDA threatens to derail the Trump administration’s mission to streamline regulations and prioritize American health. The appointment of Vinay Prasad represents a catastrophic vetting failure that demands immediate action to protect Trump’s transformative healthcare agenda.
Ms. Loomer is vile, but she is very influential, and I share her words only to illustrate that the knives are out from all directions. Myself and many others have previously devoted great effort to defending doctors from such attacks, but I think most of will sit this one out.
Drs. Prasad and Makary are on their own, and they are learning that the techniques that catapulted them to power can’t sustain them now that they are in power. They honestly thought they could appease their MAGA base with podcasts about vaccine-myocarditis, talc, and food dyes in ice cream.
However, anti-vaxxers and MAHA don’t really care about any of that. They care about doubt and outrage, and for this reason they formed a strong, but temporary alliance with Drs. Prasad and Makary regarding mask mandates and Fauci. Those are distant memories for most people now. They’ve moved on to other things, though their need for doubt and outrage remain. They can no longer get this from Drs. Prasad and Makary, who have to write cheery articles such 100 Days of Embracing Gold-Standard Science, Transparency and Common Sense.
Today, robbed of their most potent weapon, their ability to spread doubt about the medical establishment, Drs. Prasad and Makary are flailing. They are discovering that their pandemic allies were intensely loyal, not to them personally, but rather to their idea that the medical establishment couldn’t be trusted. Drs. Prasad and Makary are now learning what that feels like from the other side. They are experiencing that side of the equation now.
Yet, our FDA leaders have unintentionally accomplished something truly remarkable- they’ve managed to unite Laura Loomer and Dr. Paul Offit. Their attempt to be “nuanced” only caused everyone to distrust them, and any attempt to fix things with one group will only wreck things with the other.
The harder they pull, the worse it will get.
    • 

A Letter to the American College of Surgeons: Don’t Censor Dr. Marty Makary, Amplify His Voice.
We need to remember the doctors who literally stood behind Donald Trump, and we don’t need their permission to do so.
Jonathan Howard on July 12, 2026
Link

Dear Leaders of the American College of Surgeons,
I have written extensively about MAHA/MAGA doctors, both their COVID misinformation and incompetence/malevolence in power. Much of my writing has featured ex-FDA commissioner Dr. Marty Makary, whose tenure inspired articles such as Why Marty Makary Was the Worst FDA Commissioner in 25 Years. That article said:
I have covered the FDA for the past 25 years, and so I don’t say this lightly: Marty Makary was the worst commissioner in that time.
Makary, who resigned under pressure from the Food and Drug Administration on Tuesday, brought to the job a fundamental lack of understanding of the nature of the role, of the functions of his agency, and of the needs of the employees who worked for him. He allowed too much of the senior leadership of the agency to leave or be removed, weakened its standards, and ignored staffers who understood both the science and the political art of regulation. Toward the end of his tenure, he seemed isolated and obsessed with notching “wins” that often amounted to very little.
This outcome was unsurprising, at least to those of us who cared enough to pay attention to Dr. Makary’s words before he obtained power. We tried to use his words to warn about him.
To avoid repeating these failures in the future, we must be clear and honest about we came to this sad moment, where the Lancet is writing editorials titled Robert F Kennedy Jr: 1 Year of Failure. That article said:
The destruction that Kennedy has wrought in 1 year might take generations to repair, and there is little hope for US health and science while he remains at the helm.
MAHA/MAGA doctors like Dr. Makary are a part how we got here, as was the silence and enabling of medical leaders. Most turned a blind eye to bad faith, political actors in our profession. Even worse, some sanitized their misinformation as “thinking differently.”
Let’s be honest about Dr. Makary’s COVID history. He was ranked #2 in the article The Dishonest Doctors Who Were Fox News’ Most Frequent Medical Guests In 2021. Here’s what it revealed about him.
Makary holds a masters degree in public health and specializes in abdominal laparoscopic surgery. He is a professor of surgery at Johns Hopkins University. Makary has been described as “a darling of the anti-vaxxers” for contradicting current vaccine consensus among medical professionals. Makary has also written that there is “no compelling case” for vaccinating “healthy” children and claimed that he is “not aware of a single healthy child in the U.S. who has died of COVID-19 to date” – discounting all cases that involved disabled children with underlying health conditions. Despite Makary making numerous false predictions (saying, for example, that the United States would reach herd immunity by April) and being called out by other public experts for downplaying the risk of infectious disease, Fox regularly invited him back on-air in 2021 to underminepublic health efforts:
    • In March on The Story with Martha MacCallum, Makary predicted there was low risk of new variants causing COVID-19 surges, and on Your World with Neil Cavuto, he accused public health experts of “cry[ing] wolf” over the threat of new variants.
    • In June on America Reports, Makary went so far as to complain that discussion of new variants is “fearmongering” to “manipulate people to get vaccinated,” saying, “I’m for vaccines, but this has turned into a tool to try to coax people into it.”
    • In June on Special Report, Makary claimed it’s time to “move on and live a normal life” comparing COVID-19 cases to influenza: “right now we’re about at 150th the daily cases of a regular seasonal flu in the middle of that flu season. So people have a distorted perception of risk.” According to Makary’s own employer, Johns Hopkins, COVID-19 has a mortality rate 10 times higher that of the flu.
    • On Your World with Neil Cavuto in November, Makary undermined efforts to vaccinate children, saying kids with natural immunity should not be vaccinated. He went on to fearmonger about potential side effects of vaccinations.
    • On Fox News Primetime in November, Makary claimed to be pro-vaccine but said he stands against “obsolete” vaccine mandates, especially for children. Makary falsely asserted that “public health officials have brushed under the rug the fact that kids have died from the vaccine, it’s rare” citing myocarditis occurrences in young boys. (However the real risk of myocarditis is from COVID-19, not vaccines, and most people who develop myocarditis recover quickly.)
This is all true, and even if Trump had lost the presidency, it would have been important to remember Dr. Makary’s COVID track record. This sort of misinformation had a real world impact, though a lot of people didn’t care about it.
However, it also implies something about the future. Combined with his performance at the FDA, it means there’s no reason care about what Dr. Makary says moving forward. He has proven himself to be both a horrible prognosticator and utterly unreliable reporter of basic facts. There’s no reason to trust him in 2026. Unless he is willing to spill the beans about his former bosses, Kennedy and Trump, he has no pearls of wisdom or valuable insights to offer.
Moving forward Dr. Makary should judged entirely based on what he’s already done, with Fox News & COVID and at the FDA. He has a track record now, and it’s fair to hold him accountable for it.
You don’t feel that way, however. You recently invited Dr. Makary to speak at your annual conference and didn’t care a lick about any of that. Neither his dismal COVID track record nor his inglorious performance at the FDA mattered to you one bit. You were willing to overlook it all. You portrayed Dr. Makary as a swell guy, someone we could trust. You said:
Dr. Makary will draw on his experience in surgery, academic medicine, and federal health policy, while exploring the forces shaping the future of healthcare. His presentation will examine new trends and biomedical innovations that are positioned to positively disrupt everything from health insurance to the practice of medicine. Attendees can expect a discussion of emerging challenges and opportunities facing surgeons and other healthcare leaders.
Confirmed by a bipartisan vote of the US Senate to lead the FDA, Dr. Makary led initiatives that included accelerating drug approvals, reducing reliance on animal testing, modernizing artificial intelligence regulation, rewriting national dietary guidelines, phasing out artificial food dyes, and advancing healthier school lunch standards.
Before entering government service, Dr. Makary was a professor at the Johns Hopkins University School of Medicine and Johns Hopkins Carey Business School in Baltimore, Maryland, where he also served as chief of islet transplant surgery and held the Mark Ravitch Endowed Chair of Gastrointestinal Surgery. Dr. Makary founded the Johns Hopkins Center for Surgical Trials and Outcomes Research and has authored more than 350 peer-reviewed publications. He was elected to the National Academy of Medicine in 2019.
Dr. Makary also is the author of two New York Times bestselling books: The Price We Pay, winner of the 2020 Business Book of the Year Award, and his latest book Blind Spots, which tackles nutrition science, the microbiome, hormone replacement therapy, and emerging health trends.
This isn’t false, but it leaves out key details and is therefore fundamentally dishonest.
I can help you fill in the gaps.
My YouTube channel- the one THEY don’t want you to see- has dozens of videos of Dr. Makary, both from when he was a COVID “expert” on Fox News and from his time at the FDA. As an act of basic respect your members, you have an obligation to honestly tell them about Dr. Makary’s track record. Don’t censor it. They need to know his past credibility to judge his current credibility, and there is no better way to inform them than to play some of these videos before his speech. Dr. Makary can hardly object to hearing his own words, can he?
Though there are countless examples, here are some suggestions:
In May 2021, Dr. Makary said most of the country had herd immunity to COVID. The Delta and Omicron variants arrived immediately after this.
In July 2021, Dr. Makary speculated that immunity to COVID was “probably lifelong.” The virus was just 1.5 years old at the time, and natural immunity did not turn out to be lifelong.
Although the Omicron variant killed and hospitalized a record number of children, Dr. Makary called it “omi-cold” and “natures’ vaccine.”
Dr. Makary claimed on Fox News that Kennedy spread “true stories of children who died immediately after the (COVID) vaccine”. In reality, Kennedy stole online pictures of unvaccinated children against the wishes of their parents to use in his antivaxx propaganda.
As FDA commissioner, Dr. Makary promoted leucovorin as a cure for autism based on “incredible stories.” Soon after this, the largest paper making this claim was retracted.
Dr. Makary claimed that Tylenol in pregnancy causes autism. It does not.
As FDA commissioner, Dr. Makary promised he would share “evidence” the COVID vaccine killed children. He failed, and the FDA’s report on this topic was leaked only after Dr. Makary left the agency. It found that no deaths were definitively linked to the vaccine.
As measles spread in the spring of 2025, Dr. Makary claimed that it posed no risk to healthy children. That’s false, and it’s not an appropriate way for doctors to talk about dangerous viruses, especially those in leadership. Measles is hurting American children every day with MAHA and crew in charge.
Dr. Makary fawned over Donald Trump, saying that he has “instincts better than some of the academic elites in America.” Imagine saying that in 2026. “He’s an amazing guy. He’s a phenom. He has more energy than anybody,” he added.
And yet, according to you, Dr. Makary has the right pedigree and so with him at the microphone:
Attendees can expect a discussion of emerging challenges and opportunities facing surgeons and other healthcare leaders
This not my first time writing such a letter. I previously pleaded with conference hosts like yourselves to simply be honest and, if MAHA/MAGA doctors were speaking, simply their audience about the history using their own videos.
They declined, and imagine that this letter will also fall on deaf ears. The revisionist history will continue. The COVID Amnesia Project will seamlessly morph into the MAHA Amnesia Project, and my “vituperative tone” will be deemed the real problem, again.
I’d love to be proven wrong about this. I mean that. I would love for you to show the videos in this essay before Dr. Makary speaks. If someone says it would be rude or inappropriate to show his videos, there’s only one person to blame for that.
Until then, your delightfully sanitized announcement about Dr. Makary shows something both depressing and important about so-called medical “leaders”. They’ve appear to have learned nothing from the MAHA/MAGA debacle. Even with everything that’s happening in STEM today, their top priority is still to provide a safe space to powerful doctors, to deliberately cover up what they said.
I’d argue that we need to remember the doctors who literally stood behind Donald Trump as he said dangerous, false things, and we don’t need their permission to do so.


   Canada Bill C-51 – Regulating Natural Health Products
Steven Novella
Link
In Canada a new bill has been proposed, Bill C-51, that would make changes to the Food and Drug Act – the body of laws by which the Canadian federal government regulates food and health products in Canada. This is the equivalent of the Food and Drug Administration (FDA) in the US. It seems that Canada, like the US, is struggling to deal with a burgeoning industry of “natural health products” that are minimally regulated.
The new bill will increase government oversight of natural health products (NHP) for the purpose of ensuring higher quality standards for products and accuracy in the claims that are made for them. Proponents of the bill claim that it will serve to improve consumer protection. But the NHP industry is not happy with the increased oversight the bill would bring. Their hysterical reaction to the proposed bill is very revealing about the propaganda and deception used by the NHP industry.
This history of NHP regulation in Canada also reveals the two primary strategies by which the promoters of unscientific medicine and health products seek to advance their business. On the one hand they seek licensure, certification, and other formal recognition by the government in order to bolster their legitimacy with the public and also to keep competition at bay. When seeking such things they argue that licensure etc. will give the government the opportunity to regulate the industry and ensure quality control. They therefore take the position of consumer protection.
However – the last thing that the sellers of unscientific products and services want is real regulation. Their plan is always to put into place mechanisms for self-regulation. This way they get to have official recognition, they can erect barriers to keep out competition, but they are in charge of the standards. Therefore they are never held accountable to any external scientific or objective standard of safety or efficacy. Chiropractors, for example, only have to meet the standards established by chiropractic, even if this is completely divorced from scientific reality.
When the threat of genuine regulation is at hand, then the promoters of dubious health claims completely change their tune from consumer protection to health care freedom. Now they decry the evils of an oppressive government that would dare to tell its citizens what health products or services they can use.
Rather – rational regulations should always achieve a thoughtful balance between consumer protection and freedom. Also, certification and licensure should be used only when necessary and the foxes should never be put in charge of the hen house. Objective scientific standards must be used or otherwise the standards are pointless (except to limit competition).
If we look specifically at the history of NHP regulation in Canada we can see this switch from consumer protection to health care freedom in a very short period of time – from one end of the spectrum to the other.
Barry Green of the Ottawa Skeptics has pointed this out quite clearly. He wrote recently.
In the mid 90s, the NHP industry needed Health Canada to formally recognize NHPs through legislation in order to ensure safety and quality:
They wanted to know how consumers could be certain about such factors as purity, potency, and cleanliness of the products they purchase. They heard repeatedly that Canadians must be assured that “what’s on the label is in the bottle.”
Now, they seem to be saying that you should trust the industry to ensure safety and quality, and therefore why bother with regulations, inspections and those difficult-to-meet licensing requirements. I guess the NHP industry just wants to be treated like their products – big on claims but not on formal evidence.
Now that C-51 threatens to impose actual governmental oversight of NHP’s the industry appears to be in full panic/propaganda mode. An appeal has been repeated on dozens of websites, saying:
A new law being pushed in Canada by Big Pharma seeks to outlaw up to 60 percent of natural health products currently sold in Canada, even while criminalizing parents who give herbs or supplements to their children. The law, known as C-51, was introduced by the Canadian Minister of Health on April 8th, 2008, and it proposes sweeping changes to Canada’s Food and Drugs Act that could have devastating consequences on the health products industry.
Among the changes proposed by the bill are radical alterations to key terminology, including replacing the word “drug” with “therapeutic product” throughout the Act, thereby giving the Canadian government broad-reaching powers to regulate the sale of all herbs, vitamins, supplements and other items. With this single language change, anything that is “therapeutic” automatically falls under the Food and Drug Act. This would include bottled water, blueberries, dandelion greens and essentially all plant-derived substances.
The Act also changes the definition of the word “sell” to include anyone who gives such therapeutic products to someone else. So a mother giving an herb to her child, under the proposed new language, could be arrested for engaging in the sale of unregulated, unapproved “therapeutic substances.”
That’s right – the purpose of the law is to keep parents from giving blueberries and bottled water to their children.
The two specific changes that seem to have the purveyors of questionable health products worried include the changing of the word “drug” to “therapeutic product,” a term they previously endorsed. This means that herbs sold with health claims can be regulated as a product sold with health claims. It also means that herbs that are intended to be used as drugs – for their pharmacological effects – will be regulated just like drugs that are sold to be used as drugs – for their pharmacological effects.
There is some sense behind this change. It is reasonable to argue that the health regulatory agencies whose purpose is to protect health consumers should have the power to ensure the safety and efficacy of any product that is sold with specific health claims, regardless of its mechanism. I understand there are many subtleties to such regulation, and my purpose here is not to defend a particular formulation of any such regulation. Such laws need to consider many factors and balance many concerns – access, cost, safety, etc. Rather my point is to expose the blatant propaganda being used by the opponents of this bill and the hypocrisy it represents.
The second point of contention is expanding the concept of “sell.” Again, this is portrayed as an attempt to go after parents who are treating their children. Rather, it seems like it is crafted to avoid an obvious dodge of regulation – giving away health products and services to avoid regulation but then making a profit through donations or the selling of information, such as books and lectures. This change therefore is designed to close a loophole.
An interesting aspect of the propaganda against this law is the claim that it is being pushed by “Big Pharma,” the boogeyman of the “alternative” health industry. However, the pharmaceutical industry had nothing to gain from such regulation. In fact, pharmaceutical companies have jumped on the lucrative supplement and “natural” product bandwagon. They love having the ability to sell therapeutic products like herbs without any government regulation – no need to invest in costly research, and no one tying their hands in terms of the marketing claims they can make. What’s not to love. I would think that “Big Pharma” would be as much against C-51 as any company currently earning profits from unregulated health products.
But for propaganda purposes – Big Pharma is a convenient villain, even though they have nothing to do with this law.
It will be interesting to follow the fate of this law. Again – I am not saying that it is a perfect law or that it strikes the optimal balance between consumer protection and the free market. I am saying that any serious discussion on this topic should involve rational and objective definitions of what is a drug vs a nutritional supplement, and should incorporate reasonable attempts at protecting the public from harmful or fraudulent products, regardless of the manufacturer or the philosophical basis for the treatment.
But mostly this episode serves to expose the outrageous hypocrisy of the purveyors of unscientific or unproven treatments who are happy to be champions of consumer protection when it suits their needs, and then the next moment to decry consumer protection laws as fascist while transforming themselves into paragons of free-market virtue. Their ideological flexibility is impressive.

   Supplement Regulation: Be Careful What You Wish For
Scott Gavura
Link
A recurring theme at SBM is the regulation of supplements, and the impact and consequences of the Dietary Supplement Health and Education Act of 1994 (DSHEA). As one of SBM’s international contributors, I thought it might be helpful to look at how the DSHEA stacks up against the equivalent regulations of its neighbor to the north, Canada. Given the multiple calls for overhauls and changes to DSHEA, an international comparison may help focus the discussion around what a more science-based framework could look like.
Briefly, the DSHEA is an amendment to the U.S. Federal Food, Drug and Cosmetic Act that establishes a regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. The FDA notes:
Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements. Manufacturers must make sure that product label information is truthful and not misleading. FDA’s post-marketing responsibilities include monitoring safety, e.g. voluntary dietary supplement adverse event reporting, and product information, such as labeling, claims, package inserts, and accompanying literature. The Federal Trade Commission regulates dietary supplement advertising.
Quackwatch has excellent resources on the DSHEA, and SBM bloggers have brought up specific criticisms of the Act at posts like this, this and this. The main concerns with the Act can be summarized as:
DSHEA draws a crude distinction between food and drugs, even defining therapeutic and pharmacologically-active products (e.g., herbs, botanicals, some hormones) to be categorized as foods, and therefore eligible for DSHEA exemptions from the FDA’s drug regulations.
Manufacturers can put virtually any claim on a supplement, without any requirement to provide persuasive clinical evidence, as long as it’s accompanied by the Quack Miranda Warning: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” Disease treatment claims are not permitted, but are typically restated as permissible “structure/function” claims, implying an ability to improve the structure or function of the body only. (Colloidal silver is one example)
There is a lack of regulatory oversight of manufacturing practices.
In multi-chemical products such as herbals, there is no standardization of active ingredient(s), nor are there mandatory purity guarantees.
There are essentially no pre-marketing requirements before selling products. Once available for sale, there is little ability for the FDA to issue cease-sale orders and recalls. Regulators can block the sale of products only after significant problems have been identified (i.e., ephedra)
The regulation of marketing claims is effectively left to the Federal Trade Commission (FTC), which can prosecute manufacturers for fraud.
The Canadian Regulatory Framework
Until several years ago, Canadian natural health products fell into a regulatory grey zone. Products were treated either as drugs, or as foods. Consultation began in the late 1990′s on a new framework to provide regulation and oversight to these products. In 2004, the Natural Health Product (NHP) Regulations, under Canada’s Food and Drugs Act, became a reality. The NHP Regulations cover nutritional supplements, probiotics, traditional Chinese medicine, vitamins, herbal products, and homeopathy – many of the same products that would be considered “dietary supplements” under DSHEA. Rather than fully regulating these products as drugs, or leaving them virtually unregulated, the NHP regulations were a regulatory compromise: implementing manufacturing quality and safety standards, while significantly relaxing the standards for product efficacy claims. The Natural Health Products Directorate is the unit of Health Canada (Canada’s version of the FDA) that administers the NHP Regulations. Health Canada assures Canadians of the following:
Through the Natural Health Products Directorate, Health Canada ensures that all Canadians have ready access to natural health products that are safe, effective and of high quality, while respecting freedom of choice and philosophical and cultural diversity.
Let’s look at the DSHEA through the Canadian regulatory framework lens. Does it set a science-based example?
Lowering the Efficacy Bar
One of the biggest problems with DSHEA is that it facilitates unsubstantiated efficacy claims. While DSHEA doesn’t apply to homeopathy, the NHP regulations do. Health Canada says that regulated products are “effective,” so what’s the evidence standard being applied?
Health Canada’s Evidence for Homeopathic Medicines: Guidance Document states that applications for licenses for homeopathic products must include evidence to support the “safety, efficacy, and quality” of a homeopathic medication. All “homeopathic medicine” must be from substances referred to in homeopathic pharmacopias, such as the Homeopathic Pharmacopeia of the United States (HPUS), or other references.
Under the NHP Regulations, if randomized, double-blind, placebo-controlled trials are not conducted, manufacturers can make efficacy claims based on “traditional uses”, i.e., anecdotal evidence of use and efficacy. The two most common types of traditional use claims are provings, and references to homeopathic materia medica, which are essentially compilations of provings. There is no objective evaluation of efficacy in provings or in materia medica. Health Canada offers a list of 59 references it will accept at “evidence”, with publication dates as old as 1834 — dating back before the germ theory of disease was proposed.
Consider the popular remedy Oscilliococcinum, sold as an influenza treatment. It’s prepared by decapitating a duck, taking 35 grams of its liver and 15 grams of its heart and fermenting it for 40 days. The solution then undergoes serial dilutions (1 part in 100) 200 times in a row, (in homeopathy lexicon, “200C”) and is dried on lactose/sucrose tablets. (Wikipedia notes that that in order to obtain even a single molecule of the original fermented duck, a volume of tablets greater that the mass of the entire universe would need to be consumed.) Consulting Health Canada’s NHP database (Search NPN 80014156 here) Health Canada has registered the product, with the labelled medicinal ingredient as “Extract of the liver and heart of Annas barbariae: 200C” and approved the following recommended use (translated from French):
Homeopathic medicine to relieve flu symptoms: fever, chills, body aches, headaches.
This is one consequence of Canadian regulation: the efficacy standard has been lowered so far, it’s meaningless. The Canadian regulatory process assigns distinct registration numbers, dosages, and specific “recommended uses” to hundreds of physically indistinguishable brands of sugar pills.
Shifting categories, let’s consider an herbal product. Ginkgo biloba was discussed back in December in the SBM post Ginkgo Biloba-No Effect. Yet the product Dr. Andrew Weil, M.D. Ginkgo Biloba is approved by Health Canada (Search NPN 80003088 here) with the following recommended use:
helps to improve memory. helps to improve attention. consult a health care practitioner for use beyond 6 weeks. [sic]
Again, the evidence bar is far lower than a critical appraisal of the evidence would suggest is accurate. The result? Arguably worse than under the DSHEA. Statements based on questionable evidence gain a regulatory stamp of approval.
Manufacturing Oversight
The NHP Directorate establishes manufacturing standards and issues site licenses. Good Manufacturing Practices (GMP) must be followed. Setting aside the labelling accuracy of homeopathic remedies, the licensure should provide consumers and health professionals with more assurance that what is on the label is actually in the product. Health Canada’s FAQs include a question on DSHEA and it states:
In the United States, dietary supplements are considered as food products under the Dietary Supplements Health Education Act (DSHEA) and, as such, claims may not be made about the use of a dietary supplement to diagnose, prevent, mitigate, treat, or cure a specific disease. These products are not subject to mandatory review, approval or quality requirements, including appropriate testing for identity, purity or potency of active ingredients.
However, GMP standards also exist for supplements sold under DSHEA, so it’s not clear if the NHP regulations impose more strict requirements for Canadian products.
Standardization
The NHP Directorate has created a series of monographs about dozens of single-ingredient products which are intended to provide more standardization of product labeling, dosing and constituents. All of this is worthwhile. Unfortunately a quick scan reveals some significant discrepancies between the current state of the evidence and what’s in the monographs. Harriet Hall’s recent SBM post on glucosamine points out there’s little persuasive data to suggest it has any meaningful effects. In contrast, the current Health Canada-approved monograph for glucosamine selectively cites the positive trials, and labels it effective for osteoarthritis pain. So while the Regulations may be supporting improvements in the consistency of the the finished products, the evidence standards may be compromising their real-world utility.
Marketing and Post-Marketing Surveillance
One of most important elements of the NHP regulations is the implementation of pre-marketing registration requirements. That is, only products reviewed and deemed to meet minimal standards of product quality, safety, and the (relaxed) standard for efficacy claims are permitted to be sold. Unfortunately, even after after six years, thousands of products remain unregistered due to a backlog at Health Canada. Until then, these products continue to be sold. Despite the published standards for consumer advertising of natural health products, there seems to be little enforcement of these requirements. As noted by Tom Blackwell in the National Post,
Recent ads, for instance, tout unapproved natural remedies as being able to prevent diabetes, heart and eye disease, treat menopause and Parkinson’s and help melt away excess weight. By contrast, makers of prescription drugs are essentially barred from promoting their products directly to consumers at all.
Federal law says even natural products — considered generally safer — must be approved under the natural health regulatory system before they can publish or air any kind of ad, and even then must stick closely to the claims allowed in the licence. Many companies that are waiting for word on their applications have chosen to ignore that rule, however, while others have not even attempted to get approval, observers say.
This regulatory backlog seems to have complicated the enforcement of marketing claims, and advertising standards for both approved and unapproved products don’t seem to be facing any serious scrutiny. In Canada, the Competition Bureau is the agency most comparable to the FTC, but it doesn’t seem to have the same focus on actively and publicly prosecuting fraudulent claims. While it has on occasion required companies to change their messaging, it’s rare, and only when the company has gone beyond the already over-generous efficacy claims allowed through the regulations. Perhaps this situation will change when the registration backlog is eliminated.
With respect to product withdrawals, the Minister of Health has the authority under the NHP regulations to direct the stop sale of a product or to cancel licenses of products to prevent injury. Licenses can also be suspended for regulation contravention, or if a product does not appear to meet safety criteria. It’s difficult to directly compare the FDA to Health Canada in this regard, as most Canadian warnings echo FDA advisories for products that may or may not be sold in Canada.
A Science-Based Regulatory Framework for Supplements
Given the regulatory approaches of Canada and the USA, what might a science-based framework look like? I see at least four different perspectives towards supplements/NHPs. I’m sure more will emerge in the comments.
Consumers want products that are safe, and labeled accurately. They may consult health professionals, or make their own decisions about whether products are effective.
Science-based health advocates, like the contributors at this blog, argue that that product safety and quality are paramount, and efficacy statements must be based on good science. They argue against a different approval standard for products just because they’re deemed a “supplement.”
Free market advocates, and those that call for health “freedom” question the value of most regulation that inhibits choice, emphasizing personal responsibility over government-legislated consumer protection measures.
Supplement manufacturers generally seek a market where they face as few regulatory restrictions as possible, whether it be safety, efficacy, or quality.
Certainly, there is some common ground here. Many will likely be agreeable to a regulatory framework that give consumer and health professionals assurance that they’re being protected from health fraud and dangerous products. Even free market advocates generally accept that markets operate less effectively when consumers cannot evaluate benefits and consequences (risks). With respect to health “freedom” claims, I question if anyone anyone wants the “freedom” to be sold products that don’t contain what is claimed, or have not been evaluated to be safe. Turning to manufacturers, some may welcome more rigorous regulatory verification of their own quality processes, especially if it helps with market acceptance.
One approach to to a new framework could be to unbundle the various types of supplements and treat each according to the science. Herbal products and botanicals stands out as the most likely to benefit from some elements of the Canadian regulations. Without quality manufacturing and standardization of active ingredients, it is impossible to infer anything about a particular herb. However, with respect to homeopathy, it’s questionable if anyone benefits from the regulation of sugar pills.
The biggest differences in opinion will clearly be the standards for efficacy and safety claims. Supplements/NHPs will rarely be be supported by the rigorous data we require for prescription and over-the-counter drugs. Through the NHP regulation process, Canada effectively eliminated any meaningful efficacy requirements, to accommodate products like homeopathy. Yet if all treatment and efficacy statements are forbidden, the information will emerge elsewhere. It’s an issue that other regulators are grappling with, too. Ben Goldacre, writing in The Guardian, points out the European Union’s process, evaluating health claims for similar products, has rejected 80% of claims submitted for formal approval. Ben’s solution is unorthodox, but one that I’m starting to warm up to:
You’ll never stop companies making these claims. You’ll never stop people enjoying their claims. This game is at least 200 years old. The best solution I can foresee is an EU-mandated bullshit box, where people can say whatever they want about their product, where consumers can join in, but the game at last is clearly labelled.
Conclusion
Canada has implemented a supplement registration and regulation framework with the goal of assuring Canadians that natural health products are safe, effective, and of high quality. While its approach to manufacturing quality is laudable, there are significant shortcomings with respect to product efficacy standards, and the regulation of marketing. The DSHEA at least informs consumers that the labelled statements on supplements haven’t been evaluated by the FDA. In Canada, with approved products, such as homeopathy, recommended use statements have been both evaluated and approved.
Yet if we want to incorporate dietary supplements into science-based practices, consumers and health professionals need quality products, but also objective and transparent evaluations of efficacy. As a health professional that advises consumers on natural health products, I welcome any regulation assures me, and my patients, that what’s on label is actually in the bottle. Without this information, I can’t make evidence-based recommendations. Yet if a regulatory system doesn’t also properly inform consumers about product effectiveness and safety, how can they be expected to make rational decisions about their own health? Canada’s approach offers some lessons, but also some cautions, for those calling for supplement regulation.

Don’t supplement users deserve consumer protection, too?
Scott Gavura on June 5, 2014
Link

The Canadian Parliament, hypothetically protecting consumers since Confederation.
One of the most pervasive yet appealing health myths is the idea that natural equals safe. It’s a statement that’s repeated constantly by manufacturers of supplements and “natural” health products. It’s been the primary argument used, with considerable success, to give these products completely different regulatory structures than exist for drug products. Weaker regulation of supplements and natural health products has been a boon to manufacturers, but the same can’t be said for consumer protection. It’s effectively a buyer-beware marketplace in most parts of the world, with little accurate information available to consumers. But supplement manufacturers aren’t content with the minimal regulation that’s currently in place – they want health “freedom”. In this case, “freedom” means the right to sell any product, while being exempted from safety and regulatory requirements. New Canadian legislation is poised to raise safety standards for drugs and enhance the ability of regulators to recall dangerous products, yet consumers of natural health products are left behind. The legislation proposes to exempt anything considered a “natural health product”. This is not only bad public policy, but it has the potential to cause avoidable harm. After all, shouldn’t users of supplements and natural health products be entitled to the same safety and quality standards as those that use prescription drugs? If the supplement industry gets its way, the answer will be “no”. (There is an opportunity until June 10 for you to provide feedback on this legislation – see below.)
In late 2013 the Canadian government introduced Bill C-17, the Protecting Canadians from Unsafe Drugs Act. Also called “Vanessa’s Law”, the bill is named after the daughter of Terence Young, a Canadian Member of Parliament whose daughter died of an adverse drug reaction. The Act has been written to enhance and strengthen Canadian food and drug regulations, and is expected to bring Canadian regulations in line with international best practices for drug regulation. The Act will do the following:
    • give government the authority to recall drugs from the market (it currently must ask the manufacturer’s permission, and the decision is at the manufacturer’s discretion)
    • increase fines to manufacturers from $5,000 to $5,000,000 per day for companies that do not comply with the Food and Drugs Act
    • the ability to require companies to undertake post-marketing (real-world) research
    • the ability to force a manufacturer to change a drug’s label because of new harms or risks to health
    • make adverse event reporting mandatory for hospitals.
These changes are overdue in Canada, and welcome. There is an interesting exemption. The act applies to “therapeutic products” which is defined as:
a drug or device or any combination of drugs and devices, but does not include a natural health product within the meaning of the Natural Health Products Regulations
Even the preamble makes it clear – there are apparently no issues with natural health products:
And whereas new measures are required to further protect Canadians from the risks related to drugs and medical devices, other than natural health products
What are the consequences of excluding natural health products? Tainted drugs can be recalled, but not contaminated or mislabelled supplements (which have been documented with Canadian products). Adverse event reporting becomes mandatory for drugs and even “medical devices” (e.g., bandages) but reporting on herbal products and other supplements is not. And oddly, even some drug products are considered “natural health products” (e.g., some decongestants). The result of this legislation, if passed intact, will mean the extent to which consumers will be protected from unsafe products will vary.
Drug safety disasters like thalidomide led to the pharmaceutical regulatory framework that is generally in place around the world today. Amazingly, manufacturers of supplements and other “alternative” medicine products have been largely successful in circumventing these safety rules, convincing regulators that “natural” equals “safe”, and therefore, should be exempted from regulation. In the USA, the framework is DSHEA, which removed the onus of demonstrating safety and efficacy from the manufacturer and put the requirement to demonstrate harm on the FDA – exactly the same scenario as drugs in the early 1900′s. In Canada, the Natural Health Product regulations had a similar effect, and implemented a lowered bar for non-drug supplements. Today even homeopathic remedies in Canada are deemed safe and effective and approved with unique recommended uses.
Is there any rationale that would exempt natural health products from stronger regulatory oversight? Some (particularly the industry) point to the lack of evidence of harms. And from one perspective, that is true. Despite their widespread use, surveillance of supplements (the limited amount that occurs) reveals generally few adverse events. It could be that many products lack meaningful pharmacologic activity — either positive or negative. An adverse event is probably less likely in placebos that have no beneficial effects. But beyond efficacy, there are several other factors, unique to supplement use, that may contribute to the perception (and under-reporting) of harms from supplements. I’ve mentioned several reasons before, which include:
    • Consumers believing natural products are safe may be less likely to associate adverse events with supplement use.
    • Supplements don’t require a prescription. No health professional may be involved in measuring the response to therapy, who might be able to identify adverse events as part of a monitoring plan.
    • Side effects and harms may not be reported, as some are reluctant to share concerns with health professionals.
    • Consumers may not know how to manage an adverse event, and to whom they should report an adverse event. They may be unwilling to describe health consequences to the vendor of a product, or report in a setting like a natural foods store.
    • Users may have a distrust of “conventional” medicine which drove their initial use of the product. When adverse events were identified, they may be reluctant to consult “conventional” health care providers for assistance.
    • Some fear of losing access to supplements, which may drive a reluctance to report adverse events.
    • Supplements are commonly used for short intervals for self-limiting conditions, and long-term harms may not appear (or be detectable).
If you don’t look for it, you won’t find it. And if you set the system up to minimize even the potential of reporting, it should be no surprise that supplements are not associated with a lot of safety concerns or reports. And that’s exactly what the bill’s exemption of natural health products will do – reinforce a weak regulatory structure and make no meaningful improvements in transparency or accountability from supplement manufacturers.
Taking action
The Canadian advocacy organization Bad Science Watch has organized a campaign to press for changes in Bill C-17. It is proposing two amendments:
    • Removing the natural health products exemption.
    • Requiring companies to disclose all clinical trials data that exists for a product in an “all trials” clinical trials database.
The bill has been referred to a Standing Committee on Health which will meet on Tuesday June 10. There is a draft letter at Bad Science Watch, with the email address of the Members of Parliament that will be considering the bill. There is also a draft letter prepared by AllTrials, which elaborates on the rationale for a registry (yet does not address the NHP exemption.) If you want to provide comments that will be considered, you must do so by Tuesday, June 10.
Conclusion
Canadian consumers deserve equal protection from unsafe health products, no matter how they are categorized. In light of the questionable efficacy, safety, and product quality standards of natural health products in Canada, there is no clear rationale why Natural Health Products should be exempted from newly proposed safety enhancements. In addition, Bill C-17 represents an important opportunity to bring greater transparency to clinical trial data – a move with the potential to improve health care not just for Canadians, but for patients worldwide.

   Marketing Pharmaceuticals in today’s Regulatory Environment
Martin A. Lessem, J.D. 
Link
In the comments to my previous article I had said I would tackle the topic of how Pharmaceutical Products are marketed and how the FDA is involved in that process. Then I managed to get a new job with a different company, and have been busy getting up to speed. I still do the same thing, but with a different company and more responsibility. All of that aside, I am now up to speed, and had the good fortune to be browsing the FDA’s website when I came across, the following article: “FDA issues warnings to marketers of unapproved ‘chelation’ products”. This seemed to me a good lead in to discuss the situation down at the FDA and why it is beneficial to have an outside party look at your marketing materials before you present them to the public.
In general, the promotional review process at the FDA works as follows. A Pharmaceutical, or CAM Company decides upon an advertisement they wish to have for their product. They review it internally to ensure compliance with the regulations as they understand them, then they send it to the FDA either as an informational piece or requesting a formal review. Which one they choose is dependent on how much of a risk they feel they are willing to take, which can also come down to the risk/benefit profile of the product in question. There is a group in each Center for the FDA which handles this. For the two Centers I have primarily dealt with on these issues, it is DDMAC (Division of Drug Marketing, Advertising and Communications) in CDER (Center for Drug Evaluation and Research) and APLB (Advertising and Promotional Labeling Branch, also pronounced “Apple-Bee”) in CBER (Center for Biologics Evaluation and Research). Now this is where the path between legitimate Pharmaceuticals and CAM takes a massive divergent twist.
Pharmaceuticals have a distinct disadvantage when it comes to marketing their products. For a Pharmaceutical advertisement to be acceptable, it must have three major parts to it, not including the biggest piece of all, FDA approval as a Marketable Product. The first of these, although it seems fairly obvious, is the Drug Name. After all, the consumer must know what product it is they are seeing information about. At this point both Pharmaceuticals and CAM are still relatively similar. The next two points is where divergence occurs.
The second most important tenet in Drug Marketing is having a truthful summary. This can be explained simply as the portion of the ad where the manufacturer tells you what the product does, and conforms to the product label. This is actually a good time to draw some attention to that word, “label”. In Regulatory terms, the label refers to not only the label on the actual medical packaging, but also that neatly folded origami-looking piece of paper that you get with your pill bottles, known as the Prescribing Information. The information contained in this label details the circumstances under which a drug should be prescribed, what adverse events are known and expected, effects on geriatric populations, pediatric populations, and pregnant populations. The list goes on, and it is all in the nice piece of paper. That label limits what claims can be said about a Pharmaceutical product.
For example, you cannot say, with a Pharmaceutical product for nasal decongestion that it cures cancer, as it is not in the label. Now, if there have been clinical trials done, and it shows that it does have effects on certain types of cancer, then you could make the claim, but you need accepted and peer-reviewed Science to back the claim. The same is not true for CAM. This is why, if you are a chronic insomniac like myself and you stay up way too late, you see products promising to cure every ill you may have from foot fungus to dehydration (water has been known to do this of course) to impotence.
It is telling that in some cases, these companies do get sued for their deceptive claims. One need only go so far as to look at Berkeley Neutraceuticals, the makers of Enzyte to see this. What they were really sued for was the false promise of “Double your money back” which they offered in their ads, however, it was entered during the trial that the product really did not perform as promised. I wonder if “Smiling Bob” is still smiling?
Another very key point to Pharmaceutical Advertising is what is known as fair balance, and here is where CAM comes up 100% deficient. The key to this is understanding that fair balance tells a complete picture of the story. It gives you both the negatives and the positives in your product. I am sure many of you have seen a drug advertised on television and been wondered about all those negative things that are mentioned. That is part of the fair balance, and it is required that Pharmaceutical companies tell you this. As most CAM is regulated under the Nutritional side of the FDA this fair balance does not exist. They are not under any obligation to say, for example, “Oh, my product contains only water, so while it may quench your thirst, it will not cure your cancer.”
This fair balance must also be clear and not misleading. This became a major issue back in 2008 when Robert Jarvik, M.D. began promoting Lipitor in television commercials. In the commercials, he used the line, “I’m glad I take Lipitor, as a doctor, and a dad.” This is a very very fine line that the FDA eventually stepped in on. Robert Jarvik is, indeed, a Medical Doctor. He did complete Medical School. What he did not do, and has never claimed to have done, is completed his medical internship/residency and is not licensed to prescribe. The FDA’s fear is that, since the advertisement began with the genial line of “I’m Doctor Robert Jarvik, inventor of the Jarvik Artificial Heart.” that people would rely fully on Dr. Jarvik’s recommendation. After Pfizer was made aware of these concerns, they eventually pulled the advertisement. This is a beautiful case study on how one should always be careful not only of the message one is delivering, but also how that message is delivered.
As with everything where regulations are concerned, there are grey areas. This is where trained Regulatory Professionals come in, and we work to ensure that companies stay on the straight and narrow as much as is possible.
References:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229320.htm
http://www.casewatch.org/cp/enzytecmp.pdf
21 CFR 201
21 CFR 202
http://abcnews.go.com/GMA/OnCall/story?id=4138702&page=1

   Airborne Settles Case On False Advertising
Steven Novella 
Link
The story of Airborne – a popular supplement marketed as an “herbal health formula that boosts your immune system to help your body combat germs” – is representative of what is wrong with the supplement industry and how it is regulated in the US. Recently the company that sells Airborne – Airborne Health, Inc – agreed to pay $23.3 million to refund consumers who purchased the product (if they have proof of purchase). This was to settle a class-action law suit brought by the Center for Science in the Public Interest (CSPI) and others claiming false advertising. In the settlement the company did not admit any wrongdoing. While this can be viewed as a minor victory for science-based medicine, it actually highlights the many deficiencies in the system.
For background, Airborne was launched in 1999 as a supplement designed to ward off the common cold. It has been extremely successful, due largely to its slick packaging, a clever slogan that it was developed by a school teacher, and promotion by Oprah Winfrey. The Airborne brand of products has expanded, including pixie powder for children, Airborne seasonal, Airborne Jr., Airborne on-the-go, and others. Advertising urged users to take Airborne at the first sign of a cold or as a preventive treatment if about to enter a germ-filled area, like an airplane. They also cited a “scientific” study that demonstrated Airborne is effective.
What is in Airborne is nothing more than common vitamins and herbs. There is no reason to believe that this particular concoction has any health benefit (beyond the basic nutritional value of the vitamins) or specifically that it enhances immune function or helps fight off infections. David Schardt from CSPI is quoted as saying:
There’s no credible evidence that what’s in Airborne can prevent colds or protect you from a germy environment. Airborne is basically an overpriced, run-of-the-mill vitamin pill that’s been cleverly, but deceptively, marketed.
It should also be noted that Airborne is not without risk because it is a supplement. Airborne contains too much vitamin A. Two pills contains 10,000 IU, which is the maximum safe limit, but the instructions say to take three pills per day. So taken as directed Airborne contains more than the safe limit of vitamin A. This would also have to be added to vitamin A consumed in food, and of course many consumers may also be taking a multivitamin without realizing that Airborne is essentially just another vitamin pill itself.
Airborne is marketed as a supplement – in the US this means it falls under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA a health product can be marketed as a supplement and make “structure/function” claims for the product without any FDA oversight, as long as they place a disclaimer on their label and advertising stating that the claims have not been reviewed by the FDA and that they do not make “disease” claims for the product.
What this means is that any company can put together an essentially random combination of vitamins and herbs and make any structure/function claim they choose (boosts the immune system, gives energy, improves sleep, aids mental focus -whatever) as long as they don’t mention a specific disease by name. There is no FDA oversight to make sure their claims have been validated scientifically.
Companies are still responsible for the claims that they make, but accountability is entirely post-marketing. The Federal Trade Commission (FTC) can take action for false advertising – just as it can with toasters, vacuum cleaners, or any product. And, of course, the civil courts can always be used to seek compensation for any deception or wrong-doing by the company. But there is no pre-marketing oversight – no hurdle to get over before getting to market with specific claims.
In the case of Airborne there was no FTC action – a grass roots watchdog group, CSPI, brought a class action suit for false claims. Specifically they were able to document that there is no scientific evidence to support the claims made for Airborne. In addition, Airborne Health cited a “clinical study” to back its claim that Airborne is effective at preventing colds. But an ABC news investigation reported:
Airborne said that a double-blind, placebo-controlled study was conducted with “care and professionalism” by a company specializing in clinical trial management, GNG Pharmaceutical Services.
GNG is actually a two-man operation started up just to do the Airborne study. There was no clinic, no scientists and no doctors. The man who ran things said he had lots of clinical trial experience. He added that he had a degree from Indiana University, but the school says he never graduated.
In response to these critical news reports (and likely fear of legal ramifications) references to the clinical trial have now been removed from Airborne packaging. Elise Donahue, Airborne CEO, explained: “”We found that it confused consumers. Consumers are really not scientifically minded enough to be able to understand a clinical study.” The packaging has also been changed to remove the claim that Victoria Knight-McDowell (the school teacher) developed Airborne because she was “sick of catching colds,” and replace it with the claim that she created Airborne because she “needed help supporting her immune system.”
What we see here is the evolution of the packaging and marketing of Airborne to conform to DSHEA, which effectively shields them from legal repercussions. Scientific evidence is not needed – so why bother going through the motions of doing a “clinical study.” You are not allowed to claim that you can treat a cold, but you can “support the immune system.” Yet, the public still understands what the product is supposed to do. Airborne has created a market using deceptive claims and now they are allowed to benefit from that market.
The class action suit resulted in a settlement of $23.3 million, but the company has estimated revenue of over $150 million in 2006 alone. Such settlements are little more than the cost of doing business. The FTC is looking into also investigating the company as well, so fines may be forthcoming. While the FTC has taken up some of the slack since DSHEA, and appears sincere about wanting to crack down on fraudulent supplement claims, they are also overwhelmed and understaffed. In addition their fines are often little more than slaps on the wrist – again the cost of doing business.
This situation is not the same as otherwise legitimate companies that behave badly and need to be punished or to compensate wronged consumers. The entire existence and marketing of Airborne is based upon a deception of the consumer. Allowing such companies to continue to do business, with some tweaks to their claims and fines that are a minor inconvenience, has not been an effective protection for the consumer.
Given that Airborne is nothing more than an overpriced (and potentially unsafe) vitamin pill, and that there is no reason (either theoretically or based upon clinical evidence) to conclude that this product is of any use in fighting off germs, as is claimed, Airborne seems to be of no practical use to the consumer. It is a waste of health resources, and may serve as a source of false confidence and therefore distract consumers from effective means of avoiding infectious disease – like simple hand washing. Our current regulations have not prevented such products from getting to the marketplace, nor removed them from the market once the facts come to light.

   Threats to science-based medicine. When clinical trials for new drugs are designed by the marketing division
David Gorski
Link
THREATS TO SCIENCE-BASED MEDICINE
The theme of this blog is science-based medicine. It’s even the name given the blog by our fearless leader, Steve Novella. By “science-based” medicine we generally mean medicine that is both grounded in scientific plausibility based on our best understanding of human physiology and disease as well as in strong evidence from well-designed clinical trials, both of which are extremely important We SBM bloggers tend to concentrate mainly on so-called “alternative,” “complementary and alternative,” or “integrative” medicine because it does indeed represent a major threat to the consensus among medical professionals that medicine should be science- and evidence-based. Moreover, the infiltration of pseudoscientific and antiscientific woo into medical schools, academic medical centers, and medicine at large, coupled with large amounts of money going to promote CAM, both from the government and wealthy private foundations, does represent an extremely worrisome trend that makes all of us, who range from mid-career to retired physicians, fear for the future generation of physicians and their ability to apply science and critical thinking to the evaluation of implausible health claims, such as reiki, homeopathy, applied kinesiology, and the large variety of woo that falls under the rubric of CAM. Worse, this trend began not long after a concerted push to make medicine more science- and evidence-based and less dogma- and authority-based.
Unfortunately, though, the antiscience of implausible health claims is not the only threat that science-based medicine faces. We bloggers here at Science-Based Medicine concentrate on it because its resurgence and infiltration into the very heart of academic medicine represent a sea change in the culture of scientific medicine, which once rightly and without reservation rejected much of what CAM represents as quackery. Also, I can’t speak for others, but pseudoscience interests me; it brings up questions of why people believe irrational and clearly false propositions. That being said, at the risk of ruffling a few feathers among my co-bloggers, I have observed that, if there is one thing that this blog has not to this point emphasized sufficiently, it’s that the commerce of medicine, the very manner in which we develop new therapies, can, if not carefully observed and regulated, represent a threat to science-based medicine even more potent than Andrew Weil, David Katz, and their all-out assault on the very foundations of scientific medicine and drive to return medicine to the days of anecdote-based rather than science-based medicine.
I’m talking about pharmaceutical companies. I’m also about to destroy any opportunity I might ever have to work for or receive any funding from Merck & Company. C’est la vie. A skeptical doc’s got to do what a skeptical doc’s got to do. Not that I won’t at least partially protect myself by adding the disclaimer that the following represents my opinion, and my opinion alone. It does not represent the opinion of my university, cancer institute, or partners.
Now that that’s taken care of, let’s start with a little primer on a pernicious phenomenon known as the “seeding trial.”
PHARMACEUTICAL “SEEDING” TRIALS
What provoked my ire is a study that was published in the Annals of Internal Medicine last week, to which my attention was directed by a friend of mine, PalMD over at denialism blog, as well as over at Health Care Renewal. It is the first article in the medical literature ever to provide “smoking gun” evidence for the existence of a heretofore suspected but never truly demonstrated variety of clinical trial known as a “seeding trial.”
The clinical trial in question is what is now realized in retrospect to have been a seeding trial carried out by Merck for Vioxx. Seeding trials are a special breed of trial that is carried out either shortly after the Food and Drug Administration (FDA) approval of a new drug or while a drug is being considered for approval by the FDA. Normally, one would think that a trial shortly after FDA approval would be for the purposes of post-approval surveillance of a drug for safety and efficacy. After all, the phase III clinical trials that are used pre-approval to establish the value of a new drug are not and cannot cover nearly as many patients as will be taking the drug after it’s approved. There are sometimes rare effects that show up only after a drug has been administered to hundreds of thousands or millions of people. Given that it’s utterly impractical to test a drug on that many people before its approval, and post-approval monitoring is essential.
That’s not the kind of clinical trial we’re talking about here.
What we’re talking about is a study that appears on the surface to be a valid clinical trial–and that might actually be a valid clinical trial–but that is in reality is designed primarily not to obtain new knowledge about a drug, but rather for a different, unspoken and unrevealed purpose. This type of trial, known as a seeding trial, involves coming up with a hypothesis to be investigated that is either not that important or is scientifically redundant (i.e., studied before adequately) and then designing a study in such a way as to get the new drug into the hands of as many primary care physicians as possible in order to influence them to use the drug after it is approved.
Community primary care doctors rarely participate in clinical trials. There are many reasons for this, not the least of which is a lack of training in clinical trial methodology and ethics, but the primary reason is because they are very busy. Signing up patients for clinical trials is very time-intensive. It takes hours to check patient eligibility, explain the trial, obtain informed consent, register a patient with the clinical trial office doing the trial, and doing the necessary documentation. Most community physicians have not been trained in clinical research and do not have the skill set to deal with clinical trial issues themselves, not to mention that individual private offices, even fairly large group practices, lack the necessary infrastructure to support all the documentation and regulatory requirements of clinical trials. Moreover, many community primary care practitioners operate on razor-thin margins; spending that much time signing up patients can seriously jeopardize the financial health of their practice.
Enter the pharmaceutical company and the seeding trial. In such trials, many, many physicians are signed up as investigators, so that each doctor only has to sign up a relatively small number of patients. Thus the effort is not nearly as onerous. Not only that, but the drug company pays physicians for each patient to cover (or more than cover) lost clinical revenue and provides all the support necessary for monitoring and paperwork. Meanwhile the reward for physicians participating is the prestige that comes with being an investigator in a clinical trial, coupled with in essence no financial penalty to the doctor’s practice and not a lot of work. In reality, however, the design of the trial is usually very inefficient for purposes of asking the putative question being asked. For a real scientific question being tested in a clinical trial, more often than not it would be far more efficient to concentrate the patient accrual in a few large academic centers that could find patients much more quickly and already have the infrastructure to do clinical trials. For seeding trials, however, the exact scientific question being asked is almost besides the point, an afterthought. The real, unstated purpose of such trials is to expose as many doctors as possible to using the drug and thereby make them comfortable using it. The real purpose of seeding studies is to make these physicians advocates for the new drug. The real purpose of seeding trials is marketing, not science.
THE ADVANTAGE TRIAL FOR VIOXX
The Annals article drives this point home quite effectively with a case study of the ADVANTAGE (Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness) clinical trial run by Merck. The stated purpose of this trial, which involved 5,557 patients at 600 different sites, was to compare gastrointestinal side effects and tolerability of Merck’s new drug Vioxx with those of an established drug (Naproxen). The results of the ADVANTAGE study were published in 2003 in–of all journals–the Annals of Internal Medicine. (Yes, I do take into account that some of the venom directed at Merck in the article and the accompanying editorial might come from outrage at having been played by Merck.) Not surprisingly, the results of the ADVANTAGE trial showed that Vioxx was superior to Naproxen when it came to gastrointestinal side effects. However, there was a huge problem.
As Merck internal documents clearly show, the ADVANTAGE trial was primarily a marketing tool. Think of it as a direct-to-physician sales pitch, as demonstrated quite clearly by this document, which I urge you to take the time to read. Here’s a key passage from this document originating from Merck’s marketing department:
The ADVANTAGE (Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness) trial is the largest ever initiated prior to the launch of a Merck product. The objectives were to provide a product trial among a key physician group to accelerate uptake of VIOXX as the second entrant in a highly competitive new class and gather data important to this customer group. The trial was designed and executed in the spirit of the Merck marketing principles, as described below.
First, the trial was targeted to a select group of critical customers. The clinical trial program for VIOXX focused primarily on specialists. While they would be critical to early uptake and advocacy for VIOXX, the large majority of prescriptions in the A&A market (~60%) come from primary care physicians. The ADVANTAGE trial utilized this important group of prescribers as investigators. In addition to gaining experience with VIOXX, many of these physicians gained a highly coveted introduction to clinical research.
In other words, the introduction of these physicians to the joys and glory of clinical research was secondary, and the actual scientific question to be answered was dead last in Merck’s considerations. Indeed, the most important part of the memo appears to be the part where it is emphasized how careful the tracking of marketing-related results; i.e., numbers of Vioxx prescriptions written by study physicians during and after the study. There’s also this slide from a Merck presentation, which described the role of the marketing department in the design and execution of ADVANTAGE thusly:
    • Design protocol and oversee execution of trial
    • Select investigator sites
    • Run investigator meetings
    • Choose and manage CRO (clinical research organization)
    • Perform data analyses
    • Prepare publications
That’s right. Merck’s marketing department ran virtually every aspect of this trial.
Worse, even though the first author of the main publication resulting from ADVANTAGE was Dr. Jeffrey R. Lisse, an academic physician not employed by Merck, as reported in the New York Times, he did not have a role in data collection or analysis and was quoted thusly:
“Merck designed the trial, paid for the trial, ran the trial,” Dr. Lisse said. “Merck came to me after the study was completed and said, ‘We want your help to work on the paper.’ The initial paper was written at Merck, and then it was sent to me for editing.”
Clearly, Dr. Lisse was seriously compromised ethically by Merck, as well. He should have either refused to help or demanded a much greater role in the analysis of the data. To do otherwise was to let oneself become in essence a front man for a big pharma-produced marketing document. On the other hand, the inducements are quite hard to resist. What harried academic physician can resist being listed as the first author on a manuscript describing the results of a large, important-appearing clinical trial without having to do all that much work? I’d like to think that, if I were ever put in Dr. Lisse’s position, I could do the right thing, but I’ve never been put in that situation.
Even some officials at Merck were reportedly uneasy about this trial. For example, Dr. Edward M. Scolnick, Merck’s top scientist from 1985 until 2002, was unhappy about the ADVANTAGE trial:
In e-mail messages on April 7, 2001, to Dr. Douglas A. Greene, an executive vice president at Merck Research Laboratories, Dr. Scolnick wrote that he was especially angry because the Advantage trial had no scientific purpose. In theory, Merck set up the trial to show that Vioxx caused fewer stomach problems than naproxen. But Merck had already demonstrated that with the Vigor trial, which tracked more than 8,000 patients for a year.
He also wrote in an e-mail:
[T]he reason we have resisted doing large marketing clinical studies is just this. It opens a lot of data to FDA that compromises the large clinically meaningful trials. Small marketing studies which are intellectually redundant are extremely dangerous and the PAC [Products Advisory Committee] system with the marketing emphasis in CDP [Clinical Development Program, a part of Merck's Marketing Division] on all their studies opens Pandora’s box which we have urged against from the beginning of time. Their budget is now 179 million for CDP—as much as our phase 2/3 new chemical entities used to be. I have told [another Merck colleague] I think it is wasteful.
Dangerous and wasteful indeed. It also brings up several questions, as asked by MedinformaticsMD:
    • If the President of the Research Labs, ostensibly the head of R&D at the company, could not stop such a “seeding trial” study of a drug not yet released and/or its publication, then who was actually in charge of R&D?
    • Was the go-ahead for the study approved by erstwhile CEO Gilmartin? The Board?
    • Was there internal conflict at high levels over this and similar issues of control?
    • Why were “seeding studies” that the head of R&D himself called “intellectually redundant” and “extremely dangerous” being funded, while the needs of R&D and new drug discovery in particular were being underfunded?
The answers to these questions are critical to understanding how controls could have broken down at Merck to the point where such a travesty of a clinical trial could have been greenlighted in the first place.
SEEDING TRIALS: SUBVERTING SCIENCE-BASED MEDICINE
To boil it all down, here’s my perspective on why seeding trials such as this are inherently unethical, regardless of whether the clinical scientific question under study is worthy or the design of the trial can produce an answer to that scientific question. It all comes down to one issue: Deception. There is no way to carry out a seeding trial without deceiving virtually everyone involved below the level of study designers. First, the physicians recruited as investigators can’t be told that they are in fact study subjects as well, given that a main purpose of a seeding study is to determine whether exposing them to the use of the drug under study will change their prescribing habits and turn them into advocates for the glories of the drug. The renumeration and stroking by the drug company also compromise their objectivity to an unacceptable degree. While it’s true that no clinical investigator can ever be 100% objective because all clinical investigators have at least some degree of an emotional investment in the outcome of the studies they design and perform, that’s one reason why we have so many safeguards in the regulations governing clinical trials. Second, few, if any, reputable clinical researchers would be willing to sign on as co-investigators for a trial if they knew the primary purpose of the trial was marketing. Third, the patients recruited as human subjects can’t know one of the major questions of the study, again whether physicians’ prescribing habits can be changed. This alone means that truly informed consent on the part of the study subjects is impossible. Finally, the very committee charged with protecting the interests of human subjects in clinical trials, the Institutional Review Board (IRB), must also be kept in the dark regarding the marketing aspect of the study. The reason is obvious. Virtually no IRB would approve a human subjects study whose major purpose is clearly more for marketing than answering an important scientific and clinical question.
As an accompanying editorial by Harold C. Sox, MD, Editor of Annals of Internal Medicine, and Drummond Rennie, MD puts it:
No one told Annals the true purpose of ADVANTAGE. We learned about it when we received a letter to the editor from Dr. David Egilman, who was a consultant to the plaintiffs’ attorneys in the civil suits against Merck (7). He had access to publicly accessible trial documents, which included Merck employees’ e-mail messages that disclosed the true intent of the ADVANTAGE trial. These messages are the meat of the article about seeding trials published in this issue by Hill and colleagues (8). To our knowledge, this article is the first to provide documentary evidence that proves the existence of seeding trials. Other than an excerpt from a single industry document cited in an article by Kessler and colleagues (9), we have not had “smoking gun” evidence, in which the perpetrators are on public record about why they conducted a trial like ADVANTAGE. The article provides clear evidence that the intent of ADVANTAGE was to increase prescriptions of Vioxx (the study outcome of greatest interest to Merck seems to have been Vioxx prescribing rates). However, despite the large body of documents searched by the authors, they discovered few details about exactly how Merck’s marketing division carried out ADVANTAGE.
The documents do tell us that deception is the key to a successful seeding trial. That information–once it becomes general knowledge–could be the fatal blow for seeding trials. Institutional review boards, whose purpose is to protect humans who participate in research, would probably not likely approve an action that places patients in harms’ way in order to influence physicians’ prescribing habits. If they knew, few established clinical researchers would participate as coinvestigators. Few physicians would knowingly enroll their patients in a study that placed them at risk in order to provide a company with a marketing advantage, and few patients would agree to participate. Seeding trials can occur only because the company does not disclose their true purpose to anyone who could say “no.”
The problem for clinical investigators and busy clinicians, as well as IRBs, is identifying a seeding trial. It’s not as easy as it may seem. In fact, it can be quite difficult without knowledge that is withheld. Keep in mind that the ADVANTAGE trial is the first drug company-sponsored clinical trial for which strong evidence has come to light supporting the contention that it was in fact a seeding trial, and that evidence only came to light because there was a problem with the drug under study that led to a rash of lawsuits. Indeed, that the ADVANTAGE trial was a seeding trial did not become apparent until long after it was published, and an article in the New York Times suggested that its purpose was more for marketing than for science. One possibility is for investigators and IRBs to ask pointed questions about the intent of a trial. However, asking about the intent of the trial may not be enough, and the very issue of “intent” brings up a number of thorny issues in itself, as described again in the editorial:
Asking about intent may be the wrong approach. Does the goodness of a trial inhere in its intent or in something else? An adequately powered trial is good if it tries to answer an important scientific question on which patients should be in equipoise, even though participating physicians will become familiar with a new drug and be more likely to prescribe it. Is the same trial bad if its main purpose is to increase drug sales by habituating trial physicians to prescribing a new drug? Couldn’t the answer to this question depend on the scientific importance of the question that it addresses? The trial would be bad if it addressed a question that lacked merit but good, despite its intent, if the question had intrinsic merit. Does the motivation for the trial make it wrong to participate in it, or does addressing an important, unsettled question make the study worthwhile, despite its intent? Perhaps physicians should focus less on intent and more on the scientific question. The ADVANTAGE physicians should have been asking whether the trial addressed an issue that previous trials had already answered—or should have answered.
Personally, I would answer that a trial is “good” if it asks an important question, is well-designed and adequately powered to answer that question, and the answer to that important question is the primary purpose of the trial. If such a trial habituates its physician-investigators to using the drug being tested and persuades them of its superiority as a secondary outcome, that is not a bad thing–especially if the drug is indeed superior to older remedies. However, habituating physicians to using a new drug so that they prescribe more of it should not be considered in the design of a trial.
With regards to the scientific value of a clinical trial, further complicating the issue, it’s usually anything but a simple matter to ascertain whether the scientific hypothesis to be tested is reasonable or redundant. For example, ten years ago, when the ADVANTAGE trial was being planned and submitted to IRBs, the scientific question to be answered by the trial was not an unreasonable one–if one was not sufficiently aware of the results of the Vigor Trial to point out that the question being asked had already been answered with a high degree of confidence. Moreover, as a matter of general clinical trial design for testing new drugs, there are perfectly valid reasons for doing a trial using many community practitioners rather than academic centers, inefficiencies of this approach notwithstanding. The key advantage is to obtain “real world” data about side effects and efficacy when a drug is prescribed “in the real world,” so to speak. Academic medical centers that do a lot of clinical trials are places with a “rarified” atmosphere, so to speak, as well as resources not available to the vast majority of community physicians not affiliated with an academic medical center. It is often of considerable interest to know how a drug will work “in the wild.” In addition, some inducement is necessary to get community physicians on board, given that the constraints on their time and finances usually make being an investigator in a clinical trial too onerous to undertake. Otherwise, it takes a Herculean devotion to clinical research for a busy private clinician to take the time it takes to enroll patients in clinical trials. With that in mind, I’ve come to the conclusion that, if there is one characteristic that is common in a seed trial, it’s usually that the hypothesis to be tested is redundant. In other words, the trial is asking a question that has already been answered. Certainly, this was the case with the ADVANTAGE trial, as the incidence of gastrointestinal side effects had already been assessed and shown to be lower than those due to Naproxen in an earlier trial known as the Vigor Trial. However, it may not always be the case that the question being asked has alrady been answered. It may be that the question is simply not particularly important, which is admittedly a scientific and value judgment.
FINDING THE BALANCE BETWEEN MAMMON AND SCIENCE-BASED MEDICINE
Given the huge expenses involved in developing new medications and bringing them to market, I am under no illusions that drug development will ever be done to a significant degree by any other entities than for-profit companies, and I would still partner with a pharmaceutical company if that’s what it took to develop a future discovery I might make into a viable drug or treatment. After all, what good is “translational” research if it never gets translated, and pharmaceutical companies will always have a major role to play in such translation. Indeed, the profit motive, when harnessed and regulated properly, is an incredibly powerful incentive to develop better therapies. Unfortuantely, it can also be an equally powerful incentive for drug companies to launch trials like the ADVANTAGE trial. Moreover, pharmaceutical companies are more highly regulated than the CAM practitioners and supplement hawkers who are also threats to science-based medicine.
Nor am I under any illusion that the authors of this study are as pure as the driven snow with respect to objectivity. They clearly are not. Each and every one of them was compensated for participation in the current ongoing litigation against Merck at the request of plaintiffs. Indeed, their access to internal Merck documents reproduced in the Annals paper came about through the discovery process in this massive litigation. In other words, each and every author of this study is a hired gun for the plaintiffs suing Merck, and no doubt this Annals article will feature prominently in the many lawsuits against Merck. I’ve railed against “litigation-driven” research before in the context of, for example, the dubious and pseudoscientific “research” that antivaccinationists generate to support lawsuits against vaccine manufacturers, and this article, although not as scientific article, cannot help but be touched the same sort of taint. I acknowledge that, just as I acknowledge that this article represents only one side of the story. Even so, that particular side of the story is so compelling and so disgusting that it is very difficult to imagine a defense or documents that would come close to balancing the clear marketing purpose of the ADVANTAGE study with a legitimate scientific purpose. Although it is (barely) conceivable that that mitigating documents might come to light during Merck’s defenses against Vioxx lawsuits internal documents largely speak for themselves; res ipsa loquitur, if you will. They make it very clear that the ADVANTAGE trial was a seeding trial using a previously answered scientific question as the basis of a redundant clinical trial whose real main purpose was to “seed” experiences prescribing Vioxx to several hundred primary care physicans.
For science-based medicine to be accepted and trusted by the public, the public must be confident that the clinical trials designed to test the safety and efficacy of new drugs conform to the highest standards of science and clinical research. More importantly, they must know that these trials are as free from bias and hidden agendas as is humanly possible to achieve. No clinical trial will ever be completely free from such potential confounders, but without transparency it is much more likely that such hidden agendas will find their way into them. Also, a personal standpoint, I detest Merck’s actions because it will make it that much more difficult for honest clinical investigators like myself to win patients’ trust and persuade them to agree to participate in clinical trials, particularly trials in which a pharmaceutical company is involved. The distrust will spill over to all clinical trials, even NIH-funded trials. A final reason why seeding trials like ADVANTAGE are so pernicious is because they undermine faith in science-based medicine and contribute to the distrust of “conventional” medicine by corrupting academic physicians, community physicians induced to take part in them, and even clinical science itself. I predict–no, I know–that advocates of unscientific and implausible treatment modalities will draw sustenance for their paranoia and conspiracy-mongering about “conventional” medicine from the ADVANTAGE trial trial. I know that they will frequently shove my nose into the ADVANTAGE trial whenever I argue for scientific medicine.
Whether we advocates of scientific medicine realize it or not, Merck just made our jobs a lot harder.
REFERENCES:
1. Hill, K.P., Ross, J.S., Egilman, D.S., Krumholz, H.M. (2008). The ADVANTAGE Seeding Trial: A Review of Internal Documents. Annals of Internal Medicine, 149(4), 251-258.
2. Sox, H.C., Rennie, D. (2008). Seeding Trials: Just Say “No”. Annals of Internal Medicine, 149(4), 279-280.

   Cavalcade of Quackery: A Pantomine Horse
Wallace Sampson
Link
Last week I received the news release below that Steve Zeitzew, an orthopedic surgeon at VA Hospital Los Angeles and UCLA, sent to the Healthfraud list. It was sent to me by our colleague Liz Woeckner, President of the nonprofit research protection advocacy organization Citizens for Responsible Care in Research (CIRCARE) http://www.circare.org/
Ms. Woeckner sent it on with a cryptic comment, wondering if this action was a quid pro quo for the Chinese granting less than a dozen FDA “inspection stations” in Chinese cities. The latter is supposed to be an attempt to control the impurities and adulterants of Chinese herbal products.
But before proceeding, read for yourselves:
Monday, June 16, 2008 Contact: HHS Press Office
HHS Secretary and Chinese Minister of Health Sign Memorandum of Understanding on Traditional Chinese Medicine Research .
HHS Secretary Mike Leavitt today signed a memorandum of understanding with Chinese Vice Minister of Health Wang Guoqiang to foster collaboration between scientists in both countries in research on integrative and traditional Chinese medicine. The signing marks the opening of a two-day traditional Chinese medicine Research Roundtable at the National Institutes of Health (NIH). The roundtable features scientific presentations by researchers from China and the United States. Topics include the synthesis of Western medicine and traditional Chinese medicine, criteria for evaluating traditional Chinese medicine practices, and the application of modern scientific tools such as proteomics (the study of proteins) to the study of traditional Chinese medicine. “Many Americans incorporate alternative medical practices into their personal health care and are interested in the potential of a variety of traditional Chinese medicine approaches,” Secretary Leavitt said. “This project will advance our understanding of when and how to appropriately integrate traditional Chinese medicine with Western medical approaches to improve the health of the American and Chinese people.” The memorandum of understanding and the establishment of the international collaboration will aid in furthering scientific research on traditional Chinese medicine. Participants in the roundtable include a delegation from the Chinese State Administration on Traditional Chinese Medicine, academics from U.S. universities, and scientists and researchers from NIH, Indian Health Service and the Food and Drug Administration (FDA). Thirty-six percent of Americans use some form of complementary and alternative medicine (CAM), according to the 2002 National Health Interview Survey. In the United States, traditional Chinese medicine is an alternative medical system that is considered a part of complementary and alternative medicine. Integrative medicine combines mainstream medical practices with alternative medical practices. Traditional Chinese medicine involves numerous practices including acupuncture, tai chi, and herbal therapies. In 2007, NIH’s National Center for Complementary and Alternative Medicine (NCCAM) supported nearly $20 million in research on traditional Chinese medicine practices. Secretary Leavitt was joined at the signing by FDA Commissioner Andrew von Eschenbach, M.D., and NCCAM Director Josephine P. Briggs, M.D. The roundtable, which was coordinated by NCCAM, National Cancer Institute’s Office of Cancer Complementary and Alternative Medicine and the Fogarty International Center, is being held in advance of the Fourth Session of the United States-China Strategic Economic Dialogue, which began today in Annapolis, Md.
Each sentence reveals one or more covert messages, errors, and contrary principles which science and medicine would ignore at risk of its demise. Sound over the top? Not really; alarming at least, if government functionaries continue to set health policies indirectly by sponsoring implausible research. .
First, they perpetuate the false dichotomy of “Western” and “TC” medicines. TCM can be compared to scientific medicine or to traditional (19th century and before) Euro-American folk and empirical medicine. They obviously have not been reading us. Do the organizers know what “synthesis of Western medicine and […TCM] means? Do they mean integrating? What?I know of know no self-identified analyst or student of TCM who can make a rational scientific presentation of TCM. One of TCM’s prominent proponents considers scientific controls to be forms of biases. [Kaptchuck T, Effect of interpretive bias on research evidence. BMJ. 2003 Jun 28;326(7404):1453-5;] A concept similar to “roadblocks” to the acceptance of “CAM” in the White House Commission charges. These conceptual deviations are post-modern language distortions, propaganda tools of the “CAM/IM“ movement.
I have pointed out that scientific characteristics were never a part of TCM. It lacked objective observation, consistency of observation, classification of observed phenomena, information storage, rationality and logic, consistent written transmission, objectively descriptive language, and a method for analysis or for interpretation. The system of elements , q’i, and yin/yang did not include a method for developing theories or independent natural conepts. TCM depended on empiricism, unreliable observation, was plagued by post hoc reasoning and causality error. It lacked a concept of error and a system for self-analysis to correct error. In fact, the culture discouraged analysis and criticism, considered to be bad form and disrespectful. TCM depended on individuals who rarely communicated in a formal, direct, manner. Add to that a system that accepted manipulation to suit the mood and concept of the observer or authority. I conclude that there is nothing in TCM to study scientifically. So now they want to develop scientific criteria to apply to their observations? Proteomics? On what? Actions of herbs? Words again fail me at the glaring presumptuousness and ignorance required to conceive such a project. (the “audacity of hope?” .
“Many Americans incorporate alternative medical practices into their personal health care and are interested in the potential of a variety of traditional Chinese medicine approaches,” Secretary Leavitt said. “This project will advance our understanding of when and how to appropriately integrate traditional Chinese medicine with Western medical approaches to improve the health of the American and Chinese people.”
Here again, the assumptions have no basis. One assumption is that a significant number of Americans use [TCM.] Most surveys of use, even those biased favoring “CAM” show no single method reaching above 2 percent or so except for chiropractic and dietary supplements. Most methods lounge at the 1-3 percent level. These levels have plateaued over 2-3 decades even in the face of advertising and positive propaganda. Yet, I suppose that one percent of 300M being 3M, some sort of case could be made. But nothing but a jangling confusion of borderline and conflicting findings will result from further study. Unless they appoint people with critical analysis experience, a wide reading knowledge of the history and use of TCM, and a scientific view, their research conclusions will be indeterminate over the next 10 years or more. They will continue to rely on ideologues, advocates, self-deluded practitioners, and politically correct academics for advice and pronouncements.
They will probably exclude scientific or skeptical analysts, so there is no way they will develop a credible commentary on how best to integrate TCM and improve the health of the American and Chinese people. Well, they got it backwards again. It’s China that has to integrate scientific medicine over there. Their scientists and physicians clamor for it. The Chinese can begin with public health principles like inhibiting spitting in the streets, cleaning up their air (finally but it took the Olympics) personal hygiene, cleaning their toilets, improving their food handling methods, and other systematic changes. They might even follow their own modern physicians’ wishes, abandon their herbal industry and revive their prior inhibition of acupuncture/moxibustion methods instead of promoting the integration of TCM into our medical system.
The memorandum of understanding and the establishment of the international collaboration will aid in furthering scientific research on traditional Chinese medicine. Participants in the roundtable include a delegation from the Chinese State Administration on Traditional Chinese Medicine, academics from U.S. universities, and scientists and researchers from NIH, Indian Health Service and the Food and Drug Administration (FDA). Thirty-six percent of Americans use some form of complementary and alternative medicine (CAM), according to the 2002 National Health Interview Survey.
So there will be an international collaboration to “aid in furthering scientific research…” And they list the kinds of attendees at their 2-day conference. First, who is not there? Representation from the largest group of China’s medical community, its scientific physicians. Up to 6 years ago they outnumbered “TCM” physicians atleast 5:1, and I heard some say 10:1. The two communities of physicians practice by separate rules and traditions, the scientific ones practicing as do others throughout the world. Most of those do not even know much about TCM, and they rarely exchange professionally with the TCMers. They will not be there, of course. Who are the American “academics?” I’ll bet most will be people with NCCAM grants for TCM, some with published papers on acupuncture and TCM, but I doubt more than a token of unconflicted objective scientists, if any at all. Researchers from NIH? Bets from here they are advocates or NIH sponsored TCM researchers. Here we see the same internalized network of special interests at work again, naming one another to consulting positions. Indian health Service? Indian health Service?
They repeat the meaningless “thirty-six percent” figure, which has nothing to do with the number or percent who use TCM (<10 percent.) The true figures are published and they don’t quote them. Perfect for a presidential election year, right?
In the United States, traditional Chinese medicine is an alternative medical system that is considered a part of complementary and alternative medicine. Integrative medicine combines mainstream medical practices with alternative medical practices. Traditional Chinese medicine involves numerous practices including acupuncture, tai chi, and herbal therapies. In 2007, NIH’s National Center for Complementary and Alternative Medicine (NCCAM) supported nearly $20 million in research on traditional Chinese medicine practices.
Well, let’s let the reader incorporate this part…doesn’t add much to me except for the $20M.
OK, at this point you may have thought back up there someplace, how about the big picture? What the… is the federal government through HHS doing in this, mixing international politics with the independent and quasi-free medical scientific enterprise that is operating quite well, thank you? Changes in a scientific system come through a natural evolution based on the accumulation of bits of knowledge, with research proceeding on the basis of the preceding knowledge base. If one wants to study cultural folkway medicines and methods, research would have to be highly selective. One simply cannot study a system as a whole scientifically. That is one of “Holistic Medicine“ and “CAM‘s“ early complaints about “the Medical System,” that they claimed was structured so as to prejudice knowledge coming from traditional systems. Some even believed a conspiracy, constructed to exclude them. Neither can one study each method and material of the thousands in each tradition that is presented or discovered. The selection for research has to be based on the validity of reported observations of those methods most consilient with the scientific knowledge base. One might excuse some private business or foundation seeking some outlet for research funds and that has a personal or organizational (for profit) motive for doing some badly founded research. At least the funding source and even a profit motive would be open and apparent – as we say, transparent – even if we consider their projects highly implausible. But this attempt is a disguise – a pantomime horse hiding its real propulsion mechanism under a distracting cover.
What is HHS doing, using a cover of medical science and for what? The government doesn’t do such things without pressure from some group or perceived self-interest in negotiation. In this case, what are the respective interests? There could be several.
For China, the most apparent is awakening the American population to the hidden miracles of TCM – and the marketing of supplements. Ka Kit Hui, a practitioner in Santa Monica, Calif., been promoting TCM herbs for several decades. I debated him on the subject at Stanford in 1995 or so at which time he extolled the undiscovered miracles in TC herbal medicine. Again in a letter to the editor to JAMA in 1997 he predicted that TCM herbals would be the prime economic product of the 21st century. I dismissed the statement in a response, but here we are, nearly 1/10th the way through the century, and here is TCM herbalism making inroads. China must see a large market, a population at least a third of their’s, and in view of the differences in income, living standard, and disposable income, a market that is at least as large in dollars/yuens as China has at home – probably greater.
What motivates the US? For one, TCMers may be behind the effort. They are on a path toward legitimizing the OMD degree and licensing of TCM practice. They already have acupuncture licensure in a plurality of states. They have a dozen or more schools of TCM. The California state legislature several years ago dropped an attempt to standardize teaching in the California schools – a first step to a standard exam and thus an academic standard for licensure. But they will be back. It took naturopaths over 15 years to get their licensure and degree recognition – another history familiar to Kim Atwood and others. The rest of the ulicensed hordes are following through an accompanying though crippled series of Access to Medical Treatment Acts. They persist – getting bits here and there and then, in an alignment of the planets minute, achieving passage of licensure legislation that imprints their initials in gold.
The formation of the NCCAM was a major step for TCMers. Now an HHS officially- sanctioned 2 day conference opens the plausibility of studying more TCM just as acupuncture systematic reviews are showing indeterminacy to ineffectiveness, herbs are being found more dangerous than helpful, and products from the PRC being found adulterated with metals and with standard pharmaceuticals. A fly on the wall of certain congressmen and senators and of HHS director Leavitt could tell us a lot. (Here we go again with a FOI request.)
As for government sourced motives, as Ms. Woeckner suggested, we probably had to pay a price for the stationing of FDA offices in Chinese cities. I still fail to see what they can do about adulteration of products, much of which could be shifted to way stations in Taiwan or in the US.
Unless someone on the inside squeals or finds that whistle to blow, seems to me we are getting taken to the cleaners again. At least this time it isn’t nuclear secrets given away by a Secretary of Commerce (Hazel O’Leary 10-12 years ago) or nuclear and missile technology sales OK’d by a greedy industry CEO and an unnamed agency as Chinese influence money came through in the 1996 election.
Oh, I think I’m getting it. We graciously level the military playing field in the interest of world peace by sharing nuclear and missile technology with China in return for political contributions. We get stripes and chevrons from the public and press. Then we help level the health playing field, increasing China’s level by sharing scientific advances with Chinese medical authorities and then finance the research. We accept a lowering of American health and medical standards by adopting some of China’s methods. Ya gotta balance those equations.
And finally,
The roundtable, which was coordinated by NCCAM, National Cancer Institute’s Office of Cancer Complementary and Alternative Medicine and the Fogarty International Center, is being held in advance of the Fourth Session of the United States-China Strategic Economic Dialogue, which began today in Annapolis, Md.
Oh.

   “Integrative Medicine Experts”: Another Barrier to Effective Discipline
Kimball Atwood
Link
This is the final entry in the current series having to do with state regulation of physicians.† It is the final one merely because I’m tired of the topic, for now. There is plenty more to write about, including an event that occurred only yesterday right here at my own hospital. I’ll give a preview of that at the end of this post, but first we’ll look at another recent event.
Dazing Arizona 
Arizona’s citizens, more than most, can expect to be bamboozled by pseudomedicine. We’ve seen that the Arizona Board of Homeopathic Medical Examiners has, for years, provided a regulatory safe haven for quacks with MD and DO degrees. Although I haven’t previously mentioned it in this series, which is about quack medical doctors, Arizona is also a haven for another group of quacks: “naturopathic doctors.” Like its homeopathy board, Arizona’s Naturopathic Physicians Board of Medical Examiners has been less than committed to protecting the public from its licensees. In each board’s case, the state Office of the Auditor General has suggested numerous fixes, but there has been little indication of improvements.
Nor would improvements be expected: in the words of Edzard Ernst,
Those who believe that regulation is a substitute for evidence will find that even the most meticulous regulation of nonsense must still result in nonsense.
Arizona is also the home of one of the first academic “integrative medicine” programs, begun by Andrew Weil at the University of Arizona. We have previously seen examples of misleading language emanating from that program. We’ve also seen the program’s inordinate effect on the Federation of State Medical Boards (FSMB). We’ve seen examples of the writings of Kenneth Pelletier, one of the U of Arizona program’s consultants to the FSMB. A recent disciplinary case in Arizona illustrates the potential danger of a state medical board seeking consultation from another “integrative medicine expert” from that program.
The Arizona Medical Board had first disciplined psychiatrist John Dommisse, a practitioner of “nutritional and metabolic telemedicine,” in 2003. As has been the case for other quacks, the Board’s leniency at that time merely postponed the inevitable: new findings resulted in more investigations. Finally, in August 2008, the Board revoked Dommisse’s license to practice “allopathic” medicine in Arizona. [The misnomer itself is an indictment of how political interests get translated into regulatory schemes.]
Dommisse’s practices had included frequent “diagnoses” and reckless treatments of ‘thyoiditis,’ ‘candida overgrowth,’ ‘immune deficiency,’ ‘multiple chemical sensitivity,’ ‘vitamin deficiencies,’ ‘hormonal deficiencies,’ ‘amino acid deficiencies,’ ‘chronic mycoplasma pneumonitis,’ ‘macrocytosis,’ ‘metal toxicity,’ and more. He did not perform physical examinations, nor did he justify such diagnoses on the basis of accepted criteria; rather, he relied on dubious blood tests. An excerpt from the Board’s Findings of Fact in the most recent action (linked above, beginning on p. 10) is illustrative:
In January, 2005, Dr. Scheerer [the Board's consultant] reviewed 10 files from Dr. Dommisse’s office, which had been selected at random. The files were similar in many respects, including the following:
a. an intake sheet prior to the first appointment, consisting of the patient’s main complaints, age medical insurance, willingness to have one-third pint of blood drawn for tests, and notification that Tiburon Diagnostic Laboratory was Dr. Dommisse’s laboratory of choice and that the patient could save significant expense by paying up front privately for tests;
b. a private contract for patients on Medicare, since Dr. Dommisse does not take assignment;
c. a disclaimer form since Dr. Dommisse does not do routine physical examination, only focused examination when indicated…
d. notes in the margin of the intake sheet and a one-to-two-page report of presenting problem, medications, food and drug history, and systemic review; and
e. provisional diagnoses and recommendations with the first recommendation almost routinely being “Several vitamin, mineral, special thyroid and other blood tests to find the causes or other aggravating factors in these conditions” (this recommendation is referred to below as “the standard recommendation”).
Dr. Dommisse then orders a large number of laboratory studies that almost routinely include CBC, chemistry panel, lipid panel, thyroid panel, including anti-TPO autoantibodies, vitamin B-12, vitamin D, vitamin E, IGF-1 (growth hormone), amino acid profile, basic food panel, numerous metals, candida antibodies, Mycoplasma antibodies, and NK ["natural killer cell"] function. Other studies are also frequently ordered including testosterone, estradiol, progesterone, osteocalcin, and free insulin levels.
…
Dr. Domisse did not record a progress-follow-up note on any of the ten charts inspected.
Dr. Dommisse did not record a physicial examination, even focused, on any of the ten charts at any point in his care of the patient.
… Dr. Dommisse’s charts were exceedingly difficult to follow. The SOAP format, which stands for the patient’s Subjective complaint, the physician’s Objective findings, the physician’s Assessment or impressions or conclusion, and a Plan of treatment, is standard for every allopathic physician’s records of every office visit. Dr. Dommisse’s charts do not include any of the SOAP elements. A subsequent physician would have to spend hours analyzing Dr. Dommisse’s charts to have any idea what he did to treat the patient’s complaints with what outcome. The results of treatment were especially hard to ascertain, since Dr. Dommisse did not perform physical examinations. The laboratory results were in no order. Dr. Dommisse made comments on lab sheets that were hard to follow. Dr. Scheerer could not determine Dr. Dommisse’s thoughts on patient care from visit to visit.
Among the Board’s findings were that Dommisse had unnecessarily prescribed estrogen replacement for a 72 yo woman, and then failed to respond appropriately when she reported to him, repeatedly over several years, that she had persistent vaginal bleeding; that he had diagnosed “autoimmune thyroiditis” in almost every patient whose records were examined, without adequate supporting evidence; that he had “alter[ed] laboratory reference ranges to interpret normal laboratory results as abnormal”; that several patients developed abnormal heart rhythms or other manifestations of hyperthyroidism after Dommisse had inappropriately prescribed thyroid replacement; that after diagnosing ”aluminum toxicity” in a 29 yo woman, he “performed chelation therapy without documenting informed consent”; “that, when a patient of Dr. Dommisse decides for whatever reason to seek a second opinion, if the subsequent physician does not understand or agree with Dr. Dommisse’s care of the patient, his practice is to bully the patient”; and that he used “improper Current Procedural Terminology (‘CPT’) coding to bill at a higher rate.”
Among Dr. Dommisse’s rebuttals were these:
…he tells patients that he relies on others to perform physical examinations. He did not show the report of any physical examination by another health care provider…
Dr. Dommisse testified that psychiatrists cannot perform detailed physical examinations. They examine patients by observing them during conversations. He performed his last physical examination approximately 41 years ago.
…
Dr. Dommisse had admitted into evidence a paper he authored entitled “Hypothyroidism: Sensitive Diagnosis and Optimal Treatment of All Types and Grades—A Comprehensive Hypothesis.”
Dr. Dommisse testified that the risks of excess estrogen replacement are “ridiculous.” The dangers of thyroid hormone over-replacement have been “blown out of proportion.”
…
Dr. Dommisse testified that all the substances that he prescribes are “natural” and therefore “harmless.” He placed [a patient on] hydrocortisone, which is identical to the naturally occurring substance. Hydrocortisone cannot be patented because it is identical to the substance that occurs naturally in the body. In contrast, internists prescribe prednisone, which increases drug companies’ profits and may cause harm because it is not natural.
…
His diagnosis of mycoplasma pneumonitis was of a condition that might, if left untreated, progress to “walking pneumonia.”
…
Dr. Dommisse testified that nutritional physicians’ patients do not get tardive dyskinesia. [a devastating, irreversible complication of the long-term use of anti-psychotic medications such as Seroquel, which Dommisse commonly prescribed for anxiety]
…
Dr. Dommisse offered into evidence 21 letters from physicians in support of him, which generally attest to the success of patients that they refer to him rather than specific practices. [He] also offered into evidence letters from 119 patients about their success under his treatment.
Of the Board’s 5-6 consultants for the case, all but one agreed that Dr. Dommisse’s practices and documentation were substandard and dangerous. The exception was Randy Horwitz, MD, PhD, the medical director of the U of Arizona Center for Integrative Medicine. Discussion of his report begins on p. 40 of the Board’s findings. He seems to have bent over backward to judge Dommisse’s practices not only acceptable, but exemplary:
With respect to the Board’s charge that Dr. Dommisse had possibly committed unprofessional conduct by altering the ranges of values that the laboratory had designated as normal, Dr. Horwitz’ initial report rendered the following opinion:
In this most serious charge, I believe that the accusation was ill-stated, vague, and largely unfounded. In examining the laboratory reports in this case, it appears that Dr. Dommisse re-defined the Quest Laboratory reference range to suit his view of where the patients value should optimally lie. This was neither a malicious nor illegal act, in that the lab results form was clearly revised by Dr. Dommisse; indeed, the original reference range is still readable.
Er, wouldn’t that have been for Dr. Dommisse’s eyes only? That is, if the Board hadn’t intervened? Nope, says Horwitz:
It appears to me that Dr. Dommisse actually took the time to discuss each lab value with the patient—and likely modified or discussed his opinion of the ranges in the presence of the patient.
How could Horwitz possibly have known that?
He has circled the patient’s lab value, then noted his view of the optimal values (versus the reference range reported by Quest). Not only is it within his rights as a physician to do such, it should be encouraged. As a consultant, I am often called upon to explain the meaning of the patient’s lab values, since they are not routinely discussed in detail with the patient by the PCP. It is a refreshing change to see this level of detail in discussing lab values.
Ah, a master of self-flattery and strawman erection. No surprise, then, that bait-and-switch comes next:
I might point out that a reference range is not always equivalent to an “optimal value” for a particular lab value. In fact, the “altering” of a reference range is commonly done in Internal Medicine…
Oh really?
Regarding Dr. Dommisse’s charts being “exceedingly difficult to follow,” Dr. Horwitz again demurred: 
I saw no evidence to support these claims. The records were rather complete, and I believe that Dr. Dommisse believes everything he has written. Many conventional physicians disagree with the manner of his practice (Nutritional Medicine), but if we restrict our focus solely to the issue of these allegations, it becomes easier to reach conclusions.
Huh?
There seems to be a special language of record-keeping that only “integrative physicians” can understand:
Dr. Dommisse argued that [none of the other consultants] were his peers because they did not practice nutritional medicine. Only Dr. Horwitz was his peer, and Dr. Horwitz found no fault with his record-keeping or diagnostic practices.
…
Dr. Dommisse testified that Nutritional physicians do not follow the SOAP format in their record-keeping. Other nutritional or complementary physicians, such as Dr. Horwitz, could understand his charts.
And besides:
Dr. Dommisse testified that his patients had told him that they did not want to pay for the additional expense of having him prepare office notes in the SOAP format for each office visit. They preferred to have him spend his time focusing on treatment and care. 
I’m tempted to let that passage stand without comment, knowing that every practicing physician reading it is likely to be overcome with cynical laughter. For non-physicians, however, it might require a bit of explanation. First, real practicing physicians couldn’t imagine being paid more for writing a competent note. Anything less would be unthinkable, even if it means spending a couple of extra hours per day, without extra pay, to do it. Next, the SOAP format was devised precisely to make such documentation as efficient as possible. It is quick, to the point, and easy to follow. Finally, it is unlikely that many patients would volunteer opinions about SOAP notes. Unless, that is, those patients had been urged to do so by a doctor whose practices are not reimbursed by health insurers, and who thus charges patients directly. A doctor not like any that most of us know (other than cosmetic surgeons), but a doctor like Dommisse.
Back to Horwitz: to give him his due, he reviewed only one of Dommisse’s charts, and it’s possible that this chart was an exception to the norm. Horwitz found fault with Dommisse’s initial dosing of thyroid replacement for that patient (p. 43), but that was his only real criticism, in the midst of what otherwise was a generous exoneration.
Horwitz managed to convince the board that there is “a good-faith controversy within the allopathic medical community regarding optimal ranges [of serum vit B12 and TSH levels] for specific patients” and “regarding the appropriate diagnostic test for hypothyroidism.” (paragraph 3, pp. 54-55). Fortunately, that wasn’t enough to get Dommisse off the hook in this case. It certainly demonstrates the danger of “quackademics” judging quacks, however. It is easy to imagine that if the only consultants had been “integrative physicians,” Dommisse would still be ministering to an unwary public. Such a state of affairs already exists in some states, and there is pressure to expand it. New York is an example.
A New York State of Mind
A few months ago we saw that the New York State Board for Professional Medical Conduct had failed to revoke the license of Nicholas Gonzalez in the 1990s, although it had more than ample grounds for doing so. According to Victor Herbert, the board was swayed by the testimony of two academics. Neither was an expert in cancer, but each argued that Gonzalez had a promising cancer therapy. I suggested at the end of that long series that perhaps the reason we’re not likely to see a report of the NIH-sponsored trial of the “Gonzalez regimen” for cancer of the pancreas is that it would demonstrate that the two academics had been wrong, thus spreading much embarrassment: to the New York Board for not having revoked Gonzalez’s license, and to the NIH, Columbia University, and the pertinent IRB for having entrusted Gonzalez with the care of human subjects—which, in at least one case, proved to be more torture than care. 
Although that might not be the reason for the data embargo, the fact remains that a disconfirming outcome would remove the only historical basis for allowing Gonzalez to keep his medical license, and would be embarrassing to the institutions cited above. Even if such a trial outcome becomes public, however, it will probably not result in Gonzalez’s license being revoked. Too much time has passed, and the mood of society has changed—for the worse, regarding purveyors of implausible medical treatments. Gonzalez will probably have to injure a few more patients before the New York Board puts him back in its sights.
At about the time that Gonzalez was being investigated by the New York board, the state was beginning to succumb to the “quacks should be judged only by other quacks” argument, culminating in the Alternative Medical Practice Act of 1994. Here is a description of the Act according to the Foundation for the Advancement of Innovative Medicine (FAIM), a PPO founded by the late “diet doctor” Robert Atkins:
The New York act, Chapter 558 of 1994, amended one section of the education law and two sections of the public health law:
Education Law, Section 6527(4).
(4) This article [Article 131.] shall not be construed to affect or prevent the following:
(e) The physician’s use of whatever medical care, conventional or non-conventional, which effectively treats human disease, pain, injury, deformity, or physical condition.
and
Public Health Law, Section 230, Subdivision 1.
A state board for professional medical conduct is hereby created. . . not fewer than 2 of whom shall be physicians who dedicate a significant portion of their practice to the use of non-conventional medical treatments who may be nominated by New York state medical associations dedicated to the advancement of such medical treatments. . .
and
Public Health Law. Section 230, Subdivision 10(a) Investigation. (ii) If the investigation of cases referred to an investigation committee involves issues of clinical practice, medical experts shall be consulted. Experts may be made available by the state medical society of the state of New York, county medical societies and specialty societies, and by New York state medical associations dedicated to the advancement of non-conventional medical treatments.
[Enacted July 26, 1994]
(Note: New York utilizes legislative intent to clarify terms of laws, in this case, effectively treats is clarified to mean “has been shown to be effective but has not yet gained general acceptance in the United States.”)
Nice weasel-wording. New York has been true to that law: one of the self-described state board members, since 1995, is the Executive Director of the Beth Israel Medical Center’s Continuum for Health and Healing (CCHH), Woodson Merrell. Dr. Merrell seems to believe in every implausible medical claim, no matter how ridiculous. Thus it is unnerving to read that:
At CCHH Dr. Merrell supervises an extensive array of consumer and educational programs. These include training for medical, chiropractic and acupuncture students, as well as for residents and fellowships in integrative medicine. He is a member of the working group on curricular reform for integrative medicine at Albert Einstein College of Medicine. He is committed to public policy and practice standards in integrative medicine, having testified on integrative medicine to both Houses of Congress, as well as New York City and State agencies. He has served as Chairman of New York State’s Board of Acupuncture, and since 1995 has been a Board Member of New York State’s Office of Professional Medical Conduct. Dr. Merrell is on the Steering and Policy Committees of the national Consortium of Academic Health Centers for Integrative Medicine. This is an organization comprising 25% of the nation’s medical schools (including Harvard, Duke, Penn, Columbia, UCLA, Michigan, Einstein, Arizona, UCSF, Maryland, and Georgetown), pledged to transform medical education and physician training with integrative medicine.
…
Dr. Merrell has lectured extensively to both consumer and professional groups on integrative medicine and the nature of healing and wellness. He has been a consultant to many hospitals, medical centers and medical schools to help increase their integrative approach to healthcare. He is a frequent guest for all major media both regionally and nationally, including CBS Morning Show, CNN, MSNBC, WABC, the View, NPR, WBAI, Sirius, Time, Forbes, Barrons, Leaders, W, Elle, Self, NY Times, Wall Street Journal, NY Post, and the Daily News. Dr Merrell passionately believes that integrative medicine is the future of medicine, that there is significant evidence-basis for its use right now, and that utilizing this approach while empowering the patient and providing compassionate, relationship-centered integrative care is critical for transforming the nation’s ailing healthcare system.
Whether or not Merrell or the Alternative Medical Practice Act are responsible, New York seems to be a good home for quackery. While investigating the NIH chelation trial (TACT), I became aware of several New York physicians (TACT Co-Investigators) who practice “Questionable and Deceptive Health Care Practices” in the extreme: their websites are here, here, here, here, and here. With one exception, they seem to have escaped scrutiny by the state board. The exception is Michael Schachter, a psychiatrist who for years has openly admitted to administering Laetrile (“amygdalin“) and numerous other quack treatments. In the 1970s, Schachter was investigated by what was then called the State Board for Professional Misconduct. The Board had reason to believe that Schachter had treated cancer patients “with the drugs Laetrile or MA-7.” 
I haven’t been able to discover the eventual disposition of that case, but it seems to have bothered Schachter enough to have turned him into an activist for “health freedom.” Schachter is another former president of FAIM, and seems to have been a key player in its successful campaign to persuade the New York State legislature to enact the Alternative Medical Practice Act of 1994. According to FAIM, however, the New York Office of Professional Medical Conduct is still harrassing “good” doctors, including several who are pushing “chronic Lyme disease.” Maybe there is some hope.
The Buck Stops…Nowhere
Here is the tidbit I promised you at the beginning. A couple of days ago I received the following email pitch from a nearby group medical practice, about one of its new doctors (“redacted” by me):
We are pleased to announce that _________, M.D., has joined us as a primary care physician in our _______ Center. 
Dr. ________ comes to us from New York where she founded and ran an Internal and Integrative Medicine Practice, implementing a variety of alternative treatments, including life style modifications, nutritional and detoxification protocols, Intravenous Vitamin treatments, Oral and Intravenous Chelation methods, bioidentical hormone replacement, chronic Lyme treatments, and many others.
She completed American Academy of Environmental Medicine courses in allergy treatments and gave multiple lectures in the community to educate the population and promote the practice. Dr. _______ studied management of chronic Lyme treatment with Dr. Richard Horowitz through ILADS sponsored preceptorship and used alternative methods of testing utilizing various laboratories, including Doctor’s Data, Genova Diagnostics, Metametrix, Neuroscience, and Igenix.
Dr. __________ received her undergraduate degree from Brandeis University, her medical degree from St. George’s University and is board certified in Internal Medicine. She is the co-author of several peer reviewed journal articles.
Dr. ___________ says, ”I practice medicine of the future, which keeps my patients healthy instead of labeling them with diagnoses and providing pharmaceutical band-aids. I spend as much time as it takes to look into the root cause and dynamics of potential diseases. Integrative nutrition and healthy lifestyle completes this rejuvenation approach.”
Dr. __________ has already been made a member of the staff of “my” hospital. It seems that the materials she provided to the credentials committee didn’t include the information quoted above. Now that pertinent members of the medical staff are aware of that information, it is still not clear that anything will change, because she won’t be doing that stuff in the hospital—only in the office. I guess that’s not “our” concern.
……………………

   The Pseudomedical Pseudoprofessional Organization (PPO*)
Kimball Atwood
Link
(*Not to be confused with “Preferred Provider Organization,” which shares the acronym)
This is part of an ongoing series† discussing pitfalls of regulating physicians, but I’ve decided, in the interest of flexibility, to vary the title. A couple of weeks ago I gave some examples of how individual physicians practicing substandard, implausible medicine manage to avoid or delay being disciplined by state medical boards. I observed that the boards themselves seem reluctant or slow to act against such practices, even those that are illegal, and that this stands in contrast to their prompt actions against other types of malfeasance: those of the “low-hanging fruit” variety. In a comment, David Gorski reminded me that he had previously offered a few reasons for that discrepancy, with which I agree. Nevertheless, it seems odd that state boards don’t do better.
In an attempt to find more explanations, this week we’ll look at another tactic of practitioners of pseudomedicine: banding together to create pseudomedical pseudoprofessional organizations (PPOs), complete with pseudo-legitimate names, pseudo-legitimate conferences, pseudo-legitimate appearing websites, pseudo-”board certifications,” protocols for pseudo-therapies, patient brochures hyping pseudo-therapies, pseudo-consent forms for pseudo-therapies, pseudo-Institutional Review Boards to approve pseudo-research, pseudo-journals to publish reports of pseudo-research, very real financial contributions from pseudoscientific corporations to help pay for very real advertising, very real lobbying, very real legal representation, and more.
There are many more PPOs than we’ll be able to examine, but they have common features. We’ll also look at how some Institutions That Should Know Better respond to PPOs, which can be frightening.
We mentioned two representative PPOs in Part 1 of this series: the International Bio-Oxidative Medicine Foundation (IBOMF) and the International Oxidative Medicine Association (IOMA), each founded by the late Charles Farr, the “Father of Oxidative Medicine,” to promote intravenous hydrogen peroxide and other dubious treatments. We saw that the IOMA has recently been absorbed by another PPO of which Charles Farr was a founder: the American College for Advancement in Medicine (ACAM).
The ACAM: the Mother of all PPOs
The ACAM, founded in 1973 as the American Association of Medical Preventics “to help educate physicians and to promote the use of EDTA chelation therapy for cardiovascular disease,” stands at the center of what is probably the largest and most insidious family of organizations hyping implausible practices and the “freedom” to peddle them. These include the International College of Integrative Medicine (ICIM; formerly called the Great Lakes College of Clinical Medicine and the Great Lakes Association of Clinical Medicine); the American Board of Clinical Metal Toxicology (ABCMT; formerly the American Board of Chelation Therapy); and the American Association for Health Freedom (AAHF; formerly the American Preventive Medical Association). The roles of each are somewhat different, although there is considerable overlap: the ACAM and ICIM are primarily “educational,” the ABCMT confers “board certification” for “chelation therapy,” and the AAHF lobbies in Washington for the misleading “health freedom” agenda, among other things. (Subsequent to this posting, the AAHF changed its name to the Alliance for Natural Health.–KA)
We have provided a history of those organizations in our article about the NIH Trial to Assess Chelation Therapy (TACT). That history provides abundant documentation for each of the “pseudo-” practices named above, which I’ll not repeat here except to make a few points. First, although I used the term “largest,” these groups are actually quite small. The ACAM has about 1000 members, of which 800 live in the US. This amounts to 1/1000th of the licensed MDs and DOs in the country (there is also a huge overlap in membership among these PPOs, but I haven’t bothered with a formal census). Next, I meant “mother” in the Saddamian sense, not in the “original” sense. The ACAM and its related organizations, like most entities spawned in recent decades to promote implausible medical claims, are part of the House that Laetrile Built.
Laetrile, you’ll recall, is a quack cancer drug that reached its heyday in the 60s and 70s, when it became the most lucrative health fraud in the history of the United States. Virtually all Laetrile pushers were arch-right wing, anti-government Birchers, who had been learning how to fight for “health freedom” since the early 60s and even before. When the drug became illegal in 1979 they were madder than hornets in a stuck nest. To their advantage, but to the detriment of rational medicine and public health, they began to learn how to game the system more effectively, through friends in Congress and other means. The results have included the PPOs discussed here, the Office of Alternative Medicine and its successor, the NCCAM, the Office of Cancer Complementary and Alternative Medicine (OCCAM) of the National Cancer Institute, the attenuation of state medical boards’ authority to discipline physicians for practicing quackery, and more.
Can PPOs Really Be That Insidious?
Most honest, hard-working physicians find it hard to believe that innocuous-sounding “professional” organizations would engage in pernicious activities, but the evidence is there for anyone who bothers to look for it. Is it possible, for example, that a medical organization would create an institutional review board (IRB)—the legitimate purpose of which is to protect human subjects in clinical trials—to provide a veneer of “research” in order to shield its members from regulatory scrutiny of their dubious practices? Well, yes:
GCLAM also has an Institutional Review Board, or IRB, which reviews member’s research projects. This gives these projects IRB status and protection…
The Institutional Review Board of the Great Lakes Association of Clinical Medicine was formed in 1990. The IRB has met National Institutes of Health guidelines…
With an increase in the number of physicians who are under review from state medical boards for practicing alternative medicine, the IRB may offer protection. The IRB recommends that any GLACM members who want to organize procedures in their offices and get peer-reviewed, officially-sanctioned research contact Karen at Dr. Chappell’s office (419) 358-4627, to get guidelines for preparing a proposal.
The GLACM IRB approved numerous nonsensical, dangerous, and unethical trials until it was finally disbanded in 2001, under pressure from the FDA. One of those trials achieved notoriety in the medical ethics literature and the popular press: “Induced Malaria Therapy for HIV/AIDS,” conducted in China by Henry Heimlich (yes, he of the Maneuvre). In spite of that, ACAM and GLACM kingpin L. Terry Chappell, the secretary of the IRB that had approved the study in 1994, flew under the radar when he appeared as the star witness at Congressman (and former Laetrile champion) Dan Burton’s 1999 Hearing of the House Committee on Government Reform, where Burton bullied NHLBI Director Claude Lenfant into accepting, in principle, a chelation trial; and again when Chappell was named by the original TACT protocol (p. 284) as one of the “prominent experts in chelation therapy” appointed to the ”Liaison Committee to the American College for Advancement in Medicine”; yet again when he was made a co-investigator in the trial; and again when he was made a member of the NIH “Special Emphasis Panel” (scientific review committee) that passed judgment on the original protocol, in clear violation of NIH conflict-of-interest policies.
Is it possible that his NIH handlers were so naive? Here are Dr. Chappell’s public views of Heimlich’s malaria-for-AIDS trial, quoted in the Cincinatti Enquirer in March, 2003, only a few months before accrual of the first TACT subjects, but well after it had become clear that Highly Active Anti-Retroviral Therapy (HAART) had revolutionized the treatment of AIDS:
Malariotherapy worth investigating
Dr. Henry Heimlich should be applauded for his research on treating AIDS with malariotherapy. The type of malaria used was easily curable with medications, and indeed there were no serious complications reported in his research project. The research was carried out according to the scientific guidelines.
Medications used to treat AIDS are not highly effective, can be toxic and are prohibitively expensive. Resistance to these medications is developing.
Malariotherapy is much cheaper than conventional drugs for AIDS. Health officials from several African counties have expressed considerable interest in Heimlich’s pilot project. The therapy has the potential to be a major force against one of our greatest disease challenges.
Terry Cappell (sic), M.D., Bluffton, OH
Hmmm. As my colleague Liz Woeckner so aptly put it:
Contrary to Dr. Chappell’s assertion that no serious complications were reported in [Heimlich's] research project, two research subjects [of 30] died. On any account, death qualifies as a serious complication. (4)
You have to wonder what Dr. Chappell thinks scientific guidelines are. The trial protocol had no bibliography, so he and his fellow IRB members had no way in which to judge the scientific merit of the study they approved. IRB members didn’t know the name of the principal investigator conducting the study in China — it’s difficult to understand how they could evaluate the way in which the study was to be carried out if they didn’t know who carried it out. As part of their obligation to research subjects in the review of proposed research protocols, IRB members would need to evaluate the credentials of the investigators and the resources and policies of the institution.
Little PPO, You’re Really Lookin’ Fine!
Is this the sort of person you’d want passing judgment on, and participating as an investigator in, a dangerous, $30 million, 2000-subject trial funded by your money? I believe that at least part of the reason that this happened is found in the slick packaging of groups like the ACAM and the GLACM (now ICIM). We saw in Part 1 that ACAM conferences, including courses on the intravenous administration of the dangerous and illegal drugs disodium EDTA and hydrogen peroxide, are granted Continuing Medical Education credits by the Accreditation Council for Continuing Medical Education (ACCME). The original TACT protocol calls the ACAM “the world’s largest and most respected organization of physicians who employ chelation therapy,” and repeatedly refers to “board certification in chelation therapy” as if that were equivalent to board certification in cardiology, for example. It is not: real board certification means recognition by the American Board of Medical Specialties (ABMS). “Chelation therapy,” of course, is not so recognized.
Lest you think, reasonably, that the NIH failed to notice such shenanigans only because the fix was in (which it was, thanks to Burton), there are reasons to think that there was more to it. It is a fair assumption that for some of the insiders, such “ignorance” was willful. Many others, however, were likely fooled by the hype discussed above. Several years ago, the consumer health website InteliHealth (The Trusted Source®) posted a misleading article entitled “Finding a Doctor Who Understands Complementary And Alternative Medicine.” Like many other articles on that site, it had been written by a faculty member at the Harvard Medical School (HMS). The article advised readers to
Seek out organizations in your community for people interested in complementary and alternative therapy. Look for yoga classes, women’s health groups, or local chapters of national organizations that support alternative health, such as the American Holistic Medical Association and the American College For the Advancement of Medicine. Take a class or attend a meeting. Ask the people you meet about local doctors who provide the therapies that interest you. [Hyperlinks in the original]
I wrote to a dean at HMS to complain about that article, making the point that the ACAM existed to push “chelation therapy,” a dangerous, implausible, and discredited treatment (I also objected to the author’s recommendation of the AHMA, another PPO, but one that at least telegraphs its agenda with “Holistic”). Unbeknownst to me until a bit later, Steve Barrett of Quackwatch had previously complained directly to InteliHealth, making the more colorful point that “referring readers to ACAM members is like referring people who want to borrow money to Mafia loan sharks.”
Editor Howard LeWine replied to him, admitting that the real agenda of the ACAM had escaped the notice of the Harvard reviewers, including “experts in CAM.” What’s worse, they were still unable to discern it when they perused the ACAM website after being tipped off by Dr. Barrett! The result, by the way, was that InteliHealth dropped those recommendations—but only those recommendations—from the otherwise ditzy, promotional article, which is still featured on the website.
Speaking of Quackwatch, there you can find numerous examples of PPOs, many with dead-giveaway names like American Academy of Quantum Medicine (AAQM), but others with names that belie their true identities, ranging from the quasi-environmental American Academy of Environmental Medicine (AAEM), which is all about “toxins” and promotes the fake disease known as “multiple chemical sensitivity syndrome” (MCS), to the how-nerdy-can-you-get National Academy of Research Biochemists (NARB), which is nothing more than a purveyor of fake diplomas.
Getting back to the ACAM for a moment, it has some pretty fine-lookin’ members too, judging by the picture on the website. How holesome and committed they seem! And how versatile!
Attention, Burnt-Out Physicians: Don’t be Bored, Be “Board-Certified”! It’s Quick and Easy!
As mentioned above, legitimate “board certification” in a medical specialty or sub-specialty means being certified by a board that is recognized by the American Board of Medical Specialties. That typically involves post-graduate training in a legitimate residency for 3-7 years or more, often followed by 1-4 years of fellowship training, and passing rigorous, usually multi-part exams. To become “board-certified” by the American Board of Chelation Therapy (now the ABCMT), the last time I looked, required a weekend course, a score of 65% on an examination in which 60% of the questions were True/False, and administering 1000 unsupervised disodium ethylene diamine tetra-acetic acid (Na2EDTA) infusions.
A few years ago I compared the board membership of the ABCMT to that of the American Board of Preventive Medicine, which is recognized by the ABMS and which offers a subspecialty certification in Medical Toxicology. Unsurprisingly, there were no common members. That’s a relief: if you lift the rotten stump at the ABCMT today, you’ll find a den of vermin that’ll make you shudder. Three members, Rozema, Chappell, and Trowbridge, were members of the GLACM IRB discussed above. To the following roster, I’ve added hyperlinks to additional information that’s easy to find—don’t assume that the lack of a hyperlink implies the lack of a quack:
Chairman
Rashid A. Buttar, DO, FAAPM, FACA
Vice Chairman
James M. Holbert, MD, PhD
Secretary
John P. Trowbridge, MD
Treasurer
James Smith, DO
Directors
Theodore C. Rozema, MD, FAAFP, FACAM, CP
H. Joseph Holliday, MD
Robban Sica, MD
Advisors
Robert Rowen, MD
John L. Wilson Jr., MD
Terry Chappell, MD
Peter J. Van Der Schaar MD, PhD, CMT
William Duncan, PhD
H. Vasken Aposhian, Ph.D.
The University of Arizona
Buttar is also the President, and John Wilson the Vice-President, of another notable PPO: the North Carolina Integrative Medical Society (NCIMS). The NCIMS speaks for itself:
Our Position
Who We Are…
The North Carolina Integrative Medical Society (NCIMS) is comprised of dedicated and professional physicians deeply committed to the profession of healing, regardless of the oppression that we encounter or the consequences to us personally for staying true to our calling.
What We Do…
The NCIMS -
Is a viable opportunity for doctors to join a group of like-minded physicians who have recognized that the traditional methods of medicine are lacking. We consider ourselves the “natural option”, if you will.
Offers valuable educational opportunities to our fellow physicians and potential patients.
Helps standardize the methods of practice among the various types of non-conventional doctors.
Assists physicians in protecting themselves against being singled out just because they chose to practice and offer an alternative healthcare option to patients.
Provides a forum for our members to stay connected and share items of mutual interest.
Is a valuable public resource on issues such as malpractice, heavy metal toxicity, and other pertinent health care topics.
The NCIMS has pitted itself squarely against the “oppression” of the North Carolina Medical Board, which just happens to have caught Dr. Buttar in practices that don’t seem very professional, committed to healing, or natural. I guess they must be what the NCIMS calls “alternative healthcare options.” Funny: some very influential people think that Buttar is a great guy. One of them is Congressman Dan Burton.
Where the Money Is
I’m running out of gas, but before leaving this topic I’d like to direct you to lists of sponsors of some of the PPOs discussed above. For the ACAM, go here. Read the blurbs and help yourselves to the websites. Rosemary, Fifi, and Dr. Val are right: quackery is big business. I’ll give you a head start on the second sponsor on the list, because you won’t find this info on its website: American Biologics is the original Laetrile scamufacturer.
For sponsors of the AAHF, the ACAM’s political wing, look here. No wonder that this PPO is so gung-ho to keep DSHEA on the books:
We believe that the Dietary Supplement Health and Education Act of 1994 to be one the single most important events to happen for health freedom. That is why we believe in protecting and defending this bill.

   A New Twist for Autism: A Bogus “Biomedical” Board
Kimball Atwood
Link
Here’s a short addition to the topic of Pseudomedical Pseudoprofessional Organizations (PPOs).† New pseudo-board-certification schemes pop up like mushrooms after a spring rain, but just last week there was an announcement of one with a difference:
The American Medical Autism Board
AMAB offers the first of its kind board/diplomate certification program for medical doctors specializing in biomedical treatment of autism and related disorders. These disorders are known collectively as the Autism Spectrum Disorders (ASD). Thus, medical doctors who become certified by the American Medical Autism Board show that they specialize in biomedical treatment of ASD, and will have met the Board’s high levels of criteria for training and experience, and will have passed its rigorous certification examination.
And:
The intent of the certification process is to provide assurance to the public that a certified autism medical specialist has met the Board’s approved credential requirements in the realms of education and experience, and that he/she has passed the Board’s certification examination.
The process includes an examination that is designed to assess the knowledge and skills that are requisite to the provision of high quality patient care in the specialty of biomedical treatment of the autism spectrum disorders.
Wow. These guys could teach a thing or two to MadMen: keep’em guessing and, like a Bushitsu sensei, turn strident criticism to your favor. Other sCAM peddlers persist in suggesting that infusions of Na2EDTA and DMSA are “natural.” Pejorative uses of the term “biomedical” are common, but not here. The home page of the AMAB site might even fool you into imagining that it is legitimate, if you weren’t already aware of autism’s irresistible attraction to quackery, and if you weren’t familiar with some of the subtler dialects of woospeak. It isn’t until you read the last sentence of the “note” at the bottom of the page that you finally spot the rat that you’ve been smelling all along:
The applicants [sic] background should include one which is integrated and which draws from multiple paradigms.
It all comes into focus when you examine the Board of Directors, and then jump to the site of the US Autism & Asperger Association (USAAA), where the “Overview Course” leading to “board certification” will be held. There you find the telltale pitches for DAN, chelation, hyperbaric oxygen, “craniosacral therapy,” “toxicology,” and more. The Board’s Board and the speaker roster for the 2008 USAAA conference include the Geiers and Dan Rossignol, among others.
What a shame: the USAAA Staff, Board of Directors, and Advisory Board rosters are filled with physicians and other professionals who, for the most part, lack real credentials in biomedical research related to autism. What do they have to recommend them? Overwhelmingly, they are parents of children with autism. I find it hard to muster the contempt that I usually feel for people whose pseudoscientific eruptions contribute to horrible outcomes. Instead I feel an almost futile sense of sorrow.

   Bogus Diagnostic Tests
Kimball Atwood
Link
A few years ago a friend asked me to comment on advice given to her adult daughter by a psychiatrist whom she’d consulted for depression. The psychiatrist had recommended testing samples of saliva and urine for hormone and neurotransmitter levels, the results of which would likely indicate a need for supplements to correct deficiencies or imbalances. According to the psychiatrist, who had an academic appointment at a medical school in New York City, “I have been using these supplements with a great deal of success.” My friend is not medically or scientifically sophisticated, but this made her a little uncomfortable. In that, she was entirely justified.
During our recent panel discussion at the NECSS, a member of the audience identified himself as a clinical pathologist at a major medical center, and wondered what he might do to become involved in the good fight against encroaching pseudoscience in medical schools. Clinical pathology is the medical specialty that concerns itself, in summary, with laboratory tests—their development, their validity, their interpretation, their usefulness and, by implication, their misuse. A topic that we haven’t much featured on SBM (we touched upon it here, here and here, and probably elsewhere) is that of bogus laboratory or other diagnostic tests.
Early in my own education in modern quackery, I found it particularly distasteful not merely that quacks misuse laboratory tests, but that several commercial laboratories market misleading tests. To the untrained eye these laboratories appear to be legitimate, even to the point of their being approved by apparently legitimate certifying bodies. We’ll discuss that below, but first let’s look more closely at the psychiatrist’s recommendations to my friend’s daughter and at other examples of bogus tests.
A Full Service Company
If my friend’s daughter had followed her psychiatrist’s recommendation, she would have sent her saliva and urine samples to a company called NeuroScience, which would have had them tested for certain hormones and neurotransmitters. The psychiatrist would have chosen those tests based on prompting by NeuroScience itself. Here’s what would have happened next:
Based on the laboratory results, NeuroScience, Inc. works with healthcare providers to develop Targeted Amino Acid Therapy (TAAT™) protocols designed to address the spectrum of neurotransmitter and hormone imbalances. Addressing neurotransmitter and hormone imbalances through TAAT™ can lead to significantly improved patient outcomes for a number of today’s most challenging conditions. Why wait? Get Started with NeuroScience, Inc. today.
NeuroScience will even help providers convince insurance companies to pay for the tests. And there’s no extra waiting time, because NeuroScience sells not only the tests, but the remedies. But it sells them exclusively to practitioners, who are then expected to resell them to their patients for a markup (look here for an example of the report that the practitioner will receive). If all goes according to plan, that sweet deal will last quite a while:
It is possible to decrease chances of excitatory overload by introducing inhibitory support for one to two weeks prior to the addition of excitatory support. This 1st phase strengthens just the inhibitory system, allowing it to regain control over the excessive excitatory activity during the night. This often leads to improvements in the quality of sleep in many patients. Excitatory support is then introduced in the second phase to enhance excitatory neurotransmission throughout the day, to increase motivation and reduce fatigue.
The second phase of therapy is structured in a way that mimics the body’s natural circadian rhythms. Excitatory neurotransmitter support, if needed, is typically recommended earlier in the day, when the body requires the energetic and cognitive effects of the excitatory transmitters. Likewise, inhibitory support is typically suggested in the latter half of the day, to calm the body and set the stage for sleep.
Even though specific amino acids can change single neurotransmitter levels rapidly, it is difficult to predict when a patient will experience symptomatic improvement. Many report improvement within the first week, whereas others may require several months of continued therapy to note significant changes. It is our experience that 3-6 months is the average amount of time it takes to optimize neurotransmitters overall.
The transition to the final phase of therapy is recommended when the patient has reached their health goals and their neurotransmitter levels have been optimized, as determined through follow-up lab tests. This phase serves as a maintenance phase, whereby the dosing of products is reduced to the minimum level that maintains the symptom resolution. The unfortunate reality of any approach to neurotransmitter imbalances is that the effects of the intervention may not be maintained with discontinuation. Due to ongoing factors that influence neurotransmitter levels, including stress, diet, and genetics, some individuals will require long-term neurotransmitter support. Hence the focus of the third phase is to maintain optimal neurotransmitter levels long-term to offset factors contributing to their imbalance and in the interest of preventing a recurrence of symptoms. (emphasis added)
Wow! Not only can “addressing neurotransmitter and hormone imbalances through TAAT™ lead to significantly improved patient outcomes,” it can also lead to significantly improved practitioner incomes! What a company! What doc, squeezed by diminishing 3rd-party reimbursements, wouldn’t be tempted to sign up?
There are only a couple of problems. Hormone levels measured in saliva are almost never legitimate. There is no physiologic reason to measure most salivary hormone levels and no generally published ranges of normal levels of hormones measured in saliva. Hormones are typically measured in blood, which makes physiologic sense; some hormones and their metabolites can usefully be measured in urine, but not for the purposes that NeuroScience claims. On the other hand, it is likely easier for NeuroScience to solicit samples when blood-drawing is not involved, and easier for the company to make assertions about “test results” that are unfamiliar to most physicians or labs.
Moreover, even if the test results are technically accurate, I’m aware of no science that links them to non-optimal levels of hormones or neurotransmitters, other than in extreme cases such as pan-hypopituitarism or pheochromocytoma (which are quite different from what NeuroScience is claiming). Nor, even if the tests were entirely legitimate, is there any evidence that the proposed treatments will “optimize” neurotransmitter or hormone levels.
Finally, the conflicts of interest among the seller of the tests, the wholesaler of the supplements, and the retailer of the supplements (i.e., the physician) are obvious.
When Bogus Tests fall into the Wrong Hands
In 2005, an autistic 5 year-old boy died in the office of Dr. Roy Kerry in Butler County, PA, after receiving an intravenous injection of disodium EDTA, the same chelating agent that is being used in the NIH-sponsored Trial to Assess Chelation Therapy (TACT). Kerry, a member of the Mother of all PPOs, the American College for Advancement in Medicine (ACAM), had given this agent to the boy ostensibly to treat “heavy metal toxicity” involving aluminum, mercury, and lead, among other possibilities.
According to the PA medical board’s Factual Allegations, Kerry had used at least two bogus tests to make these purported diagnoses. The nature of the first is unclear, because in the written record Kerry described it only as “testing for the deficiency indicator.” Such vague language suggests not a legitimate blood test but, perhaps, a quack “electrodiagnostic” device such as the “Vegatest” or “Electroacupuncture according to Voll.”
The second bogus test was a “post-provocative urine sample” collected a few hours after the first chelation treatment. This yielded an “elevated” urine lead level, but that is exactly what would be expected for anyone who has just been treated with such a chelating agent, and is thus not indicative of true lead toxicity.
Kerry had also diagnosed the boy with “candidiasis” and “multiple food allergies,” two highly unlikely possibilities that suggest other bogus tests, such as “cytotoxic testing” or the paranormally-based applied kinesiology. He may or may not have used these tests, but such “diagnoses” are common among quacks who preach “detoxification” or who belong to the ACAM.
The Commercial Laboratory Hall of Shame
We are not told the name of the laboratory that Kerry used for the “provocative urine test,” but it was likely Doctor’s Data, Inc. (DDI), a company with a long history of dubious offerings. DDI and another company, Genova Diagnostics (GDX), formerly the Great Smokies Diagnostic Laboratory, sell such bogus tests as hair analysis, urinary amino acids, “intestinal permeability,” “DNA oxidative damage assay,” and various “comprehensive panels” that generate reports explicitly or implicitly calling for “detoxification” schemes, “supplements,” “nutriceuticals,” or “bioidentical hormones,” which participating practitioners are only too happy to provide. Doctor’s Data is proud of its close ties with such PPOs as the ACAM and DAN!, and like GDX is a “supporter” of the ACAM.
Genova also has a cozy relationship with naturopath Michael Murray, a long-time shill for “natural remedies” and co-editor of the Textbook of Natural Medicine, previously discussed here. One of Genova’s former divisions was BodyBalance, which peddles “test kits” directly to consumers ostensibly to measure minerals, hormones, “antioxidant reserves,” and “the body’s natural safeguard for optimal sleep, mood and cell function — melatonin” in saliva, hair, or urine. According to the current BodyBalance website,
BodyBalance is a division of Dr. Murray Natural Living, Inc., that specializes in direct to consumer health screening products. Dr. Murray is one of the world’s leading authorities on natural medicine and the author of over 30 books on natural healing. Dr. Murray and James Kammann, the General Manager of the BodyBalance Division, played key roles in the initial launching of the BodyBalance product line in 1999 when it was launched by Great Smokies Diagnostic Laboratory. BodyBalance was acquired by Dr. Murray Natural Living, Inc. in January 2007.
Our goal at BodyBalance is to help empower consumers to take charge of their health by providing them access to the world’s leading functional medicine laboratory — Genova Diagnostics (see www.GDX.net). Established in 1986 as Great Smokies Diagnostic Laboratory, Genova Diagnostics today serves over 8000 primary/specialty physicians and healthcare providers, offering over 125 specialized diagnostic assessments. BodyBalance has the exclusive rights to direct-to-consumer testing with Genova Diagnostics’ innovative tests — a lab that has achieved the highest national and certain state certification standards including CLIA (Clinical Laboratory Improvement Amendments) and the College of American Pathologists.
Regulation?
How is it that commercial laboratories can so easily flout the standards of their field? Don’t the “certifications” just mentioned mean anything? Well, yes and no. The Centers for Medicare & Medicaid Services (CMS) regulates laboratories through the program identified above, the Clinical Laboratory Improvement Amendments (CLIA). There are other certifying bodies and various state requirements. These initiatives have made it more difficult for laboratories to peddle some dubious tests, but clearly there is still ample opportunity for mischief. Doctor’s Data, for example, calls itself
a licensed CLIA laboratory with appropriate state certifications and participates in numerous quality assurance/proficiency testing programs including the College of American Pathology, New York State DOH and Le Centre de Toxicologie du Quebec.
The company offers numerous other “Qualifications,” including “Chinese Certified Hair Standard GBW 09101.” Genova Diagnostics, as previewed above, is just as confident:
a fully accredited medical laboratory, certified in the areas of clinical chemistry, bacteriology, mycology, parasitology, virology, microbiology, non-syphilis serology, general immunology, hematology, toxicology, as well as molecular genetics by six separate health agencies including the Centers for Medicare & Medicaid Services which oversees clinical labs in the United States under the federal Clinical Laboratory Improvement Amendment (CLIA).
NeuroScience also boasts of the legitimacy of its laboratory tests. It outsources these to a convenient “independent” lab, Pharmasan, which seems to be right next door and which shares its founder with NeuroScience:
Gold Standard Laboratory Testing
NeuroScience, Inc. uses an independent, CLIA certified testing lab that is licensed in every state–including New York, which holds the highest level of qualification standards.
Quackwatch: Your Guide to Bogus Diagnostic Tests
You can’t help but have noticed that many of the links in this post are to articles on Quackwatch. That’s because the site is chock full of useful information about bogus tests, far more than can be found elsewhere. There you will find a more comprehensive list of bogus tests than I’ve mentioned here, and a larger list of laboratories peddling them. You’ll also find an article on “Dubious Genetic Testing” co-authored by the Quackwatch founder, Stephen Barrett, and our own Harriet Hall, and an article about bogus “biomedical treatments” for autism showing that—surprise!—Doctor’s Data and Genova Diagnostics are major players there, too.
One place where you will find nothing at all about bogus diagnostic tests is the NCCAM website. This is unfortunate, because the site is widely touted as providing information necessary to “be an informed consumer.”
To the clinical pathologist who asked the question at NECSS, if you’re reading this, and to any others who may be out there: There is a real need for those with expertise in lab tests to get involved in the effort to expose pseudomedicine. This is especially true for any of you who are involved with CLIA. Let’s hear from you!

   When you can’t win on science, invoke the law…
David Gorski 
Link
Late last week, the anti-vaccine underground was all atwitter. The reason was the announcement of an impending press conference, scheduled for yesterday at noon in Washington, DC that proclaimed:
Investigators and Families of Vaccine-Injured Children to Unveil Report Detailing Clear Vaccine-Autism Link Based on Government’s Own Data
Report Demands Immediate Congressional Action
Directors of the Elizabeth Birt Center for Autism Law and Advocacy (EBCALA), parents and vaccine-injured children will hold a press conference on the steps of the U.S. Court of Federal Claims (717 Madison Place, NW in Washington, DC) on Tuesday, May 10 at 12:00 PM to unveil an investigation linking vaccine injury to autism. For over 20 years, the federal government has publicly denied a vaccine-autism link, while at the same time its Vaccine Injury Compensation Program (VICP) has been awarding damages for vaccine injury to children with brain damage, seizures and autism. This investigation, based on public, verifiable government data, breaks new ground in the controversial vaccine-autism debate.
The investigation found that a substantial number of children compensated for vaccine injury also have autism. The government has asserted that it “does not track” autism among the vaccine-injured. Based on this preliminary investigation, the evidence suggests that autism is at least three times more prevalent among vaccine-injured children than among children in the general population.
I could hardly wait.
After all, the anti-vaccine flacks at Age of Autism started flogging this press conference announcing this report relentlessly immediately upon its announcement. So did other anti-vaccine groups, including SafeMinds, the Autism Action Network, and others. I knew this because I’m on the mailing list for a number of anti-vaccine groups. I do it for you, to keep my finger on the pulse of the anti-vaccine movement and as an early warning system to let me know when they’re up to various forms of chicanery. Being thus plugged in to anti-vaccine blogs and various mailing lists, I can report that the entire anti-vaccine crankosphere was abuzz with excitement and anticipation over the release of this report, so much so that I was starting to wonder if there would be anything there that might be be worth paying attention to. Even FOX News took the bait.
As is usually the case when the anti-vaccine movement announces the impending announcement of some “blockbuster” study or report that will demonstrate—or so they say—beyond a shadow of a doubt that, even against the mountains of epidemiological evidence indicating no correlation between vaccines and autism, there really, truly is a good scientific reason to suspect that all that evidence is wrong and that vaccines are the cause of an “autism epidemic,” when the press conference rolled around yesterday and the report was published, I was disappointed. I thought it would be a challenge. It wasn’t. Still, I view it as my duty to explain why this report is a whole lot of nothing that in fact is entirely consistent with the current scientific consensus that vaccines don’t cause autism, not so much because I have any hope of changing any minds among those who released the report, but for the good of the fence sitters who might come across this report and find it convincing.
Not surprisingly, the report was written by anti-vaccine stalwarts, namely Mary Holland, Louis Conte, anti-vaccine lawyer Robert Krakow, and Lisa Colin and is entitled Unanswered Questions from the Vaccine Injury Compensation Program: A Review of Compensated Cases of Vaccine-Induced Brain Injury. Apparently the buildup was too great. Now that I’ve actually read this report I can’t believe it. It’s just that bad.
If there’s one thing that cranks routinely do when they can’t win their case on science is to shift to other venues to convince people that they are not, in fact, cranks. After all, if they stuck to arguing facts, science, and evidence, they wouldn’t be cranks. They also wouldn’t have a prayer of obtaining influence because the science is so much against them. So, failing at science yet again, what the anti-vaccine movement has done yet again is to move over to law. In essence, they are implying that legal decisions can mean that there is a scientific case to be made in favor of the hypothesis that vaccines cause autism. This is an utterly fallacious argument at its core, because findings of law all too often have very little to do with findings of science. Examples abound, but my favorite one is the scare over silicone breast implants during the 1980s and 1990s. The science supporting the claims that silicone from these implants was causing systemic diseases, such as cancer, autoimmune diseases, and a panoply of other conditions, was never good. In fact, it was weak to nonexistent. None of that stopped an avalanche of lawsuits from bankrupting Dow-Corning in 1995 Later, as more studies were carried out, it was found that there was no correlation between silicone implants and the conditions attributed to them. Even so, it wasn’t until 2006 that the FDA approved these implants again for cosmetic use.
Basically, law is not science, and, as much as lawyers would like you to think that the law can deal with science easily, the two cultures, law and science, are very, very different. In law, for example, the object is to win your case, not to find out how nature works and develop models (i.e., theories) that accurately describe it and predict its behavior. In law, there are no truly objective right or wrong answers about issues of science. There is only the law and how it has been interpreted by courts. Advocacy for one’s position using every tool at one’s disposal and denigrating or ignoring evidence that conflicts with that position is not just acceptable, but mandatory. And that’s what Holland et al do, with little exception. In fact, they go so far as to use the common legal tactic of making like Humpty Dumpty in this passage from Lewis Carroll’s Through the Looking Glass:
‘When I use a word,’ Humpty Dumpty said, in rather a scornful tone, ‘it means just what I choose it to mean — neither more nor less.’
‘The question is,’ said Alice, ‘whether you can make words mean so many different things.’
‘The question is,’ said Humpty Dumpty, ‘which is to be master — that’s all.’
Alice was too much puzzled to say anything; so after a minute Humpty Dumpty began again. ‘They’ve a temper, some of them — particularly verbs: they’re the proudest — adjectives you can do anything with, but not verbs — however, I can manage the whole lot of them! Impenetrability! That’s what I say!’
And that’s what Holland et al also appear to say, as well. Impenetrability based on legal jargon is their shield and their sword. They also fall back on the famous “just asking questions” ploy, so beloved of cranks, which is colloquially known among critical thinkers as JAQing off, which they do blatantly here:
This assessment of compensated cases showing an association between vaccines and autism is not, and does not purport to be, science. In no way does it explain scientific causation or even necessarily undermine the reasoning of the decisions in the Omnibus Autism Proceeding based on the scientific theories and medical evidence before the VICP. Nor does this article have anything to say about state childhood immunization mandates in general.
What this article does point to are unanswered questions about vaccines and autism, a thorny issue that affects approximately one in one hundred and ten children.10On this point, this study strongly suggests the need for further Congressional and scientific investigation to explore the association between vaccine-­induced brain injury and autism and the integrity of this federally-­administered compensation program.
If you admit that what you are peddling is not science (and it most definitely is not), and you can’t show convincing evidence of an association between vaccines and autism (which can only be shown by science anyway), then why even bother? The answer is easy if you understand the authors’ purpose. It is not to demonstrate whether there is a true correlation between vaccination and autism or whether vaccines do cause or increase the risk of autism. Rather, it is advocacy. It is persuasion. It is a tool to use to try to get legislators to change the law, science be damned.
It is propaganda.
The core of the argument in Holland et al appears to boil down to three claims. First, they claim to have found 83 cases of autism associated with vaccine-induced brain injury, which, they claim, makes autism three times more prevalent in children compensated by the Vaccine Injury Compensation Program (VICP). Second, because they base this estimate primarily on children for whom there are reports of “autistic-like” symptoms or who ultimately developed autism, they argue that there is no difference between autism and having been noted to exhibit “autism-like” behaviors or symptoms. Finally, they claim that this means that autism is three times more prevalent in VICP-compensated children than in the general population. Let’s look at these one at a time.
Looking at the second claim first, only a non-physician could make such a risibly silly argument as this and not be expected to be subjected to ridicule:
Because autistic disorder is defined only by an aggregation of symptoms, there is no meaningful distinction between the terms “autism” and “autism-­like symptoms.” This article makes the distinction only to accurately reflect the terms that the Court of Federal Claims, caregivers, and others use. It is not a distinction to which the authors attach significance.
It is not as uncommon as we would like in medicine for conditions and diseases to be defined primarily (or even only) by aggregations of symptoms. Irritable bowel syndrome is an example. Ditto tension headache. Moreover, it is often the context within which those symptoms arise that distinguish one diagnosis from another. In any case, the DSM-IV provides fairly clear diagnostic criteria for autism. If the child doesn’t have enough of these criteria to be diagnosed as autistic, that child could have “autism symptoms” but not autism. In other words, if a child shows a number of odd behaviours but not the classic triad of impairments, then they might have ASD or Asperger’s Syndrome or HFA, but they don’t have autism because the diagnosis of autism depends upon a specific set of diagnostic criteria, and the child doesn’t meet those criteria. If he did, he’d have a diagnosis of autism. It’s just that simple, but Holland et al try to obfuscate by trying to make terms like “autism-like symptoms and similar terms mean what they want them to mean.
Humpty Dumpty indeed.
Nor are diagnostic criteria for a condition like autism spectrum disorders a difficult concept for most people; certainly they aren’t for doctors. Apparently, however, they represent a very difficult concept indeed for Holland et al, who seem to be arguing that any child with autism-like symptoms must have autism. This is akin to arguing that anyone who has a belly ache or diarrhea must have irritable bowel syndrome or that someone who experiences a headache must have migraines. In addition, such an argument assumes that all symptoms are equal when it comes to making the diagnosis of autism.
Regarding the first claim, if we take at face value the claim that there are 83 children compensated by the VICP, it is first essential to compare this number to the number of children compensated by the VICP. This the authors try to do but utterly miss the point in doing it:
This discussion must start with the caveat that we are able only to interpret the subgroup of eighty-­three compensated cases that we have located. Out of a total number of approximately two thousand five hundred compensated vaccine injury claims,137 we recognize that this is a small subset.It is our hope that this preliminary study will lead to more complete study of all cases of compensated vaccine injury. Such a study might provide a far more comprehensive understanding of vaccine injury.
83/2,500 results in an estimated prevalence rate of approximately 3.3%. On the surface, this seems to support the claim that the prevalence of autism/ASD is three-fold higher in VICP-compensated children than it is estimated to be in the general population (around 1%). Of course, there’s at least one problem. The authors are even forced to admit it. Specifically, of these 83 children, Holland et al could only find documentation of autistic symptoms for only 39. The rest of those 83 were “diagnosed” solely on the basis of a parental questionnaire. This lower number results in an estimated prevalence of autism of around 1.6% in the VICP-compensated population, an estimate that is falling into the range of what we would expect in the general population. Given that the VICP population is a skewed sample, most of whom have developmental disabilities, I’d be shocked if the prevalence of autism/ASD symptoms in this group weren’t significantly higher than they are in the general population, given how much overlap there is between symptoms exhibited by children with developmental delay and children with autism. Of course, this “study” is not good evidence that the prevalence of autism/ASD even is higher in the VICP-compensated population. Taking into account the skewed population and the noise inherent in looking at a small population over 20 years, the prevalence of autism in VICP-compensated children does not appear to be detectably different than it is in the general population. That’s even accounting for very loose criteria used by the authors to define who might be autistic. As Prometheus put it:
If the prevalance is higher among people compensated by the VICP, there is a basis for further investigation. It still wouldn’t “prove” that vaccines cause autism – it would simply be an indication for further study.
If, on the other hand, the prevalence of autism among people compensated by the VICP is the same as the general population (or less – see below), the argument that “vaccines cause autism” receives yet another (totally redundant) nail in its coffin.
The problem is that the autism prevalence numbers for the general population – even the educational numbers – use much tighter criteria than used by the authors of this study.
According to a Generation Rescue telephone survey (in other words, a “study” by the anti-vaccine movement iteself), the prevalence of autism is even higher than what Holland et al found in the VICP-compensated group of children. It’s even worse than that, though. In fact, the timing of this study’s release is very, very bad indeed. In an ironic twist of fate that leads me to think that there might justice in the universe after all, shortly before the anti-vaccine movement tried to make hay out of this poorly argued, scientifically nonsensical report, a real scientific study, was released out of South Korea that found the prevalence of autism to be considerably higher than previously believed. Steve Novella even discussed this study earlier today. Basically, in this study, researchers administered a screening test for autism spectrum disorders in a population and then did more detailed tests on children who screened positive. Their results were stunning. The study estimated that the prevalence of autism spectrum disorders was 2.64% in the population studied and that 2/3 of those cases were undiagnosed. True, this study will need to be replicated, but it adds more support for the hypothesis that autism spectrum disorders are more common than previously thought and that a significant proportion of them are subclinical and thus undiagnosed. The timing of this study, of course, couldn’t be worse for Holland et al, because it simply reemphasizes that the prevalence of autism that they think they measured in the VICP population is almost certainly not higher than the prevalence in the general population.
In other words, Holland et al did all that work and wrote all those words in order to add yet more evidence to support what we already know from copious evidence from a large and robust existing body of studies: That vaccines do not cause autism.
They just refuse to realize or admit that that’s what they’ve done.

   A victory for science-based medicine
Peter Lipson 
Link
The following is a collaborative effort by Peter Lipson, MD, a usual contributor to Science-Based Medicine, and Ames Grawert, JD, a soon-to-be-sworn-in attorney working in New York City.
Proponents of science-based medicine have always had one major problem—human beings are natural scientists, but we are also very prone to cognitive mis-steps. When we follow the scientific method we have developed, we succeed very well in understanding and manipulating our environment. When we follow our instincts instead, we frequently fail to understand cause and effect. This is how people on the fringes of medicine and science survive—intentionally or otherwise, they exploit our natural tendency to have too much faith in our own non-systematic observations.
One of the most important examples of this is the anti-vaccination movement (hereafter called the “infectious disease promotion movement” or IDPM). There have always been those suspicious of medicine and science, but the IDPM has taken this a step farther. They encourage people to “go with the gut”, ignoring centuries of science and public health data in favor of superstition. It’s not hard to exploit a parent’s fears. But exploiting these fears leads to real harm as many of us in the blogosphere have documented (and documented, and documented).
The IDPM is so fixed on their false beliefs that vaccination causes some sort of serious harm that they cannot be swayed by evidence. As each piece of their hypothesis is disproved, they move on to the next. Thimerosal doesn’t lead to autism? Then maybe it’s “the toxins”. Once the idea is fixed, there is no way to dislodge it. It simply shifts around a bit.
Since there is no science to lend legitimacy to the infectious disease promoters, they must rely on appeals to emotion. Most of their websites are full of testimonials, misinformation, and outright hostility. And when they really get backed into a corner, rather than hunkering down to do some real science, they sue.
Dr. Paul Offit is a nationally known expert on vaccination. He was featured in an excellent article by WIRED reporter Amy Wallace in which he said, among other things:
She lies.
The “she” in this instance is Barbara Loe Fisher, one of the leaders of the infectious disease promotion movement. She didn’t like this at all. Among her complaints she alleges the following:
The purpose of the Wired article was to create the impression that anyone not in support of universal and mandatory vaccination is irrational, uneducated, unscientific, controlled by fear and a danger to the public health. Wallace and Offit combined in an effort to defame and discredit those not in favor of universal and mandatory vaccination and singled out Plaintiff Fisher, whom the article describes as the “movement’s brain,” and the “media’s go-to interview for … ‘parents [sic] rights’” for condemnation as a liar.
To many physicians and scientists, this type of claim is hard to understand. Science is a process for finding and understanding facts. People can become emotionally tied to their work but science doesn’t care, and scientists often have vigorous debates about their work. Real scientists and real doctors must have thick skins.
So when someone is so attached to their own scientific opinion that they feel a need to use the legal system to protect their beliefs, many of us are left scratching our heads. Why wouldn’t she just try to find evidence to support her beliefs? How can a court possibly have something useful to say about a scientific question? What the Hell?
If you’re thinking that the law shouldn’t work this way — that angry combatants in the battle of ideas shouldn’t be able to leverage defamation law into silencing their more strident critics — you’re right. And it doesn’t. For better or worse, the American first amendment is a vigorous creature. Where other countries would hold defendants liable for negligently false and offensive speech, American law prefers that ideas be spoken, and their value decided by informed citizens, rather than lawyers and judges. This is actually a relatively novel topic in conflict of laws jurisprudence, and regardless of whether its assumption about the intellectual capacity of our public is accurate, it’s a uniquely American approach to the law, and one that Fisher completely ignores.
(FYI — all cases noted below in parentheses are Supreme Court cases, and therefore circumscribe any state defamation law. We don’t even need to reach beyond federal constitutional law to show where Fisher goes wrong.)
Virginia’s defamation laws follow the traditional American model, (although it eliminates the slander/libel, or speech/print distinction). Virginia therefore requires a showing of objective falsity, and a degree of malice, before defamation can be proven. The latter is keyed partially to whether the person pleading defamation is a “public person.” Because citizens should be free to question their leaders, as a matter of free speech, courts will only hold a defendant liable for defaming a public figure if the defamation occurs with actual “Sullivan” malice (referring to a famous Supreme Court case).
Accordingly, it becomes important to define a “public person.” While a private person speaking on a public matter — e.g., a small-time attorney commenting on a high-profile case — counts as “private” (Gertz v. Robert Welch), someone who voluntarily inserts herself in the role of shaping public opinion is a public person (Curtis Publishing v. Butts).
This distinction exists precisely because of people like Fisher. While she’s not a household name, she styles herself an opinion-maker, and has taken the requisite actions to make herself just that.
Critically, when it comes to public figures, the first amendment protects hyperbole, and some pretty wicked satire, too (N.Y. Times v. Sullivan; Hustler Magazine v. Falwell). A statement about someone’s character and honesty — “she lies” — may be offensive. But it’s this kind of vigorous dialogue that the first amendment not only protects, but encourages. Any conclusion to the contrary would hold our capacity for public debate hostage to a few sensitive players who “can’t take the heat.”
If you want a poignant example of just what Fisher’s argument would deprive us of, look no farther than her complaint. While talking about alleged distortions in the Wired interview, she writes:
Although before the Wired article appeared Defendant Wallace interviewed Plaintiff Fisher at length and derived substantial information from her concerning the risks and rights issues that mandatory vaccination begets, she chose not to include content reflecting that information in her article. (emphasis ours)
Give her credit for honesty: Fisher isn’t hiding the fact that, if we accept her argument, the editorial decisions of newspapers are now suddenly subject to judicial review. It may be that American defamation law is too generous, providing too much room for offense. But the line for which Fisher advocates would change one problem for a far more grave one.
In critiquing Fisher’s decision to “lawyer up,” we might also consider her choice of forum. Why federal court? First, note that the sole basis for federal jurisdiction in Fisher’s complaint is “diversity of citizenship.” She’s not pleading a violation of federal law; she’s pleading state-law defamation, but because the Constitution’s framers imagined federal court as a neutral ground between citizens of different states, federal jurisdiction is proper.
In diversity cases, federal courts apply state substantive law (there is no federal common law*). So she’s not trying to avoid state law. I suspect this is a prestige thing. Suing in federal court sounds better than suing in state court, requires better lawyers, and therefore costs more. Call it the Birther/Orly Taitz instinct. Even though litigating in federal court is impossible given the nature of her claim, she’s spurned the (slightly) more plausible venue of state court for the glory of federal court. It’s not gone well. Count this as still further prove that Fisher’s real desire is publicity, and the slim chance of vindication — not the redress of any real legal grievance.
Fisher’s actions betray a fundamental misunderstanding of both science and law. Science requires conflict, and the law does not protect us from the consequences of our ideas or the negative opinions of others. A free society cannot thrive on suppression of conflict, and science cannot progress without an atmosphere that allows vigorous, sometimes painful, debate.
Even before knowing the outcome (which is almost certainly going to sting for Fisher), this case is a major victory for those who favor free speech and the role it plays in science. It highlights the desperation of those whose cult-like beliefs are being discarded by the reality-based community. As the foundations of their beliefs rot, they cling to the hope that the law will save them from the onslaught of science. But they are likely to discover a painful fact: just as you have a right to your own beliefs, others have the right to remark on their arbitrariness and idiocy. Science, like the law, allows us to have our own opinions, but not our own facts.

   Some Encouraging Backlash Against Nonsense
Steven Novella
Link
One of the themes of SBM is that modern health care should be based upon solid scientific ground. Interventions should be based on a risk vs benefit analysis using the best available scientific evidence (clinical and basic science).
As an extension of this, the standard of care needs to be a science-based standard. Science is (or at least should be) objective and transparent, and without such standards there is no way to have meaningful quality control. Without the filter of science there is no limit to the nonsense and magical thinking that can flow into the health care system. Increasingly we cannot afford the waste of fanciful and ineffective interventions, and even if limited resources were not an issue – individual patients deserve better.
It is for these reasons that we oppose the attempts by proponents of so-called complementary and alternative medicine (CAM) to erode or eliminate the science-based standard of care in medicine. Proponents differ mostly on how open they are about this goal, but there is no escaping the reality that at the heart of the very concept of CAM is at least a double standard – one in which the science-based bar for inclusion is lowered for some favored modalities.
Proponents will sometimes argue (against all evidence) that this is not the case but rather that there is prejudice and closed-mindedness against certain types of treatments. This is reminiscent of the claims by proponents of creationism/intelligent design that their beliefs are unfairly treated by scientists and school systems. In fact both cultural movements use the same language and tactics to promote their ideology against the defenders of a science-based standard -the “academic freedom” and “health-care freedom” strategies are two sides of the same coin.
Our primary mechanism for opposing the weakening of the science-based standard in medicine is simply to point to the rhetoric and tactics of the CAM proponents themselves. While they largely operate below the radar, when the light is shone on what they are actually doing the “shruggie” masses sometimes take notice. This occurred recently in Ontario, and provides an excellent example of all that I described above.
The conflict is about the College of Physicians and Surgeons of Ontario’s (CPSO) draft guidelines on Non-Allopathic (Non-Conventional) Therapies in Medical Practice. The first clue that these guidelines are likely to be problematic is in the title – the word “allopathic” is only used by CAM proponents. The term was coined by Samuel Hahnemann, the inventor of homeopathy, to refer to the conventional medicine of his day – prior to the incorporation of scientific methods into medicine. It does not reflect the philosophy or practice of modern medicine, and it is a pejorative term.
The guidelines also assume that “non-conventional therapies” should be incorporated into medical practice. Shouldn’t that be the real question, rather than just assuming they should be then exploring how to do so? The only justification given (the most common one given) is popularity (a fallacy deconstructed numerous times on this blog).
But that aside, here are the recommendations for how “non-conventional” therapies should be incorporated into practice:
Physicians are expected to propose both allopathic and non-allopathic therapeutic options that are clinically indicated or appropriate.
Any non-allopathic therapeutic options that physicians propose to patients must:
- have a demonstrable and reasonable connection, supported by sound clinical judgement, to the diagnosis reached;
- possess a favourable risk/benefit ratio, based on the merits of the option, the potential interactions with other treatments the patient is receiving, and other considerations the physician deems relevant;
- take into account the patient’s socio-economic status when the cost will be borne by the patient directly; and
- have a reasonable expectation of remedying or alleviating the patient’s health condition or symptoms.
Reasonable expectations of efficacy must be supported by sound evidence. The type of evidence required will depend on the nature of the therapeutic option in question, including, the risks posed to patients, and the cost of the therapy.
This superficially may sound fine, but is clearly crafted to lower the bar of scientific evidence for allowing “non-allopathic” treatments into medical practice. The guidelines stress “clinical judgment” rather than evidence-based standards. Further, the only time “sound evidence” is mentioned, it is immediately watered down by qualifying that the type of evidence will depend on the modality in question. Why is that?
The purpose of this language is to allow things like pragmatic studies (unblinded, uncontrolled studies) to serve as evidence for efficacy, something for which they are not designed. This is the sort of thing CAM proponents have been constantly calling for. Andrew Weil has advocated the inclusion of what he calls “uncontrolled clinical observation,” or what has traditional been called “anecdotal evidence.” David Katz from Yale’s Integrative Medicine program has called for “a more fluid concept of evidence.”
The evidence is absolutely clear – the CAM movement is about creating a double standard to allow in medical modalities that are not adequately science based, or to decrease the overall standard of care for medicine with healthcare freedom laws and guidelines that water-down what qualifies as evidence.
Fortunately there has been pushback against these proposed standards. The Canadian Medical Association had this to say:
“The use of complementary and alternative medicine in Canada should be founded on sound scientific evidence as to its safety, efficacy and effectiveness: the same standard by which physicians and all other elements of the health care system should be assessed. When alternative treatment modalities do demonstrate effectiveness, they are usually incorporated into the mainstream of medicine. Therefore, one could argue that complementary and alternative therapies are by definition less demonstrably effective than conventional medical treatment.”
This is exactly correct – CAM modalities by definition have not been adequately shown to be safe and effective, else they wouldn’t be CAM. In other words – we don’t need this special category of treatment. Its only practical functions are marketing and to create a double standard.
Even worse, these standards try to muzzle science-based professionals who would criticize unscientific modalities by including a provision that “non-clinical judgement” should be avoided. This too has caused push-back:
The guidelines may be “interpreted as impressing tight limits on physicians’ ability to state their honest, scientifically sound objections to pseudo-scientific medical theories and ideas,” the Committee for the Advancement of Scientific Skepticism contended. “Their non-conventional medical counterparts feel no such compunction in spreading misinformation about legitimate medical practices such as vaccination, as well as in misrepresenting the scientific standing of dubious non-conventional practices.”
This has also been a long time strategy of the CAM movement – the use of political correctness to silence legitimate criticism. This is a strategy with which I am personally very familiar – attempts at appropriately criticizing unscientific philosophies or claims are often countered with accusations of being closed-minded, bigoted, or even on the take.
Conclusion
The proposed Ontario guidelines are a transparent attempt to water down the science-based standard of modern medicine to allow for what was once called fraud and quackery into medicine, and further to shield such quackery from appropriate science-based criticism. It is no an isolated incident, but is a primary strategy of those hoping to advance CAM into modern medicine.
It is heartening, however, to see that such attempts are now meeting some backlash. Perhaps the CAM proponents have overplayed their hand a bit and those who have been uneasy with the claims of CAM proponents have felt a little more empowered to speak up. Let’s hope this trend continues.

   The fall of Andrew Wakefield
David Gorski
Link
I must admit, I never saw it coming.
At least, I never saw it coming this fast and this dramatically. After all, this is a saga that has been going on for twelve solid years now, and it’s an investigation that has been going on at least since 2004. Yes, I’m referring to that (possibly former) hero of the anti-vaccine movement, the man who is arguably the most responsible for suffering and death due to the resurgence of measles in the U.K. because of his role in frightening parents about the MMR vaccine.
I’m referring to the fall of Andrew Wakefield
Wakefield has shown an incredible ability to avoid the consequences of his actions, so much so that, as recently as the end of 2009, what has happened to him over the last month or so would have been almost unthinkable to me. No, I’m not referring to Wakefield’s having been found guilty by Britain’s General Medical Council of grossly unethical behavior with respect to his conduct while carrying out the “research” (and I use the term loosely) that resulted in his trial-lawyer funded, incompetent, and quite likely scientifically fraudulent 1998 Lancet paper. It was the study that launched the most recent (an possibly most virulent) iteration of the anti-vaccine movement, led to dramatically decreased MMR vaccination rates in the U.K., and launched a thousand quacks in the form of the “autism biomed” movement, which has in essence made autistic children the victims of unregulated and sometimes dangerous experimentation all in the name of trying to “cure” them of their autism. The price autistic children have paid for Wakefield’s pseudoscience is horrific enough, but the potential price that thousands of children, both autistic and neurotypical, are paying and will likely continue to pay in terms of suffering from vaccine-preventable diseases, will probably be even worse.
As I’ve pointed out before, I was quite happy when the British GMC told it like it is, so to speak, and found Wakefield guilty of research misconduct and in no uncertain terms called him “irresponsible and dishonest.” I was not surprised that the GMC had ruled against Wakefield; I was, however, surprised at the vehemence of the ruling and that it took three years after revelations by investigative journalist Brian Deer for the GMC to convene proceedings against Wakefield. Ironically, it was after those revelations, described in a Sunday Times investigative report and a TV news documentary on the U.K.’s Channel 4 entitled MMR: What They Didn’t Tell You, that Andrew Wakefield himself demanded the GMC investigation to “clear his name.” On February 23, 2004, the day after Brian Deer’s article Revealed: MMR research scandal that Andrew Wakefield himself was quoted as saying:
Serious allegations have been made against me in relation to the provision of clinical care for children with autism and bowel disease, and the reporting of their disease. It has been proposed that my role in this matter should be investigated by the GMC. I not only welcome this, I insist on it and I will be making contact with the GMC personally.
Be careful what you ask for, I always say.
As I pointed out, the verdict of the GMC alone was not enough to bring about Andrew Wakefield’s fall. Indeed, I’d consider it, to use baseball parlance, strike one. Or, to mix metaphors as I am wont to do at times just for the heck of it, it could be viewed as the first piece of rock or ice to start falling from a mountainside, triggering more rocks to fall and ultimately leading to an avalanche that buried Wakefield. The second strike (or second rock, to continue my habit of mixing metaphors) occurred less than a week later, when the editors of The Lancet finally did the right thing. True, it took them six years after revelations of Wakefield’s conflicts of interest in the form of payments from trial lawyers and his having applied for a patent on a vaccine to compete with the MMR plus his research misconduct in the form of having performed medically unnecessary invasive procedures such as lumbar punctures and colonoscopies on autistic children were first brought to light by investigative journalist Brian Deer, but at least they finally did the right thing. They retracted Wakefield’s 1998 Lancet article from the scientific literature. That doesn’t even cover the revelations from nearly exactly a year ago, once again revealed by Brian Deer, that Wakefield was not only in the pocket of trial lawyers who wanted to sue vaccine manufacturers to the tune of £435,643 in fees, plus £3,910 expenses but he may well have committed scientific fraud in how he carried out his Lancet study.
From my perspective, the editors should have retracted Wakefield’s study back in 2004, when ten of the original thirteen authors retracted their support for the article and its interpretation. At the time, Andrew Wakefield and Peter Harvey refused to to retract. If the the editors had had any guts back then, they would have retracted the paper then and there. It would have been the right thing to do. After all, the editors all but admitted that Wakefield had violated The Lancet‘s rules on disclosure of conflicts of interest. Come to think of it, if Andrew Wakefield and Peter Harvey had had one iota of honor, they would have retracted the paper themselves, as honorable scientists do when serious flaws are brought to light. Not surprisingly, Wakefield did no such thing, because he is not an honorable man. Moreover, it should be noted that the involuntary retraction of a scientific paper by the editors of a journal is a very rare thing, particularly by a journal as high profile as The Lancet.
Wakefield’s dishonesty and lack of honor aside, up to this point, up to the two strikes against Wakefield, his supporters continued to rally around him. Two months earlier, the anti-vaccine National Vaccine Information Center (NVIC) had invited Wakefield to be its keynote speaker at its annual pseudoscientific conference, even going so far as to award him its Humanitarian Award. Then, in the weeks leading up to the expected GMC verdict at the end of January, the anti-vaccine propaganda blog Age of Autism ramped up its praise of Andrew Wakefield, even likening him to Galileo and the GMC to the Inquisition. As they say, to claim the mantle of Galileo, it isn’t enough to be “persecuted” for your views. You have to be right. Andrew Wakefield was anything but right. AoA also published a whole series of posts by John Stone and Martin Walker trying to discredit the GMC in advance of the expected ruling, along with pure idiocy published by Mark Blaxill. There was even a defense of “that paper” by Andrew Wakefield himself, plus a new “study” published in a new autism vanity journal claiming to have replicated Wakefield’s findings. Clearly, the crew at AoA was pulling out all the stops.
As I pointed out three weeks ago, the anti-vaccine movement continued to circle the wagons after the GMC ruling, but the defenses of Andrew Wakefield and attacks on his critics continued even after the Lancet retraction. The most bizarre of these came, courtesy of–who else?–Generation Rescue. In rapid succession, GR’s spokescelebrities Jenny McCarthy and Jim Carrey released a statement, soon followed by the founder of GR, J.B. Handley. The message? Well, here’s what Jenny and Jim said in a statement entitled, appropriately enough A Statement from Jenny McCarthy & Jim Carrey: Andrew Wakefield, Scientific Censorship, and Fourteen Monkeys (mirrored on the Generation Rescue website):
Dr. Andrew Wakefield is being discredited to prevent an historic study from being published that for the first time looks at vaccinated versus unvaccinated primates and compares health outcomes, with potentially devastating consequences for vaccine makers and public health officials.
It is our most sincere belief that Dr. Wakefield and parents of children with autism around the world are being subjected to a remarkable media campaign engineered by vaccine manufacturers reporting on the retraction of a paper published in The Lancet in 1998 by Dr. Wakefield and his colleagues.
But what was the study that the nefarious Vaccine Illuminati were going so far to squelch? Take a guess:
Behind the scenes, the pressure to keep the work of Dr. Wakefield and his colleagues from being published is immense, and growing every day. Medical journals take extreme risk of backlash in publishing any studies that question the safety of the vaccination program, no matter how well-designed and thorough the research might be. Neurotoxicology, a highly-respected medical journal, deserves great credit for courageously publishing the first phase of this vaccinated monkey study.
Yes, it’s the execrable unethical waste of primates to the cause of pseudoscience that I’ve blogged about twice before under the titles Monkey Business in Autism Research and Monkey Business in Autism Research, Part II. The excellent skeptical blogger Prometheus also deconstructed the study in A “Made for Court” Study? Read those posts if you want the gory details. Suffice it to say, that once again Wakefield was pushing bad, bad science, and, unfortunately, had managed to fool the hapless and apparently naive reviewers and editors at NeuroToxicology to publish the first part of his study. J.B. Handley added to this conspiracy theory vibe, apparently while trying to channel Cuba Gooding, Jr. and Tom Cruise in Jerry McGuire by repeating “Show me the monkeys!” eleven times in the course of his post. Even David Kirby launched his own bit of dissembling nonsense on that repository of all things quackery, The Huffington Post, in a post entitled The Lancet retraction changes nothing.
I thought so, too, David, at least in terms of the lionization of Andrew Wakefield by the anti-vaccine movement, but it turns out I may be wrong, as we shall see, but it took one more thing to change everything. But what was that one more thing, that strike three, that beginning of the real avalanche that buried poor Andy?
It happened one day after J.B. Handley’s “show me the monkeys” cry (or, at least, it was noticed one day later), making me think that Handley knew something was coming. That something arrived when NeuroToxicology withdrew Wakefield’s previously accepted “monkey business” paper. Not surprisingly, the lunatic fringe of the anti-vaccine movement viewed this as still more evidence that there was some sort of conspiracy theory against Wakefield. Topping off the conspiracy-fest, Ginger Taylor drew an elaborate chart of the nefarious forces in a post she called Anatomy of a witch hunt, leading a certain friend of this blog to ask, “But what about the Illuminati and David Icke’s reptilians?” While rational people could but shake their heads in disbelief, believers reacted to the charge of conspiracy theory correctly leveled against them by lamely claiming that the American Revolution started out as a conspiracy.
Meanwhile, the reaction of AoA was, surprisingly, much more subdued and delayed. So, surprisingly, was the reaction of the very same organizations that had so defended Wakefield, such as SafeMinds. Editorials defending Wakefield still showed up on AoA, and Mark Blaxill even managed to get a pro-Wakefield editorial published in USA TODAY, but they didn’t mention the withdrawal of Wakefield’s NeuroToxicology study. This presaged something I never would have expected. On Wednesday evening, a message appeared on the Yahoo! Thoughtful House Group:
Dr. Wakefield has resigned from Thoughtful House
The needs of the children we serve must always come first. All of us at Thoughtful House are grateful to Dr. Wakefield for the valuable work he has done here. We fully support his decision to leave Thoughtful House in order to make sure that the controversy surrounding the recent findings of the General Medical Council does not interfere with the important work that our dedicated team of clinicians and researchers is doing on behalf of children with autism and their families. All of us at Thoughtful House continue to fight every day for the recovery of children with developmental disorders. We will continue to do our very best to accomplish our mission by combining the most up-to-date treatments and important clinical research that will help to shape the understanding of these conditions that are affecting an ever-increasing number of children worldwide.
Jane
Jane, in case you weren’t aware, is Jane Johnson. Yes, that Jane Johnson, as comment from Liz Ditz pointed out and provided some relevent background, first from 2008:
In 2007 alone, Thoughtful House saw 1,500 new patient requests — or about 60 percent of the center’s current total patient load — and almost a 50 percent increase in new patient requests in the last six months, says Anissa Ryland, director of operations. Thoughtful House’s funding, which comes largely from foundations and private donors, has also been rising steadily in the last two years. From 2005 to the end of 2007, the nonprofit saw a 48 percent increase in private donations and an 84 percent increase in donations from foundations and trusts, Ryland says. In the past two years, the nonprofit raked in $5.5 million in donations.
And then from Kristina Chew:
A number of celebrities and “prominent central Texans” are supporters of Thoughtful House. Former Dell Inc. executive Charlie Ball and his wife, Troylyn, are among the founders of Thoughtful House; their son has “struggled with physical and developmental problems.” The co-managing director of Thoughtful House’s board is Jane Johnson of New York, part of the family of the Johnson & Johnson health care products and services company. Johnson (who co-authored Jepson’s book, Changing the Course of Autism) and her husband, Chris, donated $1 million to lay the groundwork for Thoughtful House in 2004:
Naturally, I can’t resist suggesting that, given that a heiress of the Johnson family of the Johnson & Johnson pharmaceutical and health products company is a founding donor of Thoughtful House when it was established in 2004 and sits on its board of directors, that, by Jake Crosby’s logic on Age of Autism, Wakefield has clearly been a minion of big pharma at least since 2004. Given how often AoA fequently calls Dr. Paul Offit “Dr. PrOffit” and Robert F. Kennedy, Jr. calls him a “biostitute,” perhaps the science-based community should start calling Andrew Wakefield the same thing.
Now here was a bombshell. At first, I wasn’t even sure whether to believe it was true. After all, since its founding in 2004, Andrew Wakefield has been the face of Thoughtful House, and it was his fame that attracted patients. Few people have heard of Drs. Arthur Krigsman or Bryan Jepson, but everybody knows Wakefield, at least in the autism “biomed” circles. My guess at the time was that Wakefield’s notoriety due to the recent one-two punch of his having had an unfavorable ruling by the GMC followed by the retraction of his 1998 Lancet paper might have become a problem for Thoughtful House in that it might have brought unwanted attention from the Texas Medical Board and other local authorities. Add to that the retraction of the very last shred of Wakefield’s apparent (to anyone beside those who pay attention to his story) scientific credibility, his monkey study, and it’s possible that saner heads wanted Wakefield gone. It turns out that it was true. Wakefield was toast. On February 18, the day after the cryptic announcement appeared, Andrew Wakefield’s name disappeared from the list of Thoughtful House staff, as did his defense of his Lancet article published after the GMC ruling. On Friday, the news was confirmed by mainstream news sources. Then yesterday, Brian Deer reported:
Five days later [after the GMC ruling], the Lancet retracted Wakefield’s research. “It was utterly clear, without any ambiguity at all, that the statements in the paper were utterly false,” Dr Richard Horton, the journal’s editor, told The Guardian. “I feel I was deceived.”
The following day, Dr Joan Marie Cranmer, editor of the specialist journal Neurotoxicology, told her New York publisher that she would withdraw a new Wakefield paper, already released online, which also claimed to incriminate vaccines.
It’s understood that Cranmer “took another look at the paper” in the light of a GMC finding of research dishonesty, but a spokesman for the publisher, Elsevier, declined to comment. “It would be inappropriate to go into a lot of detail,” he said.
The Neurotoxicology decision is believed to have been the last straw at Thoughtful House, a centre founded in 2005 by the rich parents of developmentally-challenged children. The clinic was set up to enable Wakefield to continue activities which in October 2001 saw him fired from a London research position, and which eventually led to the GMC charges.
Within two days of Wakefield’s resignation, it was announced that Dr. Krigsman was also leaving Thoughtful House:
Re: Dr. Krigsman
Dr. Krigsman’s decision to relocate his clinical practice to a facility outside Thought House reflects his belief that the complexities inherent in a referral-based practice can be best addressed by his working independently. We will continue to refer patients for GI evaluations when appropriate, and we look forward to continuing to work with Dr. Krigsman on research projects. We are grateful to Dr. Krigsman for his dedication to Thoughtful House and for the work he does on behalf of the children we serve.
Just to be clear, this is official.
Jane
It looks as though a purge was under way at Thoughtful House, most likely instigated by Jane Johnson. Adding to the impression that Wakefield’s departure from Thoughtful House was not voluntary is this:
In further brief comment on the departure, Jane Johnson, a Thoughtful House board member and also executive director of the US Defeat Autism Now organisation of alternative practitioners, said that those who knew Wakefield “will not find it implausible” that he quit for the good of the centre.
Observers say that the doctor may now be the victim of a domino effect, which threatens to see him lose his fellowship of the UK’s Royal College of Pathologists, which he obtained in 2001 on the basis of a submission of his publications, and even potentially spark the collapse of a new celebrity-led American anti-vaccine movement.
So, in a period of time encompassing January 28, which is when the GMC decision was first announced, to February 17, which is when Wakefield was apparently forced to resign from his position at Thoughtful House, all the accumulated pseudoscience, dishonesty, conflicts of interest, and incompetent research finally caught up with Andrew Wakefield and reduced Thoughtful House from three practitioners of autism woo to just one. It was a breathtaking fall to those of us who have been following the case for years. So slimy and slick has Wakefield been that I had honestly thought that he could weather even the GMC ruling plus the Lancet and NeuroToxicology retractions. I was wrong. It was three strikes that sent Andy back to the dugout.
So what now?
Clearly, the retractions of Wakefield’s 1998 Lancet and his 2009 NeuroToxicology papers were the last nails in the coffin of whatever zombie of Wakefield’s scientific respectability remained to shamble about and eat the brains of hapless and unsuspecting journal editors. Those two developments guarantee that for the foreseeable future Wakefield will almost certainly not be able to fool a respectable journal into accepting one of his manuscripts again. He will thus be relegated to publishing in crank journals like JPANDS and Medical Veritas. The stream of seemingly respectable “research” would thus dry up and further compromise Thoughtful House’s ability to raise cash and attract patients not belonging to the anti-vaccine fringe–which is almost certainly why Wakefield had to go. In light of this development, I see a clinic in central America or someplace with similarly lax regulation of medical clinics in Wakefield’s future. Or maybe someplace as close as Tijuana. He could even still live in the U.S. and commute across the border.
Or maybe not. Autism pseudoscientists and quacks are nothing if not, as James Randi would put it, unsinkable rubber ducks. Wakefield is down, but I wouldn’t count him out–unfortunately. After several days of utter silence, Age of Autism’s very own Dan Olmsted published an interview with Wakefield in which Wakefield states that he will “move on to a new phase of leadership in the autism community” after leaving Thoughful House and going on the offensive to answer the GMC’s ruling. Never mind that it had been nearly four days after his resignation and two days since the mainstream press had started reporting on his departure. In that context, Wakefield’s announcement comes as anticlimactic at best.
The only question that I have remaining is this: Who would want Andy now? My top two guesses would be a position with either Generation Rescue or SafeMinds, the two premier organizations promoting autism pseudoscience these days. I fear we won’t have too long to wait for the answer promised us in his Age of Autism press release.

   The General Medical Council to Andrew Wakefield: “The panel is satisfied that your conduct was irresponsible and dishonest”
David Gorski
Link
BACKGROUND
In my not-so-humble opinion, the very kindest thing that can be said about Andrew Wakefield is that he is utterly incompetent as a scientist. After all, it’s been proven time and time again that his unethical and scientifically incompetent “study” that was published in The Lancet in 1999 claiming to find a correlation between vaccination with MMR and autistic regression in autistic children with bowel symptoms was at best dubious science and at worst fraudulent. For one thing, as investigative journalist Brian Deer found, Wakefield was in the pocket of trial lawyers, who were interested in suing vaccine manufacturers, to the tune of £435,643 in fees, plus £3,910 expenses beginning even before his infamous “study” started accruing patients. Even though the study itself used the typical careful and relatively neutral language that we all expect from scientists, Wakefield himself was not nearly so circumspect. In a press conference announcing the Lancet study, he said:
He told journalists it was a “moral issue” and he could no longer support the continued use of the three-in-one jab for measles, mumps and rubella.
“Urgent further research is needed to determine whether MMR may give rise to this complication in a small number of people,” Dr Wakefield said at the time.
And so began one of the most contentious health stories of this generation.
Wakefield’s Lancet paper, even interpreted as sympathetically as possible, concluded nothing that justified such language. Yet his rhetoric, along with sensationalistic and credulous British journalists, ignited a firestorm of fear over the MMR that has not yet subsided now, over a decade later. Vaccination rates plummeted in the UK, and measles, a disease once thought to be under control, has surged back and become endemic again. It is a feat that Jenny McCarthy and Jim Carrey appear to be trying to replicate right here in the U.S. with their wonderfully Orwellian-named Green Our Vaccines activism and ceaseless promotion of anti-vaccine messages.
More recently, at the Autism Omnibus hearings, we learned from a world expert in the polymerase chain reaction, Dr Stephen Bustin, that the techniques used in the laboratory running PCR on the clinical specimens from Wakefield’s clinical trial were so shoddy, so devoid of routine controls necessary in any PCR experiment, that the measles sequences reported as amplified in Wakefield’s followup to his Lancet study were false positives derived from plasmids with measles sequences in them contaminating the laboratory. Then, in late 2008, Mady Hornig and colleagues at Columbia University published an attempted replication of Wakefield’s study. They failed. There was no association between vaccination with MMR and autistic regression, nor could Hornig find any evidence that measles in the gut was any more common in the autistic children studied than in the neurotypical controls. This study was particularly devastating to Wakefield because it was carried out by a researcher who had previously been sympathetic to the myth that vaccines cause autism, as evidenced by her infamous “rain mouse” study and, even more close to home, using the same laboratory that had performed Wakefield’s PCR, which had apparently cleaned up its act in the years following its work on Wakefield’s specimens.
When it comes to the science, there is no doubt. No reputable scientist has been able to replicate Wakefield’s findings, and there is a remarkable convergence and agreement of findings of major studies looking for a correlation between MMR vaccination and autism: There ain’t one. Indeed, closing out 2009 was the publication of yet another study that failed to find any correlation between MMR and autism, or, as I put it at the time, yet another nail in the coffin of the myth that the MMR vaccine causes autism. Andrew Wakefield’s repeated claims that the MMR can cause or “trigger” autism in some children is deader than dead as a scientific hypothesis and without a basis in scientific or clinical evidence. True, Wakefield tried to counter with a horribly unethical and badly designed primate study that seemed custom-designed to be used in court rather than in the court of scientific inquiry. It didn’t help and only made Wakefield’s Thoughtful House, Wakefield’s Fortress of Solitude in Texas to which he retreated in the wake of the revelations about his conduct, look even worse. Even a credulously “balanced” TV story by NBC news and Matt Lauer couldn’t hide the dubiousness nature of what goes on there.
Of course, while the science refuting Wakefield’s pseudoscience and evidence showing Wakefield to be incompetent and unethical continued to roll in, a little less than a year ago, it got even worse for him. Brian Deer reported that Wakefield very well may have engaged in scientific fraud in the “research” (and I do use the term loosely) that led to the publication of his Lancet paper in 1999. Through it all, the General Medical Council began an inquiry into whether Andrew Wakefield behaved unethically in the “research” that resulted in his 1999 Lancet report. It should be pointed out that the investigation of the GMC began before Deer’s latest revelation of potential fraud; rather it was far more concerned with how Wakefield ran his study and recruited patients. Nonetheless, the revelations nearly a year ago about Wakefield’s playing fast and loose with research methodology could not help but contribute to the sense that the Good Ship Wakefield had been torpedoed below the water line and was taking on water fast.
As the investigation and hearings wound on seemingly endlessly for two and a half years, Wakefield’s supporters intermittently waged an increasingly histrionic and ridiculous propaganda offensive to try to preemptively discredit the GMC’s findings. As it became clear that finally after all this time the GMC was on the verge of announcing its ruling, I noticed that the anti-vaccine crank blog Age of Autism was ramping up an increasingly bizarre and unhinged last minute propaganda campaign, complete with reposting a hilariously inapt post by Mark Blaxill comparing Wakefield to Galileo and the GMC to the Inquisition, complete with references to Stalin and Mao (I suppose I should be relieved that Blaxill refrained from playing the Hitler card); a defense of “that paper” by Wakefield himself; claims that parent witnesses had been “silenced” at the GMC hearings; and a whole series of posts by John Stone trying to discredit the GMC.
And then on Thursday, the GMC ruled.
ANDREW WAKEFIELD: “IRRESPONSIBLE” AND “DISHONEST”
The general findings in the GMC’s ruling should have come as no surprise at all to anyone who had been following Wakefield’s activities, as I have been for the last five years, although I must admit I was pleasantly surprised by the lack of weasel words in it. On Thursday, the BBC reported:
Dr Andrew Wakefield’s 1998 Lancet study caused vaccination rates to plummet, resulting in a rise in measles — but the findings were later discredited.
The General Medical Council ruled he had acted “dishonestly and irresponsibly” in doing his research.
No kidding. Here is a sentence from the actual GMC report:
In reaching its decision, the Panel notes that the project reported in the Lancet paper was established with the purpose to investigate a postulated new syndrome and yet the Lancet paper did not describe this fact at all. Because you drafted and wrote the final version of the paper, and omitted correct information about the purpose of the study or the patient population, the Panel is satisfied that your conduct was irresponsible and dishonest.
The Panel is satisfied that your conduct at paragraph 32.a would be considered by ordinary standards of reasonable and honest people to be dishonest.
That’s about as plain a statement of Wakefield’s mendacity as I can imagine. In fact, I’m very surprised that the GMC report was so blunt. But wait, there’s more, as described in this BBC news report:
The verdict, read out by panel chairman Dr Surendra Kumar, criticised Dr Wakefield for the invasive tests, such as spinal taps, that were carried out on children and which were found to be against their best clinical interests.
The panel said Dr Wakefield, who was working at London’s Royal Free Hospital as a gastroenterologist at the time, did not have the ethical approval or relevant qualifications for such tests.
The GMC also took exception with the way he gathered blood samples. Dr Wakefield paid children £5 for the samples at his son’s birthday party. Dr Kumar said he had acted with “callous disregard for the distress and pain the children might suffer.”
He also said Dr Wakefield should have disclosed the fact that he had been paid to advise solicitors acting for parents who believed their children had been harmed by the MMR.
Two of Dr Wakefield’s former colleagues at the Royal Free were also ruled to have broken guidelines.
Professor John Walker-Smith and Professor Simon Murch both helped Dr Wakefield carry out the research.
The complete 143 page report can be read here. It is truly a damning document. While it cleared Wakefield of some charges, it found that Wakefield was in breach of managing public finances, that the funds he controlled were not used for their intended uses, and that, most shocking of all, he performed procedures on a child for research purposes without the approval of his Ethics Committee. Having found that some of the most damning allegations made against Wakefield are true, the GMC will now deliberate over what sanctions will be indicated. These can range from a rebuke to the stripping of Wakefield’s medical license from him (or, as the British put it, his being “struck off”). Of course, given that Wakefield has moved to Austin, Texas, there to form Thoughtful House, an institution dedicated to the practice of what many, including myself, consider to be autism quackery based on anti-vaccine beliefs, even if the GMC does ultimately strip Wakefield of his medical license very likely it would have little or no significant effect on his practice. After all, Wakefield does not treat children himself. He can’t. He does not have a Texas medical license. Wakefield’s partner Dr Arthur Krigsman is the one doing colonoscopies on autistic children for what appear to be questionable indications, as was portrayed in the aforementioned NBC special with Matt Lauer, and his other partner Dr Bryan Jepson treats them with DAN! protocols.
Indeed, well do I remember one part of the Lauer special in particular. Specifically, it was the part where Lauer asked for Wakefield’s anecdotal experience about whether these children “get better.” Wakefield, of course, responded in the affirmative. (Never mind that what Lauer should have asked Wakefield is whether he has data from randomized controlled clinical trials to support his belief that autistic children “get better” at Thoughtful House. He doesn’t.) Moreover, pretty much every child undergoing endoscopy at Thoughtful House (85%, according to Dr Krigsman) ends up with a diagnosis of “autistic enterocolitis,” which is, as far as science can tell, almost certainly a nonexistent syndrome given that autistic children do not appear to exhibit bowel complaints at a higher frequency than neurotypical children. In the case of Tom Kasemodal, the autistic child whose endoscopy was featured in the NBC report, Dr Krigsman was hard-pressed to find grossly visible abnormalities during the procedure. (“Mild or softer findings,” he said about Tom.) Of course, on pathology, Thoughtful House pathologists apparently found “mild inflammation.” And what did Krigsman prescribe? Lots of supplements, daily laxatives, and periodic colon cleansing. Can you imagine subjecting an autistic child to laxatives and colon cleanses? How do you get a severely autistic child to cooperate for a “colon cleanse”? I have no idea, and I don’t want to think about it.
If the NBC report with Matt Lauer is any indication, apparently such is the “medicine” practiced at Thoughful House, and I must emphasize that the GMC ruling will almost certainly do absolutely nothing to stop it. As when he was at the Royal Free Hospital in North London, Wakefield bills himself as a “researcher” and does not practice clinical medicine, at least not on the surface of it, although the NBC special sure made it look to me as though he participates as a consultant in the care of the autistic children brought to Thoughtful House. If the GMC were to “strike off” Wakefield from the rolls of licensed physicians, it would at least be a further moral victory in addition to the ruling itself, but Thoughtful House would still exist and, under Wakefield’s leadership, still be subjecting autistic children to the sorts of therapies shown on the NBC report and who knows what else.
ANDREW WAKEFIELD, “BRAVE MAVERICK DOCTORS,” AND A CULT OF PERSONALITY
In the decade since his Lancet paper began the movement that led to the resurgence of measles in the U.K., Andrew Wakefield has become a hero to the movement dedicated to the discredited idea that vaccines cause autism. He is the prototypical “brave maverick doctor” and don’t need no steeenkin’ science to know that he’s “recovering” autistic children. Evidence of this is everywhere; so I’ll pick and choose. Perhaps the most obvious manifestation of the Wakefield cult of personality is the nausea-inducing website We Support Dr Andrew Wakefield. I first became aware of this website last year after Brian Deer’s revelations regarding the likely scientific fraud committed by Andrew Wakefield came to light. Consistent with its defense of Wakefield then, on the day that the GMC’s findings were announced, the website declared it a “sad day for the future of our children” and further declared:
The General Medical Council’s (GMC) verdict today concerning Dr Andrew Wakefield brings together autism organizations across the United States who stand united in support of him, unequivocally renounce the GMC’s findings, and demand an investigation into possible conflicts of interests at the GMC. We further challenge the U.K. and U.S. governments to offer grants for gold standard research into why so many children with autism have gastrointestinal pathology, as well as any links between this pathology and the symptoms of autism, before all of the children of the world are affected.
Today’s verdict by the General Medical Council epitomized their negligence in respecting all of the sound scientific studies worldwide replicating the findings of Dr Andrew Wakefield. In the United States we will continue to fund studies replicating Wakefield’s work. We will focus more heavily on helping to educate the British public about the dangers of the MMR. We will look with renewed vigor into possible misconduct by the GMC. And, most importantly, we will continue to recover children from autism thanks, in large measure, to Dr Wakefield’s pioneering work. We have witnessed and applaud the sustained courage and dignity of Dr Andrew Wakefield. He has stood by the children, and we will stand by him.
This statement is signed by AutismOne (which I’ve discussed before), the Autism Research Institute, Generation Rescue (big surprise there, given that GR has already declared its support for Andrew Wakefield in no uncertain terms and, in the lead up to the GMC’s findings, tried its best to demonize GMC and cast doubt on the legitimacy of the entire proceeding), SafeMinds, Schafer Autism Report, Talk About Curing Autism (TACA), Unlocking Autism. In other words, organizations supporting the scientifically discredited vaccine-autism link are all lining up to support this statement. Notice how the statement alleges conflicts of interest and misconduct on the part of the GMC without any actual evidence of such COIs. Also notice how it declares that other researchers have “replicated” the findings of Andrew Wakefield. Of course, that is true if you count the dubious and researchers associated with Wakefield himself, but no reputable researchers have been able to replicate his findings. Most recently, as I pointed out above, a sympathetic researcher named Mady Hornig, who had previously published research seemingly supporting a link between thimerosal and autism, failed to replicate Wakefield’s results. Finally, notice how, despite numerous studies supporting the safety of the MMR and its lack of association with autism or bowel complaints in autism, these organizations continue to cling to the belief that the MMR is “dangerous” and vow to “educate” the public about the “dangers” of the MMR vaccine.
Consistent with previous reactions to criticisms of the anti-vaccine movement or one if its leaders, some of these organizations are also going on the attack, painting themselves as the underdog being persecuted for speaking truth to power. For instance, here’s what the TACA wrote:
The most frightening aspect of these GMC findings is the silencing effect it could cause to scientist and researchers. These verdicts now prove that researchers who stumble upon science that is controversial have to worry about losing their licenses and careers.
Consistent with the persecution complex that the anti-vaccine movement has, yesterday AoA contributor Martin Walker tried with some truly Bulwer-Lytton-worthy writing and incredibly heated rhetoric to show just how much reason has checked out among Wakefield’s defenders:
As the recitation of the crimes of Dr Wakefield came to an end, it appeared as if Dr Wakefield, had in the mid nineties, been some kind of inhuman Nazi experimenter practicing on children in the heart of England; an overlooked human vivisector who stalked a large North London hospital committing serious crimes with the two other criminals in his firm, invisible to his colleagues and unseen by the hospital administration.
It’s actually funny that Walker would mention Nazis. It was Nazi experimentation, among other things, that led to the Helsinki Declaration, the Belmont Report and the Common Rule in the US, and all the other protections for human subjects involved in clinical research. These rules are quite strict, although some would argue whether they’re even strict enough. They prevent atrocities like the Tuskegee syphilis experiment. They are the same rules that Wakefield flouted.
Undeterred by reality, Walker then likens the ruling to a knight’s jousting (and you don’t have to guess who’s the Black Knight):
Today I know will be one of those times that signify a dark night of the soul, for defendants, parents and campaigners alike. This afternoon the defendants will be knocked from their horses by rib smashing lance blows, on the ground they will lie dazed and have to figure whether it is right or even possible to remount and continue the battle. Parents will contemplate the bleak landscape of their children’s illness without any treatment and with open skepticism from medical practitioners from whom they seek help. Activists and campaigners like myself will have to face the melancholic prospect of either continuing the campaign or slipping away to support apparently more equitable battles.
This particular battle is a post-modern struggle, one in which the most powerful forces, multinational companies, reshape the world hand in hand with governments. This is a struggle from which parents and citizens have been expunged. A blind struggle, in an age where all the ties between governments and citizens have been severed, where it is no longer possible for citizens to have any real effect on either the processes of industrial science or of national politics.
It’s a post-modern struggle alright, just not in the way that Walker means.
Perhaps the most over-the-top conspiracy-packed “defense” of Andrew Wakefield comes from Mark Blaxill, published on the anti-vaccine crank blog Age of Autism and entitled Naked Intimidation: The Wakefield Inquisition is Only the Tip of the Autism Censorship Iceberg. All the hallmarks of a persecution complex and crankery are there.
Claims that the GMC finding was designed to “intimidate” those “brave maverick scientists”? Check:
The GMC proceeding is a frightening and thoroughly modern form of tyranny. It makes you shudder to think what Stalin or McCarthy might have accomplished if their public relations had been more skillful and better organized.
The extremity of the GMC’s verdict — all three men guilty on all counts — lays bare any pretense that the British medical establishment cares one whit about the welfare of its patients. Let’s put in perspective the actions at issue here. No children were harmed and no parent or guardian has complained about the care these three men provided. In fact, the procedures involved were routine, the resulting treatments standard and the careful attention to gastrointestinal illness in autistic children has recently been endorsed by a consensus statement published in the journal Pediatrics (no friend of the autism community). Considered in this light, the GMC hearing process stands exposed for what it is. It was not about medical standards. It was not about evidence. It was not even civilized. It was, rather, a naked exercise in intimidation, a fateful moment of moral decision in which the medical industrial complex exposed its ruthless, repressive essence. They are a frightening bunch and their conduct here raises issues well beyond autism.
The only thing frightening about this case is how much Andrew Wakefield got away with and how long it took for him to be exposed as the unethical fraud he’s been shown to be by Brian Deer, the GMC, and numerous other sources. It should also be noted that Wakefield was not found “guilty on all counts,” although he was found guilty on several of the most egregious counts. Blaxill really should read the whole report.
Attacks on peer review? Of course, they’re there too:
Since the National Institutes of Health (NIH) hold a virtual monopsony (“a sole or predominant buyer” in a particular market) on scientific research in the United State, NIH grant reviews are one prominent place where researchers can be effectively intimidated. One scientist, who authored a sensitive, previous publication, when asked to join in the effort to draft a review paper, demurred with the following explanation.
I have had two rejections of NIH grants in the last two weeks. This is most remarkable, in that the grants were not deemed good enough to even be scored. In my X years on the faculty, I have never had an unscored grant. Moreover, in one grant it is clear that there is a personal vendetta ongoing. This is not totally surprising but nonetheless disturbing. I am not ready to throw my career away, and I don’t look at how Andy Wakefield has handled such problems as a good model for me. It is vital that the science of this problem get out, and this is where I want to focus my attention. Therefore, I have decided that I do not want my name on [this new review publication], for I don’t need more persecution right now, and as good as the paper is (and I think it is extraordinary), it is not going to be a definitive scientific publication. I am enclosing a section I wrote-some of this is already included-feel free to use any of it.
If an intrepid researcher goes so far as to submit a paper for publication, that’s where the more overt forms of censorship can enter in, all in the guise of “peer review.” Admittedly, rejection at the point of peer review is a common part of science, but the autism problem is especially radioactive and is a place where I have seen the unmistakable cold hand of censorship take many forms: some unwelcome research can be headed off at the pass, with journal editors making clear that papers on certain autism topics are unwelcome and won’t even be sent out for review; or unwelcome papers can be sent to anonymous reviewers the editor knows to be hostile to the topic of environmental influences;
Let’s see: I just found out on Friday that not only was a revision of a paper I wrote still not deemed acceptable for publication in the journal to which I submitted it, but I also found out that I didn’t get a grant I really wanted that I had thought I had a good chance of getting. That’s academia and biomedical science. It happens all the time (although I can’t recall having had such a one-two body blow to my ego in one day). The latter case is somewhat apt in that the reviewers praised my proposed experimental design as being excellent but were skeptical of the primary hypothesis itself. Obviously, I must be too close to The Truth about breast cancer and how to treat it, and the breast cancer industry is trying to “silence” me! (Yeah, yeah, that’s what I’ll tell myself.) In any case, the complaint that “I’ve never had a grant not scored” is not indicative of “censorship.” The amount of money available for the NIH to fund grants compared to the number of grants submitted fell precipitously between 2003 and 2009. Lots of senior researchers who had never had a grant found to be “not worthy” of being given a numeric score (which indicates that the study section deemed it to be in the bottom half–or even bottom 60% — of the grants being ranked and therefore possessing no chance of being funded that round) have suddenly had grants coming back unscored. (Join the club and stop whining, those of us in the trenches ruefully respond!) In these tight fiscal times, that’s just reality. In this sort of environment, though, it’s easy for scientists to tell themselves that they’re the victim of groupthink whether there’s anything to it or not.
However, Blaxill had more in store for me. He completely shattered yet another of my irony meters when he wrote his conclusion:
The GMC verdict, that honest scientists like Andy Wakefield have “failed in their duty”, makes a mockery of the value of civil debate in an open society.
The medical industrial complex is closing ranks. It’s time for responsible citizens — health consumers and principled scientists alike — to raise their voices in opposition.
No, the anti-vaccine movement has made a mockery of civil debate in an open society. Its reflexive reaction to attack the messenger when criticized is legendary. Journalists have been the victims of it. Our fearless leader Steve Novella has been a victim of it. Paul Offit has been nearly continuously a victim of such bile and harassment, up to and including frivolous lawsuits. Sometimes, it gets incredibly vicious, as when AoA represented Paul Offit, Steve Novella, and journalists Trine Tsouderos and Amy Wallace as sitting down to have a Thanksgiving feast, the main course of which was a dead baby. I myself have been harassed similarly on many occasions.1,2,3,4,5,6,7
I suppose that’s the definition of “civil” debate from the anti-vaccine movement.
THE CULT OF ANTIVACCINATIONISM
As I have pointed out on numerous occasions before, both here and elsewhere, the anti-vaccine movement has much in common with cults. It believes, despite all scientific evidence, that vaccines cause autism and many other chronic health conditions. Its adherents see themselves as the keeper of a hidden truth that “they” don’t want you to know about, a “truth” that it desperately wants everyone to know. No facts, no science can sway them, and when one of their prophets is found to have behaved unethically, to have had massive conflicts of interest, and possibly even to have falsified research, it’s all part of a plot by The Man to keep them down.
That is why, as necessary as it is for the GMC to have ruled against Andrew Wakefield, I know that it will not stop him from plying his trade on children in Texas, and I especially know that it will only feed his cult of personality by adding martyr to his list of attributes in their eyes. It will not stop him from raking in money hand over fist. Even videos like this showing Wakefield joking over children fainting and throwing up as he prepared to draw blood from them after bribing them to agree to it won’t change that:
Yes, that is laughter and joking, and that is one incident that led the GMC to declare Andrew Wakefield’s “callous disregard” for children. That is the real Andrew Wakefield.
When will the madness end? I fear that it will only end when vaccine-preventable diseases return to the point where every parent fears them again. No, it’s more than that. Vaccine-preventable diseases are already returning. That’s why I fear it will only end when they return to the point where the fear of disease is more intense than the fear of the vaccine-autism bogeyman. In the meantime, while Third World countries clamor for life-saving vaccines and Bill Gates pledges $10 billion to bring vaccines to the world, here in the developed world we have men like Andrew Wakefield feeding an irrational fear of vaccines that threatens to reverse all the progress of the last few decades.
Maybe 20 years from now, we’ll need the Bill and Melinda Gates Foundation to be pledging billions of dollars to bring vaccines to us.

The long, strange road to passing SB 276 appears to be near its end…finally
In 2015, California passed SB 277, which eliminated religious and personal belief exemptions to school vaccine mandates. Unfortunately, there was a problem; a weakness in the law allowed antivaccine quacks to help parents get around the law by writing medical exemptions not supported by science. The long strange battle to get SB 276, the law designed to close that loophole, reveals a lot about the difficulty of legislating science-based policy, even in California.
David Gorski on September 9, 2019
Link

As I was contemplating what to write for this week’s post, I learned that a final agreement had been reached between the California legislature and Governor Gavin Newsom to pass SB 276, a bill designed to close loopholes in SB 277, the California law passed in 2015 to eliminate nonmedical “personal belief exemptions” to school vaccine mandates. As I read about SB 276, it occurred to me that we’ve written almost nothing about the bill here at SBM, other than to mention in April that it had been introduced in the California Senate by Senator Richard Pan, the same Senator who had co-sponsored SB 277.
It occurred to me that this would be a good opportunity to examine how we got to this point, some of the shenanigans pulled by Gov. Newsom, both earlier in the process of getting SB 276 passed and last week at the last minute as it was passed by the Assembly and Senate, and the reaction of the antivaccine movement to the bill.
A brief history of vaccine mandates
The success of vaccination campaigns depends upon as many members of an at-risk population as possible being vaccinated in order to achieve herd immunity. Herd immunity (these days more frequently known as community immunity, given that people don’t like being compared to cattle) has been discussed on this blog many times, most prominently by Drs. Mark Crislip and Joseph Albietz (both of whom, alas, no longer write for SBM). Basically, when a sufficiently large percentage of the population is vaccinated against a disease, even those not immune to the disease obtain a measure of protection against infection because the immunity of a large percentage of the population prevents the infectious agent from being readily spread from person to person. The agent thus never gets a “foothold” in the community, and the greater the proportion of the population vaccinated the less the chance of a susceptible individual coming into contact with an individual carrying the infection. Community immunity is very important because it helps to protect population members who can’t be vaccinated for whatever reason, be it immunodeficiency or other medical reason or because they are too young to be vaccinated. Vaccines aren’t perfect. Even highly effective vaccines only protect 90 to 100% of the vaccinated population. The precise percentage of the population that needs to be vaccinated to achieve herd/community immunity varies depending upon the efficacy of the vaccine and the infectiousness of the disease being vaccinated against, but a good, serviceable ballpark estimate is usually somewhere in the 90% and above range.
Community immunity is the reason why it is so important to vaccinate as large a percentage of the at-risk population as possible. To this end, public health officials have at times tried a number of strategies, ranging from cajoling to compulsory vaccination. A different strategy to achieve high rates of vaccination is the imposition of vaccine mandates. School vaccine mandates differ from laws requiring vaccination in that no one from the state will hunt parents down to force them to vaccinate. However, if parents want to take advantage of state services such as public schools for their children, or if they want to use services that place a lot of children together (such as day care facilities), they have to have their children vaccinated. This is a practice with very old precedent. For example, in 1827 Boston became the first city to require parents of children enrolling in public school to present evidence of vaccination against smallpox. The trend continued, as described in this review of school vaccine mandates:
The Commonwealth of Massachusetts incorporated its own school vaccination law in 1855, New York in 1862, Connecticut in 1872, and Pennsylvania in 1895. Other Northeast states soon passed their own requirements. The trend toward compulsory child vaccination as a condition of school attendance eventually spread to states in the Midwest [e.g., Indiana (1881), Illinois and Wisconsin (1882), Iowa (1889)], South [e.g., Arkansas and Virginia (1882)], and West [e.g., California (1888)], though not without considerable political debate.
School vaccine mandates, although they were opposed by antivaccination leagues from the beginning, tended to provoke less virulent opposition and better compliance than compulsory vaccination, making them not only politically more palatable, but more effective. However, over the last couple of decades the effectiveness of school vaccine mandates has been weakened by a steady expansion of non-medical exemptions, in particular religious or philosophical exemptions, a trend that has only recently started to reverse. Examples include: California passing SB 277, which eliminated PBEs altogether; Washington passing HB 1638, which removes the PBE for the MMR vaccine requirement for public schools, private schools and day care centers; Maine passing HB 586, which removes personal and religious belief exemptions for public school immunization requirements; and New York passing SB 2994, which removes the religious exemption for public school immunization requirements. Currently, 45 states allow religious exemptions that vary in requirements, while 15 states currently permit philosophical exemptions, in which parents must declare a personal belief against or philosophical objection to vaccination. Usually, parents must file a form, ranging from just once to annually, with their school district stating their personal objection to vaccination. Not surprisingly, in states that allow personal belief exemptions they are the most commonly invoked reason by parents to refuse vaccinating their children, as the number of children who qualify for medical exemptions is quite small.
The problem with personal belief exemptions
The problem with PBEs, of course, is that they can be abused, and, when antivaccine misinformation spreads, provide a mechanism by which vaccination rates plummet, leading to local populations with low vaccination rates. That’s exactly what happened in California and is happening in Texas now, so much so that I not-infrequently say that when the next big US measles outbreaks happen, they’ll probably happen in Texas. In California before SB 277, for instance, although statewide the percentage of children with parents claiming the personal belief exemption remained low, there were schools where exemption rates climbed as high as 58% (one kindergarten reported a 76% exemption rate) serving as incubators for outbreaks of measles and other contagious diseases. After all, unvaccinated children have a 23-fold higher risk of contracting pertussis and a 35-fold higher risk of contracting measles than vaccinated children. Unfortunately, non-vaccinating populations tend to cluster, and their refusal of vaccines leads to there being areas with large pockets of unvaccinated children, ripe for outbreaks of vaccine-preventable diseases.
How can states decrease the number of PBEs? There have traditionally been two approaches. One is to make PBEs more difficult to obtain than parents just signing a form, usually coupled with education. The other is to eliminate PBEs altogether. California tried the first approach before resorting to the second approach. PBEs are critical, too, as it has been shown on more than one occasion that states with more permissive laws regulating the granting of PBEs contribute to outbreaks of vaccine-preventable diseases.
AB 2109: Education before granting a PBE
Faced with the rising number of PBEs and schools with alarmingly low vaccine uptake rates, in 2012 the California legislature passed AB 2109. All AB 2109 mandated was, in essence, informed consent. Under AB 2109 parents were required to obtain a signed form from a pediatrician stating that they had been counseled on the risks and benefits of vaccines. The law, in essence, required that the parents make such a monumental decision as not to vaccinate their child only after having had a physician provide them with informed consent, so that they understood the potential consequences of not vaccinating, as well as the risk-benefit ratio for vaccination.
In response to years of abysmal vaccine uptake rates and multiple outbreaks, particularly a large pertussis outbreak in 2012, out of which was born a campaign by a mother whose baby died of pertussis to increase vaccine uptake, in 2014 the Michigan Department of Health and Human Services altered the regulations regarding requirements for parents to claim personal belief exemptions to vaccine mandates, patterning its policy change on AB 2109. Basically, starting January 1, 2015, any parent seeking a PBE was required to travel to their local county health office in order to:
    • Be educated by a local health worker about the benefits of vaccination and the risks of disease.
    • Sign the universal state form that includes a statement of acknowledgement that parents understand they may be putting their own children and others at risk by refusing vaccinations. Only the official state form is now permitted. No substitute forms are allowed any more, as they were in the past.
The rule change worked, too. PBE rates declined. However, even this rule change has led to a backlash among antivaxers, to the point where there have been attempts to “make measles great again” in Michigan by passing a law to eliminate the authority of the MDHSS to require this educational program and standardized form before a PBE will be issued. Fortunately, both attempts have failed, and there are unlikely to be any more serious attempts to eliminate the requirement, at least not while the current governor is in office. There was also similar resistance to AB 2109 in California, and unfortunately then-Governor Jerry Brown even issued a signing statement intended to water down the effect of the law by exempting parents seeking religious exemptions from the requirement to seek counseling from a physician and have the physician sign the form. It was truly a betrayal of California’s children.
Thus the stage was set for SB 277.
The Disneyland measles outbreak: Everything changes
As you can see, even a minor change in the law, such as AB 2109, stirred up fierce opposition and led a governor whose previous record in health care was quite good to betray California’s children by trying to water down the newly enacted law as a sop to religion. Obviously, the best solution to the problem of pockets of unvaccinated children due to vaccine hesitancy or refusal was to eliminate religious and other nonmedical vaccine exemptions. The problem was then that the political climate was not ripe for a law eliminating nonmedical exemptions, even though, from a public health standpoint, that would be the most effective intervention.
Then, beginning right after the Christmas holiday in 2014 and extending into 2015, an incident occurred that changed everything, at least in California: the Disneyland measles outbreak. By the time the outbreak had subsided, there had been 147 cases of measles, 133 in California and the rest in six other states, Mexico, and Canada. Public health officials believe an individual infected with the measles virus visited the Disney resort at some point between December 15 and 20, 2014, and the spread of the disease was linked to low vaccine uptake rates. Of note, in Canada, one child who was infected at Disneyland returned to a susceptible religious community near Montreal and sparked a secondary outbreak there. Of the cases whose vaccination status had been verified, 70% were unvaccinated, with 48% having a PBE and 28% being too young.
In February 2015, while the outbreak was still raging, Sen. Richard Pan, a pediatrician turned politician, introduced SB 277, a bill to eliminate nonmedical exemptions to school vaccine mandates. Over the next four months the State of California was consumed by controversy, as antivaxers pulled out all the stops to try to stop passage of the bill. If you think antivaxers were loud, persistent, and unhinged in 2012, they topped themselves in 2015. As SB 277 advanced through the California legislature, the usual suspects just about lost it, with Barbara Loe Fisher likening the bill to medical blackmail and invoking Elie Wiesel, just in case you don’t get the message that she thinks California was dealing in Nazi-like fascism. Along the way, antivaccine celebrities like Robert F. Kennedy, Jr. (who is also fond of Holocaust analogies) and Rob Schneider were trotted out with the same old pseudoscience and “health freedom” arguments, although RFK, Jr. might have done more harm to his cause than good when he explicitly likened the vaccine program to the Holocaust and was forced to apologize, although it was a classic “notpology.”
Along the way, we were also treated to images like this from Heather Barajas, who photographed herself and her child wearing badges shaped like a syringe juxtaposed with photos of Jews in Nazi Germany forced to wear yellow Stars of David:
The uproar was so great that Barajas was actually forced to take her offensive image down. I note that this is in marked contrast to this year, when antivaxer Del Bigtree donned a yellow Star of David, again likening antivaxers to Jews during the Holocaust and, in this case, the State of New York, to Nazis and proudly refused to back down.
Nonetheless, as pessimistic as I was about its chances of passage, SB 277 was indeed ultimately passed by the California legislature and signed into law by Governor Jerry Brown, who in doing so redeemed himself for his AB 2109 debacle. The law worked, too, at first. After the start of the 2016 school year, when SB 277 went into effect, PBE rates fell, although medical exemption rates did increase slightly. This increase was thought to be due to parents whose children needed medical exemptions and found it to inconvenient to get a doctor’s letter and instead opted just to claim a PBE being forced to get a doctor’s letter and get a real medical exemption.
Unfortunately, it was not long before a major flaw in SB 277 reared its ugly head, which brings us back to SB 276, a bill meant to correct that serious flaw.
SB 276: Correcting the problem with SB 277
Before SB 277 had even gone into effect, I took note of a disturbing phenomenon. Antivaccine pediatrician Dr. Bob Sears was out and about giving talks to parents about how to avoid the provisions of SB 277. Eventually, it became apparent that one aspect of SB 277, which was a compromise to get the bill passed, was an enormous boon to antivaccine quacks. That provision allowed any physician to write a letter supporting a medical exemption to school vaccine mandates, and the state had to accept it as valid. Basically, any licensed doctor can list any reason he or she wishes to in a medical exemption letter, and there’s nothing in SB 277 that lets health authorities deny the exemption. The result was entirely predictable. There rapidly emerged a cottage industry of antivaccine and antivaccine-sympathetic doctors willing to write medical exemption letters based on indications not supported by science.
In reality, there are very few scientifically and medically valid reasons for a medical exemption. For instance, immunosuppressed children should not receive attenuated live virus vaccines, although they can still receive killed vaccines, and children with a history of anaphylaxis or severe allergic reactions in response to a vaccine component should not receive vaccines with that component again. (The complete list of contraindications to various vaccines can be found here.) It wasn’t long, however, before medical exemptions based on bogus “indications” were widely for sale, thanks to various antivaccine quacks. These bogus indications include—of course!—MTHFR mutations, family history of autism, family history of autoimmune disease, food allergies, celiac, type 1 diabetes, and a wide variety of other “contraindications to vaccination.” Predictably, after the initial improvement in vaccine uptake due to SB 277, soaring numbers of medical exemptions led to a reversal of that progress, thanks to a gold rush of antivaccine quacks. Indeed, antivax groups maintain lists of “vaccine-friendly” doctors willing to write dubious medical exemptions, many of whom advertise on various antivaccine sites their willingness to write medical exemptions. Dr. Sears himself generates what appear to be basically form letters in which he inserts whatever indications he wants. There are even examples of these letters that have been posted, while in the Bay Area, five doctors wrote one-third of all medical exemption letters.
Indeed, an observational study last year highlighted the problems public health officials and school nurses were having because of this. The key findings in the structured interviews with school and public health officials included (1) frustration over the lack of authority for local health departments, (2) concern over the burden on school staff to review medical exemptions, (3) frustration with physicians who are writing problematic medical exemptions, and (4) concern about an increase in medical exemptions under SB277. For example, here’s what one immunization coordinator said:
My frustration is dealing with these doctors that would write what is thought to be maybe not completely valid medical exemptions for the students whose parents just don’t want them to get any. That’s my personal frustration, and that is shared by a lot of school nurses
Indeed.
This brings us to SB 276, which is on the verge of finally being passed into law. In response to these problems, Senator Richard Pan, who co-sponsored SB 277 and was the driving force behind getting it passed, introduced SB 276, a law that would mandate a database of medical exemptions, so that the state can keep track of which doctors are issuing the most medical exemptions, and require that requests for medical exemptions to school vaccine mandates be approved by the State Public Health Officer or designee, who could reject exemptions not supported by science. The bill’s been watered down a bit since then, with amendments removing the provision that would authorize the State Health Officer to review medical exemptions and revoke the ones he deems fraudulent or inconsistent with medical guidelines. On the other hand, the bill would require that the state health department to provide a standardized form for use for medical exemptions:
This bill would instead require the State Department of Public Health, by January 1, 2021, to develop and make available for use by licensed physicians and surgeons an electronic, standardized, statewide medical exemption request that would be transmitted using the California Immunization Registry (CAIR), and which, commencing January 1, 2021, would be the only documentation of a medical exemption that a governing authority may accept. The bill would specify the information to be included in the medical exemption form, including a certification under penalty of perjury that the statements and information contained in the form are true, accurate, and complete. The bill would, commencing January 1, 2021, require a physician and surgeon to inform a parent or guardian of the bill’s requirements and to examine the child and submit a completed medical exemption request form to the department, as specified. By expanding the crime of perjury, the bill would impose a state-mandated local program.
The bill would also require the department to annually review immunization reports from schools, to identify schools with an overall immunization rate of less than 95%, physicians and surgeons who submitted 5 or more medical exemption forms in a calendar year, and schools and institutions that do not report immunization rates to the department. It would also require a clinically trained staff member who is a physician, surgeon, or a registered nurse to review all medical exemptions meeting these conditions, authorizing the State Public Health Officer to review the exemptions identified by that staff member as fraudulent or inconsistent with established guidelines. The department can report physicians issuing fraudulent or scientifically unjustified medical exemptions to the state medical board.
Not surprisingly, resistance has been fierce. Antivaxers have protested by cosplaying Star Wars characters at Disneyland and the terrorist V from V Is For Vendetta at San Diego Comic-Con. On a more dire and serious note, Sen. Pan started receiving death threats again, and was even assaulted on the streets of Sacramento by an antivaxer named Austin Bennett. Fortunately, it was relatively minor, a shove/hit to the back of the head, and Bennett did not persist. Then, two weeks ago there was a rather large (by antivax standards, anyway) demonstration at the California State Capitol Building. Out-of-state operatives linked to the Church of Scientology were brought in to help the opposition to SB 276. Meanwhile, a reporter for the L.A. Times screwed up massively and published a puff piece full of false equivalence about Dr. Bob Sears, who, predictably, has been one of the most prominent and vocal opponents of SB 276.
Despite all that, SB 276 passed the Assembly and the Senate anyway, and by large margins, which brings us to the latest drama.
What the heck is Governor Newsom playing at?
Even before the bill had hit his desk for his signature, Governor Gavin Newsom had suggested that he was unhappy with some aspects of it. It was a move that surprised backers of the bill, because previously Gov. Newsom had signaled that he would sign the bill once it was passed by the legislature:
Medical groups and a lawmaker behind California legislation to crack down on vaccine exemptions said Wednesday they were surprised by Gov. Gavin Newsom’s last-minute call for changes to the bill, a move that inserted fresh uncertainty into one of the year’s most contentious issues.
It was the second time the Democratic governor sought to change the measure aimed at doctors who sell fraudulent medical exemptions for students, a proposal vehemently opposed by anti-vaccine activists. After expressing hesitancy with the bill and winning substantial changes to the measure in June, Newsom had committed to signing it.
The Governor shocked SB 276 supporters with these two Tweets right after the Labor Day holiday weekend:
The Governor believes it’s important to make these additional changes concurrently with the bill, so medical providers, parents and public health officials can be certain of the rules of the road once the bill becomes law. #SB276 (2/2)
— Office of the Governor of California (@CAgovernor) September 3, 2019
What did it mean? And why was Newsom asking for more changes to a bill that he had previously indicated that he would sign, after having already insisted on changes that watered the bill down in June. That was when Newsom raised concerns that SB 276 would create a bureaucracy that would interfere with the doctor-patient relationship. His office negotiated changes with the bill’s sponsors to weaken the legislation. Instead of requiring the California Department of Public Health to approve all medical exemption requests, Newsom demanded that SB 276 narrow its focus to reviewing medical exemption requests from doctors who write five or more medical exemptions in a year and to requests coming from schools or day cares with immunization rates of less than 95%. After that, he said that he would “absolutely sign” the bill when it hit his desk.
After going back on his promise June, Newsom demanded more changes:
Newsom’s new demands go further than his initial amendments accepted by Pan and legislative leaders. One change would ensure that the state will not review medical exemptions granted before January 2020. That has stirred fears that it’ll lead to a mad rush on medical exemptions this year that state public health authorities won’t be able to retroactively scrutinize.
The governor also wants to strike SB 276 language that would require doctors to sign under penalty of perjury that they are not granting exemptions for financial gain.
Pan and other lawmakers were stunned by the late amendment request, which came on Twitter only a few minutes after the last major opportunity to amend the bill in the Assembly. With SB 276 headed to Newsom’s desk, the Legislature would have to insert the governor’s changes into a separate bill.
So why would Gov. Newsom go back on his word? It’s a reversal that could really harm him in future dealings with the legislature:
Political strategists from both parties say Newsom’s late tactics represent a remarkable political mistake for the new governor that could potentially harm his reputation and dampen his ability to govern.
“When you give your word and you make a deal, you’ve got to stand by it,” said Democratic strategist Dana Williamson, longtime adviser to former Gov. Jerry Brown. “Otherwise people will think twice the next time he says there’s a deal.”
Williamson said even if the governor learned new information or had a revelation about concerns over the policy, there are avenues like legislative “cleanup” bills to address outstanding issues. She also said announcing his reservations on Twitter was not the best course of action.
“I do think he could have picked up the phone,” Williamson said.
Rob Stutzman, a Republican strategist and former adviser to Gov. Arnold Schwarzenegger, said Newsom risks making enemies in the Legislature. He and Williamson couldn’t think of a similar situation faced by Brown or Schwarzenegger.
Reaction to Newsom’s flip-flop from mainstream media sources was virtually all very negative. I, too, wondered what the heck was going on. Did Newsom or his wife have friends or family who thought their children had been injured by vaccines? Did they know antivax quacks who wrote bogus medical exemptions? Is there a big donor who’s an antivaxer? What made him change his mind? It certainly wasn’t a good look.
Fortunately, by week’s end, an agreement was struck. In brief, the Governor agreed to sign SB 276 as long as the changes he wants are passed in a second bill, SB 714; Gov. Newsom will sign both bills into law at the same time. The agreement is definitely a mixed bag. Unfortunately, it includes Gov. Newsom’s mind-numbingly bad idea to grandfather in all existing medical exemptions before January 1, 2020, which will definitely spark a panicked gold rush for vaccine exemptions over the next three and a half months. SB 714 will also unfortunately remove a provision in SB 276 that would have required doctors to certify that medical exemptions are accurate, under penalty of perjury. (It’s almost as though Gov. Newsom doesn’t want any quack doctors to face penalties for perjury.) It would appear, though, that Sen. Pan wrung some concessions from Gov. Newsom. For example:
However, Newsom’s amendment contains a key caveat: New medical exemptions would be required when a child enters kindergarten, seventh grade or changes schools. By adding that provision, permanent medical exemptions would no longer be valid throughout a child’s K-12 education. A similar approach was used when the state eliminated personal belief exemptions in 2015 under another bill by Pan that allowed immunization waivers to remain valid until a child reached kindergarten, seventh grade or changed schools.
There is also one new provision in SB 714 that actually improves SB 276. It’s a provision I wholeheartedly approve of:
SB 714, which is also written by Pan, would invalidate any medical exemption from a doctor who has faced disciplinary action by the state medical board.
Sears, who is currently subject to a 35-month probation order issued by the medical board in a vaccine case that did not involve school medical exemptions, expressed disbelief over the amendments released Friday.
“[This bill would] mean that any exemption written by a doctor who has been disciplined by the board for any reason, even one unrelated to vaccination, will be subject to revocation,” Sears said. “So the hundreds of patients I’ve written exemptions for over the past four years after having a severe vaccine reaction will lose their exemptions. This seems like a broad overreach from a government that is supposed to protect its medically fragile children.”
So, yes, the compromise is very much a mixed bag, but that’s politics, I guess. Certainly, the law in California governing school vaccine mandates will be improved after passage of SB 276 and SB 714 compared to before, but, man, the process was ugly and the Governor’s meddling was depressing to behold.
Several years ago, I occasionally got into—shall we say?—heated discussions over how far we should go with school vaccine mandates. It was always obvious that the closest to ideal policy would be to allow only medical exemptions, but my point was that, politically, it would be difficult to impossible to pass laws eliminating nonmedical exemptions. As a result, I tended to favor what I considered to be what was feasible, rather than pie-in-the-sky policies; in other words, policies like what we have in Michigan or California’s AB 2109, the goal being to make nonmedical exemptions as difficult to obtain as feasible. Such policies are admittedly halfway measures, but they do work, just not as well as eliminating nonmedical exemptions altogether. I believe that my assessment was correct, too, at least before the Disneyland measles outbreak. However, the Disneyland measles outbreak changed the equation, at least in California, making what was once not feasible suddenly possible, and Sen. Pan to his credit took advantage.
Even after that outbreak, though, eliminating nonmedical exemptions was still a hard sell, and there was a price to pay. The battle to pass SB 277 energized the antivaccine movement as never before. Worse, it led to an unholy union between small government conservatives and antivaxers, particularly in states like Texas, where antivaxers successfully politicized school vaccine mandates by appealing to conservative activists through language emphasizing “parental rights” and “health freedom” and vaccine mandates portrayed as governmental overreach. As a result, Republican candidates for office not infrequently find themselves feeling as though they have to pander to antivaxers, as they did in my own Congressional district, with the GOP being far too receptive to antivaccine arguments, far more so than Democrats.
Still, this is a battle worth fighting. Being in the midst of the largest measles outbreak in a generation has led a handful of other states to take the plunge and ban nonmedical exemptions, religious and personal belief, as I mentioned above. Even so, 45 states allow religious exemptions, while 15 states currently permit philosophical exemptions in the midst of this outbreak. We have a long way to go, and in the meantime we shouldn’t let the perfect be the enemy of good. I will support nearly any policy that will decrease the rate of nonmedical exemptions. Congratulations to Sen. Pan. He didn’t get everything he wanted, but he came close. And shame on Governor Newsom for playing politics with public health.

   Electrodermal Testing Part II: Legal and Regulatory Aspects
Harriet Hall
Link
Last week I described electrodermal testing. I’m sure many readers thought, “There oughta be a law against that.” Well, there are laws. Unfortunately, having laws and enforcing them are two different things.
Some of these devices are not approved at all. Most have received 501(k) approval from the FDA as biofeedback devices so similar to previous devices that they do not require new approval — for biofeedback. It is illegal to use the devices for anything other than biofeedback. The FDA has prohibited their sale or importation for unapproved purposes like electrodermal testing; it has sent warnings to companies, raided clinics, and confiscated machines. States have prosecuted users for practicing medicine without a license. Medical boards have chastised licensed providers. The Quackwatch website lists these regulatory actions but points out that there has been no systematic effort to drive these devices from the marketplace.
Excuses, Excuses
One electrodermal testing website admits that what it is doing is illegal and tries to fight back with this specious disclaimer:
It is important to understand that the laws in the USA forbid me from being able to treat, diagnose, cure or prevent disease. The AMA has a patent on those words and only a licensed medical doctor can do that. And although it is legal for a licensed medical doctor to violate the Hippocratic oath and prescribe toxic drugs that cause harm and sometimes even kill patients, it is illegal for me to claim you can be cured using natural, nontoxic remedies, even though thousands of people can testify how they have been healed using natural remedies.
These machines are being used to practice medicine without a license, but they think they can get around the law by offering a disclaimer and by espousing the fiction that they are not diagnosing or treating diseases but only detecting energy imbalances and advising patients about how to restore balance.
Here are some typical protestations:
    • I can only find imbalances that may be causing problems. It would be up to a medical doctor to determine if what I am finding IS the cause.
    • I wouldn’t call EAV biofeedback “treatment.” You don’t treat anything with EAV. Creating a vial of treated water for a client to take may help balance their energy. Balancing energy is not medical treatment. It is perfectly legal to own one for home usage.
    • And the reason all these people are spending money on this equipment is what??? Would they continue to invest in something that is “bogus”?
    • EAV is not anything like the medical tests that we are used to. It works by quantum physics not biology.
    • Yes, there are a bunch of enforcement actions. I assume that what is listed is about the entire list. Do you also want to list the claims made against regular M.D.s?
    • Something that shows up energetically does not necessarily mean that it is a physical condition!
    • We are only just now getting the scientific ability to test these [homeopathic] remedies by quantum physics.
In the training videos I mentioned in my previous article, the demonstrator answers questions from the audience that reveal more about the way they operate:
Q: I’m not a doctor. I have to send patients to an MD for IV infusions. What do you say when the doctor questions how you determined the patient needs it?
A: Tell him you determined it by electrodermal testing, similar to muscle testing [applied kinesiology] and ask him if what he does is any better. At least we have some monitoring device.
Q: One remedy you recommended is acid, but she has an acid problem.
A: That seems contradictory but we need it for her circulation, and the body can sort out what it needs.
Q: Is the circulation due to blockage in her superior vena cava?
A: No.
Q: Should she stop other medications or products?
A: Bring in the products and put them on the test tray. Medicine is a legal issue, so we can only show her what it does to her pancreas, we can’t tell her to stop using it. You might be liable if you told them to go off their meds.
Q: Will other medications interfere with our treatment?
A: Our treatment will not be as effective if they stay on their meds. Cancer treatments like chemo and radiation will usually interfere with our efforts. If the patient needs to stay on medication, we can give more products to balance out the effect of prescription meds on liver and to reduce med side effects.
Q: [Something about] cancer showed up on the readings. Does that mean she has cancer?
A: I don’t think she has cancer, but if she doesn’t correct the problems in her body, I can guarantee you down the road she will have problems like that. Cancer loves miasms, acidosis, poor circulation, emotional issues, and immune dysfunction. She’s got ‘em all. It’s just a matter of time. You can’t tell a person they have cancer — just that that matches the picture. Biopsy is needed for medical diagnosis. You can treat it before it gets to the biopsiable stage.
Q: What if the patient says “Every time I come in you give me something different.”
A: Well duh, do you want to be on the same thing all your life if it’s not working? If it’s fixed, why keep taking it? The body prioritizes all the time, so what it needs today will not be what it needs tomorrow.
Regulatory Actions
The FDA, state attorney generals, professional licensing boards, and foreign regulatory agencies have all taken action to stop electrodermal testers. Details of many of these cases can be found on Quackwatch.
An examination of 3 cases from my own state, Washington, highlights some of the problems with regulation.
The Ames Case
A licensed physician was using a LISTEN device to diagnose allergies. The findings of fact are interesting:
    • After he used the LISTEN machine, he wrapped the probe in tissue paper and had the patient hold the probe with tissue paper wrapped around it. When the patient asked why, he answered that he has done this so long, that he could do what the machine could do, and that he did not need the machine anymore.
    • He used the machine not only to diagnose, but to treat allergies.
    • He also used applied kinesiology, a phoney muscle testing procedure.
    • He used dubious hair and urine tests to determine that the patient had a mineral imbalance, and told him he needed treatment for metal poisoning.
    • He used what sounds like a chiropractic “activator” device on acupressure points.
    • He prescribed the Metabolic Type Diet, a diet with no scientific justification.
The Washington State Department of Health Medical Quality Assurance Commission suspended his license for 5 years. Only they didn’t, because the suspension was stayed as long as he (a) stops using the device, (b) undergoes quarterly practice reviews, and (c) pays a $5,000 fine. The MQAC’s decision was appealed but the state Supreme Court upheld the decision, saying that Ames had “led patients to believe that LISTEN could diagnose and treat allergies, when in fact it could do neither.” Note that the board and the courts only considered his use of the device and did not even address any of his other questionable practices or his basic competence to practice medicine.
The Trasker Case
Joyce Trasker was convicted of practicing medicine and veterinary medicine without a license. She used the Orion and the Asyra devices to determine a patient’s “energy signature” and to prescribe homeopathic remedies. She offered testing on saliva and blood samples sent to her by mail. Eventually she began taking these samples and the machine onto an Indian reservation to do the testing, claiming that the State had no jurisdiction there. She claimed she was not practicing medicine. She even claimed that the right to free speech protected what she was doing. Her case went all the way to the state Supreme Court. She was ordered to cease and desist and to pay a fine of $10,000.
No problem: she simply moved a short distance across the state line to Idaho where she is still offering the same electrodermal testing for $295 per test. You can mail in saliva samples, even from Washington State: her website says “Washington may not prohibit its residents from patronizing an Oregon or Idaho business.” She is also involved in a long term campaign for the freedom to choose safe unregulated health care.
A Dropped Complaint
A few years ago I found a website for a local clinic offering electrodermal testing. After I filed a complaint with the medical board, all references to electrodermal testing mysteriously vanished from the website. The doctor and his lawyers threatened the medical board with legal action if they tried to act on the complaint. The complaint was dropped.
Confusing Terminology
The variety of devices and the many variants of terminology make it difficult to identify the magnitude of the problem. These devices are illegal and cannot be sold or imported, but they are still available. On E-bay I found 6 Biomeridian systems for sale. They seem to be going for around $5000 compared to an original price of $12,000 to $17,000.
If these systems do use some kind of frequency analyzer to capture EMF and then use a frequency generator to re-introduce that same signal back into the human body for “testing,” now they have produced what the FDA considers a radiation emitting device and not a galvanic skin response meter. The QXCI, EPFX, or SCIO falls into that category. The FDA banned importation of this device after an embarrassing exposé by investigative reporters in The Seattle Times featuring patients who died because they relied on the device to treat cancer.
What Can We Do?
In his exposé, Quackwatch’s Stephen Barrett says:
The devices described in this article are used to diagnose nonexistent health problems, select inappropriate treatment, and defraud insurance companies. The practitioners who use them are either delusional, dishonest, or both. These devices should be confiscated and the practitioners who use them should be prosecuted. If you encounter any such device, please report it to the state attorney general, any relevant licensing board, the FDA, the FTC, the FBI, the Better Business Bureau, and any insurance company to which the practitioner submits claims that involve use of the device.
I echo his plea. There is an online directory of practitioners that could be helpful in identifying some of the offenders, but there are undoubtedly many more who are avoiding publicity for fear of legal consequences. We have the tools to stop most of these offenders, but first we need to identify the offenders and then we need to actually use the tools.

HOMEOPATHY

The Baloney Protection Act
Steven Novella on June 10, 2026
Link

We have had to endure a great deal of interference from government in the conduct of institutions that should be governed by science and evidence. I’m sorry to report – here is one more. Senators Mike Lee (R-UT) and Tommy Tuberville (R- AL) have recently introduced a bill that would limit the FDA’s ability to regulate the blatant pseudoscience of homeopathy. This is how they frame it: “The Homeopathic Drug Product Safety, Quality, and Transparency Act will provide a pathway for homeopathic medicinal products to be lawfully marketed by the Food and Drug Administration without needlessly banning safe products that simply do not fit into the same legal categories as traditional pharmaceuticals.”
They are promoting this bit of malfeasance with the usual tropes:
“Americans have a right to manage their own health and choose treatments that are right for them, including homeopathic methods,” said Senator Mike Lee. “The current federal regulatory framework is designed around traditional pharmaceuticals, but it is ill-equipped to review the safety and effectiveness of homeopathic products.
“I’ve long been an advocate for homeopathic medicine,” said Senator Tommy Tuberville. “The reality is that too many Americans today are hooked on pharmaceuticals when they could be using homeopathic remedies, which are often cheaper and can yield miraculous results.”
There is a lot to unpack in these statements, but let’s start with a quick review of what homeopathy is. It was invented in the late 18th century by German physician Samuel Hahnemann, based on prescientific notions. First, it uses substances which allegedly cause specific symptoms to treat those same symptoms. This is nothing but sympathetic magic (it is not based on any principles similar to vaccines, for example). These substances are often fanciful, and some even don’t exist. Oscilococcinum, still a popular homeopathic product, is nothing but artifactual air bubbles on a slide, mistaken for an organism by an ignorant and confused homeopath.
The silliness of the starting ingredients are also irrelevant – because whatever they are they are typically diluted out of existence (so homeopathy is magic squared). Homeopaths sometimes claim the “essence” of the substance remains, but there is no mechanism for this, nor for it to be stored in sugar pills or get absorbed into the body or have any effect on the body. In order for homeopathy to work one would have to believe in a chain of impossible things (even The White Queen would find this challenging).
Despite that, homeopathy has been clinically studied – and unsurprisingly, it doesn’t work. To put it more technically, there is insufficient evidence to reject the null hypothesis that homeopathic products have no specific efficacy or any effect beyond placebo for any indication. Multiple independent systematic reviews have come to this basic conclusion. Magic, it turns out, isn’t real.
Selling a product to the public that demonstrably does not work with claims that it does work is, quite simply, fraud. So why is this allowed at all? Partly because of a US Senator who was a homeopath, Royal S. Copeland (D-NY), who is responsible for creating the current framework in which the FDA regulates homeopathic products. Essentially homeopathy is in its own category, and does not require evidence for safety or efficacy. The FDA decided that homeopathy was too small a market to waste their limited resources on so they just accepted the homeopathic pharmacopoeia as a list of approved products – no evidence required.
However, in 2019 the FDA reviewed its regulation of homeopathy because of the growing industry, and they did strengthen their regulations (although not nearly enough). Mainly they required greater scrutiny of manufacturing for safety and quality concerns, while still ignoring the complete lack of any effectiveness. Meanwhile the FTC changed its regulations requiring more transparency in labeling – again, good but not far enough.
Now it seem that Tuberville and Lee are not happy with the FDA partly doing its job, so they want to stop them. Mike Lee is from Utah, which is the epicenter of the alternative health product industry in the US, so he is likely just serving this industry in his state (as Orrin Hatch did before him). He has been consistently anti-regulation of this industry, with the usually dubious justifications.
Saying that consumers have a right to make their own choices is grossly misleading. It’s like saying they should be able to drive over whatever bridge they want, or consume tainted meat, employ incompetent doctors and car mechanics, or endure unsafe work conditions. It’s nearly impossible for individual people to determine if a medicine is safe and effective from their own anecdotal use. Safety is often a matter of statistics from systematic reviews of many cases, as is efficacy. Placebo and non-specific effects also make efficacy extremely hard to accurately perceive. The existence of the homeopathic industry itself is hard proof of this.
Most people also do not even know what homeopathy is. Further most people falsely assume that if the government approves something, it must be legitimate. Over my career I have had countless conversations with both the public and fellow practitioners, and virtually no one who is not already steeped in skepticism or science based medicine have any idea what homeopathy is. Many are disbelieving when I explain it to them, believing that it can’t possibly be that nonsensical (until they look into it themselves). Given this profound lack of information, it’s hard to argue for consumer choice.
The senators are also borrowing the propaganda from the CAM industry, that scientific methods designed for drugs don’t work for homeopathy or other alternative products. This is also nonsense. Evidence is evidence – either a product is safe or it isn’t, either it works or it doesn’t. Safe and consistent manufacturing processes are also agnostic toward the type of product. This is just all pro-industry anti-consumer regulation sold with the same laughable justifications that we typically get.
So we appear to have an industry shill and a true believer trying to weaken the FDA’s ability to protect the public from clearly fraudulent and worthless products. Further, MAHA sycophants are lining up behind them.
If you live in the US, you might want to write your senator and explain that you want the FDA to actually protect US consumers from blatant health product fraud. 



A homeopathic win for consumers
Scott Gavura on August 13, 2015
Link

Do you believe in magic? It might surprise you to learn that some people believe sugar pills have healing properties. This belief system, called homeopathy, is a multi-billion dollar industry worldwide, and it’s growing. While there is no convincing evidence to demonstrate that homeopathic treatments are more effective than a placebo, many consumers and even some health professionals accept homeopathy as a legitimate health treatment, and its providers as legitimate health professionals. Responding to the perceived consumer demand for these products, government regulators have had a difficult decision to make: They could ignore homeopathy as a health practice, treating it like we might think of astrology: firmly outside of medicine. Or they could choose some form of regulation, targeting the providers (homeopaths) or the product (homeopathy), possibly with the goal of managing its use, or perhaps limiting harms to consumers. The risk of regulating nonsense, as has been described before, is the perceived legitimacy that recognition and regulation implies. Regrettably, regulation in many countries has had that exact effect. What’s worse, regulation often seems to have prioritized the commercial interests of homeopaths over the public interest, leaving consumers with little understanding that homeopathy lacks scientific credibility as a health practice. Consequently, homeopathy has attracted regular criticism from SBM’s bloggers, science and health journalists, and other science advocates over the years. It appears this advocacy is finally having an effect. Regular readers will recall several posts over the past few weeks, describing the possibility of new regulation of homeopathy by the US Food and Drug Administration (FDA). And just recently, Health Canada announced two important changes to its homeopathy regulation, which may signal a new direction. Are we witnessing the beginning of more sensible regulation of this prescientific practice?
Dilutions of grandeur
Homeopathy is considered a form of “alternative medicine” but it’s more accurately described as alternative to medicine, given homeopathic remedies don’t normally contain medicine or active ingredients. Homeopathy was invented in the 1800s based on the idea that “like cures like” (which is sympathetic magic, not science). Proponents of homeopathy believe that any substance can be an effective remedy if it’s diluted enough: cancer, boar testicles, crude oil, oxygen, and skim milk are all homeopathic “remedies”. But while they may have different labels, the products are all essentially the same. In the manufacturing process, remedies are diluted in water so dramatically that there’s mathematically almost zero possibility of even a trace of the original ingredient remaining. To homeopaths, this is a good thing, as dilution is claimed to make the “remedy” more potent, not less. These rules contradict core scientific principles as well as what we know about biology and medicine. In short if homeopathy works, the rest of medicine cannot work. And the best evidence shows that they do not work.
Health Canada, Canada’s version of the FDA, has taken the approach of licensing homeopathic remedies (it does not regulate the practice of homeopathy) as part of an overall “natural health products” framework, lumping homeopathy in alongside supplements, vitamins and practices like Traditional Chinese Medicine. Health Canada states that this licensing framework benefits consumers:
Through the Natural Health Products Directorate, Health Canada assures that all Canadians have ready access to a wide range of natural health products that are safe, effective and of high quality.
The consequence, when it comes to homeopathy, has been the regulation of the absurd. There are now hundreds of indistinguishable homeopathic remedies that have been reviewed and approved by Health Canada, based what turns out to be an astonishingly low evidence bar. Health Canada will even allow references to homeopathy textbooks written in the 1800’s as “evidence” of a product’s efficacy. There is no requirement for any randomized controlled trial or any other form of evidence that could actually show efficacy. Health Canada’s bar is so low that when the “homeopathic insect repellent” Mozi-Q was approved, I questioned aloud if there was anything that Health Canada wouldn’t approve. As the television show CBC Marketplace discovered, the answer seems to be no.
A few years ago, Health Canada (and other regulators worldwide) undertook a safety review of cough and cold remedies marketed for children. While these products had a long history of use, there was scant evidence that they did anything beneficial. Given these products had some risks, most regulators concluded that the risks outweighed the benefits. Health Canada ordered that these products could no longer be promoted for use in children, and the products were pulled off pharmacy shelves. The supplement and natural health product industry responded quickly, bringing products to market that took advantage of the special rules created for homeopathy. Soon several homeopathic “cough and cold” products were on pharmacy shelves – not because they had any evidence of efficacy, but actually because they lacked any medicine at all. These were placebos, sitting on pharmacy shelves where the old cough and cold remedies used to sit, labelled as if they could treat coughs and colds.
CBC Marketplace, having previously described how homeopathic remedies lack any medicine at all, decided to test Health Canada’s own licensing process. They applied for approval to market a homeopathic remedy they named “Nighton” to be used to treat fever and pain in infants and children. For evidence, they submitted a few pages photocopied from an old homeopathy textbook. No trials were conducted and no safety data was provided. Just some forms, a few photocopies and a fee. Perhaps not surprisingly, their product was approved and licensed. Here is the listing, still active, on the Health Canada website. As subsequent focus groups revealed, parents do assume that Health Canada’s approved products had been thoroughly tested by Health Canada for both safety and efficacy.
Health Canada has now announced that it is strengthening the rules for homeopathic cough and cold products. It will no longer allow specific health claims for homeopathic cough, cold and flu products for children 12 and under, unless those claims are supported by scientific evidence. That’s a significant change from accepting photocopies from textbooks written in the 1800s. One wonders why this rule isn’t being applied to all homeopathic remedies that are marketed. It’s especially curious given a remarkable statement Health Canada published on its website when the new requirements were announced:
Health Canada regulates homeopathic products as a type of natural health product. Health Canada reviews homeopathic products to make sure that they are safe and that the health claims (what the product claims to do) are supported by textbooks and other references used in the practice of homeopathy (e.g., pharmacopoeia, Materia medica). These products are not supported by scientific evidence.
Emphasis added.
In putting new limitations on claims made by manufacturers, Health Canada is finally acknowledging what scientifically is known as fact.
Nosodes are not vaccines
The second change recently announced by Health Canada relates to homeopathic “nosodes”. In late 2014, CBC Marketplace used hidden cameras to record reporters asking homeopaths about vaccines. The show sent young mothers (with their babies) to speak with homeopaths about immunizations and vaccines in Toronto and Vancouver. They found homeopaths were giving advice that often contradicted scientific evidence. Rather than endorsing vaccines, some homeopaths promoted “nosodes” which they believe offer vaccine-like immunity from products that are, like all homeopathy, inert sugar pills. A “nosode” is a remedy that starts with infectious material, like polio, measles or smallpox, and then it’s diluted sequentially until mathematically, there’s nothing left but water. Unbelievably, Health Canada has approved hundreds of homeopathic “nosodes” for sale over the years. Two years ago advocacy group Bad Science Watch launched a public campaign against nosodes, and succeeded in getting Health Canada’s agreement to force commercial manufacturers to place a label on their products stating “This product is not intended to be an alternative to vaccination.” Many felt this didn’t go far enough. This year, the Canadian Paediatric Society issued a strong statement on nosodes:
Nosodes are approved for human use in Canada under Health Canada’s Natural Health Products Regulations. At the time of writing, there were 179 distinct products approved for sale, including 82 with labels stating that they can be used to prevent common and important infections. However, as stated previously, there is no scientific or medical evidence that nosodes are effective in preventing infectious disease.
It is important that Canadian parents are provided with the best available evidence to make informed decisions about their children’s health. Current regulations stipulate that labelling on nosodes must include the following statement: “This product is not intended to be an alternative to vaccination”. The Canadian Paediatric Society (CPS) does not believe this proviso fully captures the fact that nosodes are clearly not a safe or efficacious alternative to vaccination. The CPS recommends that labelling on nosode products should be changed to read: “This product has not been proven to prevent infection. Health Canada advises that your child receive all routine vaccinations even if they take this product”.
In July 2015, Health Canada responded with a new warning for the label, clearly modeled on the CPS recommendation:
This product is neither a vaccine nor an alternative to vaccination. This product has not been proven to prevent infection. Health Canada does not recommend its use in children and advises that your child receive all routine vaccinations.
While this is a welcome change, it won’t help all consumers, particularly the ones that see homeopaths for treatment. Health Canada doesn’t appear to require the warning when the remedy is produced by the homeopaths themselves, but only when the products are commercially prepared. So while the labelling change is an improvement, it’s somewhat of a hollow (homeopathic?) success. It doesn’t appear to apply to homeopaths who make their own products, like the ones Marketplace filmed with hidden cameras. Nor does it remove the license of the 121 products already approved, or commit to removing these medically useless products from the market. But it’s another acknowledgment of the lack of evidence supporting homeopathy, which hopefully will continue to raise questions about the entire licensing system.
Homeopathy still has nothing to offer
The evidence is overwhelming and unequivocal: Homeopathy is a belief system, not medicine, and consequently has nothing to contribute to the practice of medicine. Despite this reality, regulators have struggled to find licensing frameworks that prioritize consumers and public health above those of homeopaths and homeopathic manufacturers. Recent changes in Canada are a modest but hopeful sign for change.

The CAM Docket: Boiron I
Jann Bellamy on March 22, 2012
Link
Author’s note: This will inaugurate a series of occasional posts observing the wheels of justice grind slowly over “CAM.”
In a previous post, I posited that CAM practitioners might well subject themselves to liability for the tort of fraudulent misrepresentation. This misrepresentation could be based on both the lack of scientific evidence of effectiveness and the lack of scientific plausibility for their treatments. One example was homeopathy, which, as Dr. Steven Novella aptly stated,
we can summarize . . . by saying it has extreme implausibility and the clinical evidence shows lack of efficacy. It should not work, and it does not work. There is no legitimate controversy about this.
In the last couple of years five lawsuits have been filed against Boiron, a somewhat prickly company based in France and the world’s largest manufacturer of homeopathic products. In 2011, Boiron had $520,000,000 in sales, although some of this revenue comes from its other products, such as dietary supplements. The plaintiffs are consumers who purchased Boiron’s homeopathic “remedies” and who now allege that they were deceived by Boiron’s false and misleading representations, allegations Boiron denies. Four of the lawsuits are pending in California and one in Illinois.
All of the suits are filed as putative class actions, which generally proceed like this: a plaintiff claims she was injured in a certain manner by the defendant’s conduct and that there are numerous others who were injured in the same, or a similar, way. She asks the court to allow her to proceed with a class action in which she will represent all those other people. In essence, the class members become plaintiffs themselves and are bound by the results of the case. (They can’t, for example, bring their own individual lawsuits.) If the plaintiff is successful, all class members are entitled to relief, including monetary damages.
Delarosa v. Boiron class action
The first suit filed was Gina Delarosa v. Boiron, in 2010. Ms. Delarosa alleged that she purchased Boiron’s Children’s Coldcalm, relying on Boiron’s representations that it was effective in relieving sneezing, runny note, congestion, and other cold symptoms, but that it didn’t work for her family. Her claims are for fraudulent misrepresentation and violation of California consumer protection laws. She sought to represent a class of other California purchasers of Children’s Coldcalm.
In the Complaint, Delarosa first hits hard on homeopathy itself, alleging that:
    • A Swiss government study conducted 110 placebo-controlled trials and found that homeopathy is no more effective than placebo.
    • The American Medical Association and Great Britain’s National Health Service stated that there is no scientific evidence to support the use of homeopathic treatments.
    • “Even homeopathy’s own supporters, such as the National Center for Complementary and Alternative Medicine, admit that ‘[t]here is [] no condition for which homeopathy has been proven to be an effective treatment.’” [Empahsis added.]
(And here I’ve been thinking all this time that only hard-core SBM types and their fellow travelers noticed NCCAM’s pro-CAM stance.)
Ms. Delarosa then hones in on Coldcalm itself, alleging:
The homeopathic ingredients in Children’s Coldcam range from various flowers, vegetables, insects, metals, and poison. In order not to poison a user, the dilutions . . . are claimed to be up to 3C and 6C.
. . . a 6C dilution gives one part ingredient to 1 trillion parts of the solution. Dilutions to this extent leave the solution with no trace of the original ingredient.
. . . The idea that a substance could be completely physically lacking and still be effective violates fundamental principles of science. . . . and runs contrary to dose-response relationship established by pharmacology.”
Thus, Ms. Delarosa alleges Boiron’s representations, made on both the package and in other advertising, that Children’s Coldcalm relieves numerous cold symptoms are false, misleading, contrary to established medical authority, and constitute unfair and deceptive business practices. She seeks actual, punitive and other damages, as well as an injunction preventing Boiron from engaging in these deceptive practices.
As might be expected, Boiron opposed the lawsuit’s proceeding as a class action. It also argued, again as might be expected, that the suit was preempted by federal law. Boiron lost on both of these issues, which was a significant victory for Ms. Delarosa and the class of other consumers she now represents. Delarosa v. Boiron, Inc., 2011 U.S. Dist. LEXIS 80562 (C.D. Cal. 2011); 275 F.R.D. 582, 2011 LEXIS 106248 (C.D. Cal. 2011).
Especially interesting was the Court’s ruling on Boiron’s preemption claim. Briefly, under the U.S. Constitution, federal law is the “supreme Law of the Land.” Thus any state law that conflicts with federal law has no effect, and the federal law “preempts” state law on the subject. Very broadly, and without getting into the complexities of the law on preemption, Boiron argued that federal law gave the FDA the exclusive right to regulate homeopathic products and that this preempted the Plaintiff’s state consumer protection law and fraud claims. Had Boiron been effective in its argument the Court would have dismissed the Complaint.
In ruling against Boiron on the preemption issue, the Court was required, for procedural reasons, to accept as true the allegations of the Plaintiff’s complaint. This means that the facts on which the Court relied in making its decision are not findings of fact in the sense a jury would make after hearing the evidence – they are simply what the Plaintiff alleges to be true. On the other hand, it is exclusively up to the courts to determine what the law is, and this Court’s interpretation of federal law regarding homeopathic products highlights their almost complete lack of regulation.
First, by way of background, the Food, Drug and Cosmetic Act [FDCA], enacted by Congress in 1938, defines “drug” to include both prescription and over-the-counter [OTC] homeopathic products recognized in the “Homeopathic Pharmacopoeia of the United States” [HPUS]. According to the FDA, the HPUS is a “compilation of standards for source, composition, and preparation of homeopathic drugs. The HPUS contains monographs of drug ingredients used in homeopathic treatment.” As the Court noted, this means that “the FDA allows a private organization to designate which homeopathic drugs meet certain (and unknown) standards” and are thus eligible for inclusion in the HPUS. [Emphasis added.]
In addition, the Court concluded:
Unlike non-homeopathic OTC drugs, homeopathic OTC drugs, including the Coldcalm product at issue here, are not evaluated by the FDA at all. . . . Although the HPUS describes how these ingredients [in homeopathic products] are prepared for homeopathic use, it does not list the drugs as fit to treat specific symptoms, ailments, or conditions. Instead, the HPUS allows the practitioner or manufacturer to set forth the substance’s indications for use.”
[Citations omitted, emphasis added.]
And:
The Court is unaware of what standards, if any, exists to ensure that homeopathic OTC drugs are safe and effective. The FDA does not impose additional standards for strength, purity, quality, safety, or efficacy on homeopathic OTC remedies, Indeed, the FDA has advised that unless a homeopathic remedy is ‘being offered for use (or promoted) significantly beyond recognized or customary practice,’ federal policies on health fraud do not apply. And perhaps most significant, ‘[a] product’s compliance with requirements of the HPUS . . . does not establish that it has been shown by appropriate means to be safe, effective, and not misbranded for its intended use.”
[Citations omitted, emphasis added.]
Finally:
As evidenced by the FDA guidance documents . . . the Court concludes that the FDA has largely abdicated any role it might have had in creating standards for homeopathic OTC drugs, and has instead attempted to delegate this authority to the non-governmental organization that determines whether homeopathic substances should be included in the HPUS. In addition, the FDA explicitly states that it makes no guarantee about the safety or efficacy of homeopathic OTC drugs even if they meet the unknown standards for inclusion in the HPUS.”
[Empahsis added.]
The Court also remarked that it could find “no record of any [FDA] investigation of homeopathic remedies due to a reported lack of efficacy.”
To recap, the FDA, the federal agency charged with regulating the safety and efficacy of drugs, has abandoned its authority to do so in the case of homeopathic drugs. Instead, it allows a private organization, employing unknown standards, to decide what homeopathic substances can be used. These substances include insects and poisons. Whatever these standards are, according to the FDA, they do not mean that homeopathic products are safe, effective or not misbranded.
The other lawsuits
In addition to fraud and state consumer protection law claims, other suits against Boiron add federal law breach of warranty claims arising out of purchases of various other Boiron products in addition to Coldcalm. All cases seek to proceed as class actions, although there has been no ruling on this issue yet.
According to the Complaint in Fernandez v. Boiron, products purchased by the Plaintiffs include:
    • Arnicare Arthritis, which purports to treat “trauma and muscle soreness” and various types of pain, including “joint pain worsened by heat and slow motion.” Among the ingredients in Arnicare Athritis are “a class B noxious weed, alpine rose, and poison ivy.”
    • Chestal, which “loosens thick mucus” and claims to relieve many types of cough, including “barking cough worse at night” and “wet cough associated with the day becoming dry at night.” Active ingredients include “a parasitic insect, wind flower, lung moss, and sea sponge that has been roasted.”
    • Quietude, a remedy for, among other things, “restless sleep associated with nervousness” and “sleeplessness associated with worries and exhaustion.” Ingredients of Quietude include “stinking nightshade, nutmeg, purple passionflower, and seeds of the jimson weed.”
As the Complaint points out, none of the ingredients are listed by their common names, but rather by “their more exotic sounding Latin names.”
In Gonzales v. Boiron, Plaintiff is suing over claims made for Oscillo which, according to the Complaint, Boiron advertises as “medicine for headache, body ache, chills & fever,” that will “slow down the spread of germs,” has “a long history of efficacy and safety” and “is the first flu medicine recommended by pharmacists.” Oscillo is advertised as “tak[ing] care of the flu within 48 hours.” But, as the Complaint alleges, the listed active ingredient in Oscillo is Anas Barbariae Hepatis et Cordis Extractum, “a fancy way to hide the truth from the general public, which that this ingredient is actually Muscocy duck liver and heart.”
According to the Complaint, the duck liver and heart “is diluted to 200CK,” which means that for every part of the purportedly active ingredient, “there is 1^399 parts of the inactive ingredient, sugar.” Cleverly, the Complaint spells out this dilution, which results in a ratio of 1:1 with 166 zeros after it. (Assuming I counted all those zeros correctly.) As the Plaintiff points out, the probability of getting one molecule of the active ingredient in a regular dose is “approximately equal to winning the Powerball every week for nearly an entire year.”
Settlement?
An interesting development, in the form of a proposed settlement, occurred last month in one of the lawsuits, Gallucci v. Boiron.
The Plaintiffs in this case seek to represent a nationwide class of all persons who purchased a number of different Boiron products since January 1, 2000. They allege that the active ingredients in these products, even if effective, are so greatly diluted as to be non-existent. Thus, Boiron’s claims regarding the products’ benefits are false and misleading.
The Plaintiffs and Boiron have proposed a settlement of the lawsuit, now pending before the Court for preliminary approval. The settlement would require Boiron to put up $5,000,000 to pay damages, an incentive award to the named Plaintiffs, attorneys fees and costs, plus expenses of administering the settlement. Payouts to claimants are reduced pro rata if $5 million doesn’t cover everything. It would also require Boiron to make changes to its labeling and advertising.
(If Boiron needs any help coughing up the $5 million, although I doubt it does, I suggest it try to claim the $1 million prize offered by the James Randi Educational Foundation to any homeopathic remedy manufacturer who can prove, via valid scientific testing, that its products work.)
Consumers who can produce proof of purchase will get a full refund with a limit of $100 per household. Consumers without proof of purchase will get $10 per product, up to $50 per household.
Because the Court in the Delarosa case has already approved a class of purchasers of Coldcalm in California, the settlement would exclude those persons, but would include all other purchasers of Boiron products in the U.S. as well as California purchases of products other than Coldcalm. This would, in the estimation of the Plaintiffs, include tens of thousands of claimants.
According to the Plaintiffs, between January 2007 and September 2011 (less than 4 of the 11-plus years covered by the settlement), 12 million units of Boiron products were purchased in mass retail stores (which doesn’t include sales in specialty natural food stores or to homeopaths), approximately $13 million in sales per year. It is not clear whether the Plaintiffs are speaking exclusively of the 800 homeopathic products Boiron sells, or are including non-homeopathic products in these numbers. However, because the Plaintiffs themselves included this information in support of their argument that the potential class of purchasers would be very large, it is reasonable to assume they are referring to homeopathic products.
So let’s do the math: If sales are $13 million per year, and the period covered is over 11 years, how can $5 million possibly be adequate to pay out all claims plus attorneys fees, costs and other expenses? Based on unit sales figures included in the proposed settlement (for mass retail sales only), over the 136 months covered by the settlement, 36,040,000 units were sold. If only 10% of these purchases resulted in a claim of $10 each, that would equal $36,040,000 alone. Plaintiffs have already estimated that notice of the proposed settlement to class members will cost almost $160,000. And documents filed in support of the proposed settlement reveal that one of Plaintiff’s attorneys was awarded $595 per hour for his work in another settled class action lawsuit. To me, this just doesn’t add up.
Even if the Plaintiffs were using total sales figures, including non-homeopathic products, let’s assume only one-half of the sales cited by the Plaintiffs are for Boiron’s homeopathic products, and stick with our assumption that only 10% of purchasers make a claim of $10 each. That still results in claims of over $18,000,000.
One task in any class action settlement is figuring out the best way to notify the class members of the proposed settlement so they can make a claim. In this case, something called the “Simmons National Consumer Survey Data” was used to determine how to reach a target audience of class members, described as “U.S. Adults who Trust Homeopathic Remedies (approx. 45 million U.S. adults).” (Sigh.) This led to the conclusion that one appropriate vehicle for notice is an ad in Natural Health Magazine. Well, they got that right. Sample advice on restless leg syndrome from the magazine’s website:
A naturopath says: Homeopathic medicine can ease specific symptoms with diluted doses of plant- and mineral-based remedies.
The treatment: Take Zincum metallicum first because it helps relieve RLS sufferers’ most common complaint—the inability to control their leg and, sometimes, arm movements. If your jerky limbs wake you up at night, try to tame them with Causticum. Use Arsenicum album to ease the creepy-crawly sensations, especially if you also feel restless or cold. But if you’re itchy and hot, try sulphur. Rhus toxicodendron and Kali carbonicum may help, too. With all remedies, start with a 6C potency and take three pellets before bed. You can also buy combination formulas that will treat numerous symptoms.”
6C “potency”? That means the original material is diluted to one part in one trillion. But I digress.
In addition, according to the proposed settlement, Boiron would change its packaging and advertising in two ways. First, “Indications of Use,” which describes the treatment and relief of symptoms or ailments, will bear this “FDA Disclaimer language:”
These ‘Uses’ have not been evaluated by the Food and Drug Administration.”
Sound familiar? It should. This is the infamous Quack Miranda Warning modified for homeopathic products. And, as we know, it has been remarkably effective in encouraging folks to do their own safety and efficacy research when purchasing dietary supplements, a $28 billion dollar a year industry in the U.S. alone. We all know plenty of people who’ve run their own randomized, placebo-controlled, double-blind studies before buying dietary supplements, right?
Second, Boiron will have to include a “Dilution Disclaimer” on packaging stating “C,K,CK and X are homepathic dilutions” and direct the consumer to further information on Boirin’s website. Yet, it appears from this link that this information is already available on the company’s website, although difficult to find. In any event, the proposed information fails to tell the reader the significance of homeopathic dilutions. Thus, under “What does ‘200CK’ mean?” we find:
200CK means that the substance has been homeopathically diluted 200 times at the rate of 1 to 100. Therefore, the original substance has been diluted to 10-200.”
This doesn’t give the reader the valuable information that such a thing is impossible. In fact, that would be a far greater dilution than one molecule in the entire observable universe. One has to assume the consumer would find this helpful in deciding whether to make a purchase.
Boiron will not be required to amend misleading information like this from its website:
Q: Is there any scientific research on homeopathic medicines?
A: An increasing number of scientific studies on homeopathy are being conducted and, in recent years, more than 150 of these studies have been published in medical journals. Clinical research is providing evidence of the efficacy of homeopathic medicines, and basic laboratory research is confirming the biological activity of highly diluted substances and helping the scientific community better understand their mechanism of action.
Noted “CAM” researcher Dr. Edzard Ernst (both here and here, among other places) and world-famous author and scientist, Dr. Richard Dawkins, among many others, beg to differ.
Conclusionem
In sum, if the settlement is approved by the court, Boiron will be required to pay out less than $5,000,000 total to settle claims of everyone in the U.S. (except for some Coldcalm purchasers in California) who, in a period of over a decade, purchased its products. It will also have to add the Quack Miranda Warning to labeling and advertising. Finally, it must give consumers information that doesn’t fully inform them what the homeopathic dilution process really means.
Nor will Boiron have to stop listing ingredients in Latin. So I’ll end with this advice to potential customers of homeopathic products, because, after all, most consumers know Latin, right? And, of course, quidquid Latine dictum sit altum videtur. It is important to remember that cuiusvis hominis est errare, nullius nisi insipientis in errore perseverare. When considering your purchase, de omnibus dubitandum. Just because the package promises a remedy for your ills, et suppositio nil ponit in esse. As to the law of similars and other homeopathic nonsense, quod gratis asseritur, gratis negatur, et hoc genus omne.
Fiat iustitia.
Coming soon: “The CAM Docket: Boiron II” and “The CAM Docket: Bach Flower Remedies.”

The CAM Docket: Boiron II
Jann Bellamy on April 19, 2012
Link
Five consumer lawsuits are pending in the U.S. against Boiron, the world’s largest manufacturer of homeopathic products. One lawsuit is also pending in Canada. As reported in a previous post, the U.S. plaintiffs claim they purchased homeopathic products, such as Coldcalm, Oscillo, Arnicare and Chestal Cough Syrup, based on Boiron’s misleading and false statements that they are effective for various ailments. Therefore, these plaintiffs allege, Boiron has defrauded consumers, as well as violated various consumer protection laws. Boiron denies these claims.
The plaintiffs’ allegations in each of the five U.S. lawsuits are based in part on the same fallacies underlying homeopathy discussed many times before here at SBM:
we can summarize . . . by saying it has extreme implausibility and the clinical evidence shows lack of efficacy. It should not work, and it does not work. There is no legitimate controversy about this.
Which raises an interesting question: how does one defend a product that appears to be indefensible? Let’s take a look.
Delarosa v. Boiron
In Delarosa v. Boiron, Inc., the first lawsuit filed and now certified as a class action by the court, there are cross-motions for summary judgment pending. I won’t make you suffer through an explanation of Rule 56 of the Federal Rules of Civil Procedure, which governs summary judgment motions. Suffice it to say that at this point each side apparently feels it has enough uncontroverted evidence to win, at least on some of the issues, without having to go to trial and is asking the judge to rule accordingly.
The plaintiff in Delarosa has the burden of proving Coldcalm does not work as advertised and that Boiron knew or should have known this. Conversely, Boiron, as the defendant, does not have to prove that Coldcalm does work as advertised or that it was unaware that Coldcalm does not work. However, in order to refute the plaintiff’s claims, Boiron has, as one would expect, offered its own evidence that Coldcalm is effective to relieve cold symptoms and that it believes in those claims. And although Boiron argues that the plaintiff cannot prevail simply by attacking homeopathy in general, the plaintiff has submitted evidence that homeopathy does not, and cannot, work. Thus, Boiron has, again as might be expected, submitted evidence on that issue.
Boiron has not yet filed a response to the plaintiff’s summary judgment motion, apparently because of a dispute over information it requested from the plaintiff in discovery. For this and other reasons, we cannot conclude that the evidence presented to this point by Boiron is all that Boiron may possess in support of homeopathy in general and Coldcalm in particular. But we do know that, in filing its own motion for summary judgment, it argues that the evidence is sufficient for the court to decide in its favor. Specifically, Boiron argues that the plaintiff cannot meet her burden of proof in showing Boiron believed its statements were false. “To the contrary,” Boiron argues, it “can provide extensive support regarding the efficacy of both homeopathic drugs generally and Children’s Coldcalm specifically.”
Plaintiff’s expert witness
One of the plaintiff’s experts, Lynn R. Willis, Ph.D, currently holds the position of Professor Emeritus at the Department of Pharmacology and Toxicology at the Indiana University School of Medicine, where he was the director of the medical pharmacology course for 23 years. [Another expert witness for the plaintiff is SBM’s own Harriet Hall, M.D.]
Dr. Willis’s sworn statement in support of the plaintiff’s motion offers this devastating, and unsurprising, analysis of homeopathy in general and Coldcalm in particular:
27. Homeopathy is based upon the ‘Law of Similars.’ Homeopaths assert that ‘like cures like’ or more precisely that one substance that causes symptoms when it is given in large doses will cure illnesses that have the same symptoms if that substance is given in an extremely small dose. There is no credible scientific evidence to support the Law of Similars. In fact, scientific evidence is contrary to the Law of Similars.
28. The dosages of homeopathic drugs are prepared through serial dilution. Serial dilution is done by taking the homeopathic drug and mixing it with water or alcohol at a specific ratio of 1:10 (X) or 1:100 (C). At each dilution the homeopathic drug is shaken in a process called succussion (also referred to as “potentizing”). Succussion is believed to activate the “vital energy” of the diluted substance. No evidence of this “vital energy” has ever been detected by modern science; nor can it be. The serial dilutions are repeated until the desired dilution is reached.
29. The ingredients in Coldcalm, the product at issue in this action, are diluted either to 3C (1:1,000,000) or 6C (1:1,000,000,000,000). There is no scientific evidence that homeopathic drugs, such as the ones found in Coldcalm, have any biological effect on the human body at such extreme dilutions. The dose-response relationship established and proven by modern medicine is contrary to the idea that such extreme dilutions of a medicinal agent can have biological effects on the human body.
30. There is no credible scientific evidence that homeopathy results in anything more than a placebo effect. Indeed, homeopathy theory and practice are contrary to modern scientific research.
. . .
44.The notion that the extreme dilutions found in Cold Calm and other homeopathic remedies should be associated with observable biologic effects and actions is wholly contrary to the proven dose-response relationships of modern pharmacology and medicine in which the intensity of drug action is directly proportional, not inversely proportional, to dose.
45. As outlined in paragraphs 33 through 41, the concentrations of the ingredients in ColdCalm have no detectable effects on the human body; however, as mentioned above, where there is no likelihood of a medicinal agent producing a tangible health benefit to a patient, any risk at all is unacceptable.
Dr. Willis goes through each ingredient in Coldcalm, which includes honeybees, poisonous plants and potassium dichromate (“a powerful oxidizing agent”), finding that, although some are dangerous (even deadly) to humans, at the dilutions stated on the label, none could possibly have any discernible effect on the human body. Dr. Willis opines not only that Coldcalm does not, and could not, have any effect on the common cold, the product itself violates homeopathy’s own precept that each treatment must be individualized, making “one size fits all” remedies inappropriate.
Boiron’s expert
To support its claims of plausibility and effectiveness, Boiron relies on Robert Charles Dumont, M.D. Dr. Dumont trained as, and practiced as, a pediatric gastroenterologist. However, he now describes himself as a “pediatric integrative specialist” with the Raby Institute for Integrative Medicine at Northwestern in Chicago, Illinois.
On its website, the Raby Institute for Integrative Medicine serves up this insult to thousands of dedicated, caring physicians who, poor slugs, practice the obviously inferior “traditional” medicine:
Our approach to healing is unlike what you might experience in a traditional medical setting. Rather than focusing solely on treating the symptoms of a disease or curing an illness, we focus on the whole patient as a unique individual – taking into account each element of a person’s health, environment, and lifestyle. We seek to restore our patients’ unique, natural balance that defines optimal health, and support them to develop health habits that maintain wellness and prevent disease.
“Unique, natural balance that defines optimal health?” What does that even mean?
In pursuit of this lofty goal, the Raby Institute offers a smorgasbord of “CAM” practices previously debunked on SBM and elsewhere, including acupuncture, reflexology, cranial sacral therapy, magnets (“Treatments include shoe inserts, knee wraps, and other bandages, to relieve soreness in joints and muscles from sports injuries”), reiki, the “HCG Longevity Diet,” detoxification, energy medicine, and, our topic here, homeopathy (“based on natural ingredients that work with your immune system rather than suppressing it”). Well, they’ve got me there. No one could argue that honeybees aren’t “natural.”
If you will permit me a digression, I cannot resist sharing this lyrical gibberish from the Raby Institute’s website describing a form of CAM with which I was heretofore unfamiliar:
Vibrational Medicine
Nearly everything around us that we touch and see carries a unique vibrational energy signature—a living pulse that connects all things. Vibrational medicine incorporates the use of this chi energy within living organisms such as plants, gemstones and crystals, water, sunlight, and even the foods we eat, to help us balance the energies in our own bodies. Vibrational medicine therapies include color therapy, crystal therapy, flower essence therapies, grounding, and herbal therapies.
If you make it up, they will come.
Turning back to Dr. Dumont and his statement filed in support of Boiron’s motion, Dr. Dumont says that he “received training in integrative medicine to include training in acupuncture, medical hypnosis, functional medicine, and mind-body medicine.” As well, he has trained in homeopathy and is currently instructor and on the board of the U.S. chapter of the Center for Education and Development of Clinical Homeopathy. In this and additional homeopathy-related training and other activities, he appears well-qualified to speak on the subject.
Dr. Dumont seems to be in agreement with Dr. Willis on the putative principles underlying homeopathic remedies and on the manner in which they are prepared. He does not specifically agree or disagree with the Dr. Willis’s conclusion, based on these principles, that homeopathic theory is contrary to current scientific research. In documents filed with the court, the only statement Dr. Dumont makes at all in this regard is that “basic laboratory research is confirming the biological activity of highly diluted substances and helping the scientific community better understand their mechanism of action.” He attaches two exhibits listing studies of homeopathy but does not indicate which specifically support this statement. Nor does he explain how “the biological activity of highly diluted substances” supports any of the highly implausible assumptions underlying homeopathy.
In answer to deposition questions as to whether there was any scientific evidence indicating how Coldcalm’s ingredients (honeybees, etc.) could relieve cold symptoms, he consistently answered to the effect that “the mechanism is not known.” The plaintiff’s attorney finally asked:
Q. do you have any idea how these things [Coldcalm’s ingredients] are supposed work to accomplish these purposes?
A. No one has any hypothesis within the scientific community how they work.
Q. And that includes you?
A. That includes me. I would have the Nobel prize if I knew.
This did not stop Dr. Dumont from opining that Coldcalm is effective as advertised. He says that there are studies supporting “the efficacy of several of the homeopathic medicines present in Children’s Coldcalm,” but does not know of any studies supporting the efficacy of Coldcalm itself. Rather, he relies on the fact that
patients who have used Coldcalm and children’s Coldcalm to relieve symptoms associated with the common cold have had success with these products. . . . My experience treating patients with Coldcalm and Children’s Coldcalm is extremely positive and I continue to regularly recommend both products to patients who are suffering from symptoms associated with the common cold.
When asked in his deposition whether the basis for his belief that Children’s Coldcalm has been effective for his patients “is just spontaneous statements by mothers indicating that it has worked for their children or them, right?” he replied, “Exactly.” [Homeopaths and their reliance on anecdotes as evidence of effectiveness is the subject of recent blog posts by Orac and Dr. Novella.]
In addition, Christophe Merville, Boiron’s director for education and pharmacy development, testified in his deposition that he was unaware of any scientific testing, research or evidence supporting the effectiveness of Coldcalm or Children’s Coldcalm.
In support of its position that Boiron did not defraud consumers because it “believes in the efficacy of both homeopathic drugs generally and Children’s Coldcalm specifically,” Boiron cites Dr. Dumont’s statement and the testimony of one of its employees, Ludovic G. Rassat. It is not clear how Dr. Dumont’s testimony is relevant to this point, as it occurred only after the suit was filed, long after Boiron made its claims for Coldcalm. Mr. Rassat testified in his deposition as follows:
A. . . . homeopathic medicine is believed to basically stimulate the body’s own ability to – to rebalance itself and get better, so this is all the concept of homeopathic medicine, and this is basically what doctors using homeopathic medicines are doing.
Q. Do you know how Children’s Coldcalm would work to stimulate the body’s ability to rebalance itself and get better?
A. Well, you see, in the back of the product, you have a list of homeopathic active ingredients.
Q. Right.
A. Each homeopathic active ingredients are basically – has been reviewed – have been – are listed in the Materia Medica as being – went through, you know, hundred (phonetic) years of clinical observations by homeopathic doctors, and that’s – all those ingredients are participating to the . . . the action of the product.
Q. Okay. Are you aware of any scientific support indicating that these active ingredients on the back of the Children’s Coldcalm label will be effective in accomplishing the purposes stated [on the packaging]?
A. Again you’re – again, the base of those – those ingredients is the Materia Medica and 200 years of clinical observations by doctors, so that’s the scientific base of those product – those ingredients.
Summation, for now
So, let’s sum up the evidence at this point:
    • Boiron has not come up with any reliable evidence that the basic principles upon which homeopathy depends are scientifically valid, and does not directly contradict plaintiffs’ experts’ statements that those principles are, in fact, scientifically invalid.
    • There are no studies, by Boiron or anyone else, demonstrating the effectiveness of Coldcalm or Children’s Coldcalm for the purposes stated on its own packaging, that is, the relief of cold symptoms.
    • Boiron’s only evidence that Coldcalm and Children’s Coldcalm are effective is anecdotal.
Does this mean that the plaintiff and the class of Coldcalm purchasers she represents will win their summary judgment motion? Not necessarily. Boiron has not filed its response to the plaintiff’s motion and may provide additional evidence when it does. Boiron could prevail on other factual issues, such as the plaintiff’s alleged lack of proof that she or her family members actually had colds when they took Coldcalm (as opposed to, for example, allergies). There are other legal issues to be decided, such as what burden of proof the plaintiff must carry to win her motion. To this point, Boiron argues that the plaintiff cannot rely solely on the implausibility and ineffectiveness of homeopathy generally, but must prove specifically that Coldcalm does not work and that Boiron knew or should have known this. It may also be that the court finds material questions of fact prevent a decision on the merits at this point.
But no matter what the ultimate outcome, this case highlights (as reported in the last post) the almost total lack of regulation of homeopathic products sold in the U.S. It also reveals that, given the need to come up with evidence sufficient to support its argument that the plaintiff cannot prove Coldcalm is ineffective or that Boiron knew that to be the case, Boiron utterly fails to overcome the overwhelming scientific evidence that homeopathy is nothing but pseudoscience.
The court has yet to rule on the parties’ cross-motions for summary judgment. I’ll keep you posted.

The CAM Docket: Boiron III, et al.
Despite denying wrongdoing, Boiron was still required to reimburse consumers for their products after losing a consumer fraud lawsuit.
Jann Bellamy on December 13, 2012
Link
Oh, the irony of it all! Quackery continues its increasingly successful assault on the citadel of medicine, viz: quackademic medicine, integrative medicine, credulous medical journal articles, shruggies, medical society support for CAM provider licensing. Will that nemesis of medical doctors, plaintiffs personal injury attorneys, turn out to be the last defenders of science in a world of health care fraught with so-called alternative medicine?
Maybe not. But the thought did occur to me while reading the Final Judgment and Order entered in Gallucci v. Boiron, the class action accusing the world’s largest manufacturer of homeopathic products of consumer fraud.
Update on Gallucci
As I reported in a previous post, the parties reached a settlement that covers:
    • everyone in the United States (save a few California purchasers party to another class action),
    • who purchased one of over 200 Boiron homeopathic products (basically, every homeopathic product Boiron sells in the U.S.),
    • over a period of about 12 years.
As is typical of settlement agreements, Boiron denies any wrongdoing. On October 31, the U.S. District Court for the Southern District of California entered a Final Judgment and Order approving the settlement. The case is closed and administration of the settlement terms has begun. Purchasers who file a valid claim will get between $10 and $100. The named plaintiffs will get a bonus of $1000 to $3500. All of this comes out of a $5,000,000 settlement fund, an amount which will be reduced after subtracting claims administration and other expenses and attorneys fees (which we’ll get to in a minute). Payments will be reduced pro rata if there is not enough to cover all claims. For reasons I explained in the earlier post, I consider this inadequate. Even more so now, when all of the deductions from the settlement fund are taken into account.
To address what the court described as “concerns that consumers may not be aware that homeopathic products have not been subject to the same FDA scrutiny as allopathic [sic] drugs,” Boiron will have to add the Quack Miranda Warning (homeopathy version) to packaging and some advertisements:
These ‘Uses’ have not been evaluated by the Food and Drug Administration.
Of course, saying that homeopathic products have not been subject to the same scrutiny as “allopathic” drugs is understating it a bit. Homeopathic products actually are subject to no scrutiny whatsoever by the FDA. As a matter of fact, the court in another case found that in practice homeopathic drugs weren’t being regulated by the FDA at all.
FDA regulation, or lack thereof, was not the only possibility for consumer confusion addressed by the settlement. In the court’s own words:
. . . to address Plaintiffs’ concern that homeopathic labels do not sufficiently explain the concept of a homeopathic dilution, Boiron has agreed to provide a Dilution Disclaimer in close proximity to the Drug Facts on each of its labels which shall state: ‘C, K, CK, and X are homeopathic dilutions: see [link created pursuant to para. 4.14 of the Settlement] for details.’ . . . The identified webpage shall provide consumers a more detailed explanation of the dilutions.
Boiron has two years to make the required changes to its packaging. While Boiron’s website currently does not refer to its information on dilutions as a “Dilution Disclaimer,” it does explain dilution and succussion, as well as “the law of similars,” in a series of short videos. Anyone who has no background in biology, physics, chemistry or medicine – in other words, most of the public – will probably find these convincing. (I also found this interesting tidbit under “Boiron In The News:” “Dr. Oz Show Features Self Massage with Arnica Gel to Keep Lymphatic System Healthy.” But I digress.)
Finally, the settlement awards the plaintiffs’ attorneys $1,250,000. Note that this is one of the amounts subtracted from the $5 million settlement fund, as explained above.
Interestingly, Gallucci managed to swallow up another class action, Fernandez v. Boiron, under circumstances the judge in Fernandez found disturbing. Fernandez, which was stayed pending court approval of the Gallucci settlement, will now likely be dismissed, as will Gonzales v. Boiron, another class action stayed pending settlement approval. Because of the breadth of the class and number of products eventually covered by the Gallucci settlement, class members and Boiron products in these other suits are encompassed by the settlement.
You too can be a plaintiff!
At least consumers are ahead of where they were before this litigation, although I imagine this new labeling information will do as much to discourage purchase of homeopathic remedies as the Quack Miranda Warning does to discourage buyers of dietary supplements. Which is to say, not at all. I was reading the order with some consternation, thinking Boiron got off light, when this thought popped into my head: “This is great!” Why? Because once the plaintiffs’ bar figures out they can make some real money suing homeopathic product manufacturers under state consumer protection laws, they will do just that. And they have.
At least two informational websites offer a free evaluation of whether a purchaser of a homeopathic product may have a cause of action against the manufacturer: LawyersandSettlements.com (for all homeopathic products) and Top Class Actions (some manufacturers excluded). The Senators (Ret.) Firm will do the same. And now that the word is out I’ll wager any plaintiffs’ attorney in the U.S. will either take one of these cases or find an attorney who will. Consumers, take note.
As might be expected, one of the law firms currently handling class actions against homeopathic products manufacturers is the Law Offices of Ronald A. Marron ALPC, the very firm representing the plaintiffs in Gallucci v. Boiron. That case did nothing to temper Mr. Marron’s low opinion of homeopathic products. Here’s what he says on the Top Class Actions website:
What is Homeopathy Fraud?
Homeopathy, or homeopathic medicine, is based on the idea that the body has the ability to heal itself, and therefore utilizes extremely low doses of medicine to increase its effectiveness. Many homeopathic remedies are so diluted that little to no molecules of the original substance remain; which some argue makes these medicines ineffective for their advertised use.
Consumers looking for natural remedies turn to homeopathic medicines based on advertisements that they’re ‘Clinically Proven’ to treat ailments, unaware that they’re throwing away millions of dollars each year on worthless placebos. Class action lawsuit attorneys have successfully argued that these companies are falsely advertising their homeopathic products can treat ailments, even though zero or just trace amounts of active ingredients are present.
It’s not just homeopathic medicine that’s falsely advertised, either. Natural and homeopathic diet supplements and beauty products can also scam consumers into believing they’re ‘Clinically Proven’ to work.
Well said! And yes, Mr. Marron, some do indeed argue that these medicines are ineffective for their advertised use, more specifically here, here, and here, among other places.
Here’s a list of some homeopathic products Mr. Marron and his firm have in their sights:
    • Nelsons Homeopathy (Rescue Remedy, Bach Original Flower Remedies, Pure & Clear, Arnileve, H+Care)
    • CVS Homeopathic Products (Flu Relief, Cold Relief, Cold Remedy, Ear Pain Relief)
    • Nature’s Innovation (Naturasil Skin Tags, Bed Bug Patrol, Naturasil Scabies)
    • Boericke & Tafel Cold/Flu
    • Homeolab USA (Kids Relief Cough & Cold)
I’m pleased to note the Marron firm is taking on dietary supplement companies too.
There are at least two class action lawsuits pending against homeopathic manufacturers Hyland’s and Standard Homeopathy. A suit in California involves seven Hyland’s products (Hyland’s Calm Forte, Teething Relief, Migraine Headache Relief, ClearAc, Poison Ivy/Oak Tablets, Colic Tablets and Leg Cramps with Quinine PM). Another lawsuit is pending in New Jersey. According to this April, 2012, news report, a $30 million dollar lawsuit was filed in Canada against Shoppers Drug Mart and Boiron alleging that they have, in their marketing of Oscillococcinum (made from the heart and liver of the Muscovy duck), committed at least 12 violations of consumer protection acts.
Delarosa v. Boiron, covered in two previous posts (here and here), remains pending in the U.S. District Court for the Central District of California. (The Gallucci settlement had to carve out the class represented in Delarosa, California consumers who purchased Boiron homeopathic cold-remedy products, because that class was certified before the one in Gallucci.) Summary judgment motions remain pending and trial is set for April of next year.
Conclusion
On the one hand, Boiron got off really cheap in the Gallucci class action, with a mere $5 million covering the vast majority of U.S. purchasers for 12 years, although that award is only part of the cost of the lawsuit to Boiron. The company will bear their own attorneys’ fees and costs as well as the estimated $7 million it will spend to change its packaging.
On the other hand, if the Delarosa case gets decided on summary judgment in the plaintiffs’ favor, with the judge making findings of fact that Boiron fraudulently sold Coldcalm in violation of the California consumer protection laws, it would be a major public relations debacle, any monetary award aside. Another big embarrassment would be a loss following a jury trial, which could result in a substantial monetary award. And even after a jury trial, only the judge has authority to order injunctive relief, which she could choose to support with written findings of fact underpinning her conclusion that Boiron violated state consumer protection laws. Many “ifs,” but we’ll see.
Even Gallucci won’t stop claims against Boiron over other products it may sell in the U.S. or outside of the 12 years covered by the settlement. Nor will it have any effect on action the FDA, Federal Trade Commission or individual state Attorneys General might take. And it won’t impact suits outside the U.S. or those against other homeopathic product manufacturers. I expect more of these will be filed due to media coverage and attorney advertising.
We haven’t even considered here the possibility of claims against health care practitioners who prescribe or sell homeopathic products. Sellers may be equally liable under consumer protection laws if they knew or should have known of homeopathy’s ineffectiveness. That would, of course, be easy enough to prove. And prescribers are vulnerable to malpractice claims.
Litigation is not the best way to solve problems that should be addressed by regulation. There is no reason the U.S. Congress could not ban the sale of homeopathic products altogether. It certainly could regulate them in a way that substantially affects the ability to market them. But, as in the case of tobacco products litigation, where the government fails in effectively regulating a product unsuitable for human consumption, sometimes litigation is the only avenue left for consumers.

Should the FDA crack down on homeopathic “remedies”?
Scott Gavura on March 26, 2015
Link

In the category of potentially dangerous complementary or alternative medicine, I can think of few products worse than ones claimed to relieve asthma, yet don’t actually contain any medicine. Yet these products exist and are widely sold. Just over a year ago I described what might be the most irresponsible homeopathic treatment ever: A homeopathic asthma spray. If there was ever a complementary or alternative product that could cause serious harm, this is it:

Among the different treatments and remedies that are considered “alternative” medicine, homeopathy is the most implausible of all. Homeopathy is an elaborate placebo system, where the “remedies” lack any actual medicine. Based on the idea that “like cures like” (which is sympathetic magic, not science), proponents of homeopathy believe that any substance can be an effective remedy if it’s diluted enough: cancer, boar testicles, crude oil, oxygen, and skim milk are all homeopathic “remedies”. (I think Berlin Wall may be my favorite, though vacuum cleaner dust is a runner-up). The dilution in the case of homeopathy is so significant that there’s mathematically no possibility of even a trace of the original ingredient in the typical remedy – they are chemically indistinguishable from a placebo. To homeopaths, this is a good thing, as dilution is claimed to make the medicine-free “remedy” more potent, not less. As would be expected with inert products, rigorous clinical trials confirm what basic science (and math) predicts: homeopathy’s effects are placebo effects. Recently Steven Novella blogged about the Australian Government’s National Health and Medical Research Council’s (NHMRC) comprehensive report on homeopathy which concluded the following:
    • Based on the assessment of the evidence of effectiveness of homeopathy, NHMRC concludes that there are no health conditions for which there is reliable evidence that homeopathy is effective.
    • Homeopathy should not be used to treat health conditions that are chronic, serious, or could become serious. People who choose homeopathy may put their health at risk if they reject or delay treatments for which there is good evidence for safety and effectiveness. People who are considering whether to use homeopathy should first get advice from a registered health practitioner. Those who use homeopathy should tell their health practitioner and should keep taking any prescribed treatments.
    • The National Health and Medical Research Council expects that the Australian public will be offered treatments and therapies based on the best available evidence.
Despite the implausibility of homeopathy and the lack of any convincing evidence it is effective, homeopathy continues to enjoy modest popularity as an “alternative” medicine system, and some national health care systems have even funded treatments. In the United States, the Food and Drug Administration is responsible for regulating homeopathy – and it does so, with a very loose hand. If you want to sell a homeopathic remedy in the United States, you are not required to show that your product actually works. Unlike prescription drugs, there are no requirements for clinical trials at all. Yet these products can be legally sold. Thanks to a former US Senator who was a homeopathy fan, any product listed in the US Homeopathic Pharmacopoeia (HPUS) is by definition a drug to the FDA, and therefore falls under its purview. Alec Gaffney, in a nice summary of the regulatory framework, notes that the FDA relies on a Compliance Policy Guide (CPG), Conditions Under Which Homeopathic Drugs May be Marketed, which defines labelling and manufacturing standards for homeopathic products. Those regulatory standards, are in a word, homeopathic themselves. The framework puts the FDA in a difficult situation, such as licensing these products as “drugs” while simultaneously acknowledging that there’s no evidence to show homeopathy works:
FDA is not aware of scientific evidence to support homeopathy as effective.
Do the current FDA standards provide adequate consumer protection, given the marketing of homeopathy for the treatment of very real conditions, like asthma? These products may be labelled “not a rescue inhaler”, but it’s fair to ask why they are sold at all, when they offer no plausible benefit. Last week the FDA issued a warning about homeopathic asthma inhalers:
The U.S. Food and Drug Administration is warning consumers not to rely on asthma products labeled as homeopathic that are sold over-the-counter (OTC). These products have not been evaluated by the FDA for safety and effectiveness.
and
OTC asthma products labeled as homeopathic are widely distributed through retail stores and via the internet. Many of these products are promoted as “natural,” “safe and effective,” and include indications that range from treatment for acute asthma symptoms, to temporary relief of minor asthma symptoms. In general, consumers can identify such products by looking for the word “HOMEOPATHIC” or “HOMŒOPATHIC” on a product’s label and looking for whether the product’s active ingredient(s) are listed in terms of dilution (e.g., “LM1” “6X” or “30C”).
Homeopathic asthma sprays are indeed widely sold, not just by Target, but by other pharmacies and online.
Now the FDA has announced plans to re-evaluate the homeopathy regulation framework, something I’m sure my American co-bloggers will applaud:
The Food and Drug Administration (FDA) is announcing a public hearing to obtain information and comments from stakeholders about the current use of human drug and biological products labeled as homeopathic, as well as the Agency’s regulatory framework for such products. These products include prescription drugs and biological products labeled as homeopathic and over-the-counter (OTC) drugs labeled as homeopathic. FDA is seeking participants for the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, and industry. FDA is seeking input on a number of specific questions, but is interested in any other pertinent information participants would like to share.
The event will be held April 20-21 in Silver Spring, Maryland. Registration is free (there will be a webcast) and you can even make an oral presentation. I strongly encourage anyone able to participate and give a science-based perspective to register and do so. It’s clear that the FDA recognizes that homeopathy is ineffective. So what does adequate and appropriate regulation, from an FDA perspective look like? Let’s hope it ensures that products like “homeopathic asthma sprays” will become a thing of the past.
More Reading
Homeopathic regulation diluted until no substance left
CAM and the Law Part 4: Regulation of Supplements and Homeopathic Remedies
An Alternative Perspective: Homeopathic Drugs, Royal Copeland, and Federal Drug Regulation

How should the FDA regulate homeopathic remedies?
Jann Bellamy on April 2, 2015
Link


The FDA announced recently that it is holding a public hearing on April 21 and 22,
to obtain information and comments from stakeholders about the current use of human drug and biological products labeled as homeopathic, as well as the Agency’s regulatory framework for such products. These products include prescription drugs and biological products labeled as homeopathic and over-the-counter (OTC) drugs labeled as homeopathic. FDA is seeking participants for the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, and industry.
It’s about time. We know that homeopathic remedies are not, and cannot be, effective. I will not plough that ground again here. Unfortunately, the FDA does not have any authority to bar these fraudulent products from sale altogether. Only Congress can do that.
In this post, I review the current regulatory framework for homeopathic products. I then explore the possibilities, given the opportunities for regulatory change presented by the FDA at this time. In doing so, I answer some of the questions posed by the FDA in its formal notice of the hearing, printed in the Federal Register.
I argue that the FDA has no statutory authority for the manner in which it currently regulates (or, actually, doesn’t regulate) homeopathic drugs. I further argue this system, largely controlled by the homeopathic industry, must be abandoned, and that there is no reason why homeopathic drugs should not be regulated just like any other OTC or prescription drug.
(Note to those wanting to submit written comments or attend the hearing: there are deadlines and other requirements for participation. You can read those in the Federal Register.)
History
The original Food, Drug and Cosmetics Act (FD&C Act), passed in 1938, authorized the FDA to demand evidence of safety for new drugs, issue standards for food, and conduct factory inspections. Significant to our purposes here, the Act was directed in part at quacks selling adulterated and misbranded remedies throughout the U.S., with little fear of reprisal.
The Kefauver-Harris Amendments of 1962 strengthened the rules for drug safety and, for the first time, required manufacturers to prove their drugs’ effectiveness. In 1992, the FD&C Act was amended again to require the drug industry to bear part of the considerable expense of the drug approval process.
Under the FD&C Act, the definition of “drug” includes:
     1.  Articles recognized in the official United States Pharmacopoeia (USP), official Homoeopathic Pharmacopoeia of the United States (HPUS);
     2.  articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and
     3.  articles (other than food) intended to affect the structure or any function of the body of man or other animals.
A homeopathic drug can fall within any of these categories. It can also fall within the definition of a “biologic” under a different federal statute making these products subject to FDA regulation. However, we’ll stick to drugs here.
In the FDA’s own estimation,
the FDA . . . ensures the safety and effectiveness of all drugs [and] biological products . . .
That statement is not entirely true. By its own admission, the FDA does not ensure the safety and effectiveness of homeopathic remedies.
Yet, the FDA’s position is now, and always has been, that nothing in the FD&C Act exempts homeopathic drugs from any approval, adulteration, and misbranding provisions (including labeling requirements) of federal law.
Why, then, does the FDA not require that homeopathic drugs be proven safe and effective prior to marketing? Why has the FDA, in the words of one federal district judge,
largely abdicated any role it might have had in creating standards for homeopathic OTC [over-the-counter] drugs, and has instead attempted to delegate this authority to the non-governmental organization that determines whether homeopathic substances should be included in the HPUS. In addition, the FDA explicitly states that it makes no guarantee about the safety or efficacy of homeopathic OTC drugs even if they meet the unknown standards for inclusion in the HPUS.
(Although the judge was talking about OTC homeopathic drugs, the same is true for the tiny percentage [about 5%] of homeopathic drugs that are prescription only.)
The FDA, like any federal agency, must act only within the authority granted it by Congress. The FDA does not cite any statutory authority for these decisions, and my research didn’t disclose any. It may well be that the FDA, in fact, has no legal authority for its neglect of homeopathic drug regulation.
There are apparently historical reasons for this neglect. For many years, most homeopathic products required a prescription and there were few homeopathic practitioners to write them. There were only a handful of established firms making homeopathic remedies. The FDA had limited resources and did not consider homeopathic products much of a safety risk. Yet, when it did finally act, what it created was, in the view of some, a recipe for a booming OTC homeopathic remedy market.
(For a more complete review of the history of homeopathic drug regulation, or the lack thereof, see Junod SJ. “An Alternative Perspective: Homeopathic Drugs, Royal Copeland, and Federal Drug Regulation,” 55 (1) Food Drug L.J. 161-83 (2000), PMID 12375600, from which I learned the historical reasons for the FDA’s forbearance.)
Since 1988, both prescription and OTC homeopathic drugs have been manufactured and sold without FDA approval under enforcement policies set out in the FDA’s Compliance Policy Guide (CPG) 400.400, “Conditions Under Which Homeopathic Drugs May be Marketed.” This 7-page document pales in comparison to the FDA pre- and post-market regulation of all other drugs and biologics. It basically covers only labeling.
CPGs are not are not regulations or laws and are not enforceable. They merely represent FDA thinking on a particular subject. Most importantly, they do not create or confer any rights for or on any person and do not bind the FDA or the public.
The FDA has now come to question whether this bare-bones guidance is sufficient. The agency cites several reasons for this.
    • The explosive growth in the OTC homeopathic remedy market. In 2007, Americans spent about $2.9 billion on the purchase of homeopathic medicine. They are being marketed as “natural, safe, and effective alternatives to other prescription and non-prescription products.”
    • Homeopathic drugs can contain a wide range of substances, including ingredients derived from plants, healthy or disease animals or human sources, minerals and chemicals. These can cause, and have caused, side effects. In 2012, there were over 10,000 reported “poison exposure cases” related to homeopathic agents, the vast majority of those attributed to children 5 and under, some of which required medical treatment.
Q & A
FDA has a list of questions in the Federal Register and encourages comments on these and other matters related to homeopathic remedies. We’ll address several of the questions here.
What are consumer and health care provider attitudes towards human drug and biological products labeled as homeopathic?
Consumers are obviously buying homeopathic remedies because they think they are safe and effective. Otherwise, why would they spend the money and ingest these substances or give them to their families? Yet, they have no reliable, objective information on which to make these decisions. (The internet is rife with unproven claims for homeopathic products.) The only source of label information is from those who are financially interested in the sale of homeopathic products.
Although I do not have statistics, naturopaths are likely the most common prescribers of homeopathic products. There are too few professional homeopaths in practice to account for much of the market and conventional medical providers widely disparage homeopathic remedies. Naturopaths, along with chiropractors and acupuncturists, regularly sell homeopathic products to their patients, giving them a financial interest that is in conflict with their ability to objectively evaluate these remedies.
The opinion of health care practitioners and scientists in general, other than the CAM practitioners just mentioned, is near-universally negative and long-standing. In fact, there are humorous videos widely available on the internet making fun of homeopathy. I will not attempt to catalog the massive amount of evidence that homeopathic remedies are no more effective than placebo, the most recent compilation of which can be found in the Australian National Health and Medical Research Council’s Statement and Advice on Homeopathy. No responsible scientist claims otherwise. The FDA is no doubt aware of the research. I do note, however, that the American Pharmacists Association is also calling for adequate regulation in their policy on homeopathy:
APhA supports the demonstration of safety and efficacy of homeopathic products from adequate, well-designed scientific studies before pharmacists advocate or sell homeopathic products. . .
APhA supports the modification of the Food, Drug and Cosmetic Act to require that homeopathic manufacturers provide evidence of efficacy and safety for all products, including products currently in the marketplace.
(Actually, no such modification is necessary as the authority is, and always has been, contained in the FD&C Act and amendments thereto.)
I expect many other voices to join the call for adequate regulation during this process.
Are the current enforcement policies under the CPG appropriate to protect and promote public health in light of the tremendous growth in the homeopathic drug market? Are there alternatives to the current enforcement policies?
No, the CPG is not appropriate. It is wholly inadequate. Yes, there are alternatives.
Actually, the answer to this question is fairly simple. There is no statutory authority in the FD&C or subsequent Acts to carve out an exception for homeopathic drugs, which is essentially what the FDA has done with CPG 400.400. The CPG basically addresses only labeling. It does not require demonstration of safety or efficacy, despite being clearly required by federal law.
In fact, the FDA has abdicated its authority to the Homeopathic Pharmacopoeia Convention of the United States, a private organization answerable to no one, to decide what homeopathic drugs are on the market. The HPCUS is rife with conflicts of interest. Decisions on the content of the HPUS are made by either practicing homeopaths, homeopathic pharmacists, or current or former officials or owners of homeopathic products manufacturing companies. It is totally controlled by industry insiders. One can only imagine the outcry if a similar organization of Big Pharma companies were calling the shots in deciding which drugs made it to market.
Apparently, the HPCUS believes it is a lawful substitute for the Agency in the drug approval process. An industry representative active in the HPCUS claims that:
Instead of the [FDA’s] new-drug-approval process [for all other drugs], premarket approval for homeopathic drugs is by way of monograph approval by HPCUS. While homeopathic drugs are subject to the FDA’s nonprescription drug review, FDA has not yet used this authority . . .
In fact, Congress has most certainly not given the HPCUS authority to grant pre-market approval. Nor is the FDA’s authority limited to “nonprescription drug review.”
The only solution is to employ the same regulatory scheme for homeopathic drugs as the FDA uses for other prescription and non-prescription drugs. Federal law requires no less.
A large majority of human drug products labeled as homeopathic are marketed as OTC drugs. These products are available for a wide variety of indications, and many of these indications have never been considered for OTC use under a formal regulatory process. What would be an appropriate regulatory process for evaluating such indications for OTC use?
There is no reason the FDA’s formal regulatory process applicable to other OTC drugs should not be employed for homeopathic drugs. Fortunately, there is precedent for a post-market review to bring homeopathic OTC drugs in line with federal law. In fact, this very process is outlined in the FDA’s announcement in the Federal Register.
In 1972, the FDA undertook a massive review of all OTC drugs (and an estimated 100,000 to 500,000 separate ingredients) to determine which could be classified as safe and effective and not misbranded. In accordance with amendments to the FD&C, the FDA was to determine which OTC drugs are generally recognized among qualified experts as safe and effective and not misbranded under prescribed, recommended, or suggested conditions.
However, at the request of homeopathic trade groups, homeopathic remedies were deferred from review. The FDA never returned to the task and OTC homeopathic drugs have never been reviewed by the FDA for safety and efficacy.
There is no reason the FDA should not take up where it left off. A caveat is in order here. While the FDA may feel obligated to include homeopathic proponents among the reviewers, the FDA should not let the proponents have the final say. Nothing in federal law suggests that Congress intended to incorporate the homeopathic industry’s pseudoscientific notions or its low quality studies into law. If the FDA feels otherwise – that it is somehow beholden to prescientific ideas and widely discredited treatments because of Congress’s reference to the HPUS – it can simply proceed under the authority granted it pursuant to the second and third definition of “drug” in the FD&C Act.
Do consumers and health care providers have adequate information to make informed decisions about drug products labeled as homeopathic? If not, what information, including, for example information in labeling, would allow consumers and health care providers to be better informed about products labeled as homeopathic?
No, they do not have adequate information. For one thing, unlike the vast amount of drug information available free to the public on the FDA’s website, there is no objective, substantive, publicly-available homeopathic drug information. The HPUS can be accessed only through an expensive paywall, the proceeds of which go to the HPCUS. Simply following the rules for other OTC drugs, including the transparency legally required in this process, would go a long way toward helping the consumer become better informed.
As a thought exercise, let’s examine the information available on the website of Hyland’s, a homeopathic remedy manufacturer, about one of its homeopathic remedies versus what an OTC label would require if it were not a homeopathic remedy. I am using the website information on the assumption that it is the same as that given on the label. (Actually, in using Latin terms, Hyland’s appears to be violating even the minimal requirements of CPG 400.400.)
According to Hyland’s, its “4 Kids Complete Allergy” is a “safe, effective formula for children 2-12 years old.” The only warning is that it should not be used to treat food allergies. The product, according to the website,
temporarily relieves the symptoms of hay fever, indoor and outdoor allergens including itchy nose and throat, itchy watery eyes, runny nose, sneezing and sinus pain.
There is no statement that these claims have not been evaluated by the FDA, which is not required for OTC drugs, because any other OTC product would, in fact, have been evaluated by the FDA.
Active ingredients, their homeopathic dilution and their purposes are listed as:
    • Acontium Napellus 6X HPUS: itchy throat, sneezing
    • Allium Cepa 6X HPUS: hay fever, runny nose, watery, itchy eyes
    • Euphrasia 6X HPUS: irritated eys, nasal discharge
    • Galphimia Glauca 12X HPUS: sneezing, runny nose
    • Histaminum Hydrochloricum 12X HPUS: ear and nose discomfort
    • Luffa Operculata 12X HPUS: sinus pain, headache
    • Natrum Muriaticum 6X HPUS: runny nose, itchy irritated eyes
    • Nux Vomica 6X HPUS: stuffy nose
    • Pulsatilla 6X HPUS: sinus pressure
    • Sabadilla 6X HPUS: hay fever, sneezing
I could not find information about what these substances are, or what 6X or 12X HPUS means, anywhere on the Hyland’s website. In fact, it took a good deal of searching to find this information on the internet. Anyone who did not have prior knowledge of homeopathic dilutions, like I do, would presumably encounter even more difficulty.
If this remedy were regulated like other OTC drugs, Hyland’s could never make the claim that its “4 Kids Complete Allergy Relief” is safe and effective without having gone through the FDA approval process. Nor could it make the “uses” claims. However, putting those substantial barriers to the sale of this product aside, what would an OTC label otherwise require if homeopathic products weren’t exempted by the FDA?
Here’s my interpretation of what the Active Ingredients list would look like, based on my internet search. Of course, the FDA requires standardized label information for all OTC products and the end result would likely be far more informative than my attempt at revision, but we’ll give it a go.
    • Aconite (a poisonous plant)
    • Onion
    • Eupharsia (a genus of about 450 species of herbaceous flowering plants in the family Orobanchaceae)
    • Galphimia glauca (a plant)
    • Histaminum Hydrochloricum (a chemical made from histamine dihydrochloride, trade name Ceplene, a salt of histamine which is used as a drug)
    • Luffa (a plant, most commonly used, in dried form, as a skin exfoliator)
    • Table salt (sodium chloride)
    • “Strychnine tree” (a major source of the highly poisonous, intensely bitter alkaloids strychnine and brucine)
    • Pulsatilla (a plant)
    • Sabadilla (Schoenocaulon officinale, a plant, parts of which are used as an insecticidal dust; toxic to honeybees.)
Homeopathic dilutions used in this product:
6X = one part of ingredient to 1,000,000 parts of water
12X= one part of ingredient to 1,000,000,000,000 parts water
I could not find any indication that many of these ingredients have been proven safe and effective for anything in any amount, and none at these dilutions. Some are downright dangerous.
It would be ludicrous to argue that a parent choosing an allergy symptom remedy for his child would not think this information is important. Yet such is the current regulatory framework for homeopathic remedies.
In sum, the FDA already has in place a well-established regulatory system for prescription and OTC drugs. There is no reason to exclude homeopathic drugs from this process any longer.

FDA and Homeopathy: Part Two.
Mark Crislip on April 3, 2015
Link

Friends, FDA, countrymen, lend me your ears;
I come to bury Homeopathy, not to praise it.
The evil that homeopaths do lives after them;
The good is oft interred with their bones;
So let it be with Homeopathy. The noble Ullman
Hath told you homeopathy was effective:
If it were so, it was a grievous fault,
And grievously hath Homeopathy answer’d it.
Here, under leave of Ullman and the rest–
For Ullman is an honourable man;
So are they all, all honourable men–
Come I to speak in Homeopathy’s funeral.
It was my nostrum, faithless and worthless to me:
But Ullman says it was effective;
And Ullman is an honourable man.
He hath brought many provings home to HPUS
Whose prescriptions did the general coffers fill:
Did this in Homeopathy seem effective?
When that the ill have died, Homeopathy hath wept:
Efficacy should be made of sterner stuff:
Yet Ullman says it was effective;
And Ullman is an honourable man.
You all did see that on the Cochrane
I thrice presented Homeopathy a meta-analysis,
Which he did thrice refuse: was this efficacy?
Yet Ullman says it was effective;
And, sure, he is an honourable man.
I speak not to disprove what Ullman spoke,
But here I am to speak what I do know.
Edward De Vere, 17th Earl of Oxford. Sort of.
We only have a vague idea as to what other bloggers are going to write about. Yesterday Jann wrote on the same topic (and Scott the week before), which I will read tomorrow after my post goes up. Why would I want my post to be informed by another’s well-reasoned and thoughtful essay? I have a reputation after all. So here is my response to the FDA.
I am writing in response to the request for recommendations concerning the regulation of homeopathic nostrums by the Food and Drug Administration (FDA).
I recognize that because of federal law the FDA has significant handicaps in the regulation of homeopathic nostrums since the Food, Drugs and Cosmetics Act of 1938 defines as a drug any product found in the US Homeopathic Pharmacopoeia (HPUS).
As a result of the Act, any nostrum in the HPUS is considered a legal medication in the US. The only premarketing evaluation required for a homeopathic nostrum is to find its way into the HPUS. Inclusion in the HPUS is usually by a homeopathic proving, a form of evaluation that does not prove either the safety or the efficacy of the nostrum.
So despite the fact that homeopathy is based on prescientific vitalism that is divorced from a modern scientific understanding of health and disease, homeopathy is protected from meeting the same standards of safety and efficacy that real medications must meet. I recognize that true, substantive regulation of homeopathy, requiring homeopathy to meet the same rigorous scientific medical standards as real pharmaceuticals, will require Congress to change the current laws governing the homeopathy.
Since homeopathic products contain no active product and have no effect on any disease or physiologic process, the need to remove a homeopathic product because of safety issues or serious side effects, such as happened with ephedra in 2004, is unlikely. Containing only water and/or sugar, homeopathic products are unlikely to suffer from issues of contamination and poor production quality that have been common with herbal and dietary supplements.
The major medical problems from homeopathy come from using the nostrums in lieu of effective medical therapies. Taking homeopathic nostrums for diseases such as asthma, meningitis, and malaria can have fatal consequences:
Moreover, some deaths were associated with “corticophobia,” with many patients preferring to use homeopathy or acupuncture.
One of many examples of relying on homeopathy resulting in death or serious illness. But it is a difficult scenario to regulate.
What then can and should be done to regulate homeopathy? Much of the use of homeopathy comes from a lack of transparency as to how homeopathic products are made and what they contain. To answer some of the questions asked by the FDA.
What are consumer and health care provider attitudes towards human drug and biological products labeled as homeopathic?
Many consumer think homeopathic products are the equivalent of herbal, vitamin, or other types of supplements. They are surprised and often express disbelief when the true nature homeopathic preparations and its dilutions are explained. Most people are unaware of what homeopathy is and homeopaths are not forthcoming with explanations.
What data sources can be identified or shared with FDA so that the Agency can better assess the risks and benefits of drug and biological products labeled as homeopathic?
The Science-Based Medicine blog (https://sciencebasedmedicine.org) has extensive reviews on homeopathy and the medical literature. Examples of the dire consequences of relying on homeopathy instead of science-based medicine can be found at the websites “What’s the Harm?” (http://whatstheharm.net/homeopathy.html) and “Discover Homeopathy” (http://discoverhomeopathy.co.uk/victims–2/).
Is there information regarding the regulation of homeopathic products in other countries that could inform FDA’s thinking in this area?
The best reviews on the complete lack of efficacy are the UK and Australian systematic reviews. They clearly demonstrate that there are no well-conducted clinical trials that demonstrates homeopathic nostrums have any effect on any disease. There is also the Swiss report on homeopathy. However, as noted by neurologist and Science-Based Medicine founder Steven Novella:
The Swiss report, which was favorable to homeopathy, was a reaction to a previous Swiss decision against homeopathy. The committee was packed with homeopaths, and not surprisingly they put a positive spin on the review.If you analyze the review you find that actually they came to the same conclusion about the data – that high quality studies show that homeopathy does not work. Then, however, they pulled a trick. As I previously reported:
The Swiss study looked at the same data, but apparently wanted to come to a favorable conclusion. So they argued for a change in the normal rules of evidence, a common strategy among CAM proponents. They decided to rely more on “real-world effectiveness,” which is just CAM newspeak for “poorly controlled studies.” In the real world we cannot control for variables and blind subjects – those are artificial conditions of rigorous trials.
The Swiss report was rigged and biased, and yet they still could not conclude that the data shows homeopathy works. They had to pull the “placebo medicine” gambit and claim that it sort of “works” even though there is no real effect from homeopathic products. Only homeopaths were apparently fooled by this ploy.
A large majority of human drug products labeled as homeopathic are marketed as OTC drugs. These products are available for a wide variety of indications, and many of these indications have never been considered for OTC use under a formal regulatory process. What would be an appropriate regulatory process for evaluating such indications for OTC use?
For OTC designation, at a minimum homeopathic should meet the same safety and efficacy as any other medications. Unlike most OTC medications, homeopathic nostrums are offered as treatments for potentially life-threatening diseases, from measles to whooping cough. Since homeopathic medications have no proven efficacy for any disease they should not be sold as OTC medications.
Allowing sugar and water to be sold as a treatment for serious illnesses and placing them next to medications with proven efficacy in drug stores gives the nostrums an undeserved credibility. Efficacy by association is not in the best interest of consumers.
Given the wide range of indications on drug products labeled as homeopathic and available OTC, what processes do companies currently use to evaluate whether such 8 products, including their indications for use, are appropriate for marketing as an OTC drug?
As an OTC product, homeopathic nostrums should meet the same standards of safety and efficacy as other medications. Patients will often turn to homeopathic products instead of seeing their doctor because see a physician costs both money and time and the homeopathic products are often less expensive. So if a patient is deciding to use a homeopathic product to treat their asthma or diabetes, it is imperative the product should have efficacy. Homeopathic nostrums never meet this criteria.
And although the FDA is not responsible for the ethics of homeopathic medications and prescribing, it is clear that selling a product that contains no active product and can have no efficacy is unethical. To quote retired physician and professor of Complementary Medicine at the University of Exeter, Edzard Ernst:
It should be axiomatic that ethics is indispensable to the practice of medicine, and is not something that can just be switched off at will. No branch of health care, including alternative medicine, can be considered exempt from it. But the subject of ethics is seldom even considered in alternative medicine; many alternative practitioners have never been taught medical ethics, and where training in this area does exist, it tends to be at best superficial…It is perhaps not surprising, therefore, that the principles of medical ethics are routinely ignored and frequently violated by promoters of alternative medicine…Medical ethics seem to me to be violated, for example: when homeopaths prescribe or recommend homeopathic vaccinations for which there is not a shred of evidence;
Selling homeopathic nostrums violates the first rule of medical ethics, that of beneficence. Physicians are expected not only to refrain from causing harm, but they also have an obligation to help their patients. Homeopathic nostrums accomplish neither.
Do consumers and health care providers have adequate information to make informed decisions about drug products labeled as homeopathic? If not, what information, including, for example, information in labeling, would allow consumers and health care providers to be better informed about products labeled as homeopathic?
The labels on homeopathic nostrums work to obscure the true nature of the product. As an example, the label of Oscillococcinum, a popular homeopathic preparation sold as a flu remedy, says it contains Anas Barbariae Hepatis et Cordis Extractum. Latin obscures the fact that the product contains Muscovy duck liver and heart, a product that has no efficacy, or reason for efficacy, against influenza. Although called an extract, letting a piece of duck liver and heart liquefy for 40 days and then diluting it in liter after liter of water (200 times) is not what most would consider an extract.
The ‘dose’ of the Oscillococcinum is 200CK which sounds strong, certainly stronger than the 10X, 30X, found in the King Bio Asthma homeopathic product, despite actually being diluted many thousand times more. If the serial dilutions of homeopathic nostrums were in plain English it would help consumers to be more aware of what they were purchasing.
It would be of benefit to the consumer to be informed that at the offered homeopathic dilution, the product should contain none of the original product.
The use of Latin and obscure dosing information runs counter to the current emphasis on health literacy: making all health care information understandable to all Americans, regardless of education. You should not have to know a dead language and college chemistry to understand your medication label.
It would also be of benefit to note on the label that no homeopathic product has ever been demonstrated to be effective for any medical condition.
For example:
Oscillococcinum: Duck heart and liver diluted to0.00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001%
This product as made should contain none of the original substance and no homeopathic product has ever been shown to treat any disease.
Given that there is no Physicians’ Desk Reference (PDR) and package insert equivalent for homeopathy, makes accurate and accessible labeling all the more important for consumers.
That the Homeopathic Pharmacopeia of the United States is behind a very expensive pay wall ($100 a day for a single user) represents an appalling barrier for consumers and health care professionals to understand homeopathic nostrums. It is in the public interest that this information be as freely available as the information in the PDR so that evaluations about the use of homeopathic nostrums can be made with all the available data. Can you imagine if the information in the PDR were equally unavailable? But big homeopathy has good reason to hide its data.
That would be transparent labeling, truth in advertising, and would protect the consumer by offering accurate and easily-understood information about the product. Cigarettes and alcohol have similar labels, clearly spelling out the contents and dangers in the product. Homeopathic nostrums and consumers deserve no less.
Accurate and easily understood labeling, free and easy access to the Homeopathic Pharmacopeia of the United States and the prohibition of OTC sales of homeopathic preparations, would all be important steps in consumer protection and the regulation of nostrums that, while legal in the US, are worthless and dangerous.
References
    • Edzard Ernst MD, PhD, FMedSci, FSB, FRCP, FRCPEd http://edzardernst.com/2015/03/wonderland–7-pseudoscience-is-a-deceit-perpetrated-on-the-weak-and-the-vulnerable/
    • Another Damning Homeopathy Report. https://sciencebasedmedicine.org/another-damning-homeopathy-report/
    • The Swiss Report on Homeopathy. https://sciencebasedmedicine.org/the-swiss-report-on-homeopathy/
    • J Travel Med. 1996 Mar 1;3(1):62. Homeopathic Resistant Malaria. http://www.ncbi.nlm.nih.gov/pubmed/9815426
    • J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):389–94. Asthma mortality in France. http://www.ncbi.nlm.nih.gov/pubmed/3624689
    • A Cautionary Tale: The Risks of Unproven Antimalarials. http://www.cdc.gov/malaria/stories/homeopathic_drugs.html
    • Death by homeopathy. http://discoverhomeopathy.co.uk/victims–2/

FDA Proposes Changes to Homeopathy Regulation
The FDA has proposed new guidelines for regulating homeopathy. They sound encouraging, and may signal a new era of actual regulation of the homeopathic industry.
Steven Novella on December 20, 2017
Link

It was almost three years ago, in April of 2015, that the Food and Drug Administration (FDA) announced it was reconsidering the way it regulates homeopathic products. We have been anxiously awaiting its decision, and finally they have published their proposed new guidelines. As with their previous proposals, there is a public comment period. Over this same time period the Federal Trade Commission (FTC) revised their own approach to homeopathy, and even gave a prod to the FDA to do the same.
So how are the new proposals? A move in the right direction, but they do not go nearly far enough. That was pretty much what we expected, and were hoping that it would be at least a significant move to actually regulate homeopathic products.
Some background
To understand the SBM position on homeopathy, you have to understand what homeopathy is. Here is a quick primer. Basically, homeopathy is a two-century-old pre-scientific medical system based on magical ideas. The first main pillar of homeopathy is that substances which cause symptoms in high doses will treat those same symptoms in extremely small doses. Often fanciful substances are used based upon silly criteria, such as if you cry when you hear piano music. The second pillar is that by diluting those same substances to an extreme degree, their “essence” is released in the final potion. Often the dilution is so great that essentially none of the original ingredient remains. I like to characterize this process as diluting fairy dust out of existence.
And yes – it is exactly that silly. Homeopathy is not the use of herbs or natural substances, as many in the public falsely believe.
Not surprisingly, when studied in proper double-blind clinical trials, homeopathy does not work. Multiple independent scientific reviews of all the published evidence have concluded that homeopathy does not work for any indication. So, how should such worthless magic potions be regulated by the FDA? Why is this even a question?
The story of the FDA and homeopathy goes back to the 1938 FDA Act. In the 1938 FDA Act, one Senator, Royal Copeland, who was a physician and homeopath, included in the bill that the provision that the Homeopathic Pharmacopeia of the United States (HPUS) would be included in the list of official drugs. The legacy of that one senator survives to today.
For much of the intervening time homeopathy was a small niche market, and the FDA determined that it was not worth its limited resources to actually regulate it. In their proposed changes, however, they acknowledge:
Until relatively recently, homeopathy was a small market for specialized products. Over the last decade, the homeopathic drug market has grown exponentially, resulting in a nearly $3 billion industry that exposes more patients to potential risks associated with the proliferation of unproven, untested products and unsubstantiated health claims.
Now that the market for homeopathic products has exploded – thanks in part to lax FDA oversight – the FDA realizes it has to do its job. They are motivated not just by the fact that homeopathic products are nonsense, but because lax regulations have led to abuse. Companies can label anything as homeopathic as an end-run around FDA oversight. They state:
During this time, the FDA has seen a corresponding increase in safety concerns, including serious adverse events, associated with drug products labeled as homeopathic. In addition, the agency has also found an increasing number of poorly manufactured products that contain potentially dangerous amounts of active ingredients that can create additional risks.
What is the FDA proposing?
The FDA is clearly trying to split the baby in their new proposed approach. By this I mean they want to protect the public from harmful health products, but at the same time respect consumer choice. I understand, politically, why they might feel they need to do that, even though I disagree. I don’t disagree with consumer choice – I disagree that that is the issue. If consumers are offered a completely fraudulent product with zero actual value, that is no choice. There has to be a line somewhere.
The FDA is proposing that they take a risk-based approach. This means they will target homeopathic products that they feel pose the greatest risk to the public. Here are their criteria:
    • products with reported safety concerns;
    • products that contain or claim to contain ingredients associated with potentially significant safety concerns;
    • products for routes of administration other than oral and topical;
    • products intended to be used for the prevention or treatment of serious and/or life-threatening diseases and conditions;
    • products for vulnerable populations; and
    • products that do not meet standards of quality, strength or purity as required under the law.
That is a reasonable list, and I agree that these criteria represent greater risk. It is also perfectly reasonable for an agency like the FDA to prioritize the higher risks first. They further state:
Given the concerns about the proliferation of potentially ineffective and harmful products labeled as homeopathic, the FDA will consider taking additional enforcement and/or regulatory actions, consistent with the current enforcement policies, which also align with the risk-based categories described in the draft guidance, in the interest of protecting the public.
Here is the proposed new guidelines document. It contains only a little more information than the press release. But here is the meat – it is a bit technical, but this is the essence of what they are proposing (in addition to the risk-based approach to priority):
The definition of “drug” in section 201(g)(1) of the FD&C Act (21 U.S.C. 321(g)) includes articles recognized in the HPUS or any of its supplements. As such, homeopathic drugs are subject to the same regulatory requirements as other drugs. Generally, a drug, including a homeopathic drug, is considered a “new drug” if it is not generally recognized as safe and effective (GRAS/E) by qualified experts for use under the conditions prescribed, recommended, or suggested in the labeling (section 201(p) of the FD&C Act) (21 U.S.C. 321(p)). FDA makes GRAS/E determinations for OTC drugs marketed under the OTC Drug Review.4 The FDA has not reviewed any drug products labeled as homeopathic under the OTC Drug Review, because the Agency categorized these products as a separate category and deferred consideration of them. (37 FR 9464, 9466 (May 11, 1972)). Under section 505(a) of the FD&C Act (21 U.S.C. 355(a)), before any “new drug” is marketed, it must be the subject of an approved application filed pursuant to section 505(b) or section 505(j) of the FD&C Act; however, a biological product with an approved license under section 351(a) of the Public Health Service Act (PHS Act) (4272 U.S.C. 262(a)) is not required to have an approved application under section 505 of the FD&C Act. Accordingly, absent a determination that a drug product labeled as homeopathic is not a “new drug” under section 201(p), all drug products labeled as homeopathic are subject to the premarket approval requirements in section 505 of the FD&C Act or section 351 of the PHS Act. There are no drug products labeled as homeopathic that are approved by FDA.
Let me break that down. They are affirming that according to FDA rules, homeopathic products are drugs. They can be regulated as drugs. Up until now the FDA has simply chosen not to actively regulate them, and deferred to the homeopathic industry. But they are putting the industry on notice that they will now actually regulate their products as drugs, based upon the risk-based priority.
They further clarify what it means to be regulated as a drug. There are two ways to get to market. The harder way is to be FDA approved as safe and effective for a specific disease indication. That is the path that requires tens or hundreds of millions of dollars and multiple studies for safety and efficacy. The second path is to be marketed as an over-the-counter drug, which requires being determined to be GRAS/E – generally recognized as safe and effective.
That paragraph further states that no homeopathic products are FDA approved or determined to be GRAS/E. They were simply given a pass up until now.
What all this seems to be saying is that the FDA is putting the industry on notice (if they adopt these proposed new guidelines) that, without specific warning, any drug product labeled as homeopathic can be regulated like any other drug. That means it can be pulled from the market because it is not FDA approved or determined to be GRAS/E. They are prioritizing high-risk products, but these guidelines apply to all drugs labeled homeopathic.
Of course, if they adopt these guidelines, the real test is how they will be enforced. The most optimistic interpretation of these proposed guidelines is that the FDA is preparing to start decimating the homeopathic product industry by systematically taking such products off the market. That would be completely appropriate, and in fact anything less is a dereliction of duty, in my opinion. They plan on starting with high-risk products, but are giving themselves permission, essentially, to work their way entirely through the industry.
The most pessimistic interpretation is that the FDA plans on sending strongly worded warning letters to producers of high-risk homeopathic products asking that they make changes to the product or its marketing so that they will no longer be considered high risk. The reality will likely be somewhere in between, and it remains to be seen where along the spectrum from heroic to pathetic they will fall.
The press release does contain some weasel phrases, such as:
We respect that some individuals want to use alternative treatments, but the FDA has a responsibility to protect the public from products that may not deliver any benefit and have the potential to cause harm.
Let’s hope that the FDA is setting the stage to correct this historic travesty. The FDA is charged, as they acknowledge, with protecting the public from harmful or worthless products. Homeopathic products are all 100% worthless – that is the clear and undeniable scientific consensus. They have the authority to regulated homeopathic products as drugs – all they need is the political will to do so. These are internal guidelines for themselves. There is no new legislation needed. All the FDA has to do is decide to do their job.
Take advantage of the public comment period (90 days from Dec 18th). Let the FDA know that the public they serve wants science-based regulations.

FDA strengthens homeopathic drug enforcement (but falls short of actually enforcing the law)
The FDA may strengthen homeopathic drug regulation with its “risk-based” enforcement policy, but this still leaves illegal homeopathic remedies on the market and falls far short of actually enforcing the law.
Jann Bellamy on November 7, 2019
Link

Two recent actions by the FDA pave the way for what is purportedly more stringent regulation of homeopathic remedies:
     1.  announcement of an interim, and a revised proposed permanent, “risk-based” enforcement policy; and,
     2.  withdrawal of Compliance Policy Guide Sec. 400.400 (“Conditions Under Which Homeopathic Drugs May be Marketed”)
Though an improvement over the FDA’s decades-long benign neglect of the burgeoning homeopathic drug industry, the FDA’s step-upped enforcement still falls far short of doing what Congress authorized the agency to do: Regulate homeopathic remedies just like any other prescription or over-the-counter (OTC) drug. Instead, the FDA will concentrate on homeopathic remedies posing significant safety and quality issues, ignoring their lack of effectiveness and the consequent bamboozlement of the public wrought by a multi-billion-dollar industry and its minions in the healthcare practitioner and retail pharmacy sectors of the snake-oil industrial complex.
(If you are unfamiliar with homeopathy and the pseudoscientific principles upon which it is based, you can find out more here.)
As the FDA itself admits, per the Federal Food, Drug and Cosmetics (FD&C) Act of 1938, the definition of “drug” includes any homeopathic remedy recognized in the Homeopathic Pharmacopeia of the United States (HPUS). Thus, according to the FDA,
homeopathic drugs are subject to the same regulatory requirements as other drugs: nothing in the FD&C Act exempts homeopathic drug products from any of the requirements related to approval, adulteration, or misbranding, including labeling requirements.
Yet, the agency also admits, the “FDA has not reviewed any homeopathic drug products under the OTC Drug Review” nor has it approved any prescription homeopathic drug, meaning “there are currently no homeopathic drug products that are approved by the FDA.” In other words, all OTC and prescription homeopathic remedies on the market today are illegal for lack of FDA approval.
With that in mind, let’s take a look the revised risk-based enforcement plan, including a brief review of the policy it replaces.
For 50 years, despite the passage of the FD&C Act in 1938, the FDA pretty much ignored homeopathic remedies. Thus, any homeopathic remedy recognized by the HPUS could be marketed, not only sans FDA approval, but basically without the FDA’s involvement at all, including post-market regulation. Recognition of a homeopathic remedy by the HPUS was, and still is, totally controlled by the homeopathic industry, in the form of the Homeopathic Pharmacopoeia Convention of the United States [HPCUS],
a private organization answerable to no one, [which] decide[s] what homeopathic drugs are on the market. The HPCUS is rife with conflicts of interest. Decisions on the content of the HPUS are made by either practicing homeopaths, homeopathic pharmacists, or current or former officials or owners of homeopathic products manufacturing companies. It is totally controlled by industry insiders. One can only imagine the outcry if a similar organization of Big Pharma companies were calling the shots in deciding which drugs made it to market.
In 1988, the FDA issued CPG Sec. 400.400, which described the “conditions under which homeopathic drug products may ordinarily be marketed”. The new policy basically continued the FDA’s benign neglect of the illegal homeopathic drug traffic, generally limiting the agency’s enforcement actions to inappropriately labeled products or those manufactured in violation of good manufacturing practice (GMP) regulations.
This left the homeopathic industry with little to fear from the FDA. Indeed, as one federal judge ruled, in 2011, in a case against homeopathic remedy manufacturer Boiron,
As evidenced by the FDA guidance documents . . . the Court concludes that the FDA has largely abdicated any role it might have had in creating standards for homeopathic OTC drugs, and has instead attempted to delegate this authority to the non-governmental organization [the HPCUS] that determines whether homeopathic substances should be included in the HPUS. In addition, the FDA explicitly states that it makes no guarantee about the safety or efficacy of homeopathic OTC drugs even if they meet the unknown standards for inclusion in the HPUS.
The court also remarked that it could find
no record of any [FDA] investigation of homeopathic remedies due to a reported lack of efficacy.
In 2015, the FDA suddenly woke up and realized that, while the agency was looking the other way, the homeopathic remedy market had grown tremendously. It therefore decided to hold a hearing “to obtain information and comments from stakeholders about the current use of human drug and biological products labeled as homeopathic, as well as the Agency’s regulatory framework for such products”. (You can read the comment filed by the Society for Science-Based Medicine here.)
Despite a lot of handwaving about hormesis, special pleading, and cherry-picked evidence presented at the hearing by the homeopathic industry and its acolytes (e.g., naturopaths and “integrative” physicians), the FDA finally decided that, while actual compliance with the FD&C Act was not yet warranted, it would propose a new risk-based enforcement policy and open it for public comment.
Published in 2017, almost three years after the hearing, the draft “Drug Products Labeled as Homeopathic: Guidance for FDA Staff and Industry” elicited thousands of comments, many deriding the FDA for its “lack of authority” to regulate homeopathic remedies, despite the FDA having carefully explained, right there in the proposed guidance, how it was pulling its punches even though it possessed the legal authority to pull the plug on the entire homeopathic industry for lack of compliance with federal law. Many others claimed that the FDA should not regulate homeopathic remedies at all, because “it worked for me,” in spite of the fact that the FDA didn’t even hint that it would heretofore require a demonstration of effectiveness for homeopathic remedies to remain on the market, despite (once again) the clear language of the FD&C Act.
While the proposed guidance marinated in this public outrage, the FDA decided that the industry-friendly CPG Sec. 400.400 would remain in place.
Then, last month, the FDA issued “Revision 1” to the 2017 draft guidance. The new draft guidance does not amend the substance of the old draft guidance. Instead, for some reason, the FDA decided it needed to beef up the rationale for its proposed risk-based approach. This means a new round of public comment has been opened, ending January 23, 2020, which will undoubtedly lead to further railing against the FDA and its “lack of authority” and so on.*
The 2019 version simply repeats the FDA’s intent to “prioritize enforcement and regulatory actions” for products falling within the following categories:
    • Products with reports of injury that, after evaluation, raise potential safety concerns (e.g., MedWatch reports).
    • Products that contain or purport to contain ingredients associated with potentially significant safety concerns, such as infectious agents (like rabid dog saliva), controlled substances, and ingredients that pose a risk of toxic effects, particularly when manufactured in low dilutions (e.g., 1X, 2X, or 1C).
    • Products for routes of administration other than oral and topical, like injectables and ophthalmic remedies (like eye drops).
    • Products intended to be used for the prevention of serious and/or life-threatening diseases or conditions, in part because they may cause users to delay or discontinue proven medical treatments. (There’s plenty to work with on this front: Homeopathic remedies for autism, the flu, adjunctive breast cancer therapy, and vaccine-preventable diseases, for starters.)
    • Products for vulnerable populations, like infants, children, pregnant women and the elderly.
    • Products with significant quality issues (e.g., contamination with bacteria) such as those made in facilities with significant deviations from current good manufacturing practices.
In addition to adding a definition of “homeopathic drug product” to the 2019 version of the draft guidance, the FDA further explained why it found this new approach to regulation necessary: Since it issued CPG Sec. 400.400, there have been multiple situations in which homeopathic drug products posed a significant risk to patients even though the product was in compliance with CPG Sec. 400.400. For example, the FDA identified 99 cases of adverse events “consistent with belladonna toxicity” and possibly related to homeopathic teething products, including infant deaths and seizures. Poisonous belladonna alkaloids in some products far exceeded the amounts stated on the label. The FDA also received more than 130 reports of loss of the sense of smell associated with the use of Zicam homeopathic remedies containing zinc. These are only two examples among many, according to the FDA. Others include “many serious violations of Current Good Manufacturing Practice requirements”.
As it did in the 2017 version, the FDA justifies its actions by saying that it employs this risk-based approach to regulation “in many instances”. Yet, as the FDA itself notes, in cases involving other types of unapproved new drugs, using this risk-based approach prioritizes actions based not only on potential safety risks, but also on lack of evidence of effectiveness and potential health fraud, circumstances certainly present with homeopathic remedies but curiously ignored by the agency in this instance. And, in those other cases of unapproved drugs, the FDA is not effectively exempting an entire category of drugs with perhaps thousands of products used by millions of Americans, a multi-billion dollar market, from the FD&C Act.
In a separate decision, also issued in October, the FDA announced the withdrawal of CPG Sec. 400.400, meaning it is no longer in effect. So, how will the FDA regulate homeopathic remedies in the interim between withdrawal of CPG Sec. 400.400 and the finalization of its 2019 draft guidance, an interim presumably of several years duration considering the glacial pace of agency action?
FDA intends to apply its general approach to prioritizing regulatory and enforcement action, which involves risk-based prioritization in light of all the facts of a given circumstance. Risk-based enforcement best reflects FDA’s public health priorities.
To me, this sounds like the agency will simply employ the risk-based approach announced in the draft guidance until the draft guidance becomes final.
Although the FDA maintains that “any homeopathic drug product that is being marketed illegally is subject to FDA enforcement action at any time,” it also says that “many homeopathic drug products will fall outside” its new risk-based enforcement policy, meaning that the majority of these admittedly illegal drugs will remain on the market with little fear that the FDA will enforce the law. In other words, as it ever was, the homeopathic industry will, for the most part, regulate itself.

*Per the Federal Register, the comments on Revision 1 to “Drug Products Labeled as Homeopathic: Draft Guidance for Food and Drug Administration Staff and Industry” (posted Oct. 25, 2019) are due on Jan. 23, 2020. But, for some reason, the FDA’s announcement of Revision 1 gives the comment due date as Dec. 24, 2019.

The Federal Trade Commission takes on homeopathy—maybe
David Gorski on September 14, 2015
Link


Well, I’m back.
OK, returning from London isn’t nearly as epic as Sam Gamgee’s final words in The Lord of the Rings returning to his wife and daughter after having accompanied Frodo, Gandalf, Bilbo, and key elves of Middle-Earth to the Grey Havens, there to say goodbye to them as they boarded a ship to the undying lands. I just love the quote. It says something to me returning home after a long journey, even if it was just a vacation to J.R.R. Tolkien’s native land. It also suggests a bit of the exhaustion after a long day of traveling, complete with a long-delayed flight, a late arrival, and a state of utter exhaustion that accompanied it, plus an unfortunate lower gastrointestinal issue.
All of this is a way of saying that this post might actually be relatively brief for a post by me…no epics this week. [Addendum: Nope. Even lower GI annoyances and exhaustion couldn’t keep me from going over 2,000 words. At least I didn’t hit 3,000.] In its nearly eight year history, I’ve never missed more than one week at SBM, and I don’t intend to start now. Specifically, with the FTC workshop on homeopathy rapidly approaching, one week from today, I couldn’t resist adding my 2 pence to the mix, now that the agenda and list of participants have been announced.
Homeopathy: The One Quackery To Rule Them All
A frequent topic on this blog is homeopathy, for reasons that regular readers no doubt understand all too well by now. Homeopathy is, as I like to call it, again borrowing from Tolkien, The One Quackery To Rule Them All. When it comes to quackery, few can even come close to homeopathy for the sheer ridiculousness of its precepts. Whether it is the Law of Similars, which claims that to cure a disease you need to use a substance that cause’s that diseases symptoms in healthy people, a “law” that has no basis in science, or the Law of Infinitesimals, which postulates that serially diluting a substance to nonexistence in the solution—with vigorous shaking (succussion) to “potentize” the mixture between each dilution step, of course—makes it stronger, few quackeries bring the pseudoscience to such a high level as homeopathy. Indeed, as I frequently like to say, for homeopathy to work, not only would much of what we know about physics and chemistry have to be wrong, but spectacularly wrong. Sure, reiki is nothing but faith healing that substitutes Eastern mystical beliefs for Christian beliefs in identifying the source of the “healing power” used, but that’s just pure magical thinking, little or no reference to science required. Few quacks can create a self-contained, self-sustaining world of pseudoscience the way homeopaths can.
Given just how utterly barmy (yes, London still lingers in my choice of language) homeopathy is, it is often puzzling to supporters of science-based medicine how it can be legal, not only in the UK, where the last time I visited England I made it a point to have my photo taken in front of the Royal London Homeopathic Hospital (which has “evolved” into the Royal London Hospital for Integrated Medicine) but right here in the US. As Jann Bellamy explained a few months ago, thanks to a quirk in the Food, Drug and Cosmetics Act (FD&C Act), passed in 1938 and history in which the FDA basically abdicated its responsibility to regulate homeopathic remedies as drugs, anything included within a publication known as the Homoeopathic Pharmacopoeia of the United States (HPUS) are, in practice, allowed to be sold. Jann makes a compelling case that, because under the FD&C Act of 1938, substances in the HPUS are defined as drugs, the FDA should have authority to regulate them as such, but, even in the wake of the Kefauver-Harris Amendments of 1962 that required manufacturers to prove safety and efficacy rather just safety before a drug could be approved, homeopathy remained largely unregulated. If it was in the HPUS, basically, it was okay.
FDA vs. FTC: A cage match made in Washington
Earlier this year, the FDA announced that it was considering modernizing how it regulates homeopathic remedies and held a hearing for public input. As was noted at the time, there were few skeptics and plenty of industry representatives and homeopaths who testified. Written comments were also solicited, and the Society for SBM submitted one, arguing that the FDA has, without legal authority, exempted homeopathic remedies from the safety and efficacy requirements applicable to other drugs under the Food, Drug and Cosmetic Act (FD&C Act). The SfSBM further argued that lax regulation of homeopathy has resulted in consumer confusion, and consumers do not understand how the FDA regulates (or, more accurately, does not regulate) homeopathic drugs and the lack of scientific evidence for homeopathy.
It turns out that the Federal Trade Commission (FTC), the federal agency responsible for preventing, identifying, and prosecuting fraudulent business practices, also submitted a comment to the FDA making the very same points, as Jann Bellamy pointed out earlier this month, referring to it as the “battle of the feds” and noting:
The FTC’s advertising substantiation policy requires that health-related efficacy claims be supported by competent and reliable scientific evidence. The FDA, despite federal law, does not require evidence of efficacy for homeopathic drugs prior to their being marketed. This creates a potential conflict between the two regulatory schemes, resulting in homeopathic over-the-counter (OTC) “drugs” on the market that both comply with FDA’s policy and violate FTC’s policy. This, says the FTC, can be harmful to consumers and create confusion for advertisers. The FTC “recommends that the FDA reconsider its regulatory framework for homeopathic medicines” and tells the FDA what it can do to remedy the situation.
Jann also noted:
I don’t know how often (if ever) one governmental agency recommends that another government agency “reconsider its regulatory framework” because its current policies cause consumer confusion, potential harm, and inhibit the former’s ability to do its job, which happens to be preventing that very same consumer confusion and harm.
Neither do I, but I do know that the FTC workshop is scheduled for next Monday and will be webcast. It is instructive to look at who has been asked to participate in the workshop. The workshop’s agenda is divided into three sessions:
    • Panel 1: Homeopathic Industry & Advertising
    • Panel 2: Scientific Support for Homepathic Advertising Claims
    • Panel 3: Legal/Regulatory Issues Presented by Homeopathic Advertising
Panel 1: The homeopathic Dream Team
Not surprisingly, the homeopathy industry mobilized to defend its ability to make huge profits selling water and sugar pills at massive markup, assembling a “homeopathic dream team” of “experts to represent our interests at the FTC event.”
For panel 1, the panelists include just some of those “dream team” members. Here is the panel:
    • John P. Borneman, Chairman and Chief Executive Officer, Standard Homeopathic Company and Hyland’s, Inc.
    • Candace Corlett, President, WSL Strategic Retail
    • Mark Land, Vice President, Operations & Regulatory Affairs, Boiron, Inc.
    • Yale Martin, Independent Retail Consultant
    • Duffy McKay, Senior Vice President, Scientific & Regulatory Affairs, Council for Responsible Nutrition
On the surface, it looks like it’s four to one, quack-apologists versus a science advocate (Duffy McKay). John Borneman and Mark Land represent manufacturers of homeopathic remedies and can predictably be expected to defend the current system, from which their companies have profited so magnificently selling quackery. Also on the surface, Yale Martin seemed like an interesting choice:
Yale Martin is an independent retail consultant residing in Bentonville, Arkansas. He retired in November 2014 from Walmart Stores, Inc. after 18 years in Walmart’s buying office. Mr. Martin spent much of his career as a buyer and for the last five years supervised Walmart’s over-the-counter (OTC) buying office, responsible for more than 4,000 OTC items retailed in Walmart’s 5,000 US stores. Previously, Mr. Martin held buying positions in Baby, Pet, Health and Beauty Aids/Cosmetics, and OTC. Mr. Martin holds a bachelor’s degree from the University of California and serves on the Board of Directors of Angie’s Artisan Treats, an organic snack food company owned by a private equity firm.
My guess is that Martin will also be on the side of the current system, given how profitable over-the-counter homeopathic remedies are, perhaps with mild tweaks. Maybe he’ll recommend some minor changes in labeling or something like that, but I highly doubt he’ll say anything substantive. Don’t believe me? Check out his testimony at the FDA hearing:
The homeopathic products sold in typical mass retailers are successfully used by tens of thousands of consumers each day. The free market system has a tendency to quickly eliminate items which do not meet consumer expectations since they are not repurchased. Items that fail to meet a retailer’s “minimum sales threshold” are quickly replaced by other items. Shelf space is the most valuable commodity a retailer has and items that disappoint consumers do not last long in any retailer.
Many, if not most, of the manufacturers of homeopathic products are conservative, long-established companies. Some of these companies are nearing 100 years old. These companies have a history of producing quality products that address health issues of importance to consumers. Any additional restrictive regulations of these homeopathic drug products would hinder the public’s access to these products and would significantly limit consumer choice.
Yes, he’ll argue that the free market will take care of all those pesky problems of determining efficacy of homeopathic products. If they don’t work, people won’t buy them! Never mind that the advertising goes out of its way to give the impression that they work. And we wouldn’t want to “limit consumer choice” by requiring that companies be able to back up their claims of efficacy and safety, now would we? Again, the free market will take care of all that, at least, if you believe Mr. Martin. Expect the same drivel at the FTC panel. Of course, he’s on the “dream team” too; so of course he’s going to defend the industry.
But what about Duffy McKay? When I read the list, I must admit that the Council for Responsible Nutrition sounded as though it might be science-based. However, I was quickly disabused of that notion when I read his bio, which reveals that he is a “licensed Naturopathic Doctor who still sees patients on a part-time basis in an integrative medical practice, and previously was co-owner and practitioner in a family-owned New Hampshire complementary and alternative medicine private practice.” Basically, the CRN is, according to its website, the “leading trade association representing dietary supplement and functional food manufacturers and ingredient suppliers,” and its member companies “manufacture popular national brands as well as the store brands marketed by major supermarkets, drug stores and discount chains.”
So, in the first panel, it’s four quacks and a marketing flack (Candace Corlett). This does not look promising at all.
Panel 2: Evidence for hope, or hope for evidence?
In panel 2, the participants include:
    • Adriene Fugh-Berman, Associate Professor, Department of Pharmacology and Physiology, Georgetown University Medical Center
    • Paul Herscu, Naturopathic Physician, Director, New England School of Homeopathy
    • Wayne B. Jonas, President & CEO, Samueli Institute
    • Richard (Rik) Lostritto, Division Director and Acting Associate Office Director for Science in the Office of Policy for Pharmaceutical Quality (OPPQ), Food and Drug Administration
    • David Riley, Academy of Integrative Health and Medicine, Integrative Medicine Institute
    • John Williamson, Branch Chief, Basic and Mechanistic Research in Complementary and Integrative Health, National Center for Integrative Health
This list is a little better. Yes, it’s stacked with advocates of “integrative medicine” (the Samueli Institute is one of the big players in this field and has been discussed here before on multiple occasions). On the other hand, Adrienne Fugh-Berman, even though she is an advocate of “complementary and alternative medicine” (CAM), is no friend of homeopathy. At the FDA hearing, she said that the evidence for homeopathy is “between scant and nil” and expressed concern about stocking homeopathic remedies right next to real medicine on pharmacy shelves because, in her view, most consumers and medical professionals have no idea what homeopathic remedies are (which is undoubtedly true), don’t know they aren’t reviewed for safety and efficacy (also undoubtedly true), and likely think they are dietary supplements or conventional OTC drugs Then, of course, it’ll be interesting to see Richard Lostritto try to defend the current FDA policy regarding homeopathy.
Finally, although it might seem unpromising that there is a Branch Chief from the NCCIH there, I do note that the NCCIH of late hasn’t exactly been that friendly to homeopathy. The last time I checked, there hasn’t been a grant from NCCIH to fund research into homeopathy since 2008. Indeed, in our discussion with Josephine Briggs in 2010, although she didn’t explicitly rule out ever funding a homeopathy grant again (probably because she couldn’t do that) she definitely seemed to agree that homeopathy was not particularly plausible and didn’t express much enthusiasm for it, given that she was likely at the time involved in developing the 2011-2015 strategic plan, that I like to refer to as “let’s do some real science for a change.”
Still, overall, the second panel is packed with homeopathy advocates.
Panel 3: Legal niceties
Finally, there is panel 3:
    • Kathleen Dunnigan, Senior Staff Attorney, National Advertising Division, Council of Better Business Bureaus
    • Elaine Lippmann, Regulatory Counsel, Food and Drug Administration
    • Al Lorman, Partner, Law Office of Alvin J. Lorman
    • Paul D. Rubin, Esq., Partner, Ropes & Gray, LLP
    • Michelle Rusk, Senior Staff Attorney, Division of Advertising Practices, Federal Trade Commission
    • Christina Guerola Sarchio, Partner, Orrick, Herrington & Sutcliffe, LLP
    • David C. Spangler, Senior Vice President, Policy, and General Counsel and Secretary, Consumer Healthcare Products Association
    • Anthony Vozzolo, Partner, Faruqi and Faruqi, LLP
Not surprisingly, given that this last panel is to discuss legal and regulatory issues, it composed of all lawyers. Unfortunately, most appear to be flacks for the homeopathy industry, with Sarchio and Rubin being arguably two of the heaviest hitting of the homeopathic flacks. They’re both part of the AHRP homeopathic dream team, and both represent Boiron, the French manufacturer responsible for the homeopathic flu remedy known as Oscillococcinum, which is a 200C dilution of Anas Barbariae Hepatis et Cordis Extractum (extract of Muscovy Duck liver and heart, respectively). I kid you not. Then there’s David Spangler, director of Consumer Healthcare Products Association’s (CHPA) legal affairs and international affairs. He is also on the AHRP’s homeopathic dream team. (The CHPA testified at the FDA hearing in April in favor of the current regulatory system.) Let’s just put it this way, the CHPA says homeopathic medicines work and refers people to the websites of manufacturers of homeopathic remedies like Boiron and Hylands for more information.
Still, all is not lost. Elaine Lippman acquitted herself well in the FDA hearing, asking hard questions of the advocates trotted out by the homeopathy industry, such as why they couldn’t do the same kinds of studies that drug companies had to do to provide evidence that their products are effective, e.g., RCTs. She even got one to admit there wasn’t any reason they couldn’t do this, and got the Consumer Healthcare Products Association (CHPA) representative to admit that they had no evidence that consumers understood the labels of homeopathic drugs. Next, Kathleen Dunnigan represents the National Advertising Division for the Council of Better Business Bureaus. She has a degree in engineering, so she might be expected to understand why homeopathy is so completely implausible from a scientific standpoint. If that is true, she could be a valuable member of the committee. In addition, Anthony Vozzolo has handled a class action suit against Hyland’s (Forcellati v. Hyland’s, Inc.), a major manufacturer of homeopathic remedies; so that’s promising.
Finally, Michelle Rusk could be very good indeed, if this presentation she gave on the FTC’s substantiation policy for dietary supplements is any indication. As Jann noted to me in an e-mail, if this policy were applied to homeopathic remedies, the industry would take a major hit.
Conclusion: Hopes and ropes
I realize that any regulatory agency considering major changes in how it regulates an industry needs to hear from advocates of that industry. That’s just politics and policy. However, it is still depressing how heavily stacked the first two panels are in favor of homeopathy and CAM advocates. The last panel is less blatantly stacked that way, but still leans towards the advocates. I happen to know, for instance, that the Center for Inquiry tried to get a representative at the workshop. As the final makeup of the workshop shows, it was unable to do so. (At least at the FDA hearing in April, Michael De Dora and other critics of homeopathy made statements.)
I realize that there is an argument to be made that the FTC has already decided that homeopathic products need to be treated, for purposes of advertising, like every other drug and are simply giving advocates every opportunity to make their case; i.e., that they are giving industry advocates enough rope to hang themselves, but even in that event one would expect that the workshop wouldn’t be quite so unbalanced in favor of homeopathy advocates.

Homeopathic industry and its acolytes make poor showing before FDA
Jann Bellamy on June 18, 2015
Link


On April 21 and 22, the FDA held a public hearing:
to obtain information and comments from stakeholders about the current use of human drug and biological products labeled as homeopathic, as well as the Agency’s regulatory framework for such products. . . . FDA is seeking participants for the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, and industry.
The FTC recently announced that it, too, is wading into the homeopathic waters. The FTC, which regulates advertising of homeopathic products, will hold a public workshop on September 21 in Washington, DC, “to examine advertising for over-the-counter (OTC) homeopathic products.” Like the FDA, it will also accept public comments online.
All of this regulatory buzz caused the FDA Law Blog to take notice. (The blog is hosted by a law firm specializing in food and drug regulation law.) A post titled “Will FTC Kill Homeopathic Products – or Will FDA?” gave this assessment:
Bottom line, if the FTC holds homeopathic products to the same scientific standards that are applied to claims for other OTC products like dietary supplements, as the FTC appears inclined to do . . . few if any homeopathic products will pass the test.
Actually, the FTC should hold homeopathic products to the same scientific standards as are applied to claims for OTC drugs, not dietary supplements, for that is how Congress classifies them. But we won’t be picky if the result is as FDA Law Blog suggests. Nor do we care who the killer is, as long as it gets done.
The homeopathic industry responded in spades to the FDA’s invitation (as I imagine it will to the FTC’s) trotting out not only its own representatives, but also sympathizers from the integrative and alternative medicine communities and consumers. These greatly outnumbered the voices of reason and science, but the industry and its acolytes were impressive in number only. The vast majority of the 7,000 online comments have also been pro-homeopathy, but that appears to have backfired, for reasons we’ll get to in a minute. (There’s still time to comment – the deadline was just extended until August 21.)
But before we get to the homeopathic dog-and-pony show, a brief background: Back in 1938, Congress passed the Food, Drug and Cosmetic Act, which required drug manufacturers to demonstrate safety before their products could be marketed. In 1962, the Act was amended to require a demonstration of efficacy as well. Although Congress specifically included homeopathic drugs, the FDA has never required the homeopathic industry to demonstrate safety or efficacy of it products prior to putting them on the market. The FDA does have homeopathic-friendly labeling requirements and the industry is required to employ good manufacturing practices. The FDA can go after a homeopathic product post-market if it presents a safety issue or is not properly labeled, but that’s it.
Interestingly, the very situation that prompted Congress to pass drug regulation laws at the beginning of the 20th century perfectly describes the homeopathic industry today. As FDA historian John Swann, PhD, recounts, back in the day:
Lee Barlett, a former shirt salesman from Pittsburgh, promoted a medicine called Banbar as being effective for diabetes. Banbar was an extract of horsetail weed.
How little things have changed. The homeopathic remedy equisetum is made from the horsetail plant, used to treat certain bladder conditions and “cure” bedwetting. If that wasn’t a big enough dose of nonsense for you, perhaps you’d be interested to know:
People who benefit most from using the homeopathic remedy equisetum are those who are bad-tempered as well as get exhausted quite easily.
Not even the shirt salesman went that far.
As Dr. Swann said of remedies like Banbar,
Products like these were, at minimum, useless remedies that picked the pocket of the user, but they could also be downright harmful.
Of course, he was describing products sold at the turn of the last century. Which, in a reasonable world, is exactly where we should have left homeopathy.
The FDA hearing
The two strongest witnesses at the hearing for reality-based medicine, as Mark Crislip would call it, were Michael DeDora of the Center for Inquiry, and Adriane Fugh-Berman, Associate Professor in the Department of Pharmacology and Physiology and the Department of Family Medicine at Georgetown University Medical Center.
Fugh-Berman is concerned about stocking homeopathic products on the shelves right next to other OTC drugs because, in her view, most consumers and medical professionals have no idea what homeopathic remedies are, don’t know they aren’t reviewed for safety and efficacy, and likely think they are dietary supplements or conventional OTC drugs. Nor does their dilution necessarily make them harmless, a point that was confirmed by Edward Krenzelok of the Rocky Mountain Poison and Drug Center in his remarks. For example, according to Fugh-Berman, Cold-EEZE contains 13.3 milligrams of zinc per lozenge. At recommended six lozenges a day, that’s about 80 milligrams of zinc a day, or ten times the RDA for adult females, eight times the RDA for males. As well, she said, products can contain snake venom, heavy metals, controlled substances, glandular extracts and other potentially dangerous ingredients.
Fugh-Bergman, who pointed out that the evidence for homeopathy is “between scant and nil,” wants to see the labels accurately describe the ingredients and their amounts in the same language used for other drugs and dietary supplements rather than the obscure vocabulary of homeopathy. She noted that, at some level of dilution, this would require expression of amounts in terms like “less than .01 nanograms.”
DeDora also spoke to the lack of evidence for homeopathy as well as its conflict with basic scientific principles, of which he said the FDA was “well aware.” He said, and I agree, that homeopathic drugs should have to meet the same standards as other drugs. That is what the law says, and that is what the FDA should do.
Both DeDora and Fugh-Berman suggested that, short of this, manufacturers put the equivalent of the Quack Miranda Warning on homeopathic drugs, a position with which I disagree for legal and other reasons. It doesn’t seem to dissuade people from taking dangerous supplements and I don’t find it consistent with Congress’s mandate that the FDA oversee the process by which manufacturers show safety and efficacy. Blowing off your duty to regulate simply by telling people you haven’t done your job seems less than satisfactory.
So much for the scientific point of view.
Appearing for the defense, if you will, was none other than Wayne Jonas, MD, of the Samueli Institute. He says we need more studies of homeopathy. Actually, we don’t, but I would have said the same thing if my salary was paid by a group that specializes in attracting government funds to study “alternative medicine.”
Amy Rothenberg, ND, whom you’ve met before here on SBM, spoke on behalf of the American Association of Naturopathic Physicians. The AANP believes the “FDA’s current regulatory approach to homeopathic products is working well.” I’ll bet they do. (Rothenberg is also trained in classical homeopathy.)
Like other naturopaths who spoke at the hearing, Rothenberg began her comments with an infomercial for naturopaths, pointing out their “extensive” classroom and clinical training, post-grad exams, and such. She talked about her use of homeopathy in her practice, including treating an autistic child. I find this interesting, because neither homeopaths or naturopaths are licensed in Massachusetts, where she practices, which means she is skating very close to, and perhaps over the line into, the practice of medicine.
Rothenberg was the only speaker who attempted to explain homeopathy’s purported mechanism of action which is, according to her, hormesis, that homeopathic canard David Gorski has already deconstructed.
The luminaries of the homeopathic industry were all there: representatives from the Homeopathic Pharmacopoeia Convention of the U.S., American Institute of Homeopathy, Homeopathic Academy of Naturopathic Physicians, Arizona Homeopathic and Integrative Medicine Association, National Center for Homeopathy, American Association of Homeopathic Pharmacists, Consumer Healthcare Products Association (a trade group), the Integrative Health Policy Association, North American Society of Homeopaths, and the Center for Education and Development of Clinical Homeopathy. The Kool-Aid flowed freely.
I can summarize all of their testimony fairly quickly:
1. Cherry-picked evidence 
This included the famous Swiss Government Report, mentioned by Wayne Jonas, among others. Needless to say, other reports, such as the recent Australian National Health and Medical Research Council: Statement on Homeopathy or Evidence Check 2: Homeopathy from the UK were absent from pro-homeopathy discussion, save Jonas’s criticism of the former, which was, according to him, “very poorly done.”
2. Special pleading 
An example from the comments of Tanya Kell, President of the North American Society of Homeopaths: Kell testified that:
there is a long, established record of both safety and efficacy in homeopathy. Homeopathic practice is based on hundreds of years of clinical experience by both physicians in this country and around the world.
Panelist and FDA regulatory attorney Elaine Lippman asked Kell what her data sources were “for that long established record particularly with respect to efficacy.”
Kell’s answer:
This is more a compilation of anecdotal evidence, so when I studies [sic] social work that was an accepted form of evidence, is just compiling anecdotal stories. [Actually, it’s not.]
Homeopathy has hundreds of millions of those, and you know, as our reputation grows, so does those anecdotal stories, and we feel that they are a legitimate source of data.
Translation: RCTs don’t apply to us.
And, from Bernardo Merizalde, MD, of the American Institute of Homeopathy:
We believe the true scientist does not discard available data because the theory doesn’t correspond to their prevailing world view.
Translation: The sciences of physics and chemistry are simply “world views” that can be ignored.
3. A whole lot of declarations that homeopathy is “safe” and “effective” and “it works” 
Which just goes to show you: these people damn well know how to form a declarative sentence. They have it down. Totally. Good for their grammar teachers!
4. Explanations of the intricate process by which the HPCUS decides which homeopathic remedies are included in the HPUS 
To which I say: GIGO.
Yet, Elaine Lippman was able to extract this confession from none other than Todd Hoover of the Homeopathic Pharmacopoeia Convention of the United States, the industry-controlled group that decides what homeopathic remedies are included in the Pharmacopoeia. She asked:
What is it about the FDA’s process of establishing efficacy through the gold standard, placebo-controlled, randomized clinical trials, what about that is inconsistent with homeopathic remedies?
To which Hoover replied:
There’s nothing inconsistent. Impractical might be a better word.
He later admitted that it is “certainly possible.” But then there was a big, fat qualifier to his admission. Why it is impractical?
The selection process and inclusion criteria that would be required might require a large population selection in order to find people who fit that particular remedy perfectly in order to demonstrate effectiveness for a given claim.
In other words, to do an RCT the homeopathic way, you would have to buy into the ridiculous nonsense of choosing remedies based on the patient’s quirky characteristics. Sound like more special pleading. In any event, this is not the way most people use homeopathy. About 95% of homeopathic products are OTC, so the user is selecting the remedy, not a homeopath.
Several other MDs testified in favor of homeopathy as well. Robert Dumont, MD, a pediatrician, said that homeopathic products were “exceptionally versatile and efficacious for many medical problems,” that he has “prescribed homeopathic medicines in the hospital for premature infants,” and used it for “nausea, vomiting and losing weight” in a patient undergoing chemotherapy. Another MD and classically trained homeopath, Karl Robinson, uses homeopathy for patients with hepatitis A. Younger Chug, MD, a pulmonologist, said he uses homeopathic products for asthma, chronic cough, croup and in situations where there is no effective drug, such as dyspnea due to vocal cord dysfunction. Another said homeopathy was “especially beneficial in our sickest patients.”
These physicians might just want to take a look at the Royal Australian College of General Practitioners recent “Position statement: homeopathy,” which includes this:
Medical practitioners should not practice homeopathy, refer patients to homeopathic practitioners, or recommend homeopathic products to their patients.
If this is the best evidence homeopathy has to offer, and the FDA decides to regulate homeopathic drugs in the same manner as all other OTC and prescription drugs (assuming it doesn’t allow homeopathic pseudoscience any place in the process), then homeopathy is indeed dead in the water, as FDA Law Blog suggests. The homeopathic industry is surely busy supplementing its poor showing before the FDA with written submissions. Speaking of which, we’ll now turn to the public comments.
Public comments
There are, as I mentioned, over 7,000 comments online. I have no idea how many more have been submitted in writing via snail mail. As I also mentioned, the FDA extended the deadline for comments until August 21, for reasons I cannot imagine. What’s more to be said?
I read through about 325 comments of the 7,000 plus (you’re welcome). They can be divided into three categories:
     1.  A tiny percentage in favor of the FDA fulfilling its duty to regulate homeopathic drugs just like it regulates other drugs, some citing research in support of their position.
     2.  Something along the lines of “you can have my homeopathic remedy when you peel it from my cold, dead fingers,” usually served up with a big dose of conspiracy theory, Big Pharma and government bashing, and Health Freedom, or HEALTH FREEDOM!!!
     3.  Anecdotes demonstrating in the writer’s mind, with absolute certainty, that homeopathy “works.”
Boiron, the homeopathic remedy manufacturer, has been chumming up consumers to post their wonderful results online. What they’ve produced instead is a treasure trove of evidence that the public is being duped by the homeopathic industry. Based on my review, here is a list of diseases and conditions for which consumers are using homeopathy:
These consumers apparently have no understanding that the perceived “effectiveness” of homeopathic products could well be due to the natural course of disease, motivated reasoning, placebo responses, regression to the mean, confirmation bias, conditioning, the post hoc ergo propter hoc fallacy, or the effects of other treatments. In fact, from a scientific standpoint, these are the only plausible explanations for the putative effectiveness of homeopathic products.
These are exactly the sort of confounding factors that the premarket approval process is designed to weed out. By putting the onus on prescription and OTC drug manufacturers to demonstrate efficacy, this process ensures that consumers will not be purchasing remedies that actually do them no good and allows calculation of the true benefit of the product itself so that a proper risk-benefit analysis can be performed. As it now stands, the homeopathic industry is allowed to exploit other, plausible explanations for the perceived effectiveness of their products in order to sell an unnecessary product for its own financial gain.
One issue raised at the hearing was consumer confusion when homeopathic drugs are sold side-by-side with other OTC drugs. Homeopathy supporters pointed to the fact that these products are labeled “homeopathic,” but this begs the question. That means nothing if the consumer doesn’t understand what “homeopathic” means. Of course, to the homeopathic industry, it means that “like cures like” and that dilution combined with vigorous shaking makes the product more, rather than less, effective.
Consumers testifying at the hearing and commenting online parroted this explanation, ironically demonstrating they have no idea what “homeopathic” really means: that the product has been produced by a method that guarantees it will not work as advertised. One consumer repeated a version of the homeopathic industry’s attempts at reconciling their scientifically untenable “theory” with basic chemistry and physics: “we now know that water holds energetic information and the energy of each substance is stored within the homeopathic remedy.” Another said they are “effective through their energetic frequency and the effect they have on the cellular electrical energies.” Not only have consumers bought into the false claim that homeopathy “works,” they’ve swallowed the pseudoscience that “explains” its putative effectiveness.
What will the FDA do? I don’t know. If it wants to do the right thing, the FDA could impose the same requirements on homeopathic drugs as other drugs, which it has the authority to do. (And, if it had done this in the past, we wouldn’t find ourselves in the current situation.) But that carries some risk: homeopathic proponents might go running to their representatives in Congress to pass a law exempting homeopathic remedies from FDA oversight altogether. Or moving them to dietary supplement classification by redefining that term.
The most politically expedient thing to do may be requiring the homeopathic industry to label its OTC products like other OTC drugs, which would include a prohibition against making disease claims that are not supported by adequate evidence and stating ingredients in terms the average consumer has some chance of understanding. This would stop short of regulating them like other OTC drugs, but may take care of the problem without having to go there.
Blog archive: The FDA and homeopathic drug regulation (or lack thereof)
Science-Based Medicine
Homeopathic regulation diluted until no substance left
Should the FDA crack down on homeopathic “remedies”
How should the FDA regulate homeopathic remedies?
FDA and Homeopathy: Part Two
Respectful Insolence
Regulating the magic that is homeopathy: The sabotage of poor reporting and false balance

Society for Science-Based Medicine: Comment to FDA on homeopathic drug regulation
The Society for Science-Based Medicine has commented on the FDA’s reconsideration of how to regulate homeopathic products.
Jann Bellamy on August 6, 2015
Link

Author’s note: The FDA has asked for public comments on the regulation of homeopathic products. The Society for Science-Based Medicine’s Comment follows, modified for this format. The Comment is based in part on two previous posts, “How should the FDA regulate homeopathic remedies?” and “Homeopathic industry and its acolytes make poor showing before the FDA.” The comment period closes August 21, 2015.
Society for Science-Based Medicine
Comment: Homeopathic Product Regulation: Evaluating the Food and Drug Administration’s Regulatory Framework After a Quarter-Century
All homeopathic products on the U.S. market today, whether over-the-counter (OTC) or prescription, fall within the definition of “drug” in the Food, Drug & Cosmetic Act of 1938. The overwhelming scientific consensus is that homeopathy is highly implausible, unsupported by scientific evidence, ineffective in treating illness and, when relied upon instead of actual medicine, dangerous and even deadly. Yet the FDA has, without statutory authority, exempted homeopathic drugs from the regulatory scheme mandated by federal law. In accordance with its consumer protection mandate, the FDA should take immediate action to remedy this by requiring that all homeopathic drugs comply with the same statutes and regulations as all other OTC and prescription drugs.
Introduction
The Society for Science-Based Medicine welcomes the FDA’s examination of homeopathic prescription and OTC drug regulation. In many respects, the current regulation of homeopathic drugs resembles that of all drugs prior to the passage of the Food, Drug & Cosmetic Act in 1938 (FD&C Act). At that time, there was no premarket regulation. The FDA was limited to post-market enforcement actions against adulterated or misbranded drugs. Drug manufacturers controlled the premarket process, much as the homeopathic industry controls the premarket process today. This includes the determination of which homeopathic ingredients are included in the Homeopathic Pharmacopœia of the United States (HPUS) by a private, non-governmental organization, the Homeopathic Pharmacopœia Convention of the United States (HPCUS), as well as homeopathic manufacturer determination of indications for product use. Then, as now, the FDA promulgated labeling requirements, but there was no FDA process ensuring that the products were safe and effective for their intended use prior to their being marketed.
According to the FDA, Americans now spend about $3 billion a year on homeopathic drugs, which contain ingredients derived from plants, healthy or diseased animals or humans, minerals and various chemicals. These drugs can cause, and have caused, side effects, some of them serious. Yet, there is no reliable scientific evidence that these drugs are efficacious for any use. As FDA historian John Swann, Ph.D., noted, prior to Congress giving the FDA authority to regulate drugs, products on the market “were, at a minimum, useless remedies that picked the pocket of the user, but they could also be downright harmful,” an observation that describes perfectly homeopathic products today.
Obviously, a system widely recognized as insufficient over 75 years ago cannot be tolerated in 2015. It was this very insufficiency that prompted Congress to pass the FD&C Act and subsequent amendments further strengthening the FDA’s hand, laws from which the homeopathic industry has been largely, and curiously, exempt. Indeed, it is entirely unclear on what statutory authority the FDA bases its exclusion of homeopathic drugs from the pre-market regulatory process applicable to all drugs under federal law. There is certainly no such exclusion in the statutes themselves.
The FDA asked for public input on specific issues regarding regulation of homeopathic drugs. The Society’s comments follow.
     1.  What are consumer and health care provider attitudes towards human drug and biological products labeled as homeopathic?
The public has spoken with its pocketbook. Consumers are unlikely to purchase a remedy for themselves and their families unless they think the product is safe and effective. These consumers are apparently unaware of several facts:
    • There has been no objective, third-party confirmation of safety and effectiveness by the FDA or otherwise.
    • Claims of efficacy are in direct contradiction to basic principles of physics and chemistry and no reputable scientific authority supports the fantastical postulates upon which homeopathic remedies are reputed to “work.”
    • Clinical trials confirm the obvious: homeopathic drugs do not work as claimed.
There could be no more compelling evidence that the current system is inadequate than the public comments posted online at regulations.gov. As of this writing, there are almost 8,000 comments, the majority of them consisting of positive anecdotes about homeopathic drug use. Considering the fact that there is no evidence of efficacy, it is clear the homeopathic industry has the public fooled.
We see, over and over, comments that homeopathic remedies are “safe and effective” or “proven safe and effective” when the consensus of the scientific community is that they are not and, in fact, cannot be effective, and we know that safety remains largely unproven. One physician testified at the FDA’s hearing that “the majority of patients . . . that I encounter have no real understanding of what homeopathy is and often confuse it with herbal medicines.”
Many commenters claim that homeopathic remedies are effective for a wide range of illnesses and conditions, not all of them self-limiting and some quite serious. Some use the word “cure;” one claimed homeopathic drugs “cured people of serious diseases.” Another claimed that a homeopathic drug brought a seven-year-old out of a coma. Yet another said homeopathy was effective for a “vast range of ailments and conditions.” A random selection of about 350 of these comments included claims that homeopathic remedies are effective for:
These consumers apparently have no understanding that the perceived “effectiveness” of homeopathic products could well be due to such things as the natural course of disease, motivated reasoning, placebo responses, regression to the mean, confirmation bias, conditioning, the post hoc ergo propter hoc fallacy, or the effect of other treatments. In fact, from a scientific standpoint, these are the only plausible explanations for the putative effectiveness of homeopathic products.
Misattributions of efficacy are exactly the sort of confounding factors that the premarket approval process is designed to weed out. By putting the onus on prescription and OTC drug manufacturers to show safety and efficacy, this process ensures that consumers will not be purchasing remedies that actually do them no good and allows calculation of the true benefit of the product itself so that a proper risk-benefit analysis can be performed. As it now stands, the homeopathic industry is allowed to exploit these other, plausible explanations for the perceived effectiveness of their products in order to sell unnecessary and ineffective remedies for their own financial gain.
If the FDA ever believed that use of homeopathic drugs by health care providers offered some measure of protection for the public, those beliefs were certainly belied by the comments of providers who employ homeopathic remedies in their practices. In fact, while the industry’s self-interest and the public’s lack of accurate information can explain the average consumer’s being misinformed, it is much harder to reconcile the use of unproven drugs rejected by the vast majority of medical practitioners, and for good reason, by those presumably educated in the scientific method.
Robert Dumont, MD, a pediatrician, testified that homeopathic products were “exceptionally versatile and efficacious for many medical problems,” that he has “prescribed homeopathic medicines in the hospital for premature infants,” and used it for “nausea, vomiting and losing weight” in a patient undergoing chemotherapy. Another MD, Karl Robinson, testified he used homeopathy for Hepatitis A. Younger Chug, MD, a pulmonologist, said he uses homeopathic products for asthma, chronic cough, croup and in situations where there is no effective drug, such as dyspnea due to vocal cord dysfunction. Another said homeopathy was “especially beneficial in our sickest patients.”
Amy Rothenberg, ND, testified she prescribed homeopathy for an autistic child. Another naturopath said that “time and again [homeopathy has been] very, very safe and effective as adjuvant therapy in restoring people’s health and vitality.” She said it had been “life changing, a child born, depression lifted, digestion improved.”
As the FDA is well aware, none of these uses are supported by adequate evidence of safety and efficacy.
     1.  What data sources can be identified or shared with FDA so that the Agency can better assess the risks and benefits of drug and biological products labeled as homeopathic?
Before this question can be addressed, the FDA will have to determine what process it will use to evaluate these data sources, whatever they might be. As the FDA itself said in its notice of the public hearing, nothing in the FD&C Act exempts drugs labeled as homeopathic from the premarket approval process or the same safety and efficacy standards as all new drugs. There is no doubt that all homeopathic drugs meet the definition of “new drug,” because they are “not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs” for uses “prescribed, recommended, or suggested” by the label. Thus, homeopathic drugs must meet the same criteria as that applied to other new drugs, whether they are prescription or OTC.
As to the data sources themselves, the FDA is fortunate that the Australian National Health and Medical Research Council (NHMRC) recently completed a comprehensive evaluation of the evidence. The resulting analysis, “Effectiveness of Homeopathy for Clinical Conditions: Evaluation of the Evidence” (2015), concluded:
There is a paucity of good-quality studies of sufficient size that examine the effectiveness of homeopathy as a treatment for any clinical condition in humans. The available evidence is not compelling and fails to demonstrate that homeopathy is an effective treatment for any of the reported clinical conditions in humans.
This led to the NHMRC Statement on Homeopathy:
Based on the assessment of the evidence of effectiveness of homeopathy, NHMRC concludes that there is no health condition for which there is reliable evidence that homeopathy is effective.
As well, the UK House of Commons Science and Technology Committee, in its “Evidence Check 2: Homeopathy,” after a review of the evidence, concluded:
In our view, the systematic reviews and meta-analyses conclusively demonstrate that homeopathic products perform no better than placebos. We could find no support from independent experts for the idea that there is good evidence for the efficacy of homeopathy.
What cannot be tolerated, in our view, is lowering the FDA’s standards to permit the consideration of “data sources” widely rejected by experts qualified by scientific training and experience. The mechanism of action for homeopathy proposed by the homeopathic industry is inconsistent with basic principles of chemistry and physics. Indeed, as has been pointed out, what we understand now about chemistry and physics would have to be proven very wrong if homeopathy actually “works.”
As Tanya Kell, President of the North American Society of Homeopaths, admitted at the hearing, the “long-established record of safety and efficacy” claimed by the industry is largely “a compilation of anecdotal evidence.” It is unthinkable that any other FDA-regulated product would be allowed on the market based on anecdotes.
At this time, the FDA has defaulted to the HPCUS to determine what ingredients can be used in homeopathic drugs and to the homeopathic industry to decide, with no reliable evidence whatsoever, safety and appropriate indications for use. The industry’s conflict of interest is obvious. What may be less obvious is that the HPCUS is controlled solely by industry insiders. The HPCUS Board, which exercises final judgment regarding which ingredients are included in the HPUS, is composed of practicing homeopaths, homeopathic pharmacists, or current or former officials or owners of homeopathic products manufacturing companies.
Yet, the FDA has claimed, in testimony before Congress, that it applies the same evidentiary standards whether a therapy is labeled conventional or complementary and alternative. In 2000, an FDA official told a House Committee:
CAM is a broad term referring to treatments that are either unapproved or not widely accepted in this country. Treatments range from botanicals and animal extracts to biofeedback to visualization techniques, chiropractic, homeopathy, massage therapy, acupuncture, and prayer. As we have emphasized, FDA relies on evidence, and is required to do so under the FD&C Act, from adequate and well-controlled studies as its basis for approval, not on theories of healing, animal studies or strongly held beliefs. Complementary and alternative treatments are as readily studied in well-controlled trials as are conventional treatments . . . [Emphasis added.]
In sum, the FDA should use only data sources that meet the same requirements as those allowed for all other FDA-regulated drugs. Conversely, the FDA should reject scientifically implausible “theories,” anecdotal evidence, homeopathic “provings” and obviously biased industry sources as the standard for homeopathic drugs.
     1.  Are the current enforcement policies under the CPG [Compliance Policy Guide] appropriate to protect and promote public health in light of the tremendous growth in the homeopathic drug market? Are there alternatives to the current enforcement policies of the CPG that would inform FDA’s regulatory oversight of drugs labeled as homeopathic? If so, please explain.
     2.  Are there areas of the current CPG that could benefit from additional clarity? If so, please explain.
Given the fact that consumers who use homeopathic drugs are not aware of the overwhelming scientific consensus that homeopathy does not, and cannot, work, and that no robust clinical trial evidence for their efficacy exists, then it is quite obvious that the current CPG is inadequate. The fact that consumers do not confine their use to self-limiting conditions is further evidence of their confusion.
The only solution is to scrap the current CPG and apply the same regulations and policies to homeopathic drugs that the FDA applies to all other OTC drugs. (This same solution is applicable to prescription homeopathic drugs as well: regulate these drugs like all other prescription drugs.) If a homeopathic drug has never been properly evaluated to determine whether it is OTC or prescription, then that should be the first step. The rest of the regulatory process follows logically from there. As we have pointed out before, and as the FDA itself has said, there no statutory authority to regulate homeopathic drugs differently than all other drugs on the market.
If the FDA concludes that removing all homeopathic products from the shelves, because they’ve never been through the appropriate regulatory process, is impractical, interim steps could be taken until all homeopathic drugs can complete the process. As a first step, the FDA can, at the very least, apply the same product labeling rules to OTC homeopathic drugs it does to all other OTC drugs. This includes listing ingredients and ingredient amounts using the same terminology as is used for all other OTC drugs. In other words, the Latin names and reference to amounts in homeopathic dilutions should be abandoned. It would also mean that no homeopathic drug could claim to be safe and effective for any disease or condition until it met the same evidentiary standards as all other OTC drugs.
     1.  Is there information regarding the regulation of homeopathic products in other countries that inform FDA’s thinking in this area?
The FDA has in place an extensive regulatory process designed to evaluate the safety and effectiveness of OTC and prescription drugs and to ensure that the public and health professionals have adequate information for their use. It is this system the FDA should employ for homeopathic drugs. To the extent other countries are employing any regulatory scheme that allows the sale of homeopathic drugs based on false claims of safety and effectiveness, that system simply suffers from the same deficiencies as those that plague the current system in this country. Consequently, they should not be adopted.
     1.  A large majority of human drug products labeled as homeopathic are marketed as OTC drugs. These products are available for a wide variety of indications, and many of these indications have never been considered for OTC use under a formal regulatory process. What would be an appropriate regulatory process for evaluating such indications for OTC use?
There is no legal or practical reason why the FDA should continue to privilege homeopathy over all other drugs by indulging the homeopathic industry and ignoring basic science and the overwhelming evidence from clinical trials that homeopathy does not and cannot work. To date, the FDA’s rationale for doing so has been the presumed safety of homeopathic drugs, due to the fact that they contain anywhere from a small amount to no active ingredient. Safety aside, in light of the public’s, and health care providers’ obvious belief in the efficacy of homeopathic products for many conditions, some of them quite serious, the FDA can no longer afford to allow these misperceptions to go unremedied by regulatory action. Again, the appropriate regulatory process is the one already in place for other OTC drugs. This should include the payment of any fees required of other OTC drug manufacturers.
     1.  Given the wide range of indications on drug products labeled as homeopathic and available OTC, what processes do companies currently use to evaluate whether such products, including their indications for use, are appropriate for marketing as an OTC drug?
We submit that the processes these companies use, whatever they are, are highly irregular to the extent they are based on homeopathic principles. There is a plethora of scientifically valid information evaluating homeopathic drugs. It is abundantly clear that the homeopathic industry has not availed itself of this information in evaluating “whether their products, including their indications for use, are appropriate for marketing as OTC drugs.”
To the extent the evaluation of homeopathic drugs by their manufacturers does not conform to the processes used by other OTC drug manufacturers, they must be scrapped. We do not believe there is a way to create some hybrid regulatory system supported by one foot resting in science and the other in pseudoscience.
     1.  Do consumers and health care providers have adequate information to make informed decisions about drug products labeled as homeopathic? If not, what information, including, for example, information in labeling, would allow consumers and health care providers to be better informed about products labeled as homeopathic?
The answer to the first question is clear: Consumers and a handful of health care providers believe that homeopathic drugs are safe and effective for many uses and that the “theory” underlying homeopathic remedies is a tenable one. A necessary corollary to that conclusion is that they have inadequate information to make informed decisions about homeopathic drugs.
The fact that these products are labeled “homeopathic” (a fact mentioned by several homeopathy proponents at the hearing) begs the question. That means nothing if the consumer doesn’t understand what “homeopathic” means. Of course, to the homeopathic industry, it means that “like cures like” and that dilution combined with vigorous shaking makes the product more, rather than less, effective. Consumers testifying at the hearing and commenting online parroted this explanation, ironically demonstrating they have no idea what “homeopathic” really means: that the product has been produced by a method that virtually guarantees it will not work as advertised.
One speaker repeated the homeopathic industry’s latest attempt at reconciling their scientifically untenable “theory” with basic chemistry and physics: “we now know that water holds energetic information and the energy of each substance is stored within the homeopathic remedy.” Another said they are “effective through their energetic frequency and the effect they have on the cellular electrical energies.” Yet another, a naturopath, claimed that homeopathy can be explained by hormesis. All of these are nonsensical from a scientific standpoint.
This is exacerbated by the fact that ingredients are listed in Latin and dilutions are listed in a code used only by the homeopathic industry. In addition to these confusing labels, consumers commented that they relied on self-help books, the internet and personal recommendations, all unreliable sources of accurate information.
Proponents of homeopathic products testifying at the hearing gave examples of available online sources. However, these sources simply repeat the unproven claims that homeopathy is safe and effective for a wide range of diseases. For example, the Consumer Healthcare Products Association, a trade group, refers viewers to the websites of two homeopathic product manufacturers, Hyland’s and Boiron, hardly objective sources of reliable information.
The website of the National Center for Homeopathy, mentioned several times in testimony, contains information that can only be described as fantastical from a scientific standpoint. Likewise, the American Institute for Homeopathy website states that homeopathic remedies “stimulate the person’s own healing power,” which is nothing more than vitalism, a pre-scientific, and long-rejected, belief in an incorporeal “healing force” erroneously credited with healing powers. It falsely claims that homeopathic drugs are “deep-acting medicines [that] can be used to treat persons experiencing many kinds of medical conditions.”
Unfortunately, the FDA’s own website has almost no information about homeopathic drugs. This paucity is striking when compared to the plethora of information available for OTC and prescription drugs, as well as the many other products the FDA regulates, such as foods and medical devices. The National Center for Complementary and Integrative Health has limited information. Fortunately for those consumers consulting NCCIH, the material is refreshingly honest: the FDA does not evaluate homeopathic remedies for safety or effectiveness, there is little evidence that it is effective for anything, and although highly diluted some products have concentrations capable of causing adverse effects.
At the hearing, the homeopathic industry was unable to produce any evidence that the consumer understands the true nature of homeopathic remedies. One industry representative testified it might be helpful to require a disclaimer on the label similar to that on dietary supplements. However, this appears to have had little effect on the public’s misplaced belief that dietary supplements are proven safe and effective, despite the fact that the FDA does not evaluate supplements prior to market and the lack of evidence that supplements are indeed either safe or effective for their advertised uses. Of course, unlike dietary supplements, where there is specific statutory authority in the Dietary Supplement Health & Education Act (DSHEA) to use this disclaimer, nothing in the FD&C Act permits the FDA to avoid its regulatory mandate in this manner.
Of note, there is popular support for the increased regulation of dietary supplements. (Again, DSHEA, unlike the FD&C Act, does not require pre-market approval.) One survey reported in the medical literature found that a substantial majority of respondents, including regular dietary supplement users, were in favor of
    • requiring the FDA to review the safety of new dietary supplements prior to their sale;
    • providing increased authority to remove from sale those products shown to be unsafe; and
    • increasing government regulation to ensure that advertising claims about dietary supplements are true.
Summary
The answer to the FDA’s questions is simple and can be summarized in a few words.
     1.  Homeopathy is highly implausible, unsupported by scientific evidence, ineffective in treating illness and, when relied upon instead of actual medicine, dangerous and even deadly.
     2.  The FDA should apply the FD&C Act as Congress intended. The law offers no exception for homeopathic products.

FDA Warns About Homeopathic Teething Products
Steven Novella on October 5, 2016
Link

The FDA recently put out a consumer warning about homeopathic teething gels and pills. The warning states:
The FDA recommends that consumers stop using these products and dispose of any in their possession.
The warning is not because all homeopathic products are inherently useless. As we have discussed here often, the basic principles of homeopathy are pure pseudoscience. The practice of diluting substances so that almost no or no active ingredient remains means that most homeopathic products are just sugar pills. Further, clinical studies show that homeopathic products don’t work. There isn’t a single homeopathic product that has been shown to be effective for a single condition with rigorous clinical trials.
The FDA acknowledges this, writing in their warning:
Homeopathic teething tablets and gels have not been evaluated or approved by the FDA for safety or efficacy. The agency is also not aware of any proven health benefit of the products, which are labeled to relieve teething symptoms in children.
This may sound confusing, since the entire homeopathic pharmacopoeia has been pre-approved by the FDA and are sold as drugs. What they are saying is that they are not approved, “for safety or efficacy.” So they are approved, but without any guarantee that they are safe or effective.
Homeopathic belladonna
In the case of homeopathic teething gels and tablet, the concern is not that they are worthless, without any proven benefit, but rather that they can be toxic to children and infants. Many people falsely assume that because most homeopathic potions are typically diluted so that no active ingredient remains, all homeopathic products therefore have no active ingredients; that is not always the case, nor is it a requirement to be considered homeopathic.
In this case, homeopathic potions can cause direct toxic harm, not just the indirect harm of fooling people into thinking a worthless sugar pill is effective medicine.
This has come up before. In 2009 the FDA issued a warning about homeopathic Zicam nasal spray, which contained real doses of zinc and was associated with anosmia, or loss of smell.
The homeopathic teething products contain, according to the FDA, real doses of belladonna, which is a toxic alkaloid. In fact, they issued a similar warning letter in 2010, although that warning was limited to Hyland’s Teething Tablets, while the new warning applies to all homeopathic teething products. In the 2010 warning they stated:
Hyland’s Teething Tablets are manufactured to contain a small amount of belladonna, a substance that can cause serious harm at larger doses. For such a product, it is important that the amount of belladonna be carefully controlled. FDA laboratory analysis, however, has found that Hyland’s Teething Tablets contain inconsistent amounts of belladonna. In addition, the FDA has received reports of serious adverse events in children taking this product that are consistent with belladonna toxicity. The FDA has also received reports of children who consumed more tablets than recommended, because the containers do not have child resistant caps.
Hyland’s Teething Tablets were reintroduced to the market in 2011 after it was “reformulated.” In response to the recent warning by the FDA, the company put out a statement in which they state:
There is no current recall of Hyland’s Baby Teething Tablets.[and]There is NO scientific link between homeopathically-prepared belladonna, or Hyland’s Baby Teething Tablets, and seizures.
There is no recall, but that may be the next step after the FDA warning. It is also ironic that Hyland’s will defend their product by saying there is no scientific link between their product and seizures, but ignores the fact that there is also NO scientific link between their product and any health benefit.
The FDA’s conundrum
Right at the bottom of the warning letter, the FDA describes itself as:
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.
They need to add to their standard self-description: “Except for homeopathic products, which we allow to be sold as drugs with unsubstantiated health claims, confusing or misleading labeling, and without evidence of safety, because we allow the homeopathic industry to regulate itself.”
The FDA has essentially abandoned its job to “protect the public health by assuring the safety, effectiveness,” of drugs when it comes to homeopathic potions.
However, last year the FDA announced that it was reconsidering its regulation of homeopathy. There was a public comment period – here is our open letter to the FDA. Now we are just waiting for the FDA to makes its decision. Will it finally do its job when it comes to homeopathy, or will it continue to take the politically easy path? You can be sure you will read about it here as soon as we know.

An Update on FDA Concerns Over Homeopathic Teething Products
Clay Jones on October 21, 2016
Link

Steven Novella recently wrote a post discussing an FDA warning against the use of homeopathic teething products over safety concerns related to the possibility of toxic amounts of belladonna. He goes into the hypocrisy of the FDA regulation of homeopathic products, a topic covered numerous times here on Science-Based Medicine, as well as the misleading initial response from Hyland’s, producers of the most popular homeopathic teething remedies in the United States and Canada. There have been some updates over the past two weeks that I’ll cover in this post.
FDA reveals concerning cases of possible serious harm
Just as the media response to the initial FDA warning announcement on September 30th was dying down, a new round of articles, like this one from CNN, were published in response to new information from the FDA. Although the data is unpublished at this time, a spokesperson from the FDA has disclosed that their investigation into adverse events related to homeopathic teething products has revealed 400 reports, including 10 deaths, since 2010. They were clear that a causal relationship between these products and the adverse events has not been proven and that the investigation is ongoing.
I also want to be very clear and point out that as proponents of scientific skepticism we must not rush to judgement regarding these new revelations. While I am certainly no fan of homeopathy, because it is abject nonsense that carries risk of both direct and indirect harm to patients without any specific benefit, there is a very real possibility that the outcomes in question had nothing to do with these products. The reports absolutely do require further investigation, in particular when considering that this exact problem has happened before in 2010.
Why we shouldn’t rush to judgement
Adverse event reporting for drugs, which homeopathic products are designated as by the FDA despite not being tested for safety or efficacy, is no different than for vaccines. Vaccines are also drugs, but they have a completely separate reporting system known as the VAERS. Both systems serve only as a guide for more directed investigation because both can be misleading or even abused by biased individuals with a self-serving agenda.
Although it is a continuous source of cerebral embogglement for me, parents frequently attribute a variety of symptoms, even significant systemic manifestations of actual illness, to teething. Seizures, vomiting, constipation, difficulty breathing, and fever appear to make up the bulk of the adverse events discovered by the FDA so far in their investigation, but I’m sure there are more. Perhaps a child was even turned into the Hulk, or at the very least Matter-Eater Lad.
Because of how common teething is, and the sad fact that hundreds of thousands of doses of homeopathic remedies are given to teething children every year, it is possible that administration was simply coincidental to the reported outcomes. Bottom line, we need to wait until the investigation is complete and published. But we have plenty of legitimate reasons to question the availability of these products.
Response from the homeopathic community
The initial response from Hyland’s to the FDA warning, as discussed in Dr. Novella’s post, was predictably to deny the link between their product and serious adverse events, and to make clear that the FDA had not actually recalled any of their products. They followed this with a press release that again trumpeted the safety of their product and even included a condescending informational video that is full of propaganda. According to the video, even doctors can make the mistake of jumping to conclusions about homeopathic belladonna. But once we learn a little bit about the science of diluting a deadly poison into non-existence, our concerns become just plain silly.
On October 11th, just prior to the publication of numerous articles mentioning the FDA revelation of possible deaths and other adverse events caused by homeopathic teething products, Hyland’s released a letter to the public from their employees, and an accompanying FAQ, announcing that they will stop distributing their teething products in the United States. It came complete with signatures of the employees and pictures of their children and grandchildren, all supposedly relieved of their suffering by Hyland’s products. In the letter, Hyland’s lamented the confusion caused by the FDA warning and the fact that some retailers have chosen to pull their products from store shelves.
This voluntary cessation of distribution only affect retail stores in the United States. Canadian parents can still purchase Hyland’s teething products and they can still be ordered online. In the UK, homeopathic products such as Hyland’s that are produced in the United States and available online are not licensed for use, and parents across the pond have been advised by their government to avoid them.
The most obnoxious response to the FDA warning, which should come as a surprise to exactly nobody, was an “ACTION ALERT” from the National Center for Homeopathy on October 17th. It’s short but full of reality-challenged misinformation, so I’ll just reproduce it here:
On September 30th, the Food and Drug Administration issued a press release warning consumers to stop using homeopathic teething tablets and gels. The sensational and dramatic headlines that followed created a public scare and led to the removal of homeopathic teething products from the shelves of stores. This was met with wide spread “anti-FDA” sentiment in social media.
The FDA later clarified that they were conducting an ongoing investigation as a response to reported serious adverse events. While the FDA’s warning about homeopathic teething preparation seems arbitrary and capricious, the media’s exaggerated fear mongering has made a bad situation worse. In fact, an FDA spokesperson told news agencies that the relationship between serious adverse events and homeopathic teething products has not yet been determined and is currently under review.
Homeopathy has a laudable and extensively documented clinical record and there are hundreds of high quality, peer-reviewed basic science, pre-clinical, and clinical studies showing its efficacy and safety. There are no studies linking homeopathically-prepared medicines and serious adverse events.
Despite these facts, groups interested in seeing homeopathy destroyed continue to hammer away at the system – making exaggerated claims that create misunderstandings about [sic] and limit consumer access.
Homeopathy is a safe, gentle, and natural system of healing that works with your body to relieve symptoms, restore itself, and improve your overall health. It has been used successfully for the last 200 years by over 250 million people worldwide. Homeopathy is growing in popularity in the United States, where homeopathic over the counter (OTC) medicines are regulated by the FDA and have been so for decades.
No studies linking homeopathy to serious adverse events? I’ll just leave this here for you to review at your leisure. About the only accurate fact in this response is the date of the FDA warning. Even worse is the fact that they link to an anti-vaccine, conspiracy laden blog post from Living Whole.
Conclusion: It’s not personal, it’s about patient safety
The FDA and supporters of science-based medicine are not out to get Hyland’s, or any proponents of homeopathic treatments for that matter. There is no personal vendetta, only the desire for patients and parents to be given legitimate information and to protect people from possible harm, especially considering the absence of any benefit from these products beyond placebo. The FDA has reason to investigate these products and to let consumers know of their concerns so that they can make informed choices.

CVS sued for deceiving consumers in sale of homeopathic remedies
A lawsuit claiming pharmacy giant CVS fraudulently deceives consumers in the sale of worthless homeopathic remedies has been filed by the Center for Inquiry (CFI), acting on behalf of the general public. CFI says co-mingling ineffective homeopathic products with science-based treatments on CVS’s retail shelves and online confuses consumers.
Jann Bellamy on July 19, 2018
Link

A lawsuit claiming pharmacy chain giant CVS fraudulently deceives consumers in the sale of worthless homeopathic remedies was filed in late June by the Center for Inquiry (CFI), acting on behalf of the general public. The suit seeks both damages and an injunction against CVS’s deceptive marketing practices in the Superior Court of the District of Columbia, alleging violations of the District’s consumer protection act.
In a press release, CFI’s president Robyn Blumner said that CFI had tried to discuss the situation with CVS:
but the concerns we raised were ignored . . . Homeopathy is a multi-billion dollar consumer fraud. If CVS would rather line its pockets than protect Americans’ heatlh, we have no choice but to take this fight to the courts.
The press release noted that, in addition to being a waste of money, using homeopathic products instead of evidence-based treatments can result in worsened or prolonged illness, and, in some cases, death. As well:
Several products have been found to contain poisonous ingredients which have affected tens of thousands of adults and children in just the last few years.
Nicholas Little, CFI’s Vice President and General Counsel, who represents CFI in the suit, charged that CVS can’t claim ignorance:
If the people in charge of the country’s largest pharmacy don’t know that homeopathy is bunk, they should be kept as far away from the American healthcare system as possible.
The suit is brought under the District of Columbia’s Consumer Protections Procedures Act (CPPA), which “establishes an enforceable right to truthful information from merchants about consumer goods” without proof that any consumers were in fact mislead, deceived or damaged. In other words, in the District of Columbia’s view, lying to consumers is wrong and should be prevented, even without the added insult of actual harm. The CPPA permits nonprofit and consumer protection organizations like CFI to file suit on behalf of the public and seek, on its behalf, treble damages or, in lieu thereof, $1,500 per violation, as well as an injunction against further violations. Although any ruling in favor of consumers would apply only within the D.C.’s tiny jurisdiction, it could send a powerful message if CVS were required to pull homeopathic products from the shelves of its 60 D.C. pharmacies and disclaim, per a court order, any intent to sell homeopathic products to D.C. residents on its website.
The complaint alleges that CVS engages in fraudulent and deceptive marketing practices in retail and online sales of homeopathic products, including CVS’s house brand, by:
using marketing, labeling and product placement to falsely present homeopathic products as equivalent to effective science-based medicines for specific diseases and symptoms.
For example, according to the complaint, homeopathic products like Oscillococcinum and its claim that it “relieves flu-like symptoms such as body aches, headache, fever, chills and fatigue” are displayed on CVS’s shelves in the “cold and flu” section, indistinguishable from FDA-approved over-the-counter remedies like Tylenol Sinus & Headache. Likewise, on CVS’s website, Oscillococcinum Quick Dissolve Pellets is nested for sale under the category path Health and Medicine > Cough, Cold, & Flu > Flu Remedies, along with Tylenol Cold + Flu Caplets, although the consumer is offered the convenience of purchasing only Oscillococcinum online. For the Tylenol product, the consumer must visit a brick-and-mortar CVS pharmacy.
CFI uses Oscillococcinum as a tutorial for the court on the nonsense behind homeopathy, explaining that it consists of “duck offal” diluted to a scientifically-impossible concoction of one part offal to 10400 parts water, a number that exceeds the estimated number of atoms in the known universe (1082). According to homeopaths, the complaint explains, the potency of the offal is preserved through “succussion,” or shaking the product and hitting it against an elastic surface, such as a leather-covered book. Homeopaths rationalize that, even without a single molecule of the original ingredient remaining, the water can “physically remember the chemical properties” of the duck offal, even though not a single molecule of the offal remains.
I am all too familiar with CVS’s deceptive marketing tactics. Last year, I came close to buying a homeopathic dry eye product at CVS for my late mother, who was suffering from cancer. Fortunately, I caught my mistake and purchased instead an evidence-based eye remedy. But the mere possibility that she might have suffered due to using a worthless product led to both my writing a post about my experience and filing a complaint with three government agencies, none of which has taken any action. Judging from the comments of those who had similar experiences with the confusing co-mingling of real and fake medicine on retail shelves, I am not alone.
The complaint correctly characterizes homeopathy as “pseudoscience” without “a shred of credible scientific evidence that it works” or “could possibly work” and as “no more accepted by the scientific community than the notion of a flat Earth.” These allegations are supported by citations to, among others:
    • The Australian National Health and Medical Research Council’s assessment that “There are no health conditions for which there is reliable evidence that homeopathy is effective.”
    • The 2010 U.K. House of Commons Science and Technology Committee report on homeopathy and its conclusion that homeopathic remedies performed no better than placebo and that the National Health Service should stop funding homeopathic remedies, an action the NHS took in 2017.
    • The Federal Trade Commission’s 2016 statement that a homeopathic remedy’s claims of efficacy, if not backed by “competent and reliable scientific evidence,” would be considered misleading without a warning to consumers that there is no scientific evidence that the product works and homeopathic “theories” are not accepted by modern experts. [Although, according to the FTC, even this admission to consumers that you are lying to them may not be enough to protect the product’s false claims.]
Thus, the complaint alleges, in marketing homeopathic products as effective treatments for specific conditions, in creating the impression that homeopathic remedies can be used interchangeably with science-based medicines, and in failing to tell consumers there is no scientific evidence that homeopathic products are beneficial for these conditions, CVS has violated the D.C.’s Consumer Protections Procedures Act.
CVS responds
Per the court’s rules, CVS must file a response and “admit or deny the allegations asserted against it” by CFI. (It may file a motion that delays its duty to respond, and the court could possibly grant a motion to dismiss the case prior to CVS’s filing its answer, but the latter seems unlikely.) Denial of any factual contentions made by CFI must be “warranted on the evidence” or “reasonably based on belief or a lack of information.” Given the overwhelming scientific consensus that homeopathy is not, and cannot be, beneficial for anything, it will be interesting to see how CVS responds to the complaint’s specific allegations of homeopathy’s pseudoscientific principles and its demonstrable lack of effectiveness. And it will be interesting to see how CVS mounts a defense to the Consumer Protections Procedures Act’s prohibitions against:
    • Representing that products have characteristics that they do not have;
    • Representing that products are of a particular standard or quality when they are in fact of a different standard or quality;
    • Misrepresentation of a material fact which has a tendency to mislead;
    • Failing to state a material fact if that failure tends to mislead;
    • Using innuendo or ambiguity as to a material fact, which has a tendency to mislead.
Barring the use of a legal defense like preemption (see below), or the successful introduction of junk science as evidence, it’s hard to see how CVS can prevail on the merits. Then again, homeopathic remedies have been sitting on the shelves of American pharmacies and other retailers for decades despite their obvious ineffectiveness and scientific implausibility, defying (admittedly tepid) government regulation and numerous lawsuits.
While an answer to the complaint is not yet due in court, CVS responded to the suit in MD Magazine by saying:
‘We believe the Center for Inquiry’s civil complaint against CVS Pharmacy has no merit. We offer certain homeopathic products in compliance with federal law and applicable regulations set forth by the FDA and the FTC,’ Mike DeAngelis, CVS Health’s senior director of corporate communications, told MD Magazine. ‘CVS is committed to assuring that the products we offer are safe, work as intended, comply with regulations and satisfy customers. In the event of a regulatory issue concerning any product we sell, we take appropriate action.’
Actually, if CVS were committed to assuring that the products it sells are safe and work as intended, it wouldn’t be selling homeopathic remedies.
CVS’s statement possibly foreshadows the defendant’s claiming that the District of Columbia’s consumer protection act is preempted by federal law, specifically the Food, Drug, and Cosmetics Act of 1938 and the Federal Trade Commission Act of 1914. This defense has not always succeeded in suits against homeopathic product manufacturers, a federal district court judge having found that the FDA has largely abdicated any role in creating standards for homeopathic OTC drugs, a situation that, sadly, has not changed. Even if the FDA were to finally adopt its proposed “risk-based” enforcement of the FD&C Act against homeopathic remedies, the FDA has frankly admitted that many homeopathic products would escape enforcement action despite the agency’s tacit admission that, since no homeopathic remedy on the market today has been approved in accordance with the FD&C Act, each and every one of them is being marketed in violation of federal law.
CVS’s statement also takes a page from the tobacco industry’s playbook – “all we are doing is selling a “legal product:”
Gareth Davies, Chief Executive of [the U.K.’s] Imperial Tobacco, says [in 1997] of Labour’s proposed advertising ban: ‘Obviously I am very much against anything that tries to reduce consumption of a legal product that is used by adults …an advertising ban will do nothing to reduce consumption.’
And this from Brown and Williamson’s ad agency, in 1969:
We will continue to bring to the American people the story of the cigarette and any other legal product based upon truth and taste. We believe that free speech and fair play are both the heritage and promise in our society of free and responsible enterprise.
But as CFI’s General Counsel told Gizmodo:
The argument isn’t that they’re illegal, it’s about how they’re marketing and selling these products . . .
Of course, homeopathic remedies should be illegal, or, at the very least, the FDA should make them to undergo the safety and effectiveness evaluation required by the FD & C Act, a mandate that the FDA continues to ignore. Until that happens, I am grateful for CFI’s suit seeking consumer protection against the sale of fraudulent products by CVS and fully support their efforts. In preparing this post, I was brought to tears by the memory of my near-failure to help alleviate the suffering of my late mother, directly attributable to confusion brought on by CVS’s deceptive product placement. Since this and many similar incidents don’t seem to bother CVS, perhaps treble damages and an injunction will change its corporate mind.
UPDATE: To explain the problems with homeopathy and why CFI is suing CVS, CFI has put up a dedicated website at centerforinquiry.org/cvs.

Junk science helps homeopathic remedy company win class action
Junk science from two of homeopathy’s biggest apologists help Hyland’s defeat a class action lawsuit for consumer false advertising claims, and nixed refunds for ineffective homeopathic remedies.
Jann Bellamy on January 19, 2017
Link

In 2012, Kim Allen and other consumers filed suit against Hyland’s, a wholly-owned subsidiary of Standard Homeopathic Co., for false advertising in a California federal district court. (Allen v. Hylands Inc., Case No. 2:12-cv-01150-DMG(MANx), U.S. District Court for the Central District of California) The judge certified a plaintiff class of purchasers of ten Hyland’s homeopathic remedies including Calms Forte, Teething Tablets (the subject of an FDA warning, also here) ClearAc (for acne), Migraine Headache Relief, Poison Ivy/Oak Tablets, Cough and Seasonal Allergy Relief, and Colic Tablets. At the 2015 trial, plaintiffs’ counsel argued to the jury that Hyland’s misled tens of thousands of purchasers and sought $255 million in refunds.
Experts with impeccable credentials testified on plaintiffs’ behalf that the principles of homeopathy are biologically impossible, that the overwhelming preponderance of the evidence from clinical trials is that it does not work, and, specifically, the Hyland’s products in question do not provide any effective relief beyond placebo. There was testimony that the FDA, the federal agency charged with regulating homeopathic remedies (however lightly) takes the position that there are little to no active ingredients in these products. Plaintiffs put into evidence the government reports from the U.K. and Australia finding there are no health conditions for which there is reliable evidence that homeopathy is effective. They also put into evidence the NCCIH’s statement that the most rigorous clinical trials and systematic analyses of the research on homeopathy have concluded that there is little evidence to support homeopathy for any specific condition.
And they lost. The jury came back with a verdict in Hyland’s favor, after a 13-day trial held in 2015. (The case only recently came to my attention in a news report on pending motion, which we’ll get to shortly.) Based on the jury’s verdict, the judge ruled in favor of Hyland’s on claims that remained to be resolved after trial. In other words, it was a complete victory for Hyland’s.
Plaintiffs have moved for a new trial, arguing that the judge erroneously instructed the jury that they had to prove that Hyland’s products “cannot” work. While the plaintiffs did argue that homeopathic remedies, indeed, cannot work, because of biological implausibility, they say that was not their only theory of the case. They argue they merely had to prove the products were ineffective, i.e., that they “do not” work, but that the judge’s instructions to the jury failed to include this theory of the case. Hyland’s, in its response to the motion for a new trial, argues that this is merely semantics; that there is no difference between the two standards.
In their motion for a new trial, Plaintiffs also say they were entitled to a jury instruction that, if a product’s “effectiveness” is solely the result of a placebo effect, an advertisement that the product is “effective” is false even though some consumers may experience positive results. (This argument is based on a decision in a case brought by the FTC against a manufacturer of cure for baldness. The court held that where evidence developed under accepted standards of scientific research demonstrates that the product has no force beyond its placebo effect, advertising it as “effective” is indeed false.) Hyland’s was allowed to introduce evidence of customer satisfaction surveys – in other words, anecdotal evidence of effectiveness – which plaintiffs argue, correctly, could simply indicate the placebo effect at work. Thus, they say, they were entitled to this particular jury instruction on placebo effects.
Finally, the plaintiffs argue that a new trial should be granted because the verdict was against the clear weight of the evidence. The court has taken the motion under consideration.
The trial consumed two weeks and several thousand pages of transcripts and documentary evidence. The case was filed in 2012, finally went to trial in 2015, and is still under consideration on the plaintiffs’ pending motion. A complete summary of the case and discussion of the evidence is far beyond the scope of this post. However, two figures we’ve met before on SBM figured prominently in the trial and I felt their testimony worthy of discussion, for the record, so to speak. (If you have a Pacer account, you can read all 483 docket entries and their associated documents. Otherwise, I have downloaded selected documents and provide links to them.)
The evidence
And what was the evidence in Hyland’s favor, proving to the jury that their product claims were true? A whopping load of junk science, hauled into the courtroom by two of homeopathy’s biggest advocates: Iris Bell, MD, PhD, and Peter Fisher, the British homeopath and physician who treats the Queen.
In testimony at trial (also here), and by affidavit, Dr. Bell, who has been a paid consultant to Standard Homeopathic Co. since 2006, held forth on homeopathy. She said that homeopathy is based on two principles: “like cures like” and “remedies will retain their biological activity if they are repeatedly diluted and agitated or shaken between each dilution.” This is hogwash, of course, but lest the jury doubt that there is “modern” science behind homeopathy, she continues:
Modern homeopathy is premised upon a non-linear dose response for these natural substances. The non-linear dose response phenomenon is explained by a well-documented observation in the research literature known as hormesis, whereby the same substance can produces effects in different or opposite directions, depends on the dose of the substance and the state or condition of the organism at the time it receives the dose. Low doses tend to produce beneficial effects, whereas high doses of the same substance tend to produce adverse or toxic effects. . . . to take advantage hormesis, homeopathic drugs are prepared at the lowest subtoxic observed level sufficient to trigger the secondary symptoms without causing the primary symptom.
And, nanoparticles! If a juror might think the whole idea of diluting a substance until there is nothing left is crazy talk, Dr. Bell says
The method by which many homeopathic medicines are made involves grinding the source material before it is further diluted and succussed. This grinding process is similar to one of two major ways in which nanoparticles of plants, mineral, or drugs are made. . .
But do we know that nanoparticles of active ingredients actually remain in homeopathic remedies so they can work their magic via hormesis? Oh, yes, we do, as Dr. Bell testified at trial:
There was a paper published by investigators at the Indian Institute of Technology stating — studying six different homeopathic medicines using electromicriscopy and other techniques of that type where they actually showed that there were nanoparticles of the source material in the verum medicines. [See Dr. Gorski’s analysis of this paper here.]
In her view, this answered criticisms that
there’s nothing there if you keep diluting it enough. At that point there is something there. Based on that original study, there were nanoparticles of course material present even at those high potencies . . .
which she testified were up to 200C. (A dilution of one molecule in the entire observable universe would be about 40C.)
She also testified:
The literature suggests that many nanoparticles are capable of having some very interesting properties that could overlap with some of the finds that have been reported in homeopathic literature on the electromagnetic signals and the optical signals.
Faced with the testimony of plaintiffs’ expert that all of this violated the laws of physics, Dr. Bell testified that she did not agree. Why?
Because the materials were there.
Except that they weren’t. And hormesis doesn’t “explain” how homeopathy “works,” either. Dr. Bell’s testimony, which is basically a rehash of stuff she’s said before, has been thoroughly debunked by David Gorski and our good friend Orac, with an assist from Harriet Hall in deconstructing the Indian lab experiment supposedly demonstrating the presence of nanoparticles in homeopathic remedies.
I won’t go into the technical details here, but suffice to say that the “nanoparticles” the Indian researchers “saw” were almost surely contaminants and that the “signaling” from the nanoparticles is based on a roundly-criticized paper by Luc Montainger et al. Per the latest “explanation” from homeopaths, once you have nanoparticles (even if you don’t), then (insert lots of handwaving) hormesis. Hormesis is a hypothesis that some substances toxic at high doses might be benign or beneficial at low doses. Of course, no nanoparticles, no hormesis, but even if these magical nanoparticles existed, trying to invoke hormeis as an explanation is, as David Gorski says, “wishful thinking on the part of homeopaths, representing extreme over-extrapolation.”
Or, more colorfully, as Dr. Gorski put it when Dr. Bell set out her nanoparticles (existence + signals) = hormesis = homeopathy works “theory” in a journal article:
I started to wonder whether I was the victim of a Sokal-style hoax here or whether Bell wrote her paper the way that David Bowie used to like to write songs: By cutting up newspaper and magazine articles and randomly splicing the words back together. In this case, it seems as though Bell cut up a bunch of nanoparticle papers and some homeopathy literature and then threw them together to produce much of this paper.
Dr. Bell also testified (by affidavit) that each of the Hyland’s products
[c]ontrary to the assertion [by plaintiffs] that the dilutions result in ‘very little, if any, of the advertised ‘active ingredients’ are present in the Products’ the dilutions of each of the triturated and/or succussed ingredients in the products at issue in this case are sufficient to provide the relief of symptoms for which they are indicated.
All of which pleased the homeopathy crowd to no end.
Dr. Bell was not the only homeopath to testify, nor the most famous. None other than Peter Fisher, the Queen’s physician, also testified on Hyland’s behalf at trial and by affidavit. (For unknown reasons, one volume of his testimony does not appear to have been filed with the court.) Dr. Fisher is a well-known defender of homeopathy and the subject of several SBM posts debunking those defenses:
    • Should physicians and managed care organizations offer homeopathy?
    • False balance for homeopathy in the BMJ
    • Homeopathy and plausibility
    • Homeopathy for fibromyalgia: The Huffington Post bombs again
He cherry-picked his way through homeopathy studies and even “explained” slides to the jury supposedly showing nanoparticles in homeopathic remedies. He also tried to attack Shang et al. for their “beautiful demonstration,” as Dr. Gorski called it, that
whatever effects due to homeopathy ‘detected’ in clinical trials are nonspecific and not detectably different from placebo effects, exactly as one would anticipate based on the basic science showing that homeopathy cannot work unless huge swaths of our current understanding of physics and chemistry are seriously in error.
I read a good portion of his testimony and I have to admit, if you didn’t know anything about science in general or homeopathy in particular, he sounds convincing, partly for reasons we’ll return to in a moment.
At this point, you might well be asking yourself: why were Bell and Fisher allowed to put their pseudoscientific “theories” into evidence in the first place? The answer is: I don’t know. When I first looked at the docket, I was expecting to see a pre-trial motion to exclude their testimony based on federal evidentiary rules and Daubert, which require the judge to act as a “gatekeeper,” insuring that expert testimony is scientifically reliable. However, while plaintiffs sought to exclude their testimony on other grounds, they never explicitly attacked it as pseudoscience in a pre-trial motion to exclude it. In fairness, I cannot question that decision because I have no idea why they made it.
The larger issues
What is striking to me about this case is how it is an exemplar of everything that is wrong with “integrative” medicine and tolerance for pseudoscience. If Iris Bell was credible as a witness, and I have to presume she was if Hyland’s won, it is at least in part because she held a faculty position at the University of Arizona, was an NIH-funded researcher, and is a licensed homeopath and physician (she trained as a psychiatrist) in Arizona. In fact, she testified that one NCCAM grant paid half her salary for ten years.
The same is true of Peter Fisher. To burnish his credibility, he testified is on the National Institute for Health and Care Excellence, a UK governmental body that advises the National Health Service on what treatments it should and shouldn’t use, the WHO’s expert advisory panel on complementary medicine, registered in homeopathy by the General Medical Council, and was for 17 years in a position of authority with the Royal London Hospital for Integrated Medicine, which is part of the University College London Hospital NHS Trusts, “one of the leading academic medical centers in the U.K.” (his words) as well as the Queen’s physician. He also testified he is the editor-in-chief of the journal Homeopathy, which, he said, is indexed in PubMed, a service of the National Library of Medicine, and published by Elsevier, “a leading international publisher of scientific medical and technical literature.”
This veneer of respectability and scientific veritas bestowed by quackademic medicine, government entities, state licensing authorities (via state legislatures who pass licensing acts), ACCME-approved courses in homeopathy, taxpayer-funded education in homeopathy, PubMed’s indexing of dubious journals, and companies that publish these “peer-reviewed” journals, allows companies like Hyland’s to rip off the public with its worthless products, and, for good measure, keeps consumers from recovering their money when they complain, no matter how scientifically air-tight their false advertising claims may be.
I have to fault the FDA here too. Had it done its job, and required homeopathic remedy manufacturers to comply with the law, manufacturers would have to prove safety and efficacy before their products went on the market. In fact, while we’re at it, we can blame Congress as well, for incorporating the entire Homeopathic Pharmacoepia into U.S. law in 1938.
I am pleased with the FTC’s announcement that it will clamp down on labeling homeopathic remedies by requiring that companies have competent and reliable scientific evidence for health-related claims, including claims that a product can treat specific conditions. It remains to be seen how much effect this will have. According to testimony at this trial, most people take homeopathic remedies based on their own past experience or recommendations from friends and family, not what they read on the labels. The FTC will still allow manufacturers to make unsubstantiated claims as long as the label says there is no scientific evidence that the product works and that the product’s claims are based only on theories of homeopathy from the 1700s that are not accepted by most modern medical experts. Given the fact that the jury in this case was essentially told the same thing by plaintiffs’ experts, I have my concerns. And, again, “modern medical experts” must overcome the positive PR homeopathy gets from its use at “modern medical” centers.
I don’t know how many homeopathic remedy class actions are pending in federal courts now. (There is at least one other suit against Hyland’s involving its teething remedy.) Perhaps it is time to set up an expert panel to review the scientific issues involved in these suits, as was done in the breast implant cases. Jurors may be confused, but there is no controversy among scientists that homeopathy does not, and cannot, work.

   Homeopathic Thuggery
Steven Novella
Link
There have been many cases now of big companies or organizations, or wealthy individuals, threatening to sue or actually suing a blogger for libel. The most famous case is that of Simon Singh who was sued by the British Chiropractic Association over comments he made in an article. Simon braved through the expensive and exhaustive legal process (which is especially onerous in England), but he is not just a lone blogger. He is a successful author and was writing for the Guardian. Eventually the BCA was forced to drop the case – but only after the blogging community rallied behind Simon, magnifying his criticisms of the BCA by orders of magnitude. By all accounts it was a PR disaster.
The blogging community as a whole is rather passionate about this issue. We exist on the premise of free and open public discourse about important issues. At SBM we take on many controversial issues and we don’t pull our punches when criticizing what we see as pseudoscience in medicine. So of course we take notice when a large company tries to bully a blogger to silence their legitimate criticism.
According to the BMJ this has happened yet again – this time the international homeopathy producer, Boiron, is threatening a lone Italian blogger because he dared to criticize their product, Oscillococcinum. The blogger, Samuele Riva, wrote two articles on his blog, blogzero.it, criticizing what our own Mark Crislip has called “oh-so-silly-coccinum.” The blog is entirely in Italian, but he is maintaining a page in English with updates on the Boiron vs Blogzero affair.
Criticizing homeopathy is always fun, because it is at the extreme absurd end of the silly pseudoscience spectrum, even among some stiff competition. But now homeopathy has a corporate face in Boiron – a large multinational corporation based in France. Boiron is the largest manufacturer of homeopathic products in the world and the second largest manufacturer of over-the-counter products in France.
What they are doing to this small blogger, in my opinion, is nothing less than corporate thuggery. They are using their resources and their corporate lawyers to try to silence completely legitimate criticism of their pseudoscientific products. Of course, they will only succeed in magnifying that criticism.
For example, Riva suggested that Boiron’s oscillococcinum has no active ingredient. Well, let’s see- the company lists the active ingredient in this product as “Anas barbariae hepatis et cordis extractum 200CK HPUS.” The “200C” means that the listed ingredient was diluted with a 1:100 dilution 200 times. Serial dilution is a funny thing – a 200c dilution is the equivalent of diluting 1ml of original ingredient into a volume of water that is the size of the known universe. This is far far beyond the point where there is any reasonable chance of there being even a single molecule of original ingredient left.
So Riva was completely justified (as have many other critics) in saying that Boiron’s 200c product has no active ingredient. In fact it is deceptive to list something that has been diluted 200C as an “active ingredient.”
Not that it matters in this case, because the original ingredient is a pseudoscience unto itself. Mark Crislip gives the full details, here is his summary:
In the 1919 flu epidemic a physician who did not understand that artifacts on the slide, probably bubbles, move randomly due to Brownian motion. Looking at the tissues of flu patients with a microscope, he found what he thought was not only the cause of influenza, but the cause of all diseases: small cocci (round balls) that oscillated under the microscope. He found these wiggling bubbles in all the tissues of all the ill people he examined and thought he discovered the true cause of all disease. Sigh. Yet another cause of all illness. He is the only person, before or since, to see these oscillating cocci. Hence the name.
That’s right, oscillococcinum does not even exist – essentially Boiron takes fairy dust and then dilutes it out of (non)existence. The “anas barbariea hepatis” is basically duck liver, which is supposed to contain the most concentrated nonexistent oscillococcinum. It’s a pseudoscience trifecta.
Boiron claims that their product treats the symptoms of flu. What does the evidence show? (Yes, there is evidence – someone bothered to test whether diluted fairy dust actually works)? Well, this is yet another interesting story. Oscillococcinum was at the center of another embarrassing controversy, this one involving the Cochrane Collaboration. They published a Cochrane review of Oscillococcinum for the flu, and the authors concluded:
Though promising, the data were not strong enough to make a general recommendation to use Oscillococcinum for first-line treatment of influenza and influenza-like syndromes. Further research is warranted but the required sample sizes are large. Current evidence does not support a preventative effect of Oscillococcinum-like homeopathic medicines in influenza and influenza-like syndromes.
This review became the poster child for what is wrong with Cochrane’s particular application of evidence-based medicine (EBM). Notice that the evidence is essentially negative, but with some positive studies – which is what we expect when studying a fancy placebo because of researcher and publication bias. But the authors concluded that the treatment is “promising” and “further research is warranted.” An SBM review of the same data would come to a very different conclusion – the data is what we would expect from an ineffective treatment. Further, the highly implausible nature of the treatment (on several levels) warrants a conclusion that it does not work, it holds no promise, and not another dime of precious research money should be wasted chasing this fantasy.
Eventually the Cochrane review was withdrawn. We interpreted this as a minor victory for SBM, although we have no way of knowing what role, if any, our criticism played in the decision to withdraw the review.
Conclusion
I hope Boiron does draw a line in the sand over their oscillococcinum product, and that it becomes the center piece of a broader public discussion about homeopathy. Most of the public does not understand what homeopathy actually is. They think it means “natural” or “herbal” medicine. They have no idea that homeopathy is about taking fanciful ingredients with a dubious connection to the symptoms in the first place, and then diluting them into oblivion, then placing a drop of the pure water that remains and placing it on a sugar pill. The resultant pill is then supposed to contain the magic vibrations of the original substance.
This rank pseudoscience, which has no place in 21st century medicine, is the business of Boiron. Let’s see them try to defend themselves and their products. Let’s see them harass bloggers and those who are just trying to expose the public to the truth. Let’s see them argue in public how air bubbles in duck liver fantastically diluted can treat the flu.

FTC Homeopathy Win
Steven Novella on November 16, 2016
Link
I love to see a regulatory agency actually do its job. Especially within medicine, where it is most important, the lack of political will seems to get in the way of properly regulating health care products and services in the way that most consumers assume they are regulated.
Homeopathy is perhaps the best example. Homeopathy is pure unadulterated pseudoscience and witchcraft. There is no legitimate scientific debate about this. Homeopaths create their potions by starting with fanciful substances that can’t work and then dilute them out of existence. The result is plain water that they claim has magical properties. Yes – that’s really what it is.
Unsurprisingly, rigorous clinical trials have shown that homeopathic potions in fact do not work.
Current regulation
Mainly for historical reasons, the FDA has categorized homeopathic products as drugs. They are not drugs, but that is how they are classified. This means that disease claims can be made for homeopathic products.
For all other drugs regulated by the FDA, the privilege of being able to claim that the drug can treat or cure a specific disease comes with a rather high bar of evidence for safety and efficacy. That seems fair – you can make specific disease claims, but you have to provide sufficienct evidence.
This is in contrast to supplements, for which companies cannot make disease claims. They can only make “structure/function” claims, that the product improves or enhances some structure or function within the body. Diseases cannot be mentioned. Additionally, companies do not need to provide any evidence to back these claims. This is a horrific back door which needs to be closed, but that is a topic for another time.
Homeopathic remedies, however, live in the regulatory netherworld. They have all the privileges of being classified as drugs, but the FDA has unilaterally decided not to enforce the requirement for providing evidence of efficacy. Rather, homeopaths can base claims entirely on their tradition. They can literally just write down a homeopathic potion in their book (the Homeopathic Materia Medica) and make whatever claims they wish. No scientific evidence is required.
Regulations under review
Last year both the FDA (Food and Drug Administration) and FTC (Federal Trade Commission) announced that they were reviewing their current regulation of homeopathic products. Keep in mind this is just about over-the-counter (OTC) products, not the practice of homeopathy by licensed homeopaths or other professionals. That is up to the states.
Both agencies had an open comment period, in which the SfSBM submitted rather strong recommendations. Both agencies have the authority to increase their regulation if they choose. It seems to me that this is purely a matter of political will.
Since the comment periods have closed we have been waiting anxiously for both agencies to announce their decisions. This could be, in the best-case scenario, a death blow to the OTC homeopathy industry.
Yesterday the FTC released their decision. Here is the key part:
The policy statement explains that the FTC will hold efficacy and safety claims for OTC homeopathic drugs to the same standard as other products making similar claims. That is, companies must have competent and reliable scientific evidence for health-related claims, including claims that a product can treat specific conditions. The statement describes the type of scientific evidence that the Commission requires of companies making such claims for their products.
That was all they had to do, and all we were asking for. Hold homeopathic products to the same requirement for evidence to back any clinical claims that they make. In essence, all we wanted was for them to do their job. The FTC now seems willing to do just that.
They further explain that companies can make claims for products based on things other than reliable scientific evidence, but that they then have to clearly explain the basis of those claims:
However, the policy statement also notes that “the FTC has long recognized that marketing claims may include additional explanatory information to prevent the claims from being misleading. Accordingly, it recognizes that an OTC homeopathic drug claim that is not substantiated by competent and reliable scientific evidence might not be deceptive if the advertisement or label where it appears effectively communicates that: 1) there is no scientific evidence that the product works; and 2) the product’s claims are based only on theories of homeopathy from the 1700s that are not accepted by most modern medical experts.
In essence, the net effect of the labeling on the product cannot be misleading to the consumer. I think this is giving some wiggle room for homeopathic manufacturers to try their best to mislead their potential customers, but this is probably the best the FTC can do within its mandate.
The FTC statement specifically notes that this policy does not violate the first amendment, which signals their primary concern. Companies still have the free speech to tell the public that they believe from their traditions that a product can work for a specific indication, as long as they also say this is not based on evidence or on modern accepted scientific concepts.
This all means that it is more important than ever to educate the public about the true nature of homeopathy. The new FTC policy only really works if the public has a basic level of scientific literacy. That is a much longer struggle.
The official FTC decision is here. The FTC has also published a much longer document in which they review all the comments that were provided to them and the information they reviewed.
Three other organizations skeptical of homeopathy, The Society for Science-Based Medicine (SSBM), The Center for Inquiry, and the Richard Dawkins Foundation for Reason and Science (the RD Foundation), also submitted comments. The comments argued that homeopathic products have no efficacy in treating illnesses and that there is no reasonable basis for homeopathic principles such as “like cures like,” the law of infinitesimal doses, or water retaining a memory of things that have been in contact with it. They pointed to the Australian NHMRC report, to a report by the UK House of Commons Science and Technology Committee that “could find no support from independent experts for the idea that there is good evidence for the efficacy of homeopathy,” and to a statement by the National Center for Complementary and Integrative Health that “There is little evidence to support homeopathy as an effective treatment for any specific condition.” The SSBM asserted, based in part on its reading of individual public comments submitted to the FDA, that consumers do not understand the nature of homeopathic drugs or the support for their claims.
If you have time the document is an interesting read. It includes comments from the homeopathic industry, which is unsurprising. They argue that homeopathy must work because people use it, and that there are positive studies of homeopathy. These are the same tired, deceptive claims they typically make.
When it comes to medical treatments, the argument from popularity is worthless because of placebo effects and the inherent difficulty of knowing if a treatment is helpful from anecdotal observation. Bloodletting was very popular for centuries. Further, they continue to cherry pick the studies they want, ignoring or dismissing the many systematic reviews which clearly show that homeopathy does not work for anything.
The bottom line is that, after more than 200 years of use, homeopaths have failed to provide solid scientific evidence that any homeopathic remedy works for any indication. They will give a lot of hand-waving explanations for why this is true, but they all fall flat. The simplest explanation for this lack of scientific evidence is that homeopathy does not work.
What about the FDA?
The FTC essentially regulates the marketing of products, their labeling, and the claims that can be made for them. They don’t regulate the products themselves, that is up to the FDA.
We are still waiting to hear the FDA’s decision on homeopathy. We hope, like the FTC, that they choose to do their job. All they have to do is enforce their mandate, and hold homeopathic “drugs” to the same requirements for evidence of safety and efficacy as all other actual drugs.
If they really do this, then I don’t see how the homeopathic OTC product market can survive. It is clear that they cannot provide scientific evidence for efficacy.
The realist in me (some might say pessimist) thinks that the FDA will tighten up regulations of homeopathy, but for political reasons will give the industry a loop hole. I predict they will simply require more accurate labeling of homeopathic products, but not require them to provide evidence of efficacy in order to remain on the market at all.
I am still hopeful they will go the distance and do the only rational and honest thing – regulate homeopathic products by the standards demanded by their category. Remember, the privilege of disease claims go hand-in-hand with high standards of scientific evidence. The FDA carved out a special exception for homeopathy, and all they need to do is make that exception go away.
If they do this, effectively shutting down the OTC homeopathy industry, I further predict that Congress will act to save the industry. They shouldn’t. They should let it die a merciful death. If only our world were that rational. Perhaps I will be pleasantly surprised.
Congress controls the FDA. They can easily pass a law that creates whatever regulatory scheme for homeopathy that they want. They did this for supplements with the Dietary Supplement Health and Education Act of 1994. This is pro-industry, anti-consumer regulation. If history is any guide, they will do the same thing for the homeopathy industry.
There is a glimmer of hope, however. Note that the FTC heard the voice of skeptics, both individuals and organizations. We have a powerful voice, if not in numbers then in the logic and evidence that backs our opinions.
Now is the time to keep the pressure up. If the FDA returns a good decision on homeopathy, we have to anticipate how the industry will respond. The decision could backfire if Congress decides to act, and things could actually get worse. Our collective voice will be more necessary than ever.
The FTC has set the stage. When the FDA gives their decision, and especially if it is a science-based one, we cannot take time to celebrate. That will be a dangerous time, and we must snap into action as quickly as the homeopathic industry surely will.
This will be an opportunity to educate the public and our politicians about homeopathy. We need to make clear that the public expects health care products to be safe and effective, and that they not be deceived by false or misleading claims. We will all need to write our representatives, to make the voice of science and reason heard as loudly as possible.

Walmart sued for deceiving customers in selling homeopathic remedies
A lawsuit claiming Walmart fraudulently deceives consumers in the sale of worthless homeopathic remedies has been filed by the Center for Inquiry (CFI), acting on behalf of the general public. CFI says co-mingling ineffective homeopathic products with science-based treatments on Walmart’s pharmacy shelves and website misleads customers into thinking they are equivalent, when “there is not a shred of credible scientific evidence” that homeopathy works, “or indeed could possibly work.”
Jann Bellamy on June 6, 2019
Link

The Center for Inquiry (CFI) recently filed suit against retail behemoth Walmart, alleging the company is committing widespread consumer fraud through the sale and marketing of worthless homeopathic remedies. According to the complaint, Walmart places both its own “Equate” brand and other homeopathic brands alongside science-based, FDA-approved over-the-counter (OTC) medicines on its pharmacy shelves, with no distinction drawn between them. Searches on the Walmart website for condition-specific remedies, such as for colds, flu, or cough, will turn up both homeopathic and science-based products. This, says CFI, falsely presents ineffective homeopathic products as equivalent alternatives to FDA-approved science-based medicines.
In a press release, CFI President Robyn Blumner said:
Despite being among the richest corporations on Earth and the largest retailer in the United States, Walmart chooses to further pad its massive wealth by tricking consumers into throwing their money away on sham medicinal products that are scientifically proven to be useless and potentially dangerous . . . We intend to put a stop to it.
Like a similar suit filed against pharmacy chain giant CVS last year (now in settlement discussions, which a recent court filing described as “productive”), CFI is suing Walmart under the District of Columbia’s Consumer Protections Procedures Act (CPPA), which “establishes an enforceable right to truthful information from merchants about consumer goods” without proof that any consumers were in fact mislead, deceived or damaged. In other words, in the District of Columbia’s view, lying to consumers is wrong and should be prevented, even without the added insult of actual harm. The CPPA permits nonprofit and consumer protection organizations like CFI to file suit on behalf of the public and seek, on its behalf, treble damages or, in lieu thereof, $1,500 per violation, as well as an injunction against further violations. D.C. is a tiny jurisdiction and any judgment in CFI’s favor would apply only to Walmart’s three retail stores located there. An injunction against fraudulent marketing on the company’s website would pack a bigger punch.
The complaint explains the ludicrous pseudoscience behind homeopathy’s claims of effectiveness: homeopathic remedies are massively diluted with water or other inert substances, often to the level where no molecules of the original substance remain in the final product, based on the notion that the greater the dilution, the greater the power of the remedy. CFI also explains the homeopathic concept of “like treats like”, that is, if something is shown to cause a symptom in an individual, the same substance can be used to treat the symptom. Thus, CFI says, homeopathy is pseudoscience, without “a shred of credible scientific evidence that it works, or indeed could possibly work”, citing U.S., Australian, and U.K. government research.
(None of this is news to SBM regulars; we’ve covered “the one quackery to rule them all” many times here on SBM, including my personal experience with just the type of deceptive marketing CFI describes in the complaint.)
As it did in the CVS complaint, CFI uses an often-mocked example of homeopathic nonsense as a tutorial on homeopathy: Oscillococcinum, “duck offal” diluted to a scientifically-impossible concoction of one part offal to 10400 parts water, a number that exceeds the estimated number of atoms in the known universe (1082 ). According to homeopaths, the complaint explains, the potency of the offal is preserved through “succussion,” or shaking the product and hitting it against an elastic surface, such as a leather-covered book. Homeopaths rationalize that, even without a single molecule of the original ingredient remaining, the water can “physically remember the chemical properties” of the duck offal, though not a single molecule of the offal remains.
Yet, the complaint notes, with photos of Walmart pharmacy shelves to prove the point, Oscillococcinum is displayed alongside FDA-approved OTC medicines like Tylenol Sinus & Headache, Alka Seltzer, and Mucinex. When “flu remedy” or “flu relief” is typed into the search box on Walmart’s website, Oscillococcinum returns as a front-page result. Thus,
Walmart is announcing that if a customer has flu-like symptoms, Tylenol Cold and Flu medicine, containing acetaminophen, a medicine tested and approved ty the FDA, is an equivalent solution to Oscilloccinum, which contains the organs of a Muscovy duck, diluted to the power of 10400.
CFI alleges that this and similar juxtapositions of homeopathic and science-based remedies causes confusion and falsely implies to the consumer that there is no difference between them.
In a news report on the lawsuit, a Walmart spokesperson said
We want to be the most trusted retailer, and we look to our suppliers to provide products that meet all applicable laws, including labeling laws. . . . Our Equate private label homeopathic products are designed to include information directly stating that the claims are not based on accepted medical evidence and have not been evaluated by the FDA.
The disclaimer is apparently based on the FTC’s 2016 Enforcement Policy Statement on the marketing of homeopathic remedies, explained in an agency press release:
the FTC will hold efficacy and safety claims for OTC homeopathic drugs to the same standard as other products making similar claims. That is, companies must have competent and reliable scientific evidence for health-related claims, including claims that a product can treat specific conditions.
Of course, as the FTC admits, homeopathic remedies can’t meet this standard:
For the vast majority of OTC homeopathic drugs, the policy statement notes, ‘the case for efficacy is based solely on traditional homeopathic theories and there are no valid studies using current scientific methods showing the product’s efficacy.’ As such, the marketing claims for these products are likely misleading, in violation of the FTC Act.
However, the FTC offers homeopathic remedy marketers an out:
the policy statement also notes that the FTC has long recognized that marketing claims may include additional explanatory information to prevent the claims from being misleading. Accordingly, it recognizes that an OTC homeopathic drug claim that is not substantiated by competent and reliable scientific evidence might not be deceptive if the advertisement or label where it appears effectively communicates that: 1) there is no scientific evidence that the product works; and 2) the product’s claims are based only on theories of homeopathy from the 1700s that are not accepted by most modern medical experts.
Most?
In other words, the FTC will permit homeopathic remedy makers to lie about the effectiveness of their products as long as they tell consumers they are lying.
But,
the FTC will carefully scrutinize the net impression of OTC homeopathic marketing claims and that if an ad conveys more substantiation than a marketer has, it will violate the FTC Act.
While Equate brand homeopathic remedies may comply with the FTC policy statement, I could not find any similar language on other brands sold by Walmart, either in the photos included as part of the complaint or the Walmart website.
In any event, the disclaimer may not matter. The legal basis of CFI’s lawsuit is not that Walmart’s homeopathic products don’t comply with federal labelling laws or are illegal (although they are; more on that in a moment). Rather, it says displaying pseudoscientific remedies alongside science-based medicines falsely implies an equivalency in effectiveness and that violates D.C.’s consumer protection law. While Walmart might try to use the disclaimer as evidence in this case that these displays are not confusing or misleading, I don’t think the court would be persuaded. Tiny print on a small package hardly overcomes the implication that products grouped together on pharmacy shelves under a sign saying, for example, “heartburn relief”, actually provide heartburn relief.
The FDA’s policy only recently switched from ignoring the Food, Drug & Cosmetics Act’s mandate that homeopathic remedies go through the same approval process as all other OTC and prescription drugs to a “risk-based” enforcement approach that tackles only the worst players in the homeopathic market, leaving the others free to foist their worthless products on consumers. As the FDA itself admitted,
many homeopathic products will likely fall outside the risk-based categories described in the [FDA’s draft] guidance [on homeopathic drugs] and remain available to consumers.
Yes, and consumers will continue to spend billions on worthless products that not only won’t help them, but may, through poor manufacturing practices or delay in effective medical care, cause serious illness or death. That is why lawsuits like CFI’s against CVS and Walmart are essential in the battle against healthcare pseudoscience. With the FDA and the FTC failing to protect consumers from products they admit are both ineffective and sold illegally, in violation of the FD&C Act, the courts are the consumer’s only refuge.

Lawsuits against US pharmacy chains selling homeopathy to proceed
An Appeals Court will permit CFI to challenge Walmart and CVS for selling homeopathy alongside conventional medicine.
Scott Gavura on October 13, 2022
Link


In 2018, the Center for Inquiry (CFI) filed a lawsuit on behalf of the general public against US pharmacy chain CVS for selling homeopathy. In 2019, it filed a similar lawsuit against Walmart, alleging fraud through their sale of these products. Both lawsuits were filed under the District of Columbia’s Consumer Protections Procedures Act (CPPA), which “establishes an enforceable right to truthful information from merchants about consumer goods and services that are or would be purchased, leased, or received in the District of Columbia”. Importantly, as Jann Bellamy noted when she blogged about these lawsuits at the time, the CPPA does not require proof that any consumers were actually mislead, deceived or damaged.
Both lawsuits were initially dismissed. Last week, in a unanimous ruling the District of Columbia Court of Appeals overturned both dismissals. The lawsuits will proceed.
Dilutions of Grandeur: The myth of homeopathy
Among all the forms of alternative medicine, homeopathy is possibly the most implausible of them all. Samuel Hahnemann invented the practice of homeopathy in the early 1800s. While the practice of medicine slowly progressed to a scientific model based on objective observations, homeopathy, on the other hand, has never progressed or evolved. Its practices today are frozen in the same prescientific beliefs of Hahnemann. Homeopathy is based on the idea that “like cures like”, in that a small dose of what causes a symptom can actually cure that symptom. Like-cures-like is simply sympathetic magic, a pre-scientific belief, and is the entire basis for homeopathy:
    • Like-cures-like: in homeopathy, a substance that is believed to cause a symptom, is diluted to treat that same symptom. Any substance is thought to be an effective remedy if it’s diluted enough: cancer, boar testicles, crude oil, oxygen, skim milk, even vacuum cleaner dust or moonlight can be (and is) a homeopathic remedy. Deciding which substances will cure which symptoms is determined by a process called a “proving” which is equally without any scientific basis. (See the homeopathic “provings” for the Berlin Wall remedy and sunlight reflected off the planet Saturn, for an example of how remedies are created.)
    • Water has a memory: the more you dilute the substance, the more powerful its effect. And I mean dilute. The 30C “potency” is a common dilution used in homeopathy – that’s a dilution of 10-60. If something has been diluted this much, you would have to give two billion doses per second, to six billion people, for 4 billion years, to deliver a single molecule of the original, pre-diluted material. The result is that most homeopathic remedies are completely inert, and don’t contain a single molecule of what’s on the label. Whether bottled as a liquid or dripped onto lactose and sold as tablets, they are pure placebo.
Despite the implausibility of homeopathy, and its detachment from the increasingly science-based practice of medicine, it retained some popularity over time, with a resurgence in the past few decades as an “alternative” medical system. Rigorous clinical trials confirm what basic science predicts: homeopathy’s effects are placebo effects. While there are plenty of clinical trials that show homeopathy is associated with positive clinical effects, they are always small, poorly controlled, and often biased. Two comprehensive reviews of the evidence are the 2010 Evidence Check from the United Kingdom’s House of Commons Science and Technology Committee and the 2014 Australian National Health and Medical Research Council review, which reached the following conclusion:
Based on the assessment of the evidence of effectiveness of homeopathy, NHMRC concludes that there are no health conditions for which there is reliable evidence that homeopathy is effective.Homeopathy should not be used to treat health conditions that are chronic, serious, or could become serious. People who choose homeopathy may put their health at risk if they reject or delay treatments for which there is good evidence for safety and effectiveness. People who are considering whether to use homeopathy should first get advice from a registered health practitioner. Those who use homeopathy should tell their health practitioner and should keep taking any prescribed treatments. The National Health and Medical Research Council expects that the Australian public will be offered treatments and therapies based on the best available evidence.
What’s the problem with homeopathy in pharmacies?
If homeopathy actually works in the way envisioned by Hahnemann and homeopaths, then the rest of medicine wouldn’t work. It is fundamentally incompatible with a scientific understanding of medicine, biochemistry, and even physics. However, when sold commercially, homeopathic “remedies” look like conventional medicine when they’re stocked on pharmacy shelves, like the photo above. The marketing and labeling of these “remedies” encourages this perception, often describing homeopathy as a “gentle” and “natural” system of healing, and putting cryptic terms like “30C” beside long Latin names of what are purported to be the active ingredients. So it is exceptionally difficult for the average consumer, who may never have heard of homeopathy, to understand that some of the products on the shelf may be inert. XKCD nailed the ethics of homeopathy in pharmacies several years ago (I pasted the hover text below):

Questions have been raised worldwide about the appropriateness of pharmacies selling homeopathy to consumers who may not realize what they’re buying. This was noted by the DC Court of Appeals in their judgement:
But, at this juncture, we cannot say that it is implausible that a reasonable consumer might understand appellees’ placement of homeopathic products alongside science-based medicines as a representation that the homeopathic products are efficacious or are equivalent alternatives to the FDA-approved over-the-counter drugs alongside which they are displayed.
What’s the basis of this lawsuit?
In 2020, the Superior Court dismissed CFI’s lawsuit because it failed to show it is a “nonprofit organization” or “public interest organization” within the meaning of the CPPA. The judge also stated that she did not find the marketing and product placement “to be an actionable representation, or to have the tendency to mislead under the CPPA”. She noted that “homeopathic” appeared on the front of the box as well as the federally-mandated disclaimer that the product had not been evaluated by the FDA (what has been called the “quack Miranda” disclaimer). The Walmart lawsuit was dismissed for similar reasons.
The Appeals Court disagreed. It accepted that CFI had a sufficient stake in the CPPA action and noted CFI’s activities regarding the regulation, testing, and marketing of homeopathy “align with consumers’ interests”. It also accepted that allegedly misleading product placement was within the scope of the CPPA. They describe a 2017 case brought forward under different state consumer-protection laws where obsolete motor oils were sold to consumers by placing them on shelves next to non-obsolete oils. The federal court denied a motion to dismiss that case based on the argument of “failure to recite a cognizable deceptive practice” even though there was a label on the oil stating it was unsuitable for most gasoline engines built after 1988. They also cited a case where CVS sold “Infant’s Acetaminophen” which was exactly the same as the CVS “Children’s Acetaminophen” but with a different photo on the package, and higher cost. The court was “…unable to conclude as a matter of law that no reasonable consumer would be deceived” even though both packages disclosed that they contained acetaminophen 160mg/5mL.
Finally, the appeals court disagreed with the superior court’s assessment that the placement of these products alongside “science-based medicines” did not have the tendency to mislead under the CPPA:
In this case, we do not find it facially implausible that a reasonable customer could believe, based on appellees’ placement of homeopathic drug products alongside FDA-approved over-the-counter drugs, that homeopathic products are comparably efficacious. We agree with CFI that whether signage and product placement influence consumers regarding the efficacy of medical products is a question that can be answered only with evidence, “not an inherently implausible assertion that can be dismissed out of hand.”
It also noted,
CFI’s complaints contains a number of conclusory allegations, but also contain numerous factual allegations and accompanying photographs to the effect that: the defendant retailers market themselves as offering products that will enable customers to get healthy; persons suffering an ailment will often turn to the pharmacy section of their neighborhood Walmart (or CVS) for relief; studies and patient experience have shown that homeopathic products are not effective; Walmart and CVS present homeopathic products alongside FDA-approved over-the-counter products, under aisle signs indicating that the aisles contain remedies for pain, colds, heartburn, and other conditions; and the retailers do so without informing customers that there is no scientific evidence that homeopathic products have any value in treating those symptoms and diseases. These factual allegations plausibly support an inference that, through their product placement practices, Walmart and CVS mislead consumers into believing that homeopathic products are equivalent alternatives to FDA-approved over-the-counter drugs.
What happens next?
This looks like a victory, but only re-opens the path for the original lawsuits, which can now proceed. The CFI Legal Director, Nick Little, concluded:
The Court of Appeals rightly recognized that giant retailers can’t just deny responsibility for how they present what are fundamentally worthless products. It’s a huge victory for consumers and their right not to be misled…DC’s highest court acknowledged what we’ve always known – CFI’s decades of work against pseudoscience like homeopathy is consumer protection work. We’re not going away, and it’s time for CVS, Walmart, and all other retailers to stop misrepresenting homeopathy as medicine.

   Taking On Homeopathy in Germany
Steven Novella
Link
Homeopathy is having a bad year. From a scientific point of view, it has had a couple of bad centuries. The progress of our scientific understanding of biology, chemistry, and physics has failed to confirm any of the core beliefs of homeopathy. Like does not cure like (this is a form of superstition known as sympathetic magic, with no basis in science). Diluting substances does not make them stronger – a notion that violates the chemical law of mass action and the laws of thermodynamics. And countless clinical studies have shown that homeopathic preparations are nothing more than placebos. That homeopathy cannot work and does not work is settled science, as much as it is possible for science to be settled.
Despite the science, homeopathy has persevered through a combination of cultural inertia and political support. But in the last year there are signs that this trend may be reversing. In the UK The House of Commons Science and Technology Committee (STC) released a report, Evidence Check 2: Homeopathy, in which they conclude that homeopathy is failed science and should be completely abandoned – no further support in the NHS and no further research.
Following that the British Medical Association has openly called for an NHS ban on homeopathy, calling the practice “witchcraft.”
Now German politicians are starting to echo the same sentiments.
Karl Lauterbach, the centre-left Social Democrats’ chair on the Bundestag health committee, told German news magazine Der Spiegel that insurers should be “prohibited from paying for homeopathy.”
and
According to Spiegel, Rainer Hess of the Federal Joint Committee for doctors and insurers also characterized the current situation as “extremely unsatisfactory.”
The common thread in the UK and Germany is rising health care costs, which is creating the political will to oppose worthless interventions like homeopathy. Up until now systems like homeopathy which are not science-based have received political support from individual believers and promoted largely through the notion of “health care freedom.” But the political climate is changing, and suddenly paying for interventions that do not work seems unnecessarily wasteful. This creates an opportunity to focus attention on interventions like homeopathy.
In Germany, as in the US, homeopathy has received support from individual politicians. According to the cited news article:
“There have already been many attempts to drop protective provisions on such remedies, but influential politicians have consistently prevented this from happening,” Hess said, adding that despite hundreds of medical studies failing to clearly prove the benefits of homeopathics, insurers are still made to pay for them.
It sounds like Germany has had their own Tom Harkin and Orin Hatch to contend with. Political support for homeopathy in the US actually goes back much further. In 1938 Senator Royal Copeland from New York, a homeopath, managed to insert into the new FDA regulations automatic approval for homeopathic products. This situation continues to today – homeopathic products do not require any testing for safety and efficacy.
It is good to hear that politicians in Germany are now openly discussing not only removing the protections that force insurance companies to pay for homeopathy, but actually banning insurance companies from paying for it. This would be similar to the BMA proposed ban on NHS support for homeopathy.
In both cases no one is proposing that homeopathy itself be banned. If an individual wants to pay for water in the mistaken belief that it is an effective remedy, they are free to do so. However, the seller should not be free to make misleading or fraudulent claims – but that is a different type of regulation. What is now being discussed in Germany and the UK is simply preventing public money from being spent on treatments which have already been proven not to work.
I would like to see these efforts spread to the US. We are facing our own health care crisis here, with a new focus on cost-effective medicine. Amazingly, Harkin was able to hijack efforts to deal with the situation (through “Obamacare”) to increase public support for unscientific medicine. This trend needs to reverse – and homeopathy seems like the low-hanging fruit to me.
With homeopathy the science could not be more clear, and recent exhaustive reviews, like Evidence Check 2: Homeopathy, have shown that it simply does not work. It should therefore be an easy political position to take, that our limited health care dollars should not be spent on ineffective medicine.

The Truth vs. Alex Jones: How the DSHEA of 1994 gave conspiracy mongers the means to fund their empires
As the HBO documentary The Truth vs. Alex Jones shows, Alex Jones promoted the conspiracy theory that the Sandy Hook massacre was a hoax to sell his supplement line. It’s a model that many Internet conspiracy theorists use, like Mike Adams. Did the DSHEA help create Alex Jones and the modern conspiracy industry?
David Gorski on April 1, 2024
Link

Last week, HBO released a rather intense documentary, The Truth vs. Alex Jones, that documents how the king of conspiracy theorists Alex Jones promoted the lie that the mass shooting at Sandy Hook Elementary School was a hoax, a false flag operation designed to provide a pretext for liberals and the government to take away Americans’ guns. Jones’ decade-long promotion of this conspiracy theory, which involved attacking parents whose children had been gunned down as “actors” and “fake” while claiming that their children never died, ended up in his losing two defamation suits, the judgment against him from one of them being the largest single defamation judgment in American history. You might wonder why I would be writing about this documentary and Alex Jones, given that the main topic of the film is a conspiracy theory not related to medicine. However, I suspect that a lot of you know that one of the major ways that Jones funds his online empire is through the sale of supplements, as was so clearly demonstrated by the filmmaker.
As I watched in horror, anger, frustration, and some relief when the parents finally won their defamation judgments, an odd thought popped to mind: The Dietary Health and Supplement Education Act of 1994 (DSHEA of 1994, which we’ve written about many times) was one thing in addition to the Internet that had made Alex Jones possible. Indeed, it made a whole online ecosystem of misinformation, disinformation, and conspiracy theories possible by providing a revenue stream that conspiracy mongers like Jones could use to fund their activities and then business empire. Let me explain.
The Truth vs. Alex Jones: One of the best documentaries I’ve ever seen
Before I discuss supplements, however, let me just say one thing. If you have HBO or Max, watch The Truth vs. Alex Jones. It is one of the best documentaries that I have ever seen. I will concede, however, that it is at times a very hard watch. It is, however, a necessary watch, at least in my opinion. For example, only 15 minutes into the film there is a segment in which Daniel Jewess, a now-retired Connecticut State Police detective who served as lead investigator for the shooting, spends six agonizing minutes of screen time explaining over photos of relevant parts of the school and interspersed with 911 calls exactly what, as far as the investigation could piece together, happened and when. He presented a detailed reconstructed timeline of how the shooter went from one classroom (Room 10) to another (Room 8) killing teachers and students (26 in all, 20 children and six adult teachers and staff), finishing with a massacre in a small restroom packed with children, where one class’s substitute teacher had told them, after which he committed suicide—all in around six minutes. Particularly moving is how Jewess says the name of each and every child and staff member killed. This segment was preceded by interviews with parents, who related what they did with their children that morning before dropping them off at school, all noting that that was the last time they had seen their children alive. Remember, these children were all between six and seven years old.
So, yes. It’s a very hard watch.
Contributing to this are segments showing the parents describing their experiences after the shooting, how the brutal murder of their child had affected their lives, and how Alex Jones’s decade-long promotion of conspiracy theories that the Sandy Hook shooting had never really happened, that it was a false flag designed to be used as a pretext to allow the government to take away the guns of patriotic Americans, and how the parents were crisis actors lying about what happened and their children either never existed or had not died had upended their lives with threats and intermittent terror. It was a campaign that began, as one lawyer for the parents who brought defamation suits against Jones, noted, “before the bodies were even cold,” less than three hours after the massacre, with Jones ramping up over the next few days:
The parents sob and whimper as they quietly talk about seeing their children, who are riddled with gunshots, cold, and distorted, and with fragments from their teachers’ body parts, who attempted to shield the kids from being shot. There’s around 20 minutes of heart-wrenching recollection of the tragedy, undercut directly after by Jones, who begins to claim that the shooting was “staged” the same day as those 26 souls’ lives were cut short. Robbie Parker, the father of slain six-year-old Emilie Parker, says he just wanted to be left alone by the media and particularly Jones, so he assembled a press conference. “I had just wanted to share something about who my daughter was,” Parker says in an interview. But as soon as the press conference wrapped, Jones and his team labeled Parker a crisis actor. This resulted in dozens and dozens of threats on Emilie’s memorial page on Facebook, calling the child a “whore” and claiming she was still alive.
Why did Jones label Parker a “crisis actor”? As Parker also explains in the interview, he was incredibly nervous right before the press conference and, as a result, had laughed nervously right before approaching the microphone. Throughout the rest of the movie, it’s shown how Jones keeps cutting to that nervous laugh, after which Parker became somber, mocking him viciously time and time again with those exaggerated fake sobs that he likes to employ for being an “actor” who, noticing the camera, had suddenly gotten back “into character.” This vile mockery pops up time and time again, as Jones repeated this mockery many times over the next decade.
In another harrowing narrative, Neil Heslin describes how he had cradled the cold body of his son Jesse Lewis one final time and seen the gunshot wound to the forehead that had killed him. Almost immediately after the original press interview in which Heslin had described this, Jones pounced, claiming that, according to the timeline he had assembled, this was not possible, demanding that Heslin explain himself and/or admit that he was lying.
As this review of the documentary notes:
This went on for 10 years. It’s still going on. Every time Jones aired another hoaxer theory, these grieving families would be hit with a fresh wave of vicious harassment: rape threats, death threats, people confronting them on the street. In the film, another mother, Jacqueline Barden, testifies in court that she and her husband received letters from people who said they’d peed on their son Daniel’s grave, or promised to dig it up, because they were convinced no one was in it. Yet another, Francine Wheeler, tells of how she was in an elevator at a conference for mothers who’d lost their children to gun violence when a woman told her that the mass shooting that killed her son Ben never happened.
“It’s just a drip, drip, drip of constant undermining of your feeling of safety and security while you’re trying to grieve for your 6-year-old child who was murdered unexpectedly in the classroom,” says director Dan Reed. “The cumulative harm is really I hope what comes out of the film.”
One of the parents noted in the film that he could always tell when Jones had aired a new Sandy Hook segment, because they would notice a large uptick in harassment and threats by Jones’ fans.
Nor does the film spare Jones’ conspirators, people whom he used as “sources” for his conspiracy theory. For example, the filmmakers include an interview with Wolfgang Halbig, one of Jones’ go-to “experts,” who kept claiming that the shooting had been staged based on anomaly hunting. For instance, one version of a video interview with one of the parents by Anderson Cooper had a moment where his nose seemed to disappear, which Halving and Jones claimed to have been due to the use of green screen. (The film notes that the copy on the CNN website does not have that video glitch.) One of Halvig’s other reasons was particularly bizarre, namely that they had not brought in helicopters to airlift the wounded out. He seemed blissfully unaware that it very rapidly appeared that there were no survivors. In fact, it turned out that there was only one survivor in the bathroom who, miraculously, had not been hit when Lanza sprayed bullets into the enclosed space, and had survived by playing dead. He also wondered why paramedics didn’t go inside the school, when in fact they had just as soon as the police had determined that Lanza was dead and there were no other shooters. (Jewess mentions talking to the chief paramedic on the scene.) Halbig is quite the nasty bit of work, too, having been arrested for possessing someone else’s identification information after he had repeatedly emailed several people and law enforcement agencies the Social Security number, birth date and other information of Leonard Pozner, whose 6-year-old son, Noah, died at Sandy Hook.
I could go on, but watch the film. I’ll just add that the difficulty in watching some of the segments is more than made up for by the deposition and courtroom footage of Alex Jones’ testimony, where, not controlling the venue and not being on his show, he alternately lied, raged, and conspiracy mongered, obviously very uncomfortable and distressed. There’s one particularly satisfying scene in which the plaintiff’s attorney confronts him on the witness stand with text messages erroneously sent by the defense attorneys that demonstrated quite clearly that Jones had lied about being bankrupt, about the revenue stream to his company, and about not having discussed Sandy Hook. Through it all, clips of Jones ranting about how both trials were “show trials” by a “kangaroo court” and how the whole thing had been scripted from the beginning play, even as both judges for the two cases end up making a summary judgment against Jones and his company, because he had failed to cooperate with discovery, even, as they characterized it, making a mockery of the process. Less satisfying was watching the final huge verdict being read down, because Jones live streamed the proceedings with him in a side box mocking the verdict and claiming he wouldn’t pay because he didn’t have any money. Worse, Jones might be right, as the final black screen included text saying how, as of March 2024, Jones had not yet paid any of the nearly $1.5 billion awarded by juries in the two states (Texas and Connecticut) to the families and was still doing his show. Also particularly disturbing was the oft-cited statistic that nearly one-quarter of Americans either deny or doubt that Sandy Hook happened, largely thanks to Alex Jones.
If there’s one thing that The Truth vs. Alex Jones demonstrates, unfortunately, it’s that the hopes of the parents for their verdict to usher in an “era of truth” was incredibly naive. I wish it were otherwise.
The DSHEA as a mechanism for funding disinformation
Regular longtime readers will likely know that we have been describing how bad a law the DSHEA is dating back to 2008, with guest contributor Dr. Peter Lipson once describing it as a “travesty of a mockery of a sham.” The DSHEA is, after all, a law pushed through by a bipartisan group of quack-friendly legislators, including Democratic Senator Tom Harkin (who was responsible for getting the National Center for Complementary and Alternative Medicine, now known as the National Center for Complementary and Integrative Health, created and funded as part of the NIH) and Republican Sen. Orrin Hatch, whose home state of Utah has become the supplement manufacturing capital of the US and who was through his entire career before his retirement a pit bull in defense of his home state supplement industry.
Because it’s been a while since we’ve discussed the DSHEA, I’ll just remind you what it does and why it’s such a bad law. Basically, as Peter Lipson described back in 2009:
DSHEA has a couple of very important consequences (aside from filling the pockets of supplement makers).
What does the FDA require of “supplements”?
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the dietary supplement manufacturer is responsible for ensuring that a dietary supplement is safe before it is marketed. FDA is responsible for taking action against any unsafe dietary supplement product after it reaches the market. Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements.* Manufacturers must make sure that product label information is truthful and not misleading.
To paraphrase: “sell whatever you want, just don’t let us catch you.”
What’s more frightening than this inexcusable lack of oversight is that many of the products marketed under DSHEA aren’t just vitamins and such, but products that claim to do the same things as real medicines. How do they get away with that?
There is a bit of a loophole. Supplement sellers can’t make specific claims that the supplement being sold can treat or prevent any disease. Moreover, when a supplement is marketed it’s more or less the honor system. No registration with the FDA is required. After all, supplements are food, not medicine! In effect, the government can’t really do anything unless problems are reported after the supplement is marketed. Even worse, the definition of “supplement” has become very broad, as Quackwatch points out:
DSHEA worsened this situation by increasing the amount of misinformation that can be directlytransmitted to prospective customers. It also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
In other words, under the DSHEA, substances that are clearly not foods can be marketed as supplements, including herbs and other botanicals (the vast majority of which are marketed as having a beneficial medicinal effect and some of which contain chemicals that do act as drugs). As long as the manufacturer is careful not to make specific health claims, it’s all good. In other words, a “nutritional support” statement claimed for a supplement must not be a “drug” claim; i.e., it must not claim that the supplement can be used for the treatment or prevention of a disease. Supplement manufacturers easily evade this requirement by making vaguer claims related to organs or systems, such as claiming that a product “boosts the immune system,” “supports heart health,” or something similar, often accompanied by what Dr. Lipson has sarcastically referred to as the “quack Miranda warning“:
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
At the bottom of the landing page of the InfoWars Store:
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product.
* The products sold on this site are not intended for use in the cure, treatment, prevention, or mitigation of any disease, including the novel coronavirus. Any suggestion to the contrary is false and is expressly disavowed.
Sure thing, Alex. Your double Quack Miranda Warning is noted.
Color me unsurprised.
In general, it doesn’t take too much searching to find supplement advertising that does claim to treat, cure, or prevent disease. That’s why I’ve argued before that the DSHEA was the greatest boon to supplement manufacturers ever. In its wake, the supplement industry exploded, racking up huge increases in sales. Moreover, so lax is the regulation of supplements that I like to point to one example of an extreme and egregious act, namely the marketing of an industrial chelator as an “antioxidant” supplement for the treatment of autism, that went on for quite some time before the FDA finally acted. Over the years, supporters of science-based medicine and sound public policy have made efforts to repeal the DSHEA or, failing that, to reform it to make it less of an enabler of grifting quacks. All have failed.
Which brings us back to Alex Jones.
I know that I’ve argued that all antivaccine misinformation (which Alex Jones also spreads but was not discussed in the film) and quackery (again, also promoted by Alex Jones but not discussed in the film much) are, like all science denial, at their core conspiracy theories. I’ve discussed, for example, the central conspiracy theory of the antivaccine movement, which posits that vaccines are dangerous and promoted for nefarious reasons (e.g., profit, control), but that “they” (the CDC, doctors, big pharma) are covering up the evidence. Similarly, all science denial takes the same form, namely that the science being denied (e.g., evolution, oncology) is accepted for nefarious reasons and all evidence showing it to be bogus is being “covered up” by powerful forces. Sandy Hook is very much the same, but what the film shows is just how integral the sale of bogus supplements was to the motivation for spreading increasingly outrageous conspiracy theories, to being the funding source for people like Alex Jones.
For example, “stories” like this:
Hook ’em with the outrageous headline and wild conspiracy story lying about how the FBI had concluded that “no one” had been killed at Sandy Hook…
And then:
Sell ’em the supplements! (Both are screenshots from The Truth vs. Alex Jones.)
InfoWars sells lots of supplements, too. One particularly effective passage involved the gang that couldn’t shoot straight, namely Jones’ defense team, again. In explaining the significance of the story above, the filmmaker notes that Jones’ lawyers had accidentally sent them attachments to emails with daily sales and revenue data. At one point, Jones is grilled on his business model, which, it had become obvious, was to sell supplements and to gin up outrage to draw viewers, some of whom would be receptive to the pitch for Jones’ line of supplements that inevitably peppered his broadcast and appeared after many segments. Indeed, after the story in the screenshot above above ran, according to the sales figures mistakenly sent to the plaintiffs’ attorneys, sales from the InfoWars supplement store immediately more than quadrupled. (See screenshot below.) One lawyer even asked, “InfoWars is actually an infomercial, right?”
The story ran on September 24, 2014. Notice how supplement sales nearly quintupled on September 25, 2014.
Make no mistake, Alex Jones sells a lot of supplements. Indeed, at one point on the stand, Jones is shown bragging about how he has the best supplements, the purest supplements, all made in Japan by experts and branded with his company. In fact, I laughed out loud when I saw that he was selling colloidal silver, of all things! There are also shots of him hawking iodine supplements after the Fukushima nuclear power plant disaster in Japan and promoting his DNA Force supplements. Just for yucks, I checked out the InfoWars Store yesterday, and, no surprise, Jones is selling lots and lots of supplements, ranging from Turbo Force Plus (which contains vitamin C, thiamine, green tea extract, and a number of other common supplements) to Brain Force Ultra (which contains a proprietary mix of ingredients including green tea leaves, ginkgo, and other herbs), and, perhaps my favorite, DNA Force Plus, which claims to “boost your body’s cellular engines” and contains CoQ10, rhodiola root extract, and a number of other ingredients. There’s a whole line of supplements under the names InfoWars Life, InfoWars MD, InfoWars Platinum, Emric’s Essentials, Dr. Jones’ Naturals (it’s not clear to me who Dr. Jones is, unless it’s referring to Alex), Summit News, and, of course, a line of cannabis products under the name Rebel Zen CBD. Unsurprisingly, he also sells prepper supplies, books, and videos.
All of this led me to wonder: Without the DSHEA, would there be an Alex Jones? Maybe, but I have my doubts. It is certainly possible that a grifting pathological liar as skillful as Jones is would be able to identify something else to sell as profitable as supplements to support his online media empire, but I doubt it. The attraction to conspiracy theories among those predisposed to purchase colloidal silver, for instance, is strong, and Jones knows that by supplying all manner of conspiracy theories, be they Sandy Hook, antivaccine, COVID-19-related, or about the “failure” of conventional medicine and how quackery works, he will attract such people, some of whom will be predisposed to his sales pitches for his supplements.
Worse, he is not the only—or even first—one to use supplements to become rich promoting conspiracy theories. Mike Adams, whom I sometimes think of a protege turned competitor of Alex Jones’ given his past work for Jones, also sells supplements and prepper supplies. I sometimes think that Adams has surpassed the master as well, in that he has weaponized a mass spectrometer to study his competitors’ products and proclaim them full of heavy metal contaminants, using his results to persuade you to buy his line of supplements. He also uses the same mass spectrometer to fear monger about vaccines by finding trace amounts of mercury in influenza vaccines, for example. Back in the late 1990s, well before Adams and Jones (and when Adams was grifting on the Y2K scare), Joe Mercola started a supplement store to fund his server charges running his website, a business that ballooned over the following two decades to turn him into a quack tycoon, with a net worth now north of $100 million.
Unfortunately, in the age of COVID-19, conspiracists like Adams, Mercola, and Jones now have many who emulate their business model, such as Dr. Peter McCullough and those running The Wellness Company, which promotes COVID-19 conspiracy theories and sells quackery to treat both COVID-19 and “vaccine injury” due to spike protein from the mRNA vaccines. A prime example includes Drs. Pierre Kory and Paul Marik, among the co-founders of the Frontline COVID-19 Critical Care (FLCCC) Alliance, which uses COVID-19 misinformation and conspiracy theories to sell ivermectin and various supplements claiming to prevent or treat COVID-19 or COVID-19 vaccine injury—and now even cancer. (Do you sense a theme yet?) The list goes on and on. Let’s put it this way. Whenever I see a new conspiracy site, I look for the supplement story. It’s usually there, and if it isn’t I can usually count on seeing one before too long, with the only major exception that I’ve found thus far being Robert F. Kennedy, Jr.’s Children’s Health Defense, which sells mainly branded T-shirts, hats, and other clothing. Maybe it’s because he’s running for President.
I’ll conclude by revisiting my question: Did the DSHEA create Alex Jones and the whole infrastructure of conspiracy theories, disinformation, and lies, an ecosystem in which he is still probably the biggest, baddest conspiracy theorist out there? In answering the question, I have to conceded that “create” is likely too strong a word. However, certainly “facilitate” is not. That’s why I feel comfortable concluding that, absent the massive supplement industry fueled by pseudoscience and conspiracy theories, Alex Jones and his ilk almost certainly would have had a much more difficult time funding their activities, much less growing to the behemoths of misinformation that threaten science-based medicine and even democracy itself. In that, the damage from the DSHEA goes beyond just its damage to medicine and the harms that it allows supplement manufacturers to cause its users to encompass damage of the sort to the parents and relatives of those killed at Sandy Hook by the conspiracy theories spread by Alex Jones.

Bills eliminating school immunizations and other anti-vaccination measures confront state legislatures
Bills eliminating school immunizations and expanding exemptions are pending in state legislatures. Other state bills strengthen immunization requirements by eliminating exemptions, among other measures. An anti-vaccination misinformation campaign is underway to influence legislators’ votes.
Jann Bellamy on February 25, 2021
Link

According to the National Conference on State Legislatures, all 50 states mandate that students get certain vaccinations against infectious diseases, many aligning their requirements with the CDC’s Advisory Committee on Immunization Practices (ACIP), and all allow exemptions for medical reasons. Currently, 45 states and Washington D.C. grant religious exemptions, which, because there are constitutional issues with a state’s inquiring into the bona fides of religious exemption claims, have become de facto “philosophical” exemptions. Fifteen states allow “philosophical” exemptions outright.
Each year, there are competing bills introduced in the state legislatures attempting to either constrict or expand school immunization requirements, including exemptions. This year is no exception. As well, public health initiatives aimed at the COVID-19 pandemic, and the appearance of vaccines to abate it, have energized the anti-vaccine and “health freedom” crowd. They’ve managed to woo sympathetic legislators into introducing bills targeting COVID-19 mitigation measures like testing, vaccination, and mask-wearing.
This week we’ll take a look at legislation affecting school vaccination requirements. In my next post, we’ll review COVID-related bills. (There is some overlap.)
First, some housekeeping. Different states have different abbreviations for legislation: House Bill 123 could be H123, HB123 or, in a state that calls one of its chambers the Assembly, A123, and all of these could be with or without a space between the letters and numbers. There’s also LD (Legislative Document) 123, LB (Legislative Bill) 123, and HF (House File) 123, among others. Some states give pre-filed bills one designation and the filed bills another. To simply things (for me), I’m going to use whatever combination of letters and numbers the particular state uses with a link to the legislature’s website, where you can find all the details.
Anti-vaccination legislation
We’ll start in Arizona. While most anti-vaccine legislation tries to put lipstick on the proverbial pig by creating exemptions so broad that they swallow the rule, an Arizona bill dispenses with the cosmetics. HB 2065 makes all school vaccinations merely recommended for attendance, not required. An unvaccinated child could not be excluded from class unless there is an active case of a disease at his or her school and the health department has declared an outbreak in the school’s area.
Oklahoma SB 350 also prohibits public and private schools from requiring any immunizations for minor children attending school. SB 477 would prevent public and private universities and other institutions of higher education from requiring student immunization against meningococcal disease, hepatitis B, measles, mumps, and rubella. Apparently, current law allowing anyone to opt out of the meningococcal disease vaccine for any reason and medical, religious and “moral” opt-outs for hepatitis B and MMR were not sufficiently subservient to “health freedom”.
To ensure that Oklahoma health officials’ hands are completely tied in all situations, higher ed school students cannot be required to undergo any vaccination, use any medical device, or undergo any medical procedure, surgical procedure, or physical examination, all of which I suspect is aimed at the COVID-19 pandemic and future public health emergencies. Not only that, but in a provision that almost certainly violates the First Amendment’s free speech guarantees and is void for vagueness to boot, the bill allows criminal misdemeanor prosecution of any employee of a higher ed institution who coerces or in any way influences a student to get vaccinated.
Likewise, Maine’s LD 156 makes vaccination completely voluntary for students, but only those attending a virtual public school or a private school.
Other state legislators are using the more traditional approach of expanding exemptions, or making them easier to get, including one bill allowing an exemption for any reason, which essentially makes immunization optional. Some bills also narrow the diseases for which vaccination may be required.
The Missouri legislature has several of these bills pending. HB 37 would add a conscientious belief exemption to the existing religious exemption at all levels of education, pre-school to post-high school. HB 566 would go even further, allowing exemptions for any reason. (HB 566 would also require the mother’s consent to inoculation of her newborn with the hepatitis B vaccine and hepatitis B immune globulin (HBIG) per ACIP guidelines when the mother tests positive for hepatitis or her status is unknown. Immunization of newborns under those circumstances are automatic under current law.)
The state would be prevented from enacting any requirement for obtaining a non-medical exemption beyond signing a form, such as watching a video or visiting the health department, and it would be required to develop an informational brochure on obtaining exemptions and make sure it is widely distributed, as well as to make exemption forms easily available.
Missouri HB 37 also freezes the diseases against which vaccination can be required to poliomyelitis, rubella, rubeola, mumps, tetanus, pertussis, diphtheria, and hepatitis B, for elementary and secondary schools, and for day care centers, preschools and nursery schools. (Required vaccinations for the latter group now use the ACIP guidelines.) It limits required immunizations to public schools, day care centers, etc., only, making vaccination requirements for private and parochial schools optional. Higher education students living in on-campus housing would no longer be required to get the meningococcal vaccine unless the housing is publicly owned, thereby eliminating the mandate for private schools and privately-owned housing at public schools. HB 35, introduced by the same sponsor as HB37, prohibits any school, city, or county from requiring additional immunizations.
Finally, failing to vaccinate your child could no longer be considered in neglect and abuse cases in Missouri. To protect the Dr. Bob Sears-type physician, providing medical exemptions, apparently no matter the circumstances, could not be considered by the medical board for any purposes, such as in disciplinary proceedings,
Minnesota already has a “conscientiously held beliefs” exemption to school vaccinations. SF 292 and HF 452 add a “genuinely and sincerely held religious belief” exemption as well, which seems superfluous. Utah HB 233, which passed the House and is now before the Senate, requires medical and “personal or religious belief” exemptions to vaccinations required by universities and other higher ed institutions, except for students “studying in a medical setting”. The bill prohibits all schools from barring any unvaccinated student, at any level of education, from in-person classes, although “nothing restricts a state or local health department from acting . . . to contain the spread of infectious disease.”
Mississippi is one of the few states allowing only medical exemptions to school vaccinations. HB 475, which died in committee, added a religious exemption. South Dakota HB 1097 amends the law allowing an exemption when “the child is an adherent to a religious doctrine whose teachings are opposed to immunization” to refocus the exemption on the parent’s opposition “because of a sincerely held religious or philosophical belief”. Connecticut HB 5578, which has 15 Republican sponsors (almost a third of the Republican House membership), would add moral and philosophical objections to the already-allowed medical and religious exemptions. Indiana HB 1279 creates a religious exemption to required vaccinations for foster home licensure. (It also creates a medical exemption.)
Current law in Massachusetts permits a medical exemption if the physician has personally examined the child and is of the opinion that “the physical condition of the child is such that his health would be endangered by such vaccination or by any of such immunizations”. Massachusetts HD2973 amends that law so that the physician can take into account “concerns regarding an increased risk of adverse events, family history, or exacerbation of pre-existing medical conditions”, whether those are recognized by experts as valid criteria or not.
In what appears to be another attempt to protect the Dr. Sears-type physician, the proposed legislation would prohibit disciplinary action against a physician providing a medical exemption in the “absence of manifest bad faith”, nor could the exemption be used “to change or negatively affect a physician’s rating or standing with any employer, insurer, hospital affiliation or academic affiliation”, thereby making it harder for the medical board and other organizations to discipline a doctor.
In New Jersey, A4659 and S2995 would prohibit any school or government entity from requiring flu vaccinations for anyone age 18 or younger. New York A3250 would prohibit flu vaccine mandates for children (age 6 months – 59 months) in childcare and preschool.
Pro-vaccination bills
In the pro-vaccination column, state bills seek to eliminate, or put restrictions on, exemptions. Others allow minors to consent to vaccination without parental approval. Some bills try to protect children by having their caregivers vaccinated.
Connecticut SB 568 and HB 6423, as well as Vermont H148, would eliminate religious belief exemptions (the only non-medical exemption allowed) to school vaccination. Nebraska currently allows parents to opt out of childhood vaccinations for children in childcare facilities for any reason. LB 447 would limit exemptions to medical reasons.
New Jersey currently permits medical and religious exemptions, but S903 would beef up the requirements. Medical exemptions must be for a specified time period and based on “valid medical reasons” as determined by the Commissioner of Health’s regulations. Those wanting a religious exemption must sign a notarized statement explaining the nature of the religious tenet implicated by the vaccine and how vaccination would violate it, and provide information showing the religious tenet is consistently held. A “general philosophical or moral objection” is not sufficient. The parent (or student, if old enough) must state that he or she “understands the risks and benefits of vaccination” and that the student may be excluded from school in the event of an outbreak.
A969 and S902 similarly strengthen the standards for medical exemptions, requiring that they be consistent with the ACIP guidelines and subjecting exemptions to review by the local board of health. Interestingly, a medical exemption can be granted based on a sibling’s “vaccine injury” but only if there is “a final determination of vaccine injury” by the federal Vaccine Injury Compensation Program or “a court of competent jurisdiction”. Among other strengthened record-keeping requirements, schools are required to post information on their student immunization rates.
Oregon SB 254 would eliminate religious and philosophical exemptions to school vaccination requirements. Only exemptions based on “an indicated medical diagnosis” would be allowed, subject to review by the boards regulating health care practitioners whose scope of practice includes granting these exemptions, this to ensure they are granted “in compliance with a reasonable interpretation of” ACIP recommendations. Unfortunately, because Oregon licenses naturopaths and gives them a broad scope of practice, “naturopathic physicians” are allowed to write exemptions; thus, the state naturopathic board will be reviewing those exemptions. This could mean a different “reasonable interpretation” than the medical or nursing boards, given naturopathic antipathy to vaccination and fabrication of “alternative” schedules. Fortunately, a legislative committee would review the regulatory boards’ work, perhaps shining some disinfecting light on naturopathic vaccination practices, or at least instilling a fear of getting caught.
New Jersey A5144 allows minors 14 years and older to get school-required vaccinations without parental consent. In New York A3192 and S3041 also allow children 14 and older to get immunizations recommended by the ACIP or approved by the state without parental consent, while A822 and S937 allow minors to get any STD vaccine and be treated for STDs without parental consent. Vermont, as well, has a bill pending (H43) permitting minors 16 and older to consent to immunizations recommended by the CDC. Late last year, the District of Columbia passed a regulation allowing minors 11 years and older to consent to ACIP-recommended vaccinations without parental approval. Several members of Congress, which has the power to reject D.C. legislation, are sponsoring a joint resolution to kill it. All bills allowing minors to get immunized without parental approval require informed consent.
New Jersey A1603 requires an HPV vaccination for all students in grades 6-12. Medical exemptions and exemptions for “bona fide religious tenets or practices of the student or the parent or guardian” are allowed, but the bill makes clear that “a general philosophical or moral objection to the vaccination shall not be sufficient”.
In Texas, companion bills HB591 and SB138 add vaccination against bacterial meningitis to required immunizations for public school students. Current exemptions for medical reasons or “reasons of conscience, including a religious belief” would still apply.
New Jersey A4576 and S2907 require all students (day care to post-high school) to get the flu vaccination, with narrowed medical and religious exemptions similar to those in the New Jersey bills cited above. New York S45 mandates the flu vaccine for children in daycare, citing the high rate of infection in this age group and their well-known lack of attention to good hygiene practices. New York A2240 adds vaccination against the flu to the required list for all children in day care and school as well.
Finally, Mississippi’s HB 433, which died in committee, would have required all school employees to have an annual flu vaccination, with only medical exemptions allowed. The State of Washington has something called “outdoor nature-based child care”, teaching a “nature-based curriculum”, in its educational armamentarium. (This sounds both lovely and a bit like an episode of Portlandia.) SB 5151 would require employees and volunteers working in “outdoor nature-based child care” to have an MMR vaccination.
The anti-vaccination forces are already out there opposing bills to increase immunizations and narrow exemptions, as well as promoting those weakening or eliminating vaccination requirements. The Alliance for Natural Health, an organization protecting your right to be bamboozled by fringe practitioners and their nostrums, has set up (via Convio) a system to contact legislators directly regarding every bill mentioned in this post, complete with canned vaccine misinformation talking points about mercury, VAERS, “overloading” the young immune system, the CDC “whistleblower“, and the like. To wit:
Other experts believe the overloading of a young immune system with so many vaccines at once can cause genetic changes.
Anyone who believes this is certainly no “expert”.
To counteract this disinformation campaign and support immunization in states with legislation pending, contact legislators via your state’s legislative website. Pro-vaccine (that is, accurate) information is available here on SBM. The CDC has a list of reliable vaccination sources you can cite as well.

Federal appeals court strikes down conversion therapy bans
A recent federal Court of Appeals decision struck down local governments’ conversion therapy bans on First Amendment grounds, characterizing licensed mental health therapists’ advice as a “viewpoint” and regulation thereof subject to strict scrutiny by the courts, a standard that, historically, is rarely met. This decision carries disturbing implications for the regulation of the practice of medicine as well as the government’s ability to prevent quack medical advice.
Jann Bellamy on December 31, 2020
Link

Local ordinances in two South Florida jurisdictions prohibiting any therapy that has the goal of changing a minor’s sexual orientation or gender identity were struck down by the U.S. Court of Appeals for the Eleventh Circuit on First Amendment grounds. A two-judge majority of the three-judge panel found the ordinances banning what is sometimes referred to as conversion therapy or Sexual Orientation Change Efforts (SOCE) were “content-based regulations of speech that cannot survive strict scrutiny.” [Otto v City of Boca Raton, Florida, 11th U.S. Circuit Court of Appeals, No. 19-10604 (2020)] The defendants/appellees have filed a petition for a rehearing en banc (that is, by the entire panel of 11th Circuit judges), joined by a number of amici curiae (organizations seeking to file a brief in support of the petition) who also supported their original appeal.
According to Forbes, 20 states and dozens of localities have enacted their own bans on conversion therapy and a number of these have been upheld by the courts. Because this decision conflicts with those of other federal Courts of Appeal upholding similar laws, the case may be headed to the U.S. Supreme Court. This could give the Supreme Court an opportunity to clarify the confusion surrounding the degree to which compensated advice from state-regulated professionals like mental health therapists, physicians, and lawyers is protected by the First Amendment.
The ordinances, in Palm Beach County and the city of Boca Raton, Florida, expressly prohibited licensed counselors from treating minors with ‘”any counseling, practice or treatment performed with the goal of changing an individual’s sexual orientation or gender identity” due to the health risk such treatment poses. Two local licensed marriage and family therapists, as the majority in the 11th Circuit opinion describes it, “provide counseling to minors who have unwanted same-sex attraction or gender identity issues” through “talk therapy” which, the therapists claim, “can reduce same-sex behavior and attraction and eliminate what they term confusion over gender identity” although they deny they seek to actually “change” the minor’s sexual orientation.
Arguing that the ordinances infringed on their First Amendment right to speak freely with their clients, the therapists sought to enjoin their enforcement. The district court denied their request and the therapists appealed to the 11th Circuit, which reversed the district court’s ruling.
The licensed therapists who brought suit were being paid to give their professional mental health advice on a matter within their scope of practice. The ordinances were designed to prohibit a particular form of mental health advice – conversion therapy – that the local governments found harmful to children, a conclusion supported by, among others, the American Psychological Association (APA) and the American Academy of Pediatrics.
Yet , instead of seeing this as a matter of professional regulation, the court treated the therapists’ advice as garden-variety speech, a “viewpoint” no different than if you or I expressed a layperson’s opinion on a mental health issue.
The APA issued a strongly-worded rebuke to the decision:
“Sexual orientation change therapy is highly unlikely to change a patient’s sexual orientation and there is real evidence of harm, according to a 2009 study of the peer-reviewed scientific literature conducted by the American Psychological Association,” said APA President Sandra L. Shullman, PhD. “The scientific research since 2009 has greatly increased the evidence that participants in such efforts believe they were harmful. Although these results came mostly from studies of adults, APA shared with the court our concern about the likely harmful effects on minors who cannot legally consent to such procedures. The presumption behind these treatments is that any sexual orientation other than heterosexuality is inherently flawed and must be fixed. Based on the available research, APA rejects the presumption that a gay or lesbian young person must change.” . . .
“The conclusion that talk therapy is merely a viewpoint expression denigrates psychotherapy and ignores the fact that licensed practicing psychologists base their professional activities on scientific evidence,” Shullman said. “This ruling is wrong-headed and may well result in harm to patients, especially minors who are often subjected to this type of therapy against their will.”
In treating spoken professional advice, such as talk therapy, as pure speech, the court creates, in my view, an artificial distinction between two forms of paid professional judgment: if you are paying, say, a physician, to give you his best medical judgment, verbal advice (e.g., “you need to exercise more and eat less”) is treated as speech protected by the First Amendment. If, however, that medical judgment comes in the form of conduct – for example, a diagnostic procedure or surgery – the First Amendment is not implicated because no speech is involved.
Some courts and legal scholars view both of these forms of expression of paid professional advice – one delivered via speech and the other delivered via conduct – as the same thing, treating state regulation of both solely as one of professional regulation that does not implicate First Amendment rights. Other courts make a distinction between professional speech and professional conduct but apply a more lenient standard of review when deciding whether a state restriction of professional speech violates the speaker’s First Amendment rights.
The majority in this case was having none of it. Basically, speech is speech, they say, and any restriction on it must pass the “strict scrutiny” test, the toughest standard of judicial review:
The local governments’ characterization of their ordinances as professional regulations cannot lower that bar. The Supreme Court has consistently rejected attempts to set aside the dangers of content-based speech regulation in professional settings: “As with other kinds of speech, regulating the content of professionals’ speech ‘pose[s] the inherent risk that the Government seeks not to advance a legitimate regulatory goal, but to suppress unpopular ideas or information.'”
The majority opinion is quoting from a recent Supreme Court case, National Institute of Family & Life Advocates v. Becerra (2018) (“NIFLA“) in which the Court struck down a California law that mandated licensed pregnancy crisis centers disclose options relating to pregnancies, such as abortion, when the centers did not provide those services. The state argued that the law was a valid regulation of professional speech. That argument was rejected by the Court, which made clear that, under the First Amendment, there is no differentiation between professional speech and other types of speech. However, the Court agreed that states have the authority to regulate professional conduct through licensing requirements and acknowledged that differentiating between professional speech and professional conduct can be difficult. The lower courts are now struggling in applying NIFLA to similar cases before them.
Decision’s effect on regulating pseudoscience
Whether to treat verbal professional advice and professional conduct the same, or to recognize it as a special category of speech (“professional speech”), or to treat it as any other speech, has enormous consequences for professional regulation. In the first case, the First Amendment is not implicated. In the second, the courts review the government’s restriction on speech to determine if it has a “rational basis” for the law. In the third, the restriction on speech must pass the highest level of court review, strict scrutiny, which means any government content-based restrictions on verbal professional advice are “presumptively unconstitutional” and can be justified “only if the government proves that they are narrowly tailored to serve compelling state interests”, a standard that is rarely met.
A quick word about “content-based speech” in case you’re wondering what that means. Laws regulating content-based speech regulate that speech based on the substance of what it communicates. This is as opposed to content-neutral laws, which apply to expression without regard to its substance. For example, a local ordinance prohibiting outdoor rock concerts between midnight and 6 AM is content-based and would probably violate the First Amendment because other types of concerts are not affected. (Yes, music is a protected form of speech.) A local ordinance prohibiting any outdoor concerts between midnight and 6 AM is content-neutral, and is constitutionally permissible under the First Amendment if the government can show a rational basis for it (e.g., noise control when most people are sleeping).
In this case, the 11th Circuit decided that “because the ordinances depend on what is said, they are content-based restrictions that must receive strict scrutiny”. Based on this, I find it hard to imagine any verbal professional advice that wouldn’t be “content-based” in this court’s view.
Returning to the court’s review of the local governments’ anti-conversion therapy ordinances, we can see how application of the strict scrutiny standard to the regulation of professional advice might hinder government attempts to control pseudoscience and quackery in health care. The court, substituting its own evaluation of the evidence against conversion therapy for that of the local governments and professional organizations, gave short shrift to their determination that the ordinances “safeguard[] the physical and psychological well-being of minors”. The documents put into evidence by the local jurisdictions and their amici curiae were dismissed by the court as “assertions rather than evidence” in part due to the lack of “rigorous research” on the type of SOCE used by the therapists in this case. [As the dissenting opinion correctly points out, it would be unethical to conduct studies, such as randomized controlled trials, that subjected children to SOCE.]
Those amici curiae included, in addition to the American Academy of Pediatrics and the APA, the National Association of Social Workers and the American Association for Marriage and Family Therapy, as well as LGBTQ rights and suicide prevention groups, all of whom urged the court to uphold the ordinances. The court rejected the professional organizations’ opposition to SOCE as “just another way of arguing that majority preference can justify a speech restriction”. Relying on anecdotal evidence to support its conclusions, the court noted that “there are individuals who perceive they have been harmed and others who perceive they have benefitted from nonaversive SOCE”.
Lack of rigorous research, conflict with mainstream medical opinion (which is merely “majority preference” in the court’s view), and anecdotal evidence are all hallmarks of quackery. Will application of this court’s analysis in cases challenging government regulation of quack “medical” advice, no matter how lacking in evidence or how dangerous, hamstring the states’ ability to protect the public? Let’s put it this way: if I were the attorney for the quacks, I would most certainly cite this case.
Even more troubling, in a statement I find startling, the court said
None of this is meant to suggest that the ordinances could necessarily be saved with just one more appropriately scoped, double-blind, peer-reviewed study. Because the ordinances discriminate based on viewpoint, their problems may go beyond insufficient evidence. As we mentioned earlier, viewpoint-based restrictions may be unconstitutional per se. But we need not decide that here [implying they might very well decide this in the future] because the ordinances are plainly unconstitutional under the ordinary test for content-based speech restrictions.
[Remember in reading this that the court considers paid professional advice a “viewpoint”.]
In other words, any content-based regulation of verbal professional advice might be unconstitutional under the First Amendment no matter how much scientific evidence supports it. Let’s parse this via a couple of hypotheticals. Suppose a state law specifically prohibited physicians from giving medical advice that falls below the standard of care. Assuming this advice is spoken or written, according to the above dictum the law would be unconstitutional per se. Or, suppose a state Medical Board disciplined a physician for substandard medical practice that took the form of spoken advice. For example, imagine that the physician told a patient not to see her oncologist anymore for treatment of her cancer, but instead to take dietary supplements, which would cure her. Would this violate the physician’s First Amendment rights as unconstitutional per se, ignoring the obvious lack of evidence and danger to health behind the physicians’ recommendations?
Sadly, the court could have avoided deciding the First Amendment issues altogether by holding that local governments are preempted from regulating the practice of mental health therapists because the State of Florida regulates this profession. (A decision, by the way, I would have agreed with.)
In my opinion, a dispositive Supreme Court decision following the 11th Circuit’s reasoning and treating all professional advice as speech subject to strict scrutiny by the courts would be debilitating to the states’ efforts to regulate professional conduct, and therefore pseudoscience and quackery in health care. (Not that they do such a great job in the first place, but still.) It also creates, as mentioned, a nonsensical distinction between a professional’s judgment executed via verbal advice and one executed via conduct. The Court could decide that such advice is outside the realm of the First Amendment altogether or, at the least, create a special category of “professional speech” (as it has with commercial speech) that is subject to a less strict standard of review.
Unfortunately, either of these results may be foreclosed by the decision in NILFA, although the Court may try to back off that decision when confronted with this little problem (links found in original):
It would be too easy to say that a religious conservative supermajority Supreme Court will, of course, declare that conversion therapy — which is derived from a far-right religious view of homosexuality — has First Amendment protection. The problem for conservatives is that using this reasoning puts into question the conservative policy of government compelling doctors to make religious antichoice speech and desired conduct in cases of abortion. For those who may not be aware, religious conservative legislatures have passed laws compelling doctors to make women undergo unnecessary, emotionally disturbing, and downright humiliating procedures in cases of abortion. It is difficult to square how the government compelling doctors to declare anti-abortion viewpoints does not disturb First Amendment guarantees, yet so-called bans on “conversion therapy” amount to government impermissibly compelling a viewpoint.
[I agree with the author’s description of this conundrum, although I totally disagree with his conclusion that the 11th Circuit’s decision was correct.]
This is not to say, by any means, that I believe all state regulation of professional speech is beyond the reach of the First Amendment. If, for example, as outlined above, a state legislature requires a physician to recite certain information to women before performing an abortion and that information is medically incorrect or unnecessary to good medical practice, it would most certainly implicate physicians’ First Amendment rights and deserve strict scrutiny by the courts. That is because it is not professional advice at all; it is the legislature’s moral judgment masquerading as such.
Happy New Year!

Consumer and public health groups push for cancer warning on alcoholic beverages
A coalition of consumer and public health groups, citing scientific consensus, is pushing for a government-required warning that alcohol consumption causes cancer on alcoholic beverage containers. Despite the evidence, we can expect alcohol industry opposition.
Jann Bellamy on January 28, 2021
Link

A coalition of consumer and public health groups is pushing for a government-required warning that alcohol consumption causes cancer on labels of liquor bottles and other alcoholic beverage containers.
Currently, federal law requires a “health statement” on the label of all alcoholic beverage containers warning that alcohol consumption “may cause health problems” — specifically, that it impairs the ability to drive or operate machinery and, during pregnancy, risks birth defects. That warning has not changed since 1988, when Congress enacted the law mandating the health statement. The law also directs the Alcohol and Tobacco Tax and Trade Bureau (“TTB”, part of the Department of the Treasury), in consultation with the Surgeon General, to “promptly” notify Congress of the need to update the health statement if “available scientific information would justify a change” and to make “specific recommendations” TTB determines “to be appropriate and in the public interest”.
According to the American Public Health Association, the American Society for Clinical Oncology, the Consumer Federation of America, a coalition of breast cancer organizations, and similarly-minded groups, the “available scientific information, accrued over more than three decades, shows that alcohol causes cancer”, yet the TTB has taken no action. Thus, the organizations (eight in all) filed a Citizen Petition (per federal regulations) with the Department of the Treasury requesting that the TTB report this scientific consensus to Congress and recommend that Congress amend the current health disclosure to state:
WARNING: According to the Surgeon General, consumption of alcoholic beverages can cause cancer, including breast and colon cancer.
The petition asks that this warning be put in rotation with the two existing health statements, citing increased consumer awareness of information that is new or different.
In support, the petition summarizes the evidence on the association between alcohol consumption and cancer, the public’s lack of awareness of that association (we’ll look at industry efforts to keep it that way in a moment), and the drinking habits of Americans.
According to the petition, quoting the National Cancer Institute, “there is a strong scientific consensus that alcohol drinking can cause several types of cancer”. American Cancer Society (ACS) researchers estimate that, in 2014, alcohol consumption was associated with an estimated 6.4% of all cancer cases in women (50,110 cases) and 4.8% of all cancers in men (37,410 cases). The largest burden “by far” was for female breast cancer (39,060 cases), per the ACS, which says that in the U.S.,
alcohol consumption represents the third largest contributor to cancer in women (behind smoking and obesity) and the fourth largest contributor to cancer in men (behind smoking, obesity, and UV radiation).
The World Health Organization’s International Agency for Research on Cancer (IARC), in 2012, considered the data on alcohol’s contribution to cancer and concluded that there is sufficient evidence in humans for the carcinogenicity of alcohol consumption causing cancers of the oral cavity, pharynx, larynx, esophagus, colorectum, liver, and female breast. The IARC also concluded that even low levels of consumption (“up to 1 drink/day”) increases the risks of some cancers. The 2016 report, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, agrees, reporting that “[e]ven one drink per day may increase the risk of breast cancer” and “light” drinking (up to one drink per day) is associated with an increased risk of cancer of the oral cavity, pharynx, and esophagus.
To top this off, the petition references research from several other organizations.
    • World Cancer Research Fund and American Institute for Cancer Research: “strong evidence that consuming alcoholic drinks increases the risk of cancers” of the mouth, pharynx, larynx, esophagus, breast, stomach, liver, and colorectum.
    • American Society of Clinical Oncology: “the relationship between drinking alcohol and cancer risk has been evaluated extensively in epidemiologic case-control and cohort studies” and “[e]ven the modest use of alcohol may increase cancer risk.”
    • American Cancer Society: “it is best not to drink alcohol” but those who do choose to drink should limit their consumption to no more than one drink per day for women and two drinks per day for men.
    • National Toxicology Program of the U.S. Department of Health and Human Services: alcohol is a known human carcinogen, a conclusion reached in 2000.
    • 2020 Dietary Guidelines Advisory Committee: Do not drink alcohol “because you think it will make you healthier”; recommends limits of one drink per day for both men and women. [Somewhat controversially, the Trump Administration rejected this recommendation, along with the Committee’s recommendation for further limiting sugar consumption.]
In addition to taking on the notion that moderate drinking does not have adverse health effects, the petition rejected the claim that there is an association between moderate drinking and health benefits, quoting the CDC:
Although past studies have indicated that moderate alcohol consumption has protective human benefits (e.g., reducing risk of heart disease), recent studies show this may not be true. While some studies have found improved health outcomes among moderate drinkers, it’s impossible to conclude whether these improved outcomes are due to moderate alcohol consumption or other differences in behaviors or genetics between people who drink moderately and people who don’t.
Despite this sobering news, according to the petition, while the evidence is limited, it indicates that few consumers are aware of the link between alcohol and cancer. A 2019 American Institute for Cancer Research survey showed that just 45% of adults identify alcohol as a cancer risk. A National Cancer Institute survey, also in 2019, found 32% of respondents identified cancer as a health condition that can result from alcohol consumption.
(Personally, based solely my own experience in over a decade of blogging at SBM, this is a refreshingly high level of knowledge about any health subject, considering the plethora of misinformation and lack of critical thinking that abounds in healthcare. But that’s just me.)
Given the fact that alcohol consumption is a totally preventable risk factor for cancer, based on our current drinking habits, the petition finds much room for improvement in Americans’ health, citing data showing:
    • More than half of the population aged 12 (!) or older reports drinking alcohol within the last 30 days.
    • Excessive drinking, associated with the greatest cancer risk, increased over the last decade.
    • In 2015, 22% of men and 10% of women reported consuming more than 7 drinks per week; 11% of men and 5% of women reported more than 14 drinks per week. (Not to minimize the gravity of these statistics, and maybe I’m just in with the wrong crowd, but I would expect these percentages to be higher.)
    • In 2018, 26.45% of people aged 18 or older reported they engaged in “binge drinking” (5 or more drinks for men, 4 or more for women, on one occasion), and close to 7% engaged in binge drinking on five or more days per month, considered “heavy drinking”.
Big Booze fights back
According to the director of food policy at the Consumer Federation of America, the petition was inspired in part by a Canadian study using an identical warning. That study both produced useful data on increased consumer awareness after warnings appeared and previewed for the petitioners how the alcohol industry will fight such warnings tooth and nail.
In 2017, Canadian researchers planned to place three different types of information labels on tens of thousands of containers of booze sold in the city of Whitehorse, Yukon. One warned of cancer risks; two others had information related to Canada’s low-risk drinking guidelines. The messages were to have been evaluated through analysis of alcohol sales data and surveys of liquor store customers in Whitehorse and in Yellowknife, Northwest Territories, which was used as a control. Unfortunately, and predictably, the alcohol industry successfully intervened and the labelling research was halted by the government a few months in. One industry strategy was to claim this research was unlawful, a claim experts later termed “groundless”, part of a game plan the industry has employed successfully in other jurisdictions.
Unfortunately for the industry, even the truncated study provided useful data: Shoppers in Whitehorse were significantly more likely to know about alcohol’s cancer risk than control groups and total alcohol sales decreased by more than 6%. The industry’s attempts to sabotage the research also produced something of a Streisand effect, garnering unflattering Canadian and international media attention.
In addition to making dubious legal claims, the alcohol industry, in fact, has a long history of misleading the public regarding connections between health and drinking, according to a 2017 Mother Jones exposé. Seemingly taking a page from the tobacco playbook, the industry has emphasized the (debunked) health benefits of alcohol (especially wine), sponsored popular sporting events like the Super Bowl and NASCAR, funded studies casting alcohol in a favorable light and doubt on unfavorable research, wined and dined researchers, contributed to political campaigns of sympathetic legislators, and participated in the revolving door between government regulators and industry employment.
A 2017 study examining alcohol industry communications with the public opined that the industry “appears to be engaged in the extensive misrepresentation of evidence about the alcohol-related risk of cancer”.
Three main industry strategies were identified: (i) denial/omission: denying, omitting or disputing the evidence that alcohol consumption increases cancer risk; (ii) distortion: mentioning cancer, but misrepresenting the risk; and (iii) distraction: focusing discussion away from the independent effects of alcohol on common cancers. Breast cancer and colorectal cancer appeared to be a particular focus for this misrepresentation.
Another study documented “pinkwashing”: alcohol products promoted with pink ribbons, partnerships with breast cancer charities, and general terms such as “breast cancer research” or “cure”.
Australian researchers examining alcohol industry trade publications found three “primary themes” evident in the articles reviewed indicating a denial of the risks associated with drinking by the industry: (1) the legitimization of alcohol as an important social and economic product, (2) the portrayal of the industry as trustworthy and benign, and (3) the strategic embedding of alcohol in various facets of everyday life.
This led the researchers to conclude that:
additional regulation of the industry and its tactics will need to proceed without industry acceptance. Clear resistance to increasing consumer protections also points to the futility of inviting industry members to the policy table.
The risks of alcohol consumption are probably not high on the new administration’s health issues “to do” list, and understandably so. Perhaps when things return to normal, if that happens and whatever “normal” may look like then, this effort might gain traction, especially considering the heavy hitters among the petitioners. On the other hand, I’d not bet against the alcohol industry drowning this one before it even reaches the Capitol.

Anti-Smoking Laws – The Proof of the Pudding
Steven Novella on March 7, 2012
Link
One consistent theme of SBM is that the application of science to medicine is not easy. We are often dealing with a complex set of conflicting information about a complex system that is difficult to predict. That is precisely why we need to take a thorough and rigorous approach to information in order to make reliable decisions.
The same is true when applied to an individual patient. Often times we cannot make a single confident diagnosis based upon objective information. We have to be content with a diagnosis that is based partly on probability or on ruling out other possibilities. Sometimes we rely upon a so-called “therapeutic trial” to help confirm a diagnosis. If, for example, it is my clinical impression that a patient is probably having seizures, but I have no objective information to verify that (EEG and MRI scans are normal, which is often the case) I can help confirm the diagnosis by giving the patient an anti-seizure medication to see if that makes the episodes stop, or at least become less frequent. Placebo effects make therapeutic trials problematic, but if you have an objective outcome measure and a fairly dramatic response to treatment, that at least raises your confidence in the diagnosis.
We can apply the same basic principle on the population level. If a public health intervention is addressing the actual cause of one or more diseases, then we should see some objective markers of disease frequency or severity decrease over time. Putting fluoride in the public water supply decreased the incidence of tooth decay. Adding iodine to salt decreased the incidence of goiter. Fortifying milk with vitamin D decreased the incidence of rickets. However, removing thimerosal from the childhood vaccine schedule did not reduce the incidence of autism (or the rate of increase in autism diagnosis). That is because calcium deficiency causes rickets, but thimerosal (or the mercury it contains) does not cause autism.
In public health there is also the equivalent of placebo effects – confounding factors in epidemiological studies. So studies need to be interpreted with caution. But if we see a consistent signal – a consistent association between a treatment and a decrease in disease incidence or severity, then our conclusion becomes more and more confident.
We are beginning to see this consistent signal with anti-smoking laws and a decrease in diseases that previous evidence suggests is increased by smoking or exposure to second-hand smoke. A recent study published in PLOS Medicine looked at the incidence of preterm birth and low birth weight in Scotland following legislation that came into effect on March 26, 2006 banning smoking in public places. Prior to the legislation preterm and low birth weight were trending up. The study found a statistically significant drop of about 10% beginning January 1, 2006, with a slight reversal two years later. They interpret these results as an anticipatory effect – smokers trying to quit in anticipation of the legislation, with some smokers failing and going back to smoking over the next two years. This conclusion is supported by the spike in nicotine patch prescriptions in January of 2006.
Further, the reduction in preterm birth and low birth weight was found among current smokers as well as never smokers. The decrease among never smokers suggests a second-hand smoke effect.
Epidemiological studies are always difficult to interpret, as I stated above, and this study is no exception. The strength of this study is that it was very thorough, looking at all pregnancies in Scotland over the study period. But there are many confounding factors, one of which pointed out by the researchers is the fact that smoking status was self-reported, and the introduction of legislation may have affected willingness to self-report smoking. Since all pregnancies were looked at, however, this would not have affected the overall decrease in these outcomes reported.
The significance of this one study is enhanced by the fact that it is part of a trend in studies showing a decrease in diseases that prior evidence suggests are worsened by smoking, following smoking bans. A study of acute myocardial infarction (AMI) in Massachusetts found a decrease of 7.4% following a statewide ban on smoking in public places. It is also significant that the decrease occurred in towns that did not have a prior local smoking ban, but not in towns that did. The effect was therefore also likely attenuated by the prior existence of local smoking bans.
A 2009 review and meta-analysis concluded:
Using 11 reports from 10 study locations, AMI risk decreased by 17% overall (IRR: 0.83, 95% CI: 0.75 to 0.92), with the greatest effect among younger individuals and nonsmokers. The IRR incrementally decreased 26% for each year of observation after ban implementation.
Using the same Scotland cohort following the 2006 ban, a study has also found a decrease in hospital admissions for asthma:
After implementation of the legislation, there was a mean reduction in the rate of admissions of 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7 to 21.8; P<0.001). The reduction was apparent among both preschool and school-age children.
Overall the data show that smoking bans reduce second hand smoke exposure, smoking, and adverse health outcomes associated with smoking. There is a fair degree of consistency in the data, and this consistency is growing as more studies are being published. We have appeared to cross the fuzzy threshold where we can conclude with a fair degree of confidence that banning smoking in public places works. In the interest of public health, reducing health care costs, and child safety, the totality of evidence strongly suggests that we should strengthen bans on smoking in public places and apply them universally.
Meanwhile, concerns that such bans would economically harm bar and restaurant owners have not been born out in the evidence. A Minnesota study, for example, found a slight increase in revenue following smoking ban laws. It seems more people are willing to go to bars if the experience does not necessarily involve being exposed to intense levels of second-hand smoke.
Smoking ban laws have passed the test of the “therapeutic trial”. Combined with the totality of evidence for the risks of smoking and second-hand smoke, this strongly supports such bans as effective public health measures.

Supplements are the Wild West of health. One Attorney General is out to change that.
Scott Gavura on April 9, 2015
Link

Bold moves from the New York State attorney general’s (AG) office are shaking up the supplement industry. In February, the AG accused four retailers (GNC, Target, Walmart, and Walgreens) of selling supplements that failed to contain their labelled ingredients. Using a testing method called “DNA barcoding“, the AG’s office concluded that few of the products it tested actually contained the labelled ingredient, and some contained undisclosed ingredients. It demanded that they stop the sale of those products. All four retailers complied.
When the recall occurred, I noted that the AG may not have had an airtight case: manufacturers and other critics challenged the AG’s methodology, claiming that DNA barcoding was unvalidated, inappropriate, and insufficient. They also stated that the DNA may not survive processing, so the absence of DNA didn’t imply a lack of the original product. Some claimed that the “contaminants” that AG found could have been acceptable fillers. The Attorney General refused to release further information about the testing methods it used, raising further questions about its validity.
Before describing what happened next, it’s important to understand how we got here. While the US Food and Drug Administration (FDA) is respected worldwide for ensuring the quality of the pharmaceuticals it regulates, the same cannot be said for its regulation of supplements. Today, the overall quality of supplements sold in the United States is unclear. Audits and recalls suggest that there is a small but persistent trend of poor manufacturing standards. Adulteration, virtually unheard of with drug products, seems to be a regular complaint with supplements. This shouldn’t surprise, as it’s likely a consequence of legislation deliberately designed to weaken the FDA from regulating and providing oversight of supplements. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from many of the requirements that are in place for prescription and over-the-counter drugs. Amazingly, it puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. A weak regulatory framework, which doesn’t require pre-sale testing of product quality and finished product specifications, might be expected to result in a weaker commitment to quality. And that might result in more erratic product quality. And that’s exactly what we find when you look at supplement sales today.
There’s an additional twist with herbal remedies, which gets to the criticism of the AG’s analysis and claims. This problem isn’t exclusive to the FDA, but is a challenge to manufacturers and regulators alike. With a herb, what should we be testing for? With a pharmaceutical product, there’s an active ingredient that is manufactured into a tablet or capsule to be predictably and consistently absorbed. We can easily measure the tablet’s contents by assay, or measure how completely it is absorbed by drawing blood levels after ingestion. The same cannot be said for herbal remedies, which are essentially unpurified, unstandardized, drugs. A single plant species may have dozens, or even hundreds of biologically-active compounds. The relative proportions of all of these ingredients may vary based on growth, harvesting, and storage conditions. Now add in the fact that there’s little evidence to demonstrate that herbal products have any meaningful, beneficial effects. If there was a positive effect, we could try to determine what ingredient (or ingredients) were the cause. With that in mind, we could test for it in supplements for sale. But because there’s a lack of evidence to establish that herbal remedies have any useful effects, we don’t even know what we should test for. Without knowing if there is an “active” chemical component, we can’t test for it. So the AG’s test of DNA barcoding represented a minimum testing standard of sorts. It was simply a test to see if the labelled herb was in the tablet or capsule. And the testing showed that even that basic assumption about herbal quality may have been premature.
Supplement vendors, industry backers, and even some industry critics were quick to point out that DNA barcoding wouldn’t detect any herb present if the herb had been processed so extensively that DNA traces had been destroyed or removed. This could be expected with herbal extracts, which are not raw herbs but rather the result of combining a herb with a solvent, in a process where some components of the herb are removed or “extracted”. The process of extraction brings with it a huge number of variables that can affect the finished product’s chemical composition.
Rather than responding to criticisms about the herbal testing the AG conducted, the AG decided to double down. In mid-February, it issued subpoenas to GNC, Walgreens, Target and Walmart, demanding that they substantiate their “structure/function claims” for their supplements. Manufacturers of supplements cannot claim that their product can prevent or treat a disease. But they are allowed to make claims that describe how their product can benefit the structure of the body, or some aspect of how it functions. A structure/function claim might be “calcium builds strong bones,” or “antioxidants maintain cell integrity” which tell you nothing about the effectiveness of the product in question. Structure-function claims don’t give consumers adequate information to determine if supplements are useful or effective, but they do allow manufacturer to imply efficacy without the requirement to provide any proof. The FDA notes:
These three types of claims are not pre-approved by FDA, but the manufacturer must have substantiation that the claim is truthful and not misleading and must submit a notification with the text of the claim to FDA no later than 30 days after marketing the dietary supplement with the claim. If a dietary supplement label includes such a claim, it must state in a “disclaimer” that FDA has not evaluated the claim. The disclaimer must also state that the dietary supplement product is not intended to “diagnose, treat, cure or prevent any disease,” because only a drug can legally make such a claim.
The disclaimer is the infamous Quack Miranda warning that in a few sentences tells you that what you’re holding is a product that hasn’t been tested or evaluated for effectiveness by the FDA.
The AG didn’t stop there, either. It subsequently demanded that four supplement manufacturers, Nature’s Way, NBTY (Sundown Naturals, Nature’s Bounty, Met-Rx, Solgar, Vitamin World and other brands), Nutraceutical Corp (Herbs for Kids brand), and Pharmavite (Nature Made brand), provide detailed information on their manufacturing and quality control practices. The AG noted:
The scientific community, public health officials, and others have raised serious doubt about the steps taken to ensure the safety and efficacy of the herbal dietary supplements taken daily by millions of Americans. As part of a broader investigation, NYAG is reviewing the sufficiency of the measures manufacturers and retailers are taking to independently assess the validity of their representations and advertising in connection with the sale of herbal supplements. We seek your company’s cooperation as an herbal dietary supplement manufacturer to address these issues and, ultimately, to resolve any deficiencies.
As you may know, NYAG recently commissioned an analysis that used DNA barcoding technology to test several popular herbal dietary supplements sold at four retailers in New York State. The results were shocking to many consumers and raise troubling legal questions. In addition to the frequent absence of genetic material associated with the plant depicted on the label from the tested supplements, more than one in three samples tested positive for the DNA of an unlisted plant species, potentially constituting a contaminated or substituted product. The contamination, substitution, or false labeling of herbal products would constitute a deceptive business practice and, even more troublingly, could expose consumers to unacceptable health risks. Of particular concern, companies selling herbal products may have inadequate proof that the substances come from the plant species they claim, not be able to easily identify the source of the ingredients, or have failed to put proper controls in place or conduct proper testing or measurement to prevent contamination.
The decision by the AG to go directly after manufacturers has brought considerable criticism from the supplement industry, with most of the criticism being centred on the fact that regulation of supplements was felt to be a matter for the FDA, and not for local (state) action. In other words, they prefer the FDA’s light touch. The president of the United Natural Products Alliance complained:
This is a massive fishing expedition and highly disruptive to these companies’ daily operations that are all part of the clearly defined federal regulatory structure for dietary supplements. We continue to be mystified as to why the NY AG has chosen to do FDA’s job. We regret to see this misplaced use of the AG’s time, taxpayer money and red tape for reputable supplement companies that are simply trying to do the right thing.
Perhaps not unexpectedly, one of the supplement’s industry’s biggest supporters has weighed in as well. Senator Orin Hatch and Senator Martin Heinrich have written a letter [PDF] to the FDA Commissioner, asking the FDA to comment on the AG’s methodology and the appropriateness of the AG’s demands. They note:
Attorney General Schneiderman has refused to make the test results and the details of the study methodology public, and questions about the appropriateness of DNA testing for herbal extracts have been raised that merit consideration. The question at the heart of this matter is whether DNA barcoding methodology is fit for the purpose of identifying DNA in botanical extracts found in dietary supplements. It is our understanding that the process of extracting an herb’s phytochemicals for use in finished products can either damage, destroy or simply leave behind the DNA this testing protocol is designed to find, which has left many scientists – both inside and outside the industry – to question whether DNA barcoding technology is an appropriate or validated method for determining the presence of herbal ingredients in finished botanical products.
Hatch and Heinrich’s letter raises questions in four areas:
     1.  Does the FDA require testing of incoming material as well as tests of finished product quality?
     2.  Does the FDA recognize DNA barcoding for the identification of botanical materials in finished extract dietary supplements? Without additional testing, is this satisfactory?
     3.  Does the FDA recommend DNA barcoding for herbal extracts? Is the current technology adequate to permit use?
     4.  Do federal laws and regulations require food labeling (including dietary supplements) to identify all ingredients? Are trace amounts of materials allowed without labelling? Can plant materials be used as excipients if they are labelled?
The AG’s prosecution has already had an effect that’s disrupting and angering the industry. GNC and the AG have already reached an agreement to put GNC’s products back on the shelves in New York stores. While noting that the products that were pulled do in fact meet FDA requirement for sale, GNC has agreed to implement additional testing of their products that go beyond FDA requirements and will be implemented nation-wide. As per the AG:
Under today’s agreement, GNC will perform DNA barcoding on the “active” plant ingredients used in its products; implement testing for contamination with allergens, both before and after production; and post prominent signage advising consumers of the processed, chemical nature of extracts. GNC will be required to implement these new procedures in all of its more than 6,000 stores nationwide, making this agreement the first in the nation to require testing standards for herbal supplements that exceed current FDA requirements.
The supplement industry seems to have mixed feelings. While this deal may have been necessary for GNC to allow its sales to resume, it raises the expectations of quality for all manufacturers, a move that is being likened to California’s move to tighten crash standards and emissions standards for vehicles. Moreover, it seems to reinforce what the AG’s message has been all along – that supplement product quality is dubious, and the AG is getting results. One industry magazine noted:
The agreement also serves to make the case in the mainstream media and the world of social media that Schneiderman was right: The marketers of dietary supplements and the companies that make the products don’t have their customers’ best interests at heart and can’t be trusted to mind their own store.
“The extensive media coverage of the NY AG’s actions has caused a profound shift in consumer attitudes, far beyond anything I’ve observed before. I’ve closely monitored reader comments to negative media coverage for years, and what I am seeing now indicates an overwhelming loss of confidence in all dietary supplements, not just herbs. Comments in the past could be summed up as ‘I don’t believe this article: I’m healthier and feel better when I take my supplements.’ Now I’m seeing, ‘Those people should be in jail, those products are useless / dangerous so I will never buy them again.’ ” Shelton said.
The story doesn’t stop there. Now the AG has teamed up with 13 other state AGs asking Congress to launch an inquiry into the herbal supplements industry. The letter notes:
The current investigation in New York and subsequent interest by other states, and the outstanding request to FDA, represent only the most recent indication of serious problems in the herbal supplements industry. The scientific community and the media have issued a series of troubling reports that suggest broader problems. Researchers, for example, measured high levels of heavy metals like lead, mercury, and arsenic in certain supplements. Products falsely identified as black cohosh—an herb commonly taken to reduce menopause symptoms—may have caused severe liver damage in certain women. And media reports have uncovered over-the-counter supplements, including those purporting to build muscle, aid weight loss, and reduce anxiety, that were secretly laced with dangerous prescription medications.
Additionally, if the producers of herbal supplements fail to identify all the ingredients on a product’s label, a consumer with food allergies, or who is taking medication for an unrelated illness, is taking a potentially serious health risk every time a contaminated herbal supplement is ingested.
The FDA has long been aware of problems in the dietary and herbal supplement supply chain, from dubious ingredient sourcing to a failure to carry out proper testing on finished products. In FY 2013, FDA inspectors cited two out of every three supplement manufacturers for allegedly violating current good manufacturing practices or “cGMPs.” More than one in five of those citations—called Form 483s—observed that the manufacturer failed to verify that a finished supplements batch met product specifications as to identity, purity, strength, or composition. A similar proportion was cited for failing to employ an appropriate test or examination to verify the identity of a dietary ingredient before incorporating it in the final product.
Specifically they want Congress, with the FDA, to address the following:
    • The adequacy and effectiveness of existing quality assurance measures for verifying the source, identity, purity, potency, and quality of ingredients and fillers;
    • The adequacy and effectiveness of existing regimes for verifying the identity, composition, purity, potency, and quality of the finished products sold by domestic manufacturers and retailers;
    • The degree to which product labels and marketing, including the use of the terms ‘natural,’ ‘herbal,’ and ‘extract,’ mislead consumers about the contents of herbal and dietary supplements, and whether the FDA should develop standards and restrictions governing their use;
    • The extent to which Congress should mandate, or direct the FDA to develop enhanced, uniform, industry-wide quality assurance and verification regimes to guarantee the source, identity, purity, and potency of materials incorporated into herbal and dietary supplements; and,
    • The extent to which Congress should mandate, or direct the FDA to develop, enhanced manufacturing and supply chain management requirements for the industry to guarantee the safety and efficacy of the finished herbal and dietary supplements.
Conclusion
It’s good to see the New York AG recognizing the serious concerns that have been identified with the supplement industry in the United States. However, for its actions to be truly effective, it needs to build a careful case. In the interests of transparency, the AG should be releasing the results of its own testing – just as it is asking manufacturers to do. And it needs to address the criticisms of its testing methods. On balance, however, these moves should be seen as beneficial to consumers, particularly if the FDA’s role is re-evaluated. Until consumers and health professionals alike have confidence that supplements are of uniform and consistent quality, it’s not possible to use them safely, or to expect that they will deliver any predictable effects. The marketplace has been overly friendly to manufacturers for years. Now it seems the tide has a chance of turning, with the focus on consumer protection. If we want to avoid playing health roulette when we shop the supplement aisle, we should strongly support efforts to strengthen the quality and safety of herbal supplements.

The post I think most about is FDA commish; there, my view is that any consulting for pharma/ device co should be disqualifying
In an interview last May, Dr. Marty Makary expressed reasonable concerns about people who left the FDA to work for industry. While noting that we live in a “free country”, Dr. Makary also worried about former FDA employees having “undue influence”. “When it comes to their influence on the operations of the FDA, that is something we cannot tolerate,” he said.
In another interview, Dr. Makary said that previous FDA commissioners, who doubted the still unproven claim the COVID vaccine killed 10 children, were “paid by big pharma” and therefore unreliable. Dr. Makary reported at a MAHA summit that in contrast to these unethical doctors, he has “taken a voluntary pledge never to work for Big Pharma for the rest of my life.” Good for him.
Dr. Makary’s right-hand man at the FDA, Dr. Vinay Prasad, has long expressed similar thoughts, writing:
    • “I am, like most Americans, sick of revolving doors & tweeps may know I have published on this topic You can’t take 400k from airbnb and 400k from carnival cruises and then shape policy that impacts their profits.”
    • “The post I think most about is FDA commish; there, my view is that any consulting for pharma/ device co should be disqualifying, but most don’t agree with me, I concede.”
    • “This is Bob Califf, current FDA commish. When not in office, he stuffs his pockets with pharma cash & takes roles in biotech that interface with FDA. When in office, he approves ineffective, costly drugs & lies about antivirals like Paxlovid. The current system is corrupt.”
Those are harsh words, but these concerns are not misplaced, and every reasonable person supports a wall between pharma and FDA regulators. There is ample evidence that pharma money influences doctors, even though most of them incorrectly feel that they are immune to such forces. A wise mentor advised me to avoid pharma long ago, and despite receiving many tempting offers, I have made $788 from pharma since 2018, all but $150 in the form of office lunches I am too weak to resist. I think it is great that this data is freely available to anyone.
Makary is a director on the board at Harrow, an ophthalmic pharmaceuticals company
However, as SBM readers know, our current medical establishment has one set of standards for themselves and an entirely different, higher set of standards for everyone else. Dr. Prasad’s concern about a doctor who stuffs his pockets with pharma cash & takes roles in biotech that interface with FDA vanished immediately upon assuming office. He no longer feels that any consulting for pharma/device co should be disqualifying for the FDA commissioner.
Similarly, Dr. Makary’s concern about the revolving door was entirely unidirectional. He expressed no concern about people leaving industry for the FDA, even though this path has greater potential for malfeasance. In fact, Dr. Makary has facilitated such journeys. He appointed Dr. George Tidmarsh to head CDER, for example, boasting in the announcement that “Dr. Tidmarsh has led the successful clinical development of seven FDA-approved drugs and served as founder and CEO of multiple biopharmaceutical companies”. Dr. Tidmarsh’s brief tenure ended in disaster precisely because of this history- he allegedly abused his powers at the FDA to enact revenge on a former business partner.
Dr. Makary also conveniently never mentions his own pharma ties. According to one news report from 2024:
Makary is a director on the board at Harrow, an ophthalmic pharmaceuticals company, and an adviser to Sidecar Health, an insurance provider that aims to lower customer costs by eliminating provider networks and drug formularies. He’s also chief medical adviser to Nava, a benefits brokerage, and chief medical officer at Sesame, a cash-pay health service market that offers compounded semaglutide.
Despite being a pancreatic surgeon with no expertise in ophthalmic products, Dr. Makary earned a pretty penny from Harrow Health, garnering $130,357 in the two years prior to becoming FDA commissioner. That’s triple the amount Dr. Robert Califf received, which prompted Dr. Prasad to say he “stuffs his pockets with pharma cash” and the “current system is corrupt.”
Aldeyra Dry Eye Disease Candidate Hit by FDA Delay
I discussed Dr. Makary’s conflicts of interest when he was nominated in my article Questions for Senators to Ask Drs. Marty Makary and Jay Bhattacharya. That first question in that article asked, “why should the American people believe you’ll represent their interests over these corporations?” That remains a fair question, especially for anyone working for an openly corrupt President in an administration where blatant conflicts of interests are the norm. Indeed, now that Dr. Makary is FDA commissioner, regulatory standards are falling, leaders like Dr. Prasad have private meetings with investors, and the headlines read On Eve of JPM, Everything’s Coming Up Big Pharma. That article said:
From the corporate jets of Teterboro Airport to the crowded halls of the J.P. Morgan Healthcare Conference, it’s a good time to be a pharmaceutical executive.
After months of fear, anxiety, and frantic negotiation, the men and women who run the world’s largest drugmakers are striding into 2026 newly unencumbered as they descend on San Francisco next week for JPM, as it’s known. President Trump, who began his second term with sharp words and escalating demands for the industry to lower its prices, has become a vocal supporter. And thanks to a series of White House photo-ops, presidential handshakes, and agreements with drugmakers, the risk of destabilizing tariffs and painful pricing policies appears to be off the table, giving Big Pharma its warmest investor reception since the height of the Covid-19 pandemic.
Meanwhile, Dr. Makary is doing promotional infomercials at industry events for untested AI wellness devices.
Give all this, I couldn’t help but notice that other ophthalmic pharmaceutical companies are having trouble with the FDA today. According to the article US FDA Declines to Approve Outlook’s Eye Disease Drug for Second Time in 2025:
Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing another blow in the company’s prolonged push to bring the treatment to market and sending its shares tumbling nearly 70% after the bell…
The U.S. Food and Drug Administration had initially declined to approve the drug, also called bevacizumab, in 2023, in part due to manufacturing issues observed during pre-approval inspections.
It again declined to approve the drug in August 2025, citing a lack of substantial evidence of effectiveness, and recommended the company submit additional data to support the application.
Outlook said on Wednesday the FDA concluded that additional data provided with the resubmission did not change its prior view, and it again recommended confirmatory evidence of efficacy to support approval.
The FDA has not indicated what type of confirmatory evidence would be acceptable for Lytenava, which is approved in the European Union and the UK, the company said.
According to the article Aldeyra Dry Eye Disease Candidate Hit by FDA Delay Amid Shifting Agency Guidance:
The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially enter the market.
At a Dec. 12 meeting, the agency requested Aldeyra submit a report for a failed trial that the regulator had previously told the company not to include in reproxalap’s new drug application, Aldeyra CEO Todd Brady, M.D., Ph.D., explained during a Dec. 16 conference call…
The Office of Specialty Medicine (OSM) oversees the Division of Ophthalmology, and Brady said that Aldeyra has had no interaction with OSM or any other part of the FDA aside from the ophthalmology office. The request to submit a report on the failed trial to the NDA, which triggered the PDUFA delay, was made by the OSM, he explained.
Extensive layoffs and leadership flux at the FDA this year has prompted fears of disrupted drug reviews and the loss of American biotech leadership. Brady said Aldeyra has seen no turnover in the ophthalmology staff that they interact with. The only major change, he noted, is that the former director of OSM retired over the summer, with a new director taking over.
It was not immediately clear who the current director of OSM is—an FDA webpage last updated in 2020 lists Charles Ganley, M.D., as acting director. At the time of publication, the FDA had not answered questions from Fierce about leadership at OSM.
It’s likely there are reasonable explanations for all this, or that it is indicative of the broader dysfunction and chaos at the FDA. But it’s also possible the FDA commissioner is exerting “undue influence” to help his former benefactor and target their competitors. It’s not my fault for wondering about this. It’s Dr. Makary’s fault for excoriating doctors who get paid by big pharma with one hand, while getting paid by big pharma with the other.



FTCw

Supreme Court rules that FTC cannot seek restitution on behalf of consumers
The U.S. Supreme Court recently ruled that the FTC lacks the authority to seek consumer refunds and other monetary relief from scammers. Without a fix from Congress, the ability of the FTC, and perhaps other agencies, to redress financial injuries caused by quacks and other frauds is greatly diminished.
Jann Bellamy on May 20, 2021
Tweet

In a unanimous decision, the U.S. Supreme Court ruled in April that the Federal Trade Commission (FTC) lacks authority to seek restitution on behalf of consumers and other monetary relief from scammers. Although the Court may be correct purely as a matter of statutory interpretation, unfortunately the decision robs the FTC of one of its most effective tools in redressing consumer fraud.
Today we’ll look at the Court’s opinion and see how it will affect a pending case of the type we’ve addressed many times here on SBM: fake cures for serious diseases. We’ll also look at a legislative fix now before Congress, as well as how the decision might impact the FDA and other federal agencies seeking consumer redress.
A loan shark finds relief
For forty years, the FTC relied on Section 13(b) of the Federal Trade Commission Act (FTC Act) to secure billions of dollars in relief for consumers in cases involving anticompetitive pharmaceutical practices, bogus medical treatments, telemarketing fraud, and data security and privacy scams, among others. Successful cases include Volkswagen’s diesel emission-cheating scandal and Herbalife’s pyramid scheme.
Section 13(b) authorizes the FTC to sue scammers in federal court for violations of the FTC Act, which prohibits, among other things, unfair or deceptive business practices, such as false advertising. It specifically authorizes a court to issue an injunction against scammers’ unlawful practices. For many years, some federal courts interpreted this broadly to mean that courts could award a full range of what are known as “equitable remedies”, including restitution of consumers’ money and disgorgement of ill-gained profits, even though those remedies are not specifically mentioned.
In testimony before Congress, the FTC Commissioners (who head the agency) described Section 13(b) as “a critical tool in support of our enforcement missions” and “the agency’s primary and most effective way of returning money to consumers that was unlawfully taken from them”. There are other provisions of the law giving the FTC the power to seek monetary damages but they are far more cumbersome and it can take years to see results.
One particularly unsavory scammer is loan shark Scott Tucker who, according to a consumer advocacy organization,
made billions exploiting economically disadvantaged consumers by making small, short-term, high-interest, unsecured loans to them, referred to as payday loans, through the internet. Tucker’s lending company, AMG Capital Management, routinely charged interest rates of 600 percent and from at least 2008 to 2012, Tucker’s company collected more than $1 billion in deceptive finance charges from consumers who could ill afford to be scammed.
Tucker was convicted on 14 counts of racketeering, conspiracy, fraud, and making false statements in legally-required disclosures and sentenced to more than 16 years in prison by a judge who described his crimes as “a scheme to extract money from people in desperate circumstances” that “created heartbreak and sorrow … not just a financial loss”. He was also ordered to forfeit the proceeds of his crimes, although whether any of that will ultimately make it into the pockets of his victims is not clear.
In addition to the criminal case, Tucker and AMG Capital were sued by the FTC. This resulted in a permanent injunction and an order to pay consumers $1.27 billion in restitution. Tucker appealed the monetary award all the way to the U.S. Supreme Court, essentially arguing that, while Section 13(b) permits the court to enjoin him from being a loan shark, it can’t make him pay his victims back.
He won. In AMG Capital Management v. FTC, the Court agreed that Section 13(b) “as currently written does not grant the Commission authority to obtain equitable monetary relief” on behalf of consumers, adding that, if the FTC wanted the authority to seek additional remedial relief for the scammed, it needed to ask Congress to amend the law.
Whatever Congress decides to do, in the meantime, the FTC’s authority to get consumers their money back remains hobbled. Take, for example, the FTC’s suit against Golden Sunrise Nutraceutical, its CEO, and Stephen Weis, M.D., its Medical Director, now pending in a U.S. District Court in California. The complaint alleges that defendants have promoted and sold dietary supplements through “plans of care” ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson’s disease, Alzheimer’s disease, ALS, schizophrenia, and other serious conditions. Their products carry names like Kemo-Herb, AnterFerron, and ImunStem, obviously crafted to imply equivalency to FDA-approved pharmaceuticals.
In “sciency” gobbledygook that will sound familiar to regular SBM readers, the defendants advertise their supplements as “creating gene rejuvenation” and “improv[ing] Telomeres for cellular rejuvenation which increases overall-health to the body and can increase human longevity”. They falsely claim, for instance, that their “Emergency D-Virus treatment plan” is FDA-approved under a Regenerative Medicine Advance Therapy designation that “acknowledges not only the effectiveness of these herbs, usually only associated with pharmaceutical drugs, but also [that they] caus[e] no side effects, a quality of dietary supplements”. Dr. Meis “strongly recommend[s]” this “treatment plan” as “uniquely qualified to treat and modify the course of the virus epidemic”.
According to the complaint, in another familiar quack sales tactic, two testimonials for Golden Sunrise Nutraceutical products feature a now-deceased NFL player diagnosed with cancer who “claims that Defendants’ Cancer treatment plan is superior to chemotherapy as a cancer treatment”. A testimonial says he experienced “Amazing Results with ImunStem & Aktiffvate for Cancer” and that, after just 3 days, “I don’t feel the tumor anymore”. “We’ve cured cancer”, he claims.
There’s more ruthless exploitation of desperately sick people for profit alleged in the complaint, but we’ll move on to the complaint’s request that the court enter an injunction to prevent current and future violations of the FTC Act by defendants, and
Award such relief as the Court finds necessary to redress injury to consumers resulting from Defendants’ violations of the FTC Act, including but not limited to, rescission or reformation of contracts [allowing consumers, for example, to get out of any obligation to pay defendants for their worthless treatments], restitution, the refund of monies paid, and the disgorgement of ill-gotten monies . . .
The FTC was successful in getting the court to issue a Temporary Restraining Order against defendants. Subsequently, the defendants themselves agreed to a preliminary injunction which, among other provisions, prevents them from claiming that their products prevent, treat, or cure any disease unless they have competent and reliable scientific evidence to support their claims. (Prediction: not going to happen.) Thus, it looks like the FTC has an excellent chance of getting a permanent injunction and, hopefully, putting the defendants out of business for good.
Unfortunately, the Supreme Court’s decision in AMG Capital forecloses the possibility that consumers will get their money back from the “plans of care” costing tens of thousands of dollars or benefit from other financial remedies the FTC seeks on their behalf. The decision also removes a huge financial incentive to settle cases such as this one. Scofflaws now know that, while they may have to shut down their scamming operations, they can keep their ill-gotten gains. As the Acting FTC Chair Rebecca Slaughter warned,
Enforcement actions will slow and redress for consumers will dry up if Congress does not act quickly to affirm our full authority under 13(b) . . .
According to Ms. Slaughter, the FTC has 24 court cases pending based on its Section 13(b) authority, which had the potential to return $2.4 billion to consumers prior to the Supreme Court decision in AMG Capital. In addition to Golden Sunrise Nutraceutical, among those cases is Nerium International (later known as Neora), an alleged pyramid scheme selling dietary supplements, skin creams, and other products. Also included is the antitrust case in which convicted felon and “pharma bro” Martin Shkreli and other defendants are accused of an elaborate scheme to preserve a monopoly for Daraprim, a life-saving drug.
Will Congress act?
A bill has just been introduced in the U.S. House of Representatives, the Consumer Protection and Recovery Act (H.R. 2668), to beef up the remedies the FTC can seek on behalf of consumers, including:
restitution for losses, rescission or reformation of contracts, refund of money, or return of property, [and]
disgorgement of any unjust enrichment . . . obtained as a result of the violation [of the FTC Act]
If passed, the new law would apply to pending as well as future cases and relief would be available for violations going back as far as 10 years.
The bill, introduced by California Rep. Tony Cardenas, has 13 Democratic co-sponsors but no Republicans have signed on as of yet. Some Republicans are pushing back and the U.S. Chamber of Commerce is opposed, although there appear to be grounds for compromise. The possibility (since realized) that Section 13(b) would be limited by the Supreme Court, and the need to address it, was discussed in a Senate hearing as well. Senate Bill 4626, with bipartisan support, would also expand the FTC’s Section 13(b) authority to seek equitable monetary relief, including refunds, for consumers, but it applies only to data privacy and data security cases.
Beyond its effect on the FTC, a law firm specializing in food and drug law has opined that the decision in AMG Capital impacts companies threatened with suit by the FDA for violation of the Food, Drug, and Cosmetic Act (FD&C Act), the provisions of which cover dietary supplements and homeopathic remedies as well as drugs. Like the FTC Act, the FD&C Act, according to the firm, does not specifically permit the FDA to recover monetary sanctions for alleged violations, although the FDA has, until now, done just that, collecting hundreds of millions of dollars. In more bad news for consumers, the firm thinks the FDA and the FTC may not be the only federal agencies negatively impacted by the AMG Capital decision.
They are not optimistic about Congress’s ability to address the problem either:
Congress could decide to implement a “legislative fix” to AMG that would apply to a multitude of federal agencies. Alternatively, as has been the case all too often, Congress may be unable to reach an agreement on how to fix AMG, and the relevant law will remain unchanged.
As if swindlers and quacks needed any more encouragement.

Battle of the feds: FTC tells FDA to do its job regulating homeopathy
Jann Bellamy on September 3, 2015
Tweet


Last month, the Society for Science-Based Medicine submitted a comment to the Food and Drug Administration (FDA) in response to its request for public comments on the agency’s current regulation (actually, lack of regulation) of homeopathic drugs. As the SFSBM pointed out, the FDA has, without legal authority, exempted homeopathic drugs from the safety and efficacy requirements applicable to other drugs under the Food, Drug and Cosmetic Act (FD&C Act). Lax regulation has resulted in consumer confusion: consumers do not understand homeopathy, how the FDA regulates homeopathic drugs, and the lack of scientific evidence underlying claims made by homeopathic drug companies.
As it turns out, we were in excellent company. The Federal Trade Commission (FTC), the agency charged with preventing fraudulent and deceptive business practices, submitted its own comment to the FDA, making these same points. (The FTC is holding its own workshop on advertising homeopathic drugs later this month. We’ll get to that shortly.)
The FTC’s advertising substantiation policy requires that health-related efficacy claims be supported by competent and reliable scientific evidence. The FDA, despite federal law, does not require evidence of efficacy for homeopathic drugs prior to their being marketed. This creates a potential conflict between the two regulatory schemes, resulting in homeopathic over-the-counter (OTC) “drugs” on the market that both comply with FDA’s policy and violate FTC’s policy. This, says the FTC, can be harmful to consumers and create confusion for advertisers. The FTC “recommends that the FDA reconsider its regulatory framework for homeopathic medicines” and tells the FDA what it can do to remedy the situation.
According to the FTC, the FTC’s and FDA’s jurisdiction over OTC drugs overlaps considerably. [The vast majority of homeopathic drugs are OTC.] Since 1971, the two agencies have cooperated in regulating the marketing of OTC products, with the FDA focusing on product labeling and the FTC on advertising. Unfortunately, the FDA’s continued exemption of homeopathic OTC drugs from regulation imposed on all other OTC products has been an impediment to this cooperation and, we might add, greatly enriched the homeopathic drug industry, which has essentially regulated itself, with the blessing of the FDA.
As the FTC points out, in 1972, the FDA deferred homeopathic drugs from a process to determine which OTC drugs were generally recognized as safe and effective if taken as directed. Despite the FDA’s assurances that it would put homeopathic drugs through the same paces, over 40 years later it has not done so. Then, in 1988, the FDA issued a Compliance Policy Guide (CPG 400.400) permitting the manufacture and distribution of homeopathic drugs without FDA approval, thereby institutionalizing the regulatory neglect that had been going on since 1938, when the FD&C Act was passed. (The FTC doesn’t use those exact words, but that is the real effect of CPG 400.400.) Not only does the CPG exempt homeopathic drugs from demonstrating efficacy, it also allows claims that the drug treats specific conditions as long as the conditions are self-limiting and not chronic. As well, the CPG requires an indication for use on the label.
Translation: the entire homeopathic drug label could be a fabrication and the FDA isn’t going to do anything about it.
FDA interferes with FTC regulation
The FTC takes a far different tack in regulating homeopathic remedies, or, at least, it would like to if not for the FDA.
The FTC’s well-established position on advertising substantiation was first announced in 1972 and has been repeatedly reaffirmed. For health, safety, or efficacy claims, the FTC has generally required that advertisers possess “competent and reliable scientific evidence,” defined as “tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons and are generally accepted in the profession to yield accurate and reliable results.” Competent and reliable scientific evidence may take different forms depending on the type of claim being made. For some claims, the substantiation required may be one or more well-designed human clinical studies. Neither the FTC Act, nor any FTC rules or policy statement, exempts advertising claims for homeopathic drugs from these standards. [Footnotes omitted.]
Given the lack of evidence of efficacy for homeopathic products, homeopathic advertising should have been doomed by the FTC’s advertising requirements long ago. But the FDA’s slack regulation has not only allowed false labeling, it has prevented the FTC from doing its job. Where the FDA’s and the FTC’s jurisdiction over advertising overlaps, the FTC has been reluctant to pursue homeopathic drug companies because of this conflict.
The FTC’s comment suggests the conflict can be resolved by the FDA taking one of three actions:
     1.  Withdraw CPG 400.400, and make homeopathic drugs subject to the same regulatory requirements as other drug products. [This is the solution advocated by SFSBM. Indeed, we feel this is exactly what Congress has told the FDA to do.]
     2.  Eliminate the requirement that an indication for use appear on the label. [Remember: the FDA requires that a use be indicated but does not require that it be truthful.] If a company wanted to include an indication on the label it could. Of course, without an indication there would be no clue as to what the product is for, and the FTC thinks most companies will include one. If the company does so, however, it will need competent and reliable scientific evidence to comply with the FTC’s advertising rules, even if the FDA continues to exempt homeopathic products from demonstrating efficacy.
     3.  Actually require that any indication appearing on the label be supported by competent and reliable scientific evidence, just as the FTC does.
In addition to the FTC-FDA regulatory conflict, the FTC commented that the CPG could lead to confusion for both consumers and advertisers. We would say, of course, that it does lead to consumer confusion. If the consumer knew the truth, why in the world would he buy a homeopathic product? It also, according to the FTC, creates a loophole allowing manufacturers to skip more stringent requirements by labeling their products “homeopathic.”
Some advertisers may believe that compliance with the FDA’s CPG means they are home free when, in fact, they could be in violation of FTC substantiation requirements. This actually happened in a proceeding involving “Earache Relief Drops,” a homeopathic OTC remedy claiming it “relieves pain, sooths & calms” and is “safe for use with antibiotics.” Of course, the manufacturer did not have competent and reliable scientific evidence that this was actually true, although it is likely correct that the product didn’t interfere with antibiotics due to the fact that homeopathic drugs rarely contain any active ingredient. Indeed, evidence that the product “relieves pain” would have been impossible to produce, given the pseudoscience upon which homeopathy is based. The manufacturer’s defense, when told to produce such evidence, was that it didn’t have to, because the FDA didn’t require it. In fact, the manufacturer was under the false impression that the FTC didn’t require any evidence either.
Evidence of consumer confusion
At the FDA hearing, the homeopathic industry was unable to produce a shred of evidence that consumers understand the true nature of homeopathic drugs. SFSBM’s comment noted the many and varied unproven claims made for homeopathy’s effectiveness in online comments from consumers, including, among numerous others, effectiveness for ADHD, cancer, coma, food poisoning, infertility, various infections, psoriasis and spider bites.
The FTC’s comment brings valuable new information to the FDA’s decision-making: actual research the FTC undertook on consumer confusion. First, the FTC, working with an outside firm, set up small focus groups to inform further research efforts. The information gained was used to formulate a “copy test,” which gauged consumer beliefs about homeopathy based on variations on the product labels. According to the FTC,
our research suggests that a significant percentage of consumers do not understand the nature of homeopathic products, how they are regulated, or the level of substantiation to support claims for those products.
In particular, consumers in the focus groups:
    • had difficulty distinguishing between herbal and homeopathic products;
    • associated homeopathic products with “natural” or, in a misconception reminiscent of the Food Babe, “non-chemical” products; and
    • did not understand how homeopathic remedies are supposed to “work,” and, when told, questioned their effectiveness.
In the copy tests, consumers:
    • misconceived the level of evidence required by regulators for various products and mistakenly believed the FDA has approved homeopathic products for efficacy;
    • did not understand how homeopathic remedies are supposed to “work,” and, when told, questioned their effectiveness; and
    • believed that homeopathic remedy manufacturers tested their products for effectiveness.
The FTC is also concerned by the mingling of conventional and homeopathic products on store shelves, the unusual terminology used in homeopathic product labeling (“it is difficult to understand what 2X means”), and the risk that consumers will chose homeopathic remedies over proven medicine.
I don’t know how often (if ever) one governmental agency recommends that another government agency “reconsider its regulatory framework” because its current policies cause consumer confusion, potential harm, and inhibit the former’s ability to do its job, which happens to be preventing that very same consumer confusion and harm. Any of the FTC’s proposed solutions would effectively kill off the consumer market for OTC homeopathic remedies. (Depending on what the FDA does, prescription homeopathic remedies could possibly escape extinction.) An FDA Law Blog post asked: “Will FTC Kill Homeopathic Products – or Will FDA?” Looks like it will be a joint effort.
FTC workshop on homeopathic drug advertising
The FTC’s September 21 workshop examining advertising of OTC homeopathic products:
will bring together a variety of stakeholders, including medical professionals, industry representatives, consumer advocates, and government regulators.
According to an e-mail I received from the FTC, there will be no speakers, unlike the FDA’s hearing. The FTC’s announcement also:
invites the public to submit research, recommendations for topics of discussion, and requests to participate as panelists. The workshop will cover topics including:
    • A look at changes in the homeopathic market, its advertising, and what consumers know;
    • The science behind homeopathy and its effectiveness;
    • The effects of recent class actions against homeopathic product companies;
    • The application of Section 5 of the FTC Act to advertising claims for homeopathic products; and
    • Public policy concerns about the current regulation of homeopathic products.
(My own request to be a panelist was, sadly, turned down.)
Based on its comment to the FDA, the FTC appears to have made up its mind on topics 1, 2, 4 and 5. With regard to topic 2, in the FTC’s comment we see hints that it doesn’t seem inclined to accept the homeopathic industry’s fantastical claims as “science” or its flawed methodology (e.g., “provings”) as reliable evidence of effectiveness. When discussing the focus group results, the FTC referred to increased consumer skepticism upon learning “the theory of homeopathy” and “the principles behind it,” suggesting that, without this information, “consumers may choose homeopathic products based on incorrect and incomplete information.” [Emphasis added.] Of course, it should go without saying that no responsible scientist would ever accept homeopathy’s underlying “theories” as competent and reliable scientific evidence. One could become worried, however, when reading the transcript of the FDA’s hearing, where naturopath/homeopath Amy Rothenberg’s statement that homeopathy could be explained by hormesis (among other pseudoscientific explanations) went without further examination by the FDA’s panel.
As to topic 3, there is a recent decision in a class action which may spur the FDA and FTC to act. Prior to the decision, class actions had been allowed to go forward despite the homeopathic companies’ claims that these suits were preempted by federal law, that is, the regulatory scheme already in place for homeopathic drugs. To which the plaintiffs replied: Regulation? What regulation? There isn’t any.
However, a class action was recently brought against Whole Foods in U.S. District Court for the Southern District of Florida, seeking both economic damages and injunctive relief, in the form of an order prohibiting further sale. The products at issue were Whole Foods’ house brand homeopathic remedies. Whole Foods was successful in its preemption defense, which knocked out the claims for injunctive relief. Essentially the court ruled that the plaintiffs were trying to ban a product that the FDA allowed, something the court could not do.
Whole Foods also won on the “primary jurisdiction” issue. This argument was based on the fact that Congress had determined the appropriate forum for deciding the issues raised by the plaintiffs – the labeling of homeopathic drugs – was the FDA, not the courts. Thus, this court must abstain from deciding those issues:
The Food and Drug Administration has the necessary experience and expertise in regulating labeling of homeopathic medication and it is within the Agency’s purview to decide whether the labels are compliant with federal law and the comprehensive regulatory scheme it has devised. . . . In this case, however, given the extensive regulatory scheme to oversee homeopathic drug marketing and the questions presented over the labels in this case, the Court finds abstention appropriate under the primary jurisdiction doctrine.
The court is correct. There is an “extensive regulatory scheme to oversee homeopathic drug marketing.” It’s just that the FDA has chosen to ignore it. Now that one court has declined to grant relief, perhaps the FDA will be further induced to, in the words of the FTC, “reconsider its regulatory framework” and force these fraudulent products off the market.
SFSBM will be submitting a comment to the FTC and we hope you will too. You can find out how here. Comments are due by November 20, 2015. You can find out more about the FTC’s standards for truthful advertising here.

FTC Slaps Down “Brain Training” Claims
Steven Novella on January 6, 2016
Link

Lumosity is a company that provides online and mobile games that it claimed are scientifically designed to enhance memory, focus, mental flexibility, and even stave off dementia. In a recent decision, the Federal Trade Commission (FTC) concluded that Luminosity’s claims are not based on adequate scientific evidence. They imposed a $50 million judgement against Lumos Labs, the company who sells Lumosity, and allowed them to settle for $2 million.
Being mentally active
The idea behind “brain training” is not a bad one, it’s just easy to misrepresent as something it isn’t. The basic notion is that using your brain makes it function better. It is better to be mentally and physically active than inactive. This overview summarized the evidence:
Given the complexity of the dynamic reciprocal relationships between stimulating activities and cognitive function in old age, additional research will be needed to address the extent to which observed effects validate a causal influence of an intellectually engaged lifestyle on cognition. Nevertheless, the hypothesis that an active lifestyle that requires cognitive effort has long-term benefits for older adults’ cognition is at least consistent with the available data.
While the evidence is less than definitive, the current evidence suggests that being mentally active does improve cognitive function. The effect appears to be most robust for activity that involves the frontal lobes (planning and executive function), integrates multiple areas of the brain, and that is novel or new.
As with dietary advice, all of the complex research can currently be boiled down to rather simple advice – be mentally active, try new things and engage in different types of mental activity. Also get regular physical exercise. Such simple advice does not sell many self-help books or subscriptions to brain-training services.
“Brain training”
The very term “brain training,” in my opinion, is inherently deceptive. It implies that something more than just learning or practice is going on. This is the crux of the FTC decision against Lumosity – they claimed that their games were scientifically designed to train your brain and thereby confer some generalizable cognitive benefits. They were, however, getting ahead of the research, and their claims happened to land on the wrong side of reality.
This was, and to some extent remains, a legitimate research question: when you engage in a specific mental activity do you get better at just that specific activity, or does your cognitive function improve in general (do you get “smarter”)?
Another way to state this question is this: how generalizable are the skills improved by engaging in a specific activity. In other words – if I engage in a word game, like a crossword puzzle, do I get better at just crossword puzzles, at similar word-based games, at all language-based games, or at all cognitive tasks? Products like Lumosity imply or directly claim that the answer is close to the extreme of generalizability – that playing specific games make you smarter.
The answer from current research, however, is close to the extreme narrow end; playing a mental-training game makes you better at that specific game, and maybe very similar games, but that’s it. Skills do not seem to transfer to untrained tasks, general cognitive function, or daily activities. They may, however, make people feel smarter.
The research is somewhat plagued by a lack of adequate control groups in many studies. The best studies do have adequate controls, which are absolutely necessary. In one study, for example, researchers compared three groups: one group was trained on programs designed to enhance reasoning, planning, and problem solving. The second group was trained on memory, attention, visuospatial processing, and mathematical calculations. The third group, the control, was given five obscure knowledge questions and asked to use the internet to find the answers.
They found no difference in outcomes for all three groups; they all improved slightly in the assessment tasks, reflecting a generic training effect, and perhaps also an observational effect and confidence effect.
I do need to emphasize this is complex research and there is some room for a range of opinions about what it says. For example, there are studies that show that playing certain video games may enhance a surgeon’s ability with virtual reality endoscopic procedures. This implies some transfer of skills, specifically visual processing. It may reflect comfort level with navigating a virtual world on a computer screen.
However, what is true for visual processing may not be true for memory, language, math, or other cognitive skills. This is part of the challenge for this research – there are countless ways to parse the specific claims.
Conclusion: Stay mentally active, there are no panaceas
The current consensus based upon existing research is that engaging in cognitive tasks is overall a good thing. Stay mentally active and engaged, and try to engage in a variety of activities and in novel activities. Video games can be part of this.
However, the evidence so far does not support the claim that specific skills learned in one task are transferable to other tasks (with the possible exception of visual processing and perhaps task switching), or are generalizable to overall cognitive function, memory, focus, or mental quickness.
There is also no evidence that games “scientifically designed” for “brain training” are any better than regular games.
The bottom line is that you will improve at whatever task you practice, and perhaps closely related tasks.
There is no evidence to support spending any amount of money on specific products. Do what interests you, challenges you, and engages you. Don’t believe the “brain training” hype.
Hopefully, the FTC decision against Lumosity will take the wind out of the sales of brain training products, and reduce the hype somewhat.

FTC settles deceptive advertising claims against amniotic stem cell clinics
An FTC settlement may kill “amniotic stem cell” treatments, but a plethora of other stem cell clinics flourish without regulatory oversight.
Jann Bellamy on October 25, 2018
Link


The Federal Trade Commission (FTC) announced last week that it has settled deceptive advertising charges against a California physician and two companies he operates based on their claims that “amniotic stem cell therapy” can treat a number of serious diseases and conditions, including Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, osteoarthritis, strokes, chronic kidney disease, and cardiovascular disease. The FTC noted two particularly egregious claims advertised on the defendants’ website, one boasting that that their stem cell therapy could restore the vision of blind patients, including a “101 year old Lady once blind for 7 years” and another claiming that they could “reverse autism symptoms.”
According to the FTC’s complaint, Bryn J. Henderson, D.O., J.D., and the two companies he owns and operates, Regenerative Medical Group and Telehealth Medical Group, earned at least $3.31 million offering stem cell therapy between 2014 and 2017. Initial stem cell therapy injections ranged from $9,500 to $15,000, and patients were encouraged to undergo multiple treatments. Follow-up “booster” treatments cost between $5,000 and $8,000 each.
The complaint, which contains a number of screenshots from a website and other media demonstrating the false treatment claims, alleges Dr. Henderson was aware that “the vast majority of amniotic stem cell research has been conducted on animal models.” As well,
There are no human clinical studies in the scientific literature showing that amniotic stem cell therapy cures, treats, or mitigates diseases or health conditions in humans, and the medical community considers amniotic stem cell therapy to be an experimental and unproven treatment. He also has not conducted any studies demonstrating that amniotic stem cell therapy cures, treats, or mitigates diseases or health conditions in humans.
The settlement, embodied in a proposed order which must be approved by the federal district court, prohibits Dr. Henderson and his companies from misrepresenting that any product or service (1) cures, mitigates, or treats any disease or health condition, or (2) that they are comparable to, or better than, conventional medical treatments, unless these claims are true and can be supported by “competent and reliable scientific evidence,” the FTC’s standard for advertising health claims.
The proposed order also imposes a $3.31 million judgment against the defendants, which is partially suspended pending payment of $525,000 to the FTC and compliance with the settlement’s terms. The FTC can use this money to provide refunds to consumers harmed by the defendants’ conduct.
The settlement requires the defendants to send a specifically-worded notice to current and former patients confessing that the FTC, described as “the nation’s leading consumer protection agency,” has told them to stop making “promises that our stem cell therapy treats a variety of serious diseases and health conditions” because the FTC
says these claims are not currently backed by competent and reliable scientific evidence. Therefore, we can’t make these claims in the future unless they can be supported by scientific proof.
A suggestion that the patient call his lawyer would be superfluous.
No actual stem cells in amniotic stem cell treatments
According to critics, amniotic stem cell treatments are promoted by physicians, chiropractors and naturopathic doctors, including at seminars where participants are encouraged to sign up on the spot. But, as they point out, there are no actual live stem cells in “amniotic stem cell treatments.” Amniotic stem cells are harvested from the placenta of volunteers immediately after giving birth. However, once this tissue is cryopreserved (i.e., freeze-dried), no stem cells survive. (SBM’s Harriet Hall has blogged about chiropractic amniotic stem cell treatments and David Gorski about naturopathic stem cell treatments, two among the many SBM blog posts on the subject of stem cells.)
The FTC apparently chose ignore this particular issue, banking instead on the fact that there is no reliable scientific evidence to support the defendants’ advertised claims for amniotic stem cell treatments, whether they contain any stem cells or not. Given how straightforward the proof of the FTC’s position would be — No papers? No trials? No evidence! — there was no need to complicate things.
(I should note that some critics of so-called “amniotic stem cell treatments” promote freeze-dried amniotic product as beneficial for orthopedic uses, although not on the basis of its containing live stem cells, which, they say, it most certainly does not. Whether there is sufficient evidence for those treatments is beyond the scope of this post.)
Paul Knoepfler, Ph.D., an expert on stem cells (and guest SBM blogger) is also dismissive of “amniotic stem cell therapy,” referring to it, in his own blog post on the FTC settlement, as “whatever that happens to actually be at any particular clinic.”
A regulatory dumpster fire
While critics of unproven stem cell treatments like Dr. Knoepfler have applauded the FTC’s action, the fact remains that regulation of stem cell clinics is something of a dumpster fire.
The FDA must approve “stem-cell based products”, unless they are being studied in an Investigational New Drug Application submitted to and allowed to proceed by the FDA. Approved stem cell products (listed here) are currently limited to blood-forming stem cells derived from cord blood approved for limited use in patients with hematopoietic disorders.
But, while the FDA has laid claim to regulatory authority over all biologic products, including stem cells, there is a big tug-of-war going on between stem cell clinics and the agency over just how far that authority extends. Some physicians, for example, argue that extracting stem cells from a patient, processing them, then re-injecting the patient’s own cells back into his body, is the practice of medicine, not the manufacture of a new biologic product and therefore not within the FDA’s purview. In between lie definitional battles over how much processing is required to transform a medical procedure into a biologic product (more than “minimal manipulation,” according to the FDA) and the intended use of the processed stem cells (e.g., whether the use is “homologous,” again according to the FDA). I highly recommend Dr. Knoepfler’s guest post for a better and much more detailed explanation of this minefield (note that some of the proposed FDA guidance he discusses has since been finalized).
In any event, in the midst of this regulatory uncertainty, hundreds of stem cell clinics have sprung up in the U.S., many offering unproven treatments, sometimes under the guise of doing a “clinical trial”. JAMA has published not one, but two, articles this year cataloguing the many crowdfunding requests asking donors to contribute to patients seeking unproven stem cell therapies.
Unfortunately, without a bright line separating legal from illegal uses of, and claims for, stem cells, the FTC and the FDA have had to play catch up in catching the bad guys (also here and here). Judging from the plethora of clinics, no one is particularly afraid of getting caught, although the FTC’s settlement might kill the amniotic “stem cell” treatment industry. In the meantime, efforts to combat unproven stem cell treatments in the academic and private sector include the International Society for Cellular Therapy Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies and the Foundation for Accreditation of Cellular Therapies program, which establishes “evidence-based requirements set by international teams of world-renowned experts vested in the improvement and progress of cellular therapy.” (Accredited organizations can be found here.)
More robust regulatory action (both rule/guidance promulgation and enforcement actions), as well as increased media coverage and private/academic efforts will eventually weed out at least some of the bad actors. In the meantime, desperate patients will continue to shell out thousands of dollars for dubious stem cell therapies.

FTC settles false advertising suit against low-level light therapy marketer with $22 million judgment
Per a settlement with the FTC, the marketers of Willow Curve, a low-level light therapy device costing hundreds of dollars, will have to stop making deceptive claims that the device treats chronic, severe pain and associated inflammation. Any health claims made for the device must be supported by “competent and reliable scientific evidence”.
Jann Bellamy on July 2, 2020
Tweet


The Federal Trade Commission (FTC) and the marketers of Willow Curve, a low-level light therapy device, have agreed to a Stipulated Order for Permanent Injunction and Monetary Judgment forbidding false claims that the device treats chronic, severe pain and associated inflammation. The Order also imposes a $22 million judgment, suspended pending the payment of $200,000 each by individual defendants Ronald Shapiro, MD (a kidney specialist) and David Sutton, co-owners of the defendant companies marketing the device, based on their ability to pay. The Order resolves a six-count Complaint filed by the FTC against the defendants for violation of federal laws against deceptive advertising.
The FTC, which had been investigating the defendants since 2017, apparently agreed with SBM’s own Dr. Harriet Hall, who wrote about the Willow Curve in 2015:
Willow Curve makes a lot of claims, but there is no credible evidence to back them up. There are a lot of unanswered questions and red flags. Even if the effect is significant, it appears to be small in magnitude. . . . I’m not persuaded that the Willow Curve has any unique advantages over other, much less expensive products. . . . My inclination would be to stick to less expensive, more evidence-based treatments until Willow Curve has been properly tested.
You heard it here first, folks.
What’s a Willow Curve?
According to the FTC’s Complaint:
Willow Curve is a curved plastic device that applies low-level light and mild heat to the site of pain, via light-emitting diodes (“LEDs”) and heat resistors. To start a 24-minute “treatment” session, consumers select from among five different settings, which differ with respect to the parameters of the light emitted, such as angle, frequency, and sweep pattern. Willow Curve also includes sensors on its curved underside that purportedly measure skin-surface temperature.
“Low level light therapy” is a confusing and, per some experts, inaccurate term, as it can refer to devices with differing light sources and with varying mechanisms of action and therapeutic intent. The devices go by many names in addition to low-level light therapy, including low-level laser therapy, cold laser therapy, low-power laser therapy, low-intensity laser, low-energy laser therapy, monochromatic infrared light energy therapy, and, when applied to acupuncture points, laser acupuncture. According to a 2018 review by Quackwatch, these devices
may bring about temporary relief of some types of pain, but there’s no reason to believe that they will influence the course of any ailment or are more effective than standard forms of heat delivery.
But if you read or heard Willow Curve’s marketing materials, you’d think it was something out of a Silicon Valley start-up, a veritable Theranos. Advertisements used words like “therapeutic laser technology” and “digital anti-inflammatory technology” with “diagnostic sensors [to] gather information that’s used to adjust the kinetic energy that stimulates your body’s own natural pain-relieving pathways”, equipped with a “smart onboard computer [that] adjusts the protocol to your needs”. The device’s “joint scanning technology collects information from at and below your skin surface. . . [and] calculates and digitally delivers multiple energy beams that change thousands of times/second” and “produces dynamic multi-band alternating pulse therapy” to boot.
Promoted as an alternative to opioids, steroid injections, and surgery, the Willow Curve was “proven to relieve pain and stiffness in minutes”, sometimes in “as little as 12 minutes”, or just “24 minutes”, or at least “the next morning”, or in “two or three days”, depending on the particular testimonial. And no side effects! In sum, “nothing short of a miracle”.
Of course, if you’re selling miracles, you can charge a lot, and Willow Curve did just that. Since around 2014, Willow Curve typically cost $599, the price rising to $799 in 2018.
Big claims can get you in big trouble. The FTC requires “competent and reliable scientific evidence” to support health claims and testimonials like those used extensively by Willow Curve only serve to convey “the implied claim that the advertiser has proof to support the underlying efficacy representation”. Willow Curve had none of this, and is now, per the Stipulated Order, permanently enjoined from claiming that any device they sell is clinically proven to:
    • Treat or relieve severe or chronic pain, including that due to rheumatoid arthritis, diabetic neuropathy, nerve damage, fibromyalgia, shingle, lupus, torn tendons, broken bones, or other specific health conditions;
    • Treat or reduce inflammation;
    • Provide pain relief comparable to drugs or surgery;
    • Restore mobility and joint function to consumers with restricted movement;
    • Reduce pain by a specific amount on pain scales or relieve pain for a certain percentage of users; or
    • Evaluate or diagnose the cause of individual consumer pain.
Which just goes to show you how expansive Willow Curve’s claims were. For example, advertising represented that the device “reduces pain by three to ten points” on a numerical pain scale and that an incredible 99% of consumers “achieve significant pain relief”.
The Order leaves open the possibility that, at some point, the defendants might actually create a device that does any or all of these things and more. If they do, they’ll have to support any advertising claim with competent and reliable scientific evidence, defined in the Order as:
tests, analyses, research, or studies (1) that have been conducted and evaluated in an objective manner by experts in the disease, condition, or function to which the representation relates; (2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that are randomized, double-blind, and placebo-controlled human clinical testing of the Device, when such experts would generally require such human clinical testing to substantiate that the representation is true.
Not FDA anything
Misrepresenting the Willow Curve’s effectiveness was not the defendants’ only sin. Various promotional materials represented that the device was “FDA Registered”, certified, or approved. But, as the FTC explains in the Complaint, the FDA classifies medical devices into one of three categories based on the risk they pose to the public. Higher-risk products (think X-ray machines) cannot be sold without pre-market approval, which requires a rigorous review of safety and efficacy data. Lower-risk devices undergo the less stringent “510(k)” review, which requires showing the new device is “substantially equivalent” to an existing device already legally marketed in the U.S. Finally, the FDA has exempted some lower-risk devices from even this less stringent level of review, “such as heating pads and topical heating devices that emit infrared light, such as Willow Curve”, requiring no FDA review before being marketed. In other words, the Willow Curve, with its alleged “digital anti-inflammatory technology” and “diagnostic sensors” and so forth is actually the regulatory equivalent of a $13.98 Walmart heating pad.
The FDA also requires that manufacturers and distributors of medical devices register annually and submit a device list so the agency knows where devices are made. The defendants never did this either. Thus, the Willow Curve was never registered, certified, or approved by the FDA, as claimed.
(Consumers may not be aware that, as the FDA explains, “Registration and Listing does not denote approval or clearance of a firm or their devices”, meaning that when you see “FDA registered” or “FDA listed” in advertising it not indicative of the efficacy or safety of the product, no matter how much the marketer would like you to believe otherwise.)
After paying hundreds of dollars for this gizmo and finding out it didn’t work as claimed, some purchasers tried to exercise their advertised right to a “risk-free trial” or a refund. Even that turned out to be a sham. Per the Complaint, consumers were required to pay shipping, handling, and other fees to return their devices. In many cases, refund requests were not honored or took a year or more to process. The FTC also charged the defendants with using deceptive “native” ads, which were commercial content disguised as independent journalistic content. Defendants are permanently enjoined from all of these deceptive and misleading practices as well.
If the individual defendants don’t pay the $200,000 each, the full $22 million judgment can come crashing down on their heads, as it will if they violate any of the other terms of the Order. And, as if in warning to similar device marketers, the FTC’s press release announced that that the suit is “the FTC’s first to challenge health claims made for a low-level light therapy device”, with the implication that others may follow.
But what about the poor consumers, stuck with their curved plastic casings embellished with LED lights? The Order does not specifically mention any relief for them, although the Order does say that the monies from the defendants “may” be deposited into a fund administered by the FTC and be used for “consumer redress”. The defendants are required by the Order to send all of their customers a letter telling them about the suit, and that the FTC says they don’t have evidence to support their health claims and can’t make any claims unless they have evidence to back it up. It does not say anything about customers recovering any money for their troubles.
The Willow Curve (now $699) is still on the market, albeit with far more subdued health claims. The consumer must also purchase a battery “specifically intended” for it ($39.99) or a charger ($29.99) to run the thing.
The website says that Willow Curve is “currently focused entirely on temporary relief for joint pain” and that a there is a “great deal of published research which is ongoing”. Two journal articles are referenced, one of which doesn’t have anything to do with joint pain. The other is more or less an opinion piece saying that “low-level laser (light) therapy [LLLT]” is “beneficial for pain relief and can accelerate the body’s ability to heal itself”. It cites some supporting evidence, but is not a critical review of the evidence, and acknowledges limitations on the therapy’s acceptance. The website also claims “the Willow Curve device is the only LLLT device recognized by the American Medical Association and was granted a unique insurance CPT Procedure code 0552T”, but I was not able to verify that information.
        ◦ Willow Curve has also rescinded its “risk-free trial” and refund policies. If you pay $699 and don’t like it, too bad. Caveat emptor!

The FTC cracks down on iV Bars for false advertising claims about its “intravenous micronutrient therapy”
One of the most popular forms of quackery sold by alternative medicine practitioners such as naturopaths is intravenous vitamin therapy, sometimes also called “intravenous micronutrient therapy” (IVMT). Most are variants of a concoction known as “Myers cocktail,” and there is no good evidence that IVMT is efficacious for any of the indications for which quacks use it. Last week, the FTC issued a proposed consent agreement based on a complaint against the company selling iV Bars for false advertising. Here’s hoping this is the beginning of something good.
David Gorski on September 24, 2018
Link

We at SBM not-infrequently write about the quackery promoted by naturopaths, “functional medicine” doctors (many of whom are naturopaths, but many of whom are also MDs like Dr. Mark Hyman), and other practitioners of alternative medicine or “integrative medicine”, the latter of which “integrates” alternative medicine with real medicine. Although there are many forms of pseudoscientific, prescientific, and unscientific treatments offered by such practitioners, one common form of “treatment,” often marketed as preventative medicine or antiaging medicine but sometimes marketed as a real treatment (or part of a real treatment) for real diseases, is intravenous vitamin therapy. One of the most common forms of this treatment is the use of high dose intravenous vitamin C to treat cancer, an idea popularized by Nobel Laureate Linus Pauling and continuing to fuel pointless research and attempts at clinical trials even today. In fairness, there is preliminary evidence that high dose vitamin C might—I repeat, might—have some use in sepsis, but in cancer it has been and remains what I like to refer to as a very long run for a very short slide.
Intravenous vitamin injections are also often included as part of chelation therapy for cardiovascular disease. Despite its being pure quackery, chelation therapy including intravenous vitamin therapy has been subjected to a large multicenter clinical trial (TACT) at the cost of $30 million that was rife with flaws in methodology, execution, and ethics. Not unexpectedly, it produced a negative result. Unfortunately, it also provided enough of a hint of a whiff of a signal (almost certainly spurious, if you look at it closely) in one subgroup (diabetics) that quacks were able to finagle $37 million more to do another multicenter clinical trial. Meanwhile, not a single quack has abandoned chelation therapy for cardiovascular disease despite the overwhelmingly negative results of TACT for every patient group except diabetics, and IV vitamin cocktails are a regular offering of quack cancer clinics and quack clinics in general as a panacea, sometimes under the name of “intravenous micronutrient therapy” (IVMT). Indeed, a 2011 survey by Caulfield and Rachul found that intravenous vitamin cocktails are among the most popular services advertised by naturopaths, be it Myer’s cocktail (basically an injected multivitamin) or vitamin C, intravenous vitamin therapy is the unproven treatment beloved by alternative medicine practitioners everywhere.
That’s why I was pleased to learn late last week that the Federal Trade Commission has, for the first time, charged a marketer and seller of intravenous therapies known as iV Cocktails with making a range of ‘deceptive and unsupported health claims’ about their ability to treat serious diseases, resulting in a proposed consent agreement:
The proposed FTC order prevents the company, which operates clinics in Texas and Colorado, and its owner from making such claims unless they can be supported by competent and reliable scientific evidence.
“This enforcement action should send a clear message to the burgeoning IV therapy industry and sellers of all healthcare products,” said Joe Simons, chairman of the FTC. “Health claims must be supported by competent and reliable scientific evidence.”
Beginning in mid-2015, FTC said the company, iV Bars, used its website and social media to advertise a variety of iV Cocktails, costing consumers $100 or more, with iV Bars claiming they could treat serious diseases including cancer, congestive heart failure, multiple sclerosis, diabetes, fibromyalgia and neurodegenerative diseases.
Because of course they did. Let’s take a look first at the sorts of claims made by the company iV Bars as enumerated in the FTC complaint and then at the FTC order.
iV Bars
As is my wont, before going through the entire FTC complaint, I headed over to the iV Bars website, knowing full well that by this late in the process the company might have purged the specific complaints that drew the unwanted attention of the FTC. Right on the front page, I was greeted with scientifically dubious and inaccurate statements, interspersed with photos of dynamic young athletes doing their thing, the first being the claim that taking vitamins orally “simply does not work,” which is, of course nonsense, as is this:
Our iV Therapy delivers replenishing fluids, vitamins, minerals & amino acids into the bloodstream with 100% absorption, where they are immediately available for your cells to use. Resulting in quicker recovery time and improved overall performance.
And:
If you are new to the concept of Intravenous Vitamin Administration, you might be wondering why you’re suddenly hearing so much about it. Why is it being relied upon by professional athletes to CEO’s and most importantly by individuals seeking to support their overall health and well-being. Intravenous Vitamin Administration represents an exciting new paradigm in allowing us to help a wide variety of vitamin deficiencies.
iV COCKTAIL BENEFITS: SPORTS RECOVERY, HYDRATION, WEDDING DISASTERS, HANGOVERS AND MORE.
So far, there are no specific claims. “Hydration” and “sports recovery” are sufficiently vague that the FDA would be unlikely to say anything about them. Ditto selling them as a remedy for hangovers. It didn’t take me long to find some real howlers under a section called The Science Behind iV Bars:
Intravenous (iV) Delivery or Intravenous Micro-nutrient Therapy (iVMT), is a method which uses nutrients such as vitamins or minerals and administers these directly into the bloodstream typically through a vein in the arm…more specifically the crook of the arm. There are several advantages of giving the body nutrients by the intra-venous method. First, by injecting substances directly into the bloodstream you eliminate any alteration in the nutrients which may occur from the actions of digestive enzymes. Second, the amount of nutrients in the blood can reach much higher, more effective levels faster than is possible by absorbing nutrients through the Gastro-Intestinal system. This may be particularly important if a client is suffering from a GI system disorder where absorption of nutrients is impaired. In some cases the IV use of micro-nutrients permits much higher levels than are possible even with a healthy GI system.
Now, in fairness, there are examples of GI conditions that impair one’s ability to absorb nutrients orally. For example, if you’ve had your stomach removed (or, more specifically, a specific part of your stomach removed), you will be unable to adequately absorb vitamin B12, the deficiency of which over time leads to a condition known as pernicious anemia. The reason is that the proximal stomach makes protein called intrinsic factor, which binds to B12 and facilitates its absorption in the distal small intestine. However, vitamin B12 deficiency can take years to develop after gastrectomy because significant stores of vitamin B12 exist in the liver. In any event, people with surgery-induced B12 malabsorption do benefit from monthly B12 injections. Gastrectomy can also impair the absorption of iron because gastric acid converts dietary iron to a form that is more readily absorbed in the duodenum.
There are a number of other conditions that can result in the malabsorption of some or all nutrients; however the symptoms of these conditions are usually not subtle, and they can be diagnosed by standard medical tests. The point is that most of these can be treated without intravenous nutrients and with targeted treatments. The sort of “shotgun” approaches epitomized by products like those sold by iV Bars are almost never needed. Let’s just put it this way. If your malabsorption of nutrients is so poor that you need intravenous vitamins and micronutrients, you probably need total parenteral nutrition (TPN), in which all your nutrient needs are provided intravenously. TPN is not infrequently used in patients who, for whatever reason, be it surgery or prolonged dysfunction of their GI tract, cannot eat for prolonged periods of time. Unfortunately, prolonged courses of TPN have a host of well known complications, some due to the fact that total nutritional support requires a central venous catheter, some due to the metabolic effects and the effect on the liver from the nutrients.
Of course, iV Bars claims that its products are “targeted” based on—of course!—science:
Although 99.9% of human DNA is the same in every person, enough of the DNA is unique to distinguish one person from another. Male or female, short or tall, thin or muscular, low or high activity level, world class athlete or weekend warrior, people are all unique and so are their nutrient requirements. Developed by a team of leading medical doctors, naturopathic doctors, biochemists, nutritionists and exercise physiologists, iV Bars profiling is a technique employed by our medical practitioners to assist in identifying a person’s specific nutrient requirements. iV Bars profiles are encrypted sets of numbers that reflect a person’s current state of health, which are used as the person’s nutrient identifier. The process begins with the selection of a cocktail, followed by a series of medical, health and lifestyle questions. The data from these questions will automatically be run through the iVBars proprietary software program which will produce your profile.
This is, of course, a seriously dubious set of claims, particularly the part about how some sort of proprietary software will identify such a highly “personalized”, “targeted”, or “precision” therapy based on a series of questions. The involvement of “naturopathic doctors” in the development of the process should tell you all you need to know about it. Of course, I’d love to know who these “leading medical doctors, naturopathic doctors, biochemists, nutritionists and exercise physiologists” are who developed this system. Somehow, I’d be willing to bet that they aren’t nearly as “leading” as iV Bars claims. Notably, I was unable to find a single name.
Not surprisingly, consistent with the FTC complaint, all I had to do was to go to Archive.org and use the almighty Wayback Machine to find a version of the company’s website from August 2016 that had a section marked “Medical” in which the company touted iV Bars for:
    • Adrenal fatigue
    • Cancer
    • Asthma
    • Colds & flu
    • Celiac disease
    • Gluten sensitivity
    • Chronic fatigue syndrome
    • Chronic pain
    • Congestive heart failure
    • Dehydration
    • Depression & anxiety
    • Diabetes
    • Effects of Aging
    • Infertility & pregnancy
    • Fibromyalgia
    • Gastrointestinal conditions
    • General wellness
    • Hangovers
    • Heavy metal toxicity
    • High blood pressure
    • Immune health
    • Aids in Weight Loss
    • Injuries
    • Low energy
    • Poor memory
    • Migraine & tension headaches
    • Neurodegenerative disorders
    • Nutrient deficiencies
    • Post surgical healing
    • Preventative care
    • Skin conditions
    • Stress
    • Revitalize hair & nails
And elsewhere:
The vitamins and minerals used in iVMT are co-factors in biochemical reactions in every cell in our bodies. As a result, iVMT can be used as an adjunct in any condition where low levels of nutrients or other nutritional deficiencies are suspected. Immune Support, Anti Aging, Athletic Performance, Allergies, Depression, Hormone Balance, Migraines, Chronic Fatigue, Inflammatory GI conditions, Fibromyalgia and many others all respond to iVMT for many patients.
I note that the company website (accessed yesterday) still includes the following conditions:
    • Adrenal Fatigue
    • Gluten Sensitivity
    • Dehydration
    • Effects of Aging
    • General Wellness
    • Hangovers
    • Heavy Metal Toxicity
    • Immune System Support
    • Aids in Weight Loss
    • Promotes Overall Well-being
    • Low energy
    • Poor Memory
    • Nutrient Deficiencies
    • Skin Conditions
    • Stress
    • Revitalizes Hair
    • Revitalizes Nails
Of course, adrenal fatigue is a fake diagnosis, as is, nearly always, “heavy metal toxicity”, and “gluten sensitivity” almost certainly doesn’t exist, as opposed to actual celiac disease, which 1% of the population suffers from. The rest are the usual vague alternative medicine “diagnoses” and problems that many quacks claim to treat. I also can’t help but acknowledge grudging admiration for the sheer brilliance of the marketing. These guys even send RNs or EMTs to you, doing private events, bachelor parties, “ladies’ nights out”, and basically any function you might want.
The FTC complaint goes into much more detail. Let’s dive in.
The FTC complaint against iV Bars
The FTC press release about the consent agreement can be found here, and a handy dandy list of links to documents related to the complaint and the consent agreement can be found here. Let’s take a look at key parts of the complaint. You can already see from my cursory perusal of the archived version of the iV Bars website that there were definite medical claims being made without evidence.
The complaint notes early on:
Respondents’ first and primary iV Bars location is housed in a NextGen Wellness Center, an upscale gym and clinic that independently offers chiropractic care, pain management therapy, physical therapy, medical massages, and counseling. New iV Bars customers create an online account and complete a short health assessment questionnaire when making their first appointment. Respondents have an arrangement with a doctor who does a quick, online review of all health assessment questionnaires that customers submit to iV Bars. Respondents pay the doctor a flat fee of $250 per month for this service. Shortly before the customer arrives, an iV Bars employee takes about five minutes to mix ingredients obtained from a local compounding pharmacy into the customer’s requested iV Cocktail. Once at iV Bars, the customer is asked to sign a release form that discloses risks and releases Respondents from liability. Thereafter an iV Bars nurse seats the customer in one of five oversized reclining chairs and administers the iV Cocktail to them over a 25-45 minute period. Respondents also maintain a “full service mobile vehicle” that allows them to “come right to your door to deliver the treatment of your needs.”
See what I mean by the brilliance of the business model? There were also “success stories” that implied that iV Bars treatments could be useful for a range of conditions, from influenza to cardiovascular disease to fibromyalgia. For example, here’s one featured in the FTC complaint. It was edited down, but I think it’s worth going back to the Wayback Machine version of the iV Bars website to quote in full:
Case #5: A 79-year-old man was seen at home in end-stage heart failure, after having suffered four myocardial infarctions. During the previous 12 months, spent mostly in the hospital, he had become progressively worse; his ejection fraction had fallen to 19 percent and his body weight had declined from 171 pounds to a severely cachectic 113 pounds. He was confined to bed and required supplemental oxygen much of the time. He also had severe peripheral occlusive arterial disease, which had resulted in the development of gangrene of six toes. A peripheral angiogram revealed complete occlusion of both femoralpopliteal arteries, with no detectable blood flow to the distal extremities. Two independent vascular surgeons had recommended bilateral abovethe- knee amputations to prevent development of septicemia. However, the cardiologist advised the patient that his heart would not last more than another month, so the patient declined the amputations.He was treated with weekly IM injections of magnesium sulfate (1 g) for eight weeks, and prescribed oral supplementation with vitamins C and E, B complex, folic acid, and zinc. The magnesium injections appeared to reduce the pain in his gangrenous toes considerably, with the benefit lasting about five days each time. Six weeks after the first injection, his ejection fraction had increased from 19 percent to 36 percent and he no longer requiredsupplemental oxygen. After eight weeks, the IM injections were replaced by weekly IV injections, consisting of 5 mL magnesium, 1 mL each of B12, B6, B5, and B complex, and a low-dose (0.2 mL) trace mineral preparation (MTE-5 containing: zinc, copper, chromium, selenium, and manganese). After a total of 18 months, his weight had increased from 113 to 147 pounds, which was remarkable as cardiac cachexia is generally considered to be irreversible. In addition, the gangrenous areas on his toes had sloughed and been replaced almost entirely by healthy tissue. Intravenous therapy was continued and eventually reduced to every other week. The patient lived for eight years and died at age 87 from multiple organ failure. Of the handful of other patients with angina or heart failure who received IV or IM injections of magnesium (with or without B vitamins), all showed significant improvement. The results with angina are consistent with those reported by others using parenteral magnesium therapy.40-42
This is, of course, an example of the post hoc ergo propter hoc fallacy that assumes that just because this patient lived eight years after four myocardial infarctions and dry gangrene of the toes it must have been the IV nutrient injections. Occasionally, even elderly people with severe cardiac disease improve, and we don’t know what other standard medical treatments he underwent. (If he was in the hospital so much, he must have undergone standard medical treatments.) As for the “gangrenous areas” of his toes sloughing and being replaced by viable tissue, it would be useful to know more. For instance, it’s not uncommon for gangrenous toes to “autoamputate,” as long as the gangrene remains “dry” (not infected), as opposed to “wet” (infected). In any event, as we’ve discussed more times than I can remember, such “case reports” and small “case series” tell very little without a control group.
The FTC complaint cites other “success stories” for people with multiple sclerosis, diabetic peripheral neuropathy, and fibromyalgia. I note from the archived web page “success stories” for muscle spasms, migraines, asthma, depression, upper respiratory tract infections, seasonal allergic rhinitis, hyperthyroidism—even narcotic withdrawal. All are questionable, and none cite anything resembling rigorous evidence. Elsewhere, the FTC complaint notes:
In addition to the “The Science Behind iV Bars” section of the iV Bars Website homepage (discussed in Part 5.B., above), the Website homepage contained a link titled “ABOUT iV BARS: THE COMPANY” that linked consumers to a page titled “THE COMPANY BEHIND THE BAG.” That page contained depictions of men and women dressed in white lab coats looking at test tubes and through microscopes. It declared, “Inspired by the early works of Dr. Myers, Aaron Keith founded iV Bars in 2015. He assembled a world class team of physicians, biochemists and physiologists to create the formulas . . . of iV Bars.” Thereafter, under the subtitle “iV Bars Research Labs,” Respondents claimed to have an “applied Biology and Chemistry Group” at a purported “iV Bars Labs” comprised of “experienced biologists, chemists, pharmacists, medical and naturopathic doctors and exercise physiologists” to, among other things, “test and approve inject-able formulations that are used in intravenous, subcutaneous and intramuscular administration”:
So basically, this is a variant of the Myers Cocktail, an intravenous cocktail of various vitamins B vitamins, vitamin C, and minerals created by Dr. John Myers, who died in 1984. Myers never actually published his recipe for the cocktail, but the doctor who took over his practice, Dr. John Gaby, published a recipe that is the current one used for Myers cocktail, even though he admitted that he didn’t know exactly what was in Myers’ original concoction. Besides being popular among naturopaths, it was reportedly also used by Michael Jackson. There is no evidence that it is efficacious for any of the conditions for which it is commonly used, other than anecdotes collected by Dr. Gaby.
As for the safety of iV Bars, the FTC notes that the “Science” section of the website and consent form listed a number of risks and possible adverse reactions, including hypotension (low blood pressure) from too-rapid infusion of magnesium; hypokalemia (low potassium), which can cause arrhythmias and for which the company acknowledged one patient having required “short term treatment in the intensive care unit”; and hypercalcemia (calcium level in the blood too high), which can also cause arrhythmias and can even be fatal.
From the consent form:
Risks: I understand there is risk of mild diarrhea, upset stomach, nausea, a feeling of pain and a warm sensation at the site of the injection, a feeling, or a sense, of being swollen over the entire body, headache and joint pain.
***Uncommon side effects are much more serious than the common side effects of Vitamin injections, and such side effects should be reported to a physician to be evaluated for seriousness. Uncommon and dangerous side effects include:
• Headache • Nausea • Diarrhea • Bloating • Constipation • Indigestion or heartburn • Abnormal bleeding • Gastrointestinal hyperactivity • Chest pain • Flushed face • Chills • Fever • upset stomach • Kidney stones • Fingernail weakening • Hair loss • Rapid heartbeat heart palpitations • Restlessness • Muscle cramps and weakness • Dizziness
***
I understand the possibility of having an allergic reaction to any of the ingredients found within the Vitamin injection is quite plausible . . . . If I experience any of these following signs of allergic reactions I should immediately consult my primary health care Physician and discontinue further use of the product. Signs of allergic reactions include, but [sic] not limited to:• Itching of skin • Hives • Rashes • Wheezing • Difficulty breathing • Swelling of mouth or throat
***
When medications are taken in conjunction with the Vitamin Injection, drug interactions could occur. These interactions can either increase your risk of bleeding or block the absorption of the Vitamins into the body.
These are a lot of risks for a treatment with no known benefit.
The consent agreement
So what is the FTC going to do about this? The full order is here, but I find it easier to quote from the press release, because the order is full of legalese:
The proposed settlement order, which is subject to public comment, prohibits iV Bars from making the false or unsubstantiated claims that its iV Cocktails: 1) are an effective treatment for any of the diseases included in the complaint; 2) produce fast, lasting results; or 3) cure, mitigate, or treat any diseases, unless the claim is supported by competent and reliable scientific evidence. The order also prohibits iV Bars from making any express or implied health, safety, or efficacy claims unless they are not misleading and are supported by scientific evidence.
In connection with the advertising, marketing, promotion, or sale of any covered product, the order prohibits iV Bars from misrepresenting that it has had medical professionals test or approve the product, or that it has a research facility. The order also prohibits iV Bars from misrepresenting the existence or conclusions of any scientific evidence, or that a product, including iV Cocktails, is scientifically or clinically proven to produce any benefit.
Finally, the order requires iV Bars to preserve any underlying scientific data and documents used to support health claims made for any product.
iV Bars also agreed to email its customers a notice stating that:
    • “Contrary to the company’s marketing materials, studies have not shown that the Myers Cocktail is an effective treatment for any disease, including nine specific diseases, ranging from cancer to multiple sclerosis and diabetes”;
    • “Consumers should consult a doctor or other healthcare provider before using any alternative disease treatments”;
    • “Consumers should talk with their doctor or healthcare provider before stopping any prescribed treatments”; and
    • “It is important for consumers to talk with their healthcare provider to ensure all aspects of their medical treatment work well together.”
I would say that this is a good start, but that it doesn’t go nearly far enough because it appears to be allowing the company to continue to market its product. Unfortunately, that’s probably because the complaint was about deceptive advertising. What really needs to happen is that the FDA needs to get involved, because this company clearly appeared to be making distinct medical claims and selling a concoction that appears all the FDA legal definitions of what constitutes a drug.
I also note that the agreement will be subject to public comment for 30 days, which will end on October 22, after which the FTC will decide whether to make the proposed consent agreement final. I would urge our readers to comment, because you know the quacks will be commenting. I found the form to submit public comment about the proposed consent agreement here.
Finally, it’s been asked, given the potential harm and the lack of evidence for stem cell therapies as marketed, whether the FTC will be targeting for-profit stem cell clinics. Given how they abuse the clinical trial process charge huge sums of money for treatments with no evidence of efficacy but evidence of harm, I, too, would ask the same question. However, I hope that this is a start for the FTC to take a much harder line on the many false advertising claims made by quack clinics and sellers of unproven and disproven treatments that quack loudly.

FTC targets physicians’ COVID claims with cease-and-desist letters
The FTC recently announced it had issued 20 more cease-and-desist demands to physicians and others claiming their products and services prevent or treat COVID-19 without sufficient scientific backing. Unfortunately, this has not stopped many of the targets from making other bogus health claims.
Jann Bellamy on February 24, 2022
Link

The Federal Trade Commission (FTC) recently announced it had issued cease-and-desist demands to 20 marketers ordering them to immediately stop making baseless claims, on their websites and via social media, that their products and services can prevent or treat COVID-19.* They were told to notify the FTC within 48 hours of specific actions they have taken to address the agency’s concerns. According to its press release, the FTC previously issued over 400 similar demands to marketers offering COVID nostrums.
While the FTC is understandably concerned about bogus COVID remedies, many of the products and services under scrutiny are the same ones we’ve covered numerous times here at SBM when sold for other diseases and conditions, yet they remain on the market: vitamins and other dietary supplements, herbs, homeopathy, IV infusions, and quack gizmos. As with other quack nostrums, COVID products and services are offered by hucksters who range from those who have no apparent education and training in medical science, or any science for that matter, to well-educated and well-trained physicians.
The FTC also advises recipients of its cease-and-desist letters
to review all other claims [in addition to COVID] for your products and immediately cease and desist from making claims that are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims.
Unfortunately, that warning appears to have had little effect on the plethora of dubious remedies offered even when the targeted COVID claims may have been taken down.
The FTC Act makes it illegal
to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including substantiating that the claims are true at the time they are made.
For the products and services marketed for COVID cited in the FTC’s letters, no such evidence “is currently known to exist”.
Today we’ll take a look at some of these recent cease-and-desist letters and see how the same old quackery has been rejiggered to meet the demands of a modern pandemic. We’ll also look at how, regrettably, similar claims for other diseases and conditions are still marketed to the public by the very same people. We’ll focus on letters sent to physicians, who should know better, as well as a few charlatans who seem to be practicing medicine without a license.
But first, before we get to these folks, I would be remiss if I didn’t tell you about . . .
“Quantum” homeopathy
A Canadian outfit, AshNu Technologies, offers “memberships” to access something called “Infoceuticals” (or “ICs”) and the equipment purportedly required to “imprint ICs onto water or apply the ICs directly to the body”. These were advertised to prevent or treat COVID-19, and are still advertised to “support”, “help”, “maintain”, “treat” and otherwise benefit mitochondrial and energy production, the cardiovascular, reproductive, respiratory, digestive, endocrine, and nervous systems, and, of course, to “cleanse” and “restore the body”.
What are ICs? To begin with, you’ll not be surprised to learn that, like many quack remedies, they “work by stimulating the body’s own healing abilities”. Specifically (I guess),
ICs are electromagnetic signals that are generated using algorithms or recorded from substances that have healing, therapeutic, or other biological effects.
A video “explains” ICs “from the point of view of the “Quantum Electrodynamic (QED) Theory”:
Here you will learn how water is able to mimic the electromagnetic spectrum of diluted substances as well as how one can record and store these electromagnetic signals – thus, creating ICs from active substances.
You can deliver these ICs to your body by either transferring them to a glass of water via a gizmo (conveniently available for purchase) and drinking it, or by applying the gizmo directly to your body. Here we demonstrate using the “Glowing IC Pad”, currently marked down from $275 to $192.50. (Other gizmos for sale do the same thing but in a different way.)
Apparently in the spirit of the homeopathic mantra “like cures like”, AshNu offered an IC that
was made with the help of a highly diluted solution of an mRNA-based vaccine. It may be used to help ease side effects and adverse reactions from the vaccine.
This nonsense caught the FTC’s eye and they were told to cease such claims, which the company apparently did.
But AshNu, having simply removed its reference to COVID-19, still offers this IC for many other conditions:
Chlorine dioxide solution, also known as miracle mineral solution (MMS), [which] has been used as an alternative means to manage various conditions such as arthritis, cold/flu, malaria, hepatitis, measles, herpes, cancer, HIV, and amyotrophic lateral sclerosis (ALS). Additionally, it has been used to improve oral and dental health.
And so on, with dozens of dietary supplements and other substances being transformed into ICs via this, um, technology, for numerous conditions, apparently without penalty.
With that bit of particularly idiotic “quantum” quackery out of the way, we’ll turn to the more serious problem of . . .
Even more physicians behaving badly
As our own Dr. David Gorski lamented in a post titled “2020 and the Pandemic: A Year of (Some) Physicians Behaving Badly”
the character of too many physicians has been found wanting, as they spent 2020 denying the pandemic, peddling quack cures, or spreading misinformation in the service of defying public health interventions.
A few more physicians recently found themselves recipients of FTC warnings in the latest tranche of letters. This is not the first time a crop of doctors has run afoul of the FTC Act for promoting COVID treatments lacking “competent and reliable scientific evidence”.
Brandon Mack M.D., an anesthesiologist, owns IVita Drip Therapy, with clinics in Wyoming and Kansas offering IV infusions concocted from various vitamins, minerals, pharmaceutical drugs and such, with names like the “Classic Cowboy” (a rebranded Myers Cocktail, a naturopathic staple) and “Forever Young” for “only $129” a pop. Since the FTC’s letter, his website no longer advertises his “Covid Blend”, promoted as
a powerhouse of immunity boosting Vitamin C, along with other essential elements working together to strengthen immune responses to serious viral illness….
But his other infusions, equally unsupported by adequate scientific evidence, remain on offer.
Similarly, although with a more glam website, a medical practice called Pretty Healthy NYC advertised, according to the FTC:
To help in the fight against coronavirus, my practice offers IV Vitamin C and Glutathione, along with a wide range of preventative and treatment-based infusion protocols, individually customized for each patient’s needs. These IV treatments are offered in our office or in the patient’s home.
One of Pretty Healthy NYC’s physicians, Roxanna Namavar, D.O., a psychiatrist, answered the call when “wellness” kook Christina Cuomo, wife of now-cancelled CNN anchor Chris Cuomo, rang up. Using what is quoted in the FTC’s cease-and-desist demand as the “Cuomo Protocol”, in a display of privilege that was deservedly criticized in the press, Dr. Namavar administered an at-home (in the Hamptons, no less) infusion containing
magnesium, NAC (a precursor to glutathione, said to be very helpful against COVID-19), vitamin C with lysine, proline, and B complex, folic acid, zinc, selenium, glutathione and caffeine (to combat the headache).
In a further obnoxious display of privilege, Dr. Namavar showed up in full hazmat gear at the same time as doctors and nurses working on the frontline in NYC hospitals were scrambling for PPE.
Again, these things don’t happen in a vacuum and plenty of nonsense remains on the website. Dr. Namavar practices “energy healing” and is “NADA certified in auricular acupuncture”. One of her partners, an M.D., practices so-called “Natural and Integrative Medicine”. They still advertise, among other services lacking adequate scientific backing, “Antiviral Infusions” as well as “Customized Cocktails”
to help rebalance your body, bring it back into homeostasis, and enhance cellular signaling.
They also practice so-called “functional medicine” which, they advertise,
Based on the results of your lab work, genetics, and symptoms, we suggest different options that elevate distinct aspects of your mood, lifestyle, and health.
The FTC cited Idaho D.O.s Christopher Peine and Peter Abraham for their promotion of “Low Dose Immunotherapy (LDI)” for treatment COVID. Their novel “discovery” was
that the body was actually responding to the COVID-19 proteins (viruses are not living organisms and are not dangerous to humans by themselves) and if we could tell the immune system to “tolerate” this protein, then we could stop the inflammatory response. . . . I decided to try this technique [previously used to “promote ‘immune tolerance’ to proteins that trigger allergies, autoimmune conditions, and inflammation”] for COVID-19 in the spring of 2020 with a mixture of coronavirus proteins from old strains of the virus.
And the results?
[S]o far, knock on wood, every patient I’ve tried it on has gotten better. Pretty much, either full resolution or near resolution, within literally hours to days.
But, as the FTC points out, they don’t have “competent and reliable scientific evidence” to support their claims and “must immediately cease”. Despite the FTC’s warning to review all of their claims, not just COVID, their clinic continues to offer LDI for chronic fatigue, endometriosis, “chronic Lyme” disease, and herpes, among other conditions. They, too, practice “functional medicine”.
Another D.O and FTC letter recipient, Texan Matthew Barker, apparently took a page from the chiropractic playbook by touting osteopathic manipulative treatment to “boost your immune system” and thereby help ward off COVID. Even more alarmingly, he claimed that an
all-natural herbal tea from Wei Labs may help prevent the Coronavirus from infecting individuals through immediate germ removal and immune support. The ingredients work together to remove germs from the throat, respiratory tract, and heart. At the same [sic], enhancing and supporting the immune system….”
Wei Labs got its own letter from the FTC about its teas and other concoctions, advertised as COVID preventatives and treatments. As the company’s website “explains”, from the Traditional Chinese Medicine viewpoint “the SARS-CoV2 virus and its infection-induced immune reaction is viewed as Cold Evil Qi” (sounds like a character in a James Bond movie). Wei Labs’ website cited ridiculous stats purportedly from an outfit called the National Administration of Traditional Chinese Medicine, such as the claim that one of its herbal formulas “has more than a 90% effective rate” in the treatment of patients diagnosed with coronavirus pneumonia.
Angelica Kokalis, an Indiana practitioner of acupuncture and TCM, who has a financial relationship with Wei Labs, was also the recipient of an FTC letter demanding she cease advertising Wei Labs products for the prevention and cure of COVID-19. She, like others, was warned to review all claims for all products she sells or is paid to promote and “immediately cease and desist making claims that are not supported by competent and reliable scientific evidence”, a review that should wipe out most of her website. Like others, she advertises many scientifically unfounded services and products, including TCM for tremors, COPD, cancer, allergies, facial paralysis, and in-vitro fertilization, among others.
Tracy Gapin, M.D., is a urologist and head of the “Gapin Institute for Elite Health and Performance”, which runs a “Precision Health Optimization & Performance Center” for men in Sarasota, Florida. Dr. Gapin, who seems fond of superlatives, was warned against advertising the “power of peptides” for “radically upgrading your health” by “boosting your immune system“, these peptides having “probably saved my life” when he personally contracted COVID, which he was “battling” but ultimately won “with Precision Health”.
In addition to physicians caught in the FTC’s net, a Texas nurse anesthetist, Glenn Cochrane, head of Krystal Anesthesia and Pain Specialists and an outfit called Infinity Functional Performance, which specializes in “lifestyle optimization”, got a letter warning him against advising that his protocol of vitamins, minerals, peptides, teas, and the drug famotidine “all available through my practice” will protect one against COVID-19. Mr. Cochrane continues to offer “functional medicine” and IV infusions such as Myers Cocktails and “Immune Boost” via his anesthesia practice. He sells dodgy diagnostics, like the “Saliva and Blood Hormone Home Test Kit”, and therapies like “testosterone replacement therapy monthly membership”. (It is not clear to me how these are within a nurse anesthetist’s scope of practice in Texas.)
In addition to actual physicians, “Dr. Monica Sava“, whose Ph.D. is in Measurement, Statistics and Evaluation, received an FTC letter for, among other things, selling
a very powerful tincture set [$500 for four tinctures!] that has now worked [for COVID] on a ton of people. And I do have a supplement protocol to boost your immune system. Aside from the fact that people taking my basic antiviral and medicinal Mushrooms have been healthy all year.
Although Connecticut does not have a Quack Protection Act, Sava certainly seems to me to be practicing medicine without a license. She offers “Holistic Immune and Lyme Healing”, which involves taking a health history and what she calls “addressing” various health issues such as “adrenal and thyroid issues”, “food allergies” and “overall inflammation” with “therapeutic grade” supplements sold through her website, all of which looks an awful lot like diagnosing and treating disease.
Like Sava, Tim Pendry of Sunshine Health Food and Wellness Center in Titusville, Florida, does not hold any health care practitioner license or, as best I can tell, have any education or training in medicine. He nevertheless felt free to dispense medical advice on the prevention and treatment of COVID, including the use of colloidal silver and dietary supplements, along with his unfavorable analysis of vaccines and pharmaceutical drugs. (Florida doesn’t have a Quack Protection Act either.) Although the FTC told him to cut that out, he still dispenses advice on topics like “when is the appropriate time to take a Statin based on blood work results” and offer diagnostics like cholesterol testing and something called “bloodwork analysis” and “blood typing”.
While we should be glad that the FTC is vigorously attacking the problem, quackery was not invented during the pandemic. Yet there seems to have been a far more aggressive effort to combat COVID quackery than, say, cancer quackery, neuroscience quackery, naturopathic quackery, or stem cell quackery. Regulators need take a more holistic approach (if I may use that term) to the problem by disciplining physicians and other professionals who promote all sorts of nonsense as well as enforcing laws against practicing medicine without a license. Congress and the state legislatures should get rid of laws that countenance quackery, like naturopathic practice acts, quack protection acts, DSHEA, and laws dumbing down the standard of care. Finally, the VA, medical schools, and other organizations (looking at you, Cleveland Clinic) should stop promoting “complementary, alternative and integrative medicine”, which encourages belief in unscientific gibberish like “energy healing”. Had the government and other institutions not so-enamored the public with “CAM” and “integrative medicine”, COVID scofflaws wouldn’t have had such a fertile field on which to sow their dangerous mischief.

*Links to all FTC COVID-19 warning letters can be found in the press release. The letters provide links to the offending websites and other internet sources of misinformation. I have not added links to the individual warning letters or the offending materials in this post, as there are so many and they are easily available from the FTC’s list, but do link to non-COVID claims. I checked to see whether some, but not all, of the offending claims have been removed. I did not check to see whether the individuals or companies have otherwise responded to the FTC.

FTC warns naturopaths, acupuncturists, physicians, and chiropractors about false and misleading COVID-19 claims 
Since March, the FTC has issued almost 250 warning letters to companies and individuals making unsubstantiated claims for COVID-19 treatments. Included among these are naturopaths, acupuncturists, physicians, and chiropractors.
Jann Bellamy on June 18, 2020
Link

The Federal Trade Commission (FTC) has issued almost 250 warning letters to individuals and companies since March demanding that they cease making (or assisting others in making) bogus claims that their nostrums can prevent or treat COVID-19. While it is not unusual for the FTC to go after health care product marketers, such as dietary supplement retailers, the agency’s warnings to licensed health care practitioners, especially regarding clinical treatments, are less common. It suggests both that the agency is taking COVID-19 very seriously and that it is actively searching the internet for COVID-19 claims, as opposed to acting solely on consumer complaints.
It is unlawful under the FTC Act to advertise that a service or product can prevent, treat, or cure human disease unless there is competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true. Because no alleged preventative or treatment currently meets this standard for COVID-19, it is fairly easy for the FTC to conclude that advertisements making such health claims run afoul of the law, with a warning letter to follow.
The FDA, which has primary responsibility for claims on product labeling, joined the FTC in some of the warning letters.
Not surprisingly, naturopathic, acupuncture, and chiropractic practices are among those warned, as well as MDs and DOs who skate along on the fringes of medicine. It is unsurprising as well that COVID-19 preventatives and treatments aren’t the only dubious therapies being offered by these practitioners, as demonstrated repeatedly on the websites cited in warning letters. While the FTC’s focus on COVID-19 is understandable, it is lamentable that so many other false and misleading claims go unaddressed, leaving those suffering from, for example, cancer, serious neurological conditions (like Alzheimer’s), and chronic health conditions (like diabetes), to the wiles of pseudoscience.
That said, it is indeed satisfying to imagine the panicky feeling practitioners must experience when, upon receiving a warning letter, they realize that the FTC, which tangles with behemoths like Apple and Microsoft with its substantial resources (including crack litigators from the Department of Justice), has honed in on their little clinic. They may have no shame, but they do have assets, and violations of the FTC Act can result in thousands of dollars in fines, injunctions against further sale of their products and services, and mandated refunds to consumers, not to mention the attorneys’ fees and costs of mounting a defense.
SBM has already covered the COVID-19 shenanigans of some CAM practitioners: chiropractors touting “adjustments” to “boost” the immune system, naturopaths (including the American Association of Naturopathic Physicians [AANP] and the California Association of Naturopathic Doctors) pushing IV Vitamin C, and acupuncturists (backed by the Chinese Government) shilling for “Traditional Chinese Medicine”.
Let’s see what the FTC’s investigators found.*
Despite an enthusiastic endorsement from the AANP, the FTC has repeatedly issued warning letters to clinics offering intravenous Vitamin C to prevent or treat COVID-19. Some of these are infusion clinics where it is unclear whether a licensed medical practitioner with prescription privileges is in charge. Since Vitamin C and other compounded infusions are prescription drugs under federal law, it is also unclear how they are operating from a legal standpoint.
One such clinic is Onus IV, in Colorado, which claims “Vitamin C is already being used to prevent and treat COVID-19 in China and Korea. And it is working.” The clinic falsely says that even small amounts of Vitamin C “dramatically decrease severity of symptoms and increase survival rates” and “large doses work better. Intravenous large doses work better still. . . .”
Detox VIP, a mobile IV service in South Florida, (with an MD medical director) also touts high dose Vitamin C infusions “as a way to increase your natural defenses against COVID-19” based on a “Chinese medical team report”.
In fact, the alleged success of Vitamin C use in China is mentioned by many clinics, an odd selling point considering the vilification of China’s response to the pandemic. According to Holistique Medical Center, a Washington naturopathic clinic offering typical naturopathic quackery like homeopathy, “Shanghai doctors [are treating COVID-19] with intravenous vitamin C, safely and effectively without any deaths reported.” A naturopathic doctor and “chiropractic internist”, who runs the Epigenetics Healing Center in Kansas, advises
Iv vitamin c in high doses are knocking covid 19 out in wuhan China. Come get yours at the Epigenetics Healing Center asap.
He goes so far as to claim that
Coronavirus? It is something that should NOT be worried about! Typically, it is only serious for the elderly and immunocompromised. Vitamin c infusions seem to mitigate any issue with it.
Medical doctors are offering IV Vitamin C as well. The LaCava Center, run by an Illinois “integrative” physician board-certified in OB/GYN, offers “VITAMIN C IV AT 50% OFF!” and says that “research shows that high dose Vitamin C is effective against COVID-19.”
The Kansas-based Riordan Clinic, staffed by an MD, a DO, and an ND, where “Vitamin C has been at the center of the mission . . . for almost 45 years” aims to “protect . . . patients from an otherwise potentially devastating exposure to COVID-19” with its signature treatment. The clinic was founded by the late Hugh Riordan, a psychiatrist who believed that nutrition and vitamins are an effective treatment for diseases such as cancer and the father of stem cell entrepreneur Neil Riordan, who has himself made a few appearances here on SBM.
To give you an idea of the geographic and provider diversity, other clinics nabbed by the FTC for promoting IV Vitamin C for COVID-19 include the Envista Medical Neck & Back Center (California MDs and DCs), Whole Health Chicago (an “integrative” practice which includes an MD, a “chiropractic physician specializing in functional medicine”, a TCM practitioner, and a homeopath), Revive and Rally Health Lounge (Kansas, run by an MD and an RN), Aspire Regenerative Health (California ND), iCRYO (a multi-state cryotherapy-infusion franchise operation with an MD Chief Medical Officer), LotusRain Naturopathic Clinic (California), Naturopathic European Medical Centre (which, despite the name and spelling, is in Wisconsin), Holgistic Personalized Healthcare/Natural Care Institute (Michigan MD and ND partnership), Traditional Chinese Medicine Clinic (Colorado Doctors of Oriental Medicine and Acupuncturists), East Valley Naturopathic (Arizona), Gonino Center for Healing (Texas DO), Hawaii Naturopathic Retreat, Health Associates Medical Group (California MD, DO, DC and LAc combo), Restore Med Clinic (California MDs), Revival Hydration (a “100% mobile” California infusion company using unspecified “medical professionals”), Sage Integrative Medicine Clinic (Washington NDs), and Vero Clinics (Illinois MD).
Acupuncture, TCM, and naturopathy for COVID-19
Acupuncture and TCM practices are well-represented among the COVID-19 advertising scofflaws. Among the FTC’s collars and their offending claims:
    • A Center for Natural Healing (California): “Treatment with Chinese Medicine has already proven in China to strongly support recovery from COVID” and “to help with the prevention and treatment of COVID-19”.
    • Inner Works Acupuncture (Oregon): “Chinese herbal medicine for COVID-19 is a great option for prevention, suspected exposure, early-stage and mild symptoms . . . [and] may help keep your respiratory illness from progressing . . .”
    • Integrative Acupuncture (Vermont): TCM “should take a primary role in effective treatment” of COVID-19.
    • Holistic Health Acupuncture (Oregon): “Herbal support for acute illness and prevention and treatment of COVID-19”.
    • Acupuncture Healing Center (Illinois): Can “facilitate the body’s response to expel the pathogen (coronavirus) . . .”
    • AcuIntegra (Tennessee): “TCM proved effective in 89% of the 1,245 confirmed COVID-19 patients” in a Chinese province.
    • Art of Wellness Acupuncture (California): “[A]cupuncture brings down fever significantly, and herbs have been shown to help resolve the severe cough”.
    • Beatty Acupuncture (Oklahoma): “Coronavirus treatment options for both Coronavirus prevention and COVID-19 positive treatment” including gummies and sprays.
    • Mind & Body Acupuncture (California): Promotes “a powerful herb – Tiger Cane” which “experts in China” found “has strongest effect for Anti coronavirus”.
And so on.
In addition to IV Vitamin C, naturopathic practices tout a variety of unsubstantiated preventatives and remedies for COVID-19, thereby catching the eye of the FTC. Typical of naturopathy, with its potpourri-of-quackery approach to practice, their recommendations varied.
We’ll start with two naturopaths who’ve made appearances here on SBM before, Paul Herscu and Amy Rothenberg (also here). Their Connecticut Naturopathic Health Care Clinic got a warning letter for claiming that products it sells, including homeopathic remedies and remedies containing zinc, elderberry, and Echinacea, can treat or prevent COVID-19.
Others naturopathic practices blessed with a warning letter include:
    • Portland Clinic of Holistic Health (Oregon): PCCH nasal spray used “once daily for prevention and several times daily for treatment” of COVID-19.
    • Ashland Natural Medicine (Oregon ND who is also a DC and homeopath): “Chinese medicine, homeopathy and western herbs appear to be helping many people with the infection[,] so our intention is to use them to treat ill people.”
    • Dr. Alan Christianson (Arizona): Touts Echinacea, Astragalus, and other “natural solutions” to the coronavirus.
    • Dr. Dale’s Wellness Center (California Traditional Naturopath and Homeopath): Sells “BioFilm Detox” claiming you can “take BioFilm Detox 20-30 minutes before you use ALLFLU or anything that you’re using to get rid of the COVID-19, but ALLFLU is the best thing to use, it’s the most effective, you feel a difference after using it once”.
    • Hansen Clinic of Natural Medicine (Arizona): Claims its PhytoBiotic product contains an ingredient that works “by blocking the release and spread of the virus within the body”.
    • LotusRain Naturopathic Clinic: In addition to Vitamin C IVs, mentioned above, the clinic offers “Hydrogen Peroxide IVs” and “AVACEN – Advanced Vascular Circulation Enhancement” as in-clinic options for preventing COVID-19.
    • Arizona Natural Medicine Physicians: On a webpage titled “Coronavirus: Supplements, Herbs & Homeopathic Remedies” this naturopathic-acupuncture practice offers “homeopathic injections such as Engystol which helps support immune function and prevent infection”.
    • Dramov Naturopathic Medical Center (Oregon): From a hyperlink labeled “COVID-19/CORONAVIRUS”, this practice takes consumers to a retail website promoting “Viral Immune Support” supplements.
    • Evergreen Naturopathic (Washington): On its “Novel Coronavirus (COVID-19) FAQ” page, the practice offers patients “personalized herb tinctures to directly confront the viral infections that are most prevalent throughout the year while strengthening and supporting both the immune system and the sensitive tissues that are most susceptible to these infections.”
    • Hawaii Naturopathic Retreat: In addition to Vitamin C IVs, the clinic offers “immune boosting packages to help you protect yourself against the coronavirus” including “antiviral supplements” and a variety of other IV treatments and injections, as well as an infrared sauna and “colonics with probiotics”.
    • Post Falls Naturopathic Clinic (Idaho): Claims it used “energetic signatures of the Coronavirus and influenza” to create the COVID-19 & Flu Immune Booster, “a new homeopathic remedy to boost your immune system”.
Other MDs and DOs, alone and in cahoots with naturopaths and chiropractors, were caught in the FTC’s dragnet as well. Again, the variety of remedies is notable. The Center for Occupational & Environmental Medicine (South Carolina MD) claims that “very sick patients” using “TML drops” would be “without fever and pretty much asymptomatic in 10-24 hours.” New Leaf Wellness (Iowa & Oklahoma DO) says patients can “Beat Covid 19 with Hormones and Glutathione”. The Holtorf Medical Group (California MD, DO, and ND) promotes colloidal silver, as does the Envista Medical Neck & Back Center (California MDs and DCs). Envista also says, in a Facebook post,
Scared of the Corona Virus. We got stem cells!!!
Dr. Adrian Hohenwarter (Pennsylvania MD) recommends “d-Lenolate Olive Leaf 60 caps”; Dr. Brownstein’s Holistic Medicine (Michigan MD), iodine, hydrogen peroxide, and vitamins; Dr. Ronald Hoffman (New York MD), melatonin, nitric oxide, and Beta glucans; Dr. Jill Carnahan (Colorado MD and another SBM post alum), antioxidants; McDonagh Medical Center (Missouri DOs), ozone and UV light therapies; and Cypress Natural Medicine (California, NDs and a DO), herbal tinctures.
Gordon Medical (California MD-ND combo) touts nebulized hydrogen peroxide, while another MD-ND practice, Renaissance Health Centre (Arizona), recommends IV hydrogen peroxide and ozone therapies.
Finally, although in smaller numbers, chiropractic practices also received FTC warning letters. Among them is Fuller Life Chiropractic (Georgia), which promoted its services to people concerned about COVID-19 by claiming
Anything that interferes with proper nerve system function will have a negative impact on your immune system. Chiropractic has been shown to be the most effective form of healthcare for restoring proper nerve system function.
Likewise, Dr. Eric Nepute, a Missouri chiropractor, in a Facebook discussion of coronavirus, suggested his patients would not come down with COVID-19
Because they’ve been getting adjusted regularly, because adjustments help improve the nervous system, which helps improve the immune system. Period.
This is straight-up traditional chiropractic vitalism and similar claims have already been called out as inappropriate, including by chiropractors themselves. The difference here is that we have none other than the FTC finding that there is no competent and reliable scientific evidence to support it. The same can be said for the ubiquitous IV Vitamin C.
Pseudoscience does not exist in a vacuum. Along with Vitamin C, homeopathy, acupuncture, and hydrogen peroxide for COVID-19, these practitioners offer dubious nostrums like hyperbaric oxygen, dietary supplements, other IV “cocktails”, bioidentical hormone replacement therapy, chelation, infrared saunas, iridology, energy “medicine”, and craniosacral therapy, among others, for many other diseases and conditions. Again, as welcome as these warning letters are, it is unfortunate that the FTC does not regularly cast a wider net and target practitioners whose claims are not backed by “competent and reliable scientific evidence”. Or, as in the case of homeopathy and some other quack remedies, any science at all.

        ◦ *Links to all FTC COVID-19 warning letters can be found here. The letters provide links to the offending websites and other internet sources of misinformation. I have not added links to the individual warning letters or the offending materials in this post, as there are so many and they are easily available from the FTC’s list. I did not check to see if these claims have been removed or whether the individuals or companies have otherwise responded to the FTC.

FTC Sues Predatory Journal
Steven Novella on September 21, 2016
Link


Because I have a university e-mail address I frequently get spam from journals I have never heard of soliciting submissions, and even offering editorial positions. I have generally ignored them, and it’s probably a good thing.
Over the last decade we have seen the rise of open-access science journals. The idea is a good one – journals charge a moderate fee to publish an article to cover costs, and then make all articles freely available online. It is a great way to leverage the power of the internet and make published science freely available. This contrasts to the subscription model where published research often sits behind a very expensive paywall.
The problem with the open-access model is that it created the means to easily generate income through predatory behavior. All you need is a website and minimal infrastructure and you can look like a real journal. Since authors are paying you to publish each article, just publish anything that gets submitted.
You can pretend to do editing and peer-review without really doing it. You can also e-mail young academics inviting them to be editors and peer-reviewers and hope that enough of them will be fooled into doing this free work for you – at least enough that you can create the superficial appearance of being a real journal. To maximize profits you can also solicit articles without being up front about the fees, and then once a paper is submitted hit the author with big fees and hold their paper (which may represent years of work) essentially hostage until they pay.
The FTC steps in
This pattern of behavior has been increasingly common, and preys disproportionately on young and third-world academics, the ones who can least afford it.
Greg Ashe is an attorney for the Federal Trade Commission (FTC). He also is an astrophysicist and so is familiar with scientific publications. He is determined to go after so-called predatory journals, and is now suing one company, OMICS, which publishes more than 700 open-access journals.
As Ashe says, the FTC is not concerned with the business model or with the peer-review process. That is not their job. They are concerned with outright fraud. Their accusation against OMICS is that they are not upfront about their fees and they are not transparent about their peer-review process.
Charging hidden fees is a bait-and-switch behavior that can be considered fraud. Scientists are not aware of the fees ($900 for one article in the case reported above) until after OMICS has their paper.
Further, presenting yourself as peer-reviewed when you are not, in order to essentially trick people into buying your service, is also fraud. These are arguably within the purview of the FTC.
The FTC case against OMICS is now a test case and is likely to have a profound effect on the open-access industry. Again, Ashe is clear to point out he is not trying to make companies like OMICS stop publishing, just change their predatory behavior.
The scientific community’s response
The FTC action comes in the wake of increasing attention from the scientific community toward predatory journals. I discussed in 2014 several efforts to expose their predatory practices.
In 2013 John Bohannon published the results of a sting operation against open-access journals. He submitted a bogus article to 304 open-access journals, and over half of them published the article without any apparent editorial or peer-review.
Jeffrey Beall maintains a list of possible predatory journals. Any author can look at his black list before submitting their article.
A 2015 study of predatory journals found:
Over the studied period, predatory journals have rapidly increased their publication volumes from 53,000 in 2010 to an estimated 420,000 articles in 2014, published by around 8,000 active journals. Early on, publishers with more than 100 journals dominated the market, but since 2012 publishers in the 10–99 journal size category have captured the largest market share. The regional distribution of both the publisher’s country and authorship is highly skewed, in particular Asia and Africa contributed three quarters of authors. Authors paid an average article processing charge of 178 USD per article for articles typically published within 2 to 3 months of submission.
There is growing concern not just about the effect this has on poor third-world researchers who are targeted by such journals, but on the communication of science itself.
It is already difficult to develop an objective and reliable view of what the totality of scientific evidence says about a specific question. There is often a lot of conflicting evidence, evidence of varying quality, and multiple sources of research bias. A scientist has to sift through all of this to tease out the real signal from this noise.
The proliferation of dubious open-access journals adds tremendously to the noise – 420,000 articles in 2014. Many of these might get filtered out because they are not indexed among legitimate peer-reviewed journals, and that’s a good thing. But they are still on the internet (they are open-access) and will pollute any search for information on the topics they cover. They are also damaging to the reputation of legitimate open-access journals.
The future
It seems clear there is an enduring place for open-access journals in science and academia. Business models may continue to evolve, but having free access to scientific information is definitely a net positive.
We are, however, in an awkward transition phase. As is often the case with new opportunities, predators swoop in and take advantage of the new territory and relative lack of oversight and regulations.
It seems that the FTC has a legitimate role to play in countering outright fraud in the industry, and they are being mindful of the limits of their purview.
Meanwhile, the academic and scientific community needs to take the problem of predatory journals very seriously and continue to explore ways of reining them in and protecting young and vulnerable academics. They also need to stem the flood of low-grade information that can potentially drown out more legitimate academic activity.

Prevagen goes P-hacking
Can post-hoc data-dredging produce competent and reliable scientific evidence for Prevagen’s claims of memory improvement? The FTC and consumer groups say “no.”
Jann Bellamy on June 21, 2018
Link

Can a protein originally found in jellyfish improve your memory?
According to ubiquitous Prevagen ads,
Our Scientists Say “Yes!”
But, according the Federal Trade Commission (FTC), the state of New York, and consumer groups, what Prevangen’s scientists actually said was “No!” Hence a lawsuit filed last year by the FTC, joined by the New York Attorney General, against Quincy Bioscience (Quincy), the maker of Prevagen, for making false or misleading statements in labeling and advertisements.
The plaintiffs lost in federal district court, a decision that is now on appeal. How the case is ultimately decided could either strengthen the FTC’s hand in pursuing dietary supplement companies with flimsy evidence for their efficacy claims or encourage companies to go data-dredging when their studies don’t yield the desired results.
Oh no! Not another Prevagen ad!
If you are a sentient being with a cable subscription, you’ve no doubt seen advertisements for Prevagen and their claim that:
In clinical trials, Prevagen has been shown to improve short-term memory.
In one version, the results are illustrated with a blue jellyfish-themed chart showing a straight shot to memory improvement in 90 days.
The TV ads are one part of an aggressive marketing campaign which includes a website, social media, radio, print ads, infomercials (“The Better Memory Show”) and a “Prevagen Express” bus that visited health food stores and health expos. By all accounts, the company’s efforts have been wildly successful, with $165 million in total sales. A month’s supply of Prevagen costs between $24 and $68, depending on the formulation and source, and is widely available at retail outlets like CVS, Walgreens and Duane Reed, as well as through online sellers, like Amazon, and healthcare practitioners.
Prevagen is not the only player in the brain supplement business. According to Newsweek:
That often-desperate pursuit of remedies has created a lucrative marketing opportunity, and the supplement industry is cashing in. Products aimed at consumers worried about brain health and memory have contributed to a more than 10-fold increase in the number of supplements marketed in the U.S. over the last two decades.
At the request of Sen. Claire McCaskill, the Government Accountability Office investigated the marketing of brain and memory supplements and issued a report last year. The GAO noted that dietary supplements claiming to improve memory had sales estimated at $643 million in 2015, almost double the 2006 sales. Its report found consumer confusion regarding the roles of the FDA and FTC in regulating memory supplements, which could affect the ability of consumers to make complaints, and suggested better coordination between the two agencies.
Prevagen is a dietary supplement containing a synthetic version of the active ingredient, apoaequorin, a protein. Apoaequorin was originally obtained from a species of jellyfish called Aequorea victoria, which, say scientists, is not nearly as glamorous as its blue-glowing photographs suggest.
According to Quincy:
Apoaequorin has been shown in laboratory studies to support neuronal cells. Based on in vitro and in vivo animal studies, we hypothesized that apoaequorin has the potential to enhance memory and cognitive function in humans. Previous work with apoaequorin in aged canines demonstrated cognitive enhancement. [Citations omitted.]
And:
In a double-blinded, placebo-controlled trial, Prevagen demonstrated the ability to improve aspects of cognitive function in participants with either normal cognitive aging or very mild impairment, as determined by pre-trial screening.
Well, not exactly, says the FTC, as we’ll see in a moment.
Quincy also claims that Prevagen has undergone “extensive” safety testing and that no adverse effects were recorded when tested at dosage levels much higher than recommended, but does not reveal (except in fuzzy photos of the journal articles) that these were studies in rodents and petri dishes, not humans.
The feds step in
Prevagen caught the eye of regulators as early as 2012, when the FDA sent the company a warning letter stating that Prevagen was both an unproved drug and not legally a dietary supplement. At the time, Prevagen was marketed as a treatment for Alzheimer’s disease and head injury, claims only FDA-approved drugs can make. In addition, the FDA pointed out, apoaequorin is not a “dietary ingredient” as defined by the Dietary Supplement Health and Education Act, so Prevagen could not legally be marketed as a dietary supplement either. The FDA’s inspectors also found that Quincy had reported only two of more than 1,000 adverse events, some requiring hospitalization, and product complaints, including heart arrhythmias, chest pain, vertigo, tremors, seizures, strokes, and worsening of multiple sclerosis.
The current status of the FDA matter is unclear, but since the warning letter, Quincy appears to have stopped explicitly touting Prevagen for diseases, focusing instead on its claim that clinical trials show Prevagen improves memory. It is this claim that put the company in the sights of the FTC and the New York AG.
Last year, the FTC, which had received a number of consumer complaints about Prevagen, and the New York Attorney General, filed suit against Quincy, alleging violations of federal and state consumer protection laws, charging them with making false and unsubstantiated claims that Prevagen improves memory, provides cognitive benefits, and is “clinically shown” to work. According to an FTC spokesperson:
The marketers of Prevagen preyed on the fears of older consumers experiencing age-related memory loss. . . . But one critical thing these marketers forgot is that their claims need to be backed up by real scientific evidence.
The complaint sought a permanent injunction against the allegedly false and misleading claims made by Quincy, refunds for consumers, and “disgorgement of ill-gotten gains,” i.e., turning over profits made from Prevagen.
At the heart of the FTC’s complaint is the Madison Memory Study, paid for and conducted by Quincy, on which the company primarily relies in making claims that Prevagen is “clinically proven” to improve memory. The trial methodology and results have never been peer-reviewed or published in a scientific journal. The only written report available to the public is a “Clinical Trial Synopsis” on the company’s website.
The FTC and Quincy agree that the study was a double-blind, placebo-controlled human clinical study using objective outcome measures of cognitive function. It involved 218 subjects taking either 10 milligrams of Prevagen or a placebo, without a no-treatment group. The subjects were tested on nine computerized cognitive tasks to assess a variety of cognitive skills, including memory and learning, at intervals over 90 days. They also agree that the Madison Memory Study failed to show a statistically significant improvement in the treatment group over the placebo group on any of the nine cognitive tasks.
Unsurprisingly, to the FTC this means, contrary to advertisements, the “double-blinded, placebo controlled trial” of Prevagen did not “demonstrate the ability to improve aspects of cognitive function.” Thus, the FTC charges: (1) there is not “competent and reliable scientific evidence” to support Prevagen’s claims, which is required of health care product advertising, and (2) the claim that Prevagen is “clinically proven” is false.
Not so fast, says Quincy. That’s because, after failing to find a treatment effect for their study population as a whole, their researchers conducted more than 30 post hoc analyses of the results, looking at data broken down by several variations of smaller subgroups for each of the nine cognitive tasks. And here they found that older treatment subgroups having low to mild initial impairment had modest levels of improvement in three of the nine cognitive tasks.
In other words, Quincy went p-hacking, and those results, they say, are sufficient to support their advertising claims.
The FTC disagrees, stating in its complaint:
This methodology greatly increases the probability that some statistically significant differences would occur by chance alone. Even so, the vast majority of these post hoc comparisons failed to show statistical significance between the treatment and placebo groups. Given the sheer number of comparisons run and the fact that they were post hoc, the few positive findings on isolated tasks for small subgroups of the study population do not provide reliable evidence of a treatment effect.
The FTC points to the blue jellyfish-themed chart, reprinted in color in the complaint, as an example of how Quincy Bioscience is fudging with the Madison Memory Study results:
It indicates that a “double blinded, placebo controlled study” showed dramatic improvement in recall tasks when, in fact, the results for the specific task referenced in the chart showed no statistically significant improvement in subjects taking Prevagen compared to subjects taking a placebo. In addition, Defendants eliminated from the chart one of the four data points in the study – day 60. At day 60, the recall task scores of subjects taking Prevagen declined from day 30, and were slightly worse than the recall task scores of subjects in the placebo group.
The FTC also takes issue with Quincy’s assertion that apoaequorin is capable of crossing the blood-brain barrier, which, according to the FTC, is essential to their claim that their product improves memory and cognition. They don’t have evidence for this, according to the complaint, and, in fact, their own safety studies show that the protein is rapidly digested in the stomach and broken down into amino acids and small peptides, like other dietary proteins.
Prevagen defends its position in a brief filed with the appellate court as appropriate and common in the dietary supplement industry. In any event, it says, there is no law requiring the level of substantiation for healthcare product claims the FTC complains it failed to meet. Rather, the FTC itself has said it will take a flexible approach to substantiation, including the acceptance of less than “gold-standard” RCT studies.
It also argues, somewhat disingenuously, that it never said apoaequorin was capable of crossing the human blood-brain barrier. Rather, based on its canine studies, its:
marketing statement thus included only an indication “that apoaequorin is capable of crossing the blood brain barrier…in dog[s.]”
Of course, unless consumers were contemplating giving Prevagen to their dogs, this wouldn’t be relevant, unless one assumes this information was included so consumers would, by implication, conclude that apoaequorin can get into their brains as well. As the FTC says:
The first step in evaluating the truthfulness and accuracy of [dietary supplement] advertising is to identify all express and implied claims an ad conveys to consumers. Advertisers must make sure that whatever they say expressly in an ad is accurate. Often, however, an ad conveys other claims beyond those expressly stated. Under FTC law, an advertiser is equally responsible for the accuracy of claims suggested or implied by the ad. Advertisers cannot suggest claims that they could not make directly.
Ongoing litigation
Quincy successfully moved to dismiss the complaint for failure to state a claim. The district court ruled that the FTC, in its allegation that the post hoc analyses were insufficient to support Prevagen’s efficacy claims:
fails to do more than point to possible sources of error but cannot allege that any actual errors occurred.
As to the FTC’s claim that apoaequorin is rapidly digested and broken down into amino acids and small peptides like any other dietary protein, the court said:
This point, contradicted by canine studies whose relevance plaintiffs challenge, loses force when applied to the results of the subgroup study which make it clear that something caused a statistically significant difference between those subjects who took Prevagen and those given a placebo.

That, of course, was the whole point of the FTC’s first argument: post-hoc data-dredging is unreliable and can’t rule out “statistically significant difference” as mere noise.
On appeal, there is a substantial argument over whether a ruling on these issues was appropriate on a motion to dismiss, where the only question should be whether the allegations of the complaint are sufficient to state a claim against the defendants. Motions to dismiss are decided at the very earliest stages of a trial and only the plaintiffs’ complaint and defendants’ answer are under consideration. Courts are not supposed to consider any evidence or rule on questions of fact, two errors that the FTC says the district court made in this case. Whatever the merits of the case, I think that the complaint should not have been dismissed, and at least one commenter, also not a party to the litigation, agrees that the Second Circuit Court of Appeals is likely to reverse on this issue, giving the parties an opportunity to more fully flesh out the evidence and their arguments.
Joining, as amici curiae (“friends of the court”), the FTC and the state of New York in arguing the district court’s decision should be overturned is an impressive array of consumer groups and academics: Truth in Advertising, Inc., AARP, Advertising Law Academics, National Consumers League (their collective brief is here), Public Citizen, Center for Science in the Public Interest, and the Collaboration for Research Integrity and Transparency (collective brief here).
I had not heard of the Collaboration for Research Integrity and Transparency and found its mission interesting, and worthy:
The Collaboration for Research Integrity and Transparency (CRIT) is a multidisciplinary initiative of Yale Law School, Yale Medical School, and Yale School of Public Health. CRIT’s mission is to promote public health by improving the transparency and integrity of biomedical and clinical data. CRIT’s scientists have conducted research showing that data transparency and integrity are crucial to the accurate and informed use of drugs, devices, and biologics. Through litigation and policy work, CRIT focuses on enforcement of statutes and rules governing the accurate reporting of clinical trial results.
The latter amici curiae group explains in its brief why post-hoc analyses of data like that used by Quincy is not reliable. In part, they say:
Because the experts in the field of medical research would not generally accept Quincy’s post hoc subgroup analyses as yielding scientifically sound and reliable results, the FTC has adequately alleged that the analyses do not substantiate the claims and properly stated a claim on which relief can be granted. Subgroup analysis refers to an evaluation of study results in a subgroup of the subjects defined by certain baseline characteristics. See Rui Wang, et al., Statistics in Medicine – Reporting of Subgroup Analyses in Clinical Trials, 357 New Eng. J. of Med. 2189 (2007). Subgroup analyses are post hoc when the subgroup levels and “the hypotheses being tested are not specified before any examination of the data.” Id. at 2190. Post hoc subgroup analyses have long been viewed with skepticism by research scientists and statisticians. See, e.g., Andrew Oxman, et al., A Consumer’s Guide to Subgroup Analyses, 116 Annals of Internal Medicine 78, 83 (1992) (stating that “there are those who ignore scientific principles in the subgroup analyses they undertake and report, go on fishing expeditions, and indulge in data-dredging exercises” and that subgroup analyses showing small, marginally significant interactions generated by post hoc exploration of a single dataset “should be viewed with great skepticism”).
As another commenter pointed out, the FDA prohibits post-hoc subgroup analyses for efficacy claims in clinical drug trials, and explains why:
The FDA is concerned both about conflicts of interest and that performing multiple subgroup analyses can increase the risk of false-positive findings. In other words, the more analyses one conducts, the more likely it is that one will find a false positive result because when groups get smaller, confidence intervals grow larger and statistical power is reduced.
If the district court’s dismissal is overturned and the case remanded for further proceedings on the merits, the FTC will be able to present this scientific consensus to the court as evidence. (Even if it isn’t, the FTC and the New York AG remain free to file an amended complaint addressing the errors the district court in their pleadings.)
As well, if the case returns to the district court, the plaintiffs/appellants will be in good company in arguing the blood-brain barrier issue. Here’s what experts have said about that:
Meanwhile, Quincy’s claims are rejected by the research community, which notes that any protein taken by mouth will be broken down into amino acids in the stomach and won’t reach the brain in its original form.
Quincy’s claims “have no legitimate reality based on the real facts of science, nutrition and memory,” says David Mead, a molecular biologist and cofounder of Varigen Biosciences in Madison.
“It’s quackery. I can’t think of anything better to say,” says Baron Chanda, an associate professor in the UW-Madison Department of Neuroscience.
“I second the ‘quackery,'” says Chanda’s neuroscience colleague, professor Edwin Chapman. “This is downright silly — no other word for it.”
And:
“It is biologically inconceivable that taking a protein by mouth would have any effect on memory,” [Dr. David S.] Seres, [director of medical nutrition at Columbia University Medical Center] concluded.
For a longer, wonkier explanation of why apoaequorin is highly unlikely to cross the blood-brain barrier, see this Medscape article.
The importance of this case to the dietary supplement industry is evidenced by the fact that several industry trade groups have joined Quincy as amici curiae: Council for Responsible Nutrition, Consumer Healthcare Products Association, Natural Products Association, and the Alliance for Natural Health – USA.
My guess is that the lower court’s decision will be reversed and the case will go back to the district court, where this case will become another in the long history of expensive and time-consuming litigation over dietary supplements, much of which could be avoided if Congress ditched DSHEA and passed a law regulating dietary supplements and their marketing meant to protect consumers, not the industry. Here’s another prediction: that’s not going to happen.

Physician Misinformation
Steven Novella on November 13, 2024
Link
When physicians spread medical misinformation, the potential harm to health is far greater than their direct patient care. And yet, in a recent study, medical boards rarely discipline physicians for spreading misinformation.
The JAMA article looked at 3128 medical board disciplinary proceedings involving physicians. Spreading misinformation to the community was the least common reason, at 0.1%. Direct patient misinformation and inappropriate advertising were tied for the next two least common reasons at 0.3%. This is an order of magnitude or more less than other causes for disciplinary action.
The limitation of this study is that we do not know what the incidence of spreading misinformation is. We also don’t know how many complaints are raised that do not result in disciplinary actions, because pending or dismissed cases are confidential and not made public. But, the authors write, there is evidence that such complaints are on the rise:
“The FSMB reported in December 2021 that about two-thirds of medical boards had seen an increase in complaints about physicians spreading COVID-19 misinformation.”
Many medical boards have also stated this is an increasing problem that they intend to crack down on, and yet this is not reflected in the numbers. A few questions are raised by this apparent disconnect. First, is it appropriate for medical boards to police what physicians say to their patients and to the public? Second, are medical boards the proper mechanism for dealing with physician misinformation? And finally, if so, how can medical boards do a better job?
Licensed professionals are generally given a lot of leeway in terms of exercising their professional judgement, and we certainly don’t want to chill discussion and debate about what the evidence says and best practices. However, a licensed professional carries and benefits from the imprimatur of authority and legitimacy conferred by the state government. They may also be certified by a professional board. In other words, they can say (in some form) – listen to me and trust me because I have MD after my name and I am a certified specialist. If that means something, then it has to mean something.
In other words, it makes no sense for licensed professionals to have it both ways – to benefit from a seal of professional approval without being held to a professional standard. For those concerned about free speech, we can also look at it this way. Physicians and other professionals are free to talk as a private citizen about anything they wish. But when they are speaking in their capacity as a professional, their speech is part of their professional conduct, and it is absolutely fair game to police that speech.
A physician speaking either directly to a patient or to the public on a health issue is speaking, to a degree, on behalf of their profession. This is what the public generally assumes. State medical boards exist to uphold the standards of the professions they license.
The Federation of State Medical Boards, responding specifically to COVID-19 misinformation, had this to say:
“Physicians who generate and spread COVID-19 vaccine misinformation or disinformation are risking disciplinary action by state medical boards, including the suspension or revocation of their medical license. Due to their specialized knowledge and training, licensed physicians possess a high degree of public trust and therefore have a powerful platform in society, whether they recognize it or not. They also have an ethical and professional responsibility to practice medicine in the best interests of their patients and must share information that is factual, scientifically grounded and consensus-driven for the betterment of public health. Spreading inaccurate COVID-19 vaccine information contradicts that responsibility, threatens to further erode public trust in the medical profession and puts all patients at risk.”
The AMA (American Medical Association) also weighed in:
“State licensing and credentialing boards must use their authorities to discipline clinicians who spread misinformation and to reinforce the nature and scope of professional and ethical obligations of government and nongovernment clinicians. Individual clinicians must also play an important role by actively and vigorously correcting misinformation disseminated by other clinicians.”
There is a broad consensus of relevant players that misinformation is dangerous, spreading misinformation is unprofessional and potentially harmful, and it should be policed and disciplined. And yet, it does not appear to be happening at the state board level.
I could not find any information on how often specialty boards suspend or remove certification for spreading misinformation. That is an even easier call – board certification is a privilege that has to be earned an maintained, and a specialty board can use whatever criteria they deem appropriate. This has happened – there are reports of many cases of doctors losing their certification for spreading misinformation, but there is no data to quantify this.
If there is a consensus that medical misinformation is harmful and violates professional ethical standards and are an appropriate target for discipline, why is action so uncommon? This gets to the second and third question – are medical boards the best mechanism for dealing with physician misinformation, and how can they do a better job?
The short answer to whether or not medical boards should be disciplining misinformation is yes. In the US state medical boards are the primary mechanism for maintaining the standard of care and holding physicians to generally accepted ethical and professional standards. That is literally their job. That doesn’t mean there are no other layers of protection. As already stated, specialty certification can and should be revoked for violating the high standards of a certified specialist.
There are other layers as well. Hospitals can use their own criteria to determine who can be on staff and who gets admitting privileges. They have committee that regularly review all their physicians, including all complaints and official disciplinary actions, and determines if action should be taken or if privileges should be continued.
There is also a legal layer, which hopefully would be the last resort. Professionals can be sued for malpractice that results in harm. It’s pretty clear that directly giving a patient for whom you are caring false health advice and misinformation is malpractice, and can result in harm. It’s less clear if this would hold up for a physician spreading misinformation publicly.
Legal scholars have been weighing in on this issue. There appears to be a good consensus that state medical boards can and should act when physicians spread misinformation directly to their patients. There is no apparent consensus when it comes to spreading misinformation to the public. There are first amendment concerns, although many scholars argue that the first amendment does not prevent medical boards from disciplining physicians for public misinformation.
However, many scholars argue that medical boards are simply not set up to police public medical misinformation. Often issues are in the gray zone, and there is legitimate disagreement about what the science says. Medical boards don’t necessarily have the proper expertise to judge what counts as misinformation and where the draw the line. But again, if not the medical boards, then who?
Perhaps what needs to happen is that state medical boards establish the infrastructure so that they can deal effectively with the physicians they regulate spreading demonstrable misinformation. This will likely mean that they need to expand their resources. They may also need to partner with professional organizations. For example, specialty boards are generally in a better position to determine what is misinformation within their specialty, and already had a history of putting together expert panels to review evidence and establish practice guidelines.
What can, and likely should, happen, therefore, is that specialty boards turn their attention to medical misinformation and establish practice guideline, not only for what physicians should do but what they should, and should not, say. State medical boards would not need to duplicate this effort, but can simply enforce it for physicians in their state.
It also should be noted that taking disciplinary action does not mean immediately removing a physicians license. That is the most extreme action, reserved for the worst offenses. In many instances a physician can simply be given a warning, or be required to take CME credits in the relevant topic. A lot of misinformation, in other words, can be dealt with through education.
For physicians who persist in spreading demonstrable misinformation despite these efforts, increasing disciplinary action would be appropriate. Physicians can be censored, their licenses can be suspended for a period of time, and they can ultimately be revoked. No one deserves an MD. If you are using your MD to harm the public health, and the profession has a moral responsibility to protect and advance the public health, then clearly action needs to be taken.
What is clear at this time is that physician misinformation is an increasing problem, worsened by social media and perhaps also by political division. And yet, the mechanisms we have in place for ensuring proper professional behavior seem to be failing when it comes to spreading misinformation. There needs to be a robust discussion within the profession, and including legal scholars, ethicists, and regulators, to improve our ability to ensure that the public is getting the most accurate medical information from professionals.


COVID

The ABIM vs. medical misinformation: Better late than never?
Last week, the New England Journal of Medicine published an editorial by the President of ABIM discussing how the board certification can be taken away from diplomates who spread medical misinformation. Is this too little, too late?
David Gorski on May 23, 2022
Link

Over its 14 years of existence, one of the core messages of Science-Based Medicine has been very consistent. We have bemoaned how easily doctors who are quacks, antivaxxers, and grifters not only manage to avoid professional penalties and keep their medical licenses and board certifications, but often to keep practicing more or less unimpeded by either state medical boards or the private boards that certify them in their chosen medical specialties. Flowing from this dismay, we have also advocated for change to empower state medical boards and specialty boards to hold doctors accountable for professional misdeeds, up to and including being able to revoke their medical licenses and board certifications. After all, without a medical license, a physician cannot practice, and without a board certification it is very difficult to practice, as Medicare and Medicaid, as well as most insurance companies, require it to reimburse a physician, and most hospitals require it to grant privileges. One has only to consider the example of Texas cancer quack Stanislaw Burzynski, who “discovered” antineoplastons in the early 1970s and has been charging large consultation fees to administer them since the late 1970s to treat cancer patients despite no good evidence that they are effective. Over the more than 40 years of having plied his quackery on cancer patients, Dr. Burzynski had managed to avoid significant sanctions from the Texas Medical Board (most recently in 2017) and the FDA for his “clinical trials” that were designed primarily as marketing tools to let him keep using antineoplastons rather than actual clinical trials to determine if antineoplastons work. So it was with great interest that I encountered an op-ed in The New England Journal of Medicine by the President and CEO of the American Board of Internal Medicine (ABIM) Richard J. Baron, MD, and the chair of its board of directors, Yul D. Ejnes, MD, titled “Physicians Spreading Misinformation on Social Media — Do Right and Wrong Answers Still Exist in Medicine?” Obviously, I think you know how I (and SBM members) will answer, but first let me start with a little context.
COVID-19: Old quacks revitalized and joined by new quacks spreading disinformation
Burzynski arguably pioneered the technique that we see so much in evidence today; he recruited his patients to use for PR and politics to spread misinformation about cancer and “health freedom.” Basically, the techniques that Burzynski used in the 1990s to pressure the FDA and Texas Medical Board were the same techniques later used to pressure state legislatures and then the US Congress to pass “right-to-try” laws in the name of “medical freedom”. The very same technique is being used to pressure legislatures to promote laws banning COVID-19 vaccine mandates, making repurposed and ineffective treatments like ivermectin available over-the-counter, and immunizing physicians against penalties for using quackery to treat COVID-19.
When the COVID-19 pandemic hit, what we’ve been warning about since 2008 about physicians promoting quackery and misinformation very quickly became a global threat to public health. The usual physician suspects from the past, whom we had long been writing about since back in the day (e.g., Rashid Buttar, Russell Blaylock, Andrew Wakefield, Paul Thomas, Bob Sears, Sherri Tenpenny, Kelly Brogan, various members of old crank medical organizations like the AAPS, etc.), many of whom had been so forgotten that they were largely unknown outside of the deepest, darkest circles of the antivax and quack Internet, soon found themselves becoming relevant—even famous—again, along with the new generation of quacks and cranks who arose to spread COVID-19 misinformation (e.g., Robert “inventor of mRNA vaccines” Malone, Peter McCullough, Simone Gold, Vinay Prasad, Marty Makary, Pierre Kory, Joseph Ladapo, Paul Marik, Vladimir Zelenko, Aaron Kheriaty, and many others). There is now a veritable army of quacks, some of whom are into serious grift (e.g., America’s Frontline Doctors running a prescription mill for ivermectin), but all of whom are spreading dangerous misinformation about COVID-19, vaccines, and unproven treatments for COVID-19 like ivermectin (which to me is now disproven), hydroxychloroquine, and many others, all while doing their damnedest to promote “health freedom,” or, as I like to put it, freedom from professional responsibility, government regulation, or any consequences whatsoever for endangering patients.
Again, this was a problem that SBM had long written about going back to the very beginning of this blog, namely how toothless state medical boards are, how easily bad and even dangerous doctors can keep practicing, and how oblivious our fellow physicians had been to the threat of medical misinformation before the pandemic, a threat to which they have only fitfully been waking up. For example, I noted at the end of 2020 how it had been a year of physicians behaving badly. Before I discuss the NEJM op-ed, I think it’s worth quoting myself from nearly a year and a half ago:
If anything, the COVID-19 pandemic has reinforced my opinion, first stated 12 years ago, that medical practice itself is a sadly weak check on BS, particularly when the medical system is stressed. Just look at the list of examples that I’ve discussed in this post and realize that there are many more that I could have discussed if I didn’t mind having this post balloon up to 10,000 words or more. The point, of course, is that all too often we physicians view ourselves as relatively immune to being led astray by “BS”, certainly far more so than others. It is that arrogance that leads to doctors like Dr. Scott Atlas pontificating on areas of medicine that he doesn’t understand and then portraying himself as Galileo when criticized for it. Don’t believe me?
After listing a number of examples of physicians spreading dangerous COVID-19 misinformation, as well as historical examples, such as Stanislaw Burzynski, Christopher Duntsch, and others, I concluded:
The bottom line is that practicing medicine is a privilege, one of the highest privileges society can grant to any human being. It is not a right. Unfortunately, all too often the law treats it more like a right, with state medical boards being loathe to strip quacks and other doctors practicing inarguably substandard medicine of their privilege to practice. That needs to change, and that change needs to include stopping physicians from abusing the privilege of their profession to spread disinformation that kills, as too many physicians did in 2020 and, sadly, are likely to continue to do in 2021.
2021 has come and gone, and we’re not far from the halfway point in 2022. What’s happened? The good news is that, as a result of the tsunami of misinformation and disinformation being promoted by physicians, a disturbing number of whom are vaccine-hesitant or outright antivax, nearly a year ago the Federation of State Medical Boards asserted that spreading dangerous medical misinformation could be grounds for a physician’s license to be suspended or revoked, although, unfortunately, the FSMB has no statutory power and all state medical boards are governed by their individual state laws, which have been under assault by “health freedom” antimaskers and antivaxxers not to discipline doctors for spreading COVID-19 misinformation. As I’ve noted before, quacks and antivaxxers targeting state medical boards is nothing new. It’s long been a tactic of theirs to target state medical boards legislatively, just as advocates for pseudomedical “disciplines” like naturopathy, acupuncture, and the like have long targeted legislators to achieve licensure in more and more states. In the past, it was mostly quack-friendly legislators prodded by powerful pseudomedicine interests. For example, in 2010, the aforementioned Buttar led a successful effort by the North Carolina Integrative Medical Society to persuade legislators to change state law to make it friendlier to practitioners of alternative medicine. Now, North Carolina law prevents its medical board from disciplining a physician for using “non-traditional” or “experimental” treatments unless it can prove they are ineffective or more harmful that prevailing treatments. The same thing is happening today, just on a scale I’ve never seen before.
Other good news is that a new medical advocacy group, No License for Disinformation (NLFD) has been formed and advocates to state medical boards and specialty medical boards to take misinformation seriously and even sanction doctors who promote it. NFLD has been quite successful since it was formed in garnering press and access to state medical board officials and specialty boards. Unfortunately, much of the rest of medicine has been very resistant to such efforts, apparently viewing them as an unacceptable assault on “freedom.” Indeed, just over the weekend, I saw statements like this about a proposed California law that would empower its medical board to discipline doctors who spread misinformation.
If your dr is treating you for Covid or goes beyond the guidelines to save you, Appreciate him or her because these are the most trying times for drs. Not only do we have to stress about every lives we take on but now we have to fight boards . This is coming I’m sure👇 pic.twitter.com/JC2m85dXmH
— sabine hazan md (@SabinehazanMD) May 19, 2022
You might remember Physicians for Informed Consent, a virulently antivax physicians’ group.
With that background, let’s look at the NEJM editorial.
The ABIM weighs in…belatedly
It’s hard to argue with the opening of the NEJM op-ed on medical misinformation:
Medicine has a truth problem. In the era of social media and heavily politicized science, “truth” is increasingly crowdsourced: if enough people like, share, or choose to believe something, others will accept it as true. This way of determining “truth” doesn’t involve scientific methods; it relies instead on “the wisdom of crowds,” which has particular power in a democratic society in which leaders and policies are chosen by the will of the group. Such choices anchor concepts like freedom and liberty. But they may not be helpful in determining whether a building will collapse, whether your brakes will stop your car — or whether a medication or vaccine works.
Growing allegiance to crowd-endorsed “facts” poses a serious challenge for the institutions and structures that the medical enterprise has developed to protect the public and ensure that people can tell who can or cannot be trusted as medical professionals or relied on for scientific knowledge. These structures include comprehensive medical education, licensure, and board certification, and leaders in all these areas are struggling to figure out how to respond to assertions by doctors on social media that are not supported by evidence and may harm patients. The Surgeon General has identified medical misinformation as a major public health threat, and many professional societies, including the American Medical Association, have called for action to combat it.
As much as I hate to say “I told you so”, I told you so, at least we’ve been telling the medical profession, state medical boards, etc., so for over 14 years. None of this is anything new, and SBM has been warning about it since 2008, with some of its member having been warning about it years before. Indeed, one of our bloggers, Val Jones, even coined a term for the attitude of physicians about alternative medicine quackery, medical misinformation, antivaccine pseudoscience, and the like, describing most physicians who didn’t take it seriously as “shruggies”—and she did it in 2008, defining a “shruggie” thusly:
Shruggie (noun): a person who doesn’t care about the science versus pseudoscience debate. When presented with descriptions of exaggerated or fraudulent health claims or practices, their response is to shrug. Shruggies are fairly inert, they will not argue the merits (or lack thereof) of complementary and alternative medicine (CAM) or pseudoscience in general. They simply aren’t all that interested in the discussion, and are somewhat puzzled by those who are.
Sound familiar? As hard as it is to believe, even more than two years into the pandemic and the tsunami of dangerous misinformation and conspiracy theories, there are still a lot of shruggies in the medical profession.
It hasn’t been just social media, either, which largely didn’t exist (at least not at the massive scale it does now) when Steve Novella founded SBM in 2008. The problem had been brewing years before on websites, blogs, Internet discussion forums, Usenet, and old-fashioned email lists. It had also been brewing in our very profession of medicine, with the rise of “complementary and alternative medicine” (CAM), later “rebranded” as “integrative medicine,” which was based on the “integration” of outright quackery into evidence-based medicine. Let’s just put it this way. When there are academic departments in medical schools that promote quackery such as reiki, naturopathy, homeopathy, and even anthroposophic medicine, it’s little wonder that medical academia has been reluctant to confront those in its ranks who promote COVID-19 contrarianism, misinformation, and even outright antivax views.
Baron and Ejnes then note:
The issue of what physicians can and cannot say on social media has been hotly debated by legal scholars and in medical journals. Coleman has observed that “professional speech” is a legally contested domain between speech that can be regulated or prohibited by licensing boards and speech protected by the First Amendment. It is also unclear when physicians’ speech on social media constitutes “medical practice.”1 Mello has questioned why First Amendment protections should extend to harmful speech that leads to death from preventable disease, when some other forms of speech — such as fraudulent commercial speech, which may be less harmful — are prohibited.2
It’s true, too. No one, not even those of us at SBM who have advocated for disciplinary actions that apply to physicians who use their status as trusted professionals to give a patina of science and the authority of medicine to fraud and conspiracy theories, have claimed that there is a bright line between misinformation/disinformation and legitimate differences in scientific and medical opinion. That being said, the ABIM does ask the right question, namely, “Do Right and Wrong Answers Still Exist in Medicine?” I’ll add a spoiler alert by pointing out that the op-ed concludes, “There aren’t always right answers, but some answers are clearly wrong.”
Exactly!
Certainly, at the very least I would agree with Baron and Ejnes that there are indeed answers that are clearly wrong in medicine. They do exist. Cranks and quacks like to wrap themselves in the observation that “medicine changes” as new evidence comes in, all in order to argue that they are doing nothing more than engaging in “debate” and to claim that their views might be vindicated or that they are at least plausible enough not to be immediately dismissed, but such arguments are subterfuge, camouflage to fool the unwary. I also like the example used by Baron and Ejnes, specifically how ABIM certifying exams are constructed specifically the use of “distrators,” answers that are wrong but plausible enough to trap those whose knowledge of the topic is insufficiently deep, although I will argue that it is actually rather simplistic and naive as a comparison to COVID-19 misinformation (and, indeed, medical misinformation and quackery in general):
Creating these exams involves bringing together academic and practicing expert clinicians from a particular field to write and critique multiple-choice questions that have a single best answer — a process that may provide a useful perspective on somewhat analogous efforts to assess the information that doctors and others disseminate through informal public channels such as social media. The challenge in writing multiple-choice exam questions is not constructing a question with a right answer; rather it’s creating the “distractors,” the wrong but plausible answers. As anyone who has taken a multiple-choice exam knows, even someone with no knowledge of the relevant field can pass a test when the wrong answers are obviously implausible. An exam question measures something important only if someone acquainted with the field might believe the wrong answers are correct. The expert clinicians spend most of their time debating the distractors: Is that answer really wrong? If anyone around the table can find a valid article that might support the choice of option C as correct, then option C can’t be used as a distractor. In these discussions, the experts are guided by peer-reviewed medical literature, not by “prevailing opinion” or what a committee member believes; they don’t take polls. They accept the methods underlying scientific studies as a safer guide to practice than the received wisdom, intuition, or even “democratic process.” Informed by that literature, they conclude that some answers are definitively wrong.
There’s also quality control in such examinations. If, for example, certain wrong answers are chosen at too high a frequency, the question or answers might be modified or dropped from future versions of the examination. The point, though, is that there are answers that are plausible scientifically, but nonetheless wrong.
There is a huge difference, though, between the example of exam questions and distractors discussed above and the real world misinformation being promoted about COVID-19, a disturbing amount of it by physicians. Specifically, physicians tend to be really good at cherry picking (or even producing) seemingly scientific papers published in the peer-reviewed medical literature to support their misinformation. The problem of misinformation and disinformation is far more complex than there just being no papers to support a particular answer. In addition, physicians can be really good at misrepresenting or distorting the findings of legitimate scientific publications in the service of their disinformation, be it demonizing COVID-19 vaccines, claiming that masks don’t work to slow the spread of COVID-19, or arguing that COVID-19 is not dangerous. In this, I have always thought that Brandolini’s law (also known as the bullshit asymmetry principle), which states that the “amount of energy needed to refute bullshit is an order of magnitude bigger than to produce it” is far too optimistic. I tend to think that it takes at least two—if not three—orders of magnitude more time and effort to refute bullshit as it does to produce it, and disinformation spreading doctors are very good indeed at producing and repackaging bullshit. Basically, the example used by Baron and Unje is very simplistic and doesn’t recognize the full magnitude of the misinformation problem. It is, however, a start, and I think they are starting to “get it”:
As the ABIM confronts the danger of medical misinformation, we recognize that there are many clinical issues on which physicians legitimately hold a spectrum of opinions, all supported by evidence; such justifiable positions would not make it as “distractors” on our exam, nor would they meet our definition of “false information,” as determined by experts consulting the literature. A whole range of statements with which many — or even most — physicians might disagree would therefore not trigger our disciplinary process. On the other hand, when someone certified by the ABIM says something like “the origin of all coronary heart disease is a clearly reversible arterial scurvy” or “children can’t spread Covid” or “vaccines don’t prevent Covid deaths or hospitalizations,” we are not dealing with valid professional disagreement; we are dealing with wrong answers.
I like that Baron and Unje didn’t just mention false claims about COVID-19 and included one about heart disease. It suggests that maybe—just maybe—they now recognize that the problem of medical misinformation being spread as “health freedom” and the “democratization” of medical knowledge is much broader than COVID-19 and predates the pandemic by decades.
Also, conspiracy theories (e.g., that COVID-19 is a “plandemic” or “casedemic” or that COVID-19 vaccines contain microchips or other tracking devices) should easily fall into this category, as not even being plausible enough to be a distractor in a multiple choice question. I am, however, a bit concerned. Again, there is no bright line between a wrong answer that’s plausible enough to be a “distractor” and bullshit, given the talent a lot of physicians have for cherry picking the scientific literature, and I have to wonder if the experts in the ABIM are up to the task of identifying certain claims as implausible. I say this because I saw no mention of the ABIM consulting experts in conspiracy theories and disinformation to adjudicate cases. We’ve documented many times throughout our 14 years of existence how physicians not acquainted with medical misinformation and quackery are often flummoxed when they encounter many of these claims. They just don’t have the background to adjudicate anything in the “gray areas” and sometimes struggle even with cases that to those of us who study quackery and misinformation are obvious.
Difficulties aside, I applaud ABIM for starting to grapple with the issue of its diplomates spreading medical misinformation and disinformation, even if they’re late and appear to have a bit of a naïve view of what medical misinformation and disinformation are. Basically, I hope that they will learn and suspect that they might have an easier time actually doing something meaningful than many state medical boards will, given the politics in a distressing number of states.
Finally, although it’s the largest, the ABIM is but one of many boards certifying various medical specialties. I, for instance, am certified by the American Board of Surgery, which has not yet stepped up to the plate, and no other board besides ABIM has yet gone as far. Certainly, I hope that a year from now I will no longer be able to say that.

The American Board of Internal Medicine finally acts against two misinformation-spreading doctors
Last week, I wrote about how COVID-19 has exposed the toothlessness of state medical boards. Last week, the American Board of Internal Medicine announced that it was going to permanently revoke the board certifications of two COVID-19 contrarian doctors, Drs. Paul Marik and Pierre Kory. Can medical specialty boards make up for the failure of state medical boards, at least partially?
David Gorski on August 7, 2023
Link

Last week, I wrote what was basically a lament and jeremiad about the longstanding failure of state medical boards to discipline quacks and antivax doctors. It is, as I discussed, a failure that dates back to before the pandemic, which is why I described how the pandemic had exposed the toothlessness of most state medical boards. My observation was based on a recent story published in The Washington Post by Lena Sun, Lauren Weber, and Hayden Godfrey that described how few physicians spreading misinformation about COVID-19 and vaccines had suffered anything in the way of discipline or penalties, much less actually had their medical licenses revoked, despite the unfortunately huge numbers of physicians who have made a name for themselves on social media for spreading fear, uncertainty, and doubt about public health interventions, treatments, and vaccines for COVID-19, with many of them selling quackery such as “spike protein detox” instead. As you might expect, I pointed out that this has been a longstanding problem with state medical boards, which are often understaffed and underfunded, incentivizing them to deal with easy, imminent threats, like doctors with substance abuse disorder, rather than cases where they have to adjudicate a standard of care an possibly devote large amounts of their limited resources to take on well-funded quacks like Stanislaw Burzynski and Rashid Buttar.
Given that I had just written about the topic of holding misbehaving physicians accountable for the harm that they do, naturally it caught my attention when I saw this Tweet on Friday from journalist Anna Merlan citing an email blast from the what is in my opinion a quack medical group, the Front Line COVID-19 Critical Care Alliance (FLCCC Alliance) about a decision apparently made by the American Board of Internal Medicine (ABIM) this week:
This has been coming for a while – we wrote about this battle last June. https://t.co/Zyy8qIxwVb
— Anna Merlan (@annamerlan) August 4, 2023
Curious, I went to the FLCCC Alliance website and Substack, where I was greeted with headlines like Two Leading COVID-19 Doctors are Facing Accusations of Spreading Misinformation by American Board of Internal Medicine (ABIM) Committee and FLCCC Doctors Plan to Fight Board Decision. It didn’t take long for allies of Drs. Pierre Kory and Paul Malik to weigh in, in particular Sen. Ron Johnson:
Here's an example from @Covid19Critical of how one member of the COVID Cartel, ABIM, uses their certification power to try to discredit two doctors who had the courage and compassion to successfully treat COVID patients. pic.twitter.com/iwu45BdGjB
— Senator Ron Johnson (@SenRonJohnson) August 4, 2023
Many of you will recognize the video as a brief “greatest hits” of COVID-19 misinformation, complete with the bogus “Pfizer whistleblower” conspiracy theory and a bit at the end about “looking at the evidence for myself.” Regular readers of SBM and my not-so-secret-other-blog know my opinion of FLCCC, namely that they’re a bunch of rank quacks who made their name selling ivermectin as a “cure” for COVID-19. Unfortunately, there are a lot of ideological useful idiots in positions of power who have portrayed the FLCCC as a group of “brave maverick doctors”—”truth tellers”—and tried to alter the law to shield them from the consequences of the misinformation they spread and the quackery they practice, even as they were part of a network creating a global market for health fraud selling ineffective repurposed drugs like hydroxychloroquine and ivermectin to treat COVID-19.
Indeed, in retrospect, I had noticed a rare email from ABIM sent to my work address earlier in the week, which made me wonder if something was up. Here’s a rather generous excerpt, given that it’s an email blast:
Second, I wanted to provide an update on our work around addressing medical misinformation. I’m sharing a piece just published in JAMA that I coauthored with Dean Schillinger, MD, Professor of Medicine in Residence at the University of California San Francisco, titled “Health Communication Science in the Balance.”
In it, we explore how and why the NIH abruptly “paused” a new $154 million research program called Advancing Health Science Communication and Practice—which was 20 months in the making—with only a vague explanation that they needed to “reconsider the scope and aims in the context of the changing legal and regulatory landscape related to communication platforms.”
It should be noted that this announcement was made June 6, 2023, just weeks ahead of a judicial order issued on July 4 in the Missouri v. Biden legal case that prohibits governmental agencies from talking with social media companies. Judge Terry A. Doughty’s order has been stayed temporarily by the Appellate Court, but it appears to have already had an impact on federal officials.
At a time when trust in the medical profession is at an all-time low, we know patients seek guidance about their health from a wide variety of other sources, including social media platforms. It is a tremendous disservice to patients everywhere when agencies like the CDC cannot even have a conversation with social media companies about how to ensure that evidence-based medical information is easily identifiable and distinguishable from snake oil.
It also hampers our collective ability across all sectors of health care to collaborate on initiatives that may help mitigate misinformation and elevate expert voices. I wrote about one such potential private-public partnership model in a piece in the Annals of Internal Medicine that you may have seen, called Addressing Viral Medical Rumors and False or Misleading Information.
In closing, I’d also like to share a recent article in the Washington Post, where reporters Lena Sun, Lauren Weber (of the Post’s misinformation team) and Hayden Godfrey undertook a comprehensive investigation of disciplinary actions taken by medical boards across all 50 states, concluding that “doctors who jeopardized patients’ lives by pushing medical misinformation during the pandemic and its aftermath have faced few repercussions.”
It’s truly a remarkable piece of journalism, and while it speaks specifically to the challenges that state medical boards are confronted with in our current environment, I’m sure we can all see aspects of ourselves and the organizations we serve in this story. It shouldn’t surprise any of us if this isn’t the last story we see like this.
First of all, the fact that political pushback seems to have shelved the $154 million research program called Advancing Health Science Communication and Practice shows just how powerful the forces promoting misinformation and resisting any effort to counter it have become. In its article listed above, the ABIM asks, “What does the ‘current regulatory and legal landscape around communication platforms’ refer to, and why does it matter?” I assume that these are rhetorical questions, as it is pretty obvious to me what they refer to and mean—and why they, unfortunately, do matter. Basically, to me it sounds as though the NIH caved to political pressure from Republicans like Sen. Ron Johnson.
Be that as it may, I did wonder from the ABIM email blast whether something was up or not, given how seldom I’ve received these emails, and apparently I was correct. The ABIM has apparently decided to take its first concrete action against FLCCC members Dr. Paul Marik and Dr. Pierre Kory. But what does this all mean? Let’s start with Merlan’s VICE article published a month and a half ago, Fringe COVID Doctors Say They’re Under Attack by Medical Certification Board.
The grifters’ “persecution” narrative
If there’s one thing that cranks, quacks, and grifters have long known, it’s that somehow being able to portray oneself as a “victim,” as “persecuted,” is the most effective way to rally followers and promote the grift, and FLCCC is no different. As Merlan reported:
In the ongoing saga of the ivermectin guys, who claim they alone hold the extremely dubious cure for COVID, it’s necessary to have an antagonist—someone they can say is threatening them for exposing the truth. Recently, it’s been the American Board of Internal Medicine, or ABIM.
Two prominent vaccine skeptics and promoters of unproven COVID treatments, Drs. Pierre Kory and Peter McCullough, said on Twitter that the board is threatening them for their work. This narrative has speedily picked up speed across the right-wing ecosystem, with one right-wing website claiming the board is going to “revoke their medical licenses,” which is not something the ABIM can do. The whole thing is a useful view into how mainstream medical bodies are struggling to deal with their still-certified but increasingly out-there colleagues. And it’s a very instructive example of how fringe medicine promoters—and their allies in Congress—immediately spin their tangles with the medical establishment into more fame and attention.
This strategy works even better if it’s coupled with pugnaciousness and a vow to “fight” the “oppressor”:
I also got a letter from ABIM detailing multiple public statements I made as misinformation (from whoever they hired to investigate me). I have massive evidence to support each statement. Bring it on ABIM, err, I mean FBI. Didn’t know investigating docs was part of your mission. https://t.co/9NC3dXkdnU
— Pierre Kory, MD MPA (@PierreKory) June 19, 2022
It was basically, the “Debate me, bro!” tactic so beloved of cranks, quacks, and conspiracy theorists disingenuously employed. I say “disingenuously” because no doubt Drs. Kory and McCullough know that the ABIM probably couldn’t do this even if it wanted to, because it would be arguing an individual case in public. Just remember that this wasn’t a serious proposal. It was all performative, as the clip from the movie Braveheart included by Dr. McCullough in his quote-Tweeted Tweet above shows:
I suppose I should be grateful that Dr. McCullough refrained from using the clip of Mel Gibson’s rendition of William Wallace’s inspirational speech to his troops before battle with the English or maybe even of Wallace’s execution, when, instead of taking the quick and merciful death promised him if he were just to ask for “mercy,” he cries out “Freedom!” as he is being tortured and disemboweled. (I was half-tempted to issue a spoiler alert, but then realized that the movie is 28 years old. Deal with it.) Basically, the martyr complex is an essential element to all good quack grifts. (Burzynski was a master of it, for example.) It doesn’t matter that, in countering charges that they are spreading misinformation, they spread misinformation:
The current situation began when McCullough, a cardiologist formerly employed by Baylor Hospital who’s become a vocal vaccine skeptic, and Kory, a co-founder of the ivermectin-promoting Frontline Covid-19 Critical Care Alliance, or FLCCC, both said that they’d received threatening letters from the ABIM, saying it was considering disciplinary sanctions against the two men from promoting misinformation. This immediately became a fairly big deal on the COVID-skeptical and ivermectin-promoting right, and the publication American Greatness immediately claimed that the body was threatening to “revoke the medical licenses” of both men.
That is, as a point of order, both wrong and very dumb: The ABIM is a certification body, not a licensing one. The ABIM certifies doctors who specialize in internal medicine and other subspecialties; that certification proves they completed a residency in their specialty and also passed a specialized exam.
This is a common misunderstanding among the public about the difference between medical licensure and board certification. In order to practice medicine, you do have to be licensed by the state in which you practice. However, you can get a medical license after just medical school and one year of internship. In general, however, to practice you also have to have completed an accredited residency in a medical specialty. Board certification involves the board for that medical specialty “certifying” that you have (1) successfully completed an accredited residency in the specialty and (2) completed a test that demonstrates a basic level of knowledge and competency in the specialty. For my specialty, the American Board of Surgery (ABS) required passing a written qualifying examination, after which I then had to pass an oral certifying examination. After that, I had to recertify every ten years by passing a written examination. It is true that the ABS has, since my last recertification, created a new track that doesn’t involve taking a test on all of general surgery, the way I did twice before after my initial board certification but rather involves self-learning, documentation of continuing medical education, case logs, and smaller, specialty-focused tests every three years. (That is the track to which I will switch when my current ten-year board certification expires in a few years.) In the medical specialties overseen by ABIM, the process of maintaining board certification can be much more involved, including submitting patient evaluations, which has led to a fair amount of resistance and pushback from physicians chafing under the requirements.
It is not my intention to comment on the process itself beyond this, but rather to explain what board certification is. Also, most hospitals will not provide privileges to a physician who is not board-certified by an accepted, recognized board, nor will insurance companies reimburse for services provided by such doctors. Of course, the wag in me can’t help but wonder why Drs. Kory and Marik are so upset given that they both appear to have abandoned traditional medical practice in which they might want to have hospital privileges and bill insurance companies and Medicare for their services in favor of the model preferred by “brave maverick doctors” who don’t practice according to science-based guidelines or scientific consensus: Cash on the barrelhead fee-for-service, no insurance accepted. As far as their livelihood goes, even if the ABIM does revoke their board certifications, the action is unlikely to have much, if any, financial impact on them. They even admit it in their response:
The loss of ABIM certification will not impact Dr. Kory or Dr. Marik’s ability to practice medicine or conduct scientific research or educational work. Some hospitals and healthcare providers require ABIM certification for employment, however the certification is not required by state medical boards or for a medical license anywhere in the U.S.
Of course it doesn’t! Neither of these doctors is practicing in an environment where board certification is even required! However, the narrative of the poor victim persecuted by big government, big tech, big pharma, and big medicine must be maintained, hence the outrage from FLCCC Alliance and Drs. Kory and Marik. Also, I’m pretty sure that there is also likely an element of pride involved, in which the likelihood of soon having something as important as their board certification revoked injures their massive egos.
In addition, Sen. Ron Johnson was at it again after the initial letter in June, publishing an open letter to the ABIM containing another “Debate me, bro!” challenge to the ABIM, even inviting ABIM representatives to one of his COVID-19 “roundtables”:
Unfortunately, the federal health agencies, public health experts and vaccine manufacturers did not accept my invitation to either event. Rather than engage in a public dialogue in which information and perspectives can be openly exchanged and debated, the individuals and organizations responsible for our pandemic response continue to attack and discredit those with a different perspective by using the vague pejorative of “spreading misinformation”.
It is well last time for the public to hear from many sides regarding COVID-19 in a public forum. The purpose of this letter is to invite you, members of your Credentials and Certification Committee, and any other medical expert of your choosing to come to Washington and engage in an open and honest interchange regarding all aspects of COVID-19, without the threat of reprisal by the ABIM or any other organization. I request your participation in a public forum on one of the following dates: July 26, July 27, July 29, August 2 or August 3.
It is also telling that Dr. McCullough didn’t announce the ABIM letter himself first, but rather appears to have just forwarded it to Sen. Johnson, who used it as a tool to promote his misinformation-packed COVID-19 roundtable events.
Also, from the wording of the letter quoted by the FLCCC Alliance, the ABIM hasn’t even actually officially revoked Dr. Marik and Kory’s board certifications yet. Before concluding that, in “accordance with ABIM bylaws, Dr. Marik and Dr. Kory will appeal the committee’s recommendation,” FLCCC rants:
The ABIM Credentials and Certification Committee has recommended that FLCCC co-founders, Paul Marik, MD and Pierre Kory, MD, MPA should have their ABIM certifications revoked for spreading what the committee considers “false or inaccurate medical information.” The committee concluded that the published peer-reviewed, clinical, and observational data that create the foundation of FLCCC protocols, educational materials and public statements are not “consensus driven scientific evidence.” In reaching their recommendation, the committee cites NIH and CDC guidelines as well as several studies that have been largely disproven or questioned for their glaring flaws, conflicts of interest or poor design. Additionally, the committee cites a National Public Radio story that was later corrected for falsely reporting that overdosing of ivermectin was causing a surge in emergency room admittance.
“What ABIM is doing is basically telling doctors that we need to take our orders from bureaucrats in Washington and certain medical journals instead of making treatment decisions based on our training and expertise,” said Pierre Kory, MD, MPA, president and chief medical officer of the FLCCC. “Threatening doctors the way the ABIM is doing, simply degrades the practice of medicine to be something that is done out of fear rather than to heal our patients in the best way we know how.”
And:
“The ABIM is doing this to us and other doctors who didn’t follow what the committee is calling ‘consensus’ as a way to scare others into silence,” said Paul Marik, MD, chairman and chief scientific officer of the FLCCC. “Following the ABIM’s ‘consensus’ will only deprive patients of important treatments that have saved lives all over the world.”
The ABIM committee continues to spread the myth that ivermectin is dangerous without critically examining the scientific and clinical evidence. In its statement the committee cites false claims that ivermectin could be “fatal” while never mentioning the 99 controlled trials – 46 of them randomized controlled trials – that showed ivermectin is highly effective in treating COVID-19 with little to no reported side effects. These trials include over a hundred and thirty thousand patients successfully treated with no severe side effects, consistent with the WHO’s finding that ivermectin ranks higher in safety than Tylenol or aspirin.
Ivermectin is indeed safe and effective when used to treat roundworm infections. The problem, of course, is that it doesn’t work for COVID-19, those “randomized controlled trials,” many of them fraudulent, not withstanding. It was always predictable that ivermectin would be highly unlikely to work as a treatment for COVID-19 just on pharmacology. As I like to point out, the concentration of ivermectin that inhibited the replication of SARS-CoV-2, the coronavirus that causes COVID-19, in cell culture was 50- to 100-fold higher than what can be safely achieved in the human bloodstream using “safe” ivermectin dosing. There’s a reason that I’ve referred to ivermectin as the “acupuncture of COVID-19 treatments” and pointed to it as an example of why science-based medicine is important not just for low plausibility alternative medicine treatments but for low plausibility treatments of all kinds—like ivermectin for COVID-19.
Also, what the FLCCC Alliance conveniently fails to mention is that the promotion of ivermectin as a cure-all for COVID-19 has indeed led people to use veterinarian formulations designed for large animals like horses and cows. As I like to point out, equine ivermectin comes packaged in syringes with “1.87% ivermectin paste. 6.08 g syringe treats up to 1,250 lbs. Safe for horses of all ages, pregnant mares, breeding stallions.” Another formulation comes as a 1% solution to be given 1 ml/110 lbs of weight. Basically, in horses the dose of ivermectin can be up to 1.200 mg, while the human dose recommended is only around 3 mg. When ivermectin promoters state that ivermectin is “very safe” in humans, they are correct, but only at the dose recommended for humans. As with many drugs, toxicity increases with increasing dose, and when you take far more than the recommended dose your risk of serious side effects increases. Fortunately, most of these side effects have been mild, but even mild side effects are too much to risk for a drug that doesn’t work. Worse, promotion of ivermectin for COVID-19 has, predictably, expanded to its being touted for cancer and even autism. The FLCCC will, of course, claim that they have never promoted ivermectin for such purposes, but their ally Tess Lawrie has. Promoting a drug—any drug—as a near-miraculous cure for one life-threatening disease will almost always lead other quacks to promote it for other conditions and diseases.
Free speech versus board certification
I will conclude by discussing how the FLCCC is also bemoaning the recommendation of the ABIM Credentials and Certification Committee to strip Drs. Kory and Marik of their board certifications as an attack on “free speech.” This is, of course, a lament that quacks throughout the decades that I’ve been writing about science-based medicine vs. quackery nearly always invoke whenever they are criticized or a medical authority tries to hold them accountable for their quackery. The FLCCC is no different. Consistent with the narrative of their conspiracy theories in which ivermectin is the “safe and effective” miracle cure for COVID-19 that “they” don’t want you to know about, there must be nefarious forces seeking to silence the FLCCC’s two heroic doctors who are only fighting for their patients. Seriously, I kid you not. You can buy merch on the FLCCC website with images of Drs. Marik and Kory like these:
Dr. Marik as Superman?
Dr. Kory as Superman?
Seriously, this is a bit too much, even for me, and I’ve seen so many brave maverick doctors portraying themselves as the heroes in an Ayn Rand novel.
It’s exactly the same narrative that Stanislaw Burzynski has employed for 45 years whenever the FDA or the Texas Medical Board made their feeble efforts to hold him accountable and that Dr. Rashid Buttar used back in 2008, when he called the North Carolina Medical Board a “rabid dog” for trying to “silence” him. It’s the same claim that quacks make about bills designed to strengthen state medical boards to act when physicians spread dangerous misinformation.
Unfortunately, it’s a very effective ploy. All too many of my colleagues chafe at any suggestion that they can be told how to practice medicine. Even though three years of a pandemic that’s killed over one million people in just the US alone has finally awakened regulatory agencies like state medical boards and professional societies to the the severity of the problem of doctors using their professional status to spread misinformation, unfortunately, we as a profession have a lot of members who either can’t or don’t want to see it as a problem and for whom the FLCCC’s defense resonates. I suspect that the reason now is similar to the reasons before the pandemic, involving our dislike of “being told what to do” and an attitude that any of us could fall victim to a bogus complaint to a state medical board or specialty board. (Ironically, I myself have experienced exactly that, when several years ago a patient of Stanislaw Burzynski reported me to my state medical board for my blog posts about her case.) I get it. I also get that a lot of my colleagues and I have to make medical decisions based on less than ideal evidence bases all the time (the “art” of medicine). Unfortunately, too many of us extrapolate that to justify what quacks do. Indeed, one mistake in framing that I see from the ABIM and state medical boards is to emphasize too strongly “spreading misinformation” as a reason for action, rather than the quackery. What physicians say will always draw a “free speech” defense. What they do—i.e., how they treat patients—is a lot less defensible and more strongly a basis for state medical boards and specialty boards to take action.
Professionalism, however, is essential to medicine, and one of the elements of professionalism is not to practice quackery or to recommend quackery, and, if there’s one thing I’ve observed, it’s that the practice and promotion of quackery almost always go hand-in-hand. In other words, physicians promoting medical misinformation (like the FLCCC) rarely just promote medical misinformation. They almost always practice what they preach, so to speak; i.e., practice quackery. After all, FLCCC doesn’t just recommend ivermectin, hydroxychloroquine, and its various and sundry “early treatment protocols” that don’t work, its members use them to treat COVID-19 patients—and are proud that they do so! It is true that the First Amendment gives physicians like Drs. Marik and Kory the freedom to say whatever they want about COVID-19 and its treatment, no matter how quacky, but it doesn’t mean that they can do so without consequences, which can be loss of board certification when their professional speech and actions wander too far outside of what can be justified with science. Revoking the licenses and board certifications of such physicians is quality control and consumer/patient protection, not “censorship.” These doctors are still free to say whatever they want, no matter what the ABIM does.
I only wish that state medical boards would do something that would really make a difference: Take away their medical licenses. Yes, I said it, and I meant it: Take away their medical licenses.

The Federation of State Medical Boards vs. COVID-19 misinformation: A losing battle so far
A few weeks ago, the Federation of State Medical Boards, which itself does not have any regulatory power but advocates for state medical boards, issued a statement that physicians who spread COVID-19 misinformation should be subject to disciplinary measures. Unfortunately, a recent report found that not a single US physician has had action taken against their medical license for doing this. Why?
David Gorski on August 23, 2021
Link
My last post for 2020 was entitled 2020 and the pandemic: A year of (some) physicians behaving badly. The reason was simple. The COVID-19 pandemic, which first hit Wuhan, China in December 2019, was declared a pandemic by the World Health Organization in March 2020, and shortly thereafter caused mass shutdowns and travel restrictions that led some physicians to reveal themselves to be very bad actors indeed in terms of spreading misinformation, advocating quackery, and outright grifting. Sure, the usual suspects (several of whom were ultimately dubbed the “Disinformation Dozen” a few months ago) were involved, which is exactly what one would expect. After all, what were doctors like Joseph Mercola, Sherri Tenpenny, Kelly Brogan, and the like going to do during a pandemic except switch their grift to the coronavirus and COVID-19 vaccines? This was utterly expected. Years—even decades—before, I had wondered how doctors like these could keep their state medical licenses.
I will admit, however, to being surprised at just how many doctors who had previously demonstrated no history of this sort of activity took the opportunity to dive head first into the COVID-19 misinformation pool. Even worse, as has been documented here, even some highly respected doctors and academics have become “COVID contrarians”. They minimize the risk of harm from the coronavirus (particularly in children), make risibly off-base predictions (e.g., “we’ll have herd immunity by April“) and advocate against mask mandates (particularly in schools) and vaccinating children—or even erroneously claim that respiratory syncytial virus (RSV) is being misdiagnosed in children as COVID-19 and that hospitalizations of children are being exaggerated. Worse, when corrected for their mistakes, they almost never seem to have the humility to admit error and move on; often they double down and act as though their statements were never refuted.
I review all this because there’s a topic I’ve been meaning to write about (and have written about a bit at my not-so-super-secret other blog) regarding the lack of professional sanctions against physicians who spread health misinformation, be it about vaccines, masks, COVID-19, or anything else. Going back to the case of cancer quacks like Dr. Stanislaw Burzynski, Dr. Rashid Buttar, and beyond, I’ve long lamented how even the most obvious quacks seem to be able to keep their medical licenses and antivaccine doctors (e.g., Dr. Bob Sears) get off with a slap on the wrist, even when their medical board actually investigates. True, there are occasional exceptions, such as Dr. Paul Thomas, a rising star in the antivaccine movement whose license was suspended because the Oregon Medical Board deemed his antivaccine practices a danger to his patients, Dr. Mark Geier, who subjected autistic children to a hormone blocker usually used in children to treat central precocious puberty, based on the belief that decreasing testosterone levels would allow the mercury from vaccines to be chelated easier with his chelation therapy, and “Lyme literate” Dr John Lentz. Basically, state medical boards seem to be (mostly) toothless when it comes to intervening to stop such dangerous doctors. This is a topic that I’ve been meaning to write about, and a few weeks ago the Federation of State Medical Boards (FSMB) gave me an excuse.
The Federation of State Medical Boards enters the fray
Historically, state medical boards seem to have problems going after outright quacks, much less physicians spreading dangerous misinformation during a global pandemic that has killed more than 600,000 people so far in the US alone. This is why I was so heartened a few weeks ago to see this statement from the Federation of State Medical Boards (FSMB), the organization that represents state medical boards:
Physicians who generate and spread COVID-19 vaccine misinformation or disinformation are risking disciplinary action by state medical boards, including the suspension or revocation of their medical license. Due to their specialized knowledge and training, licensed physicians possess a high degree of public trust and therefore have a powerful platform in society, whether they recognize it or not. They also have an ethical and professional responsibility to practice medicine in the best interests of their patients and must share information that is factual, scientifically grounded and consensus-driven for the betterment of public health. Spreading inaccurate COVID-19 vaccine information contradicts that responsibility, threatens to further erode public trust in the medical profession and puts all patients at risk.
The fact that the FSMB issued such a statement stating that physicians spreading misinformation and disinformation about COVID-19 risk disciplinary action was a big deal, at least to me. However, my enthusiasm and approval were tempered by my knowledge of how state medical boards actually operate. They are, in general, underfunded, have inadequate resources, and can only act when they receive a complaints about specific instances of poor practice or patient injury. Indeed, when a state medical board actually does act against an antivaccine physician (for instance), its penalties are often minimal, as was the case for Dr. Bob Zajac in Minnesota.
Indeed, I’ve long lamented how rare it is for a state medical board to suspend or revoke the medical license of outright quacks and how difficult it has been on the occasions when a state has tried, having written more posts over the years about this problem, both here and elsewhere. One good example that I like to cite (and did cite above but repeat here because I can’t emphasize his example enough and feel it’s worth expanding on briefly) is cancer quack Stanislaw Burzynski, who has been practicing his cancer quackery in Houston since the late 1970s and, despite the occasional attempt of the Texas Medical Board to put a stop to his activities, has managed to prevail, with only minor impediments placed on his ability to practice, leading me to lament, “How is it that in 2018 cancer Stanislaw Burzynski is still preying on desperate cancer patients?” I even lumped him together with correspondence school naturopath and “pH Miracle Living” quack Robert O. Young as examples of how poorly many states regulate medical practice. (Of course, Burzynski practices in Texas, and Young used to ply his quackery in Florida, two of the worst states for this problem.)
Elsewhere, I’ve discussed the problem before a number of times. The problem is that state medical boards tend to be reluctant to go after doctors who use unscientific treatments like “detoxification” and colon cleanses because it forces them to enforce a standard of care, because such cases are harder to prove, and because there is so much pushback. State medical boards are generally good at going after doctors who commit easily identified, clear-cut breaches in trust, such as substance abuse, defrauding insurance companies, or diddling patients. When it comes to making judgment calls about doctors practicing outside of the standard of care, they’re a lot more reluctant to do so. That’s why the only physician behaviors very likely to result in strong action consists of running a prescription mill, sexual improprieties with patients, or practicing while impaired due to abuse of alcohol or illicit substances. It’s a matter of resource allocation and prioritization. State medical boards tend to react primarily to what they perceive to be the most immediately and obviously dangerous behaviors. Practicing quackery rarely makes the cut, because medical boards tend to be loathe to make value judgments about medical practice, and proving quackery is way harder and more resource-intensive than proving that a doctor is an addict who has been practicing while impaired or has sexually abused patients.
This applies to even horrible surgeons like Dr. Christopher Duntsch, whose epic incompetence in the operating room coupled with alcohol abuse resulted in multiple “clean kills” and paralyzed patients. He was rare in that his bungled operations so alarmed colleagues that they actually took the even rarer action of complaining about him to the Texas Medical Board. Even so, all too often it took a long time to take down. Ultimately, Dr. Duntsch, who had major substance abuse problems in addition to his epic incompetence in the operating room, finally did lose his medical license and is now serving a life sentence in a Texas prison for multiple counts of aggravated assault relating to 33 botched surgeries over two years, including two that resulted in patient death. Indeed, Dr. Duntsch’s case was so remarkable that he is now the subject of an eight part series on Peacock entitled Dr. Death: The Undoctored Story, which I’ve been meaning to watch:
The good thing about the case of Dr. Duntsch is that doctors as sociopathic as he are rare. The bad thing about the case is that it took a really long time for his colleagues (who knew his reputation and had had to try to salvage his disastrous complications) and the Texas Medical Board to act.
Which brings us to COVID-19 misinformation, which can kill. Are state medical boards actually doing anything? While it’s true that it has been less than a month since the FSMB issued its statement, I thought I’d look into this.
“No physicians disciplined for COVID falsehoods”
Earlier this week, a reader made me aware of a story published in MedPage Today that looked into the question of whether state medical boards have been investigating physicians making false COVID-19 claims. Its findings were not reassuring:
Despite a national call to sanction doctors who spread COVID-19 misinformation, a MedPage Today investigation found that not one of 20 physicians who’ve peddled such falsehoods has been disciplined by their state licensing agency for doing so.
That’s not to say that complaints haven’t been filed, or that investigations haven’t been launched. These elements are confidential in most states, including the 10 contacted by MedPage Today who license the physicians.
But that means physicians who have advanced false COVID information — including Simone Gold, MD, JD; Scott Atlas, MD; Joseph Mercola, DO; Lee Merritt, MD; Sherri Tenpenny, DO; and Stella Immanuel, MD — are free to continue to misinform their patients and the public, even as the Delta variant surges.
“Our statement is a reminder to physicians that words have consequences and during a public health emergency like COVID-19, those words can mean life or death for patients,” Joe Knickrehm, vice president of communications for the Federation of State Medical Boards (FSMB), told MedPage Today via email.
Obviously, Dr. Joe Mercola is well-known to readers of this blog, my having featured him in a post last month describing his copious spreading of online COVID-19 misinformation. He is what I have long referred to as a quack tycoon, given that his net worth is north of $100 million, thanks to his online supplement and quackery sales supported by his website, which has spread antivaccine misinformation for close to 25 years. As I mentioned before, of course he pivoted to COVID-19 misinformation and antivaccine fear mongering targeting the COVID-19 vaccines, including false claims that the flu vaccine makes you more susceptible to COVID-19, that mRNA-based COVID-19 vaccines are “gene therapy” that can “permanently alter your DNA”, that the vaccines will cause global depopulation, and that ivermectin is a miracle cure for COVID-19 whose “suppression” is the “crime of the century.”
I also can’t help but note that the reporters seem not to be aware that Mercola recently moved from Illinois to Florida and appears to not be licensed in Florida. Also, he hasn’t practiced medicine for over a decade, which makes asking the Illinois Department of Financial and Professional Regulation strike me as a bit off-target, given that the only thing Mercola would lose if he lost his medical license would be prestige. (His ability to grift would remain intact.) Still, here’s the statement from the story:
In a statement, the Illinois Department of Financial and Professional Regulation said that if the agency “determines a licensee committed violations against the Act that regulates their profession, an appropriate course of action will be taken. Complaints filed with and investigations undertaken by IDFPR are confidential, unless and until a public complaint or discipline is issued by the Department.”
The largest number by far of doctors featured in this story hold medical licenses in California: Simone Gold, MD, JD; Scott Atlas, MD; Dan Erickson, DO; Artin Massihi, MD; Jeffrey Barke, MD; Jennings Ryan Staley, MD; Brian Tyson, MD. Several of these doctors are familiar. For example, Simone Gold is a prominent member of the Frontline COVID-19 Critical Care (FLCCC) Alliance, which has been promoting ivermectin as the miracle cure for COVID-19 that “they” don’t want you to know about. Unsurprisingly, last summer she was promoting hydroxychloroquine as the miracle cure for COVID-19 that “they” don’t want you to know about.
As for the rest of the doctors in the list, last year around this time Hoover Institution hack Scott Atlas, a radiologist with no expertise in infectious disease or epidemiology, rose to become one of Donald Trump’s most trusted medical advisors regarding the pandemic, even though he was very much for “natural herd immunity“. Early in the pandemic Dan Erickson and Artin Massihi published a highly dubious study that tried to estimate the prevalence of COVID-19. Jeffrey Barke, whom I had never heard of before, has a concierge practice in Newport Beach and appears to be an antimasker, having published a book a year ago entitled Covid-19 A Physician’s Take on the Exaggerated Fear of the Coronavirus. And then there was this last September:
His medically unorthodox opinions have become familiar among the voices claiming that the coronavirus has been politicized in an effort to damage President Donald Trump’s reelection campaign.
Even despite Barke’s proactive omnipresence on social media, a video he posted Sept. 17 managed to create new shock waves – to the point that Hoag Hospital, with which Barke has a business relationship, publicly distanced itself from him.
In last week’s video, Barke shares a split-screen with fellow anti-masking media star Peggy Hall. “What I do, Peggy, to protect you and to protect others when I’m in public – I think better than a mask – this is what I do,” Barke asserts, suddenly brandishing a 9-millimeter handgun.
“You know, I live in Orange County so I carry this wherever I go,” Barke continues, adding that he works for “a local sheriff’s department agency as a reserve deputy.”
The next day, Hoag tweeted that Barke’s “radical views on COVID, masking and hydroxychloroquine” are “diametrically opposite” from the hospital’s.
Well alrighty, then.
Then there’s Jennings Ryan Staley, who has his own mention on the US Department of Justice website:
Dr. Jennings Ryan Staley, previously charged with one count of mail fraud, was indicted by a federal grand jury yesterday for additional crimes arising from his business venture selling COVID-19 “treatment kits,” which he advertised to one potential customer as a “miracle cure.” Staley is a licensed physician and the former operator of Skinny Beach Med Spas in and around San Diego.
According to the new charges, which became publicly available today, Staley agreed with a Chinese supplier to smuggle hydroxychloroquine powder into the U.S., lying to U.S. Customs by mislabeling a shipment as “yam extract.” Staley is also charged with stealing the name and identifying information of one of his employees in order to create and submit a bogus prescription for hydroxychloroquine on the employee’s behalf, in order to sell the drugs at a markup to his customers.
In late March and early April 2020, Staley marketed and sold his treatment kits to Skinny Beach customers. He described his product as a “concierge medicine experience,” which included hydroxychloroquine—an anti-malarial drug that Staley described to one potential customer as a “guaranteed” cure for COVID-19. Staley’s kits were priced as high as $3,995 for a family of four, while Staley himself paid roughly $1 per tablet of hydroxychloroquine. Staley’s marketing materials, per the indictment, stressed that recipients should “NOT BELIEVE THE REPORTS THAT HYDROXYCHLOROQUINE DOESN’T WORK!”
During a phone call with a prospective customer, in reality an undercover FBI agent, Staley repeatedly promised that the drugs he was selling would cure COVID-19.
If he’s convicted, this should be a slam dunk, given that most states automatically revoke the medical license of any physician convicted of a felony, and another notice states that he pleaded guilty to “one count of importation contrary to law, admitting that he worked with a Chinese supplier to try to smuggle into the United States a barrel that he believed contained over 26 pounds of hydroxychloroquine powder by mislabeling it as ‘yam extract.'” (As a side note, hilariously, this scammer got scammed, given that the shipment turned out only to contain baking soda.)
Meanwhile, Dr. Brian Tyson appears to be a run-of-the-mill hydroxychloroquine quack with an outsized social media presence, who is now promoting ivermectin as part of a “multidrug therapy” for COVID-19:
Personally, I appreciated the FDA’s snark on this. Those of us who have criticized ivermectin believers acknowledge that, when used for its intended purpose, it’s a great drug. We just recognize that there’s no good evidence that it is as much of a “miracle” drug for COVID-19 as it is for river blindness.
I could go on and on through the list, but why bother? Instead, let’s just sample some of the responses from various state medical boards, starting with California, given the number of offenders in that state:
Carlos Villatoro, public information officer for the Medical Board of California, said in an email to MedPage Today that “publicly spreading false COVID-19 information may be considered unprofessional conduct and could be grounds for disciplinary action. The Board will review complaints it receives about its licensees on this topic, as it does with all complaints. To date, no accusation has been filed against a licensee regarding this issue.”
Let’s move on to nearby Idaho:
Yvonne Dunbar, counsel for the Idaho State Medical Board, told MedPage Today in an email, “Neither the Idaho Medical Practice Act nor the applicable administrative rules provide a basis for the Board to discipline licensees for statements made during a conference, to the media, or in any other public setting.”
However, she said the board “does have authority to investigate and possibly discipline its licensees for statements or behaviors which transpire in a health care setting … if it is established that they: ‘Engag[ed] in a pattern of unprofessional or disruptive behavior or interaction in a health care setting that interferes with patient care or could reasonably be expected to adversely impact the quality of care rendered to a patient. Such behavior does not have to have caused actual patient harm to be considered unprofessional or disruptive.'”
Unsurprisingly, many of the docs who promote COVID-19 misinformation on social media and old school media (TV, newspapers, etc.) often also practice according to that misinformation, discouraging masking, demonizing vaccines, promoting “miracle cures” such as ivermectin and hydroxychloroquine (with zinc, and other drugs and supplements, of course!) as part of their treatment protocols.
I can’t resist quoting North Carolina (about, appropriately enough, Rashid Buttar, who once famously referred to the North Carolina Medical Board as a “rabid dog“):
If the North Carolina Medical Board has information that a licensee may be spreading false or misleading information about COVID-19, it would investigate, said communications director Jean Fisher Brinkley. “Decisions about possible regulatory action would be based on the evidence gathered and, specifically, whether the Board has evidence that a violation of law or professional ethics occurred, a process that is consistent with the FSMB’s statement.”
There is a depressing similarity to all the responses, namely either that medical board of the state where the physician in question practices hasn’t received any complaints as of yet, that speech alone can’t be penalized, or that they will “investigate” if there are complaints. When a bunch of readers sent me a link to the FSMB complaint, I generally responded that I don’t expect much to come of it. More recently, I responded to those sending me this MedPage Today article, “I hate to say I told you so, but I told you so.” But why? Why is nothing happening?
The First Amendment vs. professional speech
To get an idea of why nothing is happening, I can’t help but point to the reaction of some physicians to the FSMB statement, starting with the Association of American Physicians and Surgeons (AAPS), a far right wing medical John Birch Society camouflaged as a legitimate medical professional society. I’ve written about the AAPS a number of times, relating how it’s promoted antivaccine pseudoscience blaming vaccines for autism, including a view that is extreme even among antivaccine activists, namely that the “shaken baby syndrome” is a “misdiagnosis” for vaccine injury. It’s worse than that, though. AAPS has promoted HIV/AIDS denialism, blamed immigrants for crime and disease, promoted the pseudoscience claiming that abortion causes breast cancer using some of the most execrable “science” ever, and not only rejected evidence-based guidelines as an unacceptable affront on the godlike autonomy of physicians; the very concept of a scientific consensus about anything. Let’s just put it this way. The AAPS has featured publications by antivaccine mercury militia “scientists” Mark and David Geier and many others. Unsurprisingly, in the age of COVID-19, the AAPS has seamlessly pivoted to COVID-19 denial, antimask nonsense, and antivaccine conspiracy theories.
As you might expect, the title of Dr. Tamzin Rosenwasser’s is “The Federation of State Medical Boards Channels the Soviet NKVD“. (I suppose I should be grateful that Nazis weren’t mentioned, at least in the title.) After quoting the FSMB statement, Dr. Rosenwasser goes all anti-Communist, consistent with the AAPS’s similarity to a medical John Birch Society:
The FSMB has been described as a “private lobbying organization that represents the state’s attorneys who work for medical boards.” It does not by itself have the legal authority to take a doctor’s license but is highly influential.
The NKVD, the People’s Commissariat for Internal Affairs, was the Soviet secret police agency, the precursor to the KGB.
Unsurprisingly, the editorial goes on to parrot antivaccine misinformation about the COVID-19 vaccine and COVID-19 in general, continue the author’s confusion on whether the FSMB are Communists or Nazis, and appeal to “free speech”, portraying any effort to “censor” misinformation as an unconscionable assault on free speech. It’s a very appealing argument, at least in the US, where free speech protections are embedded in the Constitution. Doctors who are antivaccine and/or promote COVID-19 misinformation often appeal to free speech (and, in the US, the First Amendment) and portray any attempts by medical licensing bodies, whatever the state or country, to discipline them for their activities as fascistic (or Communist) assaults on “free speech”.
Although there are certainly gray areas, these attacks are deceptive, for the simple reason that professional speech by a physician licensed by the state is not the same as some random fool on social media saying the same thing. When physicians use the imprimatur of authority that society has bestowed on them to add the authority of their profession to their misinformation, that is arguably an abuse their status as a physician. These physicians spreading COVID-19 misinformation disingenuously ignore the simple fact that, if they were not physicians, their misleading pontificating about how the vaccine doesn’t work or is dangerous, how we’ll have “herd immunity by April”, or touting drugs that don’t work as “miracle cures” for COVID-19 that are being “suppressed” by The Man would not be taken nearly as seriously by the public.
As part of our professional role as physicians and surgeons we are granted privileges unknown to non-physicians, including being allowed to ask patients about their deepest and darkest personal matters, administering potentially toxic drugs (such as chemotherapy for cancer), or, in the case of surgeons, removing or rearranging body parts for therapeutic effect using sharp instruments in a way that would be considered assault and battery if attempted by a non-surgeon. We are granted these incredible privileges because society has deemed us worthy after having completed four years of rigorous training in medical school followed by anywhere from three years to a decade or more of additional training in residency and fellowship. In the age of COVID-19, the entire right-wing COVID-19 disinformation ecosystem, of which the AAPS is a small but influential part on medical matters, will treat any physician whose license is sanctioned by a state medical board as a free speech martyr. This is propaganda, however, not reality, because our professional status makes our utterances on COVID-19 professional speech that is arguably part of our profession as physicians, not just an exercise of free speech, and if we abuse our professional speech, state medical boards should certainly be empowered to investigate and discipline us.
After all, as a result of the privileges granted us, society also accords our words on medical matters (and, let’s face it as ridiculous as it might seem, on many nonmedical matters too) much more weight than those coming from nonphysicians. Physicians, in my experience, often both forget about that and take advantage of it. Again, I like to emphasize that, were these physicians not physicians, a lot fewer people would give a rodent’s posterior what their latest take on COVID-19 or vaccines is. In other words, professional speech misused can have deadly consequences, particularly during a pandemic. Contrary to Dr. Rowenwasser’s ridiculous comparison to the repression carried out by the NKVD and appeal to the Nuremberg Code, it is entirely appropriate for the FSMB to recommend going after the medical license of—or otherwise disciplining—any physician promoting obvious COVID-19 and antivaccine misinformation and conspiracy theories. That is not suppression of free speech. That is professional oversight.
Advocates for science- and evidence-based medicine cannot help but be appalled at how easily physicians practicing modalities that are clearly so far outside the standard of care that they might as well be in another galaxy can continue to do so with little or no oversight or even interference by state medical boards. In essence, it takes mind-numbingly egregious offenses to motivate a board to act, be it substance abuse by a physician resulting in obvious impairment, non-science-based treatments resulting in the death or severe injury of a patient, or blatantly illegal behavior, such as running a narcotic prescription mill. Part of the problem is that the attitude among doctors seems to be that a medical license is a right, rather than what it really is: an incredible privilege bestowed upon us physicians and surgeons by society that takes an equally incredible commitment and skill to be allowed to continue to keep. That same attitude among physicians also seems to lead them to think that they should be able to say anything they want about the pandemic, even though their words are arguably professional speech (particularly given how many “COVID contrarian” doctors use their status either to sell a product or to sell themselves as “experts”).
Our patients deserve better. The vast majority of physicians are competent and try their best to deliver the best evidence-based care they can to their patients. However, doctors who consistently do not practice according to the standard of care, be it because they are incompetent, dishonest, impaired by substance abuse, or because they have come to believe in blatantly unscientific treatments that do not help and not infrequently harm patients, do not deserve to be physicians. The same is true of physicians who abuse their status in order to peddle misinformation about a virus causing a pandemic that has killed over 600,000 in the US alone and millions worldwide—and is still sickening and killing people at unacceptably high rates. I’m glad the FSMB said something about revoking the licenses of physicians who spread misinformation, but I fear that in practice implementing such a policy will be well-nigh impossible.

The Ohio State Medical Board has finally suspended the medical license of antivax quack Sherri Tenpenny
Last week, the Ohio State Medical Board suspended the medical license of Dr. Sherri Tenpenny, a longtime antivax quack. The only question is: What took them so long, and why did it take the pandemic for them to act? Also, is there less to this action than meets the eye?
David Gorski on August 14, 2023
Link

It always seems to happen whenever I’m on vacation. Last week, while I was trying to relax at home and take care of some household business that work always seems to interfere with, I got the news that the Ohio State Medical Board had finally suspended the license of Dr. Sherri Tenpenny, a notorious antivax quack practicing in the suburbs of Cleveland whose misinformation and quackery I’ve been discussing intermittently here dating back to 2011 and whom I had been discussing on my not-so-secret other blog since 2009, although I had mentioned her going back to at least 2007. Most people who have heard of Dr. Tenpenny learned of her in 2021, when she became infamous for claiming that COVID-19 vaccines cause people to become magnetized:
Two years ago, a Cleveland area physician strode into the House Health Committee room and told state lawmakers that COVID-19 vaccines magnetize their hosts and “interface” with cell towers.
Her comments, the subject of widespread ridicule, triggered a swarm of 350 complaints to the State Medical Board and a chain of events that led to the regulators indefinitely suspending the medical license Wednesday of anti-vaccine activist Sherri Tenpenny.
The term “chain of events” is important. The reason that the Board suspended Dr. Tenpenny’s medical license actually has little to do with her decades-long practice of rank quackery and promotion of antivaccine misinformation and more to do with procedural issues:
The board, charged with protecting the public and overseeing the licensure of Ohio’s doctors, yanked Tenpenny’s license on procedural grounds rather than the substance of her comments. Board staff found she flouted investigators who came to visit, declined to answer written questions, and objected wholesale to the regulators’ inquiry.
“Dr. Tenpenny, neither you nor any doctor licensed by this board is above the law, and you must comply with the investigation,” said Dr. Jonathan Feibel, an orthopedic surgeon and medical board member. “You have not done so, and therefore, until you do, your license will be suspended.”
Dr. Amol Soin, a pain management specialist and board member, said at the hearing that the suspension has nothing to do with vaccines, magnets, or cell towers, but about the board’s basic duty to oversee conduct of physicians and physicians’ responsibility to comply.
“The license to practice medicine is not a right. It’s a privilege. A privilege that is earned, and a privilege that you have to uphold,” he said. “And as you get that license, and as you obtain that privilege, you consent to certain reasonable things. And a reasonable thing you consent to… is to cooperate when someone complains about you. In this case, 350 complaints. It is a very reasonable thing to cooperate in that scenario.”
Let me just say that I do like the statement about medical licenses being a privilege, not a right. As a result of our education and training, society and the state grant us physicians the privilege of practicing medicine, a privilege that, in my case as a surgeon, allows me to commit what under other circumstances might be called assault and battery with the use of sharp instruments to remover or rearrange parts of a human being’s anatomy in order to treat cancer and other disease. It allows oncologists to administer toxic substances to treat disease. It lets us legally ask the deepest and most intimate questions about patients and their lives, all in order to diagnose and treat them. Too many of my colleagues forget what a privilege it is to be given these powers and come to treat their medical license more as a right than a privilege, a viewpoint that, unfortunately, seemingly informs the law of some states, allowing utter quacks to continue to practice, mostly unmolested by their state medical boards. (Yes, I’m talking about Texas, but not just about Texas.)
As I wrote in 2010:
If there’s one area that SBM needs to do better in, it’s regulating our own. To me, the license to practice medicine is a privilege, not a right. That I should even have to emphasize such a statement is bothersome to me, but all too often medical licenses, once obtained, seem to be treated as a right that can’t easily be taken away. That’s not to say that actually getting to the point of being licensed and board-certified isn’t difficult. It is. There’s the need to maintain excellent grades in college, after which there’s medical school and residency, both of which can be quite brutal. But once a physician is fully trained, board certified, and licensed, it seems that medical boards bend over backwards not to take away his license, seemingly even if he’s providing treatments so far outside the standard of care that they might as well be magic.
That brings me to what I’ve been emphasizing the last couple of weeks here on SBM. Even if you have a problem with state medical boards or medical specialty boards sanctioning physicians for promoting dangerous health misinformation, you should have no problem with them sanctioning physicians who practice rank quackery, as Dr. Tenpenny did. I’ll have more to say on this later, but I thought that the case of Dr. Sherri Tenpenny would be worth discussing, if only to show how long before the pandemic she had been antivax, as well as to vent a little of my frustration over how it wasn’t her quackery that got her license suspended but rather her refusal to cooperate with the Board’s investigation.
Dr. Tenpenny before the pandemic
As I said, I first mentioned Dr. Tenpenny in 2007, but I never really did a post that was primarily about her until 2009. Also, the suspension of her medical license last week reminded me that, compared to the likes of, for example, Andrew Wakefield—or even Dr. Bob Sears—I haven’t written that much about her over the years. Granted, she wasn’t a top tier antivax doc like Wakefield or Sears or a number of the others about whom I routinely wrote (and sometimes ranted) before the pandemic. She was second-tier. However, that doesn’t mean that she was unimportant in the antivaccine movement. Indeed, she was important enough to be featured on a conspiracy cruise alongside Wakefield in 2016. Or maybe that they were featured together on such a cruise was evidence of how far Wakefield had fallen by that time. I can be persuaded either way.
So who is Dr. Tenpenny? As I said, she’s been around for a long time and has practiced antivax quackery quite a while. I always find it useful to check out a quack’s website to see what the quack thinks of herself; so here is the description from Tenpenny’s website:
Dr. Sherri J. Tenpenny is an osteopathic medical doctor, board certified in osteopathic medicine, with a proficiency certification in Integrative Medicine. She was board certified in Emergency medicine from 1986 to 1998, when worked as a full-time Emergency Medicine physician and served as Director of a Level II Trauma center.
The founder of Tenpenny Integrative Medical Center, a clinic located near Cleveland, Ohio, her clinic provides natural, holistic approaches to getting well. Their success has attracted patients from all 50 states and at least 17 countries.
Dr. Tenpenny has invested 21+ years and far more than 40,000 hours researching, documenting, and exposing problems associated with vaccines. She is a frequent speaker at national and international conferences and a regular guest on radio shows, podcasts and on TV, sharing her highly researched information on why we should just say no to vaccines.
It is utterly unsurprising that Tenpenny is “certified” in Integrative Medicine, what I like to refer to as a medical pseudospecialty that is based on “integrating” quackery with medicine. I also like her claim to have spent 40,000 hours “researching, documenting, and exposing problems associated with vaccines”. Does anyone ever bother to do simple division. Divide 40,000 hours by 24 hours/day, and you get just shy of 1,667 days (or 4.6 years) if you assume that she’s working 24 hours a day, 7 days a week. That is, of course, totally unrealistic. Let’s say that she was working 8 hours/day, and then that becomes 5,000 days (or 13.7 years), but that’s still unrealistic. No one works 7 days a week full time for that long. In any case, you get the idea. Her claim of having spent 40,000 hours “researching, documenting, and exposing problems associated with vaccines” is such an exaggeration that it is utter BS.
Perusing her website, I saw once again that Tenpenny offers a variety of evidence-free quack “detox” protocols. She touts one of them thusly:
You’ve probably heard me say this countless times, almost all disease is a result of two things: Excess of toxicity and a lack of nutrients, especially minerals. Mercury, aluminum, vaccine-related chemicals, and environmental poisons including arsenic, lead, cadmium, pesticides, and volatile organic compounds are just some of what we are exposed to every day. Imagine the damaging effects of heavy metals when they are injected into our bodies through vaccines?
This is, of course, a common trope shared among “integrative medicine” quacks and antivax doctors, that “almost all disease” (at least she qualified it with an “almost,” something not all such docs do) is due to “toxicity” or bad diet, with—of course!—vaccines near the top of the sources of the “toxicity,” along with pesticides and chemicals. So what is her solution? Zeolite (which, by the way, cures cancer—that is, if you believe some of its proponents going back decades). But not just any Zeolite. Oh, no. To her, “most zeolite products do not work” because:
To most from the gut and into cells, the zeolite must be nanosized and suspended in water molecule clusters. With that formation, this natural detoxifier can travel throughout the body and even cross the blood-brain barrier. You can start to see why this is important for those who want to detox from vaccines.
Actually, I can’t, but that’s because I practice science-based medicine.
Tenpenny claims that you have to use her preferred Zeolite, Clinoptilolite Zeolite (whatever that is), which, conveniently enough, she sells on her website:
After doing extensive research, I discovered Pure Body Extra Strength manufactured and distributed by a company called Touchstone Essentials. They use a cleansing and nanosizing technology that is hands-down the most advanced on the market. The particles that are contaminating the zeolite are removed and the zeolite honey-comb is filled with alkalizing minerals. That way, the zeolite “swaps out” a beneficial mineral for a toxin it absorbs. The amount removed has been confirmed by a third-party independent laboratory.
Even better (if you believe Tenpenny):
Nanometer-sized particles can get into cells and can “mop up” toxins within hours of administration. And because this form of zeolite is encapsulated within water molecule clusters, it can be administered as a liquid spray. That makes it easy to use: just take a few sprays, morning, noon, and night. There is no odor, no taste, and no hassle.
So. Much. Water. Woo. (Plus Zeolite detox woo.) She’s also recommending Nattokinase-based quackery, which I discussed not too long ago. I’m sure she gets no kickbacks for selling this Zeolite and offers it only out the goodness of her heart, for the good of her patients. Of course she is. She also recommends a “parasite protocol” by Dr. Jason Dean. Unsurprisingly, “Dr.” Jason Dean is a chiropractor, not a real medical doctor. Meanwhile, on Amazon, you can find books by her that indicate that she has been rabidly antivax for a long, books with titles like Vaccines: The Risks, the Benefits, the Choices, a Resource Guide for Parents (2006) and Saying No to Vaccines: A Resource Guide for All Ages (2008).
You get the idea. But what about her antivax advocacy? First, let me quote something that she wrote in 2007, and ask yourself whether it sounds familiar or not:
At the beginnings of ‘Public Health’ policy, efforts were made to convince persons to participate through cooperation. Since that late 1960s, the pendulum has swung from education and collaboration to heavy handed coercion through advertisement campaigns designed to shame and terrorize parents into believing the are neglecting their children by questioning, and at times refusing, vaccines. The current example of heavy handedly slapping of parents into “compliance” is a further example of how far our freedoms have eroded. While we drop bombs and fire bullets around the world to ensure the freedom of others, we are incarcerating parents for doing what they believe is in the best interest of their children. Wake up, Americans. What will they be incarcerating us for next in the name of compliance?
Antivaxxers are nothing if not unchangingly consistent in their messaging. I also can’t help but point out the consistency of the “Nuremberg” messaging among antivaxxers, because that post reminded me that the Association of American Physicians and Surgeons (AAPS), a fake medical society that I’ve been referring to as a medical John Birch Society since at least 2008, liked to use Nuremberg comparisons about “informed consent” in 2007 (and likely for a long time before that):
WHEREAS: Safety testing of many vaccines is limited and the data are unavailable for independent scrutiny, so that mass vaccination is equivalent to human experimentation and subject to the Nuremberg Code, which requires voluntary informed consent; and
WHEREAS: The process of approving and “recommending” vaccines is tainted with conflicts of interest;
BE IT THEREFORE RESOLVED: That AAPS calls for a moratorium on vaccine mandates and for physicians to insist upon truly informed consent for the use of vaccines.
Truly, everything old is new again. But back to Sherri Tenpenny.
Does anyone remember what Tenpenny did in 2019, a few months before the pandemic, in the midst of a deadly measles outbreak in Samoa that had killed dozens of children? I frequently refer to what Robert F. Kennedy, Jr. did during that outbreak, namely how he wrote to the Prime Minister of Samoa blaming the MMR vaccine for the outbreak, rather than the dramatic decline in MMR uptake that resulted because of a tragic error by two nurses mixing up the vaccine that caused the deaths of two infants and how he and other antivaxxers swooped in to fear monger about the MMR as children were dying. Well, Tenpenny was one of the antivaxxers who swooped in, when she claimed that the outbreak had been related to the delivery of over 100,000 doses of MMR to Samoa. She and Grundvig also trotted out the old antivax trope about measles being curable with vitamin A.
Nor was this the first time that Tenpenny had spread antivax misinformation in an underdeveloped country during an outbreak of a vaccine-preventable disease that was killing children. Ten years before the deadly measles outbreak in Samoa, Tenpenny did basically the same thing when children were dying of measles in Zimbabwe. In response to reports that 30 children had died of the measles in Zimbabwe at that point, Tenpenny wrote something that will likely sound very familiar today:
Study these numbers. We’ve had SARS, Bird flu and Swine flu. On average, approx. 190 children/year die from the flu. Considering there are about 62M kids under the 14 years of age in the US, this is NOT “statistically signficant” [sic] and should not even make the radar screen. See how they manipulate parents into vaccinations?
Next year, PLEASE do not be afraid of the flu. Ever person here should pass this on to at least 25 people! Please pass this to at least 25 friends.
That’s right. To her 190 dead children were not “statistically significant,” and she was using that number to downplay the deaths of children from measles. As I asked at the time, can you imagine how Tenpenny and her ilk would descend upon me if I said that one case in a million of severe adverse reactions to vaccination is “statistically insignificant”? (I’ve never said that, of course.) Tenpenny would howl with outrage at my “insensitivity” and “callousness.” Note also how this very message has been increasingly echoed by “respectable” physicians like Dr. Vinay Prasad about COVID-19, that it kills an “insignificant” number of children. The message is the same; only the disease is different. Also, 190 children dying of any one cause is a lot! Children aren’t supposed to die.
In case you’re wondering what other quackery she practices, just take a look at her Substack post about the Board hearing, in which she bemoans the Board’s decision and lists what existing patients should do, which is to keep their appointments and be seen by one of Dr. Tenpenny’s minions working at her “integrative medicine” practice:
If you are an existing or future patient at Tenpenny Integrative Medical Center (we’ve had patients from all 50 states and more than 18 countries), please continue with your appointments for with my team:
     1.  SRT for allergies. Due for an annual tune up? Call today!
     2.  Bio-identical hormones evaluation/treatment – ask for Sandi or Dr. Clapper
     3.  Nutritional evaluation and supplement program – the entire team!
     4.  Pain relief with mannitol injections – Carla can treat you
     5.  Neuropathy relief wit Neurogenix – Mike knows all about this
     6.  Nutritional IVs – we have many – ask Danielle and Laura
     7.  Care of your unvaccinated children – ask Dr Jackson. She is trained in cranial manipulation for your babies who have crossed eyes or are struggling to nurse.
Regular readers of this blog will note that we have described how cranial manipulation/craniosacral therapy is utter quackery (even more so when inflicted upon infants); so are nutritional intravenous infusions and SRT for allergies, while the rest are, at best, unproven. SRT, in case you didn’t know, stands for Sensitivity Reduction Therapy for allergy elimination. Here’s a description of what it entails:
While you are in contact with the allergen, a series of acupuncture points along the spinal column are activated through pressure to open the energy channels connected to the central nervous system. A series of specific acupuncture points on the arms and legs are stimulated to open all the meridians flowing through the body. You will be asked to rest quietly on the treatment table while holding the allergen for 15 minutes as part of the treatment. After your treatment, you will be asked to maintain a strict avoidance of that allergen for 3 hours. In addition, you will be told to avoid all food and beverage for 3 hours after the treatment. Water is generally allowed. Be sure to eat prior to each appointment. Each session lasts about 30 min.
The actual treatment is painless and seems simple. However, it is EXTREMELY powerful and effective. There will be changes that affect your entire body’s physiology. Side effects include body aches, headaches, sweating, and nausea. Even though these reactions are uncommon, if they persist more than 48 hours, be sure to call the office for instructions.
You read that right. SRT, which apparently was invented by Dr. Tenpenny, involves the patient holding the allergen—not a good idea if the patient’s allergic reaction goes beyond hives and into, for example, anaphylaxis—while the practitioner applies acupressure to acupuncture points. Given that acupuncture is mystical, prescientific nonsense whose history has been hopelessly retconned to portray it as “ancient wisdom”, SRT strikes me as not just quackery, but potentially dangerous quackery.
It thus appears that, while her license is suspended (for however long that is), Dr. Tenpenny will do just fine with income from her integrative medicine practice. Moreover, the rest of the Substack entry asks for donations to her legal fund, podcast subscriptions (which, she notes, “will become an important part of my income too”), and other offerings. As is often the case for doctors like this, it is likely that Dr. Tenpenny will continue to do just fine financially. She might even prosper more as the latest “free speech martyr” and “brave maverick doctor” being subjected to “persecution”.
Sherri Tenpenny: Quackery meets hubris
Sherri Tenpenny has a history of antivaccine beliefs and practicing a wide variety of quackery dating back to late last millennium; yet it took her making bonkers statements about COVID-19 vaccines magnetizing people and interacting with 5G cell phone signals before the board actually tried to do anything. Before that, apparently, she had been practicing more or less untouched by the Ohio State Medical Board, selling her Zeolite quackery, refusing to vaccinate, and practicing all manner of “integrative medicine” quackery in a quiet Cleveland suburb. As I argued when I discussed the toothlessness of state medical boards and the faltering attempts of medical specialty boards to deal with physicians who spew misinformation, it is rare for advocacy of dangerous health and antivax misinformation not to be coupled with the actual practice of quackery based on that misinformation. The two almost always go hand-in-hand. For those who are uncomfortable with medical boards sanctioning physicians for speech—even though I would counter that it is not censorship but rather quality control to provide consequences for physicians who endanger public health with deadly misinformation—then surely advocates of science-based medicine who are uneasy about the conflict between the First Amendment and sanctioning physicians for spreading misinformation can get behind sanctioning physicians like Tenpenny for practicing quackery.
Unfortunately, we never got the test, because hubris carried the day, with Tenpenny, apparently under the instructions of her lawyer Thomas Renz, decided to stonewall and refuse to cooperate. I have the PDF of the medical board’s letter describing its actions, and the description of the stonewalling is truly amazing. It documents multiple attempts by Jason Alameda, a Board Enforcement Investigator, to contact Dr. Tenpenny and then:
On September 7, 2021, Ms. Pastrick mailed to Dr. Tenpenny the Board’s First Set of Interrogatories (“Interrogatories”). The Interrogatories were mailed to Dr. Tenpenny’s address of record by certified mail. (St. Ex. 2 at 2-24; St Ex. 9; Tr. at 18) Tracking information from the United States Postal Services shows that the Interrogatories were delivered on September 9, 2021. (St. Ex. 2 at 25-26) The Interrogatories asked for information regarding Dr. Tenpenny’s practice in general as well as asking specifically about her practice regarding recommendations concerning, and administration of, vaccines and whether any of her patients subsequently contracted certain illnesses. The Interrogatories also specifically ask how many doses of COVID-19 vaccines she had provided and whether she had personally received a COVID-19 vaccine. (St. Ex. 2 at 7-16) The Interrogatories also asked Dr. Tenpenny what scientific evidence she had, and specifically asked that she cite her sources for this evidence, regarding COVID-19 vaccines causing people to become magnetized or creating an interface with 5G towers; regarding the COVID-19 vaccine not injecting a real virus but strips of genetic material and patients suffering complications such as abnormal bleedings, myocarditis, strokes, and neurological complications; and regarding some major metropolitan areas liquifying dead bodies and pouring them into the water supply. (St. Ex. 2 at 18-19) Dr. Tenpenny’s responses to the Interrogatories were due by October 8, 2021. (St. Ex. 2 at 2-3)
Renz, however, responded:
In a letter dated September 20, 2021, Thomas Renz, Esq., of Renz Law, LLC., the only licensed attorney who signed the letter3, objected to the Interrogatories in their entirety, as well as an August 11, 2021 letter from the Board regarding a method of investigation into a potential violation of R.C. 4731.22 which is not part of the Notice. (St. Ex. 3) While much of the letter addresses an issue which is not the subject of the current case, as to the Interrogatories, Mr. Renz, wrote, “The September 7th Interrogatories are invasive, irrelevant to any inquiry into (St. Ex. 3 at 3) Mr. Renz further wrote that Dr. Tenpenny would not respond to the Interrogatories and asserted that “[d]eclining to cooperate in the Board’s bad faith and unjustified assault on her licensure, livelihood, and constitutional rights cannot be construed as an admission of any allegations against her.” (St. Ex. 3 at 3) Mr. Renz also wrote that most of Dr. Tenpenny’s statements which were quoted in the August 11, 2021 letter4 were “based on factual reports by third parties – including peer-reviewed studies published in mainstream medical journals.” (St. Ex. 3 at 2)
The letter also noted that Tenpenny and Renz had been informed that things could…escalate…if Tenpenny didn’t respond, up to being subpoenaed to testify and even having her license suspended:
Please be advised that you are required by law to cooperate in an investigation conducted by the Board. Failure to appear for the office conference as scheduled may result in the issuance of a subpoena to compel your appearance at a deposition. Further, failure to cooperate in the Board’s investigation, including failure to appear and/or failure to answer questions truthfully at the office conference, constitutes legal grounds for discipline that may potentially result in the denial, suspension, or revocation of your license to practice, as well as a civil penalty up to $20,000.00.
Unsurprisingly, when the Board did as it had warned and upped the ante by subpoenaing Dr. Tenpenny, Renz responded:
By letter dated October 31, 2021, Mr. Renz5 wrote, “. . . Dr. Tenpenny is in no way obligated to and will not cooperate in the Board’s bad faith and unjustified assaults on her licensure, livelihood, and constitutional rights.” (St. Ex. 5 at 1) Mr. Renz incorporated the claims and defenses made in his September 20, 2021 letter and made several additional legal arguments. He argued that there were no legal grounds for the Board’s investigation as the Board had not presented the basis to Dr. Tenpenny, and he cited to R.C. 4731.22(F)(1)6. Mr. Renz also argued that Dr. Tenpenny, as a party at a hearing, was entitled pursuant to R.C. 119.13 to have an attorney represent her and to have that attorney cross-examine witnesses7 and that the Board was attempting to mislead her on her rights by citing to R.C. 9.84 in its letter accompanying the subpoena8. (St. Ex. 5 at 1-2) Mr. Renz also alleged bad faith on the part of the Board:
Bad faith is evident by your failure to present evidence that our client violated a provision of Chapter 4731, your erroneous and misleading citation to R.C. § 9.84 regarding her right to counsel, your failure to communicate directly with our law firm regarding this subpoena, and your complete lack of any grounds whatsoever for continuing to harass Dr. Tenpenny.
(St. Ex. 5 at 2)
In addition, Mr. Renz wrote: For the foregoing reasons, the October 12, 2021, subpoena is demonstrably unlawful and unenforceable and, therefore, Dr. Tenpenny will not participate in the Board’s ongoing illegal fishing expedition. Declining to cooperate in the Board’s bad faith and unjustified assault on her licensure, livelihood, and constitutional rights cannot be construed as an admission of any allegations against her.
Mr. Renz also wrote that further attempts to enforce the subpoena or obtain responses to the Interrogatories would result in a filing requesting declaratory and injunctive relief as well as any other available remedies. (St. Ex. 5 at 3)
First, note how Renz, invoking the sort of attitude that I decry, namely the idea that a medical license is a right and not a privilege and couching his response all in the language of rights. Even so, it is the height of hubris to refuse to cooperate or answer legitimate legal demands of the State Medical Board. To be honest, one could argue that Renz was not doing his client any service in choosing this tactic, which he surely must have known would have a high likelihood of ending up with the board suspending his client’s medical license. I could be wrong, but I can only speculate that he did this precisely because he knew that this would be the likely end result and that such a suspension would allow him to portray his client as the “persecuted” victim of medical board overreach and “censorship.” If that’s true, I can only further speculate that such a tactic would be a last resort, something to invoke when you know that, after an investigation, the board would likely still suspend his client’s medical license. My only question is whether Tenpenny understood this and agreed to this hardball tactic, which the board dismissed thusly:
As to Dr. Tenpenny’s claims that the Board was attempting to investigate statements which were public and/or political speech and therefore protected by the First Amendment to the U.S. Constitution, Dr. Tenpenny has not provided sufficient evidence of what those statements were in order to enable a determination to be made of whether such statements were protected speech. Further, there is insufficient evidence to show that the Board’s investigation was initiated due to any protected speech.
Unfortunately, in the latter part of the letter, a lot is redacted, which I find curious given that the investigation was the result of 350 complaints based on her public statements and not, apparently, individual patient complaints, where one would expect private information to be protected from public view. In any event, I note that this suspension is not necessarily permanent. The Board’s letter instructs Tenpenny and Renz:
CONDITIONS FOR REINSTATEMENT OR RESTORATION: The Board shall not consider reinstatement or restoration of Dr. Tenpenny’s license to practice osteopathic medicine and surgery until all of the following conditions have been met:
     1.  Application for Reinstatement or Restoration: Dr. Tenpenny shall submit an application for reinstatement or restoration, accompanied by appropriate fees, if any.
     2.  Payment of Fine: Dr. Tenpenny shall have fully paid the fine as set forth in Paragraph B of this Order. In the Matter of Sherri J. Tenpenny, D.O. Page 17 Case No. 22-CRF-0168
     3.  Certification of Cooperation with Board Investigation: Dr. Tenpenny shall submit a written statement from the Board’s Enforcement Division that Dr. Tenpenny has fully complied with all subpoenas and interrogatories issued to her by the Board.
     4.  Additional Evidence of Fitness To Resume Practice: In the event that Dr. Tenpenny has not been engaged in the active practice of osteopathic medicine and surgery for a period in excess of two years prior to application for reinstatement or restoration, the Board may exercise its discretion under Section 4731.222, Ohio Revised Code, to require additional evidence of her fitness to resume practice.
So, basically, what it sounds to me is that all Dr. Tenpenny has to do to get her license back is to submit an application for reinstatement (plus fees), promise to start cooperating with the Board, and pay her fines. Granted, the Board will continue to investigate and there’s no guarantee that she would not still have her license suspended, perhaps permanently, after the investigation, but I’m less optimistic. After all, this blog’s history is littered with reports of utter quacks being disciplined by their state medical boards with, in essence, slaps on the wrist involving fines plus mandated education and supervision of their practices by the board for a specified period, which is what happened in the case of Stanislaw Burzynski, a cancer quack who had been practicing his quackery since the late 1970s.
In the end, this result is, as is too often the case, unsatisfying. As a friend suggested to me, we should take the “win” here (viewing this as a win), and certainly it is a good thing that Dr. Tenpenny can no longer practice medicine. Unfortunately, if she decides to start cooperating with the Ohio State Medical Board, she could well have her license reinstated while the investigation is ongoing, and the ultimate penalty might be of the “slap on the wrist” variety that I described above—or even nothing at all. In the meantime, she will be portrayed as a free speech martyr, a “medical maverick” that “They” had to “cancel” or “silence”. At least she won’t be able to inflict her quackery on patients anymore for the foreseeable future. Given her decades-long history of doing just that, I guess that I, too, reluctantly view the outcome of this case thus far as a “win”

State medical boards vs. COVID-19 misinformation, an update
The disinformation epidemic about COVID-19 has pushed state medical boards to consider disciplining physicians who promote COVID-19 disinformation. How would that work? What are the obstacles? Is it even possible? It should be, but it will be messy and complicated.
David Gorski on September 27, 2021
Link

A little over a month ago, I wrote about how the Federation of State Medical Boards (FSMB) had recently issued a statement asserting that physicians who spread COVID-19 misinformation should be subject to disciplinary measures by their state medical boards up to and including revocation of their medical licenses. Given that there have been some developments on that front since then, I thought that now would be a good time for an update and a bit more discussion on the general issue of what should be done about physicians who promote misinformation not just about COVID-19 and COVID-19 vaccines, but medical misinformation, antivaccine conspiracy theories, and pseudoscience in general. At the time of my original post, I expressed major skepticism that the FSMB’s statement would result in any action. The situation is perhaps not as bad as I had predicted then, but it’s also not so great, either.
In that post a month ago, I started by pointing out how many physicians had been behaving badly since the pandemic began 18 months ago. That was just in 2020. In 2021, the prominence (and, I fear, number) of physicians promoting health misinformation has only increased. In addition to the usual suspects jumping onto the COVID-19 misinformation grift train (several of whom were ultimately dubbed the “Disinformation Dozen“), there were academics who really should know better downplaying the pandemic and doubting the effectiveness of vaccines. Our very own Jonathan Howard even went so far as to point out how some of them have gotten to the point where, even though we know they are not antivaccine, their bloviations need to be fact-checked as though they were antivaccine. Again, it was no surprise that the usual suspects have been promoting COVID-19 misinformation. Grifters gonna grift, as I like to say, and COVID-19 was an unprecedented opportunity for physicians like Joseph Mercola, Sherri Tenpenny, Kelly Brogan, and the other usual quacks to pivot and switch their grift to the coronavirus and COVID-19 vaccines.
If it had only been the usual quacks and grifters who had jumped on the COVID-19 misinformation fraud train, possibly the situation now with respect to COVID-19 misinformation wouldn’t have deteriorated so much. After all, in contrast to the academics who have turned COVID-19 contrarian, the usual quacks and grifters are at best fringe figures with little influence outside their usual echo chambers. So let’s briefly review some of the messages being promoted by physicians who were once respected doctors and academics who have become what Dr. Howard and I like to call “COVID contrarians”. They minimize the risk of harm from the coronavirus (particularly in children), make risibly off-base predictions (e.g., “we’ll have herd immunity by April“) and advocate against mask mandates (particularly in schools) and vaccinating children—or even erroneously claim that respiratory syncytial virus (RSV) is being misdiagnosed in children as COVID-19 and that hospitalizations of children are being exaggerated. During the recent discussion over myocarditis in children associated with COVID-19 vaccination, none of them seem to be able to acknowledge that COVID-19 actually harms children, while one physician whom I used to respect whose results I used to write about on a regular basis has gone down the rabbit hole of conspiracy theories, repeating a particularly pernicious one dating back to early in the pandemic that early intubation of COVID-19 patients was killing them. That physician, Dr. John Ioannidis, even went to far as to say that doctors, “not knowing how to use mechanical ventilation, just going crazy, and intubating people who did not have to be intubated”. (Spoken like a doc who has never taken care of critically ill patients in an ICU!) And don’t even get me started on the physicians who wrote and signed on to the Great Barrington Declaration, the pre-vaccine statement that advocated letting COVID-19 rip through the “healthy” young community and using “focused protection” to keep the elderly and those at high risk of severe disease and death safe from the coronavirus.
Worse, when corrected for their mistakes, these “COVID contrarians” almost never seem to have the humility to admit error and move on; often they double down and act as though their statements were never refuted. Indeed, they often characterize criticism as “cancel culture” and loudly claim victim status whenever their efforts encounter serious pushback. We’ve recently seen an excellent example of just that from our recent discussions of the VAERS analysis looking at myocarditis after COVID-19 vaccination in teens by Tracy Beth Høeg, John Mandrola, Josh Stevenson, and Allison Krug that utterly misused the VAERS database and didn’t put the findings into context. Predictably, they and their defenders are crying “Persecution!” and blaming the blowback on “medical tribalism“. So what’s new?
The medical boards in Mississippi and Washington weigh in
On Friday, I was made aware of this news story out of Washington, which reported that the Washington Medical Commission can now discipline doctors who spread COVID-19 misinformation:
Doctors and physician’s assistants who spread misinformation about COVID-19 in Washington could face disciplinary measures. That’s after action taken this week by the Washington Medical Commission, which monitors and enforces licenses of about 34,000 physicians and physician assistants here.
During a special meeting, the commission formally adopted a position statement to that effect. The commissioners agreed unanimously that the treatment of COVID-19 must meet the same standard of care as other diseases.
That’s after reports of a surge in unsafe alternative treatments such as ivermectin, an anti-parasitic drug often used in animals. It has off-label approval for human use in limited circumstances, but both the CDC and the FDA say there’s no convincing evidence it works to prevent or treat COVID-19.
The State of Mississippi has also made a move in the same direction:
Physicians who spread misinformation about the COVID-19 vaccine could now have their license to practice medicine suspended or completely revoked, according to a new policy adopted by the Mississippi State Board of Medical Licensure.
The policy, adopted on Sept. 7, says that doctors have an “ethical and professional responsibility” to practice medicine in the best interest of their patients and share factual and scientifically-grounded information with them.
“Spreading inaccurate COVID-19 vaccine information contradicts that responsibility, threatens to further erode public trust in the medical profession and puts all patients at risk,” the policy reads.
The policy says whether physicians “recognize it or not” they possess a high degree of public trust due to their specialized knowledge and training. That gives them “a powerful platform in society.”
The policy specifically warns doctors against spreading misinformation on social media and strongly recommends physicians separate their personal and professional content online.
“Physicians must understand that actions online and content posted can affect their reputation, have consequences for their medical careers, and undermine public trust in the medical profession,” it reads.
This is a step in the right direction, although I do wonder how these new policies in Washington and Mississippi will be operationalized. Why do I wonder this? The article about the Washington Medical Commission alludes to it, but doesn’t quite get to the point where we at SBM have been for a while:
Dr. Yanling Yu, a research scientist from Lake Forest Park, serves as a public member of the commission. She expressed initial concern about following state law that protects alternative medicine, but then spoke in favor of the position statement on misinformation.
“There is no valid science at all. … Like, ivermectin, there have been patients that have been harmed by it. So that is not scientific practice of medicine. And that needs to be stopped,” Yu said.
And there you have it, the exact issue that I’ve been writing about for well over a decade, the powerlessness of state medical boards in the face of quackery. Let’s take a trip down memory lane to explain what I mean.
COVID-19 misinformation and alternative medicine
Out of curiosity, I perused my personal blog to search for the first instance when I wrote at length about the problem with state medical boards and found that it was in 2008, when the North Carolina Board of Medical Examiners finally disciplined cancer and autism quack Dr. Rashid Buttar (who, unsurprisingly, is today one of the usual quacks and grifters promoting COVID-19 and COVID-19 misinformation). Unsurprisingly, all Dr. Buttar got was the proverbial slap on the wrist, even after having called the Board a “rabid dog“. All the Board did was to restrict Dr. Buttar’s practice so that he was no longer permitted to treat children or cancer patients. Why children and cancer patients specifically? Simple. Dr. Buttar had been known for his antivaccine views that blamed mercury in the thimerosal preservative in vaccines caused autism, and his treatment was a “transdermal chelation therapy” that we disparagingly called “Buttar’s butter“, and he was a cancer quack, to boot.
Two years later, Dr. Buttar was free to practice medicine again mostly unencumbered. Basically, he signed a consent decree with the Board that reprimanded him and ordered him (1) to provide informed consent to his patients as dictated by the Board; (2) to obey all laws, as well as rules and regulations governing the practice of medicine in North Carolina; (3) to notify the Board if he changes his address; and (4) to meet with the board periodically. The informed consent forms were utterly worthless, as well. Basically, they stated that Dr. Buttar made no claims for the efficacy of anything that he was doing. It also pointed out that serious complications can occur from IV treatments. As I noted at the time, if I were to use an informed consent like this for surgery, for example, in which I “make no specific claims” that the proposed surgery will do anything therapeutic for the patient, sane practitioners would demand to know why I was allowed to do this operation in the first place!
Of course, Dr. Buttar was one of many examples of the failure of state medical boards to discipline outright quacks and antivaxxers. Worse, in one state, whistleblowers who have reported dubious practices of physicians have even been prosecuted by law enforcement, as I described in depth in 2009. The state was Texas, the same state whose medical board has been unable to shut down the practice of Houston cancer quack Dr. Stanislaw Burzynski, who has been plying his cancer quackery there since the late 1970s. Then there’s the case of Dr. Christopher Duntsch, the substance abuse-impaired neurosurgeon who was so incompetent that his fellow surgeons had seen nothing like it before. As I’ve mentioned recently Duntsch is now the subject of a Peacock series Dr. Death. My own state is not immune. This might have nothing to do with alternative medicine, but it took the FBI, not my state medical board, to finally stop Dr. Farid Fata, the oncologist who gave chemotherapy to patients who didn’t even have cancer. How did they stop him? They busted him for Medicare and Medicaid fraud for having billed over $30 million for unnecessary treatments.
You get the picture.
It’s worse than that, though. As Jann Bellamy and others here at SBM have been documenting, quacks like naturopaths, chiropractors, and other alternative medicine practitioners have been playing the long game of pushing to change state laws to legitimize their “professions”. She even has a term for it: legislative alchemy, the process in which quacks try to turn the lead of their professions into gold. She’s long documented the process for chiropractors, naturopaths (among the most persistent and successful of the legislative alchemists), acupuncturists, reflexologists, and practitioners of “integrative medicine” who “integrate” quackery with their medicine. These bills take the form of promoting bills mandating formal state licensure, expanding quacks’ scope of practice, and requiring Medicare and insurance companies to reimburse quacks for their “services”. In Florida, a new law even forces doctors who don’t support alternative treatments for pain to endorse acupuncture and other quackery as “non-opioid treatments” for pain.
This brings me back to the State of Washington. Remember how that one quote expressed concern about how the state could police physicians promoting COVID-19 misinformation when it has a law on the books that protects “integrative” (and therefore alternative) medicine practitioners? Remember how I discussed how North Carolina handled the case of Dr. Buttar? One thing I didn’t mention then but will mention now is this, quoted from a story that is no longer on the web (and not in the almighty Wayback Machine at Archive.org), although the relevant parts are preserved in my post:
The consent order, signed Friday, marks the end of a battle that Buttar had vowed to take to the U.S. Supreme Court. He said he has spent “hundreds of thousands of dollars” defending himself against the board’s allegations that he exploited patients by charging exorbitant fees for unproven therapies that didn’t work and by arbitrarily ordering expensive tests to make more money.
In recent years, Buttar led a successful effort by the N.C. Integrative Medical Society to get legislators to change state law to make it friendlier to practitioners of alternative medicine.
This is another example of “legislative alchemy”, in which influential quacks manage to persuade state legislatures to pass laws protecting “alternative medicine” practices. So what is the relevance to the ability of, for instance, the Washington Medical Commission? Simple. As we’ve documented here time and time again, if there’s one consistent aspect of alternative medicine (besides its lack of science), it’s antivaccine views. Naturopaths, chiropractors, and acupuncturists, for example, tend to be overwhelmingly antivaccine, and many even deny germ theory. If their views are “protected” somehow by state law, that would put these new directives allowing state medical boards to discipline physicians for spreading COVID-19 misinformation into direct conflict with the laws protecting “alternative and traditional” medical practices.
So here’s what I mean when I ask: How will, for example, the Washington Medical Commission operationalize this new policy, particularly if it conflicts with a law that protects alternative medicine practice? For example, if a doctor promotes germ theory denial and antivaccine views about COVID-19 under the guise of “integrative medicine” citing acupuncture (licensed) and naturopathy (also licensed), how can the Washington Medical Commission do anything about it? The state of North Carolina has also suggested that it might discipline doctors who promote COVID-19 misinformation, but how will it do so when its own law privileges alternative medicine (hidden in “integrative medicine”) almost as much as science-based medicine, thanks to the efforts of Dr. Buttar and his fellow quacks? This is a general principle that applies to any state that has legalized forms of “alternative medicine,” not just Washington or North Carolina.
That’s aside even from the consideration of where to draw the line in terms of professional speech. While it’s obvious that saying, for example, that COVID-19 vaccines don’t work is misinformation or disinformation, what about physicians who not-so-subtly raise doubts about the vaccines that rely on leaving out key pieces of information? One way has been proposed in an op-ed by doctors, a couple of whom should be familiar to regular readers here:
It’s important to understand that the wrongdoing involved is not misinformation — that is, something that a person incorrectly but innocently believes to be true. It is disinformation, which is information created and shared with the intent to deceive. For many months a well-coordinated network of disinformation doctors has been working to undermine mask-wearing and lockdowns, spread anti-vaccine conspiracy theories, and promote phony covid “cures” such as hydroxychloroquine and the horse-deworming drug ivermectin.
The best known of these groups calls itself “America’s Frontline Doctors” — though many physicians in this group have never practiced emergency medicine, and some haven’t practiced any form of medicine for years. Amid the Trump administration’s disastrous handling of the pandemic, this group was ushered into the public arena to discredit medical science. They began by trying to convince Americans that the potential for severe illness from covid-10 was a hoax, in the interest of keeping the U.S. economy open and thus fueling Donald Trump’s reelection campaign. Through their social media platforms and rallies, they continue to sow distrust of the Centers for Disease Control and Prevention and dissuade their audiences from following public health guidelines. In January, the group published a white paper denouncing vaccines. Its members have held rallies to spread their message in states including Florida, Texas and California — all of which are now experiencing covid spikes. Now, with the delta variant, those cases include a large number of very sick children.
They further note:
But these physicians will not be dissuaded by strongly worded statements. Consider Simone Gold — a California physician and noted advocate of the hydroxychloroquine “cure.” In 2020 she was one of the founders of America’s Frontline Doctors; today, as NPR reported, Gold continues to spread disinformation, discourage vaccination and promote unproven treatments for covid (for which, NPR noted, she was offering to prescribe via a $90 telehealth appointment). She was arrested after Jan. 6, when she participated in the incursion into U.S. Capitol, having come to Washington that day to speak at a “rally for health freedom.” Simone Gold is still licensed to practice medicine in the state of California.
The pessimist in me wonders if even losing their licenses would dissuade some of these doctors, many of whom seem not to be in medical practice any more, having gone into full time COVID-19 grifting. On the other hand, at least they wouldn’t be able to be ivermectin prescription mills any more. The doctors behind the op-ed cited above have gone beyond an op-ed and set up a website for reporting the worst disinformation peddlers, No License for Disinformation.
Let me finish on a more optimistic note. I’ve long said that professional speech is not the same thing as free speech. Specifically, we as physicians have a privileged status that is highly respected when it comes to our statements on medical matters (and, oddly enough, even on nonmedical matters, as nonsensical as that may seem). As a result, we have a particular professional responsibility not to spread misinformation, and professional ethics demands that we do not publicly promote quackery or disinformation. State medical boards should be enforcing this, but traditionally have not, just as they have been very reluctant to discipline outright quacks. They are understaffed and underfunded, which tends to disincentivize going after any but the most straightforward cases, such as doctors running prescription mills, sexually abusing patients, or suffering from substance abuse problems that impair their ability to practice medicine safely. Traditionally, they’ve been reluctant to engage in judgment calls on anything other than the rankest of quackery, and even then, as in the case of Dr. Burzynski, their track record is uneven at best. Policing professional speech about COVID-19 will be even more difficult.
        ◦ Even so, given the harm that physicians promoting misinformation cause, this is something that state medical boards need to undertake. If there could be one good outcome from the pandemic, it would be enhanced power of state medical boards to discipline physicians promoting medical misinformation and disinformation of all kinds, not just about COVID-19 or COVID-19 vaccines. As No License for Disinformation puts it, “Everyone has the right to an opinion. Doctors, however, are bound by an ethical and legal obligation to do no harm”. Physicians promoting misinformation and disinformation betray that obligation.

State legislatures consider bills prohibiting COVID-19 vaccination mandates and other public health measures
Bills seek to prevent the states and private employers from mandating COVID-19 vaccines and other pandemic mitigation measures. Some proposed legislation would severely handicap public health officials in combating future health emergencies.
Jann Bellamy on March 11, 2021
Link

Although, to my knowledge, no government entity or employer has actually mandated COVID-19 vaccination, legislation is pending in several states to head off any such attempts. Some of these bills attack mitigation measures like mask wearing as well, or provide religious and other exemptions to COVID-19 immunization. Other, more sweeping, bills tie the hands of public health officials with overly-broad measures going well beyond the current pandemic and exhibiting little regard to what the future may bring.
The vast majority of bills, almost to the point of exclusivity, are sponsored by Republican legislators. As is true of bills weakening or eliminating school immunization requirements, anti-vaccination organizations like the Alliance for Natural Health, which assiduously protects your right to be bamboozled by fringe medical practitioners and their nostrums, are busy lobbying state legislatures to make sure vaccination mandates and the like never see the light of day, or at least permit generous exemptions.
While I don’t believe broad COVID-19 mandates are warranted in our current circumstances, too many of these bills attack sensible public health measures like mask wearing or ban mandates in situations where they may be appropriate, like long-term care facilities. Bills broadly handicapping public health officials without thinking through the consequences are downright dangerous.
Before we get to the pending legislation, let’s look briefly at how current federal law addresses state and private employer mandates. The FDA allows administration of the three COVID-19 vaccines currently available in the U.S. under an Emergency Use Authorization (EUA) issued for each. Per the federal law allowing the FDA to issue EUAs, the Secretary of the Department of Health and Human Services must specify whether individuals may refuse the vaccine and the consequences for that refusal. Here, the FDA has made clear that anyone may refuse a COVID-19 vaccination and requires that this information be disclosed to the public. According to a recent JAMA Viewpoint article by public health and health law experts, “mandating COVID-19 vaccines under an EUA is legally and ethically problematic”.
However, at the end of last year, the Equal Employment Opportunity Commission issued pandemic-related Q&As that “favor a voluntary vaccination approach, but do not expressly prohibit a mandatory policy with appropriate ‘outs’ for disability and religious accommodations.” As best I can tell, the advice was not limited to vaccines with full FDA approval.
Where employees are unionized, a collective bargaining agreement could require bargaining over the implementation of a mandate, or even consent-based vaccination, to avoid violating federal labor laws.
In sum, federal law does not require vaccination of anyone but apparently does not prohibit private-sector employers from mandating employee vaccinations. (Please note: this is an SBM post, not legal advice. Consult a lawyer if you have questions.)
With that, let’s turn to the pending state bills. As noted in my previous post on school vaccination legislation, different states have different abbreviations for legislation. To simply things (for me), I’m going to use whatever combination of letters and numbers the particular state uses with a link to the legislature’s website, where you can find all the details.
Hog-tying public health
Legislators in several states have introduced bills curtailing the authority of health officials to implement mitigation measures in a public health emergency. These take various forms, some disallowing vaccination mandates altogether, others adding that anyone refusing voluntary vaccination in an emergency cannot be quarantined or isolated, while others still create exemptions to vaccination mandates. Some bills are directed only at COVID-19; others cover all immunization mandates. The titles of, and language used in, several bills give us a hint as to their sponsors’ ideological leanings.
Maryland HB 17, the “Consent of the Governed Act”, is an especially ham-fisted and poorly drafted reaction to the state’s handling of the COVID-19 pandemic. Current Maryland law allows the Governor to declare a state of emergency and to issue orders to mitigate that emergency, such as Gov. Larry Hogan’s orders restricting restaurant capacity, mandating mask-wearing, and similar measures.
No matter the emergency or its circumstances, HB 17 limits the duration of any state of emergency to 14 days, with a 14-day extension if approved by a two-thirds majority of the General Assembly, which must convene within 3 days of the order. Oddly, an emergency order cannot apply at all to state legislators or judges and the Governor cannot “threaten or arrest” legislators or judges for violation of an emergency order.
The Governor cannot require
any member of the public to remain indoors, wear a face covering, not congregate or assemble, close or limit capacity of a business, church, or school, or interfere with the right to obtain and try any medical treatment desired for any illness . . . or receive a vaccine or be forced under penalty of law to make any other health decision.
Private citizens would have the right to sue to enforce this proposed law and could get an injunction and treble damages (and attorneys’ fees and costs) if they can prove the emergency order is “unreasonable as applied” to them.
A similar effort to gut public health measures during emergencies is underway in Missouri. HB 1144 tracks the language of a “Right to Refuse” Model Act promoted by the “National Health Freedom Action” organization. As I described in a post last September, this group and its associates spread vaccine and COVID-19 misinformation and support laws shielding quacks, allowing the sale of unpasteurized milk, and otherwise protecting pseudoscience and those who benefit from its commodification.
HB 1144’s sweeping provisions handicap both the state government and individual business owners who try to institute protective measures such as mask wearing and building capacity limitations, giving everyone the right to refuse such measures and imposing absurd conditions on their implementation. For example, a shop owner who wants customers to wear a mask must read aloud portions of the law granting the right to refuse this and other mitigation attempts to each potential customer, give them a written copy of the law, and get a written acknowledgement of its receipt.
In South Carolina, HB 3217 allows anyone to refuse a vaccination offered as “part of any mass immunization project to protect against infectious disease, or to prevent the spread of a pandemic or a contagious or possibly contagious disease”. HB 3511 goes even further, providing that anyone who refuses a vaccination in such circumstances “may not be denied any right or privilege of citizenship”, which is defined to include “shopping”.
In another sweeping measure, South Carolina HB 3526 transfers the authority to declare a state of emergency from the Governor to the state legislature and removes “public health emergency” altogether (and well as other events) from the list of circumstances permitting an emergency declaration. Declared public health emergencies would still be allowed in some circumstances but the power to mitigate them is reduced. For example, an infectious agent, chemical agent, or the like, posing “a substantial risk” of “widespread illness” would no longer be a sufficient reason for a public health emergency, which would be limited to risks of “a significant number of human fatalities” or “a serious economic impact to the agricultural sector, including food supply”. The authority to temporarily isolate or quarantine anyone is completely removed and a court order required.
In North Dakota, HB 1320, which was, fortunately, soundly defeated, would have banned any state vaccination mandate, in any circumstances, and prohibited “making receipt of a vaccine a condition for entry, education, employment, or services”, presumably pre-empting school vaccination mandates along with the rest. It was strongly opposed by school officials and the science-based health community and supported by a North Dakota “health freedom” organization and two chiropractors, among others.
In Oklahoma, a similar bill (SB 223), provides that any state entity, including school districts, cannot “through direct or indirect means, compel or coerce any person . . . to receive any immunization”, seemingly eliminating all school vaccination requirements as well. Likewise, Oklahoma SB 352 prevents any state entity or from compelling or coercing anyone “to undergo any unwanted medical procedure”, including immunizations and face mask wearing, with persons violating the proposed law subject to misdemeanor conviction. (Private employers are specifically excepted.)
In what appears to be an attempt to cover any and all situations that could possibly arrive, Idaho HB 63, prohibits any state or local law or order that mandates “vaccination, immunization, genetic modulation, or inoculation” (or, as the bill refers to it, “forced or coerced vaccination”) in “any state of disaster or emergency or any proclaimed state of extreme emergency, insurrection, or martial law” and prohibits quarantining or isolation of those who refuse vaccination. (I had to look up “genetic modulation“. The science is beyond me but I am curious as to how it would come into play in an insurrection and such.)
With the preamble that a new law is required to “maintain the individual liberty, parental rights, and free market principles of the citizens and businesses of Nebraska”, LB 643 allows anyone to refuse vaccination during a state of emergency declared by the Governor “or anytime thereafter” without punishment, penalty, or “implication”.
A Florida bill (HB 6003) removes the authority of the state Public Health Officer, in a public health emergency, to require quarantine of anyone refusing vaccination and to require vaccination of an individual who poses a threat to the public health when quarantine is unavailable. Kentucky law currently allows the state’s health agency to require vaccination in any area where a pandemic is declared. HB 36 (the “Ensuring Bodily Autonomy and Informed Consent Act”) and SB 37 would repeal that authority.
In Tennessee, under current law, any person’s right to claim a religious exemption from immunizations and medical procedures (presumably including testing) is suspended when an epidemic threatens and an employee’s religious exemption right is suspended when necessary to protect the health of others. HB 10 (which failed in a subcommittee of the Health Committee) and SB 07 would eliminate those suspensions as well as institute blanket religious and conscience exemptions for all immunizations and medical procedures. The bills would also eliminate misdemeanor charges for physicians who fraudulently provide medical exemptions or certificates of vaccination. Specific to COVID-19, Tennessee SB 187 and HB 13 provide that government entities “shall not force, require, or coerce a person to receive an immunization or vaccination for COVID-19 against the person’s will”, although, without a state COVID-19 vaccination mandate, they would not have any authority to do so in the first place.
Washington HB 1006 creates “religious, philosophical, or personal” objections to all state-mandated immunizations, including any that might be required for state and day care center employees, and adds these exemptions to the school-mandated MMR immunization, which is currently limited to medical exemptions.
Virginia HB 2242 prohibits the state from requiring COVID-19 vaccinations and prohibits discrimination based on vaccination status in a number of situations, including health insurance coverage and state employment, where vaccine refusal is accorded the same status as other traditionally protected classes in employment discrimination law, like race, religion, and gender.
Although Wisconsin law permits health officials to mandate immunization in a public health emergency, SB 4 and AB 23 would exclude COVID-19 vaccination from this law. New York A 4269 prohibits mandatory COVID-19 vaccinations as well. In Connecticut, proposed bills prohibit the state from mandating any vaccine that has been given only an EUA (SB 405) and the COVID-19 vaccine in particular (HB 5401). Similarly, Virginia HB 2336 prohibits both public and private entities from requiring any vaccine that is not FDA-approved, presumably including those with only EUA.
Should any state entity mandate COVID-19 vaccination for any purpose, such as employment or school attendance, Washington SB 5144 allows “religious, philosophical, or personal” exemptions. In Virginia, HB 2268 adds a religious exemption to immunizations required by public health authorities during an epidemic as well as removes the suspension of the religious belief exemption for school vaccinations during an emergency or epidemic. Michigan HB 4008 adds medical and religious belief exemptions to immunizations administered during a pandemic, although parents are allowed to refuse consent for immunization of a child on any ground.
Not all bills curtail the ability to act in an emergency. New York A 416 allows the governor, in consultation with state health authorities, to determine “by clear and convincing evidence” that “the health of others is or may be endangered” by an actual or suspected “case, contact or carrier” of a contagious disease which “may pose a significant threat to the public health resulting in severe morbidity or high mortality”. Upon this determination, the “case, contact or carrier” can be detained for at least 3 days, and for up to 60 days with additional due process protections but, in any case, for no longer than they are contagious. The order can be directed at an individual or a group, who can be detained “in a medical facility or other appropriate facility . . . designated by the governor”. In addition to detention, the governor can require quarantine and order testing, vaccination, and treatment, although no medication can be required without a court order.
New York A 2081 adds COVID-19 vaccination to the list of required immunizations for residents and employees of long-term care facilities, with medical and religious exemptions as well as the right to refuse “after being fully informed of the health risks” of refusal.
Employers restricted
A number of states have legislation proposed or pending that bar employers from mandating either vaccinations in general, or COVID-19 vaccinations in particular, whether in certain circumstances or by banning them altogether.
Connecticut’s proposed HB 5402 prohibits any employer from requiring proof of COVID-19 vaccination from employees, vendors and customers, presumably including hospitals, long-term care facilities, and the like. It also bans public officials from requiring proof of vaccination as a condition of using some public facilities, like parks.
Mississippi HB 719 (which died in committee) and Wisconsin bills SB 5 and AB 25 would prohibit any employer from requiring that employees be vaccinated against COVID-19, while Kentucky SB 37 and Oklahoma HB 1057 would prohibit employers from requiring vaccination against any disease. All of these bills appear to include hospitals, nursing homes, retirement communities, and similar businesses.
In Minnesota, HF 261 requires that COVID-19 vaccines be made available to teachers and other school employees but says they (and students) can’t be required to take them. Similarly, Missouri HB 838 prohibits public employers from requiring COVID-19 vaccination for public employees, no matter where they work. North Dakota HB 1301, which was defeated, prohibited employers from requiring vaccination of employees, with hospitals, long-term care facilities, and the like excluded, although medical and religious exemptions were allowed. Interestingly, even though the bill also contained protection against liability for the transmission of communicable diseases, it was opposed by the business community, which wanted to retain the right to require employee immunization. Conversely, Oregon SB 451 prohibits immunization requirements for registered nurses and other medical staff as a condition of employment.
Pennsylvania HB 262 bars both private and state government employers from requiring any immunization or “invasive medical test”, defined to include providing tissue or bodily fluid samples (in other words, including COVID-19 testing). Employees can sue for treble damages if they are retaliated against or otherwise penalized for their refusals. Indiana SB 74 grants employees medical, religious and “conscience” exemptions from vaccinations required by an employer and prohibits, upon pain of actual and punitive damages, any discrimination against an employee claiming an exemption. Indiana HB 1488 prohibits employer-required vaccinations if the vaccine has only emergency use approval and bans the employer from inquiring into the employee’s reason for refusing the vaccine.
Given the inevitability of future pandemics and other health emergencies, I worry about how states will manage without the public health tools eliminated by this year’s proposed legislation. Fortunately, some ill-conceived bills have already been defeated. You can help ensure others suffer the same fate by contacting your state representatives.

School mask mandate wars: Politics (Florida) v. Science (North Carolina)
Florida’s governor, Ron DeSantis, dictated a state-wide ban on school mask mandates based on misinformation and pure politics, while North Carolina officials took a bipartisan approach to masking based on science.
Jann Bellamy on August 26, 2021
Link

As schools reopen across the country, mask mandates are a hot button issue. Today we look at how two conservative southern states handled mandates with vastly different approaches. In one, North Carolina, decisions are based on bipartisan compromise and science, while in the other, Florida, a dictate from the governor relies on misinformation and raw politics. I happen to live in one (Florida), but (fortunately) spend a lot of my summer in the other (North Carolina), giving me something of a front-row seat from which to view the controversy.
North Carolina
As happened in many states, North Carolina’s students, teachers, and parents were subjected to a shifting and sometimes confusing variety of studies, orders, and directives related to K-12 school closures during the 2020-21 academic year. But this past spring, after a protracted battle between the Republican-controlled legislature and Gov. Roy Cooper, a Democrat, the legislature unanimously passed, and the governor signed, a compromise bill, The Reopen Our Schools Act of 2021, paving the way for in-person instruction for the remainder of the school year.
Under the Act, local school boards could choose “Plan A” or “Plan B”, which required different safety measures for reinstituting in-person instruction, with Plan A offering expanded opportunities for reopening classrooms.
However, school boards choosing Plan A were also required to
partner with the ABC Science Collaborative of the School of Medicine at Duke University (ABC Collaborative) to allow the ABC Collaborative to collect and analyze data from . . . students in Plan A in grades six through 12. A local board shall both engage in robust contact tracing and report on requested information in the form specified by the ABC Collaborative.
By way of background, the ABC Science Collaborative describes itself as
an initiative that extends across 13 states, connecting scientists and physicians with school and community leaders to help understand the most current and relevant information about COVID-19. The program helps school leaders and state policymakers arrive at informed decisions about returning to school using data from their own communities. . . The ABC Science Collaborative is coordinated by the Duke Clinical Research Institute at the Duke University School of Medicine and is funded through grants from the National Center for Advancing Translational Sciences, the National Institutes of Health, and the Food and Drug Administration.
The ABC Collaborative was to report interim results and a final analysis to the state, the latter by June 30, 2021.
Let me pause here to remark on how extraordinary I find this provision of the Act, requiring a science-based collection and analysis of data by a reputable institution in order to inform public health policy, and in a unanimously-passed bipartisan bill to boot! With the caveat that I have not looked at legislation in any systematic way for similar provisions, in my decade-plus of posting here on SBM I cannot recall writing about a piece of legislation mandating the legitimate collection and analysis of data on which to base public health policy. In fact, although I admittedly focus on such subjects, what I regularly encounter is the wholesale incorporation of pseudoscience into state and federal laws and policies affecting the public’s health. There outta be a law, and it should look like this one.
From March to June, 2021, the ABC Collaborative, apparently expanding the reach of its original mandate, collected data from all North Carolina elementary, middle, and high schools operating under Plan A, which included in-person instruction, masking, and minimal physical distancing (3 feet or under). The data represent 100 local school districts and 14 charter schools, comprising more than 1,280,000 students and 160,000 staff. As the lead authors of the report explained in a New York Times Guest Essay, because there was a universal school mask mandate at the time of their data collection, they could not compare masked to unmasked schools. They did, however, look to data from other jurisdictions examining these situations.
The Collaborative’s final report concluded that:
North Carolina schools were highly successful in preventing the transmission of COVID-19 within school buildings and offers science-based learnings for the nation’s schools to limit COVID-19 spread.
In particular, the data showed that:
    • Proper masking is the most effective mitigation strategy to prevent COVID-19 transmission in schools when vaccination is unavailable or there are insufficient levels of vaccination among students and staff;
    • With masking in place, Plan A – full, in-person instruction – is appropriate for all grades and all schools;
    • Full-capacity bus transportation can and should resume, with the seating of up to three masked students per bus seat;
    • Some within-school guidelines can be relaxed, e.g., quarantine can be modified for people who were exposed to COVID-19 but are either vaccinated or were appropriately masked when exposed; and
    • Schools should examine safety protocols surrounding athletics. With proper safety protocols in place, particularly vaccination, schools could resume fall athletics while limiting the spread of COVID-19.
In addition to this report, the Collaborative has authored The Year in Review and a Path Forward, described as offering “a road map for school leaders and policymakers to use the latest science as they plan the path forward for K-12 in-person instruction”. (As you shall see, I know someone who could really use a copy.)
For the current (2021-22) academic year, Gov. Cooper declined to issue a state-wide mandate, opting instead to have each school district choose whether to implement a mask requirement. The Raleigh News & Observer reports that, as of August 24th, 27 of the 115 total districts have made masks optional. All of those districts are in rural or “red” areas and many have low COVID vaccination rates. Eighty-eight districts, accounting for 78% of the state’s 1.5 million public school students, have decided to require masking in school buildings and on busses; some will even require masks outdoors. At least 35 districts reversed their original decision to make masks optional, some after Gov. Cooper sent them a letter requesting the change. It is unknown how many of the state’s charter and laboratory schools, accounting for 9% of the total student population, will require masks.
According to the News & Observer, even where masks are required, a parent can request an opt-out “if a medical or learning issue” prevents masking, but the final decision on exemptions resides with each school.
Not everyone is happy with this plan, nor is everyone satisfied with the districts’ individual decisions. A doctors’ group has a petition on change.org urging Gov. Cooper to institute a statewide mask mandate for schools via executive order. In Union County, where the school board voted to make masks optional, local physicians urging the board to institute a mask requirement asked a newspaper to keep their identities confidential due to fears of retaliation. A school board member who voted to make masks optional reported personal attacks on her character and the board to the same newspaper.
Nevertheless, in sum, in North Carolina, a bipartisan law created a plan to collect and analyze data on which the state government and local school boards could base their decisions. Some districts have apparently embraced the science, while others have not. The net results is that, for now, over three-quarters of North Carolina’s public school students are under a mask mandate which, while not without some controversy, has maintained local control by decision makers acting in what they believe is their constituents’ best interests, whether or not we might agree with the results.
Florida
With this in mind, let’s turn to my home state, Florida
On July 30, 2021, Gov. Ron DeSantis issued an Executive Order that essentially banned mask mandates in Florida public schools. (Technically, it directed the state’s health and education agencies to develop rules “to ensure safety protocols for controlling the spread of COVID-19 in schools”, but the results are preordained by the Order.) He had previously ordered that all public schools be open for in-person instruction five days a week.
Gov. DeSantis’s Order was chock full of cherry-picked evidence, unsupported assertions, COVID myths, and downright falsehoods, all wrapped in a protective coating of “parental rights” talking points designed to please his base. He rested his authority to issue the Order on a new state law he signed in June of this year, the “Parents Bill of Rights”, which prevents the state and other units of government
from infringing on the fundamental rights of a parent to direct the upbringing, education, health care, or mental health of a minor child without demonstrating that such action is reasonable and necessary to achieve a compelling state interest and that such action is narrowly tailored and is not otherwise served by less restrictive means . . .
How this new law will affect cases, like this one, where parents choose “alternative” remedies over science-based treatments remains to be seen. In the case of local mask mandates, my view is that they could meet even this tough standard, but only if science is correctly applied to the matter, which, as you will see, is not part of the governor’s plan.
In the Order, the governor refutes the CDC’s mask wearing guidance as lacking “a well-grounded scientific justification”, citing a Brown University study done by an economist using now-outdated data, which Kaiser Health News concluded was “cherry-picked” by the governor and offered “little basis for his position and includes a variety of elements that are not accurate.” A pediatrics professor at the University of Florida called DeSantis’s claim “patently false”.
The Order also says that there is “no statistically-significant evidence to suggest that counties with mask requirements have fared any better than those without mask requirements during the 2020-2021 school year”. Of course, “fared any better” is vague. By what metric? Number of cases? Hospitalizations? Deaths? We don’t know because the Order cites no evidence in support of this assertion. And the general public (which is apparently who he is referring to) is not the same population as school students. However, we do know that modeling and epidemiological studies (like that of the ABC Science Collaborative) support masking in general and masking for school students in particular.
Again citing no evidence, the Order asserts that “masking children may lead to negative health and societal ramifications” and that “studies have shown that children are at a low risk of contracting a serious illness due to COVID-19 and do not play a significant role in the spread of the virus”. In fact, the most you could say is that the evidence is uncertain regarding spread and, in any event, it partly depends on the community rate, which is quite high in Florida right now. And, if it was ever true that children are at low risk of contracting COVID or experiencing serious symptoms, as SBM’s own Dr. Jonathan Howard has explained, that is no longer the case.
Finally, the Order, ensuring that even more COVID mask myths are blessed with the official imprimatur of state government, and once again without citing any evidence, claims that masks “could inhibit breathing, lead to the collection of dangerous impurities including bacteria, parasites, fungi, and other contaminants, and adversely affect communications in the classroom and student performance.” No, masks do not interfere with breathing and no, they do not collect “dangerous impurities” if you wear a clean mask (duh!). On the latter point, it is interesting that the governor, who totally trusts parents to make momentous decisions regarding their children’s health, suddenly finds they can’t be trusted with basic hygiene measures, like keeping their children’s stuff clean.
We simply do not have enough data to conclude one way or another on the effect masks have on learning but, in the words of one research psychologist who studies the cognitive and social development of children:
Ultimately, how children feel about wearing masks at school, and how much they psychologically benefit from wearing them, is going to depend on how the parents, teachers and caregivers around them present the issue.
Certainly, we can well imagine that a child, too young to fully evaluate the issue on his own, taken to a mask protest by his parents and told to hold up a sign an anti-mask sign, might become anxious and confused when his school district imposes a mask mandate.
The governor’s Order threatened local school districts with financial penalties for failure to comply, giving the Florida Commissioner of Education the authority to pursue “all legal means available to ensure school districts” obey the his dictates, including withholding state funds from noncompliant school boards.
In addition, in an incredibly irresponsible and undoubtedly politically-motivated move, the Florida Department of Health’s “How do I prevent and prepare for COVID?” webpage does not include mask-wearing, although it does include a link to the CDC at the bottom of the page. The CDC does, of course, advise to “wear a mask”, science-based advice the governor rejected.
This, I am pleased to report, has resulted in a coup against DeSantis by some school districts, who have enacted varying forms mask mandates for students and faculty in open defiance of his Executive Order. As of Wednesday morning, ten districts, including some of the largest, like Miami-Dade and Hillsborough (Tampa), representing over half of Florida’s public school students, have these mandates in place.
In response, state officials have doubled down with the threats, promising to dock the salaries of, and possibly remove, school board members who vote to enact mandates. Officials are seeking compensation records of board members voting for mandates in two districts, Alachua (Gainesville, home of the University of Florida) and Broward (Ft. Lauderdale). (Three Broward teachers recently died of COVID.) The state is expected to move against other board members this week.
The governor’s office has also doubled down on the misinformation. Just yesterday, a Washington Post news report quoted the governor’s press secretary saying, again falsely,
There is no empirical evidence to support the assertion that the benefits of forced masking of schoolchildren outweigh the potential harms. Masking kids under 12 is not recommended in many EU countries, because their health authorities have found that the risks are not well understood — and the data shows that forced masking of young children has a negligible impact on covid prevalence and spread.
The Post dutifully reported that “public health experts dispute this”, quoting a pediatric infectious disease physician from the Mayo Clinic who said that “studies have unequivocally shown that there are no negative health effects on children from wearing a mask.” As for what Europe is doing, the hypocrisy is, once again, interesting. I’m pretty certain that Gov. DeSantis would reject European public health authorities’ opinions on, say, gun control or universal health care coverage. In any event, I did not check the mask policies in each of the 28 EU countries, but reports from European health authorities like the Association of Schools of Public Health in the European Region, the European Academy of Paedatrics, and the European Centre for Disease Prevention and Control show that they have (unlike the governor) fully evaluated the evidence and recommend masking in school settings, depending on local conditions and with exceptions for certain students (like those too young or the disabled).
The federal government has now joined forces with the renegade school boards, with Pres. Biden and his Secretary of Education offering financial support and threatening litigation. Parents have filed their own lawsuits against the state, one of which is being tried in Leon County (Tallahassee) right now, with none other than Dr. Jay Bhattacharya, of Great Barrington Declaration fame, testifying on behalf of the state.
Florida’s “chaotic” school openings are playing out against Florida’s alarming COVID stats, including its pediatric cases. (I am heartbroken that these include the deaths of two children in my own community this month.) Just-opened schools are having to shut down because of COVID, almost 30,000 students, teachers and staff are in quarantine, and health departments are backlogged on contact tracing. Seventeen school employees, including teachers, have died of COVID just since August 1st. At the same time, public opinion polls show support for both mask and COVID vaccine mandates for students and teachers.
To be fair, pediatric cases in North Carolina are on the rise as well, as they are nationally, but I could not find that any schools had shut down, nor could I find any statistics on the number of students and school staff in quarantine, if any. School personnel have died from COVID in the state, although none recently that I could find.
Compare and contrast
So, in states with comparable political climates, one, North Carolina, in a bipartisan effort, looked to the data and science to inform decision-making on mask mandates and left the issue to local control, resulting in over three-quarters of public school students being under a mask mandate. In the other, Florida, the governor dictated to local school boards what they must do based on repeated misrepresentations of the evidence and is now threatening to impose financial and other penalties on school board members who have been elected to office by the citizens of their own communities, all in a state with some of the worst COVID stats in the country and in defiance of public opinion.
And here’s the really disturbing part: Gov. DeSantis’s Executive Order could have, like North Carolina’s report, set forth the actual evidence and declared parents should decide. In other words, the same result, just without the misinformation. It wouldn’t be the result the scientific and educational community might prefer, but at least the state wouldn’t be complicit in spreading falsehoods. But he didn’t. He chose to manipulate parents, the ones he claims he trusts to make the best choices for their children, with cherry-picked and fabricated “facts” (and easily debunked at that) in order to achieve the results he wanted.
Which approach do you think is best?
UPDATE: Judge throws out Gov. Ron DeSantis’ ban on mandatory masks in Florida schools. Tallahassee Democrat, August 27, 2021.

Tennessee hamstrings medical board fight against COVID misinformation and unproven treatments
A new Tennessee law hampers the state medical board’s efforts to rein in COVID misinformation and will make disciplining physicians prescribing unproven COVID treatments impossible until the board goes through cumbersome rule-making procedures, an effort that could outlast the pandemic.
Jann Bellamy on December 16, 2021
Link

Tennessee legislators have decided to encourage physician malpractice by bullying the state medical board into rescinding its COVID anti-misinformation policy and throwing huge bureaucratic obstacles in the board’s way before it can discipline physicians who use unproven COVID treatments, including downright quackery. Their blatant disregard for science, the details of which we’ll get to in a moment, comes even as the medical profession calls for more vigilance against disinformation and taking action against doctors who spread it, a subject SBM has covered extensively, along with the quack COVID treatments peddled by some physicians.
The Federation of State Medical Boards (FSMB) 2021 annual survey of member boards found that
    • 67% have experienced an increase in complaints related to licensee dissemination of false or misleading COVID-19 information;
    • 26% have made or published statements about the dissemination of false or misleading COVID-19 information; and
    • 21% have taken a disciplinary action against a licensee disseminating false or misleading COVID-19 information.
That last figure is encouraging news considering, as Dr. David Gorski lamented,
how rare it is for a state medical board to suspend or revoke the medical license of outright quacks and how difficult it has been on the occasions when a state has tried . . .
In July, the FSMB issued a statement reminding physicians who spread COVID misinformation that they risk disciplinary action. Since then, according to the FSMB, at least 15 boards published statements about false or misleading information and at least 12 boards have taken disciplinary action against a licensee. The FSMB is currently developing guidelines for medical boards to help address the spread of disinformation.
It is not clear to me why the FSBM’s statement emphasizes disinformation only and does not address the problem of physicians promoting unproven treatments like hydroxychloroquine and ivermectin.
In any event, as Dr. Gorski optimistically pointed out:
If there could be one good outcome from the pandemic, it would be enhanced power of state medical boards to discipline physicians promoting medical misinformation and disinformation of all kinds, not just about COVID-19 or COVID-19 vaccines.
Unfortunately, those who are hell-bent on protecting our “freedom” to thumb our collective noses at the common good and ignore public health measures as well as our “freedom” to access quack treatments are ever at the ready to quash any such efforts. It is thus that we find ourselves confronted with what the FSMB calls “troubling legislation” introduced in a number of states making it more difficult for licensing boards to discipline a licensee for spreading disinformation. The FSMB say it
strongly opposes any effort to restrict a board’s authority to evaluate the standard of care and assess risk for patient harm.
Which is exactly what the Tennessee legislature just accomplished in a new law that also includes sweeping anti-public health measures. With that, let’s turn to the specifics.
Tennessee: The Volunteer (to get COVID) State
The Tennessee Board of Medical Examiners, which regulates licensed physicians, voted in September to adopt a policy, based on the FSMB’s statement, that would subject physicians who create or spread COVID vaccine misinformation to disciplinary action.
According to the Chattanooga Times Free Press, at the time of the medical board meeting, at least 24 COVID-related complaints had been filed against health care practitioners and a lawyer for the board asked for guidance on how to handle three different types of these complaints:
    • Physicians sharing their personal anti-vaccine or vaccine-hesitant opinions with their patients.
    • Physicians sharing false information about vaccines in order to advise patients against vaccination.
    • Physicians spreading misinformation or disinformation to multiple patients across their practice.
In response, the board decided that physicians who disseminate false information about COVID vaccines (e.g., the myth that vaccines cause infertility) should face formal discipline, although they debated “the degree to which physicians should be allowed to express their personal opinions within the confines of the doctor-patient relationship.”
They ultimately agreed on a policy that physicians who “generate and spread COVID-19 vaccine misinformation or disinformation” risk disciplinary action. Physicians “must share information that is factual, scientifically-grounded and consensus-driven for the betterment of public health”.
In support of the policy, Dr. Melanie Blake, the boards’ president, said that
It is painfully clear to the physicians who have served on the front lines of this pandemic that COVID-19 vaccine misinformation has caused undue loss of life, loss of health, loss of jobs and other incalculable losses to our society. . . . I applaud the efforts to uphold our oath as physicians despite unprecedented challenges.
The new policy did not sit well state Rep. John Ragan (R-Oak Ridge) and some of his Republican colleagues. Ragan said that after the policy was adopted, “he received phone calls from practitioners across the state who were afraid their licenses would now be in jeopardy.” He complained that the policy did not define “misinformation” and “disinformation” and took the position that the board had, in effect, enacted a new rule without going through the formal rule-making procedure required by state law.
Ragan sent letters pressuring the board to delete the policy or risk being called before the legislature’s Joint Government Operations Committee. According to The Tennessean, an attorney who works with the board warned board members that Ragan had conveyed his “displeasure . . . in the strongest terms” and “made clear he has no qualms about moving forward with dissolving the [board] and reconstituting it with new members”, something he has “in fact done with another state agency”.
My take on Ragan’s position is that he has made a highly questionable interpretation of state administrative law and used it as a bludgeon to beat the medical board into submission lest it take action against physicians giving dubious advice about COVID, including vaccines, and promoting unproven treatments. (When you see what the Tennessee legislature subsequently did, which we’ll get to soon, I think you’ll agree with me.)
Ragan is correct that state law requires agency rules to go through a specific procedure before they can become law. This procedure can be extremely cumbersome and time-consuming, including notice to the public and an opportunity to be heard, review by the attorney general and legislature, and challenges to the rule that can take months, years even, to resolve.
But is the board’s policy a “rule”? I don’t think a fair interpretation of Tennessee law supports Ragan’s claim that it is. Without getting too much into the weeds of administrative law, a “rule” is defined by Tennessee law as an
agency statement of general applicability that implements or prescribes law or policy or describes the procedures or practice requirements of any agency.
But, the definition of “rule” specifically excludes
General policy statements that are substantially repetitious of existing law.
As board member Dr. Samantha McLerran correctly pointed out, under Tennessee law
the board has the power to discipline physicians for “unprofessional, dishonorable or unethical conduct” as well as for “making false statements or representations . . . or being guilty of fraud or deceit in the practice of medicine”.
She was of the opinion that the COVID misinformation policy fell under these existing prohibitions.
I agree. The board was simply restating the prohibitions already contained in state law as they applied to COVID, not promulgating a new rule. If Rep. Ragan’s interpretation is correct, then every time a physician is disciplined for infraction of the provisions cited by Dr. McLerren, whether or not COVID-related, he could challenge the board’s action based on the absence of a specific rule defining his conduct as unlawful.
Unfortunately, Rep. Ragan’s threats worked (sort of) and a special meeting of the medical board was called “out of an abundance of caution” based on a new state law signed by Gov. Bill Lee on November 12, according to board chair Dr. Blake. At the meeting, the board voted 7-3 to remove the policy from its website. However, displaying a lawyer-like talent for parsing words, Dr. Blake said the only request the board received was to delete the policy from the website, which it had done, but “our mission remains the same”. In other words, she confirmed that the policy itself remained in force. A Department of Health attorney then recommended that the board conduct a second vote on whether to rescind the policy outright, but the board declined and the meeting adjourned.
That “new law” (which is already being challenged in court) is sweeping legislation preventing government agencies, schools, and private businesses from imposing public health measures like vaccination and mask wearing, passed by the Tennessee legislature in a special session in October devoted to COVID. (A good summary can be found here.) It also creates a private right of action for injunctive relief and compensatory damages, as well as attorneys’ fees, for anyone “injured as a result of a violation” of the new law.
Per the Chattanooga Times Free Press, these measures
stem from anti-vaccination efforts taken up by some legislators who are being egged on by groups such as Tennessee Stands
For those of you unaware, Tennessee Stands is a conservative group that opposes masks and vaccine mandates, among other public health measures, and reportedly expressed support for the January 6th attack on the Capitol.
Specifically relating to physician discipline, during the special session, as described by MedPage Today, Rep. Chris Todd (R-Madison County) and Debra Moody (R-Covington) introduced bills limiting the medical board’s ability to discipline physicians for substandard care in COVID cases:
Rep. Todd’s bill, the Tennessee COVID-19 Treatment Freedom Act, would prevent the Tennessee Board of Medical Examiners from disciplining doctors for anything “solely related to the physician’s prescription, recommendation, use, or opinion relative to a treatment for COVID-19,” including treatments that aren’t approved by the state’s health department or the FDA.
Rep. Moody’s bill would prevent . . . [disciplinary] actions “so long as the physician exercised independent medical judgment and believes that the medical treatment is in the best interest of the patient,” and the patient consents.
The gist of these proposals, if not all of the language, made it into the final version of the legislation, which passed and was signed by the Governor despite what one law firm’s analysis described as “fierce opposition from the Tennessee business community, local school boards, health care providers, and other stakeholders”. (As an aside, all this state and federal COVID legislation has become essentially a full employment act for healthcare and employment lawyers.)
In a gigantic “screw you” aimed at the medical board, the new law requires both the medical and osteopathic boards to develop rules if they are to discipline practitioners for prescribing COVID-19 treatments. This means each board must go through the laborious and time-consuming process I briefly described earlier, including a review of the rules by the legislature’s Joint Government Operations Committee, co-chaired by none other than Rep. Ragan, before a physician can be disciplined for substandard prescribing. I assume that, until then, practitioners can prescribe whatever they want, including ivermectin, hydroxychloroquine, homeopathy, Black Oxygen Organics, Miracle Mineral Solution (bleach), herbs, dietary supplements, essential oils, and whatever else their tolerance for pseudoscience will allow, without risking discipline.
The new law also addresses monoclonal antibodies, allowing practitioners to prescribe and administer them as a treatment for or prophylaxis against COVID if they “exercise independent professional judgment” and “notwithstanding any guidance or advice from a governmental entity to the contrary”.
I am not sure where this gets the prescriber, other than the ability to disregard governmental (such as FDA or CDC) guidance. Although I could find no exact definition of what “independent professional judgment” means in medicine (the term doesn’t seem to have an agreed-upon definition), I don’t believe it means that you can toss medical science in making a treatment decision or that it absolves the physician of failure to meet standard of care. Even if government guidance would be excluded from evidence of malpractice in a disciplinary action against a practitioner, the board could still consider other evidence of standard of care, such as expert opinion and medical literature. But, of course, no disciplinary action can proceed anyway until the medical and osteopathic boards go through the cumbersome agency rule-making process.
If the board trips up and violates the new COVID law, a practitioner could bring a civil action against it per the law’s creation of a private right of action, complete with compensatory damages and attorneys’ fees. Whether this happens or not, the threat is certainly there, dampening any appetite to pursue disciplinary action which might possibly subject the board to litigation.
Not all Republicans are on board with the new law. Sen. Richard Briggs (R-Knoxville), a physician and the only Republican senator who voted against the bill, said that doctors have a responsibility to be a “reliable source of information”:
The Government Operations Committee (which will review any board disciplinary rules related to COVID), should not be telling the Board of Medical Examiners, who (are) charged with protecting the public health and safety, that they can’t do something to a doctor that’s intentionally giving known misinformation.
Sen. Heidi Campbell (D-Nashville) agrees:
Once we start as a legislature telling doctors how to practice medicine to the point we’re intervening in their ability to perform their duties, then we’ve got a big problem.
        ◦ She added that this “disdain” for science is putting Tennessee in “big, big trouble”. I think she’s right, only it’s not just in Tennessee.

Florida Surgeon General declares single positive COVID test proves immunity forever
Florida’s Surgeon General, Dr. Joseph Ladapo, continues to defy scientific consensus with new rules declaring a single positive COVID test proves one has “natural immunity” forever. This is but one example of recently enacted laws and similar efforts gutting public health protections in Florida, thanks to Ladapo and his boss, Gov. Ron DeSantis.
Jann Bellamy on December 30, 2021
Link

Once again defying the science, Florida’s new Surgeon General, Dr. Joseph Ladapo, recently issued an “emergency” rule basically declaring that a single positive COVID test, no matter when it was taken, proves that one has immunity from COVID in perpetuity.
Per legislation recently passed by the Florida Legislature and signed by Gov. Ron DeSantis, this “natural immunity” will exempt employees from private employer vaccine mandates. This is only one of several loopholes to private employer mandates created via the new law, which also guts other public health measures designed to protect Floridians from COVID infection.
The new legislation was passed in a whirlwind three-day special legislative session convened by DeSantis in November, a mere two months from the start of the regular session in January, 2022. In my view (shared by others), this was yet another act in DeSantis’s base-pleasing COVID theater, there being no valid reason any of this couldn’t wait a couple of months, or was necessary in the first place.
In addition to providing exemptions to private employer vaccine mandates, which we’ll return to in a moment, legislation passed during the special session:
Prohibits school districts from imposing mask or vaccine mandates for students and allows parents to take legal action against districts that don’t comply, as well as recover costs and attorneys’ fees. (This codifies into law DeSantis’s previously-issued executive order, and yet another Department of Health “emergency” rule, banning mandates.)
Prohibits school districts from quarantining asymptomatic students or school employees (even if exposed to COVID) unless they have a positive SARS-CoV-2 test.
Bans public employee vaccine mandates altogether (including K-12 schools, state-run healthcare facilities, and the state university system) and authorizes fines for failure to comply.
Removes the state health officer’s authority to require vaccination during a public health emergency.
Allocates $5 million to the state Attorney General to investigate complaints of violation of the new law and to fight federal vaccine mandates, with which this new legislation conflicts.
Begins a process intended to transfer responsibility for worker safety from the federal OSHA to a state agency.
The Legislature gave the Florida Department of Health, headed by Great Barrington Declaration supporter and (former?) member of the fringe grifter group, Americas Frontline Doctors, Dr. Joseph Ladapo, the job of fleshing out some of the new law’s provisions via the enactment of rules, hence the Surgeon General’s decision that positive COVID tests “prove” immunity.
Before we move on, let me update you on Dr. Ladapo’s tenure as Florida’s Surgeon General, as he’s been in the news near-continuously since he was introduced to SBM readers in September, where his casting doubt on vaccines, cheerleading for hydroxychloroquine and ivermectin, spreading misinformation about masks, and dumpster-diving in VAERS was reported. Since then, Dr. Ladapo has packed quite a bit of controversy into less than four months in office. Dr. Ladapo
got his Florida medical license in record time (two days) and then had a complaint filed against him with the medical board speedily dismissed;
was awarded an annual salary of $437,000 (the highest ever paid), including tens of thousands of dollars from the University of Florida’s medical school, where he was also hired, and given tenure, in record time (for teaching and research) on the suggestion of a wealthy DeSantis donor, although the press reports that Dr. Ladapo has yet to show up for work there;
continued to spread misinformation;
been kicked out of a state Senator’s office for refusing her request to wear a mask due to what she described to him as a “serious condition”, later identified as breast cancer, for which she was undergoing treatment. He has yet to apologize, instead making up a lame excuse about not be able to “communicate” while wearing a mask; and
starred in a PSA that barely mentioned vaccines, left out testing and mask wearing altogether, yet promoted treatments of questionable effectiveness (again).
With that, let’s turn to the exemptions to private employer vaccine mandates created by the legislature and Dr. Ladapo’s new rules implementing those exemptions.
Private Employer Vaccine Mandate Exemptions
Although DeSantis bloviated about banning all vaccine mandates, the new law, as applied to private employers, instead creates exemptions so easily met, and penalties so severe for violations, that it might as well be a ban. In fact, anyone wanting to evade a private employer vaccination mandate but unable to figure out how is probably unqualified for the workforce in the first place. Thus, DeSantis and the Legislature can claim that they are respecting a private employer’s right to make decisions about how to run his or her business while effectively gutting it.
Per the new law, if a private employer requires vaccination, an employee can opt out with:
Medical reasons, including “pregnancy or anticipated pregnancy”, based on a physician’s, P.A.’s, or nurse practitioner’s “professional opinion”, made after examining the employee, that vaccination “is not in the best medical interest of the employee”.
Sincerely held religious beliefs.
“Competent medical evidence” that the employee has immunity, “documented by the results of a valid laboratory test”.
Regular testing, at no cost to the employee.
Unspecified “employer-provided protective equipment”.
The Department of Health was directed to enact “emergency rules” to implement these exemptions within 15 days and to create forms for claiming them. Per current Florida law, emergency rules can be adopted by an agency only when
an agency finds that an immediate danger to the public health, safety, or welfare requires emergency action, [in which case] the agency may adopt any rule necessitated by the immediate danger . . .
The law also requires that the agency state
the specific facts and reasons for finding an immediate danger to the public health, safety, or welfare and its reasons for concluding that the procedure used is fair under the circumstances . . .
In this case, the Legislature obviated these prerequisites, without ever saying exactly what the emergency was or telling us what threat to the public it was supposedly alleviating, by simply declaring that “all conditions [for enacting an emergency rule] are deemed met”. It also tossed the usual requirement that emergency rules be in effect for only 90 days, allowing these very special emergency rules to remain in effect until the Department of Health could go through the regular rule-making process, which involves notice to the public, possibly a hearing, and can take months, even years, to complete (and probably won’t be completed anyway before this portion of the new law expires on its own terms on July 1, 2023).
With the usual protections for the public from government overreach conveniently short-circuited, Surgeon General Ladapo promptly issued the required emergency rules and forms.
For one, the Department of Health (presumably with a lot of “guidance” from DeSantis and Ladapo), relying on its well-known expertise in theology, decided that “based on religious reasons” included “sincerely held moral or ethical belief(s)”, an expansion that is questionable, in my view, based on the Legislature’s specifically using the term “religious reasons” in the new law. The rule also prohibits employers from inquiring “into the veracity of the employee’s religious beliefs”. In any event, the practical result of this exemption is that any employee can claim it, no questions asked.
Now, from theology we move on to the science component of the rules, or the lack thereof.
Per the Legislature’s direction to elucidate just what it meant by the term “anticipated pregnancy”, the Department decided that if the employee intends to become pregnant and is of child-bearing age, that’s an “anticipated pregnancy” and the employee’s representation must be accepted. The rule does not eliminate the requirement that a healthcare professional “document” this “medical reason” for a vaccination exemption (nor presumably could it be eliminated, based on the explicit wording of the law), leaving the employee in the curious position of having to get her doctor to sign off on her declaration that she intends to get pregnant, although the doctor, unlike the employer, is not prohibited from inquiring into the patient/employee’s statement of her intent.
More disturbingly, the Legislature, by including pregnancy and “anticipated pregnancy” as a “medical reason” for a vaccination exemption, is ignoring the advice of the CDC, the American College of Obstetricians and Gynecologists, and the Society for Maternal Fetal Medicine, among others, that COVID vaccination is safe for women who are pregnant or intend to become pregnant. Indeed, according to the CDC,
people who are pregnant or recently pregnant are more likely to get severely ill with COVID-19 compared with people who are not pregnant.
And in requiring a healthcare professional to “document an exemption based on . . . pregnancy or anticipated pregnancy”, the Legislature and the Department appear to be co-opting the medical community into endorsing its scheme. Per the exemption form devised by the Department, a physician, P.A., or nurse practitioner must declare that
It is my professional opinion . . . that COVID-19 vaccination is not in the best medical interest of the employee.
To claim an exemption based on “immunity”, the Legislature requires that
the employee must present to the employer an exemption statement demonstrating competent medical evidence that the employee has immunity to COVID-19, documented by the results of a laboratory test performed on the employee. The Department of Health shall adopt a standard for demonstrating competent medical evidence of such immunity.
Of course, the only problem is that there is no such thing as “competent medical evidence” demonstrating immunity via a lab test. Therefore, the Department adopted an “emergency rule” incorporating incompetent medical evidence to demonstrate immunity, that being an FDA-authorized or approved positive diagnostic test or a positive antibody test, even though, according to the CDC,
At this time, there is no FDA-authorized or approved test that providers or the public can use to reliably determine whether a person is protected from infection.
Diagnostic tests are designed to tell you if you have a current infection. Antibody tests look for antibodies in your immune system produced in response to the COVID-19 virus. Having a current infection does not mean you are immune from future infection. Having antibodies doesn’t mean they are sufficient to protect against an infection nor is there any agreed-upon level of antibodies that might confer protection or consensus about how long protection might last. And relying on a prior infection or the presence of antibodies to protect you sans vaccination subjects you to a much greater risk of getting reinfected than if you were vaccinated following a case of COVID. That is why the CDC (and pretty much everyone else) advises those who’ve had COVID to get vaccinated. Yet here we are.
The Department also devised an exemption form, which simply requires the employee to attach the lab test results, check a box indicating whether it is a PCR, antigen, or antibody test, and provide the test date.
Notably, there is no limitation on how old the test can be. So, if an employee had a positive diagnostic lab test in, say, January, 2020, the first time tests were made public in the U.S. (that is, almost two years ago), he can still use that result as “competent medical evidence” he has immunity.
Nor is there any limitation on how recent the test can be. Under the literal terms of the new law and the Department’s rule, an employee could submit a positive diagnostic test performed the same day, which means he should be quarantining, and meet the criteria for immunity.
In sum, in defiance of the expert consensus, the Legislature and the Dr. Ladapo have decided that (1) prior infection provides “natural immunity” from future infection in perpetuity, and (2) lab tests not designed to demonstrate “natural immunity” are a reliable way to determine this “natural immunity”.
I sense that even the Department itself is somewhat befuddled by its new rules.
When asked whether the department’s rule is making the case that natural immunity lasts forever, a department spokesperson referred a reporter back to the rule.
To ensure that private employers know the Legislature and Gov. DeSantis mean business, heavy fines can be imposed for terminating an employee for refusing vaccination: up to $10,000 for employers with fewer than 100 employees and up to $50,000 for those with greater than 100 employees. Employees can file complaints, which the law protects from public view, against their employers, triggering a requirement that the Attorney General investigate and, if she finds it appropriate, impose fines, giving the whole thing a star chamber quality.
All of this has left Florida employers in a “tough spot” according to one employment law expert, who notes that employers must now try to figure out how to comply with Florida’s new law, while at the same time comply with conflicting federal vaccine mandates per OSHA, the Centers for Medicare & Medicaid Services (covering healthcare employees), and federal contractor rules.
Meanwhile, Florida’s COVID infection rate continues to climb, again landing our state case rate in the U.S.’s top 10.

Why are physicians threatened by efforts to report doctors to their state medical board for COVID-19 misinformation?
It’s not “cancel culture” to delicense physicians promoting dangerous misinformation about COVID-19. It’s quality control. Why do so many physicians think it is?
David Gorski on January 17, 2022
Link

We at SBM have long lamented how physicians can practice quackery and promote pseudoscience while spreading medical conspiracy theories and only rarely do state medical boards do anything concrete to stop them. Indeed, so uncommon is it for a state medical board to suspend or revoke the license of even the worst quacks that, when a quack does suffer sanctions from his state medical board, we tend to write about it here. Examples include when Florida revoked the license of a “Lyme literate” doctor and New York sanctioned other promoters of the fake diagnosis that is “chronic Lyme disease“. (Of note, one of those New York doctors sued Jann Bellamy and the editors of SBM, also naming some of us who had long ago left or retired from this blog, for having written about him.) Surprisingly to me, even pediatricians and other doctors who are leaders of the antivaccine movement have largely escaped discipline from their state medical boards, to the point that it is noteworthy when they are actually disciplined, with the example of Dr. Bob Sears and Dr. Paul Thomas coming to mind.
Counterexamples also come to mind, such as Dr. Rashid Buttar, who treated autistic children and cancer patients with chelation therapy and referred to the North Carolina Medical Board as a “rabid dog“. Two years later, he was free to practice again (mostly) unencumbered, having signed a consent decree with the Board that reprimanded him and ordered him (1) to provide informed consent to his patients as dictated by the Board; (2) to obey all laws, as well as rules and regulations governing the practice of medicine in North Carolina; (3) to notify the Board if he changes his address; and (4) to meet with the board periodically. And don’t even get me started on cancer quack Dr. Stanislaw Burzynski, who has been treating patients with his ineffective “antineoplastons” for 45 years now, with at least three attempts by the Texas Medical Board failing to stop the harm, the most recent attempt ending with a consent decree in 2017 after four years. Meanwhile, doctors peddling COVID-19 misinformation, such as Dr. Lee Merritt, COVID-19 quack Dr. Simone Gold, and long-time antivax “leader” Dr. Sherri Tenpenny, are easily renewing their medical licenses. (Tenpenny has long referred to vaccines as a method of “mass destruction” and “depopulation” and more recently actually claimed that COVID-19 vaccines make you magnetic, if you remember that gem from last year.) Worse, COVID-19 denying and quackery-friendly legislators are trying to hamstring state medical boards.
In the months after the pandemic first hit in 2020, many of my colleagues were shocked to see the number of physicians promoting outright misinformation and even antivaccine quackery about COVID-19. They shouldn’t have been. This was completely foreseeable if only they had been paying attention. So was the shock expressed by colleagues that, for example, America’s Frontline Doctors (the ones pushing hydroxychloroquine in 2020 and ivermectin last year whose number included the infamous “demon sperm” doctor) didn’t suffer any consequences. Quite the opposite, in fact. One of them, Dr. Joseph Ladapo, was nominated to take charge of the public health bureaucracy in Florida, where he is now implementing all manner of unscientific and dangerous COVID-19 policies. That’s why I was heartened to see colleagues wake up to the threat of misinformation and the promotion of quackery, as manifested by the formation of No License for Disinformation, founded by Dr. Nick Sawyer and colleagues, whose goal is to change the current situation, in which doctors promoting COVID-19-related disinformation have faced virtually no consequences so far. Of course, I have argued that NLFD doesn’t go far enough and that this effort shouldn’t be primarily restricted to just COVID-19 misinformation and quackery, but do welcome the baby steps towards a more general effort to hold quacks accountable.
You’d think that the vast majority of doctors would approve of a renewed effort to purge our profession of dangerous doctors practicing COVID-19 quackery and promoting harmful misinformation. I like to hope that you’d be right, but lately I’ve been seeing a number of doctors who are very disturbed by NLFD and have been expressing their unease in op-eds and on social media. I’ve been seeing more and more of this after a Maine physician named Dr. Meryl Nass had her license suspended for promoting COVID-19 disinformation, although certainly there are doctors who agree with me:
Regulatory action for physicians who spread #COVID #misinformation:
Maine is right! This needs to become standard. We witness the routine ruining of lives & families that occurs when people are victims of misinformation and scientific untruths.
Boundaries must protect. #Safety https://t.co/NRVlXfMQb4
— WesElyMD (@WesElyMD) January 13, 2022
There were others who were—shall we say?—much less enthusiastic about this development. Why is this? Why are some doctors so uncomfortable over the idea of state medical boards sanctioning doctors who promote COVID-19 disinformation? Doctors, after all, hold a special high status in society. Because of our medical expertise, physicians’ medical credentials lend credence to their pronouncements and, when physicians promote pseudoscience and quackery, their assumed expertise is trusted by much of the public.
“Cancel culture” vs. quality control
So what do I mean by doctors who come across as threatened by an effort to hold COVID-19 disinformation-promoting doctors accountable? Of course, there were predictable responses like this from non-physicians, which were easy to dismiss:
Maine’s medical licensing board. How much were they paid to do this? They are a disgrace. Free speech is dead America. Wake up
— delete (@coffeejones123) January 13, 2022
You seem blissfully unaware that pretty much everything written off as a conspiracy theory has been subsequently proven to be correct.
Maybe a little less righteous indignation and more critical thinking would be a good thing for you.
— Bob Johnston (@Lunatic__Fringe) January 13, 2022
I do so love how conspiracy theorists love to claim that every conspiracy was a “conspiracy theory” that was later shown to be correct. One key difference between conspiracies and conspiracy theories is that conspiracies have strong evidence to support that there was an actual conspiracy.
There were, however, reactions like this from doctors:
Should doctors lose their license for misinformation? Sure, if you can distinguish between science and morality https://t.co/1XG6AyRbFA
— Saurabh Jha (@RogueRad) January 12, 2022
To be honest, I wasn’t sure what Dr. Jha’s point about this was. Moral arguments can be just as misleading if they use pseudoscience, conspiracy theories, and quackery to support them. In any event, Dr. Jonathan Howard and I responded:
Dr. Daly calls it “cancel culture”; I call it quality control.
— David Gorski, MD, PhD (@gorskon) January 13, 2022
Doctors who promote misinformation have long hidden behind the First Amendment and “free speech” dating back to long before the pandemic. One prominent example includes the Association of American Physicians and Surgeons (AAPS), which is, in essence, a medical John Birch Society camouflaged as a legitimate medical professional society. I’ve written about the AAPS a number of times, relating how it’s promoted antivaccine pseudoscience blaming vaccines for autism, including a view that is extreme even among antivaccine activists, namely that the “shaken baby syndrome” is a “misdiagnosis” for vaccine injury. It’s worse than that, though. AAPS has promoted HIV/AIDS denialism, blamed immigrants for crime and disease, promoted the pseudoscience claiming that abortion causes breast cancer using some of the most execrable “science” ever, and not only rejected evidence-based guidelines as an unacceptable affront on the godlike autonomy of physicians; the very concept of a scientific consensus about anything. Indeed, in August an AAPS member likened the recent statement by the Federation of State Medical Boards (FSMB) endorsing disciplining doctors for spreading COVID-19 misinformation to the Soviet NKVD, which led me to quip that at least he didn’t invoke Nazis.
I mention the AAPS for two reasons, first to contrast it with the doctors expressing extreme reserve about NLFD and second to disabuse readers of the concept that there aren’t a lot of crank MDs and DOs. It’s easy to make fun of the AAPS, because it is truly a home for little but medical conspiracy theorist “brave maverick doctors” who “don’t follow the herd” even when the herd is actually correct, hence the antivax and HIV/AIDS denial that has flowed from it. However, the doctors expressing reservations most assuredly are not cranks. (Although I didn’t recall ever having interacted with Dr. Daly before, I actually rather like Dr. Jha.)
What is interesting is why doctors who practice science-based medicine would react negatively, to the point of unironically echoing the whole “cancel culture” talking point, leading to a continuation of the conversation:
And they should be perhaps the echo chamber of Twitter is affecting me. Battling quackery and censorship is a challenging dual mandate.
— Ryan P. Daly, MD (@DrRyanPDaly) January 13, 2022
Actually, “Mr. Bond” makes an excellent point that echoes what we at SBM have been saying for a long time.
Then there was this:
Who decides on what is mis-information?
— Terry Maratos-Flier (@Maratosflier) January 13, 2022
A flippant response would be to ask: If state medical boards can’t be tasked at determining what is quackery and misinformation, then who can? The response, though, isn’t so flippant if you think about it, particularly in the context of my periodic laments over the last two decades over how state medical boards so rarely ever actually discipline outright quacks like Dr. Buttar or Burzynski. And if state medical boards can’t enforce even a minimal standard of professional behavior, both in terms of treating patients and public health messaging by licensed doctors, then what good are they? Sure, getting rid of doctors who are impaired due to substance abuse disorders, who assault patients, or who defraud third party payers and patients is good and necessary, but it’s not sufficient, nor is it “cancel culture” for state medical boards to sanction misinformation-spewing physicians.
Let’s take a look at the common concerns expressed by non-quack physicians about NFLD.
Start with an “easy” example
In considering the whole issue of “cancel culture” and physicians’ reactions to Dr. Nass’ suspension by Maine, let’s start with the article that Dr. Jha cited, “Physicians React: Should Docs Lose Their Licenses for Spreading False COVID Information?” The article breaks down physician responses on social media into two categories, Yes, Those Doctors Are Doing Wrong and No, Those Physicians Have a Right to Speak Their Beliefs. Since I am arguing the first point, I’ll be focusing more on the arguments for the second, most of which boil down to a fear that “science and controversial thought” were being “muzzled.” Interestingly, these sorts of arguments came from perspectives that could be considered both right and left wing. For example, here’s one who based opposition on distrust of big pharma:
Another clinician claimed the “truth is very difficult to discern from less-than-truth in a country running on a profit-oriented economic ideology.”
While, from the other side:
“Who can determine exactly what is truth?” asked another clinician. “For sure, the ‘Federal Government,’ who ‘is here to help you,’ is not qualified to make such determinations, and who are you to make such a suggestion as to remove someone’s license because they disagree with you. Give me a break!”
“What is truth?” How, very, very deep! (Really, most doctors are pretty crappy at philosophy.)
While it is true that big pharma doesn’t have the greatest track record in terms of its messaging, it does not follow from that history that it is impossible to discern good science from bad or quackery from science-based medical care, nor do past errors by the federal government imply the same thing. Similarly, it is the state governments who set up state medical boards, which are made up of physicians and stakeholders from the public, and no one—no one—is saying that the federal government (or a state government) should take away a physician license.
This is where my “easy example” comes in, specifically naming physicians who deny germ theory and use that denial to spread antivax misinformation, something I did last week on Twitter:
And, lest you claim that no doctor would ever deny germ theory, just let me say that I can provide a number of undeniable examples to you of just such doctors (e.g., Kelly Brogan), along with the receipts. (I've been writing about this sort of thing for nearly two decades.)
— David Gorski, MD, PhD (@gorskon) January 13, 2022
This, of course, is an “easy example” if you don’t overthink it. I’m not talking about, for instance, the relative contribution of host susceptibility versus the microbe to the development and severity of disease. I’m talking about the very basic concept of whether “germs” cause disease at all, the denial of which is a longstanding belief in large swaths of alternative medicine and the antivaccine pseudoscience spawned by it. I’m talking about people like Dr. Kelly Brogan:
And there are many more like her out there. State medical boards rarely do anything about them.
— David Gorski, MD, PhD (@gorskon) January 13, 2022
We at SBM have written about Dr. Brogan before. Recall that she was denying germ theory years before the pandemic. Unsurprisingly, she continues to deny germ theory when it comes to COVID-19. As I’ve said many times before, if there’s one thing that those of us who have been struggling to counter medical misinformation, quackery, and antivaccine pseudoscience frequently encounter, it’s medical professionals and scientists who have a hard time believing us when we describe just how unscientific, pseudoscientific, and just plain conspiracy-addled various beliefs underlying alternative medicine and antivaccine pseudoscience are. Surely, they seem to think, there’s no way anyone could actually believe that in 2022! How wrong they are, and among the alternative medicine beliefs that provoke the most disbelief among my colleagues (and among educated lay people) is germ theory denial. Few doctors believe me when I say there are people (and doctors) who deny basic germ theory. I have to show them the evidence.
Generally, most physicians expressing discomfort over medical board sanctions for spreading health misinformation will agree that a physician like Kelly Brogan, who denies basic germ theory, should face sanctions from her state medical board. Certainly Dr. Daly did. Therein lies the trap. By conceding that promoting one very obvious sort of medical misinformation should be sanctionable by a state medical board, the naysayers concede my main point, that state medical boards should have the power to sanction physicians who promote misinformation. The rest is just “haggling over the price” (to echo a famous joke); i.e., determining what specific sorts of misinformation should be sanctionable.
That’s when these doctors usually retreat into complaining that “dogma will prevail” if sanctioning doctors on the basis of their spreading misinformation becomes widespread. Then, even as they concede that misinformation coming from doctors can be dangerous, they won’t take a stand on where to draw the line, leading to exchanges like this:
So what misinformation would you say is worth pulling a license for?
Vaccines are full of graphene and hydra that will blow up your head when 5g comes online?
— Ryan Bedell (@ryanbeed) January 14, 2022
Notably, Dr. Ryan never answered Mr. Bedell’s very reasonable question about real world examples. Presumably he does not support sanctioning speech promoting conspiracy theories like that, but maybe I’m wrong. He never answered the question. Those of us who are trying to fight disinformation do not have the privilege and liberty of not taking stands on these questions. No one is saying that these questions are easy in general, but sometimes they are. Kelly Brogan and physicians who deny germ theory are not difficult cases, at least conceptually. I concede that implementing standards for misinformation that rises to the level of being dangerous is not easy.
“Settled science,” Or “What about scientific debate?”
Another common complaint by physicians over the move to sanction doctors promoting misinformation is that no science is “settled” and that such sanctioning will somehow inhibit “scientific debate”. For instance, here’s an example from the Medscape article:
However, many physicians worried that science and controversial thought were being muzzled.
“Absolutely no,” a doctor stated. “Who judges what is misinformation in this age where debate is canceled? Science advances with challenge and it’s not about an authority dictating the allowable opinion.”
Again, I also quote Dr. Daly, who asks the questions:
Clearly. That’s a black and white example as can be. Not the slippery slope. What theories are challengeable? Or is all science settled ?
— Ryan P. Daly, MD (@DrRyanPDaly) January 13, 2022
And appeals to the “art” of medicine:
That’s not the gotcha you think it is. I’ve literally been writing about this very topic for nearly two decades. I’m manager of a blog devoted to these sorts of discussions.
— David Gorski, MD, PhD (@gorskon) January 13, 2022
This is, of course, a very common straw man fallacy frequently invoked whenever professional and scientific sanctions against physicians spreading misinformation are advocated. Here are a couple of more examples from the Medscape article:
One specialist warned that if disinformation doctors are held responsible, then “that means a lot of doctors” will be “gone” because “almost anything that is written or said about COVID can be contested.”
Another physician warned his colleagues about suppressing new ideas: “To condemn what we didn’t try, or purposefully ignore a different approach because [it] doesn’t agree with our opinion is suppression of information.”
Here we go again with “What is truth?”
My response is simple. No one is suggesting, much less arguing, that “all science is settled” or that state medical boards should strip doctors of their medical licenses for taking medical or scientific positions that are reasonably debatable from a scientific standpoint. Certainly, I’ve never made that claim, nor have I argued anything like this. I do, however, argue that there are certain scientific conclusions in medicine that are as close to being “settled” as one can imagine, to the point that not accepting them is unscientific quackery. Basic germ theory is one. That homeopathy is physically impossible is another. As I like to say about homeopathy, for homeopathy even to have a chance of working would require not just that huge swaths of very well-established theory in physics and chemistry be wrong, but that they be spectacularly wrong. Another way of putting it is that to provide sufficient evidence to make homeopathy physically plausible would require a level of evidence that can topple major theories undergirding our current understanding of chemistry and physics. I generally conclude by saying that all theories are “challengeable”, but that simply denying them based on no evidence (or on highly dubious “evidence” and conspiracy theories) is not a “challenge” that professional societies and medical boards are obligated to take seriously as “scientific debate”.
Similarly, just because the science of COVID1-19 is rapidly evolving, having started out with us knowing little about the coronavirus, its mechanism of activity, its transmissibility, and the like, contrary to the claim that “almost anything that is written or said about COVID can be contested”, it’s not as though we know nothing about it. Even in the early days of the pandemic we knew a lot about coronaviruses, of which SARS-CoV-2, the coronavirus that causes COVID-19, was a novel example. For example, as early as January 2020, I could say with a great deal of confidence that SARS-CoV-2 was not a result of a vaccination campaign in China against the flu vaccine.
To sum it up, rapidly evolving science and a lack of knowledge do not mean no knowledge or that we cannot with a high degree of certainty know what is not true or recognized science denial and conspiracy theories when we see them. It doesn’t mean we can’t know quackery when we see it. Moreover, it’s now nearly two years since the pandemic hit the US. The “fog of war” argument about the lack of scientific knowledge regarding COVID-19 and SARS-CoV-2 is much less compelling now than it might have been in March 2020.
Aside from that, doctors also often express fears that such sanctions will shut down “nuance”:
There is tremendous multi-faceted COIs in medicine, hype, and misinterpretations of what trials actually inform us – just see poop-show of nutritional science. Let none of my comments be thought of as anti-vax, I’m pro-nuance. And Pro-vax.
— Ryan P. Daly, MD (@DrRyanPDaly) January 13, 2022
Here’s the problem. We are not dealing with “nuance,” and the fallacy that we are talking about here is not anything resembling “scientific debate”. It’s denialism. On a conceptual level, it’s no different than the denial of, for example, climate science, evolution, or that HIV causes AIDS. Indeed, germ theory denial is a form of denialism, as is antivaccinationism. Physicians who express concern that holding physicians who are promoting denialism to account will somehow shut down scientific debate are doing exactly what brothers Mark and Chris Hoofnagle warned about years ago, mistaking denialism for debate. It’s exactly the trap that disinformation peddlers want you to fall into. Denialism generally involves at least more than one of five things: conspiracy theories, fake experts, cherry picked evidence, impossible expectations (and moving goalposts), and, of course, logical fallacies.
Speaking of logical fallacies…
“It’s a slippery slope”
Another oft-expressed concern is that if state medical boards start sanctioning doctors promoting COVID-19 misinformation, it’ll be a slippery slope to their sanctioning all sorts of other things. In other words, they express fear that “gray areas” will end up being sanctioned. Examples include (and I don’t mean to keep picking on Dr. Daly, who seems sincere and dedicated to evidence-based medicine, but he sums up the common arguments rather succinctly). Here’s another invocation of the “slippery slope”:
Yes clearly. Not my larger point. There’s a role for sanctions and quality control. For each egregious example there’s is a grey zone one. Or uncommonly something we’re just frankly wrong about as a profession. Blackswans.
— Ryan P. Daly, MD (@DrRyanPDaly) January 13, 2022
And:
Not sure we are arguing the same argument here. And likely agree on many points. Arguing dualMandate of balancing quackery and censorship is a hard one with a slippery slope. Not an all or none arguement
— Ryan P. Daly, MD (@DrRyanPDaly) January 13, 2022
Again, no one claims that this is an all-or-none argument. I’ll also point out that, contrary to what some argue, a slippery slope argument is not always a logical fallacy, conceding that there can be occasional valid uses of it. The are, however rare, and I agree that is it almost always a logical fallacy that avoids the specific question at hand and instead distracts with extreme hypotheticals, all without any evidence that the action proposed will lead to the chain reaction suggested, ultimately resulting in the undesirable consequences proposed, which become increasingly improbable the farther along the chain reaction of consequences one drifts. It’s an appeal to fear, not reason.
At its essence, the slippery slope argument, whether the person deploying it realizes it or not, is always an argument to do nothing, based on invoking the fear of some inevitable awful consequence somewhere down the line if a first step is taken.
This wasn’t a doctor who said this, but it is a more extreme example of what I’m talking about:
What's next? The gulag for her? This is all disturbingly similar to Stalin's Soviet Union.
— Swamp_Yankee (@BenFranklin1171) January 13, 2022
And:
It's not the vaccine , a flu shot never gave us a yearly card, we saw health cards in nazo Germany, lest we forget.history can repeat itself. They could easily have bred and trained covid sniffing dogs to eradicate covid they chose not to
— nashville kittens12 (@Happycats678) January 13, 2022
None of the doctors that I encountered went as far as putting Nazi Germany or the Gulags at the end of their slippery slope, but at their core their arguments were not far removed from this.
Whataboutism
The final sort of argument that I’ve seen involves something known as “whataboutism” or “whataboutery”. In brief, whataboutism is a logical fallacy and rhetorical technique of distraction in which a person responds to a criticism with a counter-accusation in order to divert attention to a different topic. The origin of the term goes back to the Cold War, where it was coined to describe the oft-used technique by the Soviet Union to counter various charges made against it. The following is a classic example:
One clinician suggested enforcement against health food, drug company commercials, and talk shows: “What about all the [misinformation] at the health food stores and the like. Doctors of natural-whatever? Those info-commercials on tv. How many faxes do I get to ‘approve’ because ‘patients request’ braces and pain-treating expensive compounds advertised on TV? We tolerate those…. What about Dr Oz and the docs on talk shows claiming BS?”
This bit of whataboutism is not nearly the “gotcha” that physicians (and others) making this argument think it is, at least not to me. I’ve been arguing to do something about all of these things for a very long time, as has everyone here at SBM. Need I remind you how often we have written about the licensure of quacks, Dr. Oz, and quackery in pharmacies? And that’s just a small sample.
State medical boards vs. COVID-19 (and other) misinformation
State medical boards are in a difficult situation that has only become more so with the rise of quacks promoting COVID-19 misinformation. I’ve long lamented how reluctant they are to discipline doctors practicing quackery and promoting antivaccine conspiracy theories and other dangerous misinformation, even before the pandemic. It was a problem that few seemed to appreciate or have much desire to do anything about. Worse, whenever state medical boards actually did something about it, it became obvious that quacks had considerable political pull in some states. The example that I like to cite the most often is that of Dr. Rashid Buttar, whom I mentioned earlier. Buttar led a successful effort by the North Carolina Integrative Medical Society to get legislators to change state law to make it friendlier to practitioners of alternative medicine.
Then the pandemic hit, and finally the severity of the problem of doctors using their professional status to spread misinformation is being appreciated, perhaps for the first time. Unfortunately, we as a profession have a lot of members who either can’t or don’t want to see it as a problem. I suspect that the reason now is similar to the reasons then, involving our dislike of “being told what to do” and an attitude that any of us could fall victim to a bogus complaint to a state medical board. (Ironically, I myself have experienced exactly that, when several years ago a patient of Stanislaw Burzynski reported me to my state medical board for my blog posts about her case.) I get it. I also get that a lot of my colleagues and I have to make medical decisions based on less than ideal evidence bases all the time (the “art” of medicine). Unfortunately, too many of us extrapolate that to justify what quacks do.
        ◦ That needs to change, and we need to work to clean up our own profession. Before the pandemic, I wouldn’t have cared so much where we started, with quacks like Stanislaw Burzynski or with antivaxxers like Paul Thomas. Given that we are still in the middle of a pandemic that’s killed northward of 800K in just the US alone, starting with doctors promoting COVID-19 misinformation makes a lot of sense. As imperfect as it is and even if it doesn’t go far enough for my tastes, NLFD is as good a strategy to start with as any. Again, this is professional quality control, not “cancel culture”, and, even if it were, not all “cancel culture” is a bad thing.

Government watchdog to investigate politicization of CDC and FDA during COVID-19 pandemic
Based on numerous reports of White House interference, a government watchdog will investigate politicization of the CDC’s and FDA’s actions during the coronavirus pandemic.
Jann Bellamy on October 22, 2020
Link

The Government Accountability Office (GAO) announced last week that it would review whether the CDC’s and FDA’s scientific integrity and communications policies have been violated, as well as whether those policies are being properly implemented to assure scientific integrity throughout the agencies. The review is being conducted at the request of several U.S. Senators “in light of public reports that the Trump Administration has improperly exerted political influence on the CDC and FDA” since the onset of the COVID-19 pandemic.
As Senators Elizabeth Warren (D-MA), Gary Peters (D-Mich), and Patty Murray (D-WA), told the GAO in their request:
The CDC’s and FDA’s independence as scientific agencies is crucial to safeguarding the public health and saving lives. These agencies must be able to develop, review, and disseminate public health data, guidelines, and other information that are based on science, facts, and medical principles – not the political imperatives and moods of a president and his advisors.
Yet, they charge that
the Trump Administration has reportedly pressured the CDC and FDA throughout the COVID-19 pandemic, repeatedly applying political pressure and imposing orders on career scientists that undermine the agencies’ credibility and independence.
Citing reports from major media organizations, agency announcements, and Mr. Trump’s Twitter account, the Senators’ letter catalogued numerous instances of putative political interference in CDC and FDA decision-making, interference they say “seeds confusion, erodes public confidence, and diminishes the agencies’ credibility”. (SBM’s David Gorski lamented this erosion of trust in a recent post, “In the age of COVID-19 pandemic, can we trust the CDC and FDA anymore?“, citing a number of the same public reports relied upon by the Senators in their request to the GAO.)
Offenses against scientific integrity on the Senators’ list include:
    • The White House’s allegedly overruling CDC officials who wanted to recommend, in March, that elderly and physically fragile people not fly on commercial airlines due to the coronavirus.
    • Reported interference, in April, by Vice President Pence, and again by the White House this month, in an extension of the CDC’s “No Sail” order prohibiting cruise ship voyages, despite evidence that cruise ships have been a major source of outbreaks.
    • The Department of Health and Human Services (HHS, of which the CDC and FDA are a part) political appointees’ reported “significant efforts to edit, water down, and caveat CDC’s Morbidity and Mortality Weekly Reports”.
    • In May, the White House’s blocking the publication of the CDC’s “Opening Up America Again Framework”, eventually published only after the White House required substantive changes.
    • HHS officials accusing the CDC of “undermining the President” when it released information on pregnant women and COVID-19.
    • HHS political appointees excoriating a CDC official for remarks she made about the U.S. needing to take its virus response seriously, accusing her of being “duplicitous” and undermining the President.
    • In July, the White House ordering the CDC to stop collecting certain COVID-19 data, “instead filtering the data through a third-party contractor at HHS” resulting in “significant issues with the quality, completeness, and transparency of data”. [Although it was not cited in the list, NPR has reported on apparent irregularities in HHS’s awarding the contract and the contractor’s financial connections to Mr. Trump.]
    • Mr. Trump and Mr. Pence exerting “considerable public pressure on the CDC to revise its guidelines for schools”. This resulted in new guidance, which the White House reviewed and substantially edited.
    • The appearance of “highly-criticized” testing recommendations for asymptomatic patients (since reversed) on the CDC website, not written by CDC scientists but dropped there by HHS, “flouting the agency’s strict scientific review process” and containing “elementary errors”.
    • The FDA’s Emergency Use Authorization (EUA) for hydroxychloroquine (since revoked), a drug highly touted by Mr. Trump for COVID-19 but widely criticized for lack of quality evidence.
    • In August, Director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and National Institutes of Health head Dr. Francis Collins reportedly voiced concerns that data did not support the FDA’s EUA for convalescent plasma and the authorization was put on hold. Mr. Trump called Dr. Collins and told him to “get it done by Friday” and suggested to reporters that the FDA wanted to limit its use until after the election. On August 23, the FDA issued an EUA for convalescent plasma.
    • HHS Secretary Alex Azar allegedly overruling the FDA when he revoked the agency’s ability to regulate lab-developed diagnostic tests, including COVID-19 tests.
    • In August, Mr. Trump made a “clearly spurious” claim that the “deep state” at the FDA is delaying potential COVID-19 treatments and vaccines until after the election.
    • After remarks by the lead career official in charge of FDA vaccine review suggested that the FDA’s forthcoming guidance will set a higher bar for a vaccine EUA, Mr. Trump said it “sounds like a political move” and that the White House “may or may not” approve the guidance. After a news report that the White House had actually blocked the guidance, the Administration reversed course.
The review is grounded in the GAO’s jurisdiction to investigate and evaluate, at the request of Congress, federal programs and activities, and provide “information, analyses, options, recommendations, and other assistance to help the Congress make effective policy, funding, and oversight decisions”. The GAO has already issued three reports on the federal government’s response to the pandemic, the most recent of which criticizes the CDC on an issue raised by the Senators’ letter — guidance on reopening schools:
Portions of CDC’s guidance on reopening K-12 schools are inconsistent, and some federal guidance appears misaligned with CDC’s risk-based approach on school operating status. CDC should ensure that its federal guidance on reassessing schools’ operating status is cogent, clear, and internally consistent.
In this case, authority for the GAO review is grounded in the CDC’s and FDA’s policies on scientific integrity and the premise that those policies are being violated by the Trump Administration. According to the request, the CDC’s “Guidance on Scientific Integrity” requires that CDC employees “affirm a commitment to ensure that research and services are based on sound science, meet real public needs, and help achieve public health goals” and states that the “CDC has a responsibility to conduct the best science and is committed to disseminating scientific findings and results without being influenced by policy or political issues”. Likewise, according to the FDA’s policy on scientific integrity, the agency promotes an environment where “scientific decisions are protected from political influence”. The FDA policy requires “shielding the agency’s science and its scientific staff from political influence” and “maintaining a firm commitment to science-based, data-driven decision-making” and is “committed to a culture of openness with the media and public that values the free exchange of ideas, data and information”.
The GAO is asked to audit the implementation of these policies and “understand the extent of any undue political influence at the CDC and FDA”, an issue which raises “a larger concern about independence of CDC, FDA, and other public health agencies”. It is also asked to identify “current structures . . . in place at these agencies to allow them to independently carry out their missions” and recommend “additional structures or steps . . . to enhance the agencies’ abilities to independently carry out their missions, free from political influence”.
The review will not happen quickly. According to the GAO, “the required skills will be available to initiate an engagement in about three months”.
Interestingly, in a poll just out, 36% of respondents said they trusted health officials’ COVID-19 information at agencies such as the CDC and FDA, with 26% saying the same about their state or local governments. Sixteen percent trusted information from Mr. Trump “a great deal or quite a bit”.
Meanwhile, the revelations continue. A day before the GAO’s letter agreeing to the review, Pro Publica published an extensive exposé of the CDC’s failures during the coronavirus pandemic headlined “Inside the Fall of the CDC“. It reports the White House’s rejection of the CDC’s guidance on reopening houses of worship, including elimination of a warning about the dangers of singing. Part of the Administration’s meddling included a call from the Vice President to a CDC infectious disease expert, telling him that the White House’s edits to the guidance were not optional and the CDC’s failure to use them was “insubordinate”.
On October 14, Science ran its own in-depth news report on plummeting confidence in the CDC, titled “The inside story of how Trump’s COVID-19 coordinator [Dr. Deborah Birx] undermined the world’s top health agency”, including the charge from CDC insiders that Dr. Birx “flouted science and undermined the agency to placate the president”. As well, CDC head Dr. Robert Redfield “has quietly complied with many of the administration’s demands”.
According to Science, many CDC execs and professionals plan to leave the agency if Trump is re-elected as public confidence in the agency has eroded.
In 2015, CDC was viewed favorably by 70% of the public, the highest for any agency measured. But in March, the percentage of the public that held a “great deal” of trust in CDC dropped to 46%. In September, it was only 19%.
Also last week, The Wall Street Journal [paywall] and Axios [free] reported that an open letter from current and former CDC Epidemic Intelligence Officers, first published in May, topped 1,000 signatures. The letter begins:
We hereby express our concern about the ominous politicization and silencing of the nation’s health protection agency during the ongoing COVID-19 pandemic. In previous public health crises, CDC provided the best available information and straightforward recommendations directly to the public. It was widely respected for effectively synthesizing and applying scientific evidence from epidemiologists and biomedical researchers at CDC and worldwide. Its historic credibility was based on incomparable expertise and 70+ years of institutional memory. That focus and organization is hardly recognizable today.
Saying the “absence of national leadership on COVID-19 is unprecedented and dangerous”, the signatories “urgently call upon the American people to demand and our nation’s leaders to allow CDC to resume its indispensable role”.
All of this was before Mr. Trump, this week, called Dr. Fauci a “disaster”, claiming that people were “tired” of hearing about the virus from Fauci and “these idiots, all these idiots who got it wrong” and complaining that Fauci “loves being on television” and has made “a lot of bad calls”.
A GAO investigation into improper political influence at two of the nation’s top scientific agencies may be the least of Mr. Trump’s worries, but hopefully it will result in new safeguards against politicians meddling in science, part of a larger effort to mend the guardrails of democracy this Administration has all too easily blown through.

Note to Readers: If you are eager to learn more about the government’s COVID-19 mismanagement you can follow along on American Oversight’s COVID-19 Oversight Hub.

Is the FDA is Hiding “Evidence” the COVID Vaccine Killed Children?
It’s everything anti-vaxxers have been crowing about for decades.
Jonathan Howard on February 20, 2026
Link

Previously, I published 13 thoughts on Dr. Vinay Prasad’s “leaked” memo, which alleged the COVID vaccine killed at least 10 children. Dr. Prasad hasn’t produced a shred of evidence to support this claim, which if taken at face value, means the FDA is currently hiding the evidence while allowing a deadly product to remain on the market. It’s everything anti-vaxxers have been crowing about for decades. As such, I would like to share 6 more thoughts on this topic.
1. A Timeline Review.
    • July 2023: Although he was just a Fox News commentator at the time, Dr. Marty Makary said that “One thing RFK Jr. did is he would post true stories of children who died immediately after the vaccine. These were otherwise healthy children.” This was false. In reality, RFK stole pictures of unvaccinated children who died from other causes to sell his anti-vaccine propaganda publications.
    • September 2025: Dr. Marty Makary, now the FDA commissioner, claimed that the COVID vaccine killed children in an interview on CNN and promised a report would be released “in a few weeks.” No report is released.
    • September 2025: News organizations report that “Food and Drug Administration officials plan to present data they claim links the Covid vaccine to 25 deaths in children at what’s expected to be a closely watched vaccine advisory committee next week, a source confirmed to NBC News.” This presentation on 25 dead children does not occur.
    • November 2025: Stat News published an article titled How Two FDA Officials, Prasad and Høeg, Seized Vaccine Oversight that said:
She (Dr. Tracy Høeg ) pointed to a recent label change that required vaccine makers to warn of the risk of myocarditis for young men. And she displayed about two dozen reports of young people who had died after getting the vaccine, found in the agency’s adverse event database. While such reports do not prove causality, Høeg seemed convinced.
“Timing fits,” read a slide in her presentation, viewed by STAT. “Diagnosis fits. No better explanation found. Sufficient information provided.”
Cautiously, despite fears that they might face retribution, some of the scientists began to push back at Hoeg’s suggestion to effectively take the vaccine away from millions based on thin evidence. One participant described the mood in the room as “quiet horror.” “It was so far off base,” said the agency official, who was not authorized to speak publicly.
When it became clear that no career regulator would stand by the decision, and when vaccine center director Vinay Prasad said the move wasn’t necessary because he had already limited access to the shots, Høeg backed down.
    • November 2025: Dr. Vinay Prasad sent a “leaked” memo that said:
The team has performed an initial analysis of 96 deaths between 2021 and 2024, and concludes that no fewer than 10 are related. If anything, this represents conservative coding, where vaccines are exculpated rather than indicted in cases of ambiguity. The real number is higher.
This is a profound revelation. For the first time, the US FDA will acknowledge that COVID-19 vaccines have killed American children. Healthy young children who faced tremendously low risk of death were coerced, at the behest of the Biden administration, via school and work mandates, to receive a vaccine that could result in death. In many cases, such mandates were harmful. It is difficult to read cases where kids aged 7 to 16 may be dead as a result of covid vaccines.
    • December 2025: Dr. Makary made the media rounds to support Dr. Prasad’s claim and accuse his predecessors of a cover-up. “You’ve got to be honest,” he said, promising the evidence would soon be released.
    • December 2025: Dr. Jeremy Faust wrote an article titled FDA Vax Chief Jumped the Gun on Claims of Kid Deaths From COVID Shots that said:
According to a Dec. 5 post-marketing safety memo prepared by FDA scientists assigned to study the issue, agency scientists concluded that the actual number of deaths linked to COVID-19 vaccines in the U.S. is somewhere between zero and seven…
The final Dec. 5 memo, according to FDA employees with knowledge of the situation, states that under an established World Health Organization (WHO) framework, zero deaths were deemed “certain” to have been caused by COVID-19 vaccines, two were judged to be “probable/likely,” while five were “possible.”
Probable/likely cases are those determined to have been “unlikely” due to another cause. But for the “possible” category, an alternative explanation was determined to have been equally likely, meaning that the chance that vaccines were responsible for those deaths was 50-50 at most.
From this, it appears that the real number of deaths that FDA officials have linked to pediatric COVID-19 vaccines might be as low as zero — but probably rests in the range of two to five. This means that Prasad’s memo opened with a number of deaths that is 200% to 500% of the number that the scientists he assigned to study the problem reported.
    • January 2026: Endpoints news published an article titled FDA Report Claiming Covid Vaccine Link To Children’s Deaths Misses Deadline that said:
An end-of-the-year deadline the FDA set to share the results of an investigation into children’s deaths allegedly caused by the Covid-19 vaccine has come and gone.
The agency didn’t respond to a question about whether the release date has been delayed and if the report will be made public in the future. The FDA’s plan to release the report is entirely self-imposed, and it wasn’t clear why it hasn’t been made public yet.
The FDA has yet to release evidence a single child was killed by the COVID vaccine.
2. The FDA Has Taken Action Against Potentially Unsafe Treatments.
The current version of the FDA has shown it will not hesitate to take drastic actions based on potential safety signals. According to a recent article Regenxbio Gene Therapy Trials Suspended By Fda Over Safety Worries:
Regenxbio lost almost a fifth of its value Wednesday after the Food and Drug Administration placed a clinical hold on two of the company’s experimental gene therapies. Regulators acted after researchers found a case of brain cancer in a 5-year-old child who had received one of the treatments, RGX-111, four years earlier. The agency decided to extend the hold to the second therapy, RGX-121, because of similarities between the two and “shared risk between the clinical studies,” Regenxbio said Wednesday.
The FDA has not taken any similar actions against the COVID vaccine and in fact, in December 2025, Dr. Makary announced they rejected plans to place black box warning on them. He said:
When it comes to the black box warning, we have no plans to put that on the COVID vaccine. The safety and epidemiology center within the FDA did recommend that. It was a recommendation formally put out. But some of our scientists and leadership, like Dr. Vinay Prasad, have said it may be different today than it was in the first year of COVID when the shot came out. Because when you have those two doses three months apart, that’s when you see the side effects go way up like myocarditis in young people.
So according to Dr. Makary, Dr. Prasad has evidence that the COVID vaccine killed children, which would vindicate his years-long obsession with this topic, but when given power, he personally overruled apolitical scientists who wanted to put a warning label on it. That’s as plausible as his claim that We’ll Have Herd Immunity by April.
3. Prasad’s Sycophants Won’t Care.
Trust in the FDA has justifiably collapsed, and no one can make the affirmative case it’s thriving under its current leadership. There are perhaps 10 doctors, consumed by tribalism and groupthink, who will defend Dr. Prasad no matter what he does. After he “leaked” his memo they said:
    • Dr. John Mandrola: Surely the evidence will be forthcoming…I look forward to the details of the investigation. You should too.
    • Dr. Venk Murthy: To be clear, I believe there should a proper scientific report backing these conclusions related to vax myocarditis. I have faith that it will come in due course.
    • Dr. Anish Koka: Prasad is a prolific clinical researcher , a clinical practicing oncologist and an epidemiologist who quickly climbed the ladder of academia publishing papers about pharmaceutical industry gamesmanship and spoke about regulatory capture frequently. This made him very popular among academic lefties who enjoyed his broadsides against big pharma. This is why he ended up as a professor at the elite University of California San Francisco. The problems for Vinay started when he refused to blindly go along with his tribe on lockdowns and school closures because they appeared to violate basic common sense as well as principles that demand strong hard evidence before administering therapeutics with very real / expensive downsides!! Then when he took the same skepticism he always had towards overly broad therapies from the pharmaceutical industry to the push for the Covid vaccine for everyone regardless of their risk from the vaccine .. he really became an outcast. The truth is Prasad is very smart, very accomplished and way more logically consistent than his former tribe who can best be described as cultists. They hate him because he was the best of them and can’t be dismissed as some random eccentric crank on YouTube. America is very lucky to have him leading an agency that has lost its way.
Though these doctors had “faith” in Dr. Prasad, they’ve since moved on. Today, they aren’t the least bit bothered by his refusal to produce evidence of COVID vaccines fatalities, and without missing a beat, they are vigorously defending both his edict to unilaterally axe the Moderna flu vaccine and his subsequent reversal.  In their view, Dr. Prasad is right even when he contradicts Dr. Prasad.
An analogy can be made to Trump’s most devoted followers. Although it was his signature campaign promise in 2016, they were unbothered by his failure to get Mexico to pay for the wall. They correctly knew he was signaling his loyalty to them and his loathing of non-White immigrants. Similarly, Dr. Prasad’s sycophants knew not to take him literally. They recognized that he too was signaling support for their anti-vaxx views and that’s all that matters to them.
4. Prasad and Makary Have Also Moved On.
Drs. Prasad and Makary have also moved on. Neither of them speaks about children killed by the COVID vaccine today. They learned, correctly but unfortunately, that there’s no price to be paid for their absurd predictions and disinformation. In fact, that’s exactly how they obtained fame and power in the first place.
5. Some Quacks are Happy, Others Are Mad.
Quacks like Dr. Simone Gold, the founder of America’s Frontline Doctors who pled guilty attacking the Capitol on January 6th, have used Dr. Prasad’s claim to spread rank anti-vaccine disinformation. This shows the damage of his reckless “leadership.”
Other cranks, however, are furious that the FDA has yet to provide evidence of COVID vaccine fatalities. An article titled about Dr. Robert Malone, a member of the ACIP, titled Federal Vaccine Advisers Take Aim at Covid Shots said:
In an interview with The New York Times, Dr. Robert Malone, one of the panelists, claimed that the Food and Drug Administration was “hiding” data on the risks of Covid vaccination and had refused to share it despite multiple requests. “I am trying to force F.D.A. to come clean on that,” he said.
It pains me to say it, but based on the FDA’s public statements, Dr. Malone is entirely correct. It’s terrifying that Drs. Prasad and Makary are our best defense against his desire to take away COVID vaccines.
6. My Mind Was Open. It’s Not Anymore.
In my prior article on this topic, I bent over backwards to give Drs. Prasad and Makary the benefit of the doubt. Despite their deluge of bogus statistics and disinformation, I wrote:
But my mind is open. Maybe the FDA leaders will surprise me and do something they’ve not done the entire pandemic. If they produce high quality evidence, which is authored by reliable, apolitical FDA professionals and widely accepted by trusted experts, then I will accept it, exactly as I accepted the J&J vaccine killed some people. I will be critical of the FDA officials who missed this important signal. My loyalty is to a process, not an outcome.
Because my loyalty is still to a process, my mind is no longer open. I have seen how this FDA functions, and I don’t trust its leaders at all. In a recent interview about why he left that sinking ship, FDA legend Dr. Richard Pazdur said:
All of a sudden, I was given a press release with a quotation by myself written in it, and asked to just agree to it.
Perhaps the moment this article is published, the FDA will finally release its “evidence” the COVID vaccine killed 10 children. However, I will view it and everything the FDA leaders say with Dr. Pazdur’s warning in mind. So should you.
    • 

State legislators dispense with standard of care for COVID treatment and encourage medical misinformation
State legislatures are considering bills that protect doctors and other health care providers from being held accountable for using unproven COVID-19 treatments and spreading medical misinformation.
Jann Bellamy on February 10, 2022
Link

Legislators in several states have introduced bills, some of which have passed, protecting physicians who prescribe unproven COVID-19 prophylaxes and treatments (like hydroxychloroquine and ivermectin) from discipline by state medical boards. Other bills hamstring efforts to prevent the spread of medical misinformation.
Such proposals, typically sponsored by Republicans and supported in Republican-led statehouses, substitute the judgment of legislators, who often have no science background, for that of medical peers, and relieve physicians of the burden of adhering to a standard of care. As noted bioethicist Arthur Caplan told a reporter, this type of legislation is “purely ideology masquerading as medicine”.
Today we’ll take a look (in no particular order) at some of these efforts to sacrifice good patient care on the altar of political expediency as well as welcome pushback from the medical profession.
One bill has already become law in Tennessee where, as I explained in a previous post,
the legislature bull[ied] the state medical board into rescinding its COVID anti-misinformation policy and [threw] huge bureaucratic obstacles in the board’s way before it can discipline physicians who use unproven COVID treatments, including downright quackery.
By way of background, as noted in that post:
In July [2021], the FSMB [Federation of State Medical Boards] issued a statement reminding physicians who spread COVID misinformation that they risk disciplinary action. Since then, according to the FSMB, at least 15 boards published statements about false or misleading information and at least 12 boards have taken disciplinary action against a licensee. The FSMB is currently developing guidelines for medical boards to help address the spread of disinformation.
Although the statement did not address the use of unproven therapies, this crackdown sent physicians, under threat from being held to the standard of care, running to their friends in state government for protection from medical boards doing their job.
Like Tennessee, North Dakota has already taken action. A new law protects from discipline physicians, nurse practitioners, and pharmacists who prescribe, dispense, or administer ivermectin, although a regulatory board can still take action on another basis, such as inappropriate documentation, substandard care, or “any basis that would in the board’s determination harm the patient”.
This is somewhat of an improvement over the original bill, which would have shielded the prescription of any drug off-label for the treatment of COVID-19, as well as
distributing documented medical information, providing information regarding the licensee’s professional experience or observations, or speaking against a public official.
Which would be a cover for, say, distributing information “documented” in sketchy source material or relying on “professional experience” that flies in the face of evidence-based medicine.
The legislation was opposed by hospital, medical, and pharmacy groups, to no avail.
In a sign of just how far down the rabbit hole some legislators have gone, one of the bill’s sponsors, Rep. Bill Tveit,
responded to data showing that unvaccinated people die at a higher rate with his own data: screenshots of a self-reported article from doctor Stella Immanuel, who in October 2021 claimed she and her team treated more than 7,000 patients, of which “only eight precious souls,” who she wrote had advanced stages of COVID, died. Immanuel, who was briefly boosted by Donald Trump when he was president, has also contended that the US government is at least partially run by reptiles.
Fortunately, despite rowdy constituents who appeared at a committee hearing to support the bill, Virginia rejected a similar effort. The state legislature recently voted down a proposal that would have protected doctors and pharmacists who prescribed or dispensed ivermectin and other off-label COVID-19 treatments.
In a particularly ham-fisted attempt, a Colorado bill was introduced last year that would shield physicians, nurse practitioners, and pharmacists who prescribe or dispense any FDA-approved drug off-label for the treatment of COVID-19, specifically including hydroxychloroquine and ivermectin, as long as the patient gives “informed consent”. Not only could providers not be disciplined for prescribing, no matter their degree of negligence or the harm caused, regulators were forbidden from even initiating an investigation of such conduct. Happily, the bill failed.
A bill introduced in Pennsylvania, and now before the House Health Committee, would prohibit regulatory boards from taking disciplinary action against physicians (as well as other providers) for prescribing, with the patient’s “informed consent”, or dispensing, any therapeutic drug
for off-label use to the patient for prophylaxis or for at-home, early-stage outpatient or hospital inpatient treatment of coronavirus infections [not just COVID-19] causing respiratory syndrome-related illnesses . . . absent a showing of recklessness or gross negligence.
As originally filed, there were no circumstances under which a physician could be held responsible for inappropriate prescribing. It was only in the amended bill that recklessness or gross negligence was added to allow disciplinary action. Legally, this replaces the usual negligence standard (that is, falling below the standard of care, or what a reasonable physician would do in similar circumstances) with a very high bar. Although state law can vary, recklessness generally requires a showing that the physician was “so careless that it is considered an extreme departure from the care that a reasonable [physician] would exercise in similar circumstances”. Gross negligence “demonstrates reckless disregard for the safety or lives of others, which is so great it appears to be a conscious violation of other people’s rights to safety”.
In Wisconsin, a group of legislators recently unveiled a set of so-called “medical freedom” bills that prohibit hospitals and other health care entities and credentialing agencies (such as the state medical board) from taking action against a health care provider
for ordering an innovative or novel therapy based on his or her assessment of the patient and any available clinical data supporting the innovative or novel therapy.
The bills are startling in their breadth. They would apply to the entire range of licensed health care providers in Wisconsin including, in addition to physicians and nurses, chiropractors and massage therapists. “Innovative or novel therapy” is undefined and is not limited to drugs. Protection from disciplinary or other adverse action is not confined to treatment of COVID-19 and presumably applies to any disease or condition.
Of course, “any available clinical data” would allow the provider to cherry-pick the data to support his choice of therapies. This is evidenced by the legislators’ citation to a dodgy website, the anonymous “c19early.com”, for treatments they claim are “demonstrating clear signals of efficacy and robust safety profiles”. This includes the decidedly inefficacious ivermectin, the drug of choice among the conspiracy-minded, such as the legislators themselves, who say that
[m]any continue to speculate as to the exact reasons why the efforts of these health care professionals have been actively suppressed by those who have assumed the responsibility of dictating the response to the COVID-19 pandemic.
In another demonstration of utter cluelessness, the bills’ proponents depict the Front Line COVID-19 Critical Care Alliance [FLCCC] as
health care professionals with first-hand experience treating COVID-19 patients through each phase of the disease [who] worked tirelessly to identify and utilize early treatment options . . .
FLCCC has made several appearances here on SBM, and not in a good way. As Dr. David Gorski details, the “brave maverick doctors” of FLCCC have concocted COVID-19 protocols using ivermectin, vitamins, melatonin, zinc, mouthwash and other nostrums, but
[n]one of these protocols has anything resembling solid evidence from randomized clinical trials to support it.
A third “medical freedom” bill would prohibit pharmacists from refusing to dispense a prescribed drug unless there is an “absolute contradiction” to the patient’s taking the drug. This amends current law, which allows a pharmacist to refuse a prescription if there is simply a “contradiction”. “Absolute contradiction” means that the drug is
not safe to be used as prescribed under any circumstance because of the severe or potentially life-threatening risks involved.
This is necessary, according to the bill’s sponsors, because, citing hydroxychloroquine and ivermectin as examples,
big government, corporate media, and big pharma have waged a war of intimidation on pharmacists who distribute medicines in the treatment or prevention of COVID-19.
Fortunately, the medical profession and hospitals are pushing back. According to the Wisconsin Hospital Association:
This legislation removes the most fundamental tool hospitals use to ensure safe patient care through medical staff governance and privileging. This legislation circumvents an existing evidence-based process medical staff within a hospital use to maximize the health and safety of the patients and communities they serve.
And, from the Wisconsin Medical Society:
[W]e believe these bills are not necessary. Further, the bills appear to undermine some basic safeguards now in place that help prevent care that might fall below minimal accepted standards.
A bill has been introduced in Indiana that permits physicians and nurse practitioners to create “standing orders” allowing pharmacists to dispense ivermectin without a prescription. Per the bill, ivermectin thus dispensed is, ipso facto,
considered to be issued for a legitimate medical purpose in the usual course of professional practice.
The standing order must “specify a mechanism to document the screening performed with the patient” and the dose dispensed in the patient’s medical record, as well as a “plan for evaluating and treating adverse events”.
The pharmacist must give the person receiving ivermectin under a standing order “a standardized information sheet” that has to include “the importance of follow-up care and health care referral information” but cannot discourage the recipient from using ivermectin for the treatment of COVID-19. Physicians and nurse practitioners cannot be disciplined if the pharmacist fails to follow a standing order and pharmacists cannot be disciplined if there is a defect in the standing order.
Frankly, I am not sure how all this would work. How would the pharmacist verify that the standing order is legitimate? (I’m assuming here that the patient keeps the standing order until he wants to use it?) Does giving the patient accurate information about ivermectin, such as the overwhelming consensus that it is ineffective and its risks, constitute “discouraging” the patient from using it? Can pharmacists refuse to participate? (I assume, for one thing, that screening and other procedures will take time the busy pharmacist may not have to spend on this sort of thing.) Who is to execute this “plan” for adverse events?
In any event, this bill is identical in language to one introduced in New Hampshire, which may mean there is some as-yet-unidentified group pushing it. Fortunately, according to a local news report, multiple medical experts testified against this bill in a recent committee hearing. Also encouraging is the news that a “fact-based” coalition made up of “more than 50 business leaders, healthcare institutions and advocacy groups” has been formed in New Hampshire to educate legislators and the public about COVID-related issues.
Finally, my state of Florida, is not about to be left behind in this race to the bottom. Companion House and Senate bills would allow the medical and other health care practitioner regulatory boards to discipline health care providers for misinformation (called “free speech” in the bill) posted on social media only if the board can prove “beyond a reasonable doubt” (the evidentiary standard required for conviction in criminal cases) that the “free speech” “led to the direct physical harm” of an actual patient of the practitioner.
This is, in effect, an impossible standard to meet. Nevertheless, boards could be fined up to $1.5 million (a figure apparently pulled from nowhere) each time they try to discipline a practitioner for “free speech” but fail to prove their case beyond a reasonable doubt.
        ◦ I’m sure it was merely a coincidence, but the House bill was filed just as we were learning that a Florida physician had lodged a complaint with the medical board against our infamous Surgeon General, Dr. Joseph Ladapo, for spreading false information. To no one’s surprise, the complaint that was promptly dismissed, no threat of a $1.5 million penalty required.

Federal employment rights agency inundated with thousands of COVID-related discrimination claims
Thousands of workers have filed complaints with the EEOC alleging COVID-related employment discrimination. It may take years of litigation to sort out the application of federal anti-bias laws to these claims.
Jann Bellamy on April 7, 2022
Link

The U.S. Equal Employment Opportunity Commission (EEOC) has been inundated with COVID-related claims brought by workers charging that employers discriminated against them in violation of the Americans with Disabilities Act (ADA), Title VII of the Civil Rights Act of 1964 (Title VII), and other anti-bias laws.
The ADA, as the name implies, prohibits employment discrimination based on disability. Title VII protects employees against discrimination based on race, color, sex, national origin and, most importantly for COVID-related claims, religion. The EEOC is responsible for enforcing these and other federal laws that make it illegal to discriminate against a job applicant or an employee. Filing a charge with the EEOC is a prerequisite for workers who want to file anti-discrimination law suits against employers. The EEOC can file its own suits as well.
According to Bloomberg Law,
Since April 2020 through December 2021, the U.S. Equal Employment Opportunity Commission has received roughly 6,225 Covid-related charges of discrimination under federal civil rights laws, the latest agency data show. In addition, the commission received more than 2,700 vaccine-related charges, most of which were in 2021 when vaccine requirements were introduced. . .
About 66% of the Covid-related charges raised ADA violations, totaling around 4,125. Meanwhile, the ADA was cited in 300 of the 2,700 complaints tied to vaccines.
The EEOC has not said which of the other anti-bias laws were cited in the vaccine-related claims but, as Bloomberg Law noted, companies have reported a flood of religious exemption requests under Title VII.
The EEOC apparently views these developments as of a piece with the virus’s adverse effects on disadvantaged groups in general. In a statement issued in early March, the agency said:
The COVID-19 pandemic has proved to be a civil rights crisis in addition to a public health crisis and economic crisis . . . As we heard at our public hearing last year, it has disproportionately impacted people of color, women, older workers, individuals with disabilities, and other vulnerable workers.
The ADA and Title VII require employers to provide a reasonable accommodation to a worker’s disability or religion unless doing so would pose an undue hardship. But employers can raise a “direct threat” defense to fire or refuse to hire a worker if the worker’s disability poses a threat to the health and safety of other individuals.
As one might surmise, the intersection COVID and employment discrimination law raises many novel and difficult questions for workers and their employers, including what qualifies as a “disability” or a “reasonable accommodation” and what constitutes a “direct threat”. The EEOC previously issued guidance for addressing these and other COVID issues.
That guidance made clear, for example, that not every person with the virus will qualify as disabled, but said the virus’s aftereffects [such as long COVID] should be considered under the ADA’s three definitions for a disability. Those cover actual physical or mental impairments that substantially limit a major life activity; an employer’s perception that a worker has a disability; or the worker’s record of impairment.
As for a worker claiming a religious exemption to an employer’s vaccine mandate, the EEOC’s guidance said that the employer must provide a reasonable accommodation “for the religious belief, practice, or observance” that prevents the worker from receiving the vaccine under Title VII, unless that accommodation poses more than a “de minimis” cost or burden.
If, however, an employee requests a religious accommodation, and an employer has an objective basis for questioning either the religious nature or the sincerity of a particular belief, practice, or observance, the employer would be justified in requesting additional supporting information . . .
Further complicating the issue, the EEOC advised that “religion” is not limited to established religions like Christianity, Judaism and Islam. It also includes “religious beliefs that are new, uncommon, not part of a formal church or sect, or only held by a small number of people”. As well, “nontheistic beliefs can also be religious for purposes of the Title VII exemption as long as they ‘occupy in the life of that individual’ ‘a place parallel to that filled by. . . God in traditionally religious persons'”. Thus, “the non-discrimination provisions of the statute also protect employees who do not possess religious beliefs or engage in religious practices”.
Anti-vaxxer misinformation campaigns notwithstanding, the EEOC guidance also clarified that, since COVID-19 vaccines don’t use technology that impacts employees’ DNA in any way, the Genetic Information Nondiscrimination Act (GINA), also enforced by the EEOC, is not applicable to COVID-19 vaccine issues in the workplace. GINA prohibits employers from “using, acquiring, or disclosing genetic information”.
As has been true since Title VII was enacted in 1964, the meaning of terms in the federal anti-bias statutes has been fleshed out in litigation, a very expensive way for employers to find out whether or not their conduct violated the law. And it can be a long wait for a definitive ruling. It was not until 2020 that the U.S. Supreme Court decided that Title VII’s prohibition against sex discrimination covered LGBTQ workers, an issue that had remained up in the air for years and about which different presidential administrations (and thus the federal agencies they control) held opposing positions.
We are now at the very beginning of a long slog through administrative rulings and court decisions that will flesh out the application of employment discrimination laws to COVID-19. Even when the pandemic fades, long COVID will require workers and their employers to navigate this new territory.
So, off we go. Since the start of the COVID-19 pandemic, the EEOC itself has brought at least three lawsuits related to disability bias and COVID.
In its first disability accommodation lawsuit connected to the COVID-19 pandemic, the EEOC alleged that a Georgia pharmaceuticals manufacturing facility manager was fired after her employer denied her request to continue working from home because a heart condition heightened her COVID-19 risk. According to the complaint, other employees were allowed to continue working from home after the facility reopened but the manager’s request was denied and she was terminated.
The EEOC also filed suits, against a pharmacy and a coffee house, in Texas. According to the EEOC, a pharmacy discriminated against a pharmacy technician who suffered from asthma. He asked to wear a face mask to help protect him from the virus as an accommodation to his disability. The complaint alleges that the technician was harassed because of this accommodation request, taunted and humiliated for questioning management’s policy prohibiting masks, and sent home on at least two occasions after asking to wear a mask, all of which lead him to quit his job.
(We have to ask: What sort of pharmacy prohibits mask wearing? Not one I’d want to trade with.)
In the second Texas suit, the EEOC’s complaint alleged that a coffee shop violated the ADA when it denied two baristas with disabilities reasonable accommodations and terminated their employment. Rather than provide the disabled employees reasonable accommodations to minimize customer contact, according to the EEOC, the baristas were not allowed to return to work until a vaccine for COVID-19 was developed, despite the fact that they were ready and willing to work.
According to one lawyer practicing in this area:
Regardless of the outcome, the case serves as a reminder that wise employers should not refuse to allow employees to work based in the hopes of protecting employees from illness. Employers must first ascertain whether there is a direct threat to the employee or others. Only where an employee would pose a substantial risk of significant harm to his/ her own safety or the safety of others that cannot be significantly reduced or eliminated by reasonable accommodations should an employer deny an employee with a disability the opportunity to work.
Great advice. But you can bet that for every defense expert who will testify that a particular employee posed “a substantial risk of significant harm” that “cannot be significantly reduced or eliminated by reasonable accommodations” you can find a plaintiff’s expert willing to downplay the dangers the employee presented to fellow workers (and vice versa). In fact, testifying as plaintiffs’ experts in anti-discrimination cases could be a whole new income stream for Great Barrington Declaration types who make a living discounting the dangers of COVID-19.
In sum, long COVID won’t be the only lingering manifestation of the pandemic. We’ll have long-lasting litigation (and attorneys’ fees) as well.

Consumer groups urge feds to act against Mercola and his false COVID-19 claims
Consumer rights organizations urge the FDA and FTC to take action against Joseph Mercola and his businesses over their false, misleading, and dangerous claims that their products will prevent, treat or cure COVID-19.
Jann Bellamy on August 13, 2020
Link

Consumer and social justice groups are asking the FDA and FTC to bring enforcement actions against Joseph Mercola, D.O., and his companies (collectively, the “Mercola Group”) for false, misleading, and deceptive claims that his products will treat, cure, or prevent COVID-19 infections.
In letters sent to the two agencies (FDA here and FTC here), dated July 21st, the Center For Science in the Public Interest, Justice Catalyst, and the People’s Parity Project charge the Mercola Group with capitalizing on the coronavirus. Their deceptive marketing claims and “medical” advice, these organizations say, pose a clear danger to the public,
including the extraordinarily dangerous recommendation that individuals actually try to contract COVID-19 after using the supplements it sells to ameliorate the symptoms.
They’ve done their homework too. In 20-page letters (including extensive footnotes) and an Appendix featuring photos of products, links to Mercola Group websites, and excerpts from Mercola podcasts, they document numerous threats to the public’s health posed by Mercola and his business interests.
Before we get to the details, a brief refresher on Mercola and his history of quackery, a subject covered numerous times here on SBM.
Mercola, a doctor of osteopathy, is an alternative health tycoon, quackery promoter, and marketer of a wide range of products, including dietary supplements, protein bars, cookware, tanning beds, saunas, homeopathic remedies, underwear, cosmetics, spices, books, and pet food. According to the Washington Post, he has donated millions of his $100 million fortune to the anti-vaccine movement. One M.O. fueling his bank account is the promotion of dubious medical advice touting a remedy, then (surprise!) selling his particular brand of that remedy via a Mercola-owned company, all the while pretending that his medical counsel was never, ever intended for promotional purposes.
His quack health advice includes:
    • Vitamin C as a viable option for measles prevention.
    • Vitamin D for flu prevention.
    • Thermography as superior to mammograms for breast cancer detection.
    • Misinformation about screening colonoscopies, such as vastly overstating the complication rate.
    • Tullio Simoncini’s cancer quackery, which claims that all cancer is really a fungus because it’s “always white” and that baking soda injections are an effective treatment.
David Gorski referred to that last one as “among the most ridiculous ‘alternative cancer cures’ I’ve ever seen”, which says a lot. As Harriet Hall warns,
the safest course is to assume that anything on [Mercola’s] website is false unless you can verify it as true by consulting other sources that are reliable.
Mercola’s swindles have gotten him into trouble with the feds before. In one settlement with the FTC, Mercola and his companies paid over $5 million and agreed to stop selling tanning beds, which he claimed could reduce the risk of skin cancer.
Apparently, Mercola is not one to learn from his experiences, nor does he have any shame, which brings us back to his false and misleading COVID-19 claims. He was recently named one of the biggest social media “super-spreaders” of COVID-19 misinformation by NewsGuard, a company that evaluates and rates news and information websites. Now, consumer groups are out to stop his mendacious marketing, asking the FDA, with jurisdiction over unlawful claims that a product can prevent, treat, or cure disease, and the FTC, with jurisdiction over false and misleading advertising, to take enforcement action against the Mercola Group.
They argue that the Mercola Group is a danger to public health because it “frequently disseminates false and deceptive claims”, which are consumed by a substantial internet audience (Mercola.com “is viewed by ‘millions of people daily'”) and fueled by robust sales (“millions of dollars in products annually”).
He is, for example, preemptively downplaying the effectiveness of potential COVID-19 vaccines, even warning the public that any potential vaccine would likely be deadly. On a podcast posted April 5, 2020, Mercola told listeners complete falsehoods about the risks of vaccines, saying:
For every life being saved by a vaccine, you may have another 10, 20, 100 people who are either killed or permanently injured as a result of that vaccine.
Mercola also endorsed his podcast guest’s incendiary assertion that people would probably be dragged from their homes and vaccinated against their will.
Noting that their “false and misleading COVID-19 claims are really just a thinly-veiled and self-serving attempt to sell its products”, the consumer groups’ letters catalog the connection between Mercola’s “medical” advice, which appear in website articles (e.g., “Nutrition and Natural Strategies Offer Hope Against COVID-19”) and in his podcast, and corresponding Mercola Group products which just happen to fill Mercola’s prescription.
Following this playbook, for example, Mercola wrote articles and spoke extensively (and falsely) over the last several months about the effectiveness of vitamin C to prevent and treat COVID-19, including his claim, without evidence, that a Chinese study “is likely to show” that IV vitamin C will successfully treat COVID-19-induced pneumonia. Mercola and his podcast guests also told listeners, again without evidence, that “even a small amount of vitamin C” reduces the risk of dying from COVID-19, “even in the most severe cases”. As an alternative to IV C administered by a physician, Mercola and guests suggested “liposomal” vitamin C tablets, which are (wait for it) featured prominently in Mercola Group’s online store.
Blaming the media for hiding this information from consumers, Mercola advised on his podcast that vitamin D, which he (dangerously) recommended in high doses, will help prevent severe cases of COVID-19 when used in combination with vitamin C and other dietary supplements. Mercola also told listeners that they should use a test kit to determine current levels of vitamin D and proper dosage. Needless to say, his online store sells a vitamin D test kit ($65) as well as a test kit for vitamin D and other nutrients ($165).
Mercola, or his podcast guests, have also touted, and the Mercola Group sells:
    • Melatonin, which he claims is “proven to decrease the risks of COVID-19 infection” and can treat COVID-19 as well.
    • Glycyrrhizin, the active ingredient in licorice, which “could be a treatment for COVID-19” (as well as herpes, HIV, hepatitis, influenza, encephalitis, pneumonia, SARS, and several other viruses).
    • Molecular hydrogen, which has, according to Mercola, “powerful and antioxidant and anti-inflammatory effects, making it potentially useful for COVID-19” and “preliminary results” from prominent doctors investigating its use “are encouraging”. The most effective way to consume molecular hydrogen, he claims, is via tablets that are dissolved in water, the same form he sells.
    • Astaxanthin, a derivative of microalgae, which, Mercola says, calms the immune system and thereby reduces the risk of sepsis, organ failure, and death. (Apparently, in addition to preventing the disease, Mercola aims to cover each and every symptom and complication of COVID-19 with a product he sells.)
    • N-acetyl cysteine, which “may be effective at fighting the blood clotting and strokes occurring in many COVID-19 cases as well as reducing the risk of acute respiratory distress syndrome.”
    • Prebiotics, probiotics, and “sporebiotics”, based on Mercola’s notion that COVID-19 infections may enable Prevotella bacteria to colonize the lungs, causing severe symptoms associated with the disease. He especially touts the “sporebiotic” Bacillus spores, which, he suggests, may be even more effective than antibiotics at fighting the Prevotella.
    • Saunas, which, Mercola told his podcast listeners, can raise your core body temperature, thereby “preventatively treat[ing] any lingering infection that’s just starting to go around.” (Sadly, Mercola Group saunas are currently unavailable due to a “redesign”.)
    • Ozone, to which Mercola devoted an entire podcast: “ozone therapy appears to be even more effective than intravenous vitamin C and to me it’s tragic that no one’s touching that with a 10-foot pole to treat this.” The Mercola Group sells air purifiers touted as generating ozone.
    • Elderberry extract, spirulina, beta-glucan, lipoic acid, and sulforaphane, all of which, according to the Mercola Group’s Coronavirus Resource Guide, “may be of particular benefit against COVID-19.”
As the consumer groups patiently explain, after each description of Mercola’s mendacity, they “are not aware of any scientific evidence, let alone properly conducted RCTs, that [the product in question] prevents or treats COVID-19 infection” or there is “no credible scientific evidence” to support his claims.
After discussing previous regulatory actions involving Mercola, they argue that prior cease and desist warnings “have been insufficient to prevent this fraud and more action is needed”, up to and including warning letters followed by compliance monitoring and, if necessary, enforcement actions in federal court seeking permanent injunctions, civil penalties, and seizure of the offending products.
Among the regulatory actions described was an investigation by Illinois authorities and a call for revocation or suspension of Mercola’s medical license by the Chief of Medical Prosecutions. How that matter was resolved is not entirely clear and, as of June 25, 2020, Mercola’s medical licenses are still active in Illinois and Florida, a shameful indictment of the Medical Boards in those states.
There is something terribly wrong about a system that allows a multi-millionaire charlatan, using his medical credentials as a badge of authority, to fleece the public based on their understandable pandemic fears, all while his fellow physicians are on the front lines treating COVID-19, with far less compensation and at great risk to their safety.

Mercola and Kennedy sue Sen. Elizabeth Warren for combating their COVID misinformation
Quack tycoon Joseph Mercola and anti-vaccine crank Robert F. Kennedy, Jr., have filed a lawsuit against U.S. Sen. Elizabeth Warren claiming she violated their First Amendment rights when she complained that Amazon was peddling COVID misinformation, citing Mercola’s recent misinformation-filled book on COVID as an example.
Jann Bellamy on January 27, 2022
Link

Quack tycoon Joseph Mercola and anti-vaccine crank Robert F. Kennedy, Jr., have filed a lawsuit against U.S. Sen. Elizabeth Warren (D-MA) claiming she violated their First Amendment rights when she complained that Amazon was peddling COVID misinformation, citing Mercola’s recent misinformation-filled book on COVID as an example. Anti-GMO and anti-vaccine activist Ronnie Cummins and the book’s publisher are also plaintiffs.
According to a letter sent by Sen. Warren to Amazon last September, Amazon’s search and “Best Seller” algorithms consistently returned “highly-ranked and favorably tagged books based on falsehoods about COVID-19 vaccines and cures” when her staff performed searches for terms like “COVID-19” and “vaccine”. Mercola’s windbag-titled book, The Truth About COVID: Exposing the Great Reset, Lockdowns, Vaccine Passports, and the New Normal, which Cummins co-authored and for which Kennedy wrote the introduction, topped the list. Amazon had also tagged the book as a Best Seller and the #1 Best Seller in the “Political Freedom” category.
Mercola, Sen. Warren notes in her letter, has been identified as “the most influential spreader of coronavirus misinformation online” and is apparently using his book to drive sales of supplements, despite the fact the FDA warned him to stop selling these supplements “for the unapproved and unauthorized treatment of COVID-19”. She unfavorably compared Amazon’s lack of effort in combating misinformation to that of fellow internet behemoths Facebook and Twitter, who have more aggressively supervised their content.
Sen. Warren’s letter charged that Amazon had engaged in a “pattern and practice” of spreading falsehoods and selling inappropriate products, conduct she deemed an “unethical, unacceptable, and potentially unlawful course of action”. She asked that Amazon perform “an immediate review” of its algorithms and report on the extent to which they are directing consumers to books and other products containing COVID misinformation.
In response, Amazon basically said that the algorithms worked as described because that’s the way they are set up.
As a retailer, we respect that our customers want access to a wide variety of viewpoints on the matter, which is why we continue to list the books in question.
Or, Sen. Warren characterized the response:
they can eliminate misinformation if they want to do it—but they won’t.
And apparently they didn’t, because Mercola’s book, as of yesterday, has a five-star rating based on over 5,000 reviews, is the #2 Best Seller in the “Political Freedom” category and #1 in both the “Propaganda and Political Psychology” and “Politics of Privacy and Surveillance” categories. Among the tens of millions of titles Amazon sells, it ranks #1,153 in Books. Amazon did, however, notify the publisher that it would no longer run ads for the book, although Amazon did not cite Sen. Warren’s letter as the reason. Barnes & Noble decided not to sell the book, a decision it later reversed. Again, there is no evidence linking the bookseller’s actions to Sen. Warren’s letter to Amazon.
Mercola and Kennedy are well-known to readers of this blog, but here’s a short summary of their nefarious activities.
Mercola is a scofflaw osteopath who built a multi-million-dollar empire selling dietary supplements and various other nostrums, which he promotes by fomenting distrust in “conventional” medicine and regulatory authorities, deceptively presenting his products as the safer, more “natural” alternative. His false claims for these products have gotten him in trouble with the FDA, as Sen. Warren noted. He is also rabidly anti-vaccine and has donated generously to anti-vaccine organizations. He is prolific spreader of misinformation on COVID and well as other health topics, which aids his trafficking in quackery when consumers buy into his rhetoric and his pricey products. This book is, in my view, just another means of profiting off the pandemic.
Kennedy, in my opinion, has probably done more to sow distrust in vaccines, including routine childhood vaccinations that have saved millions of lives, than just about any other person living today. (The despicable Barbara Loe Fisher and Andrew Wakefield are his chief competitors for the all-time record.) The pandemic has presented him a golden opportunity to traffic in lies and distortions about COVID and COVID vaccines, and he’s made the most of it, earning himself a spot (along with Mercola) among the Disinformation Dozen as a major source of COVID misinformation. Just this past Sunday, Kennedy (employing a common anti-vaccine trope) compared vaccine mandates to laws in Hitler’s Germany and invoked the name of Anne Frank. This “moral and intellectual decay” was rightly called out by the Auschwitz Memorial, among many others. Kennedy later “apologized“.
Ronnie Cummins, Mercola’s co-author, is the leader of the Organic Consumers Association, also funded by Mercola, which the Genetic Literacy Project calls “one of them most aggressive of North America’s anti-GMO groups”. The group is also anti-vaccine and republishes misinformation from highly unreliable sources like Mike Adams and Alex Jones.
I have not read Mercola’s book and do not plan to. Fortunately, Jonathan Jarry of McGill University’s Office for Science and Society has, thereby giving us a reliable source as to its contents. So, before we move on to the details of the lawsuit, let’s see what he has to say about The Truth About COVID (etc. etc.).
Summarizing the book is, in effect, summarizing the misinformation surrounding COVID-19. In short, Mercola and Cummins argue that the SARS-CoV-2 coronavirus was engineered in a laboratory in Wuhan, China, and its escape was capitalized on by every cabal, government, and corporation you can think of to scare people into looking away while they stole most of the world’s financial resources for themselves. None of the diagnostic tests, treatments, or public health measures can be trusted; rather, the disease is mild and protection is afforded to smart people who have no health conditions, eat the right food, and load themselves up with the right supplements.
Fact-checking the book’s thousands of erroneous claims would require weeks and, I suspect, the publication of a two-tome book.
Jarry does take a stab at pointing out some of the book’s factual errors and exaggerations. For instance, the book insists that pandemic restrictions will be “permanent” even as those restrictions are being lifted. It touts a supplement (quercetin, which Mercola conveniently sells) based on a computer simulation, not an actual in-vivo study, that is a preprint and not peer-reviewed to boot. Mercola’s fevered conspiracy mindset sees a pandemic preparedness simulation as evidence that the whole thing was planned.
So, in sum, people who have spent years profiting off misinformation with little consequence have filed a lawsuit claiming their freedom to speak out has been impaired. With that, let’s turn to some of the particulars.
The complaint, filed in the U.S. District Court for the Western District of Washington (because that is where Amazon is) incorrectly styles Mercola an “M.D.” (he’s a D.O.) and describes him as a “board-certified and licensed physician”, itself a sad commentary on the unwillingness of medical organizations and boards to sanction egregious conduct harmful to the public’s health. Kennedy is described as “prominent lawyer and professor and the founder and CEO of Children’s Health Defense Fund”, the innocuously-titled but vociferously anti-vaccine organization
The complaint quibbles with Sen. Warren’s characterization of the book as containing “false and misleading” information, including content disparaging COVID vaccines, which they defend as merely asserting that the vaccines’ effectiveness “has been wildly exaggerated and major safety questions have gone unanswered”. They attempt to support this by claiming
many renowned scientists have questioned the safety and efficacy of the COVID vaccines and thousands of physicians have asked for more openness to alternative COVID treatments.
The “renowned scientists” they cite are physician and anti-vaccine conspiracy theorist Robert Malone and former Trump advisor Peter Navarro, an economist, writing in a Washington Times op-ed. The “thousands of physicians” are signatories to a Great Barrington Declaration-type online manifesto that anyone can sign. To give you an idea of where that is coming from, Robert Malone himself and yet another anti-vaccine MD, Peter McCollough, have signed on.
In any event, the plaintiffs contend, it doesn’t matter whether what they say is truthful or not, their book is protected by the First Amendment and Sen. Warren’s implication that Amazon’s conduct might be unlawful, as well as her previous threats bust up Amazon on anti-trust grounds (unrelated to this incident), could cause Amazon to take behind-the-scenes action to suppress their views. Suing her in both her official capacity as a U.S. Senator and individually, they seek a declaration that Sen. Warren has violated their constitutional rights, a preliminary and permanent injunction against her doing so in the future, and damages.
The U.S. Attorney for the Western District of Washington, representing her in her official capacity, filed opposition to the motion for preliminary injunction, a Motion to Dismiss (which basically says that, even if everything the plaintiffs allege in their complaint is true, they still don’t have a viable claim) and a Motion for Summary Judgment (which says that, based on all the undisputed facts, she wins).
She is represented in her individual capacity by election law expert and Democratic operative Marc Elias, who joined in the U.S. Attorney’s arguments.
The trouble with the plaintiffs’ claims, the U.S. Attorney points out, is that the plaintiffs don’t allege, nor have they presented, any evidence that Amazon or anyone else has taken any action against anyone because of Sen. Warren’s letter. In response, the plaintiffs say they don’t need any such evidence, that what they characterize as her “threat” to Amazon alone is sufficient as a matter of law.
Other defenses are raised as well, such as sovereign immunity and the Speech or Debate Clause of the Constitution, but we won’t get that much into the weeds, except to note a recent interesting case she cites, Association of American Physicians & Surgeons v. Schiff.
The Association of American Physicians & Surgeons (AAPS) sued Rep. Adam Schiff (D-CA ) after he, similarly to Sen. Warren, sent letters to Amazon, Google, and Facebook, encouraging them to use their platforms to prevent inaccurate information on vaccines and requesting information about what the companies were doing to prevent misinformation. He also, in an unrelated Congressional hearing, questioned certain legal privileges these companies enjoyed. At no time did he mention the AAPS.
SBM’s Dr. David Gorski called out the AAPS way back in 2008 as an organization that
tries to represent itself as a legitimate medical professional society, but in reality it promotes antivaccine views, HIV/AIDS denialism, and an Ayn Randian view of the world in which doctors are supermen, Medicare is unconstitutional, and the government should never interfere with physicians’ prerogatives.
It is unsurprising, then, the AAPS has been promoting dubious COVID information. In the lawsuit, the AAPS complained that, among other things, “Amazon removed from its platform for streaming videos the popular videos Vaxxed and Shoot ‘Em Up: The Truth About Vaccines“, both rank anti-vaccine propaganda.
When Amazon and other companies took action, resulting in the diminished ability of AAPS and others to spread misinformation, the AAPS took umbrage and sued Rep. Schiff although they, like Mercola et al., had no evidence that their downfall had anything to do with him.
In a February, 2021, decision, the court granted Rep. Schiff’s Motion to Dismiss the complaint based, in part, on the alternate grounds (1) that the plaintiffs had failed to allege anything but an “implied” connection between Rep. Schiff’s actions and that of the tech companies and (2) his immunity under the Speech or Debate Clause, which provides that
for any Speech or Debate in either House, [Members of Congress] shall not be questioned in any other Place.
The clause protects Members of Congress and Senators from lawsuits arising from their conduct during official legislative functions, such as hearings, as well as when they engage in other activities in service to their elected office, such investigations and gathering information.
        ◦ Whether or not she prevails on the Speech or Debate Clause defense, as pointed out in Sen. Warren’s argument in support of her motions, government officials are free to try to convince private parties to remove content protected by the First Amendment that they find dangerous to the public’s health, but they are not free to coerce that removal through threat of legal action or government sanction. In her view, and mine, Sen. Warren’s letter falls far short of “coercion”. We’ll see if the court agrees, if it reaches this question at all, and otherwise how the case is decided. Stay tuned.

Heritage Covid Commission Wants China Accountable… What About Trump?
The Heritage Foundation’s COVID-19 Commission Calls for Chinese “Accountability” for US Pandemic Damage
Allison Neitzel on July 14, 2024
Link

On July 8, The Heritage Foundation released a report from their own ‘Non-Partisan Commission on China and COVID-19’ and held an event bearing the same name as the report’s title: “Holding China Accountable for Its Role in the Most Catastrophic Pandemic of Our Time: COVID-19.” This commission, from the organization behind Trump’s Project 2025, lays out recommendations for legal and policy strategies for the White House and Congress to take against China.
.@JohnRatcliffe and the @Heritage Nonpartisan Commission on China and COVID-19 have built a blueprint to hold China accountable for Covid-19.Read the commission's recommendations 👉 https://t.co/VWupKcOud3 pic.twitter.com/VS6SiMWL85
— Heritage Foundation (@Heritage) July 9, 2024
Doubling down
I previously discussed Heritage’s “Road Map for COVID-19 Congressional Oversight” that the decidedly partisan House Select Subcommittee on the Coronavirus Pandemic (HSSCP) appears to be following. It embraces Trump’s “censored” herd immunity-pushing doctors and promotes the evidence-lacking lab leak origin theory. Unsurprisingly, this new Heritage report doubles down on the lab leak as part of their arguments to hold China accountable for U.S. pandemic damage.
HSSCP Chairman Rep. Brad Wenstrup (R-OH) gave introductory remarks at the July 8 event hosted by Heritage president Kevin Roberts. Also featured were:
    • John L. Ratcliffe, a former Republican Congressman, the Director of National Intelligence under Trump, and a Heritage visiting fellow
    • David Feith, an adjunct senior fellow at the Center for a New American Security and former Deputy Assistant Secretary of State for East Asian and Pacific Affairs in the U.S. Department of State
    • Jamie Metzel, founder of OneShared.World who served on the U.S. National Security Council and in the State Department in the Clinton administration
    • Dr. Robert Redfield, the Director of the Centers for Disease Control and Prevention (CDC) under Trump
Metzel and Redfield have both promoted the lab leak theory and testified before the HSSCP during a March 2023 hearing on COVID-19 origins as guests of the Republican subcommittee majority.
Who are these people?
Redfield, a controversial figure from the HIV crisis, has been sharply criticized for his CDC’s handling of the pandemic outbreak. Under his leadership, the CDC rejected the World Health Organization’s COVID-19 test in favor of creating a more complicated one, which faltered and wasted crucial early weeks in the U.S. response.
Later, the public messaging of Redfield’s CDC was commandeered by the Trump administration. An October 2022 report from the HSSCP’s Democrat-led predecessor, the House Select Subcommittee on the Coronavirus Crisis (HSSCC), detailed the unprecedented political control exerted over their gold-standard Morbidity and Mortality Weekly Reports during a time of crisis. While Redfield broke with Trump over the importance of masks, he was largely seen as submissive to the then-president.
Another controversial COVID-19 character from the former president’s administration, Dr. Robert Kadlec, who served as Assistant Secretary for Preparedness and Response in the Department of Health and Human Services (HHS) under Trump, is listed as a “commissioner” of the new Heritage report. Going into the pandemic, Air Force veteran Kadlec was said to have been more focused on bioweapons than his public health-focused Obama era predecessor Dr. Nicole Lurie.
In May 2020, Dr. Rick Bright, who Kadlec had removed from his position as head of the Biomedical Advanced Research and Development Authority the previous month, filed a whistleblower complaint against Kadlec and the HHS (settled the following year) and testified before Congress about the lack of leadership and plan within the pandemic response.
Trump’s Big HCQ Lie
Bright claimed he was ousted over his raising concerns about the Trump administration’s embrace of the anti-malarial drug hydroxychloroquine (HCQ) as a COVID-19 cure and their desire to make it publicly available outside of clinical trials. Trump’s promotion of HCQ as a “game changer” forced his chief medical advisor Dr. Anthony Fauci to publicly counter the president, damaging their working relationship. HCQ would prove ineffective against the virus in a major trial by early June 2020.
An August 2022 HSSCC report details Trump insiders’ behind-the-scenes “knife fight” with the Food and Drug Administration over HCQ and their relentless (but ultimately failed) attempts to get its COVID-19 emergency use authorization reapproved after it had already proven ineffective. At the same time, a group of right-wing physicians, America’s Frontline Doctors (AFLDS), was brought together in coordination with the Trump 2020 reelection campaign to publicly push the MAGA-endorsed, scientifically disproven pandemic miracle drug and instill faith in reopening the U.S. economy before a vaccine was available.
Pot, meet Kettle
Troublingly, Heritage continues to uphold Trump’s Big HCQ Lie. Pharmacist and Heritage fellow David Gortler testified before the HSSCP in March, stating that those who prescribed HCQ or its follow-up GOP “cure” ivermectin were correct to do so. They were not, and Heritage and the HSSCP have been working to protect Trump and the GOP by distracting from pandemic leadership failures and gaslighting the public.
“To the countries, physicians, & pharmacists who prescribed ivermectin or hydroxychloroquine…you were right.” – Dr. David GortlerWe’ll never forget those who gaslit Americans about COVID treatments and tried to force Americans to take the vaccine. pic.twitter.com/UJInVqdSdb
— Heritage Foundation (@Heritage) July 10, 2024
The new Heritage report opens by quantifying the U.S. pandemic damage, citing the 1.1 million American death toll and their calculation of $18 trillion in economic losses. While the report “does not rule out that many other governments, institutions, and individuals may have played contributing roles in the pandemic,” it asserts that “China has been in a league uniquely of its own in its active and aggressive opposition to honesty, transparency, and accountability regarding the virus and its spread.”
The seriousness with which the Heritage report takes the damage wrought by COVID-19 must be contrasted with the actions of public health-antagonizing and publicly non-transparent Trump during the early days of the pandemic. Despite privately confiding in journalist Bob Woodward that COVID-19 was “deadly stuff” in early February 2020, Trump tweeted that the situation was “very much under control in the USA” and referred to the virus as the Democrats’ “new hoax” during a rally later that month.
The Coronavirus is very much under control in the USA. We are in contact with everyone and all relevant countries. CDC & World Health have been working hard and very smart. Stock Market starting to look very good to me!
— Donald J. Trump (@realDonaldTrump) February 24, 2020
Casualties of politics
As Fauci recently recounted, the former president – who was focused on his 2020 re-election campaign and desperate for the pandemic to disappear – went from embracing HCQ as a pandemic quick fix to bringing in contrarian advisors like Dr. Scott Atlas who told him what he wanted to hear, science be damned.
Heritage’s “Road Map” highlights Great Barrington Declaration authors turned HSSCP “experts” Drs. Jay Bhattacharya and Martin Kulldorff, who are subjects of a June 2022 HSSCC report on their “dangerous and discredited herd immunity via mass infection strategy”, insinuated themselves into the Trump White House with Atlas. Their work was done behind the back of White House Coronavirus Response Coordinator Dr. Deborah Birx, who testified to the HSSCC in 2022 that Atlas’s presence “destroyed any cohesion in the response in the White House itself.”
Birx stated that failure to deliver “concise, consistent communication about the seriousness of the pandemic resulted in inaction early on across our agencies” and “created a false sense of security in America.” She claimed this federal mismanagement led to 130,000 preventable COVID-19 deaths before the vaccines were available.
The GOP – and groups like AFLDS – would wage war on the life-saving vaccines, creating massive public confusion leading to 232,000 preventable unvaccinated COVID-19 deaths during the delta and initial omicron waves and an increased death rate among Republican voters compared to their Democrat counterparts by 2022.
Look! Over there!
While the Heritage report claims to “lay the groundwork for holding accountable those whose negligence or overt actions exacerbated the pandemic’s severity,” this only extends to China. Through their HSSCP “Road Map,” Heritage has laid the groundwork for Trump and the MAGA GOP’s evasion of accountability for lack of leadership and exacerbation of the pandemic’s severity in the U.S. While the commission has wrangled some individuals with Democrat pedigrees in order to call themselves “non-partisan,” this report must be viewed in the context of Heritage’s other work.
There is agreement throughout the scientific community and across the political aisle that China has not been forthcoming with information regarding the COVID-19 outbreak. There should be calls for accountability for this, but not in the absence of calls for accountability for our nation’s own failures in 2020. China is not responsible for Trump’s dereliction of duty.
All over the World the CoronaVirus, a very bad “gift” from China, marches on. Not good!
— Donald J. Trump (@realDonaldTrump) May 28, 2020
There must be an understanding that China’s lack of cooperation and transparency in investigating how COVID-19 came to upend global life does not make it any more likely that the virus emerged from a lab leak at the Wuhan Institute of Virology. The consensus amongst the majority of virologists is still that the COVID-19 pandemic most likely occurred as a result of animal spillover, as has been the case in previous pandemics.
Bring in the scapegoat
But the lab leak narrative generates emotion and buzz. And, in addition to distracting from Trump’s failures, it has had the added benefit of being a narrative the HSSCP could weaponize against MAGA Public Enemy #1 – former director of the National Institute of Allergy and Infectious Diseases Anthony Fauci — via questions regarding US funding of viral research in Wuhan. Thus far,however, the HSSCP’s attempts to smear Fauci with this have fallen flat and garnered the now retired doctor support from both Democrats and the public
The same cannot be said for Peter Daszak. As the president of EcoHealth Alliance – an organization that conducts federally-funded global research into viruses, which has included work at the WIV – Daszak has been the target of a years-long unfounded attack originating under Trump, who was quick to push the lab leak narrative. Most recently, this has seen Daszak dragged before the HSSCP and debarred from funding, putting the organization’s future at risk.
EcoHealth has a decades-long track record of important work researching viral epidemics and attempting to predict and thwart viruses that pose a risk to human life. This must be understood as a form of international security. Shutting them down for a short-sighted political strategy or a geo-political agenda only harms us.
What’s to be done?
In the calls for accountability for the Trump administration’s mishandling of the pandemic outbreak and MAGA’s subsequent vengeful war on science, we must include the atrocious treatment of our own scientists over the last few years. And we must not let the deeply politically compromised Heritage Foundation drive this discussion on pandemic accountability.

“Fauci Files” and Florida’s Grand Jury Investigations Fail to Deliver
Although multiple antivaccine investigations have failed to deliver any substantive evidence of alleged crimes, the latest antivax flops won’t flip anyone.
Mallory Harris on June 13, 2024
Link

In the past few months, multiple anti-vaccine investigations have unsurprisingly failed to produce any substantive evidence of alleged crimes warranting massive tribunals. In response, one might expect conspiracy theorists to come to the realization that maybe Covid-19 vaccines weren’t actually a mass depopulation plot and stop calling for public hangings. Unfortunately, I don’t see that happening anytime soon. To understand why, I unfortunately think we need to return to Hillary Clinton’s emails.
A bit of history
In the weeks leading up to the 2016 Presidential election, WikiLeaks began publishing emails from the hacked email account of John Podesta, Hillary Clinton’s campaign chair. To be sure, those emails shed light on some shady aspects of Clinton’s charitable foundation, her ties to big money, and her candidate’s operations. Yet for those who believe that she is a cold-blooded reptilian who orders executions of her political enemies and drinks children’s blood to maintain her youthful vibrancy, the emails at first appeared underwhelming.
A lot of the emails centered around boring logistics: Podesta making plans to pick up his wife’s prescriptions, giving cooking advice to his co-workers, meeting up with his brother for dinner, and getting invited to fundraisers. The latter two emails happened to involve pizza, including mention of the now-infamous restaurant “Comet Ping Pong Pizza.” And so the Pizzagate conspiracy theory was born. In brief, adherents believed that every mention of cheese pizza in the emails was code for child pornography and Comet Ping Pong Pizza was actually hosting Satantic ritual abuse of children in its basement. This all, of course, culminated in an armed man showing up at the pizzeria to liberate the kids from the basement. But there was no abuse, no pornography, and no imprisoned kids; in fact, there wasn’t even a basement.
All this is to say that conspiracy communities do not necessarily need evidence for their claims. In fact, the very lack of evidence can often be the most galvanizing. They thrive on the idea of secret knowledge and investigations, but are not necessarily interested in what the resulting documents actually look like. And lately, leaders of anti-vaccine and Covid conspiracy theory movements have really been failing to deliver results, yet their followers don’t seem to care that their bold promises of future revelations keep falling flat.
The “Fauci Files”
One of my favorite examples in this genre was the release of the “Fauci Files,” a subplot of the larger “Twitter Files” manufactured news cycle. For those unaware, the Twitter Files consisted of Elon Musk giving a group of people access to internal documents on Twitter prior to his purchase of the company, which they then proceeded to misread and misrepresent in long threads. In December of 2022, Musk began to promote the forthcoming release of an installment focused on former NIAID Director Anthony Fauci.
The project ran into a few hiccups, with Musk stating a month later that it had to be delayed because a “key researcher can only travel to Twitter in early Feb.” But surely it would be worth the wait. After all, Musk at the time implied that legal action should be pursued against Dr. Fauci. A case (Murthy v. Missouri) was also working itself up to the Supreme Court alleging that the government, including Dr. Fauci specifically, was running a massive censorship regime to oppress oppositional voices on Twitter. So, to reiterate, the stakes were extremely high to give us something good.
Here’s what “key researcher” Paul Thacker finally came up with in April, four months and two trips to Twitter later:
The Epoch Times took this as evidence that Dr. Fauci lied under oath, quoting Great Barrington Declaration co-author and Murthy v. Missouri plaintiff Martin Kulldorff who called this finding “explosive.” As someone who has helped run social media accounts for several organizations and individuals, I found this quite amusing. Please don’t tell them about all of the times that Nancy Pelosi has texted me to ask for a donation while she was simultaneously on the floor of the House giving a speech. Or the time that Herman Cain posted a tweet downplaying the dangers of COVID-19 12 days after he died of it. And, even if Dr. Fauci did help draft a couple of tweets, pointing that out does nothing to establish his alleged involvement in a mass social media censorship campaign (again, a key claim in a case that was recently heard by the United States Supreme Court).
It is unclear to me why Thacker needed to travel to Twitter to find this publicly available information, although maybe he needed multiple visits to uncover this one email from a former Twitter employee where she says something positive about Dr. Fauci.
Incidentally, Musk stated a full week prior to the Fauci Files’ release that it was time to “move on” from the Twitter Files as “there’s not a lot…that’s left,” so users like @pepedownunder and @TruthWarrior_77 may be excused for missing the Fauci Files’ publication and inquiring about them a full nine months after their release.
Florida Man
And it’s not just Musk’s coterie overhyping an imminent epic reveal of public health malfeasance and then (much more quietly) coming back months or years later with nothing to show for it. Around the same time that Musk was teasing the Fauci Files, Florida Governor Ron DeSantis announced that he was calling for a grand jury to “investigate crimes and wrongdoing committed against Floridians related to the COVID-19 vaccine.”
Fourteen months later, the Grand Jury released its first report, a 33-page document that includes “vaccine” and related words exactly 29 times:
21 times in the introduction, to explain the charge of the grand jury and how it examined whether there was “criminal activity or wrongdoing” with respect to COVID-19 vaccines
2 times to explain assumptions underlying mathematical SIR models of disease transmission and note that COVID-19 vaccines may be assumed to both reduce susceptibility and risk of severe disease
2 times to highlight how some nonpharmaceutical interventions disrupted administration of international vaccination programs against diseases like measles
3 times to discuss the CDC’s changing guidelines about masking (in response to new data about infection and transmission amongst vaccinated people as the delta variant began to spread)
1 time in the conclusion, to note that “[t]here is a case to be made that…lockdowns enabled others in high-risk groups to ‘bridge the gap’ until 2021 when they had access to vaccines.” Notably, this claim (which the report suggests the Grand Jury may follow up on at a later date) would mean that both lockdowns and vaccines helped to save lives in Florida.
Everything else in this report is pointedly not about vaccines: It rehashes old grievances about shelter-in-place orders, masks, and other nonpharmaceutical interventions. Even those who agree with the gist of this report (that COVID-19 wasn’t as deadly as they said and that the measures implemented to prevent its spread were not worth their costs) should agree that it doesn’t remotely address the particular concerns that Governor DeSantis seemed to think it would. To be fair, the grand jury is expected to make multiple reports and has requested an extension through the end of this year to complete their investigation, so they may just be waiting on those to get to the alleged mass criminal conspiracy.
But it does seem worth comparing this pretty weak showing to Florida grand jury reports on, for example, the Parkland shooting (which called for the removal of four members of Broward County school board members) or federal immigration policies (which concluded that crimes were being “enabled by government agencies”). Even the 2006 grand jury investigation into Jeffrey Epstein, which culminated in a plea deal that has been panned as “completely unprecedented” in its leniency, led to a prostitution charge.
Much ado about nothing
In this case, we’re talking about the (purported) crime of the century, ranging from fraud that killed millions to the most egregious case of governmental censorship in US history. One of the richest men in the world gave internal company documents to his idea of a top investigative journalist and the Governor of one of the most populous states deployed state resources — all to get to the bottom of this. And there is still nothing.
As someone who always believed these theories were a load of hogwash, I may be biased, but I find the anti-climactic outcomes of these investigations to be pretty compelling evidence that there is no there there. Still, the absence of evidence isn’t evidence of absence. I think there are two other explanations that adherents to anti-vaccine conspiracy theories are likely to gravitate toward.
The first is that the grand jury and Fauci Files flopped because the folks involved didn’t do a good enough job. In fact, David Gorski of Science-Based Medicine has pointed out that Musk’s hand-picked journalist has a history of errors. At least one Covid conspiracy theorist, Trump HHS science advisor Paul Alexander, was thinking along these lines when he republished a Substack post calling the Florida grand jury “a grift, a clown show, which was set to fundraise off ‘health freedom’ sentiment for [Desantis’] political run.” (Alexander added his own commentary involving something about “moma [sic] breast milk teat suckers”). So here is one thing that Alexander and I agree on: The influencers in the Covid conspiracy movement do not deserve your money and do not have your best interests at heart. But I also think that won’t be the takeaway for their biggest fans.
The other option is one that can keep the conspiracy alive and keep powering its influencers: Maybe the people behind these crimes are just too good at covering everything up. After all, the grand jury report notes that the CDC, FDA, and US Army all declined to participate in the proceedings. So we need to keep digging, and we need you to keep doing your part at home. Members of the anti-vaccine community can stay engaged and connected with one another as they trade theories to fill in the (numerous) evidentiary gaps.
Keeping it real
Like the doomsday cult members who double down when the clock hits 12:01 and the flood is nowhere to be seen, true believers will only become more convinced when combing over Thacker’s thread or skimming the findings out of Florida, if they even saw those. Even so, it’s important that we follow up as anti-vaccine investigations continue to fall apart — especially when they were publicized prior to any findings being released by mainstream news outlets, with little to no coverage of their laughably null and irrelevant conclusions. It’s also important to remain clear-eyed that the latest flops from the anti-vaccine movement likely will not change many minds. In fact, they may just strengthen existing convictions that were never based on evidence in the first place.

The Oregon Medical Board suspends the medical license of antivax pediatrician Dr. Paul Thomas
Late last week, the Oregon Medical Board suspended the licenses of two physicians, one for bragging about not wearing a mask around his patients, the second being Dr. Paul Thomas, an antivaccine pediatrician, whose continued practice was deemed a threat to his patients. It’s time for more state medical boards to step up, as Oregon’s has.
David Gorski on December 7, 2020
Link

If there’s one thing that the COVID-19 pandemic has made all too painfully undeniable, it’s that there are a lot of healthcare professionals out who are very awful people, with very awful, unscientific beliefs about the pandemic, pushing awful unproven treatments, unscientific treatments, or even just plain quackery (often based on conspiracy theories) to prevent or treat COVID-19, while denying the efficacy of public health interventions such as masking and social distancing, using bad science to deny the severity of the pandemic, and even participating in the ongoing disinformation war against COVID-19 vaccines being waged by antivaxxers. Sadly, more than a few of these disinformation spreaders are physicians, with some of the usual antivax physician suspects jumping on the COVID-19 denial grift train so effortlessly. Sadly, physicians behaving badly is nothing new, as there are antivaccine pediatricians(!) like Dr. Bob Sears and Larry Palevsky, and many have been the times that I’ve bemoaned the seeming inability of state medical boards to act to take away the licenses of quacks like Stanislaw Burzynski (who’s managed to keep practicing in Texas since the late 1970s despite peddling nonsense) and antivaxxers who endanger their patients—or even of just run of the mill utterly incompetent surgeons.
That’s why I was so elated over the weekend to see a medical board doing what medical boards should do. I’m referring, of course, to the Oregon Medical Board, which recently decided to act against the licenses of two doctors spreading disinformation about medicine and thereby endangering their patients and the public, Dr. Steven LaTulippe and Dr. Paul Thomas, the latter of whom will be the main topic of this post, for reasons that will become apparent as you continue to read. I will, however, mention first why the Oregon Medical Board suspended Dr. LaTulippe’s license first:
From a local news story:
The Oregon Medical Board suspended the license of an Oregon doctor who said he refuses to wear a mask in his clinic while also encouraging others to not wear masks.
Dr. Steven LaTulippe told a pro-Trump rally in November that neither he nor his staff wears a mask while working in their Dallas, Ore. clinic. That violates a state order requiring health care workers to wear a face-covering in health care settings.
Members of the medical board voted Thursday evening to suspend LaTulippe’s license immediately. According to a statement on the Oregon Medical Board website, the suspension was issued “due to the board’s concern for the safety and welfare of licensee’s current and future patients.”
The indefinite suspension prevents LaTulippe from practicing medicine anywhere in the state. LaTuilippe ran a family practice clinic called South View Medical Arts in Dallas, Ore.
I found it particularly amusing that it was the Oregon Republican Party that posted the video that led to the spotlight being shone on Dr. LaTulippe’s crank beliefs and ultimately to his license being suspended:
Nice job, Oregon Republicans! More videos like this, please, so that we can identify other COVID-19 denying quacks for the Oregon Medical Board to examine! There’s so much disinformation in just Dr. LaTulippe’s brief remarks, including his claims that SARS-CoV-2, the coronavirus that causes COVID-19 is rapidly mutating and has already mutated into something else (not true), meaning that COVID-19 is “over” (whatever that means). Someone like him should not be let anywhere near COVID-19 patients, and not just because he believes so much nonsense but because his failure to adhere to infection control protocols (like facemasks) will facilitate the spread of the virus, possibly to his other patients.
The Oregon Medical Board suspends the medical license of antivaccine pediatrician Dr. Paul Thomas
I’m more interested in the story of Dr. Paul Thomas, than that of Dr. LaTulippe. The reason is that Dr. Thomas is an antivaccine pediatrician whom I’ve been covering for nearly three years at my not-so-secret other blog but who, for whatever reason, has only been briefly mentioned in passing here on SBM. He is, like Dr. Bob Sears, a pediatrician. Like Dr. Sears, he has also made a name for himself promoting antivaccine pseudoscience, propaganda, and disinformation, even writing a book, like the one written by Dr. Sears, that promotes an “alternative” vaccine schedule not based in science. Unlike Dr. Sears, he has claimed to do “science” to support his assertions that unvaccinated children are healthier than vaccinated children. (More on that later.) From my perspective, it appears that Dr. Thomas is much more into “integrative pediatrics” woo than Dr. Sears, which puts him on a similar level with another antivaccine pediatrician, Dr. Lawrence Palevsky, who showed up in the news a year and a half ago during all the measles outbreaks in Brooklyn and Rockland County, NY spreading antivaccine pseudoscience to Orthodox Jews.
The suspension of Dr. Thomas’ license last week by the Oregon Medical Board provides me with the perfect pretext to discuss him, as he’s been a rising star in the antivaccine movement since around 2017 or 2018 and recently made waves with a really awful “vaxxed/unvaxxed” study that claimed to find that unvaccinated children are healthier. More importantly, it provides me with the opportunity to discuss my belief that antivaccine physicians should lose their medical licenses because, by definition, they are practicing so far below the standard of care that they endanger their patients.
Here’s a PDF of the Oregon Medical Board’s order, issued on December 3. Let’s take a look at some key passages. First, however, note how the order points out that Oregon law allows its medical board to temporarily suspend the license of a physician without a hearing when the “Board has evidence that indicates that Licensee’s continued practice constitutes an immediate danger to the public” or finds that “that Licensee’s continued practice of medicine by a physician presents a serious danger to the public health or safety”. This is important in that I don’t recall any previous cases in which a quack or antivaxxer had their license suspended because their state medical board viewed them as such a threat to patients or public health.
Let’s get to the meat of the findings, shall we?
The Board finds that Licensee’s conduct has breached the standard of care and has placed the health and safety of many of his patients at serious risk of harm. It is therefore necessary to emergently suspend Licensee’s license to practice medicine. The acts and conduct that support this Order for Emergency Suspension follow:
3.1Licensee has published an alternative vaccination schedule that decreases the frequency of many recommended vaccines and omits others, including rotavirus. Licensee promotes his unique, “Dr. Paul approved” schedule as providing superior results to any other option, namely improved health on many measures, and fraudulently asserts that following his vaccine schedule will prevent or decrease the incidence of autism and other developmental disorders. Licensee uses this claim to solicit parental “refusal” of full vaccination for their children, thereby exposing them to multiple potentially debilitating and life-threatening illnesses, including tetanus, hepatitis, pertussis (whooping cough), rotavirus, measles, mumps, and rubella.
Licensee’s promotion of this alternative vaccination schedule exposes patients to the risk of harm in violation of ORS 677.190(1)(a), as defined by ORS 677.188(4)(a).
This, of course, is nothing new. Dr. Thomas published his book (co-authoring it with another rising star in the antivaccine movement, Jennifer Margulis), The Vaccine-Friendly Plan: Dr. Paul’s Safe and Effective Approach to Immunity and Health- from Pregnancy Through Your Child’s Teen Years, nearly five years ago. That, of course, brings up the question of why the Oregon Medical Board considered it necessary to suspend Dr. Thomas’s license on an emergent basis, before a full hearing. The most serious (to me) of Dr. Thomas’ “unprofessional or dishonorable conduct which exposed his patients to the risk of harm, as well as gross or repeated acts of negligence in violation of ORS 677.190(13)” listed by the Board in its order of emergency suspension was this one:
3.3.3Patient D, a now 9-year-old male, was completely non-immunized. Patient D sustained a large, deep scalp laceration at home in a farm setting on August 8, 2017, and was treated with colloidal silver and with his parents suturing the wound independently. Patient D subsequently developed acute tetanus requiring intubation, tracheotomy, feeding tube placement and an almost two- month ICU stay at Doernbecher Children’s Hospital. Patient D was then transferred to Legacy Rehabilitation. Licensee saw Patient D for follow-up in clinic on November 17, 2017. Licensee’s notes documented a referral to a homeopath, recommendation of fish oil supplements, and “phosphatidyl seine.” He did not document an informed consent discussion about the risk/benefit of immunization for a child who had just sustained and still had sequelae of, and remained vulnerable despite prior infection, to tetanus, a life-threatening and disabling disease that is preventable by proper vaccination. Licensee’s care placed Patient D at serious risk of harm and constitutes gross negligence.
The standard of care, of course, after a laceration resulting in what must have been a grossly contaminated wound in a child (or adult) who has either not had a tetanus vaccination or whose tetanus vaccination status is unclear or in doubt is to recommend a tetanus booster plus tetanus immune globulin (TIG). Colloidal silver won’t cut it, being quackery. Homeopathy certainly won’t cut it, being The One Quackery To Rule Them All. (I note that Dr. Thomas’ practice is an “integrative pediatrics” practice, which of course goes along with his general antivaccine bent.) Basically, if the facts of this case are as stated by the suspension order, this is gross malpractice of the most negligent kind, in my not-so-humble opinion. It’s even worse than that, because he did it twice! Not only did he not recommend tetanus vaccination (and, apparently, TIG) once when the child first presented with his laceration, but he did it a second time, not recommending it during a followup visit after the child’s hospital discharge! Tetanus infection doesn’t make you immune to a second infection, because it’s a toxin produced by Clostridium tetani, the bacteria tetanus that causes tetanus, that is dangerous. The child was still susceptible to tetanus when Dr. Thomas saw him after discharge.
That’s not all when it comes to preventable disease due to Dr. Thomas’ medical negligence, though. For instance, there were children who were hospitalized with rotavirus infections, including a ten year old girl and twins born at 35 weeks gestation, who developed rotavirus gastroenteritis at ten months of age and required hospitalization for five days. For these latter patients, the Board does note this:
Licensee’s clinic chart contains documentation of parental refusal of vaccines, but they are inconsistent regarding specific vaccines and their timing. In addition, Patient G and Patient H’s mother stated during hospitalization that she thought her children had received rotavirus vaccine. Failure to adequately document specific parental refusal and lack of providing parental clarity constitute acts of negligence.
Correct. These cases demonstrate extreme medical negligence, and there is no excuse. Similarly, so is placing the fake diagnosis of chronic Lyme disease on a girl and then not following the standard of care to work up her symptoms:
3.3.5Patient F is a 7-year-old female who Licensee followed in clinic for constipation, food allergies, mold allergies and possible “chronic Lyme disease. Review of her chart from Licensee’s clinic reveals that she was nonimmunized. Licensee ordered repeated IgE allergy panels and recommended elimination diets, vitamin supplements and provided antibiotics for acute infections. Licensee failed to provide an appropriate referral to a pediatric gastroenterologist to exclude a diagnosis of malabsorption or celiac disease, a referral to pediatric allergy/immunology or to pediatric nutrition. Licensee’s neglect to seek consultative support and oversight, and his failure to address Patient F’s lack of immunizations, placed the health of this patient at serious risk and was grossly negligent.
Not doing a proper, science-based medical workup to rule out potential medical and physiological causes of a patient’s symptoms and instead treating them for fake diagnoses constitute malpractice in my book.
There are also cases described in which Dr. Thomas measured antibody titers for measles, mumps, and rubella, using those levels to decide not to give the additional doses of the vaccine recommended. Never mind that, as the Board put it, except for “rare cases of suspected immune deficiency, there is no clinical indication for assessment of antibody titers” and regardless “of antibody titers, the standard of care requires a second dose of the recommended MMR vaccination”.
Then, as one might expect for an antivaccine pediatrician, there were cases in which the child developed a vaccine-preventable disease, such as an 11-year-old boy who was on Dr. Thomas’ delayed schedule and developed pertussis. One case like this involved not just failure to vaccinate, but gross patient mismanagement:
3.3.2Patient C is a now 7-year-old male. He was admitted to Randall Children’s Hospital in August 2013 at approximately 10 weeks of life with fever and a diagnosis of Kawasaki’s disease. Licensee saw Patient C in clinic for three days in clinic with fever. Though Dr. Thomas reevaluated Patient C daily and sent repeated labs, he made a clinical decision to treat a febrile child a less than 3 months old with intramuscular ceftriaxone on the basis of a “bagged” and not catharized urine sample and in the absence of blood cultures. Any child of this age is at higher risk for serious bacterial infection (late onset group B strep, pneumococcal bacteremia, urinary tract infection, pneumonia, meningitis) as well as inflammatory illnesses such as Kawasaki’s disease. Licensee breached the standard of care by failing to refer Patient C to the Emergency Room or hospital for definitive lab testing (guided bladder tap, blood cultures done with bedside ultrasound, possible lumbar puncture) and observation. Licensee’s management of Patient C’s illness in clinic breached the standard of care. Patient C remained non immunized for pertussis and subsequently contracted pertussis when his older brother, Patient C, became ill with pertussis on September 24, 2018.
Even I know that you have to take a persistent fever in an infant under three months old a lot more seriously than Dr. Thomas did, and I’m not even a pediatrician or internist.
Here’s a particularly interesting finding by the Board. I’ll preface this finding by noting that “integrative doctors” like Dr. Thomas almost always tout their supposedly superior ability to “listen to patient concerns” and to “work with patients”. They tout their “respect” for their patients’ wishes, negatively contrasting it with, apparently, the cold, unfeeling, dismissive behavior of science-based physicians. It turns out though, that if the following allegations recounted in the Board’s order are true, Dr. Thomas is not so respectful of parents who are pro-vaccine and want the standard vaccine schedule:
3.2Licensee is insistent and direct in his communication with parents and guardians that they should accept his alternative vaccine schedule.
What does the Board mean by that? It provides two examples:
3.2.1A patient’s mother sought subsequent treatment by Provider X after having been “reduced to tears” by Licensee’s “bullying” her into his personal vaccine schedule against her express wishes for full vaccination for her child.
3.2.2Patient A’s mother requested polio and rotavirus vaccinations for Patient A according to CDC Recommendations, but Licensee did not have those vaccines in the clinic, and Patient A would therefore not be able to get them. Patient A’s mother reported that the Licensee questioned why she wanted Patient A to get the polio vaccine and asked whether they were traveling to Africa. During the appointment, Licensee continually connected vaccines (not specific) with autism. Licensee asked her how awful she would feel if Patient A got autism and she could have prevented it.
So Dr. Thomas reduced one mother to tears because she wanted to follow the standard, science-based CDC-recommended vaccine schedule for her child, as he tried to bully her into accepting his unproven “alternative vaccine schedule.” (Funny, but doesn’t this sound like a common description by antivax mothers of pediatricians and nurses trying to persuade them to accept the CDC vaccine schedule, that of bullies.) He also tried to guilt another mother into not giving her child recommended vaccines using a false claim that vaccines cause autism, an antivaccine claim that has been tested time and time and time again through numerous studies, none of which has produced any scientifically convincing evidence that vaccines cause or even are associated with an increased risk of autism. I guess that Dr. Thomas is understanding, empathetic, and willing to work with parents, as long as the parents do what he wants them to do, rather like the caricature of science-based physicians recommending the standard CDC-recommended vaccine schedule. The word “projection” comes to mind here.
And I do love what the Board wrote here:
3.1Licensee has published an alternative vaccination schedule that decreases the frequency of many recommended vaccines and omits others, including rotavirus. Licensee promotes his unique, “Dr. Paul approved” schedule as providing superior results to any other option, namely improved health on many measures, and fraudulently asserts that following his vaccine schedule will prevent or decrease the incidence of autism and other developmental disorders. Licensee uses this claim to solicit parental “refusal” of full vaccination for their children, thereby exposing them to multiple potentially debilitating and life-threatening illnesses, including tetanus, hepatitis, pertussis (whooping cough), rotavirus, measles, mumps, and rubella.
And here:
Licensee’s false claims regarding the safety of the CDC Recommendations, his failure in following these Recommendations absent unsolicited parental refusal of vaccines, his failure to document any such refusal, and his failure to adequately vaccinate children is grossly negligent in violation of ORS 677.190(13) and exposed his patients to the risk of harm in violation of ORS 677.190(1)(a), as defined in ORS 677.188(4)(a).
Because making demonstrably false claims about vaccines in order to dissuade patients from vaccinating or parents from vaccinating their children is fraud and malpractice, as far as I’m concerned, and should be grounds to suspend or even permanently revoke a physician’s license. Dr. Thomas’s antivaccine grift has real health consequences for children, and his popularity in the Portland area has real public health risks. Indeed, he was peddling his message during a measles outbreak nearly two years ago.
Dr. Thomas: A rising star in the antivaccine movement
As I said near the beginning of this post, Dr. Thomas has been a rising star in the antivaccine movement ever since he first published his book touting his “alternative vaccine schedule”. Unsurprisingly, in his promotion of his book, one can easily find all sorts of red flags for antivaccine pseudoscience, including favorite quack tropes about “blindly following your doctor’s recommendations” or “counting on some government agency to have your best interests first,” coupled with a sales pitch for his book, his videos, and, above all, his nutritional supplements. Supplements, did I say? Oh, yes. Dr. Thomas sells lots and lots of supplements, in particular “Dr. Paul Approved Nutraceuticals” (vitamins, minerals, herbs and more) that are “selected to maintain optimal cellular function and to restore optimal cellular function for those individuals with unique dietary requirements and sensitivities”.
Because of course he does.
Unsurprisingly, Dr. Thomas has, like Dr. Palevsky, jumped on the COVID-19 denial grift train with his new book, COVID-19: Life-Saving Strategies The News Media Will Never Tell You. Here’s a rule of thumb. Whenever you see a book title about how “They” don’t want you to know something, like Kevin Trudeau, run. It’s almost certainly a scam or, at best, misinformation. I can tell just from the blurb:
Are you worried that you or a loved one might die from COVID-19? It is your healthy immune system that protects you and keeps you alive. In COVID-19: Life-Saving Strategies the News Media Will Never Tell You, Paul Thomas, M.D. provides possible solutions backed by sound science and his experience in his own clinical practice. In this book, you will discover:
    • The best type of immune-boosting diet.
    • Why a ventilator should only be used as a last resort.
    • 6 essential dietary supplements that support immunity and lung health (Hint: It’s not just about vitamin C).
    • 1 possible way to get a conventional doctor to administer vitamin C while you’re in the hospital.
    • Many other easy-to-implement key action steps to strengthen your immune system.
This book provides a way to take your destiny into your own hands and dramatically increase your chances of staying healthy. The many scientific references included in the book also make it an ideal resource for health care providers.
Hard pass.
But how did Dr. Thomas get to where he is now? Certainly, he has followed the same sort of path that Dr. Sears did, publishing a book with an “alternative vaccination schedule” that delays and omits certain vaccines based on fear-mongering antivax pseudoscience claiming that vaccines cause autism, autoimmune disease, and all sorts of other problems, but that’s not all. He’s also been good about getting favorable press coverage from local and national media figures who are prone to “false balance” when it comes to vaccine stories, as he did with Genevieve Reaume, a reporter for KATU, the Portland, OR ABC affiliate, a year and a half ago. Her story went beyond false balance and, in the midst of an MMR outbreak in Portland and Washington, basically lionized Thomas as a “brave maverick doctor” being “persecuted” by The Man for his views. The basis of the story was Dr. Thomas’ claim that he is doing “studies” of the 15,000 patients in his practice and that then those studies “showed” that unvaccinated children are rarely diagnosed with autism. Unsurprisingly, it used poor study design and incorrect statistical analyses.
As I pointed out at the time, there are issues where there are not two sides to the story. Whether the MMR vaccine causes autism is one. Worse, when it comes to conspiracy theory-based movements like the antivax movement, facts don’t matter, and presenting antivaccine pseudoscience side-by-side with science does falsely elevate the pseudoscience, no matter how much refutation to antivax pseudoscience is included. Dr. Thomas was engaging in information warfare, and it’s asymmetric warfare. He continues to do so. What do I mean?
First, Dr. Thomas has teamed up with James Lyons-Weiler, whom you might recall attacking a study that found that autism is primarily genetic and using risibly incompetent science to try to demonstrate early in the pandemic that SARS-CoV-2, the coronavirus that causes COVID-19 (which at the time was still called 2019-nCoV) was not natural and had been engineered. A while back, Dr. Thomas teamed up with Lyons-Weiler to do antivaccine “science”. One of the early fruits of that collaboration (if you can call such a rancid piece of rotten science a “fruit”) was an incompetent study, published as the COVID-19 pandemic was getting started in China, that demonized aluminum adjuvants using some really incompetent pharmacokinetic modeling. It was a wonder to behold in its awfulness. The other “collaboration” between these antivaccine cranks involved a “vaxxed/unvaxxed” study.
What is a “vaxxed/unvaxxed” or “vaccinated/unvaccinated” study? I’ll remind those who might be unfamiliar with the concept or don’t remember it. It’s any study that compares health outcomes between a vaccinated cohort of children and those of an unvaccinated cohort. In its purist form, it is a randomized, double-blind, placebo-controlled study comparing “vaxxed” to “unvaxxed.” Of course, such a study would be highly unethical because, by its very design, it would require that a group of children be intentionally placed in a control group that would be left vulnerable to vaccine-preventable diseases because the control group would only receive placebo vaccines. Antivaxxers don’t like it when that simple fact is pointed out to them, of course, because they really and truly believe that vaccines do more harm than good. Of course, it never occurs to them that their belief would make such a randomized, controlled clinical trial unethical as well, because they would be intentionally placing children into a group who would be—to them—being exposed to something they view as a grave threat to their health, vaccines. (After all, they believe that vaccines are toxins-laden interventions that cause autism, autoimmune diseases, obesity, alter DNA, render females infertile, and have created the “sickest generation” of children—and in some cases even kill.) True, their belief is erroneous, but intent matters. It all comes down to clinical equipoise, which is the genuine uncertainty over whether an intervention is on balance beneficial, harmful, or without detectable effect. A randomized controlled trial (RCT) of “vaxxed/unvaxxed” children violates clinical equipoise.
As a result, some of the savvier antivaxxers, who know that a “vaxxed/unvaxxed” RCT would be highly unethical (or who are at least willing to concede that the overwhelming view of physicians and scientists who do clinical trials is that a “vaxxed/unvaxxed” RCT would be highly unethical) have retreated back to suggesting observational “vaxxed/unvaxxed” studies, such as retrospective and epidemiological studies. The whole idea is that vaccines cause autism, the obesity epidemic, and in general the “sickest generation” of children, even though there is no evidence that they do. Of course, doing such a study is a hell of a lot more difficult than antivaxxers think, given how difficult it is to account for confounders and how many subjects are needed to provide sufficient power to detect differences in a condition whose prevalence is in the low single digit percentage range. Still, none of this has stopped antivaccine “scientists” and physicians from trying to do such studies. Unsurprisingly, the results are always dismal in that the studies are inevitably positive (i.e., claim to find that unvaccinated children are healthier than vaccinated children) but so poorly designed and executed that they are singularly uninformative and their conclusions are not supported by their data and design. Examples abound, unfortunately, such as risibly incompetent “vaxxed/unvaxxed” studies by Brian Hooker and Neil Z. Miller, studies by Anthony Mawson that were retracted and republished and retracted, Internet surveys by quacks about vaccinations, and a number of others that I could reference.
The even more rancid “fruit” of that collaboration, Thomas and Lyons-Weiler’s “vaxxed/unvaxxed” study, was published right before Thanksgiving. I’m not going to go into detail over why it was so bad, which you can just read here for the gory details. I will give you the Cliffs Notes version, which is that the study, apparently unable to find a statistically significant difference in health outcomes between vaccinated and unvaccinated children in Thomas’ practice using standard methods, Thomas and Lyons-Weiler invented a metric, the Relative Incidence of Office Visit (RIOV) and then did what sure looks to me like a lot of p-hacking to find statistically significant differences in the numbers of office visits for various diagnoses between the two groups as determined by billing records over 20 years. RIOV appears to have been designed to crank up sensitivity over specificity, thereby finding “differences” that might or might not mean anything (or even be real).
Worse, Thomas and Lyons-Weiler promise a “follow-up” study soon. I do wonder, though, how feasible that study will be given that Dr. Thomas can no longer treat patients, at least until there is a hearing before the Oregon Medical Board and possibly forever. (Obviously, I’m rooting for the latter possibility.) There will probably no effect, given that this has been a retrospective study. In any event, you can see how Thomas has teamed up with other antivaccine grifters to produce “science” to demonize vaccines.
Cry persecution!
Unsurprisingly, the reaction of antivaxxers to this news was to cry, “Persecution!” and “Freedom!” with a touch of “Fight forced vaccination!” conspiracy mongering. Indeed, on his website, Dr. Thomas posted this:
Dr. Paul now faces attacks on three fronts:
     1.  Providence Health Plans, the largest local insurance company terminated all contracts.
     2.  The State of Oregon terminated all contracts.
     3.  BREAKING NEWS, the same week his data is published and CHD Defender posts about it comes:
“By order of the Oregon Medical Board, the license of Paul Norman Thomas, MD to practice medicine is hereby suspended, effective December 3, 2020, at 5:15 p.m. Pacific Time. As of this date and time, Licensee must stop practicing medicine until further order of the Board.”
Integrative Pediatrics and our providers are fighting to preserve your right to direct your child’s medical care with Providence Health Plan (PHP) and with those covered by OHP (Oregon Health Plan). PHP and the Oregon Health Authority (OHP) intend to terminate our provider contracts in an effort to restrict your provider choices and force you and your children into compliance with CDC vaccine “recommendations.”
In an unprecedented move the Oregon Medical board suspended my license without a hearing potentially endangering countless patients.
Dr. Paul and Integrative Pediatrics have secured a team for legal action, civil lawsuits, and a class-action lawsuit against patients’ wrongful abandonment by PHP and OHA / OHP and the Oregon Medical Board.
Of course, the part about patients being “abandoned” or “endangered” is nonsense. After all, as this news story notes, Dr. Thomas has eight doctors and nurse practitioners who work for him. Surely his partner or the docs who work for him can see his patients while his license is suspended. Unsurprisingly, although his practice does very well and he is anything but poor, Dr. Thomas has started a legal defense fund, the better to milk his antivaccine fans for cold hard cash. Meanwhile, antivaxxer Robert F. Kennedy, Jr. was also rallying the antivaccine troops before this order was published:
In recent years, the Oregon Health Authority has targeted Dr. Thomas by removing his access to the CDC’s Vaccines For Children program, which pays for vaccines for low income families. Providence Health Plan and the Oregon Health Authority’s Oregon Health Plans, which are major health plans, have threatened to drop Dr. Thomas’ insurance coverage, claiming that the practice’s low vaccination rate signifies inferior care. These maneuvers could trigger a domino effect, closing down Dr. Thomas’ practice and leaving thousands of families with no pediatric care.
My response to this is that the closing of Dr. Thomas’ pediatrics practice would not be a bad thing. Quite the contrary. As for the Oregon Health Authority having removed his access to CDC’s Vaccines for Children program, I can’t help but wonder why Dr. Thomas cares, given how little enthusiasm he has for vaccinating according to the CDC schedule.
Meanwhile, Dr. Thomas’ “collaborator” took to video on Facebook:
Unsurprisingly, he starts his rant with COVID-19 disinformation, such as the “casedemic” before pivoting to ranting about the Oregon Medical Board’s action, bragging about their awful aluminum study and RIOV study. Even less surprisingly, he portrays the Board’s action as “a clear retaliation for daring to do science in the United States”. I must admit, I laughed out loud when he said that, given how utterly awful Dr. Thomas’ and his “science” was, but, hey, conspiracy mongerers gonna conspiracy monger. The Medical Board didn’t even mention the studies in its order, and state medical boards generally don’t take action regarding physician licenses based on their publications to peer-reviewed literature, no matter how awful or unethical the study. That’s not their charge, unless something in how the study was done could be proven to be a danger to patients or the public. Lyons-Weiler also pulls the “other patient” gambit because Dr. Thomas also practices—believe it or not!—addiction medicine, a truly frightening thought to me, given that he is an “integrative pediatrics” quack who is antivaccine.
Lyons-Weiler also portrays the suspension of Dr. Thomas’ license as a threat to their trial, to which I was tempted to say, “Good! It’s a scientifically crappy trial designed to generate propaganda and disinformation for the antivaccine movement”. What I’ll say instead is: How? It’s a retrospective study. The data are already there and just need to be analyzed in the manner the investigators stated that they would do. Given that there are 20 years’ worth of data, stopping now is unlikely to make any difference in the number of subjects in the study. Of course, likely Lyons-Weiler knows that, but realizes that his audience does not. He needs a threat, and he needs a hook to ask for money.
You get the idea.
State medical boards: More please!
What the Oregon Medical Board has done with Dr. Thomas (and Dr. LaTulippe) is a very rare occurrence. All too often, after being obtained for the first time medical licenses end up in practice being more like a right rather than a privilege, and it often takes incredible effort on the part of state medical boards to suspend or revoke a physician’s medical license, even quacks like Stanislaw Burzynski, who still has a Texas medical license after 40 years of Texas Medical Board efforts to stop his quackery. Look at Dr. Bob Sears, who did have his license restricted with the condition that he practice under the supervision of the Medical Board of California for three years. The list goes on.
Basically, it’s very difficult in most states (some more than others) for the state medical board to suspend or revoke a physician’s license, which is why many medical boards, by and large, tend to go after mainly the easiest, most obvious cases. That’s why the physician behaviors most likely to result in strong action against a medical license include running a prescription mill, sexual improprieties with patients, or practicing while impaired due to addiction to alcohol or illicit substances. It’s a matter of resource allocation and prioritization. State medical boards tend to react primarily to what they perceive to be the most immediately and obviously dangerous behaviors; most importantly, though, behaviors that can be definitively proven. It’s worse than that, though. In some states, Quacks like Dr. Rashid Buttar still practice and even have enough political influence among legislators to get state laws rewritten to be more favorable to quacks.
That’s why, seeing what the Oregon Medical Board did last week, suspending the licenses of two dangerous doctors in rapid succession, I can only say: More, please.

Florida strikes out against Brian Clement
Jann Bellamy on May 28, 2015
Link


Brian Clement is a charlatan. Unfortunately, that doesn’t seem to be a problem for the State of Florida. I made two (which turned into three) attempts to get the state to take action against Clement or the Hippocrates Health Institute, where he serves with his wife Anna Maria Gahns-Clement as co-director. All of them failed. Brian Clement slithered through the cracks in Florida law each time.
Before we get into the details of Florida’s failure to act, a bit of history (and there is plenty of it) is in order.
In recent months, Clement’s sordid cancer quackery has been well-documented in the media as well as in the science “blogosphere”. (I’ve listed what I hope is a — but almost certainly isn’t — complete blog archive at the end of this post. Many of the Canadian Broadcasting Corporation [CBC] and other news reports are linked in these posts.) Most of the coverage has centered on two Canadian girls suffering from lymphoblastic leukemia whose parents pulled them from conventional cancer therapies, which gave them an excellent chance of survival, in favor of treatment at the Hippocrates Health Institute (HHI), a sprawling spa in West Palm Beach, Florida, licensed as a massage establishment by the state.
Clement gave a talk in Canada, in 2014, claiming “we’ve had more people reverse cancer than any institute in the history of health care.” (“We” is the operative word here, because it later served as Clement’s ticket to avoid prosecution by the Florida Board of Medicine, as you shall soon find out.) The girls’ families were impressed.
Sadly, one of the girls, Makayla Sault, died earlier this year. The other, identified only as “JJ” in the media because of a publication ban, has returned to conventional treatment. However, her mother apparently remains under the influence of Clement: JJ is restricted to a raw foods diet and is still being followed, if that is the right word, by HHI.
Other cancer patients have been lured by the false hope Clement and Hippocrates offer: Stephanie O’Halloran, a young Irish woman, the parents of Anael L’Esperance-Nascimentol, a three-year old Canadian boy who went for treatment there, Laurie Ann Prince, Kathyrn Tachell and Kim Curry, also Canadians and all fairly young, and Lajos Tringer. (Tringer is also considering treatment by another cancer quack, Stanislaw Burzynski.) Most of these either drained their own resources or raised funds, or both, to pay the considerable expense of going to Hippocrates. Unfortunately, we know that Stephanie, Kathryn and Kimhave died. I’ve been unable to discover the fate of Aneal and Laurie Ann. Lajos is, as far as I know, still living, but very ill.
Orac, in his inimitable way, has described the services (for lack of a better term) offered at Hippocrates as “cancer quackery on steroids.”
Let’s take a look again at the sorts of treatments offered by Brian Clement as part of HHI’s “Life Transformation Program“. They include:
    • Superior nutrition through a diet of organically-grown, enzyme-rich, raw, life-giving foods
    • Detoxification
    • Wheatgrass therapies, green juice, juice fasting
    • Colonics, enemas, implants
    • Exercise, including cardio, strength training and stretching
    • Far infrared saunas, steam room
    • Ozone pools, including: dead sea salt, swimming, jacuzzi and cold plunge
    • Weekly massages
    • Bio-energy treatments
    • Med-spa & therapy services
Laughably, Clement claims to be a researcher who is “constantly in a position where I’m addressing medical conferences and universities,” and has “a body of evidential science” which demonstrates why he’s observed “tens of thousands of people recovering from catastrophic disease.” Oddly enough, even though HHI has “the number one ratio of having people reverse the aging process and reverse disease than any other organization in the history of man,” a search of PubMed does not disclose a single journal article published by Clement. Really, Mr./Dr. Clement, we implore you, let the rest of the world in on your ground-breaking discoveries. Publish in a top-flight, peer-reviewed science journal, so more lives can be saved. He also claims that “we’re in the middle of a study with the University of California to disprove genetics.” Maybe that research will show up soon in the medical literature. We can only hope.
With that background, we’ll turn to the State of Florida and its failure to stop Brian Clement, who, as we shall see, has embarked on yet another international speaking tour.
Strike one: Operating a healthcare facility without the appropriate state license
I filed a complaint against Hippocrates Health Institute with the Florida Agency for Health Care Administration (AHCA) for operating a health care facility without the proper state license. (Regrettably, none of the AHCA or Florida Department of Health documents I mention in this post are available online.) AHCA licenses health care facilities, such as health clinics and hospitals. As I did with my complaint against Clement, which we’ll get to in a minute, I informed AHCA that these allegations were not based on personal knowledge, but rather upon Canadian media reports. However, in light of what I had read, I felt an obligation to report Clement and Hippocrates to the state. It appeared to me that the health of these girls and others was at stake and that it was appropriate for the state investigate what was going on.
According to a January 28th email from AHCA:
After some additional Agency research, unfortunately this “Health Center” does not meet the definition of a Health Care Clinic, see [Florida Statutes] Section 400.9905(4),
“Clinic” means an entity where health care services are provided to individuals and which tenders charges for reimbursement for such services, including a mobile clinic and a portable equipment provider.
Since this institute is a cash-only business, it does not fall under AHCA’s regulation. The only recommendation I have, is to file complaints with the Department of Health (Board of Medicine) against the individual doctors, thanks.
In other words, since Hippocrates doesn’t get reimbursed by third party payers, such as health insurance companies, it does not need a license and AHCA had no jurisdiction to do anything about the clinic.
A Senate bill was introduced this year in the Legislature to eliminate this loophole in the health care licensing law.
According to Sen. Eleanor Sobel, one of the bill’s sponsors,
flimflam artists and snake-oil salesmen have escaped state scrutiny by running clinics that accept only cash.
Like Clement and Hippocrates, for example.
It wouldn’t matter anyway. Hippocrates would have been exempted if the bill had become law (it died in committee). The licensing law exempts non-profits. The IRS has granted Hippocrates tax-exempt status as a Section 501(c)(3) charitable organization. A non-profit that, according to its 2013 tax return, paid Brian Clement and his wife, Anna Maria, together about $1 million dollars in salary, bonuses and other unspecified income, has $30 million in assets, and took in over $17 million in revenue.
What Hippocrates does have is a massage establishment license issued by the Board of Massage Therapy, for which it pays the paltry sum of $100 per year. The law seems designed to prevent houses of prostitution from operating as fictitious massage parlors, but rank quackery doesn’t appear to be a problem as far as licensing goes.
Strike Two: Department of Health v. Brian Clement, Case No. 2014-19139
On November 13, 2014, I filed a complaint with the Florida Department of Health against Clement for practicing medicine without a license. (The Medical Quality Assurance [MQA] division of the Department investigates unlicensed practice complaints as well as complaints against licensed health care practitioners.) I explained to the MQA that I didn’t have any personal knowledge about Clement’s conduct, but was reporting him based on news stories covering Makayla’s and JJ’s treatment at Hippocrates, including the report that his degrees were from diploma mills and the fact that he is not a state licensed health care practitioner, although he says he’s an NMD on HHI’s website. I specifically included his statements about “reversing cancer,” Makayla’s grave medical condition at the time (I later reported that she had died) and the fact that HHI was continuing to provide care by analyzing the child’s blood test results which are sent by mail. Later, I spoke to an investigator with MQA and gave her links to the HHI website and to a number of Canadian media reports.
On February 10, 2015, the Department of Health issued a “Notice to Cease and Desist” in the case, stating that:
the Department has probable cause to believe that Brian Clement of Hippocrates Health Institute . . . is not licensed by the Department or the Board of Medicine and is practicing medicine without a license. . . .
Wherefore, . . . Brian Clement . . . is hereby notified to cease and desist from practicing medicine in the State of Florida unless and until Brian Clement is appropriately licensed by the Department.
The Department also ordered Clement to pay a fine of $2 500 and costs of $1 238.
On February 16th, an “Unlicensed Activity Investigative Report” was issued by the Department. As investigations go, it seems pretty cursory. It contains copies of only two of the many news reports and one of the many blog posts. Also attached are printouts from the HHI website detailing the appalling quackery offered there, which seems to have bothered exactly no one at the Department.
An investigator went undercover to an appointment with Clement, which elicited, as might be expected, only quack recommendations (including the sale of merchandise from HHI) but no smoking gun statements to the effect that Clement is an MD or specific medical diagnoses or treatments.
The report says that the investigator did not attempt to obtain a release of patient information authorization from the Canadian girls because “their names were not provided or noted in the Canadian News Release,” even though Makayla’s name is clearly given in one of the news stories attached to the investigative report itself, as well as in links to other information provided by me. And it seems that the Department could have at least attempted to discover the identity of JJ through contacting the Canadian government. After all, the ban is on publication of her name, not giving it to the authorities in another jurisdiction doing an investigation of alleged criminal activity. (Practicing medicine without a license is a felony in Florida and, according to the Department, the Sheriff’s Office was notified, although I have a feeling that one will go nowhere too.)
Another person not contacted was Steven Pugh, RN, who is suing the HHI and Clement over his being fired for refusing to follow Clement’s orders. According to a CBC news report, published well before the investigative report was issued, Pugh maintains he could not legally do what Clement told him because the orders were not issued by an MD. Pugh also reported to the CBC that Clement told patients he could “cure” them, prescribed treatments for them, would overrule what their physicians told them and used the term “Dr.” with patients (as he formerly did on the HHI website). Most disturbingly:
They (Clement and his wife) also placed restrictions on when staff could call an ambulance to take patients for emergency medical care at local hospitals, according to Pugh and other former staff.
According to this same news story, the CBC has interviewed both past and present employees who are disturbed by the Clements’ treatment of cancer patients. It also reports that a former HHI physician is suing for breach of contract, alleging he was terminated after he documented concerns that what he was being asked to do at HHI could be illegal.
A search of the public records (in this case, of the 15th Judicial Circuit Court) would have revealed Pugh’s suit, along with two others, against HHI. You’d think a decent investigation would, at the very least, include a search of the public records of the state doing the investigating.
All of this leads me to conclude that the Department should hire the CBC to do its investigations. They do a much better job.
Much to my surprise, I learned from – you’ll not be surprised – the CBC, that the Department, citing insufficient evidence, had dropped all charges against Clement. I called the Department for more information but my call was never returned. Later, when I called about the Department’s second complaint against Clement (see “Strike three,” below), I was told by a Department official why they couldn’t prosecute Clement for the unlicensed practice of medicine. He explained that HHI has a physician on its staff and, by Clement always using the collective “we” (as in, “we can reverse cancer”), he personally was not practicing medicine.
Since we’re on the subject, HHI has a new physician as Medical Director, Tina Discepola, MD. I wondered what sort of physician would associate herself with an operation like HHI and a guy like Clement, especially in light of their well-publicized troubles. Even if you fully believed in what they were doing, you’d have to be wary of stepping into the hornet’s nest of litigation and on-going investigations by the Department of Health. (Pugh has filed his own complaint against Clement.)
In any event, Dr. Discepola is certainly well acquainted with, shall we say, unconventional medical practices. According to her HHI bio, although board-certified as an emergency medicine doctor, she formerly practiced Functional Medicine in New York. She is also into acupuncture and cranial sacral manipulation. She is a Diplomate of the American Board of Integrative Holistic Medicine, Andrew Weil’s brainchild, a Diplomate of the American Board of Anti-Aging Medicine (also, here) which is not recognized as a specialty board by any of the medical specialty-credentialing organizations, and is an “active member” of the American College for the Advancement of Medicine, ditto.
Curiously, while she holds an active license to practice medicine in Florida, according to the Department of Health’s Practitioner Profile, she still lists New York as her residence and states that she does not practice in Florida. I understand that Dr. Discepola is new to Florida, and is likely unfamiliar with the laws and regulations governing medical practice in this state, but she may want to review them, including the state’s rules on physician advertising.
Dr. Paul Kotturan, the former Medical Director, is still on staff, running the “Vida Building” operation, which must surely contain more quackery per square foot than any other building in the state, including, for example, the Aqua Chi ionic detox footbath, which, if it works as advertised:
Your meridians are permeated and re-aligned back to their original strength and placement.
If there is a medical device equivalent of homeopathy, the detox footbath is it.
Strike three: Dietetics & Nutrition Practice Council v. Brian R. Clement, Case No. 2014-19150
In a letter dated March 24, I learned that this complaint had been reviewed by legal staff and recommended for submission to the next Probable Cause Panel. The complaint was another surprise from the Department for me, because I didn’t even know this particular complaint had been filed until the Department sent me an earlier letter. This time, according to the complaint, it was because Clement illegally used the initials “NMD,” which stands for “Naturopathic Medical Doctor.”
Clement is a licensed nutritional counselor in Florida, but is not a licensed naturopath. (Florida used to licensed naturopaths, but stopped issuing licenses in the 1950s, although the state allowed those with ND licenses to continue their practices. To my knowledge, none of these licensees are still practicing.) As with all types of health care practitioner licensing, nutritional counselors are required to follow certain laws and administrative rules. The complaint alleged Clement violated three separate provisions in advertising himself as an NMD.
Based on this, one might say that the Department of Health is charging Clement with practicing quackery without a license, but that’s not how they see it.
“Nutrition counselors” are no longer licensed in Florida either, but those like Clement and his wife who hold nutrition counselor licenses, can still practice. The state now licenses only registered dietician/nutritionists, who must meet more rigorous requirements than nutrition counselors. (Both are regulated by the Dietetics & Nutrition Council, which operates under the auspices of the Board of Medicine.) Neither of the Clements have the qualifications for the newer license, at the least because they didn’t graduate from an accredited school nor have they taken the current licensing exam.
Nutrition counselors are, by law, limited in their practices to advising people on appropriate nutrition intake by integrating information from an evaluation of nutritional needs, using appropriate data to determine those needs, and making appropriate nutrition recommendations.
It is striking to me that, given the reams of material documenting Clement’s inappropriate nutrition advice, it never occurred to the Department to add a count or two to the complaint for substandard practice as a nutritional counselor. What about wheatgrass, which, as Orac points out, Clement seems to regard as a virtual panacea, and raw foods diets? And what about wheatgrass enemas? Is that an “appropriate” nutrition recommendation?
In the Department’s investigative report, mentioned earlier, we learn that the investigator reviewed the Hippocrates website and confirmed that Clement was using the title NMD. (Gee, notice anything else, Mr. Investigator?) The report notes that Clement had been issued an informal Notice to Cease and Desist in the past for advertising and using the title NMD on the website. Later, when the undercover investigator revealed his true identity, Clement denied using the title “Naturopathic Medical Doctor” on the Hippocrates website, despite all the evidence to the contrary.
Brian Clement no longer uses the honorific “Dr.” nor does he list the initials “NMD” on the website. He still uses PhD on his bio page, and the covers of books advertised at the bottom of the page identify him as being an NMD. He says nothing about where he earned any of the claimed degrees. He has been referred to as “a naturopath” or “Naturopathic Medical Doctor” in a couple of news reports, information they must have gotten from somewhere. (Also: “a formally trained biochemist.”)
Clement has variously claimed his degrees came from University of Science, Arts, and Technology (USAT), where he says he earned his PhD and NMD, and Lady Malina Memorial Medical College, where he says he earned a post-grad degree. (Interestingly, for both Brian and Anna Maria, no undergraduate degree is ever mentioned.) But those institutions have been called out as diploma mills in both a CBC report and academic literature. The president of USAT denies Clement was granted an NMD degree by his school.
Anna Maria Ghans-Clement’s HHI bio say she has a PhD in nutrition from “Denmark University” but I could not find that any such institution exists. It refers to her as “working on her nursing degree,” implying that she has one, but does not say whether the degree requirements were completed. Her book covers also show her as having an NMD and one of her book covers shows the book as being authored by “Dr. Anna Maria Clement.”
Nevertheless, once again, the Department backed off. According to the Department’s letter to me of May 20, the probable cause panel determined that probable cause existed to support prosecution of Clement for allegations set forth in the complaint. However:
after the finding of probable cause, the Department discovered correspondence from [Clement’s] counsel that was not available to the probable cause panel during consideration of the case. As a result of this new information, the Department dismissed the Administrative Complaint due to insufficient evidence to prosecute.
They don’t say what information was “discovered” in this letter. A Department official did tell me in a phone conversation that Clement does, in fact, have an NMD degree and that, while he can’t practice as a naturopath, he is not prevented from using those initials after his name. I informed the official that, to my knowledge, he does not have an NMD degree, information that seemed to surprise him. In fact, the denial was reported by the CBC (yes, them again) in 2014, well before the Department acted.
So, where in the world is Brian now? According to his busy speaking schedule he is, at this moment, at the “Real Truth About Health” conference in Orlando where he is identified as an NMD. Then he is off to New York to lecture. (At the Manhattan lecture, attendees will get 10% off HHI’s three-week “Life Transformation Program,” a “$600 value.” Which means, if you do the math, the three weeks normally costs $6,000.) After that, it’s Europe: Norway, Sweden, the UK (he’s still a naturopath according to one of the London announcements), Ireland, Germany (“Dr. Clement”), France, Switzerland and Holland. The announcements indicate Clement is being circumspect about what he says, but who knows what he’ll do when he actually gets there. Clement doesn’t seem like the type who can resist grandiose pronouncements regarding his many self-proclaimed talents. And, of course, once within the confines of the vast acreage of the privately owned (but taxpayer supported) Hippocrates campus, he is virtually free from scrutiny.
The Brian Clement/Hippocrates Health Institute blog archive
Science-Based Medicine
    • Ontario fails to protect the life of a first nations girl with cancer
    • Brian Clement and the Hippocrates Health Institute finally under the spotlight, but will it matter?
    • An aboriginal girl dies of leukemia: Parental “rights” versus the right of a child to medical care
    • Florida tells Brian Clement to stop practicing medicine
    • Florida strikes out against Brian Clement
    • Brian Clement claims Hippocrates treatments “reverse” multiple sclerosis
Respectful Insolence
    • When false hope leads well-meaning people astray
    • An Ontario court dooms First Nations girl with cancer
    • An Ontario court dooms a First Nations girl with cancer: Who’s to blame?
    • A tale of two unnecessarily doomed aboriginal girls with leukemia
    • J.J. has a chance to live!
    • Brian Clement and the Hippocrates Health Institute: Cancer quackery on steroids
    • Finally, the State of Florida acts against Brian Clement and the Hippocrates Health Institute
    • Wheatgrass quack Brian Clement returns to the scene of the crime in Six Nations
Society for Science-Based Medicine
    • Canadian reporters cover Florida health scam ignored in US
    • Florida retracts cease and desist order and fine against Brian Clement
    • Florida files second complaint against Brian Clement
    • Cancer quack Brian Clement: canceled in Ireland, protested in the UK
    • Cancer quack Brian Clement’s Scadanavian tour goes south
Other blogs
    • The Seduction of Cancer Quackery
    • Hippocrates Health Institute: Five reasons not to spend $4,000
    • Staff of controversial Florida alt med spa sues claiming illegal and unethical practice

Florida tells Brian Clement to stop practicing medicine
Jann Bellamy on March 5, 2015
Link


Note: Also posted today is a brief profile of a new blog, Naturopathic Diaries: Confessions of a Former Naturopath, by Britt Marie Deegan Hermes, a trained naturopath who became disillusioned with her profession. I encourage you to have a look!
The State of Florida has finally taken action against Brian Clement.
David Gorski, Orac, and the Canadian media, especially the Canadian Broadcasting Corporation (CBC), have done an excellent job of chronicling the activities of “Dr.” Clement. All have reported on Florida’s taking action against Clement. I’ll give a brief background here, most of which comes from Dr. Gorski’s most recent post, as well as add some information and observations to theirs.
Hippocrates Health Institute, located in West Palm Beach, Florida, is licensed as a massage establishment by the state and run by Brian Clement and his wife, Anna Maria Gahns-Clement. Clement and Hippocrates came to the attention of the Canadian media when, last year, the families of two Canadian aboriginal girls withdrew their children from conventional cancer treatment, including chemotherapy. Prior to that, Clement had basked in the glory of fawning reports from local media, one of which described him as having an “inimitable, engaging style.” Another described him as coming “fresh from a detoxifying sauna” to the interview.
Had they completed conventional treatment, both girls had a very good chance of survival. The families opted instead for traditional medicine as well as “alternative medicine” at Hippocrates. Each paid a reported $18,000 for participation in a “Life Transformation Program” there. This included, for at least one of the girls, cold laser therapy, vitamin C injections and a strict raw vegetable diet.
Sadly, one of the girls, Makayla Sault, died in January. The other girl cannot be identified due to a court-ordered publication ban, but is referred to as “JJ” in news reports. As of last November, Hippocrates was still providing care for JJ by analyzing blood test results sent by mail. According to her mother, JJ must maintain a raw diet for two years with absolutely no sugar, presumably at Clement’s direction.
In previous statements, Makayla’s and JJ’s mothers identified Clement’s assurances of successful treatment at Hippocrates as the reason they decided to stop conventional cancer treatment. After all, why would any parent pay that kind of money and take her child out of the country had she not been convinced by someone that this considerable effort offered a real possibility of saving her daughter’s life? However, they are now walking back from those statements. The families are claiming that the girls’ trips to Hippocrates were a “family vacation.”
Clement has been fudging on his credentials, referring to himself variously as a naturopathic doctor, an NMD [naturopathic medical doctor] and a Ph.D. He has used the honorific “Dr.” (as recently as last November, on the HHI website) and called himself a “scientist.” But his degrees are from diploma mills. He is correct in claiming he is licensed by the state a nutritionist, a matter we’ll return to in a moment. His bio on the Hippocrates website is more circumspect since his troubles started. He still claims he is a Ph.D and is LN (licensed nutritionist).
Clement has made some wildly exaggerated claims about the effectiveness of treatments offered at Hippocrates. He’s asserts that “thousands and thousands” of people have “reversed” their cancer via Hippocrates treatments. He was recorded on video as saying:
We have the longest history on the planet Earth, the highest success rate on the planet Earth, of people healing cancer.
In response to the question “What ailments have you cured by putting your patients on a vegan diet?” posed on another video, he said:
Every known disease. Of course, we’re most notable for all of the people that have healed cancer.
And, in another video:
We’ve seen thousands and thousands of people reverse stage-four catastrophic cancer.
Medical experts have been widely quoted in news accounts debunking various nostrums offered there. David’s post last week thoroughly deconstructs these treatments:
They include almost every imaginable form of cancer quackery, including “detoxification,” colonics, wheatgrass, ozone pools, “bio-energy treatments,” the aforementioned “Cyber Scan,” and, of course, the Aqua Chi “detox footbaths.” One particularly silly treatment offered by HHI is called a “wheatgrass implant”, which, it turns out, are actually wheatgrass juice enemas. Indeed, if you believe the hype on the HHI website, there’s nothing that wheatgrass can’t do. If the HHI is to be believed, wheatgrass can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many other fantastically beneficial alleged effects. Basically, combine a raw vegan diet with a veritable cornucopia of other kinds of quackery, and you have the HHI.
Unlicensed practice
Practicing any licensed health care profession without the appropriate license is a third-degree felony in Florida, with a penalty of up to 5 years in jail and a $5,000 fine. It is subject to administrative sanctions as well, such an order to cease and desist and a fine. According to the Florida Department of Health (DOH):
The Unlicensed Activity (ULA) program protects Florida residents and visitors from the potentially serious and dangerous consequences of receiving medical and health care services from an unlicensed person. The ULA unit investigates and refers for prosecution all unlicensed health care activity complaints and allegations.
The ULA unit works in conjunction with law enforcement and the state attorney’s offices to prosecute individuals practicing without a license. In many instances, unlicensed activity is a felony level criminal offense. More importantly, receiving health care from unlicensed people is dangerous and could result in further injury, disease or even death.
And:
investigations involving the unlicensed practice of a healthcare profession are criminal investigations that require the development of sufficient evidence (probable cause) to present to law enforcement or file charges with the State Attorney’s Office in the county of occurrence.
Florida law defines the practice of medicine as:
the diagnosis, treatment, operation, or prescription for any human disease, pain, injury, deformity, or other physical or mental condition.
Last November, I filed a complaint against Brian Clement for the unlicensed practice of medicine with the DOH. I also filed a complaint against Hippocrates Health Institute with the Florida Agency for Health Care Administration (AHCA) for operating a health care facility without the proper state license. AHCA licenses health care facilities, such as health clinics and hospitals. As I stated in the complaints, these allegations were not based on personal knowledge, but rather upon Canadian media reports. However, in light of what I had read, I felt an obligation to report Clement and Hippocrates to the state. It appeared to me that the health of these girls and others was at stake and it was appropriate for the state investigate what was going on.
The AHCA complaint was resolved first, with a surprising result. According to a January 28th email from AHCA:
After some additional Agency research, unfortunately this “Health Center” does not meet the definition of a Health Care Clinic, see [Florida Statutes] Section 400.9905(4),
“Clinic” means an entity where health care services are provided to individuals and which tenders charges for reimbursement for such services, including a mobile clinic and a portable equipment provider.
Since this institute is a cash-only business, it does not fall under AHCA’s regulation. The only recommendation I have, is to file complaints with the Department of Health (Board of Medicine) against the individual doctors, thanks.
In other words, since Hippocrates doesn’t get reimbursed by third party payers, such as health insurance companies, it does not need a license and AHCA had no jurisdiction to do anything about the clinic.
Interestingly, by not accepting insurance, Hippocrates avoids the usual limitations on insurance reimbursement for unproven treatments, typically deemed “experimental” in insurance policies and therefore not covered. It is thus able to escape any scrutiny a health insurer would normally apply to the treatments offered there, scrutiny that might otherwise raise suspicions among its clients when their insurance claims were denied.
The other complaint against Clement met with more success. On February 10th, I learned that DOH had taken action. First, DOH issued a Notice to Cease and Desist, saying
The Department has probable cause to believe that Brian Clement of Hippocrates Health Institute . . . is not licensed by the Department or the Board of Medicine and is practicing medicine in violation of [state law]. The practice of medicine without an active, valid license or permit is strictly prohibited [by law] and constitutes a crime.
Wherefore, in accordance with [state law], Brian Clement . . . is hereby notified to cease and desist from practicing medicine . . . unless and until Brian Clement is appropriately licensed by the Department.
An event that, we can safely assume, won’t take place.
It goes on to state that, if he violates the Notice, DOH can seek a court order to stop the violation and recover attorneys’ fees and costs.
DOH also issued a citation in the amount of $3,738 ($2,500 fine plus costs) for practicing or attempting to practice medicine without a license.
There is no right of appeal from the cease and desist notice but he can challenge the citation. Clement can request an administrative hearing within 30 days. This means he would have an opportunity to introduce testimony and evidence on his behalf before an Administrative Law Judge. The state, of course, would introduce testimony and evidence supporting the citation. If he loses, he can file an appeal to a state appellate court. If he does not challenge the citation, he would not get a hearing and the citation becomes a final order of the agency. However, he can still get another crack at it by filing an appeal, although his ability to argue against his being cited would be greatly limited.
According to Clement’s PR person, to whom we’ll return in a moment,
We deny these allegations from the Department of Health in their entirely and are vigorously contesting these allegations through the administrative process.
So it looks like Clement will be requesting a full administrative hearing.
DOH also notified Clement that
THE CITATION DOES NOT PREVENT OTHER ADMINISTRATIVE, CIVIL OR CRIMINAL PROSECUTION INVOLVING THE SAME FACTS AS USED IN THIS AGENCY ACTION.
And indeed, the investigative report states that DOH notified the Palm Beach County Sheriff’s Office about the matter on February 13th. Prosecution would be handled by the State Attorney.
In the investigative report accompanying the citation and notice, we learn that the DOH investigator reviewed the Hippocrates website and confirmed that Clement was using the title NMD. The report notes that Clement had been issued an informal Notice to Cease and Desist in the past for advertising and using the title NMD on the website.
The report says that the investigator did not attempt to obtain a release of patient information authorization from the Canadian girls because “their names were not provided or noted in the Canadian News Release.” This omission is curious because Makayla’s name and location were in several news reports and I mentioned her as well in my communication with DOH.
We also learn that a DOH investigator, who also reviewed the website and media reports, went undercover to Hippocrates on February 10th for an appointment with Clement, using an assumed name. He discussed his (unidentified) medical condition with Clement who gave him a “menu.” Based on the exhibit referred to in the report, this menu is a handwritten list, as follows:
Lifegive [a brand sold by Hippocrates] internal cleanser
2 AM, 2 PM
Mon, Wen, Fri, Sun
Lifegive B12
1 every morning
Pollen, teaspoon AM, PM
Quinoa Burger
Rice Pasta
Non Soy Burgers
Amy [brand?] Dinners
All Grains
Clement asked the investigator to provide a copy of his blood screen results; presumably, the blood screen was done prior to the appointment. Clement also gave the investigator a “specimen collection box” and told him to forward a sample to the company listed on the box. An attached exhibit shows a “fecal collection specimen box.” According to the report, Clement didn’t diagnose the investigator but said that the Hippocrates “medical team would review” his file.
Later, when the investigator revealed his true identity, Clement denied using the title “Naturopathic Medical Doctor” on the Hippocrates website despite his earlier run in with DOH for that exact thing.
A letter from DOH dated February 23rd notified me that “Dietetics & Nutrition Practice Council v. Brian R. Clement” was under review and, after an investigation, the DOH’s attorneys would look at the case and make a recommendation to the probable cause panel of the Council. (The Council operates under the auspices of the state medical board.) Although it is not clear, it appears as if DOH views me as the complainant in that case as well although my complaint did not include any allegations specifically regarding his nutritional counselor license.
Clement does hold a “clear/active” license to practice as a nutrition counselor. Florida no longer licenses nutrition counselors but they were grandfathered in under a newer law licensing dietetics/nutritionists, who have a broader scope of practice. Because they are no longer licensed, the statute does not tell us what the original educational and training requirements were.
By law, nutrition counselors can evaluate a person’s nutrition needs:
using appropriate data to determine nutrient needs or status and make appropriate nutrition recommendations.
One would assume that “Lifegive internal cleanser” and pollen are not an “appropriate” nutrition recommendation but I do not know if that is the basis of the complaint. It could be that his credentials were not in order when he applied.
Other legal problems and a PR offensive
According to media reports, Clement’s troubles with DOH are not his only legal problems. A complaint filed against Hippocrates with the Federal Trade Commission remains open. Several former employees, including the former director of nursing and an MD, are suing him over allegations that they were fired when they expressed concerns about Clement and other employees practicing medicine without a license. One RN alleges he was fired for refusing to follow Clement’s orders, which could be legally given only by an MD.
It is interesting that the Board of Directors of Hippocrates has not, to my knowledge, asked Clement to step aside pending resolution of these legal troubles, if not outright fire him. They would certainly be within their rights to do so absent some contractual arrangement with Clements that nixes his being ordered to stop practicing medicine as a firing offense, which is unlikely. It makes one wonder how closely the Board is overseeing the operations at Hippocrates.
Clement and/or Hippocrates have hired a top Florida PR firm to help handle the media heat. One can hardly blame them, considering the fact that Clement’s media interviews were just making him look like, well, like himself. Vicki Johnson, the PR firm’s VP, accused the Toronto Star of taking Clement’s “thousands and thousands” statements “out of context.”
As (Clement) has repeatedly emphasized, what Hippocrates does is educate people about the benefits of raw foods and exercise, and how a healthy lifestyle arms the body to fend off disease and in many cases heal itself.
Johnson might want to consider relying on medical information from someplace other than Hippocrates before she speaks to the media.
Johnson claims that all blood tests are administered by a medical professional and reviewed by the medical director. All Clements and his wife do is review the “guest’s” health history, including blood tests, to make nutritional recommendations. She says the medical director is responsible for all medical decisions. As the article points out, Hippocrates houses as many as 100 people at a time but has only one licensed medical director, Dr. Paul Kotteran. Sounds like a busy guy.
Johnson also challenged criticisms from a former Hippocrates employee who accused Clement of getting “as much money as possible” from deathly ill people:
He has dedicated his life to the health and well-being of his guests . . . Hippocrates grants thousands of dollars’ worth of scholarships to guests on an annual basis.
Lucky them.
Clement himself has also denied as “erroneous” a 2013 tax return filed with the IRS reporting his income as $529,000 and his wife’s at $432,000. We’ll see if an amended tax return is filed, as is required by federal law.
Clement and Hippocrates are clearly in the sights of the media and the blogosphere. The lawsuits by employees, the FTC action, the Florida Department of Health’s continuing investigation and the possibility of criminal charges will all be followed. Too bad Clement and Hippocrates have been able to successfully rake in millions of dollars by scamming so many people, some of whom died after they withdrew from conventional treatment, before the state decided to act.
What will be the actual effect of the Notice to Cease and Desist and Citation on Clement? That remains to be seen. Neither requires that the quack treatments or sales pitches to gravely ill people and their families be stopped. Hippocrates can continue to operate as a “massage establishment.” Clement will not suffer any penalty (other than the citation) for what he has done unless the FTC or state attorney take action. Any recovery in the suits brought by employees would go to them, not to the families of those who stopped treatment and died. Hopefully, the FTC and the state attorney will act to ensure more people don’t die because they abandoned conventional treatment for quackery.

Personal Belief Exemptions for Vaccines
Steven Novella on March 4, 2015
Link
Positive change not only requires a valid argument, it requires political will. My colleagues and I have been pointing out for years that vaccines are safe and effective, and the anti-vaccine movement, which is built largely on misinformation, threatens the public health by eroding herd immunity. These arguments are no more valid today than they were five or ten years ago (except that new scientific evidence continues to support our conclusion).
We also predicted that it will likely take the significant return of vaccine-preventable diseases to muster the political will to effectively push back against the anti-vaccine movement. Parents need to be more afraid of infectious disease than the false fearmongering surrounding vaccines. We, of course, did not want this to happen, we just thought this was a likely scenario.
I did not think, however, that it would be so sudden and dramatic. The Disneyland measles outbreak created an undeniable media and popular backlash against the anti-vaccine movement. Recent evidence for this is the Jimmy Kimmel segment in which he blasted anti-vaxxers and showed a fake PSA in which real doctors express their frustration over vaccine refusers. Anti-vaxxers replied with their usual shrill nonsense, comparing Kimmel’s statements to hate speech and falsely accusing him of attacking autistic children. Kimmel responded with still more ridicule, making a mockery of anti-vaxxer tweets attacking him. Being the butt of late night comedian jokes is a reasonable sign of popular backlash.
Popular opinion, which is turning against vaccine refusers for threatening the public health, translates into political will. In the case of vaccines there is a specific focus for this political will – state laws allowing exemptions from the requirement for children to be up to date on their vaccines in order to attend public school.
All 50 states require vaccines to enter public school, and all 50 states allow for medical exemptions. Medical exemptions are not controversial; some children have medical conditions that do not allow them to be vaccinated. Their numbers are small enough that they can be protected by the herd if a sufficient number of the rest of the population are vaccinated. In fact, these sick children depend upon herd immunity.
Every state except Mississippi and West Virginia allow for religious exemptions. In the 1944 Prince v. Massachusetts case, the Supreme Court ruled:
The right to practice religion freely does not include liberty to expose the community or the child to communicable disease or the latter to ill health or death.
Ideally there would be no non-medical exemptions to vaccines. There is no legal requirement for such exemptions, and I think there is a solid case that such exemptions are not ethically defensible. Politically, however, religious exemptions specifically will be difficult to eradicate.
Twenty states allow for exemptions from vaccines based on personal belief (called philosophical or personal belief exemptions). These laws create a very low bar for parents to obtain an exemption. Often they simply have to check a box stating they don’t want to vaccinate their children, and that is sufficient. States with philosophical exemptions have 2.5 times the vaccine refusal rate as states with religious exemptions only. Essentially, the easier it is to obtain a vaccine exemption, the lower the vaccination rate. We have 50 data points showing this correlation. The state with the highest vaccination rate is Mississippi, which is close to 100% and allows for no vaccine exemptions beyond medical exemptions.
It would therefore aid vaccine compliance and herd immunity to make obtaining a vaccine refusal as difficult as possible, or simply impossible by removing them altogether. We seem to have reached a critical level of public understanding of this issue, and state lawmakers are responding by introducing bills that will reduce or eliminate non-medical vaccine exemptions. This would be a concrete step that would directly protect the public health.
Here is a list of 14 states that have recently introduced bills that would reduce or eliminate vaccine exemptions (the list may not be exhaustive). Among them is the home state of Disneyland – California. State Senator Richard Pan, who is a medical doctor, introduced the bill, which now has 26 sponsors, which apparently means it is likely to pass. As the law is currently written it would eliminate all non-medical exemptions. This may change, however, before the bill is passed.
Anti-vaxxers, of course, are firing back. The tide is turning heavily against them so they are turning up their shrillness generators to maximum. Fortunately I think this is serving only to marginalize them even further, as the Jimmy Kimmel episode demonstrates. One of their strategies is to characterize vaccine requirements as “forced vaccinations.” They want to conjure images of officers pounding down your door, holding down your child, and vaccinating them by force. This, of course, is absurd. Vaccinations are only required to attend public school. Parents can still avoid vaccination by homeschooling their children or sending them to private school (although some states require vaccinations for homeschooling as well).
Arguments based on parental rights are losing steam as the public realizes that children with medical exemptions from vaccines and their parents also have rights. Parents are saying, “your right to think that you know better than the medical community does not trump my right to protect my child from communicable diseases.” Again, humor is a good barometer of public opinion. The satirical paper, The Onion, captured this feeling perfectly with an article titled “I Don’t Vaccinate My Child Because It’s My Right To Decide What Eliminated Diseases Come Roaring Back.”
Even worse, anti-vaccine “paleo” doctor, Jack Wolfson displayed the callous face of the anti-vaccine movement when he had his 15 minutes of fame. In an interview he stated:
I’m not going to sacrifice the well-being of my child. My child is pure. It’s not my responsibility to be protecting their child.
If asked if he would feel bad if a sick child with a medical exemption caught measles from his child and died, he replied:
I could live with myself easily. It’s an unfortunate thing that people die, but people die. And I’m not going to put my child at risk to save another child.
His words did a better job of exposing the anti-vaccine movement for what it is than any commentary or criticism from the medical community.
Now is therefore the time to increase our efforts. Public opinion and the political will are there to reduce vaccine exemptions, increase vaccination rates, and protect the public health. Public and political will, however, is a fickle thing.

Stanislaw Burzynski

Stanislaw Burzynski: Using 1990s techniques to battle the FDA today
In the 1990s, cancer quack Dr. Stanislaw Burzynski and his lawyer Richard Jaffe perfected a PR strategy in which patients who believed that Burzynski had saved their lives would protest and, often aided by friendly legislators, beg the FDA (or whatever regulatory body was trying to stop Burzynski’s abuses at the time) not to let them die. It was very effective political theater, which is why Burzynski is using the same strategy today against the FDA.
David Gorski on January 20, 2014
Link
It figures that I couldn’t go three weeks into 2014 without the topic of Stanislaw Burzynski rearing its ugly head. I had hoped to make it to February or even beyond before feeling the gravitational tug of the wretched hive of ignominious and unethical behavior, but here we are, only 20 days into the new year. So be it.
2013 finished with serious setbacks for Stanislaw Burzynski and his unproven cancer treatment that he dubbed “antineoplastons” (ANPs) way back in the early 1970s. As you might recall, in November, two things happened. First, the FDA released its initial reports on its inspection of the Burzynski Clinic and Burzynski Research Institute (BRI) carried out from January to March 2013. They were damning in the extreme, pointing out the shoddy operating methods of the institutional review board (IRB) used by the BRI to approve and oversee Burzynski’s “clinical trials” (and I use the term loosely) of ANPs. Violations included using expedited approvals to review single patient protocols, something so far outside the purview of what the expedited approval process was intended for, namely approving minor tweaks to human subjects research protocols without requiring a full meeting of the IRB, that the FDA called Burzynski out for it. Other violations included failure to report serious adverse events (SAEs) and adverse events (AEs) to the FDA and/or the IRB, failure to follow proper informed consent procedures, failure to determine that risks to subjects were minimized and that risks to subjects were reasonable in relation to anticipated benefits, if any, and a lot of other violations, which are listed in my previous post on the subject.
Later in November, Liz Szabo of USA TODAY published a fantastic expose of Burzynski entitled “Doctor accused of selling false hope to families,” in which, in addition to many of the violations revealed by the FDA, it was further reported that the child whose death in the summer of 2012 triggered the FDA investigation was Josia Cotto, and that the child died of hypernatremia (elevated sodium levels in the blood) caused by ANP therapy. In response to the reports of shoddy record keeping, lack of ethics, and contributing to the death of a child, Burzynski was his characteristically cuddly self, referring to his critics as “hooligans” and “hired assassins,” while claiming that they “pretend they got sick and would like to extort money from us.” When last I wrote about Burzynski in November, his empire was struggling to strike back. Eric Merola, the film maker responsible for two pro-Burzynski propaganda movies Burzynski: Cancer Is A Serious Business and Burzynski: Cancer Is A Serious Business, Part 2, likened USA TODAY to everything from Nazi propaganda under Joseph Goebbels, to slave masters, and to the Westboro Baptist Church protesting at the funerals of gay soldiers killed in the line of duty. Meanwhile Burzynski himself tried to answer the FDA findings and failed miserably, nor did his poster presentation of singularly unimpressive results at the Society of Neuro-Oncology Meeting right before Thanksgiving help. The year ended with the Texas Medical Board using the FDA’s findings as part of the basis of charging Burzynski with false advertising, meaning that Burzynski will be spending a lot of time defending himself against the TMB in 2014.
Unfortunately, beginning in December, Burzynski and his allies decided to go back to the future, so to speak (or maybe just back to the 1990s) and resurrect the campaign that worked so well for them the last time Burzynski’s back was against the wall. Unfortunately, this strategy, rooted as it is in using cancer patients to lobby Congress to force the FDA to allow Burzynski to use antineoplastons, could work. Pro-Burzynski forces, in a nod to the past, have even hired the same lobbyist who, or so it is claimed by the pro-Burzynski forces, succeeded so brilliantly in the mid-1990s in persuading Rep. Joe Barton (R-TX), then the chair of the House Subcommittee on Oversight and Investigations, to “investigate” the FDA’s “harassment” of Burzynski.
Using patients as human shields and missiles
If you want to understand Burzynski’s new strategy to keep using ANPs, you have but to go back and examine his previous strategy, which was to milk dying cancer patients for every bit of human sympathy they can evoke from lawmakers and the public. I realize that the way I chose to phrase that might be offensive to some readers, but how Burzynski has cynically exploited the sympathy we all feel for children dying of incurable brain tumors offends me, and he’s at it again. For example, there is the case of MacKenzie Lowe, a 12-year-old girl with an inoperable brain tumor whose story, entitled Child Cancer Patient Petitions For Brain Tumor Treatment Not Yet Approved By The FDA was published in The Huffington Post at the end of November:
Last Thanksgiving, 12-year-old McKenzie Lowe was diagnosed with an inoperable brain tumor. Her family is petitioning New Hampshire’s governor to allow McKenzie to undergo Antineoplastons therapy, a treatment not approved by the FDA. The FDA has allowed 471 “compassionate use” exemptions to date, and McKenzie’s grandfather, Frank LaFountain, hopes she’ll be next in line.
“We’ve talked to survivors of this drug, who had the same condition McKenzie has,” he told HuffPost Live host Nancy Redd. “People say there aren’t any, but we know them. We’ve talked to them, and that’s what makes us so passionate about getting her this particular drug.”
And here’s the video:
Only a heartless bastard could fail to be moved by McKenzie’s story, which is, sadly, typical for pediatric patients with brain cancers. HuffPo pulled out all the stops to emphasize McKenzie’s cuteness and what a nice girl she is, while buying completely into the propaganda line that the Burzynski Clinic promotes.
It pained me to watch that video. It really did. But it also made me angry. Once again, Burzynski is offering false hope to families of cancer patients, and HuffPo deserves nothing but opprobrium for promoting the Change.org petition, which Eric Merola, producer of two propaganda “documentaries” for Burzynski is also promoting. As desperate as McKenzie’s situation is, Burzynski can’t help her. However, her family can help him, most likely unwittingly, by changing the narrative from a doctor without any training in internal medicine or oncology who is utterly unqualified to treat patients with advanced cancer who has cynically sidestepped the FDA and the Texas Medical Board for nearly 37 years while abusing the clinical trial process to keep giving a toxic, almost certainly ineffective chemotherapeutic agent to patients. And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise.
The Change.org petition for McKenzie Lowe, as well-meaning as its sponsors seem to be, is exceedingly misguided. The Friends of McKenzie Lowe are petitioning FDA Commissioner Margaret Hamburg to grant a compassionate use exemption for McKenzie so that Burzynski can treat her with ANPs. Recall that one of the very offenses that got Burzynski into hot water with the FDA was his investigational review board’s (IRB) history of playing fast and loose with single patient use protocols, in which patients were approved through the expedited approval process, which was never intended to be used for this purpose. Putting patients on compassionate single patient use requires full approval by the entire IRB. In essence, this petition is asking the FDA Commissioner to ignore those findings and let Burzynski do it again for McKenzie Lowe. One also wonders whether the Lowes know other things about Burzynski. For instance, the FDA found that he had destroyed original patient records and, most importantly of all, misclassified partial and complete responses. Suffice to say, Burzynski’s explanations are underwhelming and unconvincing.
Finally, there is the oft-repeated claim that Burzynski is the only person who has ever cured the cancer that McKenzie has. These days it is Burzynski’s favorite line, a line often parroted by his minions, particularly Eric Merola. Would that it were true! What Burzynski proponents can’t understand is that I would be very happy if there were a treatment that could actually cure children with diffuse intrinsic pontine glioma (DIPG). As I’ve discussed many times before, nearly all of Burzynski’s “cancer cure” testimonials, when examined more closely, are highly dubious with respect to whether it was actually ANPs that cured the tumor, with not a single one of them being particularly convincing when examined closely. Either there’s insufficient information (i.e., the timeline is vague), or there exists the possibility of misdiagnosis, or the mistaking of the natural reversal of pseudoprogression for an actual antitumor effect. Moreover, brainstem gliomas in children are a heterogeneous group of tumors. Moreover, many of these tumors aren’t biopsied because of their location, and are usually diagnosed by their appearance on MRI. However, MRIs, as discussed in the case of Tori Moreno, can sometimes find masses that look for all the world like tumors but aren’t. Moreover, contrary to Burzynski’s claim, there are occasional long-term survivors, some of whom received little or no therapy, such Connor Frankenberg, a child from Germany, and two patients who underwent spontaneous remission. (Yes, I know that one of the children listed is a Burzynski patient, Tori Moreno. One notes that the DIPG Registry does not mention Burzynski or ANPs at all.)
The DIPG Registry concludes that, although the vast majority of children with DIPGs do poorly:
The bottom line is: 1) we really don’t understand DIPGs, and 2) there are children who have been diagnosed with DIPGs-based on the incomplete knowledge that we currently have- who truly have had spontaneous regression of their tumors and 3) most of the children with reports of spontaneous regression have been very young.
The big problem is that, like many dubious cancer doctors, Burzynski appears not to keep good enough records to demonstrate one way or the other whether he can cure DIPG, and we already know he misclassified partial and complete responses. In brief, DIPG is a horrible disease, with only 10% surviving beyond two years, and there is no convincing evidence that Burzynski can do any better than conventional oncology, much less cure DIPG, as much as he repeats the claim that he can. Worse, he hasn’t published a single one of his completed phase II clinical trials, even though he’s had well over 15 years to complete them. With tumors this lethal, most such trials should be completed within five years.
Unfortunately, Mackenzie Lowe isn’t the only such patient being used by Burzynski’s minions. Unfortunately, now there are now at least two more.
First up, there is a Jewish boy in Houston named Raphael Elisha Cohen:
Then, the unthinkable happened. A series of symptoms in the couple’s young son, Raphael Elisha, led to the diagnosis of medulloblastoma, an aggressive form of cancer of the brain and spine. Initially, the now-6-year-old underwent surgery to remove as much of the brain tumor as possible, followed by radiation and chemotherapy.
Unfortunately, Cohen’s tumor recurred in September 2012. After this, the story became sadly familiar. Well-meaning people set up a fund to send Raphael Elisha to Houston for treatment by Stanislaw Burzynski, as described in this article:
The Cohen family, of Houston, TX, is facing a battle none of us should have to go through – aggressive brain cancer in their 6-year old son Refael Elisha. Having recently received the devastating news from their doctors that “there is nothing more we can do for him,” the Cohens are turning to a last resort – Antineoplaston Therapy at the Burzyinski clinic. However, the FDA pulled their approval for this treatment in 2012 pending further clinical trials. We are told that the FDA is nearing approval to resume this treatment, but Refael Elisha does not have time to wait.
The FDA has the power to approve a “compassionate use exemption” so Refael Elisha can undergo this therapy to try and save his life.
We are asking the FDA to grant this exemption so we can continue to fight for his life.
Several other stories were written, including this story and a blog post by Ariela Davis for the Times of Israel that gave Cohen’s story international attention. Here’s the Whitehouse.gov petition, which uses language very similar to what is quoted above.
This sort of thing infuriates me, because it really does appear as though the Cohen family is being lied to. According to this editorial, the Cohens are aware of Burzynski’s reputation. However, obviously either Burzynski, Eric Merola, or someone from the Burzynski Patient Group has been feeding them “success stories.” As I’ve explained time and time again, these “success stories” appear compelling on the surface, but if you look at them with a knowledge of how cancer progresses and how cancer treatments work it rapidly becomes apparent that they are not evidence that Burzynski’s antineoplastons can do any better against deadly cancers than conventional therapy. Think Hannah Bradley and Laura Hymas. Think Mary Jo Siegel. Think Tori Moreno. It seems as though Burzynski cured these patients, but he almost certainly did not.
In addition, Burzynski has apparently been telling patients that the FDA is “nearing approval to resume” his clinical trials almost ever since the FDA imposed a partial clinical hold on Burzynski’s antineoplaston trials in the summer of 2012. That partial clinical hold meant that no further children could be enrolled on any of Burzynski’s clinical trials. Later, in early 2013, that partial clinical hold was extended to adults. Patients who were already receiving antineoplastons could continue to receive them, but no new patients could be enrolled in Burzynski’s clinical trials. Ever since then, Burzynski’s been dangling the hope that the FDA would lift the partial clinical hold. Now, apparently, he’s using those patients to try to get the attention of the White House, and in Cohen’s case he has been very successful.
Raphael Elisha is not alone, however. There’s an adult who is also going down the same road. This adult happens to be the wife of Sammy Hagar’s drummer. She is 46 and was diagnosed with an inoperable brainstem glioma. Her name is Liza Cozad, and to send her to the Burzynski Clinic there’s a Give Forward campaign. Her Change.org petition asks for the same thing as MacKenzie Lowe and Elisha Cohen’s families are asking:
Six months ago, Liza was diagnosed with a deadly brainstem tumor – called a DIPG – it rarely strikes in adults (only about 20 in the U.S. each year) but is unfortunately common among brain tumors in children – and just as deadly – a year to a year and a half to live. No doctor can perform surgery to remove due to its location, chemo has consistently shown to be ineffective on Liza’s type of tumor, and even the radiologist tells her her best case scenario with radiation is it would return in 1-2 years, more aggressively, and they could no longer radiate. There is one drug that could save Liza’s life. The drug – ANP – has been approved for Phase III clinical trials by the FDA. This means it has been deemed safe (Phase I trials) and effective (Phase II trials). The FDA has continually denied Liza’s request for the treatment under a Single Patient Protocol (the FDA format under which she could be approved), saying they have questions for the manufacturer about the drug based on one patient out of hundreds’ response to sodium levels. They have cotinued [sic] with this for a year – each time the manufacturer answers all their questions, the FDA keeps coming back with more – all the time denying any new patients – including Liza – from receiving this drug the FDA has itself acknowledged to be safe and effective. This precious and caring young woman has been fighting her fight since April, but her health is declining. This drug has a documented 27% success rate on her exact kind of tumor – which is 27% better than her odds with all standard therapies – and with some children still cancer-free over 20 years later.
Recently Cozad and her husband posted a video appeal to YouTube:
There is, of course, no evidence that Burzynski has a 27% success rate in treating DIPG, but the video is heartbreaking. Her story is depressingly familiar to those of us who know about the Burzynski saga. After being given the diagnosis and told that radiation would only delay progression of the tumor, she went on the Internet and, as all too many patients with inoperable brain tumors do, found Stanislaw Burzynski. In her desperation, as all too many cancer patients have, Cozad latched on to the false hope that Burzynski offers. As so many of Burzynski’s patients have done, they talked to Burzynski’s “success stories,” who, being convinced themselves that Burzynski saved their lives when he almost certainly didn’t, convinced Cozad and her husband that Burzynski was the only one who could save her life.
These are the patients are petitioning various Senators and Representatives to lean on the FDA to grant the compassionate use exemption. This is what those of us who want to protect cancer patients from this sort of predation are against, parents of children with cancer who have been convinced that Burzynski is their family member’s only hope. What human being doesn’t have difficulty saying no to such an appeal, even when he knows the family’s desperation has led them down a dark path to viewing Burzynski as the only man who can save their loved one? That they are wrong is almost beside the point. What politician can say no to such an appeal? At the very least, they will look into it and put pressure on the FDA. Meanwhile those of us who stand up and say no, who try to point out that Burzynski can’t save these patients, that they are being used by him so that he can re-open his ANP clinical trials, are pummeled with arguments like the one by Randy Barnes that we should “respect the parents’ choice.” After pointing out that he is “not a fan” of the Burzynski Clinic, and “agrees with many of the criticisms leveled at Stanislaw Burzynski and his treatments,” he asserts that “Raphael Elisha’s parents are the only ones with the right and responsibility to make the best decisions they can in a horrible situation that no one who has not faced the loss of a child can possibly understand.” He then concludes:
If you choose not to sign the petition that is fine, but please, allow the Cohens the dignity they deserve by respecting their right to make the choices they deem fit for their child. Publicly fighting the Burzynski Clinic in Raphael Elisha’s name will only bring more pain to an already suffering family.
This is the argument we’re up against as well, an argument that is every bit as invalid as when it is used to defend, for example, the family of Sarah Hershberger for relying on quackery instead of chemotherapy to treat a deadly lymphoma. We can respect the parents’ decision, to the extent that they are the parents. We can try to understand the desperation that led them to it, even though they are aware of all the criticisms of Burzynski. Most parents can only imagine how they would react under similar circumstances. Even I couldn’t guarantee that I wouldn’t be tempted by the blandishments of Burzynski and his followers if I were in the same position as the Cohens. However, sympathy and respect do not equal agreement, nor do they require us to acquiesce and just “shut up” when the Cohen’s grief and desperation lead them to do something profoundly harmful to public health, to use the power of their story to persuade lawmakers to call off the FDA.
The Alliance for Natural Health joins the fray
Right after the holidays, one of the most prominent pro-quackery advocacy groups in the country, scourge of any legislator trying to regulate supplements or “natural medicine,” the Alliance for Natural Health USA (ANH-USA) launched a series of articles urging its members and followers to write to their legislators to lean on the FDA to allow Burzynski to treat patients under compassionate use protocols:
    • Exclusive: Inside USA Today’s Smear Campaign Against Dr. Burzynski
    • Dying Patients Denied Access to Dr. Burzynski’s Potentially Lifesaving Treatment
If you want to understand how much contempt the ANH-USA has for its audience, I’ll show you briefly through one passage from one of these articles. The ANH-USA complains that Liz Szabo:
Cites the lack of published random-controlled trials (RCTs) as evidence of antineoplastons’ uselessness, while omitting the fact that the efficacy of the treatment has recently been confirmed by a randomized, clinical trial by Japanese researchers. And of course ANH-USA has repeatedly had to point out that RCT’s are enormously expensive. Nobody but drug companies can afford them, and they will usually only undertake them if the treatment is under patent and therefore a government enforced monopoly. In addition, there is growing evidence that RCTs, particularly in the context of individualized treatments, should no longer be considered the “gold standard” for drug efficacy.
Of course, this is the same nonsense Burzynski’s been peddling for the last couple of years about a vaporware randomized clinical trial carried out by Hidaeki Tsuda in Japan. This trial featured prominently in Eric Merola’s second movie. Unfortunately, although the trial sounds interesting as described in Merola’s movie, it has not yet been published. Now take a look at the article linked to in the ANH diatribe. It was published in Oncology Reports (not the greatest of cancer journals) entitled “Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells”. Do you notice something? I did, immediately. More accurately, I didn’t notice something, and that something was a clinical trial. This is nothing more than yet another in vitro study, and it’s not even that compelling of one, given that it uses enormous concentrations of AS-2, 2 mg/ml, way higher than is likely to be achievable in the bloodstream, even using the massive doses of ANPs that Burzynski advocates using. Yes, Burzynski really does have that much contempt for you that he tries to pass off an in vitro study as a clinical trial.
The rest of the ANH-USA’s attacks are largely nothing more than regurgitations of past Burzynski excuses and attacks. For example, in one article the ANH-USA twists the cases of Liza Cozad and McKenzie Lowe to its own ends, all but saying that the FDA is evilly laughing and twirling its metaphorical mustache as Cozad and Lowe die, as USA TODAY dutifully promotes the agenda of its pharma masters and the FDA. Hilariously, there was a third article claiming that the FDA violated patient privacy by providing Szabo with medical records of a patient without the parents’ permission. If you click on the link now, there’s nothing there. The article has apparently been taken down. There are, however, multiple links to it elsewhere, for example, here, here, here (our old friend Merola) and here. The article still shows up on the ANH sitemap, but there’s nothing there. Apparently, the ANH took it down, which is probably because it was full of misinformation and lies. I only wish I had saved a screenshot or web archive of the article. My mistake.
Bringing it all together: The ANP Coalition
It’s taken nine months since Burzynski supporters revealed in a video of the panel discussion after a screening of Eric Merola’s movie that various Burzynski patient groups were planning to form an organization to lobby Congress for fast track approval of ANPs. Indeed, Merola and his merry band of Burzynski sycophants were quite open about wanting fast track approval for ANPs so that Burzynski could then prescribe them off-label for virtually any cancer and presumably could also sell them to any doctor who wanted to use them for whatever purpose. Of course, advertising a drug for off-label uses is against the law, which is why the FDA takes such a dim view of it, but “word of mouth” and ANP-friendly groups like the ANH would make sure that word got around fast. Unfortunately for Stash, with the deficiencies of the procedures of the Burzynski Clinic and BRI with respect to running clinical trials having been laid bare in Liz Szabo’s article in USA TODAY, fast track approval for ANPs for glioblastoma is, at best, highly unlikely. So Burzynski’s allies have fallen back on lobbying Congress to lean on the FDA to allow single patient protocols, sometimes called “compassionate use” protocols, to allow Burzynski to treat patients with ANPs even though his clinical trials are shut down. To do this, they have formed a group called the ANP Coalition:
It is our fundamental belief that the discovery of Antineoplastons (ANP) can and will herald a new age of medical science and subsequent advancements in the treatment of previously incurable diseases. This benign yet effective drug contradicts the paradigm that cancer treatments have to be harmful to be effective, and redirects modern medicine back to its salient principal Primum non nocere, “first, do no harm”.
How does the ANP Coalition intend to accomplish our mission?
We will accomplish our mission by focusing on four main goals:
    • To educate the public as to the importance and benefits of ANP.
    • To advocate for patients who need access to ANP for medical conditions.
    • To expedite regulatory approval for ANP thereby making it available to all.
    • To further research and development of ANP.
Consistent with a lot of the rhetoric used by Eric Merola and the Burzynski Patient Group, the rhetoric on the ANP Coalition site is apocalyptic, painting the battle as nothing less than one of good versus evil:
This is not a time for all good men to act; it is a time when all good people must act. We live in an age of awareness, where technology has become the great equalizer. With technology comes communication, and through communication we can educate! Once armed with education, propaganda withers and dies!
This website is designed with the sole purpose of educating the public and exposing the truth. The battle starts here in cyber space, but the war is won in the real world, by real people who participate in real ways. It will be won by you!
We are no longer an organization of patients connected by a cure; we are the collective who will not allow evil to triumph.
I can provide a hint of why the rhetoric is so amped up. One has only to look at who owns the ANPcoalition.org. The domain is registered through Domains By Proxy, which makes one wonder why the ANP Coalition would want to hide who owns the domain. First of all, the pictures on the Contact page reveal several old friends, including Ric Schiff, whose wife Laura, not coincidentally, owns a related domain, theotheranpcoalition.org, and registered it under her real name and also appears on the Contact page. (A screenshot has been saved, of course.) Also there is Mary Jo Siegel and her husband Steve. These are the people behind ANP Coalition, just as they are heavily involved in the Burzynski Patient Group. In fact, in July 2013, Ric Schiff was elected to the board of directors of the BRI, which makes his involvement in this effort a massive conflict of interest.
Predictably, Elisha Cohen, Liza Cozad, and Mackenzie Lowe are featured as the stories used to drive petitions to lawmakers and the FDA to allow compassionate use of ANPs. In addition, there are two new patients, of whom I haven’t heard before, Laura Nowosad, a 7 year old girl from Canada with a DIPG whose story is sadly familiar to anyone who covers Burzynski:
Her parents, Janusz and Mira, are an amazing couple whose lives got shattered in an instant. Laura is their only child and their whole world. They couldn’t believe that this is happening to their little girl; they were hopeful that the doctors made a wrong diagnosis and went for a second opinion. Unfortunately, this diagnosis was confirmed. Words cannot explain the feelings of hopelessness, frustration, and terror they felt when they had to be faced with the truth.
Janusz and Mira are not giving up hope! They have taken Laura to The Burzynski Clinic in Houston, Texas. This clinic has seen significant improvement in patients facing similar diagnosis as Laura, using alternative therapies not available in Canada. However, the treatment is very expensive. The initial visit costs $25,000 and each month after is $30,000.
On the same page is yet another desperate family being used by Burzynski’s minions as well, that of Isaac DeHerrera, a five year old boy whose tale is presumably so new that there isn’t yet a fundraising website that I could find or a petition to let Burzynski treat Isaac with ANPs on a compassionate use protocol. I’m sure there will be more families added as soon as Burzynski and his minions can find them. Clearly Ric and Laura Schiff and Steve and Mary Jo Siegel believe that they can duplicate the success Burzynski patients had in the 1990s, which was the last time Burzynski was in a comparable amount of trouble, with demonstrations featuring patients chanting, “FDA go away! Let me live another day!” and the intense political pressure brought to bear by a compliant Senator or Representative, the way they persuaded Joe Barton to drag then-FDA director David Kessler in front of his committee four times over two years to explain why the FDA was “harassing” Burzynski. Only this time, they have the Internet, which was only in its infancy as an organizing tool back in 1995, which allows them to produce a “Meet the Miracles” section, which, presumably, will be full of glowing testimonials of Burzynski Patient Group patients. So far, there is only Jessica Ressel, who was featured in the first Burzynski movie and whose testimonial is not convincing, as I described in detail in my review. No doubt she believes Burzynski saved her, but it is almost certainly the case that he did not, which is the only reason I can forgive her regurgitating Burzynski Clinic talking points.
Perhaps the most concerning aspect of the ANP Coalition is that it’s hired a lobbyist named Antonio C. Martinez II:
His experience with ANP extends more than 18 years back when he represented the Burzynski Patient Group in 1995 and 1996, organizing numerous patient demonstrations and a Congressional Hearing on February 29, 1996 before the U.S. House of Representatives Energy & Commerce Subcommittee on Oversight & Investigations. These efforts helped Burzynski patients obtain access to ANP through Phase II clinical studies.
This isn’t cheap. Unless Martinez is serving pro bono, his hourly rates are $250 to $400. I have no reason to doubt the claim that he worked on organizing the Congressional Hearing in 1996 at which Burzynski patients vented at the FDA, but I wonder. I’ve read both Richard Jaffe‘s Galileo’s Lawyer: Courtroom Battles in Alternative Health, Complementary Medicine and Experimental Treatments and Thomas D. Elias’ The Burzynski Breakthrough: The Most Promising Cancer Treatment and the Government’s Campaign to Squelch It. Both books describe the Congressional hearings in which Burzynski patients testified from a very pro-Burzynski standpoint. I don’t recall seeing Mr. Martinez’s name being mentioned even once, and a quick flip through the indices and relevant sections of these books did not change that assessment for me. If Martinez were so important to the 1996 hearings, one would think that Jaffe and/or Elias would mention him and at least briefly describe his role in their books. They didn’t, as far as I can tell.
So what does the ANP Coalition want to accomplish? Its list of demands is long and some are completely unrealistic. For example, on its page where it tells people how they can help, it asks people to write to Wikipedia to:
…demand removal of the “Burzynski Clinic” webpage, since it has been high jacked by a paid group who identify themselves as “The Skeptics”, and is no longer open for public contribution. The Wikipedia page on “Burzynski Clinic” is filled with untrue statements, statements taken entirely out of context, cherry-picked information, sources that do not qualify as sources under Wikipedia rules, fake sources—you name it.
The Wikipedia team has already noticed the ANP Coalition’s attempts to astroturf its article on the Burzynski Clinic.
Others, however, are not unachievable. Certainly organizing petitions and getting people to write to their lawmakers are achievable aims, and that’s what concerns me: How do we respond? In the absence of sound scientific information showing that ANPs almost certainly don’t work and are very toxic, Burzynski’s claims notwithstanding, legislators and politicians are going to go with the sympathetic story; i.e., the stories told by Burzynski supporters of children with deadly brain tumors who will die soon if they aren’t allowed to have ANP therapy. That’s why it infuriates me to see how Burzynski so cynically uses patients with deadly cancers in his battle with the FDA. Make no mistake, that is exactly what he is doing here. He dangles false hope in front of patients like Eliza Cozad, Raphael Elisha Cohen, and McKenzie Lowe, and their families do the rest for him. Even in the case that a legislator understands the lack of evidence, he might well go with a “What’s the harm?” attitude, not appreciating that the harm can be appreciable given how toxic ANPs are, not to mention the financial harm done to the family raising tens or hundreds of thousands of dollars for an ineffective treatment. That’s why information to show why, as much as we sympathize with the plight of these patients and their families, legislators should not overrule the FDA’s decision regarding antineoplastons. Indeed, the real investigation should be into why the FDA has allowed Burzynski to get away with what he’s gotten away with all these years.
I also appeal to you, our readers, for help and ideas. Visit Bob Blaskiewicz’s appeal and take action. In the meantime, let’s hear ideas for how to counter this latest initiative.

The Texas Medical Board vs. Stanislaw Burzynski, 2014 edition
Here we go again. I’ll give the Texas Medical Board credit for one thing. It’s persistent. It’s going after Stanislaw Burzynski’s medical license again. Will this finally be the time the TMB puts a stop to Burzynski’s abuse of the clinical trial process and patients? Or will this be a replay of the 1990s, with Burzynski slithering away yet again?
David Gorski on July 14, 2014
Link


As I begin this post, I’m on a miserably crowded, hot, stinky flight winging my way home from TAM. This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who claims to have much better results treating deadly brain cancers than conventional oncology, even though he is not an oncologist and has never even completed the prerequisite training for an oncology fellowship, namely an internal medicine residency. Actually, I don’t mean that in the way that you probably think I mean it. This time around, unlike the last time around, writing about Burzynski will put me in a better mood to endure being slapped into a sardine can in coach, barely able to move, barely able to type, but needing to get a blog post out on Monday.
If you remember, the last time I wrote about Burzynski, the Food and Drug Administration (FDA) had caved, and by “caved” I mean that it had lifted the partial clinical hold on Burzynski’s clinical trials. As is usual with the long and winding saga that is Burzynski, I feel compelled to give a brief review for any newbie who might encounter this post. Old hands at this story can skip ahead or just skim.
Two years ago, a child named Josia Cotto died of hypernatremia (elevated sodium level in the blood) due to receiving treatment for a brain tumor from the Burzynski Clinic using Burzynski’s “miracle drug” antineoplastons. Hypernatremia is a known complication of ANP treatment, and, as a result of this child’s death, the FDA put a partial clinical hold on Burzynski’s clinical trials for pediatric patients, which meant that he could continue to treat children already enrolled in his clinical trials but could not enroll any new patients. Six months later, this partial hold was extended to all of Burzynski’s clinical trials, and in early 2013 the FDA inspected the Burzynski Clinic and Burzynski Research Institute (BRI).
The reason why the FDA’s decision late last month to lift this clinical hold is so puzzling is because the results of the FDA’s inspection were so damning. In particular, the FDA found that Burzynski exaggerated responses to therapy using inappropriate criteria, didn’t have original scans of many patients, and played fast and loose with the rules regarding enrolling patients onto clinical trials under single patient INDs (otherwise known as compassionate use exemptions). Let’s just say that Burzynski’s institutional review board (IRB), the committee whose charge under the Common Rule (which clinical trials meant to be used as the basis for FDA approval of a drug must follow) wasn’t exactly rigorous about following federal regulations or protecting patient rights and safety, and let’s further say that Burzynski’s response was…less than convincing. More puzzling, this is not the first time that the FDA has investigated Burzynski and found the very same sorts of violations by the BRI IRB; it’s a pattern that goes back to at least 2001 and continued at least until the FDA inspection. Let’s just put it this way. IRBs are supposed to be as independent as possible, and Burzynski’s IRB has been (and still is) chaired by Carlton F. Hazlewood, PhD, who just so happens to be on the board of directors of the Burzynski Research Institute. The conflict of interest and lack of ethics are astounding. Yet the FDA still lifted the partial clinical hold, a breathtaking failure to protect cancer patients.
That was the bad news.
The Texas Medical Board tries to do the right thing
During this time, the Texas Medical Board, which has tried and failed to strip Burzynski of his medical license on multiple occasions over the last four decades, has decided to take another whack at the piñata. I’m glad it did, even though, as has been discussed before with respect to multiple cases, including Rolando Arafiles and Christopher Duntsch, the TMB is toothless by design, thanks to an anti-regulatory bias that has led to laws that have vastly weakened its already-weak regulatory authority. That’s why, although I’m not optimistic that this time the TMB will prevail where in the past it has not, I’m glad it’s giving it the old college try, which is what it has done with an amended complaint against Burzynski dated July 10, 2014. I warn you: It’s over 200 pages long, but the spacing and repetition are such that I was able to read most of it even though I was busy with TAM. It’s a devastating document that, if the allegations are proven in court, should finally end Burzynski’s career. I’ll apologize if I’m a bit pessimistic, though. Burzynski has slithered out of tighter spots before.
Still, it’s worth discussing the allegations. Because of the length of the document, I can only hit the high points, but the complaint is there for you all to read if you are so inclined. If you’ve been following the Burzynski saga it’s definitely worth taking the time to do so. The introduction sets the stage:
Board Staff alleges that Respondent created a medical practice model based on marketing his proprietary anti-cancer drugs to patients without adequate measures for patient safety and therapeutic value. Respondent misled patients knowingly by promoting these drugs as an attraction to bring patients to his medical practice when Respondent was aware that he could not legally include most of those patients in FDA-approved Phase 21 clinical trials of his proprietary anti-cancer drugs. Respondent further misled patients into paying funds as a retainer prior to receiving any evaluation, diagnosis or treatment. Respondent further misled patients into: (1) paying exorbitant charges for drugs and medical services; (2) accepting care from unlicensed persons while Respondent and Respondent’s employees misrepresented those unlicensed persons to be licensed medical doctors in Texas and the United States of America; and (3) accepting care from health care providers who had little advanced education or training related to cancer treatment while Respondent and Respondent’s employees misrepresented those health care providers to be doctors with significant advanced education or training related to cancer treatment.
Having followed the Burzynski saga for three years now, I’m always heartened to see when a regulatory or law enforcement body “gets it” the way this paragraph demonstrates that the TMB appears to “get it” now. This is in sharp contrast to the weaselly justifications by the FDA for unleashing Burzynski’s bogus clinical trials—which, recall, his own lawyer characterized as “an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment” so that Burzynski “would be able to treat almost any patient he would want to treat!”—on unsuspecting desperate cancer patients again. The new allegation that I hadn’t been aware of was the part about using health care providers with little or no education or skill and representing them to patients as being doctors. Now that’s really bad by any stretch of the imagination, and a profound betrayal of the cancer patients whose desperation led them to Burzynski.
Patient A
Several of those desperate cancer patients are described in the complaint. I’m not going to go through all the cases, because there’s a depressing similarity to them in terms of the allegations of Burzynski’s wrongdoing, but it’s worth discussing at least a couple of them. I’ll start with Patient A, not only because it’s the first patient listed but because it’s a different story than we normally see at the Burzynski clinic. This patient had suspected colon cancer. I say “suspected,” because at the time he first presented to Burzynski he had not had any biopsies.
Patient A presented to the Burzynski clinic with a diagnosis of “sigmoid colon carcinoma metastatic to the liver.” This diagnosis was made on the basis of imaging studies that showed lesions in the liver suspicious for metastases and a colonoscopy that showed a “polypoid mass consistent with high-grade dysplasia and suspicious for invasive adenocarcinoma.” This, unfortunately, is not an uncommon presentation of colon cancer, except for one thing. Usually, there’s a biopsy done. A cardinal rule for treating cancer patients is that you do not initiate treatment without a tissue diagnosis from a biopsy. This tissue both proves that the patient has cancer and identifies the kind of cancer it is. Indeed, these days, when molecularly-targeted therapy is being increasingly used, the tissue also allows analysis of gene expression patterns that can guide the choice of treatment. The situations in which it is considered acceptable to begin treatment of presumed cancer in the absence of a tissue diagnosis are very uncommon and boil down to rare cases where the imaging is pathognomonic of the kind of cancer suspected and the clinician judges that a biopsy would be too risky.
Basically, patient A should have had a biopsy of both his sigmoid colon lesion and one or more of his liver lesions. There was no reason not to do this, as colonoscopic biopsies and needle biopsies of the liver are in general low risk procedures and the treatment of colon cancer is, increasingly, being guided by newer gene tests. Now, in fairness, Patient A had refused to undergo a biopsy when his local physician had recommended it and also refused to consider chemotherapy with FOLFOX3 with Avastin after a biopsy, which is within the standard of care. However, if that’s the case then Burzynski should have refused to treat him. Not only is it considered a gross breach of the standard of care not to have a tissue diagnosis before treating a patient, but nearly all clinical trials for cancer treatments absolutely require a tissue diagnosis, which means that this patient was ineligible for any of Burzynski’s clinical trials. Instead, without even recommending a biopsy, Burzynski began to treat patient A with anticancer medications.
Now here’s the kicker:
9. At the time Patient A first met with Respondent and the other employees of the Burzynski Clinic, Respondent allowed Tolib Rakhmanov, a person who is not a licensed physician or health care provider in Texas or elsewhere in the United States of America, to represent to Patient A that Tolib Rakhmanov was a licensed medical doctor practicing medicine in Texas. Respondent and the other Burzynski Clinic employees under Respondent’s supervision and control continued to represent to Patient A and Patient A’s fiancee or to allow them to believe that Tolib Rakhmanov was a licensed medical doctor practicing medicine in Texas throughout Patient A’s treatment at the Burzynski Clinic.
10. Respondent and the other Burzynski Clinic employees under Respondent’s supervision and control referred to Tolib Rakhmanov as “Dr. Rakhmanov” in Patient A’s and Patient A’s fiancée’s presence. Respondent knew or reasonably knew that Tolib Rakhmanov signed documents, many of which were also signed by Patient A and Patient A’s fiancee, in manners that identified Tolib Rakhmanov as a medical doctor. Patient A and Patient A’s fiancée reasonably believed that Tolib Rakhmanov was a medical doctor licensed to practice medicine in the state of Texas. Respondent was responsible for the false, misleading and deceptive representation to Patient A and Patient A’s fiancée that Tolib Rakhmanov was a medical doctor licensed to practice medicine in the state of Texas.
Rakhmanov also performed tasks and services that obviously constitute the practice of medicine, including diagnosing and evaluating Patient A’s medical condition, making treatment recommendations, on numerous occasions (with all the dates listed). The TMB further alleges that Burzynski “directed and/or reasonably knew and allowed Tolib Rakhmanov, a person who is not a licensed physician or health care provider in Texas or elsewhere in the United States of America, to perform medical tasks that constituted the practice of medicine in the state of Texas in the evaluation, diagnosis and treatment of Patient A.”
Burzynski also promised the patient that he would receive ANPs and the FOLFOX/Vectibix treatment he desired, after which he demanded a large retainer for treatment. This is interesting, because Vectibix (generic name: panitumumab) is a targeted therapy that is only useful in cancers with a gene called KRAS that is not mutated. (KRAS is gene that is frequently mutated in colorectal cancer.) This is what I mean about how gene testing is becoming more important in colorectal cancer. Most colorectal cancers these days are tested for KRAS mutations to determine if Vectibix is an appropriate therapeutic regimen. According to the company’s website, Vectibix is “not indicated for the treatment of patients with KRAS-mutant mCRC [metastatic colorectal cancer] or for whom KRAS mutation status is unknown.” In other words, it was unequivocally not indicated for Patient A. That’s even leaving aside the issue of ANPs.
Actually, Patient A never received FOLFOX/Vectibix or ANPs. Instead, he received something else from Burzynski without his “adequately explaining to Patient A the difference in safety and efficacy between the therapy requested by Patient A and the therapy provided by Respondent and the employees of the Burzynski Clinic under his supervision and control.” Instead, Burzynski initiated treatment with phenylbutyrate. Remember phenylbutyrate? It’s the orphan drug that Burzynski touts as an ANP prodrug. Patient A also received a “partially FOLFOX equivalent regimen” consisting of oral Xeloda and intravenous Avastin, which I consider kind of a half-assed treatment that isn’t FOLFOX. Apparently Patient A improved for a while, which is quite possible given that he was receiving Xeloda (capecitabine), for which there is some evidence of efficacy, as well as Avastin, which is why it’s sometimes used as an alternative to FOLFOX. It’s unlikely that the phenylbutyrate did anything. I do have to note, however, that there is a passage in which “shrinkage” of a brain tumor is mentioned, which makes me think the TMB made a mistake and mixed up part of Patient B’s story with that of Patient A.
For some reason, Burzynski started changing drugs without adequate rationale. Eventually, the tumors started growing again, and the patient left Burzynski’s care, having paid an enormous amount of money, including a $4,500 monthly case management fee and a charge of $360 for 500 mg of sodium phenylbutyrate. During the course of Patient A’s treatment, Burzynski also used very expensive drugs that are not indicated for colorectal cancer, such as Afinitor (everolimus), which inhibits a protein called mTOR and is primarily used for kidney cancer and breast cancer, and Votrient (pazopanib), a tyrosine kinase inhibitor that blocks tumor growth, inhibits angiogenesis, and is used for renal cell carcinoma and soft tissue sarcoma.
The story is all very familiar if you’ve been following Burzynski and very depressing. There’s more, just in the case of Patient A, including failure to assess the patient’s mental status when recommending treatments, failing to provide anything resembling adequate informed consent, and having an ownership interest in the pharmacy dispensing the drugs Burzynski used, among other violations, but let’s move on to Patient B.
Patient B
Patient B is an interesting case, because part of it isn’t clear to me. In December 2010, Patient B had a diagnosis of brain cancer, which was successfully removed by craniotomy, which was followed by imaging studies that showed complete removal of the tumor. Post-operative chemotherapy and radiation therapy were recommended. Now here’s a part where it’s hard to understand what Burzynski did wrong if you don’t know a lot about him. The complaint alleges that Burzynski didn’t get a biopsy to confirm the existence of cancer before initiating anticancer treatment. Yet, conventional doctors had recommended postop chemotherapy and radiation, even though as far as they could tell the cancer had been completely removed. The difference is in intent. The chemotherapy and radiation therapy were being recommended as adjuvant treatments, in other words, treatments designed to decrease the risk that the tumor would recur, given that microscopic disease is almost always left behind. My guess (and it’s only a guess) is that Burzynski didn’t document that he was undertaking treatment for adjuvant purposes but rather made it sound in the medical record as though he were treating for therapeutic purposes for an existing cancer.
Later in the complaint it is alleged that “Respondent and/or employees under his direction and control failed to inform Patient B about the FDA-approved criteria for treatment with antineoplastons in one of Respondent’s sponsored clinical studies.” None of Burzynski’s trials that I can find are for the adjuvant treatment of brain cancer. They are, instead, for the treatment of existing brain tumors, most often recurrent or refractory brain tumors. Thus, Patient B almost certainly wasn’t eligible for any of Burzynski’s ANP clinical trials, because he had what we in the biz like to call “no evaluable disease,” often abbreviated NED, meaning that there wasn’t any currently detectable tumor whose response to therapy could be followed.
Next, we see the same depressing litany for Patient B as well, including lack of informed consent, failure to document treatment rationale, and, again, Burzynski Clinic staff who are not physicians being represented as such, including Tolib Rakhmanov and Larisa Tikhomirova. There again was the requirement for a large retainer to begin treatment. There was again the “bait and switch” in which Burzynski lured Patient B in with the promise of his ANP therapy and then used something different, including—of course!—phenylbutyrate, plus the usual witches’ brew of targeted drugs that we’ve seen before and that are not indicated in most brain cancers. It’s what I’ve referred to before as the “everything but the kitchen sink” approach.
In actuality, Patient B’s story in the complaint is poorly written and very confusing. I had trouble making heads or tails of part of it. It says that Patient B didn’t have any detectable tumor when he first consulted Burzynski in December 2010 and nails Burzynski for that, but then it describes Burzynski beginning treatment in February 2011 and an MRI scan:
On or about March 17, 2011, an MRI of Patient B’s brain revealed moderate decrease in the size of the brain lesion.
My guess, but I can’t be sure from the muddled and confusing description in the TMB complaint, is that this brain “lesion” was probably the inflammatory reaction to the patient’s surgery, which would have been expected to get smaller over the next three months anyway. A better way to say it would have been to be very clear from the start what the radiological findings were when the patient first approached Burzynski. If there was a lesion there, then it should have been pointed out whether it was suspicious for residual disease or whether the radiologists thought it was just normal postoperative changes. We can infer from the description that Patient B’s doctors must have thought that there was no residual disease, but then what is this “brain lesion” that was showing moderate decrease in size on March 17, 2011? I’m a cancer doctor who’s followed Burzynski, and even I’m not entirely sure what happened based on the description.
Be that as it may, many of the same complaints made against Burzynski for his treatment of Patient A apply to Patient B as well, and Patient B suffered considerable toxicity:
Respondent and other health care providers under Respondent’s direction and control treated Patient B without regard to the potential combined toxicities of drugs used pursuant to Respondent’s recommendations and directions. Respondent and other health care providers under Respondent’s direction and control referenced the case reports of other physicians not associated with the Burzynski Clinic as support for combined use of the drugs recommended and administered to Patient B. In those referenced case reports of physicians not associated with the Burzynski Clinic, however, those drugs were only used individually or in other combinations besides the combinations of drugs used for Patient B by Respondent and other health care providers under Respondent’s direction and control. In this regard, Respondent and other health care providers under Respondent’s direction and control violated the standard of care for reasons including:
a. Patient B suffered considerable toxicity affects.
b. Respondent violated the standard of care by failing to have an adequate medical rationale for this simultaneous use of these agents in anti-cancer therapy.
c. Respondent violated standards of adequate documentation by failing to document an adequate medical rationale for this simultaneous use of these agents in anti-cancer therapy.
d. Respondent also failed to adequately inform Patient B of this increased risk.
Same as it ever was. I note that Patient D’s case is a lot like Patient C’s case, one difference being that Sheryll Acelar was one of the non-physicians allegedly represented to the patient as a physician. Another name that came up as a Burzynski Clinic employees who was falsely represented to patients as being physicians was Lourdes DeLeon.
Patient G
Patient G is different in that Patient G was actually enrolled on one of Burzynski’s phase II clinical trials for a malignant astrocytoma of the optic nerve. For this patient, not only were there many of the same violations as listed for Patients A through F, but there were added allegations based on Burzynski’s treatment of the patient as part of this clinical trial:
14. Respondent failed to comply with federal regulations, the Burzynski Research Institute’s agreement with the FDA regarding the clinical study program for administration of antineoplastons and the approved protocols for the approved clinical study in which Patient G was enrolled. Such failures included Respondent’s direction and allowance for Patient G to be charged for the antineoplaston therapy and Respondent’s direction and allowance for these charges to be characterized as something else, “chemo prolong infuse” . This characterization was false, misleading and deceptive.
And:
40. The federal regulatory requirements for approval of single patient protocols for Phase 1 or Phase 2 clinical studies require that the investigator ensure that risks to patient/subjects are minimized and reasonable in relation to anticipated benefits.
41. Respondent, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, had a responsibility to ensure that risks to Patient G were minimized and reasonable in relation to anticipated benefits.
42. Ensuring that risks to patient/subjects are minimized and reasonable in relation to anticipated benefits requires (1) review of the subject’s medical records (history and physical examination) and (2) clarifying any outstanding issues with respect to the suitability of treating the patient/subject prior to granting institutional review board approval.
43. Respondent, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, failed to do the following to protect Patient G who was a patient/human subject in the clinical study of antineoplastons; (1) Respondent failed to take adequate measures to minimize risks to Patient G; and (2) Respondent failed to ensure that the risks to Patient G were reasonable in relation to anticipated benefits and the importance of the generalizable knowledge that may be expected to result.
44. Respondent’s failure, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, to ensure that risks to Patient G were minimized and reasonable in relation to anticipated benefits violated the standard of care, federal regulations, the Act and Board Rules.
This is the first time I’ve ever seen the TMB go after Burzynski for violating federal clinical trial regulations and human subjects research protections. I would like to see more of this. Another aspect of this case is unusual in that the TMB notes that the patient’s parent was allowed “to open an account whereby the public could read about Patient G’s medical and financial crisis and contribute money to that account.” The TMB alleges that Burzynski and his staff “reasonably were aware that the website that hosted this contribution account would provide any donations directly to the Burzynski Clinic to pay for the costs of Patient G’s treatment and that such costs had already been paid in advance by Patient G’s parent.” Patient G’s parent had a billing dispute with the Burzynski Clinic in which Burzynski refused to accept those donations as credit on Patient G’s account at the Burzynski Clinic and returned all the donations to the website that had acted as an intermediary for the donations. Burzynski also received significant reimbursement payments from an insurance company for Patient G’s care and refused to refund Patient G for benefits paid.
In other words, it’s all about making money from the dying and desperate.
And all the rest…
The TMB complaint also describes something that people who’ve been following the Burzynski case are well aware of, namely his advertising claims for ANPs, which are illegal under federal law because he made specific health claims for them and they are not yet FDA-approved for any indication. This is one thing that I haven’t been able to figure out. If a drug company did this, all the “natural health” advocates who defend Burzynski tooth and nail would howl bloody murder—and rightly so. But Burzynski does it, and he’s a hero being “persecuted” by the FDA and TMB. Ditto Burzynski’s failure to meet criteria for human subjects protection again and again, which are detailed very carefully in the last 30 pages or so of the complaint.
So what does it all mean? At the very least, it means that the TMB is serious this time. Does it mean that finally—finally—Burzynski is going down? I certainly hope so. Unfortunately, there’s no guarantee, and Burzynski has been found not guilty of similar charges before. Whatever happens with this case, thirty-seven years are too many, and no other cancer patient should pay hundreds of thousands of dollars for an ineffective treatment.

Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA really caves
Once more, the FDA fails to shut down Stanislaw Burzynski’s clinic and antineoplaston manufacturing operation. Cancer patients will suffer as a result of the FDA’s failure.
David Gorski on July 1, 2014
Link
It’s been a while since I wrote a substantive post for this blog about the Houston cancer doctor and Polish expat Stanislaw Burzynski who claims to have a fantastic treatment for cancer that blows away conventional treatment for cancers that are currently incurable. The time has come—and not for good reasons. The last time was primarily just a post announcing my article about Burzynski being published in Skeptical Inquirer. When last we saw Stanislaw Burzynski on this blog, it was a post that I hated to write, in which I noted that the Food and Drug Administration (FDA) had caved to patient and legislator pressure and allowed compassionate use exemptions (otherwise known as single patient INDs) to continue. The catch? Cynically, the FDA put a condition on its decision, specifically that no doctor associated with Burzynski nor Burzynski himself could administer the antineoplastons. This set off a mad scramble among Burzynski patients wanting ANPs to find a doctor willing to do all the paperwork and deal with Burzynski to administer ANPs. The family of one patient, McKenzie Lowe, managed to succeed.
It’s hard for me to believe that it’s been almost three years since I first started taking an interest in Burzynski. Three long years, but that’s less than one-twelfth the time that Burzynski has been actually been administering an unproven cancer treatment known as antineoplastons (ANPs), a drug that has not been FDA-approved, to patients, which he began doing in 1977. Yes, back when Burzynski got started administering ANPs to patients, I was just entering high school, the Internet as we know it did not exist yet (just a much smaller precursor), and disco ruled the music charts. It’s even harder for me to believe, given the way that Burzynski abuses clinical trial ethics and science, that I hadn’t paid much attention to him much earlier in my blogging career. After all, I’m a cancer surgeon, and here’s been this guy treating patients with advanced brain cancers using peptides that, according to Burzynski, do so much better against what are now incurable tumors than standard of care while charging huge sums of money to patients on “clinical trials.” It might be a cliché to quote the Dead this way, but what a long, strange trip it’s been. Because there has been a major development in this saga whose context you need to know to understand, I’m going to do a brief recap. Long-time regulars, feel free to skip the next couple of paragraphs, as they just try to bring people up to date and include a lot of links for background, or, if you haven’t already, read this summary of Burzynski’s history published earlier this year in Skeptical Inquirer. Newbies, listen up. Read the next two paragraphs. You need to know this to understand why I’m so unhappy. 
Incidents that I never blogged about here (but fortunately a certain “friend” of mine did on another blog) that have occurred since the FDA caved and (sort of) lifted the partial clinical hold on ANPs included:
    • For the first time in 37 years, Burzynski published what was purported to be the complete results of one of his phase I/II clinical trials. The results were—shall we say?—underwhelming.
    • Before that Burzynski had published 42.5% of one of his phase I/II trials, with even more unconvincing results.
Meanwhile, since he received that warning letter from the FDA late last year, in addition to making unconvincing claims excusing the issues described in the FDA warning letter, he’s been trying to enlist patients, both cute children and the semi-famous, to persuade legislators to pressure the FDA to let his clinical trials open again after they had been put on a partial clinical hold in the wake of the death of a child from hypernatremia (too much sodium in the blood), as reported by Liz Szabo in USA TODAY. All the while Burzynski has continued to charge patients large sums of money, while bragging that he didn’t charge for the actual ANPs. For those unfamiliar with the story, a partial clinical hold means that Stanislaw Burzynski can’t enroll any new patients on clinical trial but can continue to treat patients already enrolled.
Yes, three months ago—has it been that long already?—I noted with dismay that, under the onslaught of sympathetic cancer patients who understandably but incorrectly believe that Burzynski is their last chance to live, the FDA did indeed cave, although in the most weaselly way imaginable, stating that Stanislaw Burzynski could again enroll patients under compassionate use exemptions (also known as single patient INDs), even though the FDA warning letter had found gross deficiencies in the Burzynski Research Institute Institutional Review Board (BRI-IRB), which is run by an old crony of Burzynski’s who just so happens to be chair of the board of directors of the BRI and was found to be negligent in protecting patients by playing fast and loose with the regulations for enrolling patients on single patient INDs. The condition was that Burzynski himself or anyone working for him couldn’t be the physician treating the patients, leaving the patients to find a doctor willing to oversee the administration of ANPs.
And so it was for three months, with desperate patients with terminal brain tumors scrambling to find some doctor willing to do the paperwork to get the FDA to allow him to administer ANPs and also willing to work with such a disreputable character. McKenzie Lowe’s family, for instance, managed to find a retired family practitioner named Terry Bennett to agree to this. (More on this later.) Then, last week, this bombshell landed, courtesy of Liz Szabo again, in a story entitled “FDA gives controversial doc green light to restart work“:
The Food and Drug Administration has given a controversial Houston doctor the green light to resume administering experimental cancer treatments.
The FDA has lifted restrictions on a clinical trial run by Stanislaw Burzynski, who was the subject of a USA TODAY investigation last year. Burzynski, 70, has wrangled with state and federal medical authorities for nearly 40 years over his claims that he has discovered natural substances that can fight certain cancers.
You might think that my reaction upon reading this would be “WTF?” It wasn’t. However, that was only because I had had that reaction a week ago, when I read a press release from the BRI, “Burzynski Research Institute, Inc. Announces Lifting Of The FDA Partial Clinical Hold – Phase 3 Clinical Study Agreed Upon“:
The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.
The FDA’s decision to lift the clinical hold marks an important step in the development of Antineoplastons for the treatment of various forms of brain tumors in the US. At the same time, the Company is evaluating possible next steps for the Antineoplastons clinical program given the current progress and anticipated resource requirements of the ongoing program.
That was when I had my “WTF?” moment. However, noting the obviously intentionally vague language of the press release, I decided to wait until I could learn more and obtain confirmation rather than to blog the press release. For one thing, Burzynski could have just been spinning furiously, and there could have been a lot less to this press release than met the eye. It wouldn’t be the first time. Also, I just couldn’t believe that the FDA would so horrifically fail patients with brain cancer yet again the way it now has. I could sort of see why the FDA issued its previous ruling that allowed other doctors to enroll patients in single patient INDs of ANPs. At the time, the FDA was under a lot of pressure from legislators being contacted by constituents about families in their state or district with brain cancer who wanted to be treated by Burzynski. Its cynical solution must have seemed downright Solmonic at the time to the administrators who thought of it. But this? There’s nothing in the press release that says that the conditions that led to the partial clinical hold were resolved. Yesterday, however, there was this in Szabo’s story:
In a statement issued Wednesday), the FDA confirmed that it has lifted its restrictions on Burzynski because he answered all of their questions. In particular, Burzynski addressed “common and serious (and in some cases fatal) adverse drug reactions, as well as accurate information on how often tumors shrink after treatment with antineoplastons.”
Notice something missing? I did. The FDA said nothing about the BRI-IRB, which was soundly chastised for approving single patient INDs without full meetings of the committee. It also said nothing about the massive conflicts of interest that exist in the IRB and how it can’t possibly be independent. Sure, if Burzynski talked the talk adequately, I might see how the FDA might be either snowed or too tired to fight any more. I could see how it might be tempted to let him open his bogus clinical trials again—but only if Burzynski were forced to use a truly independent IRB, not his crony-packed IRB that basically rubber stamps whatever it is he wants to do with no questions and no evident effort to protect the welfare and rights of clinical trial subjects. Any IRB worth its salt will refuse to approve a clinical trial now and then and/or issue warnings to principal investigators for inadequate documentation, too many adverse events, etc. Has the BRI-IRB ever done this? Not as far as anyone I know can tell. Of course, it’s not really up to the FDA to oversee the function of IRBs. Rather, it’s more a function of the Office of Human Research Protections (OHRP). Long have I wondered: Where the heck has the OHRP been all these years?
It’s not as though Burzynski isn’t up to his old tricks again, either. Even with another physician overseeing the treatment of McKenzie Lowe, he’s managing to find ways to charge patients huge sums of money, even as he isn’t charging them for the ANPs. Indeed, the other day, Dr. Bennett, the physician who is overseeing the treatment of McKenzie Lowe whom I mentioned near the beginning of this article, was featured in an article in a local newspaper “Dr. feels misled in cancer treatment costs“. The money quotes are here:
But there was something Bennett didn’t know.
Bennett’s decision was based, in part, on a newspaper article that said Burzynski had agreed to donate the medicine required for McKenzie’s treatment. But what Bennett didn’t know is that Burzynki [sic] planned to charge the family for the clinical costs associated with the therapy.
LaFountain said the first month’s bill is expected to be $28,000. Every month after that is expected to cost $16,000. The treatment usually lasts eight to 12 months.
And health insurance won’t cover a dime of it.
And here:
Bennett says a representative of the Burzynski Clinic called him on that date seeking payment for the first month of McKenzie’s therapy. Prior to that, Bennett, who is donating his services, thought Burzynski was doing the same.
Instead, said Bennett, “I’m supposed to be the bag man for all of this. They want me to collect the 30 grand for the family and send it to Burzynski.”
Elsewhere, Bennett said, “It [the Burzynski Clinic] meets all the criteria for a bait and switch operation.” Yes, even Dr. Bennett found out the hard way how the Burzynski Clinic operates. None of this is anything new. Burzynski has been trying to dodge this tactic for years by saying that he doesn’t charge patients for his actual drug, the ANPs, giving the impression that he’s not charging them much of anything. However, the reality is that costs can rapidly add up to hundreds of thousands of dollars, which is why fundraisers by families of Burzynski patients have been a feature surrounding the Burzynski Clinic operation for decades, as has been documented time and time and time again.
This is a doctor who wants to help and is willing to take risks, even if inappropriately in this case, and he feels used by Burzynski. Indeed, his comparing himself to a “bag man” is a particularly apt metaphor, because that’s what he is in this: A bag man. It’s his job to collect the cash from the family of a dying child and ship it to Burzynski. Ironically, this news story appeared on the very same day as Burzynski’s press release, and, of course, Szabo’s story appeared yesterday. Did the FDA know Burzynski was doing this? It strains credulity to think that the FDA didn’t know about this abuse of a desperately ill child’s family, given that information regarding how it will be paid for is part of a single patient IND application, indeed part of all clinical trial applications. Indeed, that Burzynski gets away with this is yet more evidence that his IRB is nothing more than a rubber stamp, because any independent IRB would ask some very hard questions about such an arrangement. Very hard questions indeed. It’s painfully obvious that the BRI-IRB has never asked hard questions any IRB should be asking about any clinical trial Burzynski has proposed or about how his clinical trials are being carried out.
It’s even worse than that, though. Check out what I found on a website devoted to penny stocks, “Burzynski Research Institute (BZYR) Reignites On FDA Approaval” [sic]:
Focusing since 1967 on the isolation of various biochemicals produced by the human body as part of the body’s possible defense against cancer, the penny stock of Burzynski Research Institute, Inc. (BZYR) has exploded on the scene thanks to the efforts of CEO and President Stanislaw R. Burzynski, M.D., Ph.D. After notification that the U.S. Food and Drug Administration lifted its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections, shares of BZYR stock begun to trade and are putting on a good show thus far. Although only around 25 million shares issued and outstanding do not belong to the founder who is determined to treat of various forms of brain tumors, the large jump upwards has made this little biotech burz-worthy.
You know, with all the typos and English that sounds as though it were written by someone who isn’t a native English speaker, this made me suspicious that Burzynski or someone from Burzynski’s clinic wrote it. Either that, or the web page is written by non-English speakers, which seems likely given that I found the same sorts of weird-sounding sentence constructions in other articles and I know Burzynski’s people can produce serviceable English prose when they need to. Be that as it may, I have little doubt that the Burzynski clinic is trying to take advantage of the FDA decision to bolster its flagging finances, which have been reportedly hurting since the partial clinical hold was placed. Whether this article on a website hawking penny stocks has anything to do with it, I don’t know, but its appearance right around this time sure doesn’t seem coincidental to me.
So what happened? Why did the FDA cave so ignominiously? How could it ignore 37 years of Burzynski’s therapeutic misadventures and abuse of science and the clinical trial process? I have a few ideas, but none of them are satisfying, and all of them are speculation, ranging from educated to, well, just speculation. Back in the 1990s, it was powerful legislators like Joe Barton leaning on the FDA to let Burzynski be Burzynski. Today, there are no visible and obvious champions in Congress for Burzynski. Even so, that doesn’t necessarily mean that such congressional patrons don’t exist, given the campaign waged by patient families and the Burzynski clinic to get people to write their Congressmen and Senators. Another likely possibility is that the FDA is just tired. If it shuts Burzynski down, it will be portrayed for years as the bad guy denying patients a chance at life, and there will be an enormous court battle. If it decides to fight, the FDA could end up with years of litigation, and, given the FDA’s unfortunately limited budget, it has to pick its battles. Does it help the FDA’s mission overall if it drains so many resources fighting what it likely views as small fry like Burzynski that it finds late in the fiscal year that it can’t afford to go after a large drug company over lack of resources? I don’t know, but given how long Burzynski’s been at it, the FDA’s decision is still an extreme dereliction of its duty to the public.
Whatever the reason that the FDA caved, we’ll probably never know. We can make FOIA requests, but the FDA is notoriously tight with the information it permits to be releases because it’s forbidden from releasing information that might endanger trade secrets of the companies it regulates and it appears to take a fairly expansive view of what constitutes such information. At least, we’ll probably never know unless we can get a powerful Senator or Congressman (or two) interested and as outraged as we skeptics are. A Congressional investigation, as unlikely as that sounds, is probably the only thing that will get to the bottom of the FDA’s utter failure. It’s clear that in this case the FDA is no longer able or willing to protect the safety, finances, or rights of patients with advanced cancer.

The Center for Inquiry weighs in on the FDA’s mishandling of Stanislaw Burzynski’s clinical trials
The Center for Inquiry points out how what Stanislaw Burzynski is doing corrupts the clinical trial process and harms patients.
David Gorski on July 3, 2014
Link
We interrupt our usually scheduled post for an important announcement. OK, we do nothing of the sort. Scott Gavura’s post will go live a little later this morning. In the meantime, here’s a public service announcement about a frequent topic of mine, Stanislaw Burzynski, that I’d like you to read.
As you recall, last week, the FDA inexplicably decided to lift the partial clinical hold on Stanislaw Burzynski’s bogus clinical trials of antineoplastons, which he’s used since the 1990s as a pretext to charge huge sums of money for “case management fees” to patients for a treatment whose efficacy he has never demonstrated. Yesterday, the Center for Inquiry laid in, and has sent a letter to legislators:
“We are frankly stunned to hear that the clinical hold against Dr. Burzynski has been lifted,” writes CFI in its letter. For decades, Dr. Burzynski and the Houston-based Burzynski Research Institute have been trafficking in unproven and scientifically baseless cancer treatments based on compounds known as antineoplastons, derived from human urine, which Burzynski claims — without evidence — can target and destroy cancer cells. He has taken advantage of desperate patients who are at their most vulnerable, and willing to pay any price.
After the death of a six-year-old patient in 2012, the FDA placed a hold on Burzynski’s trials with children, followed by a hold on trials with adults in 2013, prohibiting him from taking on new patients on whom he could experiment and from whom he could extract more money.
Over several decades, his clinic has proven it is unable to properly protect patient rights, adhere to basic ethical or scientific protocols, or even maintain correct patient records. It has also shown it is willing to exploit desperate cancer patients and their families, milking them out of enormous sums of money. But it has yet to show even a shred of evidence that its cancer treatments have any positive effect whatsoever.
“We struggle to see why the FDA continues to enable this deceptive, antiscientific, and unethical medical adventurism and profiteering, even for patients who are terminally ill,” writes CFI. “Given the behavior of Dr. Burzynski and the Burzynski Research Institute over the course of nearly three decades of failed research and trials, and in the face of a complete lack of scientific evidence demonstrating the efficacy of their expensive and dangerous antineoplaston treatment, we find the FDA’s decision perplexing and profoundly disturbing.”
The full text of the letter can be found here.
If only groups like the American Cancer Society would write similar letters. Cancer patients have been taken advantage of for nearly four decades, and Burzynski has made a mockery of the clinical trial process for nearly 20 years. It’s gone on way too long.

Revealed by the FDA: The results of the most recent inspection of the Burzynski Clinic
The results of the latest FDA inspection of the Burzynski Clinic are in. They aren’t pretty. Why is this cancer quack still allowed to do his bogus clinical trials?
David Gorski on November 11, 2013
Link
After posting the talks that Bob Blaskiewicz and I gave at TAM this year, I realized that it’s been a while since I’ve written about the topic of those talks, namely Stanislaw Burzynski, the Houston cancer doctor who inexplicably has been permitted to continue to administer an unproven cancer treatment to children with deadly brain cancers for nearly 37 years now. Beginning in 1977, when he left Baylor College of Medicine and opened up the Burzynski Clinic, Burzynski has administered a cancer therapy that he calls antineoplastons to patients. After nearly four decades and several dozen phase II clinical trials started, he has never published a completed phase II trial. The only evidence he’s published consists mainly of cell culture studies, case reports, and couple of preliminary reports of his phase II clinical trials. Of course, Burzynski’s lawyer, Richard Jaffe, even dismissively admitted that these clinical trials are designed solely to allow Burzynski to keep giving antineoplastons.
So Burzynski operated from the late 1990s until summer 2012, charging exorbitant “case management” fees to enroll patients in his clinical trials, working with a credulous filmmaker who wanted to make a movie about him—twice—and flouting regulations designed to protect human subjects involved in clinical trials. Meanwhile, he branched out to “personalized gene-targeted cancer therapy,” which he promoted through Suzanne Somers; to AminoCare, which is basically antineoplastons sold as an antiaging nostrum (or, as Burzynski puts it, a “genetic solution to aging“); and to selling an orphan drug as a “prodrug” for antineoplastons.
So what happened in the summer of 2012? Apparently, there was a treatment-related death of a child, which led the FDA to issue a partial clinical hold on the Burzynski Clinic that prevented him from enrolling any new children on his clinical trials, although he could keep treating existing patients and enroll new adult patients. That partial clinical hold was extended to adults in January 2013, at which time the FDA arrived at the Burzynski Clinic to investigate. It was an event that was included at the tail end of Eric Merola’s second propaganda film about Stanislaw Burzynski and represented as, in essence, jackbooted fascists trying to keep the cure for cancer from The People. None of this stops credulous reporters from writing misleading articles with titles like Young mother with brain cancer given just a year to live BEATS the disease and gets married after having controversial treatment in the US, which is a story about Laura Hymas, a woman whose good fortune is most likely not due to Burzynski. Not long before that, there was another credulous article featuring another Burzynski patient, Hannah Bradley, as one of four patients treated for cancer with alternative therapies who are allegedly doing well. Again, Hannah Bradley’s good fortune is highly unlikely to be due to Burzynski’s nostrums.
All of this is why those of us who follow Burzynski have been waiting with the proverbial bated breath to find out what the FDA concluded. Just before the government shutdown the first shoe dropped, when the FDA released a warning letter to the Burzynski Research Institute (BRI). Then last week, the second shoe dropped, when the FDA released the original forms describing its findings regarding the inspection. The findings are, to put it mildly, damning in the extreme. In fact, now, more than ever, I wonder how on earth Burzynski has been allowed to continue to run clinical trials—or even practice—for so long. The findings include massive deficiencies in the Burzynski institutional review board (IRB), the committee responsible for making sure that regulations designed to protect human subjects in research are adhered to.
Stanislaw Burzynski versus human subjects protections: Human subjects protections lose
Before looking at the new FDA findings, let’s recap what is known about Burzynski’s IRB. First, we know that the IRB is headed by Carlton F. Hazlewood, PhD, who just so happens to be on the board of directors of the Burzynski Research Institute. As I noted before, given that the Burzynski Clinic has been trying for decades to commercialize antineoplastons, this is a profound conflict of interest. I also ask you to think of it this way again: What would Burzynski’s defenders say if they found out that a sitting member of the board of directors of Merck, for example, was serving on the IRB that oversees Merck’s clinical trials? Having Hazlewood serve on the BRI IRB is the same thing. True, it’s not quite as bad as having the principal investigator of a study chair the IRB overseeing his studies, as Mark Geier has done, but it’s pretty bad. Again, one wonders how Burzynski supporters would react if pharmaceutical companies or even research institutes trying to commercialize a discovery made by their investigators allowed high ranking leadership sit on their IRBs.
Last year, a certain “friend” of mine had discussed the problems with Burzynski’s IRB before, and these notes simply amplify and add detail to the problems that were already known. These notes suggest how Burzynski uses his IRB to get around some of the restrictions that were placed on him using antineoplastons. As you might recall, the Common Rule demands that all clinical trials by investigators whose institutions receive federal funding or that are being done in order to win FDA approval for a drug or device must be overseen by an IRB, whose purpose is to protect the human subjects who take place in the trials. This is an absolutely essential purpose of the IRB, its key reason for existence. It is not there to evaluate the science, except to the extent that badly designed clinical trials based on bad science endanger human subjects. Its purpose is to make sure that the risks and benefits of clinical trials are reasonably balanced, make sure that patients entering clinical trials receive adequate informed consent, and to keep an eye on the trial as it is being carried out, evaluating adverse event reports and, if necessary, shutting the trial down if there are too many or if one group starts doing too poorly relative to the other.
These are duties and functions that the Burzynski Clinic’s IRB utterly failed to carry out over the years. Before I take a look at the FDA warning letter and its accompanying notes, let’s go on a stroll down memory lane and recap some of the violations that the FDA has found in the past, gleaned from a a letter to the Burzynski Clinic Institutional Review Board from 2001; a report of a site visit to the Burzynski Clinic by the FDA Southwest Regional/District Office, Dallas District; and a warning letter from the FDA’s Human Subjects Protection Team, Division of Scientific Investigations, Office of Compliance, dated 2009:
    • Enrollment of subjects into antineoplaston study protocols prior to the protocol-specified interval following prior chemotherapy and/or radiation therapy.
    • Failure to report all serious adverse events (SAEs) and adverse events (AEs) to the agency and/or IRB.
    • Failure to follow proper informed consent procedures.
    • Failure to maintain adequate drug accountability records.
    • Discrepancies between case report forms and source documents.
    • Failure to keep a copy of the study protocol and informed consent form.
    • Failure to receive and/or require progress reports from the principal investigator for the study.
    • Failure to receive and/or require a final report from the principal investigator for the study prior to removal from the IRB’s active list of studies.
    • Failure to assure that FDA approval was obtained by the principal investigator for the study prior to the treatment of a patient under a special exception.
    • Approval of special exceptions via expedited review.
    • The IRB approved research without determining that the following criteria were met: That risks to subjects were minimized and that risks to subjects were reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result.
    • The IRB failed to prepare, maintain, and follow written procedures for conducting its initial and continuing review of research.
    • The IRB failed to ensure that informed consent would be sought from each prospective subject or the subject’s legally authorized representative.
    • The IRB failed to ensure that no member participated in the initial or continuing review of a project in which the member had a conflicting interest.
    • The IRB failed to conduct continuing reviews.
The latest round of findings from the FDA’s most recent investigation eight months ago reads like an acid flashback of investigations past. According to the FDA warning letter based on this FDA Form 483, covering the inspection dates from January 22 to February 7, 2013, here’s what the FDA dinged Burzynski for this time. The CliffsNotes version is this:
     1.  The IRB failed to follow FDA regulations regarding expedited review procedures [21 CFR 56.110(b)].
     2.  The IRB approved research without determining that the following criteria were met: risks to subjects were minimized [21 CFR 56.111(a)(1)]; risks to subjects were reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result [21 CFR 56.111(a)(2)].
     3.  The IRB failed to determine at the time of initial review that studies involving children are in compliance with 21 CFR part 50, subpart D, Additional Safeguards for Children in Clinical Investigations [21 CFR 56.109(h)]. This is a repeat violation from our 2010 inspection.
     4.  The IRB failed to prepare, maintain, and follow written procedures and maintain adequate documentation governing the functions and operations of the IRB [21 CFR 56.108(a), 21 CFR 56.108(b), and 21 CFR 56.115(a)(6)].
More detailed observations can be found in the Form 483. Basically, the Burzynski Clinic and BRI ran roughshod over human subjects protection. Most of the violations are fairly simple, even for lay people, to understand. For example, not making sure that patients enrolled on clinical trials meet the inclusion criteria, not reporting adverse events in a timely fashion, and not removing patients with adverse events from the study quickly are all fairly self-evident violations and not difficult to explain. It’s fairly easy to understand why failing to remove a patient who suffers an adverse event that the protocol says should be a reason to remove the patient from the protocol is a violation. One violation, however, is not as easy to understand for those not involved in clinical trials and therefore deserves a bit more discussion. I’m referring to Burzynski’s apparent abuse of the expedited approval process through his IRB. This seems to be the “theme” that ties together much of what is reported in this warning letter to the BRI; so I feel the need to explain a bit, in order to put it all into some context.
Quite reasonably, the Office for Human Research Protections (OHRP), the office in the Department of Health and Human Services that oversees IRBs, does not require the same sort of approval process for every sort of human subjects research. Not every study that involves human subjects research is a randomized clinical trial. For instance, in the case of human subjects research that involves pre-existing samples that have been de-identified can be exempted from full IRB review and oversight because, well, there are no human subjects to be endangered, even through linking of their identities to a specimen demonstrating a disease. Lots of research gets done this way, for example analyzing or staining pre-existing samples looking for a biomarker or a change in expression of a protein. I’ve done projects like this. This is commonly known as Exemption 4, and there are several other exempt categories.
However, Burzynski doesn’t abuse the exemption process, which, let’s face it, would be very hard to abuse for the most part. What he appears to have abused is the expedited approval process. The expedited review process generally involves approving things like minor revisions to research protocols and informed consent forms. “Expedited” generally means just that: Expedited. A full IRB review is not done, and a streamlined, faster process is used. Expedited approval can also be used for protocols that fall under categories that the Department of Health and Human Services (HHS) deems to be “minimal risk,” described thusly on the University of Kentucky website:
Expedited procedures can only be used to review a study if the only involvement of human subjects fits one or more of the categories specified in the federal regulations and if all of the procedures present no greater than “minimal risk.”
The IRB reviewer confirms that all of the research activities fit in one or more of the expedited categories. If the research includes activities that do not fit in the categories, the study is not eligible for expedited review even if the research involves “minimal risk.”
The Department of Health and Human Services defines minimal risk to mean “the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests” [45 CFR 46.102(2)(i)].
Investigators are asked to provide a risk assessment, but it is the IRB reviewer’s responsibility to determine whether the research meets the federal definition.
The IRB reviewer must consider two questions:
    • Is the probability of the harm or discomfort anticipated in the proposed research greater than that encountered ordinarily in daily life or during the performance of routine physical or psychological examinations or tests?
    • Is the magnitude of the harm or discomfort greater than that encountered ordinarily in the daily life or during the performance of routine physical or psychological examinations or tests?
If the answer is “yes” to either of these questions, then the research does not meet the definition of minimal risk.
A list of the types of research that can be approved through expedited review can be found on the OHRP website. These include things like blood draws, prospective collection of biological specimens by noninvasive means (one could collect urine specimens, for instance, under a protocol approved through the expedited review process), and research involving data that has already been collected. Here’s a hint: Approving “single patient protocols” for an investigational drug that is not FDA-approved does not fall into any of the categories for which expedited review is appropriate, particularly when so many of the patients involved are children and particularly when the drug being tested can cause severe hypernatremia. Basically, from my reading, Burzynski seems to be using the expedited review process to treat patients with antineoplastons who do not qualify for any of his numerous phase II trials, and until last year he was getting away with it. Again, one of the great mysteries is: How?
But that’s not all. The second Form 483 answers a question that many of us interested in Burzynski have wondered about for a very long time.
One mystery solved: What happened to all those complete responses?
There are two central mysteries about Stanislaw Burzynski that I would really, really like to see answered, and, hopefully, I will see them answered soon. The first is, of course: How has he gotten away with it for so many years? The second is: What are his real results? I’m not referring to the results Burzynski and his sycophants claim, but the real results? People like Paul Goldberg and others have been reporting for years that Burzynski’s results don’t seem to match his claims, with cancer experts who have seen some of his actual data reporting that Burzynski’s data “can never be useful to show true merit or lack of merit of his drug” because of an absence of rigorously reported results and independent verification” and “what we have here are bad trials that could never get past peer review of any clinical trials cooperative group.” Indeed, even back in the 1990s, serious adverse reactions were reported, mostly due to the hypernatremia. Now, thanks to these additional two FDA reports (here and here), we finally see a glimmering of light through the shroud of secrecy overlying the Burzynski Clinic.
Much of what is contained in these additional reports overlaps what I discussed before, but there is one kind of violation that does not. It’s a truly egregious violation that I find very difficult to comprehend, given how much it goes against every tenet of clinical research and clinical trials that I’ve been taught and learned over the years. It appears on this Form 483, where it’s discussed under “Observation 1,” and this other Form 483, where it’s discussed under “Observation 1” and “Observation 2.” The brief versions are stated either as “Failure to monitor the progress of an investigation under your IND”; “an investigation was not conducted in accordance with the signed statement of investigator and investigational plan”; or “failure to prepare or maintain adequate case histories with respect to observations and data pertinent to the investigation.” What does this mean? Basically, it means that the BRI misclassified tumor responses to therapy and adverse reactions. Worse, records that would allow the validation of responses to therapy are missing.
Before I get more specific, let me just briefly review what I mean by tumor response. Whenever a drug is given to treat a tumor, the response is the degree of tumor shrinkage that occurs in response to the treatment. In general, there are four categories of results defined and reported in clinical trials of new chemotherapeutic agent:
    • Complete response (CR): The tumors shrink away to the point that they are no longer detectable by physical examination, imaging studies (MRI, CT scan, etc.), or tumor markers. Obviously, this is the best possible result. This is further divided into a pathological complete response, which means that there are no detectable tumor cells in the resected tumor specimen. Obviously, when this happens, it is a very good thing and a very good prognostic sign. Sadly, it is not seen that often in clinical trials.
    • Partial response (PR): This is usually defined to mean that the tumors shrink by more than 50% (or, in the case where tumor volume cannot be measured easily, tumor markers fall by more than 50%) in response to therapy but remain detectable. More recent definitions have at times loosened this criterion to include tumors that shrink by 30% or more. Whatever the specific criteria used, a certain degree of tumor shrinkage, or evidence of tumor regression, defined before the clinical trial, must be observed.
    • Stable disease (SD): The tumors either shrink by less than the criteria for a PR or remain the same size. In some trials, this definition may be broadened to include tumors that increase in size slightly during therapy by less than, depending on the trial, 0-25%, although I’ve personally always been suspicious of calling any detectable growth above random variation in imaging measurements “stable.”
    • Progressive disease (PD): Tumors increase in size on therapy and/or new metastatic tumors appear. This is obviously strong evidence that in that patient the therapy did not work.
How tumor response is measured varies according to the tumor. Most commonly RECIST criteria are used. For brain tumors, there are criteria other than RECIST that are often used, such as the Macdonald criteria or its update, the RANO criteria. Other methods are being developed, as well. Obviously, there are pros and cons associated with each method. However, when you write a clinical trial, you have to pick one, stick with it, and use it appropriately to classify clinical trial subjects as either having CR, PR, SD, or PD. If these FDA reports are to be believed, Burzynski failed to do that. Worse, he either destroyed, or allowed to be destroyed, the original primary records used to make these determinations.
For example, the FDA notes that:
a. …For 18 of 27 (67%) of subjects, the investigator did not comply with the protocol requirements for assessing the efficacy endpoint of tumor response and recorded inaccurate assessments for tumor response in study records. For example:
    • Study [REDACTED]: Subjects 005297 and 007197 were inaccurately classified as Complete Response (CR). Subjects 004721 and 008765 were inaccurately classified as Partial Response (PR). Subjects 005974, 011373, 012184, 012206, and 12252 were inaccurately classified as Stable Disease (SD).
    • Study [REDACTED]: Subjects 06389, 11819, and 13660 were inaccurately classified as CR. Subjects 21428 and 23399 were inaccurately classified as PR.
    • Study [REDACTED]: Subject 009990 was inaccurately classified as CR. Subject 004881 was inaccurately classified as PR.
    • Study [REDACTED]: Subject 006239 was inaccurately classified as PR. Subject 004240 was inaccurately classified as SD.
b. You did not have a QA monitor properly monitor CRFs [case report forms] and subject records. The investigator destroyed critical subject case history records (target tumor measurement worksheets) or misplaced case history records (original subject CRFs) for all subjects.
Elsewhere, the FDA investigators note:
Your MRI tumor measurements initially recorded at baseline and on-treatment MRI studies for all study subjects were destroyed and are not available for FDA inspectional review.
The other Form 483 goes into a little more detail. Unfortunately, much of what I’d really, really like to know is redacted, specifically how each of these patients didn’t meet one or more of the criteria for the given response level to which Burzynski assigned them. Be that as it may, there’s plenty of damning information in these reports. For example, there are more examples of Burzynski’s failure to report adverse events (i.e., complications or bad things that happened to subjects being treated according to his protocols) in a timely fashion as required by the OHRP and the FDA. For example:
You failed to monitor as required by Section 16 of your Monitoring Plan. The investigator did not report adverse events (AEs) experienced by study subjects, including 18 cases of hypernatremia.
Now let’s look at what I mean when I said that Burzynski misclassified AEs. AEs are graded according to a system known as the Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE is nothing more than a list of AEs and SAEs (serious adverse events) commonly encountered in oncology. Each AE term is defined in the CTCAE and accompanied by a grading scale for severity. The AE terms are also organized by System Organ Classes defined by the Medical Dictionary for Regulatory Activities. The CTCAE is a long list, which can be downloaded as a Microsoft Excel spreadsheet, and it’s been updated several times. The most recent update is v.4.0, released in May 2009. Most of the AEs discussed by the FDA were from before that, so that CTCAE v.3.0 was being used to classify them. AE grades generally range from grade 1 (minor), grade 2 (moderate), grade 3 (severe), grade 4 (potentially life-threatening), to grade 5 (death).
Hypernatremia as I have discussed many times before, is a sodium concentration in the blood that is too high. If the hypernatremia is bad enough, it can be life-threatening. These reports document at least two subjects whose hypernatremia was graded a 2 when it should have been graded a 4. Of course, these two subjects pale in comparison to the number of patients whose hypernatremia either wasn’t reported or wasn’t reported for a long time. For example:
You failed to protect the rights, safety, and welfare of subjects under your care.
Forty-eight (48) subjects experienced 102 investigational overdoses between January 1, 2005 and February 22, 2013, according to the Weekly List of Hospitalizations/SAE [REDACTED] Overdose [redacted]/Catheter Infection report. Overdose incidents have been reported to you on a weekly basis during your Monday, Wednesday, and Friday staff meetings. There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects.
This last sentence bears repeating: “There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects.” So what we have here is a report finding that not only did Burzynski fail to report in a timely fashion a lot of SAEs, but that he tended to downplay the severity of the ones that he did report. Some AEs weren’t reported until as much as seven years later. Subjects also weren’t removed in a timely fashion for toxicity. For instance, one protocol stated that subjects would be removed after a third episode of Grade 3 or 4 toxicity or any single Grade 4 toxic effect that is “truly life-threatening or is not easily and rapidly reversible.” Of course, one wonders how the IRB could have approved such wording, as there is no distinction between “truly” life threatening and “life threatening” in the definition of Grade 4 toxicity. One patient had seven instances of Grade 3 or 4 toxicity but was not terminated from the trial until over a month after the seventh.
Other violations, although not as egregious, were nonetheless still quite bad. For instance, the informed consent didn’t include a statement of any additional costs to the subject that might result from the research. Several examples of patients who signed the informed consent days to weeks before they signed the billing agreement were presented. In addition, the Burzynski Clinic didn’t keep adequate records of its stocks of antineoplastons and could not account for how much was used by subjects. The number of bags of antineoplastons unaccounted for are truly staggering. One subject had 159 bags unaccounted for. Others ranged from one to 23 bags unaccounted for. Record keeping this sloppy would shut down nearly any clinical trial in and of itself.
The most serious violations of regulations designed to protect human subjects are clearly: (1) the BRI IRB’s misuse of the expedited approval process as an excuse to treat any patient Burzynski wanted to treat; (2) failure to keep original records to document baseline tumor measurements and tumor response; and (3) failure to report AEs and SAEs properly. However, there are a whole bunch of other lesser, but still serious, violations, so many that I find it hard to fathom.
The central mystery of the Stanislaw Burzynski saga
As a translational researcher who frequently works with clinical investigators, I just can’t figure out how Burzynski keeps getting away with it. Either the FDA is more impotent than I had thought, or Burzynski has some serious pull with some powerful people. If my university received even one report like one of the previous FDA reports about Burzynski, it would be quite possible that all federal research funding to the university for biomedical research would be suspended until the university fixed the problems to the satisfaction of the OHRP and FDA. Yet the FDA has found Burzynski to be deficient in numerous areas of human subjects protection multiple times over the last decade. These latest FDA Form 483 reports tell us nothing new, really, other than that Burzynski’s claims of complete responses are very likely nonsense.
If there’s one thing I’ve learned over the years about Brave Maverick Doctors, it’s that they often come to believe that the rules don’t apply to them. They crave the respectability of science, of course, but they are too impatient or too arrogant to play by the rules of science. Unfortunately, that often includes the rules designed to protect human subjects in clinical trials. We’ve seen it before with Mark and David Geier, who formed their own IRB stacked with their cronies. We’ve now seen it with Stanislaw Burzynski, who formed his own IRB. In the world of these Brave Maverick Doctors, the IRB apparently exists not to protect human subjects, but is instead viewed as a formality to funnel patients into whatever they want to do to treat them.
I’ve said it before, and I’ll say it again, though: The central mystery behind Burzynski is how he’s gotten away with what he’s gotten away with for nearly 37 years. It is the single question about Burzynski whose answer I want to know more than the answer to any other question about him before I shuffle off this mortal coil. Why does the FDA keep investigating him, finding serious violations, and giving him, in essence, a slap on the wrist? Since 2000, he’s been investigated multiple times, and he’s received FDA warnings for his violation of human subjects regulations. True, this is the first time since the 1990s that the FDA has taken substantive action against him, issuing a partial clinical hold that appears unlikely to be lifted any time soon, if ever. Still, I’m worried. If Burzynski comes up with a response that satisfies the FDA, he could conceivably have his same old bogus trials resurrected yet again. Why doesn’t the FDA shut down any clinical trials done by the BRI and Burzynski Clinic permanently? Why doesn’t it at least shut down the BRI IRB, which would have the effect of shutting down the Burzynski Clinic because no reputable IRB would ever approve the clinical trials that Burzynski proposes? To get its scientifically dubious clinical trials approved, Burzynski needs an IRB run by an old crony of his from Baylor (Carleton Hazelwood) who just so happens to be the chairman of the board of the BRI, a massive conflict of interest. Any other IRB with so many repeated violations and such a massively obvious conflict of interest would be shut down. Any other research institute with so many violations of FDA regulations would not be allowed to do clinical trials of any kind.
Yet the BRI persists. No matter how many times the FDA investigates it, no matter how many warning letters the FDA sends it, the BRI continues. In the 1990s, a powerful Congressman, Rep. Joe Barton, put serious pressure on the FDA through public hearings, the public dressing down of then-FDA director David Kessler, and who knows what behind-the-scenes pressure tactics to let Burzynski open clinical trials of antineoplastons. As Burzynski’s own lawyer put it, those trials were “all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment.” Since the FDA folded in response to Barton’s pressure in the 1990s, I haven’t heard news of Barton applying pressure to the FDA again over its investigations of Burzynski. True, the Republicans were in the minority during four years of the period since then, but even after they won the House back in 2010 I haven’t heard of any political pressure being brought to bear on the FDA. So I wonder: Is the FDA still so cowed from its previous experience that it can’t just pull the plug and shut Burzynski down completely?
It boggles the mind.

Stanislaw Burzynski and Robert O. Young: How two quacks of a feather illustrate how poorly states regulate medical practice
David Gorski on November 23, 2015
Link


One of the weaknesses in our system of regulating the practice of medicine in the United States is that, unlike most countries, we don’t have one system. We have 50 systems. That’s because the functions of licensing physicians and regulating the practice of medicine are not federal functions, but state functions. Each state sets its own laws and regulations governing the practice of medicine, making for wide variability from state to state. Some states are lax in their regulation (cough, cough, I’m talking to you, Texas), others are not so lax.
Given how often state medical boards and the other enforcement bodies states use to protect the public from professional misconduct and quackery, I thought I’d take this opportunity to update our readers on two men who have been frequent topics of discussion on this blog, Stanislaw Burzynski and Robert O. Young. The reason is that, through some bizarre confluence of events, both of them faced justice last week, in the form of a hearing due to action against Burzynski by the Texas Medical Board, and in the form of the trial of Robert O. Young in southern California.
What these two quacks share in common is that they’ve gotten away with their cancer quackery for a very long time, two decades in the case of Robert O. Young and nearly four decades in the case of Stanislaw Burzynski, with attempts by the law to bring them to heel having been largely ineffective. They are different in that one is a physician (Dr. Burzynski) and one is not (Young) and therefore different legal considerations come into play. Young, for instance, is a self-proclaimed naturopath known for his “pH Miracle Living” cure, which, he claims, can be used to cure basically any disease by “alkalinizing” the body. After two decades of running, he is being tried for practicing medicine without a license, and, of course, fraud. Burzynski, although not an oncologist, is a licensed physician in Texas and has been administering an unproven and almost certainly ineffective “natural” treatment consisting of substances derived from blood and urine that he dubbed “antineoplastons” (ANPs) back in the 1970s. He is also different in that he’s gotten away with this largely through abuse of the clinical trial process, which is regulated at the federal level through the FDA and the HHS. It is not, however, the federal government that is pursuing action against Burzynski, but rather the Texas Medical Board (TMB). Thus, while Young is on trial and could go to jail if he loses, if Burzynski loses he will only lose his license to practice medicine in the state of Texas.
Despite their differences, both Stanislaw Burzynski and Robert O. Young illuminate major shortcomings in how the legal system deals with quacks.
The Texas Medical Board Versus Stanislaw Burzynski, Round 4 (at least)
Last week as I contemplated what to write about this week, realized that it’s been a long time since I’ve written about Stanislaw Burzynski, the expat doctor who fled Poland in 1970 and for six years actually did legitimate cancer research at the Baylor College of Medicine. Convinced that he had made a major breakthrough in cancer treatment with his discovery of antineoplastons and apparently frustrated with the difficulties involved in doing legitimate clinical trials, Burzynski left Baylor and started treating patients with his home brew concoction in a private clinic. Since then, despite the fact that he has no training in medical oncology, Burzynski has treated thousands of cancer patients with ANPs beginning around the time he left Baylor and established over the intervening decades a reputation as a “miracle” cancer doctor who can cure deadly brain tumors that current conventional medicine cannot. He has managed this feat despite the fact that he’s never even come close to showing that ANPs are effective and safe against the cancers for which he uses it. Even so, the FDA has, with a brief interruption two years ago, continued to let him do his clinical trials, and the Texas Medical Board, despite at least three attempts since the early 1980s, has failed to strip Burzynski of his medical license. The best it managed to do was to put him on probation between 1994 and 2004.
It’s not because there hasn’t been a lot happening, either. Over a year ago, the Texas Medical Board decided to have another go at Burzynski. Over the last 16 months, what a long, strange trip it’s been. This week, the beginning of the climax of this effort was upon us. Indeed, what reminded me that the climax of this struggle is approaching was an e-mail from one of the several quack email lists to which I subscribe (in this case, The Truth About Cancer), which urged its members to support Burzynski:
As we’ve shared many times before, actually curing cancer would be detrimental to the pharmaceutical industry. So much so that they’re willing to do whatever it takes to silence the doctors as to keep their poisons as the only solutions.
They’re trying to do that now with Dr. Burzynski by revoking his medical license and we need your help.
We’re asking for volunteers in the Austin area to go to the State Office of Administrative Hearings on the morning of Nov 19th and exercise their right to protest these absurd charges and hearings.
It’s 9:00am on Thursday, November 19, 2015, at 300 West 15th Street, Fourth Floor, Austin, Texas. Hearings will continue through November 25, 2015, before recessing until January 19, 2016, when it will reconvene at 9:00am and continue through January 29, 2016, if necessary.
There will be a lot of media attention and we need to show how powerful our voices are and that we will NOT be silenced.
Please arrive at 8:30am and bring signs that read “Dr. Burzynski saves lives” or “Stop persecuting Dr. Burzynski” or whatever else you’re inspired to write.
Unfortunately, I personally will not be able to travel and be in Austin but I’m doing my best to tell everyone I can and I’m hoping you will too. Even if you can’t make it in person, please tell everyone you can on Facebook and other social media sites.
Hopefully, if you’re in Austin (or inspired to travel there) you can go and represent our movement in a powerful way.
Thank you for your consideration.
Ty Bollinger
Meanwhile, other Burzynski supporters were also rallying. Eric Merola, the film maker who made two massively deceptive “documentaries” (which I like to call Burzynski I and Burzynski II: Electric Boogaloo, because those are far less awkward titles than the multiple-subtitled ones Merola actually gave the movies) that amounted to the equivalent of hagiographies portraying Burzynski as the “brave maverick doctor” persecuted by the medical profession because he doesn’t play by its rules and can cure cancer where conventional oncologists cannot. Truly, it is not for nothing that I like to refer to Eric Merola as Stanislaw Burzynski’s own personal Leni Reifenstahl, even at the risk of going Godwin and even though Reifenstahl herself, were she still alive today, would recognize Merola for what he is: A talentless hack. Not surprisingly, the Alliance for Natural Health USA has also been trying to drum up support.
The whole situation is like a replay of the 1990s. If there’s one way Burzynski is very predictable it’s in his response to investigation and criticism. Whenever Burzynski is in trouble or the law actually threatens his practice, he cynically uses desperate cancer patients as “human shields” against government investigation. He did it in the 1990s, when Burzynski was being prosecuted for 75 counts of insurance fraud and violations of the Food, Drug, and Cosmetics Act. It was cynical political theater featuring media appearances of the weeping parents of children with deadly brain tumors, national press stories about demonstrations by patients chanting, “FDA go away! Let me live another day!” It worked back then, although I note that at the time Rep. Joe Barton (R-Dallas) was also putting intense pressure on the FDA, dragging then-FDA Director David Kessler in front of his committee multiple times to harangue him about his “persecution” of Burzynski. The FDA told Burzynski that he could administer ANPs, but only under the auspices of an approved clinical trial. So, urged by his lawyer Richard Jaffe, Burzynski cynically submitted 72 clinical trial protocols to use ANPs to treat pretty much any cancer he wanted to treat, and the FDA approved them all. In the intervening 16 years from 1997 to 2013, Burzynski enrolled patients on his clinical trials and charged them enormous “case management” fees for the privilege, even though doing so is completely unethical.
Of course, two years ago, Burzynski’s clinical trials were placed on partial clinical hold after the death of Josia Cotto of hypernatremia (very high sodium levels in the blood, a known complication of ANP treatment). In the wake of that decision, Burzynski went back to the tactic that had served him so well, mobilizing his patient base to do the same thing it did in the 1990s. Not long after that, the FDA gave in and let him begin his clinical trials again, albeit with conditions. Specifically, Burzynski had to provide ANPs for free, and he couldn’t be the one administering the cocktail. Then, last year, the FDA lifted all restrictions on Burzynski’s clinical trials. Burzynski had won again, but not long after that, the Texas Medical Board acted to strip Burzynski of his license.
The TMB’s 200 page complaint documents the charges that Burzynski misled patients by:
    • Making patients pay a retainer before receiving any diagnosis or treatment.
    • Performing unnecessary tests and “non-therapeutic treatment” with no potential to help them.
    • Imposing “exorbitant charges” for drugs and lab tests, without telling patients that he also owned the pharmacy and lab being used.
    • Allowing unlicensed staff to treat patients, while describing the staff as doctors.
Burzynski was also charged with prescribing unapproved combinations of toxic chemotherapy, which is quite ironic. Burzynski has been treating patients with an unapproved cancer drug (antineoplastons) for nearly four decades, but that’s not the heart of the case. Rather, the heart of the case appears to be Burzynski’s off-label use of what I like to call Burzynski’s “make it up as you go along” cocktails of expensive targeted therapies that he touted as “personalized, gene-targeted therapy” and I more accurately described as “personalized, gene-targeted therapy for dummies.”
The Houston Cancer Quack has a nice (and, unlike one of my typical posts, brief) summary of what’s been happening to Burzynski’s case over the last several months. Basically, as is commonly the situation in cases like this, there have been a number of motions and countermotions. In March, the judge rejected a large number of Burzynski’s motions to suppress evidence brought by the TMB, including testimony by FDA inspectors, FDA inspection documents, and the testimony of a former employee, the last of which looked to be particularly damaging to his defense.
Perhaps the most interesting and unexpected aspect of this whole case occurred over the summer, and when I say “unexpected,” I really mean it. Remember Richard Jaffe, whom I mentioned earlier and who was the architect of Burzynski’s wildly successful strategy of submitting over 70 clinical trials to the FDA, a strategy that served as the basis for Burzynski’s reputation and increasing wealth over the better part of the last 20 years? It was a strategy that didn’t start to fall apart until the partial clinical hold was placed on his clinical trials and Burzynski was forced to substitute his far less popular “personalized gene-targeted therapy.” The reason it was far less popular is because ANPs, for whatever reason, were viewed among the alternative cancer cure crowd as being a “natural” treatment for cancer (presumably because they were originally isolated from urine and blood) while Burzynski’s “personalized gene-targeted therapy” consisted of cocktails of expensive targeted therapies made by pharmaceutical companies. It turns out that Jaffe is no longer Burzynski’s lawyer, even though he had been working for Burzynski for decades. As Skeptics for the Protection of Cancer Patients drolly noted, those of us trying to expose Burzynski’s quackery all thought that Jaffe would be buried in the Burzynski family crypt, so tight had Burzynski and Jaffe been for so many years.
Apparently not any more.
How this shocking situation came about is not entirely clear, but it appears to involve—gasp!—enormous unpaid legal bills. Basically, a new lawyer, Dan Cogdell, started filing motions for Burzynski. It turns out that Cogdell was part of Burzynski’s legal team before. In any case, the judge became concerned that it was late in the game to be switching lawyers; so another administrative law judge heard Jaffe’s explanation in private and ruled that Jaffe had to withdraw from the case. Per Judge Suzanne Marshall’s finding, Jaffe’s continued representation would violate the mandatory withdrawal provision of Rule 1.15. This provision reads:
A lawyer ordinarily must decline employment if the employment will cause the lawyer to engage in conduct that the lawyer knows is illegal or that violates the Texas Disciplinary Rules of Professional Conduct. Rule 1.15(a)(1); cf. Rules 1.02(c), 3.01, 3.02, 3.03, 3.04, 3.08, 4.01, and 8.04. Similarly, paragraph (a)(1) of this Rule requires a lawyer to withdraw from employment when the lawyer knows that the employment will result in a violation of a rule of professional conduct or other law. The lawyer is not obliged to decline or withdraw simply because the client suggests such a course of conduct; a client may have made such a suggestion in the ill-founded hope that a lawyer will not be constrained by a professional obligation. Cf. Rule 1.02(c) and (d).
So apparently Jaffe withdrew because he was concerned that his continued representation of Burzynski would somehow result in his violating a rule of professional conduct or other law. What could this mean? The explanation came when Jaffe withdrew from representing Stanislaw Burzynski’s son, Greg Burzynski and gave the following reason:
Respondent is a vice president and an employed physician at the Burzynski cancer clinic in Houston. The clinic is owned by Respondent’s father, Stanislaw R. Burzynski. Undersigned counsel had represented Stanislaw Burzynski in a related SOAH board case.
Undersigned counsel is taking legal action against Respondent’s employer which might have a material adverse effect on Respondent’s interests as an officer and employed physician at the clinic. As a result of such action, undersigned counsel will likely have a conflict of interest with Respondent, at least until the anticipated legal action is resolved.
In other words, Jaffe is suing Burzynski. But why? It turns out that Burzynski owes Jaffe nearly a quarter of a million dollars, and Burzynski hasn’t paid. In fact, Jaffe appears to be suing to force Burzynski into involuntary chapter 7 bankruptcy.
I tried not to go into too much detail in this post (which, as regular readers know, is hard for me) because a lot of the legal wrangling and back-and-forth comes across too much as “inside baseball.” It doesn’t help that I’m not a lawyer and don’t understand a lot of it. What I do understand is that, this week and in January, the TMB is doing its best to finally put an end to Stanislaw Burzynski’s cancer quackery, and I wish them the best in this endeavor.
To me, it’s a good sign that, for whatever reason, this time around the political theater that surrounded Burzynski’s 1997 trial is minimal to nonexistent, although there are some rather laughable letters being sent to the TMB. I have yet to see photos of terminally ill cancer patients with signs trying to shame the TMB, although there is a Change.org petition with over 13,000 signatures petitioning the TMB to “Save Doctor Burzynski’s Life-Saving Cancer Treatment,” complete with a video showing Hannah Bradley as one of Burzynski’s “success stories,” even though she was almost certainly saved by conventional treatment, not Burzynski. Thus far, news coverage of the disciplinary hearing has been minimal outside of local news media. I also hope that, with the rift between Burzynski and his former consigliere and architect of the strategy that has allowed Burzynski to abuse the clinical trial process for so many years to charge patients exorbitant sums to enroll in his clinical trials, Burzynski will finally fall.
Robert O. Young finally faces justice
Robert O. Young is a quack whom I’ve written about more on my not-so-super-secret other blog than here. Basically, Young is a naturopath (or claims to be one), two of whose seemingly-impressive degrees came from diploma mills and whose degree in naturopathy came from Clayton College of Natural Health, a nonaccredited correspondence school that taught a panoply of quackery. For twenty years he’s been plying his cancer quackery (and quackery for HIV and other serious diseases) at Rancho del Sol, an avocado and grapefruit ranch in Valley Center, California that he’s turned into a plush retreat called the pH Miracle Center, where he offers juicing, cleanses, and all manner of dubious and bogus treatments. He even has a coaching program in which he trains other quacks in his method and offers “group cleanses.” (Eewww!)
When I took note of Robert O. Young’s arrest in January 2014, I experienced not a small amount of schadenfreude, for which I felt no guilt in this case. Seeing quacks hauled before a judge makes me happy. Even so, as much as I enjoyed the sight of Young in a prison jumpsuit—if only it were orange instead of blue!—I nonetheless asked at the time: Will it stop him? During the nearly two years since his arrest, his arrest and impending trial for practicing medicine without a license and fraud seemed not to deter him in the least. He still did his “pH Miracle” cruises. (What is it with cranks and cruises these days? Is this a thing?) He still has his “pH Miracle” retreats planned in Como, Italy in December and January. (I wonder what will happen if he’s convicted.) He still runs his pH Miracle Center at the Rancho del Sol. He’s been promoting the “world’s first functionally structured alkaline water kiosk” and accepting awards from International Association of Colon Hydrotherapy. His blog, Twitter feed, and Facebook page have remained active this week promoting his activities, with nary a mention of his trial. Indeed, when I was first made aware that Young’s trial had begun last week, it caught me completely by surprise, given how little I had heard about what was going on since early 2014:
The author of a popular series of books espousing an alkaline diet as a way to improve health began standing trial this week in a Vista courtroom on charges that he practiced medicine without a license and took money under false pretenses.
In opening arguments Wednesday, prosecutor Gina Darvas described the defendant, Robert O. Young, as the proverbial “man behind the curtain,” making money peddling pseudoscience to desperate, dying people. Defense attorney Paul Pfingst said Young is under attack for espousing alternative views to traditional medicine.
Young, 53, faces nine charges linked to his work at his posh Valley Center compound, The pH Miracle Living Center, where people came for $2,000-a-day retreats. He is charged with seven counts of practicing medicine without a license — including inserting intravenous lines into people — and two counts of grand theft.
The trial is slated to last approximately four weeks, and thus far it hasn’t seemed to stop Young’s social media activity, although he makes no mention of his trial. No doubt he’d love to, in order to paint himself as the victim being persecuted by The Man (and Big Pharma) to keep his natural medicines from the people (which is always good for quack business), but I’m guessing his lawyer probably nixed that idea.
For those of you not familiar with Robert O. Young, a brief recap is in order. For this, a picture (or in this case, a PowerPoint slide that I’ve used before in various talks about cancer quackery) is worth a thousand words (not that that’ll stop me from using a thousand words to describe Young if I deem it necessary).
Basically, to Young, acid is the cause of all disease, to the point that he states that “overacidification” is the cause of all disease, an overarching theory of all disease that he has dubbed The New Biology, and about which he frequently states that “the pH Miracle Lifestyle and Diet is a program focuses on the foundational principal that the body is alkaline by design and yet acidic by function. This makes this program the ultimate program for preventing and reversing aging and the onset of sickness and dis-ease. I would say that the pH Miracle Lifestyle and Diet is the diet for immortality.” (Note that another of Gorski’s rules, besides the rule that health practitioner who invokes Béchamp over Pasteur is to be avoided like the plague, is that anyone who uses the term “dis-ease” instead of “disease” is to be similarly shunned.)
For example, after a beautiful aspiring young Brazilian model named Mariana Bridi da Costa died of sepsis after a urinary tract infection so severe that she had had to have her hands and feet amputated in a desperate bid to save her life, Young wrote a post entitled “Ignorance Caused Sepsis or Systemic Acidosis That Took The Life of a Young Brazilian Woman“, in which he blamed “acidic lifestyle choices, including acidic food, drink, and drugs” and proclaimed, “Most people believe that sepsis or acidosis is an infection. It is not!” He explicitly denies germ theory to the point where he has written posts like “The Illusion of Germ Theory“, in which he refers dismissively to “Pasteurian scientific dogma,” challenges “everything in the modern construct of immunology and what is said to be the immune system,” and characterizes viruses as “molecular acids.”
Oh, and so is cancer. Well, not exactly. Cancer is…well, let me just quote Young to give you an idea:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is [sic] localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
This is, as they say, so wrong it’s not even wrong. Worse, as I described before when Young was arrested, his quackery can be blamed for at least one preventable death, that of Kim Tinkham, the woman who became briefly famous when she went on television with Oprah Winfrey, shocking even Oprah with her assertion that she was so inspired by The Secret that she had decided to go her own way and treat her stage III breast cancer with Robert Young’s “alkaline diet.” She didn’t reveal that it was Young until later, when she did testimonials for Young and appeared in an interview that was on YouTube but has since vanished down the memory hole. (True fact: I happened to have saved that video from YouTube and was therefore more than happy to provide a copy to the San Diego County District Attorney’s office last year.) Ultimately, Tinkham died of what was almost certainly metastatic breast cancer.
Based on his “alkaline diet,” Young ran a very lucrative quack spa business, both at Rancho del Sol and “on the road,” so to speak, as far away as Italy. Add to that his numerous courses and speaking engagements, and Young did quite well. Ironically, what tripped him up was not his claim that he could treat patients with diet alone, but, as is the case with many quacks, overreach. Basically, he started offering other treatments. Investigators ran a sting operation on him using officers posing as cancer patients, and Young made bogus diagnoses and offered bogus treatments. Two years later, we will see if Young is convicted.
The problem with state medical regulation
Whenever I come across egregious cases of misconduct by physicians, be they quacks like Robert O. Young or incompetent surgeons like Christopher Dunstch, I note the problems with how state medical boards function. First and foremost most state medical boards are understaffed and have too few resources for the tasks that they are charged to carry out. They are also made up of physicians, which means that (1) they tend to be reluctant to question another physician’s judgment unless the case is so far beyond the pale that no physician would fail to consider it a gross violation of the standard of care and (2) physicians tend to sympathize with other physicians and not to want to deprive them of their means to earn a living by taking their licenses away. This problem is magnified in Texas, where the TMB, by design and statute, is weak and doctors’ rights are strongly protected in their interactions with the TMB. Consequently, they tend to stick to the most egregious, easily provable cases, such as physicians who are substance-impaired, commit fraud, or diddle patients. Outside of that, in Texas it is enormously difficult to take away a physician’s license to practice. In other states the situation is not as bad, but the same considerations apply. Add to that how expensive it is to prosecute a case like the one against Burzynski, who has up until now been able to afford the best lawyers and who has had significant political pull, and it’s a wonder that the TMB decided to act. The current TMB is to be commended for this. Even though the outcome is nowhere near certain and the disciplinary proceeding might well fail, the TMB is doing the right thing at significant cost.
The bigger failure in the Burzynski case is that of the FDA. Burzynski has been running his bogus clinical trials for more than 17 years now, and it took the death of a six-year-old before the FDA shut him down, even though the FDA had investigated him multiple times before that. Worse, the shutdown was temporary. All Burzynski had to do was to file a remediation plan sufficiently convincing to the FDA that he was cleaning up his act, and he was free to enroll patients again. Whenever I see quacks ranting about the “fascistic” FDA, I roll my eyes, given how the FDA suffers from many of the same problems as state medical boards. It’s chronically underfunded, and given the current antiregulatory bent of Congress that situation is unlikely to change any time soon, even as legislators try to weaken the FDA in the name of “innovation” with misguided bills like the 21st Century Cures Act. One day, the story of why the FDA failed so monumentally in the Burzynski case will come out. I just hope I’m alive to see it, because it’s the biggest question I have remaining about him.
The law has nearly as much difficulty stopping non-physician quacks like Robert O. Young from taking advantage of desperate patients. Notice how Young could have gotten away with practically anything as long as he only recommended dietary changes to treat cancer, and it took him hiring physicians to prescribe dubious treatments to trip him up. It also doesn’t help that so many states are licensing quack specialties like naturopathy, where there is no standard of care and, let’s face it, even treatments and ideas like those advocated by Young are not beyond the pale.
Then there are even more misguided “health freedom laws” and far too much deference shown to quackery. For example, in her opening statement, prosecutor Gina Darvas said that Young’s trial “is not an attack on alternative medicine.” When I read that, my first thought was: Why the hell not? Alternative medicine for cancer costs patients’ lives!
It won’t be, though. In California, for instance, there is SB 577. This bill was passed and signed into law back in 2002 and was designed to regulate alternative medicine practitioners. Basically, it allows the practice of medicine without a license, as long as the practitioner provides clients with a clear statement that he is not a licensed physician, a list of services provided, and a description of training. Because of this, I feel for Darvas. I don’t know what her evidence includes, but based on SB 577, my guess is that her best bet will be to get Young on the fraud charges because convicting him for practicing medicine without a license is going to be difficult. The California legislature intentionally made it that way 13 years ago.
California is by no means alone, either. Jann Bellamy has pointed to bills and laws that she refers to as the quack full employment act (Colorado) and “quack protection law” (Nevada). Such are the fruits of the “health freedom” movement and the increasing acceptance of pseudoscience that prosecutors, state medical boards, and the police have a hard time prosecuting and convicting even the most egregious and long-practiced quacks, like Robert O. Young. Add to that an insufficiently-rigorous and poorly-funded regulatory structure in most states, coupled with excessive deference to the prerogatives of physicians, and you have physician-quacks like Stanislaw Burzynski getting away with administering unproven cancer treatments since the 1970s. Worse, even if the TMB is successful in its action, the worst that Burzynski will suffer is the loss of his medical license.
Let the patient beware!

The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine
After three years and countless twists and turns, the final decision by the Texas Medical Board on the sanctions to be imposed on Houston cancer quack Dr. Stanislaw Burzynski were announced on Friday. Sadly, they were not enough. The Burzynski saga should serve as a cautionary tale that the regulation of physicians and medicine is too lax, not too strict.
David Gorski on March 6, 2017
Link

I’ve been blogging here fairly regularly about Houston cancer quack Dr. Stanislaw Burzynski since 2011, and now the story is over…sort of. Unfortunately, as you will see, the ending is not satisfactory. It is, however, somewhat better than I had feared it would be. What I’m referring to, of course, is the final ruling of the Texas Medical Board (TMB) regarding Dr. Burzynski, the Houston cancer doctor who has been a frequent topic of this blog because of his practices of charging desperate cancer patient tens (or even hundreds) of thousands of dollars for his “antineoplastons” (ANPs) and, later, what he refers to as “personalized, gene-targeted cancer therapy” (or, as I like to call it, making it up as you go along). Over the course of the last several years, a credulous filmmaker by the name of Eric Merola contributed to Burzynski’s reputation in the alternative medicine world as a “brave maverick doctor” with two blatantly deceptive “documentaries”, Burzynski The Movie: Cancer Is A Serious Business and Burzynski: Cancer Is A Serious Business, Part 2, or, as I like to call it, Burzynski 2: Electric Boogaloo.
Burzynski’s is a long and tangled story, one that I’ve blogged about many times. The details up to early 2014 are covered in an article I wrote for Skeptical Inquirer entitled “Stanislaw Burzynski: Four Decades of an Unproven Cancer Cure.” Burzynski has been selling cancer quackery since roughly 1977, which is around the time he left Baylor University to set up his own private practice and manufacturing facility to make and administer his ANPs for big bucks to desperate cancer patients, many of whom had terminal brain cancers like glioblastomas. The TMB and then, beginning in the 1990s, the FDA have been trying to shut him down ever since, all with only temporary success, as when the FDA managed to put a partial clinical hold on Burzynski’s clinical trials in 2013. It was initially issued for children but then extended to adults and was based on the death of a six-year-old boy named Josia Cotto the year before, of hypernatremia (too much sodium in the blood, a known complication of ANPs delivered at the doses Burzynski uses). The success was short-lived, as the partial clinical hold was lifted a year later, because, according to the FDA, the Burzynski Clinic answered all its questions and concerns.
Most recently, in 2014 the TMB, after a long investigation, decided once again to initiate legal action to strip Burzynski of his medical license. (It had tried and failed back in the 1980s and 1990s to do just that.) Unfortunately, the final ruling came in on Friday, and Burzynski was put on probation. He still has his medical license. Yes, there are conditions and TMB oversight that he’ll have to abide by, and yes, he was fined $60,000, but I view the sanctions as not a lot more than a slap on the wrist. Once again, the TMB has failed to shut Burzynski down. Before I discuss the latest ruling, let me step back a moment, for the benefit of those unfamiliar with Burzynski and those who might not remember enough to put this ruling into context, and provide a bit of background about why I consider him a cancer quack and how he’s shown the inadequacy of the TMB and the FDA in dealing with such brazenness.
Stanislaw Burzynski: The early years
On the surface, it’s easy to mistake Stanislaw Burzynski’s story for that of a classic riches-to-rags-to-riches story. Born in 1943 in Lublin, Poland, just as the Holocaust in Poland was entering its most deadly phase, Burzynski was fortunate enough to have been born to a mother whose family was wealthy and was therefore mostly sheltered from the horror of Nazi-occupied Poland. Of course, he wasn’t even two and a half yet by the time the Third Reich fell, but that occupation was soon replaced with another one almost as bad and much more enduring, that of the Soviet Union. After the war, when Burzynski was five, his older brother Zygmunt was killed fighting the newly installed Communist regime, which affected him his whole life. Basically, he idolized the idea of fighting authority.
Very little is known about the next couple of decades, other than that Burzynski was a good student, and that he got into medical school. By 1970, he was a promising researcher and was recruited by the Polish Communist Party. He refused to join, and in retaliation the Party saw to it that he was drafted into the Polish Army. So Burzynski fled to the US “with only $20” in his pocket in 1970 to stay with an uncle. He soon found a research position in the Department of Anesthesia at the Baylor College of Medicine in a laboratory headed by Georges Ungar, a Hungarian refugee with whom he immediately hit it off. Ungar was famous at the time for proposing that memory resided in peptides in the brain and for his experiments to “transfer” memory by transferring the putative “memory” peptides from one mouse brain to another. It was a hypothesis that seemed to be supported by his experiments but soon faded from favor. At Baylor, Burzynski split his time between working on Ungar’s projects and studying his antineoplastons. He appeared to be well on his way to becoming a successful cancer researcher, securing an NIH grant in 1974 and publishing several peer-reviewed papers.
Basing his concept on cybernetic systems and information theory, Burzynski hypothesized the existence of ANPs as the mediator or regulator of information exchange in autonomous systems that carried information about differentiation to the cells and began to look for peptides in the blood of cancer patients that might correct the abnormal differentiation of cancer. I don’t need to go into detail here about the whole story. However, if you’re so disposed, you can delve into the details in my SI article, a famous The Cancer Letter article, and the NIH website. In brief, based on his hypothesis, Burzynski used gel filtration of blood and urine fractions and tested them for activity against cancer cells. Although there were many fractions initially, these days “antineoplastons” generally refer to AS-2.1 (also known as Astugenal or Fengenal) and A-10 (also known as Atengenal or Cengenal). Basically, AS-2.1 is the sodium salt of phenylacetic acid (PA), a potentially toxic chemical produced by normal metabolism and detoxified in the liver to phenylacetylglutamine (PAG). To boil ANP chemistry down to its essence, AS-2.1 is primarily a mixture of PA and PAG, and AS-10 is primarily PA. Of note, PA had been studied as a potential anticancer agent years before Burzynski discovered it and, although it has been studied intermittently for fifty years, it has shown little promise against brain tumors. More recently, Burzynski has hijacked an orphan drug for urea cycle disorders, sodium phenylbutyrate, because it is a prodrug that is metabolized into PA.
In 1976, though, when he wanted to begin his clinical trials, his ANPs weren’t even fully chemically characterized, and only one of them had been tested in mice. It didn’t work, but Burzynski excused that failure by saying that ANPs were species-specific. Earlier, in 1973, Burzynski had gotten his Texas medical license. Even though he had not done a fellowship in oncology or even a residency in any medical specialty, by 1976 he thought himself uniquely qualified to do a clinical trial of ANPs. Again, all the details are discussed elsewhere, but Burzynski managed to do a case series, although it’s not clear if it ever had ethical approval, and, when the Baylor ethics board refused to approve a clinical trial, managed to get a nearby hospital to approve it. Ultimately, he left Baylor and formed his own practice, to administer ANPs to patients, setting up his own manufacturing facility, first to isolate the peptides from gallons of urine and then to synthesize them once their chemical identities had been worked out.
As I’ve recounted before, from the late 1970s to 1998, Burzynski was under nearly constant investigation by medical authorities, beginning with the Harris County Medical Society in 1979 and continuing with the TMB and the FDA. Indeed, before this most recent ruling, the TMB has tried to strip Burzynski of his license to practice twice, failing to do so in 1993 and 2012. The latter time, Burzynski got off on a technicality.
Why I view Burzynski as a cancer quack
It is my educated opinion that Burzynski is a cancer quack. I do not make that charge lightly and will back up my opinion. Beginning in the late 1970s, he began administering ANPs to cancer patients without their having been demonstrated to be safe and effective in well-designed clinical trials. The “brave maverick doctor” that he is, he just knew they worked, and, like many cancer quacks, over the years he accumulated what seemed like “success stories.” However, as I’ve discussed many times over the last 6 years, if you look at them more closely, these “success stories” can almost always be explained by the conventional treatment patients have undergone before they turned to Burzynski. Examples abound, patients such as Hannah Bradley, Laura Hymas, Tori Moreno, and Mary Jo Siegel, and Sheila Herron. I note that, of these, Laura Hymas featured prominently as a success story, only to die of recurrent cancer a year after the second Burzynski movie featured her so prominently. Particularly memorable was a scene in which audio was played of her and her family trying to persuade her NHS oncologist to do routine tests as part of Burzynski’s clinical trial and him trying to explain to her that he can’t do that because his was an unapproved treatment and his clinical trial was not approved by the NHS. As a fellow physician, I really felt for that oncologist, who was put in a very difficult position. These are but a few of the patients. Fellow skeptic Bob Blaskiewicz maintains a blog, The Other Burzynski Patient Group, patterned on a website set up by Burzynski patients to tout the “success stories,” that documents just how many of these patients have died.
More importantly, the website documents the suffering, both physical and financial, of patients who are lured to the Burzynski Clinic by promises of cures, most often promoted by Burzynski believers like Eric Merola. (Indeed, his Burzynski movies have probably generated more business for the Burzynski Clinic than anything else in Burzynski’s 40 year history.) Basically, Burzynski charges exorbitant fees for his services. He likes to claim that he charges nothing for his ANPs, and, after the FDA cracked down on him, that was true. However, he charges huge “case management” fees. For example, Pete Cohen, Hannah Bradley’s husband, documented why his fundraising target to get his then-fiancée treated in Houston was £200,000 (approximately $246,000 at yesterday’s exchange rate, a lot more back in 2012), estimating her monthly costs to be £8,600. Moreover, £200,000 wasn’t even that high for a Burzynski patient. The prodigious fundraising required to afford Burzynski’s treatments has been documented at TOBPG and all over the blogosphere and includes cases such as that of Seán Ó’Laighin (who did not survive), Rene Louis, Jesse Bessant, Rachel Mackey, Luna Petagine, Wayne Merritt. and Chiane Cloete. A lot of these people came from the UK, and perhaps the most famous two included Billie Bainbridge, whose family raised hundreds of thousands of pounds and got celebrities to help in order to travel to Houston, and Amelia Saunders, a lovely child who was unfortunate enough to be diagnosed with a brain tumor whose parents raised over £200,000 in 12 weeks in order to pay for Burzynski’s treatments and who was featured as a great “success story” by Merola and Burzynski. What really angered me (even more than a typical Burzynski story) is that Burzynski told the father that the formation of cysts in the tumor was the tumor dying because of treatment when in reality it is quite common for tumors to outgrow their blood supply, leading to the death of cancer cells in the middle. Sadly, Amelia also ultimately died.
Here’s where Burzynski is different—and worse—than typical cancer quacks, such as those in Tijuana. Basically, unlike the vast majority of other cancer quacks, Burzynski has had clinical trials open, lots and lots of them, and he has used them as a tool to continue to be able to administer ANPs. Worse, he charges patients enrolled in his clinical trials, a practice that is very much frowned upon and considered, with very few, defined exceptions, to be unethical.
Here’s how he pulled it off. It was the prosecution brought against Burzynski by the FDA during the 1990s that spawned the oft-touted “six dozen” clinical trials. In the fall of 1995, a grand jury indicted Burzynski for seventy-five counts of insurance fraud and violations of the Food, Drug, and Cosmetics Act. As part of this process, Judge Simeon Lake of the U.S. District Court for the Southern District of Texas, ruled that Burzynski’s “continued pretrial release” was contingent upon his administering his drugs exclusively through FDA-approved clinical trials. During the trial in the 1990s, Burzynski’s PR defense against prosecution established and has remained constant ever since. When threatened, he rallies his patients around him to accuse whatever regulatory agency is pursuing Burzynski this time of cruelty and wanting to let them (or their family members die). More recently, thanks to his newfound fame after Merola’s movies, he’s taken to dispatching celebrities like Suzanne Somers, Fabio Lanza (whose sister suffered from end stage ovarian cancer), and Sammy Hagar (whose drummer’s wife suffered from a terminal brain tumor) to defend him. He’s also cultivated powerful political allies, such as Representative Joe Barton (R-Texas), who held a series of hearings featuring cancer patients who were, quite understandably, terrified that Burzynski would be convicted. (Remember, these patients were completely convinced that Burzynski was the only person who could save them.) He also used to routinely drag the FDA Commissioner in front of his committee to castigate him for “persecuting” Burzynski.
As a result, the FDA entered negotiations to let Burzynski set up clinical trials, and Burzynski’s then-lawyer Richard A. Jaffe decided to take advantage of Judge Simeone’s ruling and the political pressure on the FDA, saying, in essence, “If the judge wants clinical trials, we’ll give him clinical trials.” So that’s just what they did. Prosecutors pleaded with the FDA not to give in because it would undermine their case, but the FDA overruled them. First, patients already being treated were enrolled in a wastebasket trial known as “CAN-1”, a retrospective trial looking at all patients then being treated at the Burzynski Clinic. Of this trial, Jaffe (2008) wrote:
. . . As far as clinical trials go, it [CAN-1] was a joke. Clinical trials are supposed to be designed to test the safety or efficacy of a drug for a disease. It is almost always the case that clinical trials treat one disease. The CAN-1 protocol had almost two hundred patients in it and there were at least a dozen different types of cancers being treated. And since all the patients were already on treatment, there could not be any possibility of meaningful data coming out of the so-called clinical trial. It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
I always repeat these quotes by Jaffe because they demonstrate the cynicism behind Burzynski’s actions. It gets worse, though. The FDA also permitted Burzynski to set up nearly identical phase 2 trials for every cancer that he wanted to treat. Burzynski claimed these were based on a protocol used in a trial done by the National Cancer Institute in the early 1990s when the NCI had tried to work with Burzynski. (This effort failed because of strife between the NCI and Burzynski, who viewed the NCI as trying to sabotage the trial. These trials had but one purpose, to allow Burzynski to continue treating patients with ANPs, as Jaffe himself boasted (2008):
CAN-1 allowed Burzynski to treat all his existing patients. That solved the patients’ problems, but not the clinic’s. A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future.
The prosecution was undermined, and the first trial ended in a hung jury in 1997. A second trial on a subset of the original charges resulted in Burzynski’s acquittal. Since then, Burzynski has practiced (mostly) untroubled by the FDA, other than intermittent inspections and warning letters. The TMB tried to take away his license in 2012 and failed on the slimmest of technicalities. Basically, the TMB went after Burzynski based on the doctrine of vicarious liability, which means in essence that the TMB was arguing that Burzynski was responsible for the actions of the physicians working for him who had actually cared for the patients at the heart of the TMB’s case against Burzynski. In response, Burzynski moved to dismiss and/or strike TMB allegations against him to the extent that the allegations were based on the actions of other physicians working at his clinic. His attorney’s argument was that, under administrative law, there is no vicarious liability for the actions of others. This is apparently different from tort law (for example, medical malpractice), where the physician can be held liable for the actions of physicians working under his control or supervision in some circumstances. The bottom line is that the administrative judge ruled in Burzynski’s favor. Basically, by throwing his fellow physicians working for him under the bus, Burzynski walked. Meanwhile, since 1998 he’s been enrolling patients on clinical trials, charging them, and not publishing his full results for a long time. Recently, he has published a few reports, but they’ve all been in bottom-feeding journals and/or don’t report the whole trial. The closest thing he had to a decent publication showed that ANPs didn’t work against colorectal cancer metastatic to the liver. He even just did it again last month.
Then, in 2014 the TMB decided to try again.
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The charges
In the summer of 2014, I learned through readers that the TMB was gearing up to take another go at Burzynski. I was surprised and cheered that the Board would be willing to try again so soon after its last defeat, but I remained pessimistic that anything would actually happen. The original complaint was over 200 pages long, but basically the TMB charges fell into three main categories:
     1.  Creating a “medical practice model based on marketing his proprietary anti-cancer drugs to patients without adequate measures for safety and therapeutic value.”
     2.  Misleading patients knowingly “by promoting these drugs as an attraction to bring patients to his medical practice when he was aware that he could not legally include most of those patients in FDA-approved Phase 2 clinical trials of his proprietary anti-cancer drugs” and “into paying funds as a retainer prior to receiving any evaluation, diagnosis or treatment.”
     3.  Misleading patients into: “(1) paying exorbitant charges for drugs and medical services; (2) accepting care from unlicensed persons while Respondent and Respondent’s employees misrepresented those unlicensed persons to be licensed medical doctors in Texas and the United States of America; and (3) accepting care from health care providers who had little advanced education or training related to cancer treatment while Respondent and Respondent’s employees misrepresented those health care providers to be doctors with significant advanced education or training related to cancer treatment.
Anyone who has paid attention to Burzynski should be able to tell that charges #1 and #3 are very provable. As for Charge #2, as I’ve discussed before, the Burzynski Clinic’s trials were on partial clinical hold, Burzynski did appear to be doing a “bait and switch,” where ANPs drew the patients in, and then he’d give them his jury-rigged “gene-targeted personalized” therapy consisting of cocktails of very expensive targeted therapies that were not known to be safe and effective when administered together. To prove these charges, the TMB described 12 patients (labeled Patients A through L) whose treatment did not live up to the standard of care in one or more of these three areas. For instance, the TMB charged that Burzynski treated Patient A with ANPs for colon cancer even though the patient had never had a biopsy and that non-physicians represented themselves as physicians to them. For Patient C it was a similar story; Burzynski treated the patient for mesothelioma without biopsy confirmation and without “adequately documenting Respondent’s medical rationale.” Patient G, for example, was charged for her treatment even though she was on a clinical trial, and there were multiple failures to follow FDA regulations about human subjects.
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The proceedings
The TMB proceedings have been going on against Burzynski for well over three years now, and during that time, Burzynski has been pulling out all the stops and using all the old propaganda tactics he’s used since his patients swarmed the courthouse during his trial in the 1990s. Sadly, he’s even had some success in that journalists who should know better fell for the “false balance” trope over a patient who was being denied ANPs because an FDA inspection of his manufacturing facility had turned up serious issues. That the proceedings have dragged on this long shouldn’t be a surprise; Burzynski is an old master at this, as was his lawyer Richard Jaffe. Of course, the amusing thing is that during the proceedings Jaffe actually withdrew as Burzynski’s attorney (and his son Greg Burzynski’s attorney) and apparently sued him for $250,000 in unpaid legal bills, further delaying the proceedings. Then, in December 2015, Burzynski informed the Board that he had had a heart attack and wouldn’t be able to proceed for a time, delaying the second phase of the proceedings for several months.
Then, in October 2016, there was a major setback when administrative law judges issued a proposed decision dismissing the bulk of the charges against Burzynski, largely because of gross incompetence on the part of the TMB. For example, instead of local cancer experts from, for example, M.D. Anderson and Texas Children’s Hospital, you know, the doctors who have to clean up the mess when one of Burzynski’s patients suffers the complications of his incompetence and the toxicity of his ANPs, the TMB relied on outside experts. In fairness, we can’t know for sure why the TMB didn’t use local experts because its spokesperson wouldn’t say. Given Burzynski’s famously litigious nature and his tendency to use his patients as shields and spears against his enemies, it could well be that local oncologists were cowed and didn’t want to speak out the way Dr. Jeanine Graf, director of the pediatric intensive care unit (PICU) at Texas Children’s Hospital did to the producers of the BBC news magazine Panorama when Panorama did a story about Burzynski, stating ,point blank, that she’s never seen a Burzynski patient survive.
Here’s what we got instead:
What we got, instead, was Dr. Cynthia Wetmore, who seems to have done a decent job in most aspects, but screwed up royally when it came to someone referred to as “Patient D.” The judges noted that Wetmore claimed that Patient D “did not receive the standard of care and was exposed to medications that are not documented to cross the blood brain barrier.”
The only problem with that, per the judges, was that “contrary to Dr. Wetmore’s testimony and report, Patient D received no treatment or therapy at the Clinic.” They wrote that “such inattentiveness to the accuracy of her report raises concerns about her credibility.”
This is one thing that utterly infuriated me. Burzynski is an old hand at this. He’s been slithering away from judgments by the TMB and FDA since the late 1970s. You cannot take him down with such inattention to detail. You have to have all your ducks lined up in the proverbial row. Your case has to be airtight and rock solid. On the other hand, the Chief Administrative Law Judge Lesli G. Ginn was not without fault, because she also accepted a lot of Burzynski propaganda as well. For instance, I’ve written many times how the Burzynski Institutional Review Board (IRB), the committee that is responsible for protecting human subjects and examining the ethics of any proposed clinical trial being carried out by an institution receiving funding from the federal government or any company or entity doing the clinical trial to gain FDA approval for a treatment or drug, is hopelessly compromised and packed with Burzynski cronies. Yet Ginn wrote, apparently with a straight face:
Dr. Burzynski testified that IRB was also created in 1983, but it is a separate entity from BRI. IRB was created to supervise the ethical conduct of clinical studies by approving or disapproving clinical trial protocols; to collect data on the toxicity and the response of the investigational agent; and to evaluate data on the efficacy of the investigational agent ANP.22 IRB is not in the business of practicing medicine.23 Neither Dr. Burzynski nor any of the Clinic’s employees is a member of IRB. The IRB consists of 14 members. Carlton Hazelwood, M.D., a retired professor of pediatrics and physiology at the Baylor College of Medicine, is IRB’s chairman.24 Dr. Burzynski testified that he had no role in the selecting the board members.25
Wrong. Carlton Hazlewood is on the board of directors of the Burzynski Research Institute, as has been pointed out many times.
So things looked bad in October, but fortunately this was only a proposed judgment. What did the final judgment say?
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The Ruling
On February 15, the TMB issued a proposed decision in which Burzynski would be fined $360,000, required to pay $20,000 restitution to a patient. Unfortunately, although the proposed decision included the revocation of Burzynski’s medical license, the revocation was stayed, with Burzynski to be placed on probation with a public reprimand. In addition to the fine and his probation with reprimand, the TMB would require that Burzynski meet these conditions:
    • The billing practices of the Burzynski Clinic must be monitored and patient records reviewed.
    • Burzynski must complete a Physicians Ethics program and undergo continuing education to obtain credits of completion in several topics of medical research. (I laughed at this one. Burzynski knows medical research regulations; it’s how he’s so good at skirting them.)
    • Burzynski must submit his informed consent forms to the Board for review to show that they comply with relevant regulations and laws, and each patient must receive and sign these new forms before treatment.
    • Burzynski must inform his patients that he owns the pharmacy requires them to use. Ownership interest disclosure must be submitted to the Board for review.
    • Burzynski must pass a Medical Jurisprudence Exam.
Overall, this struck me as a fairly substantial penalty, but far less than he deserves. Worse, Burzynski would have the opportunity to submit a counterproposal, and that’s what resulted in the final decision issued on Friday, which is even less severe:
The board’s staff had originally recommended that Burzynski pay a $360,000 fine and $20,000 in restitution to a patient. They also wanted Burzynski put on probation, with the power to automatically revoke his medical license if he violated the terms.
Instead on Friday, the board opted for a lesser penalty that included a five-year probation with more lenient terms, a public reprimand, more training and oversight, along with $60,000 in fines and restitution.
Burzynski’s attorneys called the decision a win.
“It means that he gets to continue medicine. He gets to continue to save lives,” attorney Gregory Myers said.
That $60,000 includes $40,000 in fines and the aforementioned $20,000 in restitution to a patient. If Burzynski’s attorneys consider this decision a “win,” then for patients it is clearly a loss. Unfortunately, I haven’t been able to find the final final decision yet; so I don’t know exactly how the terms of his probation are more lenient.
Still, even though Burzynski can continue to practice, I have some hope. For one thing, Burzynski is no spring chicken any more. He’s 74, and he had a heart attack a little more than a year ago. The terms of his probation will likely take him through most of the rest of his 70s, and, at his age, can he really stand to practice with even more stringent monitoring? He’s always been stubborn and arrogant, and I can’t picture him tolerating the regular monitoring of his billing practices and patient charts that will occur with much equanimity at all. Will he actually complete courses on Physician Ethics and study for a medical jurisprudence exam”? I’m not sure I can see it happening. Maybe he’ll retire.
Or maybe not. That’s the problem. Burzynski is nothing if not expert at evading the spirit of constraints placed on him to continue to sell his unproven treatments to patients for exorbitant sums of money.
The failure of the FDA and state medical boards to protect the public from quacks
With the election of Donald Trump as President, I and my SBM co-conspirators have been warning about the consequences of the sort of massive deregulation that Trump wants. For instance, just this week, Jann Bellamy warned about efforts to remove impediments to “right-to-try” laws, shield wrongdoers, and hide adverse events, and Steve Novella has warned about Trump’s plan to deregulate pharmaceuticals. Before that I had been beating the drum about how every single candidate for FDA Commissioner under consideration by the Trump administration, such as Peter Thiel Crony Jim O’Neill, and honest-to-goodness pharma shill Scott Gottlieb, favor massively decreasing the amount of evidence for drug approval, when in fact the FDA functions pretty well given its underfunding and an argument can be made that the evidence bar for approval is actually too low.
Contemplating the case of Stanislaw Burzynski worries me. Consider that the FDA using its current guidelines has only been intermittently able to temporarily put a halt to Burzynski’s preying on patients in the name of clinical trials. Meanwhile, state right-to-try laws could be a boon to practitioners like Burzynski, who, indeed, has already taken advantage of the Texas right-to-try law. It’s not just Trump, though. The majority of the states are solidly held by Republicans, and, as I’ve pointed out many times before, state medical boards are generally underfunded and outgunned. That doesn’t even consider the “quack protection” and “quack full employment” laws regularly discussed by Jann Bellamy and others here that would license and protect naturopaths, chiropractors, and other quacks, all in the name of “health freedom,” a recurring theme among Trump’s candidates for FDA commissioner which is used as a justification for “right-to-try” laws.
The failure of the TMB strip Burzynski of his medical license reminds me that, if anything, the laws and regulations protecting the public from quacks are too weak, not too strong. I fear they will become a lot weaker soon.

Mandatory breast density reporting legislation: The law outpaces science, and not in a good way
David Gorski on June 8, 2015
Link
Over the years, our bloggers here at Science-Based Medicine have written time and time again about the intersection of law and science in medicine. Sometimes, we support a particular bill or law, such as laws to protect children against religion-inspired medical neglect; laws making it harder for manufacturers of homeopathic “medicines” to deceive the public; or California Bill AB 2109, a bill whose intent was to make it more difficult for parents to obtain nonmedical exemptions to vaccine mandates but whose implementation after being passed into law was profoundly sabotaged by Governor Jerry Brown. or, more recently, California SB 277, a bill currently wending its way through the California legislature that would eliminate nonmedical exemptions to school vaccine mandates and has, not surprisingly, engendered extreme resistance from the antivaccine crowd, including by Robert F. Kennedy, Jr. In the vast majority of cases we explain how the law lets us down when it comes to science in medicine, and, unfortunately, examples are many: Naturopathic licensing laws; supplement regulation (or, more appropriately, lack of regulation); misguided, deceptive, and patient-hostile “right-to-try” laws; state laws regulating medical practice that allow quackery to flourish unchecked; laws regulating pharmaceutical cost transparency that ask the wrong question.
The case I will discuss here is unusual in that it is a case of the law getting ahead of what the science says in a manner that will likely do little, if any, good for patients, cause a lot of confusion until the science is worked out better, and end up costing patients money for little or no benefit. I am referring to laws mandating the reporting of high-breast-density to women with dense breasts undergoing mammography. These laws are sweeping the country (albeit not as rapidly as “right-to-try” laws), with a total of 22 states having passed them as of today since Connecticut became the first to do so in 2009. The most recent of these laws went into effect in my own state of Michigan exactly one week ago:
Women with dense breast tissue — the sort that can hide potentially deadly tumors from routine mammograms — must be notified in writing and encouraged to consider additional tests under a new state law that is effective Monday.
While mammograms remain the gold standard for detecting breast tumors, they’re less reliable in almost half of women with dense breast tissue. Dense or fibrous tissue shows up as splotches of white on a mammogram — so do tumors.
That will likely surprise many of the millions of women who rely on mammography for catching the earliest signs of cancer, said Nancy Cappello. The Connecticut woman was shocked in 2004, when her gynecologist found a lump — advanced cancer that had already spread to her lymph nodes — just months after a mammogram deemed her cancer-free.
Yes, mammography is imperfect, and we here at SBM have not shied away from describing its imperfections (or the difficulties in general with screening asymptomatic patients for any disease) including one large study that found no reduction in breast cancer-related mortality that was relentlessly (and falsely) attacked as fraudulent by a prominent radiologist. Regular readers know that the sensitivity of mammography is not optimal, and that it likely results in significant overdiagnosis and overtreatment, particularly of the pre-cancerous entity known as ductal carcinoma in situ (DCIS). All these issues aside, a review by the World Health Organization (WHO) International Agency for Research on Cancer (IARC) of mammographic screening hot off the presses last week in the New England Journal of Medicine nonetheless concluded that, for women between the ages of 50 and 74 at least, there is sufficient evidence to conclude that mammographic screening results in a significant reduction in the risk of dying of breast cancer, although the same report affirmed doubts about the adequacy of evidence for women between the ages of 40 and 49 that the USPSTF originally used in 2009 to base its recommendation that mammographic screening not begin until age 50 for most women. In other words, mammography, as imperfect as it is, does reduce the risk of death from breast cancer in women over 50.
Breast density, mammography, and cancer risk
It has long been known that mammography tends to be less effective in women with dense breasts. What is causes “density” on mammographic imaging is the high level of fibrous and glandular tissue relative to fatty tissue compared to breasts that are not considered dense. The reasons why mammographic screening of dense breasts might be less effective are fairly simple to understand. Mammography is basically an X-ray of the breast taken in a specified, highly standardized manner. As such, the image rendered shows up as areas of white and dark, with the white representing denser tissue and the dark less dense tissue, usually fat, which lets X-rays pass through easily. Lesions suspicious for breast cancer manifest themselves as a density that stands out among the darker, less dense tissue, of which there are two kinds: a tissue density or calcifications. I could ramble on and on and on about what characteristics make a tissue density or an area of calcifications suspicious and another area of tissue density or calcifications benign-appearing (or at least much less suspicious). The details aren’t important for purposes of this post. What is important for purposes of understanding the effect of mammographic density on the ability to detect cancer is that it depends on the contrast between the denser lesions that are suspicious for cancer and the surrounding breast and fatty tissue. The less contrast there is, the harder it is for the radiologist, even with computer-aided detection, to differentiate between suspicious lesions and normal breast tissue. That’s why mammography works really well in breasts that are largely replaced by fatty tissue, as is the case in many postmenopausal women, in whom dense breast tissue is less common than in premenopausal women. Basically, as estrogen and progesterone levels plummet, over time the glandular tissue in postmenopausal breasts becomes replaced with fatty tissue.
Just to give you an idea, here are images of breasts of low, intermediate, and high density on mammography:

And here is an example of what microcalcifications look like:

And of how breast cancers appear on mammography:
You can see how it would be more difficult to see these lesions in dense breasts, especially when they are more subtle and not as obvious. Indeed, the National Cancer Institute (NCI) points out on its website that the “main cause of false-negative results is high breast density.” In any case, the reason why mammography is more problematic in women aged 40 to 49 boils down to the fact that most premenopausal women have denser breasts due to higher levels of hormones and the incidence of breast cancer is lower, such that a positive finding is much more likely to be a false positive than a true positive than it is in older women. As I’ve explained before, for a screening program to be effective, the disease being screened for has to be sufficiently common for this not to happen. There’s a reason why even the most zealous supporters of mammography don’t recommend that routine screening begin before age 40; breast cancer incidence is just too low in this age group.
So far, so clear (I hope). However, recent science has thrown a new wrinkle into the equation. That science is the consensus that has emerged over the last couple of decades, based on numerous studies, that breast density is an independent risk factor for the development of breast cancer. In other words, women who have dense breasts, all other clinical characteristics being equal, have a higher risk of developing breast cancer. According to a recent review article, women with the highest breast density have a risk that is 2 to 6 times higher than women with the lowest breast density, and that as many as 30% of postmenopausal women still have dense breasts. Breast density correlates with a number of factors, including age (negative correlation), serum and tissue hormone levels (positive correlation), genetics, and body mass index (negative). Paradoxically, although high BMI is correlated with decreased breast density, obesity is correlated with an increased risk of breast cancer in postmenopausal women.
Because breast density is an independent predictor of breast cancer risk, naturally, the question has been asked what the biology is behind this and whether it is a modifiable risk factor. (Indeed, in the interests of full disclosure, I have been involved in a study that asks that very question and uses a new ultrasound technology to quantify breast density.) It is known, for instance, that Tamoxifen can decrease breast density, and it is also known that Tamoxifen can decrease the risk of breast cancer significantly in women at high risk. Are the two related? Does Tamoxifen’s ability to decrease breast cancer risk have to do with its ability to decrease breast density? We don’t yet know. Does the decrease in breast density due to Tamoxifen cause the decrease in risk or is the decreased breast density an epiphenomenon associated with the decreased risk? We don’t yet know. Does reduction in breast density over time correlate with decreased breast cancer risk? Yes, to some extent. A recent case control study, for instance, found that women who did not develop breast cancer showed a decrease in mammographic density between first and second prediagnostic mammogram compared to women who did develop breast cancer, who did not.
In other words, it’s complicated, and the science is far from settled. We know that breast density is associated with an increased risk of breast cancer, but the biology is not well understood, we don’t yet know if it’s a modifiable risk factor, and we don’t know the molecular basis. All we know are factors that are associated with increased breast density and that increased breast density is an independent risk factor for breast cancer. Research is ongoing and likely will be ongoing for quite some time before answers start to become clear.
Mandatory breast density reporting
It’s impossible to discuss mandatory breast density reporting laws without discussing the woman who started the movement, Nancy Cappello, PhD, and her organization Are You Dense? Advocacy, whose mission is described as:
To ensure that women with dense breast tissue have access to an early breast cancer diagnosis. To that end, women need to be informed of their breast density, the limitations of mammography to find cancer in dense breast tissue and the increased risk factor of dense breast tissue.
As described in the story I first cited above, Cappello’s gynecologist found a lump months after she had had a “negative” mammogram in 2004, and she was diagnosed with stage IIIC breast cancer. As she herself relates in a recent article, “Decade of ‘Normal’ Mammography Reports–The Happygram“:
I ate healthy, exercised daily, examined my breasts regularly, and underwent yearly mammography. I had no family history of breast cancer. In 2003, my annual screening mammogram was reported as normal, just as the decade of reports before 2003. I was faithful to my health care regimen; my routine annual gynecologic examination was 6 weeks later. As my physician was examining my breasts, she felt a ridge in my right breast and ordered diagnostic mammography and ultrasound. The diagnostic mammogram revealed nothing, but the ultrasound examination revealed a 2.5-cm mass. A breast biopsy confirmed invasive cancer, which was later verified as stage IIIC breast cancer. At the time of diagnosis, my tumor was more than 1 inch in size, and it had metastasized to 13 lymph nodes. The American Cancer Society reports the 5-year survival rate for stage IIIC breast cancer as 49%, compared with stage I at 88% [1]. I expected, in the event of a cancer diagnosis, an early stage because of my faithful program of annual screening mammography. I questioned my doctors as to what had happened. This was the first time that I was told that I had extremely dense tissue and that, as breast density increases, the sensitivity of mammography decreases.
I was stunned that my doctors knew about dense breast tissue and its impact on the effectiveness of mammography but had never informed me. I also discovered that my physician received reports generated by radiologists that included more details about my mammographic results and, as in most reports, my breast tissue composition. This information is usually not reported in the patient’s “happygram” report. My decade of radiologists’ reports, unknown to me, read, “Patient has extremely dense breasts…no change from prior exam.” My radiologist knew that I had dense breasts. My doctor knew that I had dense breasts. The only person who did not know was me: the woman with the dense breasts.
Regular readers who have been paying attention to my posts on mammography and screening know that there is a huge misconception in this story, namely the belief that catching a cancer earlier results in a better chance of survival. It’s a common misunderstanding, even among physicians. Clearly, Cappello doesn’t understand the concept of lead time bias, but she’s in good company. Neither do a lot of physicians. Basically, earlier detection can make survival after diagnosis seem longer even if the treatments used have no effect at all. It seems an opportune time to explain why this is by resurrecting one of my favorite explanations for lead time bias, by Aaron Carroll:
Let’s say there’s a new cancer of the thumb killing people. From the time the first cancer cell appears, you have nine years to live, with chemo. From the time you can feel a lump, you have four years to live, with chemo. Let’s say we have no way to detect the disease until you feel a lump. The five year survival rate for this cancer is about 0, because within five years of detection, everyone dies, even on therapy.
Now I invent a new scanner that can detect thumb cancer when only one cell is there. Because it’s the United States, we invest heavily in those scanners. Early detection is everything, right? We have protests and lawsuits and now everyone is getting scanned like crazy. Not only that, but people are getting chemo earlier and earlier for the cancer. Sure, the side effects are terrible, but we want to live.
We made no improvements to the treatment. Everyone is still dying four years after they feel the lump. But since we are making the diagnosis five years earlier, our five year survival rate is now approaching 100%! Everyone is living nine years with the disease. Meanwhile, in England, they say that the scanner doesn’t extend life and won’t pay for it. Rationing! That’s why their five year survival rate is still 0%.
As I’ve said before, I don’t think screening for breast cancer is useless. Neither does the WHO. It’s just that the relationship between screening, finding cancer earlier, and increasing cancer survival is not simple. Would finding Cappello’s cancer earlier have increased her chance of survival? There’s no way of knowing because she was one of the lucky ones who survived stage IIIC cancer. In fairness, her treatment probably would have been less brutal, but it’s impossible to know in any single case whether early detection would have made a difference.
So Cappello became an advocate, and a successful one. Over the last several years, she and her collaborators have successfully gotten notification bills passed in 22 states. The new law in Michigan is typical. In the case of a finding of increased breast density, it mandates that the patient receive a letter that states:
Your mammogram shows that your breast tissue is dense. Dense breast tissue is very common and is not abnormal. However, dense breast tissue can make it harder to find cancer through a mammogram. Also, dense breast tissue may increase your risk for breast cancer. This information about the result of your mammogram is given to you to raise your awareness. Use this information to discuss with your health care provider whether other supplemental tests in addition to your mammogram may be appropriate for you, based on your individual risk. A report of your results was sent to your ordering physician. If you are self-referred, a report of your results was sent to you in addition to this summary.
So what’s wrong with this? More information is always a better thing, right? Even if it’s vague and just tells the patient to discuss the matter with her health care provider? There’s more wrong than you might think.
The problem with mandatory breast density reporting laws
There are a number of problems that these laws produce. The most difficult to navigate problems include what to recommend for these patients and how to reassure them. The reasons are simple. First, there is as yet no standardization for determining breast density, and, indeed, measuring density is still a fairly subjective process that radiologists do, with rather high interobserver variability. It is true that there are now automated systems designed to estimate breast density using image analysis, such as Volpara (there are other competing software systems), but most breast centers don’t yet have them and still use the American College of Radiology BI-RADS lexicon. My breast center does (it’s an NCI-designated Comprehensive Cancer Center, after all), but most mammography centers do not. Over time, no doubt the whole process will become much more standardized, but until then there will remain a lot of subjectivity in breast density assessments.
More importantly, indeed, most importantly of all, there is no consensus as to what to do next. As described in an editorial by Marcia Javitt, Section Editor for Women’s Imaging Director of Medical Imaging, Rambam Healthcare Campus in Israel, no large randomized clinical trials have shown that breast cancer mortality is reduced by alternative screening and “although the use of alternative imaging techniques, such as breast ultrasound, breast MRI, digital breast tomosynthesis, and molecular breast imaging (MBI) may enable the detection of mammographically occult cancers in patients with increased breast density, refinement and validation are required for successful large-scale supplemental screening.” The American Cancer Society guidelines call for MRI screening in addition to mammography for women at high lifetime risk (20-25%) to develop breast cancer, but states there is “insufficient evidence to recommend for or against MRI screening” in women whose mammographs indicate extremely dense or heterogeneous breast tissue. Javitt also notes that the potential number of women who would need to be considered for additional imaging after being informed of having heterogeneously or extremely dense breast tissue could be huge, adding that “if all of these women opt for adjunct screening procedures, a staggeringly high number of alternative screening studies in the United States could overwhelm the available resources.”
One of the most commonly suggested alternative additional modalities to use, whole breast ultrasound, is highly operator-dependent and has never been shown to decrease breast cancer mortality, although it can increase the detection rate in dense breasts, but at a cost. For example, the American College of Radiology Imaging Network (ACRIN) 6666 trial showed that using breast ultrasound to supplement mammography in women with dense breast tissue and increased risk for breast cancer resulted in improved cancer detection (an additional 4.3 cancers per thousand women screened) at the cost of an increased recall rate, a large increase in the false positive rate, and reduced positive biopsy rate. Also, there was no control group, and the study only evaluated women at increased risk of breast cancer, not women of average risk. (Once again, in the interests of full disclosure, my cancer center has developed a 3D ultrasound imaging technology that we have high hopes for.)
And I forgot to mention: The vast majority of these laws do not mandate that insurance companies pay for additional screening, which is a big problem, since most insurers don’t cover additional imaging for women with “clean” mammograms. The Affordable Care Act doesn’t require it, and, with the exception of Connecticut, Illinois, New Jersey, and Indiana, states with these mandatory reporting laws don’t require it. So, in most states that have passed these laws, women who get these notices are faced with the choice of just living with it or paying out of pocket for additional testing that has not been validated as being able to decrease their risk of dying of breast cancer. For some tests, MRI for instance, that expense could be quite high.
Finally, not all dense breasts are created equal, if you’ll excuse the cliché. Some are truly high risk, and some are not. At a website set up by radiologists to try to navigate the vagaries of these laws, BreastDensity.info, there is a flow sheet that informs us that:
     1.  If the report states her density is heterogeneously dense, this is associated with minimal risk above average (RR=1.2 compared to average breast density).
     2.  If her density is extremely dense (also sometimes called simply dense), this factor doubles her risk of breast cancer compared to average density, similar to the risk associated with a family history of breast cancer in a mother, sister, or daughter. For example, having extremely dense tissue on its own raises the 10-year risk of breast cancer in the average 50 year old woman from 1 in 42 to 1 in 21.
It also goes on to point out that, in the absence of other risk factors associated with breast cancer, elevated breast density alone does not put a woman at high risk for breast cancer. For instance, a recent prospective cohort study with over 365,000 women found that, in the absence of other risk factors for breast cancer, high breast density alone has a rather modest effect on breast cancer risk, leading the authors to warn:
Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patient–provider discussions about alternative screening strategies.
The study also found that about half of all women with heterogeneously or extremely dense breasts did not meet the threshold for high rates of interval breast cancer and that the threshold of screening all women with heterogeneously dense breasts required 1,124 supplemental tests per additional cancer case detected. In other words, an emphasis on breast density alone is probably ill-advised based on what we know now.
I can understand why women like Nancy Cappello become activists. I really can. They think they’ve been wronged by the medical system and that they’ve discovered something that doctors either aren’t aware of or didn’t think important enough to tell them. Unfortunately, in the case of breast density that something is information that is both unreliable and does not as yet have a consensus about it over what to do. As a result, what they’ve done is advocate for laws that are ahead of where the science is, but not in a good way.

Bait and switch in Oregon: Substituting quackery for opioids for Medicaid patients
The Oregon Health Authority is on the verge of passing a radical policy that would require chronic pain patients receiving Medicaid to have their opioids tapered to zero while covering “nonpharmacologic treatments for pain” that include primarily acupuncture, chiropractic, massage therapy, and other “alternative” treatments. Not surprisingly, the Oregon Chronic Pain Task Force, which is responsible for this proposed infliction of quackery on the most vulnerable, has three acupuncturists and a chiropractor sitting on it.
David Gorski on August 30, 2018
Link

[Editor’s note: Due to a personal issue, Jann Bellamy was unable to write a post for today. As a result, I filled in. Some of you might have seen this before elsewhere, but I thought the topic was important enough to discuss here on SBM as well.]
I’ve described in the past many times how advocates of “integrative medicine” (or, as I like to call it, “integrating” quackery with conventional medicine) like to co-opt science-based treatments as somehow being solely within the bailiwick of their favored unholy hybrid medicine offspring bred of a forced marriage between science and magical thinking. There are many potentially harmful aspects of this shotgun marriage, not the least of which is the dilution of the scientific basis of medicine in favor of pseudoscience. One area, however, that doesn’t get enough attention (except from me) is how integrative medicine tries to claim all “nonpharmacologic treatments for pain” as its own. I’ve described how quacks have done this.
My thinking on this issue first started to gel a couple of years ago, when the National Center for Complementary and Integrative Health (NCCIH) published its five year strategic plan for 2016-2021. In this plan, NCCIH prominently featured researching and promoting the “nonpharmacologic treatment of pain” as one of its most pressing goals. Later that year, it published a really bad review article, one based on horrible studies and huge extrapolations from weak data, that basically claimed all nonpharmacological treatment of pain as part of “complementary and alternative medicine” (CAM, now known as “integrative medicine”). Basically, although I had been getting the vibe that integrative medicine advocates were trying to claim all non-drug treatments for pain as their own before this, these two publications by NCCIH made it incredibly obvious to me that this was the new propaganda direction that integrative medicine advocates would be taking, and take it they did. It wasn’t long before JAMA joined in, followed by the American College of Physicians, the Academic Consortium for Integrative Medicine and Health (of course!), and the FDA which, in response to lobbying by acupuncturists and chiropractors, has a draft proposal outstanding to encourage physician education about acupuncture and chiropractic as “therapies that might help patients avoid prescription opioids.” Never mind that there is no good evidence that either can accomplish this goal. Meanwhile, acupuncture advocates have been busy lobbying various states to have their Medicaid programs cover acupuncture.
Which brings us to Oregon.
Oregon: The “nonpharmacologic treatments for pain” scam
There was a story last month that I had meant to write about but somehow had gotten lost in the piles and piles of links in my “to be blogged folder” about the potential horrible consequences for patients that this co-optation of nonpharmacologic treatments for pain could have for chronic pain patients, in essence sanctioning their torture. (I don’t think I’m exaggerating, or if I am it’s not by much.) It came in the form of an AP story, “Oregon officials consider limiting opioid prescriptions“:
A proposed change to the state’s Medicaid program aims to reduce the overprescribing of opioids, which has caused an epidemic of overdoses, Oregon officials said.
The proposal would limit coverage for five broad chronic pain conditions to 90 days of opioid pain relievers, The Bulletin reported Wednesday.
It would also taper off patients who have been taking opioids long-term from those medications within a year.
In turn, it would introduce alternative treatments previously unavailable under the Oregon Health Plan.
“Alternative” you say? What does that mean? If you read this blog, I bet you know exactly what that means. From The Bulletin, a central Oregon newspaper:
Oregon could have some of the country’s strictest limits on opioids for chronic pain patients under a proposal being considered for the state’s Medicaid program. The proposed change would limit Oregon Health Plan coverage for five broad chronic pain conditions to 90 days of opioid pain relievers and would force patients who have been taking opioids for longer to be tapered off those medications within a year.
Yikes! Forced tapers for chronic pain patients beginning in 2020? What, pray tell, will replace the opioids? You guessed it: yoga, acupuncture, massage, chiropractic, or physical therapy. Or, as an Oregon Health Authority spokesperson put it:
“We are in an opioid crisis in Oregon,” said Jonathan Modie, an OHA spokesman. “Over prescribing has been the main driver of overdose and death. We want to make sure patients have more non-pharmacological options such as acupuncture, massage therapy and chiropractic care.”
Well, yes. There is an opioid crisis. Deaths due to opioid overdose are at an unacceptably high level. Something needs to be done. Unfortunately, the imperative to “do something, anything” is driving some truly awful policies that will harm patients. For example, in my state, as of June 1, physicians have to run a search on every patient for whom they prescribe opioids beyond a three day course for acute pain (as in postoperative prescriptions) and document that search on a special opioid prescription form. We also have to have patients sign a consent form warning them that opioids can be addictive and can even kill them. Will this policy reduce opioid overdoses in this state? Hell if I know! There’s no good evidence to say that it will, but it might just accomplish that by making it so onerous to prescribe and get opioids, even for patients who need them, that fewer patients get opioid prescriptions and therefore fewer die. The price, of course, is a lot of patients in pain who don’t need to be. Of course, the Oregon proposal is so much worse. At least the Michigan proposal has a little bit of prior probability based on callousness: Let patients suffer by making it harder for them to get opioids and maybe overdoses will decline. It might work if as a state official you don’t mind treating some chronic pain patients with needless cruelty. The Oregon proposal, on the other hand, can’t work because it proposes encouraging the use of quackery instead of opioids.
Now that’s cruel.
Three acupuncturists and a chiropractor
Where, you might wonder, did such an incredibly non-evidence-based and, to put it quite bluntly, dumb proposal come from? It takes a little explaining, explaining that’s easier to do just by quoting:
The proposed change came out of the Chronic Pain Task Force, an ad hoc committee created to provide guidance on reducing opioid use under the Oregon Health Plan. The Oregon Health Plan has a unique structure among state Medicaid programs, relying on a prioritized list of health services ranked by experts in order of importance to patients. State lawmakers then decide where in the prioritized list to draw the line between covered and uncovered services.
Currently, the five conditions being discussed — fibromyalgia, chronic pain syndrome, chronic pain due to trauma, other chronic postprocedural pain and other chronic pain — fall below the line, and thus treatments for those conditions aren’t covered by the Oregon Health Plan. But according to the Oregon Health Authority, many patients with those five conditions are being prescribed opioids. The Oregon Health Plan has no way of knowing whether those patients are being prescribed opioids for those chronic pain conditions or for covered services and, therefore, cannot decline to cover those prescriptions.
By establishing a new entry in the prioritized list above the cutoff line, the Oregon Health Plan would then cover alternative treatments, such as yoga, acupuncture or physical therapy, but would try limit the use of opioids.
I’m all for evidence-based guidelines for just about every condition in medicine with sufficient scientific and clinical evidence upon which to base guidelines, but the key is how these guidelines are developed. Using Google to try to find various reports of the Oregon Chronic Pain Task Force, I found this Health Evidence Reviews by the Chronic Pain Task Force dated January 23, 2018 and June 7, 2018. I could see the problem right away as I perused these documents. Basically, the problem was that the review of evidence listed in the reports tended to cite the same unconvincing studies that acupuncture and integrative medicine advocates like to cite. They cited follow-ups to the infamous Vickers meta-analysis (or, as I like to call them, Son of Vickers, Bride of Vickers, and the like), the granddaddy of acupuncture meta-analyses and the one most often touted as the gold standard “proving” that acupuncture works for chronic pain. It didn’t, no matter how much acupuncture advocates strained to say it did. Then, of course, the Task Force cited the systematic review by the NCCIH that really didn’t show that acupuncture or other CAM (rebranded as “nonpharmacologic treatments for pain”) has any effect on chronic pain distinguishable from placebo.
You can listen to the panel itself debating the opioid taper at its meeting of June 7. It’s cringe-inducing. They admit there’s no evidence, and basically admit that the figures they’re bandying about for length of time for the taper to zero have basically been pulled from their nether regions:
Notice the obsession with being consistent with the “prior guidelines”. What prior guidelines, you ask? Well, in 2016, Oregon imposed similar restrictions on patients with chronic back pain. At one point, they assert that this program is working, but there’s no evidence presented that it is, nor could I find any evidence that it’s doing what is intended. Basically, they want to expand their forced taper to a much larger group of patients.
It didn’t take me long to figure out why the Chronic Pain Task Force is so “open” to alternative treatments. There are three acupuncturists (Ben Marx, David Eisen, and Laura Ocker) and a chiropractor (Mitch Hass) on the committee. Yes, you read that right. Four of the members of the Oregon Chronic Pain Task Force are quacks. They’re cruel quacks, too, as they want to force patients to taper their opioids in favor of their fraudulent “nonpharmacologic treatments for pain”.
Ocker, for one, is a high-ranking and influential quack, too. She was President of the Oregon Association of Acupuncture and Oriental Medicine from 2012-2013 and has been active promoting acupuncture legislatively in Oregon at least since 2009. Indeed, our old friend John Weeks interviewed her admiringly in May 2017, claiming that “Evidence opens Medicaid in Oregon to acupuncture,” where we also learn that Ben Marx has been one of her colleagues at the Oregon College of Oriental Medicine also working to promote acupuncture reimbursement in Oregon:
Ocker has also made available multiple documents that can guide interested parties more deeply into how to engage such a process. These include the recent Oregon Health Plan remarkable decision, following the ascendency of the opioid crisis, to “prioritize therapies such as chiropractic and osteopathic manipulation, physical therapy, acupuncture, cognitive behavioral therapy, graded exercise therapy, interdisciplinary pain management, yoga, and massage—and a treatment plan to stay active and return to previous function—over ineffective surgeries and narcotics.” Ocker believes that the looming opioid crisis has been wind at their backs during the entire process.
In other words, at least two of the acupuncturists on the Chronic Pain Task Force are not just acupuncturists. They’re advocates for acupuncture and federal and state reimbursement for acupuncture services and have been active politically for quite some time working for just that. In addition, Amber Rose Dullea is a fibromyalgia sufferer and licensed massage therapist, as well as a “coach, speaker and author.
I couldn’t help but wonder: Are there any physicians on this task force? It turns out that there are. There are two anesthesiologists (Dr. David Sibell), one of whom is a pain specialist (Dr. Kevin Cuccaro). I must admit, after perusing Dr. Cuccaro’s website, I was left with the distinct impression of woo, as I read of the “Pain Triangle”. At the very least, his publications and podcast go on about the “Pain Management Business–A multi-billion dollar empire motivated by what is profitable rather than what is best for patients”. In episode #39 of his podcast, he starts right out going on and on about the “powerful placebo,” a dead giveaway for someone whose mind is so open that his brain falls out when it comes to woo. After all, placebo effects figure prominently in the central dogma of alternative medicine. The others include a fairly unremarkable assortment of specialties, including Dr. Tracy Muday, Chief Medical Officer of Southwest Oregon Independent Practice Association and Advanced Health, Coordinated Care Organization administering Oregon Health Plan benefits to enrollees in Coos and Curry counties; Dr. Holly Jo Hodges, Medical Director at WVP Health Authority; and Dr. Ariel Smits, a family medicine doctor in Portland.
It certainly looks as though the doctors barely outnumber the quacks on this panel, and might even have the upper hand. Why is this panel like this? An Oregon Health Authority spokeswoman justified it by saying that the task force composition aimed “to represent the variety of clinicians who would be involved in the management of chronic pain.”
Here’s the actual text and the changes from previous policy on the use of opioids for chronic back pain from 2016 (yes, that was the precursor to this cursed policy):
And what is this taper process? This:
My reaction: WTF?
The backlash
Not surprisingly, groups representing chronic pain patients are not happy about these proposed guidelines. A story in STAT News from last week described how patients in Oregon are protesting, having shown up to an August 9 meeting of the Value based Benefits Subcommittee (VbBS) and the Health Evidence Review Commission (the latter of which includes a naturopath, Angela Senders, as one of its members) to make their concerns known, especially since the HERC is the committee that has to vote on the proposal, after it’s screened and approved by the VbBS. And, boy, did they ever!
The controversy has brought together an unlikely crew of protestors, including many in wheelchairs and in walkers, who, at 7:15 on a recent Thursday morning, erected a tidy encampment outside the windows of a community college lecture hall here. A security guard eyed them warily from inside, where an obscure committee would soon hear the state’s proposal to end coverage of opioids for chronic pain.
Among their signs: “Death with dignity is a law: What about LIFE with dignity?”
And:
Each used their time in the lecture hall to offer impassioned speeches, accented alternately with tears, shouts, shakes of a pill bottle, uniformly opposing the policy change.
Again and again, they reminded the committee members that they had not yet fully grappled with the question central to their proposal: Is continued reliance on opioids for chronic pain more dangerous than forcing patients off them?
And that’s the point:
Experts say the science supporting either argument is extremely limited.
“What is notably missing is any review of any literature regarding the centerpiece of their proposed policy: Forced opioid taper to zero for all persons,” said Dr. Stefan Kertesz, a pain and addiction specialist at the University of Alabama, Birmingham, School of Medicine.
Indeed, a group of pain physicians, academics, and patient advocates wrote a letter to Oregon Health officials pointing out just how wrong-headed and harmful this proposal is. The full text of the letter can be found here, but a key quote is worthy of noting:
An across-the-board denial of opioid therapy for the huge umbrella category of chronic pain is as destructive as is liberally prescribing opioids for all types of chronic pain,” the letter warns. “The denial of coverage to the Medicaid population, in particular, is likely to have a disproportionate impact on individuals with disabilities, on the sickest patients and those with multiple chronic conditions.”
Precisely. They also note that, although opioid prescribing has been declining since 2012, that decline has not correlated with a decline in opioid overdose deaths. Indeed, the authors note that opioid deaths have skyrocketed during that same period because “crisis has evolved to feature heroin and illicitly manufactured fentanyl and its analogs” and even “most deaths that involve a prescription opioid are polypharmacy—often including illicit drugs, benzodiazepines and other CNS depressants, and alcohol—and most misuse is non-medical.”
The danger of “integrating” quackery into medicine
Let’s just put it this way. Even “integrative medicine” pain specialists were appalled. The Academy of Integrative Pain Management submitted a statement. While the statement lauds the intent to make acupuncture and chiropractic (as well as other non-evidence-based treatments) “above the line” and thus reimbursable, even “integrative medicine” practitioners were horrified at the thought of forced opioid tapers. The statement also sarcastically notes Oregon’s first foray into this sort of nonsense by pointing out that it’s “in the 20th month of a similar 12-month plan to forcibly taper patients with back and spine pain off their opioid pain relievers” and then goes on to point out that this policy “is not a rousing success, yet you appear to be willing to impose it on another large group of patients.”
This proposal by the Chronic Pain Task Force in Oregon is also incredibly unethical. The reasons are simple. There is no evidence that forced opioid tapers—particularly a forced taper to zero opioids—is of any benefit for chronic pain patients, but there is considerable anecdotal evidence of potential harms, up to and including suicide. Indeed, Department of Veterans Affairs data suggests that opioid discontinuation is not associated with overdose mortality but is associated with increased suicide mortality. Moreover, denial of coverage for opioids in these patient groups will almost certainly have a disproportionate impact on patients with disabilities, on the sickest patients and those with multiple chronic conditions. These are the patients who frequently wind up on Medicaid after they can no longer work. Worse, the evidence that the modalities that will be covered and will be recommended as replacements for opioids are effective is weak to nonexistent. Indeed, the highest quality evidence shows that acupuncture, for instance, is no more than a theatrical placebo. It does not work.
If you want to see the danger of “integrating” quackery with medicine, as integrative medicine does, look no further than Oregon. Here, because of the way that integrative medicine has so successfully rebranded quackery like acupuncture as “nonpharmacologic treatments for pain” and tarted them up as being evidence based when they are not, a large state is seriously considering a policy that, if implemented, would leave an large number of the most vulnerable patients suffering unnecessarily, all because there are four quacks and at least some quack-sympathetic doctors and advocates on a panel. The opioid crisis is truly driving not just bad solutions born out of the desire to “do something”, but is being used as a “wedge” to drive more pseudoscience into medicine. Unfortunately, the fix seems to be in. There’s going to be a vote as early as October, and I’d be willing to bet—sadly—that Oregon will approve this patient-hostile policy. Then, moralizing about those who need opioids combined with magical thinking like acupuncture will leave untold patients suffering unnecessarily—all because we have to “do something”.
Don’t say I didn’t warn you this was coming somewhere, sometime. I also predict that, if Oregon gets away with this, it won’t be long before more states decide to punish chronic pain patients in the name of helping them with “nonpharmacologic treatments for pain.

Significant Ruling Against Conversion Therapy
Steven Novella on February 11, 2015
Link

The standard features of quackery are all there. Proponents of this particular therapy claim that a normal condition is a disease. They make false claims about the cause of this disease. They then charge thousands of dollars for their fake treatment to cure the fake disease, and claim success rates that are not backed by any statistics.
In this case the fake disease is homosexuality, for which there is now a solid consensus that it is a normal variation of human sexuality. The fake treatment is conversion therapy. Recently a New Jersey judge ruled that conversion therapists cannot claim that homosexuality is a disease or disorder. The Southern Poverty Law Center reports:
Superior Court Judge Peter F. Barsio Jr. found that it “is a misrepresentation in violation of [New Jersey’s Consumer Fraud Act], in advertising or selling conversion therapy services, to describe homosexuality, not as being a normal variation of human sexuality, but as being a mental illness, disease, disorder, or equivalent thereof.”
Further:
The judge also ruled that [New Jersey conversion therapy provider Jews Offering New Alternatives for Healing (JONAH)] is in violation of the Consumer Fraud Act if it offers specific success statistics for its services when “client outcomes are not tracked and no records of client outcomes are maintained” because “there is no factual basis for calculating such statistics.”
Anytime there is a ruling or new law or regulation that essentially makes it illegal to make fraudulent health claims, that is a win for the consumer. Health care consumers, including those for mental health services, are particularly vulnerable. Further, most consumers assume that such protections are already in place, and therefore have a (frequently false) sense of security that others cannot make fraudulent health claims.
(Note: I recognize that sexual orientation and gender identity are complex and represent spectrums, rather than clean dichotomies. However, since the dubious treatment and the current ruling address “homosexuality” I will use that term as a representative label.)
Homosexuality has been a target for many decades. By coincidence, a character in this season of Downton Abbey (which takes place in the 1920s), Thomas Barrow, is undergoing dubious and apparently dangerous medical treatments for his homosexuality.
Early psychiatrists differed on their views of homosexuality. Freud actually thought it was a natural variation of human sexuality, while others, such as Sandor Rado, argued that it was pathological. The pathological view prevailed, and the dominant theory was that homosexuality results from abnormal sexual development or even early childhood trauma and abuse. In the first half of the 20th century what little research was done supported the pathological hypothesis, but in retrospect this research was highly biased.
The turning point came with the research of Evelyn Hooker beginning in 1957. Her research into homosexuality addressed the inherent biases of earlier research. She studied subjects who were not already psychiatric patients. She also performed blinded evaluations in which personality traits were assessed by evaluators who did not know the sexual orientation of the subject.
With these biases eliminated, she found that homosexuals did not have any greater chance of having mental illness or poor adjustment than heterosexuals, which was a fatal blow to the view that homosexuality was a mental pathology. Her research was replicated by others, with similar results. A new consensus was forged around these more rigorous research results.
In 1974 homosexuality was removed from the DSM as a mental disorder. Now, forty years later, this remains the robust conclusion of psychological research, that homosexuality is part of the healthy spectrum of human sexuality and there is no evidence that justifies the conclusion that it is a disorder or disease.
Similarly, there is no evidence to support the claim that homosexuality results from early childhood trauma or abuse. Sexuality is a complex behavior, and there is no simple cause that can be identified. However, researchers have identified two significant contributors.
The first is genetics. While there is certainly no “gay gene”, studies have identified a genetic predisposition to homosexuality. This means that there are likely many genes that play a role, and no single gene (or even the totality of relevant genes) is deterministic.
The second biological factor is the hormonal environment in the womb, which has a known effect of brain development. There are several independent lines of evidence supporting this conclusion, from birth order effects to differences in brain scans.
The genetic and development research, however, overall is not definitive and both larger, more representative, and more nuanced research is considered necessary. The Harvard Kennedy School LGBTQ Policy Journal concludes:
Issues of sample size and selection bias, however, also plague these studies. Those who are willing to undergo brain scans, or have their brain examined upon autopsy (Swaab and Hofman 1990), may have a special and unique relationship with their sexuality. It would be more informative to study individuals across a range of sexualities and gender identities. While such studies would be unlikely to produce the striking results we currently see in the literature, they would better reflect the diversity of the human population and shed light on what differences may actually exist between people who identify as LGBT and those who do not.
Regardless of these finer points, it is clear that variations in sexual orientation and gender identity are not the result of childhood trauma or abuse, as is claimed by the conversion therapy industry.
Does conversion therapy (also called reparative therapy) work? The burden of proof, of course, is on those making claims for efficacy. The research, however, is scant and problematic. Most famously, in 2003 Spitzer published a case series in which he concluded that reparative therapy was effective. He wrote:
Either some gay men and lesbians, following reparative therapy, actually change their predominantly homosexual orientation to a predominantly heterosexual orientation or some gay men and women construct elaborate self-deceptive narratives (or even lie) in which they claim to have changed their sexual orientation, or both. For many reasons, it is concluded that the participants’ self-reports were, by-and-large, credible and that few elaborated self-deceptive narratives or lied.
The first sentence summarizes the difficulty with this research. Subjects are self-selected and they self-report their own outcomes. There are good reasons to believe that the social pressures that led them to seek out reparative therapy in the first place also motivate them to construct a narrative of efficacy. The problem was in Spitzer’s second sentence, concluding without adequate justification that the self-reports were not self-deception. In 2012 Spitzer then recanted this conclusion.
Conclusion
Sexual orientation and gender identity are complex behavioral traits that exhibit the full spectrum of possible manifestations and even flexibility. Decades of research suggest that the full spectrum is part of human sexual variation, and does not represent a pathological or disease state, nor any kind of disorder. They are not associated with any pathology, specifically with childhood trauma or abuse. Rather, sexual orientation appears to have a clear but complex biological component.
Claims for efficacy of conversion or reparative therapy are not supported by adequate clinical evidence.
The recent ruling in this ongoing case in New Jersey is encouraging, essentially ruling that practitioners of dubious conversion therapy cannot make fraudulent claims regarding the medical status of homosexuality or the efficacy of their treatment.

Lyme Testimony
Mark Crislip on May 15, 2015
Link


As the saying goes, when you do not have the facts, argue the law. This tried and (?) true approach was successful in New York where a law was passed protecting those who are, shall we say, creative in treating patients with Lyme and ‘chronic’ Lyme.
The bill protects those from investigation of misconduct:
based solely on treatment that is not universally accepted by the medical profession.
The major bone of contention has been extended courses of IV antibiotics for ‘chronic’ Lyme, but there are a wide variety of treatments that may be used by so called “Lyme literate” doctors.
The number of therapies divorced from reality that are offered to Lyme patients is remarkable. I do not know if chronic Lyme patients have greater use of pseudo-medical therapies than other pseudo-diagnoses, but I am impressed by the offerings in a recent review:
Results. More than 30 alternative treatments were identified, which fell into several broad categories: these included oxygen and reactive oxygen therapy; energy and radiation-based therapies; nutritional therapy; chelation and heavy metal therapy; and biological and pharmacological therapies ranging from certain medications without recognized therapeutic effects on Borrelia burgdorgeri to stem cell transplantation. Review of the medical literature did not substantiate efficacy or, in most cases, any rationale for the advertised treatments.
Conclusions. Providers of alternative therapies commonly target patients who believe they have Lyme disease. The efficacy of these unconventional treatments for Lyme disease is not supported by scientific evidence, and in many cases they are potentially harmful.
Why a legislature would want to abandon consumer protections and protect those providing useless and potentially dangerous therapies eludes me.
There was a nice summary in the discussion which in many ways sums up the entire history of the Science-Based Medicine blog and its entries:
Two common themes characterized the websites referenced in this study. One was the reliance on anecdotes and testimonials from patients. The second was the veneer of scientific credibility, ranging from the medical credentials of the service providers to the use of seemingly technical terminology. In virtually all cases, these testimonials and scientific expositions were used promotionally to sell therapeutic services and products. Our review of the medical literature did not yield evidence to support these health claims.
Sadly, I suspect that the above paragraph will remain relevant for as long there is an internet. Plus ça change, plus c’est la même chose.
The malignant success in NY has inspired others to have similar laws metastasize to other states. They call me Dr. Metaphor for a reason. Oddly there is no super-hero or villain with that name. And here I though all the good names were taken.
In Oregon there was a similar bill before the legislature, which read:
Permit professionals regulated by the boards to diagnose and treat, in manners consistent with the standards of care guidelines developed by the International Lyme and Associated Diseases Society, Lyme disease and associated viral, bacterial and parasitic diseases; and
(b) Establish disciplinary procedures that consider as mitigating factor whether, in diagnosing or treating Lyme disease or associated diseases, a professional who is facing discipline followed evidence-based diagnosis and treatment guidelines not recognized by the boards.
I suspect similar laws will be showing up in your state. As part of the legislative process in Oregon, there are public hearings where anyone can testify for or against a bill. I thought it would be interesting to look at some of the testimony in favor of the bill for insight into the rationalization behind supporting the bill.
There was but one letter opposing the bill from the Oregon Health Authority. Otherwise it was all testimony in favor.
Of the 58 exhibits, 35 were from patients. They have a similar theme: odd symptoms, a diagnosis of Lyme by one non-standard test or another, refusal of Oregon doctors to recognize and treat the patients for Lyme for what are probably nefarious reasons, and occasionally some improvement with alternative therapy delivered in other states.
As an IDSA-sort-of-doctor, the suffering is compelling (although not due to Lyme). The lack of precise information about testing and treatment is aggravating, making an assessment of the validity of the patient stories impossible. I am well aware of unreliability of patient histories, especially when they have a dog in the fight.
Most appear to be patients who have received creative care from the alternative Lyme world. An example (bold are my additions):
Ashley to the East Coast, where she was examined, tested, and found to have Lyme disease, along with Babesia and Ehrlichiosis (three diseases almost nonexistent in Oregon). Her Lyme doctor was shocked that her absolute classical presentation was ignored by her doctors and specialists. She improved using the ILADS standard of care.
This doctor worked with Ashley’s PCP’s who could do supportive care in Oregon. Over the next several years, we and our daughter went through a cyclical routine of Oregon support doctors discontinuing her ILADS Lyme treatment and telling us residual symptoms were not Lyme. However, the symptoms recurred, and positive blood tests, including 2 positive PCR (DNA) tests (unreliable) indicated she was still infected.
When we asked the East Coast and California Lyme specialists why she was so difficult to treat they said because she went for 9 years without any treatment, and the bacteria had penetrated bone marrow and brain (not).
Ashley stabilized to an almost normal life routine by age 20, but she missed having anything resembling a normal childhood and teen years. At this time, she is happily married and has 3 healthy children.
Our family was terribly impacted. Our “vacations” were often spent traveling to out-of-state doctors. Our children missed out on many normal family activities. We can never get back those years. We’ve spent approximately $185,000 out of pocket
That is a lot of money. No wonder the Lyme literate doctors want legislative protection from their treatments. And they say we are shills.
Some of the diagnoses and clinical courses are quite fantastical, although from the spotty information given in the testimony a true analysis is not possible. It would be interesting to compare the testimony with the whole medical record, but that is unlikely to occur.
Many were diagnosed for Lyme and other diseases using testing that may be suspect. Igenex is a popular but questionable lab, used rather than the standard two step testing. The CDC test, as they call it, has been validated by the gold standard: culture positive patients. I cannot find where Igenex has been validated, if it is on PubMed I could not locate it. The closest I could find was a report that:
IGeneX was rejected by New York three times for Lyme tests in the past decade for not having enough documentation to prove the tests worked.
And:
Several Lyme laboratories said they stood by their tests, but the process to get FDA approval was too cumbersome.
“You need a ton of documentation,” time, and money, said Jyotsna S. Shah, vice president of IGeneX Inc., a Palo Alto, Calif., lab that performs more than 25,000 Lyme tests a year for hundreds of dollars each…
…In contrast, government and academic scientists contend that the IGeneX method is highly sensitive but not adequately specific, meaning it probably returns positive readings for many people without Lyme.
Sitting in a small conference room in a nondescript building near Stanford University, Shah said IGeneX’s testing is backed up by solid science and that the company has been open about its methods. She pointed to two papers on its methods, a 2007 paper published in an alternative medicine newsletter and a 2010 paper in a journal that appears to be defunct. Neither publication is widely read or cited by other scientists.
The patients put a lot of faith in the validity of the alternative testing despite a lack of rigorous published evaluation. Perhaps because it provides the answer they want, motivated reasoning at its finest.
The most common of all follies is to believe passionately in the palpably not true. It is the chief occupation of the Lyme literate.— H. L. Mencken. Almost.
Reading the patient testimony made me sad. People suffering (I never deny the suffering of patients, only that the suffering is from Lyme), being diagnosed with multiple infections with unreliable tests and spending enormous amounts of time and money chasing the chimera of alternative treatments for their mythical illness.
More striking is that if the testimonies are correct, it documents medical treatments by the Lyme literate doctors that are, in my opinion, truly bizarro by my understanding of infectious diseases. Why such horrible medical care needs protection is understandable. Such care certainly cannot be justified by the best medicine and science.
Many of the patients noted that Lyme is an under recognized epidemic; I saw an epidemic of inappropriate tests, testing and treatment.
This was brought home by the opening testimony of the Oregon Lyme Disease Network.
They note many times more false Lyme diagnoses than real Lyme diagnoses in Oregon:
CLIA certified laboratory with CDC proficiency ratings, reported 166 CDC positive results on either Western Blot IgG or IgM test for Oregonians in 2014
Currently in Oregon Support Groups 817 patients, a combination of clinical diagnosis with supportive laboratory testing.
Patients currently in Support groups or in email connection with SG around the state: 817
While:
The State of Oregon, Cases of Selected Notifiable Diseases for 2014 — reported a total of 38 probable cases and 21 confirmed in Oregon for the year.
It is the kind of weasely statements that obscure the truth with misdirection. Lots of positive tests by labs that are certified but note they fail to mention if the tests are validated. In my opinion there are a staggering numbering of patients misdiagnosed and mistreated with Lyme.
The Oregon Lyme Disease task Force also says MDs (emphasis added):
Reject IgeneX laboratory telling patients it’s a bad lab (not sure why they say this)
Really? You really can’t discover why MDs might find Igenex questionable? It took me less five minutes to find why the non-standard Lyme testing is questionable.
No MDs testified in favor of the bill. I can see why. If the patient stories are any judge, the doctors who provided the care as mentioned in the patient narratives have reason to worry. I tend to be fairly liberal in patient care as often the what and how of patient care has uncertainty, but in the case of these testimonies? Gave me the heebie-jeebies.
There was a ND who did mention the benefits of naturopathic practice in Lyme:
I am indeed fortunate that I hold a license as a Naturopathic physician and as a consequence have a board that allows me to practice without the threat of losing my license if I choose to treat a patient diagnosis with Lyme disease.
As has been pointed out elsewhere, being a naturopath means never having to say you have standards.
So that was the testimony in favor of the bill. Patient stories of creative diagnosis and treatment and the need for those who provide those treatments to be protected and paid. Some disingenuous cherry picking from the Lyme organizations. A seeming lack of understanding why the ILADS guidelines and alternative testing are suspect and what constitutes best evidence. From my viewpoint, the testimony was a compelling argument for increased investigation into the practice Lyme literate doctors to protect patients. They did their cause little benefit.
There is a lot more information in these testimonials that would make interesting analysis if I had the time.
Despite all the testimony in favor of the bill, or perhaps because of it, the bill was amended to instead read:
The Oregon Health Authority, the Oregon Medical Board and the Oregon State Board of Nursing shall study clinical guidance regarding Lyme disease and the health outcomes related to the clinical guidance and shall report findings to the appropriate committees of the Legislative Assembly no later than March 1, 2016.
I am a newbie in the legislative arena and had a late start in the 2014–15 legislative session when Oregonians for Science-Based Medicine was started as part of SfSBM. I hope next season to start earlier and more comprehensively. That being said, Ore4SBM sent a letter opposing the bill to the Committee as well as a modified (snark free) version of my SBM post on Lyme.
The committee members also received a letter opposing the bill, written and orchestrated by yours truly, signed by 18 Oregon Infectious Disease doctors.
Did those actions have any effect to change the bill? No idea. But I like to think it did.
For now the standard for the treatment of Lyme will remain gold rather than the tin of the initial bill. It will not last. I have no doubt that further SCAM protection bills will be presented to Oregon, and other, legislatures.

Florida revokes medical license of “Lyme literate” doctor
Florida finally revoked the medical license of “Lyme literate” doctor John Lentz, who honed his diagnostic skills and treatments in ILADS seminars and treated “chronic Lyme” for almost a decade. Why does the system allow this?
Jann Bellamy on December 22, 2016
Link

The Florida Board of Medicine revoked the medical license (warning: very large PDF file) of John Lentz, MD, who operated Lentz Lyme Clinic in Destin, on November 4, 2016, by a unanimous vote. In doing so, it adopted the recommendation of an Administrative Law Judge (ALJ), issued in July of this year, following a 4-day hearing in January. The Board voted against the ALJ’s recommended imposition of a $30,000 fine.
The very presence of a “Lyme clinic” in Florida is an anomaly indicating something might be amiss. As noted by the ALJ, while it is not impossible to contract Lyme disease in Florida, it is not prevalent in the state. According to the CDC, in 2015, Florida had 0.6 confirmed cases per 100,000 population, a total of only 116 cases. Most people diagnosed in Florida were likely infected elsewhere while traveling.
But a Lyme clinic makes perfect sense, economically at least, when one understands the transmogrification of real Lyme disease into “chronic” Lyme disease and of the real specialty of infectious diseases into the “specialty” of “Lyme literate” doctors.
Real practicing infectious disease specialists go through internal medicine residencies, followed by infectious disease fellowships, take the American Board of Internal Medicine certification exam in infectious diseases, and are members of the Infectious Diseases Society of America (IDSA). “Lyme literate” doctors do residencies in any area and gain their Lyme “literacy” through seminars where no actual patient care may be involved. They are members of the International Lyme and Associated Diseases Society (ILADS), an organization that advocates very different standards than the IDSA for the diagnosis and treatment of Lyme disease and whose guidelines are based on “very low quality evidence.”
Without getting into the weeds (where ticks may be hiding) too much, real Lyme disease is an infectious disease transmitted by a tick bite. Its symptoms are a rash, fever, headache and fatigue, although not all symptoms may appear. It is diagnosed by medical history, physical exam and sometimes a blood test. It can take 4 to 6 weeks for the immune system to make antibodies against Borrelia burgdorferi, the organism responsible for the disease, and show up on a blood test. Anyone who has symptoms for longer than 6 weeks and who hasn’t been treated with antibiotics is unlikely to have Lyme disease if the blood test is negative, according to the IDSA.
A diagnosis of “chronic” Lyme, which is not recognized by medical science, is based on a collection of vague, non-specific symptoms that could be attributed to any number of things (or nothing):
Lyme is a multi-systemic illness, and may affect every part of the body causing fatigue, stiff neck, headaches, light and sound sensitivity, tinnitus (ringing in the ears), anemia, dizziness, joint and muscle pain, brain fog, tingling, numbness and burning sensations of the extremities, memory and concentration problems, difficulties with sleep (both falling asleep and frequent awakening), chest pain and palpitations and/or psychiatric symptoms like depression and anxiety.
Non-standardized and unvalidated tests are thrown into the diagnostic mix, presumably to add credibility to the diagnosis, while evidence-based testing is rejected. Standard treatment for “chronic” Lyme includes long-term antibiotics, which is both not evidence-based and potentially dangerous. Case reports in the medical literature describe the ill-effects of long-term antibiotics.
A “specialty” based on a few seminars
Lentz did a family practice residency and was board-certified in family practice until 2009, but currently holds no board certification. He graduated from medical school in 1975 and practiced in South Carolina, but moved to Florida in 2001, where he worked in a variety of practice settings, including working as an emergency room doctor in several hospitals. In 2007, he opened the Lentz Lyme Clinic. His education and training for this enterprise, according to his hearing testimony, was attendance at four courses, each lasting three to four days. He testified that the first course he took, put on by ILADS, was not until 2009. Another, also put on by ILADS, was in 2010. It featured Eva Sapi, PhD. According to information on the ILADS website, Sapi’s
recent research shows that Borrelia burgdorferi is capable forming a protective layer around itself ??” [sic] called biofilm ??” [sic] which could render it to be very resistant to antibiotics and provide a logical explanation as to why extensive antibiotic treatment for patients with a tick-bite history could fail.
This research has been parlayed into new testing and treatment regimens for “chronic” Lyme by dubious medical clinics.
The two remaining courses were taught by Dr. Carol Ann Ryser, a pediatrician whose Kansas City clinic treated, among other things, “chronic” Lyme disease. Ryser surrendered her medical license and shut down her clinic as part of a plea agreement with the feds over fraud and tax evasion charges in 2013. She was also the subject of numerous malpractice actions, one of which reveals her as a devotee of the idea that “bugs” could hide in one’s “biofilm,” necessitating lengthy antibiotic treatment.
The findings
The Department of Health’s case against Lentz involved his treatment of seven patients, as alleged in three administrative complaints consolidated for hearing. Lentz’s courses in “chronic” Lyme diagnosis and treatment were well-reflected in his practice. According to the ALJ’s Recommended Order, Lentz’s falling below the standard of care included the following:
Diagnosed Lyme disease without objective laboratory tests results from ELISA or Western blot tests.
Lentz testified he based his Lyme diagnoses on clinical presentation and CD57 blood panels. As the ALJ noted, the CD57 panel itself carries a disclaimer stating it is for investigational purposes only and should not be used as a diagnostic procedure without confirmation of the diagnosis by a medically established diagnostic product or procedure. He also used other unvalidated tests, even though at least one other had a disclaimer stating it was for research use only.
While the ALJ found that performing other tests in conjunction with the CDC-recommended ELISA and Western blot tests is not a per se departure,
the standard of care requires either ordering the ELISA and where necessary, the Western blot, or reviewing these tests previously obtained by the patient
where the exposure to the disease occurred four weeks or more in the past. In other words, just what the IDSA says. She rejected the testimony of Dr. Michael Cichon, Lentz’s infectious disease expert, who testified that the ELISA and Western blot tests had “little value” as “not credible.” ILADS also takes the position that ELISA is “unreliable” and that the Western blot test is too narrow in its reporting.
Diagnosed babesiosis and bartonellosis without appropriate testing.
This is another popular “Lyme literate” diagnosis, rejected by IDSA but given support by ILADS. The ALJ noted that both are uncommon infections and that even an infectious disease specialist might never see a case in his or her entire career, yet Lentz diagnosed several patients with these infections and treated them.
Prescribed inappropriate and excessive antibiotic therapy without medical justification.
For example, without proper testing, Lentz diagnosed one young woman who had multiple orthopedic problems (and therefore pain) with Lyme and babesiosis. He referred her for venous port placement for administration of IV antibiotics. He prescribed at one visit alone:
    • Acetaminophen-oxycodone 300 mg – 7.5 mg oral tablets, three times a day
    • Cymbalta 30 mg orally, once a day
    • Flagyl 500 mg oral tablets, 3 weeks on, 1 week off
    • Heparin, 5,000 units/ml injectable solution, once a day
    • Omnicef 300 mg oral capsules, once a day
    • Interfase Plus Prothera, a supplement
    • Boluoke lumbrokinase, a supplement
At a subsequent visit, he ordered a Fry test for bartonellosis and prescribed IV vancomycin for bartonellosis, even though she had yet to be diagnosed with that disease. Fortunately, this patient saw a real infectious diseases doctor at some point, who advised her to immediately stop the therapy prescribed by Lentz because it “was unsafe.”
If you are a medical professional, you are likely saying to yourself at this point: Heparin? Why heparin? Read on.
Prescribed the anticoagulant heparin in the treatment of Lyme, babesiosis and bartonellosis, without medical justification.
Lentz prescribed heparin for several patients. He testified that heparin was “very therapeutic for biofilm” and that it “coats the babesia so when the babesia protozoan enters the red blood cell” it “protects the red blood cells from actually allowing babesis to enter them,” a bit of pseudoscience one imagines he learned in the courses he attended.
The ALJ had a different view. She concluded that not only was its prescription in these cases a departure from the standard of care, it
was a dangerous choice for this or any other patient who did not have a need for a blood thinner.
Failed to obtain complete medical histories, failed to perform adequate physical examinations and failed to keep adequate medical records.
On some patients, he performed no history and physical, but ordered non-standard tests for Lyme disease based on e-mails sent to him by people he’d never seen in person. Reading between the lines, it appears some of his correspondents were actively seeking “Lyme literate” doctors based on information on the internet or recommendations from friends. With others, his history and physical were inadequate. For instance, he did not inquire about travel history, to see if the patients had been to Lyme-infested areas. As the ALJ said, Lentz
seems so focused on Lyme disease and its possible co-infections that he seems to pay no attention to other symptoms or complaints the patient may have.
The ALJ also found Lentz prescribed antiparasitic medication, antimalarial medication, antacids, laxatives, enzyme formulations, and supplements, without medical justification. In addition, he failed to comply with a state law requiring the immediate reporting of “diseases of public health significance,” including Lyme disease, to the Department of Health.
The ALJ did not agree with the Department of Health that Lentz’s failure to refer patients to an infectious disease specialist was below the standard of care:
the evidence was not clear and convincing that a primary care physician could not diagnose Lyme disease or babesiosis, assuming that he or she took an appropriate history, conducted a thorough physical examination, and, where warranted, ordered the appropriate objective laboratory tests.
Based on her finding that Lentz was guilty of “repeated malpractice,” the ALJ recommended revocation of his license and the fine. Because the Board of Medicine agreed with the ALJ’s findings of repeated malpractice, it had no discretion to impose a lesser penalty than revocation. In 2004, Floridians overwhelmingly approved a proposed amendment to the state constitution, subsequently enacted into Florida law via enabling legislation, dubbed the “Three Strikes Rule.” The law prohibits physicians with three or more incidents of medical malpractice, proven by clear and convincing evidence, from being licensed to practice medicine. Because Board proceedings require proof by “clear and convincing evidence,” the adjudication in this case met the statutory requirements. According to the audiotape of the Board proceedings, this is the first “three strikes” case the Board has considered, although I could not confirm this. Of course, one hopes the Board would reach the same conclusion even without the Three Strikes Rule if presented with this egregious case.
What happens next?
Lentz had 30 days to appeal the Board’s revocation to the state court of appeals. As of yesterday, I could not find that a notice of appeal had been docketed on the court’s website, but that isn’t conclusive as to whether one has been filed. If he appeals, he has a right to a stay of his license revocation “upon such conditions as are reasonable” unless the Department of Health can convince the court of appeals that a stay “would constitute a probably danger to the health, safety, or welfare of the state.”
Should he appeal, the appellate court cannot substitute its judgment for that of the Board (which is based on the ALJ’s decision) as to the weight of the evidence on any disputed finding of fact. It can, however, determine that a particular finding is “not supported by competent, substantial evidence in the record.” In this case, the ALJ repeatedly rejected the testimony of Lentz’s expert as not credible on issues such as appropriate testing and use of antibiotics. The Department of Health, on the other hand, presented the testimony of an expert in infectious diseases and family practice in support of its case. Several ID doctors who treated patients after Lentz also testified as to how they rejected Lentz’s diagnoses and took patients off his regimens. This should give Lentz little hope of overturning the Board’s decision.
In sum, starting in 2007, Lentz, an older, peripatetic family practice physician, opened a clinic specializing in diagnosing and treating certain infectious diseases, based on his having taken a few seminars. As a consequence, his patients were diagnosed with diseases they did not have by any credible assessment of their symptoms, using unvalidated tests that plainly stated they were not for diagnostic purposes, and subjected to expensive, ineffective, painful, and possibly dangerous treatments. This went on for almost a decade before the state medical board revoked his license, thus assuring (barring overturning the Board’s decision on appeal) that he will never have this opportunity again.
Yet, because of pressure from misinformed advocacy groups and physicians who eschew science, these appalling practices are being put beyond the reach of the authorities. Had Florida a law like, for example, New York’s, which greatly inhibits the medical board from taking action against “Lyme literate” physicians, Lentz might well be exonerated. Something is wrong with this system.

Another “Chronic Lyme” VIP disciplined by NY medical authorities: Bernard Raxlen
Another “Lyme literate” NY physician is on probation and under orders to clean up his act. Will other physicians treating “chronic Lyme” take note?
Jann Bellamy on November 9, 2017
Link

Bernard Raxlen, MD, who devotes more than 90% of his practice to the treatment of so-called “chronic Lyme” disease, is on a three-year probation imposed by the New York State Board for Professional Medical Conduct (BPMC). Raxlen agreed to probation and a lengthy list of practice requirements last month following allegations, filed in September, of negligence, incompetence, gross negligence, gross incompetence, and failure to maintain adequate patient records. In doing so, he becomes the second “Lyme literate” VIP disciplined by the NY medical authorities this year. Based on similar charges of professional misconduct, David Cameron, MD, was also put on probation with numerous practice restrictions in June.
Who is Bernard Raxlen, MD?
Raxlen is a psychiatrist and solo “chronic Lyme” practitioner in New York City who says he’s “successfully treated” over 3,500 cases of tick-borne disease in the past 15 years. (He named his practice “Lyme Resource Medical of New York.”) He touts a “total comprehensive treatment program which utilizes both oral and intravenous (IV) antibiotic treatment.” It doesn’t come cheap, either. An initial visit with Raxlen costs $1,200 with follow-up visits between $600 and $700. A PICC-line insertion (presumably for long-term antibiotics) is $750 and a “nutritional IV” is $150. He does not accept public or private insurance.
Raxlen has a history of disciplinary actions against him in two states stretching back almost 20 years. In Connecticut, where he was formerly licensed, he was reprimanded and paid a total of $35,000 in civil penalties in two cases arising out of his refusal to provide patient records to the Health Department and insurance companies, even though patients had signed releases. He was also disciplined for inappropriate prescribing and failing to maintain malpractice insurance. Because these infractions constituted professional misconduct in New York as well, he was subject to two disciplinary actions in that state, resulting in censure, reprimand and a $2,500 fine.
According to the Chicago Tribune, Raxlen had other professional misconduct charges brought against him by Connecticut authorities but they were ultimately dropped. The Tribune reported that, in one case, Raxlen was charged with telling a patient with Lou Gehrig’s disease (ALS) that she had Lyme disease and treating her with an illegal drug from Germany. He told the reporter that the relationship between ALS and Lyme was “unclear,” even though ALS experts concluded that there was no evidence of a connection.
Per his New York State Department of Health physician profile (just type his name into the search engine), Raxlen completed residency training in psychiatry and lists his specialty as psychiatry, but he is not board certified in any specialty. He did not train in internal medicine, family medicine or pediatrics (although he treats pediatric patients), specialties that normally treat routine Lyme infections. Nor did he train in infectious diseases, experts to whom patients with more complicated cases of Lyme would normally be referred by other practitioners.
Yet, he is described by the International Lyme and Associated Disease Society (ILADS) as a “leader in Lyme disease treatment and research.” In fact, he is a founding member of ILADS, former Secretary of the Board, and has taught a number of ILADS courses. He was a co-author of the original ILADS guidelines for the treatment of tick-borne diseases. Despite their troubling disciplinary status, both he and David Cameron are scheduled to speak at the ILADS Annual Scientific Conference, which starts today in Boston.
How can this be? How can one be a leading light in ILADS with a disciplinary history like Raxlen’s and no graduate medical education in infectious diseases?
“Lyme literate” physicians like Raxlen have fabricated a disease they call “chronic Lyme,” which they regularly “diagnose” and treat with long-term antibiotics, sometimes for months to years. Board-certified infectious diseases doctors and other “conventional” physicians all agree that “chronic Lyme” is not a valid diagnosis and rely on well-conducted trials showing that long-term antibiotics do not substantially improve the outcome for patients diagnosed with so-called “chronic Lyme.” Long-term antibiotics can, in fact, result in serious harm, including death, a subject our good friend Orac covered recently over on Respectful Insolence. Orac’s post nicely summarizes the differences between real Lyme disease and “chronic Lyme,” “a prototypical fake medical diagnosis,” and the dangers of long-term antibiotics, as have posts on SBM, here, here, here, and here.
The CDC, the Infectious Diseases Society of America (IDSA), the American Academy of Pediatrics, the American College of Physicians, the Medical Letter and the American Academy of Neurology all reject the notion that “chronic Lyme” exists and that long-term antibiotics are an appropriate treatment. There is something called “post-treatment Lyme disease syndrome,” but responsible medical authorities do not equate this syndrome with the nebulous symptoms and unvalidated lab tests of “chronic Lyme” and specifically reject the utility long-term antibiotic treatment based on well-conducted clinical trials. None of this is to say that patients who’ve been told they have “chronic Lyme” are not truly suffering, a fact that makes “Lyme literate” practices all the more reprehensible.
None of this stopped “Lyme literate” doctors from banding together to form ILADS and issuing their own guidelines for the diagnosis and treatment of “chronic Lyme,” guidelines based on very low levels of evidence that are accepted only by themselves and, in contrast to the IDSA guidelines, no other professional medical organization. ILADS teaches physicians and other practitioners how to become “Lyme literate.” ILADS, again in contrast to IDSA, is not an ACCME-accredited provider of continuing medical education although, for some inexplicable reason, the Westchester [County, NY] Medical Society has teamed up with ILADS and is using its accrediting authority to grant CME credit for some of the talks (also here) at the ILADS Scientific Conference.
Despite the lack of evidence that “chronic Lyme” is a valid diagnosis, and the lack of efficacy as well as the risks of long-term antibiotic treatment, ILADS healthcare providers currently treat more than 100,000 patients with “chronic Lyme” and tick-borne diseases in the USA and around the world. Given media reports that patients can spend $10,000 to $35,000 for treatment, “Lyme literacy” translates into millions of dollars for practitioners.
While it may be profitable, “Lyme literate” doctors risk running afoul of state medical boards. Raxlen is just one among ILADS-trained, “Lyme literate” physicians who have had their medical practices questioned by their peers, up to and including discipline imposed by state authorities (also, here and here).
With that background, let’s look at the allegations against Raxlen and the terms of his probation.
The BPMC v. Raxlen
New York’s medical misconduct procedures do not require the physician charged to stipulate to any particular acts of misconduct as a condition of settling his case. The physician can, as Raxlen did here, simply state he is unable to “successfully defend against at least one of the acts of misconduct alleged” and agree to the imposition of sanctions. This means the allegations in the state’s Statement of Charges were never proven, as it was unnecessary to reach a decision on the factual issues once Raxlen agreed to a settlement. However, per the Office of Professional Medical Conduct’s (OPMC) standard procedures, the allegations were based on expert review of Raxlen’s patients’ records and they remain uncontested by him.
The allegations of misconduct arise out of Raxlen’s care of eight patients. As is typical of “chronic Lyme” diagnosis and treatment, patients (whose identities are protected) presented with a variety of disparate symptoms, such as:
    • Patient A: freezing, burning, air hunger, weakness, fatigue, neck pain and intestinal pain.
    • Patient E: fatigue, migraines, neck pain, joint pain, numbness and tingling, irritability, sound, light and temperature sensitivity and nonrestorative sleep.
    • Patient G: back pain, abdominal pain, feet pain, extremity weakness, anxiety, depression and mood swings.
    • Patient H (who got the Hickman catheter and numerous antibiotics mentioned below): mouth, teeth and jaw pain, confusion, forgetfulness, irritability and mood swings.
Diagnosis and treatment of “chronic Lyme” is never mentioned, a wise decision on the part of the BPMC prosecutors in light of the ill-conceived New York law protecting “Lyme literate” doctors from prosecution
based solely upon the recommendation or provision of a treatment modality by a licensee that is not universally accepted by the medical profession, including but not limited to, varying modalities used in the treatment of lyme disease and other tick-borne diseases.
Instead, the BPMC focused on the fact that Raxlen had failed in the most basic tenets of good medical care, although the fingerprints of “chronic Lyme” diagnosis and treatment, such as failure to consider alternative diagnoses, prescribing IV antibiotics and using a Hickman catheter, are all over the charges. The charges included:
    • Repeatedly failing to perform or note in the patient’s chart a comprehensive history and appropriate physical exam, including (despite his being a psychiatrist) a psychiatric history, neuropsychological testing and mental health status exam.
    • Failing to construct a differential diagnosis and pursue a thorough diagnostic evaluation prior to instituting a treatment plan.
    • Inappropriate prescribing, including prescribing Rifampin for a patient on Tamoxifen and prescribing addictive medications prior to a making a diagnosis and without considering non-addictive treatment.
    • Inappropriately relying on Applied Kinesiology (which is quackery) to formulate a diagnosis.
    • Placement of a Hickman catheter without medical necessity.
    • Inappropriately administering antibiotics, including intravenous Invanz, Clindamycin, Flagyl, Rifampin, Minocycline, Mepron, Plaquenil and Bactrim, all of these for one patient.
    • Failure to present or note in the patient’s chart potential risks, benefits, side effects and safe use of prescribed medications.
    • Failure to appropriately identify, address, and/or follow-up on potential side effects.
    • Treating inappropriately with an ongoing and/or escalating medication regimen without appropriate physical exams and clinical reassessment for consideration of alternative diagnoses and treatment.
    • Poor record-keeping.
These allegations resulted in charges of negligence, incompetence, gross negligence, gross incompetence, and failure to maintain adequate patient records. As noted, Raxlen agreed to a three-year probation in addition to the imposition of conditions on his practice. He must, among other things:
    • Communicate to patients the nature of his medical role, whether it be a primary care physician responsible for the patient’s general medical condition, or for a defined or limited purpose, and/or as a practitioner of a particular medical specialty.
    • Obtain written informed consent addressing all aspects of treatment and document same, including documentation of all discussions with the patient about the nature and scope of his evaluation and treatment and the patient’s need to pursue “conventional medical care elsewhere.”
    • Document all histories and physicals.
    • Refer patients to primary care physicians, specialists or consultants for further evaluation and/or treatment where medically warranted and provide these physicians with all relevant patient information.
    • Cooperate fully with the state in enforcing the Consent Order and timely respond to all state requests for written periodic verification of his compliance and all documents.
What now?
Based on a birthdate of 1938 in his state physician profile, Raxlen is either already, or soon will be, 79 years old. One wonders whether he will continue his practice in face of these new sanctions, although his website is still trying to attract patients.
Sadly, the “chronic Lyme” lobby responsible for passing the law protecting “Lyme literate” doctors has its sights set on even greater rewards. Several bills are pending in the NY legislature which would force insurers to cover “chronic Lyme” treatment (Assembly Bill 114, Senate Bill 4713, Senate Bill 670). Other bills give them the opportunity to argue in yet another venue for insurance coverage. (Assembly Bill 4863, Senate Bill 2168, Assembly Bill 6927).
In any event, it is commendable that the Board for Professional Medical Conduct has not let New York’s unfortunate law get in the way of its prosecuting physicians who take advantage of patients with a diagnosis of “chronic Lyme,” no matter how they frame the specific charges. With two leading NY “Lyme literate” physicians now on probation and under strict orders to clean up their acts, it remains to be seen what effect this might have on other “Lyme literate” doctors in the state.

State Medical Boards should not recognize board certification in “Integrative Medicine”
Integrative medicine is not a real specialty in medicine. Let’s not treat it as though it were.
Jann Bellamy on December 8, 2016
Link

There are a number of things about so-called “integrative medicine” (or, “IM”) we don’t know, such as
    • Whether IM really offers the best of conventional medicine and CAM.
    • Whether IM produces better outcomes.
    • Whether IM is effective in the area of prevention, including obesity and cardiovascular risk.
    • Whether IM has anything to offer preventive medicine.
    • Whether future IM research will yield beneficial results.
    • Whether IM has a positive impact on utilization clinical preventive services, smoking cessation, diet, and physical activity.
    • Whether IM is cost effective.
We don’t even have a working definition of “integrative medicine,” although experience tells us that incorporating diagnoses and treatments with insufficient evidence of safety and effectiveness is an acceptable element of integrative practice, as is rebranding “conventional” practices as “integrative.”
Normally, these substantial deficiencies would get in the way of declaring that IM is anything like a real specialty in medicine. Indeed, as David Gorski has pointed out, IM is more of a brand than a specialty. Yet, as we do know, integrative medicine considers itself exempt from the rules. Thus, a few years ago, Andrew Weil, MD, an early adopter in incorporating pseudoscience into medical practice, announced his desire to create of a board certification in integrative medicine. No doubt aware that IM couldn’t fulfill the requirements of the American Board of Medical Specialties (ABMS), he turned to the American Board of Physician Specialties (ABPS), whose requirements for Board recognition are more forgiving. For example, the ABPS is willing to credit work experience as a prerequisite to board certification, as opposed to residency and fellowship training. Sure enough, a few years ago, the ABPS formally accepted board-certification in IM via the ABPS’s recognition of the American Board of Integrative Medicine (ABOIM).
Board certification is not required for medical practice in any state. However, some hospitals and insurance companies do require it as a credential. State medical boards, which regulate the practice of medicine in the U.S., also have rules on which recognizing agencies they approve. The oldest (est. 1933) and most prestigious is the American Board of Medical Specialties, whose 24 boards and 147 subspecialties, covering 750,000-plus physicians, are universally accepted by state medical boards, hospitals and health insurers. (Statistics are from 2010.)
The American Board of Physician Specialties started its board recognition program in 2005. In 2010, the ABPS recognized 16 certifying boards, representing 5,000 plus physicians. According to its website, there are now 20 boards recognized by the ABPS. Some, like orthopedic surgery, family medicine, and emergency medicine, have competing boards, one recognized by the ABMS and the other recognized by the ABPS. Others, like urgent care and disaster medicine, have only ABPS recognition. The ABPS has encountered some difficulties in gaining state medical board approval as a recognizing agency, centered on the lack of requirement of formal training in a specialty for board certification. There is a third recognizing agency, the American Osteopathic Association, which has 18 certifying boards representing about 25,000 osteopathic doctors. (Again, 2010 figures.)
Most, but not all, state medical boards, allow a physician to advertise an ABPS-recognized board certification or are neutral on the subject. (California, for example, does not.) However, because the First Amendment protects truthful advertising statements, as long as there is nothing misleading or false in claiming board certification, state medical boards can’t prevent a physician from stating he is board certified even if the recognizing agency doesn’t have board approval, although some states, like Florida, require the physician to post a disclaimer stating that the specialty certification is from a private agency and is not one approved by the medical board.
Interestingly, there is nothing to prevent a medical board from approving some, but not all, of a recognizing agency’s board certifications. Thus, even in states where ABPS boards are otherwise recognized, the state medical board could refuse to recognize a particular board that did not meet its criteria. For example, the Florida Board of Medicine has imposed additional requirements on holding oneself out as a board-certified dermatologist, even though it recognizes both the ABMS and ABPS, each of which has its own dermatology board certification.
Because the American Board of Integrative Medicine has no publicly available standards for board certification in IM, and, indeed, we don’t even know who runs the ABOIM, state medical boards should not allow physicians to claim they are board-certified in IM, at least without a disclaimer. From what little information is publicly available about the ABOIM’s requirements, we can conclude IM does not warrant state-sanctioned board certification.
Who controls the ABOIM and what are its standards?
In the first place, who are these people? The American Board of Physician Specialties has a staff list, but does not reveal who its officers and directors are. We are told that the ABPS is
composed of the Chair of each of the governing specialty boards, the President, President-Elect and Secretary/Treasurer of AAPS [American Association of Physician Specialists] and up to two public members.
But we aren’t told who they are. We are also given this rather cryptic chart.
We know even less about the American Board of Integrative Medicine. According to the ABPS website:
Complete eligibility requirements, application and examination information are available at www.aboim.org.
But if you enter that URL you are simply directed back to the ABPS website. Thus, we have no clue as to who is actually on the board of the ABOIM or who its officers or staff members are.
We also learn from the ABPS that
Each specialty board establishes its own standards although the ABPS oversees proposed changes in standards for appropriateness and adherence to standards to which all Boards must comply. All proposals by specialty boards regarding organization, structure and certification standards are first reviewed by the ABPS and then forwarded to the AAPS Board of Directors for final approval.
So, what are the ABOIM’s standards for organization, structure and certification? We don’t know. Nothing on the ABPS website tells us.
Compare this to the American Board of Medical Specialties, which tells us not only who is on its Board of Directors but also gives us links to all member specialty board websites, each of which has information on governance and standards.
Integrative Medicine is, until December 31, 2016, one of the ABPS-approved board certifications which doesn’t require formal training, except for having completed a medical residency, which can be in any specialty. Until a few days ago, the deadline was December 1. However, the ABPS just announced that
In response to the overwhelming interest for the ABOIM Limited Time Eligibility Option, ABPS has extended the deadline to submit applications to the end of the month [Dec. 31, 2016].
The E-Z way to IM board certification will cost you another $200 in addition to the regular $750 fee, which was itself bumped up from the original $500 fee if you waited until after Oct. 15 to apply.
Thus, for all its lip service about patient-centered care, holism, and the like, physician specialists who rarely come in contact with an actual patient (radiologists, pathologists) are nevertheless allowed to sit for the board exam in integrative medicine. All they need is to be board certified or board eligible in anything, have a license to practice medicine, and rack up 500 points of “documented training and experience,” which has to include at least one year of clinical experience in integrative medicine. Clinical experience is worth up to 250 points, depending on how long one had been practicing IM. The rest can be gotten by taking continuing education courses.
Clinical practice can be documented with a couple of letters. One is to verify, from an independent source (like a partner or office manager), the number of years the physician has been practicing IM. The other
will be needed to document the integrative elements of the practice. This letter should be about 1-2 pages and should provide details about the integrative practices regularly used with patients.
(What we would give to see these letters!)
Apparently, there is some concern among potential applicants about just what constitutes practicing integrative medicine for purposes of the point system. After all, as best I can tell, there are no criteria provided for what does and does not count as IM for purposes of claiming that mantle via the E-Z route. Given the fact that IM regularly purloins elements of “conventional” medicine and just as regularly discounts evidence of effectiveness as a criterion, we must imagine the list of what was acceptable as IM practice is quite liberal. Nevertheless, this confusion called for guidance from ABPS, which, unhelpfully, basically tells applicants to take a stab at it and see what happens:
Q: Can I submit documentation to ABPS staff to see if it qualifies as Integrative?
A: Unfortunately, only the Board can judge if the eligibility criteria [whatever they might be] have been met. ABPS staff is happy to provide guidance based on previous board decisions. The Board will not “pre-screen” applicants or partial applications.
After December 31, the ABOIM will require an MD or DO to complete a “fellowship” in IM unless he or she has also graduated from a naturopathic, chiropractic or oriental medical school, in which case he can go straight to the exam. You can still be board-certified or board-eligible in any specialty. This presents some interesting possibilities. The following combinations would be eligible for board certification under ABOIM rules:
    • ND/DO with board certification in anesthesiology
    • DC/MD with board certification in radiology
    • MD with board certification in pathology who completes an IM residency
The many stylings of IM fellowships
As befits IM in general, which has yet to settle on the basics, the IM fellowships listed on the ABPS website are an odd lot. (Come to think of it, that’s yet another thing we don’t know about IM in medical education: costs and return on investment.) First, it appears there are no common admission requirements. The Santa Rosa Family Medicine Residency and the University of Michigan take only those who’ve completed family practice residencies. The University of Arizona admits non-physician fellows: pharmacists, nurses and physician assistants, and physicians from all specialties are admitted. As we will see below, one fellowship program admits naturopaths, chiropractors and traditional Chinese medicine practitioners along with MDs and DOs.
There is no core curriculum or standard format for an IM fellowship. Arizona has a two-year “distance learning” IM fellowship. The University of Kansas IM program follows the more traditional format of clinical education and research. Stamford Health requires both: completion of the Arizona program plus a 300-hour acupuncture course as well as providing clinical care in a family medicine and an integrative clinic. The University of North Carolina has a fellowship in research in integrative medicine. I couldn’t find that Ohio State University, which is listed as having an IM fellowship program, offers one.
One program has a connection with questionable medical organizations. The George Washington School of Medicine & Health Sciences Integrative Medicine program advertises that it’s “curricula were developed in collaboration with the Metabolic Medical Institute (MMI).” MMI also claims it is “educationally associated” with George Washington, as well as the University of South Florida Morsani College of Medicine, and the American Academy of Anti-Aging Medicine, or “A4M” as it likes to call itself.
A4M is on Quackwatch’s list of questionable organizations. (More information on A4M here and here.) I contacted the University of South Florida by email, inquiring about the claimed link between the A4M, MMI and the USF medical school and providing links to relevant MMI and A4M websites. According to a USF Health Communications representative:
I asked the Vice Dean of our Morsani College of Medicine’s Graduate Medical Education program about this and he had never heard of it.
I sent the same email to George Washington University, whose rep said she would get back in touch with me, but never did.
MMI offers its own self-styled “fellowships” (offered to nutritionists and chiropractors as well) in Metabolic & Nutritional Medicine, Integrative Cancer Therapies (taught by a Florida physician who, according to information he provided to the Florida Department of Health, is board-certified in emergency medicine but does not have any education and training in oncology), and Stem Cell Therapies (uh-oh). Perhaps taking a page from the chiropractic “diplomate” playbook, these “fellowships” are taught in hotel conference rooms.
The newest IM fellowship program, perhaps the apotheosis of the fetishization of alternative medicine by IM proponents, is the Academy of Integrative Health & Medicine Fellowship in Integrative Medicine and Health. The director is Tieraona Low Dog, MD, formerly of Weil’s University of Arizona IM program. The assistant director is a naturopath. The program’s “academic partner” is the Oregon Collaborative for Integrative Medicine, which consists 5 schools, only one of which has a medical school, Oregon Health & Science University. The rest teach acupuncture and traditional Chinese medicine, chiropractic, and naturopathy. The curriculum was developed in conjunction with the Academic Collaborative for Integrative Health, an organization consisting solely of institutions devoted to naturopathy, chiropractic, TCM and acupuncture. It is open to physicians, naturopathic “physicians,” chiropractic “physicians,” TCM practitioners, and acupuncturists, as well as assorted other health care professionals.
We are given only the most abbreviated information about the curriculum, although we do know that it is mostly online. Faculty include “naturopathic oncologist” Lise Alschuler, whose Arizona clinic offers quack treatments for cancer and “detoxification” programs, and Jeffrey Gladd, an MD who prescribes “bioidentical hormones” and sells dietary supplements and other products to his patients. Mimi Guarneri, MD, whose LaJolla clinic offers biomat therapy, cranial sacral therapy, and a “medical intuitive” course taught by a woman who also teaches a course in speaking with the dead, is also on the faculty.
According to the AIHM,
The AIHM Interprofessional Fellowship was unanimously approved by American Board of Integrative Medicine (ABOIM) committee in 2015.
If I were a medical board member considering whether to recognize board certification in integrative medicine, I’d certainly want to know just who is doing this approving and what their standards are.
Given the paucity of information available on IM board certification, state boards might well want to look at what IM clinics affiliated with IM fellowship programs actually offer in the way of treatments. What they will find is an array of pseudoscience and unproven interventions:
    • Santa Rosa Family Medicine Residency: treatment of “adrenal fatigue“
    • Middlesex Hospital (also here): reflexology and reiki
    • University of Kansas Medical Center: IV high dose vitamin C,magnesium and glutathione
    • Maine Medical Center: homeopathy
    • Harvard’s Osher Center: cranial sacral therapy
    • University of Michigan: anthroposophic medicine
    • University of Wisconsin (also here): healing touch and heavy metal detoxification
One characteristic these IM fellowships do share is that none are accredited by the Accreditation Council for Graduate Medical Education (ACGME), which requires compliance with published standards for faculty, program content, clinical and research requirements for participants, accountability, and oversight by ACGME-approved institutions, among other means of assuring a quality program.
Conclusion: Definitely cause for concern
State medical boards should be deeply concerned about recognizing a board certification in an ill-defined “specialty” run by unidentified parties with no published standards. Those standards, whatever they may be, are apparently loose enough to allow physicians to simply summarize their practices in a page or two and take CME courses to qualify for the board exam. Or, as of January 1, 2017, complete on-line, unaccredited fellowships offered, in some cases, by organizations of dubious educational provenance. This is the system that brought us Kenneth Woliner, MD, board certified integrative physician, who recently had his medical license revoked by the Florida Board of Medicine after a patient under his care died from untreated cancer. Woliner asserted before the Board that there is a distinct standard of care for integrative medicine practitioners, one that absolved him of the patient’s death. Woliner’s case should serve as a cautionary tale for all medical boards.

Is there a distinct standard of care for “integrative” physicians? The Woliner case
We at SBM argue that there should be a single, science-based standard of care in medicine. Unfortunately, with the rise of “complementary and alternative medicine” (CAM) also called “integrative medicine,” there is a separate standard emerging that allows CAM practitioners to get away with using unproven and disproven treatments. The case of Dr. Kenneth Woliner illustrates this problem.
Jann Bellamy on October 13, 2016
Link


Florida Atlantic University student Stephanie Sofronsky was diagnosed with Hodgkin’s lymphoma in 2011, after review of her case by oncologists and pathologists at Moffitt Cancer Center in Tampa, the NIH/National Cancer Institute, and the Mayo Clinic in Jacksonville. By June of that year, a PET scan showed the cancer had progressed to her pelvic region. She decided to be treated locally by oncologist Neal Rothschild, MD, and met with him to discuss chemotherapy and ongoing management of her cancer. At this point, with Stage III Hodgkin’s lymphoma, she had an 80-85% chance of being in complete remission with appropriate treatment.
Unfortunately, at the same time, Sofronsky was also seeing Kenneth Woliner, MD, a family medicine practitioner. Despite the fact that world-renowned cancer specialists agreed that Sofronsky had Hodgkin’s lymphoma, and knowing that she was about to start chemotherapy, Dr. Woliner told Sofronsky that cancer was “low on his list” of possible medical concerns and that increased lymphoctyes shown in her tests were not indicative of cancer, insinuating that oncologists “often overreact” to the presence of lymphocytes and recommend chemotherapy before making an actual diagnosis. Dr. Woliner suggested instead that Sofronsky have her house tested for mold, which could be causing allergies, and therefore her symptoms. Convinced, Sofronsky pursued treatment for her allergies and cancelled her follow-up appointment with Dr. Rothschild.
Sofronsky complained repeatedly to Dr. Woliner of symptoms that were, as our good friend Orac points out, consistent with progressing lymphoma – back pain and pain and swelling in her lymph nodes, abdomen and legs, to the point of having to use a cane. Yet, Dr. Woliner, over the next couple of years, continued to attribute her symptoms mostly to her allergies and also thyroid issues and some other minor illnesses. On February 7, 2013, at her last visit to his office and in significant distress from pain and severe leg swelling, he ordered a 100 mg shot of iron, despite the fact that her blood tests showed she was not iron deficient. She rapidly decompensated and died in the hospital three days later of from complications of untreated Hodgkin’s lymphoma.
In 2015, the Florida Department of Health filed a complaint against Dr. Woliner alleging medical malpractice, failure to keep legible medical records, exploiting a patient for financial gain, and accepting or performing the professional responsibilities of an oncologist that he knew, or should know, he was not competent to perform. A hearing was held before an Administrative Law Judge (ALJ) in February of this year. The ALJ issued a Recommended Order in April, and, based on the facts she found, some of which I’ve set out above, she concluded:
Dr. Woliner fell below the standard of care in treating Sofronsky, by failing to timely refer her to an oncologist, educating and counseling her on the risks, including death, of not treating her cancer, and by failing to appropriately attribute her symptoms to her lymphoma.
He failed to keep legible medical records providing an adequate medical justification for his diagnoses and treatments.
He exercised influence over his patient in such a manner as to exploit her for financial gain by scheduling appointments, selling and administering drugs, and obtaining blood work when he knew or should know that none of these would reasonably alter her medical condition, treatment or life expectancy.
He practiced beyond the scope permitted by law by minimizing, if not outright rejecting, Sofronsky’s diagnosis of Hodgkin’s lymphoma, because he is not an oncologist nor was he qualified to give any advice regarding treatment of her cancer.
The ALJ recommends that his medical license be revoked, a $16,000 fine, and repayment of the money Sofronsky paid him to her estate as well as the state’s costs of prosecuting the case. The Florida Board of Medicine will make the final decision, although it has very limited legal authority to reject the ALJ’s findings of fact. It can, however, independently decide all legal issues, including the penalties.
The standard of care for “integrative” medicine, if any?
Given my interest in the intersection of science-based medicine and the law (or, more usually, the lack of intersection), I find one of the defenses presented by Dr. Woliner particularly fascinating. He argues that, even though he is Board-Certified in family practice, he is an “integrative” physician and, as such, is not held to the same standard of care as a “conventional” doctor.
And integrative he is. Dr. Woliner’s website, which advertises his board certification in family practice and calls itself “Holistic Family Practice,” also notes he is Board Certified in Integrative Medicine, certified by the American Board of Integrative Holistic Medicine, and certified in Functional Medicine. He sells patients Metagenics-brand dietary supplements and his website has an online store. His specialty list includes candida, thyroid conditions (even though he is not an endocrinologist or an ENT), food allergies (even though he is not an allergist) and “bioidentical hormones” (a marketing, not a medical, term). If you click on any of these headings expecting to find more information on the topic, you won’t. Instead, you’ll find anecdotes describing cases in which Dr. Woliner was able to figure out what was really wrong with the patient and how he successfully treated that condition, usually after other doctors had failed.
Woliner’s charming anecdotes are a perfect lesson in how unsuccessful cases are excluded from testimonials, one reason they are worthless as evidence of safety and effectiveness.
I imagine he won’t be adding the Sofronsky case to his list. You’ll also not find, under “Thyroid Conditions,” his 2005 settlement with the Board of Medicine, in which he admitted he had, among other things:
diagnosed a patient with Hashimoto’s thyroiditis who had no indication thereof clinically or biochemically,
diagnosed the patient with adrenal insufficiency who showed no biochemical indication,
overdosed the patient on thyroid medication, making him hyperthyroid, and
failed to consult with an endocrinologist instead of “treating conditions that did not exist.”
Ironically, as part of his settlement with the Board, he was required to take a course on keeping adequate medical records.
The Department of Health presented two expert witnesses at the hearing. One, an oncologist, testified to the scope of practice of oncology, which was necessary to establish that Dr. Woliner practiced outside of his, whether it be family practice or integrative medicine. The other, a board-certified family practice doctor, testified to the standard of care for that specialty, and that Dr. Woliner fell below it.
Dr. Woliner argues that neither expert’s testimony should be admitted because, as an integrative physician, only a “qualified” integrative physician can testify to the appropriate standard of care. For Dr. Woliner, that expert is Stephen Silver, MD, a Boca Raton doctor, who, interestingly, does not claim on his website (“HealthSmart MD: Private Family Medicine and Medi-Spa”) that he is an integrative specialist and actually says he follows the same standard of care as the traditional medical community. However, he does offer, among other services, “anti-aging” medicine, IV vitamins, and medical astrology. As he, um, explains,
Astrological Medical and Psychological constitution are determined at birth, affording a skilled Medical Astrologer a valuable tool when diagnosing and treating patients. . . . A Natal Chart is constructed utilizing your birthday, birth time (call mom) and birth location. Astrological Philosophy states that each soul incarnates at a precise time and in a precise place to best predispose the native to fulfill his/her life purpose. This chart describes in accurate detail the twelve (12) spheres of mundane (earth) life and your basic drives and motivations in these areas . . . I use the natal chart as invaluable tool to better understand myself, my patients and the energy flow between people. I am delighted to perform an Astrological chart analysis and profile upon request . . . The Astrological Signs and Planets are correlated with the anatomy, physiology and disease potential of the human body and provide an excellent basis for “Energy Medicine”.
Because, when your medical license is at stake and you need an expert to testify on the standard of care for integrative medicine, you call only the best. I wonder what the standard of care is for medical astrology?
Unfortunately, while the transcript of the hearing and many other documents are available online (although excruciatingly hard to find; hint: see pages 8900-10592) from the Board of Medicine, Dr. Silver’s testimony (submitted by deposition) is not included for reasons that are unclear. However, from the ALJ’s Recommended Order we learn that Dr. Silver opined Dr. Woliner’s role was that of an out-of-network, adjunct holistic doctor,
more comparable to an acupuncturist or a Reiki specialist than a medical doctor . . . [and] suggested that Respondent should not be held to the same standard of as other family medicine doctors providing primary care services.
In other words, an integrative physician has no duty to refer a patient with cancer to an oncologist, no duty to explain to her the grave consequences of her decision to forego chemotherapy, no duty to correctly attribute her symptoms to Hodgkin’s lymphoma. Doesn’t say much for integrative medicine doctors, does it?
The ALJ ultimately rejected Dr. Silver’s assertion that a different standard of care should apply, as well as Dr. Woliner’s claim that he wasn’t acting as Sofronsky’s PCP, which she found “specious.” In response to Dr. Woliner taking exception to the ALJ’s determination, the Department of Health notes, correctly, that Dr. Silver never said what this purportedly different standard actually was.
It is ironic that a physician with Dr. Woliner’s disdain for “conventional” medicine would argue that he is somehow held to a lower standard of care than a conventional physician. (I realize he doesn’t explicitly argue that the standard is lower, but that is in essence what he is saying.) Here’s what he has to say about you “traditional” doctors in an issue of Aventura, a local “lifestyle” magazine:
What is different about holistic medicine from traditional medicine?Holistic medicine requires the assessment of the whole person, body, mind and spirit, in the quest for optimal health and wellness. While traditional allopathic medicine often relies on looking at individual symptoms and covering up those symptoms with prescription drugs, a holistic approach looks for functional imbalances and seeks to treat the underlying causes of illness.
As Harriet Hall, MD, said, “this stupid CAM mantra is a vile, false accusation,” and it is a dangerous one too. Dr. Woliner’s smug attitude about “conventional” medicine led him in both this case and his previous run-in with the Board of Medicine to reject the superior education and training of specialists in two complex fields, oncology and endocrinology, in favor of his own supposed expertise as an “integrative” physician. He even used the “if the only tool you have is a hammer” analogy with Sofronsky’s mom when describing oncologists. Yet, he was so blinded by that pet all-purpose bugaboo of integrative medicine – allergies – that he kept insisting that her obvious symptoms of spreading cancer were caused by them.
Not a different standard – a lower standard
Integrative medicine gives a physician permission to lower the standard for evidence of safety and effectiveness. After all, alternative medicine that’s been proven to work is just medicine. But, it is not only in their employment of quackery that integrative physicians are a menace to patients, it is this disdain for conventional medicine too. That disdain came through loud and clear in Dr. Woliner’s testimony, where he defined “mainstream medicine” as “patentable drugs and surgery.”
In one final, sad irony, here’s what Dr. Woliner says on his website about “the ideal candidate for holistic medicine”
Anyone who is interested in actually fixing the cause of their medical problems, rather than merely attempting to cover up symptoms, is the ideal candidate for holistic medicine.
Chemotherapy had a great chance of “fixing” Sofronsky’s “medical problems” but that chance was squandered on “holistic medicine.” I hope the Board of Medicine accepts the ALJ’s recommended penalty and revokes Kenneth Woliner’s medical license. He shouldn’t get a third chance to choose arrogance over “conventional” medical treatment for his patients.

Medical debt vs. universal health insurance: The interface between SBM and policy
This blog has long argued that the best medicine is science-based medicine (SBM). The problem is that in the US SBM is often not accessible, except at ruinous cost, which is why I argue that we have to broaden our definition of SBM to include the systems that deliver it and pay for it.
David Gorski on June 20, 2022
Link

The name of this blog is Science-Based Medicine, because we seek to champion medicine that is based on rigorous science as the safest and most effective medicine. Before the pandemic, much of what we used to write about was the infiltration of pseudoscientific medicine and medicine based far more on prescientific or religious ideas than science, although common threads even since the pandemic remain. These include, but are not limited to, the antivaccine movement, COVID-19 minimization/denial (much like germ theory denial that undergirds a lot of alternative medicine and antivaccine beliefs), resistance to public health measures, and, of course, the promotion of quackery, in the case of the pandemic (among many other things) the promotion of drugs that were unproven but are now disproven as effective treatments for COVID-19; i.e., ivermectin, hydroxychloroquine, and others.
However, there’s more to SBM than rigorous basic and clinical science, a Bayesian approach to evaluating evidence that considers prior plausibility based on basic science, randomized clinical trials, and epidemiology. The most effective science-based treatments will do no good if they are not available to patients who need them, for whatever reason, and this is where, unavoidably, social sciences and politics come in. I’ve long said that we at SBM are not apolitical, although we do strive to be as nonpartisan as individuals can be given their biases. After all, opposing the licensing of quacks, the continued sale of homeopathic products without the requirement by the FDA that they demonstrate safety and efficacy, and agreeing that physicians who spread medical misinformation should face sanctions from state licensing boards (for example) are far from apolitical. In some cases they aren’t even nonpartisan, given how it was prominent Democrats who championed the National Center for Complementary and Integrative Health (NCCIH) that we have long advocated dismantling, and these days the Republican Party that is promoting resistance to public health measures designed to mitigate the impact of the pandemic. That being said, SBM will never be as effective in ameliorating human suffering if public policy considerations are not taken into account and also based as much as possible in science. What that means is that SBM cannot—and I now argue, should not—avoid social science and politics. Of course, as difficult as it is to deconstruct antivaccine misinformation, various alternative medicine pseudoscience, and false claims about COVID-19, I am well aware that looking at SBM at a more macro level in which it interacts with society at large and its political and economic systems adds even more complexity to the mix, but we do need to consider these problems—and consider them more.
What got me thinking about these issues, which I had been meaning to bring up, were two news reports about studies. I listened to one of these on NPR on the way to work on Thursday morning, a story about how 100 million people in the US live with medical debt (based on the KFF Health Care Debt Survey) that also featured brief stories about individuals who make up that figure. The second was a series of stories about a study that concluded that single payer universal health insurance (which we in the US still do not have, “Obamacare” notwithstanding) could potentially have saved hundreds of thousands of lives during the pandemic. Obviously, the two stories are related, because the cause of so much medical debt in the US is clearly the lack of universal health insurance. Many families who are uninsured or underinsured face financial catastrophe.
Medical debt: Deferring or foregoing SBM due to financial constraints
While on my way to work last Thursday, I was flipping radio stations in my car and landed on NPR, only to hear:
Elizabeth Woodruff drained her retirement account and took on three jobs after she and her husband were sued for nearly $10,000 by the New York hospital where his infected leg was amputated.
Ariane Buck, a young father in Arizona who sells health insurance, couldn’t make an appointment with his doctor for a dangerous intestinal infection because the office said he had outstanding bills.
Allyson Ward and her husband loaded up credit cards, borrowed from relatives, and delayed repaying student loans after the premature birth of their twins left them with $80,000 in debt. Ward, a nurse practitioner, took on extra nursing shifts, working days and nights.
“I wanted to be a mom,” she said. “But we had to have the money.”
The three are among more than 100 million people in America ― including 41% of adults ― beset by a health care system that is systematically pushing patients into debt on a mass scale, an investigation by KHN and NPR shows.
The investigation reveals a problem that, despite new attention from the White House and Congress, is far more pervasive than previously reported. That is because much of the debt that patients accrue is hidden as credit card balances, loans from family, or payment plans to hospitals and other medical providers.
Again, SBM can do some truly amazing things and save lives that would have been lost even a couple of decades ago. However, it can’t help if people can’t afford to access it, and it will be much less effective if people suffer such major financial consequences for having accessed it.
The number is truly staggering, given that the poll found that in the past five years, more than half of US adults report they’ve gone into debt because of medical or dental bills, with a quarter of people with health care debt owing more than $5,000 and about one in five with any amount of debt said they don’t expect ever to be able to pay it off. I’m sure that our European and Australian readers will facepalm at these findings, but they track. As the poll and news story noted, even though the Affordable Care Act (ACA) did dramatically reduce the percentage of Americans who are uninsured, an unfortunate problem with it is that a lot of the health insurance policies sold in the ACA marketplaces have high deductibles, making it very possible for less affluent people to go deeply into debt even though they ostensibly have health insurance. It’s the deductibles that get them.
Worse:
Perhaps most perversely, medical debt is blocking patients from care.
About 1 in 7 people with debt said they’ve been denied access to a hospital, doctor, or other provider because of unpaid bills, according to the poll. An even greater share ― about two-thirds ― have put off care they or a family member need because of cost.
“It’s barbaric,” said Dr. Miriam Atkins, a Georgia oncologist who, like many physicians, said she’s had patients give up treatment for fear of debt.
This last example strikes close to home, given my surgical specialty. I will admit that it’s been rare in my practice for a patient to be reluctant to undergo surgery for breast cancer. However, what is often not appreciated is that surgery is actually likely the least expensive part of the multidisciplinary care of this disease. Totalled up, the chemotherapy tends to cost a lot more, particularly when newer drugs are used, such as immune checkpoint inhibitors or the newer HER2-blocking drugs.
Indeed, the story includes the example of Cheyenne Dantona, who is now 31 but was diagnosed with a blood cancer while in college:
The cancer went into remission, but when Dantona changed health plans, she was hit with thousands of dollars of medical bills because one of her primary providers was out of network.
She enrolled in a medical credit card, only to get stuck paying even more in interest. Other bills went to collections, dragging down her credit score. Dantona still dreams of working with injured and orphaned wild animals, but she’s been forced to move back in with her mother outside Minneapolis.
“She’s been trapped,” said Dantona’s sister, Desiree. “Her life is on pause.”
Desiree Dantona said the debt has also made her sister hesitant to seek care to ensure her cancer remains in remission.
Another example:
Sherrie Foy, 63, and her husband, Michael, saw their carefully planned retirement upended when Foy’s colon had to be removed.
After Michael retired from Consolidated Edison in New York, the couple moved to rural southwestern Virginia. Sherrie had the space to care for rescued horses.
The couple had diligently saved. And they had retiree health insurance through Con Edison. But Sherrie’s surgery led to numerous complications, months in the hospital, and medical bills that passed the $1 million cap on the couple’s health plan.
When Foy couldn’t pay more than $775,000 she owed the University of Virginia Health System, the medical center sued, a once common practice that the university said it has reined in. The couple declared bankruptcy.
The Foys cashed in a life insurance policy to pay a bankruptcy lawyer and liquidated savings accounts the couple had set up for their grandchildren.
Most oncologists who practice in areas like Detroit (where I practice) have observed this phenomenon firsthand. I daresay that even oncologists who practice in more affluent areas have also seen it.
One aspect of this problem not included in the story because it is not about patients’ debt is the massive infrastructure devoted by insurance companies to prior authorizations. Again, prior authorization is a concept foreign to many other nations and refers to the requirement by an insurance company that it authorize a proposed treatment before that treatment can be undertaken and reimbursed. Failure to get prior authorization will usually mean that the insurance company won’t pay for it; so providers’ offices and hospitals are very careful to obtain prior authorization to begin treatment. Unfortunately, as known by any physician, NP, or nurse who has to deal with insurance companies’ prior authorization departments, obtaining prior authorizations can quickly descend into truly Orwellian depths of language denying them. The process is so bad that it’s often lampooned in cartoons and videos, for example, the ever-amusing Dr. Glaucomflecken.
Lest you think that the good doctor is exaggerating, I included a response with a video of an actual prior authorization call:
real life https://t.co/lOjmW6c0IN
— Amy Walsh, 〽️D (@doctordirectmd) June 16, 2022
Given how difficult and bureaucratic the entire approach to prior authorizations has become, hospitals now have significant infrastructure devoted just to prior authorizations, and small, private practice offices end up devoting ridiculous amounts of time that could be devoted to patient care just trying to make sure they can be paid for their services. I won’t dwell on this any more—nor will I even mention it again in this post—because our inconvenience as physicians dealing with insurance company bureaucracy pales in contrast to the suffering of patients who have difficulty accessing care or face the specter of going into major debt if they become ill. I merely mention it briefly to bolster the point that the current health insurance system in the US is designed not to facilitate SBM care, but to profit, and one way to profit is to deny more expensive care whenever possible. (Thus endeth the whining about this.)
To get an idea of what people give up because of medical debt, here’s a graph included with the story:

In addition:
But the medical debt on credit reports represents only a fraction of the money that Americans owe for health care, the KHN-NPR investigation shows.
    • About 50 million adults ― roughly 1 in 5 ― are paying off bills for their own care or a family member’s through an installment plan with a hospital or other provider, the KFF poll found. Such debt arrangements don’t appear on credit reports unless a patient stops paying.
    • One in 10 owe money to a friend or family member who covered their medical or dental bills, another form of borrowing not customarily measured.
    • Still more debt ends up on credit cards, as patients charge their bills and run up balances, piling high interest rates on top of what they owe for care. About 1 in 6 adults are paying off a medical or dental bill they put on a card.
Not only is the current system apparently designed to slow or deny SBM care, it is also a medical debt machine. In fact, one thing that I hadn’t appreciated that was reported in this story is how medical debt has become big business in the US. The story first notes that in the past, medical debt on this scale was unheard of because of two reasons. First, in the past doctors and hospitals often made informal arrangements for patients to pay off medical debts; for example in the 19th century male patients at New York’s Bellevue Hospital had to ferry passengers on the East River and new mothers had to scrub floors to pay their debts. Second, and more importantly, physicians often wrote off debts that patients couldn’t afford to pay, as historian Jonathan Engel was quoted saying, “There was no notion of being in medical arrears.”
Now, efforts to collect often have horrific effects:
Edy Adams, a 31-year-old medical student in Texas, was pursued by debt collectors for years for a medical exam she received after she was sexually assaulted.
Adams had recently graduated from college and was living in Chicago.
Police never found the perpetrator. But two years after the attack, Adams started getting calls from collectors saying she owed $130.58.
Illinois law prohibits billing victims for such tests. But no matter how many times Adams explained the error, the calls kept coming, each forcing her, she said, to relive the worst day of her life.
This sort of horror is the result of a system that has sprung up that makes medical debt—and collection of that debt—big business. It’s a business that hospitals, including university hospitals and nonprofits, now partake of:
Now, a highly lucrative industry is capitalizing on patients’ inability to pay. Hospitals and other medical providers are pushing millions into credit cards and other loans. These stick patients with high interest rates while generating profits for the lenders that top 29%, according to research firm IBISWorld.
Patient debt is also sustaining a shadowy collections business fed by hospitals ― including public university systems and nonprofits granted tax breaks to serve their communities ― that sell debt in private deals to collections companies that, in turn, pursue patients.
“People are getting harassed at all hours of the day. Many come to us with no idea where the debt came from,” said Eric Zell, a supervising attorney at the Legal Aid Society of Cleveland. “It seems to be an epidemic.”
I realize that some of our readers might be unhappy that I ventured into this territory or maybe think that it is an inappropriate subject for SBM. I’m also sure that someone will be unhappy that I didn’t include their favorite issue with our healthcare system as currently constituted (e.g, for-profit big pharma companies distorting clinical trial results and driving up costs). Fair enough, but that is not the topic for today. Maybe in the future.
In the meantime, I understand, but now disagree that considering the more “meta” issues of how a political system regulates and provides SBM to its citizens is any less of a topic for this blog than discussing why the latest trial for homeopathy is bogus. Over the last few years I’ve increasingly realized that, as fantastic as SBM is at alleviating suffering, saving lives, and restoring health, it’s no good if people can’t access it without worrying about being bankrupted or incurring debts that that take years to pay off. Moreover, guess who is most affected by medical debt? While the story does note that nearly half of households making $90,000 or more a year have incurred medical debt in the last five years, it also notes that it is the poor and disadvantaged who most fall prey to this system and suffer the most under it. Quite simply, the strongest predictor of medical debt is the prevalence of illness. Indeed, US counties with the highest share of residents with multiple chronic conditions, such as diabetes and heart disease, tend to have accumulated the most medical debt. That makes illness a stronger predictor of medical debt than either poverty or insurance. This system also exacerbates racial disparities in health and medical care as well, with Blacks 50% more likely and Hispanics 35% more likely than whites to owe money for care. My cancer center is home to an excellent Population Studies and Disparities Program; so I have been aware of racial and socioeconomic disparities in cancer outcomes and burden for quite some time, having increasingly appreciated the issue over the 14 years since I accepted my current employment. I now therefore argue that understanding disparities in SBM care and how to eliminate them is part of SBM.
This brings me to one area for change and improvement. Certainly, there are other needed changes to make SBM more available to all, but I’m going to start with this one.
Health insurance and the pandemic
The story that I just discussed includes this quote:
“The No. 1 reason, and the No. 2, 3, and 4 reasons, that people go into medical debt is they don’t have the money,” said Alan Cohen, a co-founder of insurer Centivo who has worked in health benefits for more than 30 years. “It’s not complicated.”
Put this way, the reason for the problem might not be complicated, but the solution is. Again, this is where the interface between SBM and society gets messy. Still, let’s look to a PNAS study published a week ago by a group led by the Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, and including investigators from the University of Florida, University of Massachusetts, Amherst, and Syracuse University. The study asked the question: What would the effect of universal health insurance have been on mortality in the US from the pandemic? Its conclusion is that universal health insurance is pandemic preparedness, and it concludes that ~212K who died of COVID-19 could have been saved in 2020 alone and that, overall, from the pandemic’s beginning until mid-March 2022, universal health care could have saved more than 338K lives from COVID-19 alone. In addition, the study estimates that single payer universal health care would also have saved the US government roughly $106 billion in health care costs associated with hospitalizations from COVID-19—plus an estimated $438 billion that could be saved in a nonpandemic year.
The methodology of the study was as follows. The authors calculated elevated mortality attributable to loss of employer-sponsored insurance and to background rates of being uninsured, summing with increased COVID-19 mortality attributable to low insurance coverage. Demographics and age-specific mortality rates due to COVID-19 were estimated, as well as prepandemic mortality, leading the authors to estimate that 338K deaths from COVID-19 alone could have been prevented over the two year period from March 2020 to March 2022. They then argue that Medicare-For-All could have saved these lives through a combination of:
    • Improved access to primary care and reduction in comorbidities.
    • Early diagnosis and access to life-saving medical care.
    • Facilitation of COVID-19 preventative measures (e.g., vaccination).
    • Alleviating pressure on hospitals during a pandemic.
There’s a large evidence base supporting the conclusion that health outcomes tend to be better with universal health care. However, I tend to agree with this analysis by Dylan Scott that points out a number of issues with the study above, not the least of which is its assumption that a single-payer universal health care system is the be-all and end-all of systemic solutions for improving health outcomes, decreasing disparities, and eliminating medical debt. For instance, it is very much true that COVID-19-associated mortality was very high in the US. We have 4% of the world’s population, but suffered 16% of the mortality burden due to COVID-19. It is also true that COVID-19 mortality was lower in countries with universal health insurance, in some cases a lot lower. However, there is the outlier of the UK, which, despite having single-payer universal health care (in the form of the National Health Service, or NHS), had a COVID-19 mortality rate almost as bad as the US.
Also:
All of these countries do have universal health care, but they do not all have a single-payer system in the vein of Sanders’s Medicare-for-all proposal. Taiwan does. But Australia utilizes a hybrid program where some people depend on public health insurance and other people use private plans. The Netherlands and Germany rely on private health insurance, heavily regulated and subsidized by the government. The UK’s National Health Service goes beyond single-payer and is fully socialized: The government not only pays for care for everyone but also runs hospitals and employs doctors directly.
I’ve often said elsewhere that universal health insurance does not have to be single-payer to be effective, and that was the main thing that irritated me about this Yale study; it assumed that only Medicare-For-All would be the answer to save all these lives from COVID-19, an assertion that it did not back up with evidence, mainly because it didn’t really seriously consider or compare other universal health insurance systems. (Also, one notes that even Medicare, which was examined in this study, only covers 80% of costs—after the deductible is met—unless one gets a Medigap policy or signs up for a Medicare Advantage plan.) Germany, for instance, has one of the oldest universal health insurance systems that dates back to the 1880s and survived the Nazi regime. It is what’s called a universal multi-payer health care system and encompasses both statutory health insurance for people who earn less than a certain salary, as well as private health insurance for those who earn more and choose to purchase their own. Moreover, clearly there have been other factors besides just universal health insurance.
As Scott notes:
Other factors might be in play beyond the specific type of health care system. As Damien Cave wrote for the New York Times in Australia, social trust seems to have been a decisive difference between the American and Australian experiences during the pandemic. The two nations share a lot of sociocultural DNA, but Aussies have much deeper trust in people in general, and their health care system specifically, than Americans do, Cave wrote. When I was reporting on South Korea’s successful Covid-19 response, Korean sources pointed in part to people there having a generally high level of trust in the government.
This also makes some intuitive sense. It follows that people in societies with more trust would be more likely to wear masks or stay home or get vaccinated not only for their own benefit but for the health of the people around them and society at large.
This brings us to the final point. SBM alone is not enough.
SBM versus values and politics
I’ve lost track of how many times when, as I discussed potential randomized controlled clinical trials (RCTs), I pointed out that sometimes the key value of SBM, namely doing best science possible to determine if a treatment works (a double-blind, placebo-controlled RCT) is not always possible because it conflicts with another value, specifically values of fairness and clinical equipoise as laid down by medical ethics. For example, I’ve long pointed out how doing a double-blind placebo-controlled RCT of the childhood vaccination schedule in the form of a “vaxxed/unvaxxed” study that some antivaxxers have periodically called for to “prove” that vaccines cause autism would be completely unethical because it would leave the control group unprotected against common childhood diseases. As a result, we have to rely on epidemiological studies to show that vaccines are not associated with autism.
The same principle operates on a much larger scale when it comes to a country’s willingness to institute public policies designed to bring SBM to as many people as possible, as Scott points out quite well:
Universal health care is a choice, a reflection of a country’s values. When reporting the Everybody Covered series, I found this quote from Princeton health care economist Uwe Reinhardt. It was in his most recent book Priced Out, which was published after he died in 2017:
Canada and virtually all European and Asian developed nations have reached, decades ago, a political consensus to treat health care as a social good.
By contrast, we in the United States have never reached a politically dominant consensus on the issue.
While traveling in Taiwan or the Netherlands, people would ask me about US health care and I would have to tell them that millions of Americans were uninsured and that people could be charged thousands of dollars for medical care. That was unfathomable to the people I met. They lived in a country where people agreed such things should never be allowed to happen.
America has never made that collective commitment to providing everyone with health care. The country paid the price for that shortsightedness during the pandemic, as this new study helps demonstrate. Whatever form it took, a universal health system would have likely prevented tens of thousands of deaths from the novel coronavirus.
As important as demonstrating how harmful medicine based on bad science and pseudoscience has been to patients and to the healthcare system in general, as well as how it has degraded standards of evidence in a manner that (I argued) facilitated the promotion of, for example, ivermectin as a miracle treatment for COVID-19, SBM in isolation is not enough. The system in which SBM is utilized is part of SBM, for better or worse. It can’t be repeated enough that SBM is much less useful if people can’t access it or the cost of accessing it is prohibitive. I’m therefore coming to the conclusion that not only is SBM necessarily political, it must be political, in order to find ways to change the dominant values in our political system in order to spark change that allows SBM to be accessible to all without ruinous cost. Unfortunately, these days we seem to be going in the wrong direction.

Legislative alchemy and abortion: How the fall of Roe v. Wade will degrade science-based medicine
The U.S. Supreme Court overturned Roe v. Wade on Friday, eliminating the federal right to an abortion. What does that mean for science-based reproductive health and science-based medicine in general? Hint: It’s not good, even for areas of medicine outside of reproductive health.
David Gorski on June 27, 2022
Link

I had another topic all teed up for today. It was yet another dubious study of COVID-19 mRNA vaccines that’s been going round the antivaccine misinformationsphere, notable not so much for anything other than that a rather famous and well-respected statistician (one whom I have personally cited before) signed on. If it continues to gain traction, there is time to come back to that study, either here or at my not-so-super-secret other blog. Unfortunately, something more urgent arose. On Friday, the US Supreme Court released its decision on Dobbs v. Jackson Women’s Health Organization, not only upholding Mississippi’s 15-week abortion ban but also ruling that there is no Constitutional right to an abortion, basically striking down the 49 year old decision that had ruled that there was such a right. While much ink, both print and digital, has been expended already on this monumental shift in US law and women’s rights, I’m going to look at it from the perspective of a longstanding topic on this blog: Law vs. science-based medicine, a topic that our recently retired contributor and legal expert Jann Bellamy used to refer to as “legislative alchemy“. In her honor, I was tempted to refer to this decision as “judicial alchemy”, but in reality what this decision unleashed even before it was announced was legislative alchemy in a huge number of states.
It’s no secret that I was raised Catholic and as a result was taught throughout my grade school and high school education (eight and a half out of thirteen years of which, counting kindergarten, were in Catholic schools, including an all-boys Catholic high school) that abortion is an absolute evil. I even believed it until well into my early adulthood. Medical school, however, coupled with my gradual drift away from religion, led me to appreciate that abortion is a necessary and integral part of reproductive health care. Although this post is a typical length for me, it’s far from an exhaustive discussion. In the spirit of full disclosure and so that no one tries to accuse me of hiding an agenda (although I’m sure someone will anyway), I will state my bias from the beginning, even though this post will not be primarily invoking arguments based on rights and I will try to stick mostly to SBM. Consistent with Roe v. Wade, women should—but no longer do—have the right to control their bodies. Leaving aside arguments of rights and when a fetus should be considered a “person”, however, I am struck by just how much the arguments of the anti-Roe forces resemble those that we at SBM have been deconstructing for nearly 15 years in their appeals to bad science and pseudoscience.
The current frenzy of abortion bans—and, make no mistake, it is a frenzy—being considered in various states represent an assault on science-based medicine every bit as non-evidence-based as bills to license naturopaths. In the very best case, these laws will make practicing science-based medicine much more difficult (and not just in reproductive health care) but in some cases impossible, forcing doctors and their patients into choices that they should never be forced to make. Many of these new laws are based on the idea that human life begins at conception, which means that embryos are human lives and that fetuses are legal persons, with all the rights of persons under the law, to the great detriment of the pregnant. (Indeed, if it becomes law that embryos have legal personhood, one can only imagine the effect that it will have on in vitro fertilization, which often involves the generation of multiple embryos, some of which end up being discarded. What will become of the millions of unused embryos sitting in liquid nitrogen tanks in fertility clinics across the US?)
In this post, I will attempt to discuss some of the outcomes that we are likely to see and that OB/GYNs are dreading. Make no mistake either, the effects are likely to go beyond the realm of reproductive health, as I will also discuss.
Think about it this way. Ideologues have long pressured legislatures to foist on doctors types of care that are not based in science, to legalize outright quackery, to require insurance companies and government payors to cover quackery, or to outlaw science-based standards of care based on their ideology. More recently, laws have been passed to make it easier for quacks to prescribe ineffective treatments for COVID-19 like ivermectin and to ban public health interventions against the disease. Abortion bans as draconian as the ones spreading throughout the country as a result of the fall of Roe v. Wade are no different in terms of ideology trumping science and evidence. As I contemplated what to write (or even whether to write) about the fall of Roe v. Wade and what it means for SBM, I came to the conclusion that it is useful to look at this decision and the laws that will flow from it through the lens of ideologues and believers overruling SBM based on their beliefs.
Let’s look at some not-so-potential consequences. We don’t have to speculate what the consequences of these laws will be for SBM. We know from history and other countries.
“The life of the mother”
Proponents of abortion bans always point to exceptions for “the life of the mother” included in every abortion ban in order to claim that such bans are not contrary to science- and evidence-based medicine and won’t harm the pregnant. But what does “the life of the mother” actually mean in practice? To the lay person, it might seem very clear: If continuing the pregnancy endangers the life of the mother, then termination is allowable even under these bans. It turns out that there are many cases where it is not that clear, and that, even in cases where it is very, very clear indeed, such bans tend to lead to situations in which optimal science-based treatment is impossible.
In fact, we don’t even have to speculate what is likely to happen. We already know, as a story published in The New Yorker over a month ago by Jessica Winter describes. It begins with a horrific anecdote from Ireland:
Savita Halappanavar’s water broke just after midnight on October 22, 2012, in a hospital in Galway, Ireland, in her seventeenth week of pregnancy. This meant two things: the fetus could not possibly survive, and Halappanavar was at risk of infection if the fetus was not immediately expelled or removed. She begged doctors to terminate her pregnancy—or, put another way, to treat her miscarriage—but they refused. A fetal heartbeat could still be detected, and the Eighth Amendment to Ireland’s constitution effectively banned abortion. After two days, Halappanavar developed sepsis; on October 28th, she went into cardiac arrest and died, at the age of thirty-one. An inquest into Halappanavar’s death found that even as her temperature and heart rate soared, even as she was entering septic shock, doctors continued to monitor the fetal heartbeat. “They were worried that, if they did a termination, they might be accused of performing an illegal act by not complying with the Eighth Amendment,” the doctor who led the inquest later said. A national outcry over Halappanavar’s death catalyzed a movement to repeal the amendment, which Ireland’s voters accomplished by referendum in 2018, with a two-thirds majority.
The science-based standard of care in such a case is, sadly, quite clear. Terminate the pregnancy before sepsis can set in. At the very least, such a ban on abortions will lead to fear and second-guessing by doctors faced with situations in which termination would be the standard-of-care to treat a given health condition in the pregnant. At the very worst, we will have cases like that of Savita Halappanavar. Clearly, hers was a dramatic case, but I included it to make a point. Exceptions to abortion bans to treat medical emergencies in order to “save the life of the mother” do not in practice protect the pregnant nearly as much as those citing them claim that they do.
The New Yorker article nicely summarizes the medical issues involved with exceptions for “the life of the mother”:
If, as expected, the Supreme Court abolishes the constitutional right to abortion in its forthcoming decision in Dobbs v. Jackson Women’s Health Organization, scenarios such as the one that killed Savita Halappanavar will become more likely to occur in the United States. Twenty-six states are likely to ban or criminalize abortion if Roe is overturned, including thirteen with “trigger bans.” These typically include a “life of the mother” exception, but the language of these exceptions varies in its scope and specifics state to state. Texas’s current six-week ban—its proponents call it the “heartbeat bill”—allows exceptions for “a medical emergency.” North Dakota would permit abortion “to prevent the pregnant female’s death.” Louisiana invokes “death or substantial risk of death,” or “permanent impairment of a life-sustaining organ,” but also requires “reasonable medical efforts under the circumstances to preserve both the life of the mother and the life of her unborn child.”
The questions implicit in these phrases—What constitutes an “emergency”? How does one define “substantial” or “reasonable”?—are left unanswered. “These laws presume a certainty that doesn’t exist in medicine,” Cara Heuser, a maternal-fetal-medicine physician in Salt Lake City, said. “How ‘life-threatening’ the situation has to be—I don’t know what that means.”
“In states where abortion becomes illegal, and particularly in states where there are criminal penalties for doctors or anyone who assists in an abortion, I fear that it will send a chill through the entire medical community,” Audrey Lance, an ob-gyn in Michigan, said. “People are going to be scared to intervene until the last minute or perhaps until it’s too late.”
Where does this fear among doctors come from? It comes from the criminalization of health care and a therapeutic operative procedure.
D&C vs. D&E for miscarriages
In addition to the very difficult medical and ethical issues that naturally come with reproductive health care doctors will now be forced to weigh, in any case in which termination of a pregnancy is the science-based standard-of-care treatment for a life-threatening condition during pregnancy, the good of the patient versus some very serious potential consequences to themselves. Why? As The New Yorker article points out, as many as 22 states are “likely or certain” to make abortion a felony, with potential penalties including jail time and fines to doctors who do the procedure. The result will be this:
A doctor who is inclined to provide an emergency termination would have to weigh her medical judgment against the possibility of criminal charges, losing her license, and never being able to practice medicine again. “There’s a very real fear: Will they force people to prove that they really had a miscarriage?” Heuser said.
We already know the answer to that question, I fear. In fact, we’ve long had examples even during the 49 years of Roe v. Wade, because Catholic hospitals have shown us, one in my very own state. This is not for someone seeking to terminate the pregnancy, but, as a Dallas OB/GYN is quoted in the article said, “This is not a person who comes to you and says, ‘I want to end this pregnancy.’ This is a person who is saying, ‘I am having a pregnancy complication, and I need you to help me.'”
Unfortunately, in the presence of punitive abortion bans:
That cry for help often goes unheeded in the presence of a fetal heartbeat, even if the demise of the pregnancy is inevitable. In 2015, the A.C.L.U. filed suit on behalf of a Michigan woman, Tamesha Means, against the United States Conference of Catholic Bishops, the body that writes the religious and ethical directives that must be followed by Catholic hospitals, which, as of 2016, accounted for about fifteen per cent of acute-care hospitals nationwide. The directives state that abortion is “never permitted,” barring “a proportionately serious pathological condition of a pregnant woman.” Means’s water broke at eighteen weeks, but she was sent home from a Catholic hospital, Mercy Health Partners, mid-miscarriage—twice—despite excruciating pain and possible infection.
At 18 weeks, the fetus is not viable outside of the uterus, and the risk of infection of the sort that killed Savita Halappanavar in Ireland after a premature rupture of membranes is very high. The science-based standard of care in nearly all such cases is to terminate the pregnancy, as described by an OB/GYN:
“Yes, there are absolutely certain medical conditions that warrant us to very urgently encourage a woman to have an abortion,” said Stacey Beck, MD and Assistant Professor at the Department of Obstetrics, Gynecology, and Reproductive Sciences, Maternal Fetal Medicine at the University of Pittsburgh Physicians
“One of the most common reasons I help women to terminate their pregnancy is because their water broke [early in pregnancy] and they have an infection,” Beck said.
If there’s a clear sign of infection, the condition can be life threatening, “because there is an extremely high risk that the infection inside of the uterus spreads very quickly into her bloodstream and she becomes septic. If she continues the pregnancy it comes at a very high risk of death.”
“Typically, if a woman breaks her water before 20 weeks into her pregnancy, it is usually strongly recommended by medical professionals that she considers an abortion,” Beck said.
It’s not just Catholic hospitals, either. Before the fall of Roe v. Wade, a number of nonreligious hospital systems would not permit their doctors to perform “abortions” as long as the fetus still had a detectable heartbeat, with predictable results:
Several physicians told me that hesitation to provide emergency-miscarriage care is not peculiar to Catholic or other religious institutions. Even in states where abortion rights are broadly intact, many hospital systems do not permit terminations for any reason; patients in need must be transferred elsewhere. Heuser, who serves as a consultant for general ob-gyns across her hospital system in Salt Lake City, told me, “I have got calls from the E.R., saying, ‘This patient is bleeding, but there’s still a heartbeat—I don’t know what to do.’ And I have had to say, ‘You are allowed to treat the patient. You need to save the patient. This is a medical emergency.’ If you hem and haw because you aren’t sure about the law or the rules—that’s dangerous for patients.”
Leilah Zahedi, a maternal-fetal-medicine physician in Tennessee, told me about a recent referral. “The patient was eighteen or nineteen weeks pregnant. She came in almost fully dilated and bleeding heavily, but the fetus still had a heart rate. The provider who transferred her was prohibited from giving her care, per the statutes of the hospital—it would have been considered an abortion. She transferred her to us because I am the only provider who is trained to do D. & E.s” in the area, Zahedi said. “When the patient reached us, within two minutes she lost 500 cc.s of blood. I said, ‘We’re done.’ I took her to the O.R. Her case was done in five minutes. She ultimately lost 2,500 cc.s of blood and needed a blood transfusion.”
That last case was what we in the biz call a near-miss. The patient could well have died and was certainly not served by all the delays due to the uncertainty at the referring hospital and then all the mechanics of being transferred to a hospital that was allowed to actually deal with the medical emergency. I would also argue that the uncertainty and fear that leads to doctors hesitating to take care of their patients according to science-based standards-of-care in these situations are a feature, not a bug, of many of these abortion bans.
Supporters of abortion bans will claim that there is a difference between an elective abortion and a therapeutic abortion (e.g., to treat a miscarriage or uterine infection after premature rupture of membranes). Here’s the problem. Both employ the same surgical procedure, and state bans in general do not distinguish between the two. To cite The New Yorker article again:
The two procedures also employ the same tools and techniques, depending on the stage of the pregnancy and the health of the pregnant person: medication or dilation and curettage (D. & C.) for early abortions; and dilation and evacuation (D. & E.) or induced labor for later abortions. (In his draft opinion reversing Roe, Justice Samuel Alito refers to D. & E. as “a barbaric practice.”)
Is a D&E still a “barbaric practice,” though, when it is used to save the life of someone who is dying from bleeding or about to go into septic shock? It’s a science-based life-saving surgical procedure. Proponents of banning abortion bans will swear up and down that it is not their intention to prevent life-saving medical and surgical care of life-threatening conditions like this in the pregnant, but it is irrefutable that abortion bans do just that. Under the best of circumstances, they insert more uncertainty, doubt, and second-guessing into the process; at worst, they force doctors to abandon SBM out of fear of prison and wait to intervene until much later in the life-threatening process, when the success rate of interventions are lower and, even when successful, come at a higher cost of complications.
What about other life-threatening conditions?
I know what some of you out there are saying now: “But, but, but those are extreme examples!” And so they are. I chose to lead with extreme examples because they illustrate most clearly the consequences of abortion bans with criminal penalties. Again, the cases described above are not even close calls from an SBM standpoint, nor were they meant to be. These patients were clearly going to die—and soon!—without surgical intervention in the form of a pregnancy termination. Even so, I’m brought back to the quote from Dr. Heuser about how these laws “presume a certainty that doesn’t exist in medicine” and her question: How life-threatening does the situation have to be to trigger an exception to the ban “for the life of the mother”?
One such condition is preeclampsia early in the pregnancy (less than 24 weeks). Preeclampsia is a disorder of pregnancy that usually develops later (after 20 weeks) and includes hypertension, severe headaches, kidney dysfunction (usually evidenced by protein in the urine), among other health issues. Major risk factors include diabetes, hypertension, kidney disease before pregnancy, autoimmune conditions (e.g., lupus or antiphospholipid syndrome), or having had high blood pressure or pre-eclampsia in a previous pregnancy. Other risk factors include a family history, age over 40, more than 10 years since a previous pregnancy, non-singleton pregnancy (twins and above), or a body mass index (BMI) of 35 or higher. Most of the time, pre-eclampsia is treatable through a combination of close monitoring and medications, although it is not “cured” until the fetus is delivered, usually at 37-38 weeks, sometimes by caesarean section.
Early severe preeclampsia, however, is more of a problem, because, again, the only treatment for preeclampsia is delivery, and the consequences of prematurity versus the risks to the mother (and fetus) of continuing the pregnancy must be carefully weighed, and sometimes when the preeclampsia is severe enough and happens long enough before fetal viability, pregnancy termination is the safest way to treat it and prevent complications such as stroke or kidney failure. Even later in pregnancy, it can sometimes be necessary:
But she says there also are cases after viability in which an abortion is safer than an induced childbirth or surgical delivery.
Cecily Kellogg, 44, a writer who lives near Philadelphia, says that was the situation she faced when she was nearly six months pregnant with twin boys in 2004 and developed severe preeclampsia. One fetus had already died and “my liver had shut down, my kidneys had shut down and they were expecting me to start seizing at any minute,” she says. The doctors said they had to quickly dilate her cervix and perform an abortion to save her. “I fought it,” she says. “But they told me I would die — that it was either me and my son or just my son.”
The bottom line is that there are well-described science-based indications for therapeutic abortions. By conflating elective abortion with these situations, abortion bans will result in deaths. Indeed, one recent study estimates that banning “all wanted induced abortions,” by increasing exposure to pregnancy-related mortality, could result in a 21% increase in pregnancy-associated deaths overall, with an even more whopping 33% increase among Blacks, which is unsurprising given that due to racial disparities in health care maternal mortality is already much higher among Black women in the US.
And don’t even get me started on legislators claiming that it is possible to “reimplant” ectopic pregnancies, for which the treatment is always surgical removal.
Before I move on to a broader discussion, I will mention one more horrific effect of these laws based on this Tweet:
Arkansas, your legislature says that it is the government’s job to legislate how mothers grieve the loss of their babies.
We are forcing women whose babies will *certainly* die to endure pregnancy and childbirth, and then to watch their babies die inevitable, painful deaths.
— Rep. Nicole Clowney (@NicoleClowneyAR) June 24, 2022
That’s right. Some of these laws do not have exceptions for cases of pregnancies in which it is discovered that the fetus has unsurvivable anomalies; the sole exception in Arkansas is now to save the life of the mother in a “medical emergency” (undefined). States with such laws would prevent the science-based standard of care, termination of pregnancies in which unsurvivable fetal anomalies are present, requiring such pregnancies to be carried to term, with all the attendant risks of complications and death. In Arkansas, apparently, pregnancies involving anencephalic fetuses (a fetal anomaly when the brain fails to develop) must be carried to term. Ditto fetuses with severe anomalies such as a lethal form of skeletal dysplasia.
Beyond reproductive healthcare
If you think that the fuzziness over what constitutes a true danger to the “life of the mother” just affects science-based healthcare decisions in reproductive health, think again.
Saturday on Twitter:
Same. (I am a breast cancer surgeon.) It doesn't happen that often, but I do take care of pregnant patients with cancer from time to time, probably more often than the average breast surgeon because I'm at an NCI-designated comprehensive cancer center.
— David Gorski, MD, PhD (@gorskon) June 25, 2022
It’s true, too. Cancer during pregnancy is an issue that comes up from time to time among breast cancer surgeons, medical oncologists, and radiation oncologists. What do we do when a breast cancer is diagnosed during pregnancy? For example, if a pregnant patient presents with a breast cancer that needs chemotherapy before surgery, it is possible to administer it relatively safely during the second and third trimesters (although long term data regarding outcomes in the children delivered after chemotherapy during pregnancy are still lacking). However, during the first trimester chemotherapy is most definitely not safe due to the teratogenic (mutation-causing) characteristics of the chemotherapy used, as this guidance from the American Cancer Society describes. It is often possible and reasonably safe to delay treatment until the pregnancy is into the second trimester—but far from always. There are cases that are sufficiently urgent that waiting to start chemotherapy will definitely result in a much higher risk of death from the cancer.
The American Cancer Society states:
Treatment choices can become complicated if there is a conflict between the best known treatment for the mother and the well-being of the baby. For example, if a woman is found to have breast cancer early in her pregnancy and needs chemotherapy right away, she may be advised to think about ending the pregnancy. A counselor or psychologist should also be part of your health care team to help give you the emotional support you may need.
Some older studies found that ending a pregnancy in order to have cancer treatment didn’t improve a woman’s prognosis (outlook). Even though there were flaws in these studies, ending the pregnancy is no longer routinely recommended when breast cancer is found. Still, this option may be discussed when looking at all the treatment choices available, especially for metastatic (stage IV) or aggressive cancers that may need treatment right away, such as inflammatory breast cancer.
It’s not just breast cancer, either, of course. These considerations are in play for any cancer diagnosed in during pregnancy that will require chemotherapy for definitive treatment. Although I’m not an oncologist, hematologic malignancies like leukemia come to mind right away. Moreover, as a physician on Twitter described the situation, there’s no bright line. The situation is complicated:
The idea of that we just automatically “know that someone will die” from something imminently is not realistic, and at that point may actually be too late.
Medicine, as with life, does not exist in black and white, but varying shades of gray.
— Taylor Nichols, MD (@tnicholsmd) June 26, 2022
Surgeons know this too, as to OB/GYNs. Dr. Nichols also correctly added that we shouldn’t “for a second think the same extremists who wanted to overturn Roe don’t also want to dramatically narrow the scope here as well.”
Again, abortion is part of healthcare, and, contrary to frequent claims from those seeking to criminalize it that it is “never necessary” to save the life of the mother, which brings us to my final section.
Is abortion ever “medically necessary”?
Some advocates of abortion bans go beyond banning it for anything other than “emergencies” in which death is imminent, an exception that, as narrow as those supporting abortion bans try to make it, is still an exception that they concede. Some refuse to admit to any exceptions and go on to deny that abortion is ever “medically necessary”. Some of these people are even doctors. For example, the American Life League circulated a statement that a disturbing number of physicians (although still under 500) signed:
I agree that there is never a situation in the law or in the ethical practice of medicine where a preborn child’s life need be intentionally destroyed by procured abortion for the purpose of saving the life of the mother. A physician must do everything possible to save the lives of both of his patients, mother and child. He must never intend the death of either.
There is never a reason in law or in practice to advocate a “life of the mother” exception for abortion. We base this statement on testimony of many pro-life physicians over the years, including John F. Hillabrand, M.D., Herbert Ratner, M.D., and Bernard N. Nathanson, M.D.
I would counter that any physician who signs such a statement have fallen prey to magical thinking that is as non-reality-based as that among antivaccine physicians, ivermectin pushers for COVID-19, and those who become naturopaths. There’s a reason (many reasons, actually) why the American College of Obstetrics and Gynecologists released this statement:
The science of medicine is not subjective, and a strongly held personal belief should never outweigh scientific evidence, override standards of medical care, or drive policy that puts a person’s health and life at risk.
Pregnancy imposes significant physiological changes on a person’s body. These changes can exacerbate underlying or preexisting conditions, like renal or cardiac disease, and can severely compromise health or even cause death. Determining the appropriate medical intervention depends on a patient’s specific condition. There are situations where pregnancy termination in the form of an abortion is the only medical intervention that can preserve a patient’s health or save their life.
As physicians, we are focused on protecting the health and lives of the patients for whom we provide care. Without question, abortion can be medically necessary.
I haven’t even discussed a large number of other medical situations in which abortion might be necessary to save the patient’s life, such as one that you might not even have considered, hyperemesis , the mental health effects of being forced to carry a nonviable pregnancy to term, which is associated with a high risk of suicide, or situations in which surgery for a life-threatening condition is unsafe during pregnancy. The list goes on and includes healthcare that you might not realize. For example, the “abortion pill” misoprostol has many other uses besides as an abortifacient; indeed, in a 2021 research paper on misoprostol use in Francophone Africa, medical sociologist Siri Suh described misoprostol as “widely recognized as an essential obstetric medication,” yet lamented that “the stigma of abortion stalls its integration into routine obstetric care and availability to the public.” In addition, the related drug mifepristone can be used in the management and treatment of fibroids and Cushing’s syndrome by blocking progesterone. Again, the list goes on. Nor have I touched much on the many other adverse effects that such restrictive abortion bans will have on health, and I would be remiss if I didn’t take an opportunity before the end of this post to emphasize how much carnage will likely result from unsafe “underground” abortions that those desperate to end their pregnancies will seek out.
Regardless of one’s position on the morality of abortion as a form of birth control (and, although I am no longer of a Catholic belief system regarding this, I can still to some extent understand), it should be clear that the strict bans that will soon be part of life in probably more than half the states are ideological, not scientific. The arguments being used to justify them are every bit as reality-challenged as those made in support of laws licensing chiropractors, acupuncturists and naturopaths, legislative efforts to protect doctors who practice quackery and those who promote the use of disproven drugs like ivermectin to treat COVID-19 from regulatory sanctions, and laws preventing public health departments from instituting measures to slow the spread of the pandemic.

New Florida law forces physicians to endorse pseudoscience
A new Florida law forces physicians to endorse chiropractic, acupuncture, and massage as non-opioid alternatives for pain, even if the physician disagrees with that advice.
Jann Bellamy on September 12, 2019
Link
Billed as an effort to combat the opioid crisis, a new Florida law requires physicians and other healthcare practitioners to endorse pseudoscience and give patients misleading information about non-opioid alternatives for the treatment of pain. It is yet another attempt at co-opting the opioid epidemic to boost so-called complementary/alternative/integrative medicine at the expense of science-based medicine.
The law imposes several requirements before a healthcare practitioner (except a pharmacist) can prescribe, order, dispense or administer a Schedule II opioid drug for pain treatment. Before we get to those requirements, it’s worth noting the first version the bill was entirely different. As originally introduced, House Bill 451 would have required the Department of Health to create a “non-opioid directive form” which patients could sign, indicating their desire not to be prescribed or administered an opioid. Any physician treating the patient could be disciplined for failing to comply with the directive. (According to one legislative analysis, similar laws have passed in several states.) The Florida Medical Association (FMA) objected and worked with the bill’s sponsor to completely revise the bill. While their concerns about disciplinary action are understandable, the version that passed is, in my view, a worse result for evidence-based medicine and good patient care.
This new law adds to the already substantial statutory and regulatory control of controlled substance prescribing in Florida. However, unlike the rest of Florida’s statute to which the new requirements were added [as Sec. 456.44(7)], it does not exempt cancer pain, terminal conditions, palliative care or certain traumatic injuries.
As of July 1, 2019, before prescribing, ordering, dispensing, or administering a Schedule II opioid drug for the treatment of pain, a physician or other healthcare provider must (except in the provision of emergency care):
     1.  Inform the patient of non-opioid alternatives for pain treatment, which may include, non-opioid drugs, interventional procedures, acupuncture, chiropractic treatments, massage therapy, physical therapy, occupational therapy, or any other appropriate therapy as determined by the health care practitioner.
     2.  Discuss the advantages and disadvantages of non-opioid alternatives.
     3.  Provide the patient with an educational pamphlet published by the Department of Health.
     4.  Document the non-opioid alternatives considered in the patient’s record.
Interestingly, as originally drafted, this new version did not mention chiropractic, acupuncture, or massage therapy. They were added later, a legislative staff analysis citing two documents in support of their inclusion. One, the CDC’s “Nonopioid Treatments for Chronic Pain“, does not actually mention any of these treatments. The second, The Joint Commission’s “Non-pharmacologic and non-opioid solutions for pain management”, relies on the recommendations of the American College of Physicians for acupuncture and massage therapy for acute and chronic low back pain, all based on low quality evidence. The Joint Commission also recommends spinal manipulative therapy, based on one systematic review and meta-analysis and one Cochrane Review, neither of which was exactly a ringing endorsement. “Chiropractic treatments” are not mentioned and, of course, chiropractors are not the exclusive providers of spinal manipulation.
In any event, physicians need not discuss options that are inappropriate for the patient, either because they just don’t apply to the patient’s condition or they are not evidence-based. Unfortunately, the same discretion is not available to physicians in complying with the rest of the law.
The Department of Health (DOH) was directed to create a pamphlet on its website “regarding the nonopioid alternatives for the treatment of pain”, including, at a minimum, information on available non-opioid treatments and the advantages and disadvantages of using them. The physician must provide patients with this pamphlet before prescribing/ordering/administering opioids. The law is unclear on whether the patient has to be given the pamphlet at each administration, resulting in multiple pamphlets being handed to, for example, the same hospital patient prescribed a Schedule II opioid every 6 hours post-surgery. (The FMA has requested guidance from the Florida Board of Medicine on the issue.)
The content of the DOH’s pamphlet is unobjectionable in many respects. It urges patients to work with their healthcare providers in deciding on the best course of treatment for pain and talk about the advantages and disadvantages of all options. It warns that some options may not be covered by insurance and may be ineffective for severe pain. It lists cold and heat, exercise, OTC meds, physical and occupational therapy, and behavioral interventions, among others, as treatment options. Unfortunately, the pamphlet’s recommendations also includes chiropractic, acupuncture, and massage therapy.
I’ll leave to others a discussion of whether physicians and other prescribers need to be second-guessed by legislators in their attempt at what one critic has described as “opiophobia”. My particular problem with the new law is that, by mandating the distribution of this pamphlet, healthcare providers are forced to essentially endorse treatments with, at best, questionable evidence of safety and effectiveness. At worst, they are forced to endorse pseudoscience administered by Florida-licensed healthcare providers whose practices will subject patients to quack remedies. Ironically, the authority to treat patients with pseudoscience was bestowed on these licensed providers by the very Legislature that is so keen to protect patients from evidence-based practitioners. That is not to say that physicians and others have not overprescribed opioids or that some corrective action is unnecessary. But pseudoscience is not the solution; it is, in fact, a problem the Legislature itself created and is doing nothing to stop.
Chiropractic, acupuncture, and massage
With that, we’ll turn to a discussion of the three problematic recommendations.
From the DOH pamphlet:
Chiropractic: Chiropractic physicians practice a hands-on approach to treat pain including manual, mechanical, electrical and natural methods, and nutrition guidance. Can help with pain management and improve general health. Aching or soreness in the spinal joints or muscles sometimes happens—usually within the first few hours after treatment.
But here’s how Florida law defines the “practice of chiropractic”:
a noncombative principle and practice consisting of the science, philosophy, and art of the adjustment, manipulation, and treatment of the human body in which vertebral subluxations and other malpositioned articulations and structures that are interfering with the normal generation, transmission, and expression of nerve impulse between the brain, organs, and tissue cells of the body, thereby causing disease, are adjusted, manipulated, or treated, thus restoring the normal flow of nerve impulse which produces normal function and consequent health by chiropractic physicians using specific chiropractic adjustment or manipulation techniques . . .
This is nonsense, of course; pseudoscientific gobbledygook, invented by an uneducated “magnetic healer” in the late 19th century and dutifully incorporated into Florida law by the Legislature. There is no such thing as the chiropractic “subluxation”. Consequently, it cannot interfere with “nerve impulse” or “cause disease”, nor can it be “adjusted” to “restore normal flow of nerve impulse” and “consequent health.”
Some chiropractors, such as now-retired Florida D.C. Sam Homola (a guest contributor here at SBM) do limit themselves to evidence-based treatment of musculoskeletal conditions with spinal manipulation. On Chirobase, Dr. Homola gives advice on how to locate a good chiropractor, but also admits “it’s not easy to find a good, properly-limited chiropractor” and warns that
“Straight” chiropractors use only spinal adjustments to treat the gamut of human illness. They are dedicated to locating and correcting (imaginary) vertebral “subluxations,” which they find in everyone’s spine. “Mixer” chiropractors offer manipulation with other methods, including such bogus methods as homeopathy, megavitamins, colon irrigation, and acupuncture. Both types might attempt to treat organic ailments—one using only spinal adjustments and the other using spinal manipulation along with vitamins, etc. Both might recommend “maintenance therapy” to prevent the development of “subluxations.”
“Chiropractic”, an ambiguous term that encompasses the entire spectrum described by Dr. Homola (for an overview, see here and here), has been the subject of numerous posts here on SBM describing, among other things, their many unsubstantiated claims in preventing or treating diseases and conditions such as ADHD, bedwetting, ear infections, colic, SIDS, concussions, reflux, autism, Alzheimer’s, Tourette’s, cancer, asthma and allergies, as well as the dangers of chiropractic treatment, including stroke, the use of unvalidated diagnostic testing, and opposition to vaccination. We have also discussed their aggressive efforts to promote themselves as primary care physicians, even to the point of creating the ersatz “specialty” of “chiropractic internist”.
Unfortunately, the physician who is forced by law to provide his or her patient with the incomplete and misleadingly benign description of chiropractic will appear to have endorsed chiropractic practices unless they take the time out of an already burdened schedule to disclaim the pamphlet’s contents. Whether the state can constitutionally mandate a physician to communicate information he or she feels is not truthful is a question we’ll return to in a moment.
Again, from the DOH pamphlet:
Acupuncture: Acupuncturists insert thin needles into the body to stimulate specific points to relieve pain and promote healing. Can help ease some types of chronic pain: low-back, neck and knee pain, and osteoarthritis pain. Can reduce the frequency of tension headaches. Bleeding, bruising and soreness may occur at insertion sites.
Where to begin? First, “acupuncture” is an imprecise term. What kind of “acupuncture”? By the reckoning of (sadly) former SBM blogger Dr. Mark Crislip there are
over 30 different types of acupuncture with many different modes of operation and fantasy explanations for their claimed effectiveness.
Second, the traditional Chinese medicine concepts on which acupuncture is based are pseudoscience. There are no meridians, no “qi” and “specific points”, i.e., “acupuncture points”, do not exist. Third, the evidence simply does not support the conclusion that acupuncture “can ease some types of chronic pain.” In fact,
Acupuncture is a theatrical placebo.
Specifically, there is insufficient evidence to unqualifiedly recommend acupuncture’s effectiveness for low-back, neck (also here), knee pain, osteoarthritis pain (also here), and tension-type headaches, especially when prior probability is considered.
Fourth, the side effects of acupuncture are not limited to “bleeding, bruising and soreness” as this overview of systematic reviews (available at the time DOH composed the pamphlet) concludes:
Minor and serious AEs [adverse events] can occur during the use of acupuncture and related modalities, contrary to the common impression that acupuncture is harmless. Serious AEs are rare, but need significant attention as mortality can be associated with them.
There are three provider choices for acupuncture treatments in Florida: a licensed acupuncturist, a physician providing “medical acupuncture”, and chiropractors, who can be eliminated from consideration based on our previous discussion.
The licensed acupuncturist’s scope of practice in Florida should give any healthcare practitioner pause:
“Acupuncture” means a form of primary health care, based on traditional Chinese medical concepts and modern oriental medical techniques, that employs acupuncture diagnosis and treatment, as well as adjunctive therapies and diagnostic techniques, for the promotion, maintenance, and restoration of health and the prevention of disease. Acupuncture shall include, but not be limited to, the insertion of acupuncture needles and the application of moxibustion to specific areas of the human body and the use of electroacupuncture, Qi Gong, oriental massage, herbal therapy, dietary guidelines, and other adjunctive therapies, as defined by board rule. [Emphasis and link added.]
Acupuncturists can also practice “Oriental medicine”, defined by Florida law as:
the use of acupuncture, electroacupuncture, Qi Gong, oriental massage, herbal therapy, dietary guidelines, and other adjunctive therapies.
The Florida Board of Acupuncture, through rulemaking, has expansively interpreted the scope of practice to include, among other diagnostic methods and treatments: auricular, hand, nose, face, foot and/or scalp acupuncture, moxibustion, cupping, [unspecified] thermal methods, magnets, gua-sha scraping techniques, reflexology, tongue diagnosis, five element correspondence, German electro acupuncture, Kirlian photography, and homeopathic remedies.
Query whether one would want to put one’s patient in the hands of someone who can employ, without limitation as to disease or condition, such a vast array of pseudoscience and quackery. Further caution may be warranted when one is made aware that acupuncturists graduate from acupuncture and Oriental medicine schools that do not require a college degree, an admissions test, or a minimum GPA for admission.
“Medical acupuncture” is, according to the American Academy of Medical Acupuncture, practiced solely by MDs and DOs, who choose treatments “based on traditional principles such as encouraging the flow of qi”, or “modern concepts such as recruiting neuroanatomical activities in segmental distributions, or a combination of these two principles.”
I have no idea what “recruiting neuroanatomical activities in segmental distributions” means. The “traditional principles” are based on pseudoscience, which undermines any notion that “medical acupuncture” is evidence-based. And, in fact, it took only a few minutes on the internet to find evidence contradicting the Academy’s claims of acupuncture’s effectiveness for a number of conditions, including insomnia, asthma, arthritis (also here and here), IBS, dysmenorrhea and pelvic pain, abdominal distension/flatulence, and persistent hiccups.
Finally, briefly,
Massage therapy: Massage therapists manually manipulate muscle, connective tissue, tendons and ligaments. Can relieve pain by relaxing painful muscles, tendons and joints. Can relieve stress and anxiety—possibly slowing pain messages to and from the brain. At certain points during a massage, there may be some discomfort— especially during deep tissue massage.
Like acupuncture, massage therapy is a non-specific term and the evidence for effectiveness of massage for pain is actually quite limited. (See also here.)
However one feels about massage therapy, health care practitioners forced to hand out the DOH pamphlet should be aware that, in addition to traditional massage, massage therapists push a number of unproven and frankly fantastical treatments like reflexology, pranic healing, cranial-sacral therapy, zero balancing, reiki, and polarity therapy, making claims of effectiveness that go beyond relief from musculoskeletal pain.
Constitutional?
While an extended legal analysis is beyond the scope of this post, I question the constitutionality of the new law in that it essentially forces physicians to endorse medical advice with which they may disagree, either on grounds of the lack of evidence for its safety and efficacy, or on the grounds that a particular type of health care providers’ practice is so infused with pseudoscience that it would be irresponsible to recommend it, whether or not there is evidence of safety and efficacy of any particular treatment.
For example, on Tuesday, a federal judge blocked North Dakota from enforcing a new law requiring physicians to inform patients it may be possible to reverse a drug-induced abortion. The judge ruled that the requirement violated the doctors’ First Amendment protections against compelled speech. Noting that the American College of Obstetricians and Gynecologists had rejected the law’s claims about “reversal” treatments as unsupported by evidence, the judge stated
State legislatures should not be mandating unproven medical treatments, or requiring physicians to provide patients with misleading and inaccurate information.
(You can find further discussion of the First Amendment and compelled speech by a constitutional law scholar here.)
The State of Florida has gotten in trouble with this sort of thing before when it tried to interfere with physicians’ discussions of gun safety with patients. (Covered here prior to the most recent decision by the 11th Circuit en banc, which overturned previous decisions upholding the law.) Physicians and their fellow healthcare providers who oppose being forced to give their patients ill-conceived state-mandated medical advice should bring the issue up with their professional associations and regulatory boards.

Is Australia’s Planned Vaping Ban A Good Idea?
Australia’s planned ban on recreational vaping has a solid base in current evidence.
Steven Novella on May 3, 2023
Link

Australia plans to ban recreational vaping in a move designed to head off what they fear is an industry that will get a new generation of young people addicted to nicotine. Part of the justification for the ban is concern over the health risks of vaping, or e-cigarettes, which use heat to turn a liquid into a vapor which is then inhaled. Often the liquid contains nicotine and may also be flavored, a practice critics argue is targeted at children.
Vaping was initially promoted as a safer alternative to smoking, and a way for smokers to quit their nicotine addiction. But at the same time non-smokers have been taking up vaping. The Australian ban seeks to eliminate this latter path, so-called recreational vaping, while making it easier for smokers to get prescriptions for vaping as a method of quitting. Australia also seeks to regulate the contents of vaping fluid, including nicotine content and flavoring. There is also concern that a ban might simply turn users toward the black market in vaping products.
Regardless of the ultimate regulatory strategy, what is the current evidence on the health effects of vaping? While there is concern that the evidence is still preliminary, there have been enough studies to spawn a number of systematic reviews. A 2021 review – Vaping and lung cancer – A review of current data and recommendations, found:
E-cigarette devices and vaping fluids demonstrably contain a series of both definite and probable oncogens including nicotine derivatives (e.g. nitrosnornicotine, nitrosamine ketone), polycyclic aromatic hydrocarbons, heavy metals (including organometal compounds) and aldehydes/other complex organic compounds. These arise both as constituents of the e-liquid (with many aldehydes and other complex organics used as flavourings) and as a result of pyrolysis/complex organic reactions in the electronic cigarette device (including unequivocal carcinogens such as formaldehyde – formed from pyrolysis of glycerol).
This study is essentially looking at hazard, the presence of known and possible cancer causing agents in vaping fluid. The reason to take this approach is that there is likely a 20 year delay between exposure and diagnosis with cancer, so by the time there is clear evidence for an actual increase in lung cancer we will already have a new generation addicted to vaping nicotine. But still, this kind of data has to be put into perspective – it is a hazard, a potential risk.
Because of this delay in terms of developing cancer, some studies focus on acute or short term lung damage. A 2021 review of these studies, E-Cigarette or Vaping Product-Associated Lung Injury: A Review, finds:
Since March 2019, there has been an ongoing epidemic of acute lung injury secondary to the use of e-cigarettes, with over 2600 cases and 60 deaths reported all over the United States.
A significant proportion of patients hospitalized with e-cigarette- or vaping product-associated lung injury have required admission in the intensive care unit, with mechanical ventilation needed in up to one-third of patients.
This acute injury is treatable, with generally (but not universally) good outcomes, but the concern is that these acute lung injury cases are the tip of the iceberg. They represent cases with symptomatic acute lung injury, which raises the possibility of chronic, asymptomatic, or mildly symptomatic lung injury. Again, this type of injury may take decades to fully appreciate.
Another 2022 review, Vaping-Associated Lung Injury: A Review, gives this summary:
Adolescents who use e-cigarettes commonly report an increased cough and wheeze, and studies have shown an association with e-cigarette use and asthma exacerbations. However, it is not yet clear if chronic e-cigarette use by itself can cause COPD in a clinical setting or if the substitution of e-cigarettes for combustible tobacco products can prevent or slow the development of COPD. There is also data to support a correlation between e-cigarette use and impaired host defence. It appears viral responses are compromised, and bacterial clearance by macrophages and neutrophils appears to be reduced. This allows increased adhesion and colonisation of bacteria and possibly an impaired infection-fighting ability.
A 2020 review, A review of toxic effects of electronic cigarettes/vaping in adolescents and young adults, also includes extrapulmonary effects.
Additionally, there have been more recent studies showing extrapulmonary effects including cardiovascular, immunologic and neuro-developmental effects. Many of these effects are likely dose-dependent.
A 2021 review of studies looking at periodontal effects found:
This study concluded that there is not enough evidence to fully characterize the impacts of vaping on periodontitis. However, within the limitations of our review and the selected included studies, the available results point to increased destruction of the periodontium leading to the development of the disease.
If we take a risk-vs-benefit approach to vaping, we can review the evidence of whether or not it works as a smoking-cessation tool. From the 2022 review above:
E-cigarette use has grown exponentially, particularly amongst adolescents. While they were originally marketed as a smoking cessation tool, evidence for a role in smoking cessation has been inconclusive. There is some evidence that nicotine-containing products may have a role in risk reduction for active smokers but, conversely, may encourage the initiation of cigarette smoking in non-smokers.
The evidence for benefit is mixed and unclear. Using vaping as a nicotine delivery alternative does seem to help some smokers quit, but the number is low (18% in one study) with a high relapse rate, perhaps higher than other methods of quitting. Meanwhile vaping leads some non-smoker to take up tobacco use, and some smokers become dual-users, with demonstrated increased toxicity. Therefore, just in terms of smoking cessation, it is unclear if there is a net benefit to vaping, which likely means that there is no large benefit.
Meanwhile, vaping is leading to a dramatic increase in younger people taking up vaping directly. There is clear evidence at that point of toxicity, exposure to hazardous materials, acute lung injury, periodontal injury, and some extrapulmonary effects. It is still unclear what the long term risks are, because there simply hasn’t been enough time to see these effects and gather that data. Also, as with smoking, we can’t ethically do a randomized controlled trial, so we must infer the risks from toxicity and epidemiological data.
The evidence clearly shows that we should not be complacent about the risks of vaping. There is legitimate cause for concern about a product that is addictive, may lead to more harmful behavior (smoking), and targeted toward children with sweet flavoring and attractive packaging, a practice that the evidence shows is clearly working. Whether or not Australia’s ban is effective or the best approach, time will tell. But the justification is reasonable.

UKs Phased Smoking Ban
Steven Novella on April 17, 2024
Link

UK MPs have just passed the Tobacco and Vapes Bill by a 383 to 67 vote. If the measure becomes law it will ban the sale of tobacco products to anyone born after January 1, 2009. This is not just an age limit – this is a permanent phased ban. If the law passes and stands, anyone born after that date will never be able to purchase tobacco products in the UK.
The measure has sparked another round of the endless debate regarding the role of the government in protecting people from themselves. Even ardent defenders of SBM can have good faith disagreements on this issue, as ultimately it is a value judgment regarding competing principles. Personally I find the arguments in favor of the ban far more compelling, but I can understand those who choose to prioritize individual liberty and worry about government overreach into our personal lives.
Such debate should at least be based on some shared understanding of the facts, so let’s review some of them. In 2024 we shouldn’t have to spend too much time defending the overwhelming consensus of scientific opinion that smoking is a significant health risk, but here’s the data. I’ll give some UK and US numbers for comparison.
In 2022, 12.9% of adults 18 and over in the UK were current smokers. In the US the percentage is 11.5%. The health impacts are significant. “There were 506,100 hospital admissions due to smoking in 2019/20, and in 2019 there were 74,800 deaths attributed to smoking among adults aged 35 and over.” In the US, according to the CDC, “Cigarette smoking kills more than 480,000 Americans each year.” This makes smoking the leading preventable cause of death.
What about the cost to society? Again from the CDC – “Cigarette smoking cost the United States more than $600 billion in 2018, including more than $240 billion in healthcare spending and nearly $372 billion in lost productivity.” In the UK – “Smokers’ need for health and social care at a younger age than non-smokers also creates costs, with smoking costing the NHS an additional £2.4bn and a further £1.2bn in social care costs.”
Smoking, therefore, has a significant cost to society in both money and lost health, and it is entirely preventable. Much of this cost is born by the government, which gives it a legitimate interest in reducing this cost.
Do smoking bans work? The short answer is yes. Social bans on smoking reduces smoking and its health consequences, as does taxes on tobacco products. There is also evidence that bans on smoking in public places reduces the negative health effects of second-hand smoke.
From what I can see so far, the debate over the phased ban in the UK is focusing on the issue of liberty, not contesting the science. This is good as that is where the debate should focus, because the science at this point is fairly clear. Tobacco use is a demonstrable health risk, it is very costly to individuals and society, and laws that make smoking more difficult are effective at reducing the behavior, improving health, and saving money. So the only questions that really remain are those surrounding personal liberty.
But there is one more science-based consideration that impacts the question of liberty – the addictive potential of nicotine and smoking. Nicotine acts upon the same dopaminergic system as other addictive drugs, in the nucleus accumbens. But it has neurological effects beyond dopamine, affecting the “GABAergic, serotonergic, noradrenergic, and brain stem cholinergic” systems. 
Further, because of the mechanism of drug delivery, nicotine can affect the brain within 20 seconds of inhaling. This strongly reinforces the pharmacological addiction and also the behavioral addiction. The consensus is that nicotine is as addictive as heroine, opioids, and cocaine, and some argue it may be more addictive.
About 68% of adults who smoke report that they would like to quit but find it difficult because of addiction. In 2018 55% of smokers made an attempt to quit, but only 7.5% did. Further, most people who regularly smoke began smoking by the time they were 15 years old. This significantly complicates the argument that smoking bans are an infringement on the liberty of adults.
Essentially people start smoking when they are teenagers, and their ability to control their behavior and make strategic life decisions is not yet fully developed. They then become addicted to nicotine and smoking, which locks in this behavior into adulthood. When they are ultimately old enough to decide that they do not want to smoke, they are already addicted and find it extremely difficult to quit. It is highly problematic to defend this scenario as the liberty of informed adults to make decisions for themselves.
Even worse, there is evidence that the tobacco industry targeted teenagers, specifically because they understood the above dynamic. We are now seeing this cycle repeat with vaping.
This is an interesting more general question – how does addiction affect liberty and personal choice? Is a decision that someone makes under the influence of biological and psychological addiction truly a free choice and an expression of their individual liberty? I think there is a strong case to be made that the answer is no. But people generally don’t like to think of themselves as biological machines, or that our freedom can be so mechanistically compromised.
There is still room for debate about the proper role of government and where we draw the line on micromanaging individual behavior. But I don’t think superficial platitudes about “liberty” are sufficient. Any discussion has to account for the health effects of tobacco, the cost to society, and the role that addiction plays in individual behavior.
Framing is also important here. We can simply frame the issue as one of consumer protection. Tobacco is a harmful and addictive product. If something similar were introduced today, it’s difficult to see that it would garner regulatory approval.

State Attorneys General pursue consumer protection law claims against stem cell clinics
State Attorneys General are pursuing stem cell clinics offering unproven therapies and engaging in fake clinical trials using state consumer protection and false advertising laws, seeking monetary penalties and injunctive relief. Until there is rational, comprehensive stem cell regulation, these actions can help fill the regulatory gap.
Jann Bellamy on March 24, 2022
Link

State Attorneys General have recently filed actions against stem cell clinics whose outsized claims for their treatments far outstripped the evidence. Today we’ll look at several of these cases and see how the states are helping fill the gap caused by the lack of effective regulation for these relatively new therapies.
Stem cell clinics are ubiquitous in the U.S. and, unfortunately, too many make claims of effectiveness that are not backed by sufficient evidence for any number of conditions, including Parkinson’s disease, ALS, stroke, traumatic brain injury, and spinal cord injuries. In addition to overstating the success of their treatments, some clinics enroll patients in what are essentially fake clinical trials, charging thousands of dollars to participate. Both financial and physical harms (for example, blindness) from worthless stem cell treatments have resulted.
Because stem cell therapies are relatively new, regulation is playing catch up. Some therapies are considered drugs or biological products by the FDA and are therefore regulated as such. Others are not. Where to draw the line between the two is a point of contention between stem cell clinics and the FDA.
The Federal Trade Commission (FTC), with its jurisdiction over “unfair or deceptive acts or practices in or affecting commerce”, including advertising claims, can also serve as a means of regulating stem cell clinics, although unfortunately after-the-fact. Rather than haggling over whether or not a therapy is subject to FDA regulation, the FTC asks, more simply: “Are your claims backed by competent and reliable scientific evidence?” Because evidence of effectiveness is limited, or nonexistent, for the vast majority of conditions, this may prove a more efficient route to shutting down dubious clinics, or at least hitting them with big financial penalties.
States, too, have their own consumer protection laws, typically enforced by the states’ Attorneys General (AGs). Under these laws, as well as specific false advertising statutes, state AGs are permitted to initiate and conduct investigations and bring lawsuits on behalf of the states’ citizens. Once a lawsuit is initiated, liability for consumer protection act-based claims for false advertising can be found without a showing that anyone was actually harmed or defrauded by the false advertising — the law merely requires that deception was likely. Such a low threshold makes these state laws particularly potent tools for state AGs seeking to hold companies liable for false or deceptive advertisements.
States sanction stem cell scams
New York
Last November, New York Attorney General Letitia James announced a $5.1 million judgment against a New York City stem cell clinic (now defunct) and its managing physician, Joel B. Singer, MD, for fraudulently advertising their stem cell therapies, settling a 2019 lawsuit brought for scamming patients out of thousands of dollars each for unproven and potentially harmful treatments. The defendants were also enjoined from fraudulent and deceptive marketing of their stem cell treatments.
The clinic advertised widely that it could treat a variety of serious medical conditions using patients’ own stem cells, including erectile dysfunction, cardiac/pulmonary disease, neurological diseases (such as Parkinson’s disease), autoimmune diseases (like lupus), and orthopedic conditions.
The clinic falsely claimed in advertising that stem cells “represent a medical breakthrough in the treatment of many chronic medical conditions”, that there was a “great deal of excitement” about using stem cells to “treat currently incurable diseases”, and that their stem cell treatments could “treat the entire body not just the injured part”. The defendants represented stem cells as “magical” or “miraculous” cells that could help diabetes patients avoid amputation and even help people suffering from rheumatoid arthritis to “throw away crutches and get younger”. Of course, as the AG noted, there is currently no adequate scientific substantiation that stem cells can effectively treat any of these conditions.
Treatments were promoted using testimonials from well-known individuals like Guardian Angels founder Curtis Sliwa and NFL player Darrel Reid without disclosing that they did not pay for these treatments, in effect compensating them for their endorsements without letting the public know. The defendants also falsely claimed that their procedures were FDA-approved and had been endorsed by several scientific and medical organizations and that patients were participating in an established research study.
The defendants charged consumers nearly $4,000 per procedure, with several consumers paying over $20,000 for multiple procedures. Most of the procedures involved adipose stem cells, derived from a patient’s own fat tissues.
Georgia
Earlier last year, in August, the Georgia Attorney General joined the FTC in filing an enforcement action in federal district court against Regenerative Medicine Institute of America, doing business as Stem Cell Institute of America, and several other corporate and individual defendants, for violations of the Georgia Fair Business Practices Act and the FTC Act.
The complaint alleges that the defendants made false and misleading claims about stem cell therapies offered to consumers in Georgia, aggressively marketing and selling these therapies, mostly to older adults. They allegedly advertised to the public and to healthcare practitioners that their therapies cure, treat, or mitigate a variety of orthopedic diseases and health conditions, and that they are comparable or superior to conventional treatments for these conditions. According to the complaint, these claims are not backed by competent and reliable scientific evidence.
Two of the defendants, Physician Business Solutions and Stem Cell Institute of America, according to the complaint, generated millions of dollars in revenue by training and advising chiropractors and other health care practitioners on how to add stem cell therapy to their practices. Another defendant, Superior Healthcare, allegedly generated revenues by selling these products directly to consumers and by contracting with clinics throughout the state to administer injections in exchange for a fee. These therapies cost approximately $5,000 per joint injection, with patients often receiving more than one injection.
The complaint reveals the creative way in which chiropractic “adjustments” gibberish, unproven stem cell treatments, and anti-“allopathic” medicine propaganda were rolled into one convenient package for chiropractors looking to earn an extra buck. From promotional material used in luring chiropractors to join the scheme, quoted in the complaint:
Stem cells help to rejuvenate the joints, allowing your adjustments to really take hold and the alignment process to occur. . .
Stem cell and regenerative therapies have recently shown incredible results with conditions that, up until now, were only treated with dangerous, unreliable surgeries or masked with pain drugs. But with these therapies, patients are experiencing seemingly miraculous outcomes. Chiropractors can be integrated with a [sic] MD or DO to offer these protocols in merely 60 days. Yet these therapies keep with the spirit of the chiropractic soul, i.e., avoiding allopathic health care, major surgery or pain drugs.
So, in sum, the way to help patients avoid allopathic health care and its attendant dangers is to team up with an allopathic practitioner to administer unproven, risky therapies.
The lawsuit, which is still pending, seeks injunctive relief, consumer restitution, disgorgement of ill-gotten gains, and civil penalties which, under Georgia law, are doubled for violations committed against elderly or disabled persons.
A similar suit was filed in 2020 by the Georgia AG against Elite Integrated Medical and other corporate and individual defendants seeking injunctive relief, consumer restitution, and civil penalties. According to that complaint, Elite made over $6.4 million by using aggressive marketing techniques and high-pressure sales tactics to convince consumers, most of whom were elderly and/or disabled, to purchase expensive, unproven stem cell treatments that are not covered by Medicare or health insurance. The AG alleges that
Elite represents that it has a staff of medical doctors who provide its products to patients, when in fact, medical doctors administer a very limited number of product injections. The vast majority of patients interact only with chiropractors and nurse practitioners, and most of the injections are administered by nurse practitioners.
As best I can tell, the suit is still pending in a Georgia state court.
Washington State
Finally, last week the Washington State Attorney General filed a civil action in state court against Seattle-based US Stemology and its owner, Tami Meraglia, MD, for deceptively marketing stem cell therapies for COVID-19 and dozens of other serious medical conditions, including asthma, lupus, Parkinson’s disease, congestive heart failure, and MS, in violation of the state’s Consumer Protection Act. The complaint alleges that there is no reliable clinical evidence that stem cell therapies can effectively treat these conditions. Dr. Meraglia began the stem cell clinic out of the basement of her “medispa”, which mostly performed aesthetic and cosmetic treatments.
According to the complaint, the defendants charged patients as much as $10,000 to participate in the clinic’s purported “patient funded research” and claimed they were treating patients as part of clinical trials. These “clinical trials” were under the supervision of an Institutional Review Board (IRB) operated by a company called the International Cell Surgical Society. Two of the primary “researchers” listed on US Stemology’s trials were also principal officers of the company operating the IRB when it approved the trials, an obvious conflict of interest.
Per the AG’s press release,
the trials themselves did not follow accepted standards of research. For example, the trials did not use a control group or a standard course of treatment for each patient, and relied solely on patient surveys to assess results. Typically, legitimate clinical trials pay patients — not charge them thousands of dollars — for agreeing to undergo experimental treatments.
In what should be an inspiration to us all to report such nefarious activity, the AG’s office was first alerted to the clinic’s false claims that it could prevent and treat COVID-19 by a concerned citizen. When investigators looked into the complaint, they found claims that the clinic’s stem cell therapies could treat dozens of other conditions, claims for which no reliable scientific evidence existed.
The lawsuit seeks injunctive relief preventing the clinic from making the allegedly false and deceptive claims, restitution for patients, and civil penalties which could, according to the AG, total in the millions of dollars.
Conclusion: A good start for individual states
Until there is a comprehensive regulatory scheme in place, unscrupulous practitioners and their associates will continue to abuse patients for profit with unproven stem cell therapies and bogus clinical trials. In the meantime, the states can help deter these greedy charlatans by vigorously pursuing stem cell scofflaws in court using state consumer protection and false advertising laws.
For reputable stem cell therapy information, an excellent source is The Niche blog, published by Paul Knoepfler, PhD, a stem cell scientist (and SBM guest blogger).

Good faith doctoring or greedy drug dealing? SCOTUS hears opioid prescribing cases
Physicians running opioid “pill mills” were convicted of violating the Controlled Substances Act and given substantial prison sentences. The U.S. Supreme Court will soon decide whether they were entitled to a “good faith” defense at trial.
Jann Bellamy onM arch 10, 2022
Link

Dr. Xiulu Ruan and Dr. John Patrick Couch, licensed physicians, owned and operated a medical clinic in Mobile, Alabama, along with a connected pharmacy solely engaged in the business of dispensing drugs prescribed at their clinic. In a little over four years, they wrote nearly 300,000 prescriptions for controlled substances. In fact, they were among the top prescribers nationally of transmucosal immediate-release fentanyl (TIRF), which is FDA-approved for breakthrough cancer pain. Though no more than 15% of their patients had a cancer diagnosis, they prescribed more than 475,000 doses of TIRF to over 1,000 patients, which at times was more than double the number of TIRF prescriptions written by the next highest U.S. prescriber.
Drs. Ruan and Couch invested over $1 million in the pharmaceutical company making Abstral, a particular brand of TIRF, at the same time “massively” increasing their prescriptions of the drug. They collected “substantial” speaking fees from the maker of a different TIRF drug, Subsys, and were paid to host weekly programs promoting the drug, a gig intended to influence their prescribing practices according to a drug rep. This strategy apparently worked. Their clinic ranked among the top 10 prescribers of Subsys nationally.
All of this caught the attention of the federal Drug Enforcement Agency (DEA). During an investigation, an agent was easily able to obtain prescriptions for controlled substances from the clinic without an adequate examination and from clinic personnel who were not licensed to prescribe them, using prescriptions that appeared to be pre-dated and signed by Dr. Couch.
Drs. Ruan and Couch were indicted and, after a jury trial in an Alabama federal district court, were each convicted on multiple counts, including violations of the Controlled Substances Act, health care, mail, and wire fraud, and racketeering conspiracy. Dr. Ruan was sentenced to 21 years in prison, Dr. Couch to 20 years.
Dr. Shakeel Kahn, also a licensed physician, operated a clinic in Arizona where he “routinely” prescribed controlled substances, including oxycodone and alprazolam, with a perfunctory examination or, in some case, no exam at all. He doctored medical records to show, falsely, that he had seen patients in person, completed assessments, made referrals, and collected samples for testing.
Dr. Kahn priced his services, mostly cash-based, according to the number of pills he prescribed: the more pills, the greater the charge. For patients who could not afford his services, he prescribed fewer pills or refused to write a prescription. Some patients who referred others to Dr. Khan were given discounted fees. At times, his clinic manager would meet patients in the parking lot to exchange prescriptions for cash.
When area pharmacies started refusing to fill his prescriptions, he opened a second practice in Wyoming, where his prescriptions were more easily filled, inviting his Arizona patients to follow him there. In 2015, Dr. Kahn wrote a high-dose prescription for oxycodone and other controlled substances for a young woman who paid him $1,250. After filling the prescriptions, the patient died two days later of an oxycodone overdose.
After a DEA investigation, which revealed he charged a $500 minimum for writing prescriptions, Dr. Kahn was indicted and tried before a jury in a federal district court in Wyoming. At trial, experts testified that that Dr. Kahn’s prescriptions were issued outside the usual course of medical practice and not issued for legitimate medical purposes. He was convicted of one count of conspiring to dispense and distribute controlled substances resulting in death, along with a number of other controlled substances offenses. He was sentenced to 25 years in prison.
At trial, in both cases, the defendant physicians requested that the judge instruct the jury on a subjective “good faith” defense – in essence, that they could not be convicted if they sincerely and honestly believed that that their prescriptions were for a legitimate medical purposes and within the usual course of professional practice. Their jury instruction requests were denied. They appealed and, in both cases, their convictions affirmed (save for one racketeering conspiracy count in the Alabama case, which was overturned but is not relevant here).
Dr. Ruan and Dr. Kahn each petitioned the U.S. Supreme Court for a writ of certiorari and both were granted, the Court consolidating the two cases. Oral arguments were heard on March 1.
The federal Controlled Substances Act (CSA) makes it illegal to knowingly or intentionally distribute a controlled substance “except as authorized”, such as when a physician prescribes a drug for a patient. DEA regulations promulgated pursuant to the CSA require that controlled substance prescriptions, to be legal,
must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.
As succinctly explained by health care lawyers in a Lexology post,
In 1975, the Supreme Court held that doctors could be convicted under the CSA when “their activities fall outside the usual course of professional practice.” But in the decades since, courts have interpreted that decision differently. Some have adopted a subjective good-faith standard and hold that practitioners cannot be convicted if they sincerely and honestly believe that their prescriptions were within the usual course of professional practice. Others have adopted an objective good-faith standard and hold that a practitioner cannot be convicted if they “reasonably believed” that their prescription was within the usual course of professional practice. A minority of courts have rejected any consideration of good faith and found it irrelevant to criminal liability.
Given that the [CSA] statute requires the “knowingly or intentionally” unauthorized distribution of a controlled substance, the Supreme Court is expected to permit the good-faith defense. The only question remains: To what extent? If a doctor honestly believed the prescription was for a legitimate medical purpose, should that absolve the conduct, or should the belief be judged on an objective standard?
[Footnotes omitted.]
Unsurprisingly, the defendants argue that the Court should adopt a subjective good faith defense.
Some interesting friends
The consolidated cases attracted no less than a dozen amici curiae (“friend of the court”) briefs, although some specifically stated they had no interest in the outcome of these defendants’ cases one way or another. Rather, they were participating solely to argue how the CSA should be interpreted in general.
Many amici, including a group of Professors of Health Law and Policy and the National Association of Criminal Defense Attorneys, argue that some federal appellate courts are interpreting the CSA in a manner that essentially criminalizes conduct that deviates from accepted medical standards (that is, conduct that is basically malpractice) without considering whether the practitioner acted without a legitimate medical purpose. This, according to the health law professors’ brief, will
criminalize mistaken or negligent prescribing for which there are already myriad civil [e.g., malpractice], administrative [e.g., medical board complaints], and even lesser criminal remedies.
The ask the Court to
clarify that the CSA’s reach only extends to practitioners who prescribe knowingly or intentionally (i.e., not in good faith) without a medical purpose outside the usual course of professional practice.
They also argue that the criminalization of prescribing practices usurps the states’ authority to regulate the practice of medicine.
Two patient advocacy groups filed amicus briefs: Compassion & Choices, which describes itself as “committed to improving care and expanding choice at the end of life” and advocating “for high quality end-of-life medical care and educate[ing] the public about available end-of-life options”, and the National Pain Advocacy Center, “an organization dedicated to improving the health and protecting the rights of people living with pain”. Both argue that denying a good faith defense to practitioners will have a chilling effect on the willingness of physicians to prescribe opioids to patients in pain and those who are at life’s end. (The National Pain Advocacy Center has been criticized for failing to disclose funding from opioid manufacturers, from whom it accepted over half a million dollars over a five-year period. Its chairman received $170,000 from Insys, the maker of Subsys, which featured in the convictions of Drs. Ruan and Couch.)
Of note to regular SBM readers, representing the “brave maverick doctor” faction of the medical community, the Association of American Physicians and Surgeons (AAPS, who we have met before) filed an amicus brief which, contrary to the neutral stance of some amici, most assuredly takes up the cause of Dr. Ruan, portraying him as someone who received a “21-year imprisonment for medicating pain” and describing him as having “acted in good faith”. This statement in AAPS’s brief caught my eye:
Most innovative physicians advance medical practice contrary to “generally recognized and accepted” treatments . . .
Yep, like the crank members of the AAPS, who promote antivaccine pseudoscience and HIV/AIDS denialism, blame immigrants for crime and disease, and claim that abortion causes breast cancer. Innovative indeed.
The health care lawyers, in a second Lexology post following oral arguments, opined that
the majority of the justices seemed prepared to adopt a subjective good-faith standard that would protect practitioners from criminal prosecutions if they sincerely and honestly believe their prescriptions were for a legitimate medical purpose and within the usual course of professional practice.
A decision is expected in June.
I am not sure how a physician could “seriously and honestly believe” his prescriptions “were for a legitimate medical purpose” if his belief is not objectively reasonable, that is, within acceptable medical standards. To me, this implies that the physician has no duty to inquire as to what the standard of care is when prescribing. In fact, any attempt to discern the standard of care could undermine his argument that his beliefs were “serious” and “honest”, counseling that he best avoid trying to find out, lest he undermine his own “beliefs”.
In any event, should the convictions of Drs. Ruan and Kahn be overturned and they are retried, I doubt any jury would buy into the n

Plexus: MLM Strikes Again
Many health-related products are sold through multilevel marketing (MLM); now the FTC is warning them to stop making false claims about COVID-19. The tactics that MLMs use to promote all their products are deceptive and are a variation on the old Ponzi scam.
Harriet Hall on September 15, 2020
Tweet


Multilevel marketing (MLM) companies have a terrible reputation, so bad that Quackwatch devotes a whole section to “MLM Watch“. Now that we are in the midst of a pandemic, MLM schemes have been quick to take advantage of public fears and are offering bogus products alleged to prevent or treat COVID-19. Quackwatch’s Consumer Health Digest reported on September 6, 2020, that Plexus and five other MLM companies have been warned by the FTC about false health and/or income claims related to the coronavirus pandemic. The other companies are Youngevity, Vivry, Melaleuca, Isagenix, and Juice+. More false claims and more FTC warning letters will surely follow.
What does MLM mean?
No, MLM doesn’t stand for “Marketing Lies and Misinformation”, but it might just as well. Is it ever legal? Basically, it’s OK for a company to reward you for selling their products, but if it rewards you for recruiting other people who have to pay you, it’s an ethically and legally questionable version of an old scam, the Ponzi scheme or pyramid scheme. Ponzi schemes are named after Charles Ponzi, a businessman who paid profits to early investors from funds obtained from later investors, telling the early investors that the money they received was earnings from their own investments. It was a system for robbing Peter to pay Paul, and when it collapsed, the Peters lost all the money they had invested. Today, typical MLM Pauls get the Peters to do the recruiting for them. More and more Peters recruit yet more Peters in order to get a portion of the commissions earned by the Peters below them in the pyramid. Eventually, the Pauls at the top of the pyramid get rich, while the Peters further down the pyramid lose money.
How it works
The company offers an overpriced, difficult-to-sell product, often a dietary supplement, with grandiose claims that it is the best of its kind and will help customers lose weight or provide other health benefits. Think about it. If they had a good, reasonably priced product, why would they resort to MLM schemes? Reputable products can be (and are) sold profitably in stores everywhere.
A trusted friend or relative persuades you individually or invites you to a group presentation in their home, sort of like a Tupperware party on steroids. They offer amazing testimonials, offer to sell you products, and tell you that you can become a distributor too and earn lots of money effortlessly from home. You will start earning royalty payments after you buy a large inventory of their products (which you soon discover you are unable to sell), but the real money comes as you recruit other distributors and get a percentage of their commissions and get your recruits to recruit even more distributors. If you recruit a large enough stable of distributors, you theoretically might make a lot of money, but the reality is that the vast majority of recruits lose money. Only a few individuals at the top of the pyramids actually benefit. And there is a high social price, as friends and family realize they have been defrauded. Early enthusiasm deteriorates into disillusion, disappointment, customer complaints, and often regulatory actions and lawsuits against the company. Remember Amway, Herbalife, Young Living, and DoTerra. Episode 1 of the (Un)Well documentary series that I reviewed in August covered two disreputable MLMs that sell essential oils.
The FTC’s warning letters remind companies of three pertinent laws:
     1.  It is unlawful to make unsupported claims of product efficacy
It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.
     2.  It is unlawful to misrepresent earnings claims
…representations about a business opportunity, including earnings claims, violate Section 5 of the FTC Act, 15 U.S.C. § 41 et seq., if they are false, misleading, or unsubstantiated and material to consumers. Express and implied earnings claims must be truthful and non-misleading to avoid being deceptive, which means that claims about the potential to achieve a wealthy lifestyle, career-level income, or significant income are false or misleading if business opportunity participants generally do not achieve such results. Even truthful testimonials from participants who do earn significant income or more will likely be misleading unless the advertising also makes clear the amount earned or lost by most participants. Your business opportunity participants and representatives must immediately cease making all express and implied earnings claims that would be false or misleading to current or prospective participants.
     3.  MLM companies are responsible for what its representatives say
You are responsible for the claims of your business opportunity participants and representatives. As the FTC stated in the January 2019 Business Guidance Concerning Multi- Level Marketing, the compensation structure of a Multi-Level Marketing entity (“MLM”) may create incentives for its participants to make certain representations to current or prospective participants. As a consequence, an MLM should (i) direct its participants not to make false, misleading, or unsubstantiated representations and (ii) monitor its participants so they don’t make false, misleading, or unsubstantiated representations.
Warning letters to Plexus failed to lead to corrective action
     3.  On June 5, 2020, the FTC sent Plexus a warning letter saying that the company and its representative had published false claims on social media alleging that their products could prevent or treat COVID-19. They gave specific examples and asked the company to review the claims, to stop making claims that weren’t supported by evidence, and to respond within 48 hours describing the actions they had taken to address the FTC’s concerns.
Truth in Advertising found that after the June 5 letter, Plexus distributors continued to make unsubstantiated claims that the “Kids Essentials Combo” (comprised of MegaKids Microbiome and XFactor Kids), would help:
        ◦ boost children’s’ immune systems
        ◦ possibly keep them virus free
        ◦ a host of health conditions that affect children including asthma, eczema, ADHD, GI issues
Earlier violations
     3.  Before the current pandemic focused attention on coronavirus claims, Plexus had received earlier warnings about its products. An FTC warning letter in 2014 mentioned specific claims on their website that promoted their products as drugs, in violation of FDA regulations for dietary supplements. The products targeted were Fast Relief, Probio5, and Biocleanse. For example, Probio5 was said to typically provide results for jock itch, migraine headaches, recurrent cystitis, and vaginal infections. And Biocleanse claimed that many people were in a low oxygen state that allowed microbes to thrive and cause diseases such as flu, Candida, and chronic fatigue; Biocleanse was said to kill these microbes by increasing the oxygen level around them.
These claims meant the products were new drugs that were misbranded. And:
The introduction of a misbranded drug into interstate commerce is a violation of section 301(a) of the Act [21 U.S.C. § 331(a)].
Those claims have been removed from the website. The company website no longer makes specific disease claims but only “support and function” claims, which are allowed under the Dietary Supplement Health and Education Act (DSHEA). But Plexus distributors have continued to make disease claims in person and on social media, and the company has done nothing to stop them.
Conclusion: A typical MLM company, not trustworthy
     3.  Plexus is typical of so many other MLM companies that defraud their distributors with false promises of easy income and allow distributors to make claims for their products that the company itself can’t legally make, claims that are not supported by acceptable evidence. Legitimate products don’t need to resort to MLM schemes to make profits.
Stephen Barrett has investigated over 150 MLM companies with health-related products. He says:
Every MLM company I have looked at has made false or deceptive claims in its promotional materials. The products that have nutritional value (such as multivitamins and low-cholesterol foods) are invariably overpriced and usually not needed. The products promoted as remedies are either bogus, unproven, or intended for conditions that are unsuitable for self-medication. In addition, none of companies I investigated gave a really clear picture of how difficult it is to earn money selling health-related MLM products…distributors must persuade prospective customers that their product is superior even though it is not and may even be identical to competing products that cost less. This requires misrepresentation.
The National Council Against Health Fraud recommends that consumers avoid health-related MLM products altogether. I think that’s excellent advice.

Decision Against Spelling to Communicate – A Small Victory for Science
Spelling to Communicate is just another form a facilitated communication, an invalid technique that was disproved decades ago but refuses to die.
Steven Novella on December 18, 2019
Link

Some pseudosciences will simply not fade away. They just keep reinventing themselves over and over again. This is partly due to the fact that snake oil peddlers don’t care about science or evidence. But also, knocking down pseudoscience does not usually result in fixing the underlying problem – a lack of sufficient critical thinking skills in the relevant population. So even well-meaning practitioners can repeat the mistakes of the past. That is why advocating for science and critical thinking will always be partly a game of whack-a-mole. Still, we can celebrate the occasional solid whack.
A recent court decision in Pennsylvania is a good victory for science in public school education for children with disabilities, but it also reveals a deep problem of pseudoscience that won’t go away. The decision relates to a technique called Spelling to Communicate, which is essentially a form of facilitated communication (FC).
FC was introduced in the 1980s, and was popular until the early 1990s. The technique is designed to help those with either poor communication or even a complete inability to communicate due to autism or some neurodevelopmental disorder. The basic concept is that such children may have greater intellectual capacity than is reflected in their ability to communicate, which may in turn be limited by purely motor deficits. In order to bypass these motor deficits and access the child’s inner thoughts, facilitators will hold the child’s arm while they point to letters on a letter board. Suddenly children thought to have been severely cognitively limited were writing poetry, and reading and writing at an advanced level.
The extreme implausibility of such results should have prompted immediate skepticism in the speech therapy community, and indeed some were skeptical, but the allure of a transforming method was just too great, and many more therapists embraced the method. FC became popular before critical research was done (always a mistake), and when that research was finally completed it unequivocally showed that the facilitator, not the client, was doing all the communication. Sometimes children were not even looking at the board, as the facilitator rapidly and precisely moved their hand across the letter board or keyboard. Facilitators were largely falling prey to the ideomotor effect, subconscious small movements of their own that were guiding (rather than merely facilitating) the hand movements.
When it became undeniably obvious that FC was nothing but self-deception, it moved rapidly to the fringe. But it never completely went away. It continues to be used by some practitioners, who simply deny the evidence, champion anecdotes, or cherry pick studies that are not designed to determine who is doing the communication.
The lessons from FC are clear, and should stand as a cautionary tale for every practitioner.
    • First, do not accept and widely use a technique that has not yet been validated by adequate research. The research should come first. Until then, new techniques should be treated as experimental.
    • When something seems too good to be true, be especially skeptical. It is the duty of every professional to do due diligence, and make sure they are not harming their clients. So don’t get caught up in a “miracle” treatment or intervention – be skeptical.
    • The research that matters most are studies designed to rigorously answer the question – is the phenomenon real? This kind of research requires proper blinding. In the case of FC (like many deceptive pseudosciences) the alleged effect vanished under proper blinding.
    • Listen to the research. Do not make excuses for negative results, or simply ignore it in favor of lesser research that is not capable of disproving your preferred method.
    • Do not underestimate the potential for self-deception.
Many people simply did not learn these lessons. They continue to champion FC. Also, as time goes by new generations of practitioners come up who may not have learned the history of FC, and so repeat the mistakes of the past. For example, in 2010 a prominent neurologist and coma researcher fell for a clear case of FC. They were simply not aware of the history and were fooled. To their credit, they eventually performed the kind of blinded test they should have done at first, and exposed the FC as invalid. Look at the video here. It is a dramatic example of how impossible it would be to actually communicate using this method. The facilitator is moving the clients hand over the letter board at an impossible speed.
Another way in which such pseudosciences survive is to simply rebrand themselves. In the case of FC we now have virtually identical methods, known as Rapid Prompting Method (RPM) and Spelling to Communicate. These methods also use a facilitator to help a client point to letters on a board. With the Spelling to Communicate method, the facilitator holds the board, rather than the clients hand, but this still allows for the ideomotor effect. Why not have a stationary board?
The facilitators often have to direct clients, ignore incoherent spelling, and “reset” them if they are not giving a meaningful response. Videos remind me of the Clever Hans effect – clients pointing at seemingly random letters until they hit the “correct” letter, which is then counted. Now of course clients exist on a spectrum, and some do have the cognitive ability to communicate but may be non-verbal or have impaired communication. So it is possible to cherry pick examples of clients who can actually communicate with a letter board, as if that validates the process itself. Such cases are not representative, and do not validate the specific techniques used, or justify the lack of proper controls.
The American Speech-Language-Hearing Association (ASHA) has reviewed the evidence for RPM and Spelling to Communicate and warned against their use. They conclude there is no evidence that the clients are actually doing the communication. They write:
According to Davis-McFarland, such positions have been and continue to be marked by deep concern about a range of potential serious harm that includes “reduced access to effective and appropriate treatment, denial of the human right to effective communication, and victimization of individuals with disabilities and their families with false hope and wasteful use of personal and professional resources.”
So officially such techniques are not evidence-based or professionally sanctioned. That does not stop private companies from using their own brand of FC in order to prey (whatever their intentions) on desperate parents. Often school systems become involved, because parents might demand that the school system uses and pays for these methods. This is where the recent courtroom victory comes in. A recent Pennsylvania court decision (ODR File Number: 21855 / 18 – 18AS, link not yet available) denied parents compensation for their private use of a company providing Spelling to Communicate.
The ruling hit many important themes. It concluded that the technique is not recommended by the ASHA because it is not scientifically valid. But further, it reaffirmed that parents cannot demand of a school system that a specific method is used. This is important because otherwise pseudoscience could be foisted onto public institutions at public expense.
This principle has broad implications. It is increasingly a problem that insurance companies are forced by legislatures to cover pseudoscientific treatments, for example. Rather proper experts should dictate the standard of care based on the best current scientific evidence available.
But also this small case reflects another reality – there is constant pressure from countless pseudosciences to infiltrate academic, scientific, professional, and public institutions. Guarding against such harmful and wasteful intrusions requires constant vigilance on the part of experts and professionals. But this, in turn, requires that professionals are properly educated about the history of specific pseudoscience, and the methods necessary to ward against them. No physician, or therapist, or speech pathologist, or similar professional should be able to get through their training without learning about basic scientific methodology, critical thinking, the pitfalls of self-deception, and the methods used by charlatans and snake-oil peddlers.
Otherwise we’ll be playing a losing game of whack-a-mole.

Washington bills: Christian Science no longer an excuse for denying medical care
Jann Bellamy on February 5, 2015
Link

All states try to protect children from neglect, abandonment and mistreatment, such as deprivation of clothing, shelter, food and medical care. This includes civil laws which permit the removal of a child from the home and other protective interventions. Criminal laws protect children as well by, for example, making nonsupport a misdemeanor or criminal neglect a felony.
Washington State law prohibits criminal mistreatment of children and other vulnerable persons, such as the frail elderly, by their caregivers. Criminal mistreatment is defined as the “deprivation of the basic necessities of life:”
food, water, shelter, clothing, and medically necessary health care, including but not limited to health-related treatment or activities, hygiene, oxygen, and medication.
Mistreatment can be either a misdemeanor or felony, depending on whether the defendant’s conduct amounts to criminal negligence or recklessness and the degree of harm caused to the victim. Punishment ranges from 90 days in jail and a $1,000 fine to 10 years in jail and a $20,000 fine.
Unfortunately, parents and other caregivers in Washington have what amounts to an almost literal “get out of jail free” card if the mistreatment takes the form of “treatment” by “duly accredited” Christian Science practitioner:
It is the intent of the legislature that a person who, in good faith, is furnished Christian Science treatment by a duly accredited Christian Science practitioner in lieu of medical care is not considered deprived of medically necessary health care or abandoned.
In other words, if a parent negligently or recklessly fails to get adequate medical care for his diabetic child, the parent could be prosecuted for criminal mistreatment. But if the parent calls in a “duly accredited” Christian Science practitioner to pray over the child instead, his conduct may be excused, even if the child suffers “great bodily harm,” in the words of the criminal mistreatment statute.
Washington law also requires the reporting of suspected child abuse or neglect to child protective services and law enforcement, who can take action to protect the child and institute criminal proceedings against the alleged abuser. Abuse or neglect includes activity that presents a danger to the child’s health, welfare or safety. Here, again, parents who employ Christian Science practitioners are given a legal pass:
A person who is being furnished Christian Science treatment by a duly accredited Christian Science practitioner will not be considered, for that reason alone, a neglected person for the purposes of this chapter.
Two bills currently pending in the Washington Legislature would repeal this special treatment for parents and caregivers who deny their children and other vulnerable people proper medical care by hiding behind a religious exemption. We’ll return to those bills in a minute.
The Christian Science political juggernaut
Christian Science is a small, secretive denomination that holds beliefs unique to Christianity and whose operations fulfill several requirements for characterization as a cult. Its association with the illness and death of children due to withholding medical care is well chronicled. Save for a few other small, fringe sects, no other Christian denomination so thoroughly rejects medical care or views faith healing and medical care as mutually exclusive. In fact, no other religious denomination period endorses these strange beliefs. It is therefore a testament to the Christian Science political lobby that its influence so outstrips its ability to deliver votes.
Even though religious exemptions from medical care, including immunization, are not constitutionally required, Christian Scientists enjoy legal exemptions that are exclusive to their religion in a number of states, such as Washington. In a majority of other states, they and the parents who employ them are protected by virtue of numerous state laws exempting faith healing from civil and criminal liability.
Christian Science lobbyists have had outsized success in gaining insurance coverage of their services as well. Jerry Coyne has written a good summary of health insurance coverage, including Medicare, Medicaid, and federal employee insurance benefits for Christian Science “nursing” and faith healing. Your tax dollars at work!
Hypocritically, Christian Science lobbyists have, at the same time, sought to exclude their believers from purchasing health insurance. The reliably pseudo-science-friendly Sen. Orrin Hatch and Sen. John Kerry supported an amendment to the original Affordable Care Act bill prohibiting an insurer from denying benefits for “religious or spiritual health care” that is recognized as deductible by the IRS. (Sen. Kerry represented Massachusetts, where the Christian Science “Mother Church” is located, in Boston.) A similar amendment was included in the House bill. Fortunately, due in part to intense lobbying by CHILD (Children’s Healthcare is a Legal Duty) and other organizations, the amendments did not survive. And, yes, that’s another benefit faith healing enjoys: religious or spiritual health care is a deductible medical expense under federal income tax regulations.
Failure in their first go-round has not stopped the Christian Scientists from lobbying for amendments to the ACA. In the last Congress, bills were sponsored at their behest to exempt everyone with “sincerely held religious beliefs” from the ACA’s mandate to purchase insurance. While the House bill passed, the Senate bill did not. Efforts to pass similar bills in this Congress may prove more successful in the Republican-controlled Senate.
Whatever you may think of the ACA, it does give children a defined set of insurance benefits, including preventative services, provided without cost to the insured. These preventative services include vaccinations. No doubt the anti-vaccination crowd will be thrilled to see those benefits denied to children whose parents chose to duck their responsibility via claiming “sincerely held religious beliefs,” an excuse they also employ in states granting immunization exemptions for religious reasons. And parents who choose “pediatric chiropractic” or naturopathy for their children wouldn’t have to pay for coverage of other evidence-based “allopathic” preventive services or care their CAM practitioner doesn’t offer.
Repealing special privileges for faith healing
Washington Senate Bill 5408 would repeal provisions of state law giving Christian Science practitioners and their clients special privileges. First, the bill repeals the statement of legislative intent, quoted earlier, shielding those who deprive children and other vulnerable persons of adequate medical care from a charge of criminal mistreatment. Providing faith healing from a “duly authorized” Christian Science practitioner will no longer be considered an excuse. This doesn’t mean these parents will necessarily be criminally liable, just that they won’t receive special consideration other parents charged with criminal mistreatment of their children don’t get.
Second, the bill removes the provision, also quoted above, granting special consideration to parents who choose faith healing over medical care in cases of suspected child neglect. No longer will the fact that the child is being “treated” by a Christian Science practitioner be a barrier placed between a legitimate determination that a child is being neglected and the ability to take action to protect the child. Again, this doesn’t mean that child authorities will necessarily intervene or that parents will face charges; they will simply be treated the same as other parents in the same situation.
The bill received a unanimous “do pass” from the Senate Committee on Human Services, Mental Health and Housing on February 2. It is now before the Rules Committee, which will decide whether it goes to the floor of the Senate for discussion. I am cautiously optimistic as several of the bill’s sponsors are on the Rules Committee, including one who is the Democratic Caucus Vice Chair, a leadership position. There is also a companion bill, House Bill 1476, with bipartisan sponsorship but it has not yet been heard in the Judiciary Committee, where it will make its first stop.
One wonders at Christian Scientist lobbying successes considering the weak testimony opposing the bill, summarized here in the Human Services, Mental Health and Housing Committee’s Report [PDF]:
The existing language was put into law after working with the Attorney General’s Office. Proponents are working under false premises, not all religions are created equal. Spiritual healing is the premise of Christian Science so if this language is repealed, what do the Christian Scientists have left? Concerns raised involved another church that does not have a good record with faith healing. Christian Scientists have practiced faith healing for generations. Getting medical help doesn’t ensure a better outcome.
Perhaps there is an RCT in the published literature, of which we are unaware, comparing Christian Science faith healing, the faith healing of “another church,” and “medical help” reporting statistically significant “better outcomes” for Christian Scientists. If you’ve got the citation, please post it in a comment.
(You can watch the committee testimony here starting at the 1:43:50 mark of the 2-hour hearing.)
Another provision of Washington law governing Christian Science practitioners won’t be repealed by this bill, but it is a good one. Along with other practitioners, day care centers, child welfare workers and the like, they have a statutory duty to report child abuse and neglect, including withholding of medical care, to the authorities. My interpretation of this is that they would have a duty to report their clients if the circumstances require.
Along with Rita Swan and the terrific folks at CHILD, these bills are endorsed by the State Medical Association, State Hospital Association, Washington Chapter of the American Academy of Pediatrics, and the Washington Association of Prosecuting Attorneys. I sense a general public weariness with claims of religious privilege when it adversely affects children. Perhaps the Disneyland measles epidemic has found the upper limits for tolerance of religious belief as a means of granting carte blanche to put the health of your children and others at risk.
You can voice your support for Senate Bill 5408 and House Bill 1476, although these comments appear to be limited to Washington residents. Otherwise, you can call or write the legislators. Contact information for Senators is here and for Representatives here.

Ezekiel Stephan: Another Pediatric Death by World View
Clay Jones on March 11, 2016
Link

Reports of a disturbing chain of events that ended in the likely preventable death of a 19-month-old Canadian child have made the rounds this week. The case was discussed by friend of Science-Based Medicine Orac (who I believe is some kind of a protocol droid) on Respectful Insolence two days ago. But even if you’ve read that excellent post, please continue reading as I have updated information and, I believe, additional insight into this unfortunate outcome.
If this is your first encounter with the story, prepare to be angry and frustrated but don’t presume to know everything that happened. The numerous news reports, beginning back in 2013 when the parents were first charged and the case went public, are not all well-written and there are discrepancies between accounts. Add to that the announcements and fundraising efforts by the family on Facebook and various other crowdfunding websites, and their alleged side of the story as reported by disreputable sources steeped in pro-woo/anti-vaccine bias, and we have one confusing mess of facts and a heap of conspiracy claims to boot. The only aspect of this case that is completely irrefutable is that a child suffered and died, and that he was failed by people who should have known better. 
The making of a tragedy
On March 18th, 2012, physicians at Alberta Children’s Hospital made the always-difficult decision to remove 19-month-old Ezekiel Stephan from life support after five days under their care. Carrying the diagnosis of brain death, there was sadly no life to support at that point. The events that led to his tragic death are currently the focus of a trial where Ezekiel’s parents stand charged with “failing to provide the necessaries of life.” I’m no lawyer, but it appears that if convicted they would face up to five years in prison, a length of time that would be unlikely to placate most folk’s demands for justice. They also stand to lose custody of their remaining children.
On February 13, 2013, Canadian news outlets first began reporting on the death and the fact that Ezekiel’s parents were being charged after a year-long investigation. The trial finally began this week and has been covered by a variety of news sources ranging in quality, with some showing clear signs of bias (Health Impact News). I have tried my best to piece together what happened. Take it all with a grain of salt considering the frailties of human memory as it passes through time and the filters of our personal biases, but some of this information was culled from taped interviews given at the time of Ezekiel’s hospitalization four years ago.
Here goes.
In late February of 2012, Ezekiel’s parents noticed that he wasn’t feeling well. He wasn’t objectively febrile or extremely ill-appearing, at least not yet. He just wasn’t as active as usual and he had a runny nose. Although not explicitly stated, he must have had some degree of cough because his family at first thought that he had croup, a common viral illness in toddlers that targets the upper airway and results in a characteristic “barking” cough. Most kids with croup don’t need medical care. So far so good.
Ezekiel’s parents, proponents of “natural” therapies and wary of conventional medicine, treated him with a variety of herbs and other home remedies. Horseradish for example. Over the next several days his condition worsened, with Ezekiel becoming “achy” and more tired, so the family contacted Lethbridge Naturopathic Medical Clinic (website is down so I can’t review it) to ask for something to help “boost Ezekiel’s immune system.”
Rather than a Naturopathic practitioner at the clinic, the family spoke to a woman “who fills holistic prescriptions.” She has now testified that they specifically mentioned the possibility that Ezekiel might have viral meningitis. According to the family, they researched meningitis online and did not think that he had symptoms consistent with a bacterial infection, a clinical distinction that can be challenging even for a seasoned clinician. In a toddler, we generally would need a sample of cerebrospinal fluid to make that call.
When asked if Ezekiel had been evaluated by a medical professional, his family claimed that a nurse had come to their home. The nurse, or midwife depending on which news report you read (many are both), was actually a friend of the family that had come at their request and she has also now testified in the trial. She stated under oath that while she did not believe that Ezekiel was seriously ill, she did mention the possibility of meningitis and that he should be seen by a medical doctor.
Two or three days later, Ezekiel was brought into the same naturopathic clinic where Dr. Tracey Tannis recommended a “tincture of echinacea.” According to a taped March 15th, 2012 interview of his father, Ezekiel was so stiff that they were unable to put him into his car seat, so they laid him flat on a mattress in the back of their vehicle for the ride to the clinic. According to more than one report, Dr. Tannis did not examine Ezekiel.
Later that evening, despite initially believing that Ezekiel was responding to the new remedy, he was found to be unconscious and not breathing. The family notified emergency medical services, initiated CPR, and drove to meet the ambulance in an attempt to save time. Ezekiel was transported to a nearby hospital in Lethridge and airlifted to Alberta Children’s where he ultimately was found to be dead. According to the family, the hospital allowed a few days for them to try both oral and IV “natural remedies” to no avail. Of course his physicians are unable to discuss protected medical information publicly so who knows what really happened in the hospital.
What killed Ezekiel Stephan?
As reported by the media as well as in the alleged family account linked to at the onset of the post, the autopsy on Ezekiel revealed meningitis, which is typically an infection related inflammation of the covering of the brain and spinal cord. I can’t find confirmation of the organism but it is exceedingly likely that it was bacterial rather than viral given the severity of his presentation. Not that viral meningitis can’t be deadly, it just usually isn’t in an otherwise-healthy older child.
The fact that Ezekiel, like his older sibling, was not vaccinated, further increases the likelihood that he died from bacterial meningitis. The most common cause of bacterial meningitis in a toddler, Streptococcus pneumoniae, as well as the bug that used to be, Haemophilus influenzae type b, are both exceedingly deadly if not treated in a timely fashion. They can cause severe neurologic injury and death even when they are.
Both infections can be prevented with a safe and effective vaccine. I’ve diagnosed zero cases of HiB meningitis and only one case of pneumococcal meningitis in 13 years of practice. Prior to these vaccines, pediatricians that far out of medical school would have seen hundreds of cases considering that 1 out of every 200 children used to suffer invasive Hib disease alone.
Not that the ultimate cause matters in this case, because a critically ill child is a critically ill child. The question jurors are being asked to answer is not whether or not Ezekiel’s parents knew what was wrong but if they failed to respond appropriately to his severe illness. Should two medically naïve parents have recognized that their child needed emergent evaluation by a trained medical professional? Did they simply make a fatal mistake or were they biased by their world view? The parents have pleaded not guilty.
Who is to blame for Ezekiel’s death?
The parents may be the focus of the trial, but are they the only parties potentially at fault for their son’s death? What about the nurse who came to the house at the parents’ request to take a look at Ezekiel? In general, I consider it to be risky, even acting as a “friend of the family not there to give a diagnosis,” to provide medical advice outside of a professional capacity at work. This is not to say that I haven’t done it in certain situations, but the more ill the child, the less of a good idea it probably is. In addition to the possibility of impaired judgement, there are also numerous cases where physicians have been sued for malpractice by friends and family members after giving requested medical advice.
I do not know if the same potential legal issues would apply in a case where the advice was given by a nurse rather than a medical doctor. But in her defense, it does appear that she recommended that the family seek appropriate medical care. If she suspected medical neglect, one could argue that she is a mandated reporter as she was potentially acting in a professional capacity. That would be an interesting case in itself. But she testified that the child did not seem that sick at the time, which could be true. It is also possible that she didn’t do that thorough of an assessment, or any assessment for that matter. You can’t tell asleep from obtunded visually or with a stethoscope.
What about the Naturopathic provider? Here it is considerably clearer. I can see only one of two possible explanations for this aspect of the case, unless you consider that maybe they left Ezekiel in the car. Actually I wouldn’t discount that if he was as uncomfortable as stated in his father’s interview three days before he died. So three possible explanations.
One possibility is that this particular practitioner is so incompetent that even when primed by the parental concern of possible viral meningitis she did not recognize a toxic child on visual assessment or during her examination. A child, I remind you, that was in such pain from infection of his meninges as to be unable to tolerate any stretching of his neck or back, and who was laying right in front of her while she prattled on about tinctures, or balms, or whatever nonsense she conveniently sells from her clinic dispensary. Either that or, as has been reported, she discussed Ezekiel’s case with the family without so much as laying a hand or stethoscope on him.
It seems very likely that an opportunity to save Ezekiel’s life was missed when he was brought to the naturopathic clinic. So far, it appears that the clinic and Dr. Tannis should face disciplinary action at the very least. They are a danger to their community and whatever worthless license the government has seen fit to bestow upon them should be burned to ashes and the ashes divided up and buried in separate locations in order to avoid any chance of it reconstituting.
It’s interesting that the “Health Nut News” article I linked to at the beginning of the post, which supposedly described the events as related by the family, did not include any mention of a call or visit to a naturopath. Maybe they forgot, although that is unlikely. Or perhaps they realize that it may be taken as evidence that they knew exactly how sick poor Ezekiel was. This alleged family account also describes how Ezekiel had improved dramatically and was in fact well enough for his worried mother to leave his side to attend church, only to suddenly and unexpectedly stop breathing. This is inconsistent with a diagnosis of meningitis resulting in complete cardiopulmonary arrest only a few hours later.
Ultimately, in regards to Ezekiel’s parents, I think application of a reasonable parent standard is probably appropriate. At what point would a reasonable parent seek out medical evaluation for their ill toddler, particularly when already concerned about the possibility of meningitis? It is perhaps a difficult assessment in this particular case, because there is so much we just don’t know, but not impossible.
Did the nurse friend really assess him at the house and find him not that ill-appearing, or did she just look at him lying there asleep/altered and think, “What are the odds he is really sick?” Did he truly improve prior to crashing suddenly like that, or was that just denial and wishful thinking? Was he really afebrile this entire time or were they just not taking his temperature? Was Ezekiel able to drink and maintain hydration? At what point did he truly become stuporous or comatose? It’s frustrating to not have more details.
In my mind, I keep coming back to the father’s taped statement on March 15, 2012. Ezekiel was so stiff they could not even sit him in a car seat. They had to place him on a mattress in the back of the car for transport to the naturopathic clinic. They already suspected possible meningitis. If that doesn’t meet the reasonable parent standard for accessing emergency medical care, what the hell does?
They did seek assistance, however. They accessed what in their biased world view counted as medical care but was in reality a hopelessly inadequate medical cargo cult, the world of naturopathy. But in my opinion a reasonable parent would have called 911 at that point or at the very least immediately driven him to the nearest emergency department.
It is possible, but unlikely, that the events on the day of his arrest went down as allegedly described by the parents in the Health Nut article. But he probably suffered for days without even Tylenol or ibuprofen for his severe head and neck pain, gradually slipping into an unconsciousness from which he would never recover. His parents, like so many before them, probably did what they thought was best in their warped reality, and kept hoping that he would eventually turn the corner.
From the minute it became clear that they had waited too long to seek real help, they probably began doing what all humans do, rationalizing and unintentionally altering their memory via the process of repeated recollection. Their memories being sent over and over again through a filter that slowly removes aspects that call into question their parenting skills or love for their child. Memories that might cast doubt on their ability to protect their child from harm were eventually replaced by conspiratorial outrage.
Conspiracy!
From the very beginning of this saga there have been claims of conspiracy from the family. In the initial news reports, Ezekiel’s grandfather questioned the charges, raising the ridiculous concern that they had something to do with his company, which goes by Truehope. Truehope’s main product is a supplement called EMPowerplus, which they claim is effective in the treatment of a variety of mental health conditions, such as depression and bipolar disorder, but also fatigue and autism.
Here’s the supposed connection between the charges against Ezekiel’s parents and Truehope. The Canadian government tried, and failed, to shut the company down for making bogus health claims over a decade ago and they haven’t forgotten about it. Big pharma is also upset about losing profits to his family’s miraculous supplement, so much so that they have managed to interfere with their online fundraising accounts as punishment. The father compares himself to Gandhi, accuses the Canadian Broadcasting Company of being out to get them, and claims that thousands of people committed suicide when EMPowerplus was temporarily confiscated by wicked Mounties. It’s all here and here. But wait, it gets worse.
As I mentioned above, Ezekiel’s parents did not vaccinate their children. Some known anti-vaccine pseudo-journalism entities, namely Health Impact News, have taken this fact and come up with the absurd conclusion that the Canadian government is making an example of the Stephan family. Because they are limited in their ability to force parents to vaccinate their children, they are attempting to scare people into doing it by threat of prosecution.
Essentially, they claim, parents of unvaccinated children will be held to a higher standard in regards to accessing medical care because they will face criminal charges if their child has a bad health outcome. The implication is that the government will see to it that these children are diagnosed with a vaccine preventable disease so that the “failing to provide the necessaries of life” charge will stick. The Stephan family has endorsed this concern on Facebook, writing that their family is being “offered up on the sacrificial alter of the vaccine industry.”
Conclusion: Distractions from a tragic and avoidable death
Ultimately we will probably never know exactly what happened in the home of Ezekiel Stephan. As I hope I’ve made abundantly clear, my take on the situation is a medically informed speculation. I believe, based on the available information, that Ezekiel’s parents should have sought appropriate medical care far sooner than they did, and that there is a good chance he would have survived had they done so. I also believe that the naturopathic clinic and Dr. Tannis, and to a much lesser degree the family friend called upon because of her nursing background, share some of the blame.
Ezekiel Stephan is not the first child to die because of an anti-medicine world view, and he certainly won’t be the last. This is also not the last time that claims of conspiracy will be used in an attempt to distract us from a tragic and avoidable death. We don’t cover cases like this on Science-Based Medicine in order to kick grieving parents while they are down, and I have no doubt that Ezekiel’s family loved him and would probably give anything to undo what happened. We discuss these cases in order to shed light on modifiable risk factors for these outcomes and gaps in the public understanding of science and medicine.
When all is said and done, I find myself at a bit of a loss for words believe it or not. A child has suffered and succumbed to a preventable and/or treatable illness. Nothing will change that. But as I and my SBM colleagues struggle to push this boulder, knowing full well what the future holds once we crest the hill, thoughts of Ezekiel and others like him will serve as inspiration to press on.

Last minute update
A forensic pathologist has now testified regarding the autopsy findings. Dr. Adeagbo concluded that Ezekiel died from both bacterial meningitis as well as pneumonia with an accompanying empyema. Empyema is typically diagnosed in the setting of a bacterial pneumonia when pus collects within the lining of the lung.
So what does this mean? It certainly makes sense from a clinical perspective. Ezekiel likely developed bacterial pneumonia caused by infection by either S. pneumo or HiB, which went untreated and developed into an empyema. At this point surgical drainage is usually necessary for recovery in addition to appropriate antibiotic treatment. His bloodstream was repeatedly showered with the pathogenic bacteria, which eventually made its way to the child’s brain.
This new information adds to my suspicion that Ezekiel was much more ill-appearing than described by his parents and the nurse who visited the family’s home. Although there may have been some degree of waxing and waning of his symptoms, particularly with the fever he almost certainly developed during the course of his illness, I am very skeptical of claims that he had any significant recovery just prior to his arrest. This also makes it more likely that he suffered a great deal prior to his death.

Parents Convicted in Death of Toddler
Steven Novella on April 27, 2016
Link
v
This is a very sad and tragic case, and I have great sympathy for the extended family of Ezekiel Stephan, the 19-month-old who died of meningitis four years ago. In my opinion, there are many victims in this case.
The jury, apparently, agreed. Yesterday they returned a guilty verdict for Ezekiel’s parents, David and Collet Stephan, who now face sentencing for failing to provide the basic necessities of life to their son. It is reported that many of the jurors were crying when the verdict was given – clearly this was a difficult and emotional case.
Just the facts
As is often the case, there are different narratives of what happened, depending on your perspective. It is likely the jury had access to more facts than the public, and so their verdict, which was clearly difficult, needs to be taken seriously. Here are the basic facts as being reported:
In March of 2012 Ezekiel became ill with flu-like symptoms. His parents report that they thought this was a normal childhood illness and would pass. His mother reported to police that she thought he had croup. They treated him with natural remedies, mostly supplements.
Of importance is the fact that David Stephan is vice-president of Truehope Nutritional Support Inc., a natural remedies company founded by his father, Anthony Stephan. According to a police interview shortly after Ezekiel’s death, David Stephan said:
“Do we have a formal education? No. Are we educated in it? Absolutely,” he said. “Has it worked for us in every single scenario in the past before this? Yes.”
“And then when he was sick there, we were giving him, above and beyond that, the olive root extract, which is an antifungal, antiviral, it’s a very powerful one,” he told Bulford.
Ezekiel was sick for 2½ weeks, during which time his parents treated him only with supplements. According to reports at one point they consulted a neighbor who is a nurse, and who told the parents Ezekiel might have meningitis. At one point Collet Stephan searched online for treatments for meningitis. She also consulted a naturopath, and picked up Echinacea as a treatment.
Ezekiel’s condition worsened until he became acutely ill, at which point his parents rushed him to the hospital. At that point they were giving him fluids through an eye dropper because he could not eat or drink. Also, he was so stiff from the meningitis that he could not sit in the car and had to be laid flat. Ezekiel was not breathing on arrival at the hospital. He was put on a breathing machine but never recovered, and was pronounced dead five days later.
Dueling narratives
Those defending the Stephans argue that they did what any parent would do, treat their child as if he had an ordinary illness until it became clear he was seriously ill at which time they sought emergency care. Some blame the Canadian system saying it was difficult to get a doctor’s appointment, and that the ambulance was delayed and did not have the proper equipment to intubate him.
They also go as far as to argue this is a witch hunt against the natural remedies community.
Critics of the Stephans argue that they unreasonably and irresponsibly delayed proper medical care for Ezekiel because of their misguided reliance on supplements and natural medicine. Clearly the jury, after hearing all the evidence, concluded that this latter narrative is closer to the truth.
During my medical education I have been on the receiving end of many parents with sick children, including children who ultimately died of meningitis. We see many children in the emergency room who are just a little sicker than a usual cold, perhaps lasting more than a day or two, or who are cranky or might be dehydrated. We rule out meningitis with a workup even in these mild and potentially early stages, because that is not a diagnosis you can afford to miss.
A child who is so stiff that they have to be laid flat is way past the point where they should have received definitive medical attention, in my opinion. This suggests that the Stephans waited longer than typical parents, until the severity of Ezekiel’s illness was undeniable.
Who’s to blame?
In tragic cases such as this there is often plenty of blame to go around. Clearly Ezekiel’s parents have the primary responsibility for his care, for providing the basic necessities of life, and a jury has now found that they failed to do so.
The prosecuting attorney had this to say:
“They definitely, definitely loved their son but as stated in our closing arguments, unfortunately sometimes love just isn’t enough,” Weich said outside court. “Parents still have to follow a standard of care as set by criminal law.”
The “standard of care” is a critical concept for any modern society. For me, that is what this case (and others like it) is really about.
The Stephans are also simultaneously victims. They consulted a naturopath, and naturopaths are licensed in Canada (and, unfortunately, in many US states). We have written extensively about naturopaths here, showing that they do not base case on a scientific standard. They use an eclectic variety of dubious and unscientific treatments, from homeopathy to “water cures,” that only seem to have in common that they are not based on scientific evidence.
Therefore, how much blame does Canada have for licensing a profession of, essentially, fake medical providers? Governments that legitimize such professions are failing in their duty to their citizens in the same manner that the Stephans failed Ezekiel. Ezekiel’s death is therefore on the heads of the naturopathic profession and the Canadian government as well.
There is also a much more diffuse blame, but still clear, on the entire alternative medicine community. The Stephans did not exist in a vacuum: they are a product of a cultural movement that seeks to legitimize what was considered health fraud just a generation ago. This is what happens when you abandon rigorous science as the basis of a medical standard of care, when you water down that scientific standard, try to subvert the proper functioning of medical science, and lobby for regulations that allow for pseudoscience and just plain bad science in medicine.
The Stephans are not an anomaly – they are a symptom of the intellectual bankruptcy and deception of the alternative medicine movement.
I am glad to hear a lawyer talk about the standard of care, but the irony of this statement is not lost on me either. Governments have been slowly abandoning the defense of the standard of care, and in a way it is hypocritical of them to condemn parents for doing what they have implicitly sanctioned.
Conclusion: Parents Nobody can ignore the basic standard of care
Given the facts as presented, I agree with the jury for convicting the Stephans. This case sets an important precedent: parents cannot ignore basic standards of care for the children under their charge because of their ideology. It doesn’t matter that you truly believe Echinacea can help with a serious infection (it can’t), you still have a responsibility to provide actual health care to sick children.
When such tragic cases occur, it is always my hope that they will help advance the discussion about what a standard of care in health care actually means, and everyone’s responsibility for upholding it. The public’s memory is short, however, and the alternative medicine propaganda machine is tireless.
Unfortunately, Ezekiel probably will not be the last victim of the lies and deceptions of alternative medicine quackery.
ADDENDUM: Orac has also discussed this case.

The Supreme Court of Canada orders a new trial for parents convicted in Ezekiel Stephan’s death
The Supreme Court of Canada has ordered a new trial for David and Collet Stephan, who had been convicted in the meningitis death of their son. The Stephans say they’re vindicated. The facts say otherwise.
Scott Gavura on May 17, 2018
Link

 
In 2016, David and Collet Stephan were found guilty of failing to provide the necessaries of life for their 19-month-old son, Ezekiel, who died of bacterial meningitis. The Stephans had ignored obvious signs that the son was seriously ill, and instead used vitamins, supplements, hot pepper, horseradish, and remedies from the family’s own home business, Truehope Nutritional Support. Ezekiel had never seen a physician in his life. He had received no vaccinations, including vaccination against Haemophilus influenza type b (Hib), a vaccine which protects against bacterial meningitis. And as he lay dying, the parents chose to use an Echinacea tincture recommended by a naturopath, who never examined the boy. His body was so stiff, he couldn’t sit in his car seat, and had to lie in a mattress in their car. The Stephans eventually called 911, but the toddler still died, and the cause of death was subsequently identified as bacterial meningitis.
David Stephan was sentenced to four months in jail. Collet Stephan was ordered to spend three months under house arrest. The Stephans appealed, but the conviction was upheld by the Alberta Court of Appeal in November 2017. However, because the ruling was not unanimous, there was an automatic right of appeal to the Supreme Court of Canada. The Stephans exercised that right.
Monday, the Supreme Court of Canada ordered a new trial. Are the Stephans vindicated? No, not even close.
Ezekiel’s last days
The Canadian Press has a concise summary of Ezekiel’s tragically short life:
August 20, 2010: Ezekiel Stephan is born at home with the assistance of birthing assistant Terry Meynders, who is also a registered nurse.
February 27, 2012: Ezekiel takes ill at the family home in Glenwood, Alta. His mother describes him as having a cold, stuffy nose and trouble breathing. “The sound he was making was heartwrenching. This isn’t the kind of sound you want to hear from your child,” she testifies later at the trial.
February 28-March 5, 2012: Ezekiel is treated for what his parents believed to be croup, an upper airway infection that leads to a barking cough. In addition to regular smoothies, they give the boy olive leaf extract, garlic, hot peppers and horseradish. They also attempt to help his breathing with cool air and a humidifier.
March 5, 2012: Ezekiel seems to improve. His father says the boy is not 100 per cent, but he no longer has any difficulty breathing and is able to go to preschool. He plays with his toys and manages to eat some solid food.
March 6, 2012: Ezekiel suffers a setback. He is “unusually lethargic,” lies in bed the entire day and his only response is to moan unhappily. He doesn’t eat or drink and is exhibiting unusual neurological symptoms.
March 7, 2012: Ezekiel seems to improve again. His abnormal movements stop and he can watch TV, but still isn’t playing normally.
March 8-10, 2012: Ezekiel’s parents note he seems to be gradually improving. He regains a bit of his appetite, but is not active or playful.
March 11, 2012: Ezekiel’s symptoms worsen again. He refuses to eat or drink and is lethargic. His parents notice his body is very stiff.
March 12, 2012: Ezekiel’s body is so stiff that his back is arched. He is getting fluids through an eyedropper because he will not drink on his own. Meynders comes to the home and checks his vitals. She suggests he could possibly have viral meningitis and says she tells the mother she should take the boy to a doctor. “It did not jump out at me that he was that seriously ill,” Meynders testifies.
March 13, 2012: The Stephans head to Lethbridge to pick up an echinacea mixture from a naturopath. Ezekiel is too stiff to sit in his car seat and has to lie on a mattress in the vehicle. Back at home that evening, the boy stops breathing on a couple of occasions before his parents leave home to meet an ambulance. The breathing equipment in the ambulance it too large to properly help a small child. The boy is taken to hospital in Cardston and then to Lethbridge for transport to Calgary by air.
March 14, 2012: Ezekiel arrives at Alberta Children’s Hospital in Calgary where doctors tell the parents the boy is showing very little brain activity and the prognosis is bleak. He is put on life support.
March 16, 2012: Ezekiel dies.
The facts seem clear in this case. Ezekiel was seriously ill with bacterial meningitis, a vaccine-preventable disease. Had he been seen by medical professionals promptly, he might be alive today. His parents endangered his life by ignoring clear signs that he was seriously ill. A registered nurse recommended a physician assessment. The parents ignored this advice.
The Supreme Court of Canada’s decision
The appeal was heard Monday, May 14. The court made the following assessment:
The Supreme Court heard arguments from the couple’s lawyer and the Crown before making the unusual move of ruling immediately from the bench.
Justice Michael Moldaver, speaking for the high court, said the trial judge did not properly instruct jurors on what would be a marked departure from reasonable behaviour “in a way that the jury could understand.”
“Accordingly we would allow the appeal, quash the convictions and order a new trial.”
Karen Molle, lawyer for the Stephans, had argued the trial judge didn’t instruct the jury properly to determine whether the Stephans acted differently than other reasonable parents.
“This jury charge gave this jury little choice but to convict,” Molle said.
Julie Morgan, representing the Crown, said the trial judge’s language was generalized but it was enough for the jury to understand the case.
“The jury would have understood what their job was,” she told the court. “They found that the appellants did not meet the community standard, when they failed to take their child to a doctor when he had meningitis, and that endangered his life.”
And from the CBC:
The Stephans’ defence lawyer, Karen Molle, told the Supreme Court judges that due to the significant “polarization of evidence” and “overabundance of medical evidence,” the charge from Alberta Court of Queen’s Bench Justice Rodney Jerke did not supply jurors with the tools they needed to properly decide the case. In the decision, Supreme Court Justice Michael Moldaver said the panel agreed that the trial judge conflated two elements of the offence to be decided by the jury and failed to sufficiently explain the concept of marked departure in a way the jury could apply and understand it.
And:
The two elements the judges believe were combined by the trial judge are actus reus and mens rea. Actus reus, Latin for guilty act, raises the question of whether the Stephans failed to provide their son with the medical attention that was necessary in the circumstances. Mens rea, Latin for guilty mind, raises the question of what level of risk could objectively be foreseen by a reasonable person. The concept of marked departure was explained by Crown Julie Morgan as actions removed from what a reasonable person would do in a specific situation, in this case meaning not taking a child displaying symptoms of meningitis to the hospital.
Now I’m a pharmacist, not a lawyer, so I will defer to experts for their assessment of the court’s ruling. What it effectively means today is that the Stephans now face another trial:
A spokeswoman for Alberta Justice said the file will return to Lethbridge Court of Queen’s Bench to set a new trial date.
“The Crown has an obligation to continually assess the evidence/file against the prosecution standards of a ‘reasonable likelihood of conviction’ and if it is ‘in the public interest to proceed’ with a case,” said spokeswoman Katherine Thompson.
Although David Stephan said the prospect of a new trial is “deeply uncomfortable for us,” he rejoiced in the Supreme Court’s decision.
“Praise be to the Lord God Almighty!!” Stephan wrote on Facebook.
What is this whole truth that David Stephan says is being withheld or destroyed? Just after the trial, he elaborated a bit – in a clip he described on his Facebook page as “Mainstream Media’s agenda begins to shine through”:
No surprise, David Stephan is as unrepentant as ever. Right from the beginning of the criminal charges, there have been claims of “conspiracy” that have continued through this week. To David Stephan, it’s all about “freedom” versus “Big Pharma” and their agenda…which appears to be, if they do have an agenda, it’s preventing children from dying from meningitis by selling a vaccine that prevents meningitis.
No choice for children harmed by pseudoscience
This is a horrible tragedy, and we haven’t seen the end of the story. Astonishingly, as a glance at the Stephans’ Facebook page shows, there is no shortage of supporters for the Stephans’ actions. Yet no matter how far the Stephans will continue to spin this, they are not victims. Ezekiel, who was denied proper medical care through the Stephans’ neglect, is the only victim. He had no voice, and no choice. If society has a duty to protect children, is it doing enough to prevent cases like these? We will see what the courts have to say.
        ◦ s

The Verdict is In: There is No Justice for Ezekiel Stephan
Ezekiel Stephan died from bacterial meningitis and his parents’ failure to seek appropriate medical care in 2012, and now they have been acquitted after the Supreme Court of Canada ordered a new trial. It appears that there may be no justice for Ezekiel.
Clay Jones on September 20, 2019
Link

In March of 2016, I wrote about the tragic 2012 death of Ezekiel Stephan. Ezekiel, who was not vaccinated, died from a preventable case of bacterial meningitis. As he suffered, being described as so stiff that he could not even be put into his car seat, his parents treated him with useless herbs and sought care from a naturopathic doctor. His parents also ignored advice from a medically trained family friend to seek appropriate medical care. Finally, as his body became overwhelmed with bacterial sepsis and his lungs and brain were developing collections of pus, his parents called emergency medical services but he had no real chance of recovery.
The Stephans were ultimately convicted of failing to provide the necessaries of life and sentenced to a few months of jail and house arrest, but were released early pending the outcome of an appeal. Ezekiel’s parents repeatedly demonstrated a lack of repentance, and his father took to claiming that they were the victims of a government (and Big Pharma) conspiracy. The Court of Appeals rejected the appeal, but because it was a 2-1 decision it was kicked up to the Supreme Court of Canada who would eventually order a new trial.
Yesterday, this new trial concluded with the acquittal of the Stephans. Despite an extremely consistent clinical presentation, the finding of diffuse inflammation/pus around the brain and spinal cord, and positive bacterial cultures in a child who was already not breathing (and almost certainly beyond any chance of recovery) by the time his parents finally chose to call for appropriate medical help, Queen’s Bench Justice Terry Clackson found that Ezekiel had viral meningitis. Furthermore, Clackson found that Ezekiel had died because the ambulance didn’t have the appropriate size oxygen mask and that the Stephan’s didn’t know he had meningitis, two patently absurd assertions clearly refuted by the facts of the case.
The medical examiner who did the autopsy testified that Ezekiel died of bacterial meningitis, but a pathologist called by the defense said the child died from a lack of oxygen to the brain when he was in an ambulance
The pathologist called by the defense was Dr. Anny Sauvageau, Alberta’s controversial former Chief Medical Officer who also disagreed with the same medical examiner in another recent high profile case. Concerns that Sauvageau might be biased were raised in the initial 2016 trial, during which she “promised to be neutral”. More concerning to me is that her disagreement with the medical examiner in this case appears to be based only on a reading of the medical examiner’s report and a 911 call which she cites as evidence that the child was asphyxiated. In a 2018 trial involving another case of parental abuse, she similarly contradicted the findings of a different medical examiner using questionable logic.
The Crown has the right to appeal this ruling, although they have not made any announcement yet in this regard. I hope that they do because I truly believe that the judge is mistaken. I don’t believe that justice has been served in the case of poor Ezekiel Stephan. And his father is already crowing about being vindicated and how this is a win for parental rights. I’ll close with this chilling quote from Judge Clackson:
Ezekiel was indeed sick, but the law does not impose a duty to seek medical attention for every sick child.
I can’t imagine many things more heartless and ignorant than that. Ezekiel wasn’t merely sick. He was in agony. He was intermittently seizing, his head pounding and his neck and back searing as pathogenic bacteria spread from his lungs to his brain through the bloodstream. He didn’t have the developmental capability to understand why, but you can be confident in the fact that he suffered as he slipped into a comatose state from which he would not recover.
Ezekiel, and all the children who have died at the hands of their parents’ world views, deserved better.

Deconstructing Justice Terry Clackson’s outrageous acquittal of David and Collet Stephans for the death of their son Ezekiel
On September 19, in a retrial ordered by the Supreme Court of Canada, Alberta Justice Terry Clackson issued a ruling acquitting David and Collet Stephan of failing to provide the necessities of life to their son Ezekiel, whose bacterial meningitis they had chosen to treat with quackery instead of medicine, leading to his death in 2012. The news reports showed that this was a very bad decision, but you have to read Justice Clackson’s actual decision to see that it’s an even worse decision than the news reports indicate, full of bad medicine, bad science, and even a hint of racism.
David Gorski on September 30, 2019
Link

Last week, Clay Jones wrote about the tragic case of Ezekiel Stephan, specifically how the ruling issued by Justice Terry Clackson a week and a half ago was a massive miscarriage of justice. Ezekiel, you might recall, was the 19-month-old son of David and Collet Stephan. He lived in Alberta with his parents David and Collet until his death from bacterial meningitis in 2012. He was a child who very likely would have lived had it not been for the fact that his parents were (and still are) heavily into alternative medicine. After he fell ill, his parents tried to treat him with “natural remedies”, his wife at one point briefly consulting with a naturopath’s office, until, by the time they sought conventional medical care, Ezekiel was in extremis, at death’s door. Basically, Ezekiel had been ill for a couple of weeks and getting sicker and sicker, but the parents didn’t seek conventional medical care until he stopped breathing, which led them finally to call an ambulance. But it was too late. Ezekiel made it to the hospital, but ultimately died.
As a result, David and Collet Stephan were tried and convicted in 2016 under Section 215 of the Criminal Code which deals with “failing to provide the necessaries of life”. David Stephan was sentenced to four months in jail, and his wife was ordered to spend three months under house arrest. Meanwhile, the Stephans’ appeal went on. (Because the decision to convict hadn’t been unanimous, the Stephans’ case could automatically be appealed to the Supreme Court of Canada.) At the time, I was actually somewhat surprised at the verdict in the first trial, as courts in the US and Canada appear to give parents wide—too wide—latitude for making decisions about what is best for their children, and great deference is generally granted to parental authority and parental “rights.” It is this deference that can cause a problem in protecting children from their parents’ belief in quackery when they become seriously ill. Before the verdict was announced, I had half expected that to happen in this case, the more so because David Stephan is a prominent member of his community, belonging to a family that runs a large nutritional supplement company, Truehope Nutritional Support. Of course, Stephan’s entire business and worldview were (and still are) inextricably linked to what happened, with his belief in “natural healing” having led to Ezekiel’s unnecessary death. That’s one reason why Dr. Jones in an earlier post had explained how Ezekiel’s death was in essence a “death by world view”.
Consistent with the Stephans’ world view believing in quackery, reports from the trial indicated that David Stephan tried to use Truehope supplements to treat his son. As far as David Stephan’s business goes, Health Canada once launched an unsuccessful court case in 2004 to stop the distribution of the company’s product Empowerplus, a product that the company claimed to be able to manage mental illnesses. The case ended in 2006 when the company was found not guilty of distributing the supplement without a drug identification number. Not surprisingly, the Stephans are antivaccine, too, and that quite possibly also had a role in Ezekiel’s death, as you will see.
Unfortunately, the 2016 Stephans’ conviction was overturned on appeal based on a technicality (if you want the gory details, which involved a conclusion that the jury hadn’t been correctly instructed before deliberating, go here), the Supreme Court of Canada ordered a new trial, and on September 19 the Stephans were acquitted after a trial before Justice Terry Clackson. Clay’s post a week and a half ago was about the expressed justified anger, dismay, and puzzlement over the judgment of Justice Clackson. As a CBC news report put it, the Stephans will face no responsibility:
An Alberta couple who treated their son’s illness with natural remedies rather than take him to a doctor have been found not guilty in the toddler’s death after a retrial.
David and Collet Stephan were tried on charges of failing to provide the necessaries of life to 19-month-old Ezekiel, who died in 2012.
Supporters in the courtroom cheered and Collet Stephan cried as she hugged her husband.
Court of Queen’s Bench Justice Terry Clackson spoke to the court in Lethbridge, Alta., for only four minutes on Thursday before releasing his written decision in the judge-alone trial.
Yes, these parents let their child suffer for days and finally die, thanks to their medical neglect, and they’re going free, although the Crown can appeal. Even worse, after the verdict they’ll now be heroes to the alternative medicine crowd in Canada (and, let’s face it, the world), for having been “falsely accused” of child neglect, being “persecuted” by the system, but finally having beaten the charges and found to be “innocent”. Yes, they’ll be heroes. Even worse still, David Stephan can go back to doing what he does best: Grifting in the service of his company’s Truehope supplements and making money by appearing at “natural health” expos, the latter being a revenue stream that his conviction had cut into severely, as expo organizers, facing very negative publicity, dropped him like the proverbial hot potato.
You might wonder why I’m writing about this case again, given that Dr. Jones covered it so recently. The answer is simple. When Dr. Jones wrote his post, Justice Clackson’s full ruling hadn’t yet been published. Now it has been, allowing me to examine in more detail the “reasoning” (such as it is) that led to what is one of the most head scratching, cringeworthy miscarriages of justice I’ve ever seen. At the time, news reports described Justice Clackson’s rationale thusly:
The judge ultimately sided with the defence’s medical experts in finding the boy had viral not bacterial meningitis and ultimately died of a lack of oxygen.
Speaking with the media after the decision was handed down, David Stephan called the last seven years an “emotional roller-coaster.”
“We didn’t know what to expect coming into today, and it’s the right decision, and it’s shocking because it’s been seven years of our life fighting this so it’s become part of our identity,” he said.
“It’s a beautiful thought that we can move on with our lives.”
Stephan said his case “helps protect parental rights” so that parents won’t be held criminally liable if they choose alternative treatments for their sick children.
This is a boy who at autopsy was found to have pus on his brain and an empyema (pus in the pleural cavity surrounding the lungs). You don’t get this from a virus, at least not in the brain. (You can, of course, get a bacterial pneumonia complicating a viral respiratory infection.) Also, as Dr. Jones described in an earlier post, by far the most likely diagnosis was haemophilus influenza, type B (HiB), to which, of course, Ezekiel was vulnerable because he hadn’t been vaccinated. (Indeed, although the medical examiner was unable to culture the HiB bacteria, PCR did apparently detect HiB DNA.) It’s just another indication how the parents’ world view not only predisposed Ezekiel to catch a deadly infection, but greatly diminished his chances of surviving that infection once he had caught it.
Justice Clackson and “accents”
The retrial basically ended up boiling down to a “battle of the expert witnesses”. In the Crown’s corner was Dr. Bamidele Adeagbo, a former medical examiner in Calgary who testified that Ezekiel’s autopsy showed Ezekiel had clearly died from bacterial meningitis. In the defense’s corner was Dr. Anny Sauvageau, who was registered as Anatomo-Pathologist in Quebec until 2011 and is currently not licensed. As Alheli Picazo notes, Dr. Sauvageau’s credentials have also come under scrutiny before. She is not boarded in forensic pathology, either, and does not have a license to practice in Alberta. Nor did she at any point examine the child, basing her conclusions on reading the autopsy report and listening to the 911 calls. In addition, Dr. Sauvageau is suing Alberta Justice for wrongful dismissal, alleging that her position was not renewed after she stood up to political pressure to change a contract for transporting bodies for the Office of the Chief Medical Examiner of Alberta. Indeed, given her pending civil litigation, the Crown’s prosecutor asked how she could be impartial. She claimed that her lawsuit is irrelevant and promised to be neutral.
Of course, I highly doubt Dr. Sauvageau’s “neutrality”. She appears to have a history of being a hired gun (excuse me, “expert witness”) for negligent parents. It turns out that the Stephans aren’t the only dangerously neglectful parents for whom she’s come up with—shall we say?—”creative” alternative explanations for the death of the neglected child. For instance, there was the case of John Clark in Calgary, a child who had been born at home, had never been vaccinated, was not fed properly and had never seen a doctor until the day before he died. Her testimony in the case brought against John’s parents Jeromie and Jennifer Clark was only somewhat less ridiculous than her testimony in defense of the Stephans. John was brought to the hospital malnourished with a clinical picture most consistent with sepsis, and Dr. Sauvageau claimed that it was an overly aggressive correction of the child’s hyponatremia (low sodium) that killed him, not the malnutrition and sepsis. While this story is marginally more plausible (overly aggressive correction of hyponatremia can indeed cause seizures), when taken in context with the whole picture, I have a hard time taking her testimony in this case seriously, either. For instance, Dr. Sauvageau also claimed that John wasn’t septic because there were never any positive blood cultures. This to me indicates that, at the very least, Dr. Sauvageau is well behind the times in her understanding of the pathophysiology of sepsis. In fact, you can be septic and still have persistently negative blood cultures. Indeed, the definition of sepsis no longer even requires a blood culture positive for bacteria, as positive blood cultures are no longer even part of the diagnostic criteria for sepsis. She also claimed that John’s small size was due to a hormonal condition, not malnutrition, based on his “body proportions”.
You get the idea.
Before I delve into Justice Clackson’s defective reasoning in terms of medicine and science, there is an issue that came up late last week that I feel obligated to deal with briefly first. Let’s take a look at Clackson’s characterization of Dr. Adeagbo. It was so bad that there was a complaint of racism:
A group of professors has sent a six-page letter to the body that oversees federally appointed judges, saying language used in a recent ruling that acquitted two parents in the death of their toddler could be perceived as racist.
“We believe that Justice (Terry) Clackson’s choice of words is inappropriate, shocks the conscience, and speaking for ourselves, undermines our confidence in the administration of justice,” says the letter to the Canadian Judicial Council and signed by 42 professors of medicine and law from across Canada.
Dr. Adeagbo is African, Nigerian specifically:
In his ruling, Clackson devotes an entire section to complaining about the way Adeagbo spoke. He says that he is, in part, summarizing the concerns the defence had about Adeagbo’s expertise as a witness but also that he had concerns with the doctor’s garbled enunciation, dropping his Hs and mispronouncing vowels, and his failure to use the appropriate definite and indefinite articles and correct endings for plurals and past tenses.
“Justice Clackson harshly mocked Dr. Adeagbo’s manner of speech and accented English, and thereby inappropriately implicated his national or ethnic origin as a person of African roots,” say the professors in their complaint. “It is hard to imagine that if Dr. Adeagbo, who is of African origin, had spoken in a typically American, Australian, British, or other more familiar accent, Justice Clackson would have been so scathing…”
While Clackson concludes, in the end, the way Adeagbo spoke had no real effect on his credibility as a witness, the letter’s signatories say the judge “formed an inappropriate view that one’s spoken expression, as rooted in one’s national or ethnic origin, is relevant to the weight of one’s testimony.”
If Dr. Adeagbo’s accent as a non-native speaker of English was “irrelevant” to how Justice Clackson viewed his credibility as a witness, then why did Clackson spend so much verbiage basically snarking on his accent? Let’s go to the ruling itself:
Dr. Adeagbo’s evidence was replete with technical medical jargon. His vocabulary was extensive. His ability to articulate his thoughts in an understandable fashion was severely compromised by: his garbled enunciation; his failure to use appropriate endings for plurals and past tenses; his failure to use the appropriate definite and indefinite articles; his repeated emphasis of the wrong syllables; his dropping his Hs; mispronouncing his vowels; and the speed of his responses. In addition, his answers were not always responsive and he would on occasion embark upon a mission to educate the parties and the Court. As a result, there were many instances when it was necessary to have Dr. Adeagbo: repeat his answers; slow down his delivery; focus on the question asked; and accept that, despite our ignorance, the question asked need to be answered. The Transcripts of his testimony are replete with many examples of the foregoing. All of this was exacerbated by the use of a video link as an accommodation to Dr. Adeagbo. However, even when present in person, as he was the final two days of his testimony, the problems I have identified, continued. Nevertheless, the profound difficulty all the participants experienced in comprehending Dr. Adeagbo’s evidence, does not form a basis for a realistic concern that he was biased or partial. In my view, all of those problems are best considered in the Cost-Benefit Analysis and, if his testimony is admitted, in the weight to be given to his evidence.
How nice of Clackson to conclude that his difficulty with English doesn’t mean that Dr. Adeagbo was biased. In any event, does anyone think that Justice Clackson would have written a paragraph like the one above if Dr. Adeagbo were white and had trouble with English because he came from a European country and English was his second language? Wait, we already know. Dr. Sauvageau, I’m told, is French-Canadian and speaks with an accent as well.
Dr. Clackson didn’t stop there, though:
[21] Dr. Adeagbo demonstrated all of the following behaviours and attitudes over the six days of his testimony. He was calm, rationale, reasonable, arrogant, petulant, exasperated, combative, argumentative and angry.
[22] Those attitudes were demonstrated not just verbally but also in Dr. Adeagbo’s movements, body language and physical antics. Again, these behaviours were more prevalent during the video-link presentation. Unfortunately, the Transcript does not adequately capture some of the behaviours I have described. Suffice to say that they were not the behaviours usually associated with a rational professional imparting opinion evidence for the benefit of the Court.
Look, I get it. Dr. Adeagbo might not have been the most likeable witness on the stand, and clearly it’s the prosecutors who messed up if that was the case. Even if he wasn’t the best performing expert witness, I also feel for Dr. Adeagbo. I’m sure being cross-examined by David Stephan (who represented himself) and Collet Stephan’s lawyers for six days was painful and frustrating in the extreme, given how they’ve tried to twist the science and evidence into pretzels of pseudoscience and conspiracy theories and how judges often grant defendants who are representing themselves wider leeway than they do lawyers. I’m also puzzled. Dr. Adeagbo was a medical examiner. Surely he must have testified in dozens of cases. That’s part of the job of a medical examiner, to be the prosecution’s expert witness on cause of death. Has any other justice ever complained about him like this before? I didn’t see any such complaints in the original case. In any event, I can totally understand why he might have gotten frustrated, but obviously wish he hadn’t. Even so, I have a hard time not strongly suspecting that Justice Clackson is racist, given how much verbiage he expended snarking on Dr. Adeagbo’s difficulty with English and his “uppity” manner and how he believed the risibly ridiculous testimony of the defense’s primary expert witness, Dr. Anny Savageau, instead. Also, Dr. Adeagbo was damned if he did, damned if he didn’t. Justice Clackson in essence complained that Dr. Adeagbo used too much jargon and then complained that he kept trying to educate the parties and the court.
The Stephan retrial ruling
Now that that has been dispensed with, let’s look at the balance of Justice Clackson’s ruling itself in which he didn’t concern himself with how annoying he found Dr. Adeagbo’s accent and demeanor. The summary tells the tale, and it’s a horrible one:
[3] The evidence plainly establishes that Ezekiel had meningitis. The main issues in dispute are:
    • Whether he had bacterial or viral meningitis;
    • Whether his death was the result of meningitis, or the result of hypoxic injury;
    • Whether the Stephans knew he had meningitis; and
    • Whether knowing that, they ought to have sought medical intervention.
[4] I have concluded that Ezekiel did have meningitis. The Stephans did not know the Ezekiel had meningitis but were alert to the possibility and monitoring for symptoms. The meningitis Ezekiel had was viral and he did not die from meningitis but from the lack of oxygen. Therefore, I have concluded that the Stephans are not guilty of the charge.
Before I get into the weeds a bit more, let me simply say that the entire premise of Justice Clackson’s ruling is a steaming, heaping pile of fetid dingo’s kidneys. Basically, he’s buying into the Stephans’ nonsense that conflates the final, most proximate cause of death (hypoxia because the child had stopped breathing) with the cause of death (the meningitis that made Ezekiel so sick that he stopped breathing). How did Ezekiel get to that point? He got to that point because his parents didn’t take him to the doctor after he got very sick and instead watched him get worse. True, from previous testimony, we know that Ezekiel did make some improvements, but it’s not unusual in the case of a serious disease for the course not to be an unrelenting downward spiral. It is, however, obvious from previous court cases that Ezekiel’s course was, overall, a downward spiral, with occasional brief improvements. We can argue about how sick a child has to be before the parents have a duty to take him to a doctor, but we already knew quite clearly that not only did the Stephans at least strongly suspect that Ezekiel had developed meningitis, but that they had asked advice of a naturopath. Indeed, here’s testimony quoted in Judge Clackson’s ruling:
Q And during your conversation with Ms. Meynders, did she ever stress that meningitis was an urgent thing that you would have to take him to the doctors for immediately?
A I’m trying to recall our conversation of what she had said. I believe with the one that she was in contact with that few weeks ago was the bacterial, and she had expressed that with bacterial, it – well, if I remember right, she expressed that meningitis was hard to diagnose, and that the bacterial is more concerning than the viral. And when I was looking at the symptoms and reading on that page, it had — it said the same thing that– that she was implying.
Q And when you were reading about the page and comparing, I take it, you compared what Ezekiel was going through to what you found on the page; is that correct?
A Yes.
Q And how did Ezekiel stack up, if at all?
A So when looking at the symptoms, even on the viral meningitis, he just had that achy slash stiff, so, like, the tension of the flu, but he didn’t have any of the other symptoms on the viral. So in my mind, I’m thinking, Well, if it – out of the two, he would — he would be closer to have a viral meningitis rather than bacterial, but at that time, like, it was uncertain.
Q So why didn’t you take him to the doctor at that point?A Because he didn’t really have any symptoms that was listed under the viral and the bacterial meningitis.
Then, as Dr. Jones noted:
Two or three days later, Ezekiel was brought into the same naturopathic clinic where Dr. Tracey Tannis recommended a “tincture of echinacea.” According to a taped March 15th, 2012 interview of his father, Ezekiel was so stiff that they were unable to put him into his car seat, so they laid him flat on a mattress in the back of their vehicle for the ride to the clinic. According to more than one report, Dr. Tannis did not examine Ezekiel.
Neck stiffness is a sign of meningitis, and neck and spine stiffness so bad that the parents couldn’t put Ezekiel into his car seat should be an incredibly worrisome sign to parents that the child is very sick.
What about the issue of whether the meningitis was viral or bacterial? As Dr. Jones described in his earlier post, viral meningitis tends to be significantly less severe than bacterial meningitis and is rarely deadly in an otherwise healthy child. Even so, my first reaction was: Why on earth should it matter? Yes, bacterial meningitis is deadlier but also easier to treat because it can respond to antibiotics, and viral meningitis has to run its course. Seriously, though. It’s part of the Court’s “reasoning” based on its erroneous conclusion that Ezekiel “only” had viral meningitis that the parents weren’t neglectful in not taking him to a doctor or hospital? Judge Clackson should realize that supportive care, such as being placed in a pediatric intensive care unit (PICU), would have maximized Ezekiel’s chances to ride out the a severe case of viral meningitis, and would have allowed a bacterial meningitis to be properly treated.
The Court also ruled that the child died of “lack of oxygen”. Well, yes, that’s what we all die of! It’s basically the common final cause of every death on the planet! The real question should have been: What had caused Ezekiel to stop breathing leading to the “lack of oxygen” that killed him? It’s clear that it was bacterial meningitis! Again, Ezekiel’s death could have been prevented by putting him in the hospital, in the PICU if necessary, for supportive care up to and including mechanical ventilation if it were to become necessary plus appropriate antibiotics, assuming the meningitis was bacterial. Justice Clackson conflated the proximal cause of Ezekiel’s death with the overall cause.
Let’s look at how Justice Clackson came to the conclusion that Ezekiel had viral meningitis, as it reveals even more intellectual bankruptcy. First, he was annoyed by Dr. Adeagbo doing what any responsible doctor would do:
[23] Again, however, while concerning, distracting and unprofessional, none of those attitudes demonstrate a bias or partiality. Rather, all may be attributed to the fact that in Dr. Adeagbo’s opinion, Ezekiel so obviously died of bacterial meningitis that it is a complete waste of time to even consider anything else. Accordingly, those attitudes do not raise a realistic concern that Dr. Adeagbo is not an appropriate expert. Those attitudes are however, relevant in the Cost-Benefit Analysis.
Well, yes, the child had pus on the brain and in his pleural spaces, but, by all means, hearing the hoofbeats, Dr. Adeagbo should have looked for zebras! What do I mean? In medical jargon, a “zebra” is an unexpected, much less common diagnosis relative to the more common ones fitting a given clinical presentation. There’s a saying in medicine that goes something like this:
    • When you hear hoofbeats look for horses not zebras.
    • If you hear hoofbeats in the distance don’t expect a zebra.
    • When you hear hooves think of horses before zebras.
The idea is that common diagnoses are far more likely to explain appropriate clinical presentations than uncommon or rare diagnoses. Sure, there are times when doctors do have to go “zebra hunting“, but from the testimony from the previous trial that I’ve read (and this one), Ezekiel’s was not one of those cases, given the purulence on the brain and in the pleural cavity, plus the presence of HiB bacterial as documented using PCR. In this clinical setting, by far the most likely diagnosis was HiB pneumonia and meningitis, with viral meningitis very much less likely.
Unfortunately, Justice Clackson let Dr. Sauvageau cast doubt on that diagnosis.
[47] Dr. Adeagbo testified that a sample of the right lung tissue across the empyema noted in the pleural cavity was taken and the Gram stain process disclosed Gram negative bacilli which is consistent with bacterial infection. All of which confirmed his opinion that the meningitis had been caused by bacterial infection. He plainly believed the empyema was part of the same bacterial infection which caused the meningitis.
[48] He ignored the presence of enterovirus in the nasal swab/wash. Supposedly, chalking that up to something common in us all.
The pleural cavity is normally sterile. There should be no bacteria there. Moreover, empyema literally means pus in the pleural cavity. As for enterovirus? That’s such an obvious deflection that I think I hurt the bridge of my nose from driving my glasses into it from all the facepalming that I did.
Then there’s this:
[50] Dr. Adeagbo also confirmed his diagnosis of bacterial meningitis by the presence of certain types of white blood cells. Again, Dr. Sauvageau came to a different conclusion. Although her evidence in the 2016 trial on this subject appears less certain then she was before me, I accept her conclusion that the relative prominence of lymphocytes excludes bacteria as the agent of infection.
[51] In result, I was left unconvinced that the meningitis was bacterial.
[52] Dr. Sauvageau explanation for why the meningitis was viral is consistent with what was observed on autopsy, the history of Ezekiel’s illness, the radiology reports, and was logically compelling. As well, Dr. Adeagbo said hemophilus influenza, which is the bacterial agent he concluded had caused the meningitis, is very rare. That fact, plus the fact that the vast majority of meningitis cases are viral in origin (para 62 infra), further supports Dr. Sauvageau’s conclusion.
[53] In result, I am satisfied the meningitis was viral.
Yes, lymphocytic meningitis in the absence of bacteria (so-called aseptic meningitis) is usually viral. However, in the presence of pus on the brain, that consideration goes out the window. Moreover, that lymphocytes predominated does not rule out bacterial meningitis, as it took me all of a minute to find Googling and doing PubMed. For instance:
The CSF findings typical of aseptic meningitis are a relatively low and predominantly lymphocytic pleocytosis, normal glucose level, and a normal to slightly elevated protein level (Table 5). Bacterial meningitis classically has a very high and predominantly neutrophilic pleocytosis, low glucose level, and high protein level. This is not the case for all patients and can vary in older patients and those with partially treated bacterial meningitis, immunosuppression, or meningitis caused by L. monocytogenes. It is important to use age-adjusted values for white blood cell counts when interpreting CSF results in neonates and young infants. In up to 57% of children with aseptic meningitis, neutrophils predominate the CSF; therefore, cell type alone cannot be used to differentiate between aseptic and bacterial meningitis in children between 30 days and 18 years of age.
And it didn’t take me long to find a paper describing acute bacterial meningitis with lymphocyte predominance in 14 out of 103 cases of documented bacterial meningitis, noting that cerebrospinal fluid lymphocytosis was “significantly more common in neonates and in those without meningismus, but occurred in all ages and without any clear identifying clinical characteristics.” (Meningismus refers to the symptoms of meningeal irritation, like stiff neck.) The authors concluded, “It [CSF lymphocytosis] is therefore of little value in differentiating bacterial meningitis from viral, fungal, and tuberculous meningitis.” A review article notes that “WBC differential may be misleading early in the course of meningitis, because more than 10 percent of cases with bacterial infection will have an initial lymphocytic predominance and viral meningitis may initially be dominated by neutrophils.” The Royal Children’s Hospital in Melbourne, for instance, explicitly states that a “predominance of lymphocytes does not exclude bacterial meningitis.”
Yet, risibly, Justice Clackson believed Dr. Sauvageau’s testimony over that of Dr. Adeagbo and even accused Dr. Adeagbo of confirmation bias:
[25] I accept that insight as a reasonable proposition which can be manifested by an expert in the steps he or she takes to defend or explain the opinion reached. In this case, I prefer to apply the label confirmation bias because the cross-examination of Dr. Adeagbo proceeded on that footing. In the cross-examination of Dr. Adeagbo, it was established that he was sure from the beginning that Ezekiel had died from bacterial meningitis. The testing done, post autopsy, was done to confirm that conclusion. There was no specific testing done to rule out viral or fungal causes for the meningitis. Despite records which could tend to support hypoxic injury and hyponatremia, no specific steps were taken to confirm or refute either possibility. These actions are consistent with Dr. Adeagbo’s assertion and attitude, that Ezekiel’s death was a crystal clear case of bacterial meningitis. He had no doubt on the subject. In that circumstance, testing for anything other than the bacteria which caused the meningitis was a waste of time. Dr. Adeagbo said, and I accept that his additional efforts to identify the bacterial agent were not done to support his opinion but done because he wanted to identify the infectious agent as he felt it was his duty to do so in the discharge of his responsibilities to the Stephans and the general public. The duty to keep them safe from a similar fate.
I’m sure any other physicians out there, especially pathologists, are laughing (or crying, or both) at this paragraph. This is how medicine is done. If clinically the case is crystal clear, as it was in Ezekiel’s case, it is a waste of time and resources to do a lot of low yield testing. Moreover, by letting himself get drawn into the “viral versus bacterial” weeds, Justice Clackson again ignored the true cause of Ezekiel’s death: The parents waited until far too late to take him to a doctor, and that’s why he died. Trying to diagnose him on the Internet isn’t enough. Seeking advice from a naturopathic quack (who didn’t even examine him) doesn’t count. At the very latest, when Ezekiel became so stiff that the Stephans couldn’t put him in his car seat, they should have taken him to the nearest emergency room.
But what about all the incriminating things that David and Collet Stephan said to police and first responders, as documented in the first trial? Judge Clackson basically made them all disappear by saying the Stephans were under stress:
[81] That is in stark contrast to the various statements they gave to police and medical staff about their observations and actions.
[82] I have concluded that I cannot rely on any of the statements to the medical staff or the police beyond what Mr. Stephan and Ms. Stephan told 911 Dispatch, the paramedics and Dr. Clark. All of those recorded exchanges are consistent with the circumstances I have just described and the Stephans’ evidence before me.
[83] I do not have evidence as to why honest people commit themselves to false facts, but the case reports confirm it can occur.
[84] Perhaps, as the defence has argued, the combination of stress, suggestion, confusion, lack of sleep, lack of nourishment and the overpowering urge to help save their child, all contributed to the content of the statements they made, in those fateful six days. In any event, I am of the view that those statements are not reliable.
How convenient for the Stephans. Not only did Judge Clackson buy their false narrative and let their obfuscations lead him astray, but he basically magically waved away all their previous statements to police and others about how sick Ezekiel had been.
Reading through the transcript, I got the distinct impression that Clackson had decided that he really didn’t like Dr. Adeagbo and didn’t want to accept his testimony, preferring that of Savageau instead. There are whole sections on voir dire and “cost-benefit” analysis in which he came up as many dubious reasons to discredit and discount Dr. Adeagbo as possible. Why? Was it racism? Possibly. It could also have possibly been because her testimony wasn’t technically beyond his ability to comprehend or because he just didn’t like Dr. Adeagbo’s manner, which he made abundantly clear in a way that stands out strikingly. This ruling is so bad that I really do think that Justice Clackson was not unbiased; he bent over backwards to find a way to rule for the defendants.
This isn’t the only time Justice Clackson has come under fire, either. He has been the subject of media attention and criticism since 2018, when the Supreme Court ordered a retrial after finding that Justice Clackson had relied on rape myths and stereotypes when acquitting a stepfather of sexual abuse charges:
The man, known only by the initials A.R.J.D. ( his name and his stepdaughter’s were under a publication ban) had initially been acquitted at trial by Alberta Court of Queen’s Bench Judge Terry Clarkson .
Clarkson let him go based on his assessment the stepdaughter didn’t do enough to avoid being alone with A.R.J.D, and didn’t display any changes in behaviour such as experiencing nightmares or losing interest in school.
Why is Justice Clackson still a judge?
“Parental rights”: License to kill
Not surprisingly, the Stephans were ecstatic over having been acquitted:
David Stephan speaking now pic.twitter.com/hqj1lniX2l
— Meghan Grant (@CBCMeg) September 19, 2019
Ah, yes, “parental rights,” the all-purpose justification that quackery-loving parents everywhere use to justify medical neglect of their children, be it treating diabetes with prayer instead of insulin, refusing chemotherapy for their children with cancer, refusing to vaccinate their children against potentially deadly diseases, and many other ways that parents abuse and neglect their children by subjecting them to treatments not supported by science. I always note when I come across people like the Stephans invoking “parental rights” that these parents always make it about them and their rights and somehow never seem to bother to consider their children as a separate, autonomous being with rights of his own, which encompass the right to good medical care and not to be subjected to medical neglect. Children are not extensions of the parents’ bodies. The parents do not own their children. They are supposed to be the guardians of the children, and in that role society gives them very wide latitude in deciding how to raise the children (too much, if you ask me). When parents medically neglect their children, then the state has to step in to protect the child’s rights.
Senator Rand Paul once said about school vaccine mandates, “The state doesn’t own the children. Parents own the children, and it is an issue of freedom.” This is the attitude of far too many parents about their children, that they own them. Sadly, it’s not just in the US where there is a widespread view that parental rights are absolute or near absolute and people react with outrage against the state and sympathy for the parents whenever the state tries to intervene. I see this in every single case of medical neglect that I write about on this blog; public opinion is almost always on the side of the parents. Sadly, prosecutors and child protective services know this too, which can’t help but restrain them. As a result, in some places, even parents who justify not treating their children with anything resembling science-based medicine using their religious beliefs have pretty much carte blanche to do whatever they want, to subject their children to whatever treatment or lack of treatment they want. The result? Lots of dead children.
If you want to see just how bad things are in the US, at least, I will briefly recount a case that I’ve discussed several times before, that of Kent Schaible, whose parents Herbert and Catherine Schaible chose prayer instead of antibiotics to treat Kent’s bacterial pneumonia. Their son, two years old at time, had been suffering from a respiratory illness for two weeks. It worsened and developed into pneumonia, as his parents prayed. The parents were convicted of involuntary manslaughter and child endangerment, were sentenced to ten years of probation, and had to promise to take their children to a doctor when they were ill (i.e., “pretty please, promise not to do it again””). That was 2009. Guess what happened in 2013? They did it again! Their 7-month-old son Brandon Scott died of bacterial pneumonia and dehydration, and once again Herbert and Catherine Schaible did nothing but pray as their child’s condition deteriorated until he finally died. It is not exaggerating in the least to say that it took two dead children, both of whom died under similar circumstances, before the state finally acted to protect the Schaible’s other children by taking their children away and sentencing the Schaibles to several years behind for third degree murder. It was nowhere near enough.
We can see this misguided deference to “parental rights” writ large in Justice Clackson’s decision:
[100] It is perhaps helpful to explain this result somewhat differently. Ezekiel was sick. Section 215 of the Criminal Code does not impose a duty to seek medical attention for every sick child. For that duty to arise there must be a risk to the child. In this case, the risk is particularized as a risk to Ezekiel’s life. The cause of that risk is further particularized as resulting from meningitis.
[101] The evidence before me does not establish that the viral meningitis Ezekiel had constituted a risk to his life. Therefore, the duty to seek medical attention did not arise.
[102] Did the duty to seek medical attention arise because Ezekiel had meningitis and his parents were aware that it was possible he had some type of meningitis and aware that some meningitis can be life threatening?
[103] One suspects that many parents when faced with the scenario which presented itself to the Stephans on March 12 would have been perfectly justified in feeling their child needed medical attention.
[104] However, as I said when addressing what the Crown must prove in Element 6, this is not a civil action. The objective analysis of what prudent parents in the circumstances would have done are captured in the other elements of this offence. The duty to act only arises on this charge, as framed, if medical intervention would have saved Ezekiel’s life. That it could have saved his life was not, in my view, sufficient.
This time, the facepalming not only bruised my nose, but it broke my glasses. I wonder if I can bill Judge Clackson for a replacement pair.
Note the argument, though. Justice Clackson seems to be saying that if there was any doubt that getting a child to a doctor would have saved his life, then that’s “reasonable doubt” and that Crown has failed to prove its case. I would counter: There is no reasonable doubt that failing to take Ezekiel to a doctor dramatically lowered his chances of survival to near zero. Even though I’m not a lawyer, even I get the feeling that Justice Clackson’s verdict appears to have been made on a matter not before the court, death as a result of negligence, not the actual charge of failure to provide the necessaries of life.
Also, the law does not impose a duty to seek medical attention for every sick child? Perhaps not—but only if the illness is obviously minor to a reasonable layperson. That was clearly not the case here. Ezekiel was, as we say in the biz, sick as snot and circling the drain. Not to take him for medical evaluation and to opt for treating him with witchcraft was child abuse at its most naked, in my not-so-humble opinion. As for the claim that Ezekiel died of oxygen deprivation because the first ambulance didn’t have the right equipment, it was pretty clear from the medical evidence that it almost certainly wouldn’t have mattered if it had. By the time the parents called EMS, Ezekiel was almost certainly too far gone to be saved. Even if he could have been saved, what about the suffering and long-term sequelae he would have suffered from bacterial meningitis treated too late?
The bottom line is that Justice Terry Clackson issued an utterly nonsensical judgment so divorced from science, medicine, and reality that I would laugh at it if the consequences weren’t so horrific. He believed the testimony of an unqualified doctor who never actually did the autopsy on Ezekiel and used only the autopsy report and the audio recordings of the 911 call and the EMS response over that of a forensic pathologist to acquit David and Collet Stephan. His ruling will both allow David Stephan to continue his grift peddling his useless supplements, which are promoted to treat real diseases and whose use are likely to lead to preventable deaths, and, worse, will likely demoralize child protective service officials and prosecutors, who are likely to think twice prosecuting medical neglect. There will be blood on Justice Clackson’s hands.
I hope that the prosecutors appeal. This ruling must be appealed. Unfortunately, I fear that the prosecutors will look at the multiple legal proceedings, the fact that it’s now seven years since Ezekiel’s death, and public opinion, and decide it’s not worth it.

Washington State’s Unconscionable, Unconstitutional Child Protection Law
Harriet Hall on January 28, 2014
Link
I recently wrote about the conflict between child protection and the religious freedom of believers in faith healing. That issue has reared its ugly head again in the state of Washington.
Washington law currently denies the children of Christian Scientists equal protection under the law governing child abuse and neglect, and it grants a special exemption from criminal prosecution for abuse and neglect to that one specific religion and not to any others. Even if you supported religious exemptions in principle, there would be no excuse for the preferential treatment of one single religion. This law is clearly unconstitutional.
Zachery Swezey didn’t need to die
This law was challenged in the Swezey case. Zachery Swezey was 17 when he died in Spokane, Washington of a ruptured appendix in March 2009. He received no medical treatment because his family belonged to the Church of the First Born, a faith-healing sect that has been responsible for a number of other avoidable deaths of children. See here for links to several of those cases. With medical care, Zachery would almost certainly be alive today. Appendicitis is one of the things conventional medicine is very good at treating; patients rarely die from it anymore; reported death rates are only a fraction of 1%.
Zachery’s parents were tried for manslaughter. The defense argued that the law exempted one faith-healing religion (Christian Science) from prosecution, and there was no rational basis for denying another faith-healing religion (Church of the First Born) the same exemption. The judge ruled that the law had a rational basis because Christian Science practitioners are licensed by the state and required to report child abuse and neglect. The judge was demonstrably wrong. Practitioners are not licensed or accredited by the state and they are not on the state’s list of mandated reporters. There was a hung jury on the manslaughter charges. The parents agreed to a plea deal to avoid jail on the other charges. They will not appeal, so there will be no formal challenge to the law’s constitutionality.
Proposed bill
State Senate bill 6295 was introduced by Sen. Mark Mullet (D) and three other Democratic senators on January 20, 2013, and was referred to the Committee on Human Services and Corrections. Its progress can be followed here.
It proposes to amend RCW 9A.42.005 and3 26.44.020; and to re-enact and amend RCW 26.44.030. The laws were enacted to protect children and dependent persons from abuse and neglect by requiring reporting of abuse and neglect and imposing criminal penalties on those found guilty of such abuse or neglect. The new bill strikes out these sections:
It is the intent of the legislature that a person who, in good faith, is furnished Christian Science treatment by a duly accredited Christian Science practitioner in lieu of medical care is not considered deprived of medically necessary health care or abandoned.
and
A person who is being furnished Christian Science treatment by a duly accredited Christian Science practitioner will not be considered, for that reason alone, a neglected person for the purposes of this chapter.
It adds this section:
Cultural and religious child-rearing practices and beliefs that differ from general community standards do not, in and of themselves, create a duty to report under this section unless there is reasonable cause to believe the practices and beliefs pose a danger to the child’s health, welfare, or safety.
The language being struck out was not even in the original bill as passed by the House and Senate, but was added by a conference committee (6 people charged with reconciling differences between the House and Senate versions of the bill) and was never debated but simply accepted pro forma.
How could anyone object to a state child protection law that requires all parents to provide medical care for seriously ill children? It should be a no-brainer. I wrote to my state senator, Bruce Dammeier (R), asking him to co-sponsor the bill, since bipartisan support would increase its chance of passing. I received no answer, and the bill was introduced with no Republican co-sponsors.
Religious shield laws that exempt members of faith-healing sects from child protection laws and from criminal prosecution for child neglect and manslaughter must be repealed. Adults have the right to reject treatment for themselves, but society has a duty to protect children from parents who would withhold lifesaving treatment and allow their children to die unnecessarily. Society’s duty is widely recognized. Just to give one example, it has long been common practice for courts to intervene and mandate lifesaving blood transfusions for the children of Jehovah’s Witnesses whose religious beliefs prohibit them.
Which way Washington?
It remains to be seen if Washington will go the way of its neighbor Oregon or its other neighbor Idaho. Oregon repealed its religious exemptions; the death rate among faith-healing sects promptly dropped, and parents have since been successfully prosecuted for manslaughter. Idaho maintains its exemptions; its cemeteries are filling up with the graves of children who died without medical care, and the parents are not being prosecuted.

A favorite tactic of the antivaccine movement: When science doesn’t support you, use the law
David Gorski on August 5, 2013
Link
As I’ve joked about before, I’m a bit like Dug the Dog from the movie Up whenever a squirrel goes by. In other words, I’m easily distracted by things that interest my primal urge to chase pseudoscience. I originally had a cancer-related topic in mind for this week’s foray into science-based medicine, but then on Friday our favorite group of antivaccine activists over at the antivaccine crank blog Age of Autism induced a squirrel to run in front of me, and the rest is history, at least for the moment. I’ll try to get back to my original topic either as a bonus post later this week or as next week’s post (unlike the topic of today’s post it’s not really particularly time sensitive). In the meantime, I’ll chase this squirrel. Sorry about that. But Dug’s gotta do what Dug’s gotta do. Besides, the topic I had in mind for this week is sufficiently complex that my ultimate post will probably end up being much better if I have a few more days to a week to think about it. At least, that’s what I keep telling myself.
If there’s one thing I’ve learned over the years opposing the antivaccine movement, it’s that these days its “Holy Grail” (well, a “holy grail”) is to have a “vaccinated versus unvaccinated” study performed, or, as it’s frequently abbreviated, a “vaxed verus unvaxed” study. The reason they want such a study so badly is not because they think there’s a scientific question that genuinely cries out for an answer. Rather, they believe it will confirm their fixed, unalterable belief that vaccines are the root of nearly all chronic health conditions children suffer today, particularly autism and autism spectrum disorders. In particular, they believe that a “vaxed versus unvaxed” study would demonstrate once and for all that vaccines are the cause of the “autism epidemic.” Hilariously, a few years back, the antivaccine group Generation Rescue tried to do such a study. It was more an utterly incompetently administered and analyzed telephone survey than anything else, and, ironically, its results actually were just as consistent with the conclusions that vaccines protect against autism as that they predispose to autism. And don’t even get me started on an even more hilariously incompetent vaxed versus unvaxed study by a German antivaccine homeopath (I know; “antivaccine homeopath” is redundant) that antivaccinationists were touting a while back. That took attempts to ape science to depressingly ridiculous extremes.
Meanwhile, other than incompetently performed studies by antivaccinationists (this one, for instance) many large, well-performed epidemiological studies have failed to find even the suggestion of a link between vaccines and autism or between mercury in the thimerosal preservative that used to be in childhood vaccines and autism, such that the Institute of Medicine reaffirmed this finding just this year. Yet, antivaccinationists remain undeterred. True, they seem to have accepted that their original Holy Grail, namely a prospective randomized, placebo-controlled trial in which one group is vaccinated and another is not, is considered highly unethical because it would intentionally leave one group of children unprotected against vaccine-preventable diseases. (I say “considered” because antivaccinationists are so convinced of the harm done by vaccines that they do not accept that a randomized controlled trial of vaccinated versus unvaccinated children would be unethical in the extreme.) Unfortunately, however, that doesn’t stop them from demanding other forms of vaxed versus unvaxed studies, even though such a study would be difficult, bias-prone, and unlikely to provide a definitive result, as I explained in detail before.
Well, they’re at it again. Antivaccinationists are trying to legislate where they have utterly failed to convince using science. It’s a standard tactic of cranks, but unfortunately there are nearly always credulous legislators who will be duped into going along or who are cranks themselves and therefore go along. Remember Dan Burton? He was antivaccine to the core and used his position as a Representative from Indiana to cause a lot of mischief with hearings on vaccines. Fortunately he’s retired now, but there are still Representatives who are either antivaccine themselves or easily duped into carrying antivaccinationist’s water.
Here’s what I mean. The other day, posted on the antivaccine crank blog, was a call for help by the antivaccine group SafeMinds to support a resolution by the House of Representatives, specifically HR 1757, The Vaccine Safety Study Act:
What is HR1757? – Also known as “The Vaccine Safety Study Act,” this bill, introduced by Rep. Bill Posey (R-FL) and Rep. Carolyn Maloney (D-NY), directs the National Institutes of Health to conduct a retrospective study of health outcomes, including autism, of vaccinated-versus-unvaccinated children, and to determine whether exposure to vaccines or vaccine components is associated with autism spectrum disorders, chronic illnesses, or other neurological conditions.
Currently before the US House Committee on Energy and Commerce, the bill, if implemented, “should bring an answer to this decades-long question,” Rep. Posey stated on the House floor.
No. It. Won’t. It would be expensive, and it would be highly unlikely to provide an answer, for the reasons I pointed out before. Moreover, contrary to the claims in the SafeMinds press release reposted by AoA, there is no compelling scientific rationale for such a study. There are no preclinical data or epidemiological observations that would mandate (or even justify) such a study from a scientific standpoint. Before such a study would be mandated, there would have to be strong evidence of a problem with vaccine safety or indication that vaccines cause autism and chronic health problems. There is no such indication. Fevered dreams of antivaccinationists don’t count.
SafeMinds cites “findings” discovered through a Freedom of Information Act (FOIA) request claiming that “risks of autism, ADD, sleep disorders and speech/language delay were consistently elevated in the more exposed group: Increased autism risk in one-month-old infants with the highest exposures ranged from 7.6 to 11.4 times higher than zero-exposure infants.” No links are provided, but my best guess is that SafeMinds is referring to Verstraeten et al., which is a very old gambit on the part of the antivaccine movement that has no validity but is frequently used to try to provide the impression of a conspiracy and government cover-up. There wasn’t. It’s Simpsonwood all over again, eight years later. Safeminds then cites another study that claims that unvaccinated children had significantly lower emergency room visits. The implication is that unvaccinated children are healthier, but, as has been pointed out before, despite what Brian Hooker says, the study shows nothing of the sort. Indeed, let’s look at what the investigators themselves said about this result:
These results suggest inherent health care–seeking behavioral differences between the 2 groups of parents. For example, published survey data31-32 have shown that parents who choose not to have their children vaccinated are less likely to trust health care professionals and more likely to use complementary/alternative medicine providers than are parents who have their children fully vaccinated. It is therefore possible that parents who delay or refuse immunizations are less likely to use the traditional health care system when their children contract minor acute illnesses but will seek medical care when their children become seriously ill. Such differences could create a selection bias in studies that attempt to examine the risk of potential adverse events following vaccination.
Emphasis mine. There was nothing in the study that claimed to show that unvaccinated children use the ER less because they are healthier.
So what about the bill itself? The introduction and background (called the “Findings”) in HR 1757 start out paying lip service to the importance of vaccines and then move on to a whole bunch of antivaccine tropes before getting to the “meat” of the bill. The bill itself is sponsored by Rep. Bill Posey (R-FL), who appears to be vying for Dan Burton’s position as the most antivaccine member of Congress, so much so that he even participated in a “Congressional panel” at this year’s antivaccine quackfest Autism One in May, following in the footsteps of prior years’ Autism One quackfests.
But what about the bill’s co-sponsor, Rep. Carolyn Maloney (D-NY)? Well, it turns out that she’s very much into antivaccine pseudoscience as well. A quick Google search of her name plus the term “vaccines” brings up a plethora of embarrassment (from a scientific viewpoint that is), much of it right on her very own website. For instance, here she touts Dan Olmsted’s incompetent and incomplete series of news stories claiming that the Amish don’t vaccinate and don’t get autism from back when he was actually a reporter (they do, and they do; it’s a myth that they don’t). She has also been known to grill CDC officials about vaccines, as shown in this YouTube video:
The above video comes from a hearing held by by the House Oversight and Government Reform Committee, chaired by Rep. Darrell Issa (R-CA). One notes that Darrell Issa is not exactly known for being a fan of science. Besides being an anthropogenic global climate change denialist, he’s prone to meddling in peer review and trying to micromanage the National Science Foundation. He’s also at the very least sympathetic to antivaccine views, holding a hearing about the “autism epidemic” and “environmental causes” (translation: it’s the vaccines) last November, a month before Rep. Dan Burton (R-IN) retired. Dan Burton, the chair of the same committee in the 1990s and into the 2000s, used it for no end of antivaccine legislative mischief when he was in control, and Darrell Issa appears to be taking up the antivaccine mantle left behind now that Burton has retired.
In any case, Maloney begins by complimenting Dan Burton for “doing such a fine job” back in the day. She then demands to know why autism prevalence has gone from 1 in 10,000 to 1 in 88, dismissively saying that she “doesn’t want to hear that we have better detection” and claiming that detection would not account for a jump from 1 in 10,000 to 1 in 88. That is, of course, a straw man argument. As I’ve pointed out many times, screening programs, broadening of diagnostic criteria, diagnostic substitution, and better detection can easily account for huge increases in the prevalence of a condition. My favorite example is ductal carcinoma in situ, whose incidence increased 16-fold in 30 years just because of mammographic screening. Other examples include hypertension and hypercholesterolemia. In reality, the prevalence of autism is probably not higher (or at least nowhere as much higher as the antivaccine movement would like you to believe) than 30 years ago. When careful studies are done, it is found that autism prevalence is the same now as it was then. So, right off the bat, we know that Maloney doesn’t want to hear the science-based answer, namely that diagnostic substitution, broadening of the diagnostic criteria, and more intensive screening programs have led to a massive increase in autism prevalence without a real, biological increase. She’s convinced that the vaccine program or some other environmental factor is causing an “autism epidemic,” and she falls for the “too many too soon” trope beloved antivaccinationists. Unfortunately, Colleen Boyle, the hapless CDC official who had to answer, appears completely unprepared for the hectoring about vaccinations to which Maloney subjects her.
I also learned that Rep. Maloney marched with Jenny McCarthy in her infamously pointless antivaccine Green Our Vaccines rally in 2008. I think that says it all about Rep. Maloney. Well, maybe not all. Her performance in last year’s hearing shows that she values anecdote above scientific evidence; she attacks straw men explanations for the increase in autism prevalence (i.e., that it’s just better detection, when it’s a combination of factors); she makes spurious and downright dumb analogies between vaccine manufacturers and tobacco companies; and she’s just plain scientifically ignorant. In other words, she fits the very picture of being antivaccine. The video above demonstrates it beyond debate. Sadly, she is not alone among our legislators.
Rep. Maloney’s clearly the Democratic counterpart to the Republican antivaccine fringe represented by Rep. Posey and former Rep. Dan Burton and has been pushing the dubious vaxed versus unvaxed study resolution for a long time. Indeed, she’s been doing this for years. I do give her some credit for making at least one change from previous versions of the bill, namely pointing out that “Nothing in this Act shall be construed to authorize the conduct or support of any study in which an individual or population is encouraged or incentivized to remain unvaccinated.” One also notes a quack-friendly clause that “To facilitate further research by the Secretary or others, the Secretary shall ensure the preservation of all data, including all data sets, collected or used for purposes of the study under this section.” One wonders whom the “others” are, one does. Does anyone want to take any bets that this clause is designed to make sure that antivaccine groups like SafeMinds have access to the complete data set of such a study to use and abuse for their ideological purposes? One wonders who provides her with these anecdotes, one does. Could it be SafeMinds, The Canary Party, and Age of Autism? Sure, it could.
But what about this time around? Amusingly (if you can ignore the waste of taxpayer money and the antivaccine impetus behind HR 1757), the bill itself demands that the each investigator of the required study:
     1.  is objective;
     2.  is qualified to carry out such study, as evidenced by training experiences and demonstrated skill;
     3.  is not currently employed by any Federal, State, or local public health agency;
     4.  is not currently a member of a board, committee, or other entity responsible for formulating immunization policy on behalf of any Federal, State, or local public health agency or any component thereof;
     5.  has no history of a strong position on the thimerosal or vaccine safety controversy; and
     6.  is not currently an employee of, or otherwise directly or indirectly receiving funds from, a pharmaceutical company or the Centers for Disease Control.
One notes that requirements #3 through #6 pretty much destroy any chance the NIH have of being able to find an investigator who meets requirement #2. As an aside, it’s also amusing to note a reaction to HR 1757 from our old buddy, now the antivaccine Robin to the crazed “health freedom” Batman (Patrick “Tim” Bolen) after having been the Boy Blunder at the antivaccine crank blog Age of Autism before he betrayed AoA and SafeMinds, Jake Crosby, who rants No More Federal Research Fraud – OPPOSE HR1757! His reason for opposing HR 1757 (other than because SafeMinds and AoA are for it)? Because he doesn’t trust the NIH:
In other words, this bill aims to mandate the National Institutes of Health (NIH) to conduct a vaccinated vs. unvaccinated study of autism and other disorders before the NIH and other federal agencies are forced to clean up their act and stop engaging in the institutional research misconduct that causes the vaccine-autism cover-up to persist. Although the initiatives of congressional representatives like Bill Posey and Carolyn Maloney to investigate malfeasance by government agencies should be commended, HR1757 only helps to legitimize and facilitate federal research misconduct by agencies like NIH, while distracting from efforts to expose government corruption. Autism Investigated supports vaccinated versus unvaccinated research conducted by independent researchers at academic institutions, but not conducted by federal agencies that merely pursue predetermined results. NIH is one of those agencies.
Poor Jake. Back when he was in high school and maybe even college I could (sort of) forgive such ignorance, but he’s a graduate student now. Unfortunately, it’s now utterly clear that he is utterly clueless about how the NIH works, which could be a real problem for him if he ever becomes an epidemiologist and wants to apply for research funding. Note that HR 1757 says that the NIH “shall conduct or support” such a study. That means the NIH, if so instructed, could simply issue an RFA (request for applications) for a grant to do a vaxed versus unvaxed study. In fact, that is almost certainly what would happen if this unscientific bill passed; the NIH almost certainly wouldn’t do the study itself; it’s not really well set up to do such a study, but, more importantly, by the very language of the bill it couldn’t. Indeed, perhaps the most amusing part of Jake’s tirade is the lack of insight into this very point. He clearly didn’t even bother to read the bill. Note the clause listed above that the investigators can’t be “currently employed by any Federal, State, or local public health agency.” Here’s a hint for Jake: The NIH is a federal agency. Seriously, I think that Jake’s just phoning it in these days.
I rather suspect that antivaccinationists are so deluded that they don’t realize that this bill actually is against their interests. What do I mean? Easy? Look at criteria #1, 2, and 5 required of any investigators recruited to do such a study. The bill states that any such investigator must (1) be objective; (2) be qualified; and (3) have “no history of a strong position on the thimerosal or vaccine safety controversy.” These three criteria alone completely rule out any investigator that would be acceptable to SafeMinds, as none of their favored investigators fit any of them! I’m also going to emulate Matt Carey the next time I see an antivaccine study and ask if the investigators have a history of a strong position on the thimerosal or vaccine safety controversy. I presume that I can just dismiss studies based on this reason alone; after all fair’s fair. That’s often the main reason why antivaccine groups dismiss the plethora of studies failing to find a link between vaccines and autism.
No, I’m all about the science; so I couldn’t do that.
Antivaccinationists have been trying to legislate science for a very long time now, and Rep. Maloney is just ignorant or antivaccine enough to be willing to be their contact person. Meanwhile, Bill Posey seems to be relatively new at the antivaccine game, but he’s clearly up and coming, and, given that the House is currently controlled by the Republican Party, he’s more likely to do more damage in the short term because he’s part of the majority party. Either way, although I realize that this bill has little chance of passing and that the lack of appropriations for the study suggest that even Reps. Maloney and Posey know it, skeptics and supporters of science-based medicine should still fight fire with fire, I say. I’m willing to bet that there are a lot more science-based people out there than antivaccinationists; so I’ll finish echoing exactly what AoA said. Only, do it from the science-based perspective and use the same tactics to oppose HR 1757:
    • First identify your own Representative in the House by clicking here: http://www.house.gov/representatives/find/.
    • Call and schedule a meeting at their district office and urge them or their staff to sign on to this absolutely critical bill.
    • If they will not commit, indicate you will call back in one week to check on progress and check with Rep. Posey’s office to confirm their commitment to co-sponsor.
    • After Labor Day confirm everything has happened and thank them for their support.
    • Also, let SafeMinds know! Answer the few simple questions on our online survey at: https://www.surveymonkey.com/s/HR1757
At the very least, write letters to your Representatives, real letters on real paper, and to Bill Posey and Carolyn Maloney as well. (E-mails are easier to ignore.) I plan on doing that much at least, even though I’m not a big fan of my current Representative (to say the least). I realize that HR 1757 is a resolution, and I realize that it probably doesn’t have a lot of support. I also realize that it appears to be stuck in committee. Let’s do our best to keep it that way. Never underestimate the antivaccine movement.
Finally, I’m serious about that last bullet point. After all, we’d like SafeMinds to know that they’ve inspired us to stand up for science, wouldn’t we?

CAM Docket: Kardashian Diet Products Klass Action
Jann Bellamy on June 13, 2013
Link
Kim, Khloe and Kourtney Kardashian permit the use of their names and images of their curvaceous bodies to promote “QuickTrim” diet products, a line of dietary supplements making overblown claims typical of the weight loss supplement industry. Their personal testimonies and formidable publicity machine (Kim alone has over 13 million followers on Twitter), “has reportedly generated $45 million in revenue since they struck the deal with New Jersey-based Windmill Health Products in 2009,” according to the N.Y. Post. Naturally, the sisters are paid for their efforts, although how that amount is calculated or how much they receive apparently is not a matter of public record.
Some Quick Trim consumers who are not as enthused about the products as the Kardashians filed two class action lawsuits last year alleging violation of consumer protection and other state and federal laws. One is pending in New York and the other in California. The judge in the California suit issued a preliminary approval of a settlement in March, a subject we’ll get to in a minute.
Keeping up with the Kardashians
For those of you lucky enough to live in a corner of the planet where news of every Kardashian family spat, marriage, divorce, pregnancy, baby and assorted other details of their extensively chronicled lives are not forced upon you via every popular media delivery device available, a bit of background is in order. Kim, Khloe and Kourtney Kardashian are sisters and stars of their own popular American TV reality show, Keeping Up With the Kardashians. The sole premise of the show appears to be that there are a lot of people extremely interested in keeping up with the Kardashians and that premise appears to be correct.
The show, which also features their mother, Kris Jenner, wife of Olympic gold medalist Bruce Jenner (who is not the sisters’ father) and various Kardashian husbands, ex-husbands, boyfriends . . . well, you get the idea. The show generated several reality show spinoffs, Kourtney and Khloe Take Miami, Kourtney and Kim Take New York, and Khloe & Lamar, Lamar being Khloe’s husband, NBA player Lamar Odom. These shows, as well as product endorsements and other commercial activities, have made the sisters multi-millionaires. Apparently these folks employ an army of publicists who ensure that the media, and you, are kept well informed of pretty much everything they want you to know about themselves, which is an awful lot. In short, the Kardashians are famous for being famous.
The New York Lawsuit
Several people who purchased QuickTrim in a number of different states brought suit in New York federal district court seeking compensatory and punitive damages in an amount greater than $5,0000,000 (but not otherwise specified), as well as injunctive relief, on behalf of themselves and a class of other QuickTrim product purchasers. Cowan et al. v. Windmill Health Products, LLC et al., Case No. 1:12-cv-01541-VM-AJP (S.D.N.Y.) has not yet been certified as a class action by the court. The Kardashian sisters, as well as companies involved in the manufacture and sale of QuickTrim products, including GNC, the retail and on-line dietary supplement seller, are named as defendants.
The suit alleges statements made by the Kardashians in advertising and the products’ labels are false and misleading, in violation of various state and federal consumer protection laws. In addition, the suit alleges that QuickTrim’s individual product weight loss and appetite suppression claims and the whole QuickTrim system, which is touted as working “synergistically” to promote weight loss and weight control, are actually drug claims within the meaning of the Food, Drug and Cosmetic Act. Because the products do not have FDA approval, plaintiffs claim their distribution also violates the Act.
The “Quick Trim Weight Loss System” includes:
    • QuickTrim Extreme Burn
    • QuickTrim Fast Cleanse
    • QuickTrim Burn & Cleanse
    • QuickTrim Hot Stix (“an antioxidant rich, delicious berry drink mix”)
    • QuickTrim Sugar & Carb Cheater
    • QuickTrim Fast Shake
    • QuickTrim Satisfy (a “chocolate fudge soft chew” to “help satisfy between meal cravings”)
    • QuickTrim Celluslim (a “body sculpting gel” to fight cellulite, smooth tone and firm, and spot-treat problem areas)
QuickTrim’s claims of easy weight loss and “detoxification” sound depressingly familiar. With apologies for the lengthy quote, the complaint alleges the following product misrepresentations, lifting language directly from product labels and ads:
QuickTrim’s labeling and advertising represents that QuickTrim products (a) are effective for “weight loss,” (b) use “research proven ingredients,” (c) “safely work to help burn calories [and] curb cravings,” (d) that the “sustained release formula allows for greater absorption and controlled release of nutrients providing optimum calorie burning,” (e) are “synergistically designed to work together” with other QuickTrim formulas,(f) “Help Cleanse and Detoxify,” (g) “Help Jump-Start Weight Loss,” (h) “Help Reduce Belly Bloating,” (i) “Help Jump Start Your Weight Loss,” (j) “Help Burn More Calories by Day,” (k) will “Flush Out [your] System Overnight,” (l) “stimulate metabolism to burn more calories and fat through the day,” (m) “help to release and burn stored fat,” (n) “help to remove toxins and impurities out of your system,” (o) “help remove excess water from under the skin,” (p) “Help Block Excess Sugar & Carbs,” (q) “Help Curb Carbohydrate Cravings,” (r) “increase the body’s ability to burn stored fats and decrease the appearance of cellulite while helping increase firmness and elasticity,” (s) “Increase lipolytic effect by 630%,” (t) “Release stored lipids at adipocytes 1064%,” (u) “Reduce indentation by 9.5%,” (v) “Reduce roughness by 32.4%,” (w) “Decrease fat deposits by 33%,” (x) “Help increase circulation to problem areas,” (y) “Help tone, smooth and firm skin,” (z) “attack cellulite by breaking down excess fat stored in the cells,” (aa) “[are] scientifically designed and clinically shown to work with your body naturally to help increase your ability to burn calories,” and also to “reduce carbohydrate cravings,” (bb) “ha[ve] been clinically tested and shown to increase metabolism by burning 278 calories (on average) per day”.
(I’ve removed some of the attorney’s editing, which is necessary for quotations in a document filed with the court but which also makes the quote harder to read.)
I searched the FDA website and could not find that the agency has issued a warning letter to any of the defendants or taken any other regulatory action regarding the QuickTrim products.
Interestingly, according to the complaint, the Kardashian sisters represented that they personally formulated and tested QuickTrim products “to make sure that this was something that really works.” I guess they are scientists in addition to being reality TV stars.
These products are not cheap. You can buy them online for between $12 to $30 a package, depending on the product and the amount supplied, but there is a hefty shipping and handling charge for most sellers, up to $14 per product. A package will last you, again depending on the product, up to 30 days.
The defendants deny any wrongdoing in their answers to the complaint. Specifically, the Kardashian sisters state in their answer
. . .that they have used QuickTrim products, and that they base their statements about QuickTrim products (including on Twitter and Facebook) on their honest opinions, experiences and beliefs about the products.
In a U.S. News & World Report article about QuickTrim and the New York lawsuit, registered dietitian Keri Gans and Adriane Fugh-Berman, a physician and associate professor in the complementary and alternative medicine master’s degree program at Georgetown University Medical Center (sigh), criticized several QuickTrim products and their unproven ingredients. (The reporters said QuickTrim did not respond to repeated requests for comment.)
According to the article, the “Burn and Cleanse 14 Day Diet System” contains products for both morning and evening which provide a total of 400 milligrams of caffeine per day, the equivalent of about 4 cups of coffee, as well as piperine (black pepper) and white willow bark extract, both of which can increase the potency of caffeine.
‘It irritates me that they’re not saying how much caffeine is in these pills,’ Fugh-Berman says. ‘Too much caffeine can make you jittery and increase your blood pressure and pulse. If you pop a couple of these pills with your Starbucks coffee, that’s not good; you could get caffeine poisoning, which can cause heart arrhythmias.’
“IsoCleanse and Flush Herbal Complex,” the evening product, is a combination of “natural” stimulants and bulk laxatives, designed to increase the movement of food and liquid through the body. This is fine, said Fugh-Berman, if you are constipated. If you’re not, “you’ll get diarrhea.” In addition, “stimulant laxatives, of which IsoCleanse is chock-full, can cause your intestines to become dependent on them for stimulation, causing constipation if you stop.”
“Fast Cleanse,” a “48-hour Super Diet Detox,” is a drink rich in fiber ingested four times a day between meals of clear soups, gelatin, fruits and vegetables. This may cause you to drop of few pounds, but Fugh-Berman says you’ll be “putting them right back on.” “Sugar & Carb Cheater” is designed for dieters concerned “that their sugar and carbohydrate intake is keeping them heavy.” I suppose a sensible solution would be to reduce one’s sugar and carb intake, but that’s just me. For those seeking a less taxing solution, the “Cheater” contains chromium, fenugreek seed, bilberry fruit, and vanadyl sulfate and is touted to keep carbs from turning into fat by blocking the enzyme that causes the conversion. To Gans, the registered dietician, “scientifically, it doesn’t make sense . . . It’s offering people false hope.”
Fugh-Berman doesn’t think anyone should take these products. Healther Mangieri, a spokeswoman for the American Dietetic Association added, “The good news is that these products are absolutely not necessary for weight loss. My suggestion is to leave them on the shelf.” Good advice all around.
In March, the judge stayed the New York suit pending the outcome of a proposed settlement in the California case. If the settlement gets final approval, the plaintiffs in the New York suit would be included in the class of QuickTrim product purchasers in the California suit, because its scope is nationwide, unless they opt out of the class, which they say they will do. However, unless their suit covers a different time period than the California action (product purchases made between August 14, 2009 and March 1, 2013), the New York plaintiffs will be able to pursue their claims only as individuals, not as representatives of a class of purchasers, barring some highly unlikely circumstances.
The California Lawsuit
So let us move from the East Coast to the West and to Anaya v. Quick Trim, LLC, et al., Case No. CIV VS 1201177, pending before the Superior Court of the State of California, County of San Bernardino. The same defendants are named, plus Kris Jenner, Jenner Communications, Inc., and additional sellers of QuickTrim products, the CVS pharmacy chain, Walmart, Amazon.com, and Drugstore.com. Also named is Vitaquest International, a New Jersey company that formulates, develops and manufactures dietary supplements for its clients. (I can just imagine the Kardashian sisters in their crisp white lab coats formulating and testing QuickTrim products in the Vitaquest laboratories.) Finally, three corporations with the cutie-pie names Kimsaprincess, Inc., Khlomoney, Inc. and 2Die4Kourt, Inc., are named as defendants.
(And here I will switch, for reasons of economy, from the actual documents filed in the New York action, which can be viewed as they appear in the court’s files for a reasonable charge, to the information available on a website set up by the California settlement administrator, which can be viewed for free. Viewing the actual documents from the California court’s files costs up to $50 per document.)
Like its New York counterpart, this suit seeks certification as a class action on behalf of purchasers of the same eight QuickTrim products. The California state court has issued a preliminary approval of a class action settlement, the details of which can be found on the website, although not nearly as much information as is available in the New York case.
The plaintiff alleges that improper statements were contained on the product labels and in advertisements, and that these statements violate state consumer protection laws and various other state and federal laws. She seeks, among other remedies, damages and injunctive relief. As is usual in such settlements, the defendants deny any wrongdoing.
If the settlement is approved, plaintiff’s counsel will get $250,000 in fees and costs and the named plaintiff, Teresa Anaya, will get $2,500. QuickTrim will have to “redesign its labeling and packaging to restate the nature of its products and its benefits.” Members of the class who file a claim (other than those who opt out of the settlement) receive different amounts depending on where they bought the product and whether they have proof of purchase. Basically, they can get either a refund or a coupon good towards purchase of another QuickTrim product. In other words, the defendants have managed to turn the settlement into a product promotion event.
We’ll have to wait until August, when the settlement proposal will have a final hearing, to find out what happens.
Conclusion
This is yet another tale of outlandish dietary supplement claims, testimonial “evidence” of effectiveness and the failure of the DSHEA to adequately protect consumers by preventing this sort of thing from happening in the first place. As I have said before, lawsuits are not the ideal way of bringing supplement companies and their enablers to justice. But until the federal law is amended, these suits remain the best way to apply some brakes to the runaway dietary supplement industry.

CAM Docket: Functional Endocrinology
Jann Bellamy on November 15, 2012
Link
One of the signature abilities of CAM practitioners is the creation of new diagnostic methods and treatments which convincingly demonstrate they have only a superficial understanding of human physiology. Here at SBM, posts have addressed such sterling examples of this phenomenon as cranial sacral therapy, applied kinesiology and chiropractic neurology. Now we have a new one on the horizon: functional endocrinology.
I don’t know who thought up this idea, but a primary promoter appears to be a Colorado chiropractor, Brandon Credeur, a 2002 graduate of Parker Chiropractic College in Texas. In additional to operating the Functional Endocrinology Center of Colorado, in Denver (where he practices with his wife, Heather Credeur, D.C.), he sold (and may still be selling) practice-building courses on functional endocrinology to other chiropractors.
What is functional endocrinolgy?
That’s a great question. Credeur’s website doesn’t give much of an explanation, although perhaps it is a new “specialty” within “Functional Medicine.” He spends most of his web video presentation on the subject talking about how M.D.s are simply prescribing drugs and not getting to the “root cause” of endocrine disorders, such as diabetes. Or, as he says, M.D.s are simply “bully[ing] the body’s physiology.” He, on the other hand, is able to ferret out what is actually causing these problems by determining exactly why your body is not producing enough hormones and proceeding to make your body produce them on its own, without drugs. He does not tell us specifically what the root cause is, how he finds it, how it his treatments supposedly work, or statistics on his results. (Testimonials, but no statistics.)
Credeur and his clinic have been the subject of a good deal of media scrutiny in the last two years, most notably from Denver’s ABC affiliate, Channel 7, which give some insight into how he operates, including patient interviews, an interview with Credeur, and a video of practice-building seminar. In addition, the Colorado Board of Chiropractic Examiners complaint against him includes copies of his ads.
According to these sources, here is what was going on: Credeur was attracting patients with seminars and “gourmet dinners,” advertised in the newspaper, where diabetics were advised “how you too may be able to reverse your diabetes and put your health on a totally new trajectory” and, like others he’s treated, “walk away from diabetes.” At these events, diabetics were told, a “clinical model for successfully reversing diabetes” would be “revealed.” He also used television commercials promising free consultations.
Some patients said they had no idea Credeur was a chiropractor and thought he was an endocrinologist. According to one, she was told by office staff that Credeur was in fact an endocrinologist and another said his office was “lined with certificates about endocrinology.” His functional endocrinology treatments were described by a patient as “a diet outlined in a book given to all patients, supplements, [and] chiropractic adjustments,” which, as a Channel 7 report pointed out, all Colorado chiropractors are licensed to do.
Another patient reported that she was attracted to Credeur’s free consultations because she had lost her job. She wanted someone to look at a lump on her neck. Creduer told her that it was probably a “thyroid disorder” and said he would get her on a healthy lifestyle and diet. Fortunately, the woman was able to see doctors at a Denver health center and the University of Colorado Hospital, where she was diagnosed with Stage 2, B-cell lymphoma and hospitalized. She too thought Credeur was an endocrinologist.
Credeur’s functional endocrinology is not cheap either. Patients reported paying thousands of dollars. A Channel 7 producer was quoted a fee of $8,600 for six months treatment, all paid up front.
The Colorado Board of Chiropractic Examiners alleged in its complaint that Credeur and other chiropractors under his supervision at the clinic violated state law and regulations by:
    • False and misleading advertising
    • Failure to take a history and do physicals on patients
    • Diagnosing patients with diseases (diabetes and celiac disease), which is beyond the scope of chiropractic practice
    • Telling patients that they could reduce their medications
    • Failure to consult with patients’ physicians
    • Making promises of cures and guaranteed results
    • Failure to keep adequate records
    • Substandard practice
In addition to the state’s complaint, a number of patients are suing Credeur in a civil action. Trial is set for April, 2013.
As well as making money from his clinic, Credeur was conducting functional endocrinology practice-building seminars for chiropractors, who were told in one seminar ad: “Discover How to Attract More Sick Patients With Real Organic & Visceral Illnesses.” His website, HelpMorePatients.com, is no longer available, but a screen shot can be viewed courtesy of the “Way Back Machine” and a video of his practice-building techniques is posted on Channel 7’s website. In it, he brags about taking in over $300,000 a month in cash and advises fellow chiropractors to avoid calling themselves “chiropractors” and to remove chiropractic paraphernalia from their offices.
So what happened to Credeur? We’ll leave that question for later.
Meanwhile, over in Utah
One of Credeur’s chiropractic functional endocrinology students and Parker Chiropractic College classmate, Utah chiropractor Brandon Babcock, has also been the subject of media attention, mostly from the Salt Lake Tribune (here, here, here and here). Babcock makes the same claims about his ability to “reverse” diabetes and the State of Utah brought charges similar to those against Credeur. Here we’ll go into a bit more detail about individual patients to demonstrate what functional endocrinology looks like in operation. (Part of Babcock’s charges have to do with his using a credit scheme to finance thousands of dollars’ worth of treatments, but we won’t go into those here. Patients are referred to by their initials.)
BB: 79 year old female with Type II diabetes, polio, recent heart valve replacement, saw ad that Babcock could reverse her diabetes and signed up for his program. Babcock did not examine BB, ask her about other meds or consult with her physicians, but did tell her to cut back on insulin and diabetes meds. BB called Babcock’s office to report declining health and legs swelling. He never called her back.
TL: 71 year old male suffering from Parkinson’s disease, dementia, thyroid problems, and diabetes. Was given supplements and prescribed “cleasing” techniques, even though he was on a strict diet at health care facility where he lived.
DO: 65 year old male, suffers from diabetes, high blood pressure and high cholesterol, had open heart surgery two years prior to seeing Babcock. Babcock told DO he could get DO off all meds, including heart med. Ordered $2,000 tests (spit DNA and stool) for DO but wouldn’t discuss results. Told DO after 2 months to stop Simvastion and reduce Metforman. When subsequent checkup at Veteran’s Administration health facility showed DO was much worse and cholesterol at dangerous levels, Babcock told DO “Not to worry. Your body is just going through a change.”
TH: 69 year old male diabetic, told by Babcock program could reduce or eliminate his insulin. Several months later TH admitted to hospital for kidney failure and pneumonia and there told to get off program’s diet and supplements.
RK: 83 year old male diabetic, told by Babcock he could reverse his diabetes and get blood sugar down to 110. Ordered same DNA and stool sample as DO. Told RK that without the program RK could have his foot cut off or go blind while driving.
DZ: Elderly female. Without any testing Babcock told her she had Hashimoto’s disease and leaky gut. Upon DZ telling Babcock she was suffering from swollen legs and cramps, he told her to eat more fish. Did not do further exam.
In addition to state administrative charges Babcock is, like Creduer, being sued by former patients, who are trying to get a class action certified of all his elderly patients treated by him for diabetes. In a newspaper report, their attorney said that her clients were charged $6,000 for supplements that cost less than $200 on-line. Babcock has also been charged by the District Attorney with 11 felony counts, 10 counts of exploitation of a vulnerable adult and one count of communications fraud.
What’s happened so far
We’ll get to a status report on these cases, but first, a look at chiropractic scope of practice.
In Colorado,
‘Chiropractic’ means that branch of the healing arts that is based on the premise that disease is attributable to the abnormal functioning of the human nervous system. It includes the diagnosing and analyzing of human ailments and seeks the elimination of the abnormal functioning of the human nervous system by [adjustment or manipulation]. . . and the use of . . . nutritional, and physical remedial measures for the . . . restoration of health . . . and the treatment of human ailments.
Colorado chiropractors cannot prescribe medications, but can prescribe dietary supplements.
Under Utah law,
Practice of chiropractic means a practice of a branch of the healing arts . . . that involves examining, diagnosing, treating, correcting or prescribing treatment for any human disease, aliment, injury, infirmity, deformity, pain, or other condition, . . .
They can advise patients regarding exercise and diet and prescribe dietary supplements, but cannot prescribe medications, although they can advise patients about the possible side effects of medications.
In one Salt Lake Tribune article, Mark Steinagel, director of the state’s Division of Professional Licensing, was quoted as saying that “diabetes treatment is within the scope of a chiropractor.”
The Utah Division of Occupational and Professional Licensing initiated an Emergency Adjudicative Proceeding against Babcock,
upon evidence that the continued practice of Brandon Babcock as a chiropractic physician represented an immediate and significant danger to the public health, safety, and welfare, and that the threat required immediate action by the agency.
The Division made findings of fact, which I briefly summarized above, and suspended Babcock’s license until further hearing. That case remains pending, as do the civil suit and criminal case. His preliminary hearing on the felony charges is set for November 20.
In July of this year, Brandon Credeur entered into a stipulation with the Colorado Board of Chiropractic Medicine (as did his wife) which completely resolves his administrative case. The Board and Credeur stipulated that Credeur did not “completely document his patient interactions in certain records reviewed by the Board” so he agrees to a Letter of Admonition and to future adequate documentation.
That’s it. But the stipulation also says (emphasis added):
The Board affirms that the scope of chiropractic practice includes diagnoses and treatment of human ailments, including those affecting the endocrine system. [Credeur] and the Board expressly agree that it is appropriate for [him] to use the term ‘functional endocrinology’ in his practice name and to describe his services provided that he continues to disclose his credentials ‘D.C.’ when referring to himself as “doctor” to make clear that he is a chiropractor and that his services are provided pursuant to his chiropractic credentials.
The civil suits are still pending. Credeur’s website remains up and running and still advertises functional endocrinology, including his claim that it can reverse diabetes “in as little as three weeks. ”
How ironic that the Babcock, the pupil, got his license suspended temporarily and 11 felony charges, while Credeur, his teacher, got off with a slap on the wrist and a confirmation that his practice of functional endocrinology is perfectly legal. Why the difference in result with similar factual allegations and similar scope of practice statutes?
A bright spot: Texas
Fortunately, M.D.s are on the case in Texas. The Texas Medical Association (TMA) has aggressively pursued chiropractors’ attempts to expand their scope of practice in lawsuits and complaints to the Texas Board of Chiropractors (TBCE). In one recent example, in August the TBCE voted against adopting rules recognizing “chiropractic neurology” as a specialty after the TMA complained. According to a Salt Lake Tribune report, the TMA is also concerned about chiropractors claiming, in TV ads similar to ones appearing in Utah, that they can treat diabetes. While a spokesperson for the TBCE said that chiropractors could “co-manage” diabetes with diet and exercise, the Board is reported to be working on a rule expressly banning chiropractors from treating thyroid disorders and diabetes. However, no such rule has been enacted or is currently proposed according to the TBCE’s website.
Confused?
It is shocking enough that chiropractors think they have the education and training to diagnose and treat endocrine disorders, which simply points up how poorly some of them are educated and trained. In other words, they don’t know enough to know they don’t know enough. It is even more shocking that a state would permit this.
These cases also highlight the mystery surrounding just what it is chiropractors claim they can do, and, more importantly, what are they competent to do. Are they primary care doctors, able to diagnose and treat all comers? Are they musculoskeletal specialists, like physical therapists? Are they limited to “detecting and correcting subluxations?” Can they specialize, as with “chiropractic neurology,” “pediatric chiropractic” and “functional endocrinology?” There is no agreement among chiropractors and no agreement among the states regulating them. If they don’t know, how is a patient supposed to know? Until all of this is resolved, the harm (financially and physically) to patients will go on and chiropractors will continue to profit.
For an update, see CAM Docket: Functional Endocrinology Update

GSK Pays $3 Billion Fine
Steven Novella on July 4, 2012
Link
The following article is reposted from NeuroLogicaBlog. Happy Independence Day to all our American readers.
The pharmaceutical giant, GlaxoSmithKline, has agreed to pay three billion dollars in fines to settle three charges of fraud brought by the FDA. This is the largest health fraud settlement in US history. What are the implications of this settlement for how the pharmaceutical industry is regulated in the US and for the role that “Big Pharma” allegedly plays in US health care?
The three fraud charges admitted to by GSK include promoting the off-label use of two anti-depressant drugs – Paxil and Wellbutrin. In the US drugs are approved for specific indications, and they can only be marketed for those indications. So-called off-label use of drugs, however, is very common. Off-label does not necessarily equate to bad medicine, or to lack of scientific evidence or rationale. Often there is solid basic science and clinical evidence to support a specific use of a drug that is not approved by the FDA. That simply means the manufacturer did not apply to the FDA for that indication, which could simply be because they did not feel they would recoup the millions of dollars they would need to spend to get approval for the additional indication. In other words, FDA approval for secondary indications is as much about marketing and finance as it is about the science.
Regardless of whether or not a specific use is evidence-based, however, the rules regulating pharmaceutical companies are very clear – they cannot market a drug for a non-approved use. Doing so breaks the law. GSK broke the law.
The second charge was that GSK held back data and made unsupported claims regarding its diabetes drug Avandia. The third charge is that their sales force used inappropriate tactics to get doctors to prescribe their drugs, including various forms of “high-priced entertainment” and large speaking fees. This practice has come under heavy scrutiny in the last decade and rules regulating what pharmaceutical reps can give to physicians have been significantly tightened. According to the settlement GSK violated those rules, not to mention basic ethical behavior.
Mark Crislip summarizes the concerns well in an article for Science-Based Medicine. He concludes that pharmaceutical companies give misleading and biased information to physicians, who are influenced by their contact with pharmaceutical reps, and that the best policy is for practicing physicians to keep a healthy distance from reps (no free lunches, no sponsored lectures, no free gifts). This has become voluntary policy in many institutions, including Yale where I work. Access of pharmaceutical reps to physicians is strictly limited.
The debate continues, however, about whether or not there can be a healthy relationship between doctors and pharmaceutical companies, or whether we need an absolute wall of separation between the two. One recent article, for example, found that doctors who have no access to pharmaceutical reps were up to four times slower to adopt new medications than physicians with some access to reps. In addition, they were also four times slower to stop using a drug that has a new black box warning, meaning that negative information about safety has come to light. It seems, therefore, that pharmaceutical companies can be a useful conduit of information to physicians, but that also comes with a lot of baggage. It seems to me that we have two choices. Either we develop new ways of quickly spreading the word about new valuable drugs and new warnings about existing drugs (pushing critical information to physicians), and/or we need to carefully monitor and regulate the pharmaceutical company distribution of this information.
The GSK settlement, in my opinion, is just the most recent evidence that industry cannot be left to their own devices without proper monitoring and regulation. There is a certain efficiency and motivation for innovation in the private sector approach to drug development. That seems worth preserving. But companies are chiefly motivated by profit, and when billions of dollars are at stake there is a huge motivation to bend the rules. We take for granted that companies are going to distort information when marketing their products to the public. Experienced and savvy consumers view all commercial and marketing activity with a skeptical eye and we do need to take some personal responsibility for protecting ourselves (let the buyer beware).
At the same time the public largely expects that with health care issues the government will play some role in protecting the public from fraud, misinformation, unsafe and ineffective products and services. The stakes are just too high to make every consumer fend for themselves in a completely unregulated wild west of health care. In addition the science behind health care products and services is complex, and it is not reasonable to expect the average citizen to be able to sift through complex technical medical research. That is essentially the reason for the existence of the FDA.
I think that with careful, thoughtful, and evidence-based regulations we can have the best of both worlds. We can have a dynamic and innovative pharmaceutical industry that is also regulated to protect the public from misinformation and fraud and to ensure a minimum standard of scientific evidence for safety and effectiveness.
What this recent settlement indicates, in my opinion, is that companies will bend the rules to maximize their own profits, and that effective regulation can bring them into line and protect the public. I also think this settlement is a significant piece of evidence against the typical “Big Pharma” conspiracy theory that government is in the hands of industry. It’s hard to dismiss $3 billion dollars as a slap on the wrist. This was a clear statement.
I hasten to add that everything I said above is also true of other private segments of the health care industry, including the supplement industry (which has large and increasing overlap with the pharmaceutical industry), and the alternative medicine industry. They like to promote this false dichotomy between the business end of medicine they decry and the “holistic” practitioners who just want to help people. This is a fiction. The people most loudly playing that card are also the ones making the most money off of selling their products, services, and information. Supplements and CAM are big business. They routinely misrepresent scientific information, make unsupported claims for their treatments, ignore data about lack of safety or effectiveness, and personally attack anyone who will dare disagree with them. And they are doing this to sell treatments that are scientifically dubious or even disproved, yet they have been remarkably successful in eliminating regulations designed to protect the public from their own fraud.
It is hypocritical to simultaneously call for more pharmaceutical company regulation and less supplement and alternative medicine regulation, but that is what they do. Rather, I think we need fair and consistent science-based regulation across the board. No double standards, no false dichotomies. I agree that GSK should be heavily fined for making unsupported claims for its products. And so should every company selling herbs, supplements, fanciful treatment, and dubious products with unsupported claims. Instead they are shielded by industry friendly and anti-consumer laws crafted by the industry itself.

GSK Investigated for Bribing Doctors
Steven Novella on April 16, 2014
Link
The BBC reports that 11 doctors and a GlaxoSmithKline regional manager in Poland have been charged with alleged corruption. The apparent scheme was simple — GSK sales reps are given targets for new prescriptions for whatever drugs they are promoting. In order to meet those targets, it is alleged that one sales rep agreed to pay doctors £100 to give educational lectures to patients. The lectures never took place, and it was understood that in exchange for the payment the doctors would prescribe more of the rep’s drug.
The case is still under investigation but one doctor has already admitted guilt, stating that the £100 was simply too tempting.
Assuming the charges are upheld, such cases are very damaging to public confidence in the system. This is similar to cases of researchers faking their published research — I cringe every time I read about such cases.
There are some important questions, however: how common are such occurrences? And is this the isolated corruption of these individuals, or is it endemic in the system? The first question is difficult to answer. We can only know about exposed cases. Given the number of physicians and drug reps in the world, however, and the fact that the number of such cases that come to light are relatively few it would seem that such cases are the exception rather than the rule.
The second question is a bit easier to answer, but of course there can always be hidden corruption. GSK, for their part, states that such behavior is against their policy. I certainly hope this is true. GSK has been caught in scandals before. As the BBC reports:
In 2012, GSK paid $3bn (£1.9bn) in the largest healthcare fraud settlement in US history after pleading guilty to promoting two drugs for unapproved uses and failing to report safety data about a diabetes drug to the Food and Drug Administration.
These cases involved illegal activity at the corporate level. The current case most likely represents corruption at the level of the individuals directly involved.
While drug reps are certainly in sales, I have only personally seen a drug rep step over the line on one occasion. A new rep, who was clearly green, actually said to me and my colleague, “What would it take to get you to prescribe more of this drug?” I don’t think he was suggesting anything like bribery, but the statement was clearly inappropriate.
Our response was to end the encounter, and then call his company to report the incident and instruct them never to send that rep to Yale ever again.
There is no way to completely prevent isolated corruption. But we should ask about which policies would best minimize the incentives and opportunities for corruption. One approach, which is gaining favor, is to simply limit access of drug reps to doctors. This has already happened quite a bit. Drug company-sponsored lunches and talks have essentially vanished. Now my interaction is limited to signing for samples.
An even more draconian approach would be to eliminate the sales divisions of pharmaceutical companies. I am not suggesting this, but this would certainly eliminate any problems resulting from sales.
There is a potential downside to this also. There is benefit to be had from the flow of information between professionals and the private sector. Sometimes the goals of sales and good medicine align, when a new drug will improve health outcomes but is underprescribed because word has not penetrated the field yet. Companies can help get the word out and improve health outcomes.
The trick is to provide objective information, not information that is skewed in favor of the drug company. This can be accomplished by simply supporting education and outreach on the part of academics, who themselves will control the content. In my experience this is what happens most often, but obviously there are opportunities for drug companies to put their thumb on the scale, for example by their choice of academics — choosing those whose views happen to align with the company’s goals.
There are also advantages to academics advising private industry, to help them spend their research dollars in a way that is most likely to bear fruit and to meet unmet needs.
There are plenty of other measures that can be taken to minimize corruption short of a total ban on interactions between industry and practitioners and researchers. Perhaps the biggest measure is to manage the culture of the sales division. This flows from the top down — if companies want to keep their names out of the scandal pages and avoid big fines, they need to systematically train their sales reps to follow appropriate behavior, and swiftly and definitively discipline those who stray.
However, no matter what a company tells their employees during retreats and seminars, if the company sets up incentives that encourage corruption, it will still happen. GSK has already stated in response to the current episode that they will end direct payments to doctors for promotional talks, and also that they will eliminate sales goals for their reps.
Conclusion
No matter how a system is configured there is the potential for corruption. Even if the entire pharmaceutical industry were nationalized, there would still be a great deal of money exchanging hands, and this creates the incentive and potential for corruption.
It is critical, therefore, to identify and eliminate systemic corruption or any elements in the system that encourage or make it easy to hide corruption. This is especially important in vital industries, such as pharmaceuticals.
I do think we have been moving in the right direction in the last two decades. The tendrils of drug companies’ sales divisions have been slowly removed from academia and doctors’ offices. Gone are the previously ubiquitous drug lunches, branded gifts, and sponsored trips. There are further steps to be taken, such as those above, to maximize transparency and minimize both actual corruption and the appearance of corruption.
Exposing cases as they come to light, and shaming drug companies into taking corrective action, is an important part of this progress.

Food fights in the courtroom
Jann Bellamy on July 24, 2014
Link
What’s in a name? Will sugar by any other name taste as sweet? Well, yes, but calling sugar “evaporated cane juice” in an ingredient list may get food manufacturers into trouble. Consumers in several class action suits allege that companies are trying to disguise the amount of sugar in their products by calling it something else.
Robin Reese filed a class action suit against Odwalla, a subsidiary of Coca-Cola, saying use of the term “evaporated cane juice” instead of sugar fooled her into thinking she was getting a healthier product when she purchased Odwalla juice. Odwalla told the judge the suit should be dismissed because it’s up to the FDA to decide the issue. The FDA issued draft guidelines, in 2009, taking the position that the term “evaporated cane juice” should not be used because it’s not a “juice” as defined in the Federal Regulations. For unknown reasons, no final guidelines were issued and food companies seem to be honoring the draft guidance more in the breach. The FDA reopened the draft guidelines for comment in March of this year, for 3 months, but still hasn’t decided. Meanwhile, similar class actions against other companies were dismissed or stayed pending the FDA’s making up its mind.
So what’s the difference, if any, between the two? Sugar company Florida Crystals told NPR the two are not the same and that evaporated cane juice is a “natural sweetener with ‘dark golden hues’ and a ‘sweet sugarcane flavor.’” Competitor U.S. Sugar begged to differ. Its rep said they are basically the same thing: “white sugar is stripped of all traces of molasses, while evaporated cane juice still has some little flecks of molasses that give it a darker caramel color.” According to this rep, from a health standpoint, there’s no real difference.
While Odwalla and other food companies may be trying to run from the word “sugar,” makers of high fructose corn syrup should be so lucky. The Corn Refiners Association asked the FDA to allow use of the term “corn sugar” instead of “high fructose corn syrup,” which, in some circles, is the equivalent of saying “poison” on the label. The FDA said no.
It’s only natural. Or not.
“Evaporated cane juice” is small potatoes compared to the food fights over “natural” ingredients. The biggest problem here is that no one really knows what” natural” means, even though it is ubiquitous in food product labeling and advertising.
The whole issue aggravates synthetic biologist Terry Johnson:
“Natural” is a word that has been used in so many contexts with so many different meanings that it’s become almost impossible to parse. Its most basic usage, to distinguish phenomena that exist only because of humankind from phenomena that don’t, presumes that humans are somehow separate from nature, and our works are un- or non-natural when compared to, say, beavers or honeybees.
When speaking of food, “natural” is even slipperier. It has different meanings in different countries, and in the US, the FDA has given up on a meaningful definition of natural food (largely in favor of “organic”, another nebulous term). In Canada, I could market corn as “natural” if I avoid adding or subtracting various things before selling it, but the corn itself is the result of thousands of years of selection by humans, from a plant that wouldn’t exist without human intervention.
Johnson’s comment is part of a terrific list titled “Ten Scientific Ideas that Scientists Wish You Would Stop Misusing” (including “quantum” and “gene”) which, in my opinion, which should be required reading for everyone.
In the last few years, dozens of class action lawsuits have been filed alleging food and other consumer products are labeled “natural” when, according to the plaintiffs, they contain synthetic ingredients. Many consumers believe that “natural” equates with “healthier” so they seek out and purchase products alleged to be made partly or wholly from natural ingredients. Mintel, a market research firm, did a consumer survey reported in a publication called Natural Foods Merchandiser. 60% of consumers read nutrition labels regularly and 51% look for “all natural” on the product label. One suit (over tortilla chips) cited a survey by Consumers Union which found that 86% of consumers understand the term “natural” to mean that the product doesn’t have any artificial ingredients in it.
My source for information on these lawsuits (including the “evaporated cane juice” cases) is a website called “Top Class Actions.” Motto:
Connecting Consumers to Settlements, Lawsuits and Attorneys
For example, here’s a “top class action” from July 11th, titled “Flushmate Toilet Class Action Settlement.”
The manufacturer of the Flushmate toilet flushing system has agreed to pay $18 million to resolve multiple class action lawsuits accusing the company selling a defective product that causes toilets to explode. If you own or owned a toilet equipped with a Series 503 Flushmate III Pressure-Assist Flushing System, you may be eligible to claim money from the class action settlement.
Of course, this suit has absolutely nothing to do with natural products, except in the broadest sense, but I couldn’t resist. To get to the suits we’re discussing in this post enter “natural” in the Top Class Actions search box.
WARNING: This website is not for use by drug and device manufacturers, consumer products manufacturers, financial institutions, publicly traded companies, large employers, or any other persons likely to have issues with the plaintiffs’ bar. Viewing this website may cause a dangerous spike in blood pressure, insomnia, depression, gastrointestinal upset, apoplexy and other symptoms of extreme aggravation.
The “natural” American meal: pizza, soda and cupcakes
My sympathies don’t lie with either side in this fight. One the one hand, it is simplistic to believe that “natural” and “healthier” are synonymous. On the other hand, companies shouldn’t be allowed to get away with false advertising. But is it false? After all, what does “natural” even mean? That’s a question we’ll return to in a minute.
And I have to wonder whether some of the consumers who file these suits are all that concerned about healthier eating. Take a look at the type of products they allege are mislabeled:
    • Waffles
    • Shakes
    • Cookies
    • Crackers
    • Snack bars
    • Enchiladas
    • Pizzas
    • Sodas
    • Ice cream
    • Cinnamon rolls
    • Buttermilk biscuits
    • Cheese
    • Pretzels
    • Chips
    • Bean dip
    • Baking mix
    • Pie
    • Cupcakes
Other consumer products have also been sued in class actions over the “natural” claim as well, including toothpaste, baby wash, sunscreen, shampoo, conditioner, shaving gel, diapers and deodorant.
Products containing GMOs are the subject of several lawsuits, including one against Heinz, alleging its distilled white vinegar is made from GMO corn, which is not really natural. Other suits allege that products containing Vitamin B12, Vitamin D2, niacin, iron, riboflavin, folic acid and ascorbic acid should not be labeled “natural.” Go figure.
The financial reward in these suits is not great, at least not for the members of the plaintiff class. While the total amount of the settlement can range from several hundred thousand to several million dollars, costs and attorneys’ fees must come out of that amount. To recover, individual consumers must file a claim with the court and generally receive only a few cents to a couple of dollars per product purchase, with a limit on the total reward, depending on whether the claimant has a proof of purchase or not. (Who saves grocery receipts in anticipation of a possible consumer lawsuit?) To add insult to injury, a claim will sometimes be rewarded with a voucher for more of the defendant’s products. If the settlement fund is not sufficient to pay all claims, each claim can be reduced pro rata.
For example, in a class action over claims of “natural” ingredients involving several dozen Kashi products, class members will get $0.50 per product, but those without proof of purchase will be capped at $25 total. The total settlement fund is $5 million. (As in all such settlements, Kashi denies plaintiffs’ claims.)
Attorney’s fees can sometimes eat up a substantial chunk of the settlement fund. In a recent class action against the maker of Nutella, plaintiffs claimed the product was misleadingly advertised as a “healthy breakfast food.” The case was settled with an agreement to alter Nutella’s label and advertising as well as a settlement fund of $1.5 million. About two thirds of that went to the attorneys. Three class members challenged the fee amount, arguing that such awards were generally limited to 25%, but a federal appeals court refused to overturn the lower court’s approval of the settlement.
Common sense
Not all plaintiffs have been successful.
An Alabama federal district judge tossed out a class action suit against Citrus World, Inc., makers of Florida Natural orange juice. The plaintiff’s complaint alleged that the juice was mislabeled as pure and natural when, in fact, it is “heavily processed, stored and flavored” before it is put on store shelves. In effect, the judge told the plaintiff to use a little common sense in the grocery store.
The plaintiff makes much ado about believing the packaged containers of orange juice contained ‘fresh squeezed’ orange juice. As a matter of common sense, whatever is in a container on a store shelf with an expiration date some weeks hence cannot contain ‘fresh’ anything. . . The fact that the plaintiff may have believed defendant hired individuals to hand squeeze fresh oranges one by one into juice cartons, then boxed up and delivered the same all over the country does not translate into a concrete injury to plaintiff upon his learning that beliefs about commercially grown and produced orange juice were incorrect.
Class action lawsuits have also been filed alleging orange juice made by Coca-Cola, under the name “Simply Orange,” and Tropicana, is not actually 100% juice nor is it natural. Plaintiffs claim that these companies use “flavor packs” to add back flavor and fragrance that is lost in processing.
So, what is “natural” anyway? That’s a question the plaintiff in a lawsuit against Nestle USA, Inc., couldn’t answer.
The complaint alleged the plaintiff bought Buitoni’s Three Cheese Tortellini and Spinach Cheese Tortellini believing that “all natural” meant they didn’t contain any unnatural, artificial or synthetic ingredients, when, in fact, they contain certain ingredients that aren’t “natural:” xanthan gum, soy lecithin, sodium citrate, maltodextrin, sodium phosphate, disodium phosphates, and ferrous sulfate. She would not have bought them had she known this, according to the complaint. The judge didn’t buy it.
The question before the court (on a motion to dismiss for failure to state a claim) was whether a reasonable consumer would likely to be deceived by the “all natural” claim. The plaintiff’s problem was that she could not provide an objective definition of just what “all natural” means. Basically, if you don’t know how to define it, you can’t say you were deceived by thinking a product failed to live up to the definition of “all natural.” This failure was not for lack of trying.
First, she tried the dictionary definition of “natural:” “produced or existing in nature” and “not artificial or manufactured.” The judge rejected this attempt, saying that consumers are obviously aware that Buitoni pastas aren’t “springing fully-formed from Ravioli tress and Tortellini bushes.”
So she tried again. This time, she argued that none of the ingredients in “natural” products can be “artificial” as that term is defined by the FDA. But the FDA’s definition applies only to flavor additives, not any of the ingredients plaintiff alleged were “unnatural.”
Finally, the plaintiff argued that none of the ingredients in a “natural” product are “synthetic” as defined by the National Organic Program (NOP). Two problems with that argument. First, the pastas weren’t labeled organic, so the NOP didn’t apply. Second, the ingredients plaintiff claimed were “synthetic” are actually permitted in products labelled “organic.”
The judge found, as a matter of law, that the description “all natural” was not deceptive because the actual ingredients were clearly disclosed on the label, quoting from another case where the plaintiff claimed “all natural” was misleading:
Because the labels clearly disclosed the presence of the [allegedly unnatural ingredients] it is not plausible that Plaintiffs believed, based on Defendant’s ‘[o]nly natural ingredients’ or ‘all natural’ representations, that the [product] did not contain [the challenged ingredients]
In other words, read the ingredients list on the label. That’s what it’s there for.

Undermining the regulation of stem cell therapies in Italy: A warning for the future?
David Gorski on May 6, 2013
Link
Stem cells are magical.
At least, if you listen to what docs and “practitioners” who run stem cell clinics in various parts of the world, usually where regulation is lax and money from First World clientele is much sought after, that’s what you could easily come to believe. Unfortunately, it’s not just Third World countries in which “stem cell clinics” have proliferated. For instance, they are not nearly uncommon enough in Europe. The example that is most troubling right now is Italy, and the reason is that there is currently a law being considered that would greatly weaken the regulation of stem cell therapies, so much so that on Friday I saw something that’s fairly rare: a major scientific journal published a pointed editorial about this new law. Specifically EMBO Journal published a commentary by an international group of scientists warning about the path that the government of Italy is considering entitled Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
Stem cell quackery is a very popular form of quackery these days because, well, stem cells are so magical-seeming. You can now find stem cell treatments offered for autism (one of which, offered at a clinic in Costa Rica, I’ve discussed before and involves injecting “stem cells” into the cerebrospinal fluid of autistic children for a cool $15,000). Kent Heckenlively, the man who took his daughter to the aforementioned Costa Rica clinic for this treatment, is not alone in subjecting his autistic child to such unproven uses of stem cells. Just a couple of months ago, a broadcast journalist in the Philippines named Karen Davila took her autistic son to the Villa Medica Clinic in Germany, which offers variants of stem cell therapy. One is known as “fresh cell therapy” and involves harvesting cells from lamb fetuses and injecting them into the patient. The other is called fat stem cell repair therapy, which is claimed to involve harvesting fat from the patient’s abdomen or thigh and then isolating “stem cells” from them to be injected back into the patient’s body.
There’s also a variation on this “stem cell” theme in China, discussed by Steve Novella a few years ago, in which Dr. Hongyun Huang runs a clinic in which he injects “stem cells” claimed to be derived from olfactory sheath cells taken from aborted fetuses into the cerebrospinal fluid of patients suffering from spinal cord injury or motor neuron disease like amyotropic lateral sclerosis (Lou Gehrig’s disease), claiming what can only be referred to as miraculous cures, sadly credulously reported by the press. He’s a little more expensive, in that he charges $20,000 (or at least he did back in 2008, when Steve wrote his post).
It’s not just neurological diseases and conditions for which stem cell treatments are offered, though. Dubious “stem cell” treatments can be easily found for virtually any disease that is currently incurable, chronic, or only treatable with great effort and not-so-great success. The list of diseases and conditions include, in addition to developmental disorders such as autism, neurological injury, and degenerative neurological diseases such as multiple sclerosis, diseases as diverse as heart disease, autoimmune diseases, respiratory disease, HIV/AIDS, diabetes, hypertension, cancer, and, of course, anti-aging. Truly, there is seemingly no disease for which some clinic, somewhere in the world (usually in Central America and China, but sometimes in Germany and the former Soviet Union) won’t be claiming miraculous cures with “stem cells.”
One example, a clinic in the Ukraine called EmCell, advertises its wares with slickly-produced infomercials, chock full of impressive-appearing graphics and animations:
It’s hard not to note that 1994, the year that this clinic came into existence, was long before legitimate stem cell therapy, other than bone marrow transplantation, had progressed to anywhere near being a viable therapy. Notice the claims of patents, mostly in Russia and the Ukraine, but a few European patents and a couple of US patents as well. I looked at one of the US patents. All it is, is a method to prepare a “cell suspension” from human embryos that, or so it is claimed, is suitable for treating HIV. You know what you don’t see on the website? Solid evidence from randomized clinical trials. There are, however, many testimonials. It doesn’t help that well-known antivaccinationist and autism quack (in my opinion) Jeff Bradstreet is apparently the US contact for EmCell.
Of course, EmCell is far from alone; it’s just one of the older and slicker “stem cell” clinics. There are many others, such as the Stem Cell Institute in Panama, the Bio-Cellular Research Organization in Ireland, the Regenerative Medicine Institute in Tijuana, among many others. Astute readers might have noticed that I use scare quotes when I discuss stem cells in the context of these clinics. That’s because it’s very much in doubt in most of these clinics whether what is being administered actually consists of stem cells. That’s where the need for regulation comes in most acutely. It’s also why what is going on in Italy right now is of great concern.
Attacking regulation of stem cell therapies in Italy
It’s been a bad year for Italian science thus far. Just last month, animal rights activists broke into the animal facility at the University of Milan and occupied it. During the occupation, they stole animals and rearranged all the cage cards so that scientists didn’t know which group of animals were which anymore, rendering their work uninterpretable and ruining years of research. Now this. If you think that the “health freedom” movement is limited just to the US and its more libertarian-leaning groups, think again. The EMBO article, by Bianco et al, starts out describing how this proposed law came to be. Noting that this is the first case in which unproven “stem cell” treatments are recognized as legitimate therapy without having been tested in rigorous clinical trials and based only upon flimsy preclinical evidence, “to be made part of a publicly funded, public health care system,” Bianco et al write (note that “MSC” = “mesenchymal stem cell”):
Patients with disparate, severe neurological diseases were and are being treated, and will continue to be treated in a major public hospital in Italy, by intravenous and intrathecal infusions of ‘MSCs’, purportedly prepared according to a unique, novel method of isolation in culture, and in vitro differentiation into neurons. This activity had previously been taking place in Trieste. In Brescia, an official agreement had been stipulated between the public hospital and a private foundation, whereby the foundation was granted permission to prepare cells with the purportedly proprietary method. Cells for infusion into patients were prepared within a GLP lab (not stringent enough for growing cells in culture before use in patients), intended for the handling of bone marrow and cord blood-derived haematopoietic cells. Patients were being treated in the hospital. Patient care in public hospitals in Italy is paid for by the Government.
More information can be found in these news reports in Nature from March and April. Here’s what happened. Apparently, Italy’s health minister, Renato Balduzzi, has been impressed by the blandishments and claims regarding adult stem cell therapy and on March 21 decreed that that a controversial (actually, let’s be honest, a quack) stem cell therapy can continue in 32 terminally ill patients, mostly children, even though the stem cells were not isolated according to Italy’s safety standards. This decision followed a prolonged campaign and media pressure to authorize the compassionate use of the therapy. As noted in this Nature report, hundreds of people protested in Rome on March 23, including a naked woman with pro-stem cell slogans painted on her body.
This particular therapy is marketed by the Stamina Foundation and has been banned multiple times. However, this time the Stamina Foundation has found a winning public relations message, pushing for “compassionate use” of its unproven therapies:
Stamina Foundation president Davide Vannoni, a psychologist at the University of Udine, says that the publicity around the treatment has won him 9,000 new patients. He hopes that further modifications to the law will allow him to expand the therapy.
A month ago, an investigatory television programme, The Hyena, reported that children with incurable diseases such as spinal muscular atrophy were being denied supposedly important treatment, and Italian show-business personalities joined the call to relax rules on stem-cell treatment.
As is my wont, I wandered over to the Stamina Foundation website. Unfortunately, it’s in Italian, and I don’t speak Italian. However, a little Google Translate allowed me to get the gist of what the Stamina Foundation is selling. For instance, this page touts MSC for everything from heart disease, to Parkinson’s disease, to multiple sclerosis, to kidney damage, to type I diabetes, to Alzheimer’s disease, to Huntington’s chorea, to spinal injuries, and just about anything else you can think of. That, in and of itself, should be a massive red flag, of course, coupled with the fact that in the news reports Vannoni admits that he’s never published his outcomes. Moreover, the only published outcome, a small trial involving five babies with type I spinal muscular atrophy treated with Vannoni’s MSCs was published in October and was entirely negative, leading the authors to conclude:
More generally, our findings highlight the risk that the combination of newspaper ‘hype’ and parental ‘hope’, with the support of courts that are sympathetic to families with children with severe disorders, may produce shortcuts in the design of clinical studies that would need more rigorous preclinical information and more accurate safety and efficacy measures and may actually put patients at risk of potential side effects of therapy.
Vannoni’s response? He claimed that the therapy didn’t work because the clinicians did not use his exact cocktail of cells.
Indeed, I can’t help but compare Vannoni unfavorably to Stanislaw Burzynski, who at least has published a few papers and case reports. They might be crappy papers, case reports, and incomplete clinical trials that, when examined closely, don’t support his claims, but he has published. Vannoni, on the other hand, seems not to care about even the appearance of not being a quack.
One aspect that Vannoni does share with Burzynski, however, is his willingness to cynically use desperate patients to try to get approval for his unproven therapies. Indeed, public hospital Spedali Civili of Brescia has been permitting the Stamina Foundation to administer MSC treatment for various neurodegenerative treatments, despite it not being one of the 13 authorized Italian stem cell factories. After an inspection in 2012, the Italian version of the FDA ordered an immediate halt to these treatments, and that’s when the protests began:
But the halt sparked protests among patients’ families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country’s Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation’s treatments at the hospital.
The open letter urged Balduzzi not to succumb to the wave of emotion and pointed out that there was no evidence that MSCs can do what Vannoni and his patients’ parents claim they can do. They also argued that “compassionate use” exemptions shouldn’t be used as a means of weakening regulation of completely unproven therapies. Indeed, it’s worth citing a couple of passages, conveniently translated into English here:
The decision seems to be dictated by emotions raised by public opinion rather than by scientifically based reasons. No scientific evidence whatsoever has been produced suggesting that mesenchymal cells may have any effect on those diseases for which it is claimed they could be employed. Moreover, no scientific description has been given of the method by which it is claimed these cells may be obtained. This seems a real subversion of the scientific and moral foundations of medicine, denying both the dignity and the traumatic experiences of patients and their relatives. We are aware of these issues and they profoundly motivate the scientific community to generate and guarantee accepted, visible and public data that will change any potential scientific hypothesis into an accepted curative procedure.
The scientists also addressed the health freedom issue head on:
The freedom of any citizen to adopt any personal health decision, including the wish to refuse any cure, does not imply that the Government is obliged to authorize all medical procedures that anyone may suggest as appropriate. In fact, although the individual choice to use an imaginary or inappropriate therapy complies with the rights of individual citizens, such therapies should not necessarily be approved by the Government and provided by public or private health structures. It is not the Government’s role to respond to pressure from patients to translate an individual choice into a therapeutic option for ready use in any health structure. Media campaigns should not become instrumental in adopting decisions on medical or health procedures. The right of single individuals to adopt snake oil as a freely chosen drug does not mean that snake oil has to be prepared in hospital pharmacies as a result of Government-authorized procedures.
In other words, the Italian government is on the brink of giving free rein to stem cell quacks, but it’s worse than that. This order, as the scientists point out, in essence allows government-funded facilities to collaborate with stem cell quacks and facilitate their treating patients.
One point that the scientists didn’t really nail, and that’s the issue of informed consent. One notes that Vannoni’s stem cell quackery has no evidence for it published in the peer-reviewed biomedical literature nor any compelling clinical trial results. Consequently, if claims are being made for this treatment it is impossible to give informed consent because there is no evidence upon which to base even a rough estimate of the chances for success weighed against the risks of the treatment. Even worse, we don’t even know that these are really stem cells. Seriously. As the scientists point out, there is no transparency, and if there’s an area of clinical research where transparency is essential, it’s stem cell research.
Sadly, the scientists’ words fell on deaf ears. In fact, Balduzzi had called a scientific review committee to examine the cases and make recommendations. It recommended against authorizing further use of the Stamina Foundation’s stem cells in a public hospital, but Balduzzi ignored the recommendations of his own panel and permitted use of the Foundation’s procedure in a terminally ill three year-old. Indeed, Balduzzi signed the order allowing the bogus MSC therapy to continue at a public hospital. On April 10, the Italian Senate amended Balduzzi’s ministerial decree with a clause that would redefine stem cell therapy as tissue transplantation, thereby releasing it from any regulatory oversight by the government. If this decree is passed by the other parliamentary chamber in Italy, the Camera dei Deputati, then dubious stem cell therapies will be out of reach of Italian drug regulators. One notes that this will be in marked contrast to European Union and US standards, which treat cells removed, treated, and reinfused as drugs, although sadly one also has to note that the attempt to redefine cell therapies as not being drugs but surgical procedures or “tissue transplantation” is not unique to Italy. Regulations for stem cell therapies are in a perpetual state of catch-up.
It’s also hard not to note that the Catholic Church apparently played a role in this scientific debacle. As noted in Nature, Vannoni’s stem cell treatments are not embryonic stem cells; they are claimed to be MSCs; i.e., “adult stem cells.” Because of its opposition to the use of embryonic stem cells, the “scientifically naïve” Vatican is enamored of the sorts of treatments offered by the Stamina Foundation, and indeed even held its Second International Vatican Adult Stem Cell meeting from April 11 to 13, described as “a shamelessly choreographed performance” in which “sick children were paraded for television, sharing the stage with stem-cell companies and scientists desperate to hawk a message that their therapies must be speeded to clinical use” and was framed as a “fight for reason and fairness against an uncaring and intransigent scientific community.”
If you go to the Stem For Life website, you’ll find a lot of anecdotes, some preclinical science described, but not a whole lot of actual compelling evidence. One anecdote in particular is as manipulative as any I’ve ever seen anywhere else. Don’t get me wrong. I do believe that eventually that stem cells, be they adult or embryonic, will be used for more and more therapies and that they will eventually allow the treatment of diseases that we currently cannot treat, but we have to be realistic and understand what is and is not known about adult and embryonic stem cells before they are used as therapies.
Why the Stamina Foundation’s stem cell treatment is highly dubious
All of this brings us back to the EMBO article. I really do have to give the authors credit for a well-written, clear explanation of why MSCs are not ready for prime time yet and therefore why deregulating them, as the Italian government appears to be on the verge of doing, is madness. They pull no punches. First, they argue in a manner that I approve of heartily (and paraphrasing Tim Minchin) that “regenerative medicine must be medicine.” In other words:
Stem cells are not a homogeneous class of cells; ‘stem cells’ are not one-size-fits-all cures. There are different kinds of stem cells in different tissues, and even when the appropriate stem cell is selected for an indication it takes years of research to learn how to administer the stem cell safely and effectively, as demonstrated by the decades of research that was required to transplant bone marrow safely and effectively. The use of stem cells in medicine must remain cognizant not only of the true biological nature of the type of cells considered for use, but also of the biology of the diseases being targeted. Treating patients with disparate neurological diseases with intravenous or intrathecal infusion of MSCs, which is being done in Italy, has no medical rationale.
You can tell a lot about a purported stem cell therapy by how the “stem cells” are isolated and administered. If the physician doing the therapy can’t tell you what specific kind of stem cells he’s using, give a good technical description of how they are isolated and purified, show preclinical evidence demonstrating that they are, in fact, stem cells, and describe how he is going to target them to the correct area, then chances are good that the therapy is dubious. As Bianco et al point out:
In the case of systemic administration of mesenchymal stem cells (MSCs), cells are introduced into the bloodstream, which is not their natural environment. They are infused in the hope that they will reach target organs that do not normally contain MSCs. There is a wealth of knowledge about their function in their natural site (the bone marrow) and a wealth of knowledge on the properties they exhibit in a tissue culture dish. But it is not clear how exogenous MSCs will behave in the brain, kidney, or the lung. As inherently osteogenic and adipogenic cells, MSCs could generate bone or fat in the wrong organs if transplanted in sufficient numbers (Breitbach et al, 2007). MSCs can also embolize in the lungs and damage the local microcirculation. Allogeneic MSCs can trigger an adverse reaction (instant blood mediated inflammatory reaction, IBMIR; Moll et al, 2012), which leads to activation of the coagulation and complement cascades, and to the death of the infused cells. IBMIR can result occasionally in thromboembolism, but we were unaware until recently that IBMIR could be triggered by MSCs. This exemplifies why infusion of MSCs must necessarily be studied in rigorously controlled and monitored clinical trials before such therapies can be considered safe in patients.
In other words, you can’t just inject the cells either into the bloodstream or the cerebrospinal fluid, and hope like hell that they “home in” to the right place and know what to do. It’s not that simple, unfortunately. Adult stem cell therapy works for bone marrow transplantation because progenitor cells are made in the bone marrow and they tend naturally to stay there when the circulation takes them through the marrow. We also have 30 years of experience using adult stem cell therapy for bone marrow transplantation. Bianco et al recount a little history about this pointing out that the first trial using bone marrow transplant between unrelated patients resulted in the deaths of all the recipients in the trial. Indeed, Donnell Thomas, we are told, spent 14 additional years in the laboratory figuring out why donors had to be matched to recipients before transplant, observing that “This illustrates how even the simplest and most promising cell therapies must be studied in depth to be delivered safely and effectively to patients.” He also notes that the situation becomes much more complex for cell therapies in which the scientific rationale for whom they might work is not known, unclear, or unproven.
Basically, it turns out that to date there are very few examples of proven stem cell therapies. There is bone marrow transplantation, of course. There are also corneal resurfacing procedures with limbal stem cells and skin regeneration with epidermal stem cells. There is also decent preclinical evidence and a few case reports for bone regeneration, and it is not unreasonable to hypothesize the use of specific types of stem cells for cardiovascular disease, although progress in this area has been disappointing.
Then, as I’ve pointed out, there’s the whole issue of exactly what kind of cell is being used. Just because someone says they are isolating and using “stem cells” does not mean that what is being isolated and used are, in fact, stem cells. Indeed, Bianco et al get almost downright sarcastic (at least as sarcastic as I’ve seen in a scientific review article) and refer to mesenchymal stem cells as “most suspicious cells,” stating:
Cells that have become known as ‘MSCs’ are locally transplantable, system-specific and self-renewing perivascular progenitors of skeletal tissues, including the haematopoietic microenvironment (Sacchetti et al, 2007). They are found in the bone marrow and have significant potential in medicine and unique biological appeal. It is therefore perhaps not surprising that multiple cases of unauthorized stem cell treatments being offered directly to the public before any approval or evidence of efficacy are centred on the use of the so-called MSCs. Lack of scientific rigour, although not unique to the MSC subfield, has flourished therein. Loose definitions and poor assays have disseminated across the scientific community as ‘gold standards’ (Dominici et al, 2006), creating huge confusion and opening the way to the completely erroneous belief that any culture of cells from any kind of connective tissue is a culture of stem cells. The apparent ease of isolation and culture, and the conceptual confusion between a stem cell as a physical and functional entity, and a culture of cells originating from stem cells ex vivo (Caplan and Correa, 2011), have contributed to the widespread use of such cells worldwide. Their nature as ‘adult’ stem cells has granted license and exemption from unwanted ethical controversy. Pressure towards development of therapies from all funding bodies around the world, a general climate dominated by the need to develop treatments (‘translational medicine’, Zerhouni (2005)) and the very existence of multiple companies ready to commercialize ‘MSCs’ have contributed, in turn, to making this particular biological object prone to misuse in the clinic and user-friendly for ill-intentioned salesmen.
This cannot be repeated often enough. Whenever a stem cell clinic claims to be using “stem cells,” are they really? What is their scientific rationale? What are their preclinical data? Do they really support the use of these cells? In the vast majority of cases, including that of the Stamina Foundation, the answer is no.
Finally, we should think of these cells in the same way we think of any “complementary and alternative therapy”—or any therapy, for that matter—and I have yet to find a better paragraph, even one of mine, arguing for the importance of there being at least a plausible mechanism:
Complementary to empirical clinical trials, a number of studies have been conducted, claiming ‘beneficial effects’ of systemically infused MSCs in animal models. The conceptual design of these studies as ‘clinical trials in a mouse’ is often flawed, detracting from the power of such studies to highlight a robust rationale for subsequent clinical use. Typically, a pharmacological effect is measured, without measuring the dose, kinetics and dynamics of the active principle, unknown at the outset. A putative active principle is often identified ex post through ex vivo reductionistic experiments. These arbitrarily single out a putative ad hoc molecular mechanism out of a maze of possible, pleiotropic, interlocking mechanisms. An arbitrary hypothesis that fits the results is pursued and alternative hypotheses are ignored. In vivo effects are often interpreted in a biased way (e.g., in studies on ischaemic heart disease, size of post-infarct scars is equated to extent of necrosis; effects of cardiac remodelling are ignored). Even though these studies sometimes specifically record the vanishing of infused cells, they fail to relate any claimed effect to kinetics of cell survival. ‘Clinical data in the mouse’ are descriptive and insufficient to offer mechanistic insight. Mechanistic insight is not a dispensable intellectual luxury. It is specifically required to develop effective therapies. It is to this end that we need mechanisms and rationale. MSCs are thought to have a role in treating GvHD and arthritis alike (Keating, 2012), owing to their generic ‘known immune modulatory effects’. The specific immune modulatory effects are not known. We have no way to model and measure them effectively in vitro or in vivo. We have, therefore, no way to distinguish those operating in GvHD from those operating in arthritis, or to tell whether they are the same or different. We have no way to tell whether these effects are unique to MSCs or shared with other kinds of cells, and which ones. While potentially crucial to advance therapies that harness immune modulation, these issues are mostly neglected. Meanwhile repetitive, expensive, small, uncontrolled phase I–II trials with i.v. infusions of MSCs continue to be pursued as useful.
I love two of the sentences in that paragraph; so I will repeat them again: Mechanistic insight is not a dispensable intellectual luxury. It is specifically required to develop effective therapies. Live them. Learn them. Love them. I do, and I try to live by them in my research.
The same admonition could be directed at, say, acupuncture, except that at least MSCs have more plausible mechanisms. However, as Bianco et al point out, preclinical data and understanding are critical to designing clinical trials that can actually give the answer that is being sought. Just taking a bunch of ill-defined cells and willy-nilly injecting them into small groups of patients with wildly disparate conditions with wildly differing mechanisms of disease is likely to be no more informative than taking some needles and sticking them willy-nilly into patients with wildly disparate conditions with wildly differing mechanisms of disease and hoping we’ll gain therapeutic insight.
There can be no compassion without safety and efficacy
One of the most potent arguments for Balduzzi’s decision in Italy is an emotional one: Look at the suffering children! They are dying! How can we possibly deny them this therapy? My response would be to rephrase that a bit by adding specific therapies other than stem cell therapies.
For example: Look at the suffering children! They are dying! How can we possibly deny them MMS enema (bleach enema) therapy?
Or: Look at the suffering children! They are dying! How can we possibly deny them homeopathy?
Or: Look at the suffering children! They are dying! How can we possibly deny them bloodletting?
Sounds ridiculous when put in those terms, doesn’t it? But, even though some day they might turn out to be wonderful treatments, right now stem cells are in the same boat. We do not know if they are effective and safe, and there is an incredible paucity of preclinical evidence to show that they do anything for the deadly diseases for which they are being used in Italy. The argument is that these severely ill children have nothing else going for them, no other therapeutic alternatives; so safety concerns can be thrown out the window. However, terminally ill patients need more safety and protection, and exposing them to unknown risks in a therapy with no evidence of efficacy is, as Bianco et al, put it, ethically unacceptable. Most people would accept the contention that someone who is severely or terminally ill has the right to take risks in search of treatment, but their willingness to take such risks because “they have nothing to lose” makes them vulnerable to any number of unproven treatments or even outright quackery. Without some sound evidence that a treatment might be effective, they are in essence taking all risk with at best an unknown and likely very small chance of benefit and at worst no benefit at all for all the risk. While personal freedom might give them the right to “roll the dice” and take large risks for minimal chance of benefit, neither physicians nor the government are obligated to facilitate their taking such risks. In fact, quite the contrary for physicians, who are ethically bound to give proper informed consent and obligated not to provide treatments without evidence of efficacy. As Bianco et al put it, “There can be no compassion without safety and efficacy.”
One can only hope that the Italian government figures that out before the Camera dei Deputati takes up the minister’s decree.

Nigeria Court Ruling on Benzene in Soft Drinks
A Nigerian court condemned the current level of benzene found in local soft drinks. Was this decision reasonable given the evidence? Is there something else going on here?
Steven Novella on April 5, 2017
Link
A recent ruling by a Nigerian high court judge has sparked a round of online discussion about the safety of certain soft drinks. The ruling actually only affects the Nigerian Bottling Company (NBC) and their manufacturing of certain Coca-Cola products, Fanta and Sprite. Before I get to the court case, here is the background science.
Benzene in soft drinks
Benzene is a known carcinogen. Long term exposure increases the risk of certain cancers, such as leukemia and myeloma. It is therefore the goal of regulatory and health agencies to minimize human exposure to benzene to levels that carry an insignificant risk.
The World Health Organization reports:
Because of the unequivocal evidence of the carcinogenicity of benzene in humans and laboratory animals and its documented chromosomal effects, quantitative risk extrapolation was used to estimate lifetime cancer risks. Based on a risk estimate using data on leukaemia from epidemiological studies involving inhalation exposure, it was calculated that a drinking water concentration of 1 µg/litre was associated with an excess lifetime cancer risk of 10-6 (10 µg/litre is associated with an excess lifetime risk of 10-5 and 100 µg/litre with an excess lifetime risk of 10-4) (15).
A “µg/litre” is a microgram per liter, which is equal to one part per billion (ppb). So regular exposure to benzene in 1 ppb had an increased lifetime risk of cancer of 10-6, which is one addition case per million people.
We are exposed to benzene in gasoline fumes, tobacco smoke, fumes from other products that contain benzene, and a small amount gets into our food and water. Smokers have 3-6 times the exposure to benzene than non-smokers. The WHO also reports that the amount from drinking water is a small overall contribution:
Exposure to benzene may vary considerably. For nonsmokers, the estimated average daily intake is 200–450 µg/day. The estimated contribution from food is 180 µg/day but, as information on benzene levels in food is very scanty, this background level should be considered only as an approximate reference point. For smokers, the intake levels are increased by a factor of 2–3 (urban areas) or 2–6 (rural areas). The levels commonly found in drinking-water are minimal compared with the intake from food and air (3).
Benzene is not directly added to soft drinks, although there may be a tiny amount from the water used to manufacture the drinks. However, benzene can form from a combination of benzoic acid, which is added as a preservative, and ascorbic acid (vitamin C). This reaction is increased by heat and light and inhibited by sugar and EDTA.So, how much benzene gets into soft drinks and how much is allowed? The various regulatory agencies around the world limit benzene from 1 to 10 ppb. At one ppb, if you drank one liter of the soft drink you would consume 1 microgram of benzene. In one review of 28 soft drink products the mean benzene levels detected were 0.45 ppb. In that survey two citrus fruit-based drinks (so they contained benzoic acid and ascorbic acid) exceeded 1ppb.Another survey of 199 soft drinks found:
The vast majority of beverages sampled contained either no detectable benzene or levels below the U.S. Environmental Protection Agency’s drinking water limit of 5 ng/g. Beverages found to contain 5 ng/g benzene or more were reformulated by the manufacturers. The amount of benzene found in the reformulated beverages ranged from none detected to 1.1 ng/g. [1 ng/g is also equal to 1 ppb – SN]
Soft drinks therefore have a very low level of benzene, with the vast majority being lower than the legal limit, but a few having just above the more stringent limits. Now, let’s put this level of exposure into context. Again, 1 ppb would give you one microgram from a liter of soft drink. Let’s use a high estimate of 5 micrograms per day from soft drinks, assuming someone drinks 5 liters a day of a soft drink at the limit of 1ppb.
The WHO, as stated above, estimates that the average person is exposed to 250-400 micrograms of benzene per day. You will inhale 32 micrograms when you fill up your car, and 40 micrograms from driving for one hour. Smokers inhale 2-7 thousand micrograms a day, and passive exposure to smoke contributes an estimated 50 micrograms per day.
Total contribution from food and water is estimated at between 1 and 3 micrograms per day, which is a small contribution to overall exposure.
The Nigerian case
The recent court case decision (the case itself was filed 10 years ago and took this long to get a decision) dealt with a lawsuit from an exporter. They attempted to export Fanta and Sprite bottled in Nigeria by the NBC to the UK. The product was tested on import into the UK and found to exceed their limit on benzoic acid (note – this refers to benzoic acid, not benzene):
The UK standards limit benzoic acid in soft drinks to a maximum of 150 mg/kg. Both Fanta and Sprite have benzoic levels of 200 mg/kg which is lower than the Nigerian regulatory limit of 250 mg/kg when combined with ascorbic acid and 300 mg/kg without ascorbic acid and also lower than the 600 mg/kg international limit set by Codex.
So the product was compliant with Nigerian and international limits, but over the stricter limit for the UK. The case focused on whether or not the NBC and the Nigerian regulatory agency (National Agency For Food and Drug Administration and Control – NAFDAC) was negligent in allowing these higher limits. NBC claimed that they bottle soft drinks for local distribution and comply with local regulations, and their product is not intended to export. The judge, apparently, did not buy this argument:
In her judgment, Justice Oyebanji said: “It is imperative to state that the knowledge of the Nigeria Bottling Company that the products were to be exported is immaterial to its being fit for human consumption. The court is in absolute agreement with the learned counsel for the claimants that soft drinks manufactured by Nigeria bottling company ought to be fit for human consumption irrespective of color or creed.
“It is manifest that NAFDAC has been grossly irresponsible in its regulatory duties to the consumers of Fanta and Sprite manufactured by Nigeria Bottling Company. In my respective view, NAFDAC has failed the citizens of this great nation by its certification as satisfactory for human consumption products, which in the United Kingdom failed sample test for human consumption, and which become poisonous in the presence of Ascorbic Acid ordinarily known as Vitamin C, which can be freely taken by the unsuspecting public with the company’s Fanta or Sprite.”
I’m no legal scholar, but that seems like a massive overreaction to me. It sounds like the judge had a political point to make. They are claiming that these products are poisonous and not fit for human consumption because they contain 200 mg/kg of benzoic acid, when the international limit is 600 mg/kg, but the UK’s limit is 150. Further, all the evidence suggests that even at the higher limit the amount of resulting benzene would be well below safety limits and an insignificant contribution to overall benzene exposure.
As always, the dose makes the poison. And, when considering overall exposure, individual sources should be put into the proper context of how much they contribute. Benzoic acid and resulting benzene from soft drinks is a non-issue. Overall the levels are extremely low, and are a minor contributor to overall benzene exposure. The Nigerian court decision has more to do with political maneuvering than the actual science.

Medical Malpractice Lawsuits
Harriet Hall on July 22, 2014
Link
We hear a lot about medical malpractice suits and how they affect the practice and the cost of medicine. Doctors sometimes get the feeling that a lawyer is looking over their shoulder as they interact with patients, and sometimes they practice “defensive medicine,” ordering unnecessary tests and doing what they think would look best in court rather than what is really in the patient’s best interests. One of my colleagues in the Air Force, a psychiatrist, said at his retirement ceremony that he considered his career a success because he had never been sued. That struck me as a sad commentary on what it means to practice medicine today.
Some of my preconceived ideas on the subject of malpractice were challenged by a recent survey. Medscape asked 3,480 U.S. physicians about their experience with malpractice suits. 60% of responding physicians reported they had never been named in a lawsuit, 31% had been sued in conjunction with other defendants like hospitals, and only 9% were sued as individuals.
Among those sued, the specialties most represented were internal medicine (15%), family medicine (13%), ob/gyn (9%), psychiatry (8%), gastroenterology (6%), cardiology (6%), and pediatrics (5%). Allergy/immunology was the lowest at 0.4%. Part of the variation is likely a reflection of the numbers of doctors practicing each specialty.
Reasons for the lawsuit: failure to diagnose (35%), failure to treat (17%), informed consent (4%), and other (45%, some legitimate and some clearly opportunistic). One respondent was sued after a laparoscopy by a patient who complained that she could no longer eat big meals and enjoy steaks; she neglected to reveal that between the laparoscopy and the suit, she had a gastric bypass and stomach stapling.
23% of respondents said the experience of being sued was horrible, one of the worst experiences of their lives. Some described harassing phone calls, a near-divorce, and a decision to stop practicing OB.
1% expected the lawsuit, 24% suspected there might be a lawsuit, and 74% had no inkling they would be sued.
We hear the horror stories about huge judgments, but most lawsuits don’t even go to trial. In 5%, the case went to trial but was settled prior to a verdict; in 16% the case went to trial and a verdict was rendered. In the rest of the cases, the suit was dismissed or settled out of court, either before or after depositions.
Even if the case didn’t go to trial, being sued was time-consuming. 28% of doctors spent more than 40 hours meeting with attorneys, gathering records, and preparing for depositions.
The length of the entire lawsuit process was most likely to be 1-2 years (39%); 28% lasted 3-5 years, and 11% went on for more than 5 years.
Outcomes: voluntarily dismissed by plaintiff (22%), dismissed by the court (13%), settled before trial (35%), settled at trial (3%), jury returned a verdict in favor of the doctor (13%), jury returned a verdict in favor of the plaintiff (2%).
Monetary award: None (57%), up to $500,000 (34%), up to $2 million (9%), over $2 million (2%).
62% thought the result of the lawsuit was fair. Only 7% thought saying “I’m sorry” would have helped. One who didn’t think so commented that a patient’s wife had interpreted his apology as an admission of guilt and a reason to sue. In most cases, defense lawyers were provided by the insurer. 70% were completely satisfied with their lawyers, 1% thought they were incompetent and destroyed the case. Some insurance policies have a “required to settle” clause; doctors were required by their insurer to settle in 9% of cases and encouraged to settle in 21%. Insurance covered the entire payout in most cases. Patients’ reactions to lawsuit: 91% said their patients didn’t know about it or didn’t mention it; in only 1% of cases, some patients left the doctor’s practice. Long term effects: 29% said they no longer trust patients and treat them differently, 6% left the practice setting, 63% reported no effects.
When asked about the worst thing about the trial, emotions came through loud and clear. One doctor was asked to “list the date, publisher, and title of every book, magazine, journal you own and/or subscribe to.” One complained that the plaintiff’s attorney lied; another said the judge fell asleep during the trial.
Advice to avoid lawsuits:
    • Follow up even when you don’t think you have to
    • Practice more defensive medicine (One commented that “It is perfectly legitimate to order every test that you feel is acceptable to prevent another suit.”)
    • Document more often, more thoroughly; document even cursory conversations.
    • Get rid of rude, demanding, noncompliant patients.
I don’t know if we should believe the Medscape study, since it was based on physicians’ voluntary responses to a questionnaire and may not have been a representative sample of the physician population. A 2011 study in The New England Journal of Medicine was based on more objective data from a large liability insurer and it got rather different results. It found that 7.4% of physicians are sued every year, with the highest rates among neurosurgeons (19.1%), cardiothoracic/vascular surgeons (18.9%), and general surgery (15.3%), and much lower rates for family medicine (5.2%), pediatrics (3.1%), and psychiatry (2.6%). It estimated that by the age of 65 years, 99% of physicians in high-risk specialties and 75% of physicians in low-risk specialties have been sued. 78% of malpractice cases did not result in payments to claimants; when they did, the median payment was $111,749. The highest mean payment was in pediatrics, over $500,000. Recently there has been a trend to decreasing amounts, not increasing.
According to some reports the number of malpractice suits and the cost of malpractice insurance are both decreasing. One source estimates that the average insurance premium for surgeons is $10,000; for internal medicine specialists, $4-6,000. But premiums vary widely by location, insurer, specialty, and type of coverage. The standard rate for a neurosurgeon practicing in Long Island in New York State is $331,295.
Various studies estimate that malpractice coverage and defensive medicine account for 2-11% of total health care spending.
I don’t question that patients should be compensated for injuries due to physician malpractice, but unfortunately the “system” tends to hurt some good doctors who are practicing good medicine, and some doctors who should lose their license get away with egregious malfeasance because they are able to inspire loyalty from their patients. I remember hearing about a surgeon whose patient returned complaining of pain. He did an x-ray, saw that he had left a surgical clamp in her abdomen, and instead of apologizing or even admitting that he had done anything wrong, he told the patient “I think that clamp has just about finished doing its job now, and we can take it out.” He charged her full price for a second surgery; she remained oblivious and was grateful for what she thought was his thorough, attentive care.
I wonder if there isn’t some better way. Hospital M&M (morbidity and mortality) conferences do a good job of not only identifying errors but of helping doctors learn from them. Judges and juries aren’t as capable of understanding the intricacies of the medical issues involved. In an ideal world, some independent body of medical experts could determine whether standard medical practice was followed and whether the physician made a mistake, and could advise the courts on the medical merits of the case. In the real world, doctors will just have to keep paying those insurance premiums, documenting everything, improving communication, and earning their patients’ trust. And lawyers will not lack for business.

Lying for the State
Peter Lipson on March 30, 2012
Link
Quacks lie. In some ways, that’s what separates us from them. Real doctors are stuck with the messy truth: with bad news, with uncertain outcomes. It’s this reliance on the truth which gives us much of our credibility.
Laws forcing doctors to lie to patients take me back to reading Kundera in the 80s; the hovering fear that everyday actions might bring the authorities to your door. These feelings affect every portion of your life, whether you are a patient or a doctor. Lying in service of the state is pervasively oppressive. Laws requiring doctors to lie have become a popular tactic in the abortion wars.
Let’s look at Texas’s law, it’s requirements, and internal contradictions.
Sec. 171.012. VOLUNTARY AND INFORMED CONSENT.
(a) Consent to an abortion is voluntary and informed only if:
(1) the physician who is to perform the abortion informs the pregnant woman on whom the abortion is to be performed of:(A) the physician’s name;(B) the particular medical risks associated with the particular abortion procedure to be employed, including, when medically accurate:(i) the risks of infection and hemorrhage;(ii) the potential danger to a subsequent pregnancy and of infertility; and(iii) the possibility of increased risk of breast cancer following an induced abortion and the natural protective effect of a completed pregnancy in avoiding breast cancer;(C) the probable gestational age of the unborn child at the time the abortion is to be performed; and(D) the medical risks associated with carrying the child to term;
We have encountered a problem. Informed consent is a medical term d’art that protects both the patient and the doctor. To the extent possible, a doctor must communicate risks and benefits of a proposed procedure in a way the patient can understand and acknowledge. These risks and benefits are not set in statutes but found in the medical literature. Statistics such as complication rates of various procedures are usually easy to find and to cite.
The statute does not use the medical definition of informed consent but it’s own concoction. It throws in “…when medically accurate…” but then insists that the doctor state information that is counterfactual (that is, a lie). In this section, the most glaring lie is that abortion is associated with breast cancer. It most certainly is not. And where are the “benefits” in “risks and benefits”? It is implied that there are none.
What about the next section?
(2) the physician who is to perform the abortion or the physician’s agent informs the pregnant woman that:(A) medical assistance benefits may be available for prenatal care, childbirth, and neonatal care;(B) the father is liable for assistance in the support of the child without regard to whether the father has offered to pay for the abortion; and(C) public and private agencies provide pregnancy prevention counseling and medical referrals for obtaining pregnancy prevention medications or devices, including emergency contraception for victims of rape or incest;
The above section is slightly murkier. It looks superficially to be innocent enough, perhaps even compassionate. This makes the lie even more dangerous. The section infantalizes the woman seeking an abortion, assuming that she needs this information to make her choice. Likely, she’s already made her choice. It’s not up to a doctor to give information that is clearly designed to topple the patients autonomy. It’s also only somewhat factual. “Medical assistance may be available…” (emphasis mine). I’m sure that’s very comforting, a real promise of assistance (sarcasm mine). I’m sure that the state can hunt down the father and find a way to make him pay child support (additional sarcasm), assuming the patient feels this is wise, safe, and desired (although the patient’s desires aren’t taken into account here). And then there are “referrals” to agencies that provide pregnancy counseling (often thinly-veiled anti-abortion offices) and to “emergency contraception” for rape and incest. If they are seeking an abortion, it’s a bit late for Plan B. And why only for rape and incest? According to the law, the crime must be reported in order to avoid some of this law’s consequences. This is problematic in ways that would take another full post.
This section assumes that it is economics or assault driving the patient to choose an abortion, that it is not a well thought-out choice by an adult who wishes control over her own body. It makes the woman invisible, except for her womb.
The following section goes on to delineate exactly how the doctor is to perform the state-mandated rape of the patient with an ultrasound probe*. This violation of trust between the physician and patient is too obvious to mention, but mention it I will. It’s bad enough to demand we lie, but to demand we commit rape is, it would seem, obviously bad.
The statute also requires the doctor to give the patient a booklet full of misinformation about abortion with trumped up descriptions of risks, and no discussion of benefits.
The statue does a lot of bad things I haven’t listed, as do similar statues being passed in other states. The point here is not that statues that essentially outlaw abortion, infantalize and shame women, and require forcible penetration are bad. Any sensible person knows this.
The other consequence is the complete destruction of the doctor-patient relationship. If the state can compel a doctor to lie to a patient in one circumstance, it can in any circumstance, and patients will no longer be able to believe anything a doctor says. They would be fools to trust us.
When the state can demand that we violate our basic responsibility to our patient—that of delivering the truth—we are no better than quacks, and deserve no better than quacks.
________________________*
Here is the ultrasound part of the statue for your revulsion:
(A) the physician who is to perform the abortion or an agent of the physician who is also a sonographer certified by a national registry of medical sonographers performs a sonogram on the pregnant woman on whom the abortion is to be performed;(B) the physician who is to perform the abortion displays the sonogram images in a quality consistent with current medical practice in a manner that the pregnant woman may view them;(C) the physician who is to perform the abortion provides, in a manner understandable to a layperson, a verbal explanation of the results of the sonogram images, including a medical description of the dimensions of the embryo or fetus, the presence of cardiac activity, and the presence of external members and internal organs; and(D) the physician who is to perform the abortion or an agent of the physician who is also a sonographer certified by a national registry of medical sonographers makes audible the heart auscultation for the pregnant woman to hear, if present, in a quality consistent with current medical practice and provides, in a manner understandable to a layperson, a simultaneous verbal explanation of the heart auscultation;(5) before receiving a sonogram under Subdivision (4)(A) and before the abortion is performed and before any sedative or anesthesia is administered, the pregnant woman completes and certifies with her signature an election form that states as follows:“ABORTION AND SONOGRAM ELECTION
(1) THE INFORMATION AND PRINTED MATERIALS DESCRIBED BY SECTIONS 171.012(a)(1)-(3), TEXAS HEALTH AND SAFETY CODE, HAVE BEEN PROVIDED AND EXPLAINED TO ME.(2) I UNDERSTAND THE NATURE AND CONSEQUENCES OF AN ABORTION.(3) TEXAS LAW REQUIRES THAT I RECEIVE A SONOGRAM PRIOR TO RECEIVING AN ABORTION.(4) I UNDERSTAND THAT I HAVE THE OPTION TO VIEW THE SONOGRAM IMAGES.(5) I UNDERSTAND THAT I HAVE THE OPTION TO HEAR THE HEARTBEAT.(6) I UNDERSTAND THAT I AM REQUIRED BY LAW TO HEAR AN EXPLANATION OF THE SONOGRAM IMAGES UNLESS I CERTIFY IN WRITING TO ONE OF THE FOLLOWING:___ I AM PREGNANT AS A RESULT OF A SEXUAL ASSAULT, INCEST, OR OTHER VIOLATION OF THE TEXAS PENAL CODE THAT HAS BEEN REPORTED TO LAW ENFORCEMENT AUTHORITIES OR THAT HAS NOT BEEN REPORTED BECAUSE I REASONABLY BELIEVE THAT DOING SO WOULD PUT ME AT RISK OF RETALIATION RESULTING IN SERIOUS BODILY INJURY.___ I AM A MINOR AND OBTAINING AN ABORTION IN ACCORDANCE WITH JUDICIAL BYPASS PROCEDURES UNDER CHAPTER 33, TEXAS FAMILY CODE.___ MY FETUS HAS AN IRREVERSIBLE MEDICAL CONDITION OR ABNORMALITY, AS IDENTIFIED BY RELIABLE DIAGNOSTIC PROCEDURES AND DOCUMENTED IN MY MEDICAL FILE.(7) I AM MAKING THIS ELECTION OF MY OWN FREE WILL AND WITHOUT COERCION.(8) FOR A WOMAN WHO LIVES 100 MILES OR MORE FROM THE NEAREST ABORTION PROVIDER THAT IS A FACILITY LICENSED UNDER CHAPTER 245 OR A FACILITY THAT PERFORMS MORE THAN 50 ABORTIONS IN ANY 12-MONTH PERIOD ONLY:I CERTIFY THAT, BECAUSE I CURRENTLY LIVE 100 MILES OR MORE FROM THE NEAREST ABORTION PROVIDER THAT IS A FACILITY LICENSED UNDER CHAPTER 245 OR A FACILITY THAT PERFORMS MORE THAN 50 ABORTIONS IN ANY 12-MONTH PERIOD, I WAIVE THE REQUIREMENT TO WAIT 24 HOURS AFTER THE SONOGRAM IS PERFORMED BEFORE RECEIVING THE ABORTION PROCEDURE. MY PLACE OF RESIDENCE IS:__________.________________________________________SIGNATURE DATE”;

Enbrel for Stroke and Alzheimer’s
Steven NovellaonMay 8, 2013
Link
A recent article in the LA times tells of a husband’s quest to find a treatment for his wife’s Alzheimer’s disease. This is a narrative that journalists know and love—the brave patient or loved-one who won’t accept the nihilism of the medical establishment, who finds a maverick doctor willing to buck the system.
The article itself at least was not gushing, it tended toward a neutral tone, but such articles do tend to instill in the public a very counterproductive attitude toward science and medicine. I would have preferred an exposé of a dubious clinic exploiting desperate patients by peddling false hope. That is a narrative in which journalists rarely engage.
The story revolves around Dr. Edward Tobinick and his practice of perispinal etanercept (Enbrel) for a long and apparently growing list of conditions. Enbrel is an FDA-approved drug for the treatment of severe rheumatoid arthritis. It works by inhibiting tumor necrosis factor (TNF), which is a group of cytokines that are part of the immune system and cause cell death. Enbrel, therefore, can be a powerful anti-inflammatory drug. Tobinick is using Enbrel for many off-label indications, one of which is Alzheimer’s disease (the focus of the LA Times story).
The Dubious Health Clinic
Before I go into the details of Tobinick’s claims, let’s review the typical features of what we commonly call the “quack clinic” or the dubious health clinic. I wrote about this in 2009, and listed the following features:
    • The clinic often has an impressive name, such as “The Institute Of,” but lacks any formal affiliation with an established institution, like a university or hospital, and was founded and may even continue to be operated by one person.
    • The clinic claims to treat or cure one or more diseases that is currently believed to be incurable. Their claims sound too good to be true.
    • There is only one clinic in the world that can perform their special procedure or that uses their proprietary treatment. Sometimes the treatment offered is new and experimental.
    • The clinic claims to cure a variety of diseases, all with different causes and pathophysiology, with a single treatment – the “one cure for all diseases” approach.
    • The clinic is often located in a country with little or no regulation.
    • The clinic claims that it is the victim of repression. Typically they will say that either Big Pharma, the medical establishment, the insurance industry – or some other convenient villain—is trying to suppress their revolutionary treatment. Alternatively, the “medical establishment” is simply closed-minded to their paradigm-shifting ideas.
    • Testimonials are used to promote the treatments offered by the clinic, but they have not published appropriate research in legitimate peer-reviewed journals.
    • When challenged by professional organizations, the clinic defends itself by appealing to politicians, using the testimonies of previous patients who believe they have been helped by the clinic and the accusation of a conspiracy of those trying to protect their monopoly.
The Institute of Neurological Recovery
Now let’s take a look at Tobinick’s clinic. It has an impressive name—a one-man institute.1 The website proclaims:
The Institute of Neurological Recovery (INR®) is pleased to provide this introduction to its pioneering medical concepts, research, and treatment programs. INR designates a group of separate medical practices that utilize innovative, patented, off-label medical treatments developed by Edward Tobinick M.D. These treatment methods are designed to target a number of neuroinflammatory conditions with unmet medical need.
Many of the features of a dubious clinic are right there—the impressive name, claim to treat many conditions with one treatment, emphasis on how innovative the treatments are. The website also claims that his treatments are patented.
This is an interesting side issue, worthy of its own post. There has been a surge in the US in recent years in medical procedure patents. However, the first (and I think only) infringement lawsuit lost its case. Medical procedure patents are generally opposed by medical organizations as counterproductive profiteering and are banned in 80 countries. They are still legal in the US but there has been a number of legislative effort recently to limit or ban them.
The patented procedure (even if not enforced) seems like just another way to market the uniqueness of the treatments offered by the dubious clinic.
The list of conditions for which Tobinick claims or even has patented use of Enbrel include Alzheimer’s, stroke, traumatic brain injury, Parkinson’s disease, carpal tunnel syndrome, brain tumor, spinal cord injury, and back pain. That quite impressive for a doctor who isn’t even a neurologist. Tobinick is an internist who, prior to curing a long list of neurological diseases, specialized in laser hair removal.
The LA Times reports:
But his claims about the back treatment led to an investigation by the California Medical Board, which placed him on probation for unprofessional conduct and made him take classes in prescribing practices and ethics.
Tobinick has since moved his practice to Florida,2 which is a very quack-friendly state.3 Its “health care freedom” law effectively shields dubious practitioners from pesky medical boards.
Plausibility and evidence
When considering just the notion that Enbrel, a TNF inhibitor, might have a broad range of applications, this is entirely plausible. It is common for immunosuppressive drugs to gain an FDA approved indication for one specific condition, such as transplant rejection or rheumatoid arthritis, and then to be used off-label for many other autoimmune conditions.
This is very tricky, however, as the immune system is complex. There are different components to the immune system, and different aspects of immunity are involved in different auto-immune conditions. Therefore there is no one immunosuppressant drug or treatment for all auto-immune conditions.
When a new immune-suppressing drug comes on the market it is common for it to be tried in a variety of conditions—but practice then follows evidence. Initially we might see some case reports, followed by a case series. If the drug shows promise, then a double-blind placebo-controlled trial would ultimately determine its effectiveness.
This is definitely a gray area of off-label use. How much evidence is necessary to justify an off-label use of a drug—and how far off label? Sometimes the popularity of a new off-label use of a drug gets ahead of the evidence. In most cases, however, eventually the research is done and practice conforms to the evidence.
The claims of Tobinick, however, are not in the gray area—they are leaps and bounds ahead of the evidence. Further, the conditions he claims to treat are not clearly immune-mediated diseases. It’s one thing to use an immune-suppressing drug to treat a disease that is known to be caused by immune activity, and probably the kind of immune activity suppressed by the drug.
Tobinick, however, is claiming that a wide range of neurological conditions not known to be immune mediated are treated by a specific immunosuppressant.
On his website he cites many studies, but none of them establish the effectiveness of Enbrel for any of the conditions he is treating. Most of them are simply identifying that TNF is increased in the condition. This is very weak evidence, however, as markers of immune activity are frequently increased in diseases that are not caused by immune activity. The immune system is very reactive — it reacts to disease with inflammation (often what we refer to as the cleanup crew). The inflammation is not causing the disease, it is simply the body’s reaction to it.
Tobinick has also started to publish case series — little more than retrospective case series reporting on his own patients. This is weak evidence even when coming from an established researcher within their own area of expertise. It is all but worthless coming from clinic like Tobinick’s.
This is where his lack of expertise is especially relevant. Such arguments are often portrayed as elitist, as if a mere internist cannot have a valuable insight into how to treat neurological disease. But medicine and research are complex and there are many pitfalls. Unless you have expertise dealing with strokes or dementia, including how to properly research these conditions, you are likely to fall for these pitfalls.
For example, in his recent case series he writes:
Significant improvement was noted irrespective of the length of time before treatment was initiated; there was evidence of a strong treatment effect even in the subgroup of patients treated more than 10 years after stroke and TBI.
This, if anything, is evidence that the observed treatment effect is mere placebo. It is very implausible that stroke or TBI deficits will be equally responsive to an anti-inflammatory treatment (or any treatment) regardless of time since the stroke or trauma.
Stroke researchers are also very familiar with what is known as the “cheerleader effect.” Take any patient with chronic deficits, give them any intervention and then encourage them to function better, and they will function better. This can result simply from trying harder, or even just the incidental physical therapy benefit of engaging in a treatment and being evaluated.
Unless all these factors are controlled for with proper blinding, no conclusions about the treatment effect are possible. Tobinick is providing the kind of evidence that is guaranteed to be positive, but not the kind of evidence that would determine if his treatments are effective or not.
Conclusion
If you strip away the gratuitous narrative in the LA Times story and just look at the facts presented, a very different narrative emerges. Ken Chiate brought his wife to Tobinick’s clinic for 165 injections of Enbrel over four years, at a cost of $800 each (that’s $132,000).4 During that time there were questionable subjective effects from the treatment, typical of placebo-only effects. Meanwhile his wife continued to relentlessly progress, as is typical of the disease, until she finally died in 2011.
According to the article, the treatments gave Chiate a sense of purpose and of hope — a false hope, it turned out. He still clings to the idea that Enbrel may be an effective treatment for Alzheimer’s disease — even though Tobinick himself has apparently moved on to treating stroke.
In my opinion, the story documents exploitation of a well-meaning and desperate husband at the hands of a dubious practitioner, practicing at the fringes of medical ethics and evidence, making bold claims without adequate justification. The story also documents the utter failure of the regulatory system to prevent (or even properly react to) such exploitation. Florida in particular appears to be a haven for such activity.

Update April 2, 2015
1 Dr. Tobinick objects to this characterization on the basis that his practice includes multiple staff and other physicians. I maintain that this characterization is appropriate because his “institute” is merely his private practice of which he is the only significant component. The “institute’s” websites are found at tobinick.com, strokebreakthrough.com, nrimed.com, painbreakthrough.com, and alzheimerbreakthrough.com. Despite having several websites, his is the only bio that appears on any of them (and he so testified in court). No other physicians are featured on the INR website, nor any of the “Institute”’s other websites.
2 Tobinick objects to the fact that the original text stated that he moved his clinic to Florida. However, the clinic did not move to Florida, Dr. Tobinick himself moved to Florida where he opened an additional clinic, where he now works, but kept his a California clinic open also.
3 Dr. Tobinick objects to my characterization of Florida as “Quack Friendly.” However, as I pointed out in the text, Florida has a healthcare freedom law that specifically shields practitioners from having action taken against their license simply because they are practicing below the standard of care. In fact I was involved in a case where the court concluded a neurologist was practicing below the standard of care, but they appealed based upon Florida’s health care freedom law and the claim that they could not be held to the standard of care, and they won on appeal.
4 Dr. Tobinick disputes this figure, claiming that the LA Times story is incorrect. He claims that he charged Chiate a total of $71,000 for the treatments. However, other news sources state that he charges thousands of dollars for the initial treatment.

Another Lawsuit To Suppress Legitimate Criticism – This Time SBM
Steven Novella on July 23, 2014
Link

I suppose it was inevitable. In fact, I’m a bit surprised it took this long. SGU Productions, the Society for Science-based medicine, and I are being sued for an article that I wrote in May of 2013 on Science-Based Medicine. My SBM piece, which was inspired by an article in the LA Times, gave this summary:
The story revolves around Dr. Edward Tobinick and his practice of perispinal etanercept (Enbrel) for a long and apparently growing list of conditions. Enbrel is an FDA-approved drug for the treatment of severe rheumatoid arthritis. It works by inhibiting tumor necrosis factor (TNF), which is a group of cytokines that are part of the immune system and cause cell death. Enbrel, therefore, can be a powerful anti-inflammatory drug. Tobinick is using Enbrel for many off-label indications, one of which is Alzheimer’s disease (the focus of the LA Times story).
The claims and practice of Dr. Tobinick have many of the red flags of a dubious medical practice, of the sort that we discuss regularly on SBM. It seems that Dr. Tobinick does not appreciate public criticism of his claims and practice, and he wants me to remove the post from SBM. In my opinion he is using legal thuggery in an attempt to intimidate me and silence my free speech because he finds its content inconvenient.
Of course, we have no intention of removing the post as we feel it is critical to the public’s interest. This is what we do at SBM – provide an objective analysis of questionable or controversial medical claims so that consumers can make more informed decisions, and to advance the state of science in medicine.
We also feel it is critical not to cave to this type of intimidation. If we do, we might as well close up shop (which I suspect the Tobinicks of the world would find agreeable). Defending against even a frivolous lawsuit can be quite expensive, but we feel it is necessary for us to fight as hard as we can to defend our rights and the work that we do here at SBM.
An interesting wrinkle of this suit is that Tobinick is claiming that my blog post is an “advertisement.” This is a legal maneuver as the threshold for forcing someone to remove an advertisement is much lower than the threshold for suppressing their free speech. I can only assume that he and his attorneys are not bothered by the fact that blog posts on SBM are blatantly not advertisements.
In the case of the Enbrel article he had to make the absurd claim that the post (which does not mention my own practice) was an advertisement for my neurology practice at Yale, designed to attack a “competitor.” He would have us believe that Yale neurology in Connecticut is concerned about a distant clinic. Further, Yale Neurology is an academic practice. Our problem is too many referrals and long wait times, not competitors. To see how desperate the claim is, he argued that because I use Botox, which can be used to treat symptoms following stroke, that his treatments for stroke represent a competitor. However, I don’t use Botox to treat stroke patients. I mostly use it to treat migraines, as I am a headache specialist.
Perhaps he feels that my 18-year career promoting science, critical thinking, and science-based medicine is just a cover so I can occasionally attack distant tangential “competitors.”
In any case, the fight is on. Here is a review of the salient points of my criticism of Tobinick:
Tobinick is not a neurologist, and yet he feels it is appropriate for him to treat multiple neurological conditions with an experimental treatment. It is generally considered unethical for physicians to practice outside of their area of competence and expertise. He is trained in internal medicine and dermatology and is certified in those specialties. He has never completed a neurology residency nor is he board certified in neurology.
Despite his lack of formal training and certification, he feels he has ushered in a “paradigm shift” in the treatment of Alzheimer’s disease – a disease that has proved challenging for actual neurologists for decades.
His treatment of choice is perispinal etanercept (Enbrel), which basically is an immunosuppressant drug. He is using this treatment for not only Alzheimer’s disease, but neurological deficits following stroke, traumatic brain injury, and pain resulting from vertebral discs. He therefore claims that the neurological deficits in these various conditions result from active inflammation (specifically tumor necrosis factor – TNF) and by inhibiting TNF “rapid improvement” in neurological function is possible.
These claims are highly implausible, and in my opinion reflect his lack of training and expertise as a neurologist. Strokes cause ischemic damage to the brain – brain cells in severe stroke die. Inflammation following stroke is incidental, not causative. Yet Tobinick claims that 10 years following a stroke, long after any neurological recovery would have occurred, patients can improve by inhibiting TNF.
He makes the same claim for Alzheimer’s disease, despite the fact that this is a neurodegenerative disease resulting in loss and destruction of brain cells. An anti-inflammatory drug is not going to bring back dead brain cells, yet he claims “rapid improvement” is possible.
The simplest explanation for the apparent response to his treatments is simply placebo effects. Stroke neurologists, for example, are acutely aware of the so-called “cheerleader” effect. Take a patient with chronic deficits, get them off the couch, give them any treatment and tell them it will make them better, and they will likely demonstrate increased functionality simply because they are making an effort they had not made for a while.
The only way to really know if the treatment itself is having any neurological benefit is with careful double-blind placebo-controlled clinical trials. Tobinick, however, has not produced such evidence. He has a long list of publications – all case series, observational studies, pilot studies, case reports, and reviews. I could not find a single double-blind placebo-controlled trial establishing the efficacy of his treatment for any of the conditions I listed above. (There are small studies for disc herniation showing conflicting results.)
At best his treatment should be considered experimental. I think the plausibility of the effects he is claiming is extremely low. It’s possible that an anti-TNF effect may be of some use, but given the type of evidence we have it is likely we are seeing mostly (if not completely) placebo effects.
Despite the preliminary nature of his evidence, the “paradigm shift” such claims would represent, and his lack of formal training in neurology, Tobinick has obtained a number of use patents for his treatments. Use patents for medical procedures are still legal in the US, although they have been banned in many other countries, and many consider them unethical. The AMA has this to say:
The intentional withholding of new medical knowledge, skills, and techniques from colleagues for reasons of personal gain is detrimental to the medical profession and to society and is to be condemned.
The case highlighted in the LA Times story involved Ken Chiate, who brought his wife who was suffering from Alzheimer’s disease to Tobinick’s clinic for 165 injections of Enbrel over four years, at a cost of $800 each (that’s $132,000). During that time there were questionable subjective effects from the treatment, typical of placebo-only effects. Meanwhile his wife’s condition continued to relentlessly progress, as is typical of the disease, until she finally died in 2011.
I am not the only one to have concerns about Tobinick’s practices. The Medical Board of California filed an accusation in 2004, amended in 2005 and 2006, stating:
    • From about 2000 to 2002, Tobinick, owned and operated a medical practice under the name “Institute for Neurological Research” in Los Angeles and Newport Beach.
    • During those years, Tobinick promoted and advertised a new off-label use for an FDA-approved drug, etanercept (Enbrel). He referred to his drug as DiskCureÂ® [sic] and advertised it as “a new and innovative approach for back or neck pain without surgery,” and as a “breakthrough” in the treatment of disc-related back and neck pain.
    • Enbrel is a genetically engineered protein and immune response modifier approved by the FDA for treating several types of arthritis but not for back pain. Tobinick’s treatment involved injecting it near the spine.
    • Until May 2002, there had been no published, peer-reviewed, scientific studies showing the effectiveness of the treatment for back pain in humans. Nor had there been an approved, pending, or investigational drug application for this use of etanercept.
    • Tobinick’s advertisements for DiskCure constituted unprofessional conduct under the California Business and Professions Code.
    • Tobinick had also failed to obtain a fictitious name permit for the Institute for Neurological Research as required by law.
Tobinick agreed to serve one year on probation during which he was required to complete courses in ethics and prescribing practices and have his practice monitored by another physician or complete a professional enhancement program.
But now he is not only up to his old tricks, but he has greatly expanded the scope of his Enbrel claims and practice. He has his own “Institute for Neurological Recovery” in which he shows videos of select patients to promote his patented treatments.
This is all, unfortunately, a far too common pattern, one with which we at SBM are very familiar. There is definitely a need here to provide critical analysis of such extraordinary medical claims. That means, also unfortunately, that we will occasionally need to spend our time and resources defending our right to do so.

Update on the Tobinick Lawsuit
Steven Novella on April 1, 2015
Link

Last year Edward Tobinick sued the Society for Science-Based Medicine, SGU Productions (the producers of the Skeptics’ Guide to the Universe podcast), Yale University, and me personally for libel and (of all things) false advertising. I am frequently asked how the suit is going so here is an update.
Background
The lawsuit involved an article I wrote on Science-Based Medicine on May 8, 2013. Dr. Tobinick’s practice involves giving perispinal etanercept to treat sciatica, Alzheimer’s disease, traumatic brain injury (TBI), and chronic deficits following stroke. He claims that he can reverse the symptoms of these various conditions within minutes. He uses highly emotional videos and anecdotal evidence to promote his treatments.
Further, he has medical use patents on these and other treatments and charges other physicians a substantial fee for training and a royalty simply for treating patients with his methods. Medical use patents are considered by the AMA and other medical organizations to be unethical and are banned in 80 countries (but not the US).
My original article was highly critical of Tobinick’s practice. I emphasized the fact that he is making dramatic clinical claims, which he himself characterizes as revolutionary, without ever having conducted a single double-blind placebo controlled trial. In my opinion none of these uses of etanercept are supported by adequate clinical evidence. In fact, there are no published double-blind placebo-controlled trials of etanercept for post-stroke symptoms or TBI. There are some studies for sciatica, but a 2013 systematic review concluded:
There was insufficient evidence to recommend these agents when treating sciatica, but sufficient evidence to suggest that larger RCTs are needed.
There is a single pilot study of etanercept for Alzheimer’s – a phase II trial with 41 subjects total. That’s it – this is hardly sufficient evidence on which to revolutionize the treatment of multiple complex neurological disorders. In fact, during the hearing, his own expert testified that we are “not there yet.”
Libel suits in the US are highly problematic, in my opinion, as there is a strong potential for them to be used as a strategic lawsuit against public participation (SLAPP). Even if a case essentially has no merits, it takes tens of thousands of dollars to defend and can be a tactic for silencing critics based on the burden of mounting a defense. In other words, unless you have lots of disposable cash or can raise it quickly, someone with money can use the legal process to chill your freedom of speech (more on this below).
Updates
Here are some updates in the case: Yale University was quickly dropped from the case, which is unsurprising as they had no connection to the article at all. SGU Productions was also dropped from the case.
A few weeks ago the Society for SBM won a summary judgment motion, and so they are therefore out of the case also. In the summary judgment the judge ruled that the original article was not commercial speech, as alleged by Dr. Tobinick. This was good news because it not only let SfSBM out of the suit, it boded well for the same issue in my case.
For background, Tobinick is alleging that my article here on SBM was “commercial speech.” The claim is absurd on its face, and so I am not surprised that the judge is not buying it. However, whether or not the claim makes sense there needs to be a specific legal basis for ruling on the claim. The judge, in the ruling for the SfSBM summary judgment, laid out the three criteria by which speech constitutes commercial speech, and the article did not meet any of those criteria. However, because the motion was brought by SfSBM the judgment on that motion applied only to them, not to me.
Just yesterday there was another update on the case. We completed a two-day hearing on Tobinick’s motion for injunctive relief. Essentially this is a motion asking the judge to order me to take down several articles and an SGU podcast in which I discuss Tobinick and the case (I’m taking bets on whether he is going to add this one to the list), pending the final outcome of the case.
Yesterday the hearing concluded and the judge ruled from the bench, denying the motion. More importantly, the judge specifically rejected Tobinick’s commercial speech claim (among other things).
This is all very good news. However, the case will still go forward (unless Tobinick comes to his senses). It will likely take many more months for the case to play itself out.
Unfortunately, even though it seems that Tobinick’s case has no merit, the overall cost of defending my right to express my opinion on the pages of SBM has already been substantial and will continue to grow.
Libel reform
This experience has certainly been an eye-opener. One reaction, however, is that my attorney, the SGU, and myself, are beginning a serious effort for libel reform. What we need is to get effective anti-SLAPP legislation passed is as many states as possible. I have already received a score of e-mails from readers and listeners willing to help with this effort, and we will be discussing it further at NECSS in a week and a half.
We have model anti-SLAPP legislation and can send it to anyone who wishes to help by contacting their state legislature and looking for someone to sponsor the bill. E-mail me if you want more details.
Another Tobinick update
Another interesting update is that I recently learned that Tobinick is the target of another claim by the state of California Medical Board. In November 2014 they filed a complaint against him for false and/or misleading advertising, deceptive advertising, unprofessional conduct, and gross negligence. Here is one key part of the claim:
…he has disseminated or caused to be disseminated false and/or misleading statements and/or claims for the purposes of or that are likely to induce, directly or indirectly, the rendering of professional services with connection with his professional practice, which contained misrepresentation of facts, were likely to mislead or deceive, created false or unjustified expectations, and/or make scientific claims that cannot be substantiated by reliable, peer reviewed, published scientific studies.
These are devastating accusations, and echo my criticisms of Tobinick. Tobinick was subject to a very similar complaint that was settled in 2006.
I will continue to give updates when anything significant happens, but it may be half a year or more before there is anything to report.
Meanwhile, let’s fight together for libel reform and protect the freedom of speech on which our entire movement depends.

Lawsuit Update
Steven Novella on June 10, 2015
Link

For those of you following the defamation lawsuit against me by Dr. Edward Tobinick, there has been a significant and positive update. For quick background, Dr. Tobinick filed a suit against me personally, the Society for Science-Based Medicine, Yale University and SGU Productions for an article I wrote here critical of his claims that perispinal etanercept can treat a variety of neurological conditions. All the defendants but me have since been removed from the case.
There are three plaintiffs in the case; Dr. Tobinick himself, his California corporation, and his Florida LLC. Last year I filed a motion to strike some of the claims as they apply to the California corporation under that state’s anti-SLAPP statute. The update is that last week the judge in the case ruled in my favor on this motion. These are public documents, so you can read the entire decision here. It concludes:
For the foregoing reasons, it is hereby ORDERED AND ADJUDGED that Steven Novella’s Special Motion to Strike (Anti-SLAPP Motion) [DE 93] is GRANTED. Tobinick M.D.’s claims for unfair competition under 28 U.S.C. § 1338(b) (Count II), trade libel (Count III), and libel per se (Count IV) are STRICKEN from the Amended Complaint.
As important as the decision itself are the judge’s reasons for the decision. She writes:
The Court concludes that (1) Tobinick M.D. is a limited public figure subject to the actual malice requirement, and (2) Tobinick M.D. has failed to establish a probability of demonstrating, by clear and convincing evidence, that Novella made the statements at issue with actual malice. Therefore, Tobinick M.D.’s unfair competition, trade libel, and libel per se claims must be stricken.
In other words, Tobinick cannot win his suit on the merits. This also means:
As a prevailing defendant, Novella is entitled to recover his attorney’s fees and costs under the anti-SLAPP statute. Cal. Civ. Proc. Code § 425.16(c)(1). He may seek to recover his fees and costs by separate motion.
This applies to only a portion of the case, as it entails only one of the three plaintiffs and only some of the claims. It is an important victory, but the case may be far from over. I will keep you updated.
The decision also highlights the importance of anti-SLAPP laws. “SLAPP” stands for strategic lawsuit against public participation and refers to the notion that some libel suits are filed not because they have merit but as a way of silencing free speech and participation in public discourse. As I have now learned first-hand, it can cost an incredible amount of money to assert your free speech. Anti-SLAPP statutes serve the purpose of protecting free speech from oppressive or harassing SLAPP suits. Effective anti-SLAPP laws allow for defendants to shut down meritless cases early, before ruinous expenses are incurred, and also allow for the recovery of fees.
This is why the SGU, myself, and my attorney are lobbying for effective anti-SLAPP laws in every state and at the federal level. We need people in every state to contact their legislature. We have a model anti-SLAPP law we can provide and will be coordinating efforts. There are also groups like the Public Participation Project supporting anti-SLAPP legislation.
Recently the Speak Free act of 2015 was introduced in the House of Representatives. This would be a fairly effective anti-SLAPP law that applies to federal cases, and may also provide protections for cases in state court as it has a provision that allows defendants to avail themselves of the federal anti-SLAPP protection. Read about it and contact your representative in support of this bill.
Right now the laws governing libel cases are broken (in most states), representing a significant infringement on our free speech. There is a clear fix, however – effective anti-SLAPP laws. We just need a political push to get these laws passed.

Tobinick Lawsuit Update – Justice Has Prevailed
sbmadmin on October 6, 2015
Link
On September 30, the U.S. District Court for the Southern District of Florida granted Dr. Novella’s motion for summary judgment, ending the lawsuit against him by Dr. Edward Tobinick and two of his companies. Earlier in the case, all of the other defendants had filed successful motions to dismiss or for summary judgment and were no longer parties to the case.
That he won the remaining issues in the case on a motion for summary judgment is highly significant. Summary judgment motions are granted sparingly by the courts. In granting his motion, the judge was required by law to view the facts in the light most favorable to Tobinick and the other plaintiffs and draw all reasonable inferences from those facts in their favor. Dr. Novella had to convince the judge that there was no dispute as to any of the relevant facts and that those undisputed facts entitled him to prevail. Because of this ruling, the case will not go to trial.
For a quick background, Tobinick filed a suit against Dr. Novella, the Society for Science-Based Medicine (SFSBM), Yale University and SGU Productions. The subject of his suit was an article Dr. Novella wrote here critical of his claims that perispinal etanercept can treat a variety of neurological conditions, as well as a second article, posted after suit was filed.
There were three plaintiffs in the case: Tobinick himself, his California corporation, and his Florida LLC. Last year Dr. Novella filed a motion to strike some of the claims brought by the California corporation under that state’s anti-SLAPP statute. In June, the judge ruled in his favor. He was awarded attorneys fees and costs as well. The judge concluded:
For the foregoing reasons, it is hereby ORDERED AND ADJUDGED that Steven Novella’s Special Motion to Strike (Anti-SLAPP Motion) [DE 93] is GRANTED. Tobinick M.D.’s claims for unfair competition under 28 U.S.C. § 1338(b) (Count II), trade libel (Count III), and libel per se (Count IV) are STRICKEN from the Amended Complaint.
A post on the Anti-SLAPP ruling is here, and here is a subsequent update. In the latter, it is mentioned that, in November, 2014, the Medical Board of California had filed a complaint against Tobinick for false and/or misleading advertising, deceptive advertising, unprofessional conduct, and gross negligence. That complaint has been dismissed.
Following the court’s Anti-SLAPP decision, Tobinick and the Florida LLC voluntarily dismissed their libel claims because of the likelihood that they would fail. All that remained in the case, therefore, were two counts: Count I for violation of the Lanham Act, and Count II for unfair competition.
The plaintiffs claimed that Dr. Novella’s posts were “false advertising” under the Lanham Act. They argued that the posts constituted “personal advertising or promotion” misrepresenting Tobinick’s treatments. To win, the plaintiffs had to show that what was said fell within the definition of “commercial speech.” They tried to get the judge to buy their argument that, because SBM and SGU have advertising, memberships, and sell merchandise, the speech contained in those outlets is commercial speech.
Or, as the judge herself described it, the plaintiffs were claiming that Dr. Novella, in cahoots with others, had concocted:
an interrelated scheme to ‘funnel money’ to Defendant Novella personally, and that the Articles [that is, the posts] are commercial speech in furtherance of this scheme.
This has always been, in our opinion, an absurd legal argument. If this were true, then every article appearing in every newspaper that has advertising is commercial speech, which means the First Amendment would be effectively gutted.
Significantly, the judge specifically rejected this view of the evidence. She found that
[b]oth Articles clearly state their intent to raise public awareness about issues pertaining to Plaintiffs’ treatments.
Later in the Order, she repeated this point:
. . . the content of the Articles is directed toward raising public awareness of scientific issues, rather than promoting an economic interest.
Our position has always been that Science-Based Medicine represents science communication (technically journalism), is largely based on professional opinions and analysis, and the purpose of which is public education and consumer protection.
The judge had already spelled out, in her earlier decision granting SfSBM’s motion for summary judgment, established precedent determining exactly what constitutes commercial speech. Dr. Novella’s blog posts did not meet any of these criteria. The judge repeated this interpretation of the law when she denied the plaintiffs’ motion for injunctive relief. In that decision she wrote:
The Court concludes that Plaintiffs have failed to demonstrate that there is a substantial likelihood that they will be able to show that the speech at issue in the two articles is commercial in nature. Accordingly, Plaintiffs have failed to demonstrate a substantial likelihood of prevailing on the merits.
Despite having twice been denied relief based on the extraordinary theory that the articles constituted commercial speech, Tobinick continued to make this argument. In fact, rather than accept the inevitable, he became creative in trying to expand the case.
In August, he filed a motion for permission to amend the complaint with yet another theory, that Dr. Novella violated the Florida Deceptive and Unfair Trade Practices Act by publishing an unfair review of Tobinick’s practice. He essentially compares SBM to the Better Business Bureau, and, repackaging his original claims, argues that the review was unfair and not objective. The judge denied his motion.
Nevertheless, he tried to amend the complaint yet again, this time with a bizarre conspiracy theory involving Dr. Novella and two other neurologists. Tobinick argued that Dr. Novella was the ringleader at the center of a web of conspiracy against him. He argued that the three neurologists were against him because they “hate innovation,” a transparently absurd claim. The judge denied leave to amend this time as well.
Having ruled against the plaintiffs on the Lanham Act, the judge was able to quickly dispose of unfair competition. Because the state law unfair competition claim, like the Lanham Act claim, was based on a theory of false advertising, that claim failed as well.
As all the plaintiffs’ claims had been resolved by the court in favor of the defendants, the judge directed the Clerk of Court to close the case.
The SBM Editorial Board
References:
Order granting the Society for Science Based Medicine summary judgement. 
Order denying Tobinick’s motion for injunctive relief.
Order granting Dr. Novella his motion to strike (Anti-SLAPP).
Order granting Dr. Novella his motion for summary judgement.
Other public documents on the case. 
